term|id|abstract|en_core_sci_md|en_ner_craft_md|en_ner_jnlpba_md|en_ner_bc5cdr_md|en_ner_bionlp13cg_md
phenylketonuria|pubmed~33427303|Phenylketonuria Is An Inherited Disease For Which The Main Treatment Is The Dietary Restriction Of The Amino Acid Phenylalanine. The Diet Has To Be Initiated In The Neonatal Period To Prevent Or Reduce Mental Handicap. However, The Diet Is Very Restrictive And Unpalatable And Can Be Difficult To Follow. A Deficiency Of The Amino Acid Tyrosine Has Been Suggested As A Cause Of Some Of The Neuropsychological Problems Exhibited In Phenylketonuria. Therefore, This Review Aims To Assess The Efficacy Of Tyrosine Supplementation For Phenylketonuria. This Is An Update Of Previously Published Versions Of This Review. To Assess The Effects Of Tyrosine Supplementation Alongside Or Instead Of A Phenylalanine-Restricted Diet For People With Phenylketonuria, Who Commenced On Diet At Diagnosis And Either Continued On The Diet Or Relaxed The Diet Later In Life. To Assess The Evidence That Tyrosine Supplementation Alongside, Or Instead Of A Phenylalanine-Restricted Diet Improves Intelligence, Neuropsychological Performance, Growth And Nutritional Status, Mortality Rate And Quality Of Life. We Searched The Cochrane Cystic Fibrosis And Genetic Disorders Group'S Trials Register Which Is Comprised Of References Identified From Comprehensive Electronic Database Searches, Handsearches Of Relevant Journals And Abstract Books Of Conference Proceedings. Additional Studies Were Identified From Handsearches Of The Journal Of Inherited Metabolic Disease (From Inception In 1978 To 1998). The Manufacturers Of Prescribable Dietary Products Used In The Treatment Of Phenylketonuria Were Also Contacted For Further References. Date Of The Most Recent Search Of The Group'S Inborn Errors Of Metabolism Trials Register: 07 December 2020. All Randomised Or Quasi-Randomised Trials Investigating The Use Of Tyrosine Supplementation Versus Placebo In People With Phenylketonuria In Addition To, Or Instead Of, A Phenylalanine-Restricted Diet. People Treated For Maternal Phenylketonuria Were Excluded. Two Authors Independently Assessed The Trial Eligibility, Methodological Quality And Extracted The Data. Six Trials Were Found, Of Which Three Trials Reporting The Results Of A Total Of 56 Participants, Were Suitable For Inclusion In The Review. The Blood Tyrosine Concentrations Were Significantly Higher In The Participants Receiving Tyrosine Supplements Than Those In The Placebo Group, Mean Difference 23.46 (95% Confidence Interval 12.87 To 34.05). No Significant Differences Were Found Between Any Of The Other Outcomes Measured. The Trials Were Assessed As Having A Low To Moderate Risk Of Bias Across Several Domains. From The Available Evidence No Recommendations Can Be Made About Whether Tyrosine Supplementation Should Be Introduced Into Routine Clinical Practice. Further Randomised Controlled Studies Are Required To Provide More Evidence. However, Given This Is Not An Active Area Of Research, We Have No Plans To Update This Review In The Future.|"[('Phenylketonuria', 'no label'), ('Inherited Disease', 'no label'), ('Main Treatment', 'no label'), ('Dietary Restriction', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Diet', 'no label'), ('Initiated', 'no label'), ('Neonatal', 'no label'), ('Period', 'no label'), ('Prevent', 'no label'), ('Reduce', 'no label'), ('Mental Handicap', 'no label'), ('Diet', 'no label'), ('Unpalatable', 'no label'), ('Deficiency', 'no label'), ('Amino Acid Tyrosine', 'no label'), ('Cause', 'no label'), ('Neuropsychological Problems Exhibited', 'no label'), ('Phenylketonuria', 'no label'), ('Review Aims', 'no label'), ('Efficacy', 'no label'), ('Tyrosine', 'no label'), ('Supplementation', 'no label'), ('Phenylketonuria', 'no label'), ('Update', 'no label'), ('Published Versions', 'no label'), ('Review', 'no label'), ('Assess', 'no label'), ('Effects', 'no label'), ('Tyrosine', 'no label'), ('Supplementation', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Commenced', 'no label'), ('Diet', 'no label'), ('Diagnosis', 'no label'), ('Continued', 'no label'), ('Diet', 'no label'), ('Diet', 'no label'), ('Assess', 'no label'), ('Evidence', 'no label'), ('Tyrosine', 'no label'), ('Supplementation', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Intelligence', 'no label'), ('Neuropsychological Performance', 'no label'), ('Growth', 'no label'), ('Nutritional Status', 'no label'), ('Mortality Rate', 'no label'), ('Cochrane Cystic Fibrosis', 'no label'), ('Genetic Disorders', 'no label'), (""Group'S Trials"", 'no label'), ('References', 'no label'), ('Identified', 'no label'), ('Comprehensive Electronic Database Searches', 'no label'), ('Handsearches', 'no label'), ('Relevant', 'no label'), ('Journals', 'no label'), ('Proceedings', 'no label'), ('Studies', 'no label'), ('Identified', 'no label'), ('Handsearches', 'no label'), ('Metabolic Disease', 'no label'), ('Inception', 'no label'), ('Manufacturers', 'no label'), ('Prescribable', 'no label'), ('Dietary Products', 'no label'), ('Treatment', 'no label'), ('Phenylketonuria', 'no label'), ('Contacted', 'no label'), ('References', 'no label'), (""Group'S"", 'no label'), ('Inborn Errors', 'no label'), ('Metabolism Trials Register', 'no label'), ('December', 'no label'), ('Randomised Or Quasi-Randomised Trials', 'no label'), ('Investigating', 'no label'), ('Tyrosine Supplementation', 'no label'), ('Placebo', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('People', 'no label'), ('Treated', 'no label'), ('Maternal', 'no label'), ('Phenylketonuria', 'no label'), ('Assessed', 'no label'), ('Trial', 'no label'), ('Eligibility', 'no label'), ('Methodological Quality', 'no label'), ('Data', 'no label'), ('Trials', 'no label'), ('Trials Reporting', 'no label'), ('Participants', 'no label'), ('Inclusion', 'no label'), ('Review', 'no label'), ('Blood Tyrosine', 'no label'), ('Concentrations', 'no label'), ('Participants', 'no label'), ('Tyrosine Supplements', 'no label'), ('Placebo Group', 'no label'), ('Mean Difference', 'no label'), ('Confidence Interval', 'no label'), ('No Significant', 'no label'), ('Differences', 'no label'), ('Outcomes', 'no label'), ('Measured', 'no label'), ('Trials', 'no label'), ('Assessed', 'no label'), ('Moderate Risk', 'no label'), ('Bias', 'no label'), ('Domains', 'no label'), ('Available', 'no label'), ('Evidence', 'no label'), ('Recommendations', 'no label'), ('Tyrosine', 'no label'), ('Supplementation', 'no label'), ('Introduced', 'no label'), ('Routine', 'no label'), ('Clinical Practice', 'no label'), ('Randomised Controlled Studies', 'no label'), ('Evidence', 'no label'), ('Active Area', 'no label'), ('Research', 'no label'), ('Plans', 'no label'), ('Update', 'no label'), ('Review', 'no label')]"|[('Amino Acid Phenylalanine', 'no label'), ('Amino Acid Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Genetic', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Inherited Disease', 'no label'), ('Amino Acid Phenylalanine', 'no label'), ('Amino Acid Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Fibrosis', 'no label'), ('Metabolic Disease', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label')]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acid', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Blood Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label')]
phenylketonuria|pubmed~32482081|Vitamin B12 Deficiency Frequently Appears In Phenylketonuria Patients Having A Diet Poor In Natural Protein. The Aims Of This Study Were To Evaluate Vitamin B12 Status In Phenylketonuria Patients By Using Combined Indicator Of Vitamin B12 Status (Cb12) As Well As Methylmalonic Acid And Homocysteine, More Specific And Sensitive Markers, In Comparison With Healthy Controls. Fifty-Three Children And Adolescents With Phenylketonuria Under Dietary Treatment And 30 Healthy Controls Were Assessed Cross-Sectionally. Serum Vitamin B12 And Folate Concentrations Were Analysed By Chemiluminescence Immunoassay. Plasma Methylmalonic Acid And Total Homocysteine Concentrations Were Measured By Liquid Chromatography-Tandem Mass Spectrometry And Liquid Chromatography, Respectively. Cb12 Was Calculated By Using A Formula Involving Blood Parameters. Methylmalonic Acid And Folate Concentrations In Phenylketonuria Group Were Higher Compared With Controls. Methylmalonic Acid Concentrations Were High In 56.5% Of The Patients And 26.7% Of The Controls With Normal Vitamin B12 Concentrations. Based On Cb12, A Significant Difference Within The Normal Values Was Detected Between The Groups. However, Although 24.5% Of Phenylketonuria Patients And 13.3% Of Controls Had Decreased Vitamin B12 Status According To Cb12, There Was No Significant Difference. Children And Adolescents With Phenylketonuria Having A Strict Diet Can Be At Risk Of Functional Vitamin B12 Deficiency. This Deficiency Can Be Accurately Determined By Measuring Methylmalonic Acid Concentrations. Calculation Of Cb12 As A Biochemical Index Did Not Provide Additional Information Compared With The Measurement Of Methylmalonic Acid Alone, But May Be Helpful For Classification Of Some Patients With Increased Methylmalonic Acid As Having Adequate Vitamin B12 Status.|[('Vitamin B12 Deficiency', 'no label'), ('Appears', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Diet', 'no label'), ('Poor', 'no label'), ('Natural Protein', 'no label'), ('Study', 'no label'), ('Evaluate', 'no label'), ('Vitamin B12', 'no label'), ('Status', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Combined Indicator', 'no label'), ('Vitamin B12 Status', 'no label'), ('Cb12', 'no label'), ('Methylmalonic Acid', 'no label'), ('Homocysteine', 'no label'), ('Sensitive', 'no label'), ('Markers', 'no label'), ('Comparison', 'no label'), ('Healthy Controls', 'no label'), ('Fifty-Three Children', 'no label'), ('Adolescents', 'no label'), ('Phenylketonuria', 'no label'), ('Dietary Treatment', 'no label'), ('Healthy Controls', 'no label'), ('Assessed', 'no label'), ('Cross-Sectionally', 'no label'), ('Serum', 'no label'), ('Vitamin B12', 'no label'), ('Folate', 'no label'), ('Concentrations', 'no label'), ('Analysed', 'no label'), ('Chemiluminescence Immunoassay', 'no label'), ('Plasma', 'no label'), ('Methylmalonic Acid', 'no label'), ('Homocysteine', 'no label'), ('Concentrations', 'no label'), ('Measured', 'no label'), ('Liquid Chromatography-Tandem Mass Spectrometry', 'no label'), ('Liquid Chromatography', 'no label'), ('Involving', 'no label'), ('Blood Parameters', 'no label'), ('Methylmalonic Acid', 'no label'), ('Folate', 'no label'), ('Concentrations', 'no label'), ('Phenylketonuria', 'no label'), ('Group', 'no label'), ('Controls', 'no label'), ('Methylmalonic Acid', 'no label'), ('Concentrations', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Normal Vitamin B12', 'no label'), ('Concentrations', 'no label'), ('Cb12, A Significant Difference', 'no label'), ('Normal Values', 'no label'), ('Detected', 'no label'), ('Groups', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Decreased', 'no label'), ('Vitamin B12', 'no label'), ('Status', 'no label'), ('Cb12', 'no label'), ('No Significant', 'no label'), ('Children', 'no label'), ('Adolescents', 'no label'), ('Phenylketonuria', 'no label'), ('Strict Diet', 'no label'), ('Risk', 'no label'), ('Functional', 'no label'), ('Vitamin B12 Deficiency', 'no label'), ('Deficiency', 'no label'), ('Measuring', 'no label'), ('Methylmalonic Acid', 'no label'), ('Concentrations', 'no label'), ('Calculation', 'no label'), ('Cb12 As A', 'no label'), ('Biochemical Index', 'no label'), ('Information', 'no label'), ('Measurement', 'no label'), ('Methylmalonic Acid Alone', 'no label'), ('Classification', 'no label'), ('Patients', 'no label'), ('Increased', 'no label'), ('Methylmalonic Acid', 'no label'), ('Adequate', 'no label'), ('Vitamin B12', 'no label'), ('Status', 'no label')]|[('Vitamin', 'no label'), ('Protein', 'no label'), ('Vitamin', 'no label'), ('Vitamin', 'no label'), ('Methylmalonic Acid', 'no label'), ('Methylmalonic Acid', 'no label'), ('Homocysteine', 'no label'), ('Folate', 'no label'), ('Vitamin', 'no label'), ('Vitamin', 'no label'), ('Acid', 'no label'), ('Methylmalonic Acid', 'no label'), ('Vitamin', 'no label')]|[('Vitamin B12', 'no label'), ('Serum Vitamin B12', 'no label')]|[('Vitamin B12', 'no label'), ('Phenylketonuria', 'no label'), ('Vitamin B12', 'no label'), ('Phenylketonuria', 'no label'), ('Vitamin B12', 'no label'), ('Methylmalonic Acid', 'no label'), ('Homocysteine', 'no label'), ('Phenylketonuria', 'no label'), ('Vitamin B12', 'no label'), ('Folate', 'no label'), ('Homocysteine', 'no label'), ('Folate', 'no label'), ('Phenylketonuria', 'no label'), ('Vitamin B12', 'no label'), ('Cb12', 'no label'), ('Phenylketonuria', 'no label'), ('Vitamin B12', 'no label'), ('Cb12', 'no label'), ('Phenylketonuria', 'no label'), ('Vitamin B12', 'no label'), ('Cb12', 'no label'), ('Methylmalonic Acid', 'no label'), ('Vitamin B12', 'no label')]|[('Vitamin B12', 'no label'), ('Phenylketonuria Patients', 'no label'), ('Vitamin B12', 'no label'), ('Phenylketonuria Patients', 'no label'), ('Vitamin B12', 'no label'), ('Methylmalonic Acid', 'no label'), ('Homocysteine', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Serum Vitamin B12', 'no label'), ('Folate', 'no label'), ('Plasma Methylmalonic', 'no label'), ('Total Homocysteine', 'no label'), ('A Formula', 'no label'), ('Blood', 'no label'), ('Methylmalonic Acid', 'no label'), ('Folate', 'no label'), ('Phenylketonuria', 'no label'), ('Methylmalonic Acid', 'no label'), ('Patients', 'no label'), ('Normal Vitamin B12', 'no label'), ('Phenylketonuria Patients', 'no label'), ('Vitamin', 'no label'), ('B12', 'no label'), ('Cb12', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Vitamin B12', 'no label'), ('Methylmalonic Acid', 'no label'), ('Cb12', 'no label'), ('Methylmalonic Acid', 'no label'), ('Patients', 'no label'), ('Methylmalonic', 'no label'), ('Vitamin', 'no label'), ('B12', 'no label')]
phenylketonuria|pubmed~34423658|Background Phenylketonuria Is The Most Common Inborn Error Of Amino Acid Metabolism, Where Oxidative Stress And Collateral Metabolic Abnormalities Are Likely To Cause Cardiac Structural And Functional Modifications. We Aim Herein To Characterize The Cardiac Phenotype Of Adult Subjects With Phenylketonuria Using Advanced Cardiac Imaging. Methods And Results Thirty-Nine Adult Patients With Phenylketonuria (Age, 30.5±8.7 Years; 10-Year Mean Phenylalanine Concentration, 924±330 Μmol/L) And 39 Age- And Sex-Matched Healthy Controls Were Investigated. Participants Underwent A Comprehensive Cardiac Magnetic Resonance And Echocardiography Examination. Ten-Year Mean Plasma Levels Of Phenylalanine And Tyrosine Were Used To Quantify Disease Activity And Adherence To Treatment. Patients With Phenylketonuria Had Thinner Left Ventricular Walls (Septal End-Diastolic Thickness, 7.0±17 Versus 8.8±1.7 Mm [<I>P</I><0.001]; Lateral Thickness, 6.1±1.4 Versus 6.8±1.2 Mm [<I>P</I>=0.004]), More Dilated Left Ventricular Cavity (End-Diastolic Volume, 87±14 Versus 80±14 Ml/M<Sup>2</Sup> [<I>P</I>=0.0178]; End-Systolic Volume, 36±9 Versus 29±8 Ml/M<Sup>2</Sup> [<I>P</I><0.001]), Lower Ejection Fraction (59±6% Versus 64±6% [<I>P</I><0.001]), Reduced Systolic Deformation (Global Circumferential Strain, -29.9±4.2 % Versus -32.2±5.0 % [<I>P</I>=0.027]), And Lower Left Ventricular Mass (38.2±7.9 Versus 47.8±11.0 G/M<Sup>2</Sup> [<I>P</I><0.001]). T1 Native Values Were Decreased (936±53 Versus 996±26 Ms [<I>P</I><0.001]), With Particular Low Values In Patients With Phenylalanine >1200 Μmol/L (909±48 Ms). Both Mean Phenylalanine (<I>P</I>=0.013) And Tyrosine (<I>P</I>=0.035) Levels Were Independently Correlated With T1; And In A Multiple Regression Model, Higher Phenylalanine Levels And Higher Left Ventricular Mass Associate With Lower T1. Conclusions Cardiac Phenotype Of Adult Patients With Phenylketonuria Reveals Some Traits Of An Early-Stage Cardiomyopathy. Regular Cardiology Follow-Up, Tighter Therapeutic Control, And Prophylaxis Of Cardiovascular Risk Factors, In Particular Dyslipidemia, Are Recommended.|[('Background', 'no label'), ('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Oxidative Stress', 'no label'), ('Collateral', 'no label'), ('Metabolic Abnormalities', 'no label'), ('Cause', 'no label'), ('Cardiac Structural', 'no label'), ('Functional', 'no label'), ('Modifications', 'no label'), ('Characterize', 'no label'), ('Cardiac', 'no label'), ('Phenotype', 'no label'), ('Adult', 'no label'), ('Subjects', 'no label'), ('Phenylketonuria', 'no label'), ('Advanced Cardiac Imaging', 'no label'), ('Results', 'no label'), ('Thirty-Nine Adult', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Age', 'no label'), ('30.5±8.7\xa0Years', 'no label'), ('Phenylalanine', 'no label'), ('Concentration', 'no label'), ('Sex-Matched', 'no label'), ('Healthy Controls', 'no label'), ('Investigated', 'no label'), ('Participants', 'no label'), ('Comprehensive', 'no label'), ('Cardiac Magnetic Resonance', 'no label'), ('Echocardiography', 'no label'), ('Examination', 'no label'), ('Mean', 'no label'), ('Plasma', 'no label'), ('Levels', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Quantify Disease Activity', 'no label'), ('Adherence', 'no label'), ('Treatment', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Thinner', 'no label'), ('Left Ventricular Walls', 'no label'), ('Septal End-Diastolic Thickness', 'no label'), ('Lateral Thickness', 'no label'), ('Dilated Left Ventricular Cavity', 'no label'), ('End-Diastolic Volume', 'no label'), ('Ml/M', 'no label'), ('Sup>2</Sup> [<I>P</I>=0.0178]', 'no label'), ('End-Systolic Volume', 'no label'), ('Ml/M', 'no label'), ('Sup>2</Sup> [<I>P</I><0.001]', 'no label'), ('Lower Ejection Fraction', 'no label'), ('<I>P</I><0.001]', 'no label'), ('Reduced Systolic Deformation', 'no label'), ('Global Circumferential Strain', 'no label'), ('Versus', 'no label'), ('<I>P</I>=0.027])', 'no label'), ('Lower Left Ventricular Mass', 'no label'), ('G/M<Sup>2</Sup> [<I>P</I><0.001]', 'no label'), ('T1', 'no label'), ('Native', 'no label'), ('Values', 'no label'), ('Decreased', 'no label'), ('Values', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Mean', 'no label'), ('Phenylalanine', 'no label'), ('<I>P</I>=0.013)', 'no label'), ('Tyrosine', 'no label'), ('<I>P</I>=0.035)', 'no label'), ('Levels', 'no label'), ('Correlated', 'no label'), ('T1', 'no label'), ('Multiple Regression Model', 'no label'), ('Higher', 'no label'), ('Phenylalanine', 'no label'), ('Levels', 'no label'), ('Higher', 'no label'), ('Left Ventricular Mass Associate', 'no label'), ('Lower T1', 'no label'), ('Cardiac', 'no label'), ('Phenotype', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Reveals', 'no label'), ('Traits', 'no label'), ('Early-Stage Cardiomyopathy', 'no label'), ('Regular Cardiology Follow-Up', 'no label'), ('Tighter Therapeutic Control', 'no label'), ('Prophylaxis', 'no label'), ('Cardiovascular Risk Factors', 'no label'), ('Dyslipidemia', 'no label'), ('Recommended', 'no label')]|[('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Prophylaxis', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Metabolic Abnormalities', 'no label'), ('Phenylketonuria', 'no label'), ('Thirty-Nine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('924±330', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Thinner Left', 'no label'), ('Septal End-Diastolic Thickness', 'no label'), ('Dilated Left Ventricular Cavity', 'no label'), ('End-Diastolic', 'no label'), ('Left Ventricular Mass (38.2±7.9 Versus 47.8±11.0 G/M', 'no label'), ('Phenylalanine', 'no label'), ('909±48', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Left Ventricular Mass Associate With Lower T1.', 'no label'), ('Phenylketonuria', 'no label'), ('Traits', 'no label'), ('Cardiomyopathy', 'no label'), ('Dyslipidemia', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Amino Acid', 'no label'), ('Stress', 'no label'), ('Collateral', 'no label'), ('Cardiac', 'no label'), ('Phenylketonuria', 'no label'), ('Cardiac', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Cardiac', 'no label'), ('Plasma', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Left Ventricular Walls', 'no label'), ('Mm', 'no label'), ('6.1±1.4 Versus', 'no label'), ('Mm', 'no label'), ('Left Ventricular', 'no label'), ('Sup>2</Sup', 'no label'), ('Sup>2</Sup', 'no label'), ('Sup>2</Sup', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Left Ventricular', 'no label'), ('Lower T1.', 'no label'), ('Cardiac', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Cardiovascular', 'no label')]
phenylketonuria|pubmed~30778886|Phenylketonuria Is A Well-Known Rare Disease Included In The Neonatal Screening Of Many Countries. Therefore, There Are Few Published Data On The Admissions And Costs Of Phenylketonuria In Spain. The Objective Of This Study Was To Assess The Number Of Admissions And The Economic Burden Of Phenylketonuria In Spain. Patients With Phenylketonuria Were Identified From A Spanish Database Containing Data From Public And Private Healthcare Centres From 1997 To 2015. The Parameters Obtained Were Characteristics Of The Patients, Type Of Admissions, Readmissions, Discharges, Length Of Stay, Medical Service, Annual Number Of Visits, Annual Number Of Patients, Visit-Associated Costs And Patient-Associated Costs. Five Hundred And Ninety-Four Patients With Phenylketonuria Were Identified: 48.32% Were Male With A Mean (Standard Deviation) Age Of 4.50 (10.23) Years. The Hospital Admissions Were Divided Into Emergency Visits (55.94%) And Scheduled Visits (43.92%). The Majority Of Patients Were Discharged Home (98.86%). The Mean (Standard Deviation) Duration Of Stay Was 4.04 (4.98) Days. The Number Of Admissions Per Year Ranged Between 13 And 88, With An Average Of 1.18 Admissions Per Patient Per Year. Finally, The Mean Cost Per Visit Increased From €1064.91 To €3709.40, And The Mean Cost Per Patient Increased From €1818.90 To €4239.32 From 1999 To 2015. The Access To Economic And Social Data On Phenylketonuria In Spain Has Been Updated. The Number Of Admissions In Spain Between 1997 And 2015 And Healthcare Costs Between 1999 And 2015 Were Calculated. There Were 24 Admissions As A Result Of A Phenylketonuria Diagnosis In 2015 And The Mean Healthcare Cost Per Patient Was €4239.32. This Information Can Help To Adapt And Improve Each Healthcare System To Take Into Consideration Rare Diseases.|[('Phenylketonuria', 'no label'), ('Well-Known Rare Disease', 'no label'), ('Neonatal', 'no label'), ('Screening', 'no label'), ('Countries', 'no label'), ('Published Data', 'no label'), ('Admissions', 'no label'), ('Costs', 'no label'), ('Phenylketonuria', 'no label'), ('Spain', 'no label'), ('Study', 'no label'), ('Admissions', 'no label'), ('Economic Burden', 'no label'), ('Phenylketonuria', 'no label'), ('Spain', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Spanish', 'no label'), ('Database', 'no label'), ('Data', 'no label'), ('Public', 'no label'), ('Parameters', 'no label'), ('Obtained', 'no label'), ('Characteristics', 'no label'), ('Patients', 'no label'), ('Type Of Admissions', 'no label'), ('Readmissions', 'no label'), ('Discharges', 'no label'), ('Length Of Stay, Medical Service', 'no label'), ('Annual Number', 'no label'), ('Visits', 'no label'), ('Annual Number', 'no label'), ('Patients', 'no label'), ('Visit-Associated Costs', 'no label'), ('Patient-Associated Costs', 'no label'), ('Ninety-Four Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Male With A Mean (Standard Deviation', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('Hospital Admissions', 'no label'), ('Scheduled', 'no label'), ('Patients', 'no label'), ('Discharged Home', 'no label'), ('Mean', 'no label'), ('Standard Deviation', 'no label'), ('Duration', 'no label'), ('Days', 'no label'), ('Admissions', 'no label'), ('Ranged\xa0', 'no label'), ('Admissions', 'no label'), ('Per Year', 'no label'), ('Cost Per Visit', 'no label'), ('Increased', 'no label'), ('Mean', 'no label'), ('Cost', 'no label'), ('Patient', 'no label'), ('Increased', 'no label'), ('Access', 'no label'), ('Economic', 'no label'), ('Social Data', 'no label'), ('Phenylketonuria', 'no label'), ('Spain', 'no label'), ('Admissions', 'no label'), ('Spain', 'no label'), ('Healthcare Costs', 'no label'), ('Calculated', 'no label'), ('Admissions', 'no label'), ('Phenylketonuria', 'no label'), ('Diagnosis', 'no label'), ('Mean Healthcare Cost', 'no label'), ('Patient', 'no label'), ('Information', 'no label'), ('Adapt', 'no label'), ('Improve', 'no label'), ('Healthcare System', 'no label'), ('Diseases', 'no label')]|[('Phenylketonuria Is A', 'no label')]|[('Per', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria Diagnosis', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Type', 'no label'), ('Patients', 'no label'), ('Ninety-Four Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patient', 'no label'), ('Phenylketonuria', 'no label'), ('Healthcare Costs Between 1999 And', 'no label'), ('Phenylketonuria', 'no label'), ('Patient', 'no label')]
phenylketonuria|pubmed~33093221|To Evaluate The Relationship Between Circulating Phenylalanine And Brain Function As Well As Neuropsychiatric Symptoms In Adults With Phenylketonuria. In This Prospective Cross-Sectional Study, Early-Treated Patients With Phenylketonuria Older Than 30 Years And Age- And Sex-Matched Controls Were Included. Extensive Neurologic Evaluation, Neuropsychological And Behavioral Testing, Sensory And Motor Evoked Potentials, And Mri Were Performed. Csf Concentrations Of Neurodegenerative Markers Were Evaluated In Addition In A Subset Of 10 Patients. Nineteen Patients With Phenylketonuria (Median Age 41 Years) With Different Phenylalanine Levels (Median 873 Μmol/L) Entered The Study. They Showed Higher Prevalence Of Neurologic Symptoms, Cognitive And Behavioral Abnormalities, Autonomic Dysfunction, Alterations In Neurophysiologic Measures, And Atrophy In Putamen And Right Thalamus Compared To Controls. In Csf, Patients With Phenylketonuria Exhibited Higher Β-Amyloid 1-42 (<I>P</I> = 0.003), Total Tau (<I>P</I> < 0.001), And Phosphorylated Tau (<I>P</I> = 0.032) Levels Compared To Controls. Plasma Phenylalanine Levels Highly Correlated With The Number Of Failed Neuropsychological Tests (<I>R</I> = 0.64, <I>P</I> = 0.003), Neuropsychiatric Symptoms (<I>R</I> = 0.73, <I>P</I> < 001), Motor Evoked Potential Latency (<I>R</I> = 0.48, <I>P</I> = 0.030), And Parietal Lobe Atrophy. Our Study Provides Strong Evidence For A Correlation Between Phenylalanine Levels And Clinical, Neuropsychological, Neurophysiologic, Biochemical, And Imaging Alterations In Adult Patients With Phenylketonuria.|[('Evaluate', 'no label'), ('Relationship', 'no label'), ('Circulating', 'no label'), ('Phenylalanine', 'no label'), ('Brain Function', 'no label'), ('Neuropsychiatric Symptoms', 'no label'), ('Adults', 'no label'), ('Phenylketonuria', 'no label'), ('Prospective Cross-Sectional Study', 'no label'), ('Early-Treated Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Sex-Matched Controls', 'no label'), ('Neurologic Evaluation', 'no label'), ('Neuropsychological', 'no label'), ('Behavioral Testing', 'no label'), ('Sensory And Motor Evoked Potentials', 'no label'), ('Mri', 'no label'), ('Csf', 'no label'), ('Concentrations', 'no label'), ('Neurodegenerative Markers', 'no label'), ('Evaluated', 'no label'), ('Subset', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Median Age', 'no label'), ('Years', 'no label'), ('Phenylalanine Levels', 'no label'), ('Median', 'no label'), ('Entered', 'no label'), ('Study', 'no label'), ('Higher', 'no label'), ('Prevalence', 'no label'), ('Neurologic Symptoms', 'no label'), ('Cognitive', 'no label'), ('Behavioral Abnormalities', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Alterations', 'no label'), ('Neurophysiologic Measures', 'no label'), ('Atrophy', 'no label'), ('Putamen', 'no label'), ('Right Thalamus', 'no label'), ('Controls', 'no label'), ('Csf', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Higher', 'no label'), ('Tau', 'no label'), ('<I>P</I> < 0.001', 'no label'), ('Phosphorylated', 'no label'), ('Tau', 'no label'), ('<I>P</I>', 'no label'), ('Levels', 'no label'), ('Controls', 'no label'), ('Plasma', 'no label'), ('Phenylalanine', 'no label'), ('Levels', 'no label'), ('Correlated', 'no label'), ('Failed Neuropsychological Tests', 'no label'), ('<I>R</I>', 'no label'), ('Neuropsychiatric Symptoms', 'no label'), ('<I>R</I>', 'no label'), ('Motor Evoked Potential Latency', 'no label'), ('<I>R</I>', 'no label'), ('Parietal Lobe Atrophy', 'no label'), ('Study', 'no label'), ('Provides', 'no label'), ('Evidence', 'no label'), ('Correlation', 'no label'), ('Phenylalanine Levels', 'no label'), ('Clinical', 'no label'), ('Neuropsychological', 'no label'), ('Neurophysiologic', 'no label'), ('Biochemical', 'no label'), ('Imaging Alterations', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tau', 'no label'), ('Tau', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Tau', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Atrophy', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Parietal Lobe Atrophy', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label')]|[('Circulating Phenylalanine', 'no label'), ('Brain', 'no label'), ('Neuropsychiatric', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Putamen', 'no label'), ('Csf', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Β-Amyloid 1', 'no label'), ('Tau', 'no label'), ('Tau', 'no label'), ('Plasma Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~33570037|Phenylketonuria Is An Inherited Metabolic Disease, Of Autosomal Recessive Transmission, Due To The Enzymatic Deficit Of Phenylalanine Hydroxylase, Which Transforms Phenylalanine Into Tyrosine. The Deficit Leads To An Increase In Phenylalanine And Its Metabolite, Phenylpyruvic Acid Which Is Responsible For The Toxicity And Symptomatology Characterized By Serious Neurological Disorders. Through This Work, We Wanted To Show: 1) The Profile Of Phenylalanine Concentrations In A Cohort Of 52 Moroccan Phenylketonuric Patients Diagnosed In Our Laboratory By Tandem Mass Spectrometry Coupled With Hplc; 2) The Value Of Biological Monitoring In The Nutritional Management Of Phenylketonuric Patients. The Results Showed That Phenylketonuria Diagnosed In Morocco Is Characterized By A Predominance Of Classic And Moderate Phenylketonuria In Both Sexes With A Median Concentration = 1,107 Μmol/L, 26 Times Higher Than That Observed In The Control Group (Median Value = 42 Μmol/L - P < 0.0001). The Phenylalanine And Tyrosine Concentrations Of 33 Phenylketonuric Patients Regularly Monitored By Our Laboratory Highlights The Effectiveness Of The Hypoproteic Diet With A Marked Improvement In Psychomotor Development, A Significant Regression In Behavioral Disorders And An Encouraging Overall Development Of Children. Conclusion: Phenylketonuria Is A Disease That Would Be Frequent In Morocco But It Is Still Diagnosed At The Stage Of Severe Mental Retardation. A Better Management Of These Patients Could Be Considered When Setting Up A Nation-Wide Neonatal Screening Program.|[('Phenylketonuria', 'no label'), ('Inherited Metabolic Disease', 'no label'), ('Autosomal Recessive Transmission', 'no label'), ('Enzymatic Deficit', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Transforms Phenylalanine Into', 'no label'), ('Tyrosine', 'no label'), ('Deficit Leads', 'no label'), ('Increase', 'no label'), ('Phenylalanine', 'no label'), ('Metabolite', 'no label'), ('Phenylpyruvic Acid', 'no label'), ('Toxicity', 'no label'), ('Symptomatology', 'no label'), ('Characterized', 'no label'), ('Serious Neurological Disorders', 'no label'), ('Work', 'no label'), ('Profile', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Cohort', 'no label'), ('Moroccan', 'no label'), ('Phenylketonuric', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Laboratory', 'no label'), ('Coupled', 'no label'), ('Hplc', 'no label'), ('Value', 'no label'), ('Biological Monitoring', 'no label'), ('Nutritional Management', 'no label'), ('Phenylketonuric', 'no label'), ('Patients', 'no label'), ('Results', 'no label'), ('Phenylketonuria', 'no label'), ('Diagnosed', 'no label'), ('Morocco', 'no label'), ('Characterized', 'no label'), ('Predominance', 'no label'), ('Classic', 'no label'), ('Moderate', 'no label'), ('Phenylketonuria', 'no label'), ('Sexes', 'no label'), ('Median', 'no label'), ('Concentration', 'no label'), ('Higher', 'no label'), ('Observed', 'no label'), ('Control Group', 'no label'), ('Median Value', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Concentrations', 'no label'), ('Phenylketonuric', 'no label'), ('Patients', 'no label'), ('Laboratory', 'no label'), ('Effectiveness', 'no label'), ('Hypoproteic Diet', 'no label'), ('Marked Improvement', 'no label'), ('Psychomotor Development', 'no label'), ('Significant', 'no label'), ('Regression', 'no label'), ('Behavioral Disorders', 'no label'), ('Development', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Frequent', 'no label'), ('Morocco', 'no label'), ('Diagnosed', 'no label'), ('Stage', 'no label'), ('Severe', 'no label'), ('Mental Retardation', 'no label'), ('Better Management', 'no label'), ('Patients', 'no label'), ('Up A', 'no label'), ('Nation-Wide', 'no label'), ('Screening Program', 'no label')]|[('Enzymatic', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Inherited Metabolic Disease', 'no label'), ('Autosomal Recessive', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Toxicity', 'no label'), ('Neurological Disorders', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Behavioral Disorders', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Deficit', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Morocco', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Patients', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Morocco', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~33932386|Phenylketonuria Is A Rare Disorder That Increases The Levels Of Phenylalanine In The Blood. As There Are Scant Articles About Anesthesia Management In Phenylketonuria Patients, This Encouraged Us To Report A Short-Time Anesthesia Management Of A Child With Phenylketonuria For Bone Fracture. The Anesthesia Was Induced With Intravenous Ketamine And Midazolam. During Procedure, He Received 100% Oxygen Via A Face Mask Throughout Spontaneous Breathing. The Operation Was Uneventful, And He Was Completely Awakened In The Recovery Room. This Report Emphasizes That In Some Situations, The Combination Of Midazolam With Ketamine Could Be Used Safely For Short Time Anesthesia In Phenylketonuria Patients.|[('Phenylketonuria', 'no label'), ('Rare', 'no label'), ('Increases', 'no label'), ('Levels', 'no label'), ('Phenylalanine', 'no label'), ('Blood', 'no label'), ('Scant Articles', 'no label'), ('Anesthesia', 'no label'), ('Management', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Management', 'no label'), ('Child', 'no label'), ('Phenylketonuria', 'no label'), ('Bone Fracture', 'no label'), ('Anesthesia', 'no label'), ('Induced', 'no label'), ('Intravenous', 'no label'), ('Ketamine', 'no label'), ('Midazolam', 'no label'), ('Procedure', 'no label'), ('Oxygen', 'no label'), ('Face Mask', 'no label'), ('Spontaneous', 'no label'), ('Breathing', 'no label'), ('Operation', 'no label'), ('Uneventful', 'no label'), ('Was Completely', 'no label'), ('Recovery', 'no label'), ('Room', 'no label'), ('Report', 'no label'), ('Emphasizes', 'no label'), ('Situations', 'no label'), ('Combination', 'no label'), ('Midazolam', 'no label'), ('Ketamine', 'no label'), ('Short Time Anesthesia', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Oxygen', 'no label'), ('Midazolam', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Fracture', 'no label'), ('Ketamine', 'no label'), ('Midazolam', 'no label'), ('Oxygen', 'no label'), ('Midazolam', 'no label'), ('Ketamine', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Blood', 'no label'), ('Anesthesia', 'no label'), ('Phenylketonuria Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Bone', 'no label'), ('Intravenous Ketamine', 'no label'), ('Midazolam', 'no label'), ('Oxygen', 'no label'), ('A Face', 'no label'), ('Midazolam', 'no label'), ('Ketamine', 'no label'), ('Phenylketonuria Patients', 'no label')]
phenylketonuria|pubmed~35270292|The Authors Present A Case Report Of A Boy With A Classical Form Of Phenylketonuria And Alazami Syndrome. The Inborn Error Of Phenylalanine Metabolism Was Diagnosed In The Neonatal Period Based On Population New-Born Screening. Despite Early Implementation Of A Low-Phenylalanine Diet And Good Biochemical Control, The Patient Developed Behavioural Disorders And Intellectual Disability. He Also Presented With Dysmorphic Features. After Long And Extensive Attempts To Establish The Genetic Cause Of This Unusual Phenotype, Finally, At The Age Of 16 The Boy Was Diagnosed With Alazami Syndrome Based On Whole Exome Sequencing. The Authors Discussed The Problem Of Neuropsychological Disorders In Patients With Phenylketonuria And Described Typical Clinical Symptoms Of Alazami Syndrome. It Was Emphasized That The Presence Of One Monogenic Disease Does Not Exclude The Coexistence Of Another One.|[('Case Report', 'no label'), ('Boy With A Classical Form', 'no label'), ('Phenylketonuria', 'no label'), ('Alazami Syndrome', 'no label'), ('Inborn Error', 'no label'), ('Phenylalanine Metabolism', 'no label'), ('Diagnosed', 'no label'), ('Neonatal', 'no label'), ('Period', 'no label'), ('Population New-Born', 'no label'), ('Screening', 'no label'), ('Early Implementation', 'no label'), ('Low-Phenylalanine Diet', 'no label'), ('Good', 'no label'), ('Biochemical Control', 'no label'), ('Patient Developed', 'no label'), ('Behavioural Disorders', 'no label'), ('Intellectual Disability', 'no label'), ('Dysmorphic Features', 'no label'), ('Long And Extensive Attempts', 'no label'), ('Establish', 'no label'), ('Genetic Cause', 'no label'), ('Unusual', 'no label'), ('Phenotype', 'no label'), ('Age', 'no label'), ('Boy Was', 'no label'), ('Diagnosed', 'no label'), ('Alazami Syndrome', 'no label'), ('Whole Exome Sequencing', 'no label'), ('Problem', 'no label'), ('Neuropsychological Disorders', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Clinical Symptoms', 'no label'), ('Alazami Syndrome', 'no label'), ('Emphasized', 'no label'), ('Presence', 'no label'), ('Monogenic Disease', 'no label'), ('Coexistence', 'no label')]|[('Phenylalanine', 'no label'), ('Genetic', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Behavioural Disorders And Intellectual Disability', 'no label'), ('Neuropsychological Disorders', 'no label'), ('Phenylketonuria', 'no label'), ('Monogenic Disease', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Low-Phenylalanine', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~29175141|Phenylketonuria Treatment Mainly Consists Of A Phenylalanine-Restricted Diet But Still Results In Suboptimal Neuropsychological Outcome, Which Is At Least Partly Based On Cerebral Monoamine Deficiencies, While, After Childhood, Treatment Compliance Decreases. Supplementation Of Large Neutral Amino Acids (Lnaas) Was Previously Demonstrated In Young Phenylketonuria Mice To Target All Three Biochemical Disturbances Underlying Brain Dysfunction In Phenylketonuria. However, Both Its Potential In Adult Phenylketonuria And The Comparison With The Phenylalanine-Restricted Diet Remain To Be Established. To This Purpose, Several Lnaa Supplements Were Compared With A Severe Phenylalanine-Restricted Diet With Respect To Brain Monoamine And Amino Acid Concentrations In Adult C57Bl/6 Pah-Enu2 Mice. Adult Phenylketonuria Mice Received A Phenylalanine-Restricted Diet, Unrestricted Diet Supplemented With Several Combinations Of Lnaas Or Ain-93M Control Diet For 6 Weeks. In Addition, Adult Wild-Type Mice On Ain-93M Diet Served As Controls. The Severe Phenylalanine-Restricted Diet In Adult Phenylketonuria Mice Significantly Reduced Plasma And Brain Phenylalanine And Restored Brain Monoamine Concentrations, While Brain Concentrations Of Most Nonphenylalanine Lnaas Remained Subnormal. Supplementation Of Eight Lnaas Was Similarly Effective As The Severe Phenylalanine-Restricted Diet To Restore Brain Monoamines, While Brain And Plasma Phenylalanine Concentrations Remained Markedly Elevated. These Results Provide Biochemical Support For The Effectiveness Of The Severe Phenylalanine-Restricted Diet And Showed The Possibilities Of Lnaa Supplementation Being Equally Effective To Restore Brain Monoamines In Adult Phenylketonuria Mice. Therefore, Lnaa Supplementation Is A Promising Alternative Treatment To Phenylalanine Restriction In Adult Phenylketonuria Patients To Further Optimize Neuropsychological Functioning.|[('Phenylketonuria', 'no label'), ('Treatment', 'no label'), ('Consists', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Suboptimal', 'no label'), ('Neuropsychological Outcome', 'no label'), ('Cerebral Monoamine Deficiencies', 'no label'), ('Childhood', 'no label'), ('Treatment', 'no label'), ('Compliance', 'no label'), ('Decreases', 'no label'), ('Supplementation', 'no label'), ('Neutral Amino Acids', 'no label'), ('Lnaas', 'no label'), ('Young Phenylketonuria', 'no label'), ('Mice', 'no label'), ('Target', 'no label'), ('Biochemical', 'no label'), ('Disturbances', 'no label'), ('Brain Dysfunction', 'no label'), ('Phenylketonuria', 'no label'), ('Potential', 'no label'), ('Adult', 'no label'), ('Phenylketonuria', 'no label'), ('Comparison', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Remain', 'no label'), ('Lnaa Supplements', 'no label'), ('Severe', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Respect', 'no label'), ('Brain', 'no label'), ('Monoamine', 'no label'), ('Amino Acid', 'no label'), ('Concentrations', 'no label'), ('Adult', 'no label'), ('C57Bl/6 Pah-Enu2', 'no label'), ('Mice', 'no label'), ('Adult', 'no label'), ('Phenylketonuria Mice', 'no label'), ('Received', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Unrestricted Diet', 'no label'), ('Supplemented', 'no label'), ('Combinations', 'no label'), ('Lnaas', 'no label'), ('Ain-93M', 'no label'), ('Weeks', 'no label'), ('Adult', 'no label'), ('Wild-Type Mice', 'no label'), ('Ain-93M Diet Served', 'no label'), ('Controls', 'no label'), ('Severe Phenylalanine-Restricted Diet', 'no label'), ('Adult', 'no label'), ('Phenylketonuria Mice', 'no label'), ('Reduced', 'no label'), ('Plasma', 'no label'), ('Brain Phenylalanine', 'no label'), ('Restored', 'no label'), ('Brain', 'no label'), ('Monoamine Concentrations', 'no label'), ('Brain', 'no label'), ('Concentrations', 'no label'), ('Nonphenylalanine Lnaas', 'no label'), ('Remained', 'no label'), ('Subnormal', 'no label'), ('Supplementation', 'no label'), ('Lnaas', 'no label'), ('Effective', 'no label'), ('Severe Phenylalanine-Restricted Diet', 'no label'), ('Restore Brain', 'no label'), ('Monoamines', 'no label'), ('Brain', 'no label'), ('Plasma', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Remained', 'no label'), ('Markedly', 'no label'), ('Elevated', 'no label'), ('Results', 'no label'), ('Biochemical', 'no label'), ('Effectiveness', 'no label'), ('Severe Phenylalanine-Restricted Diet', 'no label'), ('Possibilities', 'no label'), ('Lnaa Supplementation Being', 'no label'), ('Restore', 'no label'), ('Brain Monoamines', 'no label'), ('Adult', 'no label'), ('Phenylketonuria Mice', 'no label'), ('Lnaa Supplementation', 'no label'), ('Alternative', 'no label'), ('Treatment', 'no label'), ('Phenylalanine Restriction', 'no label'), ('Adult', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Optimize Neuropsychological Functioning', 'no label')]|[('Monoamine', 'no label'), ('Amino Acids', 'no label'), ('Mice', 'no label'), ('Monoamine', 'no label'), ('Amino Acid', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Phenylalanine', 'no label'), ('Monoamine', 'no label'), ('Monoamines', 'no label'), ('Phenylalanine', 'no label'), ('Monoamines', 'no label'), ('Mice', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Cerebral Monoamine Deficiencies', 'no label'), ('Amino Acids', 'no label'), ('Phenylketonuria', 'no label'), ('Brain Dysfunction', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Cerebral Monoamine Deficiencies', 'no label'), ('Amino Acids', 'no label'), ('Brain', 'no label'), ('Phenylketonuria', 'no label'), ('Lnaa', 'no label'), ('Brain Monoamine', 'no label'), ('Amino Acid', 'no label'), ('C57Bl/6 Pah-Enu2', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Plasma', 'no label'), ('Brain Phenylalanine', 'no label'), ('Brain Monoamine', 'no label'), ('Brain', 'no label'), ('Nonphenylalanine', 'no label'), ('Brain', 'no label'), ('Plasma Phenylalanine', 'no label'), ('Lnaa', 'no label'), ('Brain Monoamines', 'no label'), ('Lnaa', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria Patients', 'no label')]
phenylketonuria|pubmed~31237171|<B>Background:</B> Phenylketonuria Is A Well-Known Disease, Yet The Characteristics Of The Affected Population And Their Use Of Healthcare Resources Have Not Been Comprehensively Evaluated. Patient Characteristics And Use Of Resources Are Subjects Of Interest For Most Governments, Especially For A Disease Included In Newborn Screening Programs. <B>Objective:</B> The Aim Of This Study Was To Determine Characteristics And Use Of Healthcare Resources Of Patients With Phenylketonuria In The Region Of Catalonia. <B>Methods:</B> Records Of 289 Patients Admitted With Phenylketonuria Between 2007 And 2017 Were Extracted From The Padris Database That Includes Admission Data From Primary Care Centers, Hospitals (Inpatient And Outpatient Care), Extended Care Facilities, And Mental Health Centers. <B>Results:</B> The Patient Population Was Composed Of 140 Male Patients And 149 Female Patients, And 102 Patients Were Registered Via Newborn Screening During The Study Period. Patients Were Admitted On Average 2.19 Times Per Year, Mostly Into Primary Care Centers Which Concentrated The Largest Portion Of Direct Medical Expenses. Similar Percentages Of Urgent And Scheduled Admissions Were Registered Both In Primary Care And Hospitals. Annual Direct Medical Cost Of Treating Patients With Phenylketonuria Was €667 Per Patient. Finally, 66.80% Of The Patients Suffered From Chronic Conditions Affecting Two Or More Systems, Likely To Correspond To A Wide Variety Of Conditions. <B>Conclusions:</B> Altogether, Phenylketonuria Patient Demographics And Direct Medical Costs In Catalonia Have Been Revised. Patients Diagnosed With Phenylketonuria Appeared 1.3-Times More Likely To Suffer From Chronic Conditions In Distinct Organ Systems, Which Is Expected To Have An Effect On Their Use Of Healthcare Resources. These Results Support The Need To Adapt And Improve The Healthcare System, Taking Multimorbidity Into Consideration In An Effort To Control The Medical Expenses Derived.|[('Background:</B', 'no label'), ('Phenylketonuria', 'no label'), ('Characteristics', 'no label'), ('Affected Population', 'no label'), ('Healthcare Resources', 'no label'), ('Have Not', 'no label'), ('Comprehensively Evaluated', 'no label'), ('Patient', 'no label'), ('Characteristics', 'no label'), ('Resources', 'no label'), ('Subjects', 'no label'), ('Governments', 'no label'), ('Disease', 'no label'), ('Newborn Screening Programs', 'no label'), ('Objective:</B', 'no label'), ('Study', 'no label'), ('Characteristics', 'no label'), ('Healthcare Resources', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Region', 'no label'), ('Catalonia', 'no label'), ('Records', 'no label'), ('Patients', 'no label'), ('Admitted With', 'no label'), ('Phenylketonuria', 'no label'), ('Padris Database', 'no label'), ('Admission Data', 'no label'), ('Primary Care Centers', 'no label'), ('Hospitals', 'no label'), ('Inpatient', 'no label'), ('Extended Care Facilities', 'no label'), ('Mental Health Centers', 'no label'), ('Results:</B', 'no label'), ('Patient Population', 'no label'), ('Male', 'no label'), ('Patients', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Registered', 'no label'), ('Study', 'no label'), ('Period', 'no label'), ('Patients', 'no label'), ('Admitted', 'no label'), ('Per Year', 'no label'), ('Primary Care Centers', 'no label'), ('Portion', 'no label'), ('Direct Medical Expenses', 'no label'), ('Urgent', 'no label'), ('Primary Care', 'no label'), ('Hospitals', 'no label'), ('Direct Medical Cost', 'no label'), ('Treating', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Per Patient', 'no label'), ('Patients', 'no label'), ('Suffered', 'no label'), ('Chronic Conditions Affecting', 'no label'), ('Systems', 'no label'), ('Conditions', 'no label'), ('Conclusions:</B', 'no label'), ('Phenylketonuria', 'no label'), ('Patient', 'no label'), ('Demographics', 'no label'), ('Direct Medical Costs', 'no label'), ('Catalonia', 'no label'), ('Revised', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Phenylketonuria', 'no label'), ('Appeared', 'no label'), ('Chronic Conditions', 'no label'), ('Organ Systems', 'no label'), ('Effect', 'no label'), ('Healthcare Resources', 'no label'), ('Results', 'no label'), ('Adapt', 'no label'), ('Improve', 'no label'), ('Healthcare System', 'no label'), ('Multimorbidity', 'no label'), ('Effort', 'no label'), ('Medical Expenses', 'no label')]|[('Phenylketonuria Is A', 'no label'), ('Region', 'no label'), ('1.3-Times', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('140', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Multimorbidity', 'no label')]|[('B', 'no label'), ('Phenylketonuria', 'no label'), ('B', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('B', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Primary Care Centers', 'no label'), ('B', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Concentrated', 'no label'), ('Primary Care', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('B', 'no label'), ('Conclusions:</B', 'no label'), ('Phenylketonuria Patient', 'no label'), ('Patients', 'no label'), ('Phenylketonuria Appeared 1.3-Times', 'no label')]
phenylketonuria|pubmed~32281643|Parents Of Children With Phenylketonuria Are At Risk Of Reduced Quality Of Life. This Study Determined The Quality Of Life Of Parents Of Children With Phenylketonuria In Tehran Province. The Study Was Conducted In 2015 And Included Parents Of Children With Phenylketonuria Referred To Three Government Children'S Hospitals In Tehran Province That Provide Phenylketonuria Services. Data Were Collected Using The Farsi Version Of The World Health Organization Quality Of Life-Bref Questionnaire. Analysis Of Variance, T-Test, Pearson Correlation Coefficient And Multiple Linear Regression Were Used To Assess The Relationship Between Quality Of Life Domains And Sociodemographic Characteristics Of The Parent And Child. The Study Included 240 Parents; 55% Were Mothers. Quality Of Life Of Parents In Psychological, Social Relationships And Environment Domains Was Low. Significant Relationships Were Found Between: Physical Domain And Age Of Child At Phenylketonuria Diagnosis (P = 0.044); Psychological Domain And Parent'S Age (P = 0.019), Child'S Age (P = 0.007) And Parent'S Education (P = 0.015); Social Relationships Domain And Parent'S Age (P = 0.003), And Education (P = 0.002), Household Income (P = 0.025) And Child'S Age (P = 0.004; And Environmental Domain And Residence (P = 0.034), Parent'S Education (P = 0.007), Household Income (P = 0.002) And Child'S Age (P = 0.049). In The Multivariable Analysis, Parent'S Age And Education, Child'S Age, And Household Income Were Significantly Associated With Parent'S Quality Of Life. Given The Low Levels Of Quality Of Life In The Parents, Education And More Financial Support Are Recommended.|"[('Parents', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Risk', 'no label'), ('Reduced', 'no label'), ('Quality Of Life', 'no label'), ('Study', 'no label'), ('Quality', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Tehran Province', 'no label'), ('Study', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Phenylketonuria Referred', 'no label'), ('Government', 'no label'), (""Children'S Hospitals"", 'no label'), ('Tehran Province', 'no label'), ('Phenylketonuria Services', 'no label'), ('Data', 'no label'), ('Collected', 'no label'), ('Farsi Version', 'no label'), ('World Health Organization Quality Of Life-Bref Questionnaire', 'no label'), ('Analysis', 'no label'), ('Variance', 'no label'), ('T-Test', 'no label'), ('Pearson Correlation Coefficient And Multiple Linear Regression', 'no label'), ('Assess', 'no label'), ('Relationship', 'no label'), ('Quality', 'no label'), ('Sociodemographic Characteristics', 'no label'), ('Parent', 'no label'), ('Child', 'no label'), ('Study', 'no label'), ('Parents', 'no label'), ('Mothers', 'no label'), ('Quality Of Life', 'no label'), ('Parents', 'no label'), ('Psychological', 'no label'), ('Social Relationships', 'no label'), ('Environment Domains', 'no label'), ('Significant', 'no label'), ('Relationships', 'no label'), ('Physical Domain', 'no label'), ('Age', 'no label'), ('Child', 'no label'), ('Phenylketonuria Diagnosis', 'no label'), ('Psychological Domain', 'no label'), (""Parent'S"", 'no label'), ('Age', 'no label'), (""Child'S Age"", 'no label'), (""Parent'S Education"", 'no label'), ('Social Relationships Domain', 'no label'), (""Parent'S"", 'no label'), ('Age', 'no label'), ('Education', 'no label'), ('Household Income', 'no label'), (""Child'S Age"", 'no label'), ('Environmental Domain', 'no label'), ('Residence', 'no label'), (""Parent'S Education"", 'no label'), ('Household Income', 'no label'), (""Child'S Age"", 'no label'), ('Multivariable Analysis', 'no label'), (""Parent'S"", 'no label'), ('Age', 'no label'), ('Education', 'no label'), (""Child'S Age"", 'no label'), ('Household Income', 'no label'), ('Associated With', 'no label'), (""Parent'S"", 'no label'), ('Quality Of Life', 'no label'), ('Low', 'no label'), ('Levels', 'no label'), ('Quality Of Life', 'no label'), ('Parents', 'no label'), ('Education', 'no label'), ('Financial Support', 'no label'), ('Recommended', 'no label')]"|[('Domain', 'no label'), ('Domain', 'no label'), ('Domain', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria Referred', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria Diagnosis', 'no label')]|[('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~29473999|Identifying Novel Melanoma Genetic Risk Factors Informs Screening And Prevention Efforts. Mutations In The Phenylalanine Hydroxylase Gene (The Causative Gene In Phenylketonuria) Lead To Reduced Pigmentation In Untreated Phenylketonuria Patients, And Reduced Pigmentation Is Associated With Greater Melanoma Risk. Therefore, We Sought To Characterize The Relationship Between Phenylketonuria Carrier Status And Melanoma Risk. Using National Newborn Screening Reports, We Determined The United States Phenylketonuria/Hyperphenylalanemia Carrier Frequency In Caucasians To Be 1.76%. We Examined Three Publically Available Melanoma Datasets For Germline Mutations In The Phenylalanine Hydroxylase Gene Associated With Classic Phenylketonuria And/Or Hyperphenylalanemia. Mutations Were Identified In 29/814 Melanoma Patients, With A Carrier Frequency Of 3.56%. There Was A Twofold Enrichment (P-Value = 3.4 × 10<Sup>-5</Sup> ) Compared To The Caucasian Frequency Of Hyperphenylalanemia/Phenylketonuria Carriers. These Data Demonstrate A Novel Association Between Phenylalanine Hydroxylase Carrier Status And Melanoma Risk. Further, Functional Investigation Is Warranted To Determine The Link Between Phenylalanine Hydroxylase Mutations And Melanomagenesis.|[('Novel', 'no label'), ('Melanoma', 'no label'), ('Genetic Risk Factors', 'no label'), ('Informs', 'no label'), ('Screening', 'no label'), ('Prevention', 'no label'), ('Mutations', 'no label'), ('Phenylalanine Hydroxylase Gene', 'no label'), ('Causative Gene', 'no label'), ('Phenylketonuria', 'no label'), ('Lead', 'no label'), ('Reduced', 'no label'), ('Pigmentation', 'no label'), ('Untreated Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Reduced', 'no label'), ('Pigmentation', 'no label'), ('Associated With', 'no label'), ('Melanoma', 'no label'), ('Risk', 'no label'), ('Characterize', 'no label'), ('Relationship', 'no label'), ('Phenylketonuria Carrier Status', 'no label'), ('Melanoma', 'no label'), ('Risk', 'no label'), ('National Newborn Screening Reports', 'no label'), ('United States', 'no label'), ('Phenylketonuria/Hyperphenylalanemia', 'no label'), ('Carrier Frequency', 'no label'), ('Caucasians', 'no label'), ('Publically Available', 'no label'), ('Melanoma', 'no label'), ('Datasets', 'no label'), ('Germline Mutations', 'no label'), ('Phenylalanine Hydroxylase Gene', 'no label'), ('Associated With', 'no label'), ('Classic Phenylketonuria And/Or', 'no label'), ('Hyperphenylalanemia', 'no label'), ('Mutations', 'no label'), ('Identified', 'no label'), ('Melanoma', 'no label'), ('Patients', 'no label'), ('A Carrier Frequency', 'no label'), ('Enrichment', 'no label'), ('P-Value\xa0', 'no label'), ('Caucasian', 'no label'), ('Frequency', 'no label'), ('Hyperphenylalanemia/Phenylketonuria Carriers', 'no label'), ('Data Demonstrate', 'no label'), ('Association', 'no label'), ('Phenylalanine Hydroxylase Carrier Status', 'no label'), ('Melanoma', 'no label'), ('Risk', 'no label'), ('Functional Investigation', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Mutations', 'no label'), ('Melanomagenesis', 'no label')]|[('Genetic', 'no label'), ('Mutations', 'no label'), ('Phenylalanine', 'no label'), ('Gene', 'no label'), ('Gene', 'no label'), ('Phenylketonuria', 'no label'), ('Lead', 'no label'), ('Mutations', 'no label'), ('Phenylalanine', 'no label'), ('Gene', 'no label'), ('Phenylketonuria And/Or', 'no label'), ('Mutations', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Mutations', 'no label')]|[('Phenylalanine Hydroxylase Gene', 'no label'), ('Causative Gene', 'no label'), ('Germline Mutations', 'no label'), ('Phenylalanine Hydroxylase Gene', 'no label')]|[('Melanoma', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Melanoma', 'no label'), ('Phenylketonuria Carrier Status And', 'no label'), ('Melanoma', 'no label'), ('Melanoma', 'no label'), ('Phenylalanine', 'no label'), ('And/Or Hyperphenylalanemia', 'no label'), ('Melanoma', 'no label'), ('Phenylalanine', 'no label'), ('Melanoma', 'no label'), ('Phenylalanine', 'no label')]|[('Melanoma', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria Patients', 'no label'), ('Melanoma', 'no label'), ('Melanoma', 'no label'), ('Carrier', 'no label'), ('Caucasians', 'no label'), ('Be 1.76', 'no label'), ('Melanoma', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Melanoma Patients', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Melanoma', 'no label'), ('Link', 'no label'), ('Phenylalanine Hydroxylase', 'no label')]
phenylketonuria|pubmed~29153021|Starting From 1975 Phenylketonuria Is Part Of The Newborn Screening Program In Hungary. Since Then A Generation, Treated With Special Diet And Medical Foods Right After Neonatal Diagnosis Has Reached Adulthood. Thanks To Early Treatment Initiation, Children With Phenylketonuria Are Able To Lead Life To The Full. Consequently, Phenylketonuria Is No Longer Considered A Pediatric Disease. Follow Up Of Adult Patients With Phenylketonuria Is Performed In Internal Medicine Centers Specialized In Metabolic Diseases. The Outcome Of The Lifelong Special Treatment, And The Particularities Of Phenylketonuria In Adulthood Are Yet To Be Determined. The Aim Of Our Review Is To Present Recent Findings In Phenylketonuria Focusing Mainly On The Adult Care. After Long Time The First International Guidelines Appeared, New Therapies Were Put In Use, And These Current Developments Are Expected To Be Implemented In Daily Practice In The Near Future. New Challenges Must Be Met Such As Maternal Phenylketonuria, Long Term Effects Of Dietotherapy And The Sequelae Of Untreated Phenylketonuria In Adulthood. Orv Hetil. 2017; 158(46): 1857-1863.|[('Phenylketonuria', 'no label'), ('Newborn Screening Program', 'no label'), ('Hungary', 'no label'), ('Generation', 'no label'), ('Treated With', 'no label'), ('Special Diet', 'no label'), ('Medical Foods Right', 'no label'), ('Neonatal', 'no label'), ('Diagnosis', 'no label'), ('Reached Adulthood', 'no label'), ('Early Treatment', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Lead Life', 'no label'), ('Phenylketonuria', 'no label'), ('Pediatric Disease', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Performed', 'no label'), ('Internal Medicine Centers Specialized', 'no label'), ('Metabolic Diseases', 'no label'), ('Outcome', 'no label'), ('Lifelong Special Treatment', 'no label'), ('Particularities', 'no label'), ('Phenylketonuria', 'no label'), ('Adulthood', 'no label'), ('Review', 'no label'), ('Findings', 'no label'), ('Phenylketonuria', 'no label'), ('Adult Care', 'no label'), ('Long Time', 'no label'), ('First International Guidelines Appeared', 'no label'), ('New Therapies', 'no label'), ('Developments', 'no label'), ('Near', 'no label'), ('Future', 'no label'), ('Challenges', 'no label'), ('Met', 'no label'), ('Maternal', 'no label'), ('Phenylketonuria', 'no label'), ('Long Term', 'no label'), ('Effects', 'no label'), ('Dietotherapy', 'no label'), ('Sequelae', 'no label'), ('Untreated Phenylketonuria', 'no label'), ('Adulthood', 'no label'), ('Hetil', 'no label')]|[]|[]|[('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Particularities', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Put', 'no label'), ('Phenylketonuria', 'no label'), ('Dietotherapy', 'no label'), ('Phenylketonuria', 'no label')]|[('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Put', 'no label'), ('Met', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~33765361|Neurotoxic Effects Caused By High Phenylalanine (Phe) In Patients With Phenylketonuria (Pku) Can Be Avoided Through Dietary Treatment. However, Achieving The Recommended Phe Levels Has Been A Challenge. This Study Aimed To Investigate Factors Associated With Adherence To Pku Treatment Among Patients Followed At A Medical Genetics Public Service In Southern Brazil. Twenty-Nine Patients (Early Diagnosed, N = 20; Late-Diagnosed, N = 9) With Classical (N = 16) Or Mild Pku (N = 13) Aged 6-34 Years (16.4 ± 7.5) And 16 Caregivers Were Included. Blood Phe Levels Were Recorded, And Assessment Tools Measuring Barriers To Treatment, Iq, Knowledge About Disease, Treatment, And Perceived Adherence Were Collected. Classical Pku Patients Showed Higher Current Blood Phe Levels Than Mild Pku Patients (U = 37.000, P = 0.003). Lifetime And Childhood Phe Levels Were Associated With Recent Metabolic Control (Τ = 0.76, P = 0.000; Τ = 0.70, P = 0.000, Respectively). The Perception Of Barriers To Treatment Was Associated With A Higher Blood Phe Level (Τ = 0.39, P = 0.003). Tolerance To Phe, Metabolic Control Throughout Childhood, And Perceived Difficulty In Living With Demands Of Treatment Are Important Factors Of Greater Vulnerability To Poor Adherence In Pku Patients.|[('Neurotoxic', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Dietary Treatment', 'no label'), ('Recommended', 'no label'), ('Phe Levels', 'no label'), ('Study', 'no label'), ('Investigate Factors', 'no label'), ('Associated With', 'no label'), ('Adherence', 'no label'), ('Pku Treatment', 'no label'), ('Patients', 'no label'), ('Medical Genetics Public Service', 'no label'), ('Southern Brazil', 'no label'), ('Twenty-Nine', 'no label'), ('Patients', 'no label'), ('Early Diagnosed', 'no label'), ('N\xa0', 'no label'), ('Late-Diagnosed, N\xa0', 'no label'), ('Classical (N\xa0', 'no label'), ('Mild Pku (N\xa0', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Caregivers', 'no label'), ('Blood Phe Levels', 'no label'), ('Assessment', 'no label'), ('Measuring', 'no label'), ('Barriers', 'no label'), ('Treatment', 'no label'), ('Iq', 'no label'), ('Knowledge', 'no label'), ('Disease', 'no label'), ('Treatment', 'no label'), ('Perceived Adherence', 'no label'), ('Collected', 'no label'), ('Classical Pku Patients', 'no label'), ('Higher', 'no label'), ('Current', 'no label'), ('Blood Phe Levels Than Mild Pku', 'no label'), ('Patients', 'no label'), ('U\xa0', 'no label'), ('Lifetime', 'no label'), ('Childhood', 'no label'), ('Phe Levels', 'no label'), ('Associated With', 'no label'), ('Metabolic Control', 'no label'), ('Τ\xa0', 'no label'), ('Perception', 'no label'), ('Barriers', 'no label'), ('Treatment', 'no label'), ('Associated With', 'no label'), ('Higher', 'no label'), ('Blood Phe Level', 'no label'), ('Tolerance', 'no label'), ('Phe', 'no label'), ('Metabolic Control', 'no label'), ('Childhood', 'no label'), ('Perceived Difficulty', 'no label'), ('Demands', 'no label'), ('Treatment', 'no label'), ('Factors', 'no label'), ('Greater Vulnerability', 'no label'), ('Poor Adherence', 'no label'), ('Patients', 'no label')]|[('Neurotoxic', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[]|[('Neurotoxic', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Phe', 'no label'), ('Twenty-Nine', 'no label'), ('N\xa0=\xa09', 'no label'), ('N\xa0=\xa016) Or Mild Pku (N\xa0=\xa013) Aged 6-34\u2009Years (16.4\u2009', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('High Phenylalanine', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('U', 'no label'), ('Blood Phe', 'no label'), ('Phe', 'no label'), ('Pku Patients', 'no label')]
phenylketonuria|pubmed~33610470|A Subset Of Patients With Phenylketonuria Benefit From Treatment With Tetrahydrobiopterin (Bh<Sub>4</Sub>), Although There Is No Consensus On The Definition Of Bh<Sub>4</Sub> Responsiveness. The Aim Of This Study Therefore Was To Gain Insight Into The Definitions Of Long-Term Bh<Sub>4</Sub> Responsiveness Being Used Around The World. We Performed A Web-Based Survey Targeting Healthcare Professionals Involved In The Treatment Of Pku Patients. Data Were Analysed According To Geographical Region (Europe, Usa/Canada, Other). We Analysed 166 Responses. Long-Term Bh<Sub>4</Sub> Responsiveness Was Commonly Defined Using Natural Protein Tolerance (95.6%), Improvement Of Metabolic Control (73.5%) And Increase In Quality Of Life (48.2%). When A Specific Value For A Reduction In Phenylalanine Concentrations Was Reported (N = 89), 30% And 20% Were Most Frequently Used As Cut-Off Values (76% And 19% Of Respondents, Respectively). When A Specific Relative Increase In Natural Protein Tolerance Was Used To Define Long-Term Bh<Sub>4</Sub> Responsiveness (N = 71), Respondents Most Commonly Reported Cut-Off Values Of 30% And 100% (28% Of Respondents In Both Cases). Respondents From Usa/Canada (N = 50) Generally Used Less Strict Cut-Off Values Compared To Europe (N = 96). Furthermore, Respondents Working Within The Same Center Answered Differently. The Results Of This Study Suggest A Very Heterogeneous Situation On The Topic Of Defining Long-Term Bh<Sub>4</Sub> Responsiveness, Not Only At A Worldwide Level But Also Within Centers. Developing A Strong Evidence- And Consensus-Based Definition Would Improve The Quality Of Bh<Sub>4</Sub> Treatment.|[('Subset', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Benefit', 'no label'), ('Treatment', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Consensus', 'no label'), ('Definition', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Study', 'no label'), ('Definitions', 'no label'), ('Long-Term', 'no label'), ('Bh<Sub>4</Sub> Responsiveness Being', 'no label'), ('World', 'no label'), ('Performed', 'no label'), ('Web-Based Survey', 'no label'), ('Healthcare Professionals', 'no label'), ('Treatment', 'no label'), ('Pku Patients', 'no label'), ('Data', 'no label'), ('Analysed', 'no label'), ('Geographical Region', 'no label'), ('Europe', 'no label'), ('Analysed', 'no label'), ('Responses', 'no label'), ('Long-Term', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Natural Protein Tolerance', 'no label'), ('Improvement', 'no label'), ('Metabolic Control', 'no label'), ('Increase', 'no label'), ('Value', 'no label'), ('Reduction', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Reported', 'no label'), ('Cut-Off Values', 'no label'), ('Respondents', 'no label'), ('Relative Increase', 'no label'), ('Natural Protein Tolerance', 'no label'), ('Long-Term', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Respondents', 'no label'), ('Reported', 'no label'), ('Cut-Off', 'no label'), ('Values', 'no label'), ('Respondents', 'no label'), ('Cases', 'no label'), ('Respondents', 'no label'), ('Strict', 'no label'), ('Cut-Off Values', 'no label'), ('Europe', 'no label'), ('N\xa0', 'no label'), ('Respondents', 'no label'), ('Working', 'no label'), ('Study Suggest', 'no label'), ('Heterogeneous Situation', 'no label'), ('Long-Term', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Worldwide', 'no label'), ('Level', 'no label'), ('Centers', 'no label'), ('Strong', 'no label'), ('Evidence-', 'no label'), ('Consensus-Based Definition', 'no label'), ('Quality', 'no label'), ('Bh<Sub>4</Sub> Treatment', 'no label')]|[('Tetrahydrobiopterin', 'no label'), ('Region', 'no label'), ('Protein', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label')]|[('Tetrahydrobiopterin', 'no label'), ('Usa/Canada', 'no label')]|[('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh', 'no label'), ('Phenylalanine', 'no label'), ('N\xa0=', 'no label'), ('N\xa0=\xa0', 'no label'), ('N\xa0=', 'no label')]|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Gain Insight', 'no label'), ('Long-Term', 'no label'), ('Phenylalanine', 'no label'), ('Cut-Off', 'no label'), ('Cut-Off', 'no label')]
phenylketonuria|pubmed~33161754|To Investigate The Incidence Of Phenylalanine Hydroxylase (Pah) Deficiency And Pah Genotypes In Neonates In Hainan, China. <B>Methods:</B> We Performed Heal Stick To Collect Blood And Obtain Dry Blood Spot Specimens From Newborns In Hainan From January 2007 To December 2016. Phenylalanine (Phe) Concentration In These Dry Blood Spots Was Measured By The Fluorescence Method To Screen Phenylketonuria (Pku). For Suspicious Samples, The Genotypes Of The Pah Gene Were Amplified By Biotin Labeled Oligonucleotide Primers. Polymerase Chain Reaction (Pcr) Products Were Then Analyzed By Flow-Through Hybridization To Detect Genotypes. At The Same Time, Peripheral Blood Samples Of Children Suspicious Of Pku And Their Parents Were Used To Perform Gene Sequencing. <B>Results:</B> Of The 914,520 Newborns Screened, 29 Of Them Had Pah Deficiency. The Incidence Of Pah Deficiency In Hainan Was 3.17/100,000. A Total Of 58 Mutant Alleles Belonging To 15 Different Types Were Identified In The 29 Patients. In Terms Of Genotypes Frequency, The Top 4 Were: <I>C.611A > G</I> 20.7% (12/58) , <I>C.728G > A</I> 17.2%, <I>C.158G > A</I> 15.2% (9/58) And <I>C.721C > T</I> 13.8% (8/58). The Frequencies Of Other Genotypes Were All Below 10%. <B>Conclusion:</B> The Incidence Of Pah Deficiency In Hainan Is Relatively High Among All Provinces In Southern China. With A Total Frequency Of 67.2%, <I>C.611A > G</I>, <I>C.728G > A</I>, <I>C.158G > A</I> And <I>C.721C > T</I>, And Are The Most Common Pah Gene Genotypes.|[('Investigate', 'no label'), ('Incidence', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Genotypes', 'no label'), ('Neonates', 'no label'), ('Hainan', 'no label'), ('China', 'no label'), ('Methods:</B', 'no label'), ('Performed', 'no label'), ('Heal Stick', 'no label'), ('Collect Blood', 'no label'), ('Obtain', 'no label'), ('Dry Blood Spot Specimens', 'no label'), ('Newborns', 'no label'), ('Hainan', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Concentration', 'no label'), ('Dry Blood Spots', 'no label'), ('Measured', 'no label'), ('Fluorescence Method', 'no label'), ('Phenylketonuria', 'no label'), ('Suspicious', 'no label'), ('Samples', 'no label'), ('Genotypes', 'no label'), ('Pah Gene', 'no label'), ('Biotin', 'no label'), ('Labeled', 'no label'), ('Oligonucleotide Primers', 'no label'), ('Polymerase Chain Reaction', 'no label'), ('Pcr', 'no label'), ('Analyzed', 'no label'), ('Flow-Through Hybridization', 'no label'), ('Detect', 'no label'), ('Genotypes', 'no label'), ('Same Time', 'no label'), ('Peripheral Blood Samples', 'no label'), ('Children', 'no label'), ('Suspicious', 'no label'), ('Parents', 'no label'), ('Gene Sequencing', 'no label'), ('Results:</B', 'no label'), ('Newborns', 'no label'), ('Screened', 'no label'), ('Deficiency', 'no label'), ('Incidence', 'no label'), ('Pah Deficiency', 'no label'), ('Hainan', 'no label'), ('Mutant Alleles', 'no label'), ('Identified', 'no label'), ('Patients', 'no label'), ('Genotypes', 'no label'), ('Frequency', 'no label'), ('C.611A\u2009>\u2009G</I> 20.7%', 'no label'), ('<I>C.728G\u2009>\u2009A</I> 17.2%', 'no label'), ('<I>C.721C\u2009>\u2009T</I', 'no label'), ('Frequencies', 'no label'), ('Genotypes', 'no label'), ('Conclusion:</B', 'no label'), ('Incidence', 'no label'), ('Pah Deficiency', 'no label'), ('Hainan', 'no label'), ('Provinces', 'no label'), ('Southern China', 'no label'), ('Frequency', 'no label'), ('C.611A\u2009>\u2009G</I>', 'no label'), ('C.728G\u2009>\u2009A</I>', 'no label'), ('Pah Gene', 'no label'), ('Genotypes', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Genotypes', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Genotypes', 'no label'), ('Gene', 'no label'), ('Oligonucleotide Primers', 'no label'), ('Genotypes', 'no label'), ('Gene', 'no label'), ('Mutant Alleles', 'no label'), ('Genotypes', 'no label'), ('Genotypes', 'no label'), ('Gene Genotypes', 'no label')]|[('Pah Gene', 'no label'), ('58 Mutant Alleles', 'no label'), ('Pah Gene', 'no label')]|[('Phenylalanine', 'no label'), ('Dry Blood Spot', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Dry Blood Spots Was Measured By The Fluorescence Method To', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Neonates', 'no label'), ('B', 'no label'), ('Heal', 'no label'), ('Blood', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Suspicious Samples', 'no label'), ('Pah Gene', 'no label'), ('Biotin', 'no label'), ('Peripheral Blood Samples', 'no label'), ('Children', 'no label'), ('B', 'no label'), ('Pah', 'no label'), ('B', 'no label'), ('Pah', 'no label')]
phenylketonuria|pubmed~30298698|Phenylketonuria Is A Hereditary Disease Caused By The Lack Or Deficiency Of Phenylalanine Hydroxylase Enzyme Activity. Parents Of Children With Phenylketonuria Undergo Significant Stress During Their Childcare Years. They Are Also Responsible For Controlling Their Children'S Dietary Treatment And This May Affect Their Quality Of Life. The Purpose Of This Study Was To Investigate The Relationship Between Stress And Quality Of Life In Parents Of Children With Phenylketonuria. The Present Cross-Sectional Study Is A Correlation-Analytical Research Performed On Parents Of Children With Phenylketonuria In Kerman Province In Iran In 2017. In Total, 124 Parents Were Chosen By Consensus Method. Parents Completed The Perceived Stress Scale And Quality Of Life (Sf36). Spss Software Version 18 (Https://Www.Presidion.Com/Software/Ibm-Spss-Trial-Downloads/) Was Used To Analyze The Data. Total Scores Of Stress And Quality Of Life Were 28.81 ± 8.74 And 45.97 ± 21.22. There Was A Significant Negative Correlation Between Quality Of Life And Perceived Stress (P < 0.001 And Ρ = -0.58). Parents Of Children With Phenylketonuria Have Moderate Quality Of Life And Relatively High Stress. The Medical Community And Authorities Should Take Steps To Improve The Quality Of Life And Reduce Stress Experienced By Parents Of Children With Phenylketonuria.|"[('Phenylketonuria', 'no label'), ('Hereditary Disease', 'no label'), ('Lack', 'no label'), ('Deficiency', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Enzyme Activity', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Significant', 'no label'), ('Stress', 'no label'), ('Childcare', 'no label'), ('Years', 'no label'), ('Controlling', 'no label'), (""Children'S"", 'no label'), ('Dietary Treatment', 'no label'), ('Affect', 'no label'), ('Quality', 'no label'), ('Study', 'no label'), ('Investigate', 'no label'), ('Relationship', 'no label'), ('Stress', 'no label'), ('Quality Of Life', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Cross-Sectional Study', 'no label'), ('Correlation-Analytical Research', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Kerman Province', 'no label'), ('Iran', 'no label'), ('Parents', 'no label'), ('Chosen', 'no label'), ('Parents', 'no label'), ('Completed', 'no label'), ('Perceived Stress Scale', 'no label'), ('Sf36', 'no label'), ('Spss Software Version 18', 'no label'), ('Https://Www', 'no label'), ('Presidion', 'no label'), ('Analyze', 'no label'), ('Data', 'no label'), ('Total Scores', 'no label'), ('Stress', 'no label'), ('Significant', 'no label'), ('Negative', 'no label'), ('Correlation', 'no label'), ('Quality Of Life', 'no label'), ('Perceived Stress', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Moderate Quality Of Life', 'no label'), ('High Stress', 'no label'), ('Medical Community And Authorities', 'no label'), ('Quality Of Life', 'no label'), ('Reduce', 'no label'), ('Stress', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label')]"|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Sf36', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Hereditary Disease', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Kerman', 'no label'), ('Stress', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Life', 'no label'), ('Life', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~33334682|Even With Early And Continuous Treatment, Individuals With Phenylketonuria (Pku) May Exhibit Abnormalities Of Cortical White Matter (Wm). The Present Study Utilizes A New Analysis Approach Called Automated Fiber-Tract Quantification (Afq) To Advance Our Understanding Of The Tract-Specific Patterns Of Change In Wm Abnormalities In Individuals With Early-Treated Pku (Etpku). Diffusion Tensor Imaging (Dti) Data From A Sample Of 22 Individuals With Etpku And A Demographically-Matched Sample Of 21 Healthy Individuals Without Pku Was Analyzed Using Afq. In Addition, A Subsample Of 8 Individuals With Etpku Was Reevaluated Six Months Later After Demonstrating A Significant Reduction In Blood Phe Levels Following Initiation Of Sapropterin Treatment. Within-Tract Afq Analyses Revealed Significant Location-By-Group Interactions For Several Wm Tracts Throughout The Brain. In Most Cases, Etpku-Related Disruptions In Mean Diffusivity (Md) Were More Apparent In Posterior (As Compared To Anterior) Aspects Of A Given Tract. Reduction In Blood Phe Levels With The Aforementioned Etpku Subsample Was Associated With A Similar Pattern Of Improvement (Posterior-To-Anterior) Within Most Tracts. Taken Together, These Findings Suggest That There Is A Systematic Pattern Of Change In Wm Abnormalities In Individuals With Etpku In A Posterior-To-Anterior Manner Along Individual Wm Tracts.|[('Early', 'no label'), ('Continuous Treatment', 'no label'), ('Individuals', 'no label'), ('Phenylketonuria', 'no label'), ('Exhibit Abnormalities', 'no label'), ('Cortical White Matter', 'no label'), ('Study', 'no label'), ('Utilizes A', 'no label'), ('New Analysis Approach', 'no label'), ('Automated', 'no label'), ('Fiber-Tract Quantification', 'no label'), ('Afq', 'no label'), ('Advance', 'no label'), ('Tract-Specific Patterns', 'no label'), ('Change', 'no label'), ('Abnormalities', 'no label'), ('Individuals', 'no label'), ('Early-Treated Pku (Etpku)', 'no label'), ('Diffusion Tensor Imaging', 'no label'), ('Dti', 'no label'), ('Data', 'no label'), ('Sample', 'no label'), ('Individuals', 'no label'), ('Etpku', 'no label'), ('Demographically-Matched Sample', 'no label'), ('Healthy', 'no label'), ('Individuals', 'no label'), ('Pku Was Analyzed', 'no label'), ('Afq', 'no label'), ('Addition', 'no label'), ('Individuals', 'no label'), ('Etpku', 'no label'), ('Months', 'no label'), ('Reduction', 'no label'), ('Blood Phe Levels', 'no label'), ('Initiation', 'no label'), ('Sapropterin', 'no label'), ('Treatment', 'no label'), ('Within-Tract Afq Analyses', 'no label'), ('Revealed', 'no label'), ('Location-By-Group', 'no label'), ('Interactions', 'no label'), ('Tracts', 'no label'), ('Brain', 'no label'), ('Cases', 'no label'), ('Etpku-Related Disruptions', 'no label'), ('Mean Diffusivity', 'no label'), ('Md', 'no label'), ('Apparent', 'no label'), ('Posterior', 'no label'), ('Anterior', 'no label'), ('Tract', 'no label'), ('Reduction', 'no label'), ('Blood Phe Levels', 'no label'), ('Aforementioned Etpku Subsample', 'no label'), ('Associated With', 'no label'), ('Pattern', 'no label'), ('Improvement', 'no label'), ('Posterior-To-Anterior', 'no label'), ('Tracts', 'no label'), ('Findings', 'no label'), ('Suggest', 'no label'), ('Systematic Pattern', 'no label'), ('Change', 'no label'), ('Abnormalities', 'no label'), ('Individuals', 'no label'), ('Etpku', 'no label'), ('Manner', 'no label'), ('Individual', 'no label'), ('Wm Tracts', 'no label')]|[('Individuals', 'no label'), ('Individuals', 'no label'), ('Individuals', 'no label'), ('Individuals', 'no label'), ('Individuals', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Individuals', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Dti', 'no label'), ('Reduction In Blood Phe', 'no label'), ('Sapropterin', 'no label')]|[('Phenylketonuria', 'no label'), ('Cortical', 'no label'), ('Fiber-Tract', 'no label'), ('Afq', 'no label'), ('Individuals', 'no label'), ('21', 'no label'), ('Afq', 'no label'), ('Blood Phe', 'no label'), ('Sapropterin', 'no label'), ('Brain', 'no label'), ('Blood Phe', 'no label')]
phenylketonuria|pubmed~34921666|Phenylketonuria (Pku) Is A Rare, Metabolic Genetic Disorder That Can Cause Various Neuropsychological Symptoms That Often Affect Patients' Health-Related Quality Of Life, Even For Patients With Good Metabolic Control. To Date, No Patient-Reported Outcomes (Pro) Instrument Combines The Measurement Of Neuropsychological And Dietary Concepts To Capture The Broad Impact Of Pku On Quality Of Life. This Article Presents The Development Of The Pku Symptom Severity And Impacts Scale (Pku-Ssis), A Pro Instrument That Is Designed To Evaluate Neuropsychological Symptoms And Impacts In Early-Treated Patients With Pku. A Draft Instrument Was Developed Based On A Targeted Literature Review, Pku Expert Physician Interviews, And An Advisory Board Consisting Of Patients With Pku. Qualitative Interviews Combining Concept Elicitation/Cognitive Interviews Were Conducted With Patients With Classic Pku Aged At Least 15 Years Old. A Separate Sample Of 20 Patients With Pku Completed The Draft Pku-Ssis In A Paper Survey Format, To Enable Preliminary Assessment Of Any Floor And Ceiling Effects. Patient Interviews Elicited Four Key Symptom Themes: Neurocognitive Function, Emotional And Behavioral, Physical Functioning, And Physical Health. Four Impact Themes Were Also Identified: Social Function, Physical Health, Emotions, And Level Of Independence. No Floor Or Ceiling Effects Were Identified. The Final Instrument Included 22 Items, Covering Three Symptom Domains (1. Emotional, Mood, And Psychological; 2. (Neuro)Cognitive, Executive, And Intellectual Function; And 3. Physical Health), And Four Impact Domains (1. Social Relations, 2. Level Of Independence, 3. General Well-Being, And 4. Self-Care). The Pku-Ssis Will Help To Address An Important Gap In The Evaluation Of Existing And Future Treatments For Pku.|"[('Phenylketonuria', 'no label'), ('Rare', 'no label'), ('Metabolic Genetic Disorder', 'no label'), ('Neuropsychological Symptoms', 'no label'), ('Affect', 'no label'), (""Patients'"", 'no label'), ('Health-Related Quality Of Life', 'no label'), ('Patients', 'no label'), ('Good', 'no label'), ('Metabolic Control', 'no label'), ('No Patient-Reported Outcomes', 'no label'), ('Measurement', 'no label'), ('Neuropsychological', 'no label'), ('Dietary Concepts', 'no label'), ('Broad Impact', 'no label'), ('Pku On Quality Of Life', 'no label'), ('Article', 'no label'), ('Presents', 'no label'), ('Development', 'no label'), ('Pku Symptom Severity', 'no label'), ('Pku-Ssis', 'no label'), ('A Pro Instrument', 'no label'), ('Neuropsychological Symptoms', 'no label'), ('Impacts', 'no label'), ('Early-Treated', 'no label'), ('Patients', 'no label'), ('Pku.', 'no label'), ('Draft Instrument', 'no label'), ('Targeted Literature Review', 'no label'), ('Pku Expert Physician Interviews', 'no label'), ('Patients', 'no label'), ('Qualitative Interviews', 'no label'), ('Concept', 'no label'), ('Elicitation/Cognitive Interviews', 'no label'), ('Patients', 'no label'), ('Classic Pku Aged', 'no label'), ('Sample', 'no label'), ('Patients', 'no label'), ('Pku Completed', 'no label'), ('Draft Pku-Ssis', 'no label'), ('Paper Survey', 'no label'), ('Preliminary Assessment', 'no label'), ('Floor And Ceiling Effects', 'no label'), ('Patient Interviews', 'no label'), ('Key Symptom', 'no label'), ('Themes', 'no label'), ('Neurocognitive Function', 'no label'), ('Emotional', 'no label'), ('Behavioral', 'no label'), ('Physical Functioning', 'no label'), ('Physical Health', 'no label'), ('Impact', 'no label'), ('Themes', 'no label'), ('Identified', 'no label'), ('Social Function', 'no label'), ('Physical Health', 'no label'), ('Emotions', 'no label'), ('Level', 'no label'), ('No Floor', 'no label'), ('Ceiling Effects', 'no label'), ('Identified', 'no label'), ('Final Instrument', 'no label'), ('Items, Covering', 'no label'), ('Symptom Domains', 'no label'), ('Emotional', 'no label'), ('Mood', 'no label'), ('Psychological', 'no label'), ('(Neuro)Cognitive', 'no label'), ('Executive', 'no label'), ('Intellectual Function', 'no label'), ('Physical Health', 'no label'), ('Impact', 'no label'), ('Domains', 'no label'), ('Social Relations', 'no label'), ('Level', 'no label'), ('General Well-Being', 'no label'), ('Self-Care', 'no label'), ('Pku-Ssis', 'no label'), ('Will Help', 'no label'), ('Evaluation', 'no label'), ('Treatments', 'no label')]"|[('Genetic', 'no label'), ('Domains', 'no label'), ('Gap', 'no label')]|[]|[('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Independence, 3', 'no label')]
phenylketonuria|pubmed~34930395|Recently Published European Society For Phenylketonuria (Espku) Guidelines Have Recommended A Lifelong Diet With Phenylalanine (Phe) Control ≤ 600 Μmol/L For Phenylketonuria (Pku) Patients. This Study Aimed To Identify Whether Pku Adult Patients Are At A Higher Risk Of Mental Health Diagnoses If Their 2-Year Average Phe Level Is Higher Than The Espku European Guidelines. Published Studies Identified By A Literature Review Showed That Related Studies Have Been Published In American And European Pku Study Populations But Not In The United Kingdom (Uk) Study Populations. Previous Studies Also Involved A Smaller Number Of Participants Due To This Being A Rare Disease. We Undertook A Retrospective Audit At A Single Large Pku Centre In The Uk. 244 Adult Pku Patients At The Centre Were Included, 220 Of Which Had A Recorded Phe Level. Approximately 75% Of The Patients In This Study Did Not Meet The Espku European Guidelines For Phe Control. A Systematic Search Of The Electronic Patient Record Was Undertaken Looking For Mental Health Diagnoses. Compared To Two-Year Average Phe Levels ≤ 600 Μmol/L, Pku Adult Patients With Two-Year Average Phe Levels > 600 Μmol/L Were More Likely To Have Diagnoses Of Low Mood, Depression, Anxiety, Or Mood Swings, But Only Low Mood Reached Statistical Significance (P < 0.05). Pku Patients With Two-Year Average Phenylalanine Levels Greater Than Espku Guidelines May Be At Greater Risk Of Mental Health Diagnoses And Symptoms. Many Of These Adult Pku Patients Will Be Lost To Follow-Up, And Therefore May Be Receiving Treatment For Mental Health Conditions In The Community. Multicentre Uk Studies And International Collaborations Are Required To Overcome Low Participant Numbers In The Study Of This Rare Disease.|[('Published European Society', 'no label'), ('Phenylketonuria', 'no label'), ('Espku', 'no label'), ('Guidelines', 'no label'), ('Recommended', 'no label'), ('Lifelong Diet', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Control\u2009≤\u2009600\xa0', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Pku Adult', 'no label'), ('Patients', 'no label'), ('Higher', 'no label'), ('Risk', 'no label'), ('Mental Health Diagnoses', 'no label'), ('Average', 'no label'), ('Phe', 'no label'), ('Espku European', 'no label'), ('Guidelines', 'no label'), ('Published Studies', 'no label'), ('Identified', 'no label'), ('Literature Review', 'no label'), ('Studies', 'no label'), ('Published', 'no label'), ('American', 'no label'), ('Pku Study Populations', 'no label'), ('United Kingdom', 'no label'), ('Studies', 'no label'), ('Participants', 'no label'), ('Being A Rare Disease', 'no label'), ('Undertook A', 'no label'), ('Retrospective Audit', 'no label'), ('Pku Centre', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Centre', 'no label'), ('Recorded', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Did Not Meet', 'no label'), ('Espku European', 'no label'), ('Guidelines', 'no label'), ('Phe Control', 'no label'), ('Systematic', 'no label'), ('Electronic Patient Record', 'no label'), ('Mental Health Diagnoses', 'no label'), ('Average', 'no label'), ('Phe Levels\u2009≤\u2009600\xa0Μmol/L', 'no label'), ('Pku Adult', 'no label'), ('Patients', 'no label'), ('Average', 'no label'), ('Phe Levels\u2009>\u2009600\xa0', 'no label'), ('Diagnoses', 'no label'), ('Low Mood', 'no label'), ('Depression', 'no label'), ('Anxiety', 'no label'), ('Low Mood Reached Statistical Significance', 'no label'), ('Patients', 'no label'), ('Two-Year Average', 'no label'), ('Phenylalanine', 'no label'), ('Than Espku Guidelines', 'no label'), ('Greater', 'no label'), ('Risk', 'no label'), ('Mental Health Diagnoses', 'no label'), ('Symptoms', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Lost To Follow-Up', 'no label'), ('Receiving', 'no label'), ('Treatment', 'no label'), ('Mental Health Conditions', 'no label'), ('Community', 'no label'), ('Multicentre Uk Studies', 'no label'), ('International Collaborations', 'no label'), ('Overcome', 'no label'), ('Participant', 'no label'), ('Study', 'no label'), ('Rare Disease', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('≤', 'no label'), ('Phenylketonuria', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('≤', 'no label'), ('Low Mood', 'no label'), ('Depression', 'no label'), ('Anxiety', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label')]
phenylketonuria|pubmed~34974973|Large Neutral Amino Acid (Lnaa) Treatment Has Been Suggested As Alternative To The Burdensome Severe Phenylalanine-Restricted Diet. While Its Working Mechanisms And Optimal Composition Have Recently Been Further Elucidated, The Question Whether Lnaa Treatment Requires The Natural Protein-Restricted Diet, Has Still Remained. Firstly, To Determine Whether An Additional Liberalized Natural Protein-Restricted Diet Could Further Improve Brain Amino Acid And Monoamine Concentrations In Phenylketonuria Mice On Lnaa Treatment. Secondly, To Compare The Effect Between Lnaa Treatment (Without Natural Protein) Restriction And Different Levels Of A Phenylalanine-Restricted Diet (Without Lnaa Treatment) On Brain Amino Acid And Monoamine Concentrations In Phenylketonuria Mice. Btbr Pah-Enu2 Mice Were Divided Into Two Experimental Groups That Received Lnaa Treatment With Either An Unrestricted Or Semi Phenylalanine-Restricted Diet. Control Groups Included Pah-Enu2 Mice On The Ain-93 M Diet, A Severe Or Semi Phenylalanine-Restricted Diet Without Lnaa Treatment, And Wild-Type Mice Receiving The Ain-93 M Diet. After Ten Weeks, Brain And Plasma Samples Were Collected To Measure Amino Acid Profiles And Brain Monoaminergic Neurotransmitter Concentrations. Adding A Semi Phenylalanine-Restricted Diet To Lnaa Treatment Resulted In Lower Plasma Phenylalanine But Comparable Brain Amino Acid And Monoamine Concentrations As Compared To Lnaa Treatment (Without Phenylalanine Restriction). Lnaa Treatment (Without Phenylalanine Restriction) Resulted In Comparable Brain Monoamine But Higher Brain Phenylalanine Concentrations Compared To The Severe Phenylalanine-Restricted Diet, And Significantly Higher Brain Monoamine But Comparable Phenylalanine Concentrations As Compared To The Semi Phenylalanine-Restricted Diet. Present Results In Pku Mice Suggest That Lnaa Treatment In Pku Patients Does Not Need The Phenylalanine-Restricted Diet. In Pku Mice, Lnaa Treatment (Without Phenylalanine Restriction) Was Comparable To A Severe Phenylalanine-Restricted Diet With Respect To Brain Monoamine Concentrations, Notwithstanding The Higher Plasma And Brain Phenylalanine Concentrations, And Resulted In Comparable Brain Phenylalanine Concentrations As On A Semi Phenylalanine-Restricted Diet.|[('Neutral Amino Acid', 'no label'), ('Treatment', 'no label'), ('Burdensome Severe Phenylalanine-Restricted Diet', 'no label'), ('Working Mechanisms', 'no label'), ('Optimal', 'no label'), ('Composition', 'no label'), ('Question', 'no label'), ('Lnaa Treatment', 'no label'), ('Requires', 'no label'), ('Natural Protein-Restricted Diet', 'no label'), ('Remained', 'no label'), ('Liberalized Natural Protein-Restricted Diet', 'no label'), ('Brain Amino Acid', 'no label'), ('Monoamine', 'no label'), ('Concentrations', 'no label'), ('Phenylketonuria Mice', 'no label'), ('Lnaa Treatment', 'no label'), ('Compare', 'no label'), ('Effect', 'no label'), ('Lnaa Treatment', 'no label'), ('Natural Protein) Restriction', 'no label'), ('Levels', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Lnaa Treatment', 'no label'), ('Brain Amino Acid', 'no label'), ('Monoamine', 'no label'), ('Concentrations', 'no label'), ('Phenylketonuria', 'no label'), ('Mice', 'no label'), ('Btbr Pah-Enu2', 'no label'), ('Mice', 'no label'), ('Experimental Groups', 'no label'), ('Lnaa Treatment', 'no label'), ('Semi Phenylalanine-Restricted Diet', 'no label'), ('Control Groups', 'no label'), ('Pah-Enu2', 'no label'), ('Mice', 'no label'), ('Ain-93\xa0M Diet', 'no label'), ('Severe', 'no label'), ('Semi Phenylalanine-Restricted Diet', 'no label'), ('Lnaa Treatment', 'no label'), ('Wild-Type Mice', 'no label'), ('Receiving', 'no label'), ('Ain-93\xa0M', 'no label'), ('Diet', 'no label'), ('Weeks', 'no label'), ('Brain', 'no label'), ('Plasma', 'no label'), ('Samples', 'no label'), ('Measure', 'no label'), ('Amino Acid', 'no label'), ('Profiles', 'no label'), ('Brain Monoaminergic', 'no label'), ('Neurotransmitter', 'no label'), ('Concentrations', 'no label'), ('Semi Phenylalanine-Restricted Diet', 'no label'), ('Lnaa Treatment', 'no label'), ('Resulted', 'no label'), ('Plasma', 'no label'), ('Phenylalanine', 'no label'), ('Brain Amino Acid', 'no label'), ('Monoamine', 'no label'), ('Concentrations', 'no label'), ('Lnaa Treatment', 'no label'), ('Phenylalanine Restriction', 'no label'), ('Lnaa Treatment', 'no label'), ('Phenylalanine Restriction', 'no label'), ('Resulted', 'no label'), ('Brain', 'no label'), ('Monoamine', 'no label'), ('Brain', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Severe Phenylalanine-Restricted Diet', 'no label'), ('Brain', 'no label'), ('Monoamine', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Semi Phenylalanine-Restricted Diet', 'no label'), ('Pku Mice Suggest', 'no label'), ('Lnaa Treatment', 'no label'), ('Pku Patients', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Pku Mice', 'no label'), ('Lnaa Treatment', 'no label'), ('Phenylalanine Restriction', 'no label'), ('Severe', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Respect', 'no label'), ('Brain', 'no label'), ('Monoamine Concentrations', 'no label'), ('Higher', 'no label'), ('Plasma', 'no label'), ('Brain', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Resulted', 'no label'), ('Brain', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Semi Phenylalanine-Restricted Diet', 'no label')]|[('Amino Acid', 'no label'), ('Monoamine', 'no label'), ('Mice', 'no label'), ('Amino Acid', 'no label'), ('Monoamine', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Amino Acid', 'no label'), ('Monoaminergic Neurotransmitter', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acid', 'no label'), ('Monoamine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Monoamine', 'no label'), ('Phenylalanine', 'no label'), ('Monoamine', 'no label'), ('Phenylalanine', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Phenylalanine', 'no label'), ('Monoamine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Higher Plasma And Brain', 'no label')]|[('Amino Acid', 'no label'), ('Amino Acid', 'no label'), ('Monoamine', 'no label'), ('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Monoamine', 'no label'), ('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Lnaa', 'no label'), ('Brain Amino Acid', 'no label'), ('Monoamine', 'no label'), ('Phenylketonuria Mice', 'no label'), ('Lnaa', 'no label'), ('Lnaa', 'no label'), ('Brain Amino Acid', 'no label'), ('Monoamine', 'no label'), ('Phenylketonuria Mice', 'no label'), ('Mice', 'no label'), ('Lnaa', 'no label'), ('Mice', 'no label'), ('Lnaa', 'no label'), ('Mice', 'no label'), ('Brain', 'no label'), ('Plasma', 'no label'), ('Amino Acid', 'no label'), ('Brain Monoaminergic Neurotransmitter', 'no label'), ('Lnaa', 'no label'), ('Plasma Phenylalanine', 'no label'), ('Brain Amino Acid', 'no label'), ('Monoamine', 'no label'), ('Lnaa', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Brain Monoamine', 'no label'), ('Brain Phenylalanine', 'no label'), ('Brain Monoamine', 'no label'), ('Phenylalanine', 'no label'), ('Mice', 'no label'), ('Lnaa', 'no label'), ('Pku Patients', 'no label'), ('Pku Mice', 'no label'), ('Lnaa', 'no label'), ('Phenylalanine', 'no label'), ('Brain Monoamine', 'no label'), ('Plasma', 'no label'), ('Brain Phenylalanine', 'no label'), ('Brain Phenylalanine', 'no label')]
phenylketonuria|pubmed~34144002|To Estimate The Prevalence And Factors Associated With Overweight/Obesity Development In Adolescents With Early Diagnosed Phenylketonuria Treated Exclusively By Diet. In This Cross-Sectional Study Anthropometric Measurements, Serum Phenylalanine Levels, And 10 Metabolites Associated With Lipid And Carbohydrate Metabolism Were Analyzed In 101 Adolescents Aged 10-20 Years. Adolescents Were Categorized Into Overweight/Obesity And Eutrophic/Low Body Mass Index Groups. These Patients Were Compared Using Student'S T-Test, Pearson'S Chi-Square Test, Wald'S Chi-Square Test For Multivariate Analysis. Further, To Verify Whether The Prevalence Of Overweight/Obesity Found In The Study Population Was Similar To That In The General Population, The Authors Compared The Nutritional Status Of 46 Patients Aged 13-17 Years With That Of Healthy Students Of The Same Age From The National School Health Survey Using The Chi-Square Test For Adherence. The Significance Threshold Was P < 0.5. The Prevalence Of Overweight/Obesity In Adolescents Was 27.7%. There Was No Difference In Prevalence Between Sexes. Older Age Was A Protective Factor And Increased Homeostasis Model Assessment Insulin Resistance Index And High Phenylalanine And Low-Density Lipoprotein Cholesterol Levels Were Predictive Factors For Overweight/Obesity. The Equality Hypothesis Was Not Rejected In The Comparison Of Nutritional States Of 46 Patients Aged 13-17 Years And Healthy Students Of The Same Age. The Prevalence Of Overweight/Obesity In Phenylketonuria Adolescents Was Similar To What Is Found In Healthy Adolescents.|"[('Estimate', 'no label'), ('Prevalence', 'no label'), ('Factors', 'no label'), ('Associated With', 'no label'), ('Overweight/Obesity Development', 'no label'), ('Adolescents', 'no label'), ('Early Diagnosed', 'no label'), ('Phenylketonuria', 'no label'), ('Treated', 'no label'), ('Exclusively By Diet', 'no label'), ('Cross-Sectional Study', 'no label'), ('Anthropometric Measurements', 'no label'), ('Serum Phenylalanine Levels', 'no label'), ('Metabolites', 'no label'), ('Associated With', 'no label'), ('Lipid', 'no label'), ('Carbohydrate Metabolism', 'no label'), ('Analyzed', 'no label'), ('Adolescents', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Adolescents', 'no label'), ('Categorized', 'no label'), ('Overweight/Obesity', 'no label'), ('Eutrophic/Low', 'no label'), ('Body Mass Index', 'no label'), ('Groups', 'no label'), ('Patients', 'no label'), (""Student'S T-Test"", 'no label'), (""Pearson'S Chi-Square Test"", 'no label'), (""Wald'S Chi-Square Test"", 'no label'), ('Multivariate Analysis', 'no label'), ('Prevalence', 'no label'), ('Overweight/Obesity', 'no label'), ('Study Population', 'no label'), ('General Population', 'no label'), ('Compared', 'no label'), ('Nutritional Status', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Healthy Students', 'no label'), ('Same Age', 'no label'), ('National School Health Survey', 'no label'), ('Chi-Square Test', 'no label'), ('Adherence', 'no label'), ('Significance', 'no label'), ('Threshold', 'no label'), ('Prevalence', 'no label'), ('Overweight/Obesity', 'no label'), ('Adolescents', 'no label'), ('No Difference', 'no label'), ('Prevalence', 'no label'), ('Sexes', 'no label'), ('Older Age', 'no label'), ('Protective Factor', 'no label'), ('Increased', 'no label'), ('Homeostasis Model Assessment', 'no label'), ('Insulin Resistance Index', 'no label'), ('Phenylalanine', 'no label'), ('Low-Density', 'no label'), ('Lipoprotein Cholesterol Levels', 'no label'), ('Predictive Factors', 'no label'), ('Overweight/Obesity', 'no label'), ('Equality Hypothesis', 'no label'), ('Comparison', 'no label'), ('Nutritional States', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Healthy Students', 'no label'), ('Same Age', 'no label'), ('Prevalence', 'no label'), ('Overweight/Obesity', 'no label'), ('Phenylketonuria', 'no label'), ('Adolescents', 'no label'), ('Healthy', 'no label'), ('Adolescents', 'no label')]"|[('Phenylalanine', 'no label'), ('Metabolites', 'no label'), ('Lipid', 'no label'), ('Carbohydrate', 'no label'), ('Insulin', 'no label'), ('Phenylalanine', 'no label'), ('Cholesterol', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Cholesterol', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Serum Phenylalanine', 'no label'), ('Lipid', 'no label'), ('Carbohydrate', 'no label'), ('Eutrophic/Low Body', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Insulin', 'no label'), ('Low-Density Lipoprotein', 'no label'), ('Cholesterol', 'no label'), ('Patients', 'no label'), ('Phenylketonuria Adolescents', 'no label')]
phenylketonuria|pubmed~34145605|Previous Studies Have Suggested That Cognitive And Psychosocial Underfunctioning In Early-Treated Adults With Phenylketonuria (Pku) May Be Explained By Suboptimal Adherence To Dietary Treatments, However, These Studies Often Employ Small Samples, With Different Outcome Measures, Definitions And Cut-Offs. Samples Have Also Tended To Comprise Participants With A Limited Range Of Blood Phenylalanine Concentrations, And Often Individuals Who May Not Have Been Treated Early Enough To Avoid Neurological Damage. In This Study, We Explore The Impact Of Lifetime Dietary Control, As Indicated By Blood Phenylalanine Concentrations In Childhood, Adolescence And Adulthood, On Long-Term Cognitive And Psychosocial Outcomes In A Large Sample Of Adults With Pku Who Were Diagnosed By Neonatal Screening And Commenced On Dietary Treatment Within The First Month Of Life. One Hundred And Fifty-Four Participants Underwent Cognitive Testing, Assessing Attention, Learning, Working Memory, Language, Executive Functioning And Processing Speed. One Hundred And Forty-Nine Completed Measures Of Psychosocial Functioning, Documenting Educational, Occupational, Quality Of Life, Emotional And Social Outcomes Which Were Compared With A Group Of Healthy Controls. Many Adults With Pku Demonstrated Cognitive Impairments, Most Frequently Affecting Processing Speed (23%), Executive Function (20%) And Learning (12%). Cognitive Outcomes Were Related To Measures Of Historic Metabolic Control, But Only Processing Speed Was Significantly Related To Phenylalanine Concentration At The Time Of Testing After Controlling For Historic Levels. Adults With Pku Did Not, However, Differ From Controls In Educational, Occupational, Quality Of Life Or Emotional Outcomes, Or On A Measure Of Family Functioning, And Showed Only Minor Differences In Relationship Style. These Findings Have Implications For Patient Counselling And Decisions Regarding The Management Of Pku In Adulthood.|[('Studies', 'no label'), ('Suggested', 'no label'), ('Cognitive', 'no label'), ('Psychosocial', 'no label'), ('Underfunctioning', 'no label'), ('Early-Treated Adults', 'no label'), ('Phenylketonuria', 'no label'), ('Explained', 'no label'), ('Suboptimal Adherence', 'no label'), ('Dietary Treatments', 'no label'), ('Studies', 'no label'), ('Employ', 'no label'), ('Outcome Measures', 'no label'), ('Definitions', 'no label'), ('Cut-Offs', 'no label'), ('Samples', 'no label'), ('Tended', 'no label'), ('Comprise', 'no label'), ('Participants', 'no label'), ('Limited Range', 'no label'), ('Blood Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Individuals', 'no label'), ('May', 'no label'), ('Treated', 'no label'), ('Early', 'no label'), ('Neurological Damage', 'no label'), ('Study', 'no label'), ('Impact', 'no label'), ('Lifetime', 'no label'), ('Dietary Control', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Childhood', 'no label'), ('Adolescence', 'no label'), ('Adulthood', 'no label'), ('Long-Term Cognitive', 'no label'), ('Psychosocial', 'no label'), ('Outcomes', 'no label'), ('Sample', 'no label'), ('Adults', 'no label'), ('Pku Who', 'no label'), ('Diagnosed', 'no label'), ('Neonatal', 'no label'), ('Screening', 'no label'), ('Commenced', 'no label'), ('Dietary Treatment', 'no label'), ('Month', 'no label'), ('Life', 'no label'), ('Fifty-Four', 'no label'), ('Participants', 'no label'), ('Cognitive Testing', 'no label'), ('Attention', 'no label'), ('Learning', 'no label'), ('Working Memory', 'no label'), ('Language', 'no label'), ('Executive Functioning And Processing', 'no label'), ('Speed', 'no label'), ('Forty-Nine', 'no label'), ('Completed Measures', 'no label'), ('Psychosocial Functioning', 'no label'), ('Documenting Educational', 'no label'), ('Occupational', 'no label'), ('Emotional', 'no label'), ('Social', 'no label'), ('Outcomes', 'no label'), ('Group', 'no label'), ('Healthy Controls', 'no label'), ('Adults', 'no label'), ('Pku Demonstrated Cognitive Impairments', 'no label'), ('Affecting', 'no label'), ('Processing', 'no label'), ('Speed', 'no label'), ('Executive Function', 'no label'), ('Learning', 'no label'), ('Cognitive Outcomes', 'no label'), ('Measures', 'no label'), ('Historic', 'no label'), ('Metabolic Control', 'no label'), ('Processing', 'no label'), ('Speed', 'no label'), ('Phenylalanine', 'no label'), ('Concentration', 'no label'), ('Time', 'no label'), ('Testing', 'no label'), ('Controlling', 'no label'), ('Historic Levels', 'no label'), ('Adults', 'no label'), ('Pku', 'no label'), ('Differ', 'no label'), ('Controls', 'no label'), ('Educational', 'no label'), ('Occupational', 'no label'), ('Emotional Outcomes', 'no label'), ('Measure', 'no label'), ('Family Functioning', 'no label'), ('Minor Differences', 'no label'), ('Relationship', 'no label'), ('Style', 'no label'), ('Findings', 'no label'), ('Patient Counselling', 'no label'), ('Decisions', 'no label'), ('Management', 'no label'), ('Pku In Adulthood', 'no label')]|[('Phenylalanine', 'no label'), ('Individuals', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Neurological Damage', 'no label'), ('Phenylalanine', 'no label'), ('Forty-Nine', 'no label'), ('Cognitive Impairments', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Blood Phenylalanine', 'no label'), ('Blood Phenylalanine', 'no label'), ('Forty-Nine', 'no label'), ('Phenylalanine', 'no label'), ('Pku Did', 'no label'), ('Patient', 'no label'), ('Pku', 'no label')]
phenylketonuria|pubmed~34654619|Phenylalanine Hydroxylase Deficiency, Or Phenylketonuria (Pku), Is A Rare Autosomal Recessive Metabolic Disorder. Early Diagnosis Via Newborn Screening (Nbs) And Initiation Of Treatment Prevent The Development Of Cognitive Impairment And Other Co-Morbidities. The Purpose Of This Study Is To Describe The Natural History Of Pku In The United States, Including Prevalence Of Co-Morbidities And Predictors Of Outcomes. We Analyzed Data From A Self-Report Survey In The Nbs-Pku Connect Online Registry. We Describe The Participants' Nutrition Management Strategies, Barriers To Management, Outcomes Of Bone Disorders, Skin, And Psychological Co-Morbidities, And The Use Of Special Education Or Other Special Services. Predictors Of Outcomes Were Identified And Assessed, Including The Impact Of Sex, Age, Age At Diagnosis, Blood Phenylalanine Concentration, Use Of Sapropterin, Use Of Medical Food, Adherence To Prescribed Diet, Use Of Low Protein Modified Foods, Whether They Had Ever Been Off-Diet, And Use Of Tyrosine Supplementation. The 219 Respondents Included Individuals With Pku Or Hyperphenylalanemia (N = 78), Or Their Caregivers (N = 141). Most (84.3%) Started Treatment Before The Age Of Two Weeks. About One-Third Indicated That They Had Been Off-Diet At Some Point In Their Lives, And 81.4% Reported That They Currently Adhered To Their Prescribed Diet, With Adherence To Prescribed Diet Decreasing With Age. Blood Phenylalanine Concentration Was Under The Recommended Threshold Of 360 Μmol/L For 68.5% Of Participants. One-Quarter Of Respondents Reported Psychological Co-Morbidities, With Anxiety And Add/Adhd Being The Most Common. The Incidence Of Psychological Co-Morbidities Increased With Age And With Ever Having Been Off Diet. Special Education Or Other Special Services Were More Likely To Be Reported By Individuals Who Were Diagnosed After One Week Of Age. Skin Disorders Such As Acne And Eczema Were More Common In Females Than Males, And A Minority Of Participants Reported Bone Disorders. Despite Recommendations To Maintain Blood Phenylalanine Concentrations In The Therapeutic Range Throughout Life, It Is Not Uncommon For Adults With Pku To Discontinue Dietary Management Of Their Disorder. Early Diagnosis Was Associated With Reduced Need For Special Education Or Other Special Services, And Continuous Treatment Was Associated With Decreased Psychological Co-Morbidities.|"[('Phenylalanine Hydroxylase Deficiency', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Rare', 'no label'), ('Autosomal', 'no label'), ('Recessive Metabolic Disorder', 'no label'), ('Early Diagnosis', 'no label'), ('Newborn Screening', 'no label'), ('Nbs', 'no label'), ('Initiation', 'no label'), ('Treatment Prevent', 'no label'), ('Development', 'no label'), ('Cognitive Impairment', 'no label'), ('Co-Morbidities', 'no label'), ('Study', 'no label'), ('Natural History', 'no label'), ('United States', 'no label'), ('Prevalence', 'no label'), ('Co-Morbidities', 'no label'), ('Predictors', 'no label'), ('Outcomes', 'no label'), ('Analyzed', 'no label'), ('Data', 'no label'), ('Self-Report Survey', 'no label'), ('Nbs-Pku Connect Online Registry', 'no label'), (""Participants'"", 'no label'), ('Nutrition Management Strategies', 'no label'), ('Barriers', 'no label'), ('Management', 'no label'), ('Outcomes', 'no label'), ('Bone Disorders', 'no label'), ('Skin', 'no label'), ('Psychological Co-Morbidities', 'no label'), ('Special Education', 'no label'), ('Special Services', 'no label'), ('Predictors', 'no label'), ('Outcomes', 'no label'), ('Identified', 'no label'), ('Assessed', 'no label'), ('Impact', 'no label'), ('Sex', 'no label'), ('Age', 'no label'), ('Age', 'no label'), ('Diagnosis', 'no label'), ('Blood Phenylalanine Concentration', 'no label'), ('Sapropterin', 'no label'), ('Medical Food', 'no label'), ('Adherence', 'no label'), ('Diet', 'no label'), ('Low Protein Modified Foods', 'no label'), ('Off-Diet', 'no label'), ('Tyrosine', 'no label'), ('Supplementation', 'no label'), ('Respondents', 'no label'), ('Individuals', 'no label'), ('Pku Or Hyperphenylalanemia', 'no label'), ('Caregivers', 'no label'), ('N\xa0', 'no label'), ('Started Treatment', 'no label'), ('Age', 'no label'), ('Weeks', 'no label'), ('One-Third', 'no label'), ('Off-Diet', 'no label'), ('Point', 'no label'), ('Lives', 'no label'), ('Reported', 'no label'), ('Adhered', 'no label'), ('Prescribed Diet', 'no label'), ('Adherence', 'no label'), ('Prescribed Diet', 'no label'), ('Decreasing', 'no label'), ('Age', 'no label'), ('Blood Phenylalanine', 'no label'), ('Concentration', 'no label'), ('Recommended', 'no label'), ('Threshold', 'no label'), ('Participants', 'no label'), ('Respondents', 'no label'), ('Psychological', 'no label'), ('Co-Morbidities', 'no label'), ('Anxiety', 'no label'), ('Add/Adhd Being', 'no label'), ('Common', 'no label'), ('Incidence', 'no label'), ('Psychological', 'no label'), ('Co-Morbidities', 'no label'), ('Increased', 'no label'), ('Age', 'no label'), ('Been Off Diet', 'no label'), ('Special Education', 'no label'), ('Special Services', 'no label'), ('Individuals', 'no label'), ('Diagnosed', 'no label'), ('Week', 'no label'), ('Age', 'no label'), ('Skin Disorders', 'no label'), ('Acne', 'no label'), ('Eczema', 'no label'), ('Females', 'no label'), ('Males', 'no label'), ('Minority', 'no label'), ('Participants', 'no label'), ('Bone Disorders', 'no label'), ('Recommendations', 'no label'), ('Maintain', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Therapeutic Range', 'no label'), ('Life', 'no label'), ('Adults', 'no label'), ('Discontinue', 'no label'), ('Dietary Management', 'no label'), ('Disorder', 'no label'), ('Early Diagnosis', 'no label'), ('Associated With', 'no label'), ('Reduced', 'no label'), ('Need', 'no label'), ('Special Services', 'no label'), ('Continuous Treatment', 'no label'), ('Associated With', 'no label'), ('Decreased', 'no label'), ('Psychological', 'no label'), ('Co-Morbidities', 'no label')]"|[('Phenylalanine', 'no label'), ('Blood Phenylalanine', 'no label'), ('Food', 'no label'), ('Protein', 'no label'), ('Tyrosine', 'no label'), ('Individuals', 'no label'), ('Phenylalanine', 'no label'), ('Individuals', 'no label'), ('Phenylalanine', 'no label')]|[('Add/Adhd', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Cognitive Impairment', 'no label'), ('Phenylalanine', 'no label'), ('Sapropterin', 'no label'), ('Tyrosine', 'no label'), ('Hyperphenylalanemia', 'no label'), ('N\xa0=\xa078)', 'no label'), ('N\xa0=\xa0141', 'no label'), ('Phenylalanine', 'no label'), ('Anxiety', 'no label'), ('Acne', 'no label'), ('Eczema', 'no label'), ('Phenylalanine', 'no label'), ('Discontinue', 'no label'), ('Disorder', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylketonuria', 'no label'), ('Bone', 'no label'), ('Skin', 'no label'), ('Blood Phenylalanine', 'no label'), ('Sapropterin', 'no label'), ('Tyrosine', 'no label'), ('Off-Diet', 'no label'), ('Blood Phenylalanine', 'no label'), ('Skin', 'no label'), ('Bone', 'no label'), ('Blood Phenylalanine', 'no label')]
phenylketonuria|pubmed~32639944|Objectives We Investigated The Quality Of Life (Qol) In Parents Of Children With Late Treated Phenylketonuria (Pku) And Its Associated Factors. Methods We Conducted A Cross Sectional Study In The Reference Center Of Inherited Metabolic Disease In Tunisia. We Used The Tunisian Version Of The 36-Item Short-Form Health Survey Questionnaire (Sf-36). We Compared Variables In The Groups With And Without Impaired Qol And The Sf-36 Scores Between Subgroups Of Parents And Children And Between Our Sample And The Tunisian General Population Based On Published Data. We Looked For Associations Between Sf-36 Scores And Quantitative Variables. Linear Regression And Logistic Binary Regression Were Used For Multivariate Analysis. Results Sixty-Five Parents From 42 Families Participated. Qol Was Impaired In 61% Of Them. The Mean Sf-36 Score Was 55.3 ± 25.07. The Physical Component Sub-Score Was Higher Than That Reported In The Tunisian General Population (63.66 ± 27.77 Vs. 50.11 ± 8.53; P<0.001). The Mental Component Sub-Score Was Comparable To That Reported In The Tunisian General Population (46.99 ± 25.94 Vs. 47.96 ± 9.82; P=0.830). Gender (Mothers) (P=0.008), Low Monthly Income (P = 0.027), Low Education (P=0.011), And Autism In Pku Children (P = 0.001) Were Associated With Impaired Qol. Conclusions We Identified At Risk Parents For Altered Quality Of Life Among Parents Of Pku Children. Our Findings Were Used To Develop A Psychological And Social Support Strategy For At-Risk Parents And To Promote The Implementation Of Newborn Screening Of This Treatable Disease In Our Low-Income Country.|[('Objectives', 'no label'), ('Investigated', 'no label'), ('Quality Of Life (Qol)', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Late Treated Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Associated Factors', 'no label'), ('Cross Sectional Study', 'no label'), ('Reference Center', 'no label'), ('Inherited', 'no label'), ('Metabolic Disease', 'no label'), ('Tunisia', 'no label'), ('Tunisian', 'no label'), ('Version', 'no label'), ('36-Item Short-Form Health Survey Questionnaire', 'no label'), ('Sf-36', 'no label'), ('Variables', 'no label'), ('Groups', 'no label'), ('Impaired', 'no label'), ('Qol', 'no label'), ('Sf-36 Scores', 'no label'), ('Subgroups', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Sample', 'no label'), ('Tunisian', 'no label'), ('General Population', 'no label'), ('Published Data', 'no label'), ('Associations', 'no label'), ('Sf-36 Scores', 'no label'), ('Quantitative Variables', 'no label'), ('Linear Regression', 'no label'), ('Logistic Binary Regression', 'no label'), ('Multivariate Analysis', 'no label'), ('Results', 'no label'), ('Parents', 'no label'), ('Families', 'no label'), ('Qol Was Impaired', 'no label'), ('Mean Sf-36 Score', 'no label'), ('Physical Component Sub-Score', 'no label'), ('Tunisian', 'no label'), ('General Population', 'no label'), ('Mental Component Sub-Score', 'no label'), ('Tunisian', 'no label'), ('General Population', 'no label'), ('Gender', 'no label'), ('Mothers', 'no label'), ('Low Monthly Income', 'no label'), ('Low Education', 'no label'), ('Autism', 'no label'), ('Pku Children', 'no label'), ('Associated With', 'no label'), ('Impaired', 'no label'), ('Qol', 'no label'), ('Identified', 'no label'), ('Risk Parents', 'no label'), ('Altered Quality Of Life', 'no label'), ('Parents', 'no label'), ('Pku Children', 'no label'), ('Findings', 'no label'), ('Psychological', 'no label'), ('Social Support Strategy', 'no label'), ('At-Risk', 'no label'), ('Parents', 'no label'), ('Promote', 'no label'), ('Implementation', 'no label'), ('Newborn', 'no label'), ('Screening', 'no label'), ('Treatable Disease', 'no label'), ('Low-Income Country', 'no label')]|[('Sub-Score', 'no label'), ('Sub-Score', 'no label')]|[]|[('Treated Phenylketonuria', 'no label'), ('Metabolic Disease', 'no label'), ('Autism', 'no label')]|[('Parents', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('63.66', 'no label')]
phenylketonuria|pubmed~34391119|Phenylketonuria (Pku) Is A Rare, Treatable Inborn Error Of Metabolism With Frequent Neurological And Neuropsychiatric Complications, Especially In Undiagnosed Or Insufficiently Treated Individuals. Given The Wide Range Of Clinical Presentations And The Importance Of Treatment Implications, We Here Delineate The Neurological And Neuropsychiatric Symptom Spectrum In A Large Cohort Of Previously Unreported Adults With Late-Treated Pku. We Consecutively Evaluated Late-Treated Pku Cases And Pooled Clinical And Paraclinical Data, Including Video-Material, From Three Centers With Expertise In Complex Movement Disorders, Inborn Errors Of Metabolism And Pediatrics. 26 Individuals Were Included (10 Females, Median Age 52 Years). Developmental Delay And Intellectual Disability Were Omnipresent With Severe Impairment Of Expressive Communication Noted In 50% Of Cases. Movement Disorders Were Prevalent (77%), Including Tremor (38%, Mostly Postural), Stereotypies (38%), And Tics (19%). One Case Had Neurodegenerative Levodopa-Responsive Parkinsonism. Mild Ataxia Was Noted In 54% Of Cases And 31% Had A History Of Seizures. Neuropsychiatric Characteristics Included Obsessive-Compulsive (35%) And Self-Injurious Behaviors (31%), Anxiety (27%), Depression (19%) And Features Compatible With Those Observed In Individuals With Autism Spectrum Disorder (19%). Neuroimaging Revealed Mild White Matter Changes. Adherence To Dietary Treatment Was Inconsistent In The Majority Of Cases, Particularly Throughout Adolescence. A History Of Movement Disorders, Particularly Tremor, Stereotypies And Tics, In The Presence Of Developmental Delay, Intellectual Disability And Neuropsychiatric Features, Such As Obsessive-Compulsive And Self-Injurious Behaviors In Adults Should Prompt The Diagnostic Consideration Of Pku. Initiation And Adherence To (Dietary) Treatment Can Ameliorate The Severity Of These Symptoms.|[('Phenylketonuria', 'no label'), ('Rare', 'no label'), ('Treatable Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Frequent', 'no label'), ('Neurological', 'no label'), ('Neuropsychiatric Complications', 'no label'), ('Undiagnosed', 'no label'), ('Insufficiently', 'no label'), ('Treated', 'no label'), ('Individuals', 'no label'), ('Wide Range', 'no label'), ('Clinical Presentations', 'no label'), ('Treatment', 'no label'), ('Neurological And Neuropsychiatric Symptom Spectrum', 'no label'), ('Cohort', 'no label'), ('Unreported', 'no label'), ('Adults', 'no label'), ('Late-Treated', 'no label'), ('Evaluated Late-Treated Pku Cases', 'no label'), ('Pooled', 'no label'), ('Clinical', 'no label'), ('Paraclinical Data', 'no label'), ('Video-Material', 'no label'), ('Centers', 'no label'), ('Expertise', 'no label'), ('Complex Movement Disorders', 'no label'), ('Inborn Errors', 'no label'), ('Metabolism', 'no label'), ('Pediatrics', 'no label'), ('Individuals', 'no label'), ('Females', 'no label'), ('Median Age', 'no label'), ('Years', 'no label'), ('Developmental Delay', 'no label'), ('Intellectual Disability', 'no label'), ('Omnipresent', 'no label'), ('Severe Impairment', 'no label'), ('Expressive Communication Noted', 'no label'), ('Cases', 'no label'), ('Prevalent', 'no label'), ('Tremor', 'no label'), ('Postural', 'no label'), ('Stereotypies', 'no label'), ('Tics', 'no label'), ('Case', 'no label'), ('Neurodegenerative', 'no label'), ('Levodopa-Responsive Parkinsonism', 'no label'), ('Mild Ataxia', 'no label'), ('Noted', 'no label'), ('Cases', 'no label'), ('History', 'no label'), ('Seizures', 'no label'), ('Neuropsychiatric Characteristics', 'no label'), ('Obsessive-Compulsive', 'no label'), ('Self-Injurious Behaviors', 'no label'), ('Anxiety', 'no label'), ('Depression', 'no label'), ('Features', 'no label'), ('Compatible', 'no label'), ('Observed', 'no label'), ('Individuals', 'no label'), ('Autism Spectrum Disorder', 'no label'), ('Neuroimaging', 'no label'), ('Mild White', 'no label'), ('Changes', 'no label'), ('Adherence', 'no label'), ('Dietary Treatment', 'no label'), ('Inconsistent', 'no label'), ('Cases', 'no label'), ('Adolescence', 'no label'), ('History Of Movement Disorders', 'no label'), ('Tremor', 'no label'), ('Stereotypies', 'no label'), ('Tics', 'no label'), ('Developmental Delay', 'no label'), ('Intellectual Disability And Neuropsychiatric Features', 'no label'), ('Obsessive-Compulsive', 'no label'), ('Self-Injurious Behaviors', 'no label'), ('Adults', 'no label'), ('Prompt', 'no label'), ('Diagnostic', 'no label'), ('Initiation', 'no label'), ('Adherence', 'no label'), ('Dietary', 'no label'), ('Treatment', 'no label'), ('Ameliorate', 'no label'), ('Severity', 'no label'), ('Symptoms', 'no label')]|[('Individuals', 'no label'), ('Individuals', 'no label'), ('Individuals', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Movement Disorders, Inborn Errors', 'no label'), ('Impairment Of Expressive Communication', 'no label'), ('Tremor', 'no label'), ('Neurodegenerative Levodopa-Responsive Parkinsonism', 'no label'), ('Ataxia', 'no label'), ('Seizures', 'no label'), ('Obsessive-Compulsive', 'no label'), ('Self-Injurious Behaviors', 'no label'), ('Anxiety', 'no label'), ('Depression', 'no label'), ('Autism Spectrum Disorder', 'no label'), ('Movement Disorders', 'no label'), ('Tremor', 'no label'), ('Obsessive-Compulsive', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Neuropsychiatric', 'no label'), ('Neuropsychiatric Symptom', 'no label')]
phenylketonuria|pubmed~35276935|There Is An Increasing Number Of Adults And Elderly Patients With Phenylketonuria (Pku) Who Are Either Early, Late Treated, Or Untreated. The Principal Treatment Is A Phenylalanine-Restricted Diet. There Is No Established Uk Training For Dietitians Who Work With Adults Within The Specialty Of Inherited Metabolic Disorders (Imds), Including Pku. To Address This, A Group Of Experienced Dietitians Specializing In Imds Created A Standard Operating Procedure (Sop) On The Dietetic Management Of Adults With Pku To Promote Equity Of Care In Imd Dietetic Services And To Support Service Provision Across The Uk. The Group Met Virtually Over A Period Of 12 Months Until They Reached 100% Consensus On The Sop Content. Areas Of Limited Evidence Included Optimal Blood Phenylalanine Reporting Times To Patients, Protein Requirements In Older Adults, Management Of Weight And Obesity, And Management Of Disordered Eating And Eating Disorders. The Sop Does Not Include Guidance On Maternal Pku Management. The Sop Can Be Used As A Tool For Training Dietitians New To The Specialty And To Raise The Standard Of Education And Care For Patients With Pku In The Uk.|[('Adults', 'no label'), ('Elderly', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Early', 'no label'), ('Late Treated', 'no label'), ('Untreated', 'no label'), ('Principal Treatment', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Uk Training', 'no label'), ('Dietitians', 'no label'), ('Adults', 'no label'), ('Inherited', 'no label'), ('Metabolic Disorders', 'no label'), ('Imds', 'no label'), ('Group', 'no label'), ('Experienced', 'no label'), ('Dietitians Specializing', 'no label'), ('Imds Created A Standard Operating Procedure', 'no label'), ('Sop', 'no label'), ('Dietetic Management', 'no label'), ('Adults', 'no label'), ('Promote', 'no label'), ('Equity', 'no label'), ('Imd Dietetic Services', 'no label'), ('Provision', 'no label'), ('Uk', 'no label'), ('Group', 'no label'), ('Met', 'no label'), ('Period', 'no label'), ('Months', 'no label'), ('Consensus', 'no label'), ('Sop Content', 'no label'), ('Limited Evidence', 'no label'), ('Optimal', 'no label'), ('Blood Phenylalanine Reporting Times', 'no label'), ('Patients', 'no label'), ('Protein Requirements', 'no label'), ('Older Adults', 'no label'), ('Management', 'no label'), ('Weight', 'no label'), ('Obesity', 'no label'), ('Management', 'no label'), ('Disordered Eating', 'no label'), ('Sop', 'no label'), ('Guidance', 'no label'), ('Maternal', 'no label'), ('Pku Management', 'no label'), ('Sop', 'no label'), ('Tool', 'no label'), ('Training Dietitians', 'no label'), ('Specialty', 'no label'), ('Standard', 'no label'), ('Patients', 'no label')]|[('Sop', 'no label'), ('Met', 'no label'), ('Consensus', 'no label'), ('Sop', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Sop', 'no label'), ('Sop', 'no label')]|[('Imd', 'no label'), ('Sop', 'no label'), ('Sop', 'no label'), ('Sop', 'no label')]|[('Phenylketonuria', 'no label'), ('Metabolic Disorders', 'no label'), ('Phenylalanine', 'no label'), ('Obesity', 'no label')]|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Imds', 'no label'), ('Imd', 'no label'), ('Met', 'no label'), ('Blood Phenylalanine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~32159642|"To Verify The Occurrence Of Overweight In Children And Adolescents With Phenylketonuria And To Identify Possible Causal Factors. A Systematic Review Was Performed In The Scielo, Pubmed And Vhl Databases Using The Descriptors ""Phenylketonurias"", ""Overweight"", ""Child"" And ""Adolescent"". Original Articles Conducted With Children And Adolescents, Published Between 2008 And 2018 In Portuguese, English Or Spanish Languages Were Included. A Total Of 16 Articles Were Identified And, After Screening Procedures, 6 Studies Were Selected For The Review. Overweight In Children And Adolescents With Phenylketonuria Was A Frequent Occurence In The Studies Included In This Review, Ranging From 7.8 To 32.6%. The Female Sex Was The Most Affected By The Nutritional Disorder. Furthermore, A High Caloric Intake Combined With A Lack Of Stimuli To Practice Physical Activities Were Main Factors Associated With The Excessive Weight In The Population Of Interest. Excess Weight Can Be Considered A Common Outcome In Children And Adolescents With Phenylketonuria. It Is Mainly Caused By Inadequate Food Consumption And Sedentary Lifestyle. The Importance Of Early Identification Of Nutritional Disturbances In Children And Adolescents With Phenylketonuria Should Be Emphasized, In Order To Prevent Associated Chronic Diseases And To Promote Health By Encouraging Continued Healthy Eating Habits And The Regular Practice Of Physical Exercises."|[('Overweight', 'no label'), ('Children', 'no label'), ('Adolescents', 'no label'), ('Phenylketonuria', 'no label'), ('Causal Factors', 'no label'), ('Systematic Review', 'no label'), ('Performed', 'no label'), ('Scielo', 'no label'), ('Pubmed', 'no label'), ('Vhl Databases', 'no label'), ('Descriptors', 'no label'), ('Original Articles', 'no label'), ('Children', 'no label'), ('Adolescents', 'no label'), ('Published', 'no label'), ('Portuguese', 'no label'), ('English', 'no label'), ('Spanish', 'no label'), ('Languages', 'no label'), ('Articles', 'no label'), ('Identified', 'no label'), ('Screening Procedures', 'no label'), ('Studies', 'no label'), ('Review', 'no label'), ('Overweight', 'no label'), ('Children', 'no label'), ('Adolescents', 'no label'), ('Phenylketonuria', 'no label'), ('Frequent', 'no label'), ('Occurence', 'no label'), ('Studies', 'no label'), ('Review', 'no label'), ('Ranging', 'no label'), ('Female', 'no label'), ('Sex', 'no label'), ('Affected', 'no label'), ('Nutritional Disorder', 'no label'), ('High Caloric Intake', 'no label'), ('Lack', 'no label'), ('Physical Activities', 'no label'), ('Main Factors', 'no label'), ('Associated With', 'no label'), ('Excessive Weight', 'no label'), ('Population', 'no label'), ('Excess Weight', 'no label'), ('Common Outcome', 'no label'), ('Children', 'no label'), ('Adolescents', 'no label'), ('Phenylketonuria', 'no label'), ('Inadequate Food Consumption', 'no label'), ('Sedentary Lifestyle', 'no label'), ('Early Identification', 'no label'), ('Nutritional Disturbances', 'no label'), ('Children', 'no label'), ('Adolescents', 'no label'), ('Phenylketonuria', 'no label'), ('Emphasized', 'no label'), ('Order', 'no label'), ('Prevent', 'no label'), ('Chronic Diseases', 'no label'), ('Promote', 'no label'), ('Health', 'no label'), ('Healthy Eating Habits', 'no label'), ('Regular Practice', 'no label'), ('Physical Exercises', 'no label')]|[('Food', 'no label')]|[('Vhl', 'no label'), ('Sex', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Nutritional Disorder', 'no label'), ('Phenylketonuria', 'no label'), ('Nutritional Disturbances', 'no label'), ('Phenylketonuria', 'no label')]|[('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Vhl', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('High Caloric', 'no label'), ('Stimuli', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~31484718|Phenylketonuria (Pku) Is A Prototypical Model Of A Neurodevelopmental Metabolic Disease That Follows A Cascade Of Pathological Events Affecting Brain Maturation And Functioning. Neonatal Screening And Early Treatment Have Eradicated The Classical Pku Phenotype In Patients With Early And Continuously Treated Phenylketonuria (Ectpku). However, Effort Is Required To Optimise The Treatment Of The Disease To Minimise The Risk Of Lifelong Neurological, Cognitive And Behavioural Impairment, And To Solve Issues On The Variability In Clinical Outcome That Are Rather Not Understood And Has Yet Hampered A More Personalised Approach To Its Treatment. The Aim Of The Present Review Is To Focus On The Inconsistencies In The Clinical Outcome Of Adult Patients With Ectpku Unexplained By The Biochemical Markers Adopted For The Monitoring Of The Disease To Date. The Interindividual Variability Of Clinical Outcome In Late As Well As In Early Treated Patients Under Similar Biochemical Control Suggests The Existence Of Disease-Independent Determinants Influencing The Individual Vulnerability To The Neurotoxic Effect Of Phenylalanine. This Is Further Supported By The Low Predictive Power Of Blood Phenylalanine On The Clinical Outcome From The Second Decade Of Life Onwards. In Conclusion, Individual Vulnerability To The Metabolic Alterations Of Pku Contributes To The Prognosis Of Pku, Also In Patients With Ectpku. The Biological Factors Constitutive Of This Vulnerability Are Unknown (But Have Not Been The Object Of Many Studies So Far) And Should Be The Target Of Further Research As Prerequisite For A Personalised Treatment Aimed At Avoiding Burden And Costs Of Overtreatment And Clinical Consequences And Risks Of Undertreatment In Patients With Pku.|[('Phenylketonuria', 'no label'), ('Prototypical Model', 'no label'), ('Neurodevelopmental Metabolic Disease', 'no label'), ('Follows', 'no label'), ('Pathological Events', 'no label'), ('Brain Maturation', 'no label'), ('Functioning', 'no label'), ('Neonatal', 'no label'), ('Screening', 'no label'), ('Early Treatment', 'no label'), ('Eradicated', 'no label'), ('Classical Pku Phenotype', 'no label'), ('Patients', 'no label'), ('Early', 'no label'), ('Continuously', 'no label'), ('Treated', 'no label'), ('Phenylketonuria', 'no label'), ('Ectpku', 'no label'), ('Effort', 'no label'), ('Optimise', 'no label'), ('Treatment', 'no label'), ('Disease', 'no label'), ('Risk', 'no label'), ('Neurological', 'no label'), ('Cognitive', 'no label'), ('Variability', 'no label'), ('Clinical Outcome', 'no label'), ('Hampered A', 'no label'), ('Personalised Approach', 'no label'), ('Treatment', 'no label'), ('Present Review', 'no label'), ('Inconsistencies', 'no label'), ('Clinical Outcome', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Ectpku Unexplained', 'no label'), ('Biochemical Markers Adopted', 'no label'), ('Monitoring', 'no label'), ('Disease', 'no label'), ('Interindividual', 'no label'), ('Variability', 'no label'), ('Clinical Outcome', 'no label'), ('Early', 'no label'), ('Treated', 'no label'), ('Patients', 'no label'), ('Biochemical Control Suggests', 'no label'), ('Existence', 'no label'), ('Disease-Independent Determinants', 'no label'), ('Individual Vulnerability', 'no label'), ('Neurotoxic', 'no label'), ('Effect', 'no label'), ('Phenylalanine', 'no label'), ('Low Predictive Power', 'no label'), ('Blood Phenylalanine', 'no label'), ('Clinical Outcome', 'no label'), ('Individual Vulnerability', 'no label'), ('Metabolic', 'no label'), ('Alterations', 'no label'), ('Pku Contributes', 'no label'), ('Prognosis', 'no label'), ('Patients', 'no label'), ('Ectpku', 'no label'), ('Biological Factors', 'no label'), ('Constitutive', 'no label'), ('Vulnerability', 'no label'), ('Unknown', 'no label'), ('Object', 'no label'), ('Studies', 'no label'), ('Target', 'no label'), ('Research', 'no label'), ('Prerequisite', 'no label'), ('Personalised', 'no label'), ('Treatment', 'no label'), ('Burden', 'no label'), ('Costs', 'no label'), ('Overtreatment', 'no label'), ('Clinical', 'no label'), ('Consequences And', 'no label'), ('Risks', 'no label'), ('Undertreatment', 'no label'), ('Patients', 'no label')]|[('Hampered', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Neurodevelopmental Metabolic Disease', 'no label'), ('Phenylketonuria', 'no label'), ('Lifelong Neurological', 'no label'), ('Neurotoxic', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Prognosis', 'no label'), ('Undertreatment', 'no label')]|[('Phenylketonuria', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Hampered A', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Blood Phenylalanine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~33580861|Phenylketonuria (Pku) Is One Of The Commonest Inborn Error Of Amino Acid Metabolism. Before Mass Neonatal Screening Was Possible, And The Success Of Introducing Diet Therapy Right After Birth, The Typical Clinical Finds In Patients Ranged From Intellectual Disability, Epilepsy, Motor Deficits To Behavioral Disturbances And Other Neurological And Psychiatric Symptoms. Since Early Diagnosis And Treatment Became Widespread, Usually Only Those Patients Who Do Not Strictly Follow The Diet Present Psychiatric, Less Severe Symptoms Such As Anxiety, Depression, Sleep Pattern Disturbance, And Concentration And Memory Problems. Despite The Success Of Low Protein Intake In Preventing Otherwise Severe Outcomes, Pku'S Underlying Neuropathophysiology Remains To Be Better Elucidated. Oxidative Stress Has Gained Acceptance As A Disturbance Implicated In The Pathogenesis Of Pku. The Conception Of Oxidative Stress Has Evolved To Comprehend How It Could Interfere And Ultimately Modulate Metabolic Pathways Regulating Cell Function. We Summarize The Evidence Of Oxidative Damage, As Well As Compromised Antioxidant Defenses, From Patients, Animal Models Of Pku, And In Vitro Experiments, Discussing The Possible Clinical Significance Of These Findings. There Are Many Studies On Oxidative Stress And Pku, But Only A Few Went Further Than Showing Macromolecular Damage And Disturbance Of Antioxidant Defenses. In This Review, We Argue That These Few Studies May Point That Oxidative Stress May Also Disturb Redox Signaling In Pku, An Aspect Few Authors Have Explored So Far. The Reported Effect Of Phenylalanine On The Expression Or Activity Of Enzymes Participating In Metabolic Pathways Known To Be Responsive To Redox Signaling Might Be Mediated Through Oxidative Stress.|"[('Phenylketonuria', 'no label'), ('Commonest', 'no label'), ('Inborn Error', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Mass Neonatal', 'no label'), ('Screening', 'no label'), ('Success', 'no label'), ('Diet Therapy', 'no label'), ('Clinical Finds', 'no label'), ('Patients', 'no label'), ('Ranged', 'no label'), ('Intellectual Disability', 'no label'), ('Epilepsy', 'no label'), ('Motor Deficits', 'no label'), ('Behavioral Disturbances', 'no label'), ('Neurological', 'no label'), ('Psychiatric Symptoms', 'no label'), ('Early Diagnosis', 'no label'), ('Treatment', 'no label'), ('Widespread', 'no label'), ('Patients', 'no label'), ('Diet', 'no label'), ('Psychiatric', 'no label'), ('Severe', 'no label'), ('Symptoms', 'no label'), ('Anxiety', 'no label'), ('Depression', 'no label'), ('Sleep Pattern Disturbance', 'no label'), ('Concentration', 'no label'), ('Memory Problems', 'no label'), ('Success', 'no label'), ('Low Protein', 'no label'), ('Preventing', 'no label'), ('Severe', 'no label'), ('Outcomes', 'no label'), (""Pku'S Underlying"", 'no label'), ('Neuropathophysiology', 'no label'), ('Better', 'no label'), ('Oxidative Stress', 'no label'), ('Gained', 'no label'), ('Acceptance', 'no label'), ('Disturbance', 'no label'), ('Pathogenesis', 'no label'), ('Conception', 'no label'), ('Oxidative Stress', 'no label'), ('Comprehend', 'no label'), ('Modulate', 'no label'), ('Metabolic Pathways', 'no label'), ('Regulating Cell Function', 'no label'), ('Evidence', 'no label'), ('Oxidative Damage', 'no label'), ('Compromised', 'no label'), ('Antioxidant Defenses', 'no label'), ('Patients', 'no label'), ('Animal Models', 'no label'), ('In Vitro', 'no label'), ('Experiments', 'no label'), ('Clinical Significance', 'no label'), ('Findings', 'no label'), ('Studies', 'no label'), ('Oxidative Stress', 'no label'), ('Showing', 'no label'), ('Macromolecular Damage', 'no label'), ('Disturbance', 'no label'), ('Antioxidant Defenses', 'no label'), ('Review', 'no label'), ('Argue', 'no label'), ('Studies', 'no label'), ('Oxidative Stress', 'no label'), ('Redox Signaling', 'no label'), ('Aspect', 'no label'), ('Authors', 'no label'), ('Explored', 'no label'), ('Effect', 'no label'), ('Phenylalanine', 'no label'), ('Expression', 'no label'), ('Activity', 'no label'), ('Enzymes', 'no label'), ('Participating', 'no label'), ('Metabolic Pathways', 'no label'), ('Responsive', 'no label'), ('Redox Signaling', 'no label'), ('Oxidative Stress', 'no label')]"|[('Amino Acid', 'no label'), ('Protein', 'no label'), ('Cell', 'no label'), ('Animal', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Epilepsy', 'no label'), ('Anxiety', 'no label'), ('Depression', 'no label'), ('Pathogenesis', 'no label'), ('Macromolecular Damage And Disturbance Of Antioxidant Defenses', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Amino Acid', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cell', 'no label'), ('Patients', 'no label'), ('Macromolecular', 'no label'), ('Phenylalanine', 'no label')]
phenylketonuria|pubmed~31883647|Phenylketonuria (Pku) Is An Autosomal Recessive Disease Caused By Mutations In The Pah Gene, Resulting In Deficiency Of Phenylalanine Hydroxylase (Pah), An Enzyme That Converts Phenylalanine (Phe) To Tyrosine (Tyr). The Purpose Of This Study Was To Capture Real-World Data Associated With Managing Pku Under Current Standard Of Care And To Characterize A Representative Population For A Planned Gene Therapy Trial. A Retrospective Chart Review Was Conducted At Two U.S. Clinics For Individuals 10-40 Years Old Diagnosed With Pku-Related Hyperphenylalaninemia (Hpa). Demographics, Medical History, Treatments And Blood Phe Data Were Collected From Electronic Medical Records Spanning A Five-Year Period Ending In November 2017. 152 Patients Were Enrolled (65.8% Had Classical Pku). Although >95% Of Patients Were Prescribed A Phe-Restricted Diet, Blood Phe Concentrations Remained Substantially Elevated, Particularly In Patients Diagnosed With Classical Pku. As The Phe Threshold Was Lowered (Phe < 600, 360, 120 Or 30 Μmol/L), The Number Of Patients With Consecutive Lab Values Below The Threshold Decreased, Suggesting That Many Patients' Phe Levels Are Inadequately Controlled. 62.5% Of Patients Were Reported As Having A History Of At Least One Neuropsychiatric Comorbidity, And Adults Were More Likely Than Adolescents (69.5% Vs. 54.3%). 92 Of 98 Pah Genotypes Collected Were Distinct Mutations; The 6 Null-Null Genotypes Were Associated With Classical Pku. Overall The Demographics And Clinical Data Were Consistent Across Both Sites. Despite Dietary Restrictions, Mean Phe Concentrations Were > 360 Μmol/L (A Level Considered Well-Controlled Based On Current U.S. Treatment Guidelines) For Mild, Moderate, And Classical Pku Patients. There Remains An Unmet Need For Therapies To Control Phe Concentrations.|[('Phenylketonuria', 'no label'), ('Autosomal Recessive Disease', 'no label'), ('Mutations', 'no label'), ('Pah Gene', 'no label'), ('Deficiency', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Enzyme', 'no label'), ('Converts', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine (', 'no label'), ('Tyr', 'no label'), ('Study', 'no label'), ('Real-World Data', 'no label'), ('Associated With', 'no label'), ('Managing', 'no label'), ('Pku Under Current', 'no label'), ('Characterize', 'no label'), ('Representative Population', 'no label'), ('Gene Therapy', 'no label'), ('Retrospective Chart Review', 'no label'), ('U.S. Clinics', 'no label'), ('Individuals', 'no label'), ('Diagnosed', 'no label'), ('Pku-Related Hyperphenylalaninemia', 'no label'), ('Hpa', 'no label'), ('Demographics', 'no label'), ('Medical History', 'no label'), ('Treatments', 'no label'), ('Blood Phe Data', 'no label'), ('Collected', 'no label'), ('Electronic Medical Records Spanning A Five-Year Period Ending', 'no label'), ('Patients', 'no label'), ('Classical Pku', 'no label'), ('Patients', 'no label'), ('Prescribed', 'no label'), ('Phe-Restricted Diet', 'no label'), ('Blood Phe Concentrations', 'no label'), ('Remained', 'no label'), ('Elevated', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Classical Pku', 'no label'), ('Phe', 'no label'), ('Threshold', 'no label'), ('Lowered', 'no label'), ('Phe\xa0', 'no label'), ('Patients', 'no label'), ('Consecutive', 'no label'), ('Lab Values', 'no label'), ('Threshold', 'no label'), ('Decreased', 'no label'), ('Suggesting', 'no label'), ('Patients', 'no label'), ('Phe Levels', 'no label'), ('Inadequately Controlled', 'no label'), ('Patients', 'no label'), ('History', 'no label'), ('Neuropsychiatric Comorbidity', 'no label'), ('Adults', 'no label'), ('Adolescents', 'no label'), ('Genotypes', 'no label'), ('Collected', 'no label'), ('Mutations', 'no label'), ('Genotypes', 'no label'), ('Associated With', 'no label'), ('Classical Pku', 'no label'), ('Demographics', 'no label'), ('Clinical Data', 'no label'), ('Sites', 'no label'), ('Dietary', 'no label'), ('Restrictions', 'no label'), ('Mean', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Level', 'no label'), ('Well-Controlled', 'no label'), ('U.S.', 'no label'), ('Treatment Guidelines', 'no label'), ('Mild', 'no label'), ('Moderate', 'no label'), ('Classical Pku', 'no label'), ('Patients', 'no label'), ('Unmet Need', 'no label'), ('Therapies', 'no label'), ('Control', 'no label'), ('Phe Concentrations', 'no label')]|[('Mutations', 'no label'), ('Gene', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Enzyme', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Gene', 'no label'), ('Individuals', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Genotypes', 'no label'), ('Mutations', 'no label'), ('Genotypes', 'no label'), ('Phe', 'no label')]|[('Pah Gene', 'no label'), ('Phenylalanine Hydroxylase', 'no label')]|[('Phenylketonuria', 'no label'), ('Autosomal Recessive Disease', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Neuropsychiatric Comorbidity', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Pah Gene', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Blood Phe Data', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Lab', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]
phenylketonuria|pubmed~28318283|Despite Early Dietary Treatment Phenylketonuria Patients Have Lower Iq And Poorer Executive Functions Compared To Healthy Controls. Cognitive Problems In Phenylketonuria Have Often Been Associated With Phenylalanine Levels. The Present Study Examined The Cognitive Profile And Mental Health In Adult Phenylketonuria, In Relation To Phenylalanine Levels And Tetrahydrobiopterin Treatment. Fifty-Seven Early Treated Adult Patients With Phenylketonuria And 57 Healthy Matched Controls (18-40 Years) Performed Iq Subtests And Executive Function Tests From The Amsterdam Neuropsychological Tasks. They Also Completed The Adult Self-Report On Mental Health Problems. Analyses Of Variance Were Performed To Examine Group Differences. Patients With Phenylketonuria Had Normal Iqs Although Lower Than Controls. They Performed Poorer On Working Memory, Inhibitory Control, And Sustained Attention Tasks. Patients Reported Depressive And Avoidant Personality Problems More Frequently. Specifically, Patients With Childhood And Lifetime Phenylalanine ≥360 Μmol/L Had Poorer Cognitive And Mental Health Outcomes Than Controls. In A Subset Of Patients, Comparisons Between Patients On And Off Tetrahydrobiopterin Showed That Nontetrahydrobiopterin Users (Matched For Childhood, Pretreatment Phenylalanine) Were Slower (On Number Of Tasks) And Reported More Mental Health Problems. Adult Patients Had Lower Iq And Poorer Executive Functions Than Controls, Resembling Problems Observed In Younger Patients With Phenylketonuria, As Well As More Internalizing Problems. Group Differences And Phenylalanine-Outcome Associations Were Smaller Than Those Observed In Younger Populations. A Subset Of Nontetrahydrobiopterin Users, Matched For Childhood Phenylalanine Level, Had A Poorer Outcome On Some Tests Than Tetrahydrobiopterin Users, Which Might Indicate An Impact Of Tetrahydrobiopterin Treatment Beyond Lowering Phenylalanine. However, Clinical Relevance Needs Further Investigation. (Psycinfo Database Record|[('Early', 'no label'), ('Dietary Treatment', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Lower Iq', 'no label'), ('Poorer', 'no label'), ('Executive Functions', 'no label'), ('Healthy Controls', 'no label'), ('Cognitive Problems', 'no label'), ('Phenylketonuria', 'no label'), ('Associated With', 'no label'), ('Phenylalanine', 'no label'), ('Study', 'no label'), ('Cognitive Profile And Mental Health', 'no label'), ('Adult', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine Levels', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Treatment', 'no label'), ('Fifty-Seven', 'no label'), ('Treated', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Healthy Matched Controls', 'no label'), ('Years', 'no label'), ('Performed Iq Subtests And Executive Function Tests', 'no label'), ('Amsterdam Neuropsychological Tasks', 'no label'), ('Completed', 'no label'), ('Adult Self-Report On Mental Health Problems', 'no label'), ('Analyses', 'no label'), ('Variance', 'no label'), ('Performed', 'no label'), ('Examine', 'no label'), ('Group', 'no label'), ('Differences', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Normal Iqs', 'no label'), ('Lower Than', 'no label'), ('Controls', 'no label'), ('Performed', 'no label'), ('Poorer', 'no label'), ('Working Memory', 'no label'), ('Inhibitory Control', 'no label'), ('Sustained', 'no label'), ('Attention', 'no label'), ('Patients', 'no label'), ('Depressive', 'no label'), ('Avoidant Personality', 'no label'), ('Problems', 'no label'), ('Patients', 'no label'), ('Childhood', 'no label'), ('Lifetime', 'no label'), ('Phenylalanine', 'no label'), ('Poorer', 'no label'), ('Controls', 'no label'), ('Subset', 'no label'), ('Patients', 'no label'), ('Comparisons', 'no label'), ('Patients', 'no label'), ('Off Tetrahydrobiopterin', 'no label'), ('Nontetrahydrobiopterin', 'no label'), ('Users', 'no label'), ('Childhood', 'no label'), ('Pretreatment', 'no label'), ('Phenylalanine', 'no label'), ('Slower', 'no label'), ('Tasks', 'no label'), ('Mental Health Problems', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Lower Iq', 'no label'), ('Poorer', 'no label'), ('Executive Functions', 'no label'), ('Than Controls', 'no label'), ('Resembling Problems', 'no label'), ('Observed', 'no label'), ('Younger', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Internalizing Problems', 'no label'), ('Group', 'no label'), ('Differences', 'no label'), ('Phenylalanine-Outcome', 'no label'), ('Associations', 'no label'), ('Observed', 'no label'), ('Younger Populations', 'no label'), ('Subset', 'no label'), ('Nontetrahydrobiopterin Users', 'no label'), ('Matched', 'no label'), ('Childhood', 'no label'), ('Phenylalanine', 'no label'), ('Poorer Outcome', 'no label'), ('Tests', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Users', 'no label'), ('Indicate', 'no label'), ('Impact', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Treatment', 'no label'), ('Lowering', 'no label'), ('Phenylalanine', 'no label'), ('Clinical Relevance Needs', 'no label'), ('Investigation', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label')]|[('Iq', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Iq', 'no label'), ('Tetrahydrobiopterin', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Depressive', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria Patients', 'no label'), ('Lower Iq', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phenylalanine ≥360', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Nontetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Lower Iq', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Nontetrahydrobiopterin', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label')]
phenylketonuria|pubmed~33766497|In Patients With Phenylketonuria, Stability Of Blood Phenylalanine And Tyrosine Concentrations Might Influence Brain Chemistry And Therefore Patient Outcome. This Study Prospectively Investigated The Effects Of Tetrahydrobiopterin (Bh4), As A Chaperone Of Phenylalanine Hydroxylase On Diurnal And Day-To-Day Variations Of Blood Phenylalanine And Tyrosine Concentrations. Blood Phenylalanine And Tyrosine Were Measured In Dried Blood Spots (Dbs) Four Times Daily For 2 Days (Fasting, Before Lunch, Before Dinner, Evening) And Once Daily (Fasting) For 6 Days In A Randomized Cross-Over Design With A Period With Bh4 And A Period Without Bh4. The Sequence Was Randomized. Eleven Proven Bh4 Responsive Pku Patients Participated, 5 Of Them Used Protein Substitutes During Bh4 Treatment. Natural Protein Intake And Protein Substitute Dosing Was Adjusted During The Period Without Bh4 In Order To Keep Dbs Phenylalanine Levels Within Target Range. Patients Filled Out A 3-Day Food Diary During Both Study Periods. Variations Of Dbs Phenylalanine And Tyr Were Expressed In Standard Deviations (Sd) And Coefficient Of Variation (Cv). Bh4 Treatment Did Not Significantly Influence Day-To-Day Phenylalanine And Tyrosine Variations Nor Diurnal Phenylalanine Variations, But Decreased Diurnal Tyrosine Variations (Median Sd 17.6 Μmol/L, Median Cv 21.3%, P = 0.01) Compared To Diet Only (Median Sd 34.2 Μmol/L, Median Cv 43.2%). Consequently, During Bh4 Treatment Diurnal Phenylalanine/Tyrosine Ratio Variation Was Smaller, While Fasting Tyrosine Levels Tended To Be Higher. Bh4 Did Not Impact Phenylalanine Variation But Decreased Diurnal Tyrosine And Phenylalanine/Tyrosine Ratio Variations, Possibly Explained By Less Use Of Protein Substitute And Increased Tyrosine Synthesis.|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Stability', 'no label'), ('Blood Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Concentrations', 'no label'), ('Influence', 'no label'), ('Brain Chemistry', 'no label'), ('Patient Outcome', 'no label'), ('Study', 'no label'), ('Investigated', 'no label'), ('Effects', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh4', 'no label'), ('Chaperone', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Diurnal', 'no label'), ('Day-To-Day', 'no label'), ('Variations', 'no label'), ('Blood Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Concentrations', 'no label'), ('Blood Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Measured', 'no label'), ('Dried Blood Spots', 'no label'), ('Dbs', 'no label'), ('Times', 'no label'), ('Daily', 'no label'), ('Days', 'no label'), ('Fasting', 'no label'), ('Lunch', 'no label'), ('Dinner', 'no label'), ('Evening', 'no label'), ('Fasting', 'no label'), ('Days', 'no label'), ('Randomized Cross-Over Design', 'no label'), ('Period', 'no label'), ('Bh4', 'no label'), ('Period', 'no label'), ('Bh4', 'no label'), ('Sequence', 'no label'), ('Randomized', 'no label'), ('Proven', 'no label'), ('Bh4 Responsive Pku', 'no label'), ('Protein Substitutes', 'no label'), ('Bh4', 'no label'), ('Treatment', 'no label'), ('Natural Protein Intake', 'no label'), ('Protein Substitute', 'no label'), ('Dosing', 'no label'), ('Period', 'no label'), ('Bh4', 'no label'), ('Order', 'no label'), ('Phenylalanine Levels', 'no label'), ('Target Range', 'no label'), ('Patients', 'no label'), ('3-Day Food Diary', 'no label'), ('Study', 'no label'), ('Periods', 'no label'), ('Variations', 'no label'), ('Dbs', 'no label'), ('Phenylalanine', 'no label'), ('Tyr', 'no label'), ('Expressed', 'no label'), ('Standard Deviations', 'no label'), ('Sd', 'no label'), ('Coefficient Of Variation (Cv)', 'no label'), ('Bh4', 'no label'), ('Treatment', 'no label'), ('Did Not', 'no label'), ('Influence', 'no label'), ('Day-To-Day', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Variations', 'no label'), ('Diurnal', 'no label'), ('Phenylalanine', 'no label'), ('Variations', 'no label'), ('Decreased', 'no label'), ('Diurnal', 'no label'), ('Tyrosine', 'no label'), ('Variations', 'no label'), ('Median', 'no label'), ('Median', 'no label'), ('Diet', 'no label'), ('Median', 'no label'), ('Bh4', 'no label'), ('Treatment', 'no label'), ('Diurnal', 'no label'), ('Ratio', 'no label'), ('Variation', 'no label'), ('Fasting', 'no label'), ('Tyrosine Levels', 'no label'), ('Tended', 'no label'), ('Higher', 'no label'), ('Bh4', 'no label'), ('Did Not Impact', 'no label'), ('Phenylalanine', 'no label'), ('Variation', 'no label'), ('Decreased', 'no label'), ('Diurnal', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine/Tyrosine Ratio', 'no label'), ('Variations', 'no label'), ('Protein Substitute', 'no label'), ('Increased', 'no label'), ('Tyrosine Synthesis', 'no label')]|[('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Sequence', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Phenylalanine', 'no label'), ('Food', 'no label'), ('Phenylalanine', 'no label'), ('Tyr', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Protein', 'no label'), ('Tyrosine', 'no label')]|[('Tetrahydrobiopterin', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Dbs', 'no label'), ('Dbs', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Dinner', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tyr', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label')]|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Blood Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Brain', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Blood Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Blood Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Bh4 And A Period', 'no label'), ('Bh4.', 'no label'), ('Patients', 'no label'), ('Bh4', 'no label'), ('Bh4', 'no label'), ('Patients', 'no label'), ('Dbs Phenylalanine', 'no label'), ('Tyr', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Bh4', 'no label'), ('Fasting Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label')]
phenylketonuria|pubmed~34819582|Phenylketonuria (Pku) Is A Genetic Deficiency Of Phenylalanine Hydroxylase (Pah) In Liver Resulting In Blood Phenylalanine (Phe) Elevation And Neurotoxicity. A Pegylated Phenylalanine Ammonia Lyase (Peg-Pal) Metabolizing Phe Into Cinnamic Acid Was Recently Approved As Treatment For Pku Patients. A Potentially One-Time Raav-Based Delivery Of Pah Gene Into Liver To Convert Phe Into Tyrosine (Tyr), A Normal Way Of Phe Metabolism, Has Now Also Entered The Clinic. To Understand Differences Between These Two Phe Lowering Strategies, We Evaluated Pah And Pal Expression In Livers Of Pah<Sup>Enu2</Sup> Mice On Brain And Liver Functions. Both Lowered Brain Phe And Increased Neurotransmitter Levels And Corrected Animal Behavior. However, Pal Delivery Required Dose Optimization, Did Not Elevate Brain Tyr Levels And Resulted In An Immune Response. The Effect Of Hyperphenylalanemia On Liver Functions In Pku Mice Was Assessed By Transcriptome And Proteomic Analyses. We Observed An Elevation In Cyp4A10/14 Proteins Involved In Lipid Metabolism And Upregulation Of Genes Involved In Cholesterol Biosynthesis. Majority Of The Gene Expression Changes Were Corrected By Pah And Pal Delivery Though The Role Of These Changes In Pku Pathology Is Currently Unclear. Taken Together, Here We Show That Blood Phe Lowering Strategy Using Pah Or Pal Corrects Both Brain Pathology As Well As Previously Unknown Lipid Metabolism Associated Pathway Changes In Liver.|[('Phenylketonuria', 'no label'), ('Genetic Deficiency', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Liver', 'no label'), ('Resulting', 'no label'), ('Blood Phenylalanine', 'no label'), ('Elevation', 'no label'), ('Neurotoxicity', 'no label'), ('Pegylated', 'no label'), ('Phenylalanine Ammonia Lyase', 'no label'), ('Peg-Pal', 'no label'), ('Metabolizing', 'no label'), ('Phe', 'no label'), ('Cinnamic Acid', 'no label'), ('Treatment', 'no label'), ('Pku Patients', 'no label'), ('One-Time', 'no label'), ('Raav-Based Delivery', 'no label'), ('Pah Gene', 'no label'), ('Liver', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Normal Way', 'no label'), ('Phe Metabolism', 'no label'), ('Entered', 'no label'), ('Clinic', 'no label'), ('Differences', 'no label'), ('Phe', 'no label'), ('Lowering', 'no label'), ('Strategies', 'no label'), ('Evaluated', 'no label'), ('Pal Expression', 'no label'), ('Livers', 'no label'), ('Enu2</Sup> Mice', 'no label'), ('Brain', 'no label'), ('Liver Functions', 'no label'), ('Lowered', 'no label'), ('Brain', 'no label'), ('Phe', 'no label'), ('Increased', 'no label'), ('Neurotransmitter Levels', 'no label'), ('Animal Behavior', 'no label'), ('Pal Delivery', 'no label'), ('Dose', 'no label'), ('Optimization', 'no label'), ('Did Not', 'no label'), ('Brain', 'no label'), ('Levels', 'no label'), ('Resulted', 'no label'), ('Immune Response', 'no label'), ('Effect', 'no label'), ('Hyperphenylalanemia', 'no label'), ('Liver Functions', 'no label'), ('Pku Mice', 'no label'), ('Assessed', 'no label'), ('Transcriptome', 'no label'), ('Proteomic Analyses', 'no label'), ('Elevation', 'no label'), ('Cyp4A10/14 Proteins', 'no label'), ('Lipid Metabolism', 'no label'), ('Upregulation', 'no label'), ('Genes', 'no label'), ('Cholesterol', 'no label'), ('Biosynthesis', 'no label'), ('Gene Expression', 'no label'), ('Changes', 'no label'), ('Pal Delivery', 'no label'), ('Changes', 'no label'), ('Pku Pathology', 'no label'), ('Blood Phe', 'no label'), ('Pah', 'no label'), ('Pal Corrects', 'no label'), ('Brain Pathology', 'no label'), ('Lipid Metabolism', 'no label'), ('Associated Pathway', 'no label'), ('Changes', 'no label'), ('Liver', 'no label')]|[('Genetic', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Ammonia', 'no label'), ('Phe', 'no label'), ('Cinnamic Acid', 'no label'), ('Gene', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Mice', 'no label'), ('Phe', 'no label'), ('Neurotransmitter', 'no label'), ('Animal', 'no label'), ('Tyr', 'no label'), ('Mice', 'no label'), ('Proteins', 'no label'), ('Lipid', 'no label'), ('Genes', 'no label'), ('Cholesterol', 'no label'), ('Gene', 'no label'), ('Phe', 'no label'), ('Lipid', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('One-Time', 'no label'), ('Pah Gene', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Neurotoxicity', 'no label'), ('Phe', 'no label'), ('One-Time', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Phe', 'no label'), ('Lowered Brain Phe', 'no label'), ('Hyperphenylalanemia', 'no label'), ('Cholesterol', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Liver', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Pegylated Phenylalanine Ammonia Lyase', 'no label'), ('Phe', 'no label'), ('Cinnamic Acid', 'no label'), ('Pah Gene', 'no label'), ('Liver', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Pah', 'no label'), ('Livers', 'no label'), ('Pah', 'no label'), ('Mice', 'no label'), ('Brain And', 'no label'), ('Liver', 'no label'), ('Brain Phe', 'no label'), ('Brain Tyr', 'no label'), ('Immune', 'no label'), ('Hyperphenylalanemia On Liver Functions', 'no label'), ('Mice', 'no label'), ('Lipid', 'no label'), ('Cholesterol', 'no label'), ('Pku Pathology', 'no label'), ('Blood Phe', 'no label'), ('Brain Pathology', 'no label'), ('Lipid', 'no label'), ('Liver', 'no label')]
phenylketonuria|pubmed~28053173|Phenylketonuria Is Characterized By Mutations In The Phe Hydroxylase Gene That Leads To The Accumulation Of Phe In Plasma And The Brain. The Standard Of Care For Phenylketonuria Is Nutritional Management With Dietary Restriction Of Phe And The Provision Of Sufficient Protein And Energy For Growth And Health Maintenance. The Protein Requirement In Children With Phenylketonuria Is Empirically Determined Based Upon Phenylketonuria Nutritional Guidelines That Are Adjusted Individually In Response To Biochemical Markers And Growth. We Determined Dietary Protein Requirements In Children With Phenylketonuria With The Use Of The Indicator Amino Acid Oxidation (Iaao) Technique, With L-[1-<Sup>13</Sup>C]Leu As The Indicator Amino Acid. Four Children (2 Males; 2 Females) Aged 9-18 Y With Phenylketonuria [Mild Hyperphenylalanemia (Mhpa); 6-10 Mg/Dl (360-600 Μmol/L)] Were Recruited To Participate In ≥7 Separate Test Protein Intakes (Range: 0.2-3.2 G ⋅ Kg<Sup>-1</Sup> ⋅ D<Sup>-1</Sup>) With The Iaao Protocol With The Use Of L-[1-<Sup>13</Sup>C]Leu Followed By The Collection Of Breath And Urine Samples Over 8 H. The Diets Were Isocaloric And Provided Energy At 1.7 Times The Resting Energy Expenditure. Protein Was Provided As A Crystalline Amino Acid Mixture Based On An Egg Protein Pattern, Except Phe And Leu, Which Were Maintained At A Constant Across Intakes. Protein Requirement Was Determined With The Use Of A 2-Phase Linear-Regression Crossover Analysis Of The Rate Of L-[1-<Sup>13</Sup>C]Leu Tracer Oxidation. The Mean Protein Requirement Was Determined To Be 1.85 G ⋅ Kg<Sup>-1</Sup> ⋅ D<Sup>-1</Sup> (R<Sup>2</Sup> = 0.66; 95% Ci: 1.37, 2.33). This Result Is Substantially Higher Than The 2014 Phenylketonuria Recommendations (1.14-1.33 G ⋅ Kg<Sup>-1</Sup> ⋅ D<Sup>-1</Sup>; Based On 120-140% Above The Current Rda For Age). To Our Knowledge, This Is The First Study To Directly Define A Quantitative Requirement For Protein Intake In Children With Mhpa And Indicates That Current Protein Recommendations In Children With Phenylketonuria May Be Insufficient. This Trial Was Registered At Clinicaltrials.Gov As Nct01965691.|[('Phenylketonuria', 'no label'), ('Characterized', 'no label'), ('Mutations', 'no label'), ('Phe Hydroxylase Gene', 'no label'), ('Accumulation', 'no label'), ('Phe', 'no label'), ('Plasma', 'no label'), ('Brain', 'no label'), ('Standard Of Care', 'no label'), ('Phenylketonuria', 'no label'), ('Nutritional Management', 'no label'), ('Dietary Restriction', 'no label'), ('Phe', 'no label'), ('Provision', 'no label'), ('Protein', 'no label'), ('Growth', 'no label'), ('Protein Requirement', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Guidelines', 'no label'), ('Response', 'no label'), ('Biochemical', 'no label'), ('Markers', 'no label'), ('Growth', 'no label'), ('Dietary Protein', 'no label'), ('Requirements', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Indicator Amino Acid Oxidation', 'no label'), ('Iaao) Technique', 'no label'), ('L-[1-<Sup>13</Sup>C]Leu', 'no label'), ('Indicator Amino Acid', 'no label'), ('Children', 'no label'), ('Males', 'no label'), ('Females', 'no label'), ('Phenylketonuria', 'no label'), ('Mild Hyperphenylalanemia', 'no label'), ('Mhpa', 'no label'), ('Participate', 'no label'), ('⋅ D', 'no label'), ('Iaao Protocol', 'no label'), ('L-[1-<Sup>13</Sup>C]Leu', 'no label'), ('Collection', 'no label'), ('Breath', 'no label'), ('Urine Samples', 'no label'), ('Diets', 'no label'), ('Isocaloric', 'no label'), ('Times', 'no label'), ('Resting Energy Expenditure', 'no label'), ('Protein', 'no label'), ('Crystalline', 'no label'), ('Amino Acid', 'no label'), ('Egg Protein', 'no label'), ('Pattern', 'no label'), ('Phe And Leu', 'no label'), ('Constant Across Intakes', 'no label'), ('Protein Requirement', 'no label'), ('2-Phase Linear-Regression Crossover Analysis', 'no label'), ('Rate', 'no label'), ('L-[1-<Sup>13</Sup>C]Leu', 'no label'), ('Tracer Oxidation', 'no label'), ('Mean Protein Requirement', 'no label'), ('G ⋅ Kg<Sup>-1</Sup> ⋅ D<Sup>-1</Sup> (R<Sup>2</Sup>', 'no label'), ('Ci', 'no label'), ('Result', 'no label'), ('Phenylketonuria', 'no label'), ('Recommendations', 'no label'), ('⋅ D', 'no label'), ('Age', 'no label'), ('Knowledge', 'no label'), ('First Study', 'no label'), ('Quantitative', 'no label'), ('Requirement', 'no label'), ('Protein Intake', 'no label'), ('Children', 'no label'), ('Mhpa', 'no label'), ('Indicates', 'no label'), ('Protein', 'no label'), ('Recommendations', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Insufficient', 'no label'), ('Trial', 'no label'), ('Clinicaltrials', 'no label')]|[('Mutations', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('C]Leu', 'no label'), ('Amino Acid', 'no label'), ('Protein', 'no label'), ('C]Leu', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Phe', 'no label'), ('Protein', 'no label'), ('C]Leu', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label')]|[('Phe Hydroxylase Gene', 'no label'), ('C]Leu', 'no label'), ('C]Leu', 'no label'), ('C]Leu', 'no label'), ('Indicates', 'no label')]|[('Phenylketonuria', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Amino Acid', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalanemia', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Phe Hydroxylase', 'no label'), ('Phe', 'no label'), ('Plasma', 'no label'), ('Brain', 'no label'), ('Phenylketonuria', 'no label'), ('Phe', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Amino Acid', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Urine Samples Over 8 H.', 'no label'), ('Diets', 'no label'), ('A Crystalline Amino Acid', 'no label'), ('A 2-Phase', 'no label'), ('L-[1-<Sup>13</Sup', 'no label'), ('Be 1.85 G', 'no label'), ('Sup>2</Sup', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~34872082|Patients With Phenylketonuria (Pku) Must Follow A Lifelong Phenylalanine (Phe)-Restricted Diet With Additional Amino Acid Supplementations, And This May Put Them At Risk For Nutritional Disturbances. However, The Body Composition And Nutritional Status Of Adult Patients With Pku Has Only Been Partially Explored. The Current Study Aims To Assess The Body Composition Of Adult Patients With Pku Using Multifrequency Bioimpedance Analysis (Mf-Bia) And To Reveal Potential Correlations Between Therapy Adherence And Body Composition. Additionally, We Compared Body Composition Of Patients With Healthy Controls. Fifty Adult Patients With Early-Treated Pku (27 Female And 23 Male) And 40 Healthy, Age- And Gender-Matched Controls Were Included In This Single-Center, Cross-Sectional Study. Mf-Bia Was Performed On All Subjects. Additionally, We Determined Serum Nutritional Markers For All Patients. In The Pku Patient Group, Correlation Analyses Were Performed Between Body Composition Parameters And Therapy Adherence. We Compared Body Composition Of Patients With Pku And Controls Using Bia. The Proportion Of Overweight Was 56% Among All Patients With Pku. Female Patients With Pku Had Significantly Higher Body Fat Percentage Compared With Controls. In Parallel With Higher Fat Content, We Observed Lower Muscle Mass, Protein, And Mineral Content Among Female Patients With Pku Compared To Controls. Such Findings Were Not Observed In Male Patients. Female Patients With Pku Had Decreased Therapy Adherence And Had Significantly Lower Prealbumin Levels Compared With Males. There Was No Significant Correlation Observed Between Body Composition Parameters And Therapy Adherence Over The Last 10 Years In The Pku Patient Group. Although Female Patients Had Less Optimal Therapy Adherence Over The Last 10 Years Compared With Male Patients, Our Results Suggest That This Does Not Influence Body Composition Fundamentally. Our Results Suggest That Obesity Is An Important Comorbidity In Young Adult Patients With Pku, Especially In Females. We Advocate That Nutritional Assessments And Weight Management Should Be Additional Objectives Of Pku Management To Provide Optimal Care.|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Follow A', 'no label'), ('Lifelong', 'no label'), ('Phenylalanine (Phe)-Restricted', 'no label'), ('Diet', 'no label'), ('Amino Acid Supplementations', 'no label'), ('Risk', 'no label'), ('Nutritional', 'no label'), ('Disturbances', 'no label'), ('Body Composition', 'no label'), ('Nutritional Status', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Partially', 'no label'), ('Study', 'no label'), ('Assess', 'no label'), ('Body Composition', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Multifrequency Bioimpedance Analysis', 'no label'), ('Mf-Bia', 'no label'), ('Reveal', 'no label'), ('Potential', 'no label'), ('Correlations', 'no label'), ('Therapy', 'no label'), ('Adherence', 'no label'), ('Body Composition', 'no label'), ('Compared', 'no label'), ('Body Composition', 'no label'), ('Patients', 'no label'), ('Healthy Controls', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Early-Treated Pku', 'no label'), ('Female', 'no label'), ('Male', 'no label'), ('Healthy', 'no label'), ('Age- And', 'no label'), ('Gender-Matched Controls', 'no label'), ('Single-Center', 'no label'), ('Cross-Sectional Study', 'no label'), ('Mf-Bia', 'no label'), ('Performed', 'no label'), ('Subjects', 'no label'), ('Serum', 'no label'), ('Markers', 'no label'), ('Patients', 'no label'), ('Pku Patient Group', 'no label'), ('Correlation Analyses', 'no label'), ('Performed', 'no label'), ('Body Composition', 'no label'), ('Parameters', 'no label'), ('Therapy', 'no label'), ('Adherence', 'no label'), ('Compared', 'no label'), ('Body Composition', 'no label'), ('Patients', 'no label'), ('Pku And Controls', 'no label'), ('Bia', 'no label'), ('Proportion', 'no label'), ('Overweight', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Body Fat Percentage', 'no label'), ('Controls', 'no label'), ('Higher', 'no label'), ('Fat Content', 'no label'), ('Lower Muscle', 'no label'), ('Protein', 'no label'), ('Mineral Content', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Controls', 'no label'), ('Findings', 'no label'), ('Observed', 'no label'), ('Male', 'no label'), ('Patients', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Decreased Therapy', 'no label'), ('Adherence', 'no label'), ('Prealbumin', 'no label'), ('Levels', 'no label'), ('Males', 'no label'), ('No Significant', 'no label'), ('Correlation', 'no label'), ('Observed', 'no label'), ('Body Composition', 'no label'), ('Parameters', 'no label'), ('Therapy', 'no label'), ('Adherence', 'no label'), ('Years', 'no label'), ('Pku Patient Group', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Optimal', 'no label'), ('Therapy', 'no label'), ('Adherence', 'no label'), ('Years', 'no label'), ('Male', 'no label'), ('Patients', 'no label'), ('Results', 'no label'), ('Suggest', 'no label'), ('Influence', 'no label'), ('Body Composition', 'no label'), ('Suggest', 'no label'), ('Obesity', 'no label'), ('Comorbidity', 'no label'), ('Young Adult', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Females', 'no label'), ('Advocate', 'no label'), ('Nutritional Assessments', 'no label'), ('Weight Management', 'no label'), ('Pku Management', 'no label')]|[('Phenylalanine', 'no label'), ('Amino Acid Supplementations', 'no label'), ('Protein', 'no label'), ('Mineral', 'no label'), ('Prealbumin', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acid Supplementations', 'no label'), ('Put', 'no label'), ('Nutritional Disturbances', 'no label'), ('Obesity', 'no label'), ('Comorbidity', 'no label')]|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acid', 'no label'), ('Supplementations', 'no label'), ('Put', 'no label'), ('Body', 'no label'), ('Patients', 'no label'), ('Body', 'no label'), ('Patients', 'no label'), ('Body', 'no label'), ('Body', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Serum', 'no label'), ('Patients', 'no label'), ('Body', 'no label'), ('Body', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Body Fat', 'no label'), ('Fat', 'no label'), ('Muscle', 'no label'), ('Mineral', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Prealbumin', 'no label'), ('Body', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~32672365|Phenylketonuria Is An Inherited Disease Treated With Dietary Restriction Of The Amino Acid Phenylalanine. The Diet Is Initiated In The Neonatal Period To Prevent Learning Disability; However, It Is Restrictive And Can Be Difficult To Follow. Whether The Diet Can Be Relaxed Or Discontinued During Adolescence Or Should Be Continued For Life Remains A Controversial Issue, Which We Aim To Address In This Review. This Is An Updated Version Of A Previously Published Review. To Assess The Effects Of A Low-Phenylalanine Diet Commenced Early In Life For People With Phenylketonuria. To Assess The Possible Effects Of Relaxation Or Termination Of The Diet On Intelligence, Neuropsychological Outcomes And Mortality, Growth, Nutritional Status, Eating Behaviour And Quality Of Life. We Searched The Cochrane Cystic Fibrosis And Genetic Disorders Group Trials Register Comprising References Identified From Comprehensive Electronic Database Searches, Handsearches Of Relevant Journals And Abstract Books Of Conference Proceedings. Most Recent Search Of The Inborn Errors Of Metabolism Trials Register: 30 April 2020. All Randomised Or Quasi-Randomised Controlled Trials Comparing A Low-Phenylalanine Diet To Relaxation Or Termination Of Dietary Restrictions In People With Phenylketonuria. Two Authors Independently Assessed Study Eligibility And Methodological Quality, And Subsequently Extracted The Data. We Included Four Studies In This Review (251 Participants), And Found Few Significant Differences Between Treatment And Comparison Groups For The Outcomes Of Interest. Blood Phenylalanine Levels Were Significantly Lower In Participants With Phenylketonuria Following A Low-Phenylalanine Diet Compared To Those On A Less Restricted Diet, Mean Difference (Md) At Three Months -698.67 (95% Confidence Interval (Ci) -869.44 To -527.89). Intelligence Quotient Was Significantly Higher In Participants Who Continued The Diet Than In Those Who Stopped The Diet, Md After 12 Months 5.00 (95% Ci 0.40 To 9.60). However, These Results Came From A Single Study. The Results Of Non-Randomised Studies Have Concluded That A Low-Phenylalanine Diet Is Effective In Reducing Blood Phenylalanine Levels And Improving Intelligence Quotient And Neuropsychological Outcomes. We Were Unable To Find Any Randomised Controlled Studies That Have Assessed The Effect Of A Low-Phenylalanine Diet Versus No Diet From Diagnosis. In View Of Evidence From Non-Randomised Studies, Such A Study Would Be Unethical And It Is Recommended That Low-Phenylalanine Diet Should Be Commenced At The Time Of Diagnosis. There Is Uncertainty About The Precise Level Of Phenylalanine Restriction And When, If Ever, The Diet Should Be Relaxed. This Should Be Addressed By Randomised Controlled Studies; However, No New Studies Are Expected In This Area So We Do Not Plan To Update This Review.|[('Phenylketonuria', 'no label'), ('Inherited Disease', 'no label'), ('Treated With', 'no label'), ('Dietary Restriction', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Diet', 'no label'), ('Neonatal', 'no label'), ('Period', 'no label'), ('Restrictive', 'no label'), ('Diet', 'no label'), ('Discontinued', 'no label'), ('Adolescence', 'no label'), ('Life Remains', 'no label'), ('Issue', 'no label'), ('Review', 'no label'), ('Updated Version', 'no label'), ('Published Review', 'no label'), ('Assess', 'no label'), ('Effects', 'no label'), ('Low-Phenylalanine Diet', 'no label'), ('Commenced', 'no label'), ('Early', 'no label'), ('Life', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Effects', 'no label'), ('Relaxation', 'no label'), ('Termination', 'no label'), ('Diet', 'no label'), ('Intelligence', 'no label'), ('Neuropsychological Outcomes', 'no label'), ('Mortality', 'no label'), ('Growth', 'no label'), ('Nutritional Status', 'no label'), ('Eating Behaviour And Quality Of Life', 'no label'), ('Cochrane Cystic Fibrosis', 'no label'), ('Genetic Disorders', 'no label'), ('References', 'no label'), ('Identified', 'no label'), ('Comprehensive Electronic Database Searches', 'no label'), ('Handsearches', 'no label'), ('Relevant', 'no label'), ('Journals', 'no label'), ('Proceedings', 'no label'), ('Inborn Errors', 'no label'), ('Metabolism Trials Register', 'no label'), ('Randomised Or Quasi-Randomised Controlled Trials', 'no label'), ('Low-Phenylalanine Diet', 'no label'), ('Relaxation', 'no label'), ('Termination', 'no label'), ('Dietary', 'no label'), ('Restrictions', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Assessed', 'no label'), ('Study', 'no label'), ('Eligibility', 'no label'), ('Methodological Quality', 'no label'), ('Extracted', 'no label'), ('Data', 'no label'), ('Studies', 'no label'), ('Review', 'no label'), ('Participants', 'no label'), ('Differences', 'no label'), ('Treatment', 'no label'), ('Comparison', 'no label'), ('Groups', 'no label'), ('Outcomes', 'no label'), ('Blood Phenylalanine Levels', 'no label'), ('Participants', 'no label'), ('Phenylketonuria', 'no label'), ('Low-Phenylalanine Diet', 'no label'), ('Less Restricted Diet', 'no label'), ('Mean Difference', 'no label'), ('Md', 'no label'), ('Months', 'no label'), ('Confidence Interval', 'no label'), ('Ci', 'no label'), ('Intelligence Quotient', 'no label'), ('Participants', 'no label'), ('Diet Than', 'no label'), ('Stopped', 'no label'), ('Diet', 'no label'), ('Md', 'no label'), ('Months', 'no label'), ('Ci', 'no label'), ('Results', 'no label'), ('Single Study', 'no label'), ('Non-Randomised Studies', 'no label'), ('Low-Phenylalanine Diet', 'no label'), ('Effective', 'no label'), ('Reducing', 'no label'), ('Blood Phenylalanine Levels', 'no label'), ('Improving', 'no label'), ('Neuropsychological Outcomes', 'no label'), ('Randomised Controlled Studies', 'no label'), ('Assessed', 'no label'), ('Effect', 'no label'), ('Low-Phenylalanine Diet', 'no label'), ('No Diet', 'no label'), ('Diagnosis', 'no label'), ('Evidence', 'no label'), ('Non-Randomised Studies', 'no label'), ('Study', 'no label'), ('Unethical', 'no label'), ('Recommended', 'no label'), ('Low-Phenylalanine Diet', 'no label'), ('Commenced', 'no label'), ('Time', 'no label'), ('Diagnosis', 'no label'), ('Phenylalanine Restriction', 'no label'), ('Diet', 'no label'), ('Randomised Controlled Studies', 'no label'), ('No New Studies', 'no label'), ('Expected', 'no label'), ('Area', 'no label'), ('Update', 'no label'), ('Review', 'no label')]|[('Amino Acid Phenylalanine', 'no label'), ('Genetic', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Inherited Disease', 'no label'), ('Amino Acid Phenylalanine', 'no label'), ('Learning Disability', 'no label'), ('Phenylketonuria', 'no label'), ('Fibrosis', 'no label'), ('Inborn Errors', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Low-Phenylalanine', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Low-Phenylalanine', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Low-Phenylalanine', 'no label'), ('Low-Phenylalanine', 'no label'), ('Blood Phenylalanine', 'no label'), ('Low-Phenylalanine', 'no label'), ('Low-Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]
phenylketonuria|pubmed~35101330|More Than 1280 Variants In The Phenylalanine Hydroxylase (Pah) Gene Are Responsible For A Broad Spectrum Of Phenylketonuria (Pku) Phenotypes. While The Genotype-Phenotype Correlation Is Reaching 88%, For Some Inconsistent Phenotypes With The Same Genotype Additional Factors Like Tetrahydrobiopterin (Bh<Sub>4</Sub>), The Pah Co-Chaperone Dnajc12, Phosphorylation Of The Pah Residues Or Epigenetic Factors May Play An Important Role. Very Recently An Additional Player, The Long Non-Coding Rna (Lncrna) Transcript Hulc, Was Described To Regulate Pah Activity And Enhance Residual Enzyme Activity Of Some Pah Variants (E.G., The Most Common P.R408W) By Using Hulc Mimics. In This Review We Present An Overview Of The Lncrna Function And In Particular The Interplay Of The Hucl Transcript With The Pah And Discuss Potential Applications For The Future Treatment Of Some Pku Patients.|[('Variants', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Broad Spectrum', 'no label'), ('Phenylketonuria', 'no label'), ('Phenotypes', 'no label'), ('Genotype-Phenotype Correlation', 'no label'), ('Inconsistent', 'no label'), ('Phenotypes', 'no label'), ('Genotype', 'no label'), ('Factors', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Pah Co-Chaperone', 'no label'), ('Dnajc12', 'no label'), ('Phosphorylation', 'no label'), ('Pah Residues', 'no label'), ('Epigenetic Factors', 'no label'), ('Play', 'no label'), ('Player', 'no label'), ('Long Non-Coding Rna', 'no label'), ('Lncrna', 'no label'), ('Hulc', 'no label'), ('Regulate', 'no label'), ('Enhance', 'no label'), ('Residual', 'no label'), ('Enzyme Activity', 'no label'), ('Pah Variants', 'no label'), ('Common', 'no label'), ('Hulc', 'no label'), ('Mimics', 'no label'), ('Review', 'no label'), ('Lncrna', 'no label'), ('Function', 'no label'), ('Hucl Transcript', 'no label'), ('Discuss', 'no label'), ('Applications', 'no label'), ('Future', 'no label'), ('Treatment', 'no label'), ('Pku Patients', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Gene', 'no label'), ('Genotype', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Residues', 'no label'), ('Transcript Hulc', 'no label'), ('Enzyme', 'no label'), ('Hulc', 'no label'), ('Transcript', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Pah Co-Chaperone Dnajc12', 'no label'), ('Pah Variants', 'no label'), ('Hulc', 'no label'), ('Pah And', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Pah Co-Chaperone', 'no label'), ('Pah Residues', 'no label'), ('Rna', 'no label'), ('Hulc', 'no label'), ('Hulc', 'no label'), ('Lncrna', 'no label')]
phenylketonuria|pubmed~34973284|Ptc923 (Formerly Cnsa-001), An Oral Formulation Of Sepiapterin, A Natural Precursor Of Intracellular Tetrahydrobiopterin (Bh<Sub>4</Sub>), Has Been Shown In Humans To Induce Larger Increases In Circulating Bh<Sub>4</Sub> Vs. Sapropterin Dihydrochloride. Sapropterin Reduces Blood Phenylalanine (Phe) By ≥20-30% In A Minority Of Subjects With Pku. This Was A Phase 2 Randomized, Multicenter, Three-Period Crossover, Open-Label, Active Controlled, All-Comers [Regardless Of Phenylalanine Hydroxylase (Pah) Variants] Comparison Of Ptc923 60 Mg/Kg, Ptc923 20 Mg/Kg And Sapropterin 20 Mg/Kg In 24 Adults With Phenylketonuria (Pku) And Hyperphenylalaninemia. Eligible Subjects Were Adult Men Or Women (18-60 Y) With Pku. Subjects Enrolled Received 7 Days Of Once-Daily Oral Treatment With Ptc923 20 Mg/Kg/Day, Ptc923 60 Mg/Kg/Day And Sapropterin Dihydrochloride 20 Mg/Kg/Day Each In A Random Order. Treatments Were Separated By A 7-Day Washout. Subjects Maintained Their Usual Pre-Study Diet, Including Consumption Of Amino Acid Mixtures. Blood Phe Was Measured On Day 1 (Predose Baseline), Day 3, Day 5, And Day 7 Of Each Treatment Period. Least Squares Mean Changes (Se) From Baseline In Blood Phe Were: -206.4 (41.8) Μmol/L For Ptc923 60 Mg/Kg (P < 0.0001); -146.9 (41.8) Μmol/L For Ptc923 20 Mg/Kg (P = 0.0010); And - 91.5 (41.7) Μmol/L For Sapropterin (P = 0.0339). Effects Of Ptc923 60 Mg/Kg On Blood Phe Vs. Sapropterin Were Significantly Larger (P = 0.0098) And Faster In Onset With A Significantly Larger Mean Reduction In Blood Phe At Day 3 Of Treatment, P = 0.0135 (20 Mg/Kg) And P = 0.0007 (60 Mg/Kg). Only Ptc923 60 Mg/Kg Reduced Blood Phe In Classical Pku Subjects (N = 11, P = 0.0287). The Mean Blood Phe Reduction (Ptc923 60 Mg/Kg) In A Cofactor Responder Analysis (N = 8; Baseline Phe ≥300 Μmol/L And Blood Phe Reduction ≥30%) Was -463.3 Μmol/L (Se 51.5) From Baseline. Adverse Events Were Mostly Mild To Moderate, Transient, And Similar Across Treatment Groups With No Serious Adverse Events Or Discontinuations. The Substantially Significantly Better Effect Of Ptc923 60 Mg/Kg On Blood Phe Reduction Vs. Sapropterin Supports Further Clinical Development Of Ptc923 For Pku; Anzctr Number, Actrn12618001031257.|[('Formerly Cnsa-001', 'no label'), ('Oral Formulation', 'no label'), ('Sepiapterin', 'no label'), ('Natural Precursor', 'no label'), ('Intracellular', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Humans', 'no label'), ('Induce', 'no label'), ('Larger', 'no label'), ('Increases', 'no label'), ('Circulating', 'no label'), ('Bh<Sub>4</Sub> Vs', 'no label'), ('Sapropterin', 'no label'), ('Dihydrochloride', 'no label'), ('Sapropterin', 'no label'), ('Reduces', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Minority', 'no label'), ('Subjects', 'no label'), ('Was A', 'no label'), ('Phase 2 Randomized', 'no label'), ('Multicenter', 'no label'), ('Three-Period Crossover', 'no label'), ('Open-Label', 'no label'), ('Active Controlled', 'no label'), ('All-Comers', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Variants', 'no label'), ('Comparison', 'no label'), ('Sapropterin', 'no label'), ('Adults', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Subjects', 'no label'), ('Adult', 'no label'), ('Men', 'no label'), ('Women', 'no label'), ('Pku.', 'no label'), ('Subjects', 'no label'), ('Days', 'no label'), ('Once-Daily Oral Treatment', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Treatments', 'no label'), ('Separated', 'no label'), ('Washout', 'no label'), ('Subjects', 'no label'), ('Maintained', 'no label'), ('Usual Pre-Study Diet', 'no label'), ('Consumption', 'no label'), ('Amino Acid Mixtures', 'no label'), ('Blood Phe', 'no label'), ('Measured', 'no label'), ('Predose', 'no label'), ('Baseline', 'no label'), ('Day 3', 'no label'), ('Treatment', 'no label'), ('Se', 'no label'), ('Baseline', 'no label'), ('Blood Phe', 'no label'), ('Sapropterin', 'no label'), ('Effects', 'no label'), ('Blood Phe Vs', 'no label'), ('Sapropterin', 'no label'), ('Faster', 'no label'), ('Reduction', 'no label'), ('Blood Phe', 'no label'), ('Treatment', 'no label'), ('Reduced', 'no label'), ('Blood Phe', 'no label'), ('Classical Pku Subjects', 'no label'), ('N\u202f=\u202f11, P\u202f=\u202f0.0287', 'no label'), ('Mean Blood Phe Reduction', 'no label'), ('Cofactor Responder Analysis', 'no label'), ('N\u202f=\u202f8', 'no label'), ('Baseline', 'no label'), ('Phe', 'no label'), ('Blood Phe', 'no label'), ('Reduction', 'no label'), ('Se', 'no label'), ('Baseline', 'no label'), ('Adverse Events', 'no label'), ('Moderate', 'no label'), ('Transient', 'no label'), ('Treatment Groups', 'no label'), ('Serious Adverse Events', 'no label'), ('Discontinuations', 'no label'), ('Effect', 'no label'), ('Blood Phe Reduction Vs', 'no label'), ('Sapropterin Supports', 'no label'), ('Clinical Development', 'no label'), ('Actrn12618001031257', 'no label')]|[('Sepiapterin', 'no label'), ('Intracellular Tetrahydrobiopterin', 'no label'), ('Humans', 'no label'), ('Dihydrochloride', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('All-Comers', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Dihydrochloride', 'no label'), ('Amino Acid', 'no label'), ('Se', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Se', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('60\u202fMg/Kg', 'no label'), ('60\u202fMg/Kg', 'no label'), ('60\u202fMg/Kg', 'no label'), ('60\u202fMg/Kg', 'no label')]|[('Sepiapterin', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Sapropterin', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylalanine', 'no label'), ('Sapropterin', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Amino Acid', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Phe', 'no label'), ('Se', 'no label'), ('Discontinuations', 'no label'), ('Sapropterin', 'no label')]|[('Oral', 'no label'), ('Sepiapterin', 'no label'), ('Intracellular Tetrahydrobiopterin', 'no label'), ('Humans', 'no label'), ('Circulating', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Sapropterin', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('A Phase 2', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Mg/Kg', 'no label'), ('Mg/Kg', 'no label'), ('Sapropterin', 'no label'), ('Mg/Kg', 'no label'), ('Phenylketonuria', 'no label'), ('Women', 'no label'), ('Oral', 'no label'), ('Sapropterin Dihydrochloride 20', 'no label'), ('Amino Acid', 'no label'), ('Predose', 'no label'), ('Se', 'no label'), ('Blood', 'no label'), ('Mg/Kg', 'no label'), ('Mg/Kg', 'no label'), ('Sapropterin', 'no label'), ('Mg/Kg', 'no label'), ('Blood Phe', 'no label'), ('Blood Phe', 'no label'), ('Mg/Kg', 'no label'), ('Mg/Kg', 'no label'), ('Mg/Kg', 'no label'), ('Blood Phe', 'no label'), ('Blood Phe', 'no label'), ('Mg/Kg', 'no label'), ('Phe', 'no label'), ('Blood Phe', 'no label'), ('Se', 'no label'), ('Mg/Kg', 'no label'), ('Blood Phe', 'no label')]
phenylketonuria|pubmed~33485801|Sapropterin Dihydrochloride Has Been Approved For The Treatment Of Hyperphenylalaninemia In Infants And Young Children With Phenylketonuria (Pku). Sapropterin Can Reduce Phenylalanine (Phe) Levels In Tetrahydrobiopterin (Bh4)-Responsive Patients, Potentially Preventing The Intellectual Impairment Caused By Elevated Phe Levels. The Long-Term Effect Of Sapropterin On Intellectual Functioning Was Assessed Using The Full-Scale Intelligence Quotient (Fsiq) In 62 Children Who Began Treatment Before The Age Of 6 Years. Over Each 2-Year Interval, The Estimate Of Mean Change In Fsiq Was -0.5768 With A Lower Limit Of The 95% Confidence Interval (Ci) Of -1.60. At The End Of The Follow-Up Period (Year 7), The Least Squares Mean Estimate Of The Change In Fsiq From Baseline Was 1.14 With A Lower Limit Of The 95% Ci Of -3.53. These Lower Limits Were Both Within The Clinically Expected Variation Of 5 Points. During The Whole Study Period, Mean Blood Phe Levels Remained Within The American College Of Medical Genetics (Acmg) Target Range Of 120-360 Μmol/L. In Addition, Height, Weight, And Head Circumference Were Maintained Within Normal Ranges Throughout Follow-Up, As Defined By Growth Charts From The World Health Organization (Who) And Centers For Disease Control And Prevention (Cdc) For Children Below And Above The Age Of 24 Months, Respectively. All Patients (N = 65) Enrolled In This Study Experienced At Least One Adverse Event, As Expected From Previous Studies. In Conclusion, Long-Term Use Of Sapropterin In Individuals With Pku Helps To Control Blood Phe, Preserve Intellectual Functioning, And Maintain Normal Growth In Bh4-Responsive Children Who Initiated Treatment Between The Ages Of 0 To 6 Years.|[('Sapropterin Dihydrochloride', 'no label'), ('Treatment', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Infants', 'no label'), ('Young Children', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin', 'no label'), ('Reduce', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Levels', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Patients', 'no label'), ('Preventing', 'no label'), ('Intellectual Impairment', 'no label'), ('Elevated', 'no label'), ('Phe Levels', 'no label'), ('Long-Term', 'no label'), ('Effect', 'no label'), ('Sapropterin', 'no label'), ('Intellectual Functioning', 'no label'), ('Assessed', 'no label'), ('Full-Scale Intelligence Quotient', 'no label'), ('Fsiq', 'no label'), ('Children', 'no label'), ('Began', 'no label'), ('Treatment', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('2-Year Interval', 'no label'), ('Estimate', 'no label'), ('Mean Change', 'no label'), ('Fsiq', 'no label'), ('Lower Limit', 'no label'), ('Confidence Interval', 'no label'), ('Ci', 'no label'), ('Follow-Up', 'no label'), ('Period', 'no label'), ('Least Squares Mean Estimate', 'no label'), ('Change', 'no label'), ('Fsiq', 'no label'), ('Baseline', 'no label'), ('Lower Limit', 'no label'), ('Ci', 'no label'), ('Limits', 'no label'), ('Clinically Expected', 'no label'), ('Variation', 'no label'), ('Points', 'no label'), ('Whole Study', 'no label'), ('Period', 'no label'), ('Mean', 'no label'), ('Blood Phe Levels Remained', 'no label'), ('American College Of Medical Genetics', 'no label'), ('Acmg', 'no label'), ('Target Range', 'no label'), ('In Addition', 'no label'), ('Height', 'no label'), ('Weight', 'no label'), ('Head Circumference', 'no label'), ('Normal Ranges', 'no label'), ('Follow-Up', 'no label'), ('Growth Charts', 'no label'), ('World Health Organization', 'no label'), ('Centers For Disease Control And Prevention', 'no label'), ('Cdc', 'no label'), ('Children', 'no label'), ('Age', 'no label'), ('Months', 'no label'), ('Patients', 'no label'), ('N\xa0', 'no label'), ('Study', 'no label'), ('Experienced', 'no label'), ('Adverse Event', 'no label'), ('Studies', 'no label'), ('Long-Term', 'no label'), ('Sapropterin', 'no label'), ('Individuals', 'no label'), ('Pku Helps', 'no label'), ('Control Blood Phe', 'no label'), ('Preserve Intellectual Functioning', 'no label'), ('Maintain', 'no label'), ('Normal Growth', 'no label'), ('Children', 'no label'), ('Initiated', 'no label'), ('Treatment', 'no label'), ('Ages', 'no label'), ('Years', 'no label')]|[('Dihydrochloride', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Μmol/L.', 'no label'), ('Individuals', 'no label')]|[]|[('Sapropterin Dihydrochloride', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phe', 'no label'), ('Sapropterin', 'no label'), ('N\xa0=\xa0', 'no label'), ('Sapropterin', 'no label')]|[('Sapropterin Dihydrochloride', 'no label'), ('Infants', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Sapropterin', 'no label'), ('Children', 'no label'), ('Follow-Up Period', 'no label'), ('Lower Limits', 'no label'), ('Blood Phe', 'no label'), ('Head Circumference', 'no label'), ('Cdc', 'no label'), ('Children', 'no label'), ('Patients', 'no label'), ('Sapropterin', 'no label'), ('Blood', 'no label'), ('Children', 'no label')]
phenylketonuria|pubmed~35216344|Phenylketonuria (Pku) Is A Rare Autosomal Recessive Inborn Error Of Metabolism Where The Mainstay Of Treatment Is A Phe Restricted Diet Consisting Of A Combination Of Limited Amounts Of Natural Protein With Supplementation Of Phe-Free Or Low-Phe Protein Substitutes And Special Low Protein Foods. Suboptimal Outcomes May Be Related To The Different Absorption Kinetics Of Free Aas, Which Have Lower Biological Efficacy Than Natural Proteins. Physiomimic Technology<Sup>Tm</Sup> Is A Technology Engineered To Prolong Aa (Aa-Pt) Release Allowing Physiological Absorption And Masking The Odor And Taste Of Free Aas. The Aim Of These Studies Was To Assess The Impact Of Aa-Pt Formulation On Selected Functional And Metabolic Parameters Both In Acute And Long-Term Experimental Studies. Adult Rats In Fasting Conditions Were Randomized In Different Groups And Treated By Oral Gavage. Acute Aa-Pt Administration Resulted In Significantly Lower Bun At 90 Min Versus Baseline. Both Bun And Glycemia Were Modulated In The Same Direction As Intact Casein Protein. Long-Term Treatment With Aa-Pt Significantly Reduces The Protein Expression Of The Muscle Degradation Marker Bnip3L (-46%) While Significantly Increasing The Proliferation Of Market Myostatin (+58%). Animals Dosed For 15 Days With Aa-Pt Had Significantly Stronger Grip Strength (+30%) Versus Baseline. In Conclusion, The Results Suggest That The Aa-Pt Formulation May Have Beneficial Effects On Both Aa Oxidation And Catabolism With A Direct Impact On Muscle As Well As On Other Metabolic Pathways.|[('Phenylketonuria', 'no label'), ('Rare', 'no label'), ('Autosomal', 'no label'), ('Recessive Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Mainstay', 'no label'), ('Treatment', 'no label'), ('Phe Restricted Diet', 'no label'), ('Combination', 'no label'), ('Limited Amounts', 'no label'), ('Natural Protein', 'no label'), ('Supplementation', 'no label'), ('Phe-Free', 'no label'), ('Suboptimal Outcomes May', 'no label'), ('Absorption', 'no label'), ('Kinetics', 'no label'), ('Free Aas', 'no label'), ('Lower', 'no label'), ('Biological', 'no label'), ('Natural Proteins', 'no label'), ('Physiomimic Technology', 'no label'), ('Technology', 'no label'), ('Engineered', 'no label'), ('Physiological Absorption', 'no label'), ('Masking', 'no label'), ('Odor', 'no label'), ('Taste', 'no label'), ('Free Aas', 'no label'), ('Studies', 'no label'), ('Assess', 'no label'), ('Impact', 'no label'), ('Aa-Pt Formulation', 'no label'), ('Functional', 'no label'), ('Metabolic', 'no label'), ('Parameters', 'no label'), ('Acute', 'no label'), ('Experimental Studies', 'no label'), ('Adult', 'no label'), ('Rats', 'no label'), ('Fasting', 'no label'), ('Conditions', 'no label'), ('Randomized', 'no label'), ('Groups', 'no label'), ('Treated', 'no label'), ('Oral Gavage', 'no label'), ('Acute Aa-Pt Administration', 'no label'), ('Resulted', 'no label'), ('Lower', 'no label'), ('Bun', 'no label'), ('Min', 'no label'), ('Baseline', 'no label'), ('Bun', 'no label'), ('Glycemia', 'no label'), ('Modulated', 'no label'), ('Direction', 'no label'), ('Casein Protein', 'no label'), ('Long-Term Treatment', 'no label'), ('Reduces', 'no label'), ('Protein Expression', 'no label'), ('Muscle Degradation Marker', 'no label'), ('Bnip3L', 'no label'), ('Increasing', 'no label'), ('Proliferation', 'no label'), ('Market', 'no label'), ('Myostatin', 'no label'), ('Animals', 'no label'), ('Dosed', 'no label'), ('Days', 'no label'), ('Aa-Pt', 'no label'), ('Grip Strength', 'no label'), ('Baseline', 'no label'), ('Results', 'no label'), ('Suggest', 'no label'), ('Formulation', 'no label'), ('Beneficial', 'no label'), ('Effects', 'no label'), ('Aa Oxidation', 'no label'), ('Catabolism', 'no label'), ('Direct Impact', 'no label'), ('Muscle', 'no label'), ('Metabolic Pathways', 'no label')]|[('Phe', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein Foods', 'no label'), ('Rats', 'no label'), ('Bun', 'no label'), ('Bun', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Bnip3L', 'no label'), ('Myostatin', 'no label'), ('Animals', 'no label')]|[('Phe-Free Or Low-Phe Protein', 'no label'), ('Bun', 'no label'), ('Bun', 'no label')]|[('Phenylketonuria', 'no label'), ('Recessive Inborn', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Phe', 'no label'), ('Phe-Free', 'no label'), ('Low-Phe', 'no label'), ('Prolong Aa', 'no label'), ('Odor', 'no label'), ('Taste', 'no label'), ('Rats', 'no label'), ('Oral', 'no label'), ('Bun', 'no label'), ('Glycemia', 'no label'), ('Casein', 'no label'), ('Muscle', 'no label'), ('Bnip3L', 'no label'), ('Myostatin', 'no label'), ('Aa', 'no label'), ('Muscle', 'no label')]
phenylketonuria|pubmed~34800207|Phenylketonuria (Pku) Is An Inborn Error Disease In Phenylalanine Metabolism Resulting From Defects In The Stages Of Converting Phenylalanine To Tyrosine. Although The Pathophysiology Of Pku Is Not Elucidated Yet, The Toxic Effect Of Phenylalanine On The Brain Causes Severe Mental Retardation. In Relation To Learning And Memory, The Hippocampal Pka / Creb / Bdnf Pathway May Play A Role In Learning Deficits In Pku Patients. This Study Aimed To Investigate Pka/Creb/Bdnf Pathway In Hippocampus Of Chemically Induced Pku Rats With Regard To Gender. Sprague-Dawley Rat Pups Were Randomized Into Two Groups Of Both Genders. To Chemically Induce Pku, Animals Received Subcutaneous Administration Of Phenylalanine (5.2 Mmol / G) Plus P-Chlorophenylalanine, Phenylalanine Hydroxylase Inhibitor (0.9 Mmol / G); Control Animals Received 0.9% Nacl. Injections Started On The 6Th Day And Continued Until The 21St Day After Which Locomotor Activity, Learning And Memory Were Tested. In Male Pku Rats, Locomotor Activity Was Reduced. There Were No Differences In Learning And Memory Performances Of Male And Female Pku Rats. In Pku Rats, Pcreb / Creb Levels In Males Was Unchanged While It Decreased In Females. Elevated Pka Activity, Bdnf Levels And Decreased Pcreb/Creb Ratio Found In Female Pku Rats Were Not Replicated In Pku Males In Which Bdnf Is Decreased. Our Results Display That In This Disease Model A Gender Specific Differential Activation Of Camp/Pka-Creb-Bdnf Signaling Pathway In Hippocampus Occurs Investigation Of Which Can Help Us To A Better Understanding Of Disease Pathophysiology.|[('Phenylketonuria', 'no label'), ('Inborn Error Disease', 'no label'), ('Phenylalanine Metabolism', 'no label'), ('Resulting', 'no label'), ('Defects', 'no label'), ('Stages', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Pathophysiology', 'no label'), ('Pku', 'no label'), ('Toxic Effect', 'no label'), ('Phenylalanine', 'no label'), ('Brain Causes', 'no label'), ('Severe', 'no label'), ('Mental Retardation', 'no label'), ('Learning', 'no label'), ('Memory', 'no label'), ('Hippocampal', 'no label'), ('Pka', 'no label'), ('Creb', 'no label'), ('Bdnf Pathway', 'no label'), ('Play A', 'no label'), ('Learning Deficits', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Investigate', 'no label'), ('Pka/Creb/Bdnf Pathway', 'no label'), ('Hippocampus', 'no label'), ('Chemically', 'no label'), ('Induced', 'no label'), ('Rats', 'no label'), ('Regard', 'no label'), ('Gender', 'no label'), ('Sprague-Dawley Rat Pups', 'no label'), ('Randomized', 'no label'), ('Groups', 'no label'), ('Genders', 'no label'), ('Chemically Induce', 'no label'), ('Animals', 'no label'), ('Subcutaneous Administration', 'no label'), ('Phenylalanine', 'no label'), ('G', 'no label'), ('P-Chlorophenylalanine', 'no label'), ('Phenylalanine Hydroxylase Inhibitor', 'no label'), ('G', 'no label'), ('Control Animals', 'no label'), ('Nacl', 'no label'), ('Injections', 'no label'), ('Started', 'no label'), ('Day', 'no label'), ('Day', 'no label'), ('Locomotor Activity', 'no label'), ('Learning And Memory', 'no label'), ('Tested', 'no label'), ('Male Pku', 'no label'), ('Rats', 'no label'), ('Locomotor Activity', 'no label'), ('Reduced', 'no label'), ('Learning', 'no label'), ('Memory', 'no label'), ('Performances', 'no label'), ('Male', 'no label'), ('Female', 'no label'), ('Rats', 'no label'), ('Rats', 'no label'), ('Pcreb', 'no label'), ('Creb', 'no label'), ('Levels', 'no label'), ('Males', 'no label'), ('Unchanged', 'no label'), ('Decreased', 'no label'), ('Females', 'no label'), ('Elevated', 'no label'), ('Pka Activity', 'no label'), ('Bdnf Levels', 'no label'), ('Decreased', 'no label'), ('Pcreb/Creb Ratio', 'no label'), ('Female', 'no label'), ('Rats', 'no label'), ('Not Replicated', 'no label'), ('Pku Males', 'no label'), ('Bdnf', 'no label'), ('Decreased', 'no label'), ('Results', 'no label'), ('Display', 'no label'), ('Disease Model', 'no label'), ('Gender', 'no label'), ('Differential Activation', 'no label'), ('Camp/Pka-Creb-Bdnf Signaling Pathway', 'no label'), ('Hippocampus', 'no label'), ('Occurs', 'no label'), ('Investigation', 'no label'), ('Disease Pathophysiology', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Toxic', 'no label'), ('Phenylalanine', 'no label'), ('Creb', 'no label'), ('Bdnf', 'no label'), ('Rats', 'no label'), ('Rat', 'no label'), ('Animals', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Inhibitor', 'no label'), ('Animals', 'no label'), ('Nacl', 'no label'), ('Rats', 'no label'), ('Rats', 'no label'), ('Rats', 'no label'), ('Creb', 'no label'), ('Bdnf', 'no label'), ('Rats', 'no label'), ('Replicated', 'no label'), ('Bdnf', 'no label')]|[('Pka', 'no label'), ('Creb', 'no label'), ('Bdnf', 'no label'), ('Creb', 'no label'), ('Pka', 'no label'), ('Bdnf', 'no label'), ('Bdnf', 'no label')]|[('Phenylketonuria', 'no label'), ('Inborn Error Disease', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Learning Deficits', 'no label'), ('Phenylalanine', 'no label'), ('P-Chlorophenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Nacl', 'no label'), ('Camp/Pka-Creb-Bdnf', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Brain', 'no label'), ('Hippocampal Pka', 'no label'), ('Creb', 'no label'), ('Bdnf', 'no label'), ('Hippocampus Of', 'no label'), ('Phenylalanine', 'no label'), ('P-Chlorophenylalanine', 'no label'), ('Phenylalanine Hydroxylase Inhibitor', 'no label'), ('Locomotor', 'no label'), ('Locomotor', 'no label'), ('Pku Rats', 'no label'), ('Creb', 'no label'), ('Pka', 'no label'), ('Bdnf', 'no label'), ('Female Pku Rats', 'no label'), ('Bdnf', 'no label'), ('Camp/Pka-Creb-Bdnf', 'no label'), ('Hippocampus', 'no label')]
phenylketonuria|pubmed~31284588|Evidence Suggests A Role Of Long Chain Polyunsaturated Fatty Acids (Lc-Pufa), In Which Animal Foods Are Especially Rich, In Optimal Neural Development. The Lc-Pufas Docosahexaenoic Acid (Dha) And Arachidonic Acid, Found In High Concentrations In The Brain And Retina, Have Potential Beneficial Effects On Cognition, And Motor And Visual Functions. Phenylketonuria (Pku) Is The Most Common Inborn Error Of Amino Acid Metabolism. The Treatment Of Pku Consists Of A Phenylalanine-Free Diet, Which Limits The Intake Of Natural Proteins Of High Biological Value. In This Systematic Review, We Summarize The Available Evidence Supporting A Role For Lc-Pufa Supplementation As An Effective Means Of Increasing Lc-Pufa Levels And Improving Visual And Neurocognitive Functions In Pku Patients. Data From Controlled Trials Of Children And Adults (Up To 47 Years Of Age) Were Obtained By Searching The Medline And Scopus Databases Following Preferred Reporting Items For Systematic Reviews And Meta-Analyses (Prisma) Guidelines. For Each Selected Study, The Risk Of Bias Was Assessed Applying The Methodology Of The Cochrane Collaboration. The Findings Indicate That Dha Supplementation In Pku Patients From 2 Weeks To 47 Years Of Age Improves Dha Status And Decreases Visual Evoked Potential P100 Wave Latency In Pku Children From 1 To 11 Years Old. Neurocognitive Data Are Inconclusive.|[('Evidence', 'no label'), ('Suggests', 'no label'), ('Long Chain Polyunsaturated Fatty Acids', 'no label'), ('Lc-Pufa', 'no label'), ('Animal Foods', 'no label'), ('Optimal', 'no label'), ('Neural Development', 'no label'), ('Lc-Pufas Docosahexaenoic Acid', 'no label'), ('Dha', 'no label'), ('Arachidonic Acid', 'no label'), ('Concentrations', 'no label'), ('Brain', 'no label'), ('Retina', 'no label'), ('Potential', 'no label'), ('Beneficial', 'no label'), ('Effects', 'no label'), ('Cognition', 'no label'), ('Motor And Visual Functions', 'no label'), ('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Treatment', 'no label'), ('Pku Consists', 'no label'), ('Phenylalanine-Free Diet', 'no label'), ('Limits', 'no label'), ('Intake', 'no label'), ('Natural Proteins', 'no label'), ('Biological Value', 'no label'), ('Systematic Review', 'no label'), ('Available Evidence', 'no label'), ('Lc-Pufa', 'no label'), ('Supplementation', 'no label'), ('Effective', 'no label'), ('Means', 'no label'), ('Increasing', 'no label'), ('Lc-Pufa', 'no label'), ('Levels', 'no label'), ('Improving', 'no label'), ('Visual', 'no label'), ('Neurocognitive Functions', 'no label'), ('Patients', 'no label'), ('Data', 'no label'), ('Controlled Trials', 'no label'), ('Children', 'no label'), ('Adults', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Medline', 'no label'), ('Preferred Reporting Items', 'no label'), ('Systematic Reviews', 'no label'), ('Prisma', 'no label'), ('Guidelines', 'no label'), ('Study', 'no label'), ('Risk', 'no label'), ('Bias', 'no label'), ('Assessed', 'no label'), ('Methodology', 'no label'), ('Cochrane Collaboration', 'no label'), ('Findings', 'no label'), ('Indicate', 'no label'), ('Dha', 'no label'), ('Supplementation', 'no label'), ('Patients', 'no label'), ('Weeks', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Dha Status', 'no label'), ('Decreases', 'no label'), ('Visual Evoked Potential P100 Wave', 'no label'), ('Latency', 'no label'), ('Pku Children', 'no label'), ('Years', 'no label'), ('Neurocognitive Data', 'no label')]|[('Fatty Acids', 'no label'), ('Animal Foods', 'no label'), ('Arachidonic Acid', 'no label'), ('Amino Acid', 'no label'), ('Proteins', 'no label')]|[]|[('Docosahexaenoic Acid', 'no label'), ('Dha', 'no label'), ('Arachidonic Acid', 'no label'), ('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Visual Evoked Potential P100 Wave Latency In Pku Children From 1 To 11 Years Old.', 'no label')]|[('Long', 'no label'), ('Polyunsaturated Fatty Acids', 'no label'), ('Lc-Pufas Docosahexaenoic Acid', 'no label'), ('Arachidonic Acid', 'no label'), ('Brain', 'no label'), ('Retina', 'no label'), ('Error', 'no label'), ('Amino Acid', 'no label'), ('Proteins', 'no label'), ('Pku Patients', 'no label'), ('Children', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~27655443|Phenylketonuria Treatment Consists Mainly Of A Phe-Restricted Diet, Which Leads To Suboptimal Neurocognitive And Psychosocial Outcomes. Supplementation Of Large Neutral Amino Acids (Lnaas) Has Been Suggested As An Alternative Dietary Treatment Strategy To Optimize Neurocognitive Outcome In Phenylketonuria And Has Been Shown To Influence 3 Brain Pathobiochemical Mechanisms In Phenylketonuria, But Its Optimal Composition Has Not Been Established. In Order To Provide Additional Pathobiochemical Insight And Develop Optimal Lnaa Treatment, Several Targeted Lnaa Supplements Were Investigated With Respect To All 3 Biochemical Disturbances Underlying Brain Dysfunction In Phenylketonuria. Pah-Enu2 (Pku) Mice Received 1 Of 5 Different Lnaa-Supplemented Diets Beginning At Postnatal Day 45. Control Groups Included Phenylketonuria Mice Receiving An Isonitrogenic And Isocaloric High-Protein Diet Or The Ain-93M Diet, And Wild-Type Mice Receiving The Ain-93M Diet. After 6 Wk, Brain And Plasma Amino Acid Profiles And Brain Monoaminergic Neurotransmitter Concentrations Were Measured. Brain Phe Concentrations Were Most Effectively Reduced By Supplementation Of Lnaas, Such As Leu And Ile, With A Strong Affinity For The Lnaa Transporter Type 1. Brain Non-Phe Lnaas Could Be Restored On Supplementation, But Unbalanced Lnaa Supplementation Further Reduced Brain Concentrations Of Those Lnaas That Were Not (Sufficiently) Included In The Lnaa Supplement. To Optimally Ameliorate Brain Monoaminergic Neurotransmitter Concentrations, Lnaa Supplementation Should Include Tyr And Trp Together With Lnaas That Effectively Reduce Brain Phe Concentrations. The Requirement For Tyr Supplementation Is Higher Than It Is For Trp, And The Relative Effect Of Brain Phe Reduction Is Higher For Serotonin Than It Is For Dopamine And Norepinephrine. The Study Shows That All 3 Biochemical Disturbances Underlying Brain Dysfunction In Phenylketonuria Can Be Targeted By Specific Lnaa Supplements. The Study Thus Provides Essential Information For The Development Of Optimal Lnaa Supplementation As An Alternative Dietary Treatment Strategy To Optimize Neurocognitive Outcome In Patients With Phenylketonuria.|[('Phenylketonuria', 'no label'), ('Treatment Consists', 'no label'), ('Phe-Restricted Diet', 'no label'), ('Leads', 'no label'), ('Suboptimal', 'no label'), ('Neurocognitive', 'no label'), ('Psychosocial Outcomes', 'no label'), ('Supplementation', 'no label'), ('Neutral Amino Acids', 'no label'), ('Lnaas', 'no label'), ('Alternative', 'no label'), ('Dietary Treatment Strategy', 'no label'), ('Optimize', 'no label'), ('Neurocognitive Outcome', 'no label'), ('Phenylketonuria', 'no label'), ('Influence', 'no label'), ('Brain', 'no label'), ('Pathobiochemical Mechanisms', 'no label'), ('Phenylketonuria', 'no label'), ('Optimal', 'no label'), ('Composition', 'no label'), ('Established', 'no label'), ('Order', 'no label'), ('Pathobiochemical', 'no label'), ('Optimal', 'no label'), ('Lnaa Treatment', 'no label'), ('Targeted Lnaa Supplements', 'no label'), ('Investigated', 'no label'), ('Respect', 'no label'), ('Biochemical', 'no label'), ('Disturbances', 'no label'), ('Brain Dysfunction', 'no label'), ('Phenylketonuria', 'no label'), ('Pah-Enu2', 'no label'), ('Lnaa-Supplemented', 'no label'), ('Diets', 'no label'), ('Postnatal', 'no label'), ('Day', 'no label'), ('Control Groups', 'no label'), ('Phenylketonuria Mice', 'no label'), ('Receiving', 'no label'), ('Isonitrogenic', 'no label'), ('Ain-93M Diet', 'no label'), ('Wild-Type Mice', 'no label'), ('Receiving', 'no label'), ('Ain-93M Diet', 'no label'), ('Brain', 'no label'), ('Plasma', 'no label'), ('Amino Acid', 'no label'), ('Profiles', 'no label'), ('Brain Monoaminergic', 'no label'), ('Neurotransmitter', 'no label'), ('Concentrations', 'no label'), ('Measured', 'no label'), ('Brain', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Reduced', 'no label'), ('Supplementation', 'no label'), ('Lnaas', 'no label'), ('Leu And Ile', 'no label'), ('Strong', 'no label'), ('Affinity', 'no label'), ('Lnaa Transporter Type 1', 'no label'), ('Brain', 'no label'), ('Non-Phe Lnaas', 'no label'), ('Restored', 'no label'), ('Supplementation', 'no label'), ('Lnaa Supplementation', 'no label'), ('Reduced', 'no label'), ('Brain', 'no label'), ('Concentrations', 'no label'), ('Lnaas', 'no label'), ('Lnaa Supplement', 'no label'), ('Brain Monoaminergic', 'no label'), ('Neurotransmitter', 'no label'), ('Concentrations', 'no label'), ('Lnaa Supplementation', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Lnaas', 'no label'), ('Effectively Reduce', 'no label'), ('Brain', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Requirement', 'no label'), ('Tyr', 'no label'), ('Supplementation', 'no label'), ('Trp', 'no label'), ('Relative Effect', 'no label'), ('Brain', 'no label'), ('Reduction', 'no label'), ('Serotonin Than', 'no label'), ('Dopamine', 'no label'), ('Norepinephrine', 'no label'), ('Study', 'no label'), ('Biochemical', 'no label'), ('Disturbances', 'no label'), ('Brain Dysfunction', 'no label'), ('Phenylketonuria', 'no label'), ('Lnaa Supplements', 'no label'), ('Study', 'no label'), ('Provides', 'no label'), ('Essential Information', 'no label'), ('Development', 'no label'), ('Optimal', 'no label'), ('Lnaa', 'no label'), ('Supplementation', 'no label'), ('Alternative', 'no label'), ('Dietary Treatment Strategy', 'no label'), ('Optimize', 'no label'), ('Neurocognitive Outcome', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label')]|[('Amino Acids', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Amino Acid', 'no label'), ('Monoaminergic Neurotransmitter', 'no label'), ('Monoaminergic Neurotransmitter', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Phe', 'no label'), ('Serotonin Than', 'no label'), ('Dopamine', 'no label')]|[('Non-Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Amino Acids', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Brain Dysfunction', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Phe', 'no label'), ('Trp', 'no label'), ('Phe', 'no label'), ('Trp', 'no label'), ('Serotonin', 'no label'), ('Dopamine', 'no label'), ('Norepinephrine', 'no label'), ('Brain Dysfunction', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label')]|[('Amino Acids', 'no label'), ('Phenylketonuria', 'no label'), ('Brain Pathobiochemical', 'no label'), ('Phenylketonuria', 'no label'), ('Lnaa', 'no label'), ('Brain', 'no label'), ('Phenylketonuria', 'no label'), ('Mice', 'no label'), ('Phenylketonuria Mice', 'no label'), ('Mice', 'no label'), ('Brain', 'no label'), ('Plasma Amino Acid', 'no label'), ('Brain Monoaminergic Neurotransmitter', 'no label'), ('Brain Phe', 'no label'), ('Lnaa Transporter Type 1', 'no label'), ('Brain Non-Phe', 'no label'), ('Lnaa', 'no label'), ('Brain', 'no label'), ('Brain Monoaminergic Neurotransmitter', 'no label'), ('Lnaa', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Brain Phe', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Brain Phe', 'no label'), ('Serotonin', 'no label'), ('Dopamine', 'no label'), ('Norepinephrine', 'no label'), ('Brain', 'no label'), ('Phenylketonuria', 'no label'), ('Lnaa', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~32392388|Many Similarities Between Tryptophan (Trp) And Phenylalanine (Phe) Metabolisms Exist. It Is Possible That A Modification Of Trp Metabolism Might Be Seen In Phenylketonuria (Pku). As Some Of These Metabolites Have Neuroactive Properties, They Should Be Consider In Neurological Impairment Seen In This Pathology And Not Totally Explained By Blood Phe Concentrations. One Hundred And Fifty-One Adult Pku Patients (Mean Age 26.8 Years) Were Included For This Study. Plasma Trp, Kynurenine (Kyn), 3-Hydroxykynurenic Acid (3Hk), And Kynurenic Acid (Ka) Were Analyzed By Liquid Chromatography Coupled With Tandem Mass Spectrometry. Kyn And 3Hk Were Significantly Lower In Pku Patients Compared To General Population (P < .0001), And Ka Was Significantly Enhanced Is This Population (P = .009). Furthermore, 3Hk Concentration Was Significantly Different Between Pku Patients Underwent Controlled Low-Phe Diet Compared To Pku Patients Without This Diet (P = .0016). In Pku Patients With Diet, Taking Aa Substitute Enable Higher Plasma 3Hk Concentration Than Without (P = .0008) But Still Not Reaching General Population Level (P < .0001). Although Further Study Has To Be Done, It Is Clear That Trp Metabolism Is Modified In Adult Pku Patients. An Exploration Of Complete Trp Metabolism, And Not Only Trp Concentration, Is Needed In Pku Population, But Also In Other Inborn Error Of Metabolism Treated With Hypoprotidic Diet.|[('Similarities', 'no label'), ('Tryptophan', 'no label'), ('Trp', 'no label'), ('Phenylalanine (Phe)', 'no label'), ('Metabolisms', 'no label'), ('Exist', 'no label'), ('Modification', 'no label'), ('Trp Metabolism', 'no label'), ('Phenylketonuria', 'no label'), ('Metabolites', 'no label'), ('Neuroactive', 'no label'), ('Properties', 'no label'), ('Neurological Impairment', 'no label'), ('Pathology', 'no label'), ('Explained', 'no label'), ('Blood', 'no label'), ('Concentrations', 'no label'), ('Fifty-One Adult Pku Patients', 'no label'), ('Mean Age', 'no label'), ('Study', 'no label'), ('Plasma', 'no label'), ('Trp', 'no label'), ('Kynurenine', 'no label'), ('Kyn', 'no label'), ('3-Hydroxykynurenic Acid', 'no label'), ('Kynurenic Acid', 'no label'), ('Ka', 'no label'), ('Analyzed', 'no label'), ('Liquid Chromatography', 'no label'), ('Tandem Mass Spectrometry', 'no label'), ('Kyn', 'no label'), ('Pku Patients', 'no label'), ('General Population', 'no label'), ('Ka', 'no label'), ('Enhanced', 'no label'), ('Population', 'no label'), ('Concentration', 'no label'), ('Pku Patients', 'no label'), ('Controlled Low-Phe Diet', 'no label'), ('Compared', 'no label'), ('Pku Patients', 'no label'), ('Diet', 'no label'), ('Patients', 'no label'), ('Diet', 'no label'), ('Enable', 'no label'), ('Higher', 'no label'), ('Plasma', 'no label'), ('Concentration', 'no label'), ('General Population Level', 'no label'), ('Study', 'no label'), ('Trp Metabolism', 'no label'), ('Modified', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Exploration', 'no label'), ('Complete', 'no label'), ('Trp Metabolism', 'no label'), ('Trp Concentration', 'no label'), ('Pku Population', 'no label'), ('Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Treated With', 'no label'), ('Hypoprotidic Diet', 'no label')]|[('Tryptophan', 'no label'), ('Trp', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Modification', 'no label'), ('Trp', 'no label'), ('Kynurenine', 'no label'), ('Kyn', 'no label'), ('Acid', 'no label'), ('Kynurenic Acid', 'no label'), ('Trp', 'no label'), ('Trp', 'no label')]|[]|[('Tryptophan', 'no label'), ('Trp', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Metabolisms', 'no label'), ('Trp', 'no label'), ('Phenylketonuria', 'no label'), ('Neurological Impairment', 'no label'), ('Trp', 'no label'), ('Kynurenine', 'no label'), ('Kyn', 'no label'), ('Kynurenic Acid', 'no label'), ('Kyn', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Trp', 'no label')]|[('Tryptophan', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Trp', 'no label'), ('Phenylketonuria', 'no label'), ('Pathology', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Plasma Trp', 'no label'), ('Kynurenine', 'no label'), ('Kyn', 'no label'), ('Kynurenic Acid', 'no label'), ('Kyn', 'no label'), ('Patients', 'no label'), ('Pku Patients', 'no label'), ('Plasma', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Error', 'no label')]
phenylketonuria|pubmed~34920737|Phenylketonuria (Pku) Is A Metabolic Disease That Can Cause Severe And Irreversible Brain Damage Without Treatment. Here We Developed A Non-Invasive Prenatal Diagnosis (Nipd) Technique Based On Haplotypes Via Paired-End Molecular Tags And Weighting Algorithm And Applied It To The Nipd Of Pku To Evaluate Its Accuracy And Feasibility In The Early Pregnancy. A Custom-Designed Hybridization Probes Containing Regions In Phenylalanine Hydroxylase (Pah) Gene And Its 1 Mb Flanking Region Were Used For Target Sequencing On Genomic And Maternal Plasma Dna (7-13 Weeks Of Gestation) To Construct The Parental Haplotypes And The Proband'S Haplotype. Fetal Haplotype Was Then Inferred Combined With The Parental Haplotypes And The Proband'S Haplotype. The Presence Of Haplotypes Linked To Both The Maternal And Paternal Mutant Alleles Indicated Affected Fetuses. The Fetal Genotypes Were Further Validated By Invasive Prenatal Diagnosis In A Blinded Fashion. This Technique Has Been Successfully Applied In Twenty-One Cases. Six Fetuses Were Diagnosed As Patients Carrying Both Of The Mutated Haplotypes Inherited From Their Parents. Eleven Fetuses Were Carriers Of One Heterozygous Pah Variants, Six Of Which Were Paternal And Five Of Which Were Maternal. Four Fetuses Were Absence Of Pathogenic Alleles. All Results Were Consistent With The Prenatal Diagnosis Through Amniotic Fluid. The Results Showed That Our New Technique Applied To The Genotyping Of Fetuses With High Risk For Pku Achieves An Accurate Detection At An Early Stage Of Pregnancy With Low Fetal Fraction In Cell Free Dna.|"[('Phenylketonuria', 'no label'), ('Metabolic Disease', 'no label'), ('Cause Severe', 'no label'), ('Irreversible', 'no label'), ('Brain Damage', 'no label'), ('Treatment', 'no label'), ('Non-Invasive', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Haplotypes', 'no label'), ('Weighting Algorithm', 'no label'), ('Nipd', 'no label'), ('Pku To Evaluate', 'no label'), ('Accuracy', 'no label'), ('Feasibility', 'no label'), ('Early Pregnancy', 'no label'), ('Custom-Designed Hybridization Probes', 'no label'), ('Containing Regions', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Flanking Region', 'no label'), ('Target Sequencing', 'no label'), ('Genomic', 'no label'), ('Maternal', 'no label'), ('Plasma Dna', 'no label'), ('Weeks', 'no label'), ('Gestation', 'no label'), ('Parental', 'no label'), ('Haplotypes', 'no label'), (""Proband'S"", 'no label'), ('Haplotype', 'no label'), ('Fetal', 'no label'), ('Haplotype', 'no label'), ('Parental', 'no label'), ('Haplotypes', 'no label'), (""Proband'S"", 'no label'), ('Haplotype', 'no label'), ('Haplotypes', 'no label'), ('Maternal', 'no label'), ('Paternal Mutant', 'no label'), ('Affected', 'no label'), ('Fetuses', 'no label'), ('Fetal Genotypes', 'no label'), ('Validated', 'no label'), ('Invasive', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Blinded', 'no label'), ('Fashion', 'no label'), ('Technique', 'no label'), ('Successfully', 'no label'), ('Twenty-One Cases', 'no label'), ('Fetuses', 'no label'), ('Diagnosed', 'no label'), ('Patients', 'no label'), ('Carrying', 'no label'), ('Mutated Haplotypes', 'no label'), ('Inherited', 'no label'), ('Parents', 'no label'), ('Fetuses', 'no label'), ('Carriers', 'no label'), ('Heterozygous Pah Variants', 'no label'), ('Paternal', 'no label'), ('Maternal', 'no label'), ('Fetuses', 'no label'), ('Absence', 'no label'), ('Pathogenic', 'no label'), ('Alleles', 'no label'), ('Results', 'no label'), ('Consistent With', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Amniotic Fluid', 'no label'), ('Results', 'no label'), ('New Technique Applied', 'no label'), ('Genotyping', 'no label'), ('Fetuses', 'no label'), ('High Risk', 'no label'), ('Pku Achieves', 'no label'), ('Accurate', 'no label'), ('Detection', 'no label'), ('Early Stage', 'no label'), ('Pregnancy', 'no label'), ('Low Fetal Fraction', 'no label'), ('Cell Free Dna', 'no label')]"|[('Haplotypes', 'no label'), ('Molecular', 'no label'), ('Probes', 'no label'), ('Regions', 'no label'), ('Phenylalanine', 'no label'), ('Gene', 'no label'), ('Region', 'no label'), ('Genomic', 'no label'), ('Dna', 'no label'), ('Haplotypes', 'no label'), ('Haplotype', 'no label'), ('Haplotype', 'no label'), ('Haplotypes', 'no label'), ('Haplotype', 'no label'), ('Haplotypes', 'no label'), ('Mutant Alleles', 'no label'), ('Genotypes', 'no label'), ('Haplotypes', 'no label'), ('Cell', 'no label')]|[('1 Mb Flanking Region', 'no label')]|[('Phenylketonuria', 'no label'), ('Metabolic Disease', 'no label'), ('Brain Damage', 'no label'), ('Phenylalanine', 'no label'), ('Heterozygous', 'no label'), ('Diagnosis', 'no label')]|[('Phenylketonuria', 'no label'), ('Brain', 'no label'), ('Probes', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Its 1', 'no label'), ('Plasma Dna', 'no label'), ('Fetuses', 'no label'), ('Fetal', 'no label'), ('Fetuses', 'no label'), ('Patients', 'no label'), ('Fetuses', 'no label'), ('Fetuses', 'no label'), ('Amniotic Fluid', 'no label'), ('Fetuses', 'no label'), ('Fetal', 'no label'), ('Cell', 'no label'), ('Dna', 'no label')]
phenylketonuria|pubmed~34794480|"Insufficient Metabolic Control During Pregnancy Of Mothers With Phenylketonuria (Pku) Leads To Maternal Pku Syndrome, A Severe Embryo-/Fetopathy. Since Maintaining Or Reintroducing The Strict Phenylalanine (Phe) Limited Diet In Adults With Pku Is Challenging, We Evaluated The Most Important Dietary And Psychosocial Factors To Gain And Sustain Good Metabolic Control In Phenylketonuric Women Throughout Pregnancy By A Questionnaire Survey With 38 Questions Concerning Therapy Feasibility. Among Them, The Key Questions Covered 5 Essential Items Of Pku Care As Follows: General Information About Maternal Pku, Pku Training, Diet Implementation, Individual Metabolic Care, Personal Support. In Addition, All Participating Pku Mothers Were Asked To Estimate The Quality Of Their Personal Metabolic Control Of The Concluded Pregnancies. 54 Pku Mothers With 81 Pregnancies Were Approached At 12 Metabolic Centers In Germany And Austria Were Included. According To Metabolic Control, Pregnancies Of Pku Women Were Divided In Two Groups: Group ""Ideal"" (Not More Than 5% Of All Blood Phe Concentrations During Pregnancy > 360 Μmol/L; N = 23) And Group ""Suboptimal"" (All Others; N = 51). The Demand For Support Was Equally Distributed Among Groups, Concerning Both Amount And Content. Personal Support By The Direct Social Environment (Partner, Family And Friends) (""Suboptimal"" 71% Vs ""Ideal"" 78%) As Well As Individual Metabolic Care By The Specialized Metabolic Center (Both Groups Around 60%) Were Rated As Most Important Factors. The Groups Differed Significantly With Respect To The Estimation Of The Quality Of Their Metabolic Situation (P < 0.001). Group ""Ideal"" Presented A 100% Realistic Self-Assessment. In Contrast, Group ""Suboptimal"" Overestimated Their Metabolic Control In 53% Of The Pregnancies. Offspring Of Group ""Suboptimal"" Showed Clinical Signs Of Maternal Pku-Syndrome In 27%. The Development Of Training Programs By Specialized Metabolic Centers For Females With Pku In Child Bearing Age Is Crucial, Especially Since Those Mothers At Risk Of Giving Birth To A Child With Maternal Pku Syndrome Are Not Aware Of Their Suboptimal Metabolic Control. Such Programs Should Provide Specific Awareness Training For The Own Metabolic Situation And Should Include Partners And Families."|[('Insufficient', 'no label'), ('Metabolic Control', 'no label'), ('Pregnancy', 'no label'), ('Mothers', 'no label'), ('Phenylketonuria', 'no label'), ('Pku) Leads', 'no label'), ('Maternal', 'no label'), ('Pku Syndrome', 'no label'), ('Severe', 'no label'), ('Embryo-/Fetopathy', 'no label'), ('Reintroducing', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Adults', 'no label'), ('Pku', 'no label'), ('Evaluated', 'no label'), ('Dietary', 'no label'), ('Psychosocial Factors', 'no label'), ('Gain', 'no label'), ('Sustain', 'no label'), ('Metabolic Control', 'no label'), ('Phenylketonuric Women', 'no label'), ('Pregnancy', 'no label'), ('Questions', 'no label'), ('Therapy', 'no label'), ('Feasibility', 'no label'), ('Key Questions', 'no label'), ('Covered', 'no label'), ('Essential', 'no label'), ('Pku Care', 'no label'), ('General Information', 'no label'), ('Maternal Pku', 'no label'), ('Pku Training', 'no label'), ('Diet Implementation', 'no label'), ('Individual', 'no label'), ('Metabolic Care', 'no label'), ('Personal Support', 'no label'), ('Participating', 'no label'), ('Pku Mothers', 'no label'), ('Quality', 'no label'), ('Personal Metabolic Control', 'no label'), ('Concluded Pregnancies', 'no label'), ('Pku Mothers', 'no label'), ('Pregnancies', 'no label'), ('Metabolic Centers', 'no label'), ('Germany', 'no label'), ('Austria', 'no label'), ('Metabolic Control', 'no label'), ('Pregnancies', 'no label'), ('Pku Women', 'no label'), ('Groups', 'no label'), ('Group', 'no label'), ('Blood Phe', 'no label'), ('Concentrations', 'no label'), ('Pregnancy\u2009>\u2009360\xa0Μmol/L', 'no label'), ('Group', 'no label'), ('Suboptimal', 'no label'), ('Groups', 'no label'), ('Amount', 'no label'), ('Content', 'no label'), ('Personal Support', 'no label'), ('Direct Social Environment', 'no label'), ('Partner', 'no label'), ('Suboptimal', 'no label'), ('Metabolic Care', 'no label'), ('Specialized Metabolic Center', 'no label'), ('Groups', 'no label'), ('Factors', 'no label'), ('Groups', 'no label'), ('Differed', 'no label'), ('Respect', 'no label'), ('Estimation', 'no label'), ('Quality', 'no label'), ('Metabolic Situation', 'no label'), ('Group', 'no label'), ('Realistic Self-Assessment', 'no label'), ('Contrast', 'no label'), ('Group', 'no label'), ('Suboptimal', 'no label'), ('Overestimated', 'no label'), ('Metabolic Control', 'no label'), ('Pregnancies', 'no label'), ('Offspring', 'no label'), ('Group', 'no label'), ('Suboptimal', 'no label'), ('Clinical Signs', 'no label'), ('Maternal', 'no label'), ('Pku-Syndrome', 'no label'), ('Development', 'no label'), ('Training Programs', 'no label'), ('Metabolic Centers', 'no label'), ('Females', 'no label'), ('Pku In Child Bearing Age', 'no label'), ('Mothers', 'no label'), ('Risk', 'no label'), ('Giving Birth', 'no label'), ('To A Child', 'no label'), ('Maternal Pku Syndrome', 'no label'), ('Not Aware', 'no label'), ('Suboptimal', 'no label'), ('Metabolic Control', 'no label'), ('Programs', 'no label'), ('Awareness', 'no label'), ('Training', 'no label'), ('Own Metabolic Situation', 'no label'), ('Partners', 'no label'), ('Families', 'no label')]|[('Reintroducing', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Pku-Syndrome', 'no label')]|[('Pku-Syndrome', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Women', 'no label'), ('Pregnancies', 'no label'), ('Germany', 'no label'), ('Blood Phe', 'no label'), ('Pregnancies', 'no label')]
phenylketonuria|pubmed~33581706|Phenylalanine (Phe) Hydroxylase (Pah) Deficiency Leads To Hyperphenylalaninemia (Hpa) And Tyrosine (Tyr) Depletion. We Investigated Tyr Homeostasis In Patients With Pah Deficiency And The Effect Of A Slow-Release Amino Acids Therapy In Phenylketonuria (Pku). We Performed Four Complementary Investigations: (1) Tyr Concentrations Were Monitored In 114 Patients (10.6 ± 11.9 Years) With Pku On Dietary Treatment Supplemented With Traditional Amino Acid Formulations (N=52, 1175 Samples) Or Non-Pku Hpa On A Free Diet (N=62, 430 Samples); (2) Tyr Metabolism In Pku Was Quantitatively Evaluated In Three Patients By A Simple Tyr Oral Loading Test (100 Mg/Kg); (3) Diurnal And (4) Long-Term Tyr Concentrations Were Evaluated In 5 And 13 Patients With Pku, Respectively, Who Switched From Traditional To Slow-Release Amino Acids Therapy. 1) Tyr Concentrations In The Pku Population Were Subnormal And Significantly Lower Than In Non-Pku Hpa (P<0.01); (2) The Response To A Tyr Loading Test In Pku Was Normal, With Basal Tyr Concentrations Reached Within 12 H; (3) The Diurnal Metabolic Profile In Patients On Slow-Release Amino Acids Therapy Revealed Higher Morning Fasting And Nocturnal Tyr Concentrations With Respect To Traditional Therapy (P<0.01); (4) This Picture Was Confirmed At Follow-Up, With Normalization Of Morning Fasting Tyr Concentrations In Patients On Slow-Release Amino Acids Therapy (P<0.01) And Unchanged Phe Control (P=0.19). Slow-Release Amino Acids Therapy Can Improve Tyr Homeostasis In Pku. If Associated To Optimized Phe Control, Such A Metabolic Goal May Allow Long-Term Clinical Benefits In Patients With Pku.|[('Phenylalanine', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Hpa', 'no label'), ('Tyrosine (Tyr)', 'no label'), ('Depletion', 'no label'), ('Tyr Homeostasis', 'no label'), ('Patients', 'no label'), ('Pah Deficiency', 'no label'), ('Effect', 'no label'), ('Slow-Release Amino Acids Therapy', 'no label'), ('Phenylketonuria', 'no label'), ('Performed', 'no label'), ('Complementary Investigations', 'no label'), ('Tyr', 'no label'), ('Concentrations', 'no label'), ('Monitored', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Dietary Treatment', 'no label'), ('Supplemented', 'no label'), ('Traditional', 'no label'), ('Amino Acid Formulations', 'no label'), ('Samples', 'no label'), ('Non-Pku Hpa', 'no label'), ('Free Diet', 'no label'), ('Samples', 'no label'), ('Tyr Metabolism', 'no label'), ('Quantitatively Evaluated', 'no label'), ('Patients', 'no label'), ('Simple Tyr Oral Loading Test', 'no label'), ('Diurnal', 'no label'), ('Long-Term', 'no label'), ('Tyr', 'no label'), ('Concentrations', 'no label'), ('Evaluated', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Switched', 'no label'), ('Amino Acids Therapy', 'no label'), ('Tyr', 'no label'), ('Concentrations', 'no label'), ('Pku Population', 'no label'), ('Subnormal', 'no label'), ('Non-Pku Hpa', 'no label'), ('Response', 'no label'), ('Tyr Loading Test', 'no label'), ('Pku Was Normal', 'no label'), ('Basal Tyr Concentrations', 'no label'), ('Reached', 'no label'), ('Diurnal', 'no label'), ('Metabolic Profile', 'no label'), ('Patients', 'no label'), ('Slow-Release Amino Acids Therapy', 'no label'), ('Revealed', 'no label'), ('Morning', 'no label'), ('Fasting', 'no label'), ('Nocturnal', 'no label'), ('Tyr', 'no label'), ('Concentrations', 'no label'), ('Respect', 'no label'), ('Traditional Therapy', 'no label'), ('Picture', 'no label'), ('Confirmed', 'no label'), ('Follow-Up', 'no label'), ('Normalization', 'no label'), ('Morning', 'no label'), ('Fasting', 'no label'), ('Tyr', 'no label'), ('Concentrations', 'no label'), ('Patients', 'no label'), ('Slow-Release Amino Acids Therapy', 'no label'), ('Unchanged', 'no label'), ('Phe Control', 'no label'), ('Slow-Release Amino Acids Therapy', 'no label'), ('Tyr Homeostasis', 'no label'), ('Phe Control', 'no label'), ('Metabolic Goal May', 'no label'), ('Long-Term', 'no label'), ('Patients', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Tyr', 'no label'), ('Amino Acids', 'no label'), ('Tyr', 'no label'), ('Amino Acid', 'no label'), ('Tyr', 'no label'), ('Amino Acids', 'no label'), ('Tyr', 'no label'), ('Tyr', 'no label'), ('Amino Acids', 'no label'), ('Tyr', 'no label'), ('Tyr', 'no label'), ('Amino Acids', 'no label'), ('Amino Acids', 'no label'), ('Tyr', 'no label'), ('Phe', 'no label')]|[('Non-Pku Hpa', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Phenylketonuria', 'no label'), ('Amino Acid Formulations', 'no label'), ('N=52', 'no label'), ('Tyr', 'no label'), ('Tyr', 'no label'), ('Tyr', 'no label'), ('Tyr', 'no label'), ('Morning Fasting Tyr', 'no label'), ('Phe', 'no label')]|[('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Patients', 'no label'), ('Pah', 'no label'), ('A Slow-Release Amino Acids', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Amino Acid', 'no label'), ('Pku', 'no label'), ('Patients', 'no label'), ('Tyr', 'no label'), ('Patients', 'no label'), ('Amino Acids', 'no label'), ('Non-Pku Hpa', 'no label'), ('Basal Tyr', 'no label'), ('Patients', 'no label'), ('Amino Acids', 'no label'), ('Patients', 'no label'), ('Amino Acids', 'no label'), ('Amino Acids', 'no label'), ('Tyr', 'no label'), ('Phe', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31461828|Phenylketonuria (Pku) Is Treated With Dietary Restrictions And Sometimes Tetrahydrobiopterin (Bh4). Pku Patients Are At Risk For Developing Micronutrient Deficiencies, Such As Vitamin B12 And Folic Acid, Likely Due To Their Diet. Tyrosinemia Type 1 (Tt1) Is Similar To Pku In Both Pathogenesis And Treatment. Tt1 Patients Follow A Similar Diet, But Nutritional Deficiencies Have Not Been Investigated Yet. In This Retrospective Study, Biomarkers Of Micronutrients In Tt1 And Pku Patients Were Investigated And Outcomes Were Correlated To Dietary Intake And Anthropometric Measurements From Regular Follow-Up Measurements From Patients Attending The Outpatient Clinic. Data Was Analyzed Using Kruskal-Wallis, Fisher'S Exact And Spearman Correlation Tests. Furthermore, Descriptive Data Were Used. Overall, Similar Results For Tt1 And Pku Patients (With And Without Bh4) Were Observed. In All Groups High Vitamin B12 Concentrations Were Seen Rather Than B12 Deficiencies. Furthermore, All Groups Showed Biochemical Evidence Of Vitamin D Deficiency. This Study Shows That Micronutrients In Tt1 And Pku Patients Are Similar And Often Within The Normal Ranges And That Vitamin D Concentrations Could Be Optimized.|"[('Phenylketonuria', 'no label'), ('Treated With', 'no label'), ('Dietary', 'no label'), ('Restrictions', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh4', 'no label'), ('Patients', 'no label'), ('Risk', 'no label'), ('Micronutrient Deficiencies', 'no label'), ('Vitamin B12', 'no label'), ('Folic Acid', 'no label'), ('Diet', 'no label'), ('Tyrosinemia Type 1', 'no label'), ('Pathogenesis', 'no label'), ('Treatment', 'no label'), ('Patients', 'no label'), ('Diet', 'no label'), ('Nutritional Deficiencies', 'no label'), ('Investigated', 'no label'), ('Retrospective Study', 'no label'), ('Biomarkers', 'no label'), ('Micronutrients', 'no label'), ('Pku Patients', 'no label'), ('Investigated', 'no label'), ('Outcomes', 'no label'), ('Dietary Intake', 'no label'), ('Anthropometric Measurements', 'no label'), ('Regular Follow-Up Measurements', 'no label'), ('Patients', 'no label'), ('Attending', 'no label'), ('Outpatient Clinic', 'no label'), ('Data', 'no label'), ('Analyzed', 'no label'), ('Kruskal-Wallis', 'no label'), (""Fisher'S Exact And Spearman Correlation Tests"", 'no label'), ('Descriptive Data', 'no label'), ('Tt1', 'no label'), ('Pku Patients', 'no label'), ('Bh4', 'no label'), ('Observed', 'no label'), ('Groups', 'no label'), ('Vitamin B12', 'no label'), ('Concentrations', 'no label'), ('Than B12', 'no label'), ('Deficiencies', 'no label'), ('Groups', 'no label'), ('Biochemical', 'no label'), ('Evidence', 'no label'), ('Vitamin D Deficiency', 'no label'), ('Study', 'no label'), ('Micronutrients', 'no label'), ('Patients', 'no label'), ('Normal Ranges', 'no label'), ('Vitamin D', 'no label'), ('Concentrations', 'no label'), ('Optimized', 'no label')]"|[('Tetrahydrobiopterin', 'no label'), ('Micronutrients', 'no label'), ('Vitamin', 'no label'), ('Vitamin D', 'no label'), ('Micronutrients', 'no label')]|[('Tetrahydrobiopterin', 'no label'), ('B12', 'no label')]|[('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Micronutrient Deficiencies', 'no label'), ('Vitamin B12', 'no label'), ('Folic Acid', 'no label'), ('Tyrosinemia', 'no label'), ('Pathogenesis', 'no label'), ('Tt1', 'no label'), ('Nutritional Deficiencies', 'no label'), ('Micronutrients', 'no label'), ('Tt1', 'no label'), ('Tt1', 'no label'), ('Vitamin B12', 'no label'), ('B12 Deficiencies', 'no label'), ('Vitamin D Deficiency', 'no label'), ('Micronutrients', 'no label'), ('Tt1', 'no label'), ('Vitamin D', 'no label')]|[('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Patients', 'no label'), ('Vitamin', 'no label'), ('B12', 'no label'), ('Folic Acid', 'no label'), ('Tyrosinemia Type 1', 'no label'), ('Patients', 'no label'), ('Micronutrients', 'no label'), ('Patients', 'no label'), ('Regular Follow-Up', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Vitamin B12', 'no label'), ('B12', 'no label'), ('Vitamin D', 'no label'), ('Micronutrients', 'no label'), ('Patients', 'no label'), ('Vitamin D', 'no label')]
phenylketonuria|pubmed~30720885|The Aim Of The Present Meta-Analysis Was To Evaluate The Efficacy And Safety Of Sapropterin Dihydrochloride In Phenylketonuria (Pku) Patients. The Following Databases Were Searched For Randomized Controlled Trials (Rct) Regarding Pku Patients Treated With Sapropterin Dihydrochloride: Pubmed, Embase, Cochrane Library And Clinicaltrials. Two Authors Independently Selected Studies, Assessed The Risk Of Bias And Extracted Data. The Meta-Analysis Was Performed In Revman 5.3 Provided By The Cochrane Collaboration. Four Studies Met The Inclusion Criteria. In Pku Patients With Low Blood Phenylalanine (Phe) Concentration, No Significant Difference Was Indicated For The Decrease Of Phe Level (Weighted Mean Difference (Wmd) = -7.75 Μmol L<Sup>-1</Sup> ; 95% Confidence Intervals (Ci): -82.63 To 67.13, P = 0.84, I<Sup>2</Sup>  = 0%), However, The Dietary Phe Tolerance Was Significantly Improved In The Sapropterin Group (Wmd = 19.89 Mg Kg<Sup>-1</Sup>  D<Sup>-1</Sup> ; 95% Ci: 10.26 To 29.52, P < 0.0001, I<Sup>2</Sup>  = 0%). In Pku Patients With High Blood Phe Level, Sapropterin Showed A Significant Lowering In Blood Phe Concentration (Wmd = -225.31 Μmol L<Sup>-1</Sup> ; 95% Ci: -312.28 To -138.34, P < 0.00001, I<Sup>2</Sup>  = 0%). There Was No Significant Difference For Adverse Events. Sapropterin Could Bring Benefit For Pku Patients With High Or Low Phe Level, Due To Phe Reduction In A Short Time Or Dietary Phe Tolerance Improvement Respectively. Sapropterin Has An Acceptable Safety Profile.|[('Meta-Analysis', 'no label'), ('Evaluate', 'no label'), ('Efficacy', 'no label'), ('Safety', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Databases', 'no label'), ('Searched', 'no label'), ('Randomized Controlled Trials', 'no label'), ('Rct', 'no label'), ('Pku Patients', 'no label'), ('Treated', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Pubmed', 'no label'), ('Embase', 'no label'), ('Cochrane Library', 'no label'), ('Clinicaltrials', 'no label'), ('Studies', 'no label'), ('Assessed', 'no label'), ('Risk', 'no label'), ('Bias', 'no label'), ('Extracted Data', 'no label'), ('Meta-Analysis', 'no label'), ('Performed', 'no label'), ('Revman', 'no label'), ('Cochrane Collaboration', 'no label'), ('Studies', 'no label'), ('Met', 'no label'), ('Inclusion Criteria', 'no label'), ('Patients', 'no label'), ('Low Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Concentration', 'no label'), ('No Significant Difference', 'no label'), ('Decrease', 'no label'), ('Phe Level', 'no label'), ('Weighted Mean Difference', 'no label'), ('Confidence Intervals', 'no label'), ('Ci', 'no label'), ('I<Sup>2</Sup> \xa0=\xa00%', 'no label'), ('Dietary Phe Tolerance', 'no label'), ('Sapropterin Group', 'no label'), ('Wmd\xa0', 'no label'), ('Ci', 'no label'), ('Patients', 'no label'), ('High Blood Phe Level', 'no label'), ('Sapropterin', 'no label'), ('Lowering', 'no label'), ('Blood Phe Concentration', 'no label'), ('Wmd\xa0', 'no label'), ('Ci', 'no label'), ('P\xa0<\xa00.00001', 'no label'), ('No Significant Difference', 'no label'), ('Adverse Events', 'no label'), ('Sapropterin', 'no label'), ('Benefit', 'no label'), ('Pku Patients', 'no label'), ('High', 'no label'), ('Low', 'no label'), ('Phe', 'no label'), ('Level', 'no label'), ('Phe', 'no label'), ('Reduction', 'no label'), ('Short Time', 'no label'), ('Dietary Phe Tolerance', 'no label'), ('Improvement', 'no label'), ('Sapropterin', 'no label'), ('Acceptable Safety Profile', 'no label')]|[('Dihydrochloride', 'no label'), ('Dihydrochloride', 'no label'), ('Met', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Mg', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[]|[('Sapropterin Dihydrochloride', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Low Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Sapropterin', 'no label'), ('Mg', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Sapropterin', 'no label')]|[('Sapropterin Dihydrochloride', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Met', 'no label'), ('Pku Patients', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Sup>2</Sup', 'no label'), ('Phe', 'no label'), ('Sapropterin', 'no label'), ('Mg', 'no label'), ('Sup>2</Sup', 'no label'), ('Pku Patients', 'no label'), ('Blood Phe', 'no label'), ('Sapropterin', 'no label'), ('Blood Phe', 'no label'), ('Sup>2</Sup', 'no label'), ('Patients', 'no label'), ('High Or', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Sapropterin', 'no label')]
phenylketonuria|pubmed~35026061|Phenylketonuria (Pku) Is An Inherited Autosomal Recessive Disorder Of Phenylalanine Metabolism. It Is Mainly Caused By A Deficiency In Phenylalanine Hydroxylase (<I>Pah</I>) And Frequently Diagnosed With Sanger Sequencing. To Some Extent, Allelic Dropout Can Explain The Inconsistency In Genotype And Phenotype. Three Families Were Evaluated Through Dna Sequence Analysis, Multiplex Ligation-Dependent Probe Amplification (Mlpa) And Prenatal Diagnosis Technologies. The Possibility Of Inconsistency In Phenotype And Genotype With C.331C>T Variant Was Analysed. Through Pedigree Analysis, Three Mothers Carried A Homozygous C.331C>T Variant, Which Was A False-Positive Result. New Primers Were Used, And This Error Was Caused By Allelic Dropout. In This Case, C.158G>A Was Likely A Benign Variant. Sequence Variants In Primer-Binding Regions Could Cause Allelic Dropout, Creating Unpredictable Errors In Genotyping. Our Results Emphasised The Need For Careful Measures To Treat Genotype-Phenotype Inconsistencies.|[('Phenylketonuria', 'no label'), ('Inherited Autosomal Recessive Disorder', 'no label'), ('Phenylalanine Metabolism', 'no label'), ('Deficiency', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('<I>Pah</I>)', 'no label'), ('Diagnosed', 'no label'), ('Sanger Sequencing', 'no label'), ('Extent', 'no label'), ('Allelic', 'no label'), ('Dropout', 'no label'), ('Inconsistency', 'no label'), ('Genotype', 'no label'), ('Phenotype', 'no label'), ('Families', 'no label'), ('Evaluated', 'no label'), ('Dna Sequence Analysis', 'no label'), ('Multiplex Ligation-Dependent Probe Amplification', 'no label'), ('Mlpa', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Technologies', 'no label'), ('Possibility', 'no label'), ('Inconsistency', 'no label'), ('Phenotype', 'no label'), ('Genotype', 'no label'), ('C.331C>T Variant', 'no label'), ('Analysed', 'no label'), ('Pedigree Analysis', 'no label'), ('Mothers', 'no label'), ('Homozygous', 'no label'), ('C.331C>T Variant', 'no label'), ('False-Positive Result', 'no label'), ('New Primers', 'no label'), ('Error', 'no label'), ('Allelic', 'no label'), ('Dropout', 'no label'), ('Case', 'no label'), ('C.158G>A', 'no label'), ('Benign Variant', 'no label'), ('Variants', 'no label'), ('Primer-Binding Regions', 'no label'), ('Allelic', 'no label'), ('Dropout', 'no label'), ('Creating Unpredictable Errors', 'no label'), ('Genotyping', 'no label'), ('Results', 'no label'), ('Emphasised', 'no label'), ('Need', 'no label'), ('Measures', 'no label'), ('Treat', 'no label'), ('Genotype-Phenotype', 'no label'), ('Inconsistencies', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Allelic', 'no label'), ('Genotype', 'no label'), ('Dna Sequence', 'no label'), ('Probe', 'no label'), ('Genotype', 'no label'), ('Variant', 'no label'), ('Primers', 'no label'), ('Allelic', 'no label'), ('Sequence Variants', 'no label'), ('Regions', 'no label'), ('Allelic', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Inherited Autosomal Recessive Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Dna', 'no label'), ('Error', 'no label'), ('Case', 'no label')]
phenylketonuria|pubmed~34747549|Phenylketonuria (Pku) Is Caused By Phenylalanine Hydroxylase (Pah) Gene Variants. Previously, 94.21% Of Variants Were Identified Using Sanger Sequencing And Multiplex Ligation-Dependent Probe Amplification. To Investigate The Remaining Variants, We Performed Whole-Genome Sequencing For Four Patients With Pku And Unknown Genotypes To Identify Deep Intronic Or Structural Variants. We Identified Three Novel Heterozygous Variants (C.706+368T>C, C.1065+241C>A, And C.1199+502A>T) In A Deep Pah Gene Intron. We Detected A C.1199+502A>T Variant In 60% (6/10) Of Pku Patients With Genetically Undetermined Pku. In Silico Predictions Indicated That The Three Deep Variants May Impact Splice Site Selection And Result In The Inclusion Of A Pseudo-Exon. A C.1199+502A>T Pah Minigene And Reverse Transcription Pcr (Rt-Pcr) On Blood Rna From A Pku Patient With Biallelic Variants C.1199+502A>T And C.1199G>A Confirmed That The C.1199+502A>T Variant May Strengthen The Predicted Branch Point And Leads To The Inclusion Of A 25-Nt Pseudo-Exon In The Pah Mrna. Reverse Transcription Polymerase Chain Reaction (Rt-Pcr) On The Minigene Revealed That C.706+368T>C May Create An Srsf2 (Sc35) Binding Site Via A 313-Nt Pseudo-Exon, Whereas C.1065+241C>A May Produce An 81-Nt Pseudo-Exon That Strengthens The Predicted Srsf1 (Sf2/Asf) Binding Site. These Results Augment Current Knowledge Of Pah Genotypes And Show That Deep Intronic Analysis Of Pah Can Genetically Diagnose Pku.|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Gene Variants', 'no label'), ('Variants', 'no label'), ('Sanger Sequencing', 'no label'), ('Investigate', 'no label'), ('Variants', 'no label'), ('Performed', 'no label'), ('Whole-Genome Sequencing', 'no label'), ('Patients', 'no label'), ('Pku And Unknown', 'no label'), ('Genotypes', 'no label'), ('Deep Intronic', 'no label'), ('Structural', 'no label'), ('Variants', 'no label'), ('Heterozygous Variants', 'no label'), ('C.706+368T>C', 'no label'), ('C.1065+241C>A', 'no label'), ('C.1199+502A>T', 'no label'), ('Deep Pah Gene', 'no label'), ('Detected', 'no label'), ('C.1199+502A>T Variant', 'no label'), ('Pku Patients', 'no label'), ('Genetically Undetermined Pku', 'no label'), ('In Silico', 'no label'), ('Predictions', 'no label'), ('Deep Variants', 'no label'), ('Impact', 'no label'), ('Splice Site', 'no label'), ('Selection', 'no label'), ('Result', 'no label'), ('Pseudo-Exon', 'no label'), ('C.1199+502A>T Pah Minigene', 'no label'), ('Reverse Transcription Pcr', 'no label'), ('Rt-Pcr', 'no label'), ('Blood Rna', 'no label'), ('Pku Patient', 'no label'), ('Biallelic', 'no label'), ('Variants', 'no label'), ('C.1199+502A>T', 'no label'), ('Confirmed', 'no label'), ('C.1199+502A>T Variant May Strengthen', 'no label'), ('Pseudo-Exon', 'no label'), ('Pah Mrna', 'no label'), ('Reverse Transcription Polymerase Chain Reaction', 'no label'), ('Rt-Pcr', 'no label'), ('Minigene Revealed', 'no label'), ('C.706+368T>C May', 'no label'), ('Srsf2', 'no label'), ('Sc35', 'no label'), ('Binding Site', 'no label'), ('Pseudo-Exon', 'no label'), ('C.1065+241C>A', 'no label'), ('Produce', 'no label'), ('Pseudo-Exon', 'no label'), ('Strengthens', 'no label'), ('Predicted Srsf1', 'no label'), ('Sf2/Asf', 'no label'), ('Binding Site', 'no label'), ('Results', 'no label'), ('Current', 'no label'), ('Knowledge', 'no label'), ('Genotypes', 'no label'), ('Deep Intronic Analysis', 'no label'), ('Pah', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Gene', 'no label'), ('Probe', 'no label'), ('Genotypes', 'no label'), ('Intronic', 'no label'), ('Variants', 'no label'), ('Gene Intron', 'no label'), ('Variant', 'no label'), ('Genetically', 'no label'), ('Minigene', 'no label'), ('T', 'no label'), ('Variant', 'no label'), ('Mrna', 'no label'), ('Minigene', 'no label'), ('Srsf2', 'no label'), ('Sc35', 'no label'), ('Site', 'no label'), ('Genotypes', 'no label'), ('Intronic', 'no label'), ('Genetically', 'no label')]|[('Deep Pah Gene Intron', 'no label'), ('Pah Mrna', 'no label'), ('Srsf2', 'no label'), ('Srsf1 (Sf2/Asf) Binding Site', 'no label'), ('Pah Genotypes', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Heterozygous', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Patients', 'no label'), ('C.1065+', 'no label'), ('A Deep Pah', 'no label'), ('Patients', 'no label'), ('T Pah', 'no label'), ('Pcr', 'no label'), ('Blood Rna', 'no label'), ('C.1199+502A', 'no label'), ('C.706+', 'no label'), ('Srsf2', 'no label'), ('Sc35', 'no label'), ('C.1065+', 'no label'), ('Srsf1', 'no label'), ('Pah Genotypes', 'no label'), ('Pah', 'no label')]
phenylketonuria|pubmed~33491267|Phenylketonuria (Pku) Is A Genetic Disorder That If Left Untreated Can Lead To Behavioral Problems, Epilepsy, And Even Mental Retardation. Pku Results From Mutations Within The Phenylalanine-4-Hydroxylase (Pah) Gene That Encodes For The Pah Protein. The Study Of All Pah Causing Mutations Is Improbable Using Experimental Techniques. In This Study, A Collection Of In Silico Resources, Sorting Intolerant From Tolerant, Polyphen-2, Phd-Snp, And Mutpred Were Used To Identify Possible Pathogenetic And Deleterious Pah Non-Synonymous Single Nucleotide Polymorphisms (Nssnps). We Identified Two Variants Of Pah, I65N And L311P, To Be The Most Deleterious And Disease Causing Nssnps. Molecular Dynamics (Md) Simulations Were Carried Out To Characterize These Point Mutations On The Atomic Level. Md Simulations Revealed Increased Flexibility And A Decrease In The Hydrogen Bond Network For Both Mutants Compared To The Native Protein. Free Energy Calculations Using The Mm/Gbsa Approach Found That Bh<Sub>4</Sub> , A Drug-Based Therapy For Pku Patients, Had A Higher Binding Affinity For I65N And L311P Mutants Compared To The Wildtype Protein. We Also Identify Important Residues In The Bh<Sub>4</Sub> Binding Pocket That May Be Of Interest For The Rational Drug Design Of Other Pah Drug-Based Therapies. Lastly, Free Energy Calculations Also Determined That The I65N Mutation May Impair The Dimerization Of The N-Terminal Regulatory Domain Of Pah.|[('Phenylketonuria', 'no label'), ('Genetic Disorder', 'no label'), ('Left Untreated Can Lead', 'no label'), ('Behavioral Problems', 'no label'), ('Epilepsy', 'no label'), ('Mental Retardation', 'no label'), ('Mutations', 'no label'), ('Phenylalanine-4-Hydroxylase', 'no label'), ('Encodes', 'no label'), ('Pah Protein', 'no label'), ('Study', 'no label'), ('Pah Causing', 'no label'), ('Mutations', 'no label'), ('Experimental Techniques', 'no label'), ('Study', 'no label'), ('Collection', 'no label'), ('In Silico', 'no label'), ('Resources', 'no label'), ('Sorting Intolerant', 'no label'), ('Tolerant', 'no label'), ('Polyphen-2', 'no label'), ('Phd-Snp', 'no label'), ('Mutpred', 'no label'), ('Pathogenetic', 'no label'), ('Deleterious', 'no label'), ('Single Nucleotide Polymorphisms', 'no label'), ('Nssnps', 'no label'), ('Identified', 'no label'), ('Variants', 'no label'), ('Deleterious', 'no label'), ('Disease', 'no label'), ('Molecular Dynamics', 'no label'), ('Characterize', 'no label'), ('Point Mutations', 'no label'), ('Atomic Level', 'no label'), ('Md Simulations', 'no label'), ('Revealed', 'no label'), ('Increased', 'no label'), ('Flexibility', 'no label'), ('Decrease', 'no label'), ('Hydrogen Bond Network', 'no label'), ('Mutants', 'no label'), ('Native Protein', 'no label'), ('Free Energy', 'no label'), ('Calculations', 'no label'), ('Mm/Gbsa Approach', 'no label'), ('Bh<Sub>4</Sub>', 'no label'), ('Drug-Based Therapy', 'no label'), ('Pku Patients', 'no label'), ('Higher', 'no label'), ('Binding Affinity', 'no label'), ('L311P Mutants', 'no label'), ('Wildtype Protein', 'no label'), ('Residues', 'no label'), ('Bh<Sub>4</Sub> Binding Pocket', 'no label'), ('Rational Drug Design', 'no label'), ('Pah Drug-Based Therapies', 'no label'), ('Free Energy', 'no label'), ('Calculations', 'no label'), ('I65N Mutation', 'no label'), ('Impair', 'no label'), ('Dimerization', 'no label'), ('N-Terminal Regulatory Domain', 'no label')]|[('Genetic', 'no label'), ('Mutations', 'no label'), ('Gene', 'no label'), ('Protein', 'no label'), ('Mutations', 'no label'), ('Nucleotide Polymorphisms', 'no label'), ('Molecular', 'no label'), ('Mutations', 'no label'), ('Hydrogen', 'no label'), ('Mutants', 'no label'), ('Protein', 'no label'), ('Mutants', 'no label'), ('Wildtype Protein', 'no label'), ('Residues', 'no label'), ('Drug', 'no label'), ('Mutation', 'no label')]|[('Phenylalanine-4-Hydroxylase (Pah) Gene', 'no label'), ('Pah Protein', 'no label'), ('Pah, I65N And L311P, To Be The Most Deleterious', 'no label'), ('N-Terminal Regulatory Domain', 'no label')]|[('Phenylketonuria', 'no label'), ('Epilepsy', 'no label'), ('Hydrogen Bond', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine-4-Hydroxylase', 'no label'), ('Pah', 'no label'), ('Hydrogen Bond Network', 'no label'), ('Pah', 'no label')]
phenylketonuria|pubmed~34836270|The Mainstay Of Phenylketonuria Treatment Is A Low Protein Diet, Supplemented With Phenylalanine (Phe)-Free Protein Substitutes And Micronutrients. Adhering To This Diet Is Challenging, And Even Patients With Good Metabolic Control Who Follow The Dietary Prescriptions In Everyday Life Ignore The Recommendations Occasionally. The Present Study Explores The Ability Of Slow-Release Large Neutral Amino Acids (Srlnaas) To Prevent Phe Increase Following A Phe Dietary Load. Fourteen Phenylketonuric Patients Aged ≥13 Years Were Enrolled In A 6-Week Protocol. Oral Acute Phe Loads Of 250 And 500 Mg Were Added To The Evening Meal Together With Srlnaas (0.5 Gr/Kg). Phe And Tyrosine Were Dosed Before Dinner, 2H-After Dinner, And After The Overnight Fast. After Oral Phe Loads, Mean Plasma Phe Remained Stable And Below 600 Μmol/L. No Phe Peaks Were Registered. Tyrosine Levels Significantly Increased, And Phe/Tyrosine Ratio Decreased. No Adverse Events Were Registered. In Conclusion, A Single Oral Administration Of Srlnaas At The Dose Of 0.5 Gr/Kg Is Effective In Maintaining Stable Plasma Phe During Acute Oral Loads With Phe-Containing Food And May Be Added To The Dietetic Scheme In Situations In Which Patients With Generally Good Adherence To Diet Foresee A Higher Than Prescribed Phe Intake Due To Their Commitments.|[('Mainstay', 'no label'), ('Phenylketonuria', 'no label'), ('Treatment', 'no label'), ('Low Protein Diet', 'no label'), ('Supplemented', 'no label'), ('Phenylalanine (Phe)-Free Protein Substitutes', 'no label'), ('Micronutrients', 'no label'), ('Diet', 'no label'), ('Challenging', 'no label'), ('Patients', 'no label'), ('Good Metabolic Control Who', 'no label'), ('Dietary Prescriptions', 'no label'), ('Everyday', 'no label'), ('Life Ignore', 'no label'), ('Recommendations', 'no label'), ('Study', 'no label'), ('Explores', 'no label'), ('Ability', 'no label'), ('Slow-Release Large', 'no label'), ('Neutral Amino Acids', 'no label'), ('Srlnaas', 'no label'), ('Prevent', 'no label'), ('Phe', 'no label'), ('Increase', 'no label'), ('Phe', 'no label'), ('Dietary Load', 'no label'), ('Phenylketonuric Patients', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Oral Acute Phe Loads', 'no label'), ('Mg', 'no label'), ('Added', 'no label'), ('Evening Meal', 'no label'), ('Srlnaas', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Dosed', 'no label'), ('Dinner', 'no label'), ('Dinner', 'no label'), ('Overnight', 'no label'), ('Fast', 'no label'), ('Oral Phe Loads', 'no label'), ('Plasma', 'no label'), ('Stable', 'no label'), ('No Phe Peaks', 'no label'), ('Registered', 'no label'), ('Tyrosine', 'no label'), ('Levels', 'no label'), ('Increased', 'no label'), ('Ratio', 'no label'), ('Decreased', 'no label'), ('No Adverse Events', 'no label'), ('Single Oral Administration', 'no label'), ('Srlnaas', 'no label'), ('Dose', 'no label'), ('Gr/Kg', 'no label'), ('Effective', 'no label'), ('Stable', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Acute Oral Loads', 'no label'), ('Phe-Containing Food', 'no label'), ('Added', 'no label'), ('Dietetic Scheme', 'no label'), ('Situations', 'no label'), ('Patients', 'no label'), ('Good Adherence', 'no label'), ('Diet Foresee', 'no label'), ('Than Prescribed', 'no label'), ('Phe Intake', 'no label'), ('Commitments', 'no label')]|[('Protein', 'no label'), ('Protein', 'no label'), ('Micronutrients', 'no label'), ('Amino Acids', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Meal', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Phe', 'no label'), ('Food', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acids', 'no label'), ('Mg', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Dinner', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Phe/Tyrosine', 'no label'), ('Srlnaas', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine (Phe)-Free Protein', 'no label'), ('Patients', 'no label'), ('Amino Acids', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Oral Acute Phe', 'no label'), ('Mg', 'no label'), ('Meal', 'no label'), ('Tyrosine', 'no label'), ('Oral', 'no label'), ('Plasma', 'no label'), ('Below 600', 'no label'), ('Phe', 'no label'), ('Phe/Tyrosine', 'no label'), ('Oral', 'no label'), ('Gr/Kg', 'no label'), ('Plasma Phe', 'no label'), ('Acute Oral', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~34656426|In Phenylketonuria (Pku), Treatment Monitoring Is Based On Frequent Blood Phenylalanine (Phe) Measurements, As This Is The Predictor Of Neurocognitive And Behavioural Outcome By Reflecting Brain Phe Concentrations And Brain Biochemical Changes. Despite Clinical Studies Describing The Relevance Of Blood Phe To Outcome In Pku Patients, Blood Phe Does Not Explain The Variance In Neurocognitive And Behavioural Outcome Completely. In A Pku Mouse Model We Investigated 1) The Relationship Between Plasma Phe And Brain Biochemistry (Brain Phe And Monoaminergic Neurotransmitter Concentrations), And 2) Whether Blood Non-Phe Large Neutral Amino Acids (Lnaa) Would Be Of Additional Value To Blood Phe Concentrations To Explain Brain Biochemistry. To This Purpose, We Assessed Blood Amino Acid Concentrations And Brain Phe As Well As Monoaminergic Neurotransmitter Levels In In 114 Pah-Enu2 Mice On Both B6 And Btbr Backgrounds Using (Multiple) Linear Regression Analyses. Plasma Phe Concentrations Were Strongly Correlated To Brain Phe Concentrations, Significantly Negatively Correlated To Brain Serotonin And Norepinephrine Concentrations And Only Weakly Correlated To Brain Dopamine Concentrations. From All Blood Markers, Phe Showed The Strongest Correlation To Brain Biochemistry In Pku Mice. Including Non-Phe Lnaa Concentrations To The Multiple Regression Model, In Addition To Plasma Phe, Did Not Help Explain Brain Biochemistry. This Study Showed That Blood Phe Is Still The Best Amino Acid Predictor Of Brain Biochemistry In Pku. Nevertheless, Neurocognitive And Behavioural Outcome Cannot Fully Be Explained By Blood Or Brain Phe Concentrations, Necessitating A Search For Other Additional Parameters. Blood Phe Is Still The Best Amino Acid Predictor Of Brain Biochemistry In Pku. Nevertheless, Neurocognitive And Behavioural Outcome Cannot Fully Be Explained By Blood Or Brain Phe Concentrations, Necessitating A Search For Other Additional Parameters.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Treatment Monitoring', 'no label'), ('Frequent', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Measurements', 'no label'), ('Predictor', 'no label'), ('Neurocognitive', 'no label'), ('Brain', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Brain', 'no label'), ('Biochemical', 'no label'), ('Changes', 'no label'), ('Clinical Studies', 'no label'), ('Relevance', 'no label'), ('Blood Phe To Outcome', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Variance', 'no label'), ('Behavioural Outcome', 'no label'), ('Pku Mouse Model', 'no label'), ('Investigated', 'no label'), ('Relationship', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Brain Phe', 'no label'), ('Monoaminergic', 'no label'), ('Neurotransmitter', 'no label'), ('Concentrations', 'no label'), ('Blood Non-Phe Large', 'no label'), ('Neutral Amino Acids', 'no label'), ('Lnaa', 'no label'), ('Blood', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Brain Biochemistry', 'no label'), ('Assessed', 'no label'), ('Blood Amino Acid', 'no label'), ('Concentrations', 'no label'), ('Brain', 'no label'), ('Monoaminergic', 'no label'), ('Neurotransmitter', 'no label'), ('Levels', 'no label'), ('Pah-Enu2', 'no label'), ('Mice', 'no label'), ('B6', 'no label'), ('Btbr Backgrounds', 'no label'), ('Linear Regression Analyses', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Correlated', 'no label'), ('Brain', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Correlated', 'no label'), ('Brain', 'no label'), ('Serotonin', 'no label'), ('Norepinephrine', 'no label'), ('Concentrations', 'no label'), ('Correlated', 'no label'), ('Brain', 'no label'), ('Dopamine', 'no label'), ('Concentrations', 'no label'), ('Blood Markers', 'no label'), ('Phe', 'no label'), ('Correlation', 'no label'), ('Brain Biochemistry', 'no label'), ('Pku Mice', 'no label'), ('Concentrations', 'no label'), ('Multiple Regression Model', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Did Not Help', 'no label'), ('Explain', 'no label'), ('Study', 'no label'), ('Blood Phe', 'no label'), ('Best', 'no label'), ('Amino Acid', 'no label'), ('Predictor', 'no label'), ('Brain Biochemistry', 'no label'), ('Neurocognitive', 'no label'), ('Explained', 'no label'), ('Blood', 'no label'), ('Brain', 'no label'), ('Phe Concentrations', 'no label'), ('Necessitating A', 'no label'), ('Parameters', 'no label'), ('Blood Phe', 'no label'), ('Best', 'no label'), ('Amino Acid', 'no label'), ('Predictor', 'no label'), ('Brain Biochemistry', 'no label'), ('Neurocognitive', 'no label'), ('Explained', 'no label'), ('Blood', 'no label'), ('Brain', 'no label'), ('Phe Concentrations', 'no label'), ('Necessitating A', 'no label'), ('Parameters', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Mouse', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Monoaminergic Neurotransmitter', 'no label'), ('Amino Acids', 'no label'), ('Blood Amino Acid', 'no label'), ('Phe', 'no label'), ('Monoaminergic Neurotransmitter', 'no label'), ('Mice', 'no label'), ('Phe', 'no label'), ('Serotonin And', 'no label'), ('Norepinephrine', 'no label'), ('Dopamine', 'no label'), ('Phe', 'no label'), ('Mice', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Amino Acid', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Amino Acid', 'no label'), ('Phe', 'no label')]|[('B6', 'no label'), ('Non-Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Amino Acids', 'no label'), ('Amino Acid', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Serotonin', 'no label'), ('Norepinephrine', 'no label'), ('Dopamine', 'no label'), ('Phe', 'no label'), ('Amino Acid', 'no label'), ('Phe', 'no label'), ('Amino Acid', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Brain Phe', 'no label'), ('Brain', 'no label'), ('Blood', 'no label'), ('Pku Patients', 'no label'), ('Blood Phe', 'no label'), ('Mouse', 'no label'), ('Plasma Phe', 'no label'), ('Brain', 'no label'), ('Brain Phe', 'no label'), ('Monoaminergic Neurotransmitter', 'no label'), ('Blood Non-Phe', 'no label'), ('Amino Acids', 'no label'), ('Blood Phe', 'no label'), ('Brain', 'no label'), ('Blood Amino Acid', 'no label'), ('Brain Phe', 'no label'), ('Monoaminergic Neurotransmitter', 'no label'), ('Mice', 'no label'), ('B6', 'no label'), ('Plasma Phe', 'no label'), ('Brain Phe', 'no label'), ('Brain Serotonin', 'no label'), ('Norepinephrine', 'no label'), ('Brain Dopamine', 'no label'), ('Blood', 'no label'), ('Phe', 'no label'), ('Brain', 'no label'), ('Non-Phe Lnaa', 'no label'), ('Plasma Phe', 'no label'), ('Brain', 'no label'), ('Blood Phe', 'no label'), ('Amino Acid', 'no label'), ('Brain', 'no label'), ('Blood', 'no label'), ('Brain Phe', 'no label'), ('Amino Acid', 'no label'), ('Brain', 'no label'), ('Blood', 'no label'), ('Brain Phe', 'no label')]
phenylketonuria|pubmed~32823853|In Phenylketonuria (Pku), The Peptide Structure Of The Protein Substitute (Ps), Casein Glycomacropeptide (Cgmp), Is Supplemented With Amino Acids (Cgmp-Aa). Cgmp May Slow The Rate Of Amino Acid (Aa) Absorption Compared With Traditional Phenylalanine-Free Amino Acids (Phe-Free Aa), Which May Improve Nitrogen Utilization, Decrease Urea Production, And Alter Insulin Response. In Children With Pku, To Compare Pre And Postprandial Aa Concentrations When Taking One Of Three Ps'S: Phe-Free Aa, Cgmp-Aa 1 Or 2. 43 Children (24 Boys, 19 Girls), Median Age 9 Years (Range 5-16 Years) Were Studied; 11 Took Cgmp-Aa1, 18 Cgmp-Aa2, And 14 Phe-Free Aa. Early Morning Fasting Pre And 2 H Postprandial Blood Samples Were Collected For Quantitative Aa On One Occasion. A Breakfast With Allocated 20 G Protein Equivalent From Ps Was Given Post Fasting Blood Sample. There Was A Significant Increase In Postprandial Aa For All Individual Aas With All Three Ps. Postprandial Aa Histidine (<I>P</I> < 0.001), Leucine (<I>P</I> < 0.001), And Tyrosine (<I>P</I> < 0.001) Were Higher In Cgmp-Aa2 Than Cgmp-Aa1, And Leucine (<I>P</I> < 0.001), Threonine (<I>P</I> < 0.001), And Tyrosine (<I>P</I> = 0.003) Higher In Gcmp-Aa2 Than Phe-Free Aa. This Was Reflective Of The Aa Composition Of The Three Different Ps'S. In Pku, The Aa Composition Of Cgmp-Aa Influences 2 H Postprandial Aa Composition, Suggesting That A Ps Derived From Cgmp-Aa May Be Absorbed Similarly To Phe-Free Aa, But This Requires Further Investigation.|"[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Peptide Structure', 'no label'), ('Protein Substitute', 'no label'), ('Casein Glycomacropeptide', 'no label'), ('Cgmp', 'no label'), ('Supplemented', 'no label'), ('Amino Acids', 'no label'), ('Cgmp-Aa', 'no label'), ('Cgmp May Slow', 'no label'), ('Rate', 'no label'), ('Amino Acid', 'no label'), ('Traditional', 'no label'), ('Phenylalanine-Free Amino Acids', 'no label'), ('Phe-Free Aa)', 'no label'), ('Improve', 'no label'), ('Nitrogen Utilization', 'no label'), ('Decrease', 'no label'), ('Urea', 'no label'), ('Production', 'no label'), ('Alter', 'no label'), ('Insulin', 'no label'), ('Response', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Compare', 'no label'), ('Pre', 'no label'), ('Postprandial', 'no label'), ('Aa', 'no label'), ('Concentrations', 'no label'), (""Ps'S"", 'no label'), ('Phe-Free', 'no label'), ('Aa', 'no label'), ('Children', 'no label'), ('Boys', 'no label'), ('Girls', 'no label'), ('Median Age 9 Years', 'no label'), ('Range', 'no label'), ('Years', 'no label'), ('Studied', 'no label'), ('Took Cgmp-Aa1', 'no label'), ('Cgmp-Aa2', 'no label'), ('Phe-Free', 'no label'), ('Aa', 'no label'), ('Early Morning', 'no label'), ('Fasting', 'no label'), ('Postprandial', 'no label'), ('Blood Samples', 'no label'), ('Collected', 'no label'), ('Quantitative Aa', 'no label'), ('Breakfast', 'no label'), ('G Protein', 'no label'), ('Equivalent', 'no label'), ('Ps Was', 'no label'), ('Post Fasting Blood Sample', 'no label'), ('Increase', 'no label'), ('Postprandial', 'no label'), ('Ps.', 'no label'), ('Postprandial', 'no label'), ('Aa Histidine (<I>P</I> < 0.001', 'no label'), ('Leucine', 'no label'), ('<I>P</I> < 0.001', 'no label'), ('Tyrosine', 'no label'), ('<I>P</I> < 0.001)', 'no label'), ('Higher', 'no label'), ('Cgmp-Aa2', 'no label'), ('Cgmp-Aa1', 'no label'), ('Leucine', 'no label'), ('<I>P</I> < 0.001', 'no label'), ('Threonine', 'no label'), ('<I>P</I> < 0.001', 'no label'), ('Tyrosine', 'no label'), ('<I>P</I>', 'no label'), ('Higher', 'no label'), ('Gcmp-Aa2', 'no label'), ('Phe-Free Aa', 'no label'), ('Aa Composition', 'no label'), (""Ps'S."", 'no label'), ('Aa Composition', 'no label'), ('Cgmp-Aa', 'no label'), ('Influences', 'no label'), ('Postprandial', 'no label'), ('Suggesting', 'no label'), ('Cgmp-Aa May', 'no label'), ('Absorbed', 'no label'), ('Phe-Free', 'no label'), ('Aa', 'no label'), ('Requires', 'no label'), ('Investigation', 'no label')]"|[('Peptide', 'no label'), ('Protein', 'no label'), ('Glycomacropeptide', 'no label'), ('Cgmp', 'no label'), ('Amino Acids', 'no label'), ('Cgmp', 'no label'), ('Amino Acid', 'no label'), ('Amino Acids', 'no label'), ('Phe-Free Aa', 'no label'), ('Nitrogen', 'no label'), ('Urea', 'no label'), ('Insulin', 'no label'), ('Protein', 'no label'), ('Histidine', 'no label'), ('Leucine', 'no label'), ('Tyrosine', 'no label'), ('Leucine', 'no label'), ('Threonine', 'no label'), ('Tyrosine', 'no label')]|"[('Allocated 20 G Protein', 'no label'), ('Ps', 'no label'), (""Ps'S."", 'no label'), ('Ps', 'no label')]"|[('Phenylketonuria', 'no label'), ('Glycomacropeptide', 'no label'), ('Cgmp', 'no label'), ('Amino Acids', 'no label'), ('Cgmp', 'no label'), ('Amino Acid', 'no label'), ('Amino Acids', 'no label'), ('Nitrogen', 'no label'), ('Histidine', 'no label'), ('Leucine', 'no label'), ('Tyrosine', 'no label'), ('Leucine', 'no label'), ('Threonine', 'no label'), ('Tyrosine', 'no label')]|[('Phenylketonuria', 'no label'), ('Casein Glycomacropeptide', 'no label'), ('Cgmp', 'no label'), ('Amino Acids', 'no label'), ('Cgmp', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine-Free Amino', 'no label'), ('Phe-Free Aa', 'no label'), ('Nitrogen', 'no label'), ('Insulin', 'no label'), ('Children', 'no label'), ('Postprandial Aa', 'no label'), ('Phe-Free Aa', 'no label'), ('Children', 'no label'), ('Phe-Free', 'no label'), ('20 G Protein', 'no label'), ('Postprandial Aa', 'no label'), ('Leucine', 'no label'), ('Tyrosine', 'no label'), ('Leucine', 'no label'), ('Threonine', 'no label'), ('Tyrosine', 'no label'), ('Phe-Free Aa', 'no label'), ('Ps', 'no label'), ('Phe-Free Aa', 'no label')]
phenylketonuria|pubmed~32593547|Phenylketonuria (Pku) Is Characterized By A Deficiency In Phenylalanine Hydroxylase (Pah) That May Lead To Elevated Blood Phenylalanine (Phe) And Significant Neurocognitive And Neuropsychological Comorbidities. Pegvaliase (Palynziq®, Biomarin Pharmaceutical Inc.) Is A Pegylated Recombinant Anabaena Variabilis Phenylalanine Ammonia Lyase (Pal), Which Converts Phe To Trans-Cinnamic Acid And Ammonia, And Was Approved In May 2018 In The United States And In May 2019 In The European Union For Decreasing Blood Phe Levels In Adults With Pku With Blood Phe Levels >600 Μmol/L. The Efficacy And Safety Of Pegvaliase Was Assessed In Two Phase 2 Dose-Finding Studies In Adults With Pku (Pal-002, Nct00925054, And Pal-004, Nct01212744). Participants Completing These Studies Could Enroll In A Long-Term Extension Study (Pal-003, Nct00924703). Participants In Pal-002 Received Pegvaliase 0.001, 0.003, 0.01, 0.03, Or 0.1 Mg/Kg Weekly For 8 Weeks, Then Continued Treatment For A Further 8 Weeks With Dose And/Or Frequency Adjusted To Achieve Blood Phe Concentrations Of 60 To 600 Μmol/L. Participants In Pal-004 Received Pegvaliase 0.001 To 0.4 Mg/Kg 5 Days/Week For 13 Weeks, With Modifications Made To The Starting Dose In Response To Safety And/Or Efficacy, Followed By 3 Additional Weeks Of Follow-Up Assessments. The Maximum Allowable Daily Dose In Both Studies Was 1.0 Mg/Kg/Day (5.0 Mg/Kg/Week). Participants Who Completed Any Of The Phase 2 Studies (Pal-002; Pal-004; Or A Third Phase 2 Study, 165-205) Were Eligible To Enroll In An Open-Label, Multicenter, Long-Term Extension Study (Pal-003, Nct00924703). Thirty-Seven Of The 40 Enrolled Participants Completed Pal-002 And 15 Of The 16 Enrolled Participants Completed Pal-004. Mean Blood Phe At Baseline Was 1311.0 (Standard Deviation [Sd] 354) Μmol/L In Pal-002 And 1482.1 (Sd 363.5) Μmol/L In Pal-004. Mean Blood Phe Did Not Substantially Decrease With Pegvaliase Treatment In Pal-002 (-206.3 [Sd 287.1] Μmol/L At Week 16) Or Pal-004 (-410.8 [Sd 653.7] Μmol/L At Week 13). In Pal-004, Mean Blood Phe Dropped From Baseline By 929.1 Μmol/L (Sd 691.1) By Week 2; Subsequent To Dose Modifications And Interruptions, This Early Decrease In Mean Phe Level Was Not Sustained. With Increased Pegvaliase Dose And Duration In Pal-003, Mean Blood Phe Levels Steadily Decreased From Baseline, With Mean Reductions By Week 120 Of 68.8% (Sd 44.2%) In Pal-002 Participants And 75.9% (Sd 32.4%) In Pal-004 Participants. All Participants In Pal-002 And Pal-004 Reported ≥1 Adverse Event (Ae), With Higher Exposure-Adjusted Event Rates In Pal-004. The Majority Of Aes Were Mild (87.2% In Pal-002, 86.7% In Pal-004) Or Moderate (12.4% In Pal-002, 13.3% In Pal-004). The Most Commonly Reported Aes In Pal-002 Were Injection Site Reaction (50.0% Of Participants), Headache (42.1%), Injection Site Erythema (36.8%), Nausea (34.2%), And Arthralgia (29.0%), And In Pal-004 Were Arthralgia (75.0%), Headache (62.5%), Dizziness (56.3%), Injection Site Erythema (56.3%), And Injection Site Reaction (50.0%). In Two Phase 2 Dose-Finding Studies, Pegvaliase Did Not Lead To Substantial Blood Phe Reductions. Higher And More Frequent Pegvaliase Dosing In Pal-004 Led To A Substantial Initial Drop In Blood Phe, But An Increase In The Number Of Hypersensitivity Aes And Dose Reductions Or Interruptions. With Increased Dose And Duration Of Treatment In Pal-003, Mean Blood Phe Reduction Was Substantial And Sustained, And The Frequency Of Hypersensitivity Aes Decreased And Stabilized. Together, These Studies Led To The Development Of An Induction-Titration-Maintenance Regimen That Has Been Approved For Pegvaliase, With Patients Starting At A Low Weekly Dose That Gradually Increases In Dose And Frequency Until They Achieve A Standard Non-Weight-Based Daily Maintenance Dose. This Regimen Has Been Tested In A Third Phase 2 Study, As Well As In Two Successful Phase 3 Studies Of Pegvaliase.|[('Phenylketonuria', 'no label'), ('Characterized', 'no label'), ('Deficiency', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Lead', 'no label'), ('Elevated', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Significant', 'no label'), ('Neurocognitive', 'no label'), ('Neuropsychological', 'no label'), ('Pegvaliase', 'no label'), ('Palynziq®, Biomarin Pharmaceutical Inc.', 'no label'), ('Pegylated', 'no label'), ('Anabaena Variabilis', 'no label'), ('Phenylalanine Ammonia Lyase', 'no label'), ('Converts', 'no label'), ('Phe', 'no label'), ('Trans-Cinnamic Acid', 'no label'), ('Ammonia', 'no label'), ('United States', 'no label'), ('European Union', 'no label'), ('Decreasing', 'no label'), ('Blood Phe Levels', 'no label'), ('Adults', 'no label'), ('Blood Phe Levels', 'no label'), ('Efficacy', 'no label'), ('Safety', 'no label'), ('Pegvaliase', 'no label'), ('Assessed', 'no label'), ('Phase 2', 'no label'), ('Studies', 'no label'), ('Adults', 'no label'), ('Pku (Pal-002, Nct00925054, And Pal-004', 'no label'), ('Nct01212744', 'no label'), ('Participants', 'no label'), ('Completing', 'no label'), ('Studies', 'no label'), ('Enroll', 'no label'), ('Long-Term Extension Study', 'no label'), ('Pal-003', 'no label'), ('Participants', 'no label'), ('Pal-002', 'no label'), ('Pegvaliase', 'no label'), ('Weekly', 'no label'), ('Weeks', 'no label'), ('Treatment', 'no label'), ('Weeks', 'no label'), ('Dose And/Or', 'no label'), ('Frequency', 'no label'), ('Blood Phe', 'no label'), ('Concentrations', 'no label'), ('Participants', 'no label'), ('Pal-004', 'no label'), ('Received', 'no label'), ('Pegvaliase', 'no label'), ('Weeks', 'no label'), ('Modifications', 'no label'), ('Dose', 'no label'), ('And/Or', 'no label'), ('Efficacy', 'no label'), ('Weeks', 'no label'), ('Follow-Up Assessments', 'no label'), ('Maximum Allowable Daily Dose', 'no label'), ('Studies', 'no label'), ('Mg/Kg/Week', 'no label'), ('Participants', 'no label'), ('Completed', 'no label'), ('Phase 2 Studies', 'no label'), ('Pal-004', 'no label'), ('Phase 2 Study', 'no label'), ('Open-Label', 'no label'), ('Multicenter', 'no label'), ('Long-Term Extension Study', 'no label'), ('Pal-003', 'no label'), ('Thirty-Seven', 'no label'), ('Participants', 'no label'), ('Completed', 'no label'), ('Pal-002', 'no label'), ('Participants', 'no label'), ('Completed', 'no label'), ('Pal-004', 'no label'), ('Blood Phe', 'no label'), ('Baseline', 'no label'), ('Standard Deviation', 'no label'), ('Pal-004', 'no label'), ('Blood Phe', 'no label'), ('Decrease', 'no label'), ('Pegvaliase', 'no label'), ('Treatment', 'no label'), ('Pal-002', 'no label'), ('Pal-004', 'no label'), ('Pal-004', 'no label'), ('Mean Blood Phe Dropped', 'no label'), ('Baseline', 'no label'), ('Week', 'no label'), ('Dose', 'no label'), ('Modifications', 'no label'), ('Interruptions', 'no label'), ('Early', 'no label'), ('Decrease', 'no label'), ('Mean', 'no label'), ('Phe Level', 'no label'), ('Was Not Sustained', 'no label'), ('Increased', 'no label'), ('Pegvaliase Dose', 'no label'), ('Duration', 'no label'), ('Pal-003', 'no label'), ('Blood Phe Levels Steadily', 'no label'), ('Decreased', 'no label'), ('Baseline', 'no label'), ('Reductions', 'no label'), ('Week', 'no label'), ('Pal-002 Participants', 'no label'), ('Pal-004', 'no label'), ('Participants', 'no label'), ('Participants', 'no label'), ('Pal-002', 'no label'), ('Pal-004', 'no label'), ('Reported', 'no label'), ('Adverse Event', 'no label'), ('Ae', 'no label'), ('Higher', 'no label'), ('Exposure-Adjusted Event', 'no label'), ('Rates', 'no label'), ('Pal-004', 'no label'), ('Aes', 'no label'), ('Mild', 'no label'), ('Pal-004)', 'no label'), ('Moderate', 'no label'), ('Pal-004', 'no label'), ('Aes', 'no label'), ('Pal-002', 'no label'), ('Injection Site Reaction', 'no label'), ('Participants', 'no label'), ('Headache', 'no label'), ('Injection Site Erythema', 'no label'), ('Nausea', 'no label'), ('Arthralgia', 'no label'), ('Pal-004', 'no label'), ('Arthralgia', 'no label'), ('Headache', 'no label'), ('Dizziness', 'no label'), ('Injection Site Erythema', 'no label'), ('Injection Site Reaction', 'no label'), ('Phase 2 Dose-Finding Studies', 'no label'), ('Pegvaliase', 'no label'), ('Did Not Lead', 'no label'), ('Blood Phe', 'no label'), ('Reductions', 'no label'), ('Higher', 'no label'), ('Frequent', 'no label'), ('Pegvaliase', 'no label'), ('Dosing', 'no label'), ('Pal-004', 'no label'), ('Led', 'no label'), ('Drop', 'no label'), ('Blood Phe', 'no label'), ('Increase', 'no label'), ('Hypersensitivity', 'no label'), ('Aes', 'no label'), ('Dose', 'no label'), ('Reductions', 'no label'), ('Interruptions', 'no label'), ('Increased', 'no label'), ('Dose', 'no label'), ('Duration', 'no label'), ('Treatment', 'no label'), ('Pal-003', 'no label'), ('Mean Blood Phe Reduction', 'no label'), ('Sustained', 'no label'), ('Frequency', 'no label'), ('Hypersensitivity', 'no label'), ('Aes', 'no label'), ('Decreased', 'no label'), ('Stabilized', 'no label'), ('Studies', 'no label'), ('Led', 'no label'), ('Development', 'no label'), ('Induction-Titration-Maintenance Regimen', 'no label'), ('Pegvaliase', 'no label'), ('Patients', 'no label'), ('Low Weekly Dose', 'no label'), ('Increases', 'no label'), ('Dose', 'no label'), ('Frequency', 'no label'), ('Achieve A Standard Non-Weight-Based Daily Maintenance', 'no label'), ('Dose', 'no label'), ('Regimen', 'no label'), ('Tested', 'no label'), ('Phase 2 Study', 'no label'), ('Phase 3 Studies', 'no label'), ('Pegvaliase', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Lead', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Ammonia', 'no label'), ('Phe', 'no label'), ('Ammonia', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Pal-003', 'no label'), ('Phe', 'no label'), ('Aes', 'no label'), ('Aes', 'no label'), ('Lead', 'no label')]|[('Days/Week', 'no label'), ('Sd 363.5', 'no label'), ('Aes', 'no label'), ('Aes', 'no label'), ('Aes', 'no label'), ('Aes', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylalanine Ammonia', 'no label'), ('Ammonia', 'no label'), ('And/Or', 'no label'), ('Phe', 'no label'), ('And/Or', 'no label'), ('Headache', 'no label'), ('Erythema', 'no label'), ('Nausea', 'no label'), ('Arthralgia', 'no label'), ('Arthralgia', 'no label'), ('Headache', 'no label'), ('Dizziness', 'no label'), ('Erythema', 'no label'), ('Phe', 'no label'), ('Hypersensitivity', 'no label'), ('Hypersensitivity', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Biomarin Pharmaceutical', 'no label'), ('Pegylated', 'no label'), ('Phe', 'no label'), ('Ammonia', 'no label'), ('Blood Phe', 'no label'), ('Blood Phe', 'no label'), ('Pegvaliase', 'no label'), ('Pegvaliase', 'no label'), ('And/Or', 'no label'), ('Blood Phe', 'no label'), ('Pal-004', 'no label'), ('Mg/Kg', 'no label'), ('And/Or', 'no label'), ('Blood Phe', 'no label'), ('Sd] 354', 'no label'), ('Sd 363.5)', 'no label'), ('Blood Phe', 'no label'), ('Sd 287.1] Μmol/L', 'no label'), ('Pal-004', 'no label'), ('Blood Phe', 'no label'), ('Sd 691.1', 'no label'), ('Pegvaliase Dose', 'no label'), ('Blood Phe', 'no label'), ('Sd', 'no label'), ('Pal-002', 'no label'), ('Sd 32.4', 'no label'), ('Pal-004', 'no label'), ('Pal-002', 'no label'), ('Pal-004', 'no label'), ('≥1', 'no label'), ('Aes', 'no label'), ('Aes', 'no label'), ('Arthralgia', 'no label'), ('Pal-004', 'no label'), ('Arthralgia', 'no label'), ('Pegvaliase Did', 'no label'), ('Blood', 'no label'), ('Pal-004', 'no label'), ('Blood', 'no label'), ('Aes', 'no label'), ('Blood Phe', 'no label'), ('Aes', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31471952|Phenylketonuria (Pku), Which Is Caused By Mutations In The Phenylalanine Hydroxylase (Pah) Gene, Is One Of The Most Common Inherited Diseases Of Amino Acid Metabolism. Phenylketonuria Is Characterized By An Abnormal Accumulation Of Phenylalanine And Its Metabolites In Body Fluids And Brain Tissues, Subsequently Leading To Severe Brain Dysfunction. Various Pathophysiological And Molecular Mechanisms Underlying Brain Dysfunction In Pku Have Been Described. However, The Metabolic Changes And Their Impacts On The Function Of Cerebral Cortices Of Patients With Pku Remain Largely Unknown. We Measured The Levels Of Small Molecule Metabolites In The Cerebrocortical Tissues Of Pku Mice And Wild-Type Control Mice Using Liquid Chromatography-Mass Spectrometry (Lc-Ms)-Based Metabolome Analysis. Differential Metabolites Were Further Subjected To Metabolic Pathway And Enrichment Analysis. Metabolome Analysis Revealed 35 Compounds Among 143 Detected Metabolites Were Significantly Changed In Pku Mice As Compared To Those In Their Wild-Type Littermates. Metabolic Pathway And Enrichment Analysis Of These Differential Metabolites Showed That Multiple Metabolic Pathways, Including Phenylalanine, Tyrosine, And Tryptophan Biosynthesis; Valine, Leucine, And Isoleucine Biosynthesis; Alanine, Aspartate, And Glutamate Metabolism; Purine Metabolism; Arginine And Proline Metabolism And Methionine Metabolism, Were Impacted In The Cerebral Cortices Of Pku Mice. The Data Revealed That Multiple Metabolic Pathways In Cerebral Cortices Of Pku Mice Were Disturbed, Suggesting That The Disturbances Of The Metabolic Pathways Might Contribute To Neurological Or Neurodevelopmental Dysfunction In Pku, Which Could Thus Provide New Insights Into Brain Pathogenic Mechanisms In Pku As Well As Mechanistic Insights For Better Understanding The Complexity Of The Metabolic Mechanisms Of The Brain Dysfunction In Pku.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Mutations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Inherited Diseases', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Phenylketonuria', 'no label'), ('Characterized', 'no label'), ('Abnormal', 'no label'), ('Accumulation', 'no label'), ('Phenylalanine', 'no label'), ('Metabolites', 'no label'), ('Body Fluids', 'no label'), ('Brain Tissues', 'no label'), ('Severe', 'no label'), ('Brain Dysfunction', 'no label'), ('Pathophysiological', 'no label'), ('Molecular Mechanisms', 'no label'), ('Brain Dysfunction', 'no label'), ('Metabolic', 'no label'), ('Changes', 'no label'), ('Impacts', 'no label'), ('Function', 'no label'), ('Cerebral Cortices', 'no label'), ('Patients', 'no label'), ('Pku Remain Largely', 'no label'), ('Measured', 'no label'), ('Levels', 'no label'), ('Small Molecule', 'no label'), ('Cerebrocortical Tissues', 'no label'), ('Pku Mice', 'no label'), ('Wild-Type Control', 'no label'), ('Liquid Chromatography-Mass Spectrometry', 'no label'), ('Differential', 'no label'), ('Metabolites', 'no label'), ('Metabolic Pathway', 'no label'), ('Metabolome Analysis', 'no label'), ('Revealed', 'no label'), ('Compounds', 'no label'), ('Detected', 'no label'), ('Metabolites', 'no label'), ('Changed', 'no label'), ('Pku Mice', 'no label'), ('Wild-Type', 'no label'), ('Littermates', 'no label'), ('Metabolic Pathway', 'no label'), ('Analysis', 'no label'), ('Differential Metabolites', 'no label'), ('Multiple', 'no label'), ('Metabolic Pathways', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Tryptophan Biosynthesis', 'no label'), ('Valine', 'no label'), ('Leucine', 'no label'), ('Isoleucine Biosynthesis', 'no label'), ('Alanine', 'no label'), ('Aspartate', 'no label'), ('Glutamate Metabolism', 'no label'), ('Purine Metabolism', 'no label'), ('Arginine', 'no label'), ('Proline Metabolism', 'no label'), ('Methionine Metabolism', 'no label'), ('Impacted', 'no label'), ('Cerebral Cortices', 'no label'), ('Pku Mice', 'no label'), ('Data Revealed', 'no label'), ('Multiple', 'no label'), ('Metabolic Pathways', 'no label'), ('Cerebral Cortices', 'no label'), ('Pku Mice', 'no label'), ('Suggesting', 'no label'), ('Disturbances', 'no label'), ('Metabolic Pathways', 'no label'), ('Contribute', 'no label'), ('Neurological', 'no label'), ('Into\xa0', 'no label'), ('Brain', 'no label'), ('Pathogenic', 'no label'), ('Mechanisms', 'no label'), ('Mechanistic', 'no label'), ('Complexity', 'no label'), ('Metabolic', 'no label'), ('Mechanisms', 'no label'), ('Brain Dysfunction', 'no label')]|[('Mutations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Gene', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Metabolites', 'no label'), ('Molecular', 'no label'), ('Molecule Metabolites', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Metabolites', 'no label'), ('Metabolites', 'no label'), ('Mice', 'no label'), ('Metabolites', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Tryptophan', 'no label'), ('Valine', 'no label'), ('Leucine', 'no label'), ('Isoleucine', 'no label'), ('Alanine', 'no label'), ('Aspartate', 'no label'), ('Glutamate', 'no label'), ('Purine', 'no label'), ('Arginine', 'no label'), ('Proline', 'no label'), ('Methionine', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Pathogenic', 'no label')]|[('Phenylalanine Hydroxylase', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acid', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Brain Dysfunction', 'no label'), ('Brain Dysfunction', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Tryptophan', 'no label'), ('Valine', 'no label'), ('Leucine', 'no label'), ('Isoleucine', 'no label'), ('Alanine', 'no label'), ('Aspartate', 'no label'), ('Glutamate', 'no label'), ('Purine', 'no label'), ('Arginine', 'no label'), ('Proline', 'no label'), ('Methionine', 'no label'), ('Neurological Or Neurodevelopmental Dysfunction', 'no label'), ('Brain Dysfunction', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Brain Tissues', 'no label'), ('Brain', 'no label'), ('Brain', 'no label'), ('Pku', 'no label'), ('Cerebral Cortices', 'no label'), ('Patients', 'no label'), ('Cerebrocortical Tissues', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Littermates.', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Tryptophan', 'no label'), ('Valine', 'no label'), ('Leucine', 'no label'), ('Isoleucine', 'no label'), ('Alanine', 'no label'), ('Aspartate', 'no label'), ('Glutamate', 'no label'), ('Purine', 'no label'), ('Arginine', 'no label'), ('Proline', 'no label'), ('Methionine', 'no label'), ('Cerebral Cortices', 'no label'), ('Mice', 'no label'), ('Cerebral', 'no label'), ('Mice', 'no label'), ('Brain', 'no label'), ('Brain', 'no label')]
phenylketonuria|pubmed~34432558|Osteopenia Is Common In Phenylalanine Hydroxylase Deficient Phenylketonuria (Pku). Pku Is Managed By Limiting Dietary Phenylalanine. Osteopenia In Pku Might Reflect A Therapeutic Diet, With Reduced Bone Forming Materials. However, Osteopenia Occurs In Patients Who Never Received Dietary Therapy Or Following Short-Term Therapy. Humans And Animal Studies Find No Correlation Between Bone Loss, Plasma Hyperphenylalaninemia, Bone Formation, And Resorption Markers. Work In The Pah<Sup>Enu2</Sup> Mouse Recently Showed A Mesenchymal Stem Cell (Msc) Developmental Defect In The Osteoblast Pathway. Specifically, Pah<Sup>Enu2</Sup> Mscs Are Affected By Energy Dysregulation And Oxidative Stress. In Pku, Mscs Oximetry And Respirometry Show Mitochondrial Respiratory-Chain Complex 1 Deficit And Over-Representation Of Superoxide, Producing Reactive Oxygen Species Affecting Mitochondrial Function. Similar Mechanisms Are Involved In Aging Bone And Other Rare Defects Including Alkaptonuria And Homocysteinemia. Novel Interventions To Support Energy And Reduce Oxidative Stress May Restore Bone Formation Pku Patients, And In Metabolic Diseases With Related Mechanisms.|[('Osteopenia', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Dietary Phenylalanine', 'no label'), ('Osteopenia', 'no label'), ('Therapeutic Diet', 'no label'), ('Reduced', 'no label'), ('Bone Forming', 'no label'), ('Osteopenia', 'no label'), ('Occurs', 'no label'), ('Patients', 'no label'), ('Received', 'no label'), ('Dietary Therapy', 'no label'), ('Short-Term Therapy', 'no label'), ('Humans', 'no label'), ('Animal Studies', 'no label'), ('Correlation', 'no label'), ('Bone Loss', 'no label'), ('Plasma', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Bone Formation', 'no label'), ('Resorption', 'no label'), ('Markers', 'no label'), ('Work', 'no label'), ('Enu2</Sup> Mouse', 'no label'), ('Showed', 'no label'), ('Mesenchymal Stem Cell', 'no label'), ('Developmental Defect', 'no label'), ('Osteoblast Pathway', 'no label'), ('Mscs', 'no label'), ('Affected', 'no label'), ('Energy Dysregulation', 'no label'), ('Oxidative Stress', 'no label'), ('Mscs Oximetry', 'no label'), ('Respirometry', 'no label'), ('Mitochondrial', 'no label'), ('Respiratory-Chain Complex 1 Deficit', 'no label'), ('Over-Representation', 'no label'), ('Superoxide', 'no label'), ('Producing', 'no label'), ('Reactive Oxygen Species', 'no label'), ('Affecting', 'no label'), ('Mitochondrial Function', 'no label'), ('Mechanisms', 'no label'), ('Aging Bone', 'no label'), ('Rare', 'no label'), ('Defects', 'no label'), ('Alkaptonuria', 'no label'), ('Homocysteinemia', 'no label'), ('Novel', 'no label'), ('Interventions', 'no label'), ('Reduce', 'no label'), ('Oxidative Stress', 'no label'), ('Restore Bone Formation', 'no label'), ('Patients', 'no label'), ('Metabolic Diseases', 'no label'), ('Mechanisms', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Humans', 'no label'), ('Animal', 'no label'), ('Mouse', 'no label'), ('Mesenchymal Stem Cell', 'no label'), ('Osteoblast', 'no label'), ('Mitochondrial Respiratory-Chain Complex 1', 'no label'), ('Superoxide', 'no label'), ('Oxygen Species', 'no label'), ('Mitochondrial', 'no label')]|[('Mesenchymal Stem Cell', 'no label')]|[('Osteopenia', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Osteopenia', 'no label'), ('Osteopenia', 'no label'), ('Bone Loss', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Energy', 'no label'), ('Superoxide', 'no label'), ('Oxygen', 'no label'), ('Alkaptonuria', 'no label'), ('Homocysteinemia', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Bone', 'no label'), ('Patients', 'no label'), ('Humans', 'no label'), ('Bone', 'no label'), ('Plasma', 'no label'), ('Bone', 'no label'), ('Mouse', 'no label'), ('A Mesenchymal Stem Cell', 'no label'), ('Osteoblast', 'no label'), ('Mitochondrial', 'no label'), ('Complex 1', 'no label'), ('Superoxide', 'no label'), ('Mitochondrial', 'no label'), ('Bone', 'no label'), ('Bone', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~32461102|Phenylketonuria (Pku) Is The Most Prevalent Inborn Error Of Amino Acid Metabolism. The Disease Is Due To The Deficiency Of Phenylalanine (Phe) Hydroxylase Activity, Which Causes The Accumulation Of Phe. Early Diagnosis Through Neonatal Screening Is Essential For Early Treatment Implementation, Avoiding Cognitive Impairment And Other Irreversible Sequelae. Treatment Is Based On Phe Restriction In The Diet That Should Be Maintained Throughout Life. High Dietary Restrictions Can Lead To Imbalances In Specific Nutrients, Notably Lipids. Previous Studies In Pku Patients Revealed Changes In Levels Of Plasma/Serum Lipoprotein Lipids, As Well As In Fatty Acid Profile Of Plasma And Red Blood Cells. Most Studies Showed A Decrease In Important Polyunsaturated Fatty Acids, Namely Dha (22:6N-3), Aa (20:4N-6) And Epa (20:5N-6). Increased Oxidative Stress And Subsequent Lipid Peroxidation Have Also Been Observed In Pku. Despite The Evidences That The Lipid Profile Is Changed In Pku Patients, More Studies Are Needed To Understand In Detail How Lipidome Is Affected. As Highlighted In This Review, Mass Spectrometry-Based Lipidomics Is A Promising Approach To Evaluate The Effect Of The Diet Restrictions On Lipid Metabolism In Pku Patients, Monitor Their Outcome, Namely Concerning The Risk For Other Chronic Diseases, And Find Possible Prognosis Biomarkers.|[('Phenylketonuria', 'no label'), ('Prevalent', 'no label'), ('Inborn Error', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Disease', 'no label'), ('Deficiency', 'no label'), ('Phenylalanine (Phe) Hydroxylase Activity', 'no label'), ('Causes', 'no label'), ('Accumulation', 'no label'), ('Phe', 'no label'), ('Early Diagnosis', 'no label'), ('Neonatal', 'no label'), ('Screening', 'no label'), ('Early Treatment', 'no label'), ('Implementation', 'no label'), ('Cognitive Impairment', 'no label'), ('Irreversible Sequelae', 'no label'), ('Treatment', 'no label'), ('Phe', 'no label'), ('Restriction', 'no label'), ('Diet', 'no label'), ('Maintained', 'no label'), ('Life', 'no label'), ('Dietary', 'no label'), ('Restrictions', 'no label'), ('Lead', 'no label'), ('Imbalances', 'no label'), ('Nutrients', 'no label'), ('Lipids', 'no label'), ('Studies', 'no label'), ('Pku Patients', 'no label'), ('Revealed', 'no label'), ('Changes', 'no label'), ('Levels', 'no label'), ('Plasma/Serum Lipoprotein Lipids', 'no label'), ('Fatty Acid', 'no label'), ('Profile', 'no label'), ('Plasma', 'no label'), ('Red Blood Cells', 'no label'), ('Studies', 'no label'), ('Showed', 'no label'), ('Decrease', 'no label'), ('Polyunsaturated Fatty Acids', 'no label'), ('Dha', 'no label'), ('Aa', 'no label'), ('Epa', 'no label'), ('Increased', 'no label'), ('Oxidative Stress', 'no label'), ('Lipid Peroxidation', 'no label'), ('Observed', 'no label'), ('Lipid Profile', 'no label'), ('Changed', 'no label'), ('Patients', 'no label'), ('Studies', 'no label'), ('Understand', 'no label'), ('Detail', 'no label'), ('Lipidome', 'no label'), ('Affected', 'no label'), ('Review', 'no label'), ('Mass Spectrometry-Based Lipidomics', 'no label'), ('Evaluate', 'no label'), ('Effect', 'no label'), ('Diet', 'no label'), ('Restrictions', 'no label'), ('Lipid Metabolism', 'no label'), ('Patients', 'no label'), ('Monitor', 'no label'), ('Outcome', 'no label'), ('Risk', 'no label'), ('Chronic Diseases', 'no label'), ('Prognosis', 'no label'), ('Biomarkers', 'no label')]|[('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Nutrients', 'no label'), ('Lipids', 'no label'), ('Fatty Acid', 'no label'), ('Red Blood Cells', 'no label'), ('Fatty Acids', 'no label'), ('Lipid', 'no label'), ('Lipid', 'no label'), ('Lipid', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Cognitive Impairment', 'no label'), ('Phe', 'no label'), ('Fatty Acid', 'no label'), ('Polyunsaturated Fatty Acids', 'no label'), ('Dha', 'no label'), ('22:6N-3', 'no label'), ('Prognosis', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Lipids', 'no label'), ('Patients', 'no label'), ('Lipids', 'no label'), ('Fatty Acid', 'no label'), ('Plasma', 'no label'), ('Red Blood Cells', 'no label'), ('Polyunsaturated Fatty Acids', 'no label'), ('Aa (20:4N-6) And', 'no label'), ('Lipid', 'no label'), ('Lipid', 'no label'), ('Pku Patients', 'no label'), ('Lipid', 'no label'), ('Pku Patients', 'no label')]
phenylketonuria|pubmed~33625639|As One Of The Highest Prevalence Rates In The World, The Prevalence Of Phenylketonuria (Pku) In Iran Has Been Estimated At 16.5 Per 100,000 Neonates. The Objective Of This Study Was To Evaluate The Spectrum And Frequency Of Mutations Of The Phenylalanine Hydroxylase (Pah) Gene In Iranian Pku Patients. A Systematic Review Was Carried Out On Previous Studies On Pah Gene Mutations In Iranian Pku Patients. A Complete Search Was Carried Out On The On-Line Databases Of Scopus, Web Of Science, Pubmed/Medline, Proquest, Science Direct, Magiran, Sid And The Search Engine Google Scholar. The Keywords Of Phenylketonuria, Pku, Phenylalanine Hydroxylase, Pah, And Iran, As Well As Their Persian Equivalents, In All Possible Combinations Were Used. Finally, A Total Of 21 Eligible Articles With A Sample Size Of 1547 Iranian Pku Patients, Published Between 2003 And 2020, Were Included In Our Systematic Review. A Total Of 129 Different Pah Gene Mutations Including, Ivs10-11G > A (C.1066-11G > A) (19.23%), P.R261Q (C.782G > A) (7.63%), P.P281L (C.842C > T) (6.24%), Ivs2 + 5G > C (C.168 + 5G > C) (5.75%), P.R243* (C.727C > T) (3.59%), Ivs9 + 5G > A (C.969 + 5G > A) (2.84%), P.R176* (C.526C > T) (2.42%), P.Lys363Nfs*37 (C.1089Delg) (2.13%), Ivs11 + 1G > C (C.1199 + 1G > C) (2.07%) And P.L48S (C.143 T > C) (2.04%) Were Identified. The Spectrum And Frequency Of Mutations Observed In Iran Were Closer To Those Observed In The Mediterranean Countries. Our Results Are Valuable In Planning Panel-Based Studies In Provinces With Incomplete Data On Pah Gene Mutations. This Study Is A Good Reference For Genetic Counselors And Physicians Who Advise Couples In Making Decisions To Maintain Or Terminate A Pregnancy.|[('Highest', 'no label'), ('Prevalence', 'no label'), ('Rates', 'no label'), ('World', 'no label'), ('Prevalence', 'no label'), ('Phenylketonuria', 'no label'), ('Iran', 'no label'), ('Estimated', 'no label'), ('Neonates', 'no label'), ('Study', 'no label'), ('Evaluate', 'no label'), ('Spectrum', 'no label'), ('Frequency', 'no label'), ('Mutations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Iranian', 'no label'), ('Patients', 'no label'), ('Systematic Review', 'no label'), ('Studies', 'no label'), ('Gene Mutations', 'no label'), ('Iranian', 'no label'), ('Patients', 'no label'), ('Complete', 'no label'), ('Search', 'no label'), ('On-Line Databases', 'no label'), ('Scopus', 'no label'), ('Web Of Science', 'no label'), ('Pubmed/Medline', 'no label'), ('Proquest', 'no label'), ('Magiran', 'no label'), ('Engine', 'no label'), ('Google Scholar', 'no label'), ('Keywords', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Iran', 'no label'), ('Persian Equivalents', 'no label'), ('Combinations', 'no label'), ('Articles', 'no label'), ('Sample Size', 'no label'), ('Iranian', 'no label'), ('Patients', 'no label'), ('Published', 'no label'), ('Systematic Review', 'no label'), ('Pah Gene', 'no label'), ('Ivs10-11G\u2009>\u2009A', 'no label'), ('C.1066-11G\u2009>\u2009A', 'no label'), ('P.R261Q', 'no label'), ('C.782G\u2009>\u2009A', 'no label'), ('P.P281L', 'no label'), ('C.842C\u2009>\u2009T', 'no label'), ('Ivs2\u2009+\u20095G\u2009>\u2009C', 'no label'), ('C.168\u2009+\u20095G\u2009>\u2009C', 'no label'), ('P.R243* (C.727C\u2009>\u2009T', 'no label'), ('Ivs9\u2009+\u20095G\u2009>\u2009A', 'no label'), ('C.969\u2009+\u20095G\u2009>\u2009A', 'no label'), ('P.R176* (', 'no label'), ('C.526C\u2009>\u2009T', 'no label'), ('P.Lys363Nfs*37', 'no label'), ('C.1089Delg', 'no label'), ('Ivs11\u2009+\u20091G\u2009>\u2009C', 'no label'), ('C.1199\u2009+\u20091G\u2009>\u2009C', 'no label'), ('P.L48S (C.143\xa0T\u2009>\u2009C', 'no label'), ('Identified', 'no label'), ('Spectrum', 'no label'), ('Frequency', 'no label'), ('Mutations', 'no label'), ('Observed', 'no label'), ('Iran', 'no label'), ('Closer', 'no label'), ('Observed', 'no label'), ('Mediterranean Countries', 'no label'), ('Results', 'no label'), ('Panel-Based Studies', 'no label'), ('Provinces', 'no label'), ('Data', 'no label'), ('Gene Mutations', 'no label'), ('Study', 'no label'), ('Good Reference', 'no label'), ('Genetic Counselors', 'no label'), ('Physicians', 'no label'), ('Advise Couples', 'no label'), ('Decisions', 'no label'), ('Maintain', 'no label'), ('Terminate A', 'no label'), ('Pregnancy', 'no label')]|[('Mutations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Gene', 'no label'), ('Gene Mutations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Gene Mutations', 'no label'), ('Ivs10', 'no label'), ('Ivs2', 'no label'), ('+', 'no label'), ('Ivs9', 'no label'), ('+', 'no label'), ('P.L48S', 'no label'), ('Mutations', 'no label'), ('Gene Mutations', 'no label'), ('Genetic', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Pah Gene Mutations', 'no label'), ('On-Line Databases', 'no label'), ('Pah Gene Mutations', 'no label'), ('Ivs2\u2009+\u20095G\u2009>\u2009C (', 'no label'), ('Ivs9\u2009+\u20095G\u2009>\u2009A (', 'no label'), ('Ivs11\u2009+\u20091G\u2009>\u2009C', 'no label'), ('P.L48S', 'no label'), ('C.143\xa0T\u2009>\u2009C) (', 'no label'), ('Pah Gene', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('C.143', 'no label'), ('Terminate A Pregnancy', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Pah', 'no label'), ('21', 'no label'), ('Ivs10-11', 'no label'), ('Ivs9', 'no label'), ('P.Lys363Nfs*37', 'no label')]
phenylketonuria|pubmed~34684443|Although There Is A General Assumption That A Phenylalanine (Phe)-Restricted Diet Promotes Overweight In Patients With Phenylketonuria (Pku), It Is Unclear If This Presumption Is Supported By Scientific Evidence. This Systematic Review Aimed To Determine If Patients With Pku Are At A Higher Risk Of Overweight Compared To Healthy Individuals. A Literature Search Was Carried Out On Pubmed, Cochrane Library, And Embase Databases. Risk Of Bias Of Individual Studies Was Assessed Using The Quality Assessment Tool For Observational Cohort And Cross-Sectional Studies, And The Quality Of The Evidence For Each Outcome Was Assessed Using The Nutrigrade Scoring System. From 829 Articles Identified, 15 Were Included In The Systematic Review And 12 In The Meta-Analysis. Body Mass Index (Bmi) Was Similar Between Patients With Pku And Healthy Controls, Providing No Evidence To Support The Idea That A Phe-Restricted Diet Is A Risk Factor For The Development Of Overweight. However, A Subgroup Of Patients With Classical Pku Had A Significantly Higher Bmi Than Healthy Controls. Given The Increasing Prevalence Of Overweight In The General Population, Patients With Pku Require Lifelong Follow-Up, Receiving Personalised Nutritional Counselling, With Methodical Nutritional Status Monitoring From A Multidisciplinary Team In Inherited Metabolic Disorders.|[('General Assumption', 'no label'), ('Phenylalanine', 'no label'), ('Diet', 'no label'), ('Promotes', 'no label'), ('Overweight', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Presumption', 'no label'), ('Scientific Evidence', 'no label'), ('Systematic Review', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Higher', 'no label'), ('Risk', 'no label'), ('Overweight', 'no label'), ('Compared', 'no label'), ('Healthy', 'no label'), ('Individuals', 'no label'), ('Literature', 'no label'), ('Search', 'no label'), ('Pubmed', 'no label'), ('Cochrane Library', 'no label'), ('Embase Databases', 'no label'), ('Risk', 'no label'), ('Bias', 'no label'), ('Individual Studies', 'no label'), ('Assessed', 'no label'), ('Quality Assessment Tool', 'no label'), ('Observational Cohort', 'no label'), ('Cross-Sectional Studies', 'no label'), ('Quality', 'no label'), ('Evidence', 'no label'), ('Outcome', 'no label'), ('Assessed', 'no label'), ('Nutrigrade Scoring System', 'no label'), ('Articles', 'no label'), ('Identified', 'no label'), ('Systematic Review', 'no label'), ('Meta-Analysis', 'no label'), ('Body Mass Index', 'no label'), ('Bmi', 'no label'), ('Patients', 'no label'), ('Pku And Healthy Controls', 'no label'), ('No Evidence', 'no label'), ('Phe-Restricted Diet', 'no label'), ('Risk Factor', 'no label'), ('Development', 'no label'), ('Overweight', 'no label'), ('Subgroup', 'no label'), ('Patients', 'no label'), ('Classical Pku', 'no label'), ('Bmi Than', 'no label'), ('Healthy Controls', 'no label'), ('Increasing', 'no label'), ('Prevalence', 'no label'), ('Overweight', 'no label'), ('General Population', 'no label'), ('Patients', 'no label'), ('Pku Require', 'no label'), ('Lifelong Follow-Up', 'no label'), ('Receiving', 'no label'), ('Personalised', 'no label'), ('Nutritional Counselling', 'no label'), ('Methodical Nutritional Status', 'no label'), ('Monitoring', 'no label'), ('Multidisciplinary Team', 'no label'), ('Inherited', 'no label'), ('Metabolic Disorders', 'no label')]|[('Phenylalanine', 'no label'), ('Individuals', 'no label'), ('Bmi', 'no label'), ('Bmi', 'no label')]|[('Bmi', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Overweight', 'no label'), ('Metabolic Disorders', 'no label')]|[('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Bmi', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Bmi', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~34578995|Blood Phenylalanine (Phe) Is Used As The Primary Marker To Evaluate Metabolic Control. Our Study Aimed To Describe The Metabolic Control Of Patients With Phenylketonuria (Pku) Comparing Three Different Treatment Recommendations (European Guidelines/Us Guidelines/Portuguese Consensus). This Was A Retrospective, Observational, Single Centre Study In Patients With Pku Collecting Data On Blood Phe Levels From 2017. Nutritional Intake Data And Sapropterin (Bh4) Prescription Were Collected At The Last Appointment Of 2017. The Final Sample Studied Included 87 Patients (48% Females) [13 Hyperphenylalaninemia; 47 Mild Pku; 27 Classical Pku] With A Median Age Of 18 Y (Range: 1-36 Y). The Median Number Of Blood Phe Measurements For Patients Was 21 (Range: 6-89). In Patients Aged < 12 Y, The Median Blood Phe Level Was 300 Μmol/L (Range 168-480) And 474 Μmol/L (Range 156-1194) For Patients ≥ 12 Y. Overall, A Median Of 83% Of Blood Phe Levels Were Within The European Pku Guidelines Target Range. In Patients Aged ≥ 12 Years, There Was A Higher Median % Of Blood Phe Levels Within The European Pku Guidelines Target Range (≥12 Y: 84% Vs. <12 Y: 56%). In Children < 12 Y With Classical Pku (<I>N =</I> 2), Only 34% Of Blood Phe Levels Were Within Target Range For All 3 Guidelines And 49% With Mild Pku (<I>N =</I> 11). Girls Had Better Control Than Boys (89% Vs. 66% Median Phe Levels Within European Guidelines). Although It Is Clear That 50% Or More Patients Were Unable To Achieve Acceptable Metabolic Control On Current Treatment Options, A Globally Agreed Upper Phe Target Associated With Optimal Outcomes For Age Groups Is Necessary. More Studies Need To Examine How Clinics With Dissimilar Resources, Different Therapeutic Phe Targets And Frequency Of Monitoring Relate To Metabolic Control.|[('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Primary Marker', 'no label'), ('Evaluate', 'no label'), ('Metabolic Control', 'no label'), ('Study', 'no label'), ('Metabolic Control', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Treatment', 'no label'), ('Recommendations', 'no label'), ('European', 'no label'), ('Guidelines/Us', 'no label'), ('Consensus', 'no label'), ('Was A', 'no label'), ('Retrospective', 'no label'), ('Observational', 'no label'), ('Single Centre Study', 'no label'), ('Patients', 'no label'), ('Pku Collecting Data', 'no label'), ('Blood Phe Levels', 'no label'), ('Nutritional Intake', 'no label'), ('Data', 'no label'), ('Sapropterin', 'no label'), ('Bh4', 'no label'), ('Prescription', 'no label'), ('Collected', 'no label'), ('Appointment', 'no label'), ('Final', 'no label'), ('Sample', 'no label'), ('Patients', 'no label'), ('Females', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Mild Pku', 'no label'), ('Classical Pku', 'no label'), ('Median Age', 'no label'), ('Median Number', 'no label'), ('Blood Phe Measurements', 'no label'), ('Patients', 'no label'), ('Range', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Median Blood Phe Level', 'no label'), ('Patients', 'no label'), ('Median', 'no label'), ('Blood Phe Levels', 'no label'), ('European', 'no label'), ('Target Range', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Median', 'no label'), ('Blood Phe Levels', 'no label'), ('European', 'no label'), ('Target Range', 'no label'), ('Children', 'no label'), ('Classical Pku', 'no label'), ('Blood Phe Levels', 'no label'), ('Target Range', 'no label'), ('Guidelines', 'no label'), ('Mild Pku', 'no label'), ('Girls', 'no label'), ('Boys', 'no label'), ('Median', 'no label'), ('Phe Levels', 'no label'), ('European', 'no label'), ('Guidelines', 'no label'), ('Patients', 'no label'), ('Acceptable', 'no label'), ('Metabolic Control', 'no label'), ('Treatment Options', 'no label'), ('Globally Agreed', 'no label'), ('Upper', 'no label'), ('Phe', 'no label'), ('Target', 'no label'), ('Associated With', 'no label'), ('Optimal', 'no label'), ('Outcomes', 'no label'), ('Age Groups', 'no label'), ('Studies', 'no label'), ('Need', 'no label'), ('Examine', 'no label'), ('Clinics', 'no label'), ('Dissimilar', 'no label'), ('Resources', 'no label'), ('Therapeutic', 'no label'), ('Phe', 'no label'), ('Targets', 'no label'), ('Frequency', 'no label'), ('Monitoring Relate', 'no label'), ('Metabolic Control', 'no label')]|[('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Y', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Sapropterin', 'no label'), ('Patients', 'no label'), ('Blood', 'no label'), ('Patients', 'no label'), ('21', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('≥12', 'no label'), ('Children', 'no label'), ('/I> 2', 'no label'), ('Blood Phe', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Phe', 'no label')]
phenylketonuria|pubmed~33394907|Phenylketonuria (Pku) Is The Most Common Inborn Error Of Amino Acid Metabolism And Causes Neurological Manifestations Because Of Excessive Accumulation Of Phenylalanine (Phe). It Can Also Affect Adult Patients Who Discontinue Their Treatment, Even If They Had Been Under Adequate Metabolic Control During Childhood. For That Reason, It Is Recommended That Pku Treatment Should Be Continued Throughout Life And Target Phe Levels For Adult Patients Should Range Between 120 And 600 Μmol/L. The Authors Present An Adult Patient With Pku Who Discontinued Treatment And Developed Cognitive Dysfunction Because Of High Blood Levels Of Phe. Brain Magnetic Resonance Imaging (Mri) Of The Patient Was Characteristic For Pku, Presenting Periventricular And Callosal White Matter Hyperintensities In T2 And Fluid-Attenuated Inversion Recovery Sequences, Which Were Additionally Associated With True Restriction In Diffusion-Weighted Imaging Sequence, A Far Less Recognized Pku Neuroimaging Feature. Cognitive Dysfunction And Psychiatric Disorders Can Be Present In Adult Patients With Pku Who Discontinue Treatment And Have Poor Phe Metabolic Control. The Presence Of White Matter Hyperintensities In T2 And Fluid-Attenuated Inversion Recovery Mri-Sequences Is A Well-Described Neuroimaging Feature Of Pku, But Diffusion-Weighted Imaging Sequence May Also Be Reliable In Detecting Brain Lesions In Patients With Pku. Pku Lesions Should Be Considered In The Differential Diagnosis Of True Diffusion Restriction In Brain Mri Of Patients With Pku History Or Those Who Might Have Escaped Newborn Screening Diagnosis But Present Neurocognitive Dysfunction. Appropriate Treatment For The Management Of Pku Should Be Initiated For The Reversal Of The Clinical And Neuroimaging Findings.|[('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Causes', 'no label'), ('Neurological Manifestations', 'no label'), ('Excessive', 'no label'), ('Accumulation', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Discontinue', 'no label'), ('Treatment', 'no label'), ('Adequate', 'no label'), ('Metabolic Control', 'no label'), ('Childhood', 'no label'), ('Reason', 'no label'), ('Recommended', 'no label'), ('Pku Treatment', 'no label'), ('Life', 'no label'), ('Target', 'no label'), ('Phe Levels', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Adult', 'no label'), ('Patient', 'no label'), ('Pku Who Discontinued', 'no label'), ('Treatment', 'no label'), ('Developed Cognitive Dysfunction', 'no label'), ('Blood Levels', 'no label'), ('Phe', 'no label'), ('Brain Magnetic Resonance Imaging', 'no label'), ('Mri', 'no label'), ('Patient', 'no label'), ('Characteristic', 'no label'), ('Pku', 'no label'), ('Periventricular', 'no label'), ('Callosal White', 'no label'), ('Hyperintensities', 'no label'), ('T2', 'no label'), ('Fluid-Attenuated Inversion Recovery Sequences', 'no label'), ('Associated With', 'no label'), ('True Restriction', 'no label'), ('Diffusion-Weighted Imaging Sequence', 'no label'), ('Pku Neuroimaging Feature', 'no label'), ('Cognitive Dysfunction', 'no label'), ('Psychiatric Disorders', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Pku Who', 'no label'), ('Discontinue', 'no label'), ('Treatment', 'no label'), ('Poor', 'no label'), ('Phe Metabolic Control', 'no label'), ('White Matter', 'no label'), ('Hyperintensities', 'no label'), ('T2', 'no label'), ('Fluid-Attenuated Inversion', 'no label'), ('Well-Described Neuroimaging', 'no label'), ('Diffusion-Weighted Imaging Sequence', 'no label'), ('Detecting', 'no label'), ('Brain Lesions', 'no label'), ('Patients', 'no label'), ('Pku Lesions', 'no label'), ('Differential Diagnosis', 'no label'), ('True Diffusion', 'no label'), ('Brain', 'no label'), ('Mri', 'no label'), ('Patients', 'no label'), ('Pku History', 'no label'), ('Escaped', 'no label'), ('Screening Diagnosis', 'no label'), ('Neurocognitive Dysfunction', 'no label'), ('Treatment', 'no label'), ('Management', 'no label'), ('Pku Should Be Initiated', 'no label'), ('Clinical And Neuroimaging', 'no label'), ('Findings', 'no label')]|[('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Sequence', 'no label'), ('Phe', 'no label'), ('Sequence', 'no label')]|[('T2', 'no label'), ('T2', 'no label')]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Discontinue', 'no label'), ('Cognitive Dysfunction', 'no label'), ('Phe', 'no label'), ('White Matter Hyperintensities In', 'no label'), ('Cognitive Dysfunction', 'no label'), ('Psychiatric Disorders', 'no label'), ('Discontinue', 'no label'), ('White Matter Hyperintensities In T2 And Fluid-Attenuated Inversion Recovery Mri-Sequences Is A Well-Described Neuroimaging Feature Of Pku, But Diffusion-Weighted Imaging Sequence May', 'no label'), ('Neurocognitive Dysfunction', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Blood', 'no label'), ('Phe', 'no label'), ('Brain', 'no label'), ('Patient', 'no label'), ('Periventricular', 'no label'), ('Callosal', 'no label'), ('Hyperintensities', 'no label'), ('T2', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Hyperintensities', 'no label'), ('T2', 'no label'), ('Brain Lesions', 'no label'), ('Patients', 'no label'), ('Brain', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~30690773|Newborn Screening For Phenylketonuria (Pku) And Early Introduction Of Dietary Therapy Has Been Remarkably Successful In Preventing The Severe Neurological Features Of Pku, Including Mental Retardation And Epilepsy. However, Concerns Remain That Long-Term Outcome Is Still Suboptimal, Particularly In Adult Patients Who Are No Longer On Strict Phenylalanine-Restricted Diets. With Our Systematic Literature Review We Aimed To Describe The Neurological Phenotype Of Adults With Early-Treated Phenylketonuria (Etpku). The Literature Search Covered The Period From 1 January 1990 Up To 16 April 2018, Using The Nlm Medline Controlled Vocabulary. Of The 643 Records Initially Identified, 83 Were Included In The Analysis. The Most Commonly Reported Neurological Signs Were Tremor And Hyperreflexia. The Overall Quality Of Life (Qol) Of Etpku Adults Was Good Or Comparable To Control Populations, And There Was No Evidence For A Significant Incidence Of Psychiatric Disease Or Social Difficulties. Neuroimaging Revealed That Brain Abnormalities Are Present In Etpku Adults, But Their Clinical Significance Remains Unclear. Generally, Intelligence Quotient (Iq) Appears Normal But Specific Deficits In Neuropsychological And Social Functioning Were Reported In Early-Treated Adults Compared With Healthy Individuals. However, Accurately Defining The Prevalence Of These Deficits Is Complicated By The Lack Of Standardized Neuropsychological Tests. Future Research Should Employ Standardized Neurological, Neuropsychological, And Neuroimaging Protocols, And Consider Other Techniques Such As Advanced Imaging Analyses And The Recently Validated Pku-Specific Qol Questionnaire, To Precisely Define The Nature Of The Impairments Within The Adult Etpku Population And How These Relate To Metabolic Control Throughout Life.|[('Newborn', 'no label'), ('Screening', 'no label'), ('Phenylketonuria', 'no label'), ('Early Introduction', 'no label'), ('Dietary Therapy', 'no label'), ('Preventing', 'no label'), ('Severe', 'no label'), ('Neurological Features', 'no label'), ('Mental Retardation', 'no label'), ('Epilepsy', 'no label'), ('Concerns', 'no label'), ('Remain', 'no label'), ('Long-Term Outcome', 'no label'), ('Suboptimal', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Strict', 'no label'), ('Phenylalanine-Restricted Diets', 'no label'), ('Systematic Literature Review', 'no label'), ('Neurological', 'no label'), ('Phenotype', 'no label'), ('Adults', 'no label'), ('Early-Treated Phenylketonuria', 'no label'), ('Etpku', 'no label'), ('Literature Search Covered', 'no label'), ('Period', 'no label'), ('Nlm Medline Controlled Vocabulary', 'no label'), ('Records', 'no label'), ('Identified', 'no label'), ('Analysis', 'no label'), ('Neurological Signs Were Tremor', 'no label'), ('Hyperreflexia', 'no label'), ('Quality Of Life', 'no label'), ('Qol', 'no label'), ('Etpku Adults', 'no label'), ('Good', 'no label'), ('Control Populations', 'no label'), ('No Evidence', 'no label'), ('Significant', 'no label'), ('Incidence', 'no label'), ('Psychiatric Disease', 'no label'), ('Social Difficulties', 'no label'), ('Neuroimaging', 'no label'), ('Revealed', 'no label'), ('Brain Abnormalities', 'no label'), ('Etpku Adults', 'no label'), ('Clinical Significance Remains', 'no label'), ('Intelligence Quotient', 'no label'), ('Deficits', 'no label'), ('Neuropsychological', 'no label'), ('Social Functioning', 'no label'), ('Early-Treated Adults', 'no label'), ('Compared', 'no label'), ('Healthy', 'no label'), ('Individuals', 'no label'), ('Prevalence', 'no label'), ('Deficits', 'no label'), ('Complicated', 'no label'), ('Lack', 'no label'), ('Standardized Neuropsychological Tests', 'no label'), ('Research', 'no label'), ('Neuropsychological', 'no label'), ('Neuroimaging Protocols', 'no label'), ('Techniques', 'no label'), ('Advanced Imaging Analyses', 'no label'), ('Validated', 'no label'), ('Nature', 'no label'), ('Impairments', 'no label'), ('Adult', 'no label'), ('Etpku Population', 'no label'), ('Metabolic', 'no label'), ('Life', 'no label')]|[('Individuals', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Epilepsy', 'no label'), ('Phenylketonuria', 'no label'), ('Tremor', 'no label'), ('Hyperreflexia', 'no label'), ('Psychiatric Disease', 'no label'), ('Social Difficulties', 'no label'), ('Brain Abnormalities', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Tremor', 'no label'), ('Brain Abnormalities', 'no label'), ('Pku-Specific', 'no label')]
phenylketonuria|pubmed~32901468|To Avoid The Risk Of Intellectual Disabilities, Newborns In Poland Are Screened For Phenylketonuria And Are Recommended To Start A Life-Long Phenylalanine-Restricted Diet Shortly After Birth. The Aim Of This Paper Is To Evaluate The Health Care For Patients With Classical Phenylketonuria In Poland. We Reviewed The National Health Fund'S Reporting Data Concerning Information On Healthcare Services For Patients With Classical Phenylketonuria (Pku), Which Were Reported To The Payer By The Healthcare Service Providers Between 2009 And 2015. The Analysis Was Prepared Within The Framework Of Mapping The Health Care Needs Of Patients With Metabolic Diseases Published In December 2016 (Http://Www.Mapypotrzebzdrowotnych.Mz.Gov.Pl/). A Total Of 2706 Patients With Pku (Including 1180 Children) Were Registered In The Healthcare System In The Period Covered. The Estimated National Prevalence Of Pku Was 1 Per 7758 Live Births. Paediatric Patients Up To 12 Moths Of Age Accounted For Over 40% Of All Visits To Outpatient Clinics. Patients Over 28 Years Of Age Accounted For Only 1% Of All Pku Patients Receiving Specialist Outpatient Care. There Were Twice As Many Clinics Providing Health Care To Children Than To Adults. The Majority Of Adult Patients Received Healthcare From The Same Providers As Children. Sixty-Nine Percent Of Adults And 64% Of Children Were Treated In The Two Largest Outpatient Centres. There Were 12 Deaths, With A Median Age Of 63 Years. The Working-Age Adults Accounted For 50% Of The Deaths. Adult Patients With Pku Do Not Receive Sufficient Healthcare. The Discontinuation Of Healthcare By Adults With Pku Can Result From The Lack Of An Adequate Transition Process From Paediatric To Adult Care.|"[('Risk', 'no label'), ('Intellectual Disabilities', 'no label'), ('Newborns', 'no label'), ('Poland', 'no label'), ('Screened', 'no label'), ('Phenylketonuria', 'no label'), ('Life-Long Phenylalanine-Restricted Diet', 'no label'), ('Birth', 'no label'), ('Paper', 'no label'), ('Evaluate', 'no label'), ('Health Care', 'no label'), ('Patients', 'no label'), ('Classical Phenylketonuria', 'no label'), ('Poland', 'no label'), ('Reviewed', 'no label'), (""National Health Fund'S Reporting"", 'no label'), ('Data', 'no label'), ('Information', 'no label'), ('Healthcare Services', 'no label'), ('Patients', 'no label'), ('Classical Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Payer', 'no label'), ('Healthcare Service Providers', 'no label'), ('Analysis', 'no label'), ('Prepared', 'no label'), ('Framework', 'no label'), ('Health Care', 'no label'), ('Needs', 'no label'), ('Patients', 'no label'), ('Metabolic Diseases', 'no label'), ('Published', 'no label'), ('Http://Www', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Children', 'no label'), ('Healthcare System', 'no label'), ('Period Covered', 'no label'), ('Estimated National Prevalence', 'no label'), ('Pku Was 1', 'no label'), ('Live Births', 'no label'), ('Paediatric Patients', 'no label'), ('Moths', 'no label'), ('Age', 'no label'), ('Patients', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Pku Patients', 'no label'), ('Specialist', 'no label'), ('Outpatient Care', 'no label'), ('Clinics', 'no label'), ('Providing Health Care', 'no label'), ('Children', 'no label'), ('Adults', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Healthcare', 'no label'), ('Same Providers', 'no label'), ('Children', 'no label'), ('Sixty-Nine', 'no label'), ('Adults', 'no label'), ('Children', 'no label'), ('Treated', 'no label'), ('Outpatient Centres', 'no label'), ('Deaths', 'no label'), ('Median Age', 'no label'), ('Years', 'no label'), ('Working-Age Adults', 'no label'), ('Accounted', 'no label'), ('Deaths', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Pku Do Not', 'no label'), ('Receive Sufficient Healthcare', 'no label'), ('Discontinuation', 'no label'), ('Healthcare', 'no label'), ('Adults', 'no label'), ('Pku', 'no label'), ('Lack', 'no label'), ('Adequate', 'no label'), ('Transition', 'no label'), ('Process', 'no label'), ('Paediatric', 'no label')]"|[('Moths', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Classical Phenylketonuria', 'no label'), ('Classical Phenylketonuria', 'no label'), ('Metabolic Diseases', 'no label'), ('Adult', 'no label'), ('Sixty-Nine', 'no label'), ('Deaths', 'no label'), ('Deaths', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Payer', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Pku (Including 1180', 'no label'), ('Pku Was 1', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Children', 'no label'), ('Patients', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Patients', 'no label'), ('Pku Do Not', 'no label')]
phenylketonuria|pubmed~27137821|Phenylketonuria Is An Inborn Error Of Metabolism Treated With A Closely Monitored Low Phenylalanine Diet. Protein Substitutes Used For Treatment Are Supplemented With Vitamins And Micronutrients. The Aim Of This Study Was To Investigate Plasma Folic Acid Concentrations In Children With Phenylketonuria. Retrospective Analysis Of Medical Records Of 73 Patients With Phenylketonuria And 28 With Mild Hyperphenylalaninemia (On Normal Diet) Was Carried Out. Intake Of Folic Acid Was Calculated On The Basis Of Protein Substitute Intake. Folate Concentrations Were Analyzed According To Their Intake, And Concentration Of Homocysteine And Phenylalanine. In 76.7% Patients With Phenylketonuria Intake Of Folic Acid Exceeded Recommended Dietary Allowance. Serum Folic Acid Concentrations Above Upper Reference Level Were Detected In 75.3% Patients With Phenylketonuria And Only In 25% Patients With Hyperphenylalaninemia (P<0.0001). Strong Positive Correlation Between Daily Intake Of Folic Acid (With Protein Substitute) And Concentration Plasma Folic Acid (Corr=0.55, P<0.0001) Has Been Observed. Low Phenylalanine Diet Using Protein Substitutes Currently Available In Poland Predisposes To High Concentration Of Plasma Folic Acid. The Security Of Folic Acid Hipersupplementation In Patients With Phenylketonuria Requires Further Detailed Research.|[('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Treated With', 'no label'), ('Closely Monitored', 'no label'), ('Low', 'no label'), ('Phenylalanine Diet', 'no label'), ('Protein Substitutes', 'no label'), ('Treatment', 'no label'), ('Supplemented', 'no label'), ('Vitamins', 'no label'), ('Micronutrients', 'no label'), ('Study', 'no label'), ('Investigate', 'no label'), ('Plasma', 'no label'), ('Folic Acid', 'no label'), ('Concentrations', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Retrospective Analysis', 'no label'), ('Medical Records', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Mild Hyperphenylalaninemia', 'no label'), ('Normal Diet', 'no label'), ('Intake', 'no label'), ('Folic Acid', 'no label'), ('Protein Substitute', 'no label'), ('Intake', 'no label'), ('Folate', 'no label'), ('Concentrations', 'no label'), ('Analyzed', 'no label'), ('Intake', 'no label'), ('Concentration', 'no label'), ('Homocysteine', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Intake', 'no label'), ('Folic Acid', 'no label'), ('Exceeded', 'no label'), ('Recommended', 'no label'), ('Dietary Allowance', 'no label'), ('Serum Folic Acid', 'no label'), ('Concentrations', 'no label'), ('Upper Reference', 'no label'), ('Detected', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Positive', 'no label'), ('Daily Intake', 'no label'), ('Folic Acid', 'no label'), ('Protein Substitute', 'no label'), ('Concentration', 'no label'), ('Plasma', 'no label'), ('Folic Acid', 'no label'), ('Corr=0.55', 'no label'), ('Observed', 'no label'), ('Phenylalanine Diet', 'no label'), ('Protein Substitutes', 'no label'), ('Poland', 'no label'), ('Predisposes', 'no label'), ('Concentration', 'no label'), ('Plasma', 'no label'), ('Folic Acid', 'no label'), ('Security', 'no label'), ('Folic Acid', 'no label'), ('Hipersupplementation', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Requires', 'no label'), ('Research', 'no label')]|[('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Micronutrients', 'no label'), ('Folic Acid', 'no label'), ('Protein', 'no label'), ('Homocysteine', 'no label'), ('Phenylalanine', 'no label'), ('Folic Acid', 'no label'), ('Protein', 'no label'), ('Folic Acid', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Folic Acid', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Vitamins', 'no label'), ('Folic Acid', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Folic Acid', 'no label'), ('Folate', 'no label'), ('Homocysteine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Folic Acid', 'no label'), ('Folic Acid', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Folic Acid', 'no label'), ('Folic Acid', 'no label'), ('Corr=0.55', 'no label'), ('Phenylalanine', 'no label'), ('Folic Acid', 'no label'), ('Folic Acid', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Phenylalanine', 'no label'), ('Vitamins', 'no label'), ('Plasma Folic Acid', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Folic Acid', 'no label'), ('Folate', 'no label'), ('Homocysteine', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Folic Acid', 'no label'), ('Serum Folic Acid', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Folic Acid', 'no label'), ('Plasma Folic', 'no label'), ('Phenylalanine', 'no label'), ('Plasma Folic', 'no label'), ('Folic Acid', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~34116943|Pegvaliase Is An Enzyme Substitution Therapy That Reduces Blood Phenylalanine (Phe) In Adults With Phenylketonuria (Pku), And Often Allows Normalization Of Protein Intake (≥0.8 G Protein/Kg). Here We Examine The Nutrition Status Of Adults With Pku Consuming A Normal Protein Intake Without Medical Food After Being Treated With Pegvaliase For ≥1 Year. A Cross-Sectional Study Evaluating Nutritional Intake (3-Day Food Record And Food Frequency Questionnaire), Anthropometrics, Laboratory Indices Of Protein, Micronutrient, And Essential Fatty Acid (Efa) Status, And Questionnaires Evaluating Food Neophobia And Epicurean Eating Pleasure. Participants (N = 18, 61% Female) Started Pegvaliase 4.9 ± 2.1 Years Prior To Enrollment And Were Aged 38.2 ± 8.8 Years With A Mean Bmi Of 29.2 ± 4.1 Kg/M<Sup>2</Sup>. Participants Consumed A Mean Of 73.2 ± 17.6 G Protein/D (1.0 ± 0.3 G/Kg/D). Eleven Participants Had Low Blood Phe (<30 Μmol/L) With Adequate Protein Intake And Normal Indices Of Protein Status. Micronutrient And Efa Concentrations Were Normal Except For Mildly Low Vitamin D (<30 Ng/Ml, N = 12). Intakes Of Sodium, Saturated Fat, And Added Sugars Exceeded Recommendations For Healthy Adults, Though Mean Diet Quality Was Comparable To A Us Adult Reference Population. Lower Food Neophobia Scores Correlated With An Increased Aesthetic Appreciation Of Food. However, 53% Of Participants Self-Reported Having Moderate (N = 6) To High (N = 3) Food Neophobia. Participants Treated With Pegvaliase Consumed An Unrestricted Diet With Adequate Dietary Protein And, Overall, Had Normal Protein, Micronutrient, And Fatty Acid Status. Despite Low Blood Phe, Protein Nutriture Was Not Compromised. While Nutritional Deficiencies Were Not Identified, Diet Quality Was Suboptimal And Some Participants Reported Food Neophobia. Nutrition Education Remains An Important Component Of Care As Patients Adapt To A Normal Diet.|[('Pegvaliase', 'no label'), ('Enzyme Substitution Therapy', 'no label'), ('Reduces', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Adults', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Normalization', 'no label'), ('Protein Intake', 'no label'), ('G Protein/Kg', 'no label'), ('Examine', 'no label'), ('Nutrition Status', 'no label'), ('Adults', 'no label'), ('Pku Consuming A', 'no label'), ('Normal Protein Intake', 'no label'), ('Medical Food', 'no label'), ('Treated With', 'no label'), ('Pegvaliase', 'no label'), ('Year', 'no label'), ('Cross-Sectional Study', 'no label'), ('Nutritional Intake', 'no label'), ('3-Day Food Record And Food Frequency Questionnaire', 'no label'), ('Anthropometrics', 'no label'), ('Laboratory Indices', 'no label'), ('Protein', 'no label'), ('Micronutrient', 'no label'), ('Essential Fatty Acid', 'no label'), ('Questionnaires Evaluating Food Neophobia', 'no label'), ('Epicurean Eating', 'no label'), ('Pleasure', 'no label'), ('Participants', 'no label'), ('Female', 'no label'), ('Pegvaliase', 'no label'), ('Years', 'no label'), ('Enrollment', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Mean', 'no label'), ('Bmi', 'no label'), ('Kg/M', 'no label'), ('Sup>2</Sup>. Participants', 'no label'), ('Consumed', 'no label'), ('G', 'no label'), ('Protein/D', 'no label'), ('G/Kg/D', 'no label'), ('Participants', 'no label'), ('Low', 'no label'), ('Blood Phe', 'no label'), ('Adequate', 'no label'), ('Protein Intake', 'no label'), ('Normal Indices', 'no label'), ('Protein Status', 'no label'), ('Micronutrient', 'no label'), ('Efa Concentrations', 'no label'), ('Mildly', 'no label'), ('Vitamin D', 'no label'), ('Sodium', 'no label'), ('Saturated Fat', 'no label'), ('Added', 'no label'), ('Sugars', 'no label'), ('Recommendations', 'no label'), ('Healthy Adults', 'no label'), ('Mean Diet Quality', 'no label'), ('Population', 'no label'), ('Lower Food Neophobia Scores', 'no label'), ('Correlated', 'no label'), ('Increased', 'no label'), ('Aesthetic', 'no label'), ('Appreciation', 'no label'), ('Food', 'no label'), ('Participants', 'no label'), ('Self-Reported', 'no label'), ('Moderate', 'no label'), ('High', 'no label'), ('Food Neophobia', 'no label'), ('Participants', 'no label'), ('Treated', 'no label'), ('Pegvaliase', 'no label'), ('Consumed', 'no label'), ('Unrestricted Diet', 'no label'), ('Adequate', 'no label'), ('Dietary Protein', 'no label'), ('Normal Protein', 'no label'), ('Micronutrient', 'no label'), ('Fatty Acid Status', 'no label'), ('Low Blood Phe', 'no label'), ('Protein Nutriture', 'no label'), ('Nutritional Deficiencies', 'no label'), ('Diet Quality', 'no label'), ('Suboptimal', 'no label'), ('Participants', 'no label'), ('Food Neophobia', 'no label'), ('Nutrition Education', 'no label'), ('Component', 'no label'), ('Patients', 'no label'), ('Adapt', 'no label'), ('Normal Diet', 'no label')]|[('Enzyme Substitution', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Food', 'no label'), ('Food', 'no label'), ('Food', 'no label'), ('Protein', 'no label'), ('Fatty Acid', 'no label'), ('Food', 'no label'), ('±', 'no label'), ('Bmi', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Sodium', 'no label'), ('Sugars', 'no label'), ('Food', 'no label'), ('Food', 'no label'), ('Food', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Fatty Acid', 'no label'), ('Protein', 'no label'), ('Food', 'no label')]|[('Bmi', 'no label'), ('Sup>2</Sup>.', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Fatty Acid', 'no label'), ('Sup>2</Sup>.', 'no label'), ('Vitamin D', 'no label'), ('Sodium', 'no label'), ('Saturated', 'no label'), ('Fatty Acid', 'no label'), ('Nutritional Deficiencies', 'no label')]|[('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('≥0.8 G', 'no label'), ('Fatty Acid', 'no label'), ('Food', 'no label'), ('Bmi', 'no label'), ('Sup>2</Sup>.', 'no label'), ('A', 'no label'), ('Blood Phe', 'no label'), ('Intake', 'no label'), ('Vitamin D', 'no label'), ('Sodium', 'no label'), ('Fat', 'no label'), ('Sugars', 'no label'), ('Fatty Acid', 'no label'), ('Blood', 'no label'), ('Food', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31473582|This Cohort Study Aimed To Determine The Frequency Of Overweight And Obesity In Classical Phenylketonuria Children And To Identify The Possible Influence Of Metabolic Control On The Bmi Of The Studied Patients. The Study Group Included 63 Classical Phenylketonuria Patients (40 Girls And 23 Boys; Aged 5-16 Years). Their Z-Score Bmi, Metabolic Control, Educational Level Of Parents And Socioeconomic Status Were Determined. Twenty Children Were Overweight Or Obese And Only Three Were Underweight. The Percentages Of Overweight And Obese Children Were 31.7% For The Whole Group, 21.7% (5 Out Of 23) For Boys And 37.5% (15 Out Of 40) For Girls. Overweight And Obesity In These Phenylketonuria Patients Was Statistically Significantly More Frequent When Compared To National Reference Studies (P = 0.0031). The Five-Year Index Of Dietary Control And The Percentage Of Spikes Exceeding 6 And 12 Mg/Dl (Spikes 6 And 12) Indicated Better Metabolic Control In The Case Of Normal Weight Children Than Those Who Were Overweight And Obese (P < 0.049, P < 0.041 And P < 0.011, Respectively). The Odds Ratio Of Being Overweight Or Obese For Those Having Poorer Metabolic Control (Values Higher Vs Lower Than Mean) Was Statistically Significantly Higher Than For The Remaining Patients (For Spikes 12: 6.926 < 95%Ci: 2.011-23.854 > ; P < 0.002). These Results Strongly Suggest A Link Between Overweight And Diet Non-Compliance. Children With Classical Phenylketonuria Presented Higher Odds Of Being Overweight Or Obese As Compared With Reference National Studies, With Girls Only Having A Higher Frequency Of Overweight.|[('Cohort Study', 'no label'), ('Frequency', 'no label'), ('Overweight', 'no label'), ('Obesity', 'no label'), ('Classical Phenylketonuria', 'no label'), ('Children', 'no label'), ('Influence', 'no label'), ('Metabolic Control', 'no label'), ('Bmi', 'no label'), ('Patients', 'no label'), ('Study Group', 'no label'), ('Classical Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Girls', 'no label'), ('Boys', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Z-Score Bmi', 'no label'), ('Metabolic Control', 'no label'), ('Educational Level', 'no label'), ('Parents', 'no label'), ('Socioeconomic Status', 'no label'), ('Children', 'no label'), ('Overweight', 'no label'), ('Obese', 'no label'), ('Underweight', 'no label'), ('Overweight', 'no label'), ('Obese', 'no label'), ('Children', 'no label'), ('Whole Group', 'no label'), ('Boys', 'no label'), ('Girls', 'no label'), ('Overweight', 'no label'), ('Obesity', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Frequent', 'no label'), ('National Reference Studies', 'no label'), ('Five-Year Index', 'no label'), ('Dietary Control', 'no label'), ('Percentage', 'no label'), ('Spikes', 'no label'), ('Metabolic Control', 'no label'), ('Normal Weight Children', 'no label'), ('Overweight', 'no label'), ('Obese', 'no label'), ('Odds Ratio', 'no label'), ('Being Overweight', 'no label'), ('Obese', 'no label'), ('Poorer', 'no label'), ('Metabolic Control', 'no label'), ('Patients', 'no label'), ('Results', 'no label'), ('Overweight', 'no label'), ('Diet', 'no label'), ('Non-Compliance', 'no label'), ('Children', 'no label'), ('Classical Phenylketonuria', 'no label'), ('Higher', 'no label'), ('Odds', 'no label'), ('Being Overweight', 'no label'), ('Obese', 'no label'), ('Reference National Studies', 'no label'), ('Girls', 'no label'), ('Higher', 'no label'), ('Frequency', 'no label'), ('Overweight', 'no label')]|[('Bmi', 'no label'), ('Bmi', 'no label')]|[('Bmi', 'no label'), ('Z-Score Bmi', 'no label')]|[('Obesity', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Overweight', 'no label'), ('Obesity', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label')]|[('Bmi', 'no label'), ('Patients', 'no label'), ('Phenylketonuria Patients', 'no label'), ('Bmi', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Phenylketonuria Patients', 'no label'), ('Normal Weight Children', 'no label'), ('Vs Lower Than', 'no label'), ('Patients', 'no label'), ('Link', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~32054509|The Population Of Adult Patients With Early-Treated Phenylketonuria (Pku) Following Newborn Screening Is Growing Substantially. The Ideal Target Range Of Blood Phenylalanine (Phe) Levels In Adults Outside Pregnancy Is A Matter Of Debate. Therefore, Prospective Intervention Studies Are Needed To Evaluate The Effects Of An Elevated Phe Concentration On Cognition And Structural, Functional, And Neurometabolic Parameters Of The Brain. The Pico (Phenylalanine And Its Impact On Cognition) Study Evaluates The Effect Of A 4-Week Phe Load On Cognition And Cerebral Parameters In Adults With Early-Treated Pku In A Double-Blind, Randomized, Placebo-Controlled, Crossover, Noninferiority Trial. Thirty Adult Patients With Early-Treated Pku And 30 Healthy Controls Comparable To Patients With Regard To Age, Sex, And Educational Level Will Be Recruited From The University Hospitals Bern And Zurich, Switzerland. Patients Are Eligible For The Study If They Are 18 Years Of Age Or Older And Had Pku Diagnosed After A Positive Newborn Screening And Were Treated With A Phe-Restricted Diet Starting Within The First 30 Days Of Life. The Cross-Over Intervention Consists Of 4-Week Oral Phe Or Placebo Administration In Patients With Pku. The Study Design Mimics A Phe-Restricted And A Phe-Unrestricted Diet Using A Double-Blinded, Placebo-Controlled Approach. The Primary Objective Of The Pico Study Is To Prospectively Assess Whether A Temporarily Elevated Phe Level Influences Cognitive Performance (Working Memory Assessed With A N-Back Task) In Adults With Early-Treated Pku. As A Secondary Objective, The Pico Study Will Elucidate The Cerebral (Fmri, Neural Activation During A N-Back Task; Rsfmri, Functional Connectivity At Rest; Dti, White Matter Integrity; And Asl, Cerebral Blood Flow) And Neurometabolic Mechanisms (Cerebral Phe Level) That Accompany Changes In Phe Concentration. Cognition, And Structural And Functional Parameters Of The Brain Of Adult Patients With Early-Treated Pku Will Be Cross-Sectionally Compared To Healthy Controls. All Assessments Will Take Place At The University Hospital Bern, Switzerland. Central Randomization Will Be Used To Assign Participants To The Different Treatment Arms With Age, Sex, And Center Serving As The Stratification Factors. Randomization Lists Will Be Generated By An Independent Statistician. Blinding: All Trial Personnel Other Than The Statistician Generating The Randomization List And The Personnel At The Facility Preparing The Interventional Product Are Blinded To The Assigned Treatment. Using A Combination Of Neuropsychological And Neuroimaging Data, The Pico Study Will Considerably Contribute To Improve The Currently Insufficient Level Of Evidence On How Adult Patients With Early-Treated Pku Should Be Managed. The Study Is Registered At Clinicaltrials.Gov (Nct03788343) On The 27Th Of December 2018, At Kofam.Ch (Snctp000003117) On The 17Th Of December 2018, And On The International Clinical Trials Registry Platform Of The Who.|[('Population', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Early-Treated Phenylketonuria', 'no label'), ('Newborn Screening', 'no label'), ('Ideal Target Range', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Levels', 'no label'), ('Adults', 'no label'), ('Outside', 'no label'), ('Pregnancy', 'no label'), ('Prospective Intervention Studies', 'no label'), ('Evaluate', 'no label'), ('Effects', 'no label'), ('Elevated', 'no label'), ('Concentration', 'no label'), ('Cognition', 'no label'), ('Structural', 'no label'), ('Functional', 'no label'), ('Neurometabolic', 'no label'), ('Parameters', 'no label'), ('Brain', 'no label'), ('Pico', 'no label'), ('Phenylalanine', 'no label'), ('Impact', 'no label'), ('Study', 'no label'), ('Evaluates', 'no label'), ('Effect', 'no label'), ('Cognition', 'no label'), ('Cerebral Parameters', 'no label'), ('Adults', 'no label'), ('Early-Treated Pku In A Double-Blind', 'no label'), ('Randomized', 'no label'), ('Placebo-Controlled', 'no label'), ('Crossover', 'no label'), ('Noninferiority Trial', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Early-Treated Pku', 'no label'), ('Healthy Controls', 'no label'), ('Patients', 'no label'), ('Regard To Age', 'no label'), ('Sex', 'no label'), ('Educational Level Will Be', 'no label'), ('University Hospitals Bern', 'no label'), ('Switzerland', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Older', 'no label'), ('Pku Diagnosed', 'no label'), ('Positive Newborn Screening', 'no label'), ('Treated With', 'no label'), ('Phe-Restricted Diet', 'no label'), ('Life', 'no label'), ('Cross-Over Intervention Consists', 'no label'), ('Oral Phe', 'no label'), ('Placebo Administration', 'no label'), ('Patients', 'no label'), ('Study Design', 'no label'), ('Mimics A', 'no label'), ('Phe-Restricted', 'no label'), ('Phe-Unrestricted Diet', 'no label'), ('Double-Blinded', 'no label'), ('Placebo-Controlled Approach', 'no label'), ('Objective', 'no label'), ('Pico Study', 'no label'), ('Assess', 'no label'), ('Elevated', 'no label'), ('Phe', 'no label'), ('Level', 'no label'), ('Influences', 'no label'), ('Cognitive Performance', 'no label'), ('Working Memory', 'no label'), ('Assessed', 'no label'), ('N-Back Task', 'no label'), ('Adults', 'no label'), ('Early-Treated Pku', 'no label'), ('Secondary Objective', 'no label'), ('Pico Study', 'no label'), ('Will Elucidate', 'no label'), ('Cerebral', 'no label'), ('Fmri', 'no label'), ('Neural Activation', 'no label'), ('N-Back Task', 'no label'), ('Rsfmri', 'no label'), ('Functional Connectivity', 'no label'), ('Rest', 'no label'), ('Dti', 'no label'), ('White Matter Integrity', 'no label'), ('Asl', 'no label'), ('Cerebral Blood Flow', 'no label'), ('Neurometabolic Mechanisms', 'no label'), ('Cerebral Phe Level', 'no label'), ('Accompany', 'no label'), ('Changes', 'no label'), ('Phe', 'no label'), ('Concentration', 'no label'), ('Cognition', 'no label'), ('Structural', 'no label'), ('Functional', 'no label'), ('Parameters', 'no label'), ('Brain', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Early-Treated Pku Will Be', 'no label'), ('Cross-Sectionally', 'no label'), ('Healthy Controls', 'no label'), ('Assessments', 'no label'), ('University Hospital Bern', 'no label'), ('Switzerland', 'no label'), ('Central Randomization Will Be', 'no label'), ('Participants', 'no label'), ('Treatment Arms With', 'no label'), ('Age', 'no label'), ('Sex', 'no label'), ('Center', 'no label'), ('Stratification Factors', 'no label'), ('Randomization Lists', 'no label'), ('Independent Statistician', 'no label'), ('Blinding', 'no label'), ('Trial', 'no label'), ('Personnel', 'no label'), ('Statistician', 'no label'), ('Randomization List', 'no label'), ('Personnel', 'no label'), ('Facility', 'no label'), ('Interventional Product', 'no label'), ('Blinded', 'no label'), ('Assigned Treatment', 'no label'), ('Combination', 'no label'), ('Neuropsychological', 'no label'), ('Data', 'no label'), ('Pico Study', 'no label'), ('Contribute', 'no label'), ('Insufficient', 'no label'), ('Level', 'no label'), ('Evidence', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Early-Treated Pku', 'no label'), ('Managed', 'no label'), ('Study', 'no label'), ('Registered', 'no label'), ('Clinicaltrials', 'no label'), ('December\xa0', 'no label'), ('Kofam.', 'no label'), ('Snctp000003117', 'no label'), ('International Clinical Trials Registry', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Asl', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Cross-Sectionally', 'no label'), ('Ch', 'no label')]|[('Phe-Restricted And A Phe-Unrestricted Diet', 'no label'), ('Asl', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phenylalanine', 'no label'), ('A 4-Week Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Dti, White Matter Integrity; And Asl, Cerebral Blood Flow', 'no label'), ('Ch', 'no label')]|[('Patients', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Brain', 'no label'), ('Pico', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Cerebral', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Oral Phe', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Cerebral', 'no label'), ('A N-Back', 'no label'), ('Dti', 'no label'), ('Asl', 'no label'), ('Cerebral Blood Flow', 'no label'), ('Cerebral Phe', 'no label'), ('Phe', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('27Th', 'no label'), ('Ch', 'no label')]
phenylketonuria|pubmed~33055427|Phenylalanine Hydroxylase-Deficient (Pah-Deficient) Phenylketonuria (Pku) Results In Systemic Hyperphenylalaninemia, Leading To Neurotoxicity With Severe Developmental Disabilities. Dietary Phenylalanine (Phe) Restriction Prevents The Most Deleterious Effects Of Hyperphenylalaninemia, But Adherence To Diet Is Poor In Adult And Adolescent Patients, Resulting In Characteristic Neurobehavioral Phenotypes. Thus, An Urgent Need Exists For New Treatments. Additionally, Rodent Models Of Pku Do Not Adequately Reflect Neurocognitive Phenotypes, And Thus There Is A Need For Improved Animal Models. To This End, We Have Developed Pah-Null Pigs. After Selection Of Optimal Crispr/Cas9 Genome-Editing Reagents By Using An In Vitro Cell Model, Zygote Injection Of 2 Sgrnas And Cas9 Mrna Demonstrated Deletions In Preimplantation Embryos, With Embryo Transfer To A Surrogate Leading To 2 Founder Animals. One Pig Was Heterozygous For A Pah Exon 6 Deletion Allele, While The Other Was Compound Heterozygous For Deletions Of Exon 6 And Of Exons 6-7. The Affected Pig Exhibited Hyperphenylalaninemia (2000-5000 Μm) That Was Treatable By Dietary Phe Restriction, Consistent With Classical Pku, Along With Juvenile Growth Retardation, Hypopigmentation, Ventriculomegaly, And Decreased Brain Gray Matter Volume. In Conclusion, We Have Established A Large-Animal Preclinical Model Of Pku To Investigate Pathophysiology And To Assess New Therapeutic Interventions.|[('Phenylalanine Hydroxylase-Deficient', 'no label'), ('Systemic Hyperphenylalaninemia', 'no label'), ('Neurotoxicity', 'no label'), ('Severe', 'no label'), ('Developmental Disabilities', 'no label'), ('Dietary Phenylalanine', 'no label'), ('Prevents', 'no label'), ('Deleterious Effects', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Adherence', 'no label'), ('Diet', 'no label'), ('Adult', 'no label'), ('Adolescent', 'no label'), ('Patients', 'no label'), ('Characteristic', 'no label'), ('Neurobehavioral', 'no label'), ('Phenotypes', 'no label'), ('Urgent Need Exists', 'no label'), ('New Treatments', 'no label'), ('Rodent Models', 'no label'), ('Pku Do Not', 'no label'), ('Neurocognitive Phenotypes', 'no label'), ('Need', 'no label'), ('Improved', 'no label'), ('Animal Models', 'no label'), ('Pigs', 'no label'), ('Selection', 'no label'), ('Optimal', 'no label'), ('Crispr/Cas9', 'no label'), ('Genome-Editing Reagents', 'no label'), ('In Vitro', 'no label'), ('Cell Model', 'no label'), ('Zygote', 'no label'), ('Injection', 'no label'), ('Sgrnas', 'no label'), ('Cas9', 'no label'), ('Mrna', 'no label'), ('Demonstrated Deletions', 'no label'), ('Preimplantation', 'no label'), ('Embryos', 'no label'), ('Embryo Transfer', 'no label'), ('Surrogate', 'no label'), ('Founder', 'no label'), ('Animals', 'no label'), ('Pig', 'no label'), ('Heterozygous', 'no label'), ('Deletion Allele', 'no label'), ('Compound Heterozygous', 'no label'), ('Deletions', 'no label'), ('Exon 6', 'no label'), ('Exons', 'no label'), ('Affected Pig Exhibited', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Treatable', 'no label'), ('Dietary Phe Restriction', 'no label'), ('Consistent With', 'no label'), ('Classical Pku', 'no label'), ('Juvenile Growth Retardation', 'no label'), ('Hypopigmentation', 'no label'), ('Ventriculomegaly', 'no label'), ('Decreased', 'no label'), ('Brain Gray Matter', 'no label'), ('Volume', 'no label'), ('Established', 'no label'), ('Large-Animal Preclinical Model', 'no label'), ('Pku To Investigate', 'no label'), ('Pathophysiology', 'no label'), ('Therapeutic Interventions', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Rodent', 'no label'), ('Animal', 'no label'), ('Reagents', 'no label'), ('Cell', 'no label'), ('Cas9 Mrna', 'no label'), ('Deletions', 'no label'), ('Animals', 'no label'), ('Exon', 'no label'), ('Deletion Allele', 'no label'), ('Deletions', 'no label'), ('Exon', 'no label'), ('Exons', 'no label'), ('Phe', 'no label')]|[('Pah Exon 6 Deletion Allele', 'no label'), ('Exon 6', 'no label'), ('Exons 6-7', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Systemic Hyperphenylalaninemia', 'no label'), ('Neurotoxicity', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Hypopigmentation', 'no label'), ('Ventriculomegaly', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Pah-Null', 'no label'), ('Cell', 'no label'), ('Zygote', 'no label'), ('Cas9 Mrna', 'no label'), ('Embryo', 'no label'), ('A Pah Exon 6', 'no label'), ('Phe', 'no label'), ('Brain', 'no label')]
phenylketonuria|pubmed~32326614|Phenylketonuria Is An Inborn Error Of Phenylalanine (Phe) Metabolism Diagnosed By Newborn Screening And Treated Early With Diet. Although Diet Prevents Intellectual Disability, Patients Often Show Impairment Of Executive Functions, Working Memory, Sustained Attention, And Cognitive Flexibility. Large Neutral Amino Acids (Lnaas) Have Been Proposed As A Dietary Supplement For Pku Adults. Few Studies Show That Lnaas May Help In Improving Metabolic Control As Well As Cognitive Functions. In This Study, 10 Adult Pku Patients With Poor Metabolic Control Were Treated For 12 Months With Lnaas (Moviscom, 0.8-1 G/Kg/Day) And Underwent Phe And Tyrosine (Tyr) Monitoring Monthly. Neuropsychological Assessment Was Performed At T0, T+3, And T+12 Months By Using The American Psychological General Well-Being Index, The Wisconsin Card Sorting Test, The Test Of Attentional Performance, And The 9-Hole Peg Test. No Change In Plasma Phe Levels Was Observed During Lnaas Supplementation, While Tyr Levels Significantly Improved During Lnaas Supplementation (<I>P</I> = 0.03). Psychometric Tests Showed An Improvement Of Distress And Well-Being Rates, Of Executive Functions, Attention, And Vigilance, Whereas No Difference Was Noted Regarding Hand Dexterity. This Study Adds Evidence Of The Advantage Of Lnaas Supplementation In Improving Cognitive Functions And Well-Being In Patients With Pku With Poor Metabolic Control.|[('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Phenylalanine (Phe) Metabolism', 'no label'), ('Diagnosed', 'no label'), ('Newborn', 'no label'), ('Treated', 'no label'), ('Early', 'no label'), ('Diet', 'no label'), ('Diet Prevents', 'no label'), ('Intellectual Disability', 'no label'), ('Patients', 'no label'), ('Impairment', 'no label'), ('Executive Functions', 'no label'), ('Working Memory', 'no label'), ('Sustained', 'no label'), ('Attention', 'no label'), ('Cognitive Flexibility', 'no label'), ('Neutral Amino Acids', 'no label'), ('Lnaas', 'no label'), ('Dietary Supplement', 'no label'), ('Pku Adults', 'no label'), ('Studies', 'no label'), ('Lnaas', 'no label'), ('Help', 'no label'), ('Improving', 'no label'), ('Metabolic Control', 'no label'), ('Cognitive Functions', 'no label'), ('Study', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Poor Metabolic Control', 'no label'), ('Treated', 'no label'), ('Months', 'no label'), ('Lnaas', 'no label'), ('Moviscom', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Monitoring Monthly', 'no label'), ('Neuropsychological Assessment', 'no label'), ('Performed', 'no label'), ('T0', 'no label'), ('T+12', 'no label'), ('Months', 'no label'), ('American Psychological General Well-Being Index', 'no label'), ('Wisconsin Card Sorting Test', 'no label'), ('Test', 'no label'), ('Attentional Performance', 'no label'), ('No Change', 'no label'), ('Plasma', 'no label'), ('Phe Levels', 'no label'), ('Lnaas', 'no label'), ('Supplementation', 'no label'), ('Tyr', 'no label'), ('Levels', 'no label'), ('Lnaas', 'no label'), ('Supplementation', 'no label'), ('<I>P</I>', 'no label'), ('Psychometric Tests', 'no label'), ('Improvement', 'no label'), ('Distress', 'no label'), ('Well-Being Rates', 'no label'), ('Executive Functions', 'no label'), ('Attention', 'no label'), ('Vigilance', 'no label'), ('No Difference', 'no label'), ('Noted', 'no label'), ('Hand Dexterity', 'no label'), ('Study', 'no label'), ('Adds', 'no label'), ('Evidence', 'no label'), ('Advantage', 'no label'), ('Lnaas', 'no label'), ('Supplementation', 'no label'), ('Improving', 'no label'), ('Cognitive Functions', 'no label'), ('Well-Being', 'no label'), ('Patients', 'no label'), ('Pku With Poor Metabolic Control', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Amino Acids', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Amino Acids', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Amino Acids', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Plasma Phe', 'no label'), ('Tyr', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~33461585|Phenylketonuria (Pku) Is An Autosomal Recessive Inherited Disorder Characterised By A Deficiency In Phenylalanine Hydroxylase. Untreated, Pku Is Associated With A Wide Range Of Cognitive And Psychiatric Sequelae. Contemporary Management Guidelines Recommend Lifetime Dietary Control Of Phenylalanine (Phe) Levels, However Many Individuals Who Discontinue Dietary Control Subsequently Suffer Symptoms Of Anxiety, Depression And Disturbances To Cognition. We Undertook A Prospective Cohort Study Of Patients With Early-Treated Phenylketonuria Who Had Ceased Dietary Control To Test The Hypothesis That Resumption Of Dietary Control Of Pku Is Associated With Improvements In Measures Of Psychiatric Morbidity And Cognitive Functioning. We Re-Initiated Dietary Control For Early-Treated Patients With Pku And Monitored Cognitive And Psychiatric Outcomes Over A Twelve-Month Period. Assessments Included Objective Cognitive Function (Measured By Cognitive Proficiency Index (Cpi)), Anxiety And Depression Scales. General Linear Mixed Model (Glmm) Analyses Were Performed To Assess Change In Psychometric Variables From Baseline Over Twelve Months After Resumption Of Dietary Control. A Total Of Nine Patients Were Recruited. Mean Age Was 33 Years (Sd = 8.75), Five Were Female. Mean Time Off Dietary Control Was 19.1 Years (Sd = 11.3), And Mean Baseline Phenylalanine (Phe) Levels Were 1108 Μmol/L (Sd = 293). Glmm Analysis Demonstrated A Positive Relationship Between Cpi And Time On Diet (B = 0.56 [95% Ci = 0.17, 0.95]). Age, Time Off Diet, Phe Levels And Depression Scores Were Not Associated With Cognitive Function. There Was A Negative Relationship Between Time On Diet And Anxiety (B = - 0.88 95% Ci = [- 1.26, - 0.50]) And Depression Ratings (B = - 0.61, 95% Ci = [- 0.95, - 0.26]). This Study Demonstrated Improvements In Cognitive Function, Anxiety, And Depression Ratings Associated With Resumption Of Dietary Control Of Pku. Raw Phe Levels Were Not Strongly Associated With Psychiatric Or Cognitive Scores In This Cohort. These Findings Support The Importance Of Lifelong Treatment For Pku In Improving The Cognitive And Psychiatric Sequelae Of The Disease.|[('Phenylketonuria', 'no label'), ('Autosomal Recessive Inherited Disorder', 'no label'), ('Characterised', 'no label'), ('Deficiency', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Untreated', 'no label'), ('Associated With', 'no label'), ('Wide Range', 'no label'), ('Cognitive', 'no label'), ('Contemporary Management', 'no label'), ('Guidelines', 'no label'), ('Recommend Lifetime', 'no label'), ('Dietary Control', 'no label'), ('Phenylalanine (Phe) Levels', 'no label'), ('Individuals', 'no label'), ('Discontinue', 'no label'), ('Dietary Control', 'no label'), ('Suffer', 'no label'), ('Symptoms', 'no label'), ('Anxiety', 'no label'), ('Depression', 'no label'), ('Disturbances', 'no label'), ('Cognition', 'no label'), ('Undertook A', 'no label'), ('Prospective Cohort Study', 'no label'), ('Patients', 'no label'), ('Early-Treated Phenylketonuria', 'no label'), ('Ceased', 'no label'), ('Dietary Control', 'no label'), ('Hypothesis', 'no label'), ('Resumption', 'no label'), ('Dietary Control', 'no label'), ('Associated With', 'no label'), ('Improvements', 'no label'), ('Measures', 'no label'), ('Psychiatric Morbidity', 'no label'), ('Cognitive Functioning', 'no label'), ('Re-Initiated', 'no label'), ('Dietary Control', 'no label'), ('Early-Treated Patients', 'no label'), ('Pku And Monitored', 'no label'), ('Cognitive', 'no label'), ('Psychiatric Outcomes', 'no label'), ('Period', 'no label'), ('Assessments', 'no label'), ('Objective Cognitive Function', 'no label'), ('Measured', 'no label'), ('Cognitive Proficiency Index', 'no label'), ('Anxiety And Depression Scales', 'no label'), ('General Linear Mixed Model', 'no label'), ('Performed', 'no label'), ('Assess Change', 'no label'), ('Psychometric Variables', 'no label'), ('Baseline', 'no label'), ('Months', 'no label'), ('Resumption', 'no label'), ('Dietary Control', 'no label'), ('Patients', 'no label'), ('Mean Age', 'no label'), ('Female', 'no label'), ('Time Off Dietary Control', 'no label'), ('Baseline', 'no label'), ('Phenylalanine', 'no label'), ('Glmm Analysis', 'no label'), ('Positive', 'no label'), ('Relationship', 'no label'), ('Cpi And Time', 'no label'), ('Diet', 'no label'), ('Ci\u2009', 'no label'), ('Age', 'no label'), ('Time Off Diet', 'no label'), ('Phe Levels', 'no label'), ('Associated With', 'no label'), ('Cognitive Function', 'no label'), ('Was A', 'no label'), ('Negative', 'no label'), ('Relationship', 'no label'), ('Time', 'no label'), ('Diet', 'no label'), ('Ci\u2009=\u2009[', 'no label'), ('Depression', 'no label'), ('Ratings', 'no label'), ('Ci\u2009=\u2009[', 'no label'), ('Study', 'no label'), ('Improvements', 'no label'), ('Cognitive Function', 'no label'), ('Anxiety', 'no label'), ('Depression', 'no label'), ('Ratings', 'no label'), ('Associated With', 'no label'), ('Resumption', 'no label'), ('Dietary Control', 'no label'), ('Phe Levels', 'no label'), ('Not Strongly', 'no label'), ('Associated With', 'no label'), ('Psychiatric Or Cognitive Scores', 'no label'), ('Cohort', 'no label'), ('Findings', 'no label'), ('Lifelong Treatment', 'no label'), ('Improving', 'no label'), ('Cognitive', 'no label'), ('Psychiatric Sequelae', 'no label'), ('Disease', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Individuals', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Autosomal Recessive Inherited Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Cognitive And Psychiatric Sequelae', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Discontinue', 'no label'), ('Anxiety', 'no label'), ('Depression', 'no label'), ('Phenylketonuria', 'no label'), ('Psychiatric', 'no label'), ('Cognitive Proficiency Index', 'no label'), ('Anxiety', 'no label'), ('Depression', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Depression', 'no label'), ('Anxiety', 'no label'), ('Depression', 'no label'), ('Anxiety', 'no label'), ('Depression', 'no label'), ('Phe', 'no label'), ('Psychiatric', 'no label'), ('Psychiatric', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Sd', 'no label'), ('B', 'no label'), ('Phe', 'no label'), ('B', 'no label'), ('[-\xa0', 'no label'), ('B', 'no label'), ('Phe', 'no label'), ('Pku', 'no label')]
phenylketonuria|pubmed~31782540|This Study Aimed To Assess The Impact Of Phenylketonuria (Pku) And Its Treatment On Parent And Child Health-Related Quality Of Life (Hrqol) And To Identify The Parenting-Related Correlates Of Parent And Child Hrqol, As Well As Metabolic Control. Eighteen Mothers Of 2- To 12-Year-Old Children With Pku Participated And Completed A Series Of Self-Report Questionnaires Including The Pku Impact And Treatment Quality Of Life Questionnaire (Pku-Qol). Mothers Reported That The Most Significant Impact Of Pku On Hrqol Was In Relation To The Impact Of Their Child'S Anxiety During Blood Tests On Their Own Hrqol And Guilt Related To Poor Adherence To Dietary Restrictions And Supplementation Regimens. Higher Reported Intensity Of Child Emotional And Behavioural Difficulties And Parenting Stress Were Associated With Higher Scores For Pku Symptoms On The Pku-Qol, Higher Scores For Emotional, Social, And Overall Impact Of Pku, And Higher Scores For The Impact Of Dietary Restriction. Where Mothers Reported Greater Use Of Overreactivity As A Parenting Strategy, Children Tended To Have Better Lifetime Phenylalanine Levels; However, The Overall Impact Of Pku And The Impact Of Supplement Administration On Mothers' Hrqol Were Worse For These Families. These Findings Have Implications For A Holistic Family-Centred Approach To The Care Of Children With Pku And Their Families.|"[('Study', 'no label'), ('Assess', 'no label'), ('Impact', 'no label'), ('Phenylketonuria', 'no label'), ('Treatment', 'no label'), ('Parent', 'no label'), ('Health-Related Quality Of Life', 'no label'), ('Hrqol', 'no label'), ('Parenting-Related', 'no label'), ('Correlates', 'no label'), ('Parent', 'no label'), ('Hrqol', 'no label'), ('Metabolic Control', 'no label'), ('Mothers', 'no label'), ('12-Year-Old', 'no label'), ('Children', 'no label'), ('Pku Participated', 'no label'), ('Completed', 'no label'), ('Pku Impact', 'no label'), ('Treatment Quality Of Life Questionnaire', 'no label'), ('Pku-Qol', 'no label'), ('Mothers', 'no label'), ('Reported', 'no label'), ('Significant', 'no label'), ('Impact', 'no label'), ('Pku', 'no label'), ('Hrqol', 'no label'), ('Impact', 'no label'), (""Child'S Anxiety"", 'no label'), ('Blood Tests', 'no label'), ('Own Hrqol', 'no label'), ('Guilt', 'no label'), ('Poor Adherence', 'no label'), ('Dietary', 'no label'), ('Restrictions', 'no label'), ('Supplementation Regimens', 'no label'), ('Intensity', 'no label'), ('Child', 'no label'), ('Parenting Stress', 'no label'), ('Associated With', 'no label'), ('Higher Scores', 'no label'), ('Pku Symptoms', 'no label'), ('Pku-Qol', 'no label'), ('Higher Scores', 'no label'), ('Emotional', 'no label'), ('Social', 'no label'), ('Impact', 'no label'), ('Higher Scores', 'no label'), ('Impact', 'no label'), ('Dietary Restriction', 'no label'), ('Mothers', 'no label'), ('Overreactivity', 'no label'), ('Parenting Strategy', 'no label'), ('Children', 'no label'), ('Tended', 'no label'), ('Better', 'no label'), ('Lifetime', 'no label'), ('Phenylalanine Levels', 'no label'), ('Impact', 'no label'), ('Impact', 'no label'), (""Mothers'"", 'no label'), ('Hrqol', 'no label'), ('Worse', 'no label'), ('Families', 'no label'), ('Findings', 'no label'), ('Holistic Family-Centred Approach', 'no label'), ('Care', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Families', 'no label')]"|[('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Anxiety', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Life', 'no label'), ('Blood', 'no label'), ('Children', 'no label'), ('Phenylalanine', 'no label'), ('Children', 'no label')]
phenylketonuria|pubmed~34204602|The Present Study Assessed Patients' Metabolic Control Of Phenylketonuria (Pku) During The First 2020 Covid-19 Lockdown In Poland. Blood (Phenylalanine) Phe Results Of The Tests Of 535 Patients, Performed In 2019 And In The First Months Of 2020, Were Analysed. The Six-Week Lockdown Period Was Compared To The Preceding Six-Week Period As Well As To The Two Corresponding Periods Of 2019 (Three Non-Lockdown Periods). More Patients Failed To Perform Phe Tests In The Lockdown Period (32.7%) Than In Non-Lockdown Periods (15.6%, 15.1%, 17.2%; <I>P</I> < 0.001 For All). The Median Phe Levels For Those Patients Who Performed Testing In All The Four Periods Did Not Differ Between Periods. However, These Patients Tended To Perform Only One Test During The Lockdown (Ors: 1.43 To 1.60; 95% Ci: From 1.01-2.04 To 1.11-2.30, <I>P</I>-Value 0.02 To 0.005). Patients Who Did Not Take Blood During The Lockdown (46.7%) Performed Significantly Fewer Blood Tests In The Remaining Periods (Median <Iqr>: 1 <0-1> Vs. 2 <1-4>; <I>P</I> < 0.001). In Conclusion, Direct Assessment Of Patients' Compliance Based Upon Phe Levels During The Pandemic Lockdown Was Not Possible. Pre-Pandemic Non-Compliant Patients Frequently Failed To Perform The Test During The Lockdown, Whereas The Previously Compliant Ones Were More Likely To Perform Only One Test. This Strongly Suggests That Metabolic Control Might Have Worsened.|"[('Present Study', 'no label'), ('Assessed', 'no label'), ('Patients', 'no label'), ('Metabolic Control', 'no label'), ('Phenylketonuria', 'no label'), ('Covid-19', 'no label'), ('Lockdown', 'no label'), ('Poland', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Tests', 'no label'), ('Patients', 'no label'), ('Performed', 'no label'), ('Months', 'no label'), ('Analysed', 'no label'), ('Six-Week', 'no label'), ('Lockdown', 'no label'), ('Period', 'no label'), ('Six-Week', 'no label'), ('Period', 'no label'), ('Periods', 'no label'), ('Non-Lockdown Periods', 'no label'), ('Patients', 'no label'), ('Failed', 'no label'), ('Phe Tests', 'no label'), ('Lockdown Period', 'no label'), ('Non-Lockdown Periods', 'no label'), ('Median', 'no label'), ('Phe Levels', 'no label'), ('Patients', 'no label'), ('Performed Testing', 'no label'), ('Periods', 'no label'), ('Differ', 'no label'), ('Periods', 'no label'), ('Patients', 'no label'), ('Tended', 'no label'), ('Lockdown', 'no label'), ('Ors', 'no label'), ('Ci', 'no label'), ('P</I>-Value', 'no label'), ('Patients', 'no label'), ('Lockdown', 'no label'), ('Performed', 'no label'), ('Blood Tests', 'no label'), ('Periods', 'no label'), ('Median', 'no label'), ('Vs', 'no label'), ('Direct Assessment', 'no label'), (""Patients'"", 'no label'), ('Compliance', 'no label'), ('Phe Levels', 'no label'), ('Pandemic', 'no label'), ('Lockdown', 'no label'), ('Pre-Pandemic Non-Compliant', 'no label'), ('Patients', 'no label'), ('Failed', 'no label'), ('Test', 'no label'), ('Lockdown', 'no label'), ('Compliant', 'no label'), ('Ones', 'no label'), ('Test', 'no label'), ('Suggests', 'no label'), ('Metabolic Control', 'no label'), ('Worsened', 'no label')]"|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Blood', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Blood', 'no label'), ('Blood', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~33722205|Phenylketonuria (Pku) Is A Genetic Metabolic Disorder In Which Patients Have No Ability To Convert Phenylalanine To Tyrosine. Several Autoimmune Diseases Have Been Reported To Combine With Pku, Co-Existent Of Pku And Juvenile Idiopathic Arthritis (Jia) Has Not Been Presented. The Girl Was Diagnosed With Pku At The Age Of 1 Month Confirmed By Molecular Data. At The Age Of 3.5 Years, She Presented With Pain And Swelling Of Her Right Ankle, Right Knee, And Right Hip Joint. After A Serial Of Examinations, She Was Diagnosed With Jia And Treated With A Nonsteroidal Anti-Inflammatory Drug. We Report A Rare Case Of A 4-Year-Old Girl With Pku And Jia, Which Supports A Possible Interaction Between Pku And Jia. Long-Term Metabolic Disturbance May Increase The Susceptibility To Jia. Further Chronic Inflammation Could Alter The Metabolism Of Tryptophan And Tyrosine To Increase Blood Phe Concentration. In Addition, Corticosteroid And Methotrexate Therapy For Jia May Increase Blood Phe Concentration.|[('Phenylketonuria', 'no label'), ('Genetic Metabolic Disorder', 'no label'), ('Patients', 'no label'), ('No Ability', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Autoimmune Diseases', 'no label'), ('Combine', 'no label'), ('Pku And Juvenile Idiopathic Arthritis', 'no label'), ('Girl', 'no label'), ('Diagnosed', 'no label'), ('Pku', 'no label'), ('Age', 'no label'), ('Month', 'no label'), ('Confirmed', 'no label'), ('Molecular Data', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('Pain', 'no label'), ('Swelling', 'no label'), ('Right Ankle', 'no label'), ('Right Knee', 'no label'), ('Right Hip Joint', 'no label'), ('Serial', 'no label'), ('Examinations', 'no label'), ('Diagnosed', 'no label'), ('Treated With', 'no label'), ('Nonsteroidal Anti-Inflammatory Drug', 'no label'), ('Report', 'no label'), ('Rare', 'no label'), ('Case', 'no label'), ('Supports', 'no label'), ('Interaction', 'no label'), ('Pku And Jia', 'no label'), ('Long-Term', 'no label'), ('Metabolic Disturbance', 'no label'), ('Increase', 'no label'), ('Susceptibility', 'no label'), ('Chronic Inflammation', 'no label'), ('Alter', 'no label'), ('Metabolism', 'no label'), ('Tryptophan', 'no label'), ('Tyrosine', 'no label'), ('Increase', 'no label'), ('Blood Phe', 'no label'), ('Concentration', 'no label'), ('Addition', 'no label'), ('Corticosteroid', 'no label'), ('Methotrexate Therapy', 'no label'), ('Increase', 'no label'), ('Blood Phe Concentration', 'no label')]|[('Genetic', 'no label'), ('Phenylalanine', 'no label'), ('Molecular', 'no label'), ('Drug', 'no label'), ('Tryptophan', 'no label'), ('Tyrosine', 'no label'), ('Methotrexate', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Autoimmune Diseases', 'no label'), ('Juvenile Idiopathic Arthritis', 'no label'), ('Pain', 'no label'), ('Metabolic Disturbance', 'no label'), ('Inflammation', 'no label'), ('Tryptophan', 'no label'), ('Tyrosine', 'no label'), ('Methotrexate', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Pku', 'no label'), ('Tryptophan', 'no label'), ('Tyrosine', 'no label'), ('Blood Phe', 'no label'), ('Corticosteroid', 'no label'), ('Methotrexate', 'no label'), ('Blood Phe', 'no label')]
phenylketonuria|pubmed~33465300|The Impairment Of The Hepatic Enzyme Phenylalanine Hydroxylase (Pah) Causes Elevation Of Phenylalanine Levels In Blood And Other Body Fluids Resulting In The Most Common Inborn Error Of Amino Acid Metabolism (Phenylketonuria). Persistently High Levels Of Phenylalanine Lead To Irreversible Damage To The Nervous System. Therefore, Early Diagnosis Of The Affected Individuals Is Important, As It Can Prevent Clinical Manifestations Of The Disease. In This Report, The Biochemical And Genetic Findings Performed In 223 Patients Diagnosed Through The Portuguese Neonatal Screening Program (Pnsp) Are Presented. Overall, The Results Show That A High Overlap Exists Between Different Types Of Variants And Phenylalanine Levels. Molecular Analyses Reveal A Wide Mutational Spectrum In Our Population With A Total Of 56 Previously Reported Variants, Most Of Them Found In Compound Heterozygosity (74% Of The Patients). Intragenic Polymorphic Markers Were Used To Assess The Haplotypic Structure Of Mutated Chromosomes For The Most Frequent Variants Found In Homozygosity In Our Population (P.Ile65Thr, P.Arg158Gln, P.Leu249Phe, P.Arg261Gln, P.Val388Met, And C.1066-11G>A). Our Data Reveal High Heterogeneity At The Biochemical And Molecular Levels And Are Expected To Provide A Better Understanding Of The Molecular Basis Of This Disease And To Provide Clues To Elucidate Genotype-Phenotype Correlations.|[('Impairment', 'no label'), ('Hepatic Enzyme Phenylalanine Hydroxylase', 'no label'), ('Elevation', 'no label'), ('Phenylalanine Levels', 'no label'), ('Blood', 'no label'), ('Body Fluids', 'no label'), ('Resulting', 'no label'), ('Inborn Error', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Phenylketonuria', 'no label'), ('Persistently', 'no label'), ('Levels', 'no label'), ('Phenylalanine Lead', 'no label'), ('Irreversible', 'no label'), ('Damage', 'no label'), ('Nervous System', 'no label'), ('Early Diagnosis', 'no label'), ('Affected', 'no label'), ('Individuals', 'no label'), ('Prevent', 'no label'), ('Clinical Manifestations', 'no label'), ('Disease', 'no label'), ('Report', 'no label'), ('Biochemical', 'no label'), ('Genetic Findings', 'no label'), ('Performed', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Portuguese Neonatal Screening Program', 'no label'), ('Pnsp', 'no label'), ('Results', 'no label'), ('Overlap', 'no label'), ('Variants', 'no label'), ('Phenylalanine Levels', 'no label'), ('Molecular Analyses', 'no label'), ('Reveal', 'no label'), ('Wide', 'no label'), ('Mutational Spectrum', 'no label'), ('Population', 'no label'), ('Variants', 'no label'), ('Compound', 'no label'), ('Heterozygosity', 'no label'), ('Patients', 'no label'), ('Intragenic Polymorphic Markers', 'no label'), ('Assess', 'no label'), ('Haplotypic Structure', 'no label'), ('Mutated Chromosomes', 'no label'), ('Frequent', 'no label'), ('Variants', 'no label'), ('Homozygosity', 'no label'), ('Population', 'no label'), ('P.Ile65Thr', 'no label'), ('P.Arg158Gln', 'no label'), ('P.Leu249Phe', 'no label'), ('P.Arg261Gln', 'no label'), ('P.Val388Met', 'no label'), ('C.1066-11G>A', 'no label'), ('Data', 'no label'), ('Reveal', 'no label'), ('High', 'no label'), ('Heterogeneity', 'no label'), ('Biochemical', 'no label'), ('Molecular Levels', 'no label'), ('Expected', 'no label'), ('Molecular Basis', 'no label'), ('Disease', 'no label'), ('Clues', 'no label'), ('Genotype-Phenotype', 'no label'), ('Correlations', 'no label')]|[('Enzyme', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine Lead', 'no label'), ('Individuals', 'no label'), ('Genetic', 'no label'), ('Variants', 'no label'), ('Phenylalanine', 'no label'), ('Molecular', 'no label'), ('Intragenic Polymorphic', 'no label'), ('Chromosomes', 'no label'), ('Variants', 'no label'), ('Molecular', 'no label'), ('Molecular', 'no label')]|[('Hepatic Enzyme Phenylalanine Hydroxylase', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Heterozygosity', 'no label')]|[('Hepatic Enzyme Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Blood', 'no label'), ('Error', 'no label'), ('Amino Acid', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine Lead', 'no label'), ('Patients', 'no label'), ('Pnsp', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Chromosomes', 'no label'), ('C.1066-11G', 'no label')]
phenylketonuria|pubmed~33222540|Phenylketonuria (Pku) Is A Rare Autosomal Recessive Disorder Caused By A Deficiency Of Phenylalanine Hydroxylase (Pah). Its Prevalence Is Estimated To Be 1:10,000 In Europe. Pku Is The Commonest Congenital Inborn Error Of Metabolism. The Aim Of Our Study Was To Investigate The Characteristics Of Clinical Practice In Relation To Pku In Italy, In Order To Raise Awareness About The Current Management And Therapeutic Approaches Adopted. Six Italian Experts Conducted A Systematic Literature Review As Well As An Internal Survey To Investigate The Relevant Clinical Aspects. Collectively, The Expert Panel Managed A Total Of 678 Pku Patients Treated In The Early Stages Of The Condition Over A 16-Year Period Across Six Centers. The Management Of Pku Varied Markedly Between Centers, With Differences In The Composition Of The Multidisciplinary Team, Dietary Treatments, Compliance And Adherence To Management, Tetrahydrobiopterin Use, And Patient Follow-Up. Patients Were Mostly Managed By A Pediatric Reference Center From The Initial Pku Diagnosis During Newborn Screening Until Adulthood, Without Transition To A Specialized Adult Clinician. Fogginess, Concentration Reduction, Low Attention, Anxiety, Irritability, Memory Deficit, Headache, And Unstable Mood Were Common Features In Patients With Uncontrolled Blood Phenylalanine Levels (Generally Above 600 Μmol/L). A Homogeneous And Shared Approach To The Management Of Pku Patients Is Important. Our Survey Demonstrates The Current Management Of Pku In Italy, With The Aim Of Promoting The Implementation Of Therapeutic Strategies And Follow-Up, Increased Patient Compliance And Adherence, And The Achievement Of The Phenylalanine Level Targets Recommended By European Union Guidelines. Emerging Therapies Are Likely To Become A Standard Treatment For Patients Unable To Comply With Diet Therapy And Maintain Their Phenylalanine Levels Below The Threshold Values. Supplemental Data For This Article Is Available Online At Https://Doi.Org/10.1080/03007995.2020.1847717.|[('Phenylketonuria', 'no label'), ('Rare', 'no label'), ('Autosomal Recessive Disorder', 'no label'), ('Deficiency', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Prevalence', 'no label'), ('Europe', 'no label'), ('Commonest', 'no label'), ('Congenital Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Study', 'no label'), ('Investigate', 'no label'), ('Characteristics', 'no label'), ('Clinical Practice', 'no label'), ('Italy', 'no label'), ('Order', 'no label'), ('Awareness', 'no label'), ('Current', 'no label'), ('Management', 'no label'), ('Therapeutic Approaches Adopted', 'no label'), ('Italian', 'no label'), ('Systematic Literature Review', 'no label'), ('Internal Survey', 'no label'), ('Investigate', 'no label'), ('Relevant', 'no label'), ('Clinical Aspects', 'no label'), ('Expert Panel Managed A', 'no label'), ('Pku Patients', 'no label'), ('Treated', 'no label'), ('Early Stages', 'no label'), ('Condition', 'no label'), ('Centers', 'no label'), ('Management', 'no label'), ('Markedly', 'no label'), ('Centers', 'no label'), ('Differences', 'no label'), ('Composition', 'no label'), ('Multidisciplinary Team', 'no label'), ('Dietary Treatments', 'no label'), ('Compliance', 'no label'), ('Adherence', 'no label'), ('Management', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Patient Follow-Up', 'no label'), ('Patients', 'no label'), ('Pediatric Reference Center', 'no label'), ('Initial', 'no label'), ('Pku Diagnosis', 'no label'), ('Newborn Screening', 'no label'), ('Adulthood', 'no label'), ('Transition', 'no label'), ('Specialized Adult', 'no label'), ('Clinician', 'no label'), ('Fogginess', 'no label'), ('Concentration', 'no label'), ('Reduction', 'no label'), ('Low', 'no label'), ('Attention', 'no label'), ('Anxiety', 'no label'), ('Irritability', 'no label'), ('Memory Deficit', 'no label'), ('Headache', 'no label'), ('Unstable Mood', 'no label'), ('Patients', 'no label'), ('Uncontrolled', 'no label'), ('Blood Phenylalanine Levels', 'no label'), ('Homogeneous', 'no label'), ('Shared Approach', 'no label'), ('Management', 'no label'), ('Pku Patients', 'no label'), ('Survey', 'no label'), ('Demonstrates', 'no label'), ('Current', 'no label'), ('Management', 'no label'), ('Pku In Italy', 'no label'), ('Promoting', 'no label'), ('Implementation', 'no label'), ('Therapeutic Strategies', 'no label'), ('Follow-Up', 'no label'), ('Increased', 'no label'), ('Patient', 'no label'), ('Compliance', 'no label'), ('Adherence', 'no label'), ('Achievement', 'no label'), ('Phenylalanine', 'no label'), ('Level', 'no label'), ('Targets', 'no label'), ('Recommended', 'no label'), ('European Union Guidelines', 'no label'), ('Therapies', 'no label'), ('Standard Treatment', 'no label'), ('Patients', 'no label'), ('Unable', 'no label'), ('Diet Therapy', 'no label'), ('Maintain', 'no label'), ('Phenylalanine Levels', 'no label'), ('Threshold', 'no label'), ('Values', 'no label'), ('Data', 'no label'), ('Article', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Tetrahydrobiopterin', 'no label')]|[('Phenylketonuria', 'no label'), ('Recessive Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Commonest Congenital Inborn', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Anxiety', 'no label'), ('Memory Deficit', 'no label'), ('Headache', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Be 1:10,000', 'no label'), ('Error', 'no label'), ('Expert Panel Managed A', 'no label'), ('Patients', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Blood Phenylalanine', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Patient', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label')]
phenylketonuria|pubmed~31701331|Phenylketonuria (Pku) Is A Rare Autosomal Recessive Disease Characterised By High Plasma Phenylalanine Levels Inducing, If Untreated, Serious Neurological Manifestations In Children But Also, Rarely, In Adults Who Stopped Their Diet. The Objective Of The Study Was To Describe The Neurological Manifestations Observed In Adults With Pku. We Analysed Cases Reported In French Reference Centres For Inborn Errors Of Metabolism And Cases Already Reported In The Literature. We Report 8 New Cases Of Neurological Manifestations And 22 Cases In The Literature, Which Occurred In Adult Pku Patients, Associated With Chronic Or Rapid Increase Of Phenylalanine Levels, Mostly When Strict Low-Phenylalanine Diet Was Stopped Early In Life. Neurological Symptoms Consisted In Cerebellar Ataxia, Tremor, Brisk Reflexes, Visual Loss, Sensory Manifestations, And/Or Headaches. Visual Loss Was More Frequent In The New Cases (4/8) Of The Present Series Than In The Literature (4/22). These Neurological Complications Were Associated With Leucopathy On Brain Magnetic Resonance Imaging (27/29). The Start Of A Low-Phenylalanine Diet Improved Or Fully Reversed Neurological Manifestations, Even In Patients With Late Diagnosis During Adulthood. Neurological Manifestations Can Complicate Pku In Adult Patients With Elevated Phenylalanine Levels, After Long Or Short Period Of Diet Discontinuation. Neurologists Should Be Aware Of This Diagnosis, And Measure Phenylalaninemia In Case Of Neurological Symptoms Associated With Non-Specific Leucopathy On Brain Mri. Pku Patients Should Be Systematically Encouraged To Continue Their Diet And Their Medical Follow-Up To Avoid Neurological Complications.|[('Phenylketonuria', 'no label'), ('Rare', 'no label'), ('Autosomal Recessive Disease', 'no label'), ('Characterised', 'no label'), ('Plasma', 'no label'), ('Phenylalanine', 'no label'), ('Levels', 'no label'), ('Inducing', 'no label'), ('Untreated', 'no label'), ('Neurological Manifestations', 'no label'), ('Children', 'no label'), ('Rarely', 'no label'), ('Adults', 'no label'), ('Stopped Their', 'no label'), ('Diet', 'no label'), ('Study', 'no label'), ('Neurological Manifestations', 'no label'), ('Observed', 'no label'), ('Adults', 'no label'), ('Analysed', 'no label'), ('Cases', 'no label'), ('Reported', 'no label'), ('French Reference Centres', 'no label'), ('Inborn Errors', 'no label'), ('Metabolism', 'no label'), ('Cases', 'no label'), ('Literature', 'no label'), ('Cases', 'no label'), ('Neurological Manifestations', 'no label'), ('Cases', 'no label'), ('Literature', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Associated With', 'no label'), ('Chronic', 'no label'), ('Increase', 'no label'), ('Phenylalanine Levels', 'no label'), ('Low-Phenylalanine', 'no label'), ('Diet', 'no label'), ('Stopped', 'no label'), ('Early', 'no label'), ('Life', 'no label'), ('Neurological Symptoms Consisted', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Tremor', 'no label'), ('Brisk Reflexes', 'no label'), ('Visual Loss', 'no label'), ('Sensory Manifestations', 'no label'), ('And/Or', 'no label'), ('Headaches', 'no label'), ('Visual Loss', 'no label'), ('Frequent', 'no label'), ('Cases', 'no label'), ('Literature', 'no label'), ('Neurological Complications', 'no label'), ('Associated With', 'no label'), ('Leucopathy', 'no label'), ('Brain Magnetic Resonance Imaging', 'no label'), ('Low-Phenylalanine Diet', 'no label'), ('Improved', 'no label'), ('Neurological Manifestations', 'no label'), ('Patients', 'no label'), ('Late Diagnosis', 'no label'), ('Adulthood', 'no label'), ('Neurological Manifestations', 'no label'), ('Complicate', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Elevated', 'no label'), ('Phenylalanine Levels', 'no label'), ('Long Or Short', 'no label'), ('Period', 'no label'), ('Diet', 'no label'), ('Discontinuation', 'no label'), ('Neurologists', 'no label'), ('Aware', 'no label'), ('Diagnosis', 'no label'), ('Measure', 'no label'), ('Phenylalaninemia', 'no label'), ('Neurological Symptoms', 'no label'), ('Associated With', 'no label'), ('Non-Specific', 'no label'), ('Leucopathy', 'no label'), ('Brain', 'no label'), ('Mri', 'no label'), ('Patients', 'no label'), ('Diet', 'no label'), ('Medical Follow-Up', 'no label'), ('Neurological Complications', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Autosomal Recessive Disease', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Tremor', 'no label'), ('Visual Loss', 'no label'), ('Headaches', 'no label'), ('Visual Loss', 'no label'), ('Neurological Complications', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalaninemia', 'no label'), ('Neurological Complications', 'no label')]|[('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Phenylalanine', 'no label'), ('Low-Phenylalanine', 'no label'), ('Cerebellar', 'no label'), ('And/Or', 'no label'), ('Brain', 'no label'), ('Low-Phenylalanine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Brain', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~30007854|"The Aim Of This Study Was To Examine Health-Related Quality Of Life (Hrqol) Of Patients With Phenylketonuria (Pku) In Three Different Age Groups And To Investigate The Impact Of Metabolic Control And Tetrahydrobiopterin (Bh4) Treatment On Hrqol Of These Patients. Participants Were 90 Early-Treated Patients Aged 7 To 40 Years (M = 21.0, Sd = 10.1) And 109 Controls Aged 7 To 40.8 Years (M = 19.4, Sd = 8.6). Hrqol Was Assessed With The (Generic) Tno-Azl Questionnaires. Overall, Good Hrqol Was Reported For Children Below 12 Years Of Age, Although They Were Judged To Be Less Autonomic Than Their Healthy Counterparts. Adolescents Aged 12-15 Years Showed Poorer Hrqol In The Domain ""Cognitive Functioning"" Compared To Controls. For Adults ≥16 Years, Poorer Age-Controlled Hrqol Was Found For The Domains Cognition, Depressive Moods, And Anger, With A Further Trend For The Domain ""Pain"". With Respect To Metabolic Control, Only For Adult Pku-Patients Robust Associations Were Observed, Indicating Poorer Functioning, Most Notably In The Domains Cognition, Sleep, Pain, Sexuality And Anger, With Higher Historical And Concurrent Phe-Levels. With Respect To Bh4-Use, Effects On Hrqol Were Again Only Observed For Adult Pku-Patients. After Controlling For Age And Historical Phe-Levels, Small But Significant Differences In Favor Of Adult Bh4-Users Compared To Non-Users Were Observed For Hrqol-Categories Happiness, Anger, And Social Functioning. Together, These Results Show That, Particularly For Adult Pku-Patients, Hrqol-Problems Are Evident And That Many Of These Problems Are Related To (History Of) Metabolic Control. Beneficial Effects Of Bh4-Use Appear To Be Limited To Those Associated With Relief From The Practical Burdens Related To The Strict Dietary Treatment Regimen, I.E. General Mood And Sociability, Whereas Metabolic Control Is More Strongly Related To Basic Physical And Cognitive Functioning."|"[('Study', 'no label'), ('Examine', 'no label'), ('Health-Related Quality Of Life', 'no label'), ('Hrqol', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Age Groups', 'no label'), ('Investigate', 'no label'), ('Impact', 'no label'), ('Metabolic Control', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh4', 'no label'), ('Treatment', 'no label'), ('Hrqol', 'no label'), ('Patients', 'no label'), ('Participants', 'no label'), ('Early-Treated', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Sd\u202f=\u202f10.1)', 'no label'), ('Controls', 'no label'), ('Aged', 'no label'), ('Sd\u202f=\u202f8.6)', 'no label'), ('Hrqol', 'no label'), ('Assessed', 'no label'), ('Questionnaires', 'no label'), ('Good', 'no label'), ('Hrqol', 'no label'), ('Children', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Autonomic Than', 'no label'), ('Healthy Counterparts', 'no label'), ('Adolescents', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Poorer', 'no label'), ('Hrqol', 'no label'), ('Domain', 'no label'), ('Controls', 'no label'), ('Adults', 'no label'), ('Years', 'no label'), ('Poorer Age-Controlled', 'no label'), ('Hrqol', 'no label'), ('Domains Cognition', 'no label'), ('Depressive Moods', 'no label'), ('Anger', 'no label'), ('Trend', 'no label'), ('Domain ""Pain', 'no label'), ('Respect', 'no label'), ('Metabolic Control', 'no label'), ('Adult', 'no label'), ('Pku-Patients', 'no label'), ('Robust', 'no label'), ('Associations', 'no label'), ('Observed', 'no label'), ('Poorer Functioning', 'no label'), ('Domains Cognition', 'no label'), ('Sleep', 'no label'), ('Pain', 'no label'), ('Sexuality', 'no label'), ('Anger', 'no label'), ('Higher', 'no label'), ('Historical', 'no label'), ('Concurrent', 'no label'), ('Phe-Levels', 'no label'), ('Respect', 'no label'), ('Bh4-Use', 'no label'), ('Effects', 'no label'), ('Hrqol', 'no label'), ('Observed', 'no label'), ('Adult', 'no label'), ('Pku-Patients', 'no label'), ('Controlling', 'no label'), ('Age', 'no label'), ('Historical Phe-Levels', 'no label'), ('Small', 'no label'), ('Differences', 'no label'), ('Adult', 'no label'), ('Bh4-Users', 'no label'), ('Non-Users', 'no label'), ('Hrqol-Categories Happiness', 'no label'), ('Anger', 'no label'), ('Social Functioning', 'no label'), ('Results', 'no label'), ('Adult', 'no label'), ('Pku-Patients', 'no label'), ('Hrqol-Problems', 'no label'), ('Problems', 'no label'), ('History', 'no label'), ('Metabolic Control', 'no label'), ('Beneficial', 'no label'), ('Bh4-Use Appear', 'no label'), ('Associated With', 'no label'), ('Relief', 'no label'), ('Practical Burdens', 'no label'), ('Dietary Treatment', 'no label'), ('Regimen', 'no label'), ('General Mood And Sociability', 'no label'), ('Metabolic', 'no label'), ('Physical', 'no label')]"|[('Tetrahydrobiopterin', 'no label'), ('Pku-Patients', 'no label')]|[('Tetrahydrobiopterin', 'no label')]|[('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Depressive Moods', 'no label'), ('Anger', 'no label'), ('Pain', 'no label'), ('Pain', 'no label'), ('Hrqol-Categories', 'no label'), ('Anger', 'no label')]|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Sd\u202f', 'no label'), ('Sd\u202f', 'no label'), ('Children Below 12', 'no label'), ('Bh4-Use', 'no label')]
phenylketonuria|pubmed~35289300|The Physical And Functional Outcomes Of Lifelong Treatment With A Phenylalanine Restricted Diet For The Management Of Phenylketonuria (Pku) Remain Unknown. Given That The Mainstay Of Dietary Management Consists Of Modifying The Sources Of Ingested Protein, Various Aspects Of Body Protein Status Could Be Compromised. To Examine The Existing Evidence Regarding The Protein Status Of People With Pku And Identify Nutritional And Lifestyle Variables That Influence Protein Status. Studies Reporting Anthropometric, Biochemical And/Or Functional Measurements Of Body Protein Status In People With Pku Were Eligible. Medline (Ovid), Embase (Ovid), Central, Web Of Science And Scopus, And Conference Abstracts. Seventy Studies Were Included In The Review. The Majority Of Studies Assessing Protein Status Based On Anthropometric Measurements Observed No Differences Between People With Pku And Controls, Although Deficits In Muscle Mass Were Reported Within Pku Cohorts. Findings For Biochemical Assessment Of Protein Status Were Mixed And Limited Studies Assessed Protein Status Using Functional Measures. Factors Such As Participant Age, Sex, Metabolic Control, Protein Source, Type Of Protein Substitute, And Pharmacological Treatments Were Found To Modulate Protein Status Of People With Pku. Findings Were Inconclusive Regarding Body Protein Status In People With Pku. The Relationship Between Diet And Protein Status Outcomes Remains Unclear And Further Research Is Warranted To Determine The Impact Of Dietary Regimens On Physical And Functional Outcomes, And To Understand The Best Clinical Assessments To Reliably Monitor The Protein Status In People With Pku.|[('Physical And Functional', 'no label'), ('Outcomes', 'no label'), ('Lifelong Treatment With', 'no label'), ('Phenylalanine Restricted Diet', 'no label'), ('Management', 'no label'), ('Phenylketonuria', 'no label'), ('Mainstay', 'no label'), ('Dietary Management', 'no label'), ('Consists', 'no label'), ('Sources', 'no label'), ('Ingested Protein', 'no label'), ('Body Protein Status', 'no label'), ('Compromised', 'no label'), ('Evidence', 'no label'), ('Protein Status', 'no label'), ('People', 'no label'), ('Pku', 'no label'), ('Nutritional', 'no label'), ('Lifestyle', 'no label'), ('Variables', 'no label'), ('Influence', 'no label'), ('Protein Status', 'no label'), ('Studies', 'no label'), ('Reporting', 'no label'), ('Anthropometric', 'no label'), ('Biochemical', 'no label'), ('And/Or', 'no label'), ('Functional Measurements', 'no label'), ('Body Protein Status', 'no label'), ('People', 'no label'), ('Pku Were Eligible', 'no label'), ('Medline', 'no label'), ('Embase', 'no label'), ('Central', 'no label'), ('Web Of Science And Scopus', 'no label'), ('Studies', 'no label'), ('Review', 'no label'), ('Studies', 'no label'), ('Assessing', 'no label'), ('Protein Status', 'no label'), ('Anthropometric Measurements', 'no label'), ('People', 'no label'), ('Pku And Controls', 'no label'), ('Deficits', 'no label'), ('Muscle Mass', 'no label'), ('Pku Cohorts', 'no label'), ('Findings', 'no label'), ('Biochemical Assessment', 'no label'), ('Protein Status', 'no label'), ('Mixed', 'no label'), ('Limited Studies', 'no label'), ('Assessed', 'no label'), ('Protein Status', 'no label'), ('Functional Measures', 'no label'), ('Factors', 'no label'), ('Participant Age', 'no label'), ('Sex', 'no label'), ('Metabolic Control', 'no label'), ('Protein Source', 'no label'), ('Protein Substitute', 'no label'), ('Pharmacological Treatments', 'no label'), ('Modulate Protein', 'no label'), ('People', 'no label'), ('Pku', 'no label'), ('Findings', 'no label'), ('Body Protein Status', 'no label'), ('People', 'no label'), ('Pku', 'no label'), ('Relationship', 'no label'), ('Diet', 'no label'), ('Protein Status', 'no label'), ('Outcomes Remains', 'no label'), ('Research', 'no label'), ('Impact', 'no label'), ('Dietary Regimens', 'no label'), ('Physical', 'no label'), ('Functional', 'no label'), ('Clinical Assessments', 'no label'), ('Monitor', 'no label'), ('Protein Status', 'no label'), ('People', 'no label')]|[('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label')]|[]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('And/Or', 'no label'), ('Deficits In Muscle Mass', 'no label')]|[('A Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Body', 'no label'), ('People', 'no label'), ('And/Or', 'no label'), ('People', 'no label'), ('People', 'no label'), ('Pku And', 'no label'), ('Muscle', 'no label'), ('Type Of Protein', 'no label'), ('People', 'no label'), ('People', 'no label'), ('People', 'no label')]
phenylketonuria|pubmed~35248849|Dietary Treatment In Phenylketonuria (Pku) Is Known To Cause Eating Problems, But Knowledge Of Both Prevalence And Magnitude, Especially For Social Restrictions, Is Scarce. Our Aim Was To Evaluate The Social Restrictions And Eating Problems That Children With Pku And Their Caregivers Experience With Dietary Treatment. A Web-Based Questionnaire, Based On The Behavioral Pediatrics Feeding Assessment Scale With Additional Pku-Specific Questions, Was Developed In Close Collaboration With And Distributed By The Dutch Pku Association, Which Sent An E-Mail To Its Members Containing A Link To The Questionnaire. The Questionnaire Was Completed By Caregivers Of Children With Pku In The Netherlands And Caregivers Of Age-Matched Children Without Pku. Data Were Analyzed With The Kruskal-Wallis And Mann-Whitney U Test Using Spss. Compared With Caregivers Of Children In The Control Group (Ages 1-16 Y; N = 50), Caregivers Of Children With Pku (Ages 1-16 Y; N = 57) Reported More Difficulty In Offering Food Variety, Experienced More Stress When Eating An Evening Meal Outside The Home And During Vacation, And Were Stricter About (Accidental) Spilling Of Food During Dinner By The Child (P < 0.05). They Also Reported To Being Angrier, More Frustrated, And More Anxious When Feeding Their Child, And They More Often Felt That Their Child'S Eating Pattern Had A Negative Influence On The Child'S General Health (P < 0.05). This Pilot Study Provides Further Evidence That Restriction Of Social Activities And Eating Problems Associated With Dietary Restrictions Is More Common In Children With Pku, And Warrants Awareness On This Topic Among Professionals Working With These Children.|"[('Dietary Treatment', 'no label'), ('Phenylketonuria', 'no label'), ('Cause Eating', 'no label'), ('Problems', 'no label'), ('Prevalence', 'no label'), ('Magnitude', 'no label'), ('Social', 'no label'), ('Restrictions', 'no label'), ('Evaluate', 'no label'), ('Social Restrictions', 'no label'), ('Eating Problems', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Caregivers', 'no label'), ('Experience', 'no label'), ('Dietary Treatment', 'no label'), ('Web-Based Questionnaire', 'no label'), ('Behavioral Pediatrics Feeding Assessment Scale', 'no label'), ('Pku-Specific Questions', 'no label'), ('Collaboration', 'no label'), ('Dutch Pku Association', 'no label'), ('Sent', 'no label'), ('Members', 'no label'), ('Containing', 'no label'), ('Questionnaire', 'no label'), ('Questionnaire', 'no label'), ('Caregivers', 'no label'), ('Children', 'no label'), ('Netherlands', 'no label'), ('Caregivers', 'no label'), ('Age-Matched', 'no label'), ('Children', 'no label'), ('Data', 'no label'), ('Analyzed', 'no label'), ('Kruskal-Wallis And Mann-Whitney U Test', 'no label'), ('Spss', 'no label'), ('Caregivers', 'no label'), ('Children', 'no label'), ('Control Group', 'no label'), ('Caregivers', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Difficulty', 'no label'), ('Food Variety', 'no label'), ('Experienced', 'no label'), ('Stress', 'no label'), ('Eating', 'no label'), ('Evening Meal', 'no label'), ('Home', 'no label'), ('Vacation', 'no label'), ('Accidental', 'no label'), ('Child', 'no label'), ('Being Angrier', 'no label'), ('Anxious', 'no label'), ('Feeding', 'no label'), ('Child', 'no label'), ('Felt', 'no label'), (""Child'S"", 'no label'), ('Eating', 'no label'), ('Negative', 'no label'), ('Influence', 'no label'), (""Child'S"", 'no label'), ('General Health', 'no label'), ('Pilot Study', 'no label'), ('Provides', 'no label'), ('Evidence', 'no label'), ('Restriction', 'no label'), ('Social Activities', 'no label'), ('Eating Problems', 'no label'), ('Associated With', 'no label'), ('Dietary', 'no label'), ('Restrictions', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Warrants', 'no label'), ('Awareness', 'no label'), ('Professionals', 'no label'), ('Working', 'no label'), ('Children', 'no label')]"|[('Food', 'no label'), ('Meal', 'no label'), ('Food', 'no label')]|[('E-Mail', 'no label'), ('Ages 1-16 Y', 'no label'), ('Ages 1-16 Y', 'no label')]|[('Phenylketonuria', 'no label'), ('Dinner', 'no label')]|[('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Pku-Specific', 'no label'), ('Link', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('U Test', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Pku (Ages 1-16', 'no label'), ('Meal', 'no label'), ('Food', 'no label'), ('Children', 'no label'), ('Children', 'no label')]
phenylketonuria|pubmed~30266197|Phenylalanine Hydroxylase (Pah) Deficiency, Otherwise Known As Phenylketonuria (Pku), Is An Inborn Error Of Metabolism That Requires Treatment To Be Initiated In The Newborn Period And Continued Throughout Life. Due To The Challenges Of Treatment Adherence And The Resulting Cumulative Effects Of High And Labile Blood Phenylalanine, Pku Exerts A Significant Burden Of Disease. Retrospective Studies Using Large Databases Allow For Unique Perspectives On Comorbidities Associated With Rare Diseases. An Evaluation Of Comorbidities Across Various Organ Systems Is Warranted To Understand The Disease Burden In Adult Patients. The Aim Of This Insurance Claim-Based Observational Study Was To Assess The Prevalence Of Comorbid Conditions Across Various Organ Systems (E.G. Dermatological, Renal, Respiratory, Gastrointestinal, Hematological, And Others) Among Adult Pku Patients Compared With Matched Controls From The General Population. This Retrospective, Case-Controlled Study Selected Patients From United States Insurance Claims Databases From 1998 To 2014 Using International Classification Of Diseases, Ninth Revision (Icd-9) Codes For Diagnosis Of Pku. The Date Of First Diagnosis During The Study Period Was Index Date And This Was Not Necessarily The First Time The Patient Was Diagnosed With Pku. Cases Were Matched With A 1:5 Ratio With General Population (Non-Pku Controls) On Age, Sex, Race, Geographic Location, Duration Of Time In The Database And Insurance Type. Prevalence And Prevalence Ratio (Pr) Calculations For Comorbidities Across Various Organ Systems Among Adults (≥20 Years Old) With Pku Were Compared With The General Population (Non-Pku Controls). The Conditions Were Selected Based On Complications Associated With Pku And Feedback From Clinicians Treating Pku Patients. A Total Of 3691 Pku Patients And 18,455 Matched, Non-Pku Controls Were Selected, With An Average Age Of 35 Years. The Mean Healthcare Costs Incurred By The Pku Patients During Baseline, Were Approximately 4 Times That Of The Controls ($4141 Vs $1283; P < .0001). The Prevalence Rates Of Comorbidities Across Various Organ Systems During The Follow-Up Period Were Significantly Higher For Those With Pku Than In The Control Group. After Adjusting For Baseline Characteristics, The Adjusted Prevalence Ratios (Pr) Of 15 Conditions Studied (Asthma, Alopecia, Urticaria, Gallbladder Disease, Rhinitis, Esophageal Disorders, Anemia, Overweight, Gerd, Eczema, Renal Insufficiency, Osteoporosis, Gastritis/Esophagitis And Kidney Calculus) Were All Above Pr = 1.24 And Significantly Higher For The Pku Cohort (P ≤ .001). The Highest Adjusted Pr Were For Renal Insufficiency With Hypertension (Pr [95% Ci]: 2.20 [1.60-3.00]; P < .0001) And Overweight (Pr [95%Ci]: 2.06 [1.85-2.30]; P < .0001). The Prevalence Of Selected Comorbidities Across Several Organ Systems Is Significantly Higher Among Pku Patients Than For General Population Controls. Regular Screening For Common Co-Morbidities May Be Warranted As Part Of Pku Management.|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Requires', 'no label'), ('Treatment', 'no label'), ('Initiated', 'no label'), ('Newborn Period', 'no label'), ('Life', 'no label'), ('Challenges', 'no label'), ('Treatment Adherence', 'no label'), ('Cumulative', 'no label'), ('High', 'no label'), ('Labile', 'no label'), ('Phenylalanine', 'no label'), ('Pku Exerts A', 'no label'), ('Significant', 'no label'), ('Burden', 'no label'), ('Disease', 'no label'), ('Retrospective Studies', 'no label'), ('Databases', 'no label'), ('Perspectives', 'no label'), ('Comorbidities', 'no label'), ('Associated With', 'no label'), ('Rare', 'no label'), ('Diseases', 'no label'), ('Evaluation', 'no label'), ('Comorbidities', 'no label'), ('Organ Systems', 'no label'), ('Disease Burden', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Claim-Based Observational Study', 'no label'), ('Prevalence', 'no label'), ('Comorbid Conditions', 'no label'), ('Organ Systems', 'no label'), ('Renal', 'no label'), ('Respiratory', 'no label'), ('Gastrointestinal', 'no label'), ('Hematological', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Matched Controls', 'no label'), ('General Population', 'no label'), ('Retrospective', 'no label'), ('Case-Controlled Study', 'no label'), ('Patients', 'no label'), ('United States Insurance Claims Databases', 'no label'), ('International Classification Of Diseases', 'no label'), ('Diagnosis', 'no label'), ('First Diagnosis', 'no label'), ('Study Period Was Index', 'no label'), ('Date', 'no label'), ('Was Not', 'no label'), ('First Time', 'no label'), ('Patient', 'no label'), ('Diagnosed', 'no label'), ('Pku', 'no label'), ('Cases', 'no label'), ('Ratio', 'no label'), ('General Population', 'no label'), ('Non-Pku Controls', 'no label'), ('Age', 'no label'), ('Sex', 'no label'), ('Race', 'no label'), ('Geographic Location', 'no label'), ('Duration', 'no label'), ('Database', 'no label'), ('Prevalence', 'no label'), ('Prevalence', 'no label'), ('Calculations', 'no label'), ('Comorbidities', 'no label'), ('Organ Systems', 'no label'), ('Adults', 'no label'), ('Pku', 'no label'), ('General Population', 'no label'), ('Non-Pku Controls', 'no label'), ('Conditions', 'no label'), ('Complications', 'no label'), ('Associated With', 'no label'), ('Pku And Feedback', 'no label'), ('Clinicians', 'no label'), ('Treating', 'no label'), ('Patients', 'no label'), ('Pku Patients', 'no label'), ('Matched', 'no label'), ('Non-Pku Controls', 'no label'), ('Average Age', 'no label'), ('Years', 'no label'), ('Mean Healthcare Costs', 'no label'), ('Incurred', 'no label'), ('Pku Patients', 'no label'), ('Baseline', 'no label'), ('Times', 'no label'), ('Controls', 'no label'), ('Prevalence', 'no label'), ('Rates', 'no label'), ('Comorbidities', 'no label'), ('Organ Systems', 'no label'), ('Follow-Up', 'no label'), ('Period', 'no label'), ('Pku Than', 'no label'), ('Control Group', 'no label'), ('Baseline', 'no label'), ('Characteristics', 'no label'), ('Adjusted Prevalence Ratios', 'no label'), ('Conditions', 'no label'), ('Studied', 'no label'), ('Asthma', 'no label'), ('Alopecia', 'no label'), ('Urticaria', 'no label'), ('Gallbladder Disease', 'no label'), ('Rhinitis', 'no label'), ('Esophageal Disorders', 'no label'), ('Anemia', 'no label'), ('Overweight', 'no label'), ('Gerd', 'no label'), ('Eczema', 'no label'), ('Renal Insufficiency', 'no label'), ('Osteoporosis', 'no label'), ('Gastritis/Esophagitis', 'no label'), ('Pku Cohort', 'no label'), ('Renal Insufficiency', 'no label'), ('Hypertension', 'no label'), ('Ci', 'no label'), ('Overweight', 'no label'), ('Prevalence', 'no label'), ('Comorbidities', 'no label'), ('Organ Systems', 'no label'), ('Pku Patients', 'no label'), ('General Population Controls', 'no label'), ('Regular Screening', 'no label'), ('Co-Morbidities', 'no label'), ('Pku Management', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Labile Blood Phenylalanine', 'no label')]|[('Pr', 'no label'), ('Pr', 'no label'), ('2.06', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Alopecia', 'no label'), ('Urticaria', 'no label'), ('Gallbladder Disease', 'no label'), ('Rhinitis', 'no label'), ('Esophageal Disorders', 'no label'), ('Anemia', 'no label'), ('Eczema', 'no label'), ('Osteoporosis', 'no label'), ('≤', 'no label'), ('Hypertension', 'no label'), ('[95%Ci', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Labile Blood Phenylalanine', 'no label'), ('Pku Exerts A', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Ninth Revision', 'no label'), ('Patient', 'no label'), ('Insurance Type', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Gallbladder', 'no label'), ('Esophageal', 'no label'), ('Renal', 'no label'), ('Kidney Calculus', 'no label'), ('Renal', 'no label'), ('Pr [', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~33671057|We Aimed To Report The Implementation Of A Phenylketonuria (Pku) Transition Program And Study The Effects Of Follow-Up With An Adult Team On Metabolic Control, Adherence, And Loss Of Follow-Up. Fifty-Five Pku Patients Were Analysed In The Study Periods (Sp): 2 Years Before (Sp1) And After The Beginning Of Adult Care (Sp2). Retrospective Data On Metabolic Control And Number Of Clinic Appointments Were Collected For Each Sp, And Protein Intakes Were Analysed. In Sp2, Three Patients (6%) Were Lost To Follow-Up. There Was A Small But Statistically Significant Increase In Median Number Of Annual Blood Spots From Sp1 To Sp2: 11 (7-15) Vs. 14 (7-20); <I>P</I> = 0.002. Mean ± Sd Of Median Blood Phe Remained Stable (525 ± 248 Μmol/L Vs. 552 ± 225 Μmol/L; <I>P</I> = 0.100); Median % Of Blood Phe < 480 Μmol/L Decreased (51 (4-96)% Vs. 37 (5-85)%; <I>P</I> = 0.041) And Median Number Of Clinic Appointments Increased From Sp1 To Sp2: (5 (4-6) Vs. 11 (8-13); <I>P</I> < 0.001). No Significant Differences Were Found Regarding Any Parameter Of Protein Intake. Our Results Suggest That The Implementation Of An Adult Service Was Successful As Impact On Metabolic Control Was Limited And Attendance Remained High. Continuous Dietetic Care Likely Contributed To These Results By Keeping Patients In Follow-Up And Committed To Treatment.|[('Implementation', 'no label'), ('Phenylketonuria', 'no label'), ('Pku) Transition Program', 'no label'), ('Study', 'no label'), ('Effects', 'no label'), ('Follow-Up', 'no label'), ('Adult', 'no label'), ('Metabolic Control', 'no label'), ('Adherence', 'no label'), ('Loss Of Follow-Up', 'no label'), ('Fifty-Five Pku Patients', 'no label'), ('Analysed', 'no label'), ('Study Periods', 'no label'), ('Sp', 'no label'), ('Years', 'no label'), ('Sp1', 'no label'), ('Adult Care', 'no label'), ('Sp2', 'no label'), ('Retrospective Data', 'no label'), ('Metabolic Control', 'no label'), ('Clinic', 'no label'), ('Appointments', 'no label'), ('Sp', 'no label'), ('Protein Intakes', 'no label'), ('Analysed', 'no label'), ('Sp2', 'no label'), ('Patients', 'no label'), ('Lost To Follow-Up', 'no label'), ('Was A Small', 'no label'), ('Statistically Significant', 'no label'), ('Increase', 'no label'), ('Median Number', 'no label'), ('Annual', 'no label'), ('Blood Spots', 'no label'), ('Sp1', 'no label'), ('Sp2', 'no label'), ('<I>P</I> = 0.002', 'no label'), ('Median', 'no label'), ('Blood Phe Remained', 'no label'), ('Stable', 'no label'), ('Median', 'no label'), ('Blood Phe', 'no label'), ('Decreased', 'no label'), ('(5-85)%', 'no label'), ('<I>P</I> = 0.041) And Median Number', 'no label'), ('Clinic', 'no label'), ('Appointments', 'no label'), ('Increased', 'no label'), ('Sp1', 'no label'), ('Sp2', 'no label'), ('<I>P</I> < 0.001)', 'no label'), ('No Significant', 'no label'), ('Differences', 'no label'), ('Parameter', 'no label'), ('Protein Intake', 'no label'), ('Suggest', 'no label'), ('Implementation', 'no label'), ('Adult Service', 'no label'), ('Impact', 'no label'), ('Metabolic Control', 'no label'), ('Continuous Dietetic Care', 'no label'), ('Results', 'no label'), ('Patients', 'no label'), ('Follow-Up', 'no label'), ('Treatment', 'no label')]|[('Sp2', 'no label'), ('Protein', 'no label'), ('Sp1', 'no label'), ('± Sd', 'no label'), ('±', 'no label'), ('Sp1', 'no label'), ('Protein', 'no label')]|[('Sp', 'no label'), ('Sp1', 'no label'), ('± Sd', 'no label'), ('Sp1', 'no label')]|[('Phenylketonuria', 'no label')]|[('Follow-Up. Fifty-Five Pku Patients', 'no label'), ('Sp): 2', 'no label'), ('Sp1', 'no label'), ('Sp2', 'no label'), ('Patients', 'no label'), ('Blood Spots', 'no label'), ('Sp1', 'no label'), ('Sp2', 'no label'), ('Sd Of', 'no label'), ('Blood Phe', 'no label'), ('Blood Phe', 'no label'), ('Sp1', 'no label'), ('Sp2', 'no label'), ('Patients', 'no label'), ('Follow-Up', 'no label')]
phenylketonuria|pubmed~32654453|<B>Objective:</B> To Investigate The Incidence Of Phenylketonuria And Distribution Characteristics Of Phenylalanine Hydroxylase (Pah) Gene In Newborns From Hainan Province. <B>Methods:</B> Dry Blood Spot Specimens Of Heels From 380 996 Newborns In Hainan Province From January 2017 To December 2019 Were Collected. Phenylalanine (Phe) Concentrations In These Dry Blood Spots Were Measured By The Fluorescence Method To Screen Phenylketonuria (Pku). A Second Dry Blood Spot Sample Will Be Collected If Suspicious Samples Were Detected After Initial Screening. Tandem Mass Spectrometry Were Used To Detect The Concentrations Of Phe And Tyrosine. Urine Samples Of The Suspected Newborns Were Sent Out For Urotrexate Spectrum Analysis And Tetrahydrobiopterin Loading Test. Pcr And Flow-Through Rapid Hybridization Method Were Employed To Detect Pah Gene Mutations. Meanwhile, Peripheral Blood Samples Of Suspicious Newborns Of Pku And Their Parents Were Collected To Perform Gene Sequencing. <B>Results:</B> Among The 380 996 Newborns, 39 Were Suspected And 14 Were Diagnosed With Pku, Including 11 Cases Of Pah Deficiency And 3 Cases Of Tetrahydrobiopterin Deficiency. Of 14 Confirmed Cases, There Were 8 Male Cases And 6 Female Cases. In The Newborn Population Of Hainan Province, The Annual Incidence Of Pku Was 1.22/100 000. Thirteen Pah Gene Mutations Were Detected In Confirmed Cases: C.728G>A, C.158G>A, C.1238G>C, C.611A>G, C.1068C>A, C.706+5G>A, C.740G>T, C.1081A>T, C.793T>G, C.1223G>A, C.721C>T, C.331C>T And C.1174T>A. <B>Conclusions:</B> Pku Has A High Incidence In Newborn Population Of Hainan Province In The Past Three Years. The Pah Gene Has A Wide Spectrum Of Mutations. Two Rare Mutations Were Also Found: C.793T>G And C.706+5G>A.|[('Objective:</B', 'no label'), ('Investigate', 'no label'), ('Incidence', 'no label'), ('Phenylketonuria', 'no label'), ('Distribution', 'no label'), ('Characteristics', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Newborns', 'no label'), ('Hainan Province', 'no label'), ('Methods:</B', 'no label'), ('Dry Blood Spot', 'no label'), ('Heels', 'no label'), ('Newborns', 'no label'), ('Hainan Province', 'no label'), ('Collected', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Dry Blood Spots', 'no label'), ('Measured', 'no label'), ('Fluorescence Method', 'no label'), ('Phenylketonuria', 'no label'), ('Dry Blood Spot', 'no label'), ('Collected', 'no label'), ('Suspicious', 'no label'), ('Samples', 'no label'), ('Detected', 'no label'), ('Initial', 'no label'), ('Screening', 'no label'), ('Tandem Mass Spectrometry', 'no label'), ('Detect', 'no label'), ('Concentrations', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Urine Samples', 'no label'), ('Suspected', 'no label'), ('Newborns', 'no label'), ('Urotrexate Spectrum Analysis', 'no label'), ('Tetrahydrobiopterin Loading Test', 'no label'), ('Pcr', 'no label'), ('Flow-Through Rapid Hybridization Method', 'no label'), ('Employed', 'no label'), ('Detect', 'no label'), ('Pah Gene', 'no label'), ('Peripheral Blood Samples', 'no label'), ('Suspicious', 'no label'), ('Newborns', 'no label'), ('Pku And Their Parents', 'no label'), ('Collected', 'no label'), ('Gene Sequencing', 'no label'), ('Results:</B', 'no label'), ('Newborns', 'no label'), ('Suspected', 'no label'), ('Diagnosed', 'no label'), ('Pku', 'no label'), ('Cases', 'no label'), ('Pah Deficiency', 'no label'), ('Cases', 'no label'), ('Tetrahydrobiopterin Deficiency', 'no label'), ('Confirmed', 'no label'), ('Cases', 'no label'), ('Male Cases', 'no label'), ('Female', 'no label'), ('Cases', 'no label'), ('Newborn Population', 'no label'), ('Hainan Province', 'no label'), ('Annual', 'no label'), ('Incidence', 'no label'), ('Pku Was 1.22/100', 'no label'), ('Pah Gene Mutations', 'no label'), ('Detected', 'no label'), ('Confirmed', 'no label'), ('Cases', 'no label'), ('C.728G>A', 'no label'), ('C.158G>A', 'no label'), ('C.1238G>C', 'no label'), ('C.611A>G', 'no label'), ('C.1068C>A', 'no label'), ('C.706+5G>A', 'no label'), ('C.740G>T', 'no label'), ('C.1081A>T', 'no label'), ('C.793T>G', 'no label'), ('C.1223G>A', 'no label'), ('C.721C>T', 'no label'), ('C.331C>T', 'no label'), ('C.1174T>A. <B>Conclusions:</B> Pku Has A', 'no label'), ('Incidence', 'no label'), ('Newborn Population', 'no label'), ('Hainan Province', 'no label'), ('Years', 'no label'), ('Pah Gene', 'no label'), ('Has A Wide Spectrum', 'no label'), ('Mutations', 'no label'), ('Rare', 'no label'), ('Mutations', 'no label'), ('C.793T>G', 'no label'), ('C.706+5G>A.', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Gene', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Gene Mutations', 'no label'), ('Gene', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Gene Mutations', 'no label'), ('Gene', 'no label'), ('Mutations', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Pah Gene', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Pah Gene Mutations', 'no label'), ('Pah Gene', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Dry Blood Spot', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Dry Blood Spots', 'no label'), ('Phenylketonuria', 'no label'), ('Dry Blood Spot Sample Will Be', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('C.740G', 'no label')]|[('B', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('B', 'no label'), ('Blood', 'no label'), ('Newborns', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Blood Spots', 'no label'), ('Suspicious Samples', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Newborns', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Peripheral Blood Samples', 'no label'), ('Suspicious Newborns', 'no label'), ('B', 'no label'), ('Pah', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Pku Was 1.22/100', 'no label'), ('Pah Gene', 'no label'), ('C.706+5G', 'no label'), ('C.1223G>', 'no label'), ('A.', 'no label'), ('B', 'no label'), ('Pah Gene', 'no label'), ('C.706+5G', 'no label')]
phenylketonuria|pubmed~34826353|Pegvaliase Is Approved To Reduce Phenylalanine (Phe) Levels For People With Phenylketonuria (Pku). Prism-1 (Nct01819727) And Prism-2 (Nct01889862) Data Were Analyzed To Evaluate The Relationship Between Phe And Inattention In Adult Participants With Pku. In The Modified-Intent-To-Treat Population (N = 156), Baseline Mean (Se) Plasma Phe Was 1263 (29) Μmol/L And The Attention Deficit Hyperactivity Disorder Rating Scale-Iv Inattentive (Ia) Symptoms Score Was 9.8 (0.5). Mean (Se) Ia Scores Fell 9.0 (1.1) In Quartile 1 (Phe Reduction Between 1166 And 2229 Μmol/L) Versus 4.3 (0.7) In Quartile 4 (Phe Reduction Of 139 Μmol/L To Increase Of 934 Μmol/L), P = 0.004. Least Squares Mean (Se) Change From Baseline Ia Score Was -7.9 (0.7) For Participants With Final Phe ≤ 360 Μmol/L And -4.5 (0.7) For Final Phe > 360 Μmol/L, P < 0.001. In The Inattention Subgroup, Ia Scores Fell 13.3 (1.5) In Quartile 1 (Phe Reduction Between 1288 And 2229 Μmol/L) Versus 6.2 (1.3) In Quartile 4 (Phe Reduction Of 247 To Increase Of 934 Μmol/L), P = 0.009. Inattention Symptoms Improved Among Those Whose Phe Levels Decreased, Particularly Those With High Baseline Ia Scores. Ia Improvements Were Larger Among Participants With The Greatest Plasma Phe Reductions, Supporting This Value As A Therapeutic Goal.|[('Pegvaliase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Levels', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Prism-1', 'no label'), ('Data', 'no label'), ('Analyzed', 'no label'), ('Evaluate', 'no label'), ('Relationship', 'no label'), ('Phe', 'no label'), ('Inattention', 'no label'), ('Adult', 'no label'), ('Participants', 'no label'), ('Population', 'no label'), ('Baseline Mean (Se) Plasma', 'no label'), ('Phe', 'no label'), ('Attention Deficit Hyperactivity Disorder Rating Scale-Iv Inattentive (Ia) Symptoms Score', 'no label'), ('Phe', 'no label'), ('Reduction', 'no label'), ('Quartile 4', 'no label'), ('Phe', 'no label'), ('Reduction', 'no label'), ('Increase', 'no label'), ('P\xa0', 'no label'), ('Least Squares Mean (Se) Change', 'no label'), ('Baseline', 'no label'), ('Ia Score', 'no label'), ('Participants', 'no label'), ('Final', 'no label'), ('Final', 'no label'), ('Inattention Subgroup', 'no label'), ('Ia Scores', 'no label'), ('Phe', 'no label'), ('Reduction', 'no label'), ('Quartile 4', 'no label'), ('Phe', 'no label'), ('Reduction', 'no label'), ('Increase', 'no label'), ('P\xa0', 'no label'), ('Inattention Symptoms', 'no label'), ('Improved', 'no label'), ('Phe Levels', 'no label'), ('Decreased', 'no label'), ('Baseline', 'no label'), ('Improvements', 'no label'), ('Larger', 'no label'), ('Participants', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Reductions', 'no label'), ('Value', 'no label'), ('Therapeutic Goal', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Se', 'no label'), ('Phe', 'no label'), ('Se', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Se', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Prism-1', 'no label'), ('Ia', 'no label'), ('Ia', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('N\xa0=\xa0156)', 'no label'), ('Phe', 'no label'), ('Attention Deficit Hyperactivity Disorder Rating Scale-Iv Inattentive', 'no label'), ('Phe', 'no label'), ('≤', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Pegvaliase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Phe', 'no label'), ('Se', 'no label'), ('Plasma Phe', 'no label'), ('Deficit Hyperactivity', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Se', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Ia', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Plasma', 'no label')]
phenylketonuria|pubmed~29941359|"Phenylketonuria (Pku) Is A Genetic Inborn Error In Metabolism That Impacts Many People Globally, With Profound Individual And Societal Consequences When Left Untreated. The Journey Of Phenylalanine Ammonia Lyase (Pal) From Plant Enzyme To Enzyme Substitution Therapy For Pku Is A Fascinating Story That Illustrates The Importance Of Collaboration Between Basic Scientists And Industry In The Drug Development Process. The Story Begins With The Curiosity Of Plant Physiologists About The Origin Of Lignin, A Polymer Involved In Maintaining The Rigidity Of Plants. They Learned That The Critical Element In This Synthesis Was An Intermediary Enzyme That Deaminates Phenylalanine To Cinnamic Acid And Ammonia (Later Called Phenylalanine Ammonia Lyase Or Pal). Recognition Of This Ability To Metabolize Phenylalanine Led To Subsequent Consideration Of Pal As A Treatment For Pku. This Was Initially Attempted As Enteral Therapy With Extracted Enzyme, But That Showed Only Minimal Efficacy. Crucially, Further Development Of Pal As A Therapy For Pku Required Quantities Of Enzyme That Could Only Be Obtained After Successfully Cloning The Gene, Expressing The Enzyme In Vitro And Modifying The Protein Via Pegylation To Enable Parenteral Administration Of This Non-Mammalian Enzyme. Ultimately, Pegylated Pal Was Developed As An Enzyme Substitution Therapy For Pku Now Approved Under The Name ""Palynziq."" The Multidisciplinary Academic-Industrial Partnership Engaged Throughout This Process Has Been Key To The Successful Pursuit Of This Therapeutic Possibility And Serves As A Model For The Development Of Future Innovative Therapies."|"[('Phenylketonuria', 'no label'), ('Genetic Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Impacts', 'no label'), ('People', 'no label'), ('Individual', 'no label'), ('Societal', 'no label'), ('Consequences', 'no label'), ('Left Untreated', 'no label'), ('Journey', 'no label'), ('Phenylalanine Ammonia Lyase', 'no label'), ('Plant Enzyme', 'no label'), ('Enzyme Substitution Therapy', 'no label'), ('Fascinating', 'no label'), ('Story', 'no label'), ('Collaboration', 'no label'), ('Basic Scientists', 'no label'), ('Industry', 'no label'), ('Drug Development Process', 'no label'), ('Story Begins', 'no label'), ('Curiosity', 'no label'), ('Plant Physiologists', 'no label'), ('Origin', 'no label'), ('Lignin', 'no label'), ('Polymer', 'no label'), ('Rigidity', 'no label'), ('Plants', 'no label'), ('Learned', 'no label'), ('Critical Element', 'no label'), ('Synthesis', 'no label'), ('Intermediary Enzyme', 'no label'), ('Deaminates', 'no label'), ('Phenylalanine', 'no label'), ('Cinnamic Acid', 'no label'), ('Ammonia', 'no label'), ('Phenylalanine Ammonia Lyase', 'no label'), ('Recognition', 'no label'), ('Metabolize', 'no label'), ('Phenylalanine', 'no label'), ('Treatment', 'no label'), ('Attempted', 'no label'), ('Enteral Therapy', 'no label'), ('Extracted Enzyme', 'no label'), ('Efficacy', 'no label'), ('Development', 'no label'), ('Therapy', 'no label'), ('Pku Required Quantities', 'no label'), ('Enzyme', 'no label'), ('Successfully Cloning', 'no label'), ('Gene', 'no label'), ('Expressing', 'no label'), ('Enzyme', 'no label'), ('In Vitro', 'no label'), ('Protein', 'no label'), ('Pegylation', 'no label'), ('Enable', 'no label'), ('Parenteral Administration', 'no label'), ('Non-Mammalian', 'no label'), ('Enzyme', 'no label'), ('Pegylated Pal', 'no label'), ('Enzyme Substitution Therapy', 'no label'), ('Pku Now Approved Under The Name ""Palynziq', 'no label'), ('Multidisciplinary', 'no label'), ('Process', 'no label'), ('Therapeutic Possibility', 'no label'), ('Model', 'no label'), ('Development', 'no label'), ('Innovative Therapies', 'no label')]"|[('Genetic', 'no label'), ('Phenylalanine Ammonia', 'no label'), ('Plant Enzyme', 'no label'), ('Drug', 'no label'), ('Lignin', 'no label'), ('Plants', 'no label'), ('Enzyme', 'no label'), ('Phenylalanine', 'no label'), ('Ammonia', 'no label'), ('Phenylalanine Ammonia', 'no label'), ('Phenylalanine', 'no label'), ('Enzyme', 'no label'), ('Gene', 'no label'), ('Protein', 'no label'), ('Enzyme Substitution', 'no label')]|[('Non-Mammalian Enzyme', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Ammonia', 'no label'), ('Lignin', 'no label'), ('Rigidity', 'no label'), ('Phenylalanine', 'no label'), ('Cinnamic Acid', 'no label'), ('Ammonia', 'no label'), ('Metabolize Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('People', 'no label'), ('Phenylalanine Ammonia Lyase', 'no label'), ('Pku Is A', 'no label'), ('Lignin', 'no label'), ('Phenylalanine', 'no label'), ('Cinnamic Acid', 'no label'), ('Ammonia', 'no label'), ('Phenylalanine Ammonia Lyase', 'no label'), ('Phenylalanine', 'no label'), ('Enteral', 'no label'), ('Non-Mammalian', 'no label')]
phenylketonuria|pubmed~32141105|White Matter Pathologies, As Well As Intellectual Disability, Microcephaly, And Other Central Nervous System Injuries, Are Clinical Traits Commonly Ascribed To Classic Phenylketonuria (Pku). Pku Is An Inherited Metabolic Disease Elicited By The Deficiency Of Phenylalanine Hydroxylase. Accumulation Of L-Phenylalanine (Phe) And Its Metabolites Is Found In Tissues And Body Fluids In Phenylketonuric Patients. In Order To Mitigate The Clinical Findings, Rigorous Dietary Phe Restriction Constitutes The Core Of Therapeutic Management In Pku. Myelination Is The Process Whereby The Oligodendrocytes Wrap Myelin Sheaths Around The Axons, Supporting The Conduction Of Action Potentials. White Matter Injuries Are Implicated In The Brain Damage Related To Pku, Especially In Untreated Or Poorly Treated Patients. The Present Review Summarizes Evidence Toward Putative Mechanisms Driving The White Matter Pathology In Pku Patients.|[('White Matter Pathologies', 'no label'), ('Intellectual Disability', 'no label'), ('Microcephaly', 'no label'), ('Central Nervous System Injuries', 'no label'), ('Clinical Traits', 'no label'), ('Ascribed', 'no label'), ('Classic Phenylketonuria', 'no label'), ('Inherited Metabolic Disease', 'no label'), ('Deficiency', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Accumulation', 'no label'), ('L-Phenylalanine (Phe)', 'no label'), ('Metabolites', 'no label'), ('Tissues', 'no label'), ('Body Fluids', 'no label'), ('Phenylketonuric', 'no label'), ('Patients', 'no label'), ('Order', 'no label'), ('Mitigate', 'no label'), ('Clinical Findings', 'no label'), ('Dietary Phe Restriction', 'no label'), ('Constitutes', 'no label'), ('Core', 'no label'), ('Therapeutic Management', 'no label'), ('Myelination', 'no label'), ('Process Whereby', 'no label'), ('Oligodendrocytes', 'no label'), ('Wrap Myelin Sheaths', 'no label'), ('Axons', 'no label'), ('Conduction', 'no label'), ('Action Potentials', 'no label'), ('White Matter Injuries', 'no label'), ('Brain Damage', 'no label'), ('Untreated', 'no label'), ('Treated', 'no label'), ('Patients', 'no label'), ('Review', 'no label'), ('Summarizes', 'no label'), ('Mechanisms', 'no label'), ('Driving', 'no label'), ('White Matter Pathology', 'no label'), ('Pku Patients', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('L-Phenylalanine', 'no label'), ('Phe', 'no label'), ('Metabolites', 'no label'), ('Phe', 'no label'), ('Oligodendrocytes', 'no label'), ('Myelin', 'no label')]|[]|[('Microcephaly', 'no label'), ('Central Nervous System Injuries', 'no label'), ('Phenylketonuria', 'no label'), ('Inherited Metabolic Disease', 'no label'), ('Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('Phe', 'no label'), ('Brain Damage', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('L-Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tissues', 'no label'), ('Body Fluids', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Oligodendrocytes Wrap', 'no label'), ('Myelin', 'no label'), ('Axons', 'no label'), ('Brain', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~30135593|In This Study, Children With Phenylketonuria And Healthy Control Subjects Were Assessed For Glutathione Peroxidase (Gsh-Px), Superoxide Dismutase (Sod), Catalase (Cat) Activity, Malondialdehyde (Mda), Glutathione (Gsh), Retinol, Cholecalciferol, Α-Tocopherol, Phylloquinone, Total Sialic Acid (Tsa), Lipid Bound Sialic Acid (Lsa), Total Antioxidant (Tas), Total Oxidation (Tos), And Amino Acid Levels, And The Relationships Of These Variables With Phenylketonuria Were Evaluated. The Study Included 60 Children With Phenylketonuria And 30 Control Subjects. Children With Phenylketonuria Were Divided Into Hyperphenylalaninemia (Hpa) And Amino Acid Mixture (Aam) Groups. The Hpa Group Had Significantly Lower Levels Of Gsh-Px, Cat, Gsh, Tas, Α-Aminobutyric Acid, And Taurine Levels (P < 0.01, P < 0.05, P < 0.05, P < 0.001, P < 0.01, P < 0.05, Respectively) Than The Control Group. Additionally, The Aam Group Had Significantly Lower Levels Of Cat, Tas, And Phylloquinones (P < 0.05, P < 0.05, P < 0.05, Respectively) Than The Control Group. It Was Observed In Our Study That In The Hpa Group, A Significantly Strong Positive Linear Correlation Was Observed Between Phenylalanine And Α-Aminoadipic Acid (R = 0.777; P = 0.002). It Was Concluded That The Levels Of Α-Aminoadipic Acid And Phylloquinone Might Be An Appropriate Choice For The Determination Of Phenylketonuria In Parallel With The Levels Of Phenylalanine. Α-Aminobutyric Acid And Phylloquinone As A Supplement Can Decrease Hpa Damage.|[('Study', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Healthy Control Subjects', 'no label'), ('Assessed', 'no label'), ('Glutathione Peroxidase', 'no label'), ('Gsh-Px', 'no label'), ('Superoxide Dismutase', 'no label'), ('Sod', 'no label'), ('Catalase', 'no label'), ('Malondialdehyde', 'no label'), ('Mda', 'no label'), ('Glutathione', 'no label'), ('Gsh', 'no label'), ('Retinol', 'no label'), ('Cholecalciferol', 'no label'), ('Α-Tocopherol', 'no label'), ('Phylloquinone', 'no label'), ('Total Sialic Acid', 'no label'), ('Tsa', 'no label'), ('Lipid Bound', 'no label'), ('Sialic Acid', 'no label'), ('Lsa', 'no label'), ('Total Antioxidant', 'no label'), ('Tas', 'no label'), ('Total Oxidation', 'no label'), ('Amino Acid', 'no label'), ('Levels', 'no label'), ('Relationships', 'no label'), ('Variables', 'no label'), ('Phenylketonuria', 'no label'), ('Evaluated', 'no label'), ('Study', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Control Subjects', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Hpa', 'no label'), ('Amino Acid Mixture', 'no label'), ('Groups', 'no label'), ('Hpa Group', 'no label'), ('Levels', 'no label'), ('Gsh-Px', 'no label'), ('Cat', 'no label'), ('Gsh', 'no label'), ('Tas', 'no label'), ('Α-Aminobutyric Acid', 'no label'), ('Taurine', 'no label'), ('Levels', 'no label'), ('Control Group', 'no label'), ('Aam Group', 'no label'), ('Levels', 'no label'), ('Cat', 'no label'), ('Tas', 'no label'), ('Phylloquinones', 'no label'), ('Control Group', 'no label'), ('Observed', 'no label'), ('Study', 'no label'), ('Hpa Group', 'no label'), ('Positive Linear Correlation', 'no label'), ('Observed', 'no label'), ('Phenylalanine', 'no label'), ('Α-Aminoadipic Acid', 'no label'), ('Levels', 'no label'), ('Α-Aminoadipic Acid', 'no label'), ('Phylloquinone', 'no label'), ('Determination', 'no label'), ('Phenylketonuria', 'no label'), ('Levels', 'no label'), ('Phenylalanine', 'no label'), ('Α-Aminobutyric Acid', 'no label'), ('Phylloquinone', 'no label'), ('Supplement', 'no label'), ('Decrease', 'no label'), ('Hpa Damage', 'no label')]|[('Glutathione Peroxidase', 'no label'), ('Superoxide Dismutase', 'no label'), ('Sod', 'no label'), ('Catalase', 'no label'), ('Malondialdehyde', 'no label'), ('Glutathione', 'no label'), ('Gsh', 'no label'), ('Retinol', 'no label'), ('Cholecalciferol', 'no label'), ('Phylloquinone', 'no label'), ('Sialic Acid', 'no label'), ('Lipid', 'no label'), ('Sialic Acid', 'no label'), ('Tas', 'no label'), ('Amino Acid', 'no label'), ('Amino Acid', 'no label'), ('Tas', 'no label'), ('Taurine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Glutathione Peroxidase', 'no label'), ('Superoxide Dismutase', 'no label'), ('Sod', 'no label'), ('Catalase', 'no label'), ('Aam', 'no label'), ('Cat, Tas, And Phylloquinones (P\u2009<\u20090.05, P\u2009<\u20090.05, P\u2009<\u20090.05, Respectively) Than The', 'no label')]|[('Phenylketonuria', 'no label'), ('Superoxide', 'no label'), ('Sod', 'no label'), ('Malondialdehyde', 'no label'), ('Glutathione', 'no label'), ('Retinol', 'no label'), ('Cholecalciferol', 'no label'), ('Phylloquinone', 'no label'), ('Amino Acid', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Amino Acid Mixture', 'no label'), ('Taurine', 'no label'), ('Phenylalanine', 'no label'), ('Phylloquinone', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phylloquinone', 'no label')]|[('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Glutathione Peroxidase', 'no label'), ('Superoxide Dismutase', 'no label'), ('Sod', 'no label'), ('Catalase', 'no label'), ('Malondialdehyde', 'no label'), ('Glutathione', 'no label'), ('Gsh', 'no label'), ('Retinol', 'no label'), ('Cholecalciferol', 'no label'), ('Phylloquinone', 'no label'), ('Lipid', 'no label'), ('Sialic Acid', 'no label'), ('Amino Acid', 'no label'), ('Variables', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Hpa', 'no label'), ('Cat', 'no label'), ('Gsh', 'no label'), ('Taurine', 'no label'), ('Aam', 'no label'), ('Cat', 'no label'), ('Hpa', 'no label'), ('Phenylalanine', 'no label'), ('Α-Aminoadipic Acid', 'no label'), ('Phylloquinone', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine.', 'no label'), ('Phylloquinone', 'no label'), ('Hpa', 'no label')]
phenylketonuria|pubmed~31675115|Phenylketonuria (Pku) Is A Metabolic Condition Which, Left Untreated, Results In Severe And Irreversible Brain Damage. Newborn Screening And The Development Of The Low Phenylalanine (Phe) Diet Have Transformed The Outcomes For People With Pku. Those Who Have Benefited From Early Treatment Are Now Approaching Their Fifth And Sixth Decade. It Is Therefore Timely To Consider Multi-Morbidity In Pku And The Effects Of Ageing, In Parallel With The Wider Benefits Of Emerging Treatment Options In Addition To Dietary Relaxation. We Have Conducted The First Literature Review Of Co-Morbidity And Ageing In The Context Of Pku. Avenues Explored Have Emerged From Limited Study Of Multi-Morbidity To Date And The Knowledge And Critical Enquiry Of The Authors. Findings Suggest Pku To Have A Wider Impact Than Brain Development, And Result In Several Intriguing Questions That Require Investigation To Attain The Best Outcomes For People With Pku In Adulthood Moving Through To Older Age. We Recognise The Difficulty In Studying Longitudinal Outcomes In Rare Diseases And Emphasise The Necessity To Develop Pku Registries And Cohorts That Facilitate Well-Designed Studies To Answer Some Of The Questions Raised In This Review. Whilst Awaiting New Information In These Areas We Propose That Clinicians Engage With Patients To Make Personalised And Well-Informed Decisions Around Phe Control And Assessment For Co-Morbidity.|[('Phenylketonuria', 'no label'), ('Metabolic Condition', 'no label'), ('Left Untreated', 'no label'), ('Results', 'no label'), ('Severe', 'no label'), ('Irreversible', 'no label'), ('Brain Damage', 'no label'), ('Newborn Screening', 'no label'), ('Development', 'no label'), ('Low Phenylalanine (Phe) Diet', 'no label'), ('Transformed', 'no label'), ('Outcomes', 'no label'), ('People', 'no label'), ('Pku', 'no label'), ('Early Treatment', 'no label'), ('Multi-Morbidity', 'no label'), ('Effects Of', 'no label'), ('Ageing', 'no label'), ('Benefits', 'no label'), ('Treatment Options', 'no label'), ('Dietary Relaxation', 'no label'), ('First Literature Review', 'no label'), ('Co-Morbidity', 'no label'), ('Ageing', 'no label'), ('Context', 'no label'), ('Emerged', 'no label'), ('Limited Study', 'no label'), ('Multi-Morbidity', 'no label'), ('Date', 'no label'), ('Knowledge', 'no label'), ('Critical', 'no label'), ('Enquiry', 'no label'), ('Authors', 'no label'), ('Findings', 'no label'), ('Suggest', 'no label'), ('Impact', 'no label'), ('Brain Development', 'no label'), ('Questions', 'no label'), ('Require', 'no label'), ('Investigation', 'no label'), ('Attain', 'no label'), ('Best Outcomes', 'no label'), ('People', 'no label'), ('Pku In Adulthood Moving', 'no label'), ('Older Age', 'no label'), ('Difficulty', 'no label'), ('Longitudinal Outcomes', 'no label'), ('Rare', 'no label'), ('Diseases', 'no label'), ('Necessity', 'no label'), ('Pku Registries', 'no label'), ('Cohorts', 'no label'), ('Well-Designed Studies', 'no label'), ('Questions', 'no label'), ('Raised', 'no label'), ('Review', 'no label'), ('Awaiting', 'no label'), ('New Information', 'no label'), ('Clinicians', 'no label'), ('Engage', 'no label'), ('Patients', 'no label'), ('Personalised', 'no label'), ('Well-Informed', 'no label'), ('Decisions', 'no label'), ('Phe Control', 'no label'), ('Assessment', 'no label'), ('Co-Morbidity', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Brain Damage', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Co-Morbidity', 'no label'), ('Phe', 'no label'), ('Co-Morbidity', 'no label')]|[('Phenylketonuria', 'no label'), ('Brain', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('People', 'no label'), ('Brain', 'no label'), ('People', 'no label'), ('Patients', 'no label'), ('Phe', 'no label')]
phenylketonuria|pubmed~33375644|Phenylketonuria (Pku) Is A Common Inborn Error Of Amino Acid Metabolism In Which The Enzyme Phenylalanine Hydroxylase, Which Converts Phenylalanine To Tyrosine, Is Functionally Impaired Due To Pathogenic Variants In The <I>Pah</I> Gene. Thirty-Four Brazilian Patients With A Biochemical Diagnosis Of Pku, From 33 Unrelated Families, Were Analyzed Through Next-Generation Sequencing In The Ion Torrent Pgm™ Platform. Phenotype-Genotype Correlations Were Made Based On The Biopku Database. Three Patients Required Additional Sanger Sequencing Analyses. Twenty-Six Different Pathogenic Variants Were Identified. The Most Frequent Variants Were C.1315+1G>A (<I>N</I> = 8/66), C.473G>A (<I>N</I> = 6/66), And C.1162G>A (<I>N</I> = 6/66). One Novel Variant, C.524C>G (P.Pro175Arg), Was Found In One Allele And Was Predicted As Likely Pathogenic By The American College Of Medical Genetics And Genomics (Acmg) Criteria. The Molecular Modeling Of P.Pro175Arg Indicated That This Substitution Can Affect Monomers Binding In The Pah Tetramer, Which Could Lead To A Change In The Stability And Activity Of This Enzyme. Next-Generation Sequencing Was A Fast And Effective Method For Diagnosing Pku And Is Useful For Patient Phenotype Prediction And Genetic Counseling.|[('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Enzyme Phenylalanine Hydroxylase', 'no label'), ('Converts', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Functionally Impaired', 'no label'), ('Pathogenic', 'no label'), ('Variants', 'no label'), ('<I>Pah</I> Gene', 'no label'), ('Brazilian', 'no label'), ('Patients', 'no label'), ('Biochemical Diagnosis', 'no label'), ('Unrelated', 'no label'), ('Families', 'no label'), ('Analyzed', 'no label'), ('Next-Generation Sequencing', 'no label'), ('Ion Torrent Pgm™ Platform', 'no label'), ('Phenotype-Genotype', 'no label'), ('Correlations', 'no label'), ('Biopku Database', 'no label'), ('Patients', 'no label'), ('Sanger Sequencing Analyses', 'no label'), ('Pathogenic Variants', 'no label'), ('Identified', 'no label'), ('Frequent', 'no label'), ('Variants', 'no label'), ('C.1315+1G>A', 'no label'), ('<I>N</I>', 'no label'), ('C.473G>A', 'no label'), ('<I>N</I>', 'no label'), ('C.1162G>A', 'no label'), ('<I>N</I>', 'no label'), ('Variant', 'no label'), ('C.524C>G', 'no label'), ('P.Pro175Arg', 'no label'), ('Allele', 'no label'), ('Pathogenic', 'no label'), ('American College Of Medical Genetics And Genomics (Acmg) Criteria', 'no label'), ('Molecular Modeling', 'no label'), ('P.Pro175Arg', 'no label'), ('Indicated', 'no label'), ('Substitution', 'no label'), ('Monomers', 'no label'), ('Binding', 'no label'), ('Pah Tetramer', 'no label'), ('Lead', 'no label'), ('Change', 'no label'), ('Stability', 'no label'), ('Activity', 'no label'), ('Enzyme', 'no label'), ('Next-Generation Sequencing', 'no label'), ('Was A Fast And Effective Method', 'no label'), ('Diagnosing', 'no label'), ('Patient', 'no label'), ('Phenotype', 'no label'), ('Prediction', 'no label'), ('Genetic Counseling', 'no label')]|[('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Gene', 'no label'), ('Ion', 'no label'), ('Variants', 'no label'), ('Allele', 'no label'), ('Pathogenic', 'no label'), ('Molecular', 'no label'), ('Lead To', 'no label'), ('Genetic', 'no label')]|[('Pah Tetramer', 'no label')]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('C.473G', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Patients', 'no label'), ('Ion', 'no label'), ('Patients', 'no label'), ('C.1315+1G', 'no label'), ('C.473G>A', 'no label')]
phenylketonuria|pubmed~31469949|Phenylketonuria (Pku) Is A Metabolic Disease. It Is Manifested By A Complete Or Partial Inability To Convert Phenylalanine (Phe) To Tyrosine And Leads To Increased Concentrations Of Phe In The Blood And In Other Tissues, Including The Brain, Causing Irreversible Neurological Damage If Left Untreated. Low-Phenylalanine Diet Is A Key Component Of Classical Pku Therapy. The Objective Of This Study Was To Assess The Effectiveness Of Classical Phenylketonuria Therapy And Compliance With Doctors' Recommendations In The First 5 Years Of Life. Data Was Collected From All Diagnosed And Treated Patients (N = 57) Born 1999-2010. Phenylalanine Blood Levels, The Number Of Visits To A Specialist Outpatients' Center, The Number Of Blood Tests, As Well As Socioeconomic Status (Ses) And Parents' Education Level Have Been Analyzed, And Potential Relationships Have Been Assessed. In The 1St Year Of Life Patients Visited Their Doctors (Odds Ratio (Or) = 6.8267; 95% Confidence Interval (95% Ci) = 2.827-16.5163; P < 0.0001) And Had Their Blood Collected (Or = 2.7875; 95% Ci = 1.0467-7.4234; P < 0.0402) Significantly More Frequently Than In The 2Nd Year. This Tendency Persisted Into Subsequent Years. Similarly, In Infancy They Had Statistically Significantly Lower Odds Of Exceeding More Than 40% Of Their Phe Levels Over Therapeutic Range Than 1 Year Later (Or = 3.6078; 95% Ci = 1.4859-8.7599; P < 0.0046). No Pku Child Had More Than 70% Of Phe Levels Over The Therapeutic Range In The 1St Year Of Life, Whereas 4 Years Later There Were 18 Such Children. Phe Levels Were Correlated With The Number Of Visits To A Specialist (Ρ = 0.39) And The Number Of Phe Blood Tests With Index Of Dietary Control (Ρ = -0.33). The Effectiveness Of Therapy And Compliance With The Doctor'S Recommendations Seem To Depend Neither On The Level Of Education Of The Patient'S Parents Nor On Their Ses. Therapy Effectiveness And Patients' Compliance In Pku Is Very Good In Infancy. However, Both Deteriorate In Subsequent Years. Moreover, They Do Not Seem To Depend On The Family Background.|"[('Phenylketonuria', 'no label'), ('Metabolic Disease', 'no label'), ('Manifested', 'no label'), ('Complete', 'no label'), ('Partial', 'no label'), ('Convert Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Leads', 'no label'), ('Increased', 'no label'), ('Concentrations', 'no label'), ('Phe', 'no label'), ('Blood', 'no label'), ('Tissues', 'no label'), ('Brain', 'no label'), ('Irreversible', 'no label'), ('Neurological Damage', 'no label'), ('Left Untreated', 'no label'), ('Low-Phenylalanine', 'no label'), ('Diet', 'no label'), ('Key Component', 'no label'), ('Classical Pku Therapy', 'no label'), ('Study', 'no label'), ('Assess', 'no label'), ('Effectiveness', 'no label'), ('Classical Phenylketonuria Therapy', 'no label'), ('Compliance', 'no label'), ('Doctors', 'no label'), ('Recommendations', 'no label'), ('Years', 'no label'), ('Data', 'no label'), ('Collected', 'no label'), ('Diagnosed', 'no label'), ('Treated', 'no label'), ('Patients', 'no label'), ('Phenylalanine Blood Levels', 'no label'), ('Specialist', 'no label'), (""Outpatients' Center"", 'no label'), ('Blood Tests', 'no label'), ('Socioeconomic Status', 'no label'), (""Parents'"", 'no label'), ('Education', 'no label'), ('Analyzed', 'no label'), ('Potential', 'no label'), ('Relationships', 'no label'), ('Assessed', 'no label'), ('1St Year Of Life Patients', 'no label'), ('Doctors', 'no label'), ('Odds Ratio', 'no label'), ('Confidence Interval', 'no label'), ('Ci', 'no label'), ('Blood Collected', 'no label'), ('Ci', 'no label'), ('Year', 'no label'), ('Tendency Persisted', 'no label'), ('Years', 'no label'), ('Infancy', 'no label'), ('Odds', 'no label'), ('Phe Levels', 'no label'), ('Therapeutic Range', 'no label'), ('Than 1 Year', 'no label'), ('Ci', 'no label'), ('No Pku Child', 'no label'), ('Phe Levels', 'no label'), ('Therapeutic Range', 'no label'), ('1St Year Of Life', 'no label'), ('Years', 'no label'), ('Children', 'no label'), ('Phe Levels', 'no label'), ('Correlated', 'no label'), ('Phe Blood Tests', 'no label'), ('Dietary Control', 'no label'), ('Effectiveness', 'no label'), ('Therapy', 'no label'), ('Compliance', 'no label'), (""Doctor'S"", 'no label'), ('Recommendations', 'no label'), ('Seem', 'no label'), ('Level', 'no label'), ('Education', 'no label'), (""Patient'S"", 'no label'), ('Parents', 'no label'), ('Therapy', 'no label'), ('Effectiveness', 'no label'), ('Patients', 'no label'), ('Compliance', 'no label'), ('Infancy', 'no label'), ('Deteriorate', 'no label'), ('Years', 'no label'), ('Family Background', 'no label')]"|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Phe', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Metabolic Disease', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Phe', 'no label'), ('Neurological Damage', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Phe', 'no label'), ('Blood', 'no label'), ('Tissues', 'no label'), ('Brain', 'no label'), ('Low-Phenylalanine', 'no label'), ('Patients', 'no label'), ('Blood', 'no label'), ('Blood', 'no label'), ('Patients', 'no label'), ('Blood', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Children', 'no label'), ('Blood', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Seem', 'no label')]
phenylketonuria|pubmed~30333522|Despite A Strict Dietary Control, Patient With Hyperphenylalaninemia Or Phenylketonuria May Show Cognitive And/Or Behavioral Disorders. These Comorbid Deficits Are Of Great Concern To Patients, Families, And Health Organizations. However, Biomarkers Capable Of Detecting Initial Stages Of Neurological Damage Are Not Commonly Employed. The Pathogenesis Of Phenylketonuria Is Complex In Nature. Increasingly, The Role Of Oxidative Stress Has Gained Acceptance And Biomarkers Reflecting Oxidative Damage To The Brain And Easily Accessible In Peripheral Biofluids Have Been Validated Using Mass Spectrometry Techniques. In The Present Review, The Role Of Oxidative Stress In The Pathogenesis Of Phenylketonuria And Hyperphenylalaninemia Has Been Updated. Moreover, We Report On Newly Validated Brain-Specific Lipid Peroxidation Biomarkers And Inform On Their Relevance In The Detection And Monitoring Of Neurological Damage In Phenylketonuric Patients. In Preliminary Studies, A Correlation Between Lipid Peroxidation Biomarkers And Neurological Dysfunction In Patients With Pku Was Reported. However, There Is A Need Of Adequately Powered Trials To Confirm The Validity Of These Biomarkers For Early Detection Of Brain Damage, Initiation Of Treatment, And Reliably Monitor Evolving Disease Both In Phenylketonuria And Hyperphenylalaninemia.|[('Strict', 'no label'), ('Dietary Control', 'no label'), ('Patient', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phenylketonuria', 'no label'), ('Cognitive And/Or', 'no label'), ('Behavioral Disorders', 'no label'), ('Comorbid Deficits', 'no label'), ('Great Concern', 'no label'), ('Patients', 'no label'), ('Families', 'no label'), ('Health Organizations', 'no label'), ('Biomarkers', 'no label'), ('Capable', 'no label'), ('Detecting', 'no label'), ('Initial', 'no label'), ('Stages', 'no label'), ('Neurological Damage', 'no label'), ('Employed', 'no label'), ('Pathogenesis', 'no label'), ('Phenylketonuria', 'no label'), ('Complex', 'no label'), ('Nature', 'no label'), ('Oxidative Stress', 'no label'), ('Gained', 'no label'), ('Acceptance', 'no label'), ('Biomarkers', 'no label'), ('Oxidative Damage', 'no label'), ('Brain', 'no label'), ('Accessible', 'no label'), ('Peripheral Biofluids', 'no label'), ('Validated', 'no label'), ('Mass Spectrometry Techniques', 'no label'), ('Review', 'no label'), ('Oxidative Stress', 'no label'), ('Pathogenesis', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Report', 'no label'), ('Lipid Peroxidation', 'no label'), ('Biomarkers', 'no label'), ('Relevance', 'no label'), ('Detection', 'no label'), ('Monitoring', 'no label'), ('Neurological Damage', 'no label'), ('Phenylketonuric', 'no label'), ('Patients', 'no label'), ('Preliminary Studies', 'no label'), ('Correlation', 'no label'), ('Lipid Peroxidation', 'no label'), ('Biomarkers', 'no label'), ('Neurological Dysfunction', 'no label'), ('Patients', 'no label'), ('Pku Was', 'no label'), ('Adequately Powered Trials', 'no label'), ('Confirm', 'no label'), ('Validity', 'no label'), ('Biomarkers', 'no label'), ('Early Detection', 'no label'), ('Brain Damage', 'no label'), ('Initiation', 'no label'), ('Treatment', 'no label'), ('Monitor Evolving Disease', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label')]|[('Phenylketonuria Is Complex', 'no label'), ('Lipid', 'no label'), ('Lipid', 'no label')]|[]|[('Hyperphenylalaninemia', 'no label'), ('Phenylketonuria', 'no label'), ('Cognitive And/Or Behavioral Disorders', 'no label'), ('Comorbid Deficits', 'no label'), ('Neurological Damage', 'no label'), ('Pathogenesis', 'no label'), ('Phenylketonuria', 'no label'), ('Pathogenesis', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Neurological Damage', 'no label'), ('Neurological Dysfunction', 'no label'), ('Brain Damage', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label')]|[('Patient', 'no label'), ('Hyperphenylalaninemia Or', 'no label'), ('Phenylketonuria', 'no label'), ('And/Or', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Brain', 'no label'), ('Peripheral Biofluids', 'no label'), ('Phenylketonuria', 'no label'), ('Lipid', 'no label'), ('Patients', 'no label'), ('Lipid', 'no label'), ('Patients', 'no label'), ('Brain', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~32698408|Phenylketonuria (Pku) Is The Most Common Inborn Error Of Amino Acid Metabolism. Although Dietary And, In Some Cases, Pharmacological Treatment Has Been Successful In Preventing Intellectual Disability In Pku Patients Who Are Treated Early, Suboptimal Outcomes Have Been Reported, Including Bone Mineral Disease. In This Systematic Review, We Summarize The Available Evidence On Bone Health In Pku Patients, Including Data On Bone Mineral Density (Bmd) And Bone Turnover Marker Data. Data From Cohort And Cross-Sectional Studies Of Children And Adults (Up To 40 Years Of Age) Were Obtained By Searching The Medline And Scopus Databases Following Preferred Reporting Items For Systematic Reviews And Meta-Analyses (Prisma) Guidelines. For Each Selected Study, Quality Assessment Was Performed Applying The Risk Of Bias In Non-Randomized Studies Of Interventions (Robins I) Tool. We Found That Mean Bmd Was Lower In Pku Patients Than In Reference Groups, But Was Within The Normal Range In Most Patients When Expressed As Z-Score Values. Furthermore, Data Revealed A Trend Towards An Imbalance Between Bone Formation And Bone Resorption, Favoring Bone Removal. Data On Serum Levels Of Minerals And Hormones Involved In Bone Metabolism Were Very Heterogeneous, And The Analyses Were Inconclusive. Clinical Trials That Include The Analysis Of Fracture Rates, Especially In Older Patients, Are Needed To Gather More Evidence On The Clinical Implications Of Lower Bmd In Pku Patients.|[('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Dietary', 'no label'), ('Cases', 'no label'), ('Pharmacological Treatment', 'no label'), ('Preventing', 'no label'), ('Intellectual Disability', 'no label'), ('Patients', 'no label'), ('Treated', 'no label'), ('Early', 'no label'), ('Suboptimal', 'no label'), ('Outcomes', 'no label'), ('Bone Mineral Disease', 'no label'), ('Systematic Review', 'no label'), ('Available Evidence', 'no label'), ('Bone Health', 'no label'), ('Patients', 'no label'), ('Data', 'no label'), ('Bone Mineral Density', 'no label'), ('Bmd', 'no label'), ('Bone', 'no label'), ('Turnover Marker', 'no label'), ('Data', 'no label'), ('Data', 'no label'), ('Cohort', 'no label'), ('Cross-Sectional Studies', 'no label'), ('Children', 'no label'), ('Adults', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Medline', 'no label'), ('Preferred Reporting Items', 'no label'), ('Systematic Reviews', 'no label'), ('Prisma', 'no label'), ('Guidelines', 'no label'), ('Study', 'no label'), ('Quality Assessment', 'no label'), ('Performed', 'no label'), ('Risk', 'no label'), ('Bias', 'no label'), ('Non-Randomized Studies', 'no label'), ('Interventions', 'no label'), ('Robins I) Tool', 'no label'), ('Mean', 'no label'), ('Bmd', 'no label'), ('Pku Patients', 'no label'), ('Groups', 'no label'), ('Normal Range', 'no label'), ('Patients', 'no label'), ('Expressed', 'no label'), ('Z-Score Values', 'no label'), ('Data Revealed', 'no label'), ('Trend', 'no label'), ('Imbalance', 'no label'), ('Bone Formation', 'no label'), ('Bone Resorption', 'no label'), ('Bone', 'no label'), ('Removal', 'no label'), ('Data', 'no label'), ('Serum', 'no label'), ('Levels', 'no label'), ('Minerals', 'no label'), ('Hormones', 'no label'), ('Involved', 'no label'), ('Bone Metabolism', 'no label'), ('Heterogeneous', 'no label'), ('Analyses', 'no label'), ('Clinical Trials', 'no label'), ('Analysis', 'no label'), ('Fracture Rates', 'no label'), ('Older Patients', 'no label'), ('Evidence', 'no label'), ('Clinical', 'no label'), ('Lower Bmd', 'no label'), ('Patients', 'no label')]|[('Amino Acid', 'no label'), ('Mineral', 'no label'), ('Mineral', 'no label'), ('Minerals', 'no label'), ('Hormones', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Fracture', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Amino Acid', 'no label'), ('Patients', 'no label'), ('Bone Mineral Disease', 'no label'), ('Bone', 'no label'), ('Pku Patients', 'no label'), ('Bone Mineral Density', 'no label'), ('Bone', 'no label'), ('Children', 'no label'), ('Bmd', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Bone', 'no label'), ('Bone', 'no label'), ('Bone', 'no label'), ('Serum', 'no label'), ('Minerals And', 'no label'), ('Bone', 'no label'), ('Patients', 'no label'), ('Lower Bmd', 'no label')]
phenylketonuria|pubmed~34331785|The Aim Of This Study Was To Assess The Long-Term Safety And Efficacy Of Sapropterin In A Real-World Setting In Japanese Patients With Tetrahydrobiopterin (Bh4)-Responsive Phenylketonuria. This Post-Marketing Surveillance Study Enrolled All Of The Patients In Japan With Confirmed Bh4-Responsive Pku Who Were Administrated Sapropterin Between July 2008 And October 2017. Patients Were Observed At Least Every 3 Months During Follow Up, With Key Data Collected On Treatment Exposure/Duration, Effectiveness According To Physician'S Judgement, Serum Phenylalanine Levels, And Adverse Events. Of 87 Enrolled Patients, 85 Patients (Male, 42.4%; Outpatients, 96.5%) Were Included In The Safety And Efficacy Analysis Sets. Treatment Started At Age <4 Years In 43 (50.6%) Patients And The Most Common Starting Daily Dose Was 5-10 Mg/Kg (N = 41, 48.2%) With The Overall Duration Of Treatment Between 0.2 And 17.2 Years. Serum Phenylalanine Levels, According To Loading Tests, Reduced From A Baseline Level Of 9.66 Mg/Dl (Range 0.48-36.80 Mg/Dl) By >30% In 84 Patients. Treatment Was Deemed Effective In 79 Of 85 Patients (92.9%, 95% Confidence Interval: 85.3-97.4). One Patient (1.2%) Experienced An Adverse Drug Reaction (Alanine Aminotransferase Increased) 50 Days After The Start Of Administration, Which Resolved Without Complications With Continued Treatment. Sapropterin Appears Well Tolerated And Highly Effective In Japanese Patients Treated In A Real-World Setting, Including Those Who Start Treatment At Age <4 Years And Pregnant Women.|"[('Study', 'no label'), ('Assess', 'no label'), ('Long-Term Safety', 'no label'), ('Efficacy', 'no label'), ('Sapropterin', 'no label'), ('Real-World Setting', 'no label'), ('Japanese', 'no label'), ('Patients', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylketonuria', 'no label'), ('Post-Marketing Surveillance Study', 'no label'), ('Patients', 'no label'), ('Japan', 'no label'), ('Confirmed Bh4-Responsive Pku Who Were Administrated', 'no label'), ('Sapropterin', 'no label'), ('Patients', 'no label'), ('Observed', 'no label'), ('Months', 'no label'), ('Follow Up', 'no label'), ('Treatment', 'no label'), ('Exposure/Duration', 'no label'), ('Effectiveness', 'no label'), (""Physician'S"", 'no label'), ('Judgement', 'no label'), ('Serum Phenylalanine Levels', 'no label'), ('Adverse Events', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Male', 'no label'), ('Outpatients', 'no label'), ('Safety', 'no label'), ('Efficacy', 'no label'), ('Sets', 'no label'), ('Treatment', 'no label'), ('Age', 'no label'), ('Patients', 'no label'), ('Duration', 'no label'), ('Treatment', 'no label'), ('Years', 'no label'), ('Serum', 'no label'), ('Phenylalanine Levels', 'no label'), ('Reduced', 'no label'), ('Baseline', 'no label'), ('Level', 'no label'), ('Range', 'no label'), ('Patients', 'no label'), ('Treatment', 'no label'), ('Deemed', 'no label'), ('Effective', 'no label'), ('Patients', 'no label'), ('Confidence Interval', 'no label'), ('Patient', 'no label'), ('Experienced', 'no label'), ('Adverse Drug Reaction', 'no label'), ('Alanine Aminotransferase', 'no label'), ('Increased', 'no label'), ('Administration', 'no label'), ('Resolved', 'no label'), ('Complications', 'no label'), ('Treatment', 'no label'), ('Sapropterin', 'no label'), ('Appears', 'no label'), ('Tolerated', 'no label'), ('Effective', 'no label'), ('Japanese', 'no label'), ('Patients', 'no label'), ('Treated', 'no label'), ('Real-World Setting', 'no label'), ('Start Treatment', 'no label'), ('Age', 'no label'), ('Pregnant Women', 'no label')]"|[('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Drug', 'no label'), ('Alanine Aminotransferase', 'no label')]|[]|[('Sapropterin', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Adverse Drug Reaction', 'no label'), ('Alanine', 'no label'), ('Sapropterin', 'no label')]|[('Sapropterin', 'no label'), ('Patients', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Patients', 'no label'), ('Sapropterin', 'no label'), ('Patients', 'no label'), ('Serum Phenylalanine', 'no label'), ('87', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('5-10', 'no label'), ('Mg/Kg', 'no label'), ('Serum Phenylalanine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patient', 'no label'), ('Alanine Aminotransferase', 'no label'), ('Patients', 'no label'), ('Women', 'no label')]
phenylketonuria|pubmed~27869385|Phenylketonuria Is A Metabolic Disorder Characterized By Severe Neurological Involvement And Behavioral Disorder, Whose Early Diagnosis Enables An Effective Treatment To Avoid Disease Sequelae, Thus Changing The Prognosis. Objective: To Characterize A Family With Phenylketonuria In Colombia At Clinical, Biochemical And Molecular Levels. Materials And Methods: The Population Consisted Of Seven Individuals Of A Consanguineous Family With Four Children With Suggestive Symptoms Of Phenylketonuria. After Signing An Informed Consent, Blood And Urine Samples Were Taken For Colorimetric Tests And High Performance Liquid And Thin Layer Chromatographies. Dna Extraction And Sequencing Of The 13 Exons Of The Pah Gene Were Performed In All Subjects. We Designed Primers For Each Exon With The Primer 3 Software Using Automatic Sequencing Equipment Abiprism 3100 Avant. Sequences Were Analyzed Using The Seqscape, V2.0, Software. Results: We Described The Clinical And Molecular Characteristics Of A Colombian Family With Phenylketonuria And Confirmed The Presence Of The Mutation C.398_401Delatca. We Established A Genotype-Phenotype Correlation, Highlighting The Interesting Clinical Variability Found Among The Affected Patients Despite Having The Same Mutation In All Of Them. Conclusions: Early Recognition Of This Disease Is Very Important To Prevent Its Neurological And Psychological Sequelae, Given That Patients Reach Old Age Without Diagnosis Or Proper Management.|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Characterized', 'no label'), ('Severe', 'no label'), ('Neurological Involvement', 'no label'), ('Behavioral Disorder', 'no label'), ('Early Diagnosis', 'no label'), ('Enables', 'no label'), ('Effective', 'no label'), ('Treatment', 'no label'), ('Avoid Disease Sequelae', 'no label'), ('Prognosis', 'no label'), ('Characterize', 'no label'), ('Family', 'no label'), ('Phenylketonuria', 'no label'), ('Colombia', 'no label'), ('Clinical', 'no label'), ('Biochemical', 'no label'), ('Molecular Levels', 'no label'), ('Population Consisted', 'no label'), ('Individuals', 'no label'), ('Consanguineous', 'no label'), ('Children', 'no label'), ('Suggestive Symptoms', 'no label'), ('Phenylketonuria', 'no label'), ('Signing', 'no label'), ('Informed Consent', 'no label'), ('Blood', 'no label'), ('Urine Samples', 'no label'), ('Colorimetric Tests', 'no label'), ('High Performance Liquid', 'no label'), ('Dna Extraction', 'no label'), ('Sequencing', 'no label'), ('Exons', 'no label'), ('Pah Gene', 'no label'), ('Performed', 'no label'), ('Subjects', 'no label'), ('Designed Primers', 'no label'), ('Exon With', 'no label'), ('Primer 3 Software', 'no label'), ('Automatic Sequencing Equipment Abiprism 3100 Avant.', 'no label'), ('Sequences', 'no label'), ('Analyzed', 'no label'), ('Seqscape', 'no label'), ('Clinical', 'no label'), ('Molecular', 'no label'), ('Characteristics', 'no label'), ('Colombian', 'no label'), ('Phenylketonuria', 'no label'), ('Confirmed', 'no label'), ('Presence', 'no label'), ('Mutation C.398_401Delatca', 'no label'), ('Correlation', 'no label'), ('Clinical Variability', 'no label'), ('Affected', 'no label'), ('Patients', 'no label'), ('Mutation', 'no label'), ('Early Recognition', 'no label'), ('Disease', 'no label'), ('Prevent', 'no label'), ('Neurological', 'no label'), ('Psychological Sequelae', 'no label'), ('Patients', 'no label'), ('Reach', 'no label'), ('Old Age', 'no label'), ('Diagnosis', 'no label'), ('Management', 'no label')]|[('Phenylketonuria', 'no label'), ('Molecular', 'no label'), ('Individuals', 'no label'), ('Dna', 'no label'), ('Exons', 'no label'), ('Gene', 'no label'), ('Primers', 'no label'), ('Exon', 'no label'), ('Primer', 'no label'), ('Sequences', 'no label'), ('Molecular', 'no label'), ('Mutation', 'no label'), ('Mutation', 'no label')]|[('13 Exons', 'no label'), ('Pah Gene', 'no label')]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Behavioral Disorder', 'no label'), ('Prognosis', 'no label'), ('Phenylketonuria', 'no label'), ('Consanguineous', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Individuals', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Blood', 'no label'), ('Urine Samples', 'no label'), ('Liquid', 'no label'), ('Layer Chromatographies', 'no label'), ('Pah Gene', 'no label'), ('Primer 3', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~34864852|There Remains A Limited Understanding Of The Metabolic Perturbations, Beyond Phenylalanine (Phe) Metabolism, That Contribute To Phenotypic Variability In Phenylketonuria (Pku). This Study Aimed To Characterize Changes In The Pku Plasma Metabolome Following A 5-D Metabolic Camp Intervention And To Compare Pku Profiles With Those Of Matched Healthy Controls. In 28 Females (Aged 12-57 Y), Fasting Plasma Samples Were Collected On The First (Day 1) And Final (Day 5) Days Of Camp To Measure Metabolic Control And To Complete Untargeted Metabolomic Profiling. Three-Day Dietary Records Were Collected To Assess Changes In Dietary Adherence And Composition. Univariate (Wilcoxon Signed-Rank And Mann-Whitney U Test) And Multivariate (Random Forest, Hierarchical Clustering) Analyses Were Performed To Identify Clinical And Metabolic Features That Were Associated With The Intervention And Disease State. Relative To Healthy Controls, Phe Catabolites, Ketones, And Carnitine- And Glycine-Conjugated Fatty Acids Were Elevated In Females With Pku At Baseline, Whereas Fatty Acylcholine Metabolites Were Substantially Lower. After The Camp Intervention, Plasma Phe Concentrations Decreased [Median Change: -173 Μmol/L (Iqr: -325, -28 Μmol/L)] And 70% Of Pku Participants Demonstrated Improved Dietary Adherence By Decreasing Phe Intake And/Or Increasing Medical Food Consumption. This Was Accompanied By A Shift In Abundance For 223 Metabolites (Q < 0.05). Compounds Associated With The Metabolism Of Phe, Fatty Acids, And Choline Contributed Most To Profile Differences Between Camp Days 1 And 5. In Females With Pku, Untargeted Metabolomics Identified Prominent Perturbations In Amino Acid And Lipid Metabolites Associated With Bioenergetic Impairment And Oxidative Stress. Choline-Conjugated Lipids Could Have Fundamental Roles In These Pathways And They Have Not Been Previously Evaluated In Pku. A Short-Term Camp Intervention Was Effective For Improving Or Fully Normalizing The Abundance Of The Identified Discriminatory Metabolites.|[('Remains', 'no label'), ('Metabolic Perturbations', 'no label'), ('Phenylalanine', 'no label'), ('Contribute', 'no label'), ('Phenotypic', 'no label'), ('Variability', 'no label'), ('Phenylketonuria', 'no label'), ('Study', 'no label'), ('Characterize', 'no label'), ('Changes', 'no label'), ('Pku Plasma Metabolome', 'no label'), ('5-D', 'no label'), ('Metabolic Camp', 'no label'), ('Intervention', 'no label'), ('Compare', 'no label'), ('Pku Profiles', 'no label'), ('Healthy Controls', 'no label'), ('Females', 'no label'), ('Fasting', 'no label'), ('Plasma', 'no label'), ('Collected', 'no label'), ('Final', 'no label'), ('Days', 'no label'), ('Camp', 'no label'), ('Metabolic Control', 'no label'), ('Untargeted', 'no label'), ('Metabolomic Profiling', 'no label'), ('Three-Day', 'no label'), ('Dietary Records', 'no label'), ('Assess', 'no label'), ('Changes', 'no label'), ('Dietary Adherence', 'no label'), ('Composition', 'no label'), ('Univariate', 'no label'), ('Wilcoxon Signed-Rank And Mann-Whitney U Test', 'no label'), ('Multivariate', 'no label'), ('Random Forest', 'no label'), ('Hierarchical Clustering) Analyses', 'no label'), ('Performed', 'no label'), ('Clinical', 'no label'), ('Metabolic', 'no label'), ('Associated With', 'no label'), ('Intervention', 'no label'), ('Disease State', 'no label'), ('Healthy Controls', 'no label'), ('Phe Catabolites', 'no label'), ('Ketones', 'no label'), ('Glycine-Conjugated Fatty Acids', 'no label'), ('Elevated', 'no label'), ('Females', 'no label'), ('Pku', 'no label'), ('Baseline', 'no label'), ('Fatty Acylcholine', 'no label'), ('Metabolites', 'no label'), ('Camp Intervention', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Decreased', 'no label'), ('Median Change', 'no label'), ('Pku Participants', 'no label'), ('Dietary Adherence', 'no label'), ('Decreasing', 'no label'), ('Phe Intake', 'no label'), ('And/Or', 'no label'), ('Increasing', 'no label'), ('Medical Food Consumption', 'no label'), ('Shift', 'no label'), ('Abundance', 'no label'), ('Metabolites', 'no label'), ('Q\xa0<\xa00.05', 'no label'), ('Compounds', 'no label'), ('Associated With', 'no label'), ('Metabolism', 'no label'), ('Phe', 'no label'), ('Fatty Acids', 'no label'), ('Choline', 'no label'), ('Contributed', 'no label'), ('Profile Differences', 'no label'), ('Camp', 'no label'), ('Females', 'no label'), ('Pku', 'no label'), ('Untargeted Metabolomics', 'no label'), ('Identified', 'no label'), ('Perturbations', 'no label'), ('Amino Acid', 'no label'), ('Lipid Metabolites', 'no label'), ('Associated With', 'no label'), ('Bioenergetic Impairment', 'no label'), ('Oxidative Stress', 'no label'), ('Choline-Conjugated Lipids', 'no label'), ('Fundamental Roles', 'no label'), ('Pathways', 'no label'), ('Evaluated', 'no label'), ('Short-Term', 'no label'), ('Camp', 'no label'), ('Effective', 'no label'), ('Improving', 'no label'), ('Normalizing', 'no label'), ('Abundance', 'no label'), ('Discriminatory', 'no label'), ('Metabolites', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Ketones', 'no label'), ('Fatty Acids', 'no label'), ('Metabolites', 'no label'), ('Phe', 'no label'), ('Food', 'no label'), ('Metabolites', 'no label'), ('Phe', 'no label'), ('Fatty Acids', 'no label'), ('Choline', 'no label'), ('Amino Acid', 'no label'), ('Lipids', 'no label'), ('Metabolites', 'no label')]|[('Carnitine-', 'no label'), ('-325, -28 Μmol/L)] And 70% Of', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Ketones', 'no label'), ('Fatty Acylcholine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('And/Or', 'no label'), ('Phe', 'no label'), ('Fatty Acids', 'no label'), ('Choline', 'no label'), ('Amino Acid And Lipid Metabolites', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Plasma', 'no label'), ('U Test', 'no label'), ('Phe Catabolites', 'no label'), ('Ketones', 'no label'), ('Fatty Acids', 'no label'), ('Fatty Acylcholine', 'no label'), ('Plasma Phe', 'no label'), ('Pku', 'no label'), ('Phe', 'no label'), ('And/Or', 'no label'), ('Phe', 'no label'), ('Fatty Acids', 'no label'), ('Choline', 'no label'), ('Amino Acid', 'no label'), ('Lipid', 'no label'), ('Lipids', 'no label')]
phenylketonuria|pubmed~31237861|Background Phenylketonuria (Pku) Is One Of The Most Common Types Of Inborn Error Of Metabolism. The Mainstay Of Therapy For Pku Has Been Dietary Phenylalanine (Phe) Restriction. Sapropterin Dihydrochloride Has Been Shown To Be Effective In Reducing Phe Levels In Pku Patients. Methods This Study Was A Clinical Trial Performed In The Pediatric Endocrine Clinic Of Imam Reza Hospital, Mashhad, Iran. Results All Children Between 1 And 10 Years Of Age With A Diagnosis Of Pku Whose Serum Phe Levels Were Between 120 And 360 Μmol/L, In Khorasan Razavi Province In The North-East Of Iran, Were Enrolled. Twenty-Four Patients Were Enrolled In The Study. Intervention: A Free Diet For 72 H Was Allowed And Then A 20-Mg/Kg/Day Dose Of Kuvan® Was Administered. More Than 30% Reduction In Blood Phe Levels Was Described As Responsive. Eight Patients Responded To The Loading Test And Were Eligible For The Second Stage Of The Study. In This Stage, Phe Powder In Combination With Kuvan Was Provided. Patients' Serum Phe Was Measured Weekly For 3 Months. All Eight Patients Showed Phe Tolerance In 3 Months, And Their Serum Phe Levels Remained Within The Range. Conclusions Treatment With Kuvan Can Help Reduce Blood Phe Levels In Our Pediatric Pku Population And Allows Patients To Follow A More Liberal Diet.|"[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Mainstay', 'no label'), ('Therapy', 'no label'), ('Dietary Phenylalanine', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Effective', 'no label'), ('Reducing', 'no label'), ('Phe', 'no label'), ('Levels', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Clinical Trial', 'no label'), ('Performed', 'no label'), ('Pediatric Endocrine Clinic', 'no label'), ('Imam Reza Hospital', 'no label'), ('Mashhad', 'no label'), ('Iran', 'no label'), ('Children', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Diagnosis', 'no label'), ('Pku Whose Serum', 'no label'), ('Khorasan Razavi', 'no label'), ('Province', 'no label'), ('North-East', 'no label'), ('Iran', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Intervention', 'no label'), ('Free Diet', 'no label'), ('Dose', 'no label'), ('Kuvan® Was Administered', 'no label'), ('Reduction', 'no label'), ('Blood Phe Levels', 'no label'), ('Responsive', 'no label'), ('Patients', 'no label'), ('Loading Test', 'no label'), ('Second Stage', 'no label'), ('Study', 'no label'), ('Stage', 'no label'), ('Phe Powder', 'no label'), ('Combination', 'no label'), ('Kuvan', 'no label'), (""Patients'"", 'no label'), ('Serum Phe', 'no label'), ('Weekly', 'no label'), ('Months', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Tolerance', 'no label'), ('Months', 'no label'), ('Serum', 'no label'), ('Range', 'no label'), ('Treatment', 'no label'), ('Kuvan', 'no label'), ('Reduce', 'no label'), ('Blood Phe Levels', 'no label'), ('Pediatric Pku Population', 'no label'), ('Patients', 'no label'), ('Liberal Diet', 'no label')]"|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Dihydrochloride', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Dihydrochloride', 'no label'), ('Phe', 'no label'), ('Pku Patients', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Serum', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Serum Phe', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Serum', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31640267|The Standard Treatment For Phenylketonuria (Pku) Is A Lifelong Low-Phenylalanine (Phe) Diet, Supplemented With Phe-Free Protein Substitutes; However, Adult Patients Often Show Poor Adherence To Therapy. Alternative Treatment Options Include The Use Of Large Neutral Amino Acids (Lnaa). The Aim Of This Study Was To Determine The Phe, Tyrosine (Tyr), And Phe/Tyr Ratio In A Cohort Of Sub-Optimally Controlled Adult Patients With Classical Pku Treated With A New Lnaa Formulation. Twelve Patients Received A Phe-Restricted Diet Plus A Slow-Release Lnaa Product Taken Three Times Per Day, At A Dose Of 1 G/Kg Body Weight (Mean 0.8 ± 0.24 G/Kg/Day), Over A 12-Month Period. The Product Is In A Microgranulated Formulation, Which Incorporates All Amino Acids And Uses Sodium Alginate As A Hydrophilic Carrier To Prolong Its Release. This Lnaa Formulation Provides Up To 80% Of The Total Protein Requirement, With The Rest Of The Protein Supplied By Natural Food. Patients Had Fortnightly Measurements Of Phe And Tyr Levels Over A 12-Month Period After The Introduction Of Lnaa. All Patients Completed The 12-Month Treatment Period. Overall, Adherence To The New Lnaa Tablets Was Very Good Compared With A Previous Amino Acid Mixture, For Which Taste Was A Major Complaint By Patients. Phe Levels Remained Unchanged (<I>P</I> = 0.0522), And Tyr Levels Increased (<I>P</I> = 0.0195). Consequently, The Phe/Tyr Ratio Decreased Significantly (<I>P</I> < 0.05) In The Majority Of Patients Treated. In Conclusion, Lnaa Treatment Increases Tyr Levels In Sub-Optimally Controlled Adult Pku Patients, While Offering The Potential To Improve Their Adherence To Treatment.|[('Standard Treatment', 'no label'), ('Phenylketonuria', 'no label'), ('Low-Phenylalanine (Phe) Diet', 'no label'), ('Supplemented', 'no label'), ('Phe-Free Protein Substitutes', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Poor Adherence', 'no label'), ('Therapy', 'no label'), ('Alternative', 'no label'), ('Treatment Options', 'no label'), ('Neutral Amino Acids', 'no label'), ('Lnaa', 'no label'), ('Study', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Phe/Tyr', 'no label'), ('Ratio', 'no label'), ('Cohort', 'no label'), ('Sub-Optimally Controlled Adult', 'no label'), ('Patients', 'no label'), ('Classical Pku Treated With', 'no label'), ('Patients', 'no label'), ('Phe-Restricted Diet Plus A Slow-Release Lnaa Product', 'no label'), ('Times', 'no label'), ('Per Day', 'no label'), ('Dose', 'no label'), ('G/Kg Body Weight', 'no label'), ('Period', 'no label'), ('Product', 'no label'), ('Microgranulated Formulation', 'no label'), ('Amino Acids', 'no label'), ('Uses', 'no label'), ('Sodium Alginate', 'no label'), ('Hydrophilic Carrier', 'no label'), ('Release', 'no label'), ('Lnaa Formulation', 'no label'), ('Provides', 'no label'), ('Total Protein Requirement', 'no label'), ('Rest', 'no label'), ('Protein Supplied By Natural Food', 'no label'), ('Patients', 'no label'), ('Fortnightly Measurements', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Levels', 'no label'), ('Period', 'no label'), ('Lnaa', 'no label'), ('Patients', 'no label'), ('Completed', 'no label'), ('Treatment', 'no label'), ('Adherence', 'no label'), ('Tablets', 'no label'), ('Amino Acid Mixture', 'no label'), ('Taste', 'no label'), ('Major Complaint', 'no label'), ('Patients', 'no label'), ('Phe Levels', 'no label'), ('Remained', 'no label'), ('Unchanged', 'no label'), ('<I>P</I>', 'no label'), ('Tyr Levels', 'no label'), ('Increased', 'no label'), ('<I>P</I> = 0.0195', 'no label'), ('Phe/Tyr', 'no label'), ('Ratio', 'no label'), ('Decreased', 'no label'), ('<I>P</I> < 0.05)', 'no label'), ('Patients', 'no label'), ('Treated', 'no label'), ('Lnaa Treatment', 'no label'), ('Increases', 'no label'), ('Tyr', 'no label'), ('Levels', 'no label'), ('Sub-Optimally Controlled Adult', 'no label'), ('Patients', 'no label'), ('Potential', 'no label'), ('Adherence', 'no label'), ('Treatment', 'no label')]|[('Phe', 'no label'), ('Protein', 'no label'), ('Amino Acids', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Amino Acids', 'no label'), ('Sodium Alginate', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Food', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Amino Acid', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Tyr', 'no label')]|[('Per', 'no label')]|[('Phenylketonuria', 'no label'), ('Low-Phenylalanine', 'no label'), ('Phe', 'no label'), ('Amino Acids', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Amino Acids And', 'no label'), ('Sodium Alginate', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Amino Acid', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Tyr', 'no label')]|[('Phenylketonuria', 'no label'), ('Low-Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe-Free', 'no label'), ('Patients', 'no label'), ('Amino Acids', 'no label'), ('Phe', 'no label'), ('Phe/Tyr', 'no label'), ('Patients', 'no label'), ('A New Lnaa', 'no label'), ('Patients', 'no label'), ('Amino Acids', 'no label'), ('Sodium Alginate As', 'no label'), ('Prolong', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Patients', 'no label'), ('Tablets', 'no label'), ('Amino Acid', 'no label'), ('Patients', 'no label'), ('Tyr', 'no label'), ('Phe/Tyr', 'no label'), ('Patients', 'no label'), ('Lnaa', 'no label')]
phenylketonuria|pubmed~32674279|The Gold Standard Treatment For Phenylketonuria (Pku) Is A Lifelong Low-Phenylalanine (Phe) Diet Supplemented With Phe-Free Protein Substitutes. Adherence To Therapy Becomes Difficult After Childhood. Supplementing With Large Neutral Amino Acids (Lnaas) Has Been Proposed As An Alternative Medication To Phe-Free Protein Substitutes (I.E., Amino Acid Mixtures). The Aim Of This Study Was To Evaluate Adherence To Therapy And Quality Of Life (Qol) In A Cohort Of Sub-Optimally Controlled Adult Pku Patients Treated With A New Lnaa Formulation. Twelve Patients Were Enrolled In A 12-Month-Trial Of Slow-Release Lnaas (1G/Kg/Day) Plus A Phe-Restricted Diet. Medication Adherence Was Measured With The Morisky Green Levine Medication Adherence Scale; The Qol Was Measured Using The Phenylketonuria-Quality Of Life (Pku-Qol) Questionnaire. Phe, Tyrosine (Tyr) Levels, And Phe/Tyr Ratios Were Measured Fortnightly. Before Treatment, 3/12 Patients Self-Reported A 'Medium' Adherence To Medication And 9/12 Reported A Low Adherence; 60% Of Patients Reported A Full Adherence Over The Past Four Weeks. After 12 Months Of Lnaa Treatment, All Patients Self-Reported A High Adherence To Medication, With 96% Reporting A Full Adherence. Phe Levels Remained Unchanged, While Tyr Levels Increased In Most Patients. The Phy/Tyr Ratio Decreased. All Patients Had A Significant Improvement In The Qol. Lnaas May Give Patients A Further Opportunity To Improve Medication Adherence And, Consequently, Their Qol.|[('Gold Standard Treatment', 'no label'), ('Phenylketonuria', 'no label'), ('Low-Phenylalanine (Phe) Diet', 'no label'), ('Supplemented', 'no label'), ('Phe-Free Protein Substitutes', 'no label'), ('Adherence', 'no label'), ('Therapy', 'no label'), ('Becomes', 'no label'), ('Difficult', 'no label'), ('Supplementing', 'no label'), ('Neutral Amino Acids', 'no label'), ('Lnaas', 'no label'), ('Alternative Medication', 'no label'), ('Amino Acid Mixtures', 'no label'), ('Study', 'no label'), ('Evaluate Adherence', 'no label'), ('Therapy', 'no label'), ('Quality Of Life', 'no label'), ('Qol', 'no label'), ('Cohort', 'no label'), ('Sub-Optimally Controlled Adult', 'no label'), ('Patients', 'no label'), ('Treated With', 'no label'), ('Patients', 'no label'), ('Slow-Release Lnaas', 'no label'), ('Plus A', 'no label'), ('Phe-Restricted Diet', 'no label'), ('Medication Adherence', 'no label'), ('Measured', 'no label'), ('Morisky Green Levine Medication Adherence Scale', 'no label'), ('Qol', 'no label'), ('Measured', 'no label'), ('Phenylketonuria-Quality', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Levels', 'no label'), ('Phe/Tyr', 'no label'), ('Ratios', 'no label'), ('Measured', 'no label'), ('Fortnightly', 'no label'), ('Treatment', 'no label'), ('Patients', 'no label'), ('Adherence', 'no label'), ('Medication', 'no label'), ('Reported', 'no label'), ('Low', 'no label'), ('Adherence', 'no label'), ('Patients', 'no label'), ('Adherence', 'no label'), ('Weeks', 'no label'), ('Months', 'no label'), ('Lnaa Treatment', 'no label'), ('Patients', 'no label'), ('Self-Reported', 'no label'), ('High Adherence', 'no label'), ('Medication', 'no label'), ('Reporting A', 'no label'), ('Adherence', 'no label'), ('Phe Levels', 'no label'), ('Remained', 'no label'), ('Unchanged', 'no label'), ('Tyr Levels', 'no label'), ('Increased', 'no label'), ('Patients', 'no label'), ('Phy/Tyr', 'no label'), ('Ratio', 'no label'), ('Decreased', 'no label'), ('Patients', 'no label'), ('Significant', 'no label'), ('Improvement', 'no label'), ('Qol', 'no label'), ('Lnaas', 'no label'), ('Patients', 'no label'), ('Opportunity', 'no label'), ('Medication Adherence', 'no label'), ('Qol', 'no label')]|[('Phe', 'no label'), ('Protein', 'no label'), ('Amino Acids', 'no label'), ('Protein', 'no label'), ('Amino Acid', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Low-Phenylalanine', 'no label'), ('Phe', 'no label'), ('Amino Acids', 'no label'), ('Amino Acid', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label')]|[('Phenylketonuria', 'no label'), ('Low-Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe-Free', 'no label'), ('Amino Acids', 'no label'), ('Phe-Free', 'no label'), ('Amino Acid', 'no label'), ('Patients', 'no label'), ('A New Lnaa', 'no label'), ('Patients', 'no label'), ('Green Levine', 'no label'), ('Phe', 'no label'), ('Phe/Tyr Ratios', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lnaa', 'no label'), ('Patients', 'no label'), ('Tyr', 'no label'), ('Patients', 'no label'), ('Phy/Tyr', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~32661828|Phenylketonuria (Pku) Is The Most Common Inborn Error Of Amino Acids Metabolism. Pku Management Aims To Keep As Soon As Possible Blood Phenylalanine (Phe), A Non-Acutely Neurotoxic Metabolite, Within Safe Ranges Through A Dietary Phe Restriction Tailored To Individual Dietary Phe Tolerance. Information On Initial Neonatal Management Of Pku, When Phe Tolerance Is Still Unknown, Is Scanty. We Reviewed The Metabolic Data From 304 Patients With Pah Deficiency Detected At Newborn Screening Within The Last 37 Years. In Keeping With The General Neonatal Management Of Intoxication-Type Inborn Errors Of Metabolism, Initial Management Consisted In A Phe Wash-Out Through The Exclusive Administration Of Normocaloric Phe-Free Formulas Until Normalization Of Blood Phe. Based On Genotype And Phe Tolerance Assessed At Follow-Up, 55 Patients Had Classic Pku (18%), 50 Mild Pku (17%), And 199 Non-Pku Hyperphenylalaninemia (Hpa) (65%). The Duration Of Phe Wash-Out Amounted To 7 ± 2 Days In Classic Pku, 4 ± 2 Days In Mild Pku, And < 24 H In Non-Pku Hpa (P < 0.001). After The Wash-Out, Dietary Phe Re-Introduction And Its Upwardly Titration Allowed The Assessment Of Individual Metabolic Phenotype. During The First 6 Years Of Life, Phe Tolerance Was Stable In Classic Pku (~ 200 Mg/Day) But Increased In Milder Forms, Allowing Unrestricted Diet In Non-Pku Hpa. Neonatal Phe Wash-Out In Pku Ensures The Earliest Correction Of Hpa. This Metabolic Reset Also Facilitates The Prompt Definition Of Individual Phe Tolerance, Allowing Anticipation Of Dietary Personalization And Optimization Of Longitudinal Metabolic Control.|[('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Amino Acids Metabolism', 'no label'), ('Pku Management', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Non-Acutely', 'no label'), ('Neurotoxic', 'no label'), ('Metabolite', 'no label'), ('Safe Ranges', 'no label'), ('Dietary Phe Restriction', 'no label'), ('Tailored', 'no label'), ('Dietary Phe Tolerance', 'no label'), ('Information', 'no label'), ('Initial', 'no label'), ('Neonatal', 'no label'), ('Management', 'no label'), ('Phe', 'no label'), ('Tolerance', 'no label'), ('Reviewed', 'no label'), ('Metabolic', 'no label'), ('Data', 'no label'), ('Patients', 'no label'), ('Pah Deficiency', 'no label'), ('Detected', 'no label'), ('Newborn', 'no label'), ('Screening', 'no label'), ('Years', 'no label'), ('General Neonatal Management', 'no label'), ('Intoxication-Type Inborn Errors', 'no label'), ('Metabolism', 'no label'), ('Initial', 'no label'), ('Management Consisted', 'no label'), ('Phe Wash-Out', 'no label'), ('Exclusive Administration', 'no label'), ('Normocaloric Phe-Free Formulas', 'no label'), ('Normalization', 'no label'), ('Blood Phe', 'no label'), ('Genotype', 'no label'), ('Phe Tolerance', 'no label'), ('Assessed', 'no label'), ('Follow-Up', 'no label'), ('Patients', 'no label'), ('Classic Pku', 'no label'), ('Mild Pku', 'no label'), ('Non-Pku Hyperphenylalaninemia', 'no label'), ('Hpa', 'no label'), ('Duration', 'no label'), ('Phe Wash-Out', 'no label'), ('Days', 'no label'), ('Classic', 'no label'), ('Days', 'no label'), ('Mild Pku', 'no label'), ('Non-Pku Hpa', 'no label'), ('Wash-Out', 'no label'), ('Dietary', 'no label'), ('Phe', 'no label'), ('Re-Introduction', 'no label'), ('Upwardly Titration', 'no label'), ('Assessment', 'no label'), ('Individual', 'no label'), ('Metabolic', 'no label'), ('Phenotype', 'no label'), ('Life', 'no label'), ('Phe Tolerance', 'no label'), ('Stable', 'no label'), ('Increased', 'no label'), ('Milder Forms', 'no label'), ('Allowing Unrestricted Diet', 'no label'), ('Non-Pku Hpa', 'no label'), ('Neonatal', 'no label'), ('Phe Wash-Out', 'no label'), ('Earliest', 'no label'), ('Correction', 'no label'), ('Hpa', 'no label'), ('Metabolic Reset', 'no label'), ('Prompt', 'no label'), ('Definition', 'no label'), ('Phe Tolerance', 'no label'), ('Allowing Anticipation', 'no label'), ('Dietary Personalization', 'no label'), ('Optimization', 'no label'), ('Longitudinal Metabolic Control', 'no label')]|[('Amino Acids', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Genotype', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Non-Pku Hpa', 'no label')]|[('Phenylketonuria', 'no label'), ('Amino Acids Metabolism', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Neurotoxic', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Intoxication-Type Inborn Errors', 'no label'), ('Phe', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Amino Acids', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Pah', 'no label'), ('Intoxication-Type', 'no label'), ('Phe-Free', 'no label'), ('Blood', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('H In Non-Pku Hpa', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]
phenylketonuria|pubmed~31030702|To Provide A Comprehensive Systematic Review Of The Literature By Examining Studies Published On All Cognitive Aspects Of Children With Early And Continuously Treated Phenylketonuria (Ect-Pku) Included In The Databases Medline, Psycinfo, And Psycarticle. In Addition To A Classical Approach, We Summarized Methodology And Results Of Each Study In Order To Discuss Current Theoretical And Methodological Issues. We Also Examined Recent Advances In Biochemical Markers And Treatments Of Pku, With Implications For Future Research On Metabolic Control And Its Role As A Determinant Of Neuropsychological Outcome. Consistent With Previous Reviews, The Hypothesis Of A Specific And Central Executive Impairment In Children With Ect-Pku Was Suggested. However, Findings Are Inconclusive Regarding The Nature Of Executive Impairments As Well As Their Specificity, Impact On Everyday Life, Persistence Over Time, And Etiology. Given The Current State Of The Science, We Suggest Future Directions For Research That Utilizes A Developmental And Integrative Approach To Examine The Effects Of Recent Advances In Biochemical Markers And Treatment Of Pku. (Jins, 2019, 25, 624-643).|[('Comprehensive', 'no label'), ('Systematic Review', 'no label'), ('Literature', 'no label'), ('Studies', 'no label'), ('Published', 'no label'), ('Cognitive Aspects', 'no label'), ('Children', 'no label'), ('Early', 'no label'), ('Continuously', 'no label'), ('Treated', 'no label'), ('Phenylketonuria', 'no label'), ('Ect-Pku', 'no label'), ('Databases Medline', 'no label'), ('Psycinfo', 'no label'), ('Psycarticle', 'no label'), ('Classical Approach', 'no label'), ('Methodology', 'no label'), ('Study', 'no label'), ('Order', 'no label'), ('Theoretical', 'no label'), ('Methodological Issues', 'no label'), ('Advances', 'no label'), ('Biochemical', 'no label'), ('Markers', 'no label'), ('Treatments', 'no label'), ('Future', 'no label'), ('Research', 'no label'), ('Metabolic Control', 'no label'), ('Determinant', 'no label'), ('Neuropsychological Outcome', 'no label'), ('Reviews', 'no label'), ('Hypothesis', 'no label'), ('Specific', 'no label'), ('Central Executive Impairment', 'no label'), ('Children', 'no label'), ('Ect-Pku', 'no label'), ('Findings', 'no label'), ('Nature', 'no label'), ('Executive Impairments', 'no label'), ('Specificity', 'no label'), ('Impact', 'no label'), ('Everyday', 'no label'), ('Time', 'no label'), ('Etiology', 'no label'), ('State', 'no label'), ('Science', 'no label'), ('Suggest', 'no label'), ('Directions', 'no label'), ('Research', 'no label'), ('Developmental', 'no label'), ('Effects', 'no label'), ('Advances', 'no label'), ('Biochemical', 'no label'), ('Markers', 'no label'), ('Treatment', 'no label'), ('Jins', 'no label')]|[]|[]|[('Phenylketonuria', 'no label')]|[('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label')]
phenylketonuria|pubmed~34772434|Children With Phenylketonuria (Pku) Need A Special Diet To Avoid A Variety Of Physical And Psychological Complications. The Aim Of This Study Was To Compare And Assess The Effects Of Two Interventions On And Levels Of Phenylalanine And Micronutrients In Children With Pku. Forty-Six Children With Pku (Ages 1-12 Years) And Their Caregivers Were Randomly Assigned To One Of Two 10-Week Interventions: A Caregiver Educational Intervention Based On The Integrative Model Of Behvioral Prediction (Imbp) And Supplementary Low-Protein-Modified Foods. Outcomes Consisted Of Children'S Plasma Phenylalanine And Micronutrients (I.E., Vitamin B12, Vitamin D3, And Zinc) And Hemoglobin Levels. To Assess The Sustainability Of Outcomes, We Also Compared The Children'S Phenylalanine Level At Five-Time Points Including Baseline And 10-Week, 6 Months, 12 Months, And 24 Months Follow-Ups. In Addition, Caregivers Of Both Groups Were Asked To Complete A Questionnaire To Assess How Well The Interventions Were Implemented As Well As Satisfaction With Interventions. While A Large Percentage Of Children Had Phenylalanine Levels Out Of Range Indicating Non-Adherence (69.6% And 81% In The Educational And Food Items Group, Respectively), Micronutrient Deficiencies Were Not Prevalent In The Patient Cohort. The Levels Of Phenylalanine In Both Groups Decreased Significantly Over Time. However, Conducting A Repeated-Measures Anova To Evaluating The Change In Groups Across Five-Time Points, Revealed A Significant Difference Between Groups (F = 4.68, P = 0.03). That Is, The Educational Intervention Was More Effective In Lowering The Children'S Phenylalanine Level. At 24-Month Follow-Up, The Percentage Of Children With A Normal Range Of Phenylalanine Level In The Educational And Food Items Groups Increased To 73.9 And 57.1 Percent, Respectively, From 26 And 38 Percent At Baseline. There Were No Significant Changes In Children'S Micronutrients Level Following The Interventions, Except In The Hemoglobin. In This Way, At 10-Week Follow-Up, The Mean Hemoglobin Of Children In The Educational Group Reduced Significantly (P = 0.041). However, There Was No Significant Difference Between The Two Groups. In General, All Caregivers Completed The Process Evaluation Checklist, The Feedback Was Largely Positive. The Results Of This Study Demonstrated That Both Educational And Providing Food Item Interventions Resulted In A Significant Reduction In Phenylalanine Levels. Empowering Caregivers Of Patients, Creating And Fortifying Social Networks, Providing Favorable Social Supports, And Providing Access To Special Food Items May Be Effective In Controlling Pku. Iranian Registry Of Clinical Trials (Irct20180506039548N1). Registered 6Th Jun 2018, Https://Www.Irct.Ir/Trial/30977 .|"[('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Special Diet', 'no label'), ('Physical', 'no label'), ('Psychological', 'no label'), ('Complications', 'no label'), ('Study', 'no label'), ('Compare', 'no label'), ('Assess', 'no label'), ('Effects', 'no label'), ('Interventions', 'no label'), ('Levels', 'no label'), ('Phenylalanine', 'no label'), ('Micronutrients', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Years', 'no label'), ('Caregivers', 'no label'), ('Randomly Assigned', 'no label'), ('Interventions', 'no label'), ('Caregiver', 'no label'), ('Integrative Model', 'no label'), ('Behvioral Prediction', 'no label'), ('Imbp', 'no label'), ('Supplementary', 'no label'), ('Outcomes Consisted', 'no label'), (""Children'S"", 'no label'), ('Plasma', 'no label'), ('Phenylalanine', 'no label'), ('Micronutrients', 'no label'), ('I.E.', 'no label'), ('Vitamin B12', 'no label'), ('Vitamin D3', 'no label'), ('Zinc', 'no label'), ('Hemoglobin Levels', 'no label'), ('Assess', 'no label'), ('Sustainability', 'no label'), ('Outcomes', 'no label'), (""Children'S"", 'no label'), ('Phenylalanine', 'no label'), ('Level', 'no label'), ('Five-Time', 'no label'), ('Points', 'no label'), ('Baseline', 'no label'), ('Months', 'no label'), ('Months', 'no label'), ('Months', 'no label'), ('Addition', 'no label'), ('Caregivers', 'no label'), ('Groups', 'no label'), ('Complete A Questionnaire', 'no label'), ('Interventions', 'no label'), ('Satisfaction', 'no label'), ('Interventions', 'no label'), ('Percentage', 'no label'), ('Children', 'no label'), ('Phenylalanine Levels', 'no label'), ('Range Indicating Non-Adherence', 'no label'), ('Educational And Food Items Group', 'no label'), ('Micronutrient Deficiencies', 'no label'), ('Not Prevalent', 'no label'), ('Patient Cohort', 'no label'), ('Levels', 'no label'), ('Phenylalanine', 'no label'), ('Groups', 'no label'), ('Decreased', 'no label'), ('Time', 'no label'), ('Conducting A', 'no label'), ('Repeated-Measures Anova', 'no label'), ('Change', 'no label'), ('Groups', 'no label'), ('Five-Time', 'no label'), ('Points', 'no label'), ('Revealed', 'no label'), ('Groups', 'no label'), ('Educational Intervention', 'no label'), ('Effective', 'no label'), (""Children'S"", 'no label'), ('Phenylalanine', 'no label'), ('Level', 'no label'), ('Follow-Up', 'no label'), ('Percentage', 'no label'), ('Children', 'no label'), ('Normal Range', 'no label'), ('Phenylalanine Level', 'no label'), ('Educational And Food Items Groups', 'no label'), ('Increased', 'no label'), ('Baseline', 'no label'), ('Changes', 'no label'), (""Children'S"", 'no label'), ('Micronutrients', 'no label'), ('Level', 'no label'), ('Interventions', 'no label'), ('Hemoglobin', 'no label'), ('Follow-Up', 'no label'), ('Hemoglobin', 'no label'), ('Children', 'no label'), ('Educational Group', 'no label'), ('Reduced', 'no label'), ('No Significant Difference', 'no label'), ('Groups', 'no label'), ('General', 'no label'), ('Caregivers', 'no label'), ('Completed', 'no label'), ('Process Evaluation Checklist', 'no label'), ('Feedback', 'no label'), ('Positive', 'no label'), ('Study', 'no label'), ('Educational And Providing Food Item Interventions', 'no label'), ('Resulted', 'no label'), ('Reduction', 'no label'), ('Phenylalanine Levels', 'no label'), ('Empowering Caregivers', 'no label'), ('Patients', 'no label'), ('Creating', 'no label'), ('Fortifying', 'no label'), ('Social Networks', 'no label'), ('Favorable', 'no label'), ('Social Supports', 'no label'), ('Access', 'no label'), ('Effective', 'no label'), ('Controlling Pku', 'no label'), ('Iranian', 'no label'), ('Registry', 'no label'), ('Clinical Trials', 'no label'), ('Https://Www.', 'no label')]"|[('Phenylalanine', 'no label'), ('Micronutrients', 'no label'), ('Phenylalanine', 'no label'), ('Micronutrients', 'no label'), ('Vitamin B12', 'no label'), ('Vitamin D3', 'no label'), ('Zinc', 'no label'), ('Hemoglobin', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Food', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Food', 'no label'), ('Micronutrients', 'no label'), ('Hemoglobin', 'no label'), ('Hemoglobin', 'no label'), ('Food', 'no label'), ('Phenylalanine', 'no label'), ('Food', 'no label')]|[('Hemoglobin', 'no label'), ('Hemoglobin', 'no label'), ('Hemoglobin', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Micronutrients', 'no label'), ('Phenylalanine', 'no label'), ('Micronutrients', 'no label'), ('Vitamin B12', 'no label'), ('Vitamin D3', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Micronutrient Deficiencies', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Micronutrients', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Pku (Ages 1-12', 'no label'), ('Supplementary Low-Protein-Modified', 'no label'), ('Children', 'no label'), ('Plasma Phenylalanine', 'no label'), ('Micronutrients', 'no label'), ('Vitamin B12', 'no label'), ('Vitamin D3', 'no label'), ('Hemoglobin', 'no label'), ('Children', 'no label'), ('Phenylalanine', 'no label'), ('Five-Time Points', 'no label'), ('Children', 'no label'), ('Phenylalanine', 'no label'), ('Food', 'no label'), ('Patient', 'no label'), ('Phenylalanine', 'no label'), ('Five-Time', 'no label'), ('Children', 'no label'), ('Phenylalanine', 'no label'), ('Children', 'no label'), ('Phenylalanine', 'no label'), ('Children', 'no label'), ('Micronutrients', 'no label'), ('Hemoglobin', 'no label'), ('Hemoglobin', 'no label'), ('Children', 'no label'), ('Phenylalanine', 'no label'), ('Caregivers', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~33896013|Phenylketonuria (Pku) Is The Most Common Inborn Error Of Metabolism Of The Liver, And Results From Mutations Of Both Alleles Of The Phenylalanine Hydroxylase Gene (Pah). As Such, It Is A Suitable Target For Gene Therapy Via Gene Delivery With A Recombinant Adeno-Associated Virus (Aav) Vector. Here We Use The Synthetic Aav Vector Anc80 Via Systemic Administration To Deliver A Functional Copy Of A Codon-Optimized Human Pah Gene, With Or Without An Intron Spacer, To The Pah<Sup>Enu2</Sup> Mouse Model Of Pku. Dose-Dependent Transduction Of The Liver And Expression Of Pah Mrna Were Present With Both Vectors, Resulting In Significant And Durable Reduction Of Circulating Phenylalanine, Reaching Near Control Levels In Males. Coat Color Of Treated Pah<Sup>Enu2</Sup> Mice Reflected An Increase In Pigmentation From Brown To The Black Color Of Control Animals, Further Indicating Functional Restoration Of Phenylalanine Metabolism And Its Byproduct Melanin. There Were No Adverse Effects Associated With Administration Of Aav Up To 5 × 10<Sup>12</Sup> Vg/Kg, The Highest Dose Tested. Only Minor And/Or Transient Variations In Some Liver Enzymes Were Observed In Some Of The Aav-Dosed Animals Which Were Not Associated With Pathology Findings In The Liver. Finally, There Was No Impact On Cell Turnover Or Apoptosis As Evaluated By Ki-67 And Tunel Staining, Further Supporting The Safety Of This Approach. This Study Demonstrates The Therapeutic Potential Of Aav Anc80 To Safely And Durably Cure Pku In A Mouse Model, Supporting Development For Clinical Consideration.|[('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Liver', 'no label'), ('Results', 'no label'), ('Mutations', 'no label'), ('Alleles', 'no label'), ('Phenylalanine Hydroxylase Gene', 'no label'), ('Target', 'no label'), ('Gene Therapy', 'no label'), ('Gene Delivery', 'no label'), ('Recombinant Adeno-Associated Virus', 'no label'), ('Synthetic Aav Vector Anc80', 'no label'), ('Systemic Administration', 'no label'), ('Deliver', 'no label'), ('Functional', 'no label'), ('Codon-Optimized Human Pah Gene', 'no label'), ('Intron Spacer', 'no label'), ('Enu2</Sup> Mouse Model', 'no label'), ('Dose-Dependent', 'no label'), ('Transduction', 'no label'), ('Liver', 'no label'), ('Expression', 'no label'), ('Pah Mrna', 'no label'), ('Vectors', 'no label'), ('Reduction', 'no label'), ('Circulating', 'no label'), ('Phenylalanine', 'no label'), ('Near Control', 'no label'), ('Levels', 'no label'), ('Males', 'no label'), ('Coat Color', 'no label'), ('Treated Pah<Sup>Enu2</Sup> Mice', 'no label'), ('Increase', 'no label'), ('Pigmentation', 'no label'), ('Brown', 'no label'), ('Black Color', 'no label'), ('Functional Restoration', 'no label'), ('Phenylalanine Metabolism', 'no label'), ('Byproduct', 'no label'), ('Melanin', 'no label'), ('No Adverse Effects', 'no label'), ('Associated With', 'no label'), ('Administration', 'no label'), ('Aav Up', 'no label'), ('Vg/Kg', 'no label'), ('Highest', 'no label'), ('Dose', 'no label'), ('And/Or', 'no label'), ('Transient', 'no label'), ('Variations', 'no label'), ('Liver Enzymes', 'no label'), ('Observed', 'no label'), ('Aav-Dosed Animals', 'no label'), ('Associated With', 'no label'), ('Pathology', 'no label'), ('Findings', 'no label'), ('Liver', 'no label'), ('No Impact', 'no label'), ('Cell', 'no label'), ('Turnover', 'no label'), ('Apoptosis', 'no label'), ('Evaluated', 'no label'), ('Ki-67', 'no label'), ('Tunel Staining', 'no label'), ('Safety', 'no label'), ('Approach', 'no label'), ('Study', 'no label'), ('Demonstrates', 'no label'), ('Therapeutic', 'no label'), ('Potential', 'no label'), ('Aav Anc80', 'no label'), ('Durably Cure', 'no label'), ('Mouse Model', 'no label'), ('Supporting Development', 'no label'), ('Clinical Consideration', 'no label')]|[('Mutations', 'no label'), ('Alleles', 'no label'), ('Phenylalanine', 'no label'), ('Gene', 'no label'), ('Gene', 'no label'), ('Gene', 'no label'), ('Aav', 'no label'), ('Anc80', 'no label'), ('Human', 'no label'), ('Gene', 'no label'), ('Intron', 'no label'), ('Mouse', 'no label'), ('Mrna', 'no label'), ('Phenylalanine', 'no label'), ('Mice', 'no label'), ('Animals', 'no label'), ('Phenylalanine', 'no label'), ('Melanin', 'no label'), ('Aav', 'no label'), ('Enzymes', 'no label'), ('Animals', 'no label'), ('Cell', 'no label'), ('Aav Anc80', 'no label'), ('Mouse', 'no label')]|[('Phenylalanine Hydroxylase Gene', 'no label'), ('Synthetic Aav Vector Anc80', 'no label'), ('Human Pah Gene', 'no label'), ('Intron Spacer', 'no label'), ('Pah Mrna', 'no label'), ('Aav Anc80', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Liver', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Copy', 'no label'), ('Human Pah', 'no label'), ('Intron', 'no label'), ('Mouse', 'no label'), ('Liver', 'no label'), ('Pah Mrna', 'no label'), ('Circulating Phenylalanine', 'no label'), ('Mice', 'no label'), ('Black Color', 'no label'), ('Phenylalanine', 'no label'), ('Melanin', 'no label'), ('And/Or', 'no label'), ('Liver', 'no label'), ('Pathology', 'no label'), ('Liver', 'no label'), ('Cell', 'no label'), ('Ki-67', 'no label'), ('Mouse', 'no label')]
phenylketonuria|pubmed~31492166|Patients With Phenylketonuria (Pku) Are Exposed To Multiple Cardiovascular Risk Factors, But The Clinical Significance Of These Abnormalities Is Yet Unknown. The Purpose Of This Study Was To Characterize The Cardiovascular Phenotype In Adult Patients With Pku By Clinical And Dietary Data, Measurements Of Biochemical Markers, And Non-Invasive Examination Of Vascular Functions. Twenty-Three Adult Patients With Pku (Age: 18-47 Y; 30.8 ± 8.4 Y) And 28 Healthy Controls (Age: 18-47 Y; 30.1 ± 9.1 Y) Were Included In This Study. Pku Patients Had Significantly Higher Systolic And Diastolic Blood Pressure, Increased Resting Heart Rate And A Higher Body Mass Index. Total Cholesterol And Non-Hdl Cholesterol Levels Were Significantly Increased In Pku Patients, Whereas Plasma Levels Of Hdl Cholesterol And Its Subfraction Hdl2 (But Not Hdl3) Were Significantly Decreased. The Inflammatory Markers C-Reactive Protein And Serum Amyloid A Protein And The Serum Oxidative Stress Marker Malondialdehyde Were Significantly Higher In Patients With Pku. Venous Occlusion Plethysmography Showed Marked Reduction In Post-Ischemic Blood Flow And The Carotid To Femoral Pulse Wave Velocity Was Significantly Increased Demonstrating Endothelial Dysfunction And Increased Vascular Stiffness. This Study Shows That The Cardiovascular Phenotype Of Adult Pku Patients Is Characterized By An Accumulation Of Traditional Cardiovascular Risk Factors, High Levels Of Inflammatory And Oxidative Stress Markers, Endothelial Dysfunction And Vascular Stiffness. These Data Indicate The Need For Early Cardiovascular Risk Reduction In Patients With Pku.|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Exposed', 'no label'), ('Multiple', 'no label'), ('Cardiovascular', 'no label'), ('Risk Factors', 'no label'), ('Clinical Significance', 'no label'), ('Abnormalities', 'no label'), ('Study', 'no label'), ('Characterize', 'no label'), ('Cardiovascular', 'no label'), ('Phenotype', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Pku By Clinical And Dietary Data', 'no label'), ('Measurements', 'no label'), ('Biochemical', 'no label'), ('Markers', 'no label'), ('Non-Invasive Examination', 'no label'), ('Vascular Functions', 'no label'), ('Twenty-Three Adult', 'no label'), ('Patients', 'no label'), ('Pku (Age', 'no label'), ('Healthy Controls', 'no label'), ('Age', 'no label'), ('Study', 'no label'), ('Patients', 'no label'), ('Systolic', 'no label'), ('Diastolic Blood Pressure', 'no label'), ('Increased Resting Heart Rate', 'no label'), ('Body Mass Index', 'no label'), ('Total Cholesterol', 'no label'), ('Cholesterol Levels', 'no label'), ('Increased', 'no label'), ('Pku Patients', 'no label'), ('Plasma', 'no label'), ('Levels', 'no label'), ('Hdl\xa0Cholesterol', 'no label'), ('Subfraction Hdl2', 'no label'), ('Hdl3', 'no label'), ('Decreased', 'no label'), ('Inflammatory Markers', 'no label'), ('C-Reactive Protein', 'no label'), ('Serum', 'no label'), ('Amyloid A Protein', 'no label'), ('Serum Oxidative Stress Marker', 'no label'), ('Malondialdehyde', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Venous Occlusion Plethysmography', 'no label'), ('Reduction', 'no label'), ('Post-Ischemic Blood Flow', 'no label'), ('Carotid', 'no label'), ('Femoral Pulse Wave Velocity', 'no label'), ('Increased', 'no label'), ('Demonstrating Endothelial Dysfunction', 'no label'), ('Increased', 'no label'), ('Vascular Stiffness', 'no label'), ('Study', 'no label'), ('Cardiovascular', 'no label'), ('Phenotype', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Characterized', 'no label'), ('Accumulation', 'no label'), ('Traditional', 'no label'), ('Cardiovascular', 'no label'), ('Risk Factors', 'no label'), ('Levels', 'no label'), ('Inflammatory', 'no label'), ('Oxidative Stress', 'no label'), ('Markers', 'no label'), ('Endothelial Dysfunction', 'no label'), ('Vascular Stiffness', 'no label'), ('Data Indicate', 'no label'), ('Need', 'no label'), ('Early', 'no label'), ('Cardiovascular', 'no label'), ('Risk Reduction', 'no label'), ('Patients', 'no label')]|[('Y', 'no label'), ('Cholesterol', 'no label'), ('Cholesterol', 'no label'), ('Hdl', 'no label'), ('Cholesterol', 'no label'), ('Hdl2', 'no label'), ('Protein', 'no label'), ('Serum Amyloid A Protein', 'no label'), ('Malondialdehyde', 'no label')]|[('Inflammatory Markers C-Reactive Protein', 'no label'), ('Serum Amyloid A Protein', 'no label')]|[('Phenylketonuria', 'no label'), ('Cholesterol', 'no label'), ('Cholesterol', 'no label'), ('Cholesterol', 'no label'), ('Amyloid A Protein And The Serum Oxidative Stress Marker', 'no label'), ('Malondialdehyde', 'no label'), ('Venous Occlusion Plethysmography', 'no label'), ('Endothelial Dysfunction', 'no label'), ('Vascular Stiffness', 'no label'), ('Endothelial Dysfunction', 'no label'), ('Vascular Stiffness', 'no label')]|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Multiple Cardiovascular Risk', 'no label'), ('Cardiovascular', 'no label'), ('Patients', 'no label'), ('Vascular', 'no label'), ('Patients', 'no label'), ('Pku (Age: 18-47', 'no label'), ('Patients', 'no label'), ('Blood', 'no label'), ('Heart', 'no label'), ('Cholesterol', 'no label'), ('Non-Hdl Cholesterol', 'no label'), ('Pku Patients', 'no label'), ('Plasma', 'no label'), ('Hdl', 'no label'), ('Cholesterol', 'no label'), ('Hdl3', 'no label'), ('Serum Amyloid A', 'no label'), ('Serum', 'no label'), ('Stress Marker', 'no label'), ('Malondialdehyde', 'no label'), ('Patients', 'no label'), ('Venous', 'no label'), ('Blood', 'no label'), ('Femoral', 'no label'), ('Wave', 'no label'), ('Endothelial', 'no label'), ('Vascular', 'no label'), ('Cardiovascular', 'no label'), ('Patients', 'no label'), ('Cardiovascular', 'no label'), ('Endothelial', 'no label'), ('Vascular', 'no label'), ('Cardiovascular', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~32899700|Protein Is The Most Satiating Macronutrient, Increasing Secretion Of Gastrointestinal Hormones And Diet Induced Thermogenesis. In Phenylketonuria (Pku), Natural Protein Is Restricted With Approximately 80% Of Intake Supplied By A Synthetic Protein Source, Which May Alter Satiety Response. Casein Glycomacropeptide (Cgmp-Aa), A Carbohydrate Containing Peptide And Alternative Protein Substitute To Amino Acids (Aa), May Enhance Satiety Mediated By Its Bioactive Properties. In A Three-Year Longitudinal; Prospective Study, The Effect Of Aa And Two Different Amounts Of Cgmp-Aa (Cgmp-Aa Only (Cgmp100) And A Combination Of Cgmp-Aa And Aa (Cgmp50) On Satiety, Weight And Body Mass Index (Bmi) Were Compared. 48 Children With Pku Completed The Study. Median Ages Of Children Were: Cgmp100; (<I>N</I> = 13), 9.2 Years; Cgmp50; (<I>N</I> = 16), 7.3 Years; And Aa (<I>N</I> = 19), 11.1 Years. Semi-Quantitative Dietary Assessments And Anthropometry (Weight, Height And Bmi) Were Measured Every Three Months. The Macronutrient Contribution To Total Energy Intake From Protein, Carbohydrate And Fat Was Similar Across The Groups. Adjusting For Age And Gender, No Differences In Energy Intake, Weight, Bmi, Incidence Of Overweight Or Obesity Was Apparent Between The Groups. In This Three-Year Longitudinal Study, There Was No Indication To Support A Relationship Between Cgmp And Satiety, As Evidenced By Decreased Energy Intake, Thereby Preventing Overweight Or Obesity. Satiety Is A Complex Multi-System Process That Is Not Fully Understood.|[('Protein', 'no label'), ('Satiating Macronutrient', 'no label'), ('Increasing', 'no label'), ('Secretion', 'no label'), ('Gastrointestinal Hormones', 'no label'), ('Diet', 'no label'), ('Induced', 'no label'), ('Thermogenesis', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Natural Protein', 'no label'), ('Intake', 'no label'), ('Synthetic Protein Source', 'no label'), ('Alter', 'no label'), ('Satiety', 'no label'), ('Response', 'no label'), ('Casein Glycomacropeptide', 'no label'), ('Cgmp-Aa', 'no label'), ('Carbohydrate Containing', 'no label'), ('Peptide', 'no label'), ('Amino Acids', 'no label'), ('Aa', 'no label'), ('Enhance Satiety', 'no label'), ('Bioactive Properties', 'no label'), ('Three-Year Longitudinal', 'no label'), ('Prospective Study', 'no label'), ('Effect', 'no label'), ('Aa', 'no label'), ('Amounts', 'no label'), ('Cgmp-Aa (', 'no label'), ('Cgmp100', 'no label'), ('Combination', 'no label'), ('Cgmp-Aa And Aa', 'no label'), ('Cgmp50', 'no label'), ('Satiety', 'no label'), ('Weight', 'no label'), ('Body Mass Index', 'no label'), ('Bmi', 'no label'), ('Children', 'no label'), ('Pku Completed', 'no label'), ('Study', 'no label'), ('Median Ages', 'no label'), ('Children', 'no label'), ('Cgmp100', 'no label'), ('Years', 'no label'), ('Cgmp50', 'no label'), ('Years', 'no label'), ('Aa', 'no label'), ('<I>N</I>', 'no label'), ('Years', 'no label'), ('Semi-Quantitative Dietary Assessments', 'no label'), ('Anthropometry', 'no label'), ('Weight', 'no label'), ('Height', 'no label'), ('Bmi', 'no label'), ('Measured', 'no label'), ('Months', 'no label'), ('Macronutrient', 'no label'), ('Contribution', 'no label'), ('Total Energy Intake', 'no label'), ('Protein', 'no label'), ('Carbohydrate', 'no label'), ('Fat', 'no label'), ('Groups', 'no label'), ('Age', 'no label'), ('Gender', 'no label'), ('No Differences', 'no label'), ('Energy Intake', 'no label'), ('Weight', 'no label'), ('Bmi', 'no label'), ('Incidence', 'no label'), ('Overweight', 'no label'), ('Obesity', 'no label'), ('Apparent', 'no label'), ('Groups', 'no label'), ('Three-Year Longitudinal Study', 'no label'), ('Indication', 'no label'), ('Relationship', 'no label'), ('Cgmp And Satiety', 'no label'), ('Decreased Energy Intake', 'no label'), ('Preventing', 'no label'), ('Overweight', 'no label'), ('Obesity', 'no label'), ('Satiety', 'no label'), ('Complex', 'no label'), ('Multi-System Process', 'no label')]|[('Protein', 'no label'), ('Hormones', 'no label'), ('Protein', 'no label'), ('Synthetic Protein', 'no label'), ('Glycomacropeptide', 'no label'), ('Carbohydrate', 'no label'), ('Peptide', 'no label'), ('Protein', 'no label'), ('Amino Acids', 'no label'), ('Bmi', 'no label'), ('Cgmp50', 'no label'), ('Bmi', 'no label'), ('Protein', 'no label'), ('Carbohydrate', 'no label'), ('Bmi', 'no label'), ('Cgmp', 'no label')]|[('Natural Protein', 'no label')]|[('Phenylketonuria', 'no label'), ('Glycomacropeptide', 'no label'), ('Amino Acids', 'no label'), ('Satiety', 'no label'), ('Overweight', 'no label'), ('Obesity', 'no label'), ('Cgmp', 'no label'), ('Satiety', 'no label'), ('Obesity', 'no label'), ('Satiety', 'no label')]|[('Gastrointestinal Hormones', 'no label'), ('Phenylketonuria', 'no label'), ('Glycomacropeptide', 'no label'), ('Amino Acids', 'no label'), ('Aa', 'no label'), ('Aa', 'no label'), ('Bmi', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Aa', 'no label'), ('Bmi', 'no label'), ('Carbohydrate', 'no label'), ('Fat', 'no label'), ('Bmi', 'no label'), ('Cgmp', 'no label')]
phenylketonuria|pubmed~34057292|Phenylketonuria (Pku), A Deficiency In The Activity Of The Enzyme Phenylalanine Hydroxylase, Leads To Toxic Levels Of Phenylalanine (Phe) In The Blood And Brain. Pegvaliase (Recombinant Anabaena Variabilis Phenylalanine Ammonia Lyase Conjugated With Polyethylene Glycol) Is Approved To Manage Pku In Patients Aged Greater Than Or Equal To 18 Years In The United States And In Patients Aged Greater Than Or Equal To 16 Years In The European Union. Pharmacokinetic, Pharmacodynamic, And Immunogenicity Results From Five Open-Label Pegvaliase Trials Were Assessed. Studies With Induction/Titration/Maintenance (I/T/M) Dosing Regimens Demonstrated Pharmacokinetic Stabilization And Sustained Efficacy Associated With Maintenance Doses (20, 40, Or 60 Mg/Day). Immune-Mediated Pegvaliase Clearance Was High During Induction/Titration Phases When The Early Immune Response Was Peaking. The Combination Of Low Drug Dosage And High Drug Clearance Led To Low Drug Exposure And Minimal Decreases In Blood Phe Levels During Induction/Titration. Higher Drug Exposure And Substantial Reductions In Blood Phe Levels Were Observed Later In Treatment As Drug Clearance Was Reduced Due To The Maturation Of The Immune Response, Which Allowed For Increased Dosing To Target Levels. The Incidence Of Hypersensitivity Reactions Was Temporally Associated With The Peaking Of The Early Antidrug Immune Response And Decreased With Time As Immune Response Matured After The First 6 Months Of Treatment. These Results Support An I/T/M Dosing Regimen And Suggest A Strategy For Administration Of Other Nonhuman Biologics To Achieve Efficacy And Improve Tolerability.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Deficiency', 'no label'), ('Activity', 'no label'), ('Enzyme Phenylalanine Hydroxylase', 'no label'), ('Leads', 'no label'), ('Toxic Levels', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Blood', 'no label'), ('Recombinant Anabaena Variabilis', 'no label'), ('Phenylalanine Ammonia', 'no label'), ('Lyase Conjugated', 'no label'), ('Polyethylene Glycol', 'no label'), ('Manage', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Equal', 'no label'), ('Years', 'no label'), ('United States', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Equal', 'no label'), ('Years', 'no label'), ('European Union', 'no label'), ('Pharmacokinetic', 'no label'), ('Pharmacodynamic', 'no label'), ('Immunogenicity', 'no label'), ('Open-Label Pegvaliase Trials', 'no label'), ('Assessed', 'no label'), ('Studies', 'no label'), ('Induction/Titration/Maintenance', 'no label'), ('I/T/M', 'no label'), ('Dosing Regimens', 'no label'), ('Pharmacokinetic', 'no label'), ('Stabilization', 'no label'), ('Sustained', 'no label'), ('Efficacy', 'no label'), ('Associated With', 'no label'), ('Maintenance Doses', 'no label'), ('Immune-Mediated Pegvaliase', 'no label'), ('Clearance', 'no label'), ('Induction/Titration', 'no label'), ('Phases', 'no label'), ('Early', 'no label'), ('Immune Response', 'no label'), ('Peaking', 'no label'), ('Combination', 'no label'), ('Low Drug Dosage', 'no label'), ('High', 'no label'), ('Drug Clearance', 'no label'), ('Drug Exposure', 'no label'), ('Minimal', 'no label'), ('Decreases', 'no label'), ('Blood Phe Levels', 'no label'), ('Induction/Titration', 'no label'), ('Higher', 'no label'), ('Drug Exposure', 'no label'), ('Reductions', 'no label'), ('Blood Phe Levels', 'no label'), ('Observed', 'no label'), ('Treatment', 'no label'), ('Drug Clearance', 'no label'), ('Reduced', 'no label'), ('Maturation', 'no label'), ('Immune Response', 'no label'), ('Increased', 'no label'), ('Dosing', 'no label'), ('Target', 'no label'), ('Levels', 'no label'), ('Incidence', 'no label'), ('Hypersensitivity Reactions', 'no label'), ('Temporally', 'no label'), ('Associated With', 'no label'), ('Early', 'no label'), ('Antidrug', 'no label'), ('Immune Response', 'no label'), ('Decreased', 'no label'), ('Time', 'no label'), ('Immune Response Matured', 'no label'), ('Months', 'no label'), ('Treatment', 'no label'), ('Results', 'no label'), ('I/T/M', 'no label'), ('Dosing', 'no label'), ('Regimen', 'no label'), ('Strategy', 'no label'), ('Administration', 'no label'), ('Nonhuman Biologics', 'no label'), ('Efficacy', 'no label'), ('Improve', 'no label'), ('Tolerability', 'no label')]|[('Toxic', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Polyethylene Glycol', 'no label'), ('Drug', 'no label'), ('Drug', 'no label'), ('Drug', 'no label'), ('Phe', 'no label'), ('Drug', 'no label'), ('Phe', 'no label'), ('Drug', 'no label'), ('Early Antidrug', 'no label'), ('Nonhuman', 'no label')]|[('Early Antidrug Immune Response And', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylalanine Ammonia Lyase', 'no label'), ('Conjugated', 'no label'), ('Polyethylene Glycol', 'no label'), ('Hypersensitivity', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Blood', 'no label'), ('Brain.', 'no label'), ('Conjugated', 'no label'), ('Polyethylene Glycol', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Doses', 'no label'), ('Pegvaliase', 'no label'), ('Immune', 'no label'), ('Blood Phe', 'no label'), ('Blood Phe', 'no label'), ('Immune', 'no label'), ('Immune', 'no label'), ('Nonhuman Biologics', 'no label')]
phenylketonuria|pubmed~26278115|Previous Studies Investigating The Known Risk Factors Of Atherosclerosis In Phenylketonuria Patients Have Shown Conflicting Results. The Primary Aim Of Our Study Was To Investigate The Serum Atherogenic Markers In Adolescent Classical Phenylketonuria Patients And Compare These Parameters With Healthy Peers. The Secondary Aim Was To Compare These Atherogenic Markers In Well-Controlled And Poorly Controlled Patients. A Total Of 59 Patients (Median Age: 12.6 Years, Range: 11-17 Years) And 44 Healthy Controls (Median Age: 12.0 Years, Range: 11-15 Years) Were Enrolled In Our Study. Phenylketonuria Patients Were Divided Into Two Groups: Well-Controlled (Serum Phenylalanine Levels Below 360 Μmol/L; 24 Patients) And Poorly Controlled Patients (Serum Phenylalanine Levels Higher Than 360 Μmol/L). The Mean High-Density Lipoprotein Cholesterol Levels Of Well-Controlled Patients (1.0±0.2 Mmol/L) Were Significantly Lower Compared With Poorly Controlled Patients And Controls (1.1±0.2 Mmol/L, P=0.011 And 1.4±0.2 Mmol/L, P<0.001, Respectively). Poorly Controlled Patients Had Lower High-Density Lipoprotein Cholesterol Levels Than Healthy Controls (P=0.003). Homocysteine Levels Of Both Well-Controlled (9.8±6.4 Μmol/L) And Poorly Controlled (9.2±5.6 Μmol/L) Patients Were Higher Compared With Controls (5.8±1.8 Μmol/L, P<0.01). The Mean Platelet Volume Of Well-Controlled Patients (9.5±1.1 Fl) Was Higher Than That Of Poorly Controlled Patients And Controls (8.9±0.8 Fl, P=0.024 And 7.7±0.6 Fl, P<0.001, Respectively). Lower High-Density Lipoprotein Cholesterol And Higher Homocysteine And Mean Platelet Volume Levels Were Detected In Phenylketonuria Patients. In Particular, These Changes Were More Prominent In Well-Controlled Patients. We Conclude That Phenylketonuria Patients Might Be At Risk For Atherosclerosis, And Therefore Screening For Atherosclerotic Risk Factors Should Be Included In The Phenylketonuria Therapy And Follow-Up In Addition To Other Parameters.|[('Studies', 'no label'), ('Investigating', 'no label'), ('Risk Factors', 'no label'), ('Atherosclerosis', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Investigate', 'no label'), ('Serum', 'no label'), ('Atherogenic Markers', 'no label'), ('Adolescent', 'no label'), ('Classical Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Compare', 'no label'), ('Parameters', 'no label'), ('Healthy Peers', 'no label'), ('Secondary', 'no label'), ('Compare', 'no label'), ('Atherogenic Markers', 'no label'), ('Well-Controlled', 'no label'), ('Poorly Controlled', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Median Age', 'no label'), ('Years', 'no label'), ('Range', 'no label'), ('Years', 'no label'), ('Healthy Controls', 'no label'), ('Median Age', 'no label'), ('Years', 'no label'), ('Range', 'no label'), ('Years', 'no label'), ('Study', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Divided', 'no label'), ('Groups', 'no label'), ('Well-Controlled', 'no label'), ('Serum Phenylalanine Levels', 'no label'), ('Patients', 'no label'), ('Poorly Controlled', 'no label'), ('Patients', 'no label'), ('Serum Phenylalanine Levels Higher', 'no label'), ('Mean High-Density', 'no label'), ('Lipoprotein Cholesterol', 'no label'), ('Levels', 'no label'), ('Well-Controlled Patients', 'no label'), ('Compared', 'no label'), ('Poorly Controlled', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Mmol/L', 'no label'), ('Mmol/L', 'no label'), ('Poorly Controlled', 'no label'), ('Patients', 'no label'), ('Lower High-Density', 'no label'), ('Lipoprotein Cholesterol', 'no label'), ('Homocysteine', 'no label'), ('Levels', 'no label'), ('Well-Controlled', 'no label'), ('Poorly Controlled', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Platelet Volume', 'no label'), ('Well-Controlled Patients', 'no label'), ('Higher', 'no label'), ('Poorly Controlled', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Fl', 'no label'), ('High-Density', 'no label'), ('Lipoprotein Cholesterol', 'no label'), ('Higher', 'no label'), ('Homocysteine', 'no label'), ('Mean', 'no label'), ('Platelet Volume Levels', 'no label'), ('Detected', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Changes', 'no label'), ('Well-Controlled', 'no label'), ('Patients', 'no label'), ('Conclude', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Risk', 'no label'), ('Atherosclerosis', 'no label'), ('Screening', 'no label'), ('Atherosclerotic Risk Factors', 'no label'), ('Phenylketonuria Therapy', 'no label'), ('Follow-Up', 'no label'), ('Parameters', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Cholesterol', 'no label'), ('Cholesterol', 'no label'), ('Homocysteine', 'no label'), ('5.8±1.8', 'no label'), ('Platelet', 'no label'), ('Cholesterol', 'no label'), ('Homocysteine', 'no label'), ('Platelet', 'no label')]|[]|[('Atherosclerosis', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Cholesterol', 'no label'), ('Cholesterol', 'no label'), ('Homocysteine', 'no label'), ('9.2±5.6', 'no label'), ('Cholesterol', 'no label'), ('Homocysteine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Atherosclerosis', 'no label'), ('Atherosclerotic', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria Patients', 'no label'), ('Serum', 'no label'), ('Phenylketonuria Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Serum Phenylalanine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Serum Phenylalanine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('P=0.011 And', 'no label'), ('Mmol/L', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Platelet', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Fl', 'no label'), ('Homocysteine', 'no label'), ('Platelet', 'no label'), ('Phenylketonuria Patients', 'no label'), ('Patients', 'no label'), ('Conclude', 'no label'), ('Phenylketonuria Patients', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~32450880|Phenylketonuria (Pku) Is An Inherited Metabolic Disorder Characterized By Reduced Activity Of Phenylalanine Hydroxylase Resulting In Elevated Blood Phenylalanine (Phe) Concentration. Despite Some Obvious Ocular Changes, The Disorder Has Been Poorly Recognized By Ophthalmologists. Neurophysiologic Tests Imply Prolonged Reaction Time Correlating With Increased Phenylalanine Blood Concentrations. We Aimed To Test Saccadic Reaction Time In Pku Patients In Dependency Of Blood Phenylalanine Concentrations. Nineteen Biochemically Diagnosed Pku Patients And 100 Controls Completed Comprehensive Ophthalmologic And Orthoptic Examinations Including Saccadometry By Infrared Based Video-Oculography. Peak Velocity, Gain, And Particularly Latency Of Reflexive Saccades Were Compared To Controls, And Regression Analysis Was Performed. Latency Of Reflexive Saccades Was Not Associated With The Current Phenylalanine Concentration. Although In 10 Out Of 19 Patients Phenylalanine Concentrations Were Outside The Age-Related Therapeutic Range, Latency Differed Little Between Pku Patients And The Controls, As Well As Peak Velocity And Gain. Ocular Findings Occurred As Partial Hypopigmentation Of The Iris In One Late Diagnosed Patient Aged 36 Years, And As Bilateral Cataracts (Possibly Due To Steroid Intake) With Refractive Amblyopia, Strabismus, High Myopia, And Glaucoma In Another Late Diagnosed Patient Aged 46 Years. Visual Acuity Was Reduced In Eight Pku Patients. Saccadometry, Particularly Saccadic Reaction Time, Is Not Useful In The Monitoring Of Phenylketonuria. Ophthalmic Examination Is Recommended In Pku Patients, As The Occurrence Of Ocular Pathologies Was Relatively High.|[('Phenylketonuria', 'no label'), ('Inherited', 'no label'), ('Metabolic Disorder', 'no label'), ('Characterized', 'no label'), ('Reduced', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Resulting', 'no label'), ('Elevated Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Concentration', 'no label'), ('Obvious', 'no label'), ('Ocular', 'no label'), ('Changes', 'no label'), ('Disorder', 'no label'), ('Recognized', 'no label'), ('Ophthalmologists', 'no label'), ('Neurophysiologic Tests', 'no label'), ('Prolonged', 'no label'), ('Reaction Time Correlating', 'no label'), ('Increased', 'no label'), ('Phenylalanine', 'no label'), ('Blood Concentrations', 'no label'), ('Test', 'no label'), ('Saccadic Reaction', 'no label'), ('Time', 'no label'), ('Patients', 'no label'), ('Dependency', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Biochemically Diagnosed', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Completed', 'no label'), ('Comprehensive', 'no label'), ('Ophthalmologic', 'no label'), ('Orthoptic Examinations', 'no label'), ('Saccadometry', 'no label'), ('Infrared Based Video-Oculography', 'no label'), ('Peak Velocity', 'no label'), ('Gain', 'no label'), ('Latency', 'no label'), ('Reflexive Saccades', 'no label'), ('Controls', 'no label'), ('Regression Analysis', 'no label'), ('Performed', 'no label'), ('Latency', 'no label'), ('Reflexive Saccades', 'no label'), ('Associated With', 'no label'), ('Phenylalanine', 'no label'), ('Concentration', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Age-Related', 'no label'), ('Therapeutic Range', 'no label'), ('Latency Differed', 'no label'), ('Pku Patients', 'no label'), ('Controls', 'no label'), ('Peak Velocity', 'no label'), ('Gain', 'no label'), ('Ocular Findings', 'no label'), ('Partial', 'no label'), ('Hypopigmentation', 'no label'), ('Iris', 'no label'), ('Late Diagnosed', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Bilateral Cataracts', 'no label'), ('Steroid Intake', 'no label'), ('Refractive Amblyopia', 'no label'), ('Strabismus', 'no label'), ('High Myopia', 'no label'), ('Glaucoma', 'no label'), ('Late Diagnosed Patient', 'no label'), ('Aged', 'no label'), ('Visual Acuity', 'no label'), ('Reduced', 'no label'), ('Pku Patients', 'no label'), ('Saccadometry', 'no label'), ('Saccadic Reaction', 'no label'), ('Monitoring', 'no label'), ('Phenylketonuria', 'no label'), ('Ophthalmic Examination', 'no label'), ('Patients', 'no label'), ('Ocular Pathologies', 'no label'), ('High', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Dependency Of Blood Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Hypopigmentation', 'no label'), ('Cataracts', 'no label'), ('Steroid', 'no label'), ('Strabismus', 'no label'), ('Glaucoma', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Ocular', 'no label'), ('Phenylalanine', 'no label'), ('Blood', 'no label'), ('Patients', 'no label'), ('Blood Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Iris', 'no label'), ('Patient', 'no label'), ('Steroid', 'no label'), ('Patient', 'no label'), ('Phenylketonuria', 'no label'), ('Pku Patients', 'no label'), ('Ocular Pathologies', 'no label')]
phenylketonuria|pubmed~34857247|Obesity Prevalence In People With Phenylketonuria (Pku) Is Comparable To That Of The General Population But The Underlying Aetiology Remains Unknown. To Assess Body Composition, Dietary Intake, Moderate Physical Activity Duration (Mpad) And Energy Expenditure (Mpaee), Resting Metabolic Rate (Rmr), Diet-Induced Thermogenesis (Dit), Fasting And Postprandial Fat (Fox) And Carbohydrate Oxidation (Choox), In Pku People And Healthy Controls. Participants Were Pku People (N = 16) And Healthy Controls (N = 15). Body Composition Was Measured With Stable Isotopes Using Deuterium As Tracer, Dietary Intake From 4-Day Food Diaries, Mpad And Mpaee From 7-Day Activity Counts Measured By Triaxial Accelerometers, Calibrated Against Individual Rates Of Oxygen Consumption And Carbon Dioxide Production, Rmr, Dit, Fox And Choox By Indirect Calorimetry. Body Composition, Dit, Fox, Choox And Rmr Did Not Differ Between The Pku And The Control Groups. Mpad (Pku, 73 ± 26 Min/Week; Control, 152 ± 43 Min/Week) And Mpaee (Pku, 404 ± 127 Kcal/Week; Control, 741 ± 153 Kcal/Week) Were Lower (P < 0.05) In The Pku Than The Control Group. Raised Phenylalanine Levels Were Inversely Related With Mpad And Mpaee. Energy Intake And Energy Provided By Protein Did Not Differ Between The Groups, While Energy Proportion Obtained From Carbohydrate Was Higher (Pku, 60 ± 2%; Control, 51 ± 2%; P < 0.05) And From Fat Lower (Pku, 24 ± 2%; Control, 35 ± 3%; P < 0.05) In The Pku Than In The Control Group. People With Pku Spent Less Time And Expend Less Energy In Moderate Physical Activity And Have A Higher Intake Of Energy From Cho Which May Be Involved In The Underlying Mechanisms Of Obesity In Pku.|[('Obesity', 'no label'), ('Prevalence', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('General Population', 'no label'), ('Aetiology Remains', 'no label'), ('Assess', 'no label'), ('Body Composition', 'no label'), ('Dietary Intake', 'no label'), ('Moderate', 'no label'), ('Physical Activity Duration', 'no label'), ('Mpad', 'no label'), ('Energy Expenditure', 'no label'), ('Mpaee', 'no label'), ('Resting Metabolic Rate', 'no label'), ('Rmr', 'no label'), ('Thermogenesis', 'no label'), ('Dit', 'no label'), ('Fasting', 'no label'), ('Postprandial', 'no label'), ('Fat (Fox)', 'no label'), ('Carbohydrate Oxidation', 'no label'), ('Choox', 'no label'), ('Pku People', 'no label'), ('Healthy Controls', 'no label'), ('Participants', 'no label'), ('Pku People', 'no label'), ('N\xa0', 'no label'), ('Healthy Controls', 'no label'), ('N\xa0', 'no label'), ('Body Composition', 'no label'), ('Measured', 'no label'), ('Stable Isotopes', 'no label'), ('Deuterium', 'no label'), ('Tracer', 'no label'), ('Dietary Intake', 'no label'), ('4-Day Food Diaries', 'no label'), ('Mpad', 'no label'), ('Mpaee', 'no label'), ('7-Day Activity Counts', 'no label'), ('Measured', 'no label'), ('Triaxial', 'no label'), ('Accelerometers', 'no label'), ('Calibrated Against', 'no label'), ('Rates', 'no label'), ('Oxygen Consumption', 'no label'), ('Carbon Dioxide', 'no label'), ('Production', 'no label'), ('Rmr', 'no label'), ('Dit', 'no label'), ('Fox', 'no label'), ('Choox', 'no label'), ('Calorimetry', 'no label'), ('Body Composition', 'no label'), ('Dit', 'no label'), ('Fox', 'no label'), ('Choox', 'no label'), ('Rmr', 'no label'), ('Differ', 'no label'), ('Pku And The Control Groups', 'no label'), ('Mpad', 'no label'), ('Control', 'no label'), ('Mpaee', 'no label'), ('Control', 'no label'), ('Pku Than', 'no label'), ('Control Group', 'no label'), ('Raised', 'no label'), ('Phenylalanine Levels', 'no label'), ('Inversely', 'no label'), ('Mpad', 'no label'), ('Energy Intake', 'no label'), ('Protein', 'no label'), ('Groups', 'no label'), ('Energy Proportion', 'no label'), ('Carbohydrate', 'no label'), ('Higher', 'no label'), ('Control', 'no label'), ('Fat Lower', 'no label'), ('Control', 'no label'), ('Pku Than', 'no label'), ('Control Group', 'no label'), ('People', 'no label'), ('Pku Spent Less Time', 'no label'), ('Expend Less Energy', 'no label'), ('Moderate', 'no label'), ('Physical Activity', 'no label'), ('Higher', 'no label'), ('Intake', 'no label'), ('Energy', 'no label'), ('Mechanisms', 'no label'), ('Obesity', 'no label')]|[('Carbohydrate', 'no label'), ('Isotopes', 'no label'), ('Deuterium', 'no label'), ('Food', 'no label'), ('Oxygen', 'no label'), ('Dioxide', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Carbohydrate', 'no label'), ('Spent', 'no label')]|[]|[('Obesity', 'no label'), ('Phenylketonuria', 'no label'), ('N\xa0=\xa016) And Healthy Controls (N\xa0=\xa015)', 'no label'), ('Deuterium', 'no label'), ('Oxygen', 'no label'), ('Carbon Dioxide', 'no label'), ('Phenylalanine', 'no label'), ('Energy', 'no label'), ('Obesity', 'no label')]|[('People', 'no label'), ('Phenylketonuria', 'no label'), ('Carbohydrate', 'no label'), ('Deuterium', 'no label'), ('Mpad', 'no label'), ('Oxygen', 'no label'), ('Carbon Dioxide', 'no label'), ('Fox', 'no label'), ('Phenylalanine', 'no label'), ('Mpad', 'no label'), ('Fat Lower', 'no label'), ('Cho', 'no label')]
phenylketonuria|pubmed~34524592|To Gain Insight Into The Potential Protective Mechanisms Of Low Phenylalanine Diet (Lpd) In Phenylketonuria (Pku), Gene Expression Profiles Were Studied In The Cerebral Cortex And Hippocampus Of A Pku Mouse Model (Btbr-Pah<Sup>Enu2</Sup>). Pku Mice Were Fed With Low Phe Diet (Lpd-Pku Group) And Normal Diet (Pku Group). Wild-Type Mice Were Treated With Normal Diet (Wt Group) As Control. After 12 Weeks, We Detected Gene Expression In The Cerebral Cortex And Hippocampus Of The Three Groups By Rna-Sequencing, And Then Screened The Differentially-Expressed Genes (Degs) Among The Groups By Bioinformatics Analyses. We Found That The Transcriptional Profiles Of Both Cerebral Cortex And Hippocampus Changed Markedly Between Pku And Wt Mice. Furthermore, Lpd Changed The Transcriptional Profiles Of The Cerebral Cortex And The Hippocampus Of Pku Mice Significantly, Especially In The Cerebral Cortex, With Overlaps Of Genes That Changed With The Disease And Altered By Lpd Treatment. In The Cerebral Cortex, Hundreds Of Degs Enriched In A Wide Spectrum Of Biological Processes, Molecular Function, And Cellular Component, Including Nervous System Development, Axon Development And Guidance, Calcium Ion Binding, Modulation Of Chemical Synaptic Transmission, And Regulation Of Protein Kinase Activity. In The Hippocampus, The Overlapping Genes Were Enriched In Positive Regulation Of Long Term Synaptic, Negative Regulation Of Excitatory Postsynaptic Potential, Positive Regulation Of Synapse Assembly. Our Results Showed That Genes Impaired In Pku And Then Rescued By Lpd Might Indicate The Potential Protective Capability Of Lpd In The Pku Brain.|[('Gain Insight', 'no label'), ('Protective Mechanisms', 'no label'), ('Low Phenylalanine Diet', 'no label'), ('Lpd', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Gene Expression Profiles', 'no label'), ('Cerebral Cortex', 'no label'), ('Hippocampus', 'no label'), ('Pku Mouse Model', 'no label'), ('Btbr-Pah<Sup>Enu2</Sup>)', 'no label'), ('Pku Mice', 'no label'), ('Fed', 'no label'), ('Low Phe Diet', 'no label'), ('Lpd-Pku Group', 'no label'), ('Normal Diet', 'no label'), ('Pku Group', 'no label'), ('Wild-Type Mice', 'no label'), ('Treated With', 'no label'), ('Normal Diet', 'no label'), ('Wt Group', 'no label'), ('Control', 'no label'), ('Weeks', 'no label'), ('Detected', 'no label'), ('Gene Expression', 'no label'), ('Cerebral Cortex', 'no label'), ('Hippocampus', 'no label'), ('Groups', 'no label'), ('Rna-Sequencing', 'no label'), ('Screened', 'no label'), ('Differentially-Expressed Genes', 'no label'), ('Degs', 'no label'), ('Groups', 'no label'), ('Transcriptional Profiles', 'no label'), ('Cerebral Cortex', 'no label'), ('Hippocampus', 'no label'), ('Changed', 'no label'), ('Markedly', 'no label'), ('Pku And Wt Mice', 'no label'), ('Lpd', 'no label'), ('Changed', 'no label'), ('Transcriptional Profiles', 'no label'), ('Cerebral Cortex', 'no label'), ('Hippocampus', 'no label'), ('Pku Mice', 'no label'), ('Cerebral Cortex', 'no label'), ('Genes', 'no label'), ('Changed', 'no label'), ('Disease', 'no label'), ('Lpd Treatment', 'no label'), ('Cerebral Cortex', 'no label'), ('Degs', 'no label'), ('Wide Spectrum', 'no label'), ('Biological Processes', 'no label'), ('Molecular Function', 'no label'), ('Cellular Component', 'no label'), ('Nervous System Development', 'no label'), ('Axon Development', 'no label'), ('Guidance', 'no label'), ('Calcium Ion Binding', 'no label'), ('Modulation', 'no label'), ('Chemical Synaptic Transmission', 'no label'), ('Regulation', 'no label'), ('Protein Kinase Activity', 'no label'), ('Hippocampus', 'no label'), ('Overlapping Genes', 'no label'), ('Positive Regulation', 'no label'), ('Long Term Synaptic', 'no label'), ('Negative Regulation', 'no label'), ('Postsynaptic', 'no label'), ('Potential', 'no label'), ('Positive Regulation', 'no label'), ('Synapse', 'no label'), ('Assembly', 'no label'), ('Results', 'no label'), ('Genes', 'no label'), ('Impaired', 'no label'), ('Rescued', 'no label'), ('Lpd', 'no label'), ('Potential', 'no label'), ('Protective Capability', 'no label'), ('Lpd', 'no label'), ('Pku Brain', 'no label')]|[('Phenylalanine', 'no label'), ('Gene', 'no label'), ('Mouse', 'no label'), ('Mice', 'no label'), ('Phe', 'no label'), ('Mice', 'no label'), ('Wt', 'no label'), ('Gene', 'no label'), ('Genes', 'no label'), ('Wt Mice', 'no label'), ('Mice', 'no label'), ('Genes', 'no label'), ('Molecular', 'no label'), ('Cellular', 'no label'), ('Calcium Ion', 'no label'), ('Chemical Synaptic', 'no label'), ('Protein', 'no label'), ('Excitatory Postsynaptic Potential', 'no label'), ('Genes', 'no label')]|[('Differentially-Expressed Genes', 'no label'), ('Overlapping Genes', 'no label'), ('Lpd', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phe', 'no label'), ('Calcium', 'no label')]|[('Gain Insight', 'no label'), ('Phenylalanine', 'no label'), ('Lpd', 'no label'), ('Phenylketonuria', 'no label'), ('Cerebral Cortex', 'no label'), ('Hippocampus Of A Pku Mouse', 'no label'), ('Mice', 'no label'), ('Phe', 'no label'), ('Mice', 'no label'), ('Cerebral Cortex', 'no label'), ('Hippocampus', 'no label'), ('Cerebral Cortex', 'no label'), ('Hippocampus', 'no label'), ('Mice', 'no label'), ('Lpd', 'no label'), ('Cerebral Cortex', 'no label'), ('Hippocampus Of', 'no label'), ('Mice', 'no label'), ('Cerebral Cortex', 'no label'), ('Lpd', 'no label'), ('Cerebral Cortex', 'no label'), ('Cellular', 'no label'), ('Axon', 'no label'), ('Calcium Ion', 'no label'), ('Synaptic', 'no label'), ('Protein Kinase', 'no label'), ('Synaptic', 'no label'), ('Lpd', 'no label'), ('Lpd', 'no label')]
phenylketonuria|pubmed~34474089|Many Countries Do Not Have A Newborn Screening (Nbs) Program, And Immigrants From Such Countries Are At Risk For Late Diagnosis Of Phenylketonuria (Pku). In This International Survey, 52 Of 259 Patients (20%) With Late Diagnosed Pku Were Immigrants, And 145 Of The 259 (55%) Were Born Before Nbs Or In A Location Without Nbs.|[('Countries', 'no label'), ('Newborn Screening', 'no label'), ('Immigrants', 'no label'), ('Countries', 'no label'), ('Risk', 'no label'), ('Late Diagnosis', 'no label'), ('Phenylketonuria', 'no label'), ('International Survey', 'no label'), ('Patients', 'no label'), ('Late Diagnosed Pku', 'no label'), ('Immigrants', 'no label'), ('Born', 'no label'), ('Nbs', 'no label'), ('Location', 'no label'), ('Nbs', 'no label')]|[]|[]|[('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~29981005|Recent Studies Have Shown That Patients With Phenylketonuria (Pku), Even With The Early Diagnosis And Continuous Treatment, May Have Symptoms Of Attention-Deficit Hyperactivity Disorder (Adhd) And That The Prevalence Of Adhd In This Population Would Be Higher Than In The General Population. This Study Aims To Determine The Prevalence Of Adhd In A Sample Of Pku Patients From Southern Brazil. Patients Were Prospectively Assessed By Clinical Interviews, Neurological Examination, And Application Of The Mta-Snap-Iv Scales For Patients Aged 5-17 Years And The Adult Self-Report Scale For Patients Over 17 Years. Thirty-One Patients (Mean Age = 17.4; Early Diagnosis = 27) Were Followed. Patients With Adhd And Younger Than 17 Years Had A Median Phe In The Last 6 Months Of Life Higher Than Those Without The Diagnosis Of Adhd (Adhd Patients = 617.1 Μmol/L, No-Adhd Patients 393.2 Μmol/L, And P = 0.03). There Was A Predominantly Hyperactive/Impulsivity Clinical Presentation Of Adhd (N = 4/5 Patients), Which Differs From That Reported Elsewhere In The Literature. Future Studies Are Essential To Better Define The Clinical Presentation Of Adhd In These Patients And Further Elucidate Its Pathophysiology.|[('Studies', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Early Diagnosis', 'no label'), ('Continuous Treatment', 'no label'), ('May', 'no label'), ('Symptoms', 'no label'), ('Attention-Deficit Hyperactivity Disorder', 'no label'), ('Adhd', 'no label'), ('Prevalence', 'no label'), ('Adhd', 'no label'), ('Population', 'no label'), ('Higher', 'no label'), ('General Population', 'no label'), ('Study', 'no label'), ('Prevalence', 'no label'), ('Adhd', 'no label'), ('Sample', 'no label'), ('Pku Patients', 'no label'), ('Southern Brazil', 'no label'), ('Patients', 'no label'), ('Assessed', 'no label'), ('Clinical Interviews', 'no label'), ('Neurological Examination', 'no label'), ('Mta-Snap-Iv Scales', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Adult Self-Report Scale', 'no label'), ('Patients', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Mean Age\u2009', 'no label'), ('Early Diagnosis', 'no label'), ('Followed', 'no label'), ('Patients', 'no label'), ('Adhd', 'no label'), ('Younger Than 17\xa0', 'no label'), ('Years', 'no label'), ('Median', 'no label'), ('Phe', 'no label'), ('Months', 'no label'), ('Life Higher', 'no label'), ('Diagnosis', 'no label'), ('Adhd', 'no label'), ('Adhd', 'no label'), ('Patients', 'no label'), ('No-Adhd Patients', 'no label'), ('Hyperactive/Impulsivity Clinical Presentation', 'no label'), ('Adhd', 'no label'), ('Patients', 'no label'), ('Differs', 'no label'), ('Literature', 'no label'), ('Studies', 'no label'), ('Clinical Presentation', 'no label'), ('Adhd', 'no label'), ('Patients', 'no label'), ('Pathophysiology', 'no label')]|[('Adhd', 'no label'), ('Adhd', 'no label'), ('Adhd', 'no label'), ('Phe', 'no label'), ('Adhd', 'no label'), ('Adhd', 'no label'), ('Adhd', 'no label'), ('Adhd', 'no label')]|[('No-Adhd', 'no label')]|[('Phenylketonuria', 'no label'), ('Attention-Deficit Hyperactivity Disorder', 'no label'), ('Phe', 'no label')]|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Attention-Deficit Hyperactivity Disorder', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Last 6', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~34294923|Phenylketonuria (Pku) Is A Rare Disease Caused By Biallelic Mutations In The Pah Gene That Result In An Inability To Convert Phenylalanine (Phe) To Tyrosine, Elevated Blood Phe Levels And Severe Neurological Complications If Untreated. Most Patients Are Unable To Adhere To The Protein-Restricted Diet, And Thus Do Not Achieve Target Blood Phe Levels. We Engineered A Strain Of E. Coli Nissle 1917, Designated Synb1618, Through Insertion Of The Genes Encoding Phenylalanine Ammonia Lyase And L-Amino Acid Deaminase Into The Genome, Which Allow For Bacterial Consumption Of Phe Within The Gastrointestinal Tract. Synb1618 Was Studied In A Phase 1/2A Randomized, Placebo-Controlled, Double-Blind, Multi-Centre, In-Patient Study ( Nct03516487 ) In Adult Healthy Volunteers (N = 56) And Patients With Pku And Blood Phe Level ≥600 Mmol L<Sup>-1</Sup> (N = 14). Participants Were Randomized To Receive A Single Dose Of Synb1618 Or Placebo (Part 1) Or Up To Three Times Per Day For Up To 7 Days (Part 2). The Primary Outcome Of This Study Was Safety And Tolerability, And The Secondary Outcome Was Microbial Kinetics. A D5-Phe Tracer (15 Mg Kg<Sup>-1</Sup>) Was Used To Study Exploratory Pharmacodynamic Effects. Synb1618 Was Safe And Well Tolerated With A Maximum Tolerated Dose Of 2 × 10<Sup>11</Sup> Colony-Forming Units. Adverse Events Were Mostly Gastrointestinal And Of Mild To Moderate Severity. All Participants Cleared The Bacteria Within 4 Days Of The Last Dose. Dose-Responsive Increases In Strain-Specific Phe Metabolites In Plasma (Trans-Cinnamic Acid) And Urine (Hippuric Acid) Were Observed, Providing A Proof Of Mechanism For The Potential To Use Engineered Bacteria In The Treatment Of Rare Metabolic Disorders.|[('Phenylketonuria', 'no label'), ('Rare Disease', 'no label'), ('Biallelic Mutations', 'no label'), ('Pah Gene', 'no label'), ('Result', 'no label'), ('Convert Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Elevated Blood Phe Levels', 'no label'), ('Severe', 'no label'), ('Neurological Complications', 'no label'), ('Untreated', 'no label'), ('Patients', 'no label'), ('Protein-Restricted Diet', 'no label'), ('Target', 'no label'), ('Blood Phe Levels', 'no label'), ('Engineered', 'no label'), ('Strain', 'no label'), ('E. Coli Nissle 1917', 'no label'), ('Designated Synb1618', 'no label'), ('Insertion', 'no label'), ('Genes', 'no label'), ('Encoding', 'no label'), ('Phenylalanine Ammonia', 'no label'), ('Lyase', 'no label'), ('L-Amino Acid Deaminase', 'no label'), ('Genome', 'no label'), ('Bacterial', 'no label'), ('Consumption', 'no label'), ('Phe', 'no label'), ('Gastrointestinal Tract', 'no label'), ('Phase 1/2A Randomized', 'no label'), ('Placebo-Controlled', 'no label'), ('Double-Blind', 'no label'), ('Multi-Centre', 'no label'), ('Nct03516487', 'no label'), ('Adult Healthy Volunteers', 'no label'), ('Patients', 'no label'), ('Pku And Blood Phe Level', 'no label'), ('Participants', 'no label'), ('Randomized', 'no label'), ('Dose', 'no label'), ('Synb1618', 'no label'), ('Placebo', 'no label'), ('Times', 'no label'), ('Days', 'no label'), ('Primary Outcome', 'no label'), ('Study', 'no label'), ('Tolerability', 'no label'), ('Secondary Outcome', 'no label'), ('Microbial', 'no label'), ('Kinetics', 'no label'), ('Tracer', 'no label'), ('Study', 'no label'), ('Exploratory', 'no label'), ('Pharmacodynamic Effects', 'no label'), ('Synb1618', 'no label'), ('Safe', 'no label'), ('Maximum Tolerated Dose', 'no label'), ('Adverse Events', 'no label'), ('Gastrointestinal', 'no label'), ('Mild', 'no label'), ('Moderate', 'no label'), ('Severity', 'no label'), ('Participants', 'no label'), ('Cleared', 'no label'), ('Bacteria', 'no label'), ('Days', 'no label'), ('Last Dose', 'no label'), ('Dose-Responsive Increases', 'no label'), ('Strain-Specific Phe', 'no label'), ('Metabolites', 'no label'), ('Plasma', 'no label'), ('Trans-Cinnamic Acid', 'no label'), ('Urine', 'no label'), ('Hippuric Acid', 'no label'), ('Observed', 'no label'), ('Mechanism', 'no label'), ('Potential', 'no label'), ('Engineered Bacteria', 'no label'), ('Treatment', 'no label'), ('Rare', 'no label'), ('Metabolic Disorders', 'no label')]|[('Mutations', 'no label'), ('Gene', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Coli Nissle', 'no label'), ('Insertion', 'no label'), ('Genes', 'no label'), ('Phenylalanine Ammonia', 'no label'), ('Genome', 'no label'), ('Phe', 'no label'), ('Bacteria', 'no label')]|[('Pah Gene', 'no label'), ('Synb1618', 'no label'), ('Synb1618', 'no label'), ('Per', 'no label'), ('Synb1618', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Neurological Complications', 'no label'), ('L-Amino Acid', 'no label'), ('Phe', 'no label'), ('N\u2009=\u200956) And', 'no label'), ('≥600', 'no label'), ('Mg', 'no label'), ('Hippuric Acid', 'no label'), ('Metabolic Disorders', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Blood', 'no label'), ('E. Coli Nissle', 'no label'), ('Synb1618', 'no label'), ('Phenylalanine Ammonia', 'no label'), ('Lyase', 'no label'), ('L-Amino Acid Deaminase', 'no label'), ('Phe', 'no label'), ('Gastrointestinal', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Blood Phe', 'no label'), ('Synb1618', 'no label'), ('Part 1', 'no label'), ('Part 2', 'no label'), ('Mg', 'no label'), ('Phe', 'no label'), ('Plasma', 'no label'), ('Urine', 'no label'), ('Hippuric Acid', 'no label')]
phenylketonuria|pubmed~33672234|Aspartame Is A Phenylalanine Containing Sweetener, Added To Foods And Drinks, Which Is Avoided In Phenylketonuria (Pku). However, The Amount Of Phenylalanine Provided By Aspartame Is Unidentifiable From Food And Drinks Labels. We Performed A Cross-Sectional Online Survey Aiming To Examine The Accidental Aspartame Consumption In Pku. 206 Questionnaires (58% Female) Were Completed. 55% Of Respondents (<I>N</I> = 114) Were Adults With Pku Or Their Parent/Carers And 45% (<I>N</I> = 92) Were Parents/Carers Of Children With Pku. 74% (<I>N</I> = 152/206) Had Consumed Food/Drinks Containing Aspartame. Repeated Accidental Aspartame Consumption Was Common And More Frequent In Children (<I>P</I> < 0.0001). The Aspartame Containing Food/Drinks Accidentally Consumed Were Fizzy Drinks (68%, <I>N</I> = 103/152), Fruit Squash (40%, <I>N</I> = 61/152), Chewing Gum (30%, <I>N</I> = 46/152), Flavoured Water (25%, <I>N</I> = 38/152), Ready To Drink Fruit Squash Cartons (23%, <I>N</I> = 35/152) And Sports Drinks (21%, <I>N</I> = 32/152). The Main Reasons Described For Accidental Consumption, Were Manufacturers' Changing Recipes (81%, <I>N</I> = 123/152), Inability To Check The Ingredients In Pubs/Restaurants/Vending Machines (59%, <I>N</I> = 89/152) Or Forgetting To Check The Label (32%, <I>N</I> = 49/152). 23% (<I>N</I>= 48/206) Had Been Prescribed Medicines Containing Aspartame And 75% (<I>N</I> = 36/48) Said That Medicines Were Not Checked By Medics When Prescribed. 85% (<I>N</I> = 164/192) Considered The Sugar Tax Made Accidental Aspartame Consumption More Likely. Some Of The Difficulties For Patients Were Aspartame Identification In Drinks Consumed In Restaurants, Pubs, Vending Machines (77%, <I>N</I> = 158/206); Similarities In Appearance Of Aspartame And Non-Aspartame Products (62%, <I>N</I> = 127/206); Time Consuming Shopping/Checking Labels (56%, <I>N</I> = 115/206); And Unclear Labelling (55%, <I>N</I> = 114/206). These Issues Caused Anxiety For The Person With Pku (52%, <I>N</I> = 106/206), Anxiety For Parent/Caregivers (46%, <I>N</I> = 95/206), Guilt For Parent/Carers (42%, <I>N</I> = 87/206) And Social Isolation (42%, <I>N</I> = 87/206). It Is Important To Understand The Impact Of Aspartame And Legislation Such As The Sugar Tax On People With Pku. Policy Makers And Industry Should Ensure That The Quality Of Life Of People With Rare Conditions Such As Pku Is Not Compromised Through Their Action.|"[('Aspartame', 'no label'), ('Phenylalanine Containing', 'no label'), ('Sweetener', 'no label'), ('Added', 'no label'), ('Foods', 'no label'), ('Drinks', 'no label'), ('Phenylketonuria', 'no label'), ('Amount', 'no label'), ('Phenylalanine', 'no label'), ('Aspartame', 'no label'), ('Unidentifiable', 'no label'), ('Food And Drinks', 'no label'), ('Performed', 'no label'), ('Cross-Sectional Online Survey', 'no label'), ('Accidental Aspartame', 'no label'), ('Consumption', 'no label'), ('Questionnaires', 'no label'), ('Female', 'no label'), ('Completed', 'no label'), ('Respondents', 'no label'), ('<I>N</I> = 114) Were Adults', 'no label'), ('Pku Or', 'no label'), ('Parent/Carers', 'no label'), ('<I>N</I>', 'no label'), ('Parents/Carers', 'no label'), ('Children', 'no label'), ('<I>N</I>', 'no label'), ('Consumed', 'no label'), ('Food/Drinks', 'no label'), ('Containing', 'no label'), ('Aspartame', 'no label'), ('Accidental Aspartame', 'no label'), ('Consumption', 'no label'), ('Frequent', 'no label'), ('Children', 'no label'), ('<I>P</I> < 0.0001', 'no label'), ('Aspartame', 'no label'), ('Containing', 'no label'), ('Accidentally Consumed', 'no label'), ('Fizzy Drinks', 'no label'), ('Fruit Squash', 'no label'), ('Chewing Gum', 'no label'), ('Flavoured Water', 'no label'), ('Ready', 'no label'), ('Fruit Squash Cartons', 'no label'), ('Sports Drinks', 'no label'), ('Accidental Consumption', 'no label'), (""Manufacturers'"", 'no label'), ('Changing Recipes', 'no label'), ('Ingredients', 'no label'), ('Pubs/Restaurants/Vending Machines', 'no label'), ('Forgetting', 'no label'), ('Label', 'no label'), ('<I>N</I>= 48/206', 'no label'), ('Medicines', 'no label'), ('Containing Aspartame', 'no label'), ('<I>N</I>', 'no label'), ('Medicines', 'no label'), ('Not Checked', 'no label'), ('Prescribed', 'no label'), ('<I>N</I> = 164/192)', 'no label'), ('Sugar', 'no label'), ('Tax', 'no label'), ('Accidental Aspartame', 'no label'), ('Consumption', 'no label'), ('Difficulties', 'no label'), ('Patients', 'no label'), ('Aspartame', 'no label'), ('Identification', 'no label'), ('Drinks', 'no label'), ('Consumed', 'no label'), ('Restaurants', 'no label'), ('Pubs', 'no label'), ('Similarities', 'no label'), ('Appearance', 'no label'), ('Aspartame', 'no label'), ('Time Consuming Shopping/Checking Labels', 'no label'), ('Unclear Labelling', 'no label'), ('Issues', 'no label'), ('Person', 'no label'), ('Anxiety For Parent/Caregivers', 'no label'), ('Guilt', 'no label'), ('Parent/Carers', 'no label'), ('Social Isolation', 'no label'), ('Impact', 'no label'), ('Aspartame', 'no label'), ('Legislation', 'no label'), ('Sugar', 'no label'), ('Tax', 'no label'), ('People', 'no label'), ('Pku.', 'no label'), ('Industry', 'no label'), ('Ensure', 'no label'), ('Quality Of Life', 'no label'), ('People', 'no label'), ('Rare', 'no label'), ('Conditions', 'no label'), ('Compromised', 'no label'), ('Action', 'no label')]"|[('Aspartame Is A Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Aspartame', 'no label'), ('Food', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Water', 'no label'), ('Aspartame', 'no label'), ('Tax', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Tax', 'no label')]|[('Food/Drinks', 'no label'), ('Food/Drinks', 'no label'), ('N</I>=', 'no label'), ('Tax', 'no label'), ('Tax', 'no label')]|[('Aspartame', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Flavoured', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Anxiety', 'no label'), ('Anxiety', 'no label'), ('Aspartame', 'no label')]|[('Aspartame', 'no label'), ('A Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Aspartame', 'no label'), ('Drinks Labels', 'no label'), ('Aspartame', 'no label'), ('Children', 'no label'), ('Food/Drinks', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Children', 'no label'), ('Aspartame', 'no label'), ('Food/Drinks', 'no label'), ('Fizzy Drinks', 'no label'), ('Fruit Squash', 'no label'), ('Gum', 'no label'), ('Aspartame', 'no label'), ('Sugar Tax', 'no label'), ('Aspartame', 'no label'), ('Patients', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Aspartame', 'no label'), ('Sugar Tax', 'no label'), ('People', 'no label'), ('People', 'no label')]
phenylketonuria|pubmed~29390883|Phenylketonuria (Pku, Omim 261600) Caused By Phenylalanine Hydroxylase (Pah) Deficiency Is An Autosomal Recessive Disease That Is Characterized By Abnormalities Of Phenylalanine Metabolism. In This Study, A Total Of 77 Patients, Originating From The Central Region Of China And Who Were Diagnosed With Pah Deficiency At The Third Affiliated Hospital Of Zhengzhou University, Were Enrolled In This Study. The 13 Exons And 12 Flanking Introns Of The Pah Gene Were Analyzed By Sanger Sequencing And Next Generation Sequencing. The Sequencing Data Were Aligned To The Hg19, Pahvdb And Hgmd Databases To Characterize The Genotypes Of Pku Patients, And Genotype-Phenotype Correlations And Bh4 Responsiveness Predictions Were Performed Using Biopkudb. In Total, 149 Alleles Were Characterized Among The 154 Pku Alleles. These Mutations Were Located In Exons 2-13, And Intron 12 Of The Pah Gene, With A Relative Frequency Of ≥5%, For Ex6-96A>G, P.R241C, P.R243Q, P.V399V And P.R53H. Additionally, A Novel Variant, P.D84G, Was Identified. The Genotype Correlated With Clinical Symptoms In 33.3-100% Of The Cases, Depending On The Disease Severity, And Bh4 Responsiveness Predictions Show That Only Five Patients With Mhp-Pku And One Patient With Mild-Pku Were Predicted To Be Bh4 Responsive. In Conclusion, We Have Characterized The Mutational Spectrum Of Pah In The Central Region Of China And Have Identified A Novel Mutation. The Hotspot Mutation Information Might Be Useful For Screening, Diagnosis And Treatment Of Pku.|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Autosomal Recessive Disease', 'no label'), ('Characterized', 'no label'), ('Abnormalities', 'no label'), ('Phenylalanine Metabolism', 'no label'), ('Study', 'no label'), ('Patients', 'no label'), ('Central Region', 'no label'), ('China', 'no label'), ('Diagnosed', 'no label'), ('Pah Deficiency', 'no label'), ('Affiliated Hospital', 'no label'), ('Zhengzhou University', 'no label'), ('Study', 'no label'), ('Exons', 'no label'), ('Flanking', 'no label'), ('Introns', 'no label'), ('Pah Gene', 'no label'), ('Analyzed', 'no label'), ('Sanger Sequencing', 'no label'), ('Next Generation Sequencing', 'no label'), ('Sequencing Data', 'no label'), ('Aligned', 'no label'), ('Hg19', 'no label'), ('Pahvdb', 'no label'), ('Hgmd Databases', 'no label'), ('Characterize', 'no label'), ('Genotypes', 'no label'), ('Pku Patients', 'no label'), ('Genotype-Phenotype', 'no label'), ('Correlations', 'no label'), ('Bh4', 'no label'), ('Responsiveness', 'no label'), ('Predictions', 'no label'), ('Performed', 'no label'), ('Biopkudb', 'no label'), ('Alleles', 'no label'), ('Characterized', 'no label'), ('Pku Alleles', 'no label'), ('Mutations', 'no label'), ('Exons', 'no label'), ('Intron', 'no label'), ('Pah Gene', 'no label'), ('Relative Frequency', 'no label'), ('Ex6-96A>G', 'no label'), ('P.R241C', 'no label'), ('P.R243Q', 'no label'), ('P.V399V', 'no label'), ('Variant', 'no label'), ('P.D84G', 'no label'), ('Identified', 'no label'), ('Genotype', 'no label'), ('Correlated', 'no label'), ('Clinical Symptoms', 'no label'), ('Cases', 'no label'), ('Disease Severity', 'no label'), ('Bh4', 'no label'), ('Responsiveness', 'no label'), ('Predictions', 'no label'), ('Patients', 'no label'), ('Mhp-Pku', 'no label'), ('Patient', 'no label'), ('Mild-Pku', 'no label'), ('Predicted', 'no label'), ('Bh4 Responsive', 'no label'), ('Characterized', 'no label'), ('Mutational Spectrum', 'no label'), ('Central Region', 'no label'), ('China', 'no label'), ('Identified', 'no label'), ('Novel', 'no label'), ('Mutation', 'no label'), ('Hotspot Mutation Information', 'no label'), ('Screening', 'no label'), ('Diagnosis', 'no label'), ('Treatment', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Region', 'no label'), ('Exons', 'no label'), ('Introns', 'no label'), ('Gene', 'no label'), ('Pahvdb', 'no label'), ('Hgmd', 'no label'), ('Genotypes', 'no label'), ('Alleles', 'no label'), ('Alleles', 'no label'), ('Mutations', 'no label'), ('Exons', 'no label'), ('Intron', 'no label'), ('Gene', 'no label'), ('Ex6', 'no label'), ('Genotype', 'no label'), ('Region', 'no label'), ('Mutation', 'no label'), ('Mutation', 'no label')]|[('13 Exons', 'no label'), ('Pah Gene', 'no label'), ('Hgmd', 'no label'), ('Exons 2-13, And Intron 12', 'no label'), ('Pah Gene', 'no label'), ('Pah', 'no label')]|[('Phenylketonuria', 'no label'), ('261600', 'no label'), ('Phenylalanine', 'no label'), ('Autosomal Recessive Disease', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Pah', 'no label'), ('Pah Gene', 'no label'), ('Pahvdb', 'no label'), ('Bh4 Responsiveness', 'no label'), ('Intron 12', 'no label'), ('Pah Gene', 'no label'), ('Ex6', 'no label'), ('P.V399V', 'no label'), ('P.D84G', 'no label'), ('Bh4 Responsiveness', 'no label'), ('Patients', 'no label'), ('Patient', 'no label'), ('Pah', 'no label')]
phenylketonuria|pubmed~30284526|It Has Been Nearly 70 Years Since The Discovery That Strict Adherence To A Diet Low In Phenylalanine Prevents Severe Neurological Sequelae In Patients With Phenylalanine Hydroxylase Deficiency (Phenylketonuria; Pku). Today, Dietary Treatment With Restricted Phenylalanine Intake Supplemented With Non-Phenylalanine Amino Acids To Support Growth And Maintain A Healthy Body Composition Remains The Mainstay Of Therapy. However, A Better Understanding Is Needed Of The Factors That Influence N Balance In The Context Of Amino Acid Supplementation. The Aim Of The Present Paper Is To Summarise Considerations For Improving N Balance In Patients With Pku, With A Focus On Gaining Greater Understanding Of Amino Acid Absorption, Disposition And Utilisation. In Addition, The Impact Of Phenylalanine-Free Amino Acids On 24 H Blood Phenylalanine/Tyrosine Circadian Rhythm Is Evaluated. We Compare The Effects Of Administering Intact Protein V. Free Amino Acid On Protein Metabolism And Discuss The Possibility Of Improving Outcomes By Administering Amino Acid Mixtures So That Their Absorption Profile Mimics That Of Intact Protein. Protein Substitutes With The Ability To Delay Absorption Of Phenylalanine And Tyrosine, Mimicking Physiological Absorption Kinetics, Are Expected To Improve The Rate Of Assimilation Into Protein And Minimise Fluctuations In Quantitative Plasma Amino Acid Levels. They May Also Help Maintain Normal Glycaemia And Satiety Sensation. This Is Likely To Play An Important Role In Improving The Management Of Patients With Pku.|[('Years', 'no label'), ('Discovery', 'no label'), ('Strict', 'no label'), ('Adherence', 'no label'), ('Diet', 'no label'), ('Low', 'no label'), ('Phenylalanine', 'no label'), ('Prevents', 'no label'), ('Severe', 'no label'), ('Neurological Sequelae', 'no label'), ('Patients', 'no label'), ('Phenylalanine Hydroxylase Deficiency', 'no label'), ('Phenylketonuria', 'no label'), ('Dietary Treatment', 'no label'), ('Restricted Phenylalanine Intake', 'no label'), ('Supplemented', 'no label'), ('Non-Phenylalanine Amino Acids', 'no label'), ('Growth', 'no label'), ('Maintain', 'no label'), ('Healthy', 'no label'), ('Body Composition', 'no label'), ('Mainstay', 'no label'), ('Therapy', 'no label'), ('Factors', 'no label'), ('Influence', 'no label'), ('Balance', 'no label'), ('Context', 'no label'), ('Amino Acid', 'no label'), ('Supplementation', 'no label'), ('Present Paper', 'no label'), ('Summarise Considerations', 'no label'), ('Improving', 'no label'), ('N Balance', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Focus', 'no label'), ('Amino Acid Absorption', 'no label'), ('Disposition', 'no label'), ('Utilisation', 'no label'), ('Impact', 'no label'), ('Phenylalanine-Free Amino Acids', 'no label'), ('Blood', 'no label'), ('Evaluated', 'no label'), ('Compare', 'no label'), ('Effects', 'no label'), ('Administering', 'no label'), ('Intact Protein V. Free Amino Acid', 'no label'), ('Protein Metabolism', 'no label'), ('Discuss', 'no label'), ('Possibility', 'no label'), ('Improving', 'no label'), ('Outcomes', 'no label'), ('Administering', 'no label'), ('Amino Acid', 'no label'), ('Mixtures', 'no label'), ('Absorption Profile', 'no label'), ('Mimics', 'no label'), ('Intact Protein', 'no label'), ('Ability', 'no label'), ('Delay Absorption', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Physiological Absorption', 'no label'), ('Kinetics', 'no label'), ('Expected', 'no label'), ('Rate', 'no label'), ('Assimilation Into Protein', 'no label'), ('Fluctuations', 'no label'), ('Quantitative', 'no label'), ('Plasma', 'no label'), ('Amino Acid', 'no label'), ('Levels', 'no label'), ('Help Maintain', 'no label'), ('Normal Glycaemia', 'no label'), ('Satiety', 'no label'), ('Sensation', 'no label'), ('Improving', 'no label'), ('Management', 'no label'), ('Patients', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acids', 'no label'), ('Amino Acid', 'no label'), ('Amino Acid', 'no label'), ('Amino Acids', 'no label'), ('Protein', 'no label'), ('Amino Acid', 'no label'), ('Protein', 'no label'), ('Amino Acid', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Protein', 'no label'), ('Amino Acid', 'no label')]|[]|[('Phenylalanine', 'no label'), ('Neurological Sequelae', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Non-Phenylalanine Amino Acids To Support Growth And Maintain A Healthy Body Composition Remains The Mainstay Of Therapy', 'no label'), ('N Balance', 'no label'), ('Amino Acid', 'no label'), ('N Balance', 'no label'), ('Amino Acid Absorption', 'no label'), ('Amino Acids', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Amino Acid', 'no label'), ('Satiety', 'no label')]|[('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Non-Phenylalanine Amino', 'no label'), ('Body', 'no label'), ('Amino Acid', 'no label'), ('Patients', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine-Free Amino', 'no label'), ('H Blood Phenylalanine/Tyrosine', 'no label'), ('Amino Acid', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Plasma Amino Acid', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~34579066|Nitrogen Balance Is The Difference Between Nitrogen Excreted As Urea And Nitrogen Ingested, Mainly In Proteins. Increased Circulating Concentrations Of Amino Acids (Aa) In The Bloodstream Are Usually Associated With Proportional Increases In The Production And Excretion Of Urea. Previously, We Reported Results From A Randomized, Controlled, Single-Dose, Crossover Trial In Healthy Adult Volunteers (N = 30) (Trial Registration: Isrctn11016729), In Which A Test Product (Prolonged-Release Aa Mixture Formulated With Physiomimic Technology™ (Pt™)) Significantly Slowed Down The Release And Reduced The Peak Plasma Concentrations Of Essential Aas Compared With A Free Aa Mixture (Reference Product) While Maintaining Essential Aa Bioavailability. Here, We Report An Assessment Of The Nitrogen Balance From The Same Study. The Amount Of Nitrogen Contained In Plasma Aas, Levels Of Blood Urea Nitrogen (Bun) (<I>P</I> < 0.0001) And Changes In Bun (<I>P</I> < 0.0001) Were Smaller After The Test Product Compared With The Reference Product. These Findings Suggest That The Production Of Urea In Proportion To Systemic Aa Availability Was Significantly Smaller After The Administration Of The Test Product Compared With The Reference Product And That The Test Product Conferred The Increased Utilization Of Aas For Protein Synthesis And Reduced Their Oxidation And Conversion To Urea. In The Clinical Setting, It Is Possible That The Effects Of Pt™ Observed On The Disposition Of Free Aas In This Study May Translate To Health Benefits In Terms Of Physiological Body Composition And Growth If Used For The Treatment Of Subjects With Phenylketonuria (Pku). Further Investigation In Patients With Pku Is Warranted.|[('Nitrogen Balance', 'no label'), ('Difference', 'no label'), ('Nitrogen Excreted', 'no label'), ('Urea', 'no label'), ('Nitrogen Ingested', 'no label'), ('Proteins', 'no label'), ('Increased', 'no label'), ('Circulating', 'no label'), ('Concentrations', 'no label'), ('Amino Acids', 'no label'), ('Aa', 'no label'), ('Bloodstream', 'no label'), ('Associated With', 'no label'), ('Proportional', 'no label'), ('Increases', 'no label'), ('Production', 'no label'), ('Excretion', 'no label'), ('Urea', 'no label'), ('Randomized', 'no label'), ('Controlled', 'no label'), ('Single-Dose', 'no label'), ('Crossover Trial', 'no label'), ('Healthy Adult Volunteers', 'no label'), ('Trial Registration', 'no label'), ('Prolonged-Release Aa Mixture', 'no label'), ('Physiomimic Technology™', 'no label'), ('Slowed Down', 'no label'), ('Release', 'no label'), ('Reduced', 'no label'), ('Plasma', 'no label'), ('Concentrations', 'no label'), ('Essential Aas', 'no label'), ('Free Aa Mixture', 'no label'), ('Essential', 'no label'), ('Bioavailability', 'no label'), ('Assessment', 'no label'), ('Nitrogen Balance', 'no label'), ('Amount', 'no label'), ('Nitrogen Contained', 'no label'), ('Plasma', 'no label'), ('Levels', 'no label'), ('Blood Urea Nitrogen', 'no label'), ('Bun', 'no label'), ('<I>P</I> < 0.0001)', 'no label'), ('Changes', 'no label'), ('Bun', 'no label'), ('<I>P</I> < 0.0001)', 'no label'), ('Test Product', 'no label'), ('Reference Product', 'no label'), ('Findings', 'no label'), ('Suggest', 'no label'), ('Production', 'no label'), ('Urea', 'no label'), ('Systemic', 'no label'), ('Availability', 'no label'), ('Administration', 'no label'), ('Test Product', 'no label'), ('Reference Product', 'no label'), ('Test Product', 'no label'), ('Conferred', 'no label'), ('Increased', 'no label'), ('Utilization', 'no label'), ('Protein Synthesis', 'no label'), ('Reduced', 'no label'), ('Oxidation', 'no label'), ('Conversion', 'no label'), ('Urea', 'no label'), ('Clinical Setting', 'no label'), ('Effects', 'no label'), ('Pt™', 'no label'), ('Observed', 'no label'), ('Disposition', 'no label'), ('Free Aas', 'no label'), ('Study May Translate To Health Benefits', 'no label'), ('Physiological Body Composition', 'no label'), ('Growth', 'no label'), ('Treatment', 'no label'), ('Subjects', 'no label'), ('Phenylketonuria', 'no label'), ('Investigation', 'no label'), ('Patients', 'no label'), ('Pku', 'no label')]|[('Nitrogen', 'no label'), ('Nitrogen', 'no label'), ('Urea', 'no label'), ('Nitrogen', 'no label'), ('Proteins', 'no label'), ('Amino Acids', 'no label'), ('Urea', 'no label'), ('Nitrogen', 'no label'), ('Nitrogen', 'no label'), ('Nitrogen', 'no label'), ('Bun', 'no label'), ('Urea', 'no label'), ('Protein', 'no label')]|[('Bun', 'no label')]|[('Nitrogen', 'no label'), ('Nitrogen', 'no label'), ('Urea', 'no label'), ('Nitrogen', 'no label'), ('Amino Acids', 'no label'), ('Urea', 'no label'), ('Nitrogen', 'no label'), ('Nitrogen', 'no label'), ('Blood Urea Nitrogen', 'no label'), ('Urea', 'no label'), ('Pt', 'no label'), ('Phenylketonuria', 'no label')]|[('Nitrogen', 'no label'), ('Nitrogen', 'no label'), ('Urea', 'no label'), ('Nitrogen', 'no label'), ('Amino Acids', 'no label'), ('Bloodstream', 'no label'), ('Urea', 'no label'), ('Plasma', 'no label'), ('Free Aa', 'no label'), ('Aa', 'no label'), ('Nitrogen', 'no label'), ('Nitrogen', 'no label'), ('Plasma', 'no label'), ('Blood Urea', 'no label'), ('Nitrogen', 'no label'), ('Bun', 'no label'), ('Urea', 'no label'), ('Urea', 'no label'), ('Body', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~34017006|Phenylketonuria (Pku; Also Known As Phenylalanine Hydroxylase (Pah) Deficiency) Is An Autosomal Recessive Disorder Of Phenylalanine Metabolism, In Which Especially High Phenylalanine Concentrations Cause Brain Dysfunction. If Untreated, This Brain Dysfunction Results In Severe Intellectual Disability, Epilepsy And Behavioural Problems. The Prevalence Varies Worldwide, With An Average Of About 1:10,000 Newborns. Early Diagnosis Is Based On Newborn Screening, And If Treatment Is Started Early And Continued, Intelligence Is Within Normal Limits With, On Average, Some Suboptimal Neurocognitive Function. Dietary Restriction Of Phenylalanine Has Been The Mainstay Of Treatment For Over 60 Years And Has Been Highly Successful, Although Outcomes Are Still Suboptimal And Patients Can Find The Treatment Difficult To Adhere To. Pharmacological Treatments Are Available, Such As Tetrahydrobiopterin, Which Is Effective In Only A Minority Of Patients (Usually Those With Milder Pku), And Pegylated Phenylalanine Ammonia Lyase, Which Requires Daily Subcutaneous Injections And Causes Adverse Immune Responses. Given The Drawbacks Of These Approaches, Other Treatments Are In Development, Such As Mrna And Gene Therapy. Even Though Pah Deficiency Is The Most Common Defect Of Amino Acid Metabolism In Humans, Brain Dysfunction In Individuals With Pku Is Still Not Well Understood And Further Research Is Needed To Facilitate Development Of Pathophysiology-Driven Treatments.|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Deficiency', 'no label'), ('Autosomal Recessive Disorder', 'no label'), ('Phenylalanine Metabolism', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Cause', 'no label'), ('Brain Dysfunction', 'no label'), ('Untreated', 'no label'), ('Brain Dysfunction Results', 'no label'), ('Severe', 'no label'), ('Intellectual Disability', 'no label'), ('Epilepsy', 'no label'), ('Behavioural Problems', 'no label'), ('Prevalence', 'no label'), ('Varies', 'no label'), ('Worldwide', 'no label'), ('Newborns', 'no label'), ('Early Diagnosis', 'no label'), ('Newborn', 'no label'), ('Screening', 'no label'), ('Treatment', 'no label'), ('Early', 'no label'), ('Continued', 'no label'), ('Intelligence', 'no label'), ('Normal Limits', 'no label'), ('Suboptimal', 'no label'), ('Neurocognitive Function', 'no label'), ('Dietary Restriction', 'no label'), ('Phenylalanine', 'no label'), ('Mainstay', 'no label'), ('Treatment', 'no label'), ('Years', 'no label'), ('Successful', 'no label'), ('Outcomes', 'no label'), ('Suboptimal', 'no label'), ('Patients', 'no label'), ('Treatment Difficult', 'no label'), ('Pharmacological', 'no label'), ('Treatments', 'no label'), ('Available', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Effective', 'no label'), ('Minority', 'no label'), ('Patients', 'no label'), ('Milder', 'no label'), ('Pegylated', 'no label'), ('Phenylalanine', 'no label'), ('Lyase', 'no label'), ('Requires', 'no label'), ('Daily', 'no label'), ('Subcutaneous Injections', 'no label'), ('Causes', 'no label'), ('Adverse', 'no label'), ('Immune Responses', 'no label'), ('Drawbacks', 'no label'), ('Approaches', 'no label'), ('Treatments', 'no label'), ('Development', 'no label'), ('Mrna And Gene Therapy', 'no label'), ('Pah Deficiency', 'no label'), ('Common', 'no label'), ('Defect', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Humans', 'no label'), ('Brain Dysfunction', 'no label'), ('Individuals', 'no label'), ('Pku', 'no label'), ('Research', 'no label'), ('Facilitate Development', 'no label'), ('Pathophysiology-Driven Treatments', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Ammonia', 'no label'), ('Mrna', 'no label'), ('Gene', 'no label'), ('Amino Acid', 'no label'), ('Humans', 'no label'), ('Individuals', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Autosomal Recessive Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Brain Dysfunction', 'no label'), ('Brain Dysfunction', 'no label'), ('Epilepsy', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Pegylated Phenylalanine Ammonia', 'no label'), ('Amino Acid Metabolism In Humans', 'no label'), ('Brain Dysfunction', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Brain', 'no label'), ('Brain', 'no label'), ('1:10,000 Newborns', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Patients', 'no label'), ('Pegylated Phenylalanine Ammonia Lyase', 'no label'), ('Immune', 'no label'), ('Mrna', 'no label'), ('Pah', 'no label'), ('Amino Acid', 'no label'), ('Humans', 'no label'), ('Brain', 'no label'), ('Individuals', 'no label'), ('Pathophysiology-Driven', 'no label')]
phenylketonuria|pubmed~33990606|Engineered Bacteria (Synthetic Biotics) Represent A New Class Of Therapeutics That Leverage The Tools Of Synthetic Biology. Translational Testing Strategies Are Required To Predict Synthetic Biotic Function In The Human Body. Gut-On-A-Chip Microfluidics Technology Presents An Opportunity To Characterize Strain Function Within A Simulated Human Gastrointestinal Tract. Here, We Apply A Human Gut-Chip Model And A Synthetic Biotic Designed For The Treatment Of Phenylketonuria To Demonstrate Dose-Dependent Production Of A Strain-Specific Biomarker, To Describe Human Tissue Responses To The Engineered Strain, And To Show Reduced Blood Phenylalanine Accumulation After Administration Of The Engineered Strain. Lastly, We Show How In Vitro Gut-Chip Models Can Be Used To Construct Mechanistic Models Of Strain Activity And Recapitulate The Behavior Of The Engineered Strain In A Non-Human Primate Model. These Data Demonstrate That Gut-Chip Models, Together With Mechanistic Models, Provide A Framework To Predict The Function Of Candidate Strains In Vivo.|[('Engineered Bacteria', 'no label'), ('Synthetic Biotics', 'no label'), ('Represent', 'no label'), ('New Class', 'no label'), ('Therapeutics', 'no label'), ('Leverage', 'no label'), ('Tools', 'no label'), ('Synthetic Biology', 'no label'), ('Translational Testing', 'no label'), ('Synthetic Biotic Function', 'no label'), ('Human Body', 'no label'), ('Gut-On-A-Chip', 'no label'), ('Microfluidics Technology', 'no label'), ('Presents', 'no label'), ('Opportunity', 'no label'), ('Characterize', 'no label'), ('Strain Function', 'no label'), ('Simulated Human Gastrointestinal Tract', 'no label'), ('Apply', 'no label'), ('Human', 'no label'), ('Synthetic Biotic Designed', 'no label'), ('Treatment', 'no label'), ('Phenylketonuria', 'no label'), ('Demonstrate', 'no label'), ('Dose-Dependent', 'no label'), ('Production', 'no label'), ('Strain-Specific Biomarker', 'no label'), ('Human Tissue', 'no label'), ('Responses', 'no label'), ('Engineered Strain', 'no label'), ('Reduced', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Accumulation', 'no label'), ('Administration', 'no label'), ('Engineered Strain', 'no label'), ('In Vitro', 'no label'), ('Gut-Chip', 'no label'), ('Models', 'no label'), ('Mechanistic Models', 'no label'), ('Strain Activity', 'no label'), ('Recapitulate', 'no label'), ('Behavior', 'no label'), ('Engineered Strain', 'no label'), ('Non-Human Primate Model', 'no label'), ('Data Demonstrate', 'no label'), ('Gut-Chip', 'no label'), ('Models', 'no label'), ('Mechanistic Models', 'no label'), ('Provide', 'no label'), ('Framework', 'no label'), ('Function', 'no label'), ('Strains', 'no label'), ('In Vivo', 'no label')]|[('Bacteria', 'no label'), ('Human', 'no label'), ('Human', 'no label'), ('Human', 'no label'), ('Human', 'no label'), ('Phenylalanine', 'no label')]|[('Human Gut-Chip Model And A Synthetic Biotic Designed For', 'no label')]|[('Human Gastrointestinal Tract', 'no label'), ('Phenylketonuria', 'no label'), ('Reduced Blood Phenylalanine', 'no label')]|[('Human Body.', 'no label'), ('Human Gastrointestinal', 'no label'), ('Human', 'no label'), ('Phenylketonuria', 'no label'), ('Human Tissue Responses', 'no label'), ('Blood Phenylalanine', 'no label')]
phenylketonuria|pubmed~29436795|Phenylketonuria Is One Of The Most Important Congenital Disorders And An Autosomal Recessive Metabolic Disease That Can Cause Irreversible Brain Damages, Mental Retardation, And Cognitive Disorders If Left Untreated. In Order To Reduce The Genetic Abnormalities Caused By This Metabolic Disease, Screening Programs Are Implemented. The Quality Of The Program Must Be Properly Assessed To Achieve The Objectives Of This Program If Promoting Children'S Health Is Of Concern. The Descriptive-Analytic Method Is Adopted Here To Assess The Phenylketonuria Screening Program In Practice In Chaharmahal And Bakhtiari Province Since 2012 And Analyze The Incidence And Program Coverage. The Quality Of The Screening Program Is Assessed Through Analyzing The Time Of Diagnosis, Beginning Of The Treatment And The Healthcare Centers' Facilities With Checklists. The Parental And The Staff Awareness Is Assessed Through Knowledge Measuring Questionnaires. Cumulative Incidence Of Phenylketonuria In Chaharmahal And Bakhtiari Province From 2012 To 2015, Is 1 In Every 6662 Live Births. The Program Coverage Across The Region Is 100%. The Recorded On-Time Sampling Index Before 5 Days Of Age, Indicate 84.6 % In 2015 From 80% In 2012. The Treatment Begun Before The Newborn 4 Weeks Was Over In All Cases. Program Sensitivity Was 100 %, And Its Specificity Was 99.9%. Staff Awareness Is Fair With No Impact On Parental Awareness. General Quality Of The Screening Program Is Appropriate, And As To Sensitivity And On-Time Curing Specificity, Higher Staff And Parental Awareness Supervision Are Recommended As Well.|"[('Phenylketonuria', 'no label'), ('Congenital Disorders', 'no label'), ('Autosomal Recessive Metabolic Disease', 'no label'), ('Irreversible', 'no label'), ('Brain Damages', 'no label'), ('Mental Retardation', 'no label'), ('Cognitive Disorders', 'no label'), ('Left Untreated', 'no label'), ('Order', 'no label'), ('Genetic Abnormalities', 'no label'), ('Metabolic Disease', 'no label'), ('Screening Programs', 'no label'), ('Quality', 'no label'), ('Program', 'no label'), ('Assessed', 'no label'), ('Program', 'no label'), ('Promoting', 'no label'), (""Children'S"", 'no label'), ('Health', 'no label'), ('Concern', 'no label'), ('Descriptive-Analytic Method', 'no label'), ('Assess', 'no label'), ('Phenylketonuria Screening Program', 'no label'), ('Practice', 'no label'), ('Chaharmahal', 'no label'), ('Bakhtiari Province', 'no label'), ('Analyze', 'no label'), ('Incidence', 'no label'), ('Program', 'no label'), ('Coverage', 'no label'), ('Quality', 'no label'), ('Screening Program', 'no label'), ('Assessed', 'no label'), ('Time', 'no label'), ('Diagnosis', 'no label'), ('Treatment', 'no label'), (""Healthcare Centers' Facilities"", 'no label'), ('Checklists', 'no label'), ('Parental', 'no label'), ('Staff', 'no label'), ('Awareness', 'no label'), ('Assessed', 'no label'), ('Knowledge Measuring', 'no label'), ('Questionnaires', 'no label'), ('Cumulative', 'no label'), ('Incidence', 'no label'), ('Phenylketonuria', 'no label'), ('Chaharmahal', 'no label'), ('Bakhtiari Province', 'no label'), ('Live Births', 'no label'), ('Program', 'no label'), ('Coverage', 'no label'), ('Region', 'no label'), ('Recorded On-Time Sampling Index', 'no label'), ('Days', 'no label'), ('Age', 'no label'), ('Treatment', 'no label'), ('Newborn 4', 'no label'), ('Weeks', 'no label'), ('Cases', 'no label'), ('Program', 'no label'), ('Sensitivity', 'no label'), ('Specificity', 'no label'), ('Staff', 'no label'), ('Awareness', 'no label'), ('No Impact', 'no label'), ('Parental', 'no label'), ('Awareness', 'no label'), ('General Quality', 'no label'), ('Screening Program', 'no label'), ('Appropriate', 'no label'), ('Sensitivity', 'no label'), ('On-Time', 'no label'), ('Specificity', 'no label'), ('Higher', 'no label'), ('Staff', 'no label'), ('Parental', 'no label'), ('Awareness', 'no label'), ('Supervision', 'no label')]"|[('Genetic', 'no label'), ('Region', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Congenital Disorders And', 'no label'), ('Autosomal Recessive Metabolic Disease', 'no label'), ('Brain Damages', 'no label'), ('Cognitive Disorders', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label')]|"[('Phenylketonuria', 'no label'), ('Brain', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), (""Healthcare Centers' Facilities"", 'no label'), ('Phenylketonuria', 'no label')]"
phenylketonuria|pubmed~34784942|Phenylketonuria (Pku) Is A Rare Inherited Metabolic Disorder Caused By Defects In The Phenylalanine-Hydroxylase Gene (Pah), The Enzyme Catalyzing The Conversion Of Phenylalanine To Tyrosine. Pah Impairment Causes Phenylalanine Accumulation In The Blood And Brain, With A Broad Spectrum Of Pathophysiological And Neurological Consequences For Patients. Prevalence Of Disease Varies, With Peaks In Some Regions And Countries, Including Italy. A Recent Expert Survey Described The Real-Life Of Clinical Practice For Pku In Italy, Revealing Inhomogeneities In Disease Management, Particularly Concerning Approach To Pharmacotherapy With Sapropterin Hydrochloride, Analogous Of The Natural Pah Co-Factor, Allowing Disease Control In A Subset Of Patients. Therefore, The Purpose Of This Paper Is To Continue The Work Initiated With The Expert Survey Paper, To Provide National Guidances Aiming To Harmonize And Optimize Patient Care At A National Level. The Consensus Group, Convened By 10 Steering Committee Members, Consisted Of A Multidisciplinary Crowd Of 46 Experts In The Management Of Pku In Italy. The Steering Committee Met In A Series Of Virtual Meeting In Order To Discuss On Clinical Focuses To Be Developed And Analyzed In Guidance Statements, On The Basis Of Expert Practice Based Evidence, Large Systematic Literature Review Previously Performed In The Expert Survey Paper, And Evidence Based Consensus Published. Statements Were Re-Discussed And Refined During Consensus Conferences In The Widest Audience Of Experts, And Finally Submitted To The Whole Consensus Group For A Modified-Delphi Voting. Seventy Three Statements, Divided In Two Main Clinical Areas, Pku Management And Pharmacotherapy, Achieved Large Consensus In A Multidisciplinary Group Of Expert In Different Aspects Of Disease. Importantly, These Statements Involve Guidances For The Use Of Sapropterin Dihydrochloride, Still Not Sufficiently Implemented In Italy, And A Set Of Good Practice To Approach The Use Of Novel Enzyme Replacement Treatment Pegvaliase. This Evidence-Based Consensus Provides A Minimum Set Of Guidances For Disease Management To Be Implemented In All Pku Centers. Moreover, These Guidances Represent The First Statement For Sapropterin Dihydrochloride Use, Implementation And Standardization In Italy, And A Guide For Approaching Pegvaliase Treatment At A National Level On A Consistent Basis.|[('Phenylketonuria', 'no label'), ('Rare', 'no label'), ('Inherited', 'no label'), ('Metabolic Disorder', 'no label'), ('Caused By', 'no label'), ('Defects', 'no label'), ('Phenylalanine-Hydroxylase Gene', 'no label'), ('Enzyme Catalyzing', 'no label'), ('Conversion', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Impairment', 'no label'), ('Causes', 'no label'), ('Phenylalanine', 'no label'), ('Accumulation', 'no label'), ('Blood', 'no label'), ('Brain', 'no label'), ('Broad Spectrum', 'no label'), ('Pathophysiological', 'no label'), ('Neurological', 'no label'), ('Consequences', 'no label'), ('Patients', 'no label'), ('Prevalence', 'no label'), ('Disease Varies', 'no label'), ('Peaks', 'no label'), ('Regions', 'no label'), ('Countries', 'no label'), ('Italy', 'no label'), ('Recent Expert Survey', 'no label'), ('Real-Life', 'no label'), ('Clinical Practice', 'no label'), ('Italy', 'no label'), ('Inhomogeneities', 'no label'), ('Disease Management', 'no label'), ('Approach', 'no label'), ('Pharmacotherapy', 'no label'), ('Sapropterin', 'no label'), ('Hydrochloride', 'no label'), ('Natural Pah Co-Factor', 'no label'), ('Allowing Disease', 'no label'), ('Subset', 'no label'), ('Patients', 'no label'), ('Paper', 'no label'), ('Work', 'no label'), ('Expert Survey Paper', 'no label'), ('National Guidances', 'no label'), ('Harmonize', 'no label'), ('Optimize', 'no label'), ('Patient Care', 'no label'), ('At A National Level', 'no label'), ('Consensus Group', 'no label'), ('Consisted', 'no label'), ('Multidisciplinary', 'no label'), ('Experts', 'no label'), ('Management', 'no label'), ('Pku In Italy', 'no label'), ('Steering Committee', 'no label'), ('Met', 'no label'), ('Order', 'no label'), ('Discuss', 'no label'), ('Clinical Focuses', 'no label'), ('Analyzed', 'no label'), ('Guidance', 'no label'), ('Statements', 'no label'), ('Expert Practice', 'no label'), ('Evidence', 'no label'), ('Systematic Literature Review', 'no label'), ('Performed', 'no label'), ('Expert Survey Paper', 'no label'), ('Evidence', 'no label'), ('Consensus', 'no label'), ('Published', 'no label'), ('Statements', 'no label'), ('Re-Discussed', 'no label'), ('Consensus', 'no label'), ('Conferences', 'no label'), ('Audience', 'no label'), ('Experts', 'no label'), ('Whole Consensus', 'no label'), ('Group', 'no label'), ('Modified-Delphi Voting', 'no label'), ('Statements', 'no label'), ('Divided', 'no label'), ('Clinical Areas', 'no label'), ('Pku Management', 'no label'), ('Pharmacotherapy', 'no label'), ('Consensus', 'no label'), ('Multidisciplinary Group', 'no label'), ('Expert', 'no label'), ('Disease', 'no label'), ('Statements', 'no label'), ('Guidances', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Still Not Sufficiently Implemented', 'no label'), ('Italy', 'no label'), ('Enzyme Replacement Treatment Pegvaliase', 'no label'), ('Evidence-Based Consensus Provides A Minimum Set', 'no label'), ('Implemented', 'no label'), ('Pku Centers', 'no label'), ('Guidances Represent', 'no label'), ('First Statement', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Implementation', 'no label'), ('Standardization', 'no label'), ('Italy', 'no label'), ('Pegvaliase', 'no label'), ('National Level', 'no label')]|[('Gene', 'no label'), ('Enzyme', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Met', 'no label'), ('Enzyme Replacement', 'no label'), ('Consensus', 'no label'), ('Dihydrochloride', 'no label')]|[('Phenylalanine-Hydroxylase Gene', 'no label')]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Sapropterin Hydrochloride', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Sapropterin Dihydrochloride', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Blood', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('Sapropterin Hydrochloride', 'no label'), ('Natural Pah', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Met', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Sapropterin Dihydrochloride', 'no label')]
phenylketonuria|pubmed~34289149|Extremely Low Birthweight (Elbw) Neonates Require A High Protein Intake, But This Can Be Challenging In The Very Rare Cases When They Also Have Phenylketonuria (Pku). This Is Due To A Lack Of Suitable Parenteral Nutrition Or Enteral Formula. Our Aim Was To Analyse Tolerance To Phenylalanine In These Infants. There Are Approximately 110 000 Children Born In The Czech Republic Each Year. A Neonatal Screening Programme From 2005 To 2020 Found That 320 Neonates Had Pku, Including 30 Premature Neonates With A Birth Weight Of Less Than 2500 G. This Study Focused On Three Neonates Who Were Born With Elbws Of 720, 740 And 950 G, Respectively. Phenylalanine Levels Normalised In Elbw Neonates With Pku Within 1 Week Of The Introduction Of Low-Phenylalanine Parenteral Or Enteral Nutrition. The Tolerance To Phenylalanine Was Very High (70-110 Mg/Kg) In The First Months Of Life, Due To A Rapid Weight Gain, But Significantly Decreased During Infancy. Extremely Low Birthweight Neonates With Pku Need Special Dietary Management. Regular Assessments Of Phenylalanine Are Necessary During The First Weeks Of Life To Allow Prompt Dietary Adjustments That Reflect Rapid Weight Gain And Transitory High Tolerance To Phenylalanine.|[('Low Birthweight', 'no label'), ('Neonates', 'no label'), ('Require', 'no label'), ('Protein Intake', 'no label'), ('Cases', 'no label'), ('Phenylketonuria', 'no label'), ('Lack', 'no label'), ('Parenteral Nutrition', 'no label'), ('Enteral Formula', 'no label'), ('Tolerance', 'no label'), ('Phenylalanine', 'no label'), ('Infants', 'no label'), ('Children', 'no label'), ('Czech Republic', 'no label'), ('Year', 'no label'), ('Neonatal', 'no label'), ('Screening Programme', 'no label'), ('Neonates', 'no label'), ('Premature Neonates', 'no label'), ('A Birth Weight', 'no label'), ('Study', 'no label'), ('Focused', 'no label'), ('Neonates', 'no label'), ('Elbws', 'no label'), ('Phenylalanine Levels', 'no label'), ('Normalised', 'no label'), ('Elbw Neonates', 'no label'), ('Week', 'no label'), ('Low-Phenylalanine', 'no label'), ('Parenteral', 'no label'), ('Enteral Nutrition', 'no label'), ('Tolerance', 'no label'), ('Phenylalanine', 'no label'), ('Months', 'no label'), ('Life', 'no label'), ('Rapid Weight Gain', 'no label'), ('Decreased', 'no label'), ('Infancy', 'no label'), ('Low', 'no label'), ('Neonates', 'no label'), ('Pku Need Special', 'no label'), ('Dietary Management', 'no label'), ('Regular Assessments', 'no label'), ('Phenylalanine', 'no label'), ('Weeks', 'no label'), ('Prompt', 'no label'), ('Dietary', 'no label'), ('Adjustments', 'no label'), ('Weight Gain', 'no label'), ('Transitory High Tolerance', 'no label'), ('Phenylalanine', 'no label')]|[('Protein', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Low-Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Weight Gain', 'no label'), ('Phenylalanine', 'no label'), ('Weight Gain', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Enteral', 'no label'), ('Phenylalanine', 'no label'), ('Children', 'no label'), ('Neonates', 'no label'), ('Phenylalanine', 'no label'), ('Pku Within 1', 'no label'), ('Low-Phenylalanine', 'no label'), ('Enteral', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]
phenylketonuria|pubmed~32703178|Phenylketonuria (Pku), Which Is Characterized By A Deficiency Of Phenylalanine Hydroxylase Activity, Is An Autosomal Recessive Disorder Of Phenylalanine (Phe) Metabolism. Newborn Screening Is The Main Population-Based Public Health Screening Program That Allows Successful Identification And Treatment Of Pku With Low-Phe Diet. The Aim Of This Study Was To Evaluate The Epidemiology Of Pku Screening In Iranian Newborns. The Present Study Was Designed Based On Moose Protocol And Reporting Was Done In Accordance With The Prisma Guidelines. The Protocol Of This Systematic Review Was Published In Prospero Before It Was Performed (Crd42020162626). A Comprehensive Search Was Done In 10/10/2019 To Find Related Literature On International Online Databases Web Of Science, Scopus, Embase, Science Direct, Pubmed/Medline, Ebsco, Cinahl, Cochrane Library, National Online Databases And The Google Scholar Search Engine. Heterogeneity Among Studies Was Assessed By I<Sup>2</Sup> Index And Q Test. All Meta-Analyses Were Performed Using Comprehensive Meta-Analysis Software Ver. 2. P < 0.05 Was Considered Significant. Finally, 18 Studies With 3,339,327 Iranian Neonates Were Included. The Prevalence Of Suspected Hyperphenylalaninemia (Hpa) Was Estimated To Be 45.6/100,000 (95% Ci: 23.9-87.1). The Prevalence Of Suspected Hpa In Girls And Boys Infants In Iran Was Estimated To Be 38.0/100,000 (95% Ci: 15.1-95.5) And 43.3/100,000 (95% Ci: 16.2-116.2), Respectively. The Prevalence Of Pku Was Estimated To Be 16.5/100,000 (95% Ci: 12.9-21.2). The Prevalence Of Pku In Girls And Boys Infants Was Estimated To Be 13.3/100,000 (95% Ci: 7.5-15.8) And 10.9/100,000 (95% Ci: 7.5-15.8), Respectively. The Prevalence Of Mild To Moderate Hpa Was Estimated 9.7/100,000 (95% Ci: 5.1-18.4) And The Prevalence Of Classical Pku Was Estimated 4.4/100,000 (95% Ci: 2.5-7.8). Sensitivity Analysis For All Meta-Analysis With The Omission Of One Study Showed That Overall Estimation Is Still Robust. The Results Of This Meta-Analysis Showed That Pku Is Prevalent In Iranian Neonates. It Should Be Considered That For Pku There Is A Highly Effective Dietary Treatment Which Can Prevent The Clinical Symptoms Of Pku If Initiated Early After Detection By Newborn Screening.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Characterized', 'no label'), ('Deficiency', 'no label'), ('Phenylalanine Hydroxylase Activity', 'no label'), ('Autosomal Recessive Disorder', 'no label'), ('Phenylalanine (Phe) Metabolism', 'no label'), ('Newborn', 'no label'), ('Screening', 'no label'), ('Public Health Screening Program', 'no label'), ('Identification', 'no label'), ('Treatment', 'no label'), ('Pku With Low-Phe Diet', 'no label'), ('Study', 'no label'), ('Evaluate', 'no label'), ('Epidemiology', 'no label'), ('Pku Screening', 'no label'), ('Iranian', 'no label'), ('Newborns', 'no label'), ('Present Study', 'no label'), ('Moose Protocol', 'no label'), ('Prisma Guidelines', 'no label'), ('Protocol', 'no label'), ('Systematic Review', 'no label'), ('Published', 'no label'), ('Prospero', 'no label'), ('Performed', 'no label'), ('Crd42020162626', 'no label'), ('Comprehensive', 'no label'), ('Search', 'no label'), ('Literature', 'no label'), ('International Online Databases Web Of Science', 'no label'), ('Scopus', 'no label'), ('Embase', 'no label'), ('Pubmed/Medline', 'no label'), ('Ebsco', 'no label'), ('Cinahl', 'no label'), ('Cochrane Library', 'no label'), ('National Online Databases', 'no label'), ('Google Scholar Search Engine', 'no label'), ('Heterogeneity', 'no label'), ('Studies', 'no label'), ('Assessed', 'no label'), ('Sup>2</Sup> Index And Q Test', 'no label'), ('Meta-Analyses', 'no label'), ('Performed', 'no label'), ('Comprehensive Meta-Analysis Software Ver', 'no label'), ('Significant', 'no label'), ('Studies', 'no label'), ('Iranian', 'no label'), ('Neonates', 'no label'), ('Prevalence', 'no label'), ('Suspected', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Hpa', 'no label'), ('Ci', 'no label'), ('Prevalence', 'no label'), ('Suspected', 'no label'), ('Hpa', 'no label'), ('Girls', 'no label'), ('Boys Infants', 'no label'), ('Iran', 'no label'), ('Ci:\xa015.1-95.5)', 'no label'), ('Ci', 'no label'), ('Prevalence', 'no label'), ('Pku Was', 'no label'), ('Ci', 'no label'), ('Prevalence', 'no label'), ('Girls', 'no label'), ('Boys Infants', 'no label'), ('Ci', 'no label'), ('Ci', 'no label'), ('Prevalence', 'no label'), ('Mild', 'no label'), ('Moderate', 'no label'), ('Hpa', 'no label'), ('Ci', 'no label'), ('Prevalence', 'no label'), ('Classical Pku', 'no label'), ('Ci', 'no label'), ('Sensitivity Analysis', 'no label'), ('Meta-Analysis', 'no label'), ('Omission', 'no label'), ('Study', 'no label'), ('Estimation', 'no label'), ('Robust', 'no label'), ('Meta-Analysis', 'no label'), ('Showed', 'no label'), ('Prevalent', 'no label'), ('Iranian', 'no label'), ('Neonates', 'no label'), ('Effective', 'no label'), ('Dietary Treatment', 'no label'), ('Prevent', 'no label'), ('Clinical Symptoms', 'no label'), ('Early', 'no label'), ('Detection', 'no label'), ('Newborn', 'no label'), ('Screening', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Autosomal Recessive Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Hyperphenylalaninemia', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Prisma', 'no label'), ('Prospero', 'no label'), ('Neonates', 'no label'), ('Hpa', 'no label'), ('Be 38.0/100,000', 'no label'), ('Pku', 'no label'), ('Pku', 'no label'), ('Pku', 'no label')]
phenylketonuria|pubmed~34828281|Establishing The Genotypes Of Patients With Hyperphenylalaninemia (Hpa)/Phenylketonuria (Pku, Mim#261600) Has Been Considered A Cornerstone For Rational Medical Management. However, Knowledge Of The Phenylalanine Hydroxylase Gene (<I>Pah)</I> Mutational Spectrum In Latin American Populations Is Still Limited. Herein, We Aim To Update The Mutational <I>Pah</I> Spectrum In The Largest Cohort Of Hpa/Pku Mexican Patients (<I>N</I> = 124) Reported To Date. The Biallelic <I>Pah</I> Genotype Was Investigated By Sanger Automated Sequencing, And Genotypes Were Correlated With Documented Biochemical Phenotypes And Theoretical Tetrahydrobiopterin (Bh<Sub>4</Sub>) Responsiveness. Patients Were Biochemically Classified As Having Classic Pku (50%, 62/124), Mild Pku (20.2%, 25/124) And Mild Hpa (29.8%, 37/124). Furthermore, 78.2% Of The Included Patients (97/124) Were Identified By Newborn Screening. A Total Of 60 Different Pathogenic Variants Were Identified, Including Three Novel Ones (C. 23Del, C. 625_626Insc And C. 1315 + 5_1315 + 6Insgtgtaacag), The Main Categories Being Missense Changes (58%, 35/60) And Those Affecting The Catalytic Domain (56.6%, 34/60), And C. 60 + 5G > T Was The Most Frequent Variant (14.5%, 36/248) Mainly Restricted (69.2%) To Patients From The Central And Western Parts Of Mexico. These 60 Types Of Variants Constituted 100 Different Biallelic Pah Genotypes, With The Predominance Of Compound-Heterozygous Ones (96/124, 77%). The Expected Bh<Sub>4</Sub> Responsiveness Based On The <I>Pah</I> Genotype Was Estimated In 52% Of Patients (65/124), Mainly Due To The P. (Val388Met) (Rs62516101) Allele. Instead, Our Study Identified 27 Null Variants With An Allelic Phenotype Value Of Zero, With A Predominance Of C. 60 + 5G > T, Which Predicts The Absence Of Bh<Sub>4</Sub> Responsiveness. An Identical Genotype Reported In Biopkudb Was Found In 92/124 (74%) Of Our Patients, Leading To A Genotype-Phenotype Concordance In 80/92 (86.9%) Of Them. The High Number Of Variants Found Confirms The Heterogeneous And Complex Mutational Landscape Of Hpa/Pku In Mexico.|[('Genotypes', 'no label'), ('Patients', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('(Hpa)/Phenylketonuria', 'no label'), ('Mim#261600', 'no label'), ('Considered', 'no label'), ('Cornerstone', 'no label'), ('Medical Management', 'no label'), ('Knowledge', 'no label'), ('Phenylalanine Hydroxylase Gene', 'no label'), ('Mutational Spectrum', 'no label'), ('Latin American', 'no label'), ('Update', 'no label'), ('Mutational <I>Pah</I> Spectrum', 'no label'), ('Largest', 'no label'), ('Cohort', 'no label'), ('Hpa/Pku', 'no label'), ('Mexican', 'no label'), ('Patients', 'no label'), ('<I>N</I>', 'no label'), ('Biallelic', 'no label'), ('Genotype', 'no label'), ('Investigated', 'no label'), ('Sanger Automated Sequencing', 'no label'), ('Genotypes', 'no label'), ('Correlated', 'no label'), ('Documented', 'no label'), ('Biochemical', 'no label'), ('Phenotypes', 'no label'), ('Theoretical', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Responsiveness', 'no label'), ('Patients', 'no label'), ('Biochemically Classified', 'no label'), ('Classic Pku', 'no label'), ('Mild Pku', 'no label'), ('Mild Hpa', 'no label'), ('Patients', 'no label'), ('Identified', 'no label'), ('Newborn', 'no label'), ('Screening', 'no label'), ('Pathogenic Variants', 'no label'), ('Identified', 'no label'), ('Novel', 'no label'), ('Ones', 'no label'), ('C. 23Del', 'no label'), ('6Insgtgtaacag', 'no label'), ('Main Categories', 'no label'), ('Being', 'no label'), ('Missense Changes', 'no label'), ('Affecting', 'no label'), ('Catalytic Domain', 'no label'), ('T', 'no label'), ('Frequent', 'no label'), ('Variant', 'no label'), ('Restricted', 'no label'), ('Patients', 'no label'), ('Central', 'no label'), ('Western Parts', 'no label'), ('Mexico', 'no label'), ('Variants', 'no label'), ('Biallelic', 'no label'), ('Genotypes', 'no label'), ('Predominance', 'no label'), ('Compound-Heterozygous Ones', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('<I>Pah</I> Genotype', 'no label'), ('Estimated', 'no label'), ('Patients', 'no label'), ('P. (', 'no label'), ('Val388Met', 'no label'), ('Rs62516101', 'no label'), ('Allele', 'no label'), ('Study', 'no label'), ('Identified', 'no label'), ('Null Variants', 'no label'), ('Allelic', 'no label'), ('Phenotype', 'no label'), ('Value', 'no label'), ('Zero', 'no label'), ('Predominance', 'no label'), ('C. 60', 'no label'), ('T', 'no label'), ('Predicts', 'no label'), ('Absence', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Genotype', 'no label'), ('Reported', 'no label'), ('Biopkudb', 'no label'), ('Patients', 'no label'), ('Concordance', 'no label'), ('High Number', 'no label'), ('Variants', 'no label'), ('Found Confirms', 'no label'), ('Heterogeneous', 'no label'), ('Complex', 'no label'), ('Mutational Landscape', 'no label'), ('Hpa/Pku', 'no label'), ('Mexico', 'no label')]|[('Genotypes', 'no label'), ('Phenylalanine', 'no label'), ('Gene', 'no label'), ('Mutational', 'no label'), ('Genotype', 'no label'), ('Genotypes', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Pathogenic Variants', 'no label'), ('C. 23Del', 'no label'), ('C.', 'no label'), ('C.', 'no label'), ('+', 'no label'), ('C.', 'no label'), ('T', 'no label'), ('Variant', 'no label'), ('Genotypes', 'no label'), ('Genotype', 'no label'), ('Allele', 'no label'), ('Variants', 'no label'), ('Allelic', 'no label'), ('T', 'no label'), ('Genotype', 'no label')]|[('Phenylalanine Hydroxylase Gene', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Null Variants', 'no label')]|[('Hyperphenylalaninemia', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh', 'no label'), ('Compound-Heterozygous Ones (96/124', 'no label'), ('P.', 'no label')]|[('Patients', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Patients', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('97/124', 'no label'), ('C. 625_626Insc', 'no label'), ('C. 1315 +', 'no label'), ('C. 60 + 5G', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('C. 60 + 5G', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31103398|Phenylketonuria (Pku) Is An Inherited Metabolic Disease Caused By Phenylalanine Hydroxylase (Pah) Deficiency. As The Resulting High Blood Phenylalanine (Phe) Concentration Can Have Detrimental Effects On Brain Development And Function, International Guidelines Recommend Lifelong Control Of Blood Phe Concentration With Dietary And/Or Medical Therapy. Sapropterin Dihydrochloride Is A Synthetic Preparation Of Tetrahydrobiopterin (6R-Bh4), The Naturally Occurring Cofactor Of Pah. It Acts As A Pharmacological Chaperone, Reducing Blood Phe Concentration And Increasing Dietary Phe Tolerance In Bh4-Responsive Patients With Pah Deficiency. Protocols To Establish Responsiveness To Sapropterin Dihydrochloride Vary Widely. Two Meetings Were Held With An International Panel Of Clinical Experts In Pku Management To Develop Recommendations For Sapropterin Dihydrochloride Response Testing. At The First Meeting, Regional Differences And Similarities In Testing Practices Were Discussed Based On Guidelines, A Literature Review, Outcomes Of A Global Physician Survey, And Case Reports. Statements Developed Based On The Discussions Were Sent To All Participants For Consensus (>70% Of Participants) Evaluation Using A 7-Level Rating System, And Further Discussed During The Second Meeting. The Experts Recommend Sapropterin Dihydrochloride Response Testing In Patients With Untreated Blood Phe Concentrations Of 360-2000 Μmol/L, Except In Those With Two Null Mutations. For Neonates, A 24-H Sapropterin Dihydrochloride Loading Test Is Recommended; Responsiveness Is Defined As A Decrease In Blood Phe ≥30%. For Older Infants, Children, Adolescents, And Adults, A Test Duration Of ≥48 H Or A 4-Week Trial Is Recommended. The Main Endpoint For A 48-H To 7-Day Trial Is A Decrease In Blood Phe, While Improved Phe Tolerance Is The Endpoint To Be Assessed During A Longer Trial. Longer Trials May Not Be Feasible In Some Locations Due To Lack Of Reimbursement For Hospitalization, While A 4-Week Trial May Not Be Possible Due To Limited Access To Sapropterin Dihydrochloride Or Public Health Regulation. A 48-H Response Test Should Be Considered In Pregnant Patients Who Cannot Achieve Blood Phe ≤360 Μmol/L With A Phe-Restricted Diet. Durability Of Response And Clinical Benefits Of Sapropterin Dihydrochloride Should Be Assessed Over The Long Term. Harmonization Of Protocols Is Expected To Improve Identification Of Responders And Comparability Of Test Results Worldwide.|[('Phenylketonuria', 'no label'), ('Inherited Metabolic Disease', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('High Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Concentration', 'no label'), ('Detrimental Effects', 'no label'), ('Brain Development', 'no label'), ('Function', 'no label'), ('International Guidelines Recommend', 'no label'), ('Lifelong Control', 'no label'), ('Blood Phe Concentration', 'no label'), ('Dietary And/Or Medical Therapy', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Synthetic', 'no label'), ('Preparation', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Occurring', 'no label'), ('Cofactor', 'no label'), ('Pharmacological', 'no label'), ('Chaperone', 'no label'), ('Reducing', 'no label'), ('Blood Phe Concentration', 'no label'), ('Increasing', 'no label'), ('Dietary Phe', 'no label'), ('Tolerance', 'no label'), ('Patients', 'no label'), ('Pah Deficiency', 'no label'), ('Protocols', 'no label'), ('Establish', 'no label'), ('Responsiveness', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Meetings', 'no label'), ('International Panel', 'no label'), ('Clinical Experts', 'no label'), ('Pku Management', 'no label'), ('Recommendations', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Response Testing', 'no label'), ('Regional Differences', 'no label'), ('Similarities', 'no label'), ('Testing Practices', 'no label'), ('Guidelines', 'no label'), ('Literature Review', 'no label'), ('Outcomes', 'no label'), ('Global Physician Survey', 'no label'), ('Case Reports', 'no label'), ('Statements', 'no label'), ('Developed', 'no label'), ('Discussions', 'no label'), ('Sent', 'no label'), ('Participants', 'no label'), ('Consensus', 'no label'), ('Participants', 'no label'), ('Evaluation', 'no label'), ('7-Level Rating System', 'no label'), ('Meeting', 'no label'), ('Experts', 'no label'), ('Recommend', 'no label'), ('Sapropterin', 'no label'), ('Response Testing', 'no label'), ('Patients', 'no label'), ('Untreated Blood Phe', 'no label'), ('Concentrations', 'no label'), ('Null Mutations', 'no label'), ('Neonates', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Loading Test', 'no label'), ('Recommended', 'no label'), ('Responsiveness', 'no label'), ('Decrease', 'no label'), ('Blood Phe', 'no label'), ('Older Infants', 'no label'), ('Children', 'no label'), ('Adolescents', 'no label'), ('Adults', 'no label'), ('Test', 'no label'), ('Duration', 'no label'), ('Recommended', 'no label'), ('7-Day Trial', 'no label'), ('Decrease', 'no label'), ('Blood Phe', 'no label'), ('Phe', 'no label'), ('Tolerance', 'no label'), ('Assessed', 'no label'), ('Longer Trial', 'no label'), ('Longer Trials', 'no label'), ('Feasible', 'no label'), ('Locations', 'no label'), ('Lack', 'no label'), ('Reimbursement', 'no label'), ('Hospitalization', 'no label'), ('Access', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Public Health Regulation', 'no label'), ('Response Test', 'no label'), ('Pregnant Patients', 'no label'), ('Blood Phe', 'no label'), ('Phe-Restricted Diet', 'no label'), ('Durability', 'no label'), ('Response', 'no label'), ('Clinical Benefits', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Assessed', 'no label'), ('Long Term', 'no label'), ('Harmonization', 'no label'), ('Protocols', 'no label'), ('Identification', 'no label'), ('Responders', 'no label'), ('Comparability', 'no label'), ('Test Results', 'no label'), ('Worldwide', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Dihydrochloride', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phe', 'no label'), ('Dihydrochloride', 'no label'), ('Dihydrochloride', 'no label'), ('Dihydrochloride', 'no label'), ('Mutations', 'no label'), ('Dihydrochloride', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Dihydrochloride', 'no label'), ('Dihydrochloride', 'no label')]|[('Tetrahydrobiopterin', 'no label'), ('Null Mutations', 'no label')]|[('Phenylketonuria', 'no label'), ('Inherited Metabolic Disease', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('And/Or', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Phe', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('H', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Sapropterin Dihydrochloride', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phe', 'no label'), ('Brain', 'no label'), ('Blood Phe', 'no label'), ('And/Or', 'no label'), ('Dihydrochloride', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Cofactor', 'no label'), ('Pah', 'no label'), ('Acts', 'no label'), ('Chaperone', 'no label'), ('Blood Phe', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Pah', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Null', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Blood Phe', 'no label'), ('Children', 'no label'), ('H Or A', 'no label'), ('A 48-H', 'no label'), ('Blood', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Sapropterin Dihydrochloride', 'no label')]
phenylketonuria|pubmed~25812600|Phenylketonuria Results From A Deficiency Of The Enzyme Phenylalanine Hydroxylase. Dietary Restriction Of Phenylalanine Keeps Blood Phenylalanine Concentration Low. Most Natural Foods Are Excluded From Diet And Supplements Are Used To Supply Other Nutrients. Recent Publications Report A Decrease In Blood Phenylalanine Concentration In Some Patients Treated With Sapropterin Dihydrochloride. We Examined The Evidence For The Use Of Sapropterin Dihydrochloride To Treat Phenylketonuria. This Is An Update Of A Previously Published Cochrane Review.  To Assess The Safety And Efficacy Of Sapropterin Dihydrochloride In Lowering Blood Phenylalanine Concentration In People With Phenylketonuria. We Identified Relevant Trials From The Group'S Inborn Errors Of Metabolism Trials Register. Date Of Last Search: 11 August 2014.We Also Searched Clinicaltrials.Gov And Current Controlled Trials. Last Search: 4 September 2014We Contacted The Manufacturers Of The Drug (Biomarin Pharmaceutical Inc.) For Information Regarding Any Unpublished Trials. Randomized Controlled Trials Comparing Sapropterin With No Supplementation Or Placebo In People With Phenylketonuria Due To Phenylalanine Hydroxylase Deficiency. Two Authors Independently Assessed Trials And Extracted Outcome Data. Two Placebo-Controlled Trials Were Included. One Trial Administered 10 Mg/Kg/Day Sapropterin In 89 Children And Adults With Phenylketonuria Whose Diets Were Not Restricted And Who Had Previously Responded To Saproterin.This Trial Measured Change In Blood Phenylalanine Concentration. The Second Trial Screened 90 Children (4 To 12 Years) With Phenylketonuria Whose Diet Was Restricted, For Responsiveness To Sapropterin. Forty-Six Responders Entered The Placebo-Controlled Part Of The Trial And Received 20 Mg/Kg/Day Sapropterin. This Trial Measured Change In Both Phenylalanine Concentration And Protein Tolerance. Both Trials Reported Adverse Events. The Trials Showed An Overall Low Risk Of Bias; But Both Are Biomarin-Sponsored. One Trial Showed A Significant Lowering In Blood Phenylalanine Concentration In The Sapropterin Group (10 Mg/Kg/Day), Mean Difference -238.80 Μmol/L (95% Confidence Interval -343.09 To -134.51); A Second Trial (20 Mg/Kg/Day Sapropterin) Showed A Non-Significant Difference, Mean Difference -51.90 Μmol/L (95% Confidence Interval -197.27 To 93.47). The Second Trial Also Reported A Significant Increase In Phenylalanine Tolerance, Mean Difference18.00 Mg/Kg/Day (95% Confidence Interval 12.28 To 23.72) In The 20 Mg/Kg/Day Sapropterin Group. There Is Evidence Of Short-Term Benefit From Using Sapropterin In Some People With Sapropterin-Responsive Forms Of Phenylketonuria; Blood Phenylalanine Concentration Is Lowered And Protein Tolerance Increased. There Are No Serious Adverse Events Associated With Using Sapropterin In The Short Term.There Is No Evidence On The Long-Term Effects Of Sapropterin And No Clear Evidence Of Effectiveness In Severe Phenylketonuria.|"[('Phenylketonuria', 'no label'), ('Results', 'no label'), ('Deficiency', 'no label'), ('Enzyme Phenylalanine Hydroxylase', 'no label'), ('Dietary Restriction', 'no label'), ('Phenylalanine Keeps', 'no label'), ('Blood Phenylalanine Concentration', 'no label'), ('Low', 'no label'), ('Natural Foods', 'no label'), ('Diet', 'no label'), ('Supplements', 'no label'), ('Nutrients', 'no label'), ('Publications', 'no label'), ('Report', 'no label'), ('Decrease', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Concentration', 'no label'), ('Patients', 'no label'), ('Treated', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Evidence', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Phenylketonuria', 'no label'), ('Update', 'no label'), ('Published Cochrane Review', 'no label'), ('Safety', 'no label'), ('Efficacy', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Blood Phenylalanine', 'no label'), ('Concentration', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Identified\xa0Relevant Trials', 'no label'), (""Group'S"", 'no label'), ('Inborn Errors', 'no label'), ('Metabolism Trials Register', 'no label'), ('Searched', 'no label'), ('Clinicaltrials', 'no label'), ('2014We Contacted', 'no label'), ('Manufacturers', 'no label'), ('Drug (Biomarin Pharmaceutical Inc.', 'no label'), ('Information', 'no label'), ('Unpublished Trials', 'no label'), ('Randomized Controlled Trials', 'no label'), ('Sapropterin', 'no label'), ('Supplementation', 'no label'), ('Placebo', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase Deficiency', 'no label'), ('Assessed', 'no label'), ('Trials', 'no label'), ('Extracted Outcome Data', 'no label'), ('Placebo-Controlled Trials', 'no label'), ('Trial', 'no label'), ('Administered', 'no label'), ('Sapropterin', 'no label'), ('Children', 'no label'), ('Adults', 'no label'), ('Phenylketonuria', 'no label'), ('Diets', 'no label'), ('Not Restricted', 'no label'), ('Saproterin', 'no label'), ('Trial', 'no label'), ('Measured', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Concentration', 'no label'), ('Second Trial', 'no label'), ('Children', 'no label'), ('Years', 'no label'), ('Phenylketonuria', 'no label'), ('Diet', 'no label'), ('Responsiveness', 'no label'), ('Sapropterin', 'no label'), ('Forty-Six Responders', 'no label'), ('Entered', 'no label'), ('Placebo-Controlled Part', 'no label'), ('Trial', 'no label'), ('Sapropterin', 'no label'), ('Trial', 'no label'), ('Measured', 'no label'), ('Phenylalanine Concentration', 'no label'), ('Protein Tolerance', 'no label'), ('Trials', 'no label'), ('Adverse Events', 'no label'), ('Trials', 'no label'), ('Low', 'no label'), ('Risk', 'no label'), ('Bias', 'no label'), ('Biomarin-Sponsored', 'no label'), ('Trial', 'no label'), ('Lowering', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Concentration', 'no label'), ('Sapropterin Group', 'no label'), ('Mean Difference -238.80', 'no label'), ('Confidence Interval', 'no label'), ('Second Trial', 'no label'), ('Sapropterin', 'no label'), ('Non-Significant Difference', 'no label'), ('Mean Difference', 'no label'), ('Confidence Interval', 'no label'), ('Increase', 'no label'), ('Phenylalanine Tolerance', 'no label'), ('Difference18.00 Mg/Kg/Day', 'no label'), ('Confidence Interval', 'no label'), ('Sapropterin', 'no label'), ('Group', 'no label'), ('Evidence', 'no label'), ('Short-Term', 'no label'), ('Benefit', 'no label'), ('Sapropterin', 'no label'), ('People', 'no label'), ('Sapropterin-Responsive Forms', 'no label'), ('Phenylketonuria', 'no label'), ('Blood Phenylalanine Concentration', 'no label'), ('Lowered', 'no label'), ('Protein Tolerance', 'no label'), ('Increased', 'no label'), ('Serious Adverse Events', 'no label'), ('Associated With', 'no label'), ('Sapropterin', 'no label'), ('Short Term', 'no label'), ('No Evidence', 'no label'), ('Long-Term', 'no label'), ('Effects', 'no label'), ('Sapropterin', 'no label'), ('Evidence', 'no label'), ('Effectiveness', 'no label'), ('Severe', 'no label'), ('Phenylketonuria', 'no label')]"|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Foods', 'no label'), ('Nutrients', 'no label'), ('Phenylalanine', 'no label'), ('Dihydrochloride', 'no label'), ('Dihydrochloride', 'no label'), ('Dihydrochloride', 'no label'), ('Phenylalanine', 'no label'), ('Drug', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Trial', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Lowering Blood Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Sapropterin', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Phenylalanine', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Blood Phenylalanine', 'no label'), ('Blood Phenylalanine', 'no label'), ('Patients', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Blood Phenylalanine', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Biomarin', 'no label'), ('Sapropterin', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Sapropterin', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Diets', 'no label'), ('Saproterin', 'no label'), ('Blood Phenylalanine', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Phenylalanine', 'no label'), ('Blood Phenylalanine', 'no label'), ('Sapropterin', 'no label'), ('Phenylalanine', 'no label'), ('Sapropterin', 'no label'), ('Short-Term', 'no label'), ('Sapropterin', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Blood Phenylalanine', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label')]
phenylketonuria|pubmed~33656145|To Characterize Metabolic Control And Verify Whether It Has Any Relation With Socioeconomic, Demographic, And Body Composition Variables In Children And Adolescents With Phenylketonuria (Pku) Diagnosed In The Neonatal Period. This Cohort Study Collected Retrospective Data Of 53 Phenylketonuric Children And Adolescents. Data On Family Income, Housing, And Mother'S Age And Schooling Level Were Collected, And Anthropometric Measures Of Body Composition And Distribution Were Taken. All Dosages Of Phenylalanine (Phe) From The Last Five Years (2015-2019) Were Evaluated And Classified Regarding Their Adequacy (Cutoffs: 0-12 Years: 2-6 Mg/Dl; 12-19 Years: 2-10 Mg/Dl). Adequate Metabolic Control Was Considered If ≥7%) Of The Dosages Were Within Desired Ranges. The Mean (±Standard Deviation) Age In The Last Year Was 10.1±4.6 Years. Most Of Them Were Under 12 Years Old (33/53; 62.3%) And Had The Classic Form Of The Disease (39/53; 73.6%). Better Metabolic Control Was Observed Among Adolescents (68.4 Versus 51.4%; P=0.019). Overweight Was Found In 9/53 (17%) And Higher Serum Phe Levels (P<0.001) Were Found In This Group Of Patients. Metabolic Control With 70% Or More Phe Level Adequacy Decreased Along With The Arm Muscle Area (Ama) (Ptendency=0.042), Being 70.0% Among Those With Low Reserve (Low Ama), And 18.5% Among Those With Excessive Reserve (High Ama). Adequate Metabolic Control Was Observed In Most Patients. The Findings Suggest That, In This Sample, The Levels Of Phenylalanine May Be Related To Changes In Body Composition.|"[('Characterize', 'no label'), ('Metabolic Control', 'no label'), ('Socioeconomic', 'no label'), ('Demographic', 'no label'), ('Body Composition', 'no label'), ('Variables', 'no label'), ('Children', 'no label'), ('Adolescents', 'no label'), ('Phenylketonuria', 'no label'), ('Diagnosed', 'no label'), ('Neonatal', 'no label'), ('Period', 'no label'), ('Cohort Study', 'no label'), ('Retrospective Data', 'no label'), ('Phenylketonuric Children', 'no label'), ('Adolescents', 'no label'), ('Data', 'no label'), ('Family Income', 'no label'), ('Housing', 'no label'), (""Mother'S"", 'no label'), ('Age', 'no label'), ('Schooling', 'no label'), ('Collected', 'no label'), ('Anthropometric Measures', 'no label'), ('Body Composition', 'no label'), ('Distribution', 'no label'), ('Dosages', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Years', 'no label'), ('Evaluated', 'no label'), ('Adequacy', 'no label'), ('Cutoffs', 'no label'), ('Years', 'no label'), ('Years', 'no label'), ('Adequate', 'no label'), ('Metabolic Control', 'no label'), ('Dosages', 'no label'), ('Desired Ranges', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('Years', 'no label'), ('Classic Form', 'no label'), ('Disease', 'no label'), ('Metabolic Control', 'no label'), ('Observed', 'no label'), ('Adolescents', 'no label'), ('Overweight', 'no label'), ('Higher', 'no label'), ('Serum Phe Levels', 'no label'), ('Group', 'no label'), ('Patients', 'no label'), ('Metabolic Control', 'no label'), ('Phe Level', 'no label'), ('Adequacy', 'no label'), ('Decreased', 'no label'), ('Arm Muscle Area', 'no label'), ('Ptendency=0.042', 'no label'), ('Low Reserve', 'no label'), ('Low Ama', 'no label'), ('Excessive Reserve', 'no label'), ('High Ama', 'no label'), ('Adequate', 'no label'), ('Metabolic Control', 'no label'), ('Observed', 'no label'), ('Patients', 'no label'), ('Findings', 'no label'), ('Suggest', 'no label'), ('Sample', 'no label'), ('Levels', 'no label'), ('Phenylalanine', 'no label'), ('Changes', 'no label'), ('Body Composition', 'no label')]"|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phenylalanine', 'no label')]|[('Body', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Body', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Serum Phe', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Muscle', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Body', 'no label')]
phenylketonuria|pubmed~30678510|This Study'S Aim Was To Identify The Genetic Causes In A Patient With Phenylketonuria And Hearing Loss, Liver Disease, Developmental And Mental Retardation, Hypotonia, And External Ophthalmoplegia. Whole-Exome Sequencing And Sanger Sequencing Analysis Were Used To Determine The Genetic Causes Of Manifestations In A Young Boy With Hearing Loss, Liver Disease, Develop-Mental And Mental Retardation, Hypotonia, And External Ophthalmoplegia. We Found That The Child Harbored Polymerase Gamma ( Polg) Compound Heterozygous Mutations, C.2617G>A (P.E873K) And C.3550G>A (P.D1184N), And Phenylalanine Hydroxylase ( Pah) Compound Heterozygous Mutations, C.721C>T (P.R241C) And C.728G>A (P.R243Q). Among Them, The Polg P.E873K Mutation Is A Novel Mutation And Is Not Present In The Exome Aggregation Consortium Database, Genome Aggregation Database, And 1000 Genomes Database. The Two Heterozygous Mutations Were Each Inherited From Both Of The Child'S Parents. This Finding Suggested That The Phenotype And The Genotype Were Segregated. Using Whole-Exome Sequencing, We Not Only Identified Pah Mutations Causing Phenylketonuria, But Also Identified The Genetic Cause Of The Mitochondrial Disease And Found A Novel Polg Mutation. Our Findings Could Be Useful In Helping Future Parents Obtain Healthy Embryos Through Assisted Reproductive Technology.|"[(""Study'S"", 'no label'), ('Genetic Causes', 'no label'), ('Patient', 'no label'), ('Phenylketonuria', 'no label'), ('Hearing Loss', 'no label'), ('Liver Disease', 'no label'), ('Developmental And Mental Retardation', 'no label'), ('Hypotonia', 'no label'), ('External Ophthalmoplegia', 'no label'), ('Whole-Exome Sequencing', 'no label'), ('Sanger Sequencing Analysis', 'no label'), ('Genetic Causes', 'no label'), ('Manifestations', 'no label'), ('Young Boy With', 'no label'), ('Hearing Loss', 'no label'), ('Liver Disease', 'no label'), ('Develop-Mental And Mental Retardation', 'no label'), ('Hypotonia', 'no label'), ('External Ophthalmoplegia', 'no label'), ('Child Harbored Polymerase Gamma', 'no label'), ('Polg', 'no label'), ('Compound', 'no label'), ('Heterozygous Mutations', 'no label'), ('C.2617G>A (P.E873K', 'no label'), ('C.3550G>A', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Compound', 'no label'), ('Heterozygous Mutations', 'no label'), ('C.721C>T', 'no label'), ('P.R241C', 'no label'), ('C.728G>A', 'no label'), ('P.R243Q', 'no label'), ('Polg P.E873K Mutation', 'no label'), ('Novel', 'no label'), ('Mutation', 'no label'), ('Exome Aggregation Consortium Database', 'no label'), ('Genome Aggregation Database', 'no label'), ('Genomes Database', 'no label'), ('Heterozygous Mutations', 'no label'), ('Inherited', 'no label'), (""Child'S"", 'no label'), ('Parents', 'no label'), ('Suggested', 'no label'), ('Phenotype', 'no label'), ('Genotype', 'no label'), ('Segregated', 'no label'), ('Whole-Exome Sequencing', 'no label'), ('Identified', 'no label'), ('Mutations', 'no label'), ('Causing', 'no label'), ('Phenylketonuria', 'no label'), ('Identified', 'no label'), ('Genetic Cause', 'no label'), ('Mitochondrial Disease', 'no label'), ('Polg', 'no label'), ('Mutation', 'no label'), ('Findings', 'no label'), ('Future', 'no label'), ('Parents', 'no label'), ('Healthy', 'no label'), ('Embryos', 'no label'), ('Assisted Reproductive Technology', 'no label')]"|[('Genetic', 'no label'), ('Genetic', 'no label'), ('Mutations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Mutations', 'no label'), ('T', 'no label'), ('Polg', 'no label'), ('Mutation', 'no label'), ('Mutation', 'no label'), ('Genome', 'no label'), ('Mutations', 'no label'), ('Genotype', 'no label'), ('Mutations', 'no label'), ('Genetic', 'no label'), ('Mitochondrial', 'no label'), ('Polg Mutation', 'no label')]|[('Pah Mutations', 'no label')]|[('Phenylketonuria', 'no label'), ('Hearing Loss', 'no label'), ('Liver Disease', 'no label'), ('Hypotonia', 'no label'), ('External Ophthalmoplegia', 'no label'), ('Hearing Loss', 'no label'), ('Liver Disease', 'no label'), ('Hypotonia', 'no label'), ('External Ophthalmoplegia', 'no label'), ('Heterozygous', 'no label'), ('Phenylalanine', 'no label'), ('Heterozygous', 'no label'), ('K', 'no label'), ('Heterozygous', 'no label'), ('Phenylketonuria', 'no label'), ('Mitochondrial Disease', 'no label')]|[('Phenylketonuria', 'no label'), ('Liver', 'no label'), ('Liver', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Polg', 'no label'), ('K', 'no label'), ('Pah', 'no label'), ('Phenylketonuria', 'no label'), ('Mitochondrial', 'no label'), ('Polg', 'no label')]
phenylketonuria|pubmed~34344399|During The Initial 26-Week Spark (Safety Paediatric Efficacy Pharmacokinetic With Kuvan®) Study, Addition Of Sapropterin Dihydrochloride (Kuvan®; A Synthetic Formulation Of The Natural Cofactor For Phenylalanine Hydroxylase, Tetrahydrobiopterin; Bh<Sub>4</Sub>), To A Phenylalanine (Phe)-Restricted Diet, Led To A Significant Improvement In Phe Tolerance Versus A Phe-Restricted Diet Alone In Patients Aged 0-4 Years With Bh<Sub>4</Sub>-Responsive Phenylketonuria (Pku) Or Mild Hyperphenylalaninaemia (Hpa). Based On These Results, The Approved Indication For Sapropterin In Europe Was Expanded To Include Patients < 4 Years Of Age. Herein, We Present Results Of The Spark Extension Study (Nct01376908), Evaluating The Long-Term Safety, Dietary Phe Tolerance, Blood Phe Concentrations And Neurodevelopmental Outcomes In Patients < 4 Years Of Age At Randomisation, Over An Additional 36 Months Of Treatment With Sapropterin. All 51 Patients Who Completed The 26-Week Spark Study Period Entered The Extension Period. Patients Who Were Previously Treated With A Phe-Restricted Diet Only ('Sapropterin Extension' Group; N = 26), Were Initiated On Sapropterin At 10 Mg/Kg/Day, Which Could Be Increased Up To 20 Mg/Kg/Day. Patients Previously Treated With Sapropterin Plus Phe-Restricted Diet, Remained On This Regimen In The Extension Period ('Sapropterin Continuous' Group; N = 25). Dietary Phe Tolerance Increased Significantly At The End Of The Study Versus Baseline (Week 0), By 38.7 Mg/Kg/Day In The 'Sapropterin Continuous' Group (95% Ci 28.9, 48.6; P < 0.0001). In The 'Sapropterin Extension' Group, A Less Pronounced Effect Was Observed, With Significant Differences Versus Baseline (Week 27) Only Observed Between Months 9 And 21; Dietary Phe Tolerance At The End Of Study Increased By 5.5 Mg/Kg/Day Versus Baseline (95% Ci - 2.8, 13.8; P = 0.1929). Patients In Both Groups Had Normal Neuromotor Development And Growth Parameters. Long-Term Treatment With Sapropterin Plus A Phe-Restricted Diet In Patients Who Initiated Sapropterin At < 4 Years Of Age With Bh<Sub>4</Sub>-Responsive Pku Or Mild Hpa Maintained Improvements In Dietary Phe Tolerance Over 3.5 Years. These Results Continue To Support The Favourable Risk/Benefit Profile For Sapropterin In Paediatric Patients (< 4 Years Of Age) With Bh<Sub>4</Sub>-Responsive Pku. Frequent Monitoring Of Blood Phe Levels And Careful Titration Of Dietary Phe Intake To Ensure Adequate Levels Of Protein Intake Is Necessary To Optimise The Benefits Of Sapropterin Treatment. Trial Registration Clinicaltrials.Gov, Nct01376908. Registered 17 June 2011, Https://Clinicaltrials.Gov/Ct2/Show/Nct01376908 .|"[('Initial', 'no label'), ('26-Week Spark', 'no label'), ('Paediatric Efficacy', 'no label'), ('Pharmacokinetic', 'no label'), ('Kuvan®) Study', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Kuvan', 'no label'), ('Synthetic Formulation', 'no label'), ('Natural Cofactor', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh<Sub>4</Sub>)', 'no label'), ('Phenylalanine (Phe)-Restricted', 'no label'), ('Diet', 'no label'), ('Significant', 'no label'), ('Improvement', 'no label'), ('Phe Tolerance', 'no label'), ('Phe-Restricted Diet Alone', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Bh<Sub>4</Sub>-Responsive Phenylketonuria', 'no label'), ('Mild Hyperphenylalaninaemia', 'no label'), ('Hpa', 'no label'), ('Results', 'no label'), ('Approved', 'no label'), ('Indication', 'no label'), ('Sapropterin', 'no label'), ('Europe', 'no label'), ('Patients', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Spark Extension Study', 'no label'), ('Evaluating', 'no label'), ('Long-Term Safety', 'no label'), ('Dietary Phe Tolerance', 'no label'), ('Blood Phe Concentrations', 'no label'), ('Neurodevelopmental Outcomes', 'no label'), ('Patients', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Randomisation', 'no label'), ('Months', 'no label'), ('Treatment', 'no label'), ('Sapropterin', 'no label'), ('Patients', 'no label'), ('Completed', 'no label'), ('26-Week Spark Study', 'no label'), ('Period Entered', 'no label'), ('Extension', 'no label'), ('Period', 'no label'), ('Patients', 'no label'), ('Treated With', 'no label'), ('Phe-Restricted Diet', 'no label'), ('Sapropterin', 'no label'), (""Extension' Group"", 'no label'), ('Initiated', 'no label'), ('Sapropterin', 'no label'), ('Increased', 'no label'), ('Patients', 'no label'), ('Treated', 'no label'), ('Sapropterin Plus', 'no label'), ('Phe-Restricted Diet', 'no label'), ('Remained', 'no label'), ('Regimen', 'no label'), ('Extension Period', 'no label'), (""Continuous'"", 'no label'), ('Group', 'no label'), ('Dietary Phe Tolerance', 'no label'), ('Increased', 'no label'), ('Study', 'no label'), ('Baseline', 'no label'), ('Week', 'no label'), ('Sapropterin', 'no label'), (""Continuous' Group"", 'no label'), ('Ci', 'no label'), ('Sapropterin', 'no label'), (""Extension' Group"", 'no label'), ('Pronounced', 'no label'), ('Observed', 'no label'), ('Differences', 'no label'), ('Baseline', 'no label'), ('Week', 'no label'), ('Observed', 'no label'), ('Months', 'no label'), ('Dietary Phe Tolerance', 'no label'), ('Study', 'no label'), ('Increased', 'no label'), ('Baseline', 'no label'), ('Ci', 'no label'), ('Patients', 'no label'), ('Groups', 'no label'), ('Normal Neuromotor Development', 'no label'), ('Growth', 'no label'), ('Parameters', 'no label'), ('Long-Term', 'no label'), ('Treatment', 'no label'), ('Sapropterin Plus A', 'no label'), ('Phe-Restricted Diet', 'no label'), ('Patients', 'no label'), ('Initiated', 'no label'), ('Sapropterin', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Bh<Sub>4</Sub>-Responsive Pku', 'no label'), ('Improvements', 'no label'), ('Dietary Phe Tolerance', 'no label'), ('Years', 'no label'), ('Results', 'no label'), ('Favourable Risk/Benefit', 'no label'), ('Profile', 'no label'), ('Sapropterin', 'no label'), ('Paediatric', 'no label'), ('Patients', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Bh<Sub>4</Sub>-Responsive Pku', 'no label'), ('Frequent', 'no label'), ('Monitoring', 'no label'), ('Blood Phe Levels', 'no label'), ('Titration', 'no label'), ('Dietary Phe Intake', 'no label'), ('Ensure', 'no label'), ('Adequate', 'no label'), ('Levels', 'no label'), ('Protein Intake', 'no label'), ('Benefits', 'no label'), ('Sapropterin', 'no label'), ('Treatment', 'no label'), ('Trial', 'no label'), ('Registration', 'no label'), ('Clinicaltrials', 'no label'), ('Https://Clinicaltrials', 'no label'), ('Gov/Ct2/Show/Nct01376908', 'no label')]"|[('Dihydrochloride', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Hyperphenylalaninaemia', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Protein', 'no label')]|[('Phenylalanine Hydroxylase, Tetrahydrobiopterin; Bh<Sub>4</Sub>), To A Phenylalanine (Phe)-Restricted Diet, Led To A', 'no label'), ('Risk/Benefit', 'no label')]|[('Sapropterin Dihydrochloride', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninaemia', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Phe', 'no label'), ('Sapropterin', 'no label'), ('Phe', 'no label'), ('Ensure', 'no label'), ('Sapropterin', 'no label')]|[('Sapropterin Dihydrochloride', 'no label'), ('Natural Cofactor', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('A Phenylalanine', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Sapropterin', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Sapropterin', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Patients', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Phe', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Sapropterin', 'no label'), ('Patients', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Patients', 'no label'), ('Blood', 'no label'), ('Phe', 'no label'), ('Ensure', 'no label'), ('Sapropterin', 'no label')]
phenylketonuria|pubmed~27413125|To Prevent Cognitive Impairment, Phenylketonuria Requires Lifelong Management Of Blood Phenylalanine (Phe) Concentration With A Low-Phe Diet. The Diet Restricts Intake Of Phe From Natural Proteins In Combination With Traditional Amino Acid Medical Foods (Aa-Mfs) Or Glycomacropeptide Medical Foods (Gmp-Mfs) That Contain Primarily Intact Protein And A Small Amount Of Phe. We Investigated The Efficacy And Safety Of A Low-Phe Diet Combined With Gmp-Mfs Or Aa-Mfs Providing The Same Quantity Of Protein Equivalents In Free-Living Subjects With Phenylketonuria. This 2-Stage, Randomized Crossover Trial Included 30 Early-Treated Phenylketonuria Subjects (Aged 15-49 Y), 20 With Classical And 10 With Variant Phenylketonuria. Subjects Consumed, In Random Order For 3 Wk Each, Their Usual Low-Phe Diet Combined With Aa-Mfs Or Gmp-Mfs. The Treatments Were Separated By A 3-Wk Washout With Aa-Mfs. Fasting Plasma Amino Acid Profiles, Blood Phe Concentrations, Food Records, And Neuropsychological Tests Were Obtained. The Frequency Of Medical Food Intake Was Higher With Gmp-Mfs Than With Aa-Mfs. Subjects Rated Gmp-Mfs As More Acceptable Than Aa-Mfs And Noted Improved Gastrointestinal Symptoms And Less Hunger With Gmp-Mfs. Ancova Indicated No Significant Mean ± Se Increase In Plasma Phe (62 ± 40 Μmol/L, P = 0.136), Despite A Significant Increase In Phe Intake From Gmp-Mfs (88 ± 6 Mg Phe/D, P = 0.026). Aa-Mfs Decreased Plasma Phe (-85 ± 40 Μmol/L, P = 0.044) With Stable Phe Intake. Blood Concentrations Of Phe Across Time Were Not Significantly Different (Aa-Mfs = 444 ± 34 Μmol/L, Gmp-Mfs = 497 ± 34 Μmol/L), Suggesting Similar Phe Control. Results Of The Behavior Rating Inventory Of Executive Function Were Not Significantly Different. Gmp-Mfs Provide A Safe And Acceptable Option For The Nutritional Management Of Phenylketonuria. The Greater Acceptability And Fewer Side Effects Noted With Gmp-Mfs Than With Aa-Mfs May Enhance Dietary Adherence For Individuals With Phenylketonuria. This Trial Was Registered At Www.Clinicaltrials.Gov As Nct01428258.|[('Prevent Cognitive Impairment', 'no label'), ('Phenylketonuria', 'no label'), ('Requires', 'no label'), ('Lifelong Management', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Concentration', 'no label'), ('Low-Phe Diet', 'no label'), ('Diet Restricts', 'no label'), ('Intake', 'no label'), ('Phe', 'no label'), ('Natural Proteins', 'no label'), ('Combination', 'no label'), ('Traditional', 'no label'), ('Amino Acid Medical Foods', 'no label'), ('Aa-Mfs', 'no label'), ('Glycomacropeptide Medical Foods', 'no label'), ('Gmp-Mfs', 'no label'), ('Intact Protein', 'no label'), ('Amount', 'no label'), ('Phe', 'no label'), ('Investigated', 'no label'), ('Efficacy', 'no label'), ('Safety', 'no label'), ('Low-Phe Diet', 'no label'), ('Gmp-Mfs Or Aa-Mfs Providing', 'no label'), ('Quantity', 'no label'), ('Protein Equivalents', 'no label'), ('Free-Living Subjects', 'no label'), ('Phenylketonuria', 'no label'), ('Randomized Crossover Trial', 'no label'), ('Early-Treated Phenylketonuria', 'no label'), ('Subjects', 'no label'), ('Classical', 'no label'), ('Variant Phenylketonuria', 'no label'), ('Subjects', 'no label'), ('Consumed', 'no label'), ('Random Order', 'no label'), ('Usual Low-Phe Diet', 'no label'), ('Aa-Mfs Or Gmp-Mfs', 'no label'), ('Treatments', 'no label'), ('Separated', 'no label'), ('Washout With', 'no label'), ('Aa-Mfs', 'no label'), ('Fasting', 'no label'), ('Plasma', 'no label'), ('Amino Acid', 'no label'), ('Profiles', 'no label'), ('Blood Phe Concentrations', 'no label'), ('Food Records', 'no label'), ('Neuropsychological Tests', 'no label'), ('Frequency', 'no label'), ('Medical Food Intake', 'no label'), ('Gmp-Mfs Than', 'no label'), ('Aa-Mfs', 'no label'), ('Subjects', 'no label'), ('Than Aa-Mfs', 'no label'), ('Noted', 'no label'), ('Gastrointestinal Symptoms', 'no label'), ('Hunger', 'no label'), ('Gmp-Mfs', 'no label'), ('Ancova', 'no label'), ('No Significant', 'no label'), ('Se', 'no label'), ('Increase', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Increase', 'no label'), ('Phe Intake', 'no label'), ('Gmp-Mfs', 'no label'), ('Mg Phe/D', 'no label'), ('Aa-Mfs Decreased', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Stable Phe Intake', 'no label'), ('Blood Concentrations', 'no label'), ('Phe', 'no label'), ('Time', 'no label'), ('Aa-Mfs', 'no label'), ('Suggesting', 'no label'), ('Phe Control', 'no label'), ('Behavior Rating Inventory', 'no label'), ('Executive Function', 'no label'), ('Gmp-Mfs Provide', 'no label'), ('Safe', 'no label'), ('Acceptable', 'no label'), ('Option', 'no label'), ('Nutritional Management', 'no label'), ('Phenylketonuria', 'no label'), ('Acceptability', 'no label'), ('Side Effects', 'no label'), ('Noted', 'no label'), ('Gmp-Mfs Than', 'no label'), ('Aa-Mfs May', 'no label'), ('Enhance', 'no label'), ('Dietary Adherence', 'no label'), ('Individuals', 'no label'), ('Phenylketonuria', 'no label'), ('Trial', 'no label'), ('Www', 'no label'), ('Clinicaltrials', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Proteins', 'no label'), ('Amino Acid', 'no label'), ('Foods', 'no label'), ('Glycomacropeptide', 'no label'), ('Foods', 'no label'), ('Protein', 'no label'), ('Phe', 'no label'), ('Protein', 'no label'), ('Variant', 'no label'), ('Amino Acid', 'no label'), ('Food', 'no label'), ('Food', 'no label'), ('Phe', 'no label'), ('±', 'no label'), ('Phe', 'no label'), ('±', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Individuals', 'no label')]|[]|[('Cognitive Impairment', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Amino Acid', 'no label'), ('Aa-Mfs', 'no label'), ('Glycomacropeptide', 'no label'), ('Phe', 'no label'), ('Aa-Mfs', 'no label'), ('Protein Equivalents', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Variant Phenylketonuria', 'no label'), ('Aa-Mfs', 'no label'), ('Aa-Mfs', 'no label'), ('Amino Acid', 'no label'), ('Aa-Mfs', 'no label'), ('Aa-Mfs', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Mg', 'no label'), ('Aa-Mfs', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Aa-Mfs', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Amino Acid', 'no label'), ('Glycomacropeptide', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Aa-Mfs', 'no label'), ('Plasma Amino Acid', 'no label'), ('Blood Phe', 'no label'), ('Gastrointestinal Symptoms', 'no label'), ('Plasma Phe', 'no label'), ('Phe', 'no label'), ('Plasma Phe', 'no label'), ('Phe', 'no label'), ('Blood', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Aa-Mfs', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~31923802|Phenylketonuria (Pku) Is The Most Common Inborn Error Of Amino Acid Metabolism In Europe. The Reasons Underlying The High Prevalence Of Heterozygous Carriers Are Not Clearly Understood. We Aimed To Look For Pathogenic Pah Variant Enrichment According To Geographical Areas And Patients' Ethnicity Using A Multiethnic Nationwide Cohort Of Patients With Pku In France. We Subsequently Appraised The Population Differentiation, Balancing Selection And The Molecular Evolutionary History Of The Pah Locus. The French Nationwide Pku Study Included Patients Who Have Been Referred At The National Level To The University Hospital Of Nancy, And For Whom A Molecular Diagnosis Of Phenylketonuria Was Made By Sanger Sequencing. We Performed Enrichment Analyses By Comparing Alternative Allele Frequencies Using Fisher'S Exact Test With Bonferroni Adjustment. We Estimated The Amount Of Genetic Differentiation Among Populations Using Wright'S Fixation Index (Fst). To Estimate The Molecular Evolutionary History Of The Pah Gene, We Performed Phylogenetic And Evolutionary Analyses Using Whole-Genome And Exome-Sequencing Data From Healthy Individuals And Non-Pku Patients, Respectively. Finally, We Used Exome-Wide Association Study To Decipher Potential Genetic Loci Associated With Population Divergence On Pah. The Study Included 696 Patients And Revealed 132 Pathogenic Pah Variants. Three Geographical Areas Showed Significant Enrichment For A Pathogenic Pah Variant: North Of France (P.Arg243Leu), North-West Of France (P.Leu348Val), And Mediterranean Coast (P.Ala403Val). One Pah Variant (P.Glu280Gln) Was Significantly Enriched Among North-Africans (Or = 23·23; 95% Ci: 9·75-55·38). Pah Variants Exhibiting A Strong Genetic Differentiation Were Significantly Enriched In The 'Biopterin_H' Domain (Or = 6·45; 95% Ci: 1·99-20·84), Suggesting A Balancing Selection Pressure On The Biopterin Function Of Pah. Phylogenetic And Timetree Analyses Were Consistent With Population Differentiation Events On European-, African-, And Asian-Ancestry Populations. The Five Pah Variants Most Strongly Associated With A High Selection Pressure Were Phylogenetically Close And Were Located Within The Biopterin Domain Coding Region Of Pah Or In Its Vicinity. Among The Non-Pah Loci Potentially Associated With Population Divergence, Two Reached Exome-Wide Significance: Sspo (Sco-Spondin) And Dbh (Dopamine Beta-Hydroxylase), Involved In Neuroprotection And Metabolic Adaptation, Respectively. Our Data Provide Evidence On The Combination Of Evolutionary And Adaptive Events In Populations With Distinct Ancestries, Which May Explain The Overdominance Of Some Genetic Variants On Pah. French National Institute Of Health And Medical Research (Inserm) Umr_S 1256.|"[('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Europe', 'no label'), ('High Prevalence', 'no label'), ('Heterozygous Carriers', 'no label'), ('Pathogenic', 'no label'), ('Variant', 'no label'), ('Enrichment', 'no label'), ('Geographical Areas', 'no label'), ('Patients', 'no label'), ('Ethnicity', 'no label'), ('Multiethnic Nationwide Cohort', 'no label'), ('Patients', 'no label'), ('Pku In France', 'no label'), ('Appraised', 'no label'), ('Population', 'no label'), ('Differentiation', 'no label'), ('Selection', 'no label'), ('Molecular Evolutionary History', 'no label'), ('Pah Locus', 'no label'), ('French Nationwide Pku Study', 'no label'), ('Patients', 'no label'), ('Referred', 'no label'), ('National Level To The University Hospital', 'no label'), ('Nancy', 'no label'), ('Molecular Diagnosis', 'no label'), ('Phenylketonuria', 'no label'), ('Sanger Sequencing', 'no label'), ('Performed Enrichment Analyses', 'no label'), ('Alternative', 'no label'), ('Allele', 'no label'), ('Frequencies', 'no label'), (""Fisher'S Exact Test"", 'no label'), ('Bonferroni Adjustment', 'no label'), ('Estimated', 'no label'), ('Amount', 'no label'), ('Genetic Differentiation', 'no label'), ('Populations', 'no label'), (""Wright'S Fixation Index"", 'no label'), ('Fst', 'no label'), ('Molecular Evolutionary History', 'no label'), ('Pah Gene', 'no label'), ('Performed', 'no label'), ('Phylogenetic', 'no label'), ('Evolutionary Analyses', 'no label'), ('Whole-Genome', 'no label'), ('Exome-Sequencing Data', 'no label'), ('Healthy', 'no label'), ('Individuals', 'no label'), ('Non-Pku Patients', 'no label'), ('Exome-Wide Association Study', 'no label'), ('Decipher', 'no label'), ('Genetic Loci', 'no label'), ('Associated With', 'no label'), ('Population', 'no label'), ('Divergence', 'no label'), ('Study', 'no label'), ('Patients', 'no label'), ('Revealed', 'no label'), ('Pathogenic', 'no label'), ('Variants', 'no label'), ('Geographical Areas', 'no label'), ('Significant', 'no label'), ('Enrichment', 'no label'), ('Pathogenic', 'no label'), ('North', 'no label'), ('France', 'no label'), ('P.Arg243Leu', 'no label'), ('North-West', 'no label'), ('France', 'no label'), ('Mediterranean Coast', 'no label'), ('Pah Variant (P.Glu280Gln)', 'no label'), ('North-Africans', 'no label'), ('Ci', 'no label'), ('Variants', 'no label'), ('Exhibiting', 'no label'), ('Genetic Differentiation', 'no label'), (""Biopterin_H' Domain"", 'no label'), ('Ci', 'no label'), ('Suggesting', 'no label'), ('Balancing', 'no label'), ('Selection Pressure', 'no label'), ('Biopterin Function', 'no label'), ('Phylogenetic', 'no label'), ('Timetree Analyses', 'no label'), ('Consistent With', 'no label'), ('Population Differentiation Events', 'no label'), ('African-', 'no label'), ('Asian-Ancestry Populations', 'no label'), ('Pah', 'no label'), ('Variants', 'no label'), ('Strongly', 'no label'), ('Associated With', 'no label'), ('High Selection Pressure', 'no label'), ('Phylogenetically Close', 'no label'), ('Biopterin', 'no label'), ('Domain Coding Region', 'no label'), ('Vicinity', 'no label'), ('Non-Pah Loci', 'no label'), ('Associated With', 'no label'), ('Population', 'no label'), ('Divergence', 'no label'), ('Exome-Wide', 'no label'), ('Significance', 'no label'), ('Sspo', 'no label'), ('Sco-Spondin', 'no label'), ('Dbh', 'no label'), ('Dopamine Beta-Hydroxylase', 'no label'), ('Neuroprotection', 'no label'), ('Metabolic', 'no label'), ('Adaptation', 'no label'), ('Data Provide', 'no label'), ('Evidence', 'no label'), ('Combination', 'no label'), ('Evolutionary', 'no label'), ('Adaptive Events', 'no label'), ('Populations', 'no label'), ('Ancestries', 'no label'), ('Explain', 'no label'), ('Overdominance', 'no label'), ('Genetic Variants', 'no label'), ('French National Institute Of Health And Medical Research (Inserm) Umr_S 1256', 'no label')]"|[('Amino Acid', 'no label'), ('Pathogenic', 'no label'), ('Variant', 'no label'), ('Molecular', 'no label'), ('Molecular', 'no label'), ('Allele', 'no label'), ('Genetic', 'no label'), ('Molecular', 'no label'), ('Gene', 'no label'), ('Individuals', 'no label'), ('Genetic Loci', 'no label'), ('Pathogenic', 'no label'), ('Pathogenic', 'no label'), ('Variant', 'no label'), ('Variants', 'no label'), ('Genetic', 'no label'), ('Domain', 'no label'), ('Biopterin', 'no label'), ('Timetree', 'no label'), ('Variants', 'no label'), ('Biopterin Domain', 'no label'), ('Region', 'no label'), ('Non-Pah Loci', 'no label'), ('Sspo', 'no label'), ('Dopamine Beta-Hydroxylase', 'no label'), ('Genetic Variants', 'no label')]|"[('Pah Locus', 'no label'), ('Alternative Allele', 'no label'), ('Pah Gene', 'no label'), ('Pah Variant', 'no label'), (""'Biopterin_H' Domain"", 'no label'), ('Pah Variants', 'no label'), ('Non-Pah Loci', 'no label'), ('Dbh', 'no label')]"|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Heterozygous', 'no label'), ('Referred', 'no label'), ('Phenylketonuria', 'no label'), ('Biopterin', 'no label'), ('Biopterin', 'no label'), ('Dopamine', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Amino Acid', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Pah Locus', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Pah Gene', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Pah Variant', 'no label'), ('Biopterin', 'no label'), ('Biopterin', 'no label'), ('Non-Pah Loci', 'no label'), ('Sspo', 'no label'), ('Dbh', 'no label'), ('Dopamine Beta-Hydroxylase', 'no label')]
phenylketonuria|pubmed~31778858|Phenylketonuria (Pku) Is An Autosomal Recessive Metabolic Disorder Characterized By An Inability To Metabolize The Amino Acid Phenylalanine (Phe). If Left Untreated, An Accumulation Of Phe Results In Neurodevelopmental, Neurological And Psychological Impairments. Advancements In Detection And Treatment Of Pku Have Improved Outcomes And Life Expectancy For These Patients, Emphasizing The Need For Life-Long, Specialized Care. Due To The Paucity Of Adult-Focused Pku Clinics, Patients Who Are Well Into Adulthood Are Still Being Treated In Pediatric Centers. This Retrospective Study Evaluates The Perceived Expectations, Benefits And Challenges Of 50 Adult Pku Patients (Mean Age 31.3 ± 10.4 Years) Transitioning From A Pediatric To Adult Care Setting Using A Transition Questionnaire Administered At The First Clinic Visit At The Adult Pku Care Center. Patients Reported A Lack Of Access To Adult Resources And Adult-Specific Pku Educational Material In Their Pediatric Pku Clinic. In Contrast, The Established Relationships With The Pediatric Health Care Team And Familiarity With Treatment Plans Were Aspects Of Pediatric Care That Patients Enjoyed. The Results From This Study Will Contribute To The Optimization Of Adult Pku Patient Care, Establishment Of Strategies For Transitioning Adults With Pku And Other Metabolic Disorders From Pediatric To Adult Care, And Support The Need To Establish Adult-Only Pku Care Facilities.|[('Phenylketonuria', 'no label'), ('Autosomal Recessive Metabolic Disorder', 'no label'), ('Characterized', 'no label'), ('Metabolize', 'no label'), ('Amino Acid Phenylalanine', 'no label'), ('Phe', 'no label'), ('Left Untreated', 'no label'), ('Accumulation', 'no label'), ('Phe Results', 'no label'), ('Neurodevelopmental', 'no label'), ('Neurological', 'no label'), ('Psychological Impairments', 'no label'), ('Advancements', 'no label'), ('Detection', 'no label'), ('Treatment', 'no label'), ('Pku', 'no label'), ('Improved', 'no label'), ('Outcomes', 'no label'), ('Patients', 'no label'), ('Need', 'no label'), ('Life-Long', 'no label'), ('Specialized Care', 'no label'), ('Adult-Focused Pku Clinics', 'no label'), ('Patients', 'no label'), ('Treated', 'no label'), ('Pediatric Centers', 'no label'), ('Retrospective Study', 'no label'), ('Evaluates', 'no label'), ('Perceived', 'no label'), ('Expectations', 'no label'), ('Benefits', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Pediatric', 'no label'), ('Transition Questionnaire Administered', 'no label'), ('First Clinic Visit', 'no label'), ('Adult Pku Care Center', 'no label'), ('Patients', 'no label'), ('Lack', 'no label'), ('Pediatric Pku Clinic', 'no label'), ('Contrast', 'no label'), ('Relationships', 'no label'), ('Pediatric Health Care', 'no label'), ('Team', 'no label'), ('Familiarity', 'no label'), ('Treatment Plans', 'no label'), ('Pediatric Care', 'no label'), ('Patients', 'no label'), ('Enjoyed', 'no label'), ('Results', 'no label'), ('Study', 'no label'), ('Optimization', 'no label'), ('Adult', 'no label'), ('Pku Patient Care', 'no label'), ('Strategies', 'no label'), ('Adults', 'no label'), ('Pku', 'no label'), ('Metabolic Disorders', 'no label'), ('Pediatric', 'no label'), ('Establish', 'no label'), ('Pku Care Facilities', 'no label')]|[('Amino Acid Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Autosomal Recessive Metabolic Disorder', 'no label'), ('Amino Acid Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Neurodevelopmental', 'no label'), ('Metabolic Disorders', 'no label')]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Pku', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patient', 'no label')]
phenylketonuria|pubmed~31960483|Phenylketonuria (Pku) Is An Inborn Disease Caused By Defective Phenylalanine Hydroxylase, Which Consequently Results In The Accumulation Of Phenylalanine In The Brain Leading To Further Complications. One Of The Promising Approaches In Dietary Treatment Is The Supplementation Of Large Neutral Amino Acid (Lnaa). The Lnaa Compete With Phenylalanine For The Common L-Type Lnaa Transporter Across The Blood-Brain Barrier, And Decrease Phenylalanine Levels In The Brain. In This Study, The Earlier Lnaa-Enriched Protein Model Was Improved (Protein Model-66) And Validated In Silico. The Reverse Translated And Codon-Optimized Synthetic Lnaa66 Gene Was Cloned Into Ppiczαc And Expressed In Pichia Pastoris. The Expressed Protein Was Purified By His Select Affinity Chromatography. Sds-Page And Western Blotting Analysis Showed A Band At An Expected Molecular Weight Of 12 Kda, Confirming The Expression Of The Modeled Protein. To Our Knowledge, This Is The First Report Showing The Cloning And Expression Of An In Silico Designed Lnaa-Enriched Protein. Practical Applications: One Of The Promising Dietary Treatment Of Phenylketonuria (Pku) Is The Supplementation Of Large Neutral Amino Acid (Lnaa), Wherein High Levels Of Lnaa Compete With Phenylalanine For The Same L-Type Lnaa Transporter, And Consequently Decrease Phenylalanine Accumulation In The Brain, Thereby Decreasing Neurological Complications. For The First Time, Here, We Are Showing That An In Silico Designed And Validated Protein Model-66, Rich In Lnaa, Can Be Successfully Cloned And Expressed In Pichia Pastoris. The Complete Biochemical And Structural Characterization Of This Protein Will Give A Clear Insight Into Its Potential Application For Pku Treatment. The Protein Can Be Potentially Used As A Supplement To Treat Pku To Those Who Are Non-Adherent To The Restricted, Non-Palatable, And Expensive Diet. Furthermore, This Novel And Effective Strategy Of In Silico Designing, Cloning And Expression Can Be Exploited To Develop Proteins For Various Applications Of Industrial, Food, Medical, And Academic Relevance.|[('Phenylketonuria', 'no label'), ('Inborn Disease', 'no label'), ('Defective', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Accumulation', 'no label'), ('Phenylalanine', 'no label'), ('Brain', 'no label'), ('Complications', 'no label'), ('Approaches', 'no label'), ('Dietary Treatment', 'no label'), ('Supplementation', 'no label'), ('Neutral Amino Acid', 'no label'), ('Lnaa', 'no label'), ('Lnaa Compete', 'no label'), ('Phenylalanine', 'no label'), ('L-Type Lnaa Transporter', 'no label'), ('Blood-Brain Barrier', 'no label'), ('Decrease', 'no label'), ('Phenylalanine', 'no label'), ('Levels', 'no label'), ('Brain', 'no label'), ('Study', 'no label'), ('Protein Model', 'no label'), ('Protein Model-66', 'no label'), ('Validated', 'no label'), ('In Silico', 'no label'), ('Reverse Translated', 'no label'), ('Codon-Optimized', 'no label'), ('Synthetic Lnaa66 Gene', 'no label'), ('Expressed', 'no label'), ('Pichia Pastoris', 'no label'), ('Expressed Protein', 'no label'), ('Sds-Page', 'no label'), ('Western Blotting Analysis', 'no label'), ('Expected Molecular Weight', 'no label'), ('Expression', 'no label'), ('Protein', 'no label'), ('Knowledge', 'no label'), ('First Report', 'no label'), ('Cloning', 'no label'), ('Expression', 'no label'), ('In Silico', 'no label'), ('Designed', 'no label'), ('Dietary Treatment', 'no label'), ('Phenylketonuria', 'no label'), ('Supplementation', 'no label'), ('Neutral Amino Acid', 'no label'), ('Lnaa', 'no label'), ('Wherein High Levels', 'no label'), ('Lnaa Compete', 'no label'), ('Phenylalanine', 'no label'), ('L-Type Lnaa Transporter', 'no label'), ('Decrease', 'no label'), ('Phenylalanine', 'no label'), ('Accumulation', 'no label'), ('Brain', 'no label'), ('Decreasing', 'no label'), ('Neurological Complications', 'no label'), ('First Time', 'no label'), ('In Silico', 'no label'), ('Designed', 'no label'), ('Successfully', 'no label'), ('Cloned', 'no label'), ('Expressed', 'no label'), ('Pichia Pastoris', 'no label'), ('Complete', 'no label'), ('Biochemical', 'no label'), ('Structural', 'no label'), ('Characterization', 'no label'), ('Protein', 'no label'), ('Give A', 'no label'), ('Application', 'no label'), ('Pku Treatment', 'no label'), ('Protein', 'no label'), ('Non-Adherent', 'no label'), ('Restricted', 'no label'), ('Non-Palatable', 'no label'), ('Expensive Diet', 'no label'), ('Novel', 'no label'), ('Effective', 'no label'), ('Strategy', 'no label'), ('In Silico', 'no label'), ('Designing', 'no label'), ('Cloning', 'no label'), ('Expression', 'no label'), ('Exploited', 'no label'), ('Proteins', 'no label'), ('Industrial', 'no label'), ('Food', 'no label'), ('Medical', 'no label'), ('Academic', 'no label'), ('Relevance', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Gene', 'no label'), ('Pichia Pastoris', 'no label'), ('Protein', 'no label'), ('His', 'no label'), ('Molecular', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Pichia Pastoris', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Proteins', 'no label'), ('Food', 'no label')]|[('Synthetic Lnaa66 Gene', 'no label'), ('Sds-Page', 'no label')]|[('Phenylketonuria', 'no label'), ('Inborn Disease', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Neurological Complications', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Brain', 'no label'), ('Phenylalanine', 'no label'), ('Blood-Brain Barrier', 'no label'), ('Phenylalanine', 'no label'), ('Brain', 'no label'), ('Lnaa-Enriched Protein', 'no label'), ('Pichia Pastoris', 'no label'), ('A Band', 'no label'), ('Phenylketonuria', 'no label'), ('Lnaa', 'no label'), ('Phenylalanine', 'no label'), ('L-Type Lnaa', 'no label'), ('Phenylalanine', 'no label'), ('Brain', 'no label'), ('Rich', 'no label'), ('Lnaa', 'no label'), ('Pichia Pastoris', 'no label'), ('A Clear Insight', 'no label'), ('Proteins', 'no label')]
phenylketonuria|pubmed~33819046|Phenylketonuria (Pku) Is A Disease Of The Catabolism Of Phenylalanine (Phe), Caused By An Impaired Function Of The Enzyme Phenylalanine Hydroxylase. Therapeutics Is Based On The Restriction Of Phe Intake, Which Mostly Requires A Modification Of The Diet. Dietary Restrictions Can Lead To Imbalances In Specific Nutrients, Including Lipids. In The Present Study, The Plasma Phospholipidome Of Pku And Healthy Children (Ct) Was Analyzed By Hydrophilic Interaction Liquid Chromatography-Tandem Mass Spectrometry And Gas Chromatography-Mass Spectrometry. Using This Approach, 187 Lipid Species Belonging To Nine Different Phospholipid Classes And Three Ceramides Were Identified. Principal Component Analysis Of The Lipid Species Data Set Showed A Distinction Between Pku And Ct Groups. Univariate Analysis Revealed That 146 Species Of Phospholipids Were Significantly Different Between Both Groups. Lipid Species Showing Significant Variation Included Phosphatidylcholines, Containing Polyunsaturated Fatty Acids (Pufa), Which Were More Abundant In Pku. The High Level Of Pufa-Containing Lipid Species In Children With Pku May Be Related To A Diet Supplemented With Pufa. This Study Was The First Report Comparing The Plasma Polar Lipidome Of Pku And Healthy Children, Highlighting That The Phospholipidome Of Pku Children Is Significantly Altered Compared To Ct. However, Further Studies With Larger Cohorts Are Needed To Clarify Whether These Changes Are Specific To Phenylketonuric Children.|[('Phenylketonuria', 'no label'), ('Disease', 'no label'), ('Catabolism', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Impaired Function', 'no label'), ('Enzyme Phenylalanine Hydroxylase', 'no label'), ('Therapeutics', 'no label'), ('Restriction', 'no label'), ('Phe Intake', 'no label'), ('Requires', 'no label'), ('Modification', 'no label'), ('Diet', 'no label'), ('Dietary Restrictions', 'no label'), ('Lead', 'no label'), ('Imbalances', 'no label'), ('Nutrients', 'no label'), ('Lipids', 'no label'), ('Study', 'no label'), ('Plasma', 'no label'), ('Phospholipidome', 'no label'), ('Pku And Healthy Children', 'no label'), ('Ct', 'no label'), ('Analyzed', 'no label'), ('Hydrophilic Interaction Liquid Chromatography-Tandem Mass Spectrometry', 'no label'), ('Gas Chromatography-Mass Spectrometry', 'no label'), ('Approach', 'no label'), ('Lipid Species', 'no label'), ('Belonging', 'no label'), ('Phospholipid Classes', 'no label'), ('Ceramides', 'no label'), ('Identified', 'no label'), ('Principal Component Analysis', 'no label'), ('Lipid Species', 'no label'), ('Data Set', 'no label'), ('Pku And Ct Groups', 'no label'), ('Univariate Analysis', 'no label'), ('Revealed', 'no label'), ('Species', 'no label'), ('Phospholipids', 'no label'), ('Groups', 'no label'), ('Lipid Species', 'no label'), ('Variation', 'no label'), ('Phosphatidylcholines', 'no label'), ('Containing Polyunsaturated Fatty Acids', 'no label'), ('Pufa', 'no label'), ('Abundant', 'no label'), ('Level', 'no label'), ('Pufa-Containing', 'no label'), ('Lipid Species', 'no label'), ('Children', 'no label'), ('Pku May', 'no label'), ('Diet', 'no label'), ('Supplemented', 'no label'), ('Pufa', 'no label'), ('Study', 'no label'), ('First Report', 'no label'), ('Comparing', 'no label'), ('Plasma Polar', 'no label'), ('Pku And Healthy', 'no label'), ('Children', 'no label'), ('Phospholipidome', 'no label'), ('Pku Children', 'no label'), ('Ct', 'no label'), ('Studies', 'no label'), ('Larger', 'no label'), ('Cohorts', 'no label'), ('Changes', 'no label'), ('Phenylketonuric Children', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Modification', 'no label'), ('Nutrients', 'no label'), ('Phospholipidome', 'no label'), ('Lipid Species', 'no label'), ('Phospholipid', 'no label'), ('Ceramides', 'no label'), ('Lipid Species', 'no label'), ('Phospholipids', 'no label'), ('Lipid', 'no label'), ('Phosphatidylcholines', 'no label'), ('Fatty Acids', 'no label'), ('Pufa', 'no label'), ('Lipid', 'no label'), ('Pufa', 'no label'), ('Phospholipidome', 'no label')]|[('Ct', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phosphatidylcholines', 'no label'), ('Polyunsaturated Fatty Acids', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Lipids', 'no label'), ('Plasma Phospholipidome', 'no label'), ('Pku', 'no label'), ('Children', 'no label'), ('Chromatography-Mass', 'no label'), ('Phospholipid', 'no label'), ('Ceramides', 'no label'), ('Lipid Species Data', 'no label'), ('Phospholipids', 'no label'), ('Phosphatidylcholines', 'no label'), ('Polyunsaturated Fatty Acids', 'no label'), ('Pufa', 'no label'), ('Lipid Species In', 'no label'), ('Children', 'no label'), ('Pufa', 'no label'), ('Plasma Polar', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Children', 'no label')]
phenylketonuria|pubmed~31603834|Phenylketonuria, Also Known As Pku, Is The Most Frequent Congenital Inborn Error Of Metabolism. The Severe Form Or Classic Pku Untreated Causes Intellectual Disability, Although With The Early Detection Programs In The Neonatal Period, Diagnosis And Treatment Prevent The Appearance Of The Symptoms. Despite Early Diagnosis And Treatment We Have Observed Some Neurotoxicity In Treated Pku Patients. We Analyzed The Factors Involved Apart From The Toxicity Due To The High Cerebral Concentrations Of Phenylalanine (Phe), The Defects Of Synthesis Of Neurotransmitters, The Alteration Of Cerebral Myelination, The Effect Of The Elevation Of Phe In The Processes Of Transport And Distribution Of Neutral Amino Acids With An Abnormal Synthesis Of Brain Proteins, Plasma And Cerebral Tyrosine Deficiency, The Neurotoxicity Of Phe Metabolites, The Defect Of Cholesterol Biosynthesis Or The Increase Of Oxidative Stress. White Matter Alterations In Early Treated Pku Patients Have An Important Role In Neurological Manifestations. The Treatment Of Pku Is For Life And Is Based On The Reduction Of Foods Containing Phe Combined With The Administration Of A Special Formula Or Tetrahydrobiopterin (Bh4) Treatment. New Therapeutic Options Will Be Analyzed.|[('Phenylketonuria', 'no label'), ('Frequent', 'no label'), ('Congenital Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Severe Form Or Classic Pku', 'no label'), ('Untreated Causes', 'no label'), ('Intellectual Disability', 'no label'), ('Early Detection', 'no label'), ('Neonatal', 'no label'), ('Period', 'no label'), ('Diagnosis', 'no label'), ('Treatment Prevent', 'no label'), ('Appearance', 'no label'), ('Symptoms', 'no label'), ('Early Diagnosis', 'no label'), ('Treatment', 'no label'), ('Observed', 'no label'), ('Neurotoxicity', 'no label'), ('Treated', 'no label'), ('Patients', 'no label'), ('Analyzed', 'no label'), ('Factors', 'no label'), ('Toxicity', 'no label'), ('Cerebral', 'no label'), ('Concentrations', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Defects', 'no label'), ('Synthesis', 'no label'), ('Neurotransmitters', 'no label'), ('Alteration', 'no label'), ('Cerebral Myelination', 'no label'), ('Effect', 'no label'), ('Elevation', 'no label'), ('Phe', 'no label'), ('Processes', 'no label'), ('Transport', 'no label'), ('Distribution', 'no label'), ('Neutral Amino Acids', 'no label'), ('Abnormal Synthesis', 'no label'), ('Brain Proteins', 'no label'), ('Plasma', 'no label'), ('Cerebral Tyrosine Deficiency', 'no label'), ('Neurotoxicity', 'no label'), ('Phe Metabolites', 'no label'), ('Defect', 'no label'), ('Cholesterol Biosynthesis', 'no label'), ('Increase', 'no label'), ('Oxidative Stress', 'no label'), ('White Matter', 'no label'), ('Alterations', 'no label'), ('Early', 'no label'), ('Treated', 'no label'), ('Pku Patients', 'no label'), ('Neurological Manifestations', 'no label'), ('Treatment', 'no label'), ('Life', 'no label'), ('Reduction', 'no label'), ('Foods', 'no label'), ('Containing', 'no label'), ('Phe', 'no label'), ('Administration', 'no label'), ('Special Formula', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh4', 'no label'), ('Treatment', 'no label'), ('Therapeutic Options', 'no label'), ('Will Be', 'no label'), ('Analyzed', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Amino Acids', 'no label'), ('Proteins', 'no label'), ('Tyrosine', 'no label'), ('Cholesterol', 'no label'), ('Foods', 'no label'), ('Phe', 'no label'), ('Tetrahydrobiopterin', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Congenital Inborn Error', 'no label'), ('Neurotoxicity', 'no label'), ('Toxicity', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Cerebral Myelination', 'no label'), ('Phe', 'no label'), ('Amino Acids', 'no label'), ('Cerebral Tyrosine', 'no label'), ('Neurotoxicity', 'no label'), ('Phe', 'no label'), ('Cholesterol', 'no label'), ('Phe', 'no label'), ('Tetrahydrobiopterin', 'no label')]|[('Error', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Neurotransmitters', 'no label'), ('Cerebral', 'no label'), ('Phe', 'no label'), ('Amino Acids', 'no label'), ('Brain', 'no label'), ('Plasma', 'no label'), ('Cerebral Tyrosine', 'no label'), ('Phe', 'no label'), ('Cholesterol', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('A Special Formula', 'no label'), ('Tetrahydrobiopterin', 'no label')]
phenylketonuria|pubmed~31491833|Phenylketonuria (Pku) Is A Recessive Disorder Characterized By Disruption In The Metabolism Of The Amino Acid Phenylalanine (Phe). Prior Research Indicates That Individuals With Pku Have Substantial White Matter (Wm) Compromise. Much Less Is Known About Gray Matter (Gm) In Pku, But A Small Body Of Research Suggests Volumetric Differences Compared To Controls. To Date, Developmental Trajectories Of Gm Structure In Individuals With Pku Have Not Been Examined, Nor Have Trajectories Of Wm And Gm Been Examined Within A Single Study. To Address This Gap In The Literature, We Compared Longitudinal Brain Development Over A Three-Year Period In Individuals With Pku (N = 35; 18 Male) And Typically-Developing Controls (N = 71; 35 Male) Aged 7-21 Years. Using Diffusion Tensor Imaging (Dti) And Structural Magnetic Resonance Imaging (Mri), We Observed Whole-Brain And Regional Wm Differences Between Individuals With Pku And Controls, Which Were Often Exacerbated With Increasing Age. In Marked Contrast With Trajectories Of Wm Development, Trajectories Of Gm Development Did Not Differ Between Individuals With Pku And Controls, Indicating That Neuropathology In Pku Is More Prominent In Wm Than Gm. Within Individuals With Pku, Mediation Analyses Revealed That Whole-Brain Mean Diffusivity (Md) And Regional Md In The Corpus Callosum And Centrum Semiovale Mediated The Relationship Between Dietary Treatment Compliance (I.E., Phe Control) And Executive Abilities, Suggesting A Plausible Neurobiological Mechanism By Which Phe Control May Influence Cognitive Outcomes. Our Findings Clarify The Specificity, Timing, And Cognitive Consequences Of Whole-Brain And Regional Wm Pathology, With Implications For Treatment And Research In Pku.|[('Phenylketonuria', 'no label'), ('Recessive Disorder', 'no label'), ('Characterized', 'no label'), ('Disruption', 'no label'), ('Metabolism', 'no label'), ('Amino Acid Phenylalanine', 'no label'), ('Phe', 'no label'), ('Research Indicates', 'no label'), ('Individuals', 'no label'), ('Pku', 'no label'), ('White Matter', 'no label'), ('Compromise', 'no label'), ('Gray Matter', 'no label'), ('Gm', 'no label'), ('Small Body', 'no label'), ('Research Suggests', 'no label'), ('Volumetric', 'no label'), ('Controls', 'no label'), ('Developmental Trajectories', 'no label'), ('Gm', 'no label'), ('Structure', 'no label'), ('Individuals', 'no label'), ('Pku', 'no label'), ('Gm', 'no label'), ('Single Study', 'no label'), ('Literature', 'no label'), ('Longitudinal', 'no label'), ('Brain Development', 'no label'), ('Three-Year', 'no label'), ('Period', 'no label'), ('Individuals', 'no label'), ('Pku (N\u202f=\u202f35; 18 Male)', 'no label'), ('Typically-Developing Controls', 'no label'), ('Male', 'no label'), ('Years', 'no label'), ('Diffusion Tensor Imaging', 'no label'), ('Dti', 'no label'), ('Structural Magnetic Resonance Imaging', 'no label'), ('Mri', 'no label'), ('Whole-Brain', 'no label'), ('Regional Wm Differences', 'no label'), ('Individuals', 'no label'), ('Pku And Controls', 'no label'), ('Exacerbated', 'no label'), ('Increasing', 'no label'), ('Age', 'no label'), ('Contrast', 'no label'), ('Trajectories', 'no label'), ('Wm Development', 'no label'), ('Trajectories', 'no label'), ('Gm', 'no label'), ('Development', 'no label'), ('Did Not Differ', 'no label'), ('Individuals', 'no label'), ('Pku And Controls', 'no label'), ('Indicating', 'no label'), ('Neuropathology', 'no label'), ('Wm Than Gm', 'no label'), ('Individuals', 'no label'), ('Pku', 'no label'), ('Mediation Analyses', 'no label'), ('Revealed', 'no label'), ('Whole-Brain Mean Diffusivity', 'no label'), ('Md', 'no label'), ('Regional Md', 'no label'), ('Corpus Callosum', 'no label'), ('Centrum', 'no label'), ('Semiovale', 'no label'), ('Relationship', 'no label'), ('Dietary Treatment', 'no label'), ('Compliance', 'no label'), ('Phe Control', 'no label'), ('Executive Abilities', 'no label'), ('Suggesting', 'no label'), ('Neurobiological', 'no label'), ('Mechanism', 'no label'), ('Phe Control May Influence', 'no label'), ('Cognitive Outcomes', 'no label'), ('Findings', 'no label'), ('Specificity', 'no label'), ('Timing', 'no label'), ('Cognitive', 'no label'), ('Consequences', 'no label'), ('Whole-Brain', 'no label'), ('Regional Wm Pathology', 'no label'), ('Treatment', 'no label'), ('Research', 'no label')]|[('Amino Acid Phenylalanine', 'no label'), ('Phe', 'no label'), ('Individuals', 'no label'), ('Individuals', 'no label'), ('Gap', 'no label'), ('Individuals', 'no label'), ('Individuals', 'no label'), ('Individuals', 'no label'), ('Individuals', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Recessive Disorder', 'no label'), ('Amino Acid Phenylalanine', 'no label'), ('Phe', 'no label'), ('Dti', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Gm Structure', 'no label'), ('Individuals', 'no label'), ('Brain', 'no label'), ('Individuals', 'no label'), ('Pku (N\u202f', 'no label'), ('Gm Development Did', 'no label'), ('Corpus Callosum', 'no label'), ('Phe', 'no label')]
phenylketonuria|pubmed~24051226|In Our Phenylketonuria (Pku) Cohort Of 120 Patients, We Uncovered A Couple Of Cases Of Undiagnosed Mild Phenylketonuria (Mpku)/Hyperphenylalaninemia (Mhpa) In Maternal Parents Of The Pku Cohort. This Finding Prompted Us To Evaluate The Risk Of Either Mild Phenylketonuria Or Mild Hyperphenylalaninemia In The Parent Population Whose Children Were Diagnosed With Hyperphenylalaninemia (Hpa). Taking Into Account The Phenylalanine Hydroxylase (Pah) Mutation Carrier Frequency And The Pah Mild Mutation Rate, We Estimated That The Prevalence Of The Parental Mpku/Mhpa Varied Widely, From 1/74 In Turkey To 1/708 In Lithuania. The Benefits Of The Parental Detection Procedure Described Here Are The Prevention Of Further Maternal Pku Syndrome, The Follow-Up Of The Newly Detected Patients And The Accuracy Of The Genetic Counseling Provided To These Families. This Very Simple Procedure Should Be Incorporated Into Neonatal Pku Management Of The Hospitals In Countries Where A Routine Systematic Neonatal Screening Is Operational. |[('Phenylketonuria', 'no label'), ('Pku) Cohort', 'no label'), ('Patients', 'no label'), ('Uncovered', 'no label'), ('Couple', 'no label'), ('Cases', 'no label'), ('Undiagnosed', 'no label'), ('Mild Phenylketonuria (Mpku)/Hyperphenylalaninemia', 'no label'), ('Mhpa', 'no label'), ('Maternal Parents', 'no label'), ('Pku Cohort', 'no label'), ('Evaluate', 'no label'), ('Risk', 'no label'), ('Mild Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Parent Population', 'no label'), ('Children', 'no label'), ('Diagnosed', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Hpa', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Mutation Carrier', 'no label'), ('Mutation Rate', 'no label'), ('Estimated', 'no label'), ('Prevalence', 'no label'), ('Parental Mpku/Mhpa', 'no label'), ('Turkey', 'no label'), ('Lithuania', 'no label'), ('Benefits', 'no label'), ('Parental Detection Procedure', 'no label'), ('Prevention', 'no label'), ('Maternal Pku Syndrome', 'no label'), ('Follow-Up', 'no label'), ('Detected', 'no label'), ('Patients', 'no label'), ('Accuracy', 'no label'), ('Genetic Counseling', 'no label'), ('Families', 'no label'), ('Pku Management', 'no label'), ('Hospitals', 'no label'), ('Countries', 'no label'), ('Routine', 'no label'), ('Systematic Neonatal', 'no label'), ('Screening', 'no label'), ('Operational', 'no label')]|[('Mutation', 'no label'), ('Mutation', 'no label'), ('Genetic', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylketonuria (Mpku)/Hyperphenylalaninemia', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Carrier', 'no label'), ('Pah', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~32722073|In Phenylketonuria (Pku), Variable Dietary Advice Provided By Health Professionals And Social Media Leads To Uncertainty For Patients/Caregivers Reliant On Accurate, Evidence Based Dietary Information. Over Four Years, 112 Consensus Statements Concerning The Allocation Of Foods In A Low Phenylalanine Diet For Pku Were Developed By The British Inherited Metabolic Disease Dietitians Group (Bimdg-Dg) From 34 Pku Treatment Centres, Utilising 10 Rounds Of Delphi Consultation To Gain A Majority (≥75%) Decision. A Mean Of 29 Uk Dietitians (Range: 18-40) And 18 Treatment Centres (Range: 13-23) Contributed In Each Round. Statements Encompassed All Foods/Food Groups Divided Into Four Categories Based On Defined Protein/Phenylalanine Content: (1) Foods High In Protein/Phenylalanine (Best Avoided); (2) Foods Allowed Without Restriction Including Fruit/Vegetables Containing Phenylalanine ≤75 Mg/100 G And Most Foods Containing Protein ≤0.5 G/100 G; (3) Foods That Should Be Calculated/Weighed As An Exchange Food If They Contain Protein Exchange Ingredients (Categorized Into Foods With A Protein Content Of: >0.1 G/100 G (Milk/Plant Milks Only), >0.5 G/100 G (Bread/Pasta/Cereal/Flours), >1 G/100 G (Cook-In/Table-Top Sauces/Dressings), >1.5 G/100 G (Soya Sauces)); And (4) Fruit/Vegetables Containing Phenylalanine >75 Mg/100 G Allocated As Part Of The Protein/Phenylalanine Exchange System. These Statements Have Been Endorsed And Translated Into Practical Dietary Management Advice By The Medical Advisory Dietitians For The National Society For Pku (Nspku).|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Variable Dietary Advice', 'no label'), ('Health Professionals', 'no label'), ('Social Media Leads', 'no label'), ('Patients/Caregivers Reliant', 'no label'), ('Accurate', 'no label'), ('Evidence', 'no label'), ('Dietary Information', 'no label'), ('Years', 'no label'), ('Consensus', 'no label'), ('Statements', 'no label'), ('Allocation', 'no label'), ('Foods', 'no label'), ('Low', 'no label'), ('Pku Were Developed', 'no label'), ('British Inherited Metabolic Disease', 'no label'), ('Group', 'no label'), ('Bimdg-Dg', 'no label'), ('Pku Treatment Centres', 'no label'), ('Delphi Consultation', 'no label'), ('Majority', 'no label'), ('Decision', 'no label'), ('Uk Dietitians', 'no label'), ('Contributed', 'no label'), ('Statements', 'no label'), ('Encompassed', 'no label'), ('Foods/Food Groups', 'no label'), ('Divided', 'no label'), ('Categories', 'no label'), ('Protein/Phenylalanine', 'no label'), ('Content', 'no label'), ('Foods', 'no label'), ('Protein/Phenylalanine', 'no label'), ('Foods', 'no label'), ('Restriction', 'no label'), ('Fruit/Vegetables', 'no label'), ('Containing', 'no label'), ('Phenylalanine', 'no label'), ('Foods', 'no label'), ('Protein', 'no label'), ('G/100 G', 'no label'), ('Foods', 'no label'), ('Exchange Food', 'no label'), ('Protein Exchange Ingredients', 'no label'), ('Categorized Into Foods', 'no label'), ('Protein', 'no label'), ('Content', 'no label'), ('Milk/Plant', 'no label'), ('Milks', 'no label'), ('G/100 G', 'no label'), ('Bread/Pasta/Cereal/Flours', 'no label'), ('G/100 G', 'no label'), ('Cook-In/Table-Top', 'no label'), ('Sauces/Dressings', 'no label'), ('G/100 G', 'no label'), ('Fruit/Vegetables', 'no label'), ('Containing', 'no label'), ('Phenylalanine', 'no label'), ('Protein/Phenylalanine Exchange System', 'no label'), ('Statements', 'no label'), ('Been Endorsed', 'no label'), ('Translated', 'no label'), ('Practical', 'no label'), ('Dietary Management Advice', 'no label'), ('Medical Advisory Dietitians', 'no label'), ('National Society For Pku (Nspku)', 'no label')]|[('Foods', 'no label'), ('Phenylalanine', 'no label'), ('Foods', 'no label'), ('Foods', 'no label'), ('Phenylalanine', 'no label'), ('Foods', 'no label'), ('Protein', 'no label'), ('Foods', 'no label'), ('Food', 'no label'), ('Protein', 'no label'), ('Foods', 'no label'), ('Protein', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Metabolic Disease', 'no label'), ('≥75', 'no label'), ('Protein/Phenylalanine', 'no label'), ('Protein/Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Protein/Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients/Caregivers', 'no label'), ('Phenylalanine', 'no label'), ('Gain A', 'no label'), ('29 Uk', 'no label'), ('Protein/Phenylalanine', 'no label'), ('Protein/Phenylalanine', 'no label'), ('Fruit/Vegetables', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Protein/Phenylalanine Exchange', 'no label')]
phenylketonuria|pubmed~32069237|Background Phenylketonuria (Pku) Is A Common Metabolic Disorder With Great Burden If Left Untreated Or Undiagnosed. Genetic Variations In The Phenylalanine Hydroxylase (Pah) Gene May Be Widely Varied Across Different Regions Of A Country. By Knowing The Most Common Mutations, Diagnostic Work-Ups Will Be Offered Sooner And With Lower Costs For Patients. The Present Study Defines The Most Common Genetic Variations In The Pah Gene In Khorasan Province Of Iran. Methods The Present Cross-Sectional Study Took Place In Khorasan Province Of Iran Within A 6-Year Period Starting From 2012 To 2018. Every Patient Who Had Been Referred As Suspicious Pku Cases Or Referred For Prenatal Diagnosis Was Included In The Present Study. Results A Total Number Of 122 Individuals With A Mean Age Of 26.22 Years Were Enrolled In The Present Study. The Most Frequent Genetic Variations In The Pah Gene Were C.1066-11G > A And C.143 T > C. Exon 7 Carried The Most Genetic Variations Compared To Any Single Exon. Also, Three Patients Had Compound Heterozygous Status For C.727 C > T/C.1066-11 G > A In Exon 7 And 11 Of The Pah Gene. Conclusions Mutations In The Pah Gene Are Widely Varied Among Different Populations, And Our Results Confirmed This Fact. Determination Of The Most Prevalent Mutations And Polymorphisms In Each Region Will Reduce The Time And Cost Of Diagnosing Such Preventable Diseases And Will Therefore Reduce The Disease Burden.|[('Phenylketonuria', 'no label'), ('Common', 'no label'), ('Metabolic Disorder', 'no label'), ('Great', 'no label'), ('Burden', 'no label'), ('Left Untreated', 'no label'), ('Undiagnosed', 'no label'), ('Genetic Variations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Regions', 'no label'), ('Country', 'no label'), ('Common', 'no label'), ('Mutations', 'no label'), ('Diagnostic Work-Ups Will Be Offered', 'no label'), ('Lower Costs', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Defines', 'no label'), ('Genetic Variations', 'no label'), ('Pah Gene', 'no label'), ('Khorasan Province', 'no label'), ('Iran', 'no label'), ('Cross-Sectional Study', 'no label'), ('Took Place', 'no label'), ('Khorasan Province', 'no label'), ('Iran', 'no label'), ('Period', 'no label'), ('Patient', 'no label'), ('Referred', 'no label'), ('Suspicious', 'no label'), ('Pku Cases', 'no label'), ('Referred', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Study', 'no label'), ('Individuals', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Study', 'no label'), ('Frequent', 'no label'), ('Genetic Variations', 'no label'), ('Pah Gene', 'no label'), ('C.1066-11G\u2009>\u2009A', 'no label'), ('Genetic Variations', 'no label'), ('Exon', 'no label'), ('Patients', 'no label'), ('Compound Heterozygous Status', 'no label'), ('C.727 C\u2009>\u2009T/C.1066-11 G\u2009>\u2009A', 'no label'), ('Pah Gene', 'no label'), ('Mutations', 'no label'), ('Pah Gene', 'no label'), ('Populations', 'no label'), ('Confirmed', 'no label'), ('Fact', 'no label'), ('Determination', 'no label'), ('Prevalent', 'no label'), ('Mutations', 'no label'), ('Polymorphisms', 'no label'), ('Region', 'no label'), ('Will Reduce', 'no label'), ('Time', 'no label'), ('Cost', 'no label'), ('Diagnosing', 'no label'), ('Preventable Diseases', 'no label'), ('Reduce', 'no label'), ('Disease Burden', 'no label')]|[('Genetic', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Gene', 'no label'), ('Regions', 'no label'), ('Mutations', 'no label'), ('Genetic', 'no label'), ('Gene', 'no label'), ('Individuals', 'no label'), ('Genetic', 'no label'), ('Gene', 'no label'), ('C. Exon', 'no label'), ('Genetic', 'no label'), ('Exon', 'no label'), ('Exon', 'no label'), ('Gene', 'no label'), ('Mutations', 'no label'), ('Gene', 'no label'), ('Mutations', 'no label'), ('Polymorphisms', 'no label'), ('Region', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Pah Gene', 'no label'), ('Pah Gene', 'no label'), ('Exon 7', 'no label'), ('Exon 7', 'no label'), ('Pah Gene', 'no label'), ('Pah Gene', 'no label')]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Referred', 'no label'), ('C.143', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Work-Ups', 'no label'), ('Lower Costs', 'no label'), ('Patients', 'no label'), ('Pah Gene', 'no label'), ('A 6-Year', 'no label'), ('Patient', 'no label'), ('Suspicious Pku', 'no label'), ('C.143 T', 'no label'), ('Patients', 'no label'), ('C.727 C', 'no label'), ('Pah Gene', 'no label'), ('Pah Gene', 'no label')]
phenylketonuria|pubmed~31864970|Providing Adequate Amounts Of Protein In Preterm Infants Suffering From A Metabolic Disease That Requires A Reduced Intake Of Natural Protein Is Challenging. Phenylketonuria (Pku) Is An Inborn Error Of Metabolism Affecting The Enzymatic Conversion Of Phenylalanine To Tyrosine. The Dietary Treatment Of Pku Aims To Lower Phenylalanine Concentrations In The Blood By Implementing A Low-Phenylalanine Diet Restrictive In Natural Protein. We Describe The Nutritional Management Of Three Preterm Infants, Two With Very Low Birth Weight, With Pku Detected By Newborn Screening. All Three Infants Tolerated High Amounts Of Phenylalanine; Two Were Breastfed Unrestrictedly During Late Prematurity. We Show That Nutrition Of Preterm Infants With Pku According To Recommendations Of Early And Intensive Nutrition With A High Intake Of Protein Is Feasible Even In Infants With Impaired Enteral Feeding. Due To A High Phenylalanine Tolerance Of Pku Infants During Prematurity, There Is No Need For A Phenylalanine-Free Parenteral Amino Acid Mixture. During The Catabolic State Of Prematurity Preterm Infants With Pku Have Phenylalanine Requirements Comparable To Healthy Preterm Infants.|[('Adequate', 'no label'), ('Amounts', 'no label'), ('Protein', 'no label'), ('Preterm Infants', 'no label'), ('Suffering', 'no label'), ('Metabolic Disease', 'no label'), ('Requires', 'no label'), ('Reduced Intake', 'no label'), ('Natural Protein', 'no label'), ('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Affecting', 'no label'), ('Enzymatic', 'no label'), ('Conversion', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Dietary Treatment', 'no label'), ('Pku Aims', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Blood', 'no label'), ('Low-Phenylalanine Diet', 'no label'), ('Restrictive', 'no label'), ('Natural Protein', 'no label'), ('Nutritional Management', 'no label'), ('Preterm Infants', 'no label'), ('Very Low Birth Weight', 'no label'), ('Pku Detected', 'no label'), ('Newborn', 'no label'), ('Screening', 'no label'), ('Infants', 'no label'), ('Tolerated High Amounts', 'no label'), ('Phenylalanine', 'no label'), ('Breastfed', 'no label'), ('Unrestrictedly', 'no label'), ('Late Prematurity', 'no label'), ('Nutrition', 'no label'), ('Preterm Infants', 'no label'), ('Pku', 'no label'), ('Recommendations', 'no label'), ('Early', 'no label'), ('Intensive Nutrition', 'no label'), ('High Intake', 'no label'), ('Protein', 'no label'), ('Infants', 'no label'), ('Impaired', 'no label'), ('Enteral Feeding', 'no label'), ('High', 'no label'), ('Phenylalanine', 'no label'), ('Tolerance', 'no label'), ('Pku Infants', 'no label'), ('Prematurity', 'no label'), ('Phenylalanine-Free Parenteral', 'no label'), ('Amino Acid Mixture', 'no label'), ('Catabolic State', 'no label'), ('Prematurity Preterm Infants', 'no label'), ('Pku Have Phenylalanine', 'no label'), ('Requirements', 'no label'), ('Healthy Preterm Infants', 'no label')]|[('Protein', 'no label'), ('Protein', 'no label'), ('Enzymatic', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Metabolic Disease', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Preterm', 'no label'), ('Phenylalanine', 'no label'), ('Prematurity', 'no label'), ('Preterm', 'no label'), ('Impaired Enteral Feeding', 'no label'), ('Phenylalanine', 'no label'), ('Prematurity', 'no label'), ('Amino Acid', 'no label'), ('Prematurity', 'no label'), ('Phenylalanine', 'no label')]|[('Intake', 'no label'), ('Error', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Pku Aims', 'no label'), ('Lower Phenylalanine', 'no label'), ('Blood', 'no label'), ('Low-Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Recommendations', 'no label'), ('Infants', 'no label'), ('Enteral', 'no label'), ('A High Phenylalanine', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label')]
phenylketonuria|pubmed~29153023|Patients With Phenylketonuria Have Lower Bone Mineral Density Compared To Healthy People, However, The Ethiology Of These Alterations Is Not Clear. Hungarian Data Were Missing In This Topic. The Main Aim Of Our Study Was To Survey The Correlation Between Metabolic Control And Change Of Bone Mineral Density In Early Treated Hungarian Adult Patients With Phenylketonuria. In This Monocentric Study Bone Mineral Density Of 59 Adult Pku Patients Have Been Repeatedly Measured In A 4-Year Interval Using Dual-Energy X-Ray Absorptiometry. Two Subgroups Have Been Established Based On Average Blood Phenylalanine Levels. The Correlation Between The Change In Bone Mineral Density And Average Phenylalanine, Tyrosine Concentrations Have Been Determined While Initial Bone Mineral Density And Change Have Also Been Examined In The Subgroups. Mean Phenylalanine Concentration Was 614 (182-1222) Micromol/L, Whereas Mean Tyrosine Concentration Was 49 (24-99) Micromol/L And The Calculated Ratio Was 16 (4,5-35). Three Patients Have Had Severely Decreased Bone Mineral Density In Either Localisation While 22 Have Had Mild Decrease. Low Bone Mineral Density Compared To Cronological Age Has Been Found By 9 Patient. The Mean Change Was +0.0380 (-0.1550-0.7800) G/Cm<Sup>2</Sup> In Femur, And +0.0120 (-0.57300-0.3130) G/Cm<Sup>2</Sup> In The Lumbar Spine. There Was A Correlation In The Change In Z-Score Neither With Mean Phenylalanine Nor With Tyrosine Concentration. Bone Mineral Density Was Not Changed And Hardly Influenced By The Metabolic Control In Early-Treated Young Adult Phenylketonuria Patients In A Few Years Interval. Orv Hetil. 2017; 158(47): 1868-1872.|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Lower Bone', 'no label'), ('Mineral Density', 'no label'), ('Healthy People', 'no label'), ('Ethiology', 'no label'), ('Alterations', 'no label'), ('Not Clear', 'no label'), ('Hungarian', 'no label'), ('Data', 'no label'), ('Study', 'no label'), ('Correlation', 'no label'), ('Metabolic Control', 'no label'), ('Bone Mineral', 'no label'), ('Density', 'no label'), ('Early', 'no label'), ('Treated', 'no label'), ('Hungarian', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Monocentric Study', 'no label'), ('Bone Mineral Density', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Measured', 'no label'), ('Dual-Energy X-Ray Absorptiometry', 'no label'), ('Subgroups', 'no label'), ('Average', 'no label'), ('Blood Phenylalanine Levels', 'no label'), ('Correlation', 'no label'), ('Change', 'no label'), ('Bone Mineral Density', 'no label'), ('Average', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Concentrations', 'no label'), ('Initial', 'no label'), ('Bone Mineral Density', 'no label'), ('Change', 'no label'), ('Subgroups', 'no label'), ('Phenylalanine', 'no label'), ('Concentration', 'no label'), ('Micromol/L', 'no label'), ('Tyrosine', 'no label'), ('Concentration', 'no label'), ('Micromol/L', 'no label'), ('Calculated Ratio', 'no label'), ('Patients', 'no label'), ('Severely', 'no label'), ('Decreased', 'no label'), ('Bone Mineral', 'no label'), ('Localisation', 'no label'), ('Mild', 'no label'), ('Decrease', 'no label'), ('Bone Mineral Density', 'no label'), ('Cronological Age', 'no label'), ('Patient', 'no label'), ('Mean Change', 'no label'), ('Femur', 'no label'), ('Lumbar Spine', 'no label'), ('Correlation', 'no label'), ('Change', 'no label'), ('Z-Score', 'no label'), ('Mean', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine Concentration', 'no label'), ('Bone Mineral Density', 'no label'), ('Changed', 'no label'), ('Influenced', 'no label'), ('Metabolic Control', 'no label'), ('Early-Treated Young Adult', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Years Interval', 'no label'), ('Hetil', 'no label')]|[('Mineral', 'no label'), ('Mineral', 'no label'), ('Mineral', 'no label'), ('Phenylalanine', 'no label'), ('Mineral', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Mineral', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Mineral', 'no label'), ('Mineral', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Mineral', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Ethiology', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label')]|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Bone Mineral Density', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Blood Phenylalanine', 'no label'), ('Bone Mineral', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Bone Mineral', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Patients', 'no label'), ('Bone Mineral Density', 'no label'), ('Bone Mineral', 'no label'), ('Sup>2</Sup', 'no label'), ('Femur', 'no label'), ('Sup>2</Sup', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label')]
phenylketonuria|pubmed~34199184|There Is Agreement That The Pandemic Has Affected The Healthcare System And Behaviour Of Patients. This Study Aims To Identify Problems Encountered By Patients With Phenylketonuria (Pku) And Their Parents/Caregivers During The Six-Week Pandemic Lockdown In Poland (15 March To 30 April 2020). To Determine The Factors That Influenced Health And Treatment-Related Issues, As Well As The Respondents' Perception Of The Impact Of The Pandemic, Study Participants Were Asked To Complete A Non-Validated Online Questionnaire Comprising 31 Questions (Including 27 Single-Choice, Two Multiple-Choice And Two Open-Ended Ones). A Total Of 571 Patients Or Their Parents Completed The Questionnaire, With 9.5% Of Respondents Not Performing Any Blood Phenylalanine (Phe) Test In The Analysed Period, 21.3% Declaring A Blood Phe Increase, And 15.3% A Decrease. Increased Problems In Contacting The Doctor Or Dietitian Were Reported By 26.1% Of Subjects, Whereas 39.3% Of Them Felt Restricted Access To Dietary Products. Most (63.4%) Participants Were Satisfied With Remote Contact With Their Pku Clinic. Better Compliance Was Associated With Higher Odds Of Acceptance Of Remote Contact And Of Reporting Fewer Problems With Contacting The Doctor, And With Lower Odds Of Missing Phe Testing. Self-Reported High Stress Was Associated With Higher Odds Of Reporting The Limited Availability Of Low-Phe Products And Phe-Free Formulas, As Well As With Increased Phe Concentrations And Non-Pku-Related Health Problems. These Patients Also Had Poor Dietary Compliance And Experienced More Problems In Contacting Specialists. Health And Treatment-Related Problems Experienced During The Pandemic Lockdown Were Related To A Higher Intensity Of Stress In Patient'S Family And Worse Therapy Compliance Before The Pandemic. Previous Experience Of Remote Visits Resulted In A Better Perception Of This Method Of Contact. It Seems That This Form Of Communication Should Be Popularized And Improved To Increase Therapy Effectiveness In Case Of Different Limitations In The Future. Special Attention Should Be Paid To Vulnerable Patients Who May Be At Extra Risk When The Provision Of Standard Care Is Affected.|"[('Agreement', 'no label'), ('Pandemic', 'no label'), ('Healthcare System', 'no label'), ('Behaviour', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Problems', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Parents/Caregivers', 'no label'), ('Six-Week', 'no label'), ('Pandemic', 'no label'), ('Lockdown', 'no label'), ('Poland', 'no label'), ('Factors', 'no label'), ('Influenced', 'no label'), ('Health And Treatment-Related Issues', 'no label'), (""Respondents'"", 'no label'), ('Perception', 'no label'), ('Impact', 'no label'), ('Pandemic', 'no label'), ('Study Participants', 'no label'), ('Non-Validated Online Questionnaire', 'no label'), ('Comprising', 'no label'), ('Questions', 'no label'), ('Multiple-Choice', 'no label'), ('Open-Ended Ones', 'no label'), ('Patients', 'no label'), ('Parents', 'no label'), ('Completed', 'no label'), ('Questionnaire', 'no label'), ('Respondents', 'no label'), ('Blood Phenylalanine', 'no label'), ('Analysed', 'no label'), ('Period', 'no label'), ('Declaring A', 'no label'), ('Blood Phe Increase', 'no label'), ('Decrease', 'no label'), ('Increased', 'no label'), ('Problems', 'no label'), ('Doctor', 'no label'), ('Dietitian', 'no label'), ('Subjects', 'no label'), ('Dietary Products', 'no label'), ('Participants', 'no label'), ('Satisfied', 'no label'), ('Remote', 'no label'), ('Contact With', 'no label'), ('Pku Clinic', 'no label'), ('Compliance', 'no label'), ('Associated With', 'no label'), ('Higher', 'no label'), ('Odds', 'no label'), ('Acceptance', 'no label'), ('Remote', 'no label'), ('Contact', 'no label'), ('Problems', 'no label'), ('Doctor', 'no label'), ('Odds', 'no label'), ('Phe Testing', 'no label'), ('Associated With', 'no label'), ('Higher', 'no label'), ('Odds', 'no label'), ('Reporting', 'no label'), ('Low-Phe Products', 'no label'), ('Phe-Free', 'no label'), ('Formulas', 'no label'), ('Increased', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Non-Pku-Related Health Problems', 'no label'), ('Patients', 'no label'), ('Poor', 'no label'), ('Dietary Compliance', 'no label'), ('Experienced', 'no label'), ('Problems', 'no label'), ('Contacting Specialists', 'no label'), ('Treatment-Related Problems', 'no label'), ('Pandemic Lockdown', 'no label'), ('Higher', 'no label'), ('Intensity', 'no label'), ('Stress', 'no label'), (""Patient'S"", 'no label'), ('Family', 'no label'), ('Therapy', 'no label'), ('Compliance', 'no label'), ('Pandemic', 'no label'), ('Remote Visits', 'no label'), ('Resulted', 'no label'), ('Better', 'no label'), ('Perception', 'no label'), ('Method', 'no label'), ('Contact', 'no label'), ('Form', 'no label'), ('Communication', 'no label'), ('Increase', 'no label'), ('Therapy', 'no label'), ('Effectiveness', 'no label'), ('Limitations', 'no label'), ('Attention', 'no label'), ('Paid', 'no label'), ('Vulnerable', 'no label'), ('Patients', 'no label'), ('Extra Risk', 'no label'), ('Provision', 'no label'), ('Standard Care', 'no label'), ('Affected', 'no label')]"|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Declaring A Blood Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Blood Phenylalanine', 'no label'), ('Blood Phe', 'no label'), ('Lower Odds', 'no label'), ('Phe', 'no label'), ('Phe-Free', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Stress', 'no label'), ('Patient', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31364419|Phenylketonuria (Pku) Is Considered To Be A Paradigm For A Monogenic Metabolic Disorder But Was Never Thought To Be A Primary Application For Human Gene Therapy Due To Established Alternative Treatment. However, Somewhat Unanticipated Improvement In Neuropsychiatric Outcome Upon Long-Term Treatment Of Adults With Pku With Enzyme Substitution Therapy Might Slowly Change This Assumption. In Parallel, Pku Was For A Long Time Considered To Be An Excellent Test System For Experimental Gene Therapy Of A Mendelian Autosomal Recessive Defect Of The Liver Due To An Outstanding Mouse Model And The Easy To Analyze And Well-Defined Therapeutic End Point, That Is, Blood L-Phenylalanine Concentration. Lifelong Treatment By Targeting The Mouse Liver (Or Skeletal Muscle) Was Achieved Using Different Approaches, Including (1) Recombinant Adeno-Associated Viral (Raav) Or Nonviral Naked Dna Vector-Based Gene Addition, (2) Genome Editing Using Base Editors Delivered By Raav Vectors, And (3) By Delivering Raavs For Promoter-Less Insertion Of The <I>Pah</I>-Cdna Into The <I>Pah</I> Locus. In This Article We Summarize The Gene Therapeutic Attempts Of Correcting A Mouse Model For Pku And Discuss The Future Implications For Human Gene Therapy.|[('Phenylketonuria', 'no label'), ('Paradigm', 'no label'), ('Monogenic Metabolic Disorder', 'no label'), ('Never Thought', 'no label'), ('Primary Application', 'no label'), ('Human Gene Therapy', 'no label'), ('Alternative Treatment', 'no label'), ('Improvement', 'no label'), ('Neuropsychiatric Outcome', 'no label'), ('Long-Term Treatment', 'no label'), ('Adults', 'no label'), ('Enzyme Substitution Therapy', 'no label'), ('Slowly Change', 'no label'), ('Assumption', 'no label'), ('Long Time', 'no label'), ('Excellent Test System', 'no label'), ('Gene Therapy', 'no label'), ('Mendelian Autosomal', 'no label'), ('Recessive Defect', 'no label'), ('Liver', 'no label'), ('Outstanding Mouse Model', 'no label'), ('Analyze', 'no label'), ('Well-Defined', 'no label'), ('Blood L-Phenylalanine Concentration', 'no label'), ('Lifelong Treatment', 'no label'), ('Targeting', 'no label'), ('Mouse Liver', 'no label'), ('Skeletal Muscle', 'no label'), ('Approaches', 'no label'), ('Recombinant Adeno-Associated Viral', 'no label'), ('Raav', 'no label'), ('Nonviral', 'no label'), ('Naked Dna Vector-Based', 'no label'), ('Gene Addition', 'no label'), ('Genome Editing', 'no label'), ('Base Editors', 'no label'), ('Raav Vectors', 'no label'), ('Delivering Raavs', 'no label'), ('Promoter-Less', 'no label'), ('Insertion', 'no label'), ('<I>Pah</I>-Cdna Into', 'no label'), ('<I>Pah</I> Locus', 'no label'), ('Article', 'no label'), ('Gene Therapeutic Attempts', 'no label'), ('Correcting', 'no label'), ('Mouse Model', 'no label'), ('Pku And Discuss', 'no label'), ('Human Gene Therapy', 'no label')]|[('Human Gene', 'no label'), ('Enzyme Substitution', 'no label'), ('Gene', 'no label'), ('Mouse', 'no label'), ('L-Phenylalanine', 'no label'), ('Mouse', 'no label'), ('Viral', 'no label'), ('Dna Vector-Based Gene', 'no label'), ('Genome', 'no label'), ('Insertion', 'no label'), ('Pah</I>-Cdna', 'no label'), ('Locus', 'no label'), ('Gene', 'no label'), ('Mouse', 'no label'), ('Human Gene', 'no label')]|[('Human Gene', 'no label'), ('Easy To Analyze And Well-Defined Therapeutic End Point', 'no label'), ('Dna Vector-Based Gene', 'no label'), ('Base Editors', 'no label'), ('Human Gene', 'no label')]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Autosomal Recessive Defect', 'no label'), ('L-Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Be A', 'no label'), ('Be A', 'no label'), ('Human Gene', 'no label'), ('Liver', 'no label'), ('Mouse', 'no label'), ('Blood L-Phenylalanine', 'no label'), ('Mouse Liver', 'no label'), ('Skeletal Muscle', 'no label'), ('Dna', 'no label'), ('Promoter-Less', 'no label'), ('Mouse', 'no label'), ('Human Gene', 'no label')]
phenylketonuria|pubmed~33308842|Lifelong Dietary Treatment Is Recommended In The Management Of Phenylketonuria (Pku). Accordingly, An Increasing Adult Population Require Age-Specific Pku Guidelines On Protein Requirements To Support Changing Metabolic Demands Across The Lifespan. Given That Protein Intake For Dietary Management Of Pku Is Primarily (52-80%) Derived From Protein Substitutes, The Prescribing Practice Of Protein Substitutes Must Be Underpinned By Robust Evidence. Whilst Dietary Guidelines For Pku Management Is Evolving To Incorporate Adult Specific Protein Recommendations, The Scientific Evidence Underpinning These Guidelines Is Currently Limited. Instead, The Determination Of Protein Requirements For People With Pku Have Previously Been Extrapolated From Estimates Derived From The General Healthy Population, Based On Arguably Outdated Nitrogen Balance Methodology. Furthermore, A Compensatory Factor Of 20-40% Has Been Incorporated To Account For The Reduced Uptake And Utilisation Of The Elemental Amino Acids Contained In Protein Substitutes. However, Research Informing This Compensatory Factor Has Been Conducted In Younger Adults, With The Majority Of Studies In Non-Pku Individuals. Given Extensive Evidence That The Muscle Anabolic Response To Ingested Protein Is Impaired In Older Vs. Young Adults, The Validity Of Current Dietary Protein Recommendations For Adults And Older Adults With Pku Has Been Challenged. This Narrative Review Aims To Critically Evaluate The Existing Scientific Evidence Underpinning Current Guidelines On Protein Requirements For Adults With Pku, Highlighting Existing Gaps In Knowledge And Directions For Future Research. We Argue That Current Guidelines On Protein Requirements Need Updating To Optimise Long-Term Physical And Functional Outcomes In Older Adults With Pku.|[('Lifelong', 'no label'), ('Dietary Treatment', 'no label'), ('Recommended', 'no label'), ('Management', 'no label'), ('Phenylketonuria', 'no label'), ('Increasing', 'no label'), ('Adult', 'no label'), ('Population', 'no label'), ('Age-Specific Pku Guidelines', 'no label'), ('Protein Requirements', 'no label'), ('Metabolic', 'no label'), ('Lifespan', 'no label'), ('Protein Intake', 'no label'), ('Dietary Management', 'no label'), ('Pku', 'no label'), ('Protein Substitutes', 'no label'), ('Prescribing Practice', 'no label'), ('Protein Substitutes', 'no label'), ('Robust', 'no label'), ('Evidence', 'no label'), ('Dietary Guidelines', 'no label'), ('Pku Management', 'no label'), ('Evolving', 'no label'), ('Incorporate Adult', 'no label'), ('Protein Recommendations', 'no label'), ('Scientific Evidence', 'no label'), ('Guidelines', 'no label'), ('Determination', 'no label'), ('Protein Requirements', 'no label'), ('People', 'no label'), ('Pku', 'no label'), ('Estimates', 'no label'), ('General Healthy Population', 'no label'), ('Nitrogen Balance Methodology', 'no label'), ('Compensatory Factor', 'no label'), ('Reduced', 'no label'), ('Uptake', 'no label'), ('Utilisation', 'no label'), ('Elemental Amino Acids', 'no label'), ('Contained In Protein Substitutes', 'no label'), ('Research Informing', 'no label'), ('Compensatory Factor', 'no label'), ('Younger Adults', 'no label'), ('Studies', 'no label'), ('Non-Pku Individuals', 'no label'), ('Evidence', 'no label'), ('Muscle', 'no label'), ('Anabolic Response', 'no label'), ('Impaired', 'no label'), ('Older Vs', 'no label'), ('Young Adults', 'no label'), ('Validity', 'no label'), ('Current', 'no label'), ('Dietary Protein', 'no label'), ('Recommendations', 'no label'), ('Adults', 'no label'), ('Older Adults', 'no label'), ('Pku', 'no label'), ('Challenged', 'no label'), ('Narrative Review', 'no label'), ('Critically Evaluate', 'no label'), ('Scientific Evidence', 'no label'), ('Guidelines', 'no label'), ('Protein Requirements', 'no label'), ('Adults', 'no label'), ('Pku', 'no label'), ('Gaps', 'no label'), ('Knowledge', 'no label'), ('Directions', 'no label'), ('Future', 'no label'), ('Research', 'no label'), ('Argue', 'no label'), ('Guidelines', 'no label'), ('Protein Requirements', 'no label'), ('Need', 'no label'), ('Optimise', 'no label'), ('Long-Term', 'no label'), ('Physical', 'no label'), ('Functional', 'no label'), ('Outcomes', 'no label'), ('Older Adults', 'no label')]|[('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Nitrogen', 'no label'), ('Amino Acids', 'no label'), ('Protein', 'no label'), ('Individuals', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Gaps', 'no label'), ('Protein', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Nitrogen', 'no label')]|[('Phenylketonuria', 'no label'), ('People', 'no label'), ('Pku', 'no label'), ('Nitrogen', 'no label'), ('20-40', 'no label'), ('Elemental Amino Acids', 'no label'), ('Muscle', 'no label')]
phenylketonuria|pubmed~30146451|Phenylketonuria (Pku) Is Caused By A Deficiency In Phenylalanine Hydroxylase Enzyme Activity That Leads To Phenylalanine (Phe) Accumulation In The Blood And Brain. Elevated Blood Phe Levels Are Associated With Complications In Adults, Including Neurological, Psychiatric, And Cognitive Issues. Even With Nutrition And Pharmacological Management, The Majority Of Adults With Pku Do Not Maintain Blood Phe Levels At Or Below Guideline Recommended Levels. Pegvaliase, Pegylated Recombinant Anabaena Variabilis Phenylalanine Ammonia Lyase (Pal), Converts Phe To Trans-Cinnamic Acid And Ammonia, And Is An Investigational Enzyme Substitution Therapy To Lower Blood Phe In Adults With Pku. Pegvaliase Was Administered Using An Induction, Titration, And Maintenance Dosing Regimen In Adults With Pku Naïve To Pegvaliase Treatment. Doses Were Gradually Increased Until Blood Phe ≤ 600 Μmol/L Was Achieved. The Maintenance Dose Was The Dose At Which Participants Achieved And Sustained Blood Phe ≤ 600 Μmol/L For At Least 4 Weeks Without Dose Modification. Analyses Were Performed For Participants Who Achieved (Group A, N = 11) And Did Not Achieve (Group B, N = 13) Maintenance Dose During The First 24 Weeks Of Study Treatment. Baseline Mean Blood Phe For Group A And Group B Were 1135 Μmol/L And 1198 Μmol/L, Respectively. Mean Blood Phe ≤ 600 Μmol/L Was Achieved For Group A By Week 11 (Mean Blood Phe Of 508 ± 483 Μmol/L) And For Group B By Week 48 (Mean Blood Phe Of 557 ± 389 Μmol/L). The Most Common Adverse Events Involved Hypersensitivity Reactions, Which Were Mostly Mild To Moderate In Severity And Decreased Over Time. One Participant In Group B Had Four Acute Systemic Hypersensitivity Events Of Anaphylaxis Consistent With Clinical National Institute Of Allergy And Infectious Disease/Food Allergy And Anaphylaxis Network Criteria; All Events Were Non-Ige Mediated And Resolved Without Sequelae, With Pegvaliase Dosing Discontinued After The Fourth Event. The Incidence And Titers Of Anti-Drug Antibodies Were Generally Lower In Group A Compared To Group B. Pegvaliase Administered With An Induction, Titration, And Maintenance Dosing Regimen Demonstrated Substantial Efficacy At Reducing Blood Phe In Both Group A And Group B By Week 48, With A Manageable Safety Profile In Most Participants. Blood Phe Reduction Due To Pegvaliase Appears To Be Related To Dose, Treatment Duration, And Individual Immune Response; Given Additional Time On Treatment And Dose Titration, Later Phe Responders (Group B) Achieved Benefit Similar To Early Phe Responders (Group A), With Similar Long-Term Safety Profiles.|[('Phenylketonuria', 'no label'), ('Deficiency', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Enzyme Activity', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Accumulation', 'no label'), ('Blood', 'no label'), ('Brain', 'no label'), ('Elevated', 'no label'), ('Blood Phe Levels', 'no label'), ('Associated With', 'no label'), ('Complications', 'no label'), ('Adults', 'no label'), ('Neurological', 'no label'), ('Psychiatric', 'no label'), ('Cognitive Issues', 'no label'), ('Nutrition', 'no label'), ('Pharmacological Management', 'no label'), ('Adults', 'no label'), ('Pku Do Not', 'no label'), ('Maintain', 'no label'), ('Blood Phe Levels', 'no label'), ('Guideline', 'no label'), ('Recommended Levels', 'no label'), ('Pegvaliase', 'no label'), ('Pegylated Recombinant Anabaena Variabilis', 'no label'), ('Phenylalanine Ammonia Lyase', 'no label'), ('Converts', 'no label'), ('Phe', 'no label'), ('Trans-Cinnamic Acid', 'no label'), ('Ammonia', 'no label'), ('Investigational Enzyme Substitution Therapy', 'no label'), ('Lower Blood Phe', 'no label'), ('Adults', 'no label'), ('Pku.', 'no label'), ('Administered', 'no label'), ('Induction', 'no label'), ('Titration', 'no label'), ('Maintenance', 'no label'), ('Dosing', 'no label'), ('Regimen', 'no label'), ('Adults', 'no label'), ('Pku Naïve', 'no label'), ('Pegvaliase Treatment', 'no label'), ('Doses', 'no label'), ('Increased', 'no label'), ('Blood Phe\u202f≤\u202f600\u202fΜmol/L Was Achieved', 'no label'), ('Maintenance', 'no label'), ('Dose', 'no label'), ('Dose', 'no label'), ('Participants', 'no label'), ('Achieved', 'no label'), ('Sustained', 'no label'), ('Blood Phe\u202f≤\u202f600\u202fΜmol/L For At Least 4\u202f', 'no label'), ('Weeks', 'no label'), ('Dose', 'no label'), ('Analyses', 'no label'), ('Performed', 'no label'), ('Participants', 'no label'), ('Achieved', 'no label'), ('Group A', 'no label'), ('N\u202f=\u202f11)', 'no label'), ('Did Not Achieve', 'no label'), ('Group B', 'no label'), ('Maintenance', 'no label'), ('Dose', 'no label'), ('Weeks', 'no label'), ('Study Treatment', 'no label'), ('Baseline', 'no label'), ('Blood Phe', 'no label'), ('Group', 'no label'), ('Group', 'no label'), ('Blood Phe\u202f≤\u202f600\u202fΜmol/L Was Achieved', 'no label'), ('Group', 'no label'), ('Mean Blood Phe', 'no label'), ('Group', 'no label'), ('Week', 'no label'), ('Mean Blood Phe', 'no label'), ('Common Adverse Events', 'no label'), ('Hypersensitivity Reactions', 'no label'), ('Moderate', 'no label'), ('Severity', 'no label'), ('Decreased', 'no label'), ('Time', 'no label'), ('Participant', 'no label'), ('Group B', 'no label'), ('Acute Systemic Hypersensitivity Events', 'no label'), ('Anaphylaxis', 'no label'), ('Clinical National Institute Of Allergy And Infectious Disease/Food Allergy', 'no label'), ('Anaphylaxis', 'no label'), ('Network Criteria', 'no label'), ('Events', 'no label'), ('Non-Ige', 'no label'), ('Resolved', 'no label'), ('Sequelae', 'no label'), ('Pegvaliase', 'no label'), ('Dosing', 'no label'), ('Discontinued', 'no label'), ('Fourth Event', 'no label'), ('Incidence', 'no label'), ('Titers', 'no label'), ('Anti-Drug Antibodies', 'no label'), ('Group', 'no label'), ('Group', 'no label'), ('B. Pegvaliase', 'no label'), ('Administered', 'no label'), ('Induction', 'no label'), ('Titration', 'no label'), ('Maintenance', 'no label'), ('Dosing', 'no label'), ('Regimen', 'no label'), ('Efficacy', 'no label'), ('Reducing', 'no label'), ('Blood Phe', 'no label'), ('Group', 'no label'), ('Group', 'no label'), ('Week', 'no label'), ('Manageable Safety Profile', 'no label'), ('Participants', 'no label'), ('Blood Phe', 'no label'), ('Reduction', 'no label'), ('Pegvaliase', 'no label'), ('Appears', 'no label'), ('Dose', 'no label'), ('Treatment Duration', 'no label'), ('Individual', 'no label'), ('Immune Response', 'no label'), ('Time', 'no label'), ('Treatment', 'no label'), ('Dose', 'no label'), ('Titration', 'no label'), ('Phe Responders', 'no label'), ('Group B', 'no label'), ('Benefit', 'no label'), ('Early', 'no label'), ('Phe', 'no label'), ('Responders', 'no label'), ('Group A', 'no label'), ('Long-Term Safety', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Ammonia', 'no label'), ('Phe', 'no label'), ('Ammonia', 'no label'), ('Enzyme Substitution', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Antibodies', 'no label'), ('Phe', 'no label')]|[('Non-Ige', 'no label'), ('Anti-Drug Antibodies', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Psychiatric', 'no label'), ('Phenylalanine Ammonia', 'no label'), ('Ammonia', 'no label'), ('≤', 'no label'), ('≤', 'no label'), ('≤', 'no label'), ('Hypersensitivity', 'no label'), ('Hypersensitivity', 'no label'), ('Anaphylaxis', 'no label'), ('Allergy', 'no label'), ('Allergy', 'no label'), ('Anaphylaxis', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Blood', 'no label'), ('Brain', 'no label'), ('Blood Phe', 'no label'), ('Blood Phe', 'no label'), ('Phe', 'no label'), ('Ammonia', 'no label'), ('Blood', 'no label'), ('Blood', 'no label'), ('Blood Phe For Group A', 'no label'), ('Blood', 'no label'), ('Blood Phe Of', 'no label'), ('Blood Phe Of', 'no label'), ('Blood Phe', 'no label'), ('Blood Phe', 'no label'), ('Pegvaliase', 'no label'), ('Immune', 'no label'), ('Phe', 'no label')]
phenylketonuria|pubmed~32143624|Classical Homocystinuria (Hcu), An Inborn Error Of Homocysteine Metabolism, Has Previously Been Estimated To Affect Approximately 1 In 100,000-200,000 People In The United States (Us). Hcu Is Poorly Detected By Newborn Screening, Resulting In Underestimates Of Its Prevalence. This Study Compared Characteristics, Healthcare Use And Costs, And Projected Prevalence Between Patients With Diagnosed Hcu, Elevated Total Homocysteine (Thcy), And Diagnosed Phenylketonuria (Pku). Patients In The Marketscan® Research Databases Were Identified With Strictly-Defined Hcu (> 2 Diagnoses, Including 1 Icd-10), Broadly-Defined Hcu (> 1 Icd-10), Elevated Thcy (> 20 Μmol/L) Without An Hcu Diagnosis, Or > 1 Icd-9/Icd-10 Pku Diagnosis During 1/1/2010-12/31/2016 (First Qualifying Claim = Index). Demographics And Healthcare Utilization And Costs Per Patient Per Month (Pppm) Were Compared Between All Cohorts, Frequencies Of Comorbidities And Medications Were Compared Between Hcu And Elevated Thcy Patients, And Healthcare Provider Types Were Assessed Among Hcu Patients. The Prevalence Of Patients Meeting Each Cohort Definition Was Projected To The United States (Us) Population. Patients With Strictly-Defined (N = 2450) And Broadly-Defined (N = 6613) Hcu, And With Elevated Thcy (N = 2017), Were Significantly Older Than Pku Patients (N = 5120) (57 Vs. 56 Vs. 53 Vs. 18 Years; P < 0.05). Vitamin D Deficiency, Hyperlipidemia, Folic Acid/B Vitamins, And Lipid-Lowering Medications, Among Others, Were More Common Among Diagnosed Hcu Patients Vs. Those With Elevated Thcy (All P < 0.05). Rates Of Healthcare Utilization Were Generally Higher Among Hcu And Elevated Thcy Patients, Compared To Pku, Though Total Healthcare Costs Were Similar Between Groups. Most Hcu Patients (~ 38%) Received Their Index Diagnosis From A Primary Care Physician; Very Few (~ 1%) Had Any Claim From A Geneticist During Their Enrollment. The Age-Adjusted National Prevalence Of Hcu Was Projected At 31,162 (95% Ci: 30,411 - 31,913; ~ 1 In 10,000 Of The Us Population) Using The Broad Definition. The Actual Prevalence Of Hcu May Be > 10 Times Prior Estimates, At 1 In 10,000 In The Us, And This Study Suggests That Hcu Is Not Being Diagnosed Until Later In Life. Improvements To Newborn Screening, Detection In Young Children, And Physician Education Regarding Hcu Among Patients May Be Necessary To Alleviate The Burden Of This Genetic Disease.|[('Classical Homocystinuria', 'no label'), ('Hcu', 'no label'), ('Inborn Error', 'no label'), ('Homocysteine Metabolism', 'no label'), ('Estimated', 'no label'), ('People', 'no label'), ('United States', 'no label'), ('Hcu', 'no label'), ('Detected', 'no label'), ('Newborn', 'no label'), ('Screening', 'no label'), ('Underestimates', 'no label'), ('Prevalence', 'no label'), ('Study', 'no label'), ('Characteristics', 'no label'), ('Healthcare Use And Costs', 'no label'), ('Projected Prevalence', 'no label'), ('Patients', 'no label'), ('Diagnosed Hcu', 'no label'), ('Elevated Total Homocysteine', 'no label'), ('Thcy', 'no label'), ('Diagnosed Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Marketscan® Research Databases', 'no label'), ('Strictly-Defined Hcu', 'no label'), ('Diagnoses', 'no label'), ('Icd-10', 'no label'), ('Broadly-Defined Hcu', 'no label'), ('Icd-10', 'no label'), ('Elevated', 'no label'), ('Thcy', 'no label'), ('Hcu Diagnosis', 'no label'), ('Pku Diagnosis', 'no label'), ('First Qualifying', 'no label'), ('Claim\u2009', 'no label'), ('Demographics', 'no label'), ('Healthcare', 'no label'), ('Utilization', 'no label'), ('Costs', 'no label'), ('Patient', 'no label'), ('Pppm', 'no label'), ('Cohorts', 'no label'), ('Frequencies', 'no label'), ('Comorbidities', 'no label'), ('Medications', 'no label'), ('Hcu', 'no label'), ('Elevated', 'no label'), ('Thcy', 'no label'), ('Patients', 'no label'), ('Healthcare Provider Types', 'no label'), ('Assessed', 'no label'), ('Hcu', 'no label'), ('Patients', 'no label'), ('Prevalence', 'no label'), ('Patients', 'no label'), ('Cohort Definition', 'no label'), ('United States', 'no label'), ('Patients', 'no label'), ('Strictly-Defined', 'no label'), ('Broadly-Defined', 'no label'), ('Elevated', 'no label'), ('Thcy', 'no label'), ('Older Than Pku Patients', 'no label'), ('Vitamin D Deficiency', 'no label'), ('Hyperlipidemia', 'no label'), ('Folic', 'no label'), ('Vitamins', 'no label'), ('Lipid-Lowering Medications', 'no label'), ('Diagnosed Hcu Patients Vs', 'no label'), ('Elevated', 'no label'), ('Thcy', 'no label'), ('Rates', 'no label'), ('Healthcare Utilization', 'no label'), ('Higher', 'no label'), ('Hcu', 'no label'), ('Elevated', 'no label'), ('Thcy', 'no label'), ('Patients', 'no label'), ('Total Healthcare Costs', 'no label'), ('Groups', 'no label'), ('Hcu Patients', 'no label'), ('Index Diagnosis', 'no label'), ('Primary Care Physician', 'no label'), ('Claim', 'no label'), ('Geneticist', 'no label'), ('Enrollment', 'no label'), ('Age-Adjusted National Prevalence', 'no label'), ('Hcu Was', 'no label'), ('Projected', 'no label'), ('Ci', 'no label'), ('Population', 'no label'), ('Broad Definition', 'no label'), ('Actual Prevalence', 'no label'), ('Hcu May', 'no label'), ('Times', 'no label'), ('Estimates', 'no label'), ('Study', 'no label'), ('Suggests', 'no label'), ('Hcu', 'no label'), ('Not Being', 'no label'), ('Diagnosed', 'no label'), ('Improvements', 'no label'), ('Newborn', 'no label'), ('Screening', 'no label'), ('Detection', 'no label'), ('Young Children', 'no label'), ('Physician', 'no label'), ('Education', 'no label'), ('Hcu', 'no label'), ('Patients', 'no label'), ('Burden', 'no label'), ('Genetic Disease', 'no label')]|[('Homocystinuria', 'no label'), ('Homocysteine', 'no label'), ('Homocysteine', 'no label'), ('Folic Acid/B Vitamins', 'no label'), ('Genetic', 'no label')]|[('Hcu', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Per', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label')]|[('Homocystinuria', 'no label'), ('Homocysteine', 'no label'), ('Homocysteine', 'no label'), ('Phenylketonuria', 'no label'), ('Hcu Diagnosis', 'no label'), ('Hcu', 'no label'), ('N\u2009=\u20092450', 'no label'), ('N\u2009', 'no label'), ('N\u2009', 'no label'), ('N\u2009=\u20095120', 'no label'), ('Vitamin D Deficiency', 'no label'), ('Hyperlipidemia', 'no label'), ('Folic', 'no label'), ('Vitamins', 'no label'), ('Hcu', 'no label'), ('Hcu May Be', 'no label')]|[('Hcu', 'no label'), ('Error', 'no label'), ('Homocysteine', 'no label'), ('People', 'no label'), ('Patients', 'no label'), ('Hcu', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Patient', 'no label'), ('Hcu', 'no label'), ('Patients', 'no label'), ('Hcu Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Hcu', 'no label'), ('Patients', 'no label'), ('Vitamin D', 'no label'), ('Folic Acid/B Vitamins', 'no label'), ('Hcu Patients Vs', 'no label'), ('Hcu', 'no label'), ('Patients', 'no label'), ('Hcu Patients', 'no label'), ('A Primary Care', 'no label'), ('Hcu', 'no label'), ('~\u20091', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Hcu', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31463830|Having A Child With Phenylketonuria Is Extremely Stressful For The Parents. These Parents Always Look For Solutions For Negative Effects Of Their Child'S Disease. Parents' Strategies Are Affected By Various Background Factors And Vary According To Parents' Culture, Religion, Education, Etc. The Present Study Was Aimed At Assessing The Effect Of Spirituality On The Life Of Parents With A Pku Child, And The Effect Of Child Disease On The Parents' Spirituality. The Study Was Conducted In Kerman, Iran, In 2018; 21 Participants (14 Mothers, 6 Fathers With Pku Children, And One Nurse) Were Selected Using Purposive Sampling. A Semi-Structured In-Depth Interview Was Conducted With The Selected Participants. The Transcribed Interviews Were Analyzed Using Conventional Qualitative Content Analysis. One Main Theme And Two Categories Emerged From The Analyzed Data. The Main Theme Of The Supportive Role Of Spirituality Consists Of Two Categories: Spiritual Growth And Grabbing To The String Of Spirituality. The First Levels Of Spiritual Growth Include Modeling And Considering Imams' Lives, The Increase In Trust In God, The Increase In Mental And Spiritual Tolerance, And Being Close To God. The Levels Of Achieving Spirituality Include The Remembrance Of God, Thanking God, And Giving Donations. According To The Results Of This Study, Providing Spiritual Care By The Nurses For The Patient And Their Family Is Important. Nurses Should Pay Attention To This Subject Because The Patients And Their Family Can Achieve More Relaxation And Increased Tolerance And Higher Satisfaction.|"[('Child', 'no label'), ('Phenylketonuria', 'no label'), ('Extremely Stressful', 'no label'), ('Parents', 'no label'), ('Parents', 'no label'), ('Solutions', 'no label'), ('Negative', 'no label'), (""Child'S Disease"", 'no label'), (""Parents'"", 'no label'), ('Strategies', 'no label'), ('Affected', 'no label'), ('Background Factors', 'no label'), (""Parents'"", 'no label'), ('Culture', 'no label'), ('Religion', 'no label'), ('Education', 'no label'), ('Etc', 'no label'), ('Present Study', 'no label'), ('Assessing', 'no label'), ('Effect', 'no label'), ('Spirituality', 'no label'), ('Life', 'no label'), ('Parents', 'no label'), ('A Pku Child', 'no label'), ('Effect', 'no label'), ('Child Disease', 'no label'), (""Parents'"", 'no label'), ('Spirituality', 'no label'), ('Study', 'no label'), ('Kerman', 'no label'), ('Iran', 'no label'), ('Participants', 'no label'), ('Mothers', 'no label'), ('Fathers', 'no label'), ('Pku Children', 'no label'), ('Nurse', 'no label'), ('Purposive Sampling', 'no label'), ('Semi-Structured In-Depth Interview', 'no label'), ('Participants', 'no label'), ('Transcribed Interviews', 'no label'), ('Analyzed', 'no label'), ('Conventional', 'no label'), ('Qualitative Content Analysis', 'no label'), ('Categories', 'no label'), ('Emerged', 'no label'), ('Analyzed Data', 'no label'), ('Supportive Role', 'no label'), ('Spirituality', 'no label'), ('Consists', 'no label'), ('Categories', 'no label'), ('Spiritual Growth', 'no label'), ('Grabbing', 'no label'), ('String', 'no label'), ('Spirituality', 'no label'), ('Levels', 'no label'), ('Spiritual Growth', 'no label'), (""Imams'"", 'no label'), ('Lives', 'no label'), ('Increase', 'no label'), ('Trust', 'no label'), ('Increase', 'no label'), ('Mental', 'no label'), ('Spiritual', 'no label'), ('Levels', 'no label'), ('Spirituality', 'no label'), ('Remembrance', 'no label'), ('God', 'no label'), ('Thanking God', 'no label'), ('Donations', 'no label'), ('Study', 'no label'), ('Providing Spiritual Care', 'no label'), ('Nurses', 'no label'), ('Patient', 'no label'), ('Family', 'no label'), ('Nurses', 'no label'), ('Pay Attention', 'no label'), ('Subject', 'no label'), ('Patients', 'no label'), ('Family', 'no label'), ('Relaxation', 'no label'), ('Increased', 'no label'), ('Tolerance', 'no label'), ('Higher', 'no label'), ('Satisfaction', 'no label')]"|[]|[]|[('Phenylketonuria', 'no label'), ('Spirituality', 'no label'), ('Spirituality', 'no label')]|[('Phenylketonuria', 'no label'), ('Culture', 'no label'), ('Kerman', 'no label'), ('Transcribed', 'no label'), ('Spiritual Growth', 'no label'), ('Patient', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31503351|This Study Aimed To Investigate And Improve The Usefulness Of The 48-Hour Bh<Sub>4</Sub> Loading Test And To Assess Genotype For Bh<Sub>4</Sub> Responsiveness Prediction, Using The New Definition Of Bh<Sub>4</Sub> Responsiveness From The European Guidelines, As Well As An Amended Definition. Applying The Definition Of The European Guidelines (≥100% Increase In Natural Protein Tolerance) And An Amended Definition (≥100% Increase In Natural Protein Tolerance Or Tolerating A Safe Natural Protein Intake) To A Previous Dataset, We First Assessed The Positive Predictive Value (Ppv) Of The 48-Hour Bh<Sub>4</Sub> Loading Test Using A Cutoff Value Of 30%. Then, We Tried To Improve This Ppv By Using Different Cutoff Values And Separate Time Points. Last, Using The Biopku Database, We Compared Predicted Bh<Sub>4</Sub> Responsiveness (According To Genotype) And Genotypic Phenotype Values (Gpvs) In Bh<Sub>4</Sub> -Responsive And Bh<Sub>4</Sub> -Unresponsive Patients. The Ppv Of The 48-Hour Loading Test Was 50.0% Using The Definition Of The European Guidelines, And 69.4% When Applying The Amended Definition Of Bh<Sub>4</Sub> Responsiveness. Higher Cutoff Values Led To A Higher Ppv, But Resulted In An Increase In False-Negative Tests. Parameters For Genotype Overlapped Between Bh<Sub>4</Sub> -Responsive And Bh<Sub>4</Sub> -Unresponsive Patients, Although Bh<Sub>4</Sub> Responsiveness Was Not Observed In Patients With A Gpv Below 2.4. The 48-Hour Bh<Sub>4</Sub> Loading Test Is Not As Useful As Previously Considered And Cannot Be Improved Easily, Whereas Genotype Seems Mainly Helpful In Excluding Bh<Sub>4</Sub> Responsiveness. Overall, The Definition Of Bh<Sub>4</Sub> Responsiveness And Bh<Sub>4</Sub> Responsiveness Testing Require Further Attention.|[('Study', 'no label'), ('Investigate', 'no label'), ('Improve', 'no label'), ('Usefulness', 'no label'), ('48-Hour', 'no label'), ('Bh<Sub>4</Sub> Loading Test', 'no label'), ('Assess', 'no label'), ('Genotype', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Prediction', 'no label'), ('New Definition', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('European', 'no label'), ('Guidelines', 'no label'), ('Amended Definition', 'no label'), ('Definition', 'no label'), ('European Guidelines', 'no label'), ('Increase', 'no label'), ('Natural Protein Tolerance', 'no label'), ('Increase', 'no label'), ('Natural Protein Tolerance', 'no label'), ('Tolerating', 'no label'), ('Safe Natural Protein Intake', 'no label'), ('Dataset', 'no label'), ('Assessed', 'no label'), ('Positive Predictive Value', 'no label'), ('Ppv', 'no label'), ('48-Hour', 'no label'), ('Bh<Sub>4</Sub> Loading Test', 'no label'), ('Cutoff Value', 'no label'), ('Ppv', 'no label'), ('Cutoff Values', 'no label'), ('Separate', 'no label'), ('Time Points', 'no label'), ('Biopku Database', 'no label'), ('Predicted', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Genotype', 'no label'), ('Genotypic Phenotype Values', 'no label'), ('Gpvs', 'no label'), ('Bh<Sub>4</Sub> -Responsive And Bh<Sub>4</Sub> -Unresponsive', 'no label'), ('Patients', 'no label'), ('Ppv', 'no label'), ('48-Hour Loading Test', 'no label'), ('Definition', 'no label'), ('European', 'no label'), ('Guidelines', 'no label'), ('Amended Definition', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Cutoff Values', 'no label'), ('Higher', 'no label'), ('Ppv', 'no label'), ('Resulted', 'no label'), ('Increase', 'no label'), ('False-Negative Tests', 'no label'), ('Parameters', 'no label'), ('Genotype', 'no label'), ('Overlapped', 'no label'), ('Bh<Sub>4</Sub> -Responsive And Bh<Sub>4</Sub> -Unresponsive', 'no label'), ('Patients', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Observed', 'no label'), ('Patients', 'no label'), ('48-Hour', 'no label'), ('Bh<Sub>4</Sub> Loading Test', 'no label'), ('Improved', 'no label'), ('Genotype', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Definition', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Testing', 'no label'), ('Require', 'no label'), ('Attention', 'no label')]|[('Genotype', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Genotypic', 'no label'), ('Genotype', 'no label'), ('Genotype', 'no label')]|[]|[]|[('Ppv', 'no label'), ('Patients', 'no label'), ('Ppv', 'no label'), ('Ppv', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('A Gpv Below', 'no label')]
phenylketonuria|pubmed~33138040|The Composition And Functioning Of The Gut Microbiota, The Complex Population Of Microorganisms Residing In The Intestine, Is Strongly Affected By Endogenous And Exogenous Factors, Among Which Diet Is Key. Important Perturbations Of The Microbiota Have Been Observed To Contribute To Disease Risk, As In The Case Of Neurological Disorders, Inflammatory Bowel Disease, Obesity, Diabetes, Cardiovascular Disease, Among Others. Although Mechanisms Are Not Fully Clarified, Nutrients Interacting With The Microbiota Are Thought To Affect Host Metabolism, Immune Response Or Disrupt The Protective Functions Of The Intestinal Barrier. Similarly, Key Intermediaries, Whose Presence May Be Strongly Influenced By Dietary Habits, Sustain The Communication Along The Gut-Brain-Axis, Influencing Brain Functions In The Same Way As The Brain Influences Gut Activity. Due To The Role Of Diet In The Modulation Of The Microbiota, Its Composition Is Of High Interest In Inherited Errors Of Metabolism (Iems) And May Reveal An Appealing Therapeutic Target. In Iems, For Example In Phenylketonuria (Pku), Since Part Of The Therapeutic Intervention Is Based On Chronic Or Life-Long Tailored Dietetic Regimens, Important Variations Of The Microbial Diversity Or Relative Abundance Have Been Observed. A Holistic Approach, Including A Healthy Composition Of The Microbiota, Is Recommended To Modulate Host Metabolism And Affected Neurological Functions.|[('Composition', 'no label'), ('Functioning', 'no label'), ('Gut Microbiota', 'no label'), ('Complex Population', 'no label'), ('Microorganisms Residing', 'no label'), ('Intestine', 'no label'), ('Affected', 'no label'), ('Endogenous', 'no label'), ('Exogenous Factors', 'no label'), ('Diet', 'no label'), ('Perturbations', 'no label'), ('Microbiota', 'no label'), ('Observed', 'no label'), ('Contribute', 'no label'), ('Disease Risk', 'no label'), ('Neurological Disorders', 'no label'), ('Inflammatory Bowel Disease', 'no label'), ('Obesity', 'no label'), ('Diabetes', 'no label'), ('Cardiovascular Disease', 'no label'), ('Mechanisms', 'no label'), ('Clarified', 'no label'), ('Nutrients Interacting', 'no label'), ('Microbiota', 'no label'), ('Host Metabolism', 'no label'), ('Immune Response', 'no label'), ('Disrupt', 'no label'), ('Protective Functions', 'no label'), ('Intestinal Barrier', 'no label'), ('Key Intermediaries', 'no label'), ('Presence', 'no label'), ('Influenced', 'no label'), ('Dietary Habits', 'no label'), ('Sustain', 'no label'), ('Communication', 'no label'), ('Brain Functions', 'no label'), ('Brain', 'no label'), ('Influences', 'no label'), ('Gut Activity', 'no label'), ('Diet', 'no label'), ('Modulation', 'no label'), ('Microbiota', 'no label'), ('Composition', 'no label'), ('Inherited Errors', 'no label'), ('Metabolism', 'no label'), ('Iems', 'no label'), ('May', 'no label'), ('Reveal', 'no label'), ('Appealing', 'no label'), ('Therapeutic', 'no label'), ('Target', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Therapeutic Intervention', 'no label'), ('Chronic', 'no label'), ('Life-Long Tailored Dietetic Regimens', 'no label'), ('Variations', 'no label'), ('Microbial', 'no label'), ('Diversity', 'no label'), ('Abundance', 'no label'), ('Observed', 'no label'), ('Holistic Approach', 'no label'), ('Healthy Composition', 'no label'), ('Microbiota', 'no label'), ('Host Metabolism', 'no label'), ('Affected', 'no label'), ('Neurological Functions', 'no label')]|[('Microorganisms', 'no label'), ('Nutrients', 'no label')]|[]|[('Neurological Disorders', 'no label'), ('Inflammatory Bowel Disease', 'no label'), ('Obesity', 'no label'), ('Diabetes', 'no label'), ('Cardiovascular Disease', 'no label'), ('Phenylketonuria', 'no label')]|[('Gut Microbiota', 'no label'), ('Intestine', 'no label'), ('Microbiota', 'no label'), ('Cardiovascular Disease', 'no label'), ('Clarified', 'no label'), ('Microbiota', 'no label'), ('Immune', 'no label'), ('Intestinal Barrier', 'no label'), ('Brain', 'no label'), ('Brain', 'no label'), ('Iems', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~33022955|We Aimed To Assess If The Same Cognitive Batteries Can Be Used Cross-Nationally To Monitor The Effect Of Phenylketonuria (Pku). We Assessed Whether A Battery, Previously Used With English Adults With Pku (Awpku), Was Also Sensitive To Impairments In Italian Awpku. From Our Original Battery, We Selected A Number Of Tasks That Comprehensively Assessed Visual Attention, Visuo-Motor Coordination, Executive Functions (Particularly, Reasoning, Planning, And Monitoring), Sustained Attention, And Verbal And Visual Memory And Learning. When Verbal Stimuli/Or Responses Were Involved, Stimuli Were Closely Matched Between The Two Languages For Psycholinguistic Variables. We Administered The Tasks To 19 Italian Awpku And 19 Italian Matched Controls And Compared Results From With 19 English Awpku And 19 English Matched Controls Selected From A Previously Tested Cohort. Participant Election Was Blind To Cognitive Performance And Metabolic Control, But Participants Were Closely Matched For Age And Education. The Italian Awpku Group Had Slightly Worse Metabolic Control But Showed Levels Of Performance And Patterns Of Impairment Similar To The English Awpku Group. The Italian Results Also Showed Extensive Correlations Between Adult Cognitive Measures And Metabolic Measures Across The Life Span, Both In Terms Of Phenylalanine (Phe) Levels And Phe Fluctuations, Replicating Previous Results In English. These Results Suggest That Batteries With The Same And/Or Matched Tasks Can Be Used To Assess Cognitive Outcomes Across Countries Allowing Results To Be Compared And Accrued. Future Studies Should Explore Potential Differences In Metabolic Control Across Countries To Understand What Variables Make Metabolic Control Easier To Achieve.|[('Assess', 'no label'), ('Same Cognitive Batteries', 'no label'), ('Cross-Nationally To Monitor', 'no label'), ('Effect', 'no label'), ('Phenylketonuria', 'no label'), ('Assessed', 'no label'), ('Battery', 'no label'), ('English Adults', 'no label'), ('Pku (Awpku)', 'no label'), ('Sensitive', 'no label'), ('Impairments', 'no label'), ('Italian', 'no label'), ('Awpku', 'no label'), ('Original Battery', 'no label'), ('Tasks', 'no label'), ('Comprehensively', 'no label'), ('Assessed', 'no label'), ('Visual Attention', 'no label'), ('Visuo-Motor Coordination', 'no label'), ('Executive Functions', 'no label'), ('Reasoning', 'no label'), ('Planning', 'no label'), ('Monitoring', 'no label'), ('Sustained', 'no label'), ('Attention', 'no label'), ('Verbal', 'no label'), ('Visual Memory', 'no label'), ('Learning', 'no label'), ('Verbal Stimuli/Or', 'no label'), ('Responses', 'no label'), ('Stimuli', 'no label'), ('Languages', 'no label'), ('Psycholinguistic Variables', 'no label'), ('Administered', 'no label'), ('Tasks', 'no label'), ('Italian', 'no label'), ('Awpku', 'no label'), ('Italian', 'no label'), ('Matched Controls', 'no label'), ('English Awpku', 'no label'), ('English Matched Controls', 'no label'), ('Tested Cohort', 'no label'), ('Participant Election', 'no label'), ('Metabolic Control', 'no label'), ('Participants', 'no label'), ('Age', 'no label'), ('Education', 'no label'), ('Italian', 'no label'), ('Awpku Group', 'no label'), ('Worse', 'no label'), ('Metabolic Control', 'no label'), ('Levels', 'no label'), ('Performance', 'no label'), ('Patterns', 'no label'), ('Impairment', 'no label'), ('English Awpku Group', 'no label'), ('Italian Results', 'no label'), ('Correlations', 'no label'), ('Adult', 'no label'), ('Cognitive Measures', 'no label'), ('Metabolic Measures', 'no label'), ('Life Span', 'no label'), ('Phenylalanine (Phe) Levels', 'no label'), ('Phe', 'no label'), ('Fluctuations', 'no label'), ('Replicating', 'no label'), ('English', 'no label'), ('Results', 'no label'), ('Suggest', 'no label'), ('Batteries', 'no label'), ('And/Or', 'no label'), ('Matched Tasks', 'no label'), ('Assess', 'no label'), ('Cognitive Outcomes', 'no label'), ('Countries', 'no label'), ('Allowing Results', 'no label'), ('Compared', 'no label'), ('Accrued', 'no label'), ('Studies', 'no label'), ('Potential', 'no label'), ('Differences', 'no label'), ('Metabolic Control', 'no label'), ('Countries', 'no label'), ('Variables', 'no label'), ('Metabolic Control Easier', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Verbal', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('And/Or', 'no label'), ('Accrued', 'no label')]
phenylketonuria|pubmed~33719565|<B><I>Introduction:</I></B> The Prognosis Of Phenylketonuria (Pku) In Terms Of Neurocognitive Outcome Is Directly Related To Lifelong Phenylalanine (Phe) Levels And Adherence To Treatment. Monitoring And Treatment Of Pku Patients Can Be Complicated In Challenging Circumstances As Pandemics. This Study Aims To Evaluate The Impact Of Telemedicine For Monitoring And Treatment Of Pku Patients On Metabolic Outcome During Coronavirus Disease-19 (Covid-19) Outbreak. <B><I>Materials And Methods:</I></B> Patients Who Were Diagnosed As Pku And Treated With Low Phe Diet, Tetrahydrobiopterin (Bh4), Or Bh4 Adjunct With Low Phe Diet Were Enrolled. Study Period Was Divided Into Two Periods: Prepandemic Period Wherein Patients Were Followed Up In Outpatients' Clinic And During Pandemic Wherein Telemedicine Was Used. Demographic Findings, Laboratory Results, And Therapy Responses Were Reviewed Retrospectively And Compared Between The Two Periods. All Procedures Were In Accordance With The Ethical Standards Of The Local Ethical Committee Of Cerrahpasa Medical Faculty (17/11/2020-151640) And With The Helsinki Declaration Of 1975, As Revised In 2013. <B><I>Results:</I></B> Ninety-Three (<I>N</I> = 93) Patients Were Enrolled To This Study. The Ratio Of The Samples With Phe Levels In The Recommended Ranges Was Found To Be Statistically Higher During The Pandemic Wherein An Online Monitoring System Was Used In All Treatment Modalities (<I>P</I>< 0.05). The Decrease In Phe Washout Frequency Was Statistically Significant During The Pandemic In The Low Phe Diet Group (P < 0.05). Considering The Relationship Between Phe Tolerance Before And During The Pandemic, A Significant Increase In Phe Tolerance Was Noted During The Pandemic In The Low Phe Diet Group (<I>P</I>< 0.05). <B><I>Conclusions:</I></B> Telemedicine Can Be An Appropriate And Effective Monitoring Option For Pku Patients During The Covid-19 Pandemic.|"[('B><I>Introduction:</I></B> The Prognosis', 'no label'), ('Phenylketonuria', 'no label'), ('Neurocognitive Outcome', 'no label'), ('Phenylalanine (Phe) Levels', 'no label'), ('Adherence', 'no label'), ('Treatment', 'no label'), ('Monitoring', 'no label'), ('Treatment', 'no label'), ('Pku Patients', 'no label'), ('Complicated', 'no label'), ('Circumstances', 'no label'), ('Pandemics', 'no label'), ('Study', 'no label'), ('Evaluate', 'no label'), ('Impact', 'no label'), ('Telemedicine', 'no label'), ('Monitoring', 'no label'), ('Treatment', 'no label'), ('Pku Patients', 'no label'), ('Metabolic Outcome', 'no label'), ('Coronavirus Disease-19', 'no label'), ('Covid-19', 'no label'), ('Outbreak', 'no label'), ('B><I>Materials', 'no label'), ('Methods:</I></B>', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Treated With', 'no label'), ('Low Phe Diet', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh4', 'no label'), ('Bh4 Adjunct', 'no label'), ('Low Phe Diet', 'no label'), ('Study', 'no label'), ('Period Was Divided', 'no label'), ('Periods', 'no label'), ('Prepandemic', 'no label'), ('Period', 'no label'), ('Wherein Patients', 'no label'), ('Followed Up', 'no label'), (""Outpatients'"", 'no label'), ('Clinic', 'no label'), ('Pandemic Wherein Telemedicine', 'no label'), ('Demographic Findings', 'no label'), ('Laboratory Results', 'no label'), ('Therapy', 'no label'), ('Responses', 'no label'), ('Reviewed', 'no label'), ('Retrospectively', 'no label'), ('Periods', 'no label'), ('Procedures', 'no label'), ('Ethical Standards', 'no label'), ('Local Ethical Committee', 'no label'), ('Cerrahpasa Medical Faculty', 'no label'), ('Helsinki Declaration', 'no label'), ('B><I>Results:</I></B> Ninety-Three', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Ratio', 'no label'), ('Samples', 'no label'), ('Phe Levels', 'no label'), ('Recommended Ranges', 'no label'), ('Statistically Higher', 'no label'), ('Pandemic Wherein', 'no label'), ('Online Monitoring System', 'no label'), ('Treatment', 'no label'), ('<I>P</I>< 0.05)', 'no label'), ('Decrease', 'no label'), ('Phe Washout Frequency', 'no label'), ('Statistically Significant', 'no label'), ('Pandemic', 'no label'), ('Low Phe Diet Group', 'no label'), ('Relationship', 'no label'), ('Phe', 'no label'), ('Pandemic', 'no label'), ('Increase', 'no label'), ('Phe Tolerance', 'no label'), ('Noted', 'no label'), ('Pandemic', 'no label'), ('Low Phe Diet Group', 'no label'), ('<I>P</I>< 0.05)', 'no label'), ('B><I>Conclusions:</I></B> Telemedicine', 'no label'), ('Appropriate', 'no label'), ('Effective', 'no label'), ('Monitoring Option', 'no label'), ('Pku Patients', 'no label'), ('Covid-19', 'no label'), ('Pandemic', 'no label')]"|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Coronavirus Disease-19', 'no label'), ('Phe', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phe', 'no label'), ('Ninety-Three', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Pandemic', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Pandemic', 'no label')]|[('Tetrahydrobiopterin', 'no label')]|[('B><I', 'no label'), ('Prognosis', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phe', 'no label'), ('B><I', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('B><I', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Coronavirus Disease-19', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Phe', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh4', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Outpatients', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Covid-19', 'no label')]
phenylketonuria|pubmed~30373601|People With Phenylketonuria (Pku) Who Respond To Tetrahydrobiopterin (Bh4) Often Decrease Dependence On Medical Food (Mf) Following Increased Phenylalanine (Phe) Tolerance. Responders To Bh4 May Experience A Reduction In Certain Nutrients If Not Compensated Through Intact Foods Or Supplements. This Study Investigated B6, B12, Folate, And Iron Status Based On Blood Levels And Dietary Intake In Patients With Pku Responsive To Bh4 Over 1 Year. Fifty-Eight Patients With Pku, Ages 4-50 Years Were Recruited And Initiated On Bh4 Therapy. Patients Were Monitored For Bh4 Response, And Nutritional Status Was Recorded At Regular Intervals Over 12 Months. The Analysis Included 33 Patients With Known Bh4 Response Status And Complete Nutritional Data. Nutrient Intake Was Determined By National Data System For Research (Ndsr) Analysis Of Self Reported 3 Day Diet Records And Compared To Dietary Reference Intakes (Dris). Blood Biomarkers Were Analyzed By Quest Diagnostics And Compared To Laboratory Reference Ranges. Patient Laboratory Values Were Compared To Controls From The National Health And Examination Survey (Nhanes). Differences In Nutrient Intakes Across Time Points Were Examined, Stratified By Age, Using Nonparametric Methods. Statistical Analyses Were Completed With Sas 9.4, With Significance Set At Α = 0.05. Medical Food Intake Declined Among Pediatric (P < 0.01) And Adult (P = 0.06) Bh4 Responders Over 1 Year. Among Those < 18 Years Of Age, Mean Percent Of Calories Obtained From Mf Declined From 21.3 To 4.7%. In Adults, Percent Calories From Mf Dropped From 19.5 To 4.0%. Though Maintaining Laboratory And Dietary Values Within Reference Ranges, Responders < 18 Years Experienced A Significant Decline In Serum B12 (P = 0.01), Dietary Folate (P = 0.006), And Dietary Iron (P = 0.004) Over The Study. Although Mean Dietary And Laboratory Values For B12, B6, Folate, And Iron In Bh4 Responders And Non-Responders Were Adequate At Baseline And 12-Month Follow-Up, Responders Experienced A Significant Decline In Serum B12 Over 1 Year, Which May Be Explained By Decreased Intake Of Fortified Mf. Both Response Groups Had Lower Serum B12 Than Nhanes Controls At Baseline And 12 Months. Results Indicate A Need To Monitor B12 Concentrations And Consider Micronutrient Supplementation, With Special Attention To Pediatric Patients With Pku.|[('People', 'no label'), ('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh4', 'no label'), ('Decrease', 'no label'), ('Dependence', 'no label'), ('Medical Food', 'no label'), ('Mf', 'no label'), ('Increased', 'no label'), ('Phenylalanine (Phe) Tolerance', 'no label'), ('Responders', 'no label'), ('Bh4', 'no label'), ('Experience', 'no label'), ('Reduction', 'no label'), ('Nutrients', 'no label'), ('Compensated', 'no label'), ('Intact Foods', 'no label'), ('Supplements', 'no label'), ('Study', 'no label'), ('Investigated', 'no label'), ('B12', 'no label'), ('Folate', 'no label'), ('Iron Status', 'no label'), ('Blood Levels', 'no label'), ('Dietary Intake', 'no label'), ('Patients', 'no label'), ('Pku Responsive', 'no label'), ('Year', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Years', 'no label'), ('Initiated', 'no label'), ('Bh4 Therapy', 'no label'), ('Patients', 'no label'), ('Bh4', 'no label'), ('Response', 'no label'), ('Nutritional Status', 'no label'), ('Regular Intervals', 'no label'), ('Months', 'no label'), ('Analysis', 'no label'), ('Patients', 'no label'), ('Bh4', 'no label'), ('Response Status', 'no label'), ('Complete', 'no label'), ('Nutritional', 'no label'), ('Data', 'no label'), ('Nutrient Intake', 'no label'), ('National Data System', 'no label'), ('Analysis', 'no label'), ('Day Diet Records', 'no label'), ('Dietary Reference Intakes', 'no label'), ('Dris', 'no label'), ('Blood Biomarkers', 'no label'), ('Analyzed', 'no label'), ('Laboratory Reference Ranges', 'no label'), ('Patient', 'no label'), ('Laboratory Values', 'no label'), ('Controls', 'no label'), ('National Health And Examination Survey', 'no label'), ('Nhanes', 'no label'), ('Differences', 'no label'), ('Nutrient Intakes', 'no label'), ('Stratified By Age', 'no label'), ('Nonparametric Methods', 'no label'), ('Statistical Analyses', 'no label'), ('Completed', 'no label'), ('Significance Set', 'no label'), ('Medical Food Intake', 'no label'), ('Declined', 'no label'), ('Pediatric', 'no label'), ('Adult', 'no label'), ('Bh4', 'no label'), ('Responders', 'no label'), ('Year', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Calories', 'no label'), ('Obtained', 'no label'), ('Declined', 'no label'), ('Adults', 'no label'), ('Percent Calories', 'no label'), ('Dropped', 'no label'), ('Laboratory', 'no label'), ('Dietary Values', 'no label'), ('Reference Ranges', 'no label'), ('Responders', 'no label'), ('Years', 'no label'), ('Experienced', 'no label'), ('Significant', 'no label'), ('Decline', 'no label'), ('Serum B12', 'no label'), ('Dietary Folate', 'no label'), ('Dietary Iron', 'no label'), ('Study', 'no label'), ('Dietary', 'no label'), ('Laboratory Values', 'no label'), ('B12', 'no label'), ('B6', 'no label'), ('Folate', 'no label'), ('Iron', 'no label'), ('Bh4', 'no label'), ('Responders', 'no label'), ('Non-Responders', 'no label'), ('Adequate', 'no label'), ('Baseline', 'no label'), ('Follow-Up', 'no label'), ('Responders', 'no label'), ('Experienced', 'no label'), ('Significant', 'no label'), ('Decline', 'no label'), ('Serum B12', 'no label'), ('Year', 'no label'), ('Explained', 'no label'), ('Decreased Intake', 'no label'), ('Fortified', 'no label'), ('Mf', 'no label'), ('Response Groups', 'no label'), ('Lower Serum B12 Than', 'no label'), ('Nhanes Controls', 'no label'), ('Baseline', 'no label'), ('Months', 'no label'), ('Results', 'no label'), ('Indicate', 'no label'), ('Monitor B12', 'no label'), ('Concentrations', 'no label'), ('Consider', 'no label'), ('Micronutrient', 'no label'), ('Supplementation', 'no label'), ('Special Attention', 'no label'), ('Pediatric', 'no label'), ('Patients', 'no label')]|[('Food', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Nutrients', 'no label'), ('Foods', 'no label'), ('Folate', 'no label'), ('Iron', 'no label'), ('Nutrient', 'no label'), ('Nutrient', 'no label'), ('Food', 'no label'), ('Folate', 'no label'), ('Iron', 'no label'), ('Folate', 'no label'), ('Iron', 'no label')]|[('Tetrahydrobiopterin', 'no label'), ('B12, B6, Folate, And Iron In', 'no label')]|[('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Compensated', 'no label'), ('B12', 'no label'), ('Folate', 'no label'), ('B12', 'no label'), ('Folate', 'no label'), ('B12', 'no label'), ('Folate', 'no label'), ('Iron', 'no label'), ('B12', 'no label'), ('Fortified', 'no label'), ('B12', 'no label'), ('Nhanes', 'no label'), ('B12', 'no label')]|[('People', 'no label'), ('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Bh4', 'no label'), ('Experience A', 'no label'), ('B12', 'no label'), ('Folate', 'no label'), ('Iron', 'no label'), ('Blood', 'no label'), ('Patients', 'no label'), ('Bh4 Over 1', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Bh4', 'no label'), ('Regular Intervals Over', 'no label'), ('Patients', 'no label'), ('Bh4', 'no label'), ('Blood', 'no label'), ('Calories', 'no label'), ('Calories', 'no label'), ('Serum B12', 'no label'), ('Folate', 'no label'), ('Iron', 'no label'), ('B12', 'no label'), ('B6', 'no label'), ('Folate', 'no label'), ('Iron', 'no label'), ('Bh4 Responders', 'no label'), ('Serum B12 Over 1', 'no label'), ('Serum B12', 'no label'), ('B12', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~34636993|Retinal Alterations In Inherited Metabolic Diseases Associated With Neurodegeneration Are Poorly Studied. The Objective Was To Study Retinal Thickness, Specifically The Components Of The Ganglion Cell Complex (Gcc)-Nerve Fiber Layer (Nfl), Ganglion Cell Layer (Gcl), And Inner Plexiform Layer (Ipl)-Using Spectral-Domain Optical Coherence Tomography (Sd-Oct) In Two Different Diseases With Potential Dopaminergic Depletion, Phenylketonuria (Pku) And Gaucher Disease Type 3 (Gd3). Retinal Layers In 19 Patients With Pku, 15 Patients With Gd3, And 93 Healthy Individuals Were Measured Using Peripapillary Ring Scan And Macular Sd-Oct. Linear Mixed Models Were Computed Including An Adjustment For Age, Sex, And Spherical Equivalent. We Calculated Spearman'S Rank Correlations Between Retinal Layer Measurements And Clinical And/Or Laboratory Parameters. Thinning Of Total Retinal Thickness Was Found In The Macular Inner Ring (P = 0.002), And Outer Ring (P = 0.012), Sparing The Fovea (P = 0.12) In Pku, While In Gd3, All Subfields Were Thinned (Fovea P < 0.001, Inner Ring P = 0.047, Outer Ring 0.07). In Both Conditions, Thinning Was Most Evident In The Nfl, Gcl, And Ipl, While Opl (Outer Plexiform Layer) Was Thickened. Peripapillary Retinal Nerve Fiber Layer Measurements Remained Normal. Gcl And Ipl In Pku Correlated With Tyrosine Serum Concentration. Thinning Of The Nfl, Gcl, And Ipl, With Thickened Opl, Are Both Found In Pku And In Gd3. Low Dopamine Concentrations In The Retina Might Promote These Effects. However, These Data Do Not Give Evidence That Retinal Measurements Can Be Used As A Biomarker For Disease Severity In Patients With Gd3.|"[('Retinal', 'no label'), ('Alterations', 'no label'), ('Inherited', 'no label'), ('Metabolic Diseases', 'no label'), ('Associated With', 'no label'), ('Neurodegeneration', 'no label'), ('Objective', 'no label'), ('Study', 'no label'), ('Retinal', 'no label'), ('Thickness', 'no label'), ('Components', 'no label'), ('Ganglion Cell Complex', 'no label'), ('Fiber Layer', 'no label'), ('Nfl', 'no label'), ('Ganglion Cell Layer', 'no label'), ('Gcl', 'no label'), ('Inner Plexiform Layer (Ipl)-Using Spectral-Domain Optical Coherence Tomography', 'no label'), ('Sd-Oct', 'no label'), ('Diseases', 'no label'), ('Potential', 'no label'), ('Dopaminergic', 'no label'), ('Depletion', 'no label'), ('Phenylketonuria', 'no label'), ('Gaucher Disease Type 3', 'no label'), ('Gd3', 'no label'), ('Retinal Layers', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Patients', 'no label'), ('Gd3', 'no label'), ('Healthy', 'no label'), ('Individuals', 'no label'), ('Measured', 'no label'), ('Peripapillary Ring Scan', 'no label'), ('Macular Sd-Oct.', 'no label'), ('Linear Mixed Models', 'no label'), ('Computed', 'no label'), ('Adjustment', 'no label'), ('Age', 'no label'), ('Sex', 'no label'), ('Spherical', 'no label'), ('Equivalent', 'no label'), (""Spearman'S Rank"", 'no label'), ('Correlations', 'no label'), ('Retinal Layer', 'no label'), ('Measurements', 'no label'), ('Clinical', 'no label'), ('Laboratory Parameters', 'no label'), ('Thinning', 'no label'), ('Retinal', 'no label'), ('Thickness', 'no label'), ('Macular Inner Ring', 'no label'), ('Outer Ring', 'no label'), ('Sparing', 'no label'), ('Fovea', 'no label'), ('Gd3', 'no label'), ('Subfields', 'no label'), ('Thinned', 'no label'), ('Inner Ring P\u2009=\u20090.047', 'no label'), ('Outer Ring 0.07', 'no label'), ('Conditions', 'no label'), ('Thinning', 'no label'), ('Nfl', 'no label'), ('Gcl', 'no label'), ('Ipl', 'no label'), ('Opl', 'no label'), ('Outer Plexiform Layer', 'no label'), ('Thickened', 'no label'), ('Peripapillary Retinal Nerve', 'no label'), ('Fiber Layer', 'no label'), ('Measurements', 'no label'), ('Remained Normal', 'no label'), ('Gcl', 'no label'), ('Ipl', 'no label'), ('Tyrosine Serum', 'no label'), ('Concentration', 'no label'), ('Thinning', 'no label'), ('Nfl', 'no label'), ('Gcl', 'no label'), ('Ipl', 'no label'), ('Thickened', 'no label'), ('Opl', 'no label'), ('Found', 'no label'), ('Gd3', 'no label'), ('Dopamine', 'no label'), ('Concentrations', 'no label'), ('Retina', 'no label'), ('Promote', 'no label'), ('Effects', 'no label'), ('Data', 'no label'), ('Evidence', 'no label'), ('Retinal', 'no label'), ('Measurements', 'no label'), ('Biomarker', 'no label'), ('Disease Severity', 'no label'), ('Patients', 'no label'), ('Gd3', 'no label')]"|[('Cell Complex', 'no label'), ('Nfl', 'no label'), ('Cell', 'no label'), ('Gcl', 'no label'), ('Dopaminergic', 'no label'), ('Gd3', 'no label'), ('Gd3', 'no label'), ('Individuals', 'no label'), ('Gd3', 'no label'), ('Nfl', 'no label'), ('Gcl', 'no label'), ('Ipl', 'no label'), ('Opl', 'no label'), ('Gcl', 'no label'), ('Ipl', 'no label'), ('Tyrosine', 'no label'), ('Nfl', 'no label'), ('Gcl', 'no label'), ('Ipl', 'no label'), ('Gd3', 'no label'), ('Dopamine', 'no label'), ('Gd3', 'no label')]|[('Ganglion Cell Complex', 'no label'), ('Nfl', 'no label'), ('Ipl', 'no label'), ('Opl', 'no label'), ('Peripapillary Retinal Nerve Fiber Layer', 'no label'), ('Gcl', 'no label'), ('Ipl', 'no label'), ('Nfl', 'no label'), ('Ipl', 'no label')]|[('Neurodegeneration', 'no label'), ('Gcl', 'no label'), ('Phenylketonuria', 'no label'), ('Gaucher Disease', 'no label'), ('Gcl', 'no label'), ('Peripapillary Retinal Nerve Fiber Layer Measurements Remained Normal', 'no label'), ('Gcl', 'no label'), ('Tyrosine', 'no label'), ('Nfl', 'no label'), ('Gcl', 'no label'), ('Dopamine', 'no label')]|[('Retinal Alterations', 'no label'), ('Retinal', 'no label'), ('Ganglion Cell Complex', 'no label'), ('Fiber Layer', 'no label'), ('Nfl', 'no label'), ('Ganglion Cell Layer', 'no label'), ('Gcl', 'no label'), ('Inner Plexiform Layer', 'no label'), ('Phenylketonuria', 'no label'), ('Gaucher Disease Type 3', 'no label'), ('Gd3', 'no label'), ('Retinal Layers', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Gd3', 'no label'), ('Peripapillary', 'no label'), ('Macular', 'no label'), ('Retinal Layer', 'no label'), ('And/Or', 'no label'), ('Retinal', 'no label'), ('Macular Inner', 'no label'), ('Fovea (P\u2009', 'no label'), ('Gd3', 'no label'), ('Subfields', 'no label'), ('Fovea P', 'no label'), ('Inner', 'no label'), ('Outer', 'no label'), ('Nfl', 'no label'), ('Gcl', 'no label'), ('Ipl', 'no label'), ('Opl', 'no label'), ('Retinal Nerve', 'no label'), ('Gcl', 'no label'), ('Ipl', 'no label'), ('Tyrosine Serum', 'no label'), ('Nfl', 'no label'), ('Gcl', 'no label'), ('Ipl', 'no label'), ('Opl', 'no label'), ('Pku', 'no label'), ('Gd3', 'no label'), ('Dopamine', 'no label'), ('Retina', 'no label'), ('Retinal', 'no label'), ('Patients', 'no label'), ('Gd3', 'no label')]
phenylketonuria|pubmed~30546086|Phenylketonuria (Pku) Is A Rare Metabolic Disorder That Requires Life-Long Management To Reduce Phenylalanine (Phe) Concentrations Within The Recommended Range. The Availability Of Pegvaliase (Palynziq™, An Enzyme That Can Metabolize Phe) As A New Therapy Necessitates The Provision Of Guidance For Its Use. A Steering Committee Comprising 17 Health-Care Professionals With Experience In Using Pegvaliase Through The Clinical Development Program Drafted Guidance Statements During A Series Of Face-To-Face Meetings. A Modified Delphi Methodology Was Used To Demonstrate Consensus Among A Wider Group Of Health-Care Professionals With Experience In Using Pegvaliase. Guidance Statements Were Developed For Four Categories: (1) Treatment Goals And Considerations Prior To Initiating Therapy, (2) Dosing Considerations, (3) Considerations For Dietary Management, And (4) Best Approaches To Optimize Medical Management. A Total Of 34 Guidance Statements Were Included In The Modified Delphi Voting And Consensus Was Reached On All After Two Rounds Of Voting. Here We Describe Evidence- And Consensus-Based Recommendations For The Use Of Pegvaliase In Adults With Pku. The Manuscript Was Evaluated Against The Appraisal Of Guidelines For Research And Evaluation (Agree Ii) Instrument And Is Intended For Use By Health-Care Professionals Who Will Prescribe Pegvaliase And Those Who Will Treat Patients Receiving Pegvaliase.|[('Phenylketonuria', 'no label'), ('Rare', 'no label'), ('Metabolic Disorder', 'no label'), ('Requires', 'no label'), ('Life-Long Management', 'no label'), ('Reduce', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Recommended Range', 'no label'), ('Pegvaliase', 'no label'), ('Palynziq™', 'no label'), ('Enzyme', 'no label'), ('Can Metabolize Phe', 'no label'), ('New Therapy', 'no label'), ('Necessitates', 'no label'), ('Provision', 'no label'), ('Guidance', 'no label'), ('Steering Committee', 'no label'), ('Health-Care Professionals', 'no label'), ('Experience', 'no label'), ('Pegvaliase', 'no label'), ('Clinical Development Program', 'no label'), ('Guidance', 'no label'), ('Statements', 'no label'), ('Series', 'no label'), ('Meetings', 'no label'), ('Modified Delphi Methodology', 'no label'), ('Demonstrate Consensus', 'no label'), ('Wider Group', 'no label'), ('Health-Care Professionals', 'no label'), ('Experience', 'no label'), ('Pegvaliase', 'no label'), ('Guidance', 'no label'), ('Statements', 'no label'), ('Categories', 'no label'), ('Treatment Goals', 'no label'), ('Considerations', 'no label'), ('Therapy', 'no label'), ('Dosing', 'no label'), ('Considerations', 'no label'), ('Considerations', 'no label'), ('Dietary Management', 'no label'), ('Optimize', 'no label'), ('Medical Management', 'no label'), ('Guidance', 'no label'), ('Statements', 'no label'), ('Modified Delphi Voting', 'no label'), ('Voting', 'no label'), ('Evidence-', 'no label'), ('Consensus-Based Recommendations', 'no label'), ('Pegvaliase', 'no label'), ('Adults', 'no label'), ('Manuscript Was Evaluated', 'no label'), ('Appraisal', 'no label'), ('Guidelines', 'no label'), ('Research', 'no label'), ('Agree Ii) Instrument', 'no label'), ('Use By Health-Care Professionals', 'no label'), ('Will Prescribe Pegvaliase', 'no label'), ('Will Treat', 'no label'), ('Patients', 'no label'), ('Pegvaliase', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Enzyme', 'no label'), ('Consensus', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Metabolize Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Pegvaliase', 'no label'), ('Face-To-Face', 'no label'), ('Pegvaliase', 'no label'), ('Pegvaliase', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31352540|Phenylketonuria (Pku) Is The Most Common Inborn Error Of Amino Acid Metabolism. Usually Diagnosed Within The First Month Of Birth, It Is Essential That The Patient Strictly Follow The Dietary Restriction Of Natural Protein Intake. Otherwise, Pku Impacts The Development Of The Brain Severely And May Result In Microcephaly, Epilepsy, Motor Deficits, Intellectual Disability, And Psychiatric And Behavioral Disorders. The Neuropathology Associated With Pku Includes Defects Of Myelination, Insufficient Synthesis Of Monoamine Neurotransmitters, Amino Acid Imbalance Across The Blood-Brain Barrier, And Involves Intermediary Metabolic Pathways Supporting Energy Homeostasis And Antioxidant Defenses In The Brain. Considering That The Production Of Reactive Oxygen Species (Ros) Is Inherent To Energy Metabolism, We Investigated The Association Of Creatine+Pyruvate (Cr + Pyr), Both Energy Substrates With Antioxidants Properties, As A Possible Treatment To Mitigate Oxidative Stress And Phosphotransfer Network Impairment Elicited In The Brain Of Young Wistar Rats By Chemically-Induced Pku. We Induced Pku Through The Administration Of Α-Methyl-L-Phenylalanine And Phenylalanine For 7 Days, With And Without Cr + Pyr Supplementation, Until Postpartum Day 14. The Cotreatment With Cr + Pyr Administered Concurrently With Pku Induction Prevented Ros Formation And Part Of The Alterations Observed In Antioxidants Defenses And Phosphotransfer Network Enzymes In The Cerebral Cortex, Hippocampus, And Cerebellum. If Such Prevention Also Occurs In Pku Patients, Supplementing The Phenylalanine-Restricted Diet With Antioxidants And Energetic Substrates Might Be Beneficial To These Patients.|[('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Diagnosed', 'no label'), ('Month', 'no label'), ('Birth', 'no label'), ('Patient', 'no label'), ('Dietary Restriction', 'no label'), ('Natural Protein Intake', 'no label'), ('Pku Impacts', 'no label'), ('Development', 'no label'), ('Brain', 'no label'), ('Severely', 'no label'), ('Result', 'no label'), ('Microcephaly', 'no label'), ('Epilepsy', 'no label'), ('Motor Deficits', 'no label'), ('Intellectual Disability', 'no label'), ('Psychiatric And Behavioral Disorders', 'no label'), ('Neuropathology', 'no label'), ('Associated With', 'no label'), ('Pku Includes', 'no label'), ('Defects', 'no label'), ('Myelination', 'no label'), ('Insufficient', 'no label'), ('Synthesis', 'no label'), ('Monoamine Neurotransmitters', 'no label'), ('Amino Acid', 'no label'), ('Imbalance', 'no label'), ('Blood-Brain Barrier', 'no label'), ('Intermediary', 'no label'), ('Metabolic Pathways', 'no label'), ('Energy Homeostasis', 'no label'), ('Antioxidant Defenses', 'no label'), ('Brain', 'no label'), ('Production', 'no label'), ('Reactive Oxygen Species', 'no label'), ('Ros', 'no label'), ('Energy Metabolism', 'no label'), ('Investigated', 'no label'), ('Association', 'no label'), ('Creatine+Pyruvate (', 'no label'), ('Cr\u2009+\u2009Pyr', 'no label'), ('Energy Substrates', 'no label'), ('Antioxidants', 'no label'), ('Properties', 'no label'), ('Treatment', 'no label'), ('Mitigate', 'no label'), ('Oxidative Stress', 'no label'), ('Phosphotransfer Network Impairment', 'no label'), ('Brain', 'no label'), ('Young Wistar Rats', 'no label'), ('Chemically-Induced Pku', 'no label'), ('Induced', 'no label'), ('Administration', 'no label'), ('Α-Methyl-L-Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Days', 'no label'), ('Cr\u2009+\u2009Pyr', 'no label'), ('Supplementation', 'no label'), ('Postpartum Day', 'no label'), ('Cotreatment', 'no label'), ('Cr\u2009+\u2009Pyr Administered', 'no label'), ('Pku Induction', 'no label'), ('Ros', 'no label'), ('Formation', 'no label'), ('Alterations', 'no label'), ('Observed', 'no label'), ('Antioxidants', 'no label'), ('Defenses', 'no label'), ('Phosphotransfer Network', 'no label'), ('Enzymes', 'no label'), ('Cerebral Cortex', 'no label'), ('Hippocampus', 'no label'), ('Cerebellum', 'no label'), ('Prevention', 'no label'), ('Occurs', 'no label'), ('Patients', 'no label'), ('Supplementing', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Antioxidants', 'no label'), ('Energetic Substrates', 'no label'), ('Beneficial', 'no label'), ('Patients', 'no label')]|[('Amino Acid', 'no label'), ('Protein', 'no label'), ('Monoamine Neurotransmitters', 'no label'), ('Amino Acid', 'no label'), ('Oxygen Species', 'no label'), ('Antioxidants', 'no label'), ('Rats', 'no label'), ('Α-Methyl-L-Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Antioxidants', 'no label'), ('Enzymes', 'no label'), ('Antioxidants', 'no label')]|[('Pyr', 'no label'), ('Pyr', 'no label')]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Microcephaly', 'no label'), ('Epilepsy', 'no label'), ('Psychiatric', 'no label'), ('Behavioral Disorders', 'no label'), ('Myelination', 'no label'), ('Amino Acid', 'no label'), ('Oxygen', 'no label'), ('Cr', 'no label'), ('Phenylalanine', 'no label'), ('Cr', 'no label'), ('Cr', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Amino Acid', 'no label'), ('Patient', 'no label'), ('Brain', 'no label'), ('Monoamine Neurotransmitters', 'no label'), ('Amino Acid', 'no label'), ('Blood-Brain Barrier', 'no label'), ('Intermediary', 'no label'), ('Brain', 'no label'), ('Creatine+Pyruvate', 'no label'), ('Cr', 'no label'), ('Pyr', 'no label'), ('Phosphotransfer Network', 'no label'), ('Brain', 'no label'), ('Wistar Rats', 'no label'), ('Α-Methyl-L-Phenylalanine', 'no label'), ('Phenylalanine For 7', 'no label'), ('Cr', 'no label'), ('Pyr', 'no label'), ('Cr', 'no label'), ('Pyr', 'no label'), ('Ros', 'no label'), ('Phosphotransfer Network', 'no label'), ('Cerebral Cortex', 'no label'), ('Pku Patients', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~33461111|Phenylketonuria (Pku) Is An Autosomal Recessive Disorder Whereby Deficiencies In Phenylalanine Metabolism Cause Progressive Neurological Dysfunction. Managing Pku Is Challenging, With Disease Monitoring Focussed On Short-Term Phenylalanine Control Rather Than Measures Of Neuronal Damage. Conventional Imaging Lacks Sensitivity, However Diffusion Kurtosis Imaging (Dki), A New Mri Method May Reveal Subclinical White Matter Structural Changes In Pku. This Cohort Study Involved Adults With Pku Recruited During Routine Clinical Care. Mri, Neurocognitive Assessment And Historical Phenylalanine (Phe) Levels Were Collected. A Hypothesis-Generating Case Study Comparing Diet-Compliant And Non-Compliant Siblings Confirmed That Dki Metrics Are Sensitive To Dietary Adherence And Prompted A Candidate Metric (K<Sub>Rad</Sub>/K<Sub>Fa</Sub> Ratio). We Then Tested This Metric In A Replication Cohort (Pku = 20; Controls = 43). Both Siblings Scored Outside The Range Of Controls For All Dki-Based Metrics, With Severe Changes In The Periventricular White Matter And A Gradient Of Severity Toward The Cortex. K<Sub>Rad</Sub>/K<Sub>Fa</Sub> Provided Clear Separation By Diagnosis In The Replication Cohort (P < 0.001 In Periventricular, Deep And Pericortical Compartments). The Ratio Also Correlated Negatively With Attention (R = -0.51 & -0.50, P < 0.05) And Positively With 3-Year Mean Phe (R = 0.45 & 0.58, P < 0.01). Dki Reveals Regionally-Specific, Progressive Abnormalities Of Brain Diffusion Characteristics In Pku, Even In The Absence Of Conspicuous Clinical Signs Or Abnormalities On Conventional Mri. A Dki-Based Marker Derived From These Scores (K<Sub>Rad</Sub>/K<Sub>Fa</Sub> Ratio) Was Sensitive To Cognitive Impairment And Pku Control Over The Medium Term And May Provide A Meaningful Subclinical Biomarker Of End-Organ Damage.|[('Phenylketonuria', 'no label'), ('Autosomal Recessive Disorder', 'no label'), ('Deficiencies', 'no label'), ('Phenylalanine Metabolism', 'no label'), ('Cause', 'no label'), ('Progressive Neurological Dysfunction', 'no label'), ('Pku', 'no label'), ('Disease Monitoring', 'no label'), ('Focussed', 'no label'), ('Short-Term', 'no label'), ('Phenylalanine', 'no label'), ('Measures', 'no label'), ('Neuronal Damage', 'no label'), ('Conventional Imaging', 'no label'), ('Lacks', 'no label'), ('Sensitivity', 'no label'), ('Diffusion Kurtosis Imaging', 'no label'), ('Dki', 'no label'), ('New Mri Method', 'no label'), ('Reveal', 'no label'), ('Subclinical White', 'no label'), ('Structural', 'no label'), ('Changes', 'no label'), ('Cohort Study', 'no label'), ('Adults', 'no label'), ('Routine', 'no label'), ('Clinical Care', 'no label'), ('Mri', 'no label'), ('Neurocognitive Assessment', 'no label'), ('Historical', 'no label'), ('Phenylalanine', 'no label'), ('Levels', 'no label'), ('Collected', 'no label'), ('Hypothesis-Generating Case Study', 'no label'), ('Diet-Compliant', 'no label'), ('Non-Compliant Siblings', 'no label'), ('Confirmed', 'no label'), ('Dki Metrics', 'no label'), ('Sensitive', 'no label'), ('Dietary Adherence', 'no label'), ('Candidate Metric', 'no label'), ('Ratio', 'no label'), ('Tested', 'no label'), ('Metric', 'no label'), ('Replication Cohort', 'no label'), ('Controls\xa0', 'no label'), ('Siblings', 'no label'), ('Scored', 'no label'), ('Range', 'no label'), ('Controls', 'no label'), ('Dki-Based Metrics', 'no label'), ('Severe', 'no label'), ('Changes', 'no label'), ('Periventricular White', 'no label'), ('Gradient', 'no label'), ('Severity', 'no label'), ('Cortex', 'no label'), ('Separation', 'no label'), ('Diagnosis', 'no label'), ('Replication Cohort', 'no label'), ('Periventricular', 'no label'), ('Deep', 'no label'), ('Pericortical Compartments', 'no label'), ('Ratio', 'no label'), ('Correlated', 'no label'), ('Attention', 'no label'), ('R\xa0', 'no label'), ('P\xa0<\xa00.05) And Positively With', 'no label'), ('Mean Phe', 'no label'), ('P\xa0<\xa00.01', 'no label'), ('Dki Reveals', 'no label'), ('Regionally-Specific', 'no label'), ('Progressive Abnormalities', 'no label'), ('Brain Diffusion', 'no label'), ('Characteristics', 'no label'), ('Absence', 'no label'), ('Signs Or Abnormalities', 'no label'), ('Conventional', 'no label'), ('Mri', 'no label'), ('Dki-Based Marker', 'no label'), ('Scores', 'no label'), ('Ratio', 'no label'), ('Sensitive', 'no label'), ('Cognitive Impairment', 'no label'), ('Pku Control', 'no label'), ('Medium Term', 'no label'), ('Provide', 'no label'), ('Meaningful', 'no label'), ('Subclinical Biomarker', 'no label'), ('End-Organ', 'no label'), ('Damage', 'no label')]|[('Phenylalanine', 'no label'), ('Neuronal', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Autosomal Recessive Disorder Whereby Deficiencies', 'no label'), ('Phenylalanine', 'no label'), ('Neurological Dysfunction', 'no label'), ('Phenylalanine', 'no label'), ('Neuronal Damage', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('K', 'no label'), ('Cognitive Impairment', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Short-Term Phenylalanine', 'no label'), ('Neuronal', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Periventricular', 'no label'), ('Cortex', 'no label'), ('Periventricular', 'no label'), ('Brain', 'no label'), ('K', 'no label')]
phenylketonuria|pubmed~26759449|Autism Has Been Reported In Untreated Patients With Phenylketonuria. The Authors Aimed To Explore Autism In 15 Tunisian And 4 Algerian Phenylketonuria Patients, And Report Their Clinical, Biochemical And Molecular Peculiarities. The Childhood Autism Rating Scale And The Autism Diagnostic Interview-Revised Were Used For The Diagnosis Of Autism. Five Exons Of Phenylalanine Hydroxylase Gene (7, 6, 10, 11, And 5) Were Amplified By Polymerase Chain Reaction And Directly Sequenced. Among These Patients, 15 Were Suffering From Autism At The Time Of Evaluation. Six Mutations Were Identified: P.E280K, P.G352Vfs, Ivs10Nt11, P.I224T, P.R261Q, And P.R252W. There Was No Correlation Between Autism And Mutations Affecting The Phenylalanine Hydroxylase Gene, But The Age Of Diet Onset Was The Determining Factor In Autistic Symptoms' Evolution.|"[('Autism', 'no label'), ('Untreated Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Autism', 'no label'), ('Tunisian', 'no label'), ('Algerian Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Report', 'no label'), ('Clinical', 'no label'), ('Biochemical', 'no label'), ('Molecular Peculiarities', 'no label'), ('Childhood Autism Rating Scale', 'no label'), ('Autism Diagnostic Interview-Revised', 'no label'), ('Diagnosis', 'no label'), ('Autism', 'no label'), ('Exons', 'no label'), ('Phenylalanine Hydroxylase Gene', 'no label'), ('Amplified', 'no label'), ('Polymerase Chain Reaction', 'no label'), ('Patients', 'no label'), ('Suffering', 'no label'), ('Autism', 'no label'), ('Time', 'no label'), ('Evaluation', 'no label'), ('Mutations', 'no label'), ('P.E280K', 'no label'), ('P.G352Vfs', 'no label'), ('P.I224T', 'no label'), ('P.R261Q', 'no label'), ('Correlation', 'no label'), ('Autism', 'no label'), ('Mutations', 'no label'), ('Affecting', 'no label'), ('Phenylalanine Hydroxylase Gene', 'no label'), ('Age', 'no label'), ('Diet Onset', 'no label'), ('Factor', 'no label'), (""Autistic Symptoms'"", 'no label'), ('Evolution', 'no label')]"|[('Molecular', 'no label'), ('Exons', 'no label'), ('Phenylalanine', 'no label'), ('Gene', 'no label'), ('Mutations', 'no label'), ('Mutations', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylalanine Hydroxylase Gene', 'no label'), ('Phenylalanine Hydroxylase Gene', 'no label')]|[('Autism', 'no label'), ('Phenylketonuria', 'no label'), ('Autism', 'no label'), ('Phenylketonuria', 'no label'), ('Autism', 'no label'), ('Autism', 'no label'), ('Phenylalanine', 'no label'), ('Autism', 'no label'), ('K', 'no label'), ('Autism', 'no label'), ('Phenylalanine', 'no label'), ('Autistic', 'no label')]|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Algerian Phenylketonuria Patients', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Patients', 'no label'), ('Phenylalanine Hydroxylase', 'no label')]
phenylketonuria|pubmed~30144897|Phenylketonuria (Pku) Has A Very High Prevalence Throughout The World. Nowadays, Number Of Studies About Impact Of This Metabolic Disease On Patients Increasing. The Aim Of Our Study Is To Examine Pku Patients' Quality Of Life According To Pku-Qol Questionnaires. Patients (N = 63) Diagnosed With Pku Were Included This Study; Child (9-11 Years (N = 20)), Adolescent (12-15 Years (N = 22)) And Adult (18-35 Years (N = 21)). Pku-Qol Questionnaires (Include 4 Modules) Developed For Pku Patients Were Used. In Accordance With Purpose, Data Were Analysed By Nonparametric Tests (Kruskal Wallis One-Way Analysis Of Variance Test And Mann-Whitney U Test), According To Results Of Normality Tests. Most Of The Individuals Were Female (65,1%) And Mean Age Was 15,7 ± 6,4 Years. Symptoms; There Were Statistically Significant Differences In All Domains Excluding Tiredness. Especially, Median Score Of Slow Thinking Was Very Frequent Symptom In Children As 100,0. Pku In General; There Were Found That Median Scores Were Higher In Children. Phe-Free Amino Acid Supplement Administration: As The Age Increased, Scores Were Lower. Dietary Protein Restriction: Overall Difficulty Following Dietary Protein Restriction And Food Enjoyment Were Found Similar In Groups (P > 0,05). It Was Concluded That Pku Affects Younger People More Negatively.|"[('Phenylketonuria', 'no label'), ('Prevalence', 'no label'), ('World', 'no label'), ('Studies', 'no label'), ('Impact', 'no label'), ('Metabolic Disease', 'no label'), ('Patients', 'no label'), ('Increasing', 'no label'), ('Study', 'no label'), ('Examine', 'no label'), (""Patients'"", 'no label'), ('Quality Of Life', 'no label'), ('Pku-Qol Questionnaires', 'no label'), ('Patients', 'no label'), ('N\xa0', 'no label'), ('Diagnosed', 'no label'), ('Pku', 'no label'), ('Study', 'no label'), ('Child', 'no label'), ('Years', 'no label'), ('Adolescent', 'no label'), ('Years', 'no label'), ('Adult', 'no label'), ('Years', 'no label'), ('Pku-Qol Questionnaires', 'no label'), ('Modules', 'no label'), ('Pku Patients', 'no label'), ('Purpose', 'no label'), ('Data', 'no label'), ('Analysed', 'no label'), ('Nonparametric Tests', 'no label'), ('Kruskal Wallis One-Way Analysis', 'no label'), ('Variance Test', 'no label'), ('Normality Tests', 'no label'), ('Individuals', 'no label'), ('Female', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Symptoms', 'no label'), ('Statistically Significant', 'no label'), ('Differences', 'no label'), ('Domains', 'no label'), ('Tiredness', 'no label'), ('Median Score', 'no label'), ('Slow Thinking', 'no label'), ('Symptom', 'no label'), ('Children', 'no label'), ('General', 'no label'), ('Median Scores', 'no label'), ('Higher', 'no label'), ('Children', 'no label'), ('Phe-Free', 'no label'), ('Amino Acid Supplement', 'no label'), ('Administration', 'no label'), ('Age', 'no label'), ('Increased', 'no label'), ('Scores', 'no label'), ('Dietary Protein', 'no label'), ('Restriction', 'no label'), ('Difficulty', 'no label'), ('Dietary Protein Restriction', 'no label'), ('Food Enjoyment', 'no label'), ('Groups', 'no label'), ('P\xa0>\xa00,05', 'no label'), ('Younger People', 'no label')]"|[('Individuals', 'no label'), ('Domains', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Food', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Metabolic Disease', 'no label'), ('N\xa0=\xa063', 'no label'), ('N\xa0=\xa020)', 'no label'), ('N\xa0=\xa022)', 'no label'), ('N\xa0=\xa021)', 'no label'), ('Tiredness', 'no label'), ('Amino Acid', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Variance Test', 'no label'), ('U Test', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Phe-Free Amino', 'no label'), ('People', 'no label')]
phenylketonuria|pubmed~31485704|This Study Was Carried Out To Establish A Non-Invasive Prenatal Diagnosis Method For Phenylketonuria (Pku) Based On Droplet Digital Pcr (Ddpcr) And To Evaluate Its Accuracy By Comparison With Conventional Invasive Diagnostic Methods. A Total Of 24 Pku Pedigrees That Required Prenatal Diagnosis Were Studied, In Which The Genetic Mutations In The Probands And Parents Were Unambiguous. Prenatal Diagnosis Of Sibling Fetuses Was Performed Using Traditional Invasive Prenatal Diagnostic Methods As A Standard. At The Same Time, Cell-Free Dna (Cfdna) Was Extracted From Maternal Plasma And The Fetal Genes Contained Within Were Typed And Quantified Using Ddpcr Method. Invasive Prenatal Diagnosis Determined That 3 Of The 24 Fetuses Were Affected, 8 Of Them Were Normal, And 13 Were Heterozygous Carriers Of Pathogenic Mutations. Successful Non-Invasive Prenatal Diagnosis Analysis Of Pah Gene Mutations Was Performed For 8 Of The Families Using Ddpcr Method. Non-Invasive Prenatal Diagnosis Results Were Consistent With The Results Of The Invasive Prenatal Diagnoses And No False Positive Or False Negative Results Were Found. In Conclusion, This Study Is The First To Establish Non-Invasive Prenatal Diagnosis Of Pku Based On Ddpcr. The Method Showed High Sensitivity And Specificity From Cfdna, Indicating That Ddpcr Is A Reliable Non-Invasive Prenatal Diagnosis Tool For Pku Diagnosis. Graphical Abstract.|[('Study', 'no label'), ('Establish A', 'no label'), ('Non-Invasive', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Method', 'no label'), ('Phenylketonuria', 'no label'), ('Droplet Digital Pcr', 'no label'), ('Ddpcr', 'no label'), ('Evaluate', 'no label'), ('Accuracy', 'no label'), ('Comparison', 'no label'), ('Conventional Invasive Diagnostic Methods', 'no label'), ('Pedigrees', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Studied', 'no label'), ('Genetic Mutations', 'no label'), ('Probands', 'no label'), ('Parents', 'no label'), ('Unambiguous', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Sibling', 'no label'), ('Fetuses', 'no label'), ('Performed', 'no label'), ('Traditional Invasive', 'no label'), ('Prenatal Diagnostic Methods', 'no label'), ('Standard', 'no label'), ('Same Time', 'no label'), ('Cell-Free Dna', 'no label'), ('Cfdna', 'no label'), ('Maternal', 'no label'), ('Plasma', 'no label'), ('Fetal Genes', 'no label'), ('Contained', 'no label'), ('Typed', 'no label'), ('Quantified', 'no label'), ('Ddpcr Method', 'no label'), ('Invasive', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Fetuses', 'no label'), ('Affected', 'no label'), ('Normal', 'no label'), ('Heterozygous Carriers', 'no label'), ('Pathogenic Mutations', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Analysis', 'no label'), ('Pah Gene', 'no label'), ('Families', 'no label'), ('Ddpcr Method', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Consistent With', 'no label'), ('Results', 'no label'), ('Invasive Prenatal Diagnoses', 'no label'), ('No False Positive', 'no label'), ('False Negative Results', 'no label'), ('Study', 'no label'), ('Establish', 'no label'), ('Non-Invasive', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Pku Based', 'no label'), ('Ddpcr', 'no label'), ('Method', 'no label'), ('Sensitivity', 'no label'), ('Specificity', 'no label'), ('Cfdna', 'no label'), ('Indicating', 'no label'), ('Ddpcr', 'no label'), ('Non-Invasive', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Pku Diagnosis', 'no label'), ('Graphical Abstract', 'no label')]|[('Genetic Mutations', 'no label'), ('Dna', 'no label'), ('Genes', 'no label'), ('Carriers', 'no label'), ('Gene Mutations', 'no label')]|[('Fetal Genes', 'no label'), ('Pah Gene Mutations', 'no label')]|[('Phenylketonuria', 'no label'), ('Heterozygous', 'no label')]|[('Phenylketonuria', 'no label'), ('Fetuses', 'no label'), ('Dna', 'no label'), ('Plasma', 'no label'), ('Fetal', 'no label'), ('Fetuses', 'no label'), ('Pah Gene', 'no label')]
phenylketonuria|pubmed~32161022|Disabled Individuals May Be At Risk For Common And Rare Infections. We Report On A 13-Year-Old Female Who Had A Diagnosis Of Phenylketonuria (Pku). The Child Received A Percutaneous Endoscopic Gastrostomy (Peg) Feeding Tube At Five Years Of Age For The Supplementation Of Her Specialized Formula. After Eight Years, She No Longer Required The Gastrostomy Tube For Formula Supplementation, And She Presented For The Closure Of The Gastrocutaneous Fistula Tract. The Histological Examination Revealed Acute And Chronic Inflammation And Colonization By Gram-Positive Bacteria With A Characteristic Tetrad Packet Arrangement Known As <I>Clostridium Ventriculi</I> (Formerly <I>Sarcina Ventriculi</I>). A Review Of The Literature Evidenced The Rarity Of This Infection In Children. This Patient Is The 11<Sup>Th</Sup> Case Of Such Infection In Literature, And The First Patient Affected With Pku. Physically And Mentally Disabled Children Are Particularly Vulnerable To Infection Because Of Their Different Feeding Abilities, Toilet Needs, And Sanitary Arrangements.|[('Disabled', 'no label'), ('Individuals', 'no label'), ('Risk', 'no label'), ('Common', 'no label'), ('Report', 'no label'), ('Female', 'no label'), ('Diagnosis', 'no label'), ('Phenylketonuria', 'no label'), ('Child', 'no label'), ('Received', 'no label'), ('Percutaneous Endoscopic Gastrostomy (Peg) Feeding Tube', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Supplementation', 'no label'), ('Specialized Formula', 'no label'), ('Years', 'no label'), ('Gastrostomy Tube', 'no label'), ('Formula', 'no label'), ('Supplementation', 'no label'), ('Closure', 'no label'), ('Gastrocutaneous Fistula Tract', 'no label'), ('Histological Examination Revealed', 'no label'), ('Acute', 'no label'), ('Chronic Inflammation', 'no label'), ('Colonization', 'no label'), ('Gram-Positive Bacteria', 'no label'), ('Characteristic Tetrad Packet', 'no label'), ('Review', 'no label'), ('Literature', 'no label'), ('Rarity', 'no label'), ('Infection', 'no label'), ('Children', 'no label'), ('Patient', 'no label'), ('Infection', 'no label'), ('Literature', 'no label'), ('First Patient', 'no label'), ('Affected', 'no label'), ('Physically', 'no label'), ('Mentally Disabled', 'no label'), ('Children', 'no label'), ('Vulnerable', 'no label'), ('Infection', 'no label'), ('Feeding Abilities', 'no label'), ('Toilet Needs', 'no label'), ('Arrangements', 'no label')]|[('Individuals', 'no label'), ('Bacteria', 'no label'), ('Clostridium Ventriculi</I', 'no label')]|[]|[('Infections', 'no label'), ('Phenylketonuria', 'no label'), ('Gastrocutaneous Fistula Tract', 'no label'), ('Inflammation', 'no label'), ('Clostridium', 'no label'), ('Infection', 'no label'), ('Infection', 'no label'), ('Infection', 'no label')]|[('Phenylketonuria', 'no label'), ('Tube', 'no label'), ('Formula', 'no label'), ('Gastrocutaneous Fistula', 'no label'), ('Clostridium', 'no label'), ('Sarcina', 'no label'), ('Children', 'no label'), ('Patient', 'no label'), ('Patient', 'no label'), ('Children', 'no label'), ('Toilet', 'no label')]
phenylketonuria|pubmed~32821049|The Prognosis For Phenylketonuria (Pku) Has Been Improved By Neonatal Screening And Dietary Management Via A Low-Phenylalanine Diet. This Treatment Must Be Followed Throughout Life, Which Induces Severe Compliance Problems. Drug Treatment With Sapropterin (Or Bh4) Has Come To Help A Reduced Percentage Of Patients Who Respond To This Drug. A Subcutaneous Enzyme Therapy Is Available In The Usa And Has Obtained European Marketing Authorization, But Generates Significant Side Effects, Which Limits Its Effectiveness. New Therapeutic Options For Pku Are Currently Being Developed, In Particular Gene Therapy. The Purpose Of This Article Is To Take Stock Of The Pathophysiology And The Various New Therapeutic Modalities Currently In Development.|[('Prognosis', 'no label'), ('Phenylketonuria', 'no label'), ('Improved', 'no label'), ('Neonatal', 'no label'), ('Screening', 'no label'), ('Dietary Management', 'no label'), ('Low-Phenylalanine', 'no label'), ('Diet', 'no label'), ('Treatment', 'no label'), ('Life', 'no label'), ('Induces', 'no label'), ('Severe', 'no label'), ('Compliance', 'no label'), ('Problems', 'no label'), ('Drug Treatment', 'no label'), ('Sapropterin', 'no label'), ('Bh4', 'no label'), ('Help A', 'no label'), ('Reduced', 'no label'), ('Percentage', 'no label'), ('Patients', 'no label'), ('Drug', 'no label'), ('Subcutaneous Enzyme Therapy', 'no label'), ('Usa', 'no label'), ('European', 'no label'), ('Marketing Authorization', 'no label'), ('Significant', 'no label'), ('Side Effects', 'no label'), ('Limits', 'no label'), ('Effectiveness', 'no label'), ('Therapeutic Options', 'no label'), ('Being', 'no label'), ('Gene Therapy', 'no label'), ('Article', 'no label'), ('Stock', 'no label'), ('Pathophysiology', 'no label'), ('Therapeutic Modalities', 'no label'), ('Development', 'no label')]|[('Drug', 'no label'), ('Drug', 'no label'), ('Enzyme', 'no label'), ('Gene', 'no label')]|[]|[('Prognosis', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin', 'no label')]|[('Phenylketonuria', 'no label'), ('Low-Phenylalanine', 'no label'), ('Sapropterin', 'no label'), ('Help A', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~32668217|Phenylketonuria (Pku), Caused By Variants In The Phenylalanine Hydroxylase (Pah) Gene, Is The Most Common Autosomal-Recessive Mendelian Phenotype Of Amino Acid Metabolism. We Estimated That Globally 0.45 Million Individuals Have Pku, With Global Prevalence 1:23,930 Live Births (Range 1:4,500 [Italy]-1:125,000 [Japan]). Comparing Genotypes And Metabolic Phenotypes From 16,092 Affected Subjects Revealed Differences In Disease Severity In 51 Countries From 17 World Regions, With The Global Phenotype Distribution Of 62% Classic Pku, 22% Mild Pku, And 16% Mild Hyperphenylalaninemia. A Gradient In Genotype And Phenotype Distribution Exists Across Europe, From Classic Pku In The East To Mild Pku In The Southwest And Mild Hyperphenylalaninemia In The South. The C.1241A>G (P.Tyr414Cys)-Associated Genotype Can Be Traced From Northern To Western Europe, From Sweden Via Norway, To Denmark, To The Netherlands. The Frequency Of Classic Pku Increases From Europe (56%) Via Middle East (71%) To Australia (80%). Of 758 Pah Variants, C.1222C>T (P.Arg408Trp) (22.2%), C.1066-11G>A (Ivs10-11G>A) (6.4%), And C.782G>A (P.Arg261Gln) (5.5%) Were Most Common And Responsible For Two Prevalent Genotypes: P.[Arg408Trp];[Arg408Trp] (11.4%) And C.[1066-11G>A];[1066-11G>A] (2.6%). Most Genotypes (73%) Were Compound Heterozygous, 27% Were Homozygous, And 55% Of 3,659 Different Genotypes Occurred In Only A Single Individual. Pah Variants Were Scored Using An Allelic Phenotype Value And Correlated With Pre-Treatment Blood Phenylalanine Concentrations (N = 6,115) And Tetrahydrobiopterin Loading Test Results (N = 4,381), Enabling Prediction Of Both A Genotype-Based Phenotype (88%) And Tetrahydrobiopterin Responsiveness (83%). This Study Shows That Large Genotype Databases Enable Accurate Phenotype Prediction, Allowing Appropriate Targeting Of Therapies To Optimize Clinical Outcome.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Variants', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Autosomal-Recessive Mendelian', 'no label'), ('Phenotype', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Estimated', 'no label'), ('Million', 'no label'), ('Individuals', 'no label'), ('Global Prevalence', 'no label'), ('Live Births', 'no label'), ('Japan', 'no label'), ('Genotypes', 'no label'), ('Metabolic', 'no label'), ('Phenotypes', 'no label'), ('Affected Subjects', 'no label'), ('Revealed', 'no label'), ('Differences', 'no label'), ('Disease Severity', 'no label'), ('Countries', 'no label'), ('World Regions', 'no label'), ('Global Phenotype Distribution', 'no label'), ('Classic', 'no label'), ('Mild Pku', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Gradient', 'no label'), ('Genotype', 'no label'), ('Phenotype', 'no label'), ('Distribution Exists', 'no label'), ('Europe', 'no label'), ('Classic Pku', 'no label'), ('East', 'no label'), ('Southwest', 'no label'), ('Mild Hyperphenylalaninemia', 'no label'), ('South', 'no label'), ('C.1241A>G (P.Tyr414Cys)-Associated', 'no label'), ('Genotype', 'no label'), ('Northern', 'no label'), ('Western Europe', 'no label'), ('Sweden', 'no label'), ('Norway', 'no label'), ('Denmark', 'no label'), ('Netherlands', 'no label'), ('Frequency', 'no label'), ('Classic Pku', 'no label'), ('Increases', 'no label'), ('Europe', 'no label'), ('Middle East', 'no label'), ('Australia', 'no label'), ('Variants', 'no label'), ('C.1222C>T', 'no label'), ('C.1066-11G>A', 'no label'), ('C.782G>A (P.Arg261Gln)', 'no label'), ('Common', 'no label'), ('Prevalent', 'no label'), ('Genotypes', 'no label'), ('P.[Arg408Trp];[Arg408Trp]', 'no label'), ('C.[1066-11G>A];[1066-11G>A]', 'no label'), ('Genotypes', 'no label'), ('Compound Heterozygous', 'no label'), ('Homozygous', 'no label'), ('Genotypes', 'no label'), ('Occurred', 'no label'), ('Individual', 'no label'), ('Variants', 'no label'), ('Scored', 'no label'), ('Allelic', 'no label'), ('Value', 'no label'), ('Correlated', 'no label'), ('Pre-Treatment', 'no label'), ('Blood Phenylalanine Concentrations', 'no label'), ('Tetrahydrobiopterin Loading Test Results', 'no label'), ('Enabling Prediction', 'no label'), ('Genotype-Based Phenotype', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Responsiveness', 'no label'), ('Study', 'no label'), ('Genotype', 'no label'), ('Databases', 'no label'), ('Enable', 'no label'), ('Accurate', 'no label'), ('Phenotype', 'no label'), ('Prediction', 'no label'), ('Targeting', 'no label'), ('Therapies', 'no label'), ('Optimize', 'no label'), ('Clinical Outcome', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Gene', 'no label'), ('Amino Acid', 'no label'), ('Individuals', 'no label'), ('Genotypes', 'no label'), ('Genotype', 'no label'), ('Genotype', 'no label'), ('T', 'no label'), ('Ivs10', 'no label'), ('Genotypes', 'no label'), ('Genotypes', 'no label'), ('Genotypes', 'no label'), ('Allelic', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Genotype', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Pah Variants', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Tetrahydrobiopterin', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acid', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Tetrahydrobiopterin', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Amino Acid', 'no label'), ('C.1066-11G', 'no label'), ('Ivs10-11G', 'no label'), ('C.[1066-11G', 'no label'), ('Blood Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Tetrahydrobiopterin', 'no label')]
phenylketonuria|pubmed~33581730|In Phenylketonuria (Pku), Modified Casein Glycomacropeptide Supplements (Cgmp-Aa) Are Used As An Alternative To The Traditional Phenylalanine (Phe)-Free L-Amino Acid Supplements (L-Aa). However, Studies Focusing On The Long-Term Nutritional Status Of Cgmp-Aa Are Lacking. This Retrospective Study Evaluated The Long-Term Impact Of Cgmp-Aa Over A Mean Of 29 Months In 11 Patients With A Mean Age At Cgmp-Aa Onset Of 28 Years (Range 15-43) [8 Females; 2 Hyperphenylalaninaemia (Hpa), 3 Mild Pku, 3 Classical Pku And 3 Late-Diagnosed]. Outcome Measures Included Metabolic Control, Anthropometry, Body Composition And Biochemical Parameters. Cgmp-Aa, Providing 66% Of Protein Equivalent Intake From Protein Substitute, Was Associated With No Significant Change In Blood Phe With Cgmp-Aa Compared With Baseline (562 ± 289 Μmol/L Vs 628 ± 317 Μmol/L; P = 0.065). In Contrast, Blood Tyrosine Significantly Increased On Cgmp-Aa (52.0 ± 19.2 Μmol/L Vs 61.4 ± 23.8 Μmol/L; P = 0.027). Biochemical Nutritional Markers Remained Unchanged Which Is An Encouraging Finding In Adults With Pku, Many Of Whom Are Unable To Maintain Full Adherence With Nutritionally Fortified Protein Substitutes. Longitudinal, Prospective Studies With Larger Sample Sizes Are Necessary To Fully Understand The Metabolic Impact Of Using Cgmp-Aa In Pku.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Casein Glycomacropeptide Supplements', 'no label'), ('Cgmp-Aa', 'no label'), ('Traditional Phenylalanine (Phe)-Free L-Amino Acid Supplements', 'no label'), ('Studies', 'no label'), ('Long-Term Nutritional Status', 'no label'), ('Cgmp-Aa', 'no label'), ('Lacking', 'no label'), ('Retrospective Study Evaluated', 'no label'), ('Long-Term', 'no label'), ('Impact', 'no label'), ('Cgmp-Aa', 'no label'), ('Months', 'no label'), ('Patients', 'no label'), ('Mean Age', 'no label'), ('Cgmp-Aa Onset', 'no label'), ('Females', 'no label'), ('Hyperphenylalaninaemia', 'no label'), ('Hpa', 'no label'), ('Mild Pku', 'no label'), ('Classical Pku', 'no label'), ('Outcome Measures', 'no label'), ('Metabolic Control', 'no label'), ('Anthropometry', 'no label'), ('Body Composition', 'no label'), ('Biochemical', 'no label'), ('Parameters', 'no label'), ('Cgmp-Aa', 'no label'), ('Protein\xa0', 'no label'), ('Equivalent Intake', 'no label'), ('Protein Substitute', 'no label'), ('Associated With', 'no label'), ('No Significant Change', 'no label'), ('Blood Phe', 'no label'), ('Cgmp-Aa', 'no label'), ('Baseline', 'no label'), ('Contrast', 'no label'), ('Blood Tyrosine', 'no label'), ('Increased', 'no label'), ('Cgmp-Aa', 'no label'), ('Biochemical', 'no label'), ('Nutritional', 'no label'), ('Markers', 'no label'), ('Remained', 'no label'), ('Unchanged', 'no label'), ('Adults', 'no label'), ('Maintain', 'no label'), ('Adherence', 'no label'), ('Nutritionally Fortified Protein Substitutes', 'no label'), ('Longitudinal', 'no label'), ('Prospective Studies', 'no label'), ('Sample Sizes', 'no label'), ('Understand', 'no label'), ('Metabolic', 'no label'), ('Impact', 'no label'), ('Cgmp-Aa', 'no label')]|[('Glycomacropeptide', 'no label'), ('Hyperphenylalaninaemia', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Tyrosine', 'no label'), ('Protein', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Glycomacropeptide', 'no label'), ('Phenylalanine', 'no label'), ('L-Amino Acid', 'no label'), ('Hyperphenylalaninaemia', 'no label'), ('Tyrosine', 'no label')]|[('Phenylketonuria', 'no label'), ('Casein Glycomacropeptide Supplements', 'no label'), ('Phenylalanine', 'no label'), ('L-Amino Acid', 'no label'), ('Patients', 'no label'), ('Body', 'no label'), ('Blood', 'no label'), ('Blood Tyrosine', 'no label')]
phenylketonuria|pubmed~33546689|Phenylketonuria (Pku) Screening Is A Public Health Measure Taken To Diagnose And Treat The Patients With Pku To Prevent Severe Neurological Disorders In Them. The Present Study Was Aimed At Analyzing The Policies Of The National Pku Screening (Naps) Program In Iran. Pku Screening Program Policies Were Analyzed In Compliance With The Policy Triangle Model. Document Review And 38 Semi-Structured Interviews Were Used For Data Collection. Document Review Data Were Analyzed Using Content Analysis, And Interview Data Were Analyzed Using Framework Analysis. The National Pku Screening (Naps) Program Was A Decision Made At The Genetics Department Of Ministry Of Health And Medical Education (Mohme) In Iran. Many Internal And External Stakeholders Were Involved In It And Valid Evidence Was Used To Formulate The Policies. Despite Some Opposition And Insufficient Support, The Program Was Implemented Due To The Continuous Persistence Of Parents, Interested Executives, Formulated Valid Content And A Top-Down Approach. The Main Barriers Included Rapid Substitution Of Managers, Shortage Of Phe-Free Milk, Little Awareness Of Patients' Families, Social Stigma, And Inadequate Co-Operation Of Some Hospital Administrators. The Policy Triangle Framework Contributed To Explaining The Different Components Of The Pku Screening Program. A Successful Pku Screening Program Requires More Stability Of Senior Managers In Mohme, Enough Human Resources And Phe-Free Milk, Educating Patients' Families, And Commitment Of Hospitals Administrators. Meanwhile, All The Stakeholders Need To Be Involved In The Program Effectively.|"[('Phenylketonuria', 'no label'), ('Pku) Screening', 'no label'), ('Public Health Measure', 'no label'), ('Diagnose', 'no label'), ('Treat', 'no label'), ('Patients', 'no label'), ('Pku To Prevent Severe', 'no label'), ('Neurological Disorders', 'no label'), ('Present Study', 'no label'), ('Policies', 'no label'), ('National Pku Screening', 'no label'), ('Iran', 'no label'), ('Pku Screening Program', 'no label'), ('Policies', 'no label'), ('Analyzed', 'no label'), ('Compliance', 'no label'), ('Policy Triangle Model', 'no label'), ('Document Review', 'no label'), ('Semi-Structured Interviews', 'no label'), ('Data Collection', 'no label'), ('Document Review', 'no label'), ('Data', 'no label'), ('Analyzed', 'no label'), ('Content Analysis', 'no label'), ('Interview Data', 'no label'), ('Analyzed', 'no label'), ('Framework Analysis', 'no label'), ('National Pku Screening', 'no label'), ('Was A Decision', 'no label'), ('Genetics Department', 'no label'), ('Mohme', 'no label'), ('Iran', 'no label'), ('Internal And External Stakeholders', 'no label'), ('Valid', 'no label'), ('Evidence', 'no label'), ('Policies', 'no label'), ('Opposition', 'no label'), ('Insufficient', 'no label'), ('Support', 'no label'), ('Program', 'no label'), ('Continuous', 'no label'), ('Persistence', 'no label'), ('Parents', 'no label'), ('Interested Executives', 'no label'), ('Valid', 'no label'), ('Content', 'no label'), ('Top-Down Approach', 'no label'), ('Main Barriers', 'no label'), ('Substitution', 'no label'), ('Managers', 'no label'), ('Shortage', 'no label'), ('Phe-Free', 'no label'), ('Milk', 'no label'), ('Awareness', 'no label'), (""Patients'"", 'no label'), ('Families', 'no label'), ('Social Stigma', 'no label'), ('Inadequate', 'no label'), ('Co-Operation', 'no label'), ('Hospital Administrators', 'no label'), ('Policy Triangle Framework', 'no label'), ('Components', 'no label'), ('Pku Screening Program', 'no label'), ('Pku Screening Program', 'no label'), ('Requires', 'no label'), ('Stability', 'no label'), ('Senior Managers', 'no label'), ('Mohme', 'no label'), ('Human Resources And Phe-Free Milk', 'no label'), ('Educating', 'no label'), ('Patients', 'no label'), ('Families', 'no label'), ('Commitment', 'no label'), ('Hospitals Administrators', 'no label'), ('Stakeholders', 'no label'), ('Need', 'no label'), ('Program', 'no label')]"|[('Human', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Neurological Disorders', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Phe-Free Milk', 'no label'), ('Patients', 'no label'), ('Human', 'no label'), ('Phe-Free Milk', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~35064867|In Our Previous Study, A 3D Structure Of Lnaa66 Model Protein Containing 4-5 Α-Helices, High Large Neutral Amino Acids (Lnaa) And Lacking Phenylalanine Was Designed, Refined, Expressed In Pichia Pastoris And Confirmed By Western Blotting. Here The Study Is Focused On The Characterization Of The Expressed And Purified Recombinant Lnaa66 Protein. The Results Revealed That The Expressed Protein Had 68.59% Of Lnaa Enrichment, Containing 41.6% Of Α-Helix, 50.4% Turns And 8% Β-Sheet, Which Are As Per The In Silico Designed Protein. The Lc-Esi-Ms/Ms Results Confirmed The Recombinant Protein By Identifying The First 30 N-Terminal Amino Acids With A Sequence Coverage Of ~ 29%. The Protein Was Digested Entirely Into Smaller Molecular Weight Fragments When Treated With Digestive Enzymes Mimicking The Human Gi Tract Digestion, Which Indicated Complete Digestibility Of The Protein. These Results Suggest That The Protein Can Be Utilized For The Envisioned Application Of Dietary Treatment For Phenylketonuria.|[('Study', 'no label'), ('3D', 'no label'), ('Structure', 'no label'), ('Lnaa66 Model', 'no label'), ('Protein Containing 4-5', 'no label'), ('Neutral Amino Acids', 'no label'), ('Lnaa', 'no label'), ('Lacking', 'no label'), ('Phenylalanine', 'no label'), ('Refined', 'no label'), ('Expressed', 'no label'), ('Pichia Pastoris', 'no label'), ('Confirmed', 'no label'), ('Western Blotting', 'no label'), ('Study', 'no label'), ('Focused', 'no label'), ('Characterization', 'no label'), ('Expressed', 'no label'), ('Purified', 'no label'), ('Protein', 'no label'), ('Results', 'no label'), ('Revealed', 'no label'), ('Expressed Protein', 'no label'), ('Lnaa Enrichment', 'no label'), ('Containing', 'no label'), ('Α-Helix', 'no label'), ('Turns', 'no label'), ('In Silico', 'no label'), ('Protein', 'no label'), ('Lc-Esi-Ms/Ms Results', 'no label'), ('Confirmed', 'no label'), ('Recombinant Protein', 'no label'), ('N-Terminal Amino Acids', 'no label'), ('Sequence', 'no label'), ('Coverage', 'no label'), ('Protein Was Digested', 'no label'), ('Molecular Weight Fragments', 'no label'), ('Treated With', 'no label'), ('Digestive Enzymes', 'no label'), ('Human Gi Tract Digestion', 'no label'), ('Complete', 'no label'), ('Digestibility', 'no label'), ('Protein', 'no label'), ('Results', 'no label'), ('Suggest', 'no label'), ('Protein', 'no label'), ('Dietary Treatment', 'no label'), ('Phenylketonuria', 'no label')]|[('Protein', 'no label'), ('Amino Acids', 'no label'), ('Phenylalanine', 'no label'), ('Pichia Pastoris', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Amino Acids', 'no label'), ('Sequence', 'no label'), ('Protein', 'no label'), ('Molecular', 'no label'), ('Fragments', 'no label'), ('Enzymes', 'no label'), ('Human', 'no label'), ('Protein', 'no label'), ('Protein', 'no label')]|[('Lnaa66 Model Protein Containing 4-5', 'no label'), ('Per', 'no label')]|[('Amino Acids', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acids', 'no label'), ('Phenylketonuria', 'no label')]|[('Amino Acids', 'no label'), ('Phenylalanine', 'no label'), ('Pichia Pastoris', 'no label'), ('Lnaa', 'no label'), ('Lc-Esi-Ms/Ms', 'no label'), ('Amino Acids', 'no label'), ('Human Gi', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~30165883|Even Though Early Dietary Management Of Phenylketonuria (Pku) Successfully Prevents Severe Neurological Impairments, Deficits In Cognitive Functioning Are Still Observed. These Deficits Are Believed To Be The Result Of Elevated Levels Of Phenylalanine Throughout Life. Research On Cognitive Functioning In Adults With Pku (Awpku) Often Focuses On Domains Shown To Be Compromised In Children With Pku, Such As Attention And Executive Functions, Whereas Other Cognitive Domains Have Received Less Attention. This Systematic Review Aimed To Provide An Overview Of Cognitive Functioning Across Domains Examined In Early Treated (Et) Awpku. A Systematic Search Was Performed In Ovid Medline(R), Psycinfo, Web Of Science, Cochrane, Scopus, Embase, Sciencedirect, And Pubmed For Observational Studies On Cognitive Performance In Et Awpku. Twenty-Two Peer-Reviewed Publications, Reporting On Outcomes From 16 Studies Were Reviewed. Collectively, The Results Most Consistently Showed Deficits In Vigilance, Working Memory And Motor Skills. Deficits In Other Cognitive Domains Were Less Consistently Observed Or Were Understudied. Furthermore, Despite Reports Of Several Associations Between Cognitive Performance And Phenylalanine (Phe) Levels Throughout Life The Relationship Remains Unclear. Inconsistencies In Findings Across Studies Could Be Explained By The Highly Heterogeneous Nature Of Study Samples, Resulting In Large Inter- And Intra-Variability In Phe Levels, As Well As The Use Of A Variety Of Tests Across Cognitive Domains, Which Differ In Sensitivity. The Long-Term Cognitive Outcomes Of Early And Continuous Management Of Pku Remain Unclear. To Better Understand The Development Of Cognitive Deficits In Et Awpku, Future Research Would Benefit From 1) (Inter)National Multicentre-Studies; 2) More Homogeneous Study Samples; 3) The Inclusion Of Other Nutritional Measures That Might Influence Cognitive Functioning (E.G. Phe Fluctuations, Phe:Tyrosine Ratio And Micronutrients Such As Vitamin B12); And 4) Careful Selection Of Appropriate Cognitive Tests.|[('Early', 'no label'), ('Dietary Management', 'no label'), ('Phenylketonuria', 'no label'), ('Prevents', 'no label'), ('Severe', 'no label'), ('Neurological Impairments', 'no label'), ('Deficits', 'no label'), ('Cognitive Functioning', 'no label'), ('Observed', 'no label'), ('Deficits', 'no label'), ('Believed', 'no label'), ('Elevated', 'no label'), ('Levels', 'no label'), ('Phenylalanine', 'no label'), ('Life', 'no label'), ('Research', 'no label'), ('Adults', 'no label'), ('Pku (Awpku)', 'no label'), ('Focuses', 'no label'), ('Domains', 'no label'), ('Compromised', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Attention', 'no label'), ('Executive Functions', 'no label'), ('Cognitive Domains', 'no label'), ('Attention', 'no label'), ('Systematic Review', 'no label'), ('Cognitive Functioning', 'no label'), ('Domains', 'no label'), ('Examined', 'no label'), ('Early', 'no label'), ('Treated (Et) Awpku', 'no label'), ('Systematic', 'no label'), ('Search', 'no label'), ('Performed', 'no label'), ('Psycinfo', 'no label'), ('Web Of Science', 'no label'), ('Cochrane', 'no label'), ('Scopus', 'no label'), ('Embase', 'no label'), ('Sciencedirect', 'no label'), ('Pubmed', 'no label'), ('Observational Studies', 'no label'), ('Cognitive Performance', 'no label'), ('Et Awpku', 'no label'), ('Reporting', 'no label'), ('Outcomes', 'no label'), ('Studies', 'no label'), ('Reviewed', 'no label'), ('Consistently', 'no label'), ('Deficits', 'no label'), ('Vigilance', 'no label'), ('Working Memory', 'no label'), ('Motor Skills', 'no label'), ('Deficits', 'no label'), ('Cognitive Domains', 'no label'), ('Observed', 'no label'), ('Understudied', 'no label'), ('Reports', 'no label'), ('Associations', 'no label'), ('Cognitive Performance', 'no label'), ('Phenylalanine (Phe) Levels', 'no label'), ('Life', 'no label'), ('Relationship Remains', 'no label'), ('Inconsistencies', 'no label'), ('Findings', 'no label'), ('Studies', 'no label'), ('Heterogeneous Nature', 'no label'), ('Study Samples', 'no label'), ('Inter-', 'no label'), ('Intra-Variability', 'no label'), ('Phe Levels', 'no label'), ('Tests', 'no label'), ('Cognitive Domains', 'no label'), ('Differ', 'no label'), ('Sensitivity', 'no label'), ('Long-Term Cognitive Outcomes', 'no label'), ('Early', 'no label'), ('Continuous Management', 'no label'), ('Pku Remain Unclear', 'no label'), ('Understand', 'no label'), ('Development', 'no label'), ('Cognitive Deficits', 'no label'), ('Et Awpku', 'no label'), ('Future', 'no label'), ('Research Would Benefit', 'no label'), ('(Inter)National Multicentre-Studies', 'no label'), ('Homogeneous Study Samples', 'no label'), ('Nutritional Measures', 'no label'), ('Influence', 'no label'), ('Cognitive Functioning', 'no label'), ('E.G. Phe Fluctuations', 'no label'), ('Phe', 'no label'), ('Ratio', 'no label'), ('Micronutrients', 'no label'), ('Vitamin B12', 'no label'), ('Selection', 'no label'), ('Appropriate', 'no label'), ('Cognitive Tests', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Micronutrients', 'no label'), ('Vitamin B12', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Neurological Impairments', 'no label'), ('Deficits In Cognitive Functioning', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Cognitive Deficits', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Vitamin B12', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Children', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Et', 'no label'), ('E.G.', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Vitamin', 'no label'), ('B12', 'no label')]
phenylketonuria|pubmed~34738361|Phenylketonuria (Pku) Is An Inherited Disorder Of Amino Acid Metabolism, The Treatment Of Which Often Requires A Special Diet To Prevent Adverse Neuropsychiatric Outcomes. In The Covid-19 Pandemic, Which Has Had A Substantial Effect On The Whole World Since The Beginning Of 2020, Pku Patients Represent A Vulnerable Population Because They May Be Dependent On Special Nutritional Products, Have Limited Access To Routine Care And Display Increased Levels Of Anxiety. For This Reason, An Online Questionnaire Assessing The Anxiety Levels And Various Personal Opinions And Practices Regarding The Pandemic Was Sent To The Pku Patients Managed At Our Clinic, Who Were 12 Years Of Age Or Older. Ninety-Eight Patients Responded To The Questionnaire. Median Age Of The Participants Was 19 Years. Most Patients Were Compliant With The Hygiene And Social Distancing Recommendations Regarding The Spread Of Covid-19. Of The Patients, 61.2% Felt More Anxious Since The Pandemic. The Most Common Concern Was The Possibility Of Not Being Able To Obtain Special Nutritional Products (58.2%). Anxiety Level Was Significantly Higher In Females. These Data Suggest That Food Security Is An Important Issue Of Concern In Pku Patients. In Line With The Changing World After The Pandemic, Different Strategies Should Be Considered In The Management Of Patients With Inborn Errors Of Metabolism, Including Pku.|[('Phenylketonuria', 'no label'), ('Inherited Disorder', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Treatment', 'no label'), ('Requires', 'no label'), ('Special Diet', 'no label'), ('Prevent Adverse', 'no label'), ('Neuropsychiatric Outcomes', 'no label'), ('Covid-19', 'no label'), ('Pandemic', 'no label'), ('Substantial Effect', 'no label'), ('Whole World', 'no label'), ('Pku Patients', 'no label'), ('Represent', 'no label'), ('Vulnerable Population', 'no label'), ('Dependent', 'no label'), ('Special Nutritional Products', 'no label'), ('Limited Access', 'no label'), ('Routine Care', 'no label'), ('Display', 'no label'), ('Increased', 'no label'), ('Levels', 'no label'), ('Anxiety', 'no label'), ('Reason', 'no label'), ('Online Questionnaire', 'no label'), ('Assessing', 'no label'), ('Anxiety Levels', 'no label'), ('Personal Opinions', 'no label'), ('Practices', 'no label'), ('Pandemic Was Sent', 'no label'), ('Pku Patients', 'no label'), ('Clinic', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Patients', 'no label'), ('Questionnaire', 'no label'), ('Median Age', 'no label'), ('Participants', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Compliant', 'no label'), ('Hygiene', 'no label'), ('Social Distancing', 'no label'), ('Recommendations', 'no label'), ('Spread', 'no label'), ('Covid-19', 'no label'), ('Patients', 'no label'), ('Felt', 'no label'), ('Anxious', 'no label'), ('Pandemic', 'no label'), ('Common', 'no label'), ('Concern', 'no label'), ('Possibility', 'no label'), ('Not Being', 'no label'), ('Special', 'no label'), ('Nutritional Products', 'no label'), ('Anxiety Level', 'no label'), ('Females', 'no label'), ('Data Suggest', 'no label'), ('Food Security', 'no label'), ('Concern', 'no label'), ('Patients', 'no label'), ('Changing World', 'no label'), ('Pandemic', 'no label'), ('Strategies', 'no label'), ('Management', 'no label'), ('Patients', 'no label'), ('Inborn Errors', 'no label'), ('Metabolism', 'no label')]|[('Amino Acid', 'no label'), ('Food', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Inherited Disorder', 'no label'), ('Amino Acid', 'no label'), ('Anxiety', 'no label'), ('Anxiety', 'no label'), ('Anxiety', 'no label'), ('Inborn Errors', 'no label')]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Covid-19', 'no label'), ('Patients', 'no label'), ('Routine Care', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Line', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~29973227|Deficiency Of Phenylalanine Hydroxylase Causes Phenylketonuria (Pku) With Elevated Phenylalanine (Phe) Levels And Associated Neuropsychiatric And Neurocognitive Symptoms. Pegvaliase (Pegylated Phenylalanine Ammonia Lyase) Is An Investigational Agent To Lower Plasma Phe In Adults With Pku. This Study Aimed To Characterize The Long-Term Efficacy, Safety, And Immunogenicity Of Pegvaliase In Adults With Pku. Pal-003 Is An Ongoing, Open-Label, Long-Term Extension Study Of The Pegvaliase Dose-Finding Parent Phase 2 Studies. Participants Continued The Dose Of Pegvaliase From One Of Three Parent Studies, With Dose Adjustments To Achieve A Plasma Phe Concentration Between 60 And 600 Μmol/L. Mean (Standard Deviation [Sd]) Plasma Phe At Treatment-Naïve Baseline For 80 Participants In The Parent Studies Was 1302.4 (351.5) Μmol/L. In The 68 Participants Who Entered The Extension Study, Plasma Phe Decreased 58.9 (39)% From Baseline, To 541.6 (515.5) Μmol/L At Week 48 Of Treatment. Plasma Phe Concentrations ≤120 Μmol/L, ≤360 Μmol/L, And ≤ 600 Μmol/L Were Achieved By 78.7, 80.0, And 82.5% Of Participants, Respectively. Mean (Sd) Protein Intake At Baseline Was 69.4 (40.4) G/Day (Similar To The Recommended Intake For The Unaffected Population) And Remained Stable Throughout The Study. All Participants Experienced Adverse Events (Aes), Which Were Limited To Mild Or Moderate Severity In Most (88.8%); The Most Common Aes Were Injection-Site Reaction (72.5%), Injection-Site Erythema (67.5%), Headache (67.5%), And Arthralgia (65.0%). The Ae Rate Decreased From 58.3 Events Per Person-Year In The Parent Studies To 18.6 Events Per Person-Year In The Extension Study. Pegvaliase Treatment In Adults With Pku Produced Meaningful And Persistent Reductions In Mean Plasma Phe Concentration With A Manageable Safety Profile For Most Subjects That Continued With Long-Term Treatment. Clinicaltrials.Gov , Nct00924703. Registered June 18, 2009, Https://Clinicaltrials.Gov/Ct2/Show/Nct00924703.|[('Deficiency', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylketonuria', 'no label'), ('Elevated', 'no label'), ('Levels', 'no label'), ('Pegvaliase', 'no label'), ('Pegylated', 'no label'), ('Phenylalanine Ammonia', 'no label'), ('Lyase', 'no label'), ('Investigational Agent', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Adults', 'no label'), ('Study', 'no label'), ('Characterize', 'no label'), ('Long-Term Efficacy', 'no label'), ('Safety', 'no label'), ('Immunogenicity', 'no label'), ('Pegvaliase', 'no label'), ('Adults', 'no label'), ('Pal-003', 'no label'), ('Ongoing', 'no label'), ('Open-Label', 'no label'), ('Long-Term Extension Study', 'no label'), ('Pegvaliase Dose-Finding Parent Phase 2 Studies', 'no label'), ('Participants', 'no label'), ('Dose', 'no label'), ('Pegvaliase', 'no label'), ('Parent Studies', 'no label'), ('Dose', 'no label'), ('Adjustments', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Concentration', 'no label'), ('Mean', 'no label'), ('Standard Deviation', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Treatment-Naïve', 'no label'), ('Baseline', 'no label'), ('Participants', 'no label'), ('Parent Studies', 'no label'), ('Participants', 'no label'), ('Entered', 'no label'), ('Extension Study', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Decreased', 'no label'), ('Baseline', 'no label'), ('Week', 'no label'), ('Treatment', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Participants', 'no label'), ('Baseline', 'no label'), ('G/Day', 'no label'), ('Recommended Intake', 'no label'), ('Unaffected Population', 'no label'), ('Remained Stable', 'no label'), ('Study', 'no label'), ('Participants', 'no label'), ('Experienced', 'no label'), ('Adverse Events', 'no label'), ('Aes', 'no label'), ('Mild', 'no label'), ('Moderate', 'no label'), ('Severity', 'no label'), ('Common', 'no label'), ('Aes', 'no label'), ('Injection-Site Reaction', 'no label'), ('Injection-Site Erythema', 'no label'), ('Headache', 'no label'), ('Arthralgia', 'no label'), ('Ae Rate', 'no label'), ('Decreased', 'no label'), ('Events', 'no label'), ('Person-Year', 'no label'), ('Parent Studies', 'no label'), ('Events', 'no label'), ('Person-Year', 'no label'), ('Extension Study', 'no label'), ('Pegvaliase Treatment', 'no label'), ('Adults', 'no label'), ('Pku Produced Meaningful', 'no label'), ('Persistent', 'no label'), ('Reductions', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Concentration', 'no label'), ('Manageable Safety Profile', 'no label'), ('Subjects', 'no label'), ('Long-Term', 'no label'), ('Treatment', 'no label'), ('Clinicaltrials', 'no label'), ('Https://Clinicaltrials', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Ammonia', 'no label'), ('Phe', 'no label'), ('Pal-003 Is', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Protein', 'no label'), ('Aes', 'no label'), ('Aes', 'no label'), ('Phe', 'no label')]|[('Aes', 'no label'), ('Per', 'no label'), ('Per', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Pegylated Phenylalanine Ammonia', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('≤', 'no label'), ('Erythema', 'no label'), ('Headache', 'no label'), ('Arthralgia', 'no label'), ('Phe', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Neuropsychiatric', 'no label'), ('Pegylated Phenylalanine', 'no label'), ('Pegvaliase', 'no label'), ('Pegvaliase', 'no label'), ('Pegvaliase', 'no label'), ('Plasma Phe', 'no label'), ('Sd]', 'no label'), ('Plasma Phe', 'no label'), ('Plasma Phe', 'no label'), ('Aes', 'no label'), ('Aes', 'no label'), ('Arthralgia', 'no label'), ('Plasma Phe', 'no label')]
phenylketonuria|pubmed~34711827|In Phenylketonuria (Pku) Patients, A Genetic Defect In The Enzyme Phenylalanine Hydroxylase (Pah) Leads To Elevated Systemic Phenylalanine (Phe), Which Can Result In Severe Neurological Impairment. As A Treatment For Pku, Escherichia Coli Nissle (Ecn) Strain Synb1618 Was Developed Under Synlogic'S Synthetic Biotic™ Platform To Degrade Phe From Within The Gastrointestinal (Gi) Tract. This Clinical-Stage Engineered Strain Expresses The Phe-Metabolizing Enzyme Phenylalanine Ammonia Lyase (Pal), Catalyzing The Deamination Of Phe To The Non-Toxic Product Trans-Cinnamate (Tca). In The Present Work, We Generate A More Potent Ecn-Based Pku Strain Through Optimization Of Whole Cell Pal Activity, Using Biosensor-Based High-Throughput Screening Of Mutant Pal Libraries. A Lead Enzyme Candidate From This Screen Is Used In The Construction Of Synb1934, A Chromosomally Integrated Strain Containing The Additional Phe-Metabolizing And Biosafety Features Found In Synb1618. Head-To-Head, Synb1934 Demonstrates An Approximate Two-Fold Increase In In Vivo Pal Activity Compared To Synb1618.|"[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Genetic Defect', 'no label'), ('Enzyme Phenylalanine Hydroxylase', 'no label'), ('Elevated', 'no label'), ('Systemic Phenylalanine', 'no label'), ('Phe', 'no label'), ('Severe', 'no label'), ('Neurological Impairment', 'no label'), ('Treatment', 'no label'), ('Pku', 'no label'), ('Escherichia Coli Nissle', 'no label'), (""Synlogic'S"", 'no label'), ('Synthetic Biotic™', 'no label'), ('Phe', 'no label'), ('Gastrointestinal (Gi) Tract', 'no label'), ('Clinical-Stage Engineered Strain Expresses', 'no label'), ('Phe-Metabolizing', 'no label'), ('Enzyme Phenylalanine Ammonia Lyase', 'no label'), ('Catalyzing', 'no label'), ('Deamination', 'no label'), ('Phe', 'no label'), ('Non-Toxic Product Trans-Cinnamate', 'no label'), ('Tca', 'no label'), ('Work', 'no label'), ('Ecn-Based', 'no label'), ('Pku Strain', 'no label'), ('Optimization', 'no label'), ('Whole Cell', 'no label'), ('Pal Activity', 'no label'), ('Biosensor-Based High-Throughput Screening', 'no label'), ('Mutant Pal Libraries', 'no label'), ('Lead Enzyme Candidate', 'no label'), ('Screen', 'no label'), ('Construction', 'no label'), ('Synb1934', 'no label'), ('Chromosomally Integrated Strain', 'no label'), ('Phe-Metabolizing', 'no label'), ('Features', 'no label'), ('Synb1618', 'no label'), ('Synb1934', 'no label'), ('Demonstrates', 'no label'), ('Approximate Two-Fold', 'no label'), ('Increase', 'no label'), ('In Vivo', 'no label'), ('Pal Activity', 'no label'), ('Synb1618', 'no label')]"|[('Genetic', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Escherichia Coli Nissle', 'no label'), ('Phe', 'no label'), ('Enzyme', 'no label'), ('Ammonia', 'no label'), ('Phe', 'no label'), ('Cell', 'no label'), ('Mutant', 'no label'), ('Lead Enzyme', 'no label')]|[('Enzyme Phenylalanine Hydroxylase', 'no label'), ('Synb1618', 'no label'), ('Synb1934', 'no label'), ('Synb1934', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Neurological Impairment', 'no label'), ('Phenylalanine Ammonia', 'no label'), ('Phe', 'no label'), ('Non-Toxic', 'no label'), ('Trans-Cinnamate', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Pah', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Escherichia Coli Nissle', 'no label'), ('Gastrointestinal', 'no label'), ('Phe', 'no label'), ('Whole Cell', 'no label'), ('Synb1618', 'no label'), ('Synb1618', 'no label')]
phenylketonuria|pubmed~26666653|Mutations In Phenylalanine Hydroxylase (Pah) Gene Cause Phenylketonuria. Sapropterin (Bh4), The Enzyme Cofactor, Is An Important Therapeutical Strategy In Phenylketonuria. However, Pah Is A Highly Polymorphic Gene And It Is Difficult To Identify Bh4-Responsive Genotypes. We Seek Here To Improve Prediction Of Bh4-Responsiveness Through Comparison Of Genotypes, Bh4-Loading Test, Predictions Of Responsiveness According To The Literature And Types And Locations Of Mutations. A Total Of 364 French Patients Among Which, 9 % Had Mild Hyperphenylalaninemia, 17.7 % Mild Phenylketonuria And 73.1 % Classical Phenylketonuria, Benefited From A 24-Hour Bh4-Loading Test And Had The Pah Gene Sequenced And Analyzed By Multiplex Ligation Probe Amplification. Overall, 31.6 % Of Patients Were Bh4-Responsive. The Number Of Different Mutations Found Was 127, Including 26 New Mutations. The Mutations C.434A > T, C.500A > T, C.529G > C, C.1045 T > G And C.1196 T > C Were Newly Classified As Being Bh4-Responsive. We Identified 261 Genotypes, Among Which 46 Were Newly Recognized As Being Bh4-Responsive. Even Though Patients Carry 2 Responsive Alleles, Bh4-Responsiveness Cannot Be Predicted With Certainty Unless They Present Mild Hyperphenylalaninemia. Bh4-Responsiveness Cannot Be Predicted In Patients Carrying One Responsive Mutation Only. In General, The Milder The Phenotype Is, The Stronger The Bh4-Response Is. Almost Exclusively Missense Mutations, Particularly In Exons 12, 11 And 8, Are Associated With Bh4-Responsiveness And Any Other Type Of Mutation Predicts A Negative Response. This Study Is The First Of Its Kind, In A French Population, To Identify The Phenotype Associated With Several Combinations Of Pah Mutations. As Others, It Highlights The Necessity Of Performing Simultaneously Bh4 Loading Test And Molecular Analysis In Monitoring Phenylketonuria Patients.|[('Mutations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Gene Cause', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin', 'no label'), ('Bh4', 'no label'), ('Enzyme Cofactor', 'no label'), ('Therapeutical Strategy', 'no label'), ('Phenylketonuria', 'no label'), ('Difficult', 'no label'), ('Genotypes', 'no label'), ('Prediction', 'no label'), ('Bh4-Responsiveness', 'no label'), ('Comparison', 'no label'), ('Genotypes', 'no label'), ('Bh4-Loading Test', 'no label'), ('Predictions', 'no label'), ('Responsiveness', 'no label'), ('Literature', 'no label'), ('Types', 'no label'), ('Locations', 'no label'), ('Mutations', 'no label'), ('French', 'no label'), ('Patients', 'no label'), ('Mild Hyperphenylalaninemia', 'no label'), ('Mild Phenylketonuria', 'no label'), ('Classical Phenylketonuria', 'no label'), ('Benefited', 'no label'), ('24-Hour Bh4-Loading Test', 'no label'), ('Pah Gene', 'no label'), ('Analyzed', 'no label'), ('Multiplex Ligation Probe Amplification', 'no label'), ('Patients', 'no label'), ('Mutations', 'no label'), ('New Mutations', 'no label'), ('Mutations', 'no label'), ('C.434A\u2009>\u2009T', 'no label'), ('C.500A\u2009>\u2009T', 'no label'), ('C.529G\u2009>\u2009C', 'no label'), ('C.1045\xa0T\u2009>\u2009G', 'no label'), ('C.1196\xa0T\u2009>\u2009C', 'no label'), ('Being', 'no label'), ('Genotypes', 'no label'), ('Being', 'no label'), ('Patients', 'no label'), ('Carry 2 Responsive Alleles', 'no label'), ('Bh4-Responsiveness', 'no label'), ('Predicted', 'no label'), ('Certainty', 'no label'), ('Mild', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Bh4-Responsiveness', 'no label'), ('Predicted', 'no label'), ('Patients', 'no label'), ('Carrying', 'no label'), ('Responsive Mutation', 'no label'), ('General', 'no label'), ('Milder', 'no label'), ('Phenotype', 'no label'), ('Stronger', 'no label'), ('Missense Mutations', 'no label'), ('Exons', 'no label'), ('Associated With', 'no label'), ('Bh4-Responsiveness', 'no label'), ('Mutation', 'no label'), ('Predicts', 'no label'), ('Negative', 'no label'), ('Response', 'no label'), ('Study', 'no label'), ('Kind', 'no label'), ('French Population', 'no label'), ('Phenotype', 'no label'), ('Associated With', 'no label'), ('Combinations', 'no label'), ('Pah Mutations', 'no label'), ('Necessity', 'no label'), ('Simultaneously', 'no label'), ('Bh4 Loading Test', 'no label'), ('Molecular Analysis', 'no label'), ('Monitoring', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label')]|[('Mutations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Gene', 'no label'), ('Enzyme', 'no label'), ('Polymorphic Gene', 'no label'), ('Genotypes', 'no label'), ('Genotypes', 'no label'), ('Mutations', 'no label'), ('Gene', 'no label'), ('Probe', 'no label'), ('Mutations', 'no label'), ('Mutations', 'no label'), ('Mutations', 'no label'), ('Genotypes', 'no label'), ('Mutation', 'no label'), ('Mutations', 'no label'), ('Exons', 'no label'), ('Mutation', 'no label'), ('Mutations', 'no label'), ('Molecular', 'no label')]|[('Pah', 'no label'), ('Polymorphic Gene', 'no label'), ('Pah Gene', 'no label'), ('Exons 12, 11 And 8, Are Associated', 'no label'), ('Pah Mutations', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phenylketonuria', 'no label'), ('Classical Phenylketonuria', 'no label'), ('C.1045\xa0T\u2009', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Sapropterin', 'no label'), ('Phenylketonuria', 'no label'), ('Pah Is', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Pah Gene', 'no label'), ('Patients', 'no label'), ('C.1045\xa0T\u2009', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Pah', 'no label'), ('Bh4', 'no label'), ('Phenylketonuria Patients', 'no label')]
phenylketonuria|pubmed~31615158|The Nutritional And Metabolic Characteristics Of Adult Phenylketonuria (Pku) Patients In The Uk With Varying Dietary Adherence Is Unknown. In Other Countries, Nutritional And Metabolic Abnormalities Have Been Reported In Nonadherent Patients Compared To Adherent Counterparts. A Pooled Analysis Of Primary Baseline Data From Two Uk Multi-Centre Studies Was Therefore Performed To Establish Whether This Is True From A Uk Perspective. Adult Pku Patients Who Had Provided 3-Day Food Records And Amino Acid Blood Samples Were Included And Grouped According To Dietary Adherence (Adherent; <I>N</I> = 16 Vs. Nonadherent; <I>N</I> = 14). Nonadherent Patients Consumed Greater Amounts Of Natural Protein Compared To Adherent Patients (61.6 ± 30.7 Vs. 18.3 ± 7.7 G/Day; <I>Q</I> <I><</I> 0.001). In Contrast, The Contribution Of Protein Substitutes To Total Protein Intake Was Lower In Nonadherent Compared To Adherent Patients (3.9 ± 9.2 G/Day Vs. 58.6 ± 10.2 G/Day; <I>Q</I> < 0.001). Intakes Of Iron, Zinc, Vitamin D<Sub>3</Sub>, Magnesium, Calcium, Selenium, Iodine, Vitamin C, Vitamin A And Copper Were Significantly Lower In Nonadherent Compared To Adherent Patients And Were Below Uk Reference Nutrient Intakes. Similarly, Intakes Of Thiamin, Riboflavin, Niacin, Vitamin B<Sub>6</Sub> And Phosphorus Were Significantly Lower In Nonadherent Compared To Adherent Patients But Met The Uk Reference Nutrient Intakes. Phenylalanine Concentrations In Nonadherent Patients Were Significantly Higher Than Adherent Patients (861 ± 348 Vs. 464 ± 196 Μmol/L; <I>Q</I><I>=</I>0.040) And Fell Outside Of European Treatment Target Ranges. This Study Shows The Nutritional And Metabolic Consequences Of Deviation From Phenylalanine Restriction And Intake Of Pku Protein Substitutes In Nonadherent Adult Pku Patients. Collectively, These Data Further Underlie The Importance Of Life-Long Adherence To The Pku Diet.|[('Nutritional', 'no label'), ('Metabolic', 'no label'), ('Characteristics', 'no label'), ('Adult Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Dietary Adherence', 'no label'), ('Countries', 'no label'), ('Nutritional', 'no label'), ('Metabolic Abnormalities', 'no label'), ('Nonadherent', 'no label'), ('Patients', 'no label'), ('Adherent', 'no label'), ('Counterparts', 'no label'), ('Pooled Analysis', 'no label'), ('Primary Baseline', 'no label'), ('Data', 'no label'), ('Uk Multi-Centre Studies', 'no label'), ('Performed', 'no label'), ('Establish', 'no label'), ('Uk Perspective', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Food Records', 'no label'), ('Amino Acid', 'no label'), ('Blood Samples', 'no label'), ('Grouped', 'no label'), ('Dietary Adherence', 'no label'), ('Adherent', 'no label'), ('Nonadherent', 'no label'), ('Nonadherent', 'no label'), ('Patients', 'no label'), ('Consumed', 'no label'), ('Greater', 'no label'), ('Amounts', 'no label'), ('Natural Protein', 'no label'), ('Compared', 'no label'), ('Adherent', 'no label'), ('Patients', 'no label'), ('G/Day', 'no label'), ('Contrast', 'no label'), ('Contribution', 'no label'), ('Protein Substitutes', 'no label'), ('Nonadherent', 'no label'), ('Adherent', 'no label'), ('Patients', 'no label'), ('G/Day Vs', 'no label'), ('G/Day', 'no label'), ('Iron', 'no label'), ('Zinc', 'no label'), ('Vitamin D', 'no label'), ('Sub>3</Sub>', 'no label'), ('Magnesium', 'no label'), ('Calcium', 'no label'), ('Selenium', 'no label'), ('Iodine', 'no label'), ('Vitamin C', 'no label'), ('Vitamin A', 'no label'), ('Copper', 'no label'), ('Nonadherent', 'no label'), ('Adherent', 'no label'), ('Patients', 'no label'), ('Uk Reference Nutrient Intakes', 'no label'), ('Intakes', 'no label'), ('Thiamin', 'no label'), ('Riboflavin', 'no label'), ('Niacin', 'no label'), ('Vitamin B<Sub>6</Sub> And', 'no label'), ('Phosphorus', 'no label'), ('Nonadherent', 'no label'), ('Adherent', 'no label'), ('Patients', 'no label'), ('Met', 'no label'), ('Uk Reference Nutrient Intakes', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Nonadherent', 'no label'), ('Patients', 'no label'), ('Than Adherent', 'no label'), ('Patients', 'no label'), ('Q</I><I>=</I>0.040', 'no label'), ('European', 'no label'), ('Treatment', 'no label'), ('Target Ranges', 'no label'), ('Study', 'no label'), ('Nutritional', 'no label'), ('Metabolic', 'no label'), ('Consequences Of Deviation', 'no label'), ('Phenylalanine Restriction', 'no label'), ('Intake', 'no label'), ('Pku Protein Substitutes', 'no label'), ('Patients', 'no label'), ('Data', 'no label'), ('Life-Long Adherence', 'no label'), ('Pku Diet', 'no label')]|[('Food', 'no label'), ('Amino Acid', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Iron', 'no label'), ('Zinc', 'no label'), ('Vitamin D', 'no label'), ('Magnesium', 'no label'), ('Calcium', 'no label'), ('Selenium', 'no label'), ('Iodine', 'no label'), ('Vitamin C', 'no label'), ('Vitamin A', 'no label'), ('Copper', 'no label'), ('Thiamin', 'no label'), ('Riboflavin', 'no label'), ('Niacin', 'no label'), ('Vitamin B', 'no label'), ('Phosphorus', 'no label'), ('Met', 'no label'), ('Phenylalanine', 'no label'), ('±', 'no label'), ('±', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label')]|[('Copper', 'no label')]|[('Adult Phenylketonuria', 'no label'), ('Nutritional And Metabolic Abnormalities', 'no label'), ('Amino Acid Blood Samples', 'no label'), ('Iron', 'no label'), ('Zinc', 'no label'), ('Vitamin D', 'no label'), ('Magnesium', 'no label'), ('Calcium', 'no label'), ('Selenium', 'no label'), ('Iodine', 'no label'), ('Vitamin C', 'no label'), ('Vitamin A', 'no label'), ('Copper', 'no label'), ('Thiamin', 'no label'), ('Riboflavin', 'no label'), ('Niacin', 'no label'), ('Vitamin B', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('A Uk', 'no label'), ('Patients', 'no label'), ('Amino Acid', 'no label'), ('Blood Samples', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Iron', 'no label'), ('Zinc', 'no label'), ('Vitamin D', 'no label'), ('Magnesium', 'no label'), ('Calcium', 'no label'), ('Selenium', 'no label'), ('Iodine', 'no label'), ('Vitamin C', 'no label'), ('Vitamin A', 'no label'), ('Copper', 'no label'), ('Patients', 'no label'), ('Below Uk', 'no label'), ('Thiamin', 'no label'), ('Riboflavin', 'no label'), ('Niacin', 'no label'), ('Vitamin B', 'no label'), ('Phosphorus', 'no label'), ('Patients', 'no label'), ('Met', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Pku Protein', 'no label')]
phenylketonuria|pubmed~31480383|Noncompliance Is Widespread In Adults With Pku And Is Associated With Adverse Metabolic, Nutritional And Cognitive Abnormalities. Returning To The Pku Diet Is Important For This At-Risk Population, Yet For Many This Is Challenging To Achieve. Strategies That Ease The Return To The Pku Diet, While Offering Nutritional And Cognitive Advantages, Are Needed. Twelve Pku Adults (33.7 ± 2.6 Years), Who Had Been Noncompliant For 4.5 Years (Range: 1 To 11 Years), Took 33 G Of A Low-Volume, Nutrient-Enriched, Protein Substitute Daily For 28 Days. Outcomes Of Eating Behaviour, Nutrient Intake And Mood Were Assessed At Entry (Baseline, Days 1-3) And After The Intervention Period (Days 29-31). At Baseline, Intakes Of Natural Protein And Estimated Phenylalanine Were High (66.4 G And 3318.5 Mg, Respectively) And Intakes Of Calcium, Magnesium, Iron, Zinc, Iodine And Vitamin D Were Below Country-Specific Recommendations. With Use Of The Experimental Protein Substitute, Natural Protein And Estimated Phenylalanine Intake Declined (<I>P</I> = 0.043 For Both). Fat And Saturated Fat Intakes Also Decreased (<I>P</I> = 0.019 And <I>P</I> = 0.041, Respectively), While Energy And Carbohydrate Intake Remained Unchanged. Micronutrient Intake Increased (<I>P</I> ≤ 0.05 For All Aforementioned) To Levels Well Within Reference Nutrient Intake Recommendations. Blood Vitamin B<Sub>12</Sub> And Vitamin D Increased By 19.8% And 10.4%, Respectively. Reductions In Anxiety And Confusion Were Also Observed During The Course Of The Study Yet Should Be Handled As Preliminary Data. This Study Demonstrates That Reintroducing A Low-Volume, Nutrient-Enriched Protein Substitute Delivers Favourable Nutritional And Possible Mood Benefits In Noncompliant Pku Patients, Yet Longer-Term Studies Are Needed To Further Confirm This. This Preliminary Knowledge Should Be Used In The Design Of New Strategies To Better Facilitate Patients' Return To The Pku Diet, With The Approach Described Here As A Foundation.|[('Noncompliance', 'no label'), ('Adults', 'no label'), ('Pku', 'no label'), ('Associated With', 'no label'), ('Adverse', 'no label'), ('Metabolic', 'no label'), ('Nutritional', 'no label'), ('Cognitive Abnormalities', 'no label'), ('Pku Diet', 'no label'), ('At-Risk Population', 'no label'), ('Strategies', 'no label'), ('Return To', 'no label'), ('Pku Diet', 'no label'), ('Nutritional', 'no label'), ('Cognitive Advantages', 'no label'), ('Pku Adults', 'no label'), ('Years', 'no label'), ('Years', 'no label'), ('Years', 'no label'), ('Took 33 G Of A Low-Volume', 'no label'), ('Protein Substitute', 'no label'), ('Daily', 'no label'), ('Days', 'no label'), ('Outcomes', 'no label'), ('Eating Behaviour', 'no label'), ('Nutrient Intake', 'no label'), ('Mood', 'no label'), ('Assessed', 'no label'), ('Entry', 'no label'), ('Baseline', 'no label'), ('Days', 'no label'), ('Intervention Period', 'no label'), ('Days', 'no label'), ('Baseline', 'no label'), ('Intakes Of Natural Protein', 'no label'), ('Estimated', 'no label'), ('Phenylalanine', 'no label'), ('High', 'no label'), ('Intakes', 'no label'), ('Calcium', 'no label'), ('Magnesium', 'no label'), ('Iron', 'no label'), ('Zinc', 'no label'), ('Iodine', 'no label'), ('Vitamin D', 'no label'), ('Experimental Protein Substitute', 'no label'), ('Natural Protein', 'no label'), ('Estimated', 'no label'), ('Phenylalanine Intake', 'no label'), ('Declined', 'no label'), ('<I>P</I>', 'no label'), ('Fat And Saturated Fat Intakes', 'no label'), ('Decreased', 'no label'), ('<I>P</I>', 'no label'), ('Energy', 'no label'), ('Carbohydrate Intake', 'no label'), ('Remained', 'no label'), ('Unchanged', 'no label'), ('Micronutrient Intake', 'no label'), ('Increased', 'no label'), ('<I>P</I>', 'no label'), ('Aforementioned', 'no label'), ('Levels', 'no label'), ('Reference', 'no label'), ('Nutrient', 'no label'), ('Intake', 'no label'), ('Recommendations', 'no label'), ('Blood Vitamin B<Sub>12</Sub> And Vitamin D', 'no label'), ('Increased', 'no label'), ('Reductions', 'no label'), ('Anxiety', 'no label'), ('Confusion', 'no label'), ('Course', 'no label'), ('Study', 'no label'), ('Handled', 'no label'), ('Preliminary', 'no label'), ('Data', 'no label'), ('Study', 'no label'), ('Demonstrates', 'no label'), ('Reintroducing A', 'no label'), ('Low-Volume', 'no label'), ('Nutrient-Enriched Protein', 'no label'), ('Delivers', 'no label'), ('Favourable', 'no label'), ('Nutritional', 'no label'), ('Mood Benefits', 'no label'), ('Patients', 'no label'), ('Longer-Term Studies', 'no label'), ('Confirm', 'no label'), ('Preliminary', 'no label'), ('Knowledge', 'no label'), ('Design', 'no label'), ('Strategies', 'no label'), ('Facilitate', 'no label'), ('Patients', 'no label'), ('Return To', 'no label'), ('Pku Diet', 'no label'), ('Foundation', 'no label')]|[('Protein', 'no label'), ('Nutrient', 'no label'), ('Protein', 'no label'), ('Phenylalanine', 'no label'), ('Calcium', 'no label'), ('Magnesium', 'no label'), ('Iron', 'no label'), ('Zinc', 'no label'), ('Iodine', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Phenylalanine', 'no label'), ('Carbohydrate', 'no label'), ('Protein', 'no label')]|[('Ease', 'no label'), ('Natural Protein', 'no label'), ('Natural Protein', 'no label')]|[('Nutritional And Cognitive Abnormalities', 'no label'), ('Nutritional And Cognitive Advantages', 'no label'), ('Phenylalanine', 'no label'), ('Mg', 'no label'), ('Calcium', 'no label'), ('Magnesium', 'no label'), ('Iron', 'no label'), ('Zinc', 'no label'), ('Vitamin D', 'no label'), ('Phenylalanine', 'no label'), ('≤', 'no label'), ('Vitamin B', 'no label'), ('Vitamin D', 'no label'), ('Anxiety', 'no label'), ('Confusion', 'no label')]|[('Days 1-3', 'no label'), ('Phenylalanine', 'no label'), ('Calcium', 'no label'), ('Magnesium', 'no label'), ('Iron', 'no label'), ('Zinc', 'no label'), ('Iodine', 'no label'), ('Vitamin D', 'no label'), ('Phenylalanine', 'no label'), ('Fat', 'no label'), ('Fat', 'no label'), ('Carbohydrate', 'no label'), ('Blood Vitamin B', 'no label'), ('Vitamin D', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~33185574|Phenylalanine Hydroxylase Deficiency Is An Autosomal Recessive Inborn Error Of Phenylalanine Metabolism. Εven In Cases With Negative Newborn Screening For Inborn Errors Of Metabolism, The Possibility Of A Metabolic Disorder Including Pku Should Be Considered In Any Child Presenting Symptoms Of Developmental Disorders. Late Diagnosed Pku Patients Require A More Specialized And Individualized Management Than If They Were Early Treatment Cases. We Discuss A Case Of A Child With Typical Autistic Symptomatology, In Whom Years Later A Diagnosis Of Phenylketonuria Was Set, Even Neonatal Screening Was Negative. Τhe Patient Was Placed On A Phenylalanine-Restricted Diet. After A Period Of Clinical Improvement, Severe Behavioral Problems With Aggressiveness And Anxiety Were Presented. Less Restrictive Diet Ameliorated The Symptomatology. This Case Highlights The Major Medical Importance Of Adequate Newborn Screening Policy, In Order To Avoid Missed Diagnosed Cases. Pku May Be Presented As Autism Spectrum Disorder. Dietary Management Needs Individualized Attentive Monitoring.|[('Phenylalanine Hydroxylase Deficiency', 'no label'), ('Recessive Inborn Error', 'no label'), ('Phenylalanine Metabolism', 'no label'), ('Cases', 'no label'), ('Negative Newborn', 'no label'), ('Inborn Errors', 'no label'), ('Metabolism', 'no label'), ('Possibility', 'no label'), ('Metabolic Disorder', 'no label'), ('Pku', 'no label'), ('Child Presenting Symptoms', 'no label'), ('Developmental Disorders', 'no label'), ('Late Diagnosed', 'no label'), ('Patients', 'no label'), ('Require', 'no label'), ('Specialized', 'no label'), ('Individualized', 'no label'), ('Early Treatment', 'no label'), ('Cases', 'no label'), ('Discuss', 'no label'), ('Child', 'no label'), ('Autistic Symptomatology', 'no label'), ('Years', 'no label'), ('Diagnosis', 'no label'), ('Neonatal', 'no label'), ('Screening', 'no label'), ('Patient', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Period', 'no label'), ('Clinical Improvement', 'no label'), ('Severe', 'no label'), ('Behavioral', 'no label'), ('Problems', 'no label'), ('Aggressiveness', 'no label'), ('Restrictive Diet', 'no label'), ('Ameliorated', 'no label'), ('Symptomatology', 'no label'), ('Medical', 'no label'), ('Adequate', 'no label'), ('Newborn', 'no label'), ('Screening Policy', 'no label'), ('Order', 'no label'), ('Missed Diagnosed Cases', 'no label'), ('Autism Spectrum Disorder', 'no label'), ('Dietary Management', 'no label'), ('Needs Individualized Attentive Monitoring', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Metabolic Disorder', 'no label'), ('Autistic', 'no label'), ('Phenylketonuria', 'no label'), ('Anxiety', 'no label'), ('Autism Spectrum Disorder', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('A Case', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~31102715|Phenylketonuria (Pku), Caused By Phenylalanine Hydroxylase (Pah) Gene Variants, Is A Common Autosomal Inherited Metabolic Disease. So Far, 1111 Pah Variants Have Been Revealed. The Residual Activity Of The Pah Variants Is The Key Determinant Of The Metabolic Phenotype And Bh<Sub>4</Sub> Responsiveness In Pku Patients. In This Study, The Spectrum Of Pah Variants In 1083 Chinese Pku Patients Was Analyzed. Then 20 Variants (P.L52F, P.R86P, P.L128P, P.L142P, P.D163N, P.C203G, P.E214G, P.F260L, P.M276T, P.L311R, P.P314A, P.L364F, P.Q375H, P.F382I, P.A395S, P.V412D, P.E108*, P.C203*, P.C284* And P.E353*) Were Expressed In Cos-7 Cells. The Residual Activities And Protein Expression Levels Were Detected By Isotope-Dilution Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry (Lc-Esi-Ms/Ms) And Western Blotting, Respectively. We Compared The Results Of The Phenotypic Prediction Based On Apv And Pah Activity Respectively, And Further Explored The Relationship Between Residual Activity And Phenotype In Pku Patients. We Reported 9 Newly Discovered Pah Variants For The First Time, Thereby Expanding The Spectrum Of Pah Variants. Among The 20 Variants In Our Assay, 8 Variants Showed Mild Impaired Residual Activities (48-92%) And Approximately Normal Protein Expression Levels Compared To The Wild-Type Pah. In Contrast, 9 Variants Showed Severely Impaired Residual Activities (0-34%) And Reduced Protein Expression. However, Three Variants (P.L52F, P.F260L And P.P314A) Showed Impaired Residual Activities (5%, 32% And 29%), Although The Proteins Were Well Expressed. We Assigned Apv Scores For 14 Variants, In Which The Results Of The Phenotypic Prediction Were Consistent For 12/14 (86%) Variants Based On Apv And Residual Activity Respectively, And The Residual Activity Correctly Predicted 17/22 (77%) Of The Patients. Our Study Helped To Further Understand The Genotype-Phenotype Correlation In Pku Patients.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Gene Variants', 'no label'), ('Autosomal Inherited', 'no label'), ('Metabolic Disease', 'no label'), ('Variants', 'no label'), ('Revealed', 'no label'), ('Residual', 'no label'), ('Activity', 'no label'), ('Variants', 'no label'), ('Determinant', 'no label'), ('Metabolic', 'no label'), ('Phenotype', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Spectrum', 'no label'), ('Variants', 'no label'), ('Chinese Pku', 'no label'), ('Patients', 'no label'), ('Analyzed', 'no label'), ('Variants', 'no label'), ('P.L142P', 'no label'), ('P.D163N', 'no label'), ('P.C203G', 'no label'), ('P.E214G', 'no label'), ('P.M276T', 'no label'), ('P.L311R', 'no label'), ('P.P314A', 'no label'), ('P.L364F', 'no label'), ('P.Q375H', 'no label'), ('P.V412D', 'no label'), ('P.E108*,', 'no label'), ('P.C203*, P.C284* And P.E353*)', 'no label'), ('Expressed', 'no label'), ('Cos-7 Cells', 'no label'), ('Residual Activities', 'no label'), ('Protein Expression', 'no label'), ('Detected', 'no label'), ('Isotope-Dilution Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry', 'no label'), ('Lc-Esi-Ms/Ms', 'no label'), ('Western Blotting', 'no label'), ('Results', 'no label'), ('Phenotypic Prediction', 'no label'), ('Apv', 'no label'), ('Relationship', 'no label'), ('Residual', 'no label'), ('Activity', 'no label'), ('Phenotype', 'no label'), ('Patients', 'no label'), ('Discovered', 'no label'), ('Variants', 'no label'), ('First Time', 'no label'), ('Spectrum', 'no label'), ('Variants', 'no label'), ('Variants', 'no label'), ('Assay', 'no label'), ('Variants', 'no label'), ('Mild Impaired Residual Activities', 'no label'), ('Normal Protein', 'no label'), ('Levels', 'no label'), ('Wild-Type Pah', 'no label'), ('Contrast', 'no label'), ('Variants', 'no label'), ('Severely Impaired', 'no label'), ('Residual Activities', 'no label'), ('Reduced', 'no label'), ('Protein Expression', 'no label'), ('Variants', 'no label'), ('P.P314A)', 'no label'), ('Impaired Residual Activities', 'no label'), ('Proteins', 'no label'), ('Expressed', 'no label'), ('Assigned Apv Scores', 'no label'), ('Variants', 'no label'), ('Results', 'no label'), ('Phenotypic Prediction', 'no label'), ('Variants', 'no label'), ('Apv', 'no label'), ('Residual', 'no label'), ('Activity', 'no label'), ('Residual', 'no label'), ('Activity', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Understand', 'no label'), ('Genotype-Phenotype Correlation', 'no label'), ('Pku Patients', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Gene', 'no label'), ('Variants', 'no label'), ('Cells', 'no label'), ('Protein', 'no label'), ('Variants', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Proteins', 'no label')]|[('Pah Variants', 'no label'), ('Pah Variants', 'no label'), ('Cos-7 Cells', 'no label'), ('Pah Variants', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Metabolic Disease', 'no label'), ('P.L364F', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Far', 'no label'), ('Pku Patients', 'no label'), ('Patients', 'no label'), ('P.C203G', 'no label'), ('P.L364F', 'no label'), ('P.Q375H', 'no label'), ('P.F382I', 'no label'), ('Cos-7 Cells', 'no label'), ('Pah', 'no label'), ('Proteins', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~29579554|Phenylketonuria (Pku) Is The Most Common Form Of Amino Acid Metabolism Disorders With Autosomal Recessive Inheritance. The Brain Damage Can Be Prevented By Early Diagnosis And A Phenylalanine-Restricted Diet. Untreated Or Late-Treated Patients May Show Mental Retardation And Other Cognitive Dysfunctions, As Well As Motor Disability And/Or Epilepsy. Three Patients With Pku And Epilepsy Were Recognized To Have Reflex Epileptic Features, And There Were Ten Consecutive Adult Patients With Pku And Epilepsy Who Were Evaluated Retrospectively. Medical History, Ages At Diagnosis And Therapy Onset, Age At Seizure Onset, Seizure Types And Reflex Features, Neurological Findings, Cranial Imaging, Electroencephalography (Eeg) Findings, And Final Clinical Condition Were Evaluated. Reflex Epilepsy Features Were Examined In Detail. The Cases (6 Females, 4 Males) Were Diagnosed At Ages Between 3.5Months And 12Years. All Patients Had Various Degrees Of Mental-Motor Retardation And Focal Or Generalized Seizures With Age At Seizure Onset Varied Between Neonatal Period And 15Years. Three Patients Had Febrile Seizure, 3 Patients Had Myoclonia, And 3 Patients Had Status Epilepticus. All Patients Had Abnormal Eeg Findings Except One. There Was A Slowing Of Background Activity, And Generalized Discharges Were Observed In 7 Patients; 3 Of Them Had Asymmetrical Discharges. One Patient Had Right Hippocampal Sclerosis (Hs), And Another Patient Had Hypointensities In The Basal Ganglia And Corpus Callosum. Reflex Features Were Clinically Observed In 3 Of The Patients; However, Eeg Results Did Not Show Any Related Findings. One Patient Had Reflex Seizures Triggered By Photic Stimuli, Hot Water, And Startling; One By Photic Stimuli; And The Other One By Startling. Reports On The Clinical And Electrophysiological Features Of Adult Patients With Pku Were Scant. We Emphasized That Reflex Clinical Features May Be Observed In This Metabolic Disease, And Focal Epileptiform Abnormalities And Asymmetry May Be Present In Electrophysiological Evaluation Besides The Rare Association With Hs.|[('Phenylketonuria', 'no label'), ('Common', 'no label'), ('Form', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Autosomal Recessive Inheritance', 'no label'), ('Brain Damage', 'no label'), ('Prevented', 'no label'), ('Early Diagnosis', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Untreated Or Late-Treated Patients', 'no label'), ('Show Mental Retardation', 'no label'), ('Cognitive Dysfunctions', 'no label'), ('Motor Disability And/Or', 'no label'), ('Epilepsy', 'no label'), ('Patients', 'no label'), ('Pku And Epilepsy', 'no label'), ('Reflex', 'no label'), ('Epileptic Features', 'no label'), ('Consecutive', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Pku And Epilepsy Who', 'no label'), ('Evaluated', 'no label'), ('Retrospectively', 'no label'), ('Medical History', 'no label'), ('Ages', 'no label'), ('Diagnosis', 'no label'), ('Therapy', 'no label'), ('Onset', 'no label'), ('Age', 'no label'), ('Seizure', 'no label'), ('Onset', 'no label'), ('Seizure', 'no label'), ('Types', 'no label'), ('Reflex', 'no label'), ('Features', 'no label'), ('Neurological Findings', 'no label'), ('Cranial Imaging', 'no label'), ('Electroencephalography', 'no label'), ('Eeg', 'no label'), ('Findings', 'no label'), ('Final', 'no label'), ('Clinical Condition', 'no label'), ('Evaluated', 'no label'), ('Reflex Epilepsy', 'no label'), ('Features', 'no label'), ('Detail', 'no label'), ('Cases', 'no label'), ('Females', 'no label'), ('Males', 'no label'), ('Diagnosed', 'no label'), ('Ages', 'no label'), ('Patients', 'no label'), ('Degrees', 'no label'), ('Mental-Motor Retardation', 'no label'), ('Focal', 'no label'), ('Generalized Seizures', 'no label'), ('Age', 'no label'), ('Seizure', 'no label'), ('Onset', 'no label'), ('Neonatal', 'no label'), ('Period', 'no label'), ('Patients', 'no label'), ('Febrile Seizure', 'no label'), ('Patients', 'no label'), ('Myoclonia', 'no label'), ('Patients', 'no label'), ('Status Epilepticus', 'no label'), ('Patients', 'no label'), ('Abnormal', 'no label'), ('Eeg', 'no label'), ('Findings', 'no label'), ('Slowing', 'no label'), ('Activity', 'no label'), ('Generalized Discharges', 'no label'), ('Observed', 'no label'), ('Patients', 'no label'), ('Asymmetrical Discharges', 'no label'), ('Patient', 'no label'), ('Right Hippocampal Sclerosis', 'no label'), ('Hs', 'no label'), ('Patient', 'no label'), ('Hypointensities', 'no label'), ('Basal Ganglia', 'no label'), ('Corpus Callosum', 'no label'), ('Reflex', 'no label'), ('Features', 'no label'), ('Observed', 'no label'), ('Patients', 'no label'), ('Eeg Results', 'no label'), ('Findings', 'no label'), ('Patient', 'no label'), ('Reflex Seizures', 'no label'), ('Triggered By', 'no label'), ('Photic Stimuli', 'no label'), ('Hot Water', 'no label'), ('Startling', 'no label'), ('Photic Stimuli', 'no label'), ('Startling', 'no label'), ('Reports', 'no label'), ('Clinical', 'no label'), ('Electrophysiological Features', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Pku Were Scant', 'no label'), ('Emphasized', 'no label'), ('Reflex', 'no label'), ('Clinical Features', 'no label'), ('Observed', 'no label'), ('Metabolic Disease', 'no label'), ('Focal Epileptiform Abnormalities', 'no label'), ('Asymmetry', 'no label'), ('Electrophysiological Evaluation', 'no label'), ('Rare', 'no label'), ('Association', 'no label'), ('Hs', 'no label')]|[('Amino Acid', 'no label'), ('Water', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Amino Acid Metabolism Disorders', 'no label'), ('Autosomal Recessive Inheritance', 'no label'), ('Brain Damage', 'no label'), ('Cognitive Dysfunctions', 'no label'), ('Epilepsy', 'no label'), ('Epilepsy', 'no label'), ('Epileptic', 'no label'), ('Epilepsy', 'no label'), ('Seizure', 'no label'), ('Seizure', 'no label'), ('Epilepsy', 'no label'), ('Seizures', 'no label'), ('Seizure', 'no label'), ('Febrile Seizure', 'no label'), ('Myoclonia', 'no label'), ('Status Epilepticus', 'no label'), ('Seizures', 'no label'), ('Metabolic Disease', 'no label'), ('Epileptiform Abnormalities', 'no label')]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('And/Or', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cranial', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patient', 'no label'), ('Patient', 'no label'), ('Hypointensities', 'no label'), ('Basal Ganglia', 'no label'), ('Corpus Callosum', 'no label'), ('Patients', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Hs', 'no label')]
phenylketonuria|pubmed~30389586|Phenylketonuria (Pku) Is A Metabolic Disorder Caused By Mutations In The Phenylalanine Hydroxylase (Pah) Gene. After Thalassemia, Pku Is Considered As The Most Common Autosomal Recessive Diseases In The Iranian Population. Therefore, An Efficient Diagnostic Strategy Is Required To Identify Disease-Causing Mutations In This Population. Following Our First Report In 2003, Here We Presented A Comprehensive Study On The Mutation Spectrum Of The Pah Gene In The Iranian Population. This Study Was Performed On 280 Unrelated Chromosomes From 140 Iranian Patients With Classic Pku. All 13 Exons As Well As Exon-Intron Boundaries Of The Pah Gene Were Analyzed By Direct Dna Sequencing. Thirty Four Different Mutations Were Identified By A Mutation Detection Rate Of 100%. Ivs10-11G > A, P.P281L, R261Q, P.F39Del And Ivs11+1G > C Were The Most Prevalent Mutations With Frequencies Of 26.07%, 19.3%, 12.86%, 6.07 And 3.93%, Respectively. All Other Mutations Represented A Relative Frequency Less Than 3.5%. The Data From This Study Provided A Comprehensive Spectrum Of The Pah Gene Mutations Which Can Facilitate Carrier Detection And Prenatal Diagnosis Of Pku Disease In The Iranian Population.|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Caused By', 'no label'), ('Mutations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Thalassemia', 'no label'), ('Pku', 'no label'), ('Autosomal Recessive Diseases', 'no label'), ('Iranian', 'no label'), ('Population', 'no label'), ('Efficient Diagnostic Strategy', 'no label'), ('Disease-Causing Mutations', 'no label'), ('Population', 'no label'), ('Comprehensive Study', 'no label'), ('Mutation Spectrum', 'no label'), ('Pah Gene', 'no label'), ('Iranian', 'no label'), ('Population', 'no label'), ('Study', 'no label'), ('Unrelated Chromosomes', 'no label'), ('Iranian', 'no label'), ('Patients', 'no label'), ('Classic Pku', 'no label'), ('Exons', 'no label'), ('Exon-Intron Boundaries', 'no label'), ('Pah Gene', 'no label'), ('Analyzed', 'no label'), ('Direct Dna Sequencing', 'no label'), ('Mutations', 'no label'), ('Mutation Detection', 'no label'), ('P.P281L', 'no label'), ('R261Q', 'no label'), ('P.F39Del', 'no label'), ('Ivs11+1G\xa0>\xa0C', 'no label'), ('Prevalent', 'no label'), ('Mutations', 'no label'), ('Frequencies', 'no label'), ('Mutations', 'no label'), ('Represented A Relative Frequency', 'no label'), ('Data', 'no label'), ('Study', 'no label'), ('Comprehensive Spectrum', 'no label'), ('Pah Gene Mutations', 'no label'), ('Facilitate Carrier', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Pku Disease', 'no label'), ('Iranian', 'no label'), ('Population', 'no label')]|[('Mutations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Gene', 'no label'), ('Mutations', 'no label'), ('Mutation', 'no label'), ('Gene', 'no label'), ('Chromosomes', 'no label'), ('Exons', 'no label'), ('Gene', 'no label'), ('Dna', 'no label'), ('Mutations', 'no label'), ('Mutation', 'no label'), ('Ivs10', 'no label'), ('P.F39Del', 'no label'), ('Mutations', 'no label'), ('Mutations', 'no label'), ('Gene Mutations', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Pah Gene', 'no label'), ('13 Exons', 'no label'), ('Pah Gene', 'no label'), ('Pah Gene Mutations', 'no label')]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Thalassemia', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Pah Gene', 'no label'), ('Chromosomes', 'no label'), ('Patients', 'no label'), ('Pah Gene', 'no label'), ('Dna', 'no label'), ('Ivs11+1G', 'no label'), ('Pah Gene', 'no label'), ('Carrier', 'no label'), ('Pku Disease', 'no label')]
phenylketonuria|pubmed~33076399|The Nutritional Composition Of Special Low Protein Foods (Slpfs) Is Controlled Under Eu Legislation For 'Foods For Special Medical Purposes (Fsmp)'. They Are Designed To Meet The Energy Needs Of Patients Unable To Eat A Normal Protein Containing Diet. In Phenylketonuria (Pku), The Macronutrient Contribution Of Slpfs Has Been Inadequately Examined. A 3-Year Longitudinal Prospective Study Investigating The Contribution Of Slpfs To The Macronutrient Intake Of Children With Early Treated Pku. 48 Children (27 Boys) With A Mean Recruitment Age Of 9.3 Y Were Studied. Semi-Quantitative Dietary Assessments And Food Frequency Questionnaires (Ffq) Were Collected Three To Four Times/Year For 3 Years. The Mean Energy Intake Provided By Slpfs Was 33% (Sd ± 8), And This Figure Was 42% (Sd ± 13) For Normal Food And 21% (Sd ± 5) For Protein Substitutes (Ps). Slpfs Supplied A Mean Intake Of 40% Carbohydrate (Sd ± 10), 51% Starch (Sd ± 18), 21% Sugar (Sd ± 8), And 38% Fat (Sd ± 13). Fibre Intake Met 83% Of The Scientific Advisory Committee On Nutrition (Sacn) Reference Value, With 50% Coming From Slpfs With Added Gums And Hydrocolloids. Low Protein Bread, Pasta And Milk Provided The Highest Energy Contribution, And The Intake Of Sweet Slpfs (E.G., Biscuits, Cakes, And Chocolate) Was Minimal. Children Averaged Three Portions Fruit/Vegetable Daily, And Children Aged ≥ 12 Y Had Irregular Meal Patterns. Slpfs Provide Essential Energy In Phenylalanine Restricted Diets. Optimising The Nutritional Quality Of Slpfs Deserves More Attention.|[('Nutritional Composition', 'no label'), ('Slpfs', 'no label'), ('Controlled', 'no label'), ('Special Medical Purposes', 'no label'), ('Fsmp', 'no label'), ('Energy Needs', 'no label'), ('Patients', 'no label'), ('Unable', 'no label'), ('Normal Protein', 'no label'), ('Diet', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Macronutrient', 'no label'), ('Contribution', 'no label'), ('Slpfs', 'no label'), ('Longitudinal Prospective Study', 'no label'), ('Investigating', 'no label'), ('Contribution', 'no label'), ('Slpfs', 'no label'), ('Macronutrient Intake', 'no label'), ('Children', 'no label'), ('Early', 'no label'), ('Treated Pku', 'no label'), ('Children', 'no label'), ('Boys', 'no label'), ('Mean Recruitment Age', 'no label'), ('Studied', 'no label'), ('Semi-Quantitative Dietary Assessments', 'no label'), ('Food Frequency Questionnaires', 'no label'), ('Ffq', 'no label'), ('Times/Year', 'no label'), ('Years', 'no label'), ('Mean Energy Intake', 'no label'), ('Slpfs', 'no label'), ('Sd', 'no label'), ('Normal Food', 'no label'), ('Protein Substitutes', 'no label'), ('Slpfs', 'no label'), ('Mean Intake', 'no label'), ('Carbohydrate', 'no label'), ('Sd', 'no label'), ('Starch', 'no label'), ('Sd', 'no label'), ('Sugar', 'no label'), ('Sd', 'no label'), ('Fibre Intake', 'no label'), ('Met', 'no label'), ('Scientific Advisory Committee', 'no label'), ('Slpfs', 'no label'), ('Added', 'no label'), ('Gums', 'no label'), ('Hydrocolloids', 'no label'), ('Protein Bread', 'no label'), ('Pasta', 'no label'), ('Milk', 'no label'), ('Energy Contribution', 'no label'), ('Intake', 'no label'), ('Sweet Slpfs', 'no label'), ('E.G.', 'no label'), ('Biscuits', 'no label'), ('Cakes', 'no label'), ('Chocolate', 'no label'), ('Minimal', 'no label'), ('Children', 'no label'), ('Averaged', 'no label'), ('Portions', 'no label'), ('Fruit/Vegetable Daily', 'no label'), ('Children', 'no label'), ('Aged', 'no label'), ('Irregular', 'no label'), ('Meal Patterns', 'no label'), ('Slpfs', 'no label'), ('Phenylalanine', 'no label'), ('Diets', 'no label'), ('Nutritional Quality', 'no label'), ('Slpfs Deserves', 'no label'), ('Attention', 'no label')]|[('Protein Foods', 'no label'), ('Foods', 'no label'), ('Protein', 'no label'), ('Food', 'no label'), ('Food', 'no label'), ('Protein', 'no label'), ('Carbohydrate', 'no label'), ('Starch', 'no label'), ('Met', 'no label'), ('Protein', 'no label'), ('Portions', 'no label'), ('Y', 'no label'), ('Meal', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Starch', 'no label'), ('Cakes', 'no label'), ('Chocolate', 'no label'), ('Phenylalanine', 'no label')]|[('Eu', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Slpfs', 'no label'), ('Slpfs', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Slpfs', 'no label'), ('Sd ±', 'no label'), ('Figure', 'no label'), ('Sd ± 13', 'no label'), ('Sd ± 5', 'no label'), ('Slpfs Supplied A', 'no label'), ('Sd ± 10', 'no label'), ('Starch', 'no label'), ('Sd ± 18', 'no label'), ('Sugar', 'no label'), ('Sd ±', 'no label'), ('Fat (', 'no label'), ('Sd ± 13', 'no label'), ('Met', 'no label'), ('Slpfs', 'no label'), ('Gums', 'no label'), ('Pasta', 'no label'), ('Milk', 'no label'), ('Sweet Slpfs', 'no label'), ('Biscuits', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Meal', 'no label'), ('Phenylalanine', 'no label'), ('Slpfs', 'no label')]
phenylketonuria|pubmed~31141484|Background Phenylketonuria (Pku) Management Practices Differ Between And Within Countries. In 2007, The Portuguese Society For Metabolic Disorders (Spdm) Approved The Portuguese Consensus (Pc) For The Nutritional Treatment Of Pku. The Recently Published European Pku Guidelines (Epg, 2017) Systematically Reviewed Recent Evidence And Aimed To Harmonise Treatment Protocols In Europe. The Objective Of This Study Was To Appraise The Epg Acceptance And Implementation In Portuguese Treatment Centres. Methods An Electronic Questionnaire Was Prepared And The Link Was Sent To 135 Spdm Members. It Outlined The 10 Epg Key Recommendations And Compared Each Statement With The Consensus Recommendations Published By Spdm. Responses Were Recorded And Descriptive Analyses Were Performed. Results Twenty-Five Professionals Completed The Questionnaire, And Over Half (56%) Were Nutritionists/Dieticians. At Least One Questionnaire From Each Of The 10 National Treatment Centres Was Returned. In General, Responders Accepted Most Of The Recommendations. However, Only The Recommendation About Target Phenylalanine (Phe) Concentrations Between 120 And 360 Μmol/L For Patients <12 Years Received 100% Consensus With A Further Seven Recommendations Gaining Over 70% Consensus. Almost Half Of The Professionals (48%, N = 12) Required Further Discussion About The Epg-Safe Upper Target Blood Phe Concentration (600 Μmol/L) Suggested For Patients Aged ≥12 Years. Almost One Third (32%, N = 8) Failed To Agree With The Recommendation In The Epg-Proposed Classification Of Phe Hydroxylase (Pah) Deficiency. Conclusions The Epg Received Overall Good Acceptance, But There Was Divided Opinion About Some Recommendations Which Require Further Discussion Before Implementation By The Portuguese Treatment Centres.|[('Phenylketonuria', 'no label'), ('Pku) Management', 'no label'), ('Practices', 'no label'), ('Differ', 'no label'), ('Countries', 'no label'), ('Portuguese Society', 'no label'), ('Spdm', 'no label'), ('Pc', 'no label'), ('Nutritional Treatment', 'no label'), ('Published European Pku Guidelines', 'no label'), ('Epg', 'no label'), ('Systematically Reviewed', 'no label'), ('Evidence', 'no label'), ('Harmonise Treatment Protocols', 'no label'), ('Europe', 'no label'), ('Study', 'no label'), ('Epg Acceptance', 'no label'), ('Implementation', 'no label'), ('Portuguese Treatment Centres', 'no label'), ('Electronic Questionnaire', 'no label'), ('Prepared', 'no label'), ('Link Was Sent', 'no label'), ('Spdm', 'no label'), ('Members', 'no label'), ('Epg', 'no label'), ('Recommendations', 'no label'), ('Statement', 'no label'), ('Consensus', 'no label'), ('Recommendations', 'no label'), ('Published', 'no label'), ('Spdm', 'no label'), ('Responses', 'no label'), ('Performed', 'no label'), ('Professionals', 'no label'), ('Completed', 'no label'), ('Questionnaire', 'no label'), ('Nutritionists/Dieticians', 'no label'), ('National Treatment Centres', 'no label'), ('Returned', 'no label'), ('General', 'no label'), ('Responders', 'no label'), ('Recommendations', 'no label'), ('Recommendation', 'no label'), ('Target', 'no label'), ('Phenylalanine (Phe) Concentrations', 'no label'), ('Patients', 'no label'), ('Years', 'no label'), ('Received', 'no label'), ('Consensus', 'no label'), ('Recommendations', 'no label'), ('Consensus', 'no label'), ('Professionals', 'no label'), ('Epg-Safe', 'no label'), ('Upper', 'no label'), ('Target', 'no label'), ('Blood Phe Concentration', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Failed', 'no label'), ('Recommendation', 'no label'), ('Epg-Proposed Classification', 'no label'), ('Phe Hydroxylase', 'no label'), ('Epg', 'no label'), ('Acceptance', 'no label'), ('Was Divided Opinion', 'no label'), ('Recommendations', 'no label'), ('Require', 'no label'), ('Implementation', 'no label'), ('Portuguese Treatment Centres', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Consensus', 'no label'), ('Epg-Proposed', 'no label')]|[('Epg-Safe Upper Target Blood Phe Concentration (600 Μmol/L) Suggested', 'no label')]|[('Phenylketonuria', 'no label'), ('Metabolic Disorders', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Link', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Phe Hydroxylase', 'no label')]
phenylketonuria|pubmed~31112507|Background Phenylketonuria (Pku), A Rare, Inherited Metabolic Condition, Is Treated With A Strict Low-Phenylalanine (Phe) Diet, Supplemented With Phe-Free Protein Substitute. The Optimal Nutritional Management Of A Sporting Individual With Pku Has Not Been Described. Therefore, Guidelines For The General Athlete Have To Be Adapted. Case Presentation Three Clinical Scenarios Of Sporting Patients With Pku Are Given, Illustrating Dietary Adaptations To Usual Management And Challenges To Attain Optimal Sporting Performance. Therefore, The Main Objectives Of Sports Nutrition In Pku Are To (1) Maintain A High Carbohydrate Diet; (2) Carefully Monitor Hydration Status; And (3) Give Attention To The Timing Of Protein Substitute Intake In The Immediate Post-Exercise Recovery Phase. Optimal Energy Intake Should Be Given Prior To, During And Post Exercise Training Sessions Or Competition. Fortunately, A Usual Low-Phe Diet Is Rich In Carbohydrate, But Attention Is Required On The Types Of Special Low-Protein Foods Chosen. Acute Exercise Does Not Seem To Influence Blood Phe Concentrations, But Further Evidence Is Needed. Summary Well-Treated Pku Patients Should Be Able To Participate In Sports Activities, But This Is Associated With Increased Nutritional Requirements And Dietary Adjustments. Conclusions It Should Be The Goal Of All Sporting Patients With Pku To Maintain Good Metabolic Phe Control And Attain Maximal Athletic Performance.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Rare', 'no label'), ('Inherited', 'no label'), ('Metabolic Condition', 'no label'), ('Treated With', 'no label'), ('Strict', 'no label'), ('Low-Phenylalanine (Phe) Diet', 'no label'), ('Supplemented', 'no label'), ('Phe-Free Protein', 'no label'), ('Optimal', 'no label'), ('Nutritional Management', 'no label'), ('Sporting', 'no label'), ('Individual With', 'no label'), ('Pku Has Not', 'no label'), ('Guidelines', 'no label'), ('General Athlete', 'no label'), ('Case Presentation', 'no label'), ('Clinical Scenarios', 'no label'), ('Sporting', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Illustrating', 'no label'), ('Dietary Adaptations', 'no label'), ('Usual Management', 'no label'), ('Attain Optimal Sporting', 'no label'), ('Performance', 'no label'), ('Sports Nutrition', 'no label'), ('Maintain', 'no label'), ('High Carbohydrate Diet', 'no label'), ('Monitor Hydration Status', 'no label'), ('Attention', 'no label'), ('Timing', 'no label'), ('Protein Substitute', 'no label'), ('Intake', 'no label'), ('Immediate Post-Exercise Recovery', 'no label'), ('Phase', 'no label'), ('Optimal', 'no label'), ('Energy Intake', 'no label'), ('Post Exercise', 'no label'), ('Training Sessions', 'no label'), ('Competition', 'no label'), ('Usual Low-Phe Diet', 'no label'), ('Carbohydrate', 'no label'), ('Attention', 'no label'), ('Special Low-Protein Foods', 'no label'), ('Chosen', 'no label'), ('Acute Exercise', 'no label'), ('Does Not Seem', 'no label'), ('Influence', 'no label'), ('Blood Phe', 'no label'), ('Concentrations', 'no label'), ('Evidence', 'no label'), ('Well-Treated Pku', 'no label'), ('Patients', 'no label'), ('Participate', 'no label'), ('Sports Activities', 'no label'), ('Associated With', 'no label'), ('Increased', 'no label'), ('Nutritional', 'no label'), ('Dietary', 'no label'), ('Adjustments', 'no label'), ('Goal', 'no label'), ('Sporting Patients', 'no label'), ('Good', 'no label'), ('Metabolic Phe Control', 'no label')]|[('Phe', 'no label'), ('Protein', 'no label'), ('Carbohydrate', 'no label'), ('Protein', 'no label'), ('Foods', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Low-Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Low-Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe-Free', 'no label'), ('Patients', 'no label'), ('High Carbohydrate', 'no label'), ('Rich', 'no label'), ('Carbohydrate', 'no label'), ('Seem', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Sports', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~29623884|Phenylketonuria (Pku, Omim 261600) Is An Autosomal Recessive Inborn Error Of Metabolism Caused By A Deficiency Of The Hepatic Enzyme Phenylalanine Hydroxylase (Pah; Ec 1.14.16.1). If Untreated, The Disease Leads To An Important Intellectual Disability (Iq <50). Although Many Facts Are Common Between Phenylalanine (Phe) And Tryptophan (Trp) Metabolism, Little Is Known About Trp Metabolism Modification In Pku. Our Aim Was To Evaluate The Modifications Of Trp Metabolism In A Phenylketonuric Population. A Monocentric Study Was Conducted Between October 2016 And March 2017. Every Phenylketonuric Fasting Adults Were Included During Their Annual Follow Up. For Each Patient, 9 Analytes Of Trp Metabolism Were Quantified In Peripheral Blood Using Liquid Chromatography Coupled With Tandem Mass Spectrometry. Mann And Whitney Tests (P <0.05) Were Carried Out In Statview 5.0 Software. A Total Of 6 Pku Patients Were Studied. Significant Modification Of Trp Metabolism Was Shown. Indeed, Three Analytes, I.E. Tryptophan, Kynurenine And 3-Hydroxykynurenic Acid, Were Significantly Lower In Phenylketonuric Than In Healthy Population (P-Value <0.05), Without Known Confounding Factors. This Study Shows A Significant Modification Of Trp Metabolism In Peripheral Blood Of Phenylketonuric Patients. Nevertheless, More Investigations Are Necessary To Confirm The Modification Of Trp Metabolism In Pku And To Determine How This Metabolism Is Involved In Neurological Symptoms.|[('Phenylketonuria', 'no label'), ('Autosomal', 'no label'), ('Recessive Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Deficiency', 'no label'), ('Hepatic Enzyme Phenylalanine Hydroxylase', 'no label'), ('Untreated', 'no label'), ('Disease Leads', 'no label'), ('Intellectual Disability', 'no label'), ('Facts', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tryptophan (Trp) Metabolism', 'no label'), ('Trp Metabolism', 'no label'), ('Modification', 'no label'), ('Evaluate', 'no label'), ('Modifications', 'no label'), ('Trp Metabolism', 'no label'), ('Phenylketonuric Population', 'no label'), ('Monocentric Study', 'no label'), ('Phenylketonuric Fasting Adults', 'no label'), ('Annual', 'no label'), ('Follow Up', 'no label'), ('Patient', 'no label'), ('Analytes', 'no label'), ('Trp Metabolism', 'no label'), ('Quantified', 'no label'), ('Peripheral Blood', 'no label'), ('Liquid Chromatography', 'no label'), ('Tandem Mass Spectrometry', 'no label'), ('Mann And Whitney Tests', 'no label'), ('Statview 5.0 Software', 'no label'), ('Pku Patients', 'no label'), ('Significant', 'no label'), ('Modification', 'no label'), ('Trp Metabolism', 'no label'), ('Analytes', 'no label'), ('Tryptophan', 'no label'), ('Kynurenine', 'no label'), ('3-Hydroxykynurenic Acid', 'no label'), ('Phenylketonuric Than', 'no label'), ('Healthy Population', 'no label'), ('P-Value', 'no label'), ('Confounding Factors', 'no label'), ('Study', 'no label'), ('Shows A', 'no label'), ('Significant', 'no label'), ('Modification', 'no label'), ('Trp Metabolism', 'no label'), ('Peripheral Blood', 'no label'), ('Phenylketonuric', 'no label'), ('Patients', 'no label'), ('Investigations', 'no label'), ('Confirm', 'no label'), ('Modification', 'no label'), ('Trp Metabolism', 'no label'), ('Metabolism', 'no label'), ('Neurological Symptoms', 'no label')]|[('Enzyme', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tryptophan', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Modification', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Tryptophan', 'no label'), ('Kynurenine', 'no label'), ('Trp', 'no label'), ('Trp', 'no label')]|[('Hepatic Enzyme Phenylalanine Hydroxylase', 'no label')]|[('Phenylketonuria', 'no label'), ('261600', 'no label'), ('Autosomal Recessive Inborn', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tryptophan', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Tryptophan', 'no label'), ('Kynurenine', 'no label'), ('Trp', 'no label'), ('Trp', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Hepatic Enzyme Phenylalanine Hydroxylase', 'no label'), ('Pah; Ec 1.14.16.1', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tryptophan', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Trp', 'no label'), ('Peripheral Blood', 'no label'), ('Patients', 'no label'), ('Trp', 'no label'), ('Analytes', 'no label'), ('I.E. Tryptophan', 'no label'), ('Kynurenine', 'no label'), ('Trp', 'no label'), ('Peripheral Blood', 'no label'), ('Patients', 'no label'), ('Trp', 'no label'), ('Pku', 'no label')]
phenylketonuria|pubmed~34294862|The Development Of Therapeutics Depends On Predictions Of Clinical Activity From Pre-Clinical Data. We Have Previously Described Synb1618, An Engineered Bacterial Therapeutic (Synthetic Biotic) For The Treatment Of Phenylketonuria (Pku), A Rare Genetic Disease That Leads To Accumulation Of Plasma Phenylalanine (Phe) And Severe Neurological Complications. Synb1618 Consumes Phe In Preclinical Models, Healthy Human Volunteers, And Pku Patients. However, It Remains Unclear To What Extent Phe Consumption By Synb1618 In The Gastrointestinal Tract Lowers Plasma Phe Levels In Pku Patients. Here, We Construct A Mechanistic Model That Predicts Synb1618 Function In Non-Human Primates And Healthy Subjects By Combining In Vitro Simulations And Prior Knowledge Of Human Physiology. In Addition, We Extend A Model Of Plasma Phe Kinetics In Pku Patients, In Order To Estimate Plasma Phe Lowering By Synb1618. This Approach Provides A Framework That Can Be Used More Broadly To Define The Therapeutic Potential Of Synthetic Biotics.|[('Development', 'no label'), ('Therapeutics', 'no label'), ('Depends', 'no label'), ('Predictions', 'no label'), ('Clinical Activity', 'no label'), ('Pre-Clinical Data', 'no label'), ('Synb1618', 'no label'), ('Engineered Bacterial', 'no label'), ('Therapeutic', 'no label'), ('Synthetic Biotic', 'no label'), ('Treatment', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Rare', 'no label'), ('Genetic Disease', 'no label'), ('Leads', 'no label'), ('Accumulation', 'no label'), ('Plasma', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Severe', 'no label'), ('Neurological Complications', 'no label'), ('Consumes', 'no label'), ('Phe', 'no label'), ('Preclinical Models', 'no label'), ('Healthy Human Volunteers', 'no label'), ('Patients', 'no label'), ('Extent', 'no label'), ('Phe', 'no label'), ('Consumption', 'no label'), ('Synb1618', 'no label'), ('Gastrointestinal Tract', 'no label'), ('Plasma', 'no label'), ('Phe Levels', 'no label'), ('Patients', 'no label'), ('Construct A', 'no label'), ('Mechanistic Model', 'no label'), ('Predicts', 'no label'), ('Synb1618', 'no label'), ('Function', 'no label'), ('Non-Human Primates', 'no label'), ('Healthy Subjects', 'no label'), ('In Vitro', 'no label'), ('Simulations', 'no label'), ('Knowledge', 'no label'), ('Human Physiology', 'no label'), ('Extend A Model', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Kinetics', 'no label'), ('Patients', 'no label'), ('Order', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Lowering', 'no label'), ('Synb1618', 'no label'), ('Provides', 'no label'), ('Framework', 'no label'), ('Therapeutic', 'no label'), ('Potential', 'no label'), ('Synthetic Biotics', 'no label')]|[('Bacterial Therapeutic', 'no label'), ('Genetic', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Human', 'no label'), ('Phe', 'no label'), ('Synb1618', 'no label'), ('Phe', 'no label'), ('Synb1618', 'no label'), ('Non-Human Primates', 'no label'), ('Human', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Synb1618', 'no label'), ('Synb1618', 'no label'), ('Synb1618', 'no label'), ('Synb1618', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Neurological Complications', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Synb1618', 'no label'), ('Phenylketonuria', 'no label'), ('Plasma Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Human', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Synb1618', 'no label'), ('Gastrointestinal', 'no label'), ('Plasma Phe', 'no label'), ('Pku Patients', 'no label'), ('Non-Human', 'no label'), ('Human Physiology', 'no label'), ('Plasma Phe', 'no label'), ('Plasma Phe', 'no label'), ('Synb1618', 'no label')]
phenylketonuria|pubmed~32899129|Dietary Restriction Of Phenylalanine Combined With A Protein Substitute Prevents Intellectual Disability In Patients With Phenylketonuria (Pku). However, Current Protein Substitutes Are Associated With Low Adherence Owing To Unpalatability And Burdensome Administration Regimens. This Prospective, Observational Acceptability Study In Children With Pku Assessed The Use Of A Prolonged-Release Protein Substitute Designed With An Ethyl Cellulose And Arginate Coating Masking The Bitter Taste, Smell And Reducing The Osmolarity Of Free Amino Acids. The Study Product Was Mixed With The Subject'S Food Or Drink And Replaced ≥1 Dose Per Day Of The Subject'S Usual Protein Substitute For 7 Days. Seven Of 13 Subjects Were Able To Take Their Prescribed Dose Over The 7 Day Period. Most Subjects Mixed The Test Protein Substitute With Food Or Fruit Juice. Reduced Blood Phenylalanine Levels (<I>N</I> = 5) And Improved Phenylalanine/Tyrosine Ratio (<I>N</I> = 4) Were Recorded From Baseline To Day 7, Respectively. Four Subjects Reported Fewer Gastrointestinal Symptoms Compared To Baseline. There Were No Cases Of Diarrhoea, Constipation, Bloating, Nausea Or Vomiting. No Adverse Reactions Were Reported. In Conclusion, The Novel Prolonged-Release Protein Substitute Was Taken In A Different Way To A Typical Protein Substitute And Enabled Satisfactory Blood Phenylalanine Control. The Study Product Was Well Tolerated; Subjects Experienced Fewer Gastrointestinal Symptoms Than With Their Previous Treatment. Although The Results Of This Pilot Study Provide Reassuring Data, Longer-Term Studies Evaluating Adherence And Blood Phenylalanine Control Are Necessary.|"[('Dietary Restriction', 'no label'), ('Phenylalanine', 'no label'), ('Protein Substitute', 'no label'), ('Prevents', 'no label'), ('Intellectual Disability', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Protein Substitutes', 'no label'), ('Associated With', 'no label'), ('Low', 'no label'), ('Adherence', 'no label'), ('Unpalatability', 'no label'), ('Burdensome Administration Regimens', 'no label'), ('Prospective', 'no label'), ('Observational Acceptability Study', 'no label'), ('Children', 'no label'), ('Pku Assessed', 'no label'), ('Prolonged-Release Protein', 'no label'), ('Ethyl Cellulose', 'no label'), ('Arginate Coating Masking', 'no label'), ('Bitter Taste', 'no label'), ('Smell', 'no label'), ('Reducing', 'no label'), ('Osmolarity', 'no label'), ('Free Amino Acids', 'no label'), ('Study Product', 'no label'), (""Subject'S Food Or Drink"", 'no label'), ('Dose', 'no label'), (""Subject'S"", 'no label'), ('Protein', 'no label'), ('Days', 'no label'), ('Subjects', 'no label'), ('Prescribed Dose', 'no label'), ('Day', 'no label'), ('Period', 'no label'), ('Subjects', 'no label'), ('Test Protein', 'no label'), ('Substitute With', 'no label'), ('Food Or Fruit', 'no label'), ('Reduced', 'no label'), ('Blood Phenylalanine Levels', 'no label'), ('<I>N</I>', 'no label'), ('Phenylalanine/Tyrosine Ratio', 'no label'), ('<I>N</I> = 4)', 'no label'), ('Baseline', 'no label'), ('Subjects', 'no label'), ('Gastrointestinal Symptoms', 'no label'), ('Compared', 'no label'), ('Baseline', 'no label'), ('Cases', 'no label'), ('Diarrhoea', 'no label'), ('Constipation', 'no label'), ('Bloating', 'no label'), ('Nausea Or Vomiting', 'no label'), ('No Adverse Reactions', 'no label'), ('Prolonged-Release Protein', 'no label'), ('Typical Protein', 'no label'), ('Enabled', 'no label'), ('Satisfactory', 'no label'), ('Blood Phenylalanine Control', 'no label'), ('Study Product', 'no label'), ('Tolerated', 'no label'), ('Subjects', 'no label'), ('Experienced', 'no label'), ('Gastrointestinal Symptoms', 'no label'), ('Treatment', 'no label'), ('Pilot Study', 'no label'), ('Reassuring', 'no label'), ('Data', 'no label'), ('Longer-Term Studies', 'no label'), ('Evaluating', 'no label'), ('Adherence', 'no label'), ('Blood Phenylalanine Control', 'no label')]"|[('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Ethyl Cellulose', 'no label'), ('Amino Acids', 'no label'), ('Food', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Food', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Enabled Satisfactory Blood Phenylalanine', 'no label')]|[]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Diarrhoea', 'no label'), ('Constipation', 'no label'), ('Bloating', 'no label'), ('Nausea', 'no label'), ('Vomiting', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Ethyl Cellulose', 'no label'), ('Arginate', 'no label'), ('Bitter Taste', 'no label'), ('Amino', 'no label'), ('Food', 'no label'), ('Fruit Juice', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phenylalanine/Tyrosine', 'no label'), ('Gastrointestinal', 'no label'), ('Enabled', 'no label'), ('Blood Phenylalanine', 'no label'), ('Gastrointestinal Symptoms', 'no label'), ('Blood Phenylalanine', 'no label')]
phenylketonuria|pubmed~30247930|In May 2018, The Us Food And Drug Administration Approved Pegvaliase-Pqpz (Palynziq*), The First Enzyme Substitution Therapy For The Treatment Of Phenylketonuria (Pku). This Article Provides An Overview Of The Mechanism Of Action, Pharmacokinetic Properties, Clinical Efficacy, And The Safety And Tolerability Profile Of Pegvaliase. Relevant Information Was Identified Through A Comprehensive Literature Search Of Several Databases Using The Keywords Pegvaliase, Ravpal-Peg, And Phenylketonuria. Additional Information Was Gathered From The Pegvaliase Package Insert, Posters Presented At Scientific Meetings, And Materials Provided From The Manufacturer, Biomarin. Pegvaliase Is Effective In Decreasing Blood Phenylalanine Levels, And Is Associated With A Manageable Side-Effect Profile. Phase Iii Clinical Trial Data Demonstrated That 60.7% Of Patients Were Able To Achieve Blood Phenylalanine Levels Less Than The Guideline Recommended 360 Μmol/L At 24 Months. Brief Sub-Studies Also Showed The Improvement In Inattention Symptoms In Patients Treated With Pegvaliase, Compared To Placebo. Pegvaliase Is A Promising New Treatment Option For Adults Living With Pku. Further Studies Are Warranted To Determine Long-Term Safety And Clinical Efficacy In Sub-Populations.|[('Pegvaliase-Pqpz', 'no label'), ('Palynziq*)', 'no label'), ('Enzyme Substitution Therapy', 'no label'), ('Treatment', 'no label'), ('Phenylketonuria', 'no label'), ('Article Provides', 'no label'), ('Mechanism', 'no label'), ('Action', 'no label'), ('Pharmacokinetic Properties', 'no label'), ('Clinical Efficacy', 'no label'), ('Safety', 'no label'), ('Tolerability', 'no label'), ('Pegvaliase', 'no label'), ('Relevant', 'no label'), ('Information', 'no label'), ('Identified', 'no label'), ('Comprehensive', 'no label'), ('Databases', 'no label'), ('Keywords Pegvaliase', 'no label'), ('Ravpal-Peg', 'no label'), ('Phenylketonuria', 'no label'), ('Information', 'no label'), ('Gathered', 'no label'), ('Pegvaliase Package Insert', 'no label'), ('Posters', 'no label'), ('Scientific Meetings', 'no label'), ('Manufacturer', 'no label'), ('Biomarin', 'no label'), ('Pegvaliase', 'no label'), ('Effective', 'no label'), ('Decreasing', 'no label'), ('Blood Phenylalanine Levels', 'no label'), ('Associated With', 'no label'), ('Manageable Side-Effect Profile', 'no label'), ('Phase Iii Clinical Trial', 'no label'), ('Data', 'no label'), ('Patients', 'no label'), ('Blood Phenylalanine', 'no label'), ('Levels', 'no label'), ('Guideline', 'no label'), ('Recommended', 'no label'), ('Months', 'no label'), ('Sub-Studies', 'no label'), ('Improvement', 'no label'), ('Inattention Symptoms', 'no label'), ('Patients', 'no label'), ('Treated With', 'no label'), ('Pegvaliase', 'no label'), ('Placebo', 'no label'), ('Pegvaliase', 'no label'), ('New Treatment Option', 'no label'), ('Adults', 'no label'), ('Living', 'no label'), ('Studies', 'no label'), ('Long-Term Safety', 'no label'), ('Clinical Efficacy', 'no label'), ('Sub-Populations', 'no label')]|[('Food', 'no label'), ('Drug', 'no label'), ('Enzyme Substitution', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Us Food', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Pegvaliase Package', 'no label'), ('Blood Phenylalanine', 'no label'), ('Patients', 'no label'), ('Blood Phenylalanine', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~34003092|Phenylketonuria Is The Most Common Inborn Error Of Metabolism And Causes Irreversible Mental Retardation If Left Untreated. Its Newborn Screening Was Made Possible By The Technique Of Blood Collection On Filter Paper Developed By Robert Guthrie. Neonatal Pku Screening Began In France In The Early 1970S. It Was Initially Carried Out By A Bacteriological Method, Then By Fluorometry, And Finally, Since 2020, By Tandem Mass Spectrometry. More Than 35 Million Newborns Have Been Screened To Date. This Resulted In The Diagnosis Of More Than 3,500 Children With Pku Or Mild Hyperphenylalaninemia. The Management Of These Children Has Improved Over Time, In Particular Thanks To The Techniques Of Biochemistry And Molecular Genetics Which Lead To An Accurate Diagnosis And The Arrival Of Drug Treatment By Sapropterin. Thanks To This Screening, Which Allows For Early Management, The Prognosis Of Pku Has Been Transformed And, Although Neurological Or Behavioral Problems May Arise, These Patients Are Living Normally Today.|[('Phenylketonuria', 'no label'), ('Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Causes', 'no label'), ('Irreversible Mental Retardation', 'no label'), ('Left Untreated', 'no label'), ('Newborn Screening', 'no label'), ('Technique', 'no label'), ('Blood Collection', 'no label'), ('Filter Paper', 'no label'), ('Neonatal', 'no label'), ('Pku Screening Began', 'no label'), ('France', 'no label'), ('Early', 'no label'), ('Bacteriological Method', 'no label'), ('Fluorometry', 'no label'), ('Tandem Mass Spectrometry', 'no label'), ('Than 35 Million', 'no label'), ('Diagnosis', 'no label'), ('Children', 'no label'), ('Pku Or Mild', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Management', 'no label'), ('Children', 'no label'), ('Time', 'no label'), ('Techniques', 'no label'), ('Biochemistry And Molecular Genetics', 'no label'), ('Lead', 'no label'), ('Accurate Diagnosis', 'no label'), ('Arrival', 'no label'), ('Drug Treatment', 'no label'), ('Sapropterin', 'no label'), ('Screening', 'no label'), ('Early Management', 'no label'), ('Prognosis', 'no label'), ('Transformed', 'no label'), ('Neurological', 'no label'), ('Behavioral', 'no label'), ('Arise', 'no label'), ('Patients', 'no label'), ('Living', 'no label')]|[('Molecular', 'no label'), ('Lead', 'no label'), ('Drug', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Sapropterin', 'no label'), ('Prognosis', 'no label')]|[('Error', 'no label'), ('Blood Collection', 'no label'), ('Children', 'no label'), ('Pku Or', 'no label'), ('Children', 'no label'), ('Sapropterin', 'no label'), ('Pku', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31052331|Phenylalanine (Phe) Tolerance Is Highly Variable In Phenylketonuria (Pku) And Rarely Described In Patients Aged ≥12 Years. Patients ≥12 Years Of Age With Pku Were Systematically Challenged With Additional Natural Protein (Np) If Blood Phe Levels Remained Below 480 Μmol/L (I.E., Upper Target Blood Phe Level For Patients Aged ≥12 Years Using Portuguese Pku Guidelines). In Pku Patients, Np Tolerance Was Calculated At Baseline And A Median Of 6 Months After Systematic Challenge With Np Whilst Patients Were Maintaining A Blood Phe ≤480 Μmol/L. Anthropometry Was Assessed At Both Times. Routine Blood Phe Levels Were Collected. We Studied 40 Well-Controlled Pku Patients (10 Hyperphenylalaninemia (Hpa), 23 Mild And 7 Classic Pku), On A Low-Phe Diet With A Mean Age Of 17 Years (12-29 Years). Median Daily Np Intake Significantly Increased Between Assessments (35 Vs. 40 G/Day, <I>P</I> = 0.01). Twenty-Six Patients (65%) Were Able To Increase Their Median Np Intake By A Median 12 G/Day (2-42 G)/Day And Still Maintain Blood Phe Within Target Range. Out Of The Previous 26 Patients, 20 (77%) (8 Hpa, 11 Mild And 1 Classical Pku) Increased Np From Animal Sources (E.G. Dairy Products, Fish And Meat) And 6 Patients (23%) (3 Mild And 3 Classical Pku) From Plant Foods (Bread, Pasta, Potatoes). Median Protein Equivalent Intake From Phe-Free/Low-Phe Protein Substitute Decreased (0.82 Vs. 0.75 G/Kg, <I>P</I> = 0.01), While Median Blood Phe Levels Remained Unchanged (279 Vs. 288 Μmol/L, <I>P</I> = 0.06). Almost Two-Thirds Of Patients With Pku Tolerated Additional Np When Challenged And Still Maintained Blood Phe Within The National Target Range. This Suggests That Some Patients With Pku Treated By A Low-Phe Diet Only May Over Restrict Their Np Intake. In Order To Minimise The Burden Of Treatment And Optimise Np Intake, It Is Important To Challenge With Additional Np At Periodic Intervals.|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Highly Variable', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Pku Were Systematically', 'no label'), ('Challenged', 'no label'), ('Natural Protein', 'no label'), ('Blood Phe Levels Remained', 'no label'), ('Upper', 'no label'), ('Target', 'no label'), ('Blood Phe Level', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Portuguese Pku Guidelines', 'no label'), ('Patients', 'no label'), ('Tolerance', 'no label'), ('Calculated', 'no label'), ('Baseline', 'no label'), ('Median', 'no label'), ('Months', 'no label'), ('Systematic', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Anthropometry', 'no label'), ('Assessed', 'no label'), ('Times', 'no label'), ('Routine', 'no label'), ('Blood Phe Levels', 'no label'), ('Collected', 'no label'), ('Well-Controlled Pku', 'no label'), ('Patients', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Hpa', 'no label'), ('Mild', 'no label'), ('Classic Pku', 'no label'), ('Low-Phe Diet', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Years', 'no label'), ('Median Daily Np Intake', 'no label'), ('Increased', 'no label'), ('Assessments', 'no label'), ('G/Day', 'no label'), ('<I>P</I>', 'no label'), ('Twenty-Six', 'no label'), ('Patients', 'no label'), ('Increase', 'no label'), ('Median', 'no label'), ('Median', 'no label'), ('G/Day', 'no label'), ('G)/Day', 'no label'), ('Maintain', 'no label'), ('Blood Phe', 'no label'), ('Target Range', 'no label'), ('Patients', 'no label'), ('Hpa', 'no label'), ('Mild', 'no label'), ('Classical Pku', 'no label'), ('Increased', 'no label'), ('Animal', 'no label'), ('Sources', 'no label'), ('E.G. Dairy Products', 'no label'), ('Fish', 'no label'), ('Meat', 'no label'), ('Patients', 'no label'), ('Plant Foods', 'no label'), ('Bread', 'no label'), ('Pasta', 'no label'), ('Potatoes', 'no label'), ('Median Protein', 'no label'), ('Equivalent Intake', 'no label'), ('Phe-Free/Low-Phe Protein', 'no label'), ('Decreased', 'no label'), ('G/Kg', 'no label'), ('<I>P</I>', 'no label'), ('Median', 'no label'), ('Blood Phe Levels', 'no label'), ('Remained', 'no label'), ('Unchanged', 'no label'), ('Two-Thirds', 'no label'), ('Patients', 'no label'), ('Pku Tolerated Additional', 'no label'), ('Challenged', 'no label'), ('Blood Phe', 'no label'), ('National Target Range', 'no label'), ('Suggests', 'no label'), ('Patients', 'no label'), ('Pku Treated By A Low-Phe Diet', 'no label'), ('Np Intake', 'no label'), ('Order', 'no label'), ('Burden', 'no label'), ('Treatment', 'no label'), ('Optimise', 'no label'), ('Intake', 'no label'), ('Periodic Intervals', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Animal', 'no label'), ('Fish', 'no label'), ('Plant Foods', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Phe', 'no label')]|[]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phe', 'no label'), ('Np', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Blood', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Pku Patients', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('E.G. Dairy', 'no label'), ('Fish', 'no label'), ('Meat', 'no label'), ('Patients', 'no label'), ('Pasta', 'no label'), ('Potatoes', 'no label'), ('Phe-Free/Low-Phe', 'no label'), ('G/Kg', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~28302355|Reduction Of Bone Mineral Density And The Risk Of Osteopenia Have Been Reported To Occur In Phenylketonuria (Pku) Patients. This Study Aimed To Evaluate The Short-Term Effects Of Calcium Supplementation In Phenylketonuric Children And Adolescents. The Study Included 18 Patients With Pku Aged 5-18 Yr (61% Male) Under Clinical And Nutritional Treatment. Evaluation Of Food Intake, Anthropometry, And Biochemical And Phalangeal Quantitative Ultrasound Were Performed Before (Phase 1) And After (Phase 2) Calcium Supplementation (1000 Mg/D) For 34 D. Statistical Analysis Was Performed Using T Test For Paired Samples, Wilcoxon'S Test, And Mcnemar'S Test (P <0.05). There Was An Inadequate Intake Of Phosphorus And Vitamin D, The Same Occurring With Serum Concentrations Of These Nutrients. About 50% Of The Patients Had An Accumulation Of Adipose Tissue Measures, With A Negative Correlation Between Z-Score, Body Mass Index, And Phalangeal Quantitative Ultrasound (Amplitude-Dependent Speed Of Sound [Ad-Sos]). There Was A Significant Difference In Urinary Phosphorus Excretion With Higher Values Before Supplementation. Comparison Of The Two Phases Revealed Significantly Higher Ad-Sos Values After The Supplementation (P = 0.017). The Reduction In Phosphorus Excretion Associated With Increased Ad-Sos Between The Two Phases Suggested Increased Bone Formation, And Showed No Negative Effects In Relation To Short-Term Calcium Supplementation In Children And In Adolescents With Pku.|"[('Reduction', 'no label'), ('Bone Mineral Density', 'no label'), ('Risk', 'no label'), ('Osteopenia', 'no label'), ('Occur', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Evaluate', 'no label'), ('Short-Term Effects', 'no label'), ('Calcium', 'no label'), ('Supplementation', 'no label'), ('Phenylketonuric Children', 'no label'), ('Adolescents', 'no label'), ('Study', 'no label'), ('Patients', 'no label'), ('Pku Aged 5-18 Yr (61% Male)', 'no label'), ('Clinical', 'no label'), ('Nutritional Treatment', 'no label'), ('Evaluation', 'no label'), ('Food Intake', 'no label'), ('Anthropometry', 'no label'), ('Biochemical', 'no label'), ('Phalangeal Quantitative Ultrasound', 'no label'), ('Phase', 'no label'), ('Calcium Supplementation', 'no label'), ('Statistical Analysis', 'no label'), ('Performed', 'no label'), ('T Test', 'no label'), ('Paired Samples', 'no label'), (""Wilcoxon'S Test"", 'no label'), (""Mcnemar'S Test"", 'no label'), ('Inadequate Intake', 'no label'), ('Phosphorus', 'no label'), ('Vitamin D', 'no label'), ('Occurring', 'no label'), ('Serum', 'no label'), ('Concentrations', 'no label'), ('Nutrients', 'no label'), ('Patients', 'no label'), ('Accumulation', 'no label'), ('Adipose Tissue', 'no label'), ('Measures', 'no label'), ('Negative', 'no label'), ('Correlation', 'no label'), ('Z-Score', 'no label'), ('Body Mass Index', 'no label'), ('Phalangeal Quantitative Ultrasound', 'no label'), ('Amplitude-Dependent Speed Of Sound [Ad-Sos]', 'no label'), ('Difference', 'no label'), ('Urinary Phosphorus', 'no label'), ('Excretion', 'no label'), ('Higher', 'no label'), ('Values', 'no label'), ('Supplementation', 'no label'), ('Comparison', 'no label'), ('Phases', 'no label'), ('Revealed', 'no label'), ('Higher', 'no label'), ('Ad-Sos', 'no label'), ('Values', 'no label'), ('Supplementation', 'no label'), ('Reduction', 'no label'), ('Phosphorus', 'no label'), ('Excretion', 'no label'), ('Associated With', 'no label'), ('Increased', 'no label'), ('Ad-Sos', 'no label'), ('Phases', 'no label'), ('Increased', 'no label'), ('Bone Formation', 'no label'), ('No Negative', 'no label'), ('Effects', 'no label'), ('Short-Term', 'no label'), ('Calcium', 'no label'), ('Supplementation', 'no label'), ('Children', 'no label'), ('Adolescents', 'no label')]"|[('Mineral', 'no label'), ('Calcium', 'no label'), ('Food', 'no label'), ('Calcium', 'no label'), ('Phosphorus', 'no label'), ('Nutrients', 'no label'), ('Phosphorus', 'no label'), ('Phosphorus', 'no label'), ('Calcium', 'no label')]|[]|[('Osteopenia', 'no label'), ('Phenylketonuria', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Phosphorus And Vitamin D', 'no label'), ('Calcium', 'no label')]|[('Bone Mineral', 'no label'), ('Phenylketonuria', 'no label'), ('Calcium', 'no label'), ('Children', 'no label'), ('Patients', 'no label'), ('Pku Aged 5', 'no label'), ('Food', 'no label'), ('Phalangeal', 'no label'), ('Calcium', 'no label'), ('Phosphorus', 'no label'), ('Vitamin D', 'no label'), ('Serum', 'no label'), ('Patients', 'no label'), ('Adipose Tissue', 'no label'), ('Phalangeal', 'no label'), ('Sound [', 'no label'), ('Phosphorus', 'no label'), ('Phosphorus', 'no label'), ('Bone', 'no label'), ('Calcium', 'no label'), ('Children', 'no label')]
phenylketonuria|pubmed~30829006|"Genetic Heterogeneity And Compound Heterozygosis Give Rise To A Continuous Spectrum Of Phenylalanine Hydroxylase Deficiency And Metabolic Phenotypes In Phenylketonuria (Pku). The Most Used Parameters For Evaluating Phenotype In Pku Are Pretreatment Phenylalanine (Phe) Levels, Tolerance For Dietary Phe, And Phe Overloading Test. Phenotype Can Vary From A ""Classic"" (Severe) Form To Mild Hyperphenylalaninemia, Which Does Not Require Dietary Treatment. A Subset Of Patients Is Responsive To Treatment By The Cofactor Tetrahydrobiopterin (Bh<Sub>4</Sub> ). Genotypes Of Pku Patients From Rio De Janeiro, Brazil, Were Compared To Predicted And Observed Phenotypes. Genotype-Based Estimations Of Responsiveness To Bh<Sub>4</Sub> Were Also Conducted. Phenotype Was Defined By Pretreatment Phe Levels. A Standard Prediction System Based On Arbitrary Assigned Values Was Employed To Measure Genotype-Phenotype Concordance. Patients Were Also Estimated As Bh<Sub>4</Sub> -Responders According To The Responsiveness Previously Reported For Their Mutations And Genotypes. A 48.3% Concordance Rate Between Genotype-Predicted And Observed Phenotypes Was Found. When The Predicted Phenotypes Included Those Reported At The Biopku Database, The Concordance Rate Reached 77%. A Total Of 18 Genotypes From 30 Patients (29.4%) Were Estimated As Of Potential Or Probable Bh<Sub>4</Sub> Responsiveness. Inconsistencies Were Observed In Genotypic Combinations Including The Common ""Moderate"" Mutations P.R261Q, P.V388M, And P.I65T And The Mild Mutations P.L48S, P.R68S, And P.L249F. The High Discordance Rate Between Genotype-Predicted And Observed Metabolic Phenotypes In This Study Seems To Be Due Partially To The High Frequency Of The So-Called ""Moderate"" Common Mutations, P.R261Q, P.V388M, And P.I65T, Which Are Reported To Be Associated To Erratic Or More Severe Than Expected Metabolic Phenotypes. Although Our Results Of Bh<Sub>4</Sub> Estimated Responsiveness Must Be Regarded As Tentative, It Should Be Emphasized That Genotyping And Genotype-Phenotype Association Studies Are Important In Selecting Patients To Be Offered A Bh<Sub>4</Sub> Overload Test, Especially In Low-Resource Settings Like Brazil."|[('Genetic Heterogeneity', 'no label'), ('Compound Heterozygosis', 'no label'), ('Give Rise', 'no label'), ('Continuous Spectrum', 'no label'), ('Phenylalanine Hydroxylase Deficiency', 'no label'), ('Metabolic', 'no label'), ('Phenotypes', 'no label'), ('Phenylketonuria', 'no label'), ('Parameters', 'no label'), ('Evaluating', 'no label'), ('Phenotype', 'no label'), ('Pretreatment', 'no label'), ('Phenylalanine', 'no label'), ('Levels', 'no label'), ('Tolerance', 'no label'), ('Dietary Phe', 'no label'), ('Phe Overloading Test', 'no label'), ('Phenotype', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Dietary Treatment', 'no label'), ('Subset', 'no label'), ('Patients', 'no label'), ('Responsive To Treatment', 'no label'), ('Cofactor Tetrahydrobiopterin', 'no label'), ('Genotypes', 'no label'), ('Pku Patients', 'no label'), ('Rio De Janeiro', 'no label'), ('Brazil', 'no label'), ('Predicted', 'no label'), ('Observed', 'no label'), ('Phenotypes', 'no label'), ('Estimations', 'no label'), ('Responsiveness', 'no label'), ('Bh<Sub>4</Sub> Were', 'no label'), ('Phenotype', 'no label'), ('Pretreatment', 'no label'), ('Phe Levels', 'no label'), ('Standard Prediction System', 'no label'), ('Arbitrary Assigned Values', 'no label'), ('Employed', 'no label'), ('Measure', 'no label'), ('Concordance', 'no label'), ('Patients', 'no label'), ('Bh<Sub>4</Sub>', 'no label'), ('Responsiveness', 'no label'), ('Mutations', 'no label'), ('Genotypes', 'no label'), ('Concordance Rate', 'no label'), ('Genotype-Predicted', 'no label'), ('Observed', 'no label'), ('Phenotypes', 'no label'), ('Predicted', 'no label'), ('Phenotypes', 'no label'), ('Biopku Database', 'no label'), ('Concordance Rate', 'no label'), ('Genotypes', 'no label'), ('Patients', 'no label'), ('Estimated', 'no label'), ('Potential', 'no label'), ('Probable', 'no label'), ('Bh<Sub>4</Sub> Responsiveness', 'no label'), ('Inconsistencies', 'no label'), ('Observed', 'no label'), ('Genotypic Combinations', 'no label'), ('Mutations', 'no label'), ('P.V388M', 'no label'), ('P.I65T', 'no label'), ('Mild Mutations', 'no label'), ('High Discordance Rate', 'no label'), ('Genotype-Predicted', 'no label'), ('Observed', 'no label'), ('Metabolic', 'no label'), ('Phenotypes', 'no label'), ('Study', 'no label'), ('High Frequency', 'no label'), ('Moderate', 'no label'), ('Mutations', 'no label'), ('P.V388M', 'no label'), ('P.I65T', 'no label'), ('Associated To', 'no label'), ('Severe', 'no label'), ('Than Expected', 'no label'), ('Metabolic', 'no label'), ('Phenotypes', 'no label'), ('Bh<Sub>4</Sub> Estimated Responsiveness', 'no label'), ('Emphasized', 'no label'), ('Genotyping', 'no label'), ('Genotype-Phenotype Association Studies', 'no label'), ('Patients', 'no label'), ('Offered A', 'no label'), ('Bh<Sub>4</Sub> Overload Test', 'no label'), ('Low-Resource Settings', 'no label'), ('Brazil', 'no label')]|[('Genetic', 'no label'), ('Heterozygosis', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Genotypes', 'no label'), ('Phe', 'no label'), ('Mutations', 'no label'), ('Genotypes', 'no label'), ('Genotypes', 'no label'), ('Genotypic', 'no label'), ('Mutations', 'no label'), ('Mutations', 'no label'), ('Mutations', 'no label')]|[]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh', 'no label'), ('Phe', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Cofactor Tetrahydrobiopterin', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('P.I65T', 'no label'), ('P.I65T', 'no label'), ('Patients', 'no label'), ('Be Offered A', 'no label')]
phenylketonuria|pubmed~30706953|Biogenic Amines Synthesis In Phenylketonuria (Pku) Patients With High Phenylalanine (Phe) Concentration Is Thought To Be Impaired Due To Inhibition Of Tyrosine And Tryptophan Hydroxylases And Competition With Amino Acids At The Blood-Brain Barrier. Dopamine And Serotonin Deficits Might Explain Brain Damage And Progressive Neuropsychiatric Impairment In Adult Pku Patients. Ten Early Treated Adult Pku Patients (Mean Age 38.2 Years) And 15 Age-Matched Controls Entered The Study. Plasma And Cerebrospinal Fluid (Csf) Phe, 5-Hydroxyindoleacetic Acid (5-Hiaa), 5-Hydroxytryptophan (5-Htp), 3,4-Dihydroxy-L-Phenylalanine (L-Dopa) And Homovanillic Acid (Hva) Were Analyzed. Voxel-Based Morphometry Statistical Nonparametric Mapping Was Used To Test The Age-Corrected Correlation Between Gray Matter Atrophy And Csf Biogenic Amines Levels. 5-Hiaa And 5-Htp Were Significantly Reduced In Pku Patients Compared To Controls. Significant Negative Correlations Were Found Between Csf 5-Hiaa, Hva, And 5-Htp And Phe Levels. A Decrease In 5-Hiaa And 5-Htp Concentrations Correlated With Precuneus And Frontal Atrophy, Respectively. Lower Hva Levels Correlated With Occipital Atrophy. Biogenic Amines Deficits Correlate With Specific Brain Atrophy Patterns In Adult Pku Patients, In Line With Serotonin And Dopamine Projections. These Findings May Support A More Rigorous Phe Control In Adult Pku To Prevent Neurotransmitter Depletion And Accelerated Brain Damage Due To Aging.|[('Biogenic Amines', 'no label'), ('Synthesis', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('High Phenylalanine', 'no label'), ('Phe', 'no label'), ('Concentration', 'no label'), ('Impaired', 'no label'), ('Inhibition', 'no label'), ('Tyrosine', 'no label'), ('Tryptophan Hydroxylases', 'no label'), ('Competition', 'no label'), ('Amino Acids', 'no label'), ('Blood-Brain Barrier', 'no label'), ('Dopamine', 'no label'), ('Serotonin Deficits', 'no label'), ('Brain Damage', 'no label'), ('Progressive Neuropsychiatric Impairment', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Treated Adult', 'no label'), ('Patients', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Controls', 'no label'), ('Entered', 'no label'), ('Study', 'no label'), ('Plasma', 'no label'), ('Cerebrospinal Fluid', 'no label'), ('Phe', 'no label'), ('5-Hydroxyindoleacetic Acid', 'no label'), ('5-Hydroxytryptophan', 'no label'), ('5-Htp', 'no label'), ('L-Dopa', 'no label'), ('Homovanillic Acid', 'no label'), ('Hva', 'no label'), ('Analyzed', 'no label'), ('Voxel-Based Morphometry', 'no label'), ('Statistical Nonparametric Mapping', 'no label'), ('Age-Corrected Correlation', 'no label'), ('Gray Matter Atrophy', 'no label'), ('Csf', 'no label'), ('Biogenic Amines', 'no label'), ('Levels', 'no label'), ('5-Htp', 'no label'), ('Reduced', 'no label'), ('Pku Patients', 'no label'), ('Controls', 'no label'), ('Significant', 'no label'), ('Negative', 'no label'), ('Correlations', 'no label'), ('Csf', 'no label'), ('Hva', 'no label'), ('5-Htp', 'no label'), ('Phe Levels', 'no label'), ('Decrease', 'no label'), ('5-Htp', 'no label'), ('Concentrations', 'no label'), ('Correlated', 'no label'), ('Precuneus', 'no label'), ('Frontal Atrophy', 'no label'), ('Hva', 'no label'), ('Levels', 'no label'), ('Correlated', 'no label'), ('Occipital Atrophy', 'no label'), ('Biogenic Amines', 'no label'), ('Deficits', 'no label'), ('Correlate', 'no label'), ('Brain Atrophy', 'no label'), ('Patterns', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Serotonin', 'no label'), ('Dopamine', 'no label'), ('Projections', 'no label'), ('Findings', 'no label'), ('Phe Control', 'no label'), ('Prevent', 'no label'), ('Neurotransmitter', 'no label'), ('Depletion', 'no label'), ('Accelerated', 'no label'), ('Brain Damage', 'no label'), ('Aging', 'no label')]|[('Amines', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Amino Acids', 'no label'), ('Dopamine', 'no label'), ('Phe', 'no label'), ('5-Hydroxyindoleacetic Acid', 'no label'), ('3,4-Dihydroxy-L-Phenylalanine', 'no label'), ('L-Dopa', 'no label'), ('Homovanillic Acid', 'no label'), ('Hva', 'no label'), ('Hva', 'no label'), ('Phe', 'no label'), ('Hva', 'no label'), ('Serotonin And', 'no label'), ('Phe', 'no label'), ('Neurotransmitter', 'no label')]|[('5-Hiaa And 5-Htp', 'no label'), ('5-Hiaa And 5-Htp', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tryptophan', 'no label'), ('Amino Acids', 'no label'), ('Dopamine', 'no label'), ('Serotonin Deficits', 'no label'), ('Brain Damage', 'no label'), ('Neuropsychiatric Impairment', 'no label'), ('5-Hydroxyindoleacetic Acid', 'no label'), ('5-Hydroxytryptophan', 'no label'), ('3,4-Dihydroxy-L-Phenylalanine', 'no label'), ('L-Dopa', 'no label'), ('Homovanillic Acid', 'no label'), ('Atrophy', 'no label'), ('Phe', 'no label'), ('Atrophy', 'no label'), ('Occipital Atrophy', 'no label'), ('Brain Atrophy', 'no label'), ('Serotonin', 'no label'), ('Dopamine', 'no label'), ('Brain Damage', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('High Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tryptophan Hydroxylases', 'no label'), ('Amino Acids', 'no label'), ('Dopamine', 'no label'), ('Serotonin', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('Plasma', 'no label'), ('5-Hydroxyindoleacetic Acid', 'no label'), ('5-Hydroxytryptophan', 'no label'), ('L-Dopa', 'no label'), ('Homovanillic Acid', 'no label'), ('Gray', 'no label'), ('Csf Biogenic Amines', 'no label'), ('Patients', 'no label'), ('Csf', 'no label'), ('Phe', 'no label'), ('Precuneus', 'no label'), ('Frontal', 'no label'), ('Brain', 'no label'), ('Line', 'no label'), ('Serotonin', 'no label'), ('Dopamine', 'no label'), ('Neurotransmitter', 'no label'), ('Brain', 'no label')]
phenylketonuria|pubmed~31779649|The Objective Was To Deepen The Understanding Of The Causes Of Individual Variability In Phenylketonuria (Pku) By Investigating Which Metabolic Variables Are Most Important For Predicting Cognitive Outcomes (Phe Average Vs Phe Variation) And By Assessing The Risk Of Cognitive Impairment Associated With Adopting A More Relaxed Approach To The Diet Than Is Currently Recommended. We Analysed Associations Between Metabolic And Cognitive Measures In A Mixed Sample Of English And Italian Early-Treated Adults With Pku (N = 56). Metabolic Measures Were Collected Through Childhood, Adolescence And Adulthood; Cognitive Measures Were Collected In Adulthood. Metabolic Measures Included Average Phe Levels (Average Of Median Values For Each Year In A Given Period) And Average Phe Variations (Average Yearly Standard Deviations). Cognition Was Measured With Iq And A Battery Of Cognitive Tasks. Phe Variation Was As Important, If Not More Important, Than Phe Average In Predicting Adult Outcomes And Contributed Independently. Phe Variation Was Particularly Detrimental In Childhood. Together, Childhood Phe Variation And Adult Phe Average Predicted Around 40% Of The Variation In Cognitive Scores. Poor Cognitive Scores (> 1 Sd From Controls) Occurred Almost Exclusively In Individuals With Poor Metabolic Control And The Risk Of Poor Scores Was About 30% Higher In Individuals With Phe Values Exceeding Recommended Thresholds. Our Results Provide Support For Current European Guidelines (Average Phe Value = < 360 Μmol/L In Childhood; = < 600 Μmo/L From 12 Years Onwards), But They Suggest An Additional Recommendation To Maintain Stable Levels (Possibly Phe Sd = < 180 Μmol/L Throughout Life). We Investigated The Relationship Between How Well People With Phenylketonuria Control Blood Phe Throughout Their Life And Their Ability To Carry Out Cognitive Tasks In Adulthood. We Found That Avoiding Blood Phe Peaks Was As Important If Not More Important That Maintaining Average Low Phe Levels. This Was Particularly Essential In Childhood. We Also Found That Blood Phe Levels Above Recommended European Guidelines Was Associated With Around 30% Increase In The Risk Of Poor Cognitive Outcomes.|[('Objective', 'no label'), ('Causes', 'no label'), ('Variability', 'no label'), ('Phenylketonuria', 'no label'), ('Investigating', 'no label'), ('Metabolic', 'no label'), ('Variables', 'no label'), ('Predicting', 'no label'), ('Cognitive Outcomes', 'no label'), ('Phe', 'no label'), ('Variation', 'no label'), ('Assessing', 'no label'), ('Risk', 'no label'), ('Cognitive Impairment', 'no label'), ('Associated With', 'no label'), ('Adopting', 'no label'), ('Diet Than', 'no label'), ('Recommended', 'no label'), ('Analysed', 'no label'), ('Associations', 'no label'), ('Metabolic', 'no label'), ('Cognitive Measures', 'no label'), ('Sample', 'no label'), ('English', 'no label'), ('Italian', 'no label'), ('Early-Treated Adults', 'no label'), ('Pku (N\xa0', 'no label'), ('Metabolic Measures', 'no label'), ('Collected', 'no label'), ('Childhood', 'no label'), ('Adolescence', 'no label'), ('Adulthood', 'no label'), ('Cognitive Measures', 'no label'), ('Collected', 'no label'), ('Adulthood', 'no label'), ('Metabolic Measures', 'no label'), ('Average', 'no label'), ('Phe Levels', 'no label'), ('Median Values', 'no label'), ('Year', 'no label'), ('Period', 'no label'), ('Average', 'no label'), ('Phe', 'no label'), ('Variations', 'no label'), ('Deviations', 'no label'), ('Cognition', 'no label'), ('Measured', 'no label'), ('Battery', 'no label'), ('Cognitive Tasks', 'no label'), ('Phe', 'no label'), ('Variation', 'no label'), ('Than Phe', 'no label'), ('Average', 'no label'), ('Predicting', 'no label'), ('Adult', 'no label'), ('Outcomes', 'no label'), ('Contributed', 'no label'), ('Phe', 'no label'), ('Variation', 'no label'), ('Detrimental', 'no label'), ('Childhood', 'no label'), ('Childhood', 'no label'), ('Phe', 'no label'), ('Variation', 'no label'), ('Adult', 'no label'), ('Phe Average', 'no label'), ('Predicted', 'no label'), ('Variation', 'no label'), ('Cognitive Scores', 'no label'), ('Poor Cognitive Scores', 'no label'), ('Sd', 'no label'), ('Controls', 'no label'), ('Exclusively', 'no label'), ('Individuals', 'no label'), ('Poor Metabolic Control', 'no label'), ('Risk', 'no label'), ('Poor Scores', 'no label'), ('Higher', 'no label'), ('Individuals', 'no label'), ('Phe Values', 'no label'), ('Recommended Thresholds', 'no label'), ('Results', 'no label'), ('Provide Support', 'no label'), ('European', 'no label'), ('Guidelines', 'no label'), ('Average', 'no label'), ('Phe Value', 'no label'), ('Childhood', 'no label'), ('Suggest', 'no label'), ('Recommendation', 'no label'), ('Stable Levels', 'no label'), ('Phe Sd\u2009=\u2009<\u2009180\u2009Μmol/L Throughout Life', 'no label'), ('Investigated', 'no label'), ('Relationship', 'no label'), ('Well People', 'no label'), ('Phenylketonuria', 'no label'), ('Blood Phe', 'no label'), ('Life', 'no label'), ('Cognitive Tasks', 'no label'), ('Adulthood', 'no label'), ('Blood Phe Peaks', 'no label'), ('Average', 'no label'), ('Low', 'no label'), ('Phe Levels', 'no label'), ('Essential', 'no label'), ('Childhood', 'no label'), ('Blood Phe Levels Above', 'no label'), ('European', 'no label'), ('Associated With', 'no label'), ('Increase', 'no label'), ('Risk', 'no label'), ('Poor Cognitive Outcomes', 'no label')]|[('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Individuals', 'no label'), ('Individuals', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Iq', 'no label')]|[('Phenylketonuria', 'no label'), ('Cognitive Impairment', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Phe', 'no label'), ('Pku (N\xa0', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Iq And A Battery', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Individuals', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Blood Phe', 'no label'), ('Blood', 'no label'), ('Phe', 'no label'), ('Blood Phe', 'no label')]
phenylketonuria|pubmed~32049652|Background Diet Plays An Integral Role In The Maintenance Of Oral Health, But Dietary Modifications Due To Medical Problems Such As Phenylketonuria (Pku) Can Have Adverse Effects On Oral Health. This Descriptive Study Was Performed To Evaluate The Oral Health Status Of Children With Pku. Methods One Hundred And Ninety-Seven Patients With Pku Aged Between 1 And 22 Years Were Evaluated. Clinical Evaluations Were Performed By One Experienced Dentist Regarding Dental Caries, Gingival Health And Dental Erosion. Categorical Variables Were Assessed With Descriptive Statistics. Differences In Feeding Frequencies And Sociodemographic Characteristics Were Compared Regarding Dental Caries Using Chi-Square (Χ2) Tests. Results One Hundred And Thirty-Two Patients (67%) Had Dental Caries. The Mean Plaque Index (Pi) And Gingival Index (Gi) Values Were 1.37 ± 0.58 And 1.40 ± 0.64, Respectively, Which Shows Moderate Plaque Accumulation And Moderate Gingival Inflammation. Of The Patients, 85.3% Did Not Brush Their Teeth Regularly And 90.4% Had Never Visited A Dentist Before. No Statistically Significant Differences Were Found In Dental Caries According To Feeding Frequencies (P = 0.448). Conclusions Despite The High Prevalence Of Caries In Patients With Pku, Most Had Never Seen A Dentist. Physicians Must Encourage Patients With Pku And Their Parents To Have Regular Dental Visits To Maintain An Optimal General And Oral Health.|[('Background', 'no label'), ('Diet', 'no label'), ('Plays', 'no label'), ('Integral', 'no label'), ('Maintenance', 'no label'), ('Oral Health', 'no label'), ('Dietary Modifications', 'no label'), ('Medical Problems', 'no label'), ('Phenylketonuria', 'no label'), ('Have Adverse Effects', 'no label'), ('Oral Health', 'no label'), ('Descriptive Study', 'no label'), ('Evaluate', 'no label'), ('Oral Health Status', 'no label'), ('Children', 'no label'), ('Ninety-Seven', 'no label'), ('Patients', 'no label'), ('Pku Aged', 'no label'), ('Years', 'no label'), ('Evaluated', 'no label'), ('Clinical Evaluations', 'no label'), ('Performed', 'no label'), ('Experienced', 'no label'), ('Dentist', 'no label'), ('Dental Caries', 'no label'), ('Gingival Health And Dental', 'no label'), ('Erosion', 'no label'), ('Categorical Variables', 'no label'), ('Assessed With', 'no label'), ('Descriptive Statistics', 'no label'), ('Feeding', 'no label'), ('Frequencies', 'no label'), ('Sociodemographic Characteristics', 'no label'), ('Dental Caries', 'no label'), ('Chi-Square (Χ2) Tests', 'no label'), ('Thirty-Two', 'no label'), ('Patients', 'no label'), ('Dental Caries', 'no label'), ('Mean Plaque Index', 'no label'), ('Pi', 'no label'), ('Gingival Index', 'no label'), ('Moderate', 'no label'), ('Plaque', 'no label'), ('Accumulation', 'no label'), ('Moderate', 'no label'), ('Gingival Inflammation', 'no label'), ('Patients', 'no label'), ('Not Brush', 'no label'), ('Teeth', 'no label'), ('Regularly', 'no label'), ('Never Visited A', 'no label'), ('Dentist', 'no label'), ('Statistically Significant', 'no label'), ('Differences', 'no label'), ('Dental Caries', 'no label'), ('Feeding', 'no label'), ('Frequencies', 'no label'), ('High Prevalence', 'no label'), ('Caries', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Dentist', 'no label'), ('Physicians', 'no label'), ('Encourage', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Parents', 'no label'), ('Regular Dental Visits', 'no label'), ('Maintain', 'no label'), ('Optimal', 'no label'), ('General', 'no label'), ('Oral Health', 'no label')]|[('Pi', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Caries', 'no label'), ('Caries', 'no label'), ('Caries', 'no label'), ('Inflammation', 'no label'), ('Caries', 'no label'), ('Caries', 'no label')]|[('Integral', 'no label'), ('Oral', 'no label'), ('Phenylketonuria', 'no label'), ('Oral', 'no label'), ('Oral', 'no label'), ('Children', 'no label'), ('Ninety-Seven Patients', 'no label'), ('Patients', 'no label'), ('Pi', 'no label'), ('Gingival', 'no label'), ('Gingival', 'no label'), ('Patients', 'no label'), ('Brush', 'no label'), ('Caries', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Oral', 'no label')]
phenylketonuria|pubmed~31587319|Low Bone Mineral Density (Bmd) As A Risk Factor For Fractures Has Been A Long-Standing Concern In Phenylketonuria (Pku). It Is Hypothesised That The Disease Itself Or The Dietary Treatment Might Lead To A Low Bmd. Previous Studies Show Conflicting Results Of Bmd In Pku Due To Differences In Age, Techniques To Assess Bmd And Criteria Used. To Assess The Prevalence Of Low Bmd And Define Possible Risk Factors In A Large Number Of Adult, Early Treated Pku (Etpku) Patients. European Centres Were Invited For A Survey, Collecting Retrospective Data Including Results Of Dual-Energy X-Ray Absorptiometry (Dxa) Scans Of Adult Etpku Patients. Bmd Of 183 Adult Etpku Patients Aged 18-46 (Median Age 28, All Females Premenopausal) Years Was Lower Than In The General Population At Most Skeletal Sites But The Frequency Of Low Bmd (Z-Score <-2) Was At Maximum 5.5%. No Risk Factors For Low Bmd In Pku Patients Could Be Identified. Low Bmd Occurs Only In A Small Subset Of Pku Patients. Dxa Scans Should Be Considered For Well Controlled Patients From Age 35-40 Years And Up And On Indication In Those Pku Patients Considered To Be At Increased Risk For Fractures.|[('Low', 'no label'), ('Bone Mineral Density', 'no label'), ('Bmd', 'no label'), ('Risk Factor', 'no label'), ('Fractures', 'no label'), ('Long-Standing', 'no label'), ('Phenylketonuria', 'no label'), ('Hypothesised', 'no label'), ('Disease', 'no label'), ('Dietary Treatment', 'no label'), ('Lead', 'no label'), ('Low', 'no label'), ('Bmd', 'no label'), ('Studies', 'no label'), ('Bmd', 'no label'), ('Age', 'no label'), ('Techniques', 'no label'), ('Assess', 'no label'), ('Bmd', 'no label'), ('Criteria', 'no label'), ('Assess', 'no label'), ('Prevalence', 'no label'), ('Low', 'no label'), ('Bmd', 'no label'), ('Risk Factors', 'no label'), ('Adult', 'no label'), ('Early Treated Pku (Etpku)', 'no label'), ('Patients', 'no label'), ('European Centres', 'no label'), ('Retrospective Data', 'no label'), ('Results', 'no label'), ('Dual-Energy X-Ray Absorptiometry', 'no label'), ('Adult', 'no label'), ('Etpku', 'no label'), ('Patients', 'no label'), ('Bmd', 'no label'), ('Adult', 'no label'), ('Etpku', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Median Age', 'no label'), ('Females', 'no label'), ('Premenopausal', 'no label'), ('Years', 'no label'), ('General Population', 'no label'), ('Skeletal Sites', 'no label'), ('Frequency', 'no label'), ('Low Bmd', 'no label'), ('Z-Score', 'no label'), ('No Risk Factors', 'no label'), ('Low', 'no label'), ('Bmd', 'no label'), ('Patients', 'no label'), ('Identified', 'no label'), ('Low', 'no label'), ('Bmd', 'no label'), ('Occurs', 'no label'), ('Pku Patients', 'no label'), ('Dxa Scans', 'no label'), ('Well Controlled Patients', 'no label'), ('Age', 'no label'), ('Indication', 'no label'), ('Patients', 'no label'), ('Increased', 'no label'), ('Risk', 'no label'), ('Fractures', 'no label')]|[('Mineral', 'no label'), ('Lead To A Low', 'no label'), ('Dxa', 'no label'), ('Dxa', 'no label')]|[('Pku', 'no label')]|[('Fractures', 'no label'), ('Phenylketonuria', 'no label'), ('Dual-Energy', 'no label'), ('Fractures', 'no label')]|[('Bone Mineral Density', 'no label'), ('Phenylketonuria', 'no label'), ('Bmd', 'no label'), ('Bmd', 'no label'), ('Bmd', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Skeletal Sites', 'no label'), ('Bmd (Z-Score <', 'no label'), ('Pku Patients', 'no label'), ('Bmd', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31608347|Management Of Phenylketonuria (Pku) Requires Lifelong Restriction Of Phenylalanine (Phe) Intake Using Specialized Medical Foods To Prevent Neurocognitive Impairment In Affected Patients. However, Dietary Adherence Is Challenging To Maintain While Ensuring Adequate Nutrition, Which Can Lead To Sub-Optimal Clinical Outcomes. Metabolomics Offers A Systematic Approach To Identify New Biomarkers Of Disease Progression In Pku When Using Urine As A Surrogate For Blood Specimens That Is More Accurate Than Self-Reported Diet Records. Herein, The Plasma And Urine Metabolome Of A Cohort Of Classic Pku Patients (Median Age = 11 Years; N = 22) Mainly Prescribed (78%) A Phe-Restricted Diet Were Characterized Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry (Msi-Ce-Ms). Overall, There Was Good Mutual Agreement Between Plasma Phe And Tyrosine (Tyr) Concentrations Measured From Pku Patients When Using An Amino Acid Analyzer Based On Uplc-Uv As Compared To Msi-Ce-Ms With A Mean Bias Of 12% (N = 82). Longitudinal Measurements Of Recently Diagnosed Pku Infants (N = 3) Revealed Good Long-Term Regulation Of Blood Phe With Dietary Management, And Only Occasional Episodes Exceeding The Recommended Therapeutic Range (>360 Μm) Unlike Older Pku Patients. Plasma Metabolomic Studies Demonstrated That Non-Adherent Pku Patients Had Lower Circulating Concentrations Of Tyr, Arginine, 2-Aminobutyric Acid, And Propionylcarnitine (Q < 0.05, Fdr) That Were Inversely Correlated To Phe (R ≈ -0.600 To -0.830). Nontargeted Metabolite Profiling Also Revealed Urinary Biomarkers Associated With Poor Dietary Adherence Among Pku Patients, Including Elevated Concentrations Of Catabolites Indicative Of Phe Intoxication (E.G., Phenylpyruvic Acid, Phenylacetylglutamine, Hydroxyphenylacetic Acid). Additionally, Pku Patients With Poor Blood Phe Control Had Lower Excretion Of Urinary Compounds Derived From Co-Metabolism Of Tyr Due To Microbiota Activity (E.G., Cresol Sulfate, Phenylsulfate), As Well As Several Metabolites Associated With Inadequate Nutrient Intake, Including Low Carnitine And B Vitamin Status (E.G., Folic Acid, Vitamin B12). Interestingly, An Unknown Urinary Metabolite Was Strongly Correlated With Phe Excretion In Pku Patients (R = 0.861), Which Was Subsequently Identified As Imidazole Lactic Acid When Using High Resolution Ms/Ms. Overall, Urine Profiling Offers A Non-Invasive Approach For Better Treatment Monitoring Of Individual Pku Patients, Which Can Also Guide The Design Of Novel Therapies That Improve Adherence To Phe-Restricted Diets Without Acquired Nutritional Deficiencies.|[('Management', 'no label'), ('Phenylketonuria', 'no label'), ('Requires', 'no label'), ('Restriction', 'no label'), ('Phenylalanine (Phe) Intake', 'no label'), ('Specialized Medical Foods', 'no label'), ('Prevent Neurocognitive Impairment', 'no label'), ('Affected', 'no label'), ('Patients', 'no label'), ('Dietary Adherence', 'no label'), ('Maintain', 'no label'), ('Adequate', 'no label'), ('Nutrition', 'no label'), ('Lead', 'no label'), ('Clinical Outcomes', 'no label'), ('Metabolomics Offers A', 'no label'), ('Systematic Approach', 'no label'), ('Biomarkers', 'no label'), ('Disease Progression', 'no label'), ('Urine', 'no label'), ('Surrogate', 'no label'), ('Blood Specimens', 'no label'), ('Accurate', 'no label'), ('Than Self-Reported Diet Records', 'no label'), ('Plasma', 'no label'), ('Urine Metabolome', 'no label'), ('Cohort', 'no label'), ('Patients', 'no label'), ('Median Age', 'no label'), ('Years', 'no label'), ('Prescribed', 'no label'), ('Phe-Restricted Diet', 'no label'), ('Characterized', 'no label'), ('Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry', 'no label'), ('Good Mutual Agreement', 'no label'), ('Plasma', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Concentrations', 'no label'), ('Measured', 'no label'), ('Pku Patients', 'no label'), ('Amino Acid Analyzer', 'no label'), ('Bias', 'no label'), ('Longitudinal Measurements', 'no label'), ('Diagnosed Pku Infants', 'no label'), ('Revealed', 'no label'), ('Long-Term Regulation', 'no label'), ('Blood Phe', 'no label'), ('Dietary Management', 'no label'), ('Occasional Episodes', 'no label'), ('Recommended Therapeutic Range', 'no label'), ('Older Pku', 'no label'), ('Patients', 'no label'), ('Plasma', 'no label'), ('Metabolomic Studies', 'no label'), ('Non-Adherent', 'no label'), ('Patients', 'no label'), ('Circulating', 'no label'), ('Concentrations', 'no label'), ('Tyr', 'no label'), ('Arginine', 'no label'), ('2-Aminobutyric Acid', 'no label'), ('Propionylcarnitine', 'no label'), ('Fdr', 'no label'), ('Inversely', 'no label'), ('Correlated', 'no label'), ('Phe', 'no label'), ('Nontargeted', 'no label'), ('Metabolite', 'no label'), ('Profiling', 'no label'), ('Revealed', 'no label'), ('Urinary Biomarkers', 'no label'), ('Associated With', 'no label'), ('Poor', 'no label'), ('Dietary Adherence', 'no label'), ('Pku Patients', 'no label'), ('Elevated', 'no label'), ('Concentrations', 'no label'), ('Catabolites', 'no label'), ('Indicative', 'no label'), ('Phe Intoxication', 'no label'), ('Phenylpyruvic Acid', 'no label'), ('Phenylacetylglutamine', 'no label'), ('Hydroxyphenylacetic Acid', 'no label'), ('Pku Patients', 'no label'), ('Poor Blood Phe Control', 'no label'), ('Excretion', 'no label'), ('Urinary Compounds', 'no label'), ('Co-Metabolism', 'no label'), ('Tyr', 'no label'), ('Microbiota Activity', 'no label'), ('Cresol Sulfate', 'no label'), ('Phenylsulfate', 'no label'), ('Metabolites', 'no label'), ('Associated With', 'no label'), ('Inadequate', 'no label'), ('Nutrient Intake', 'no label'), ('Low', 'no label'), ('Carnitine', 'no label'), ('B Vitamin Status', 'no label'), ('Folic Acid', 'no label'), ('Vitamin B12', 'no label'), ('Unknown', 'no label'), ('Urinary Metabolite', 'no label'), ('Correlated', 'no label'), ('Phe', 'no label'), ('Excretion', 'no label'), ('Pku Patients', 'no label'), ('Identified', 'no label'), ('Imidazole Lactic Acid', 'no label'), ('Resolution', 'no label'), ('Ms/Ms', 'no label'), ('Urine Profiling', 'no label'), ('Offers A', 'no label'), ('Non-Invasive', 'no label'), ('Approach', 'no label'), ('Better Treatment', 'no label'), ('Monitoring', 'no label'), ('Pku Patients', 'no label'), ('Design', 'no label'), ('Therapies', 'no label'), ('Improve', 'no label'), ('Adherence', 'no label'), ('Phe-Restricted Diets', 'no label'), ('Acquired', 'no label'), ('Nutritional Deficiencies', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Foods', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Amino Acid', 'no label'), ('Tyr', 'no label'), ('Arginine', 'no label'), ('Propionylcarnitine', 'no label'), ('Catabolites', 'no label'), ('Phe', 'no label'), ('Phenylacetylglutamine', 'no label'), ('Tyr', 'no label'), ('Cresol Sulfate', 'no label'), ('Phenylsulfate', 'no label'), ('Nutrient', 'no label'), ('Carnitine', 'no label'), ('Folic Acid', 'no label'), ('Vitamin B12', 'no label'), ('Phe', 'no label'), ('Imidazole Lactic Acid', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Neurocognitive Impairment', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Tyr', 'no label'), ('Amino Acid Analyzer', 'no label'), ('Tyr', 'no label'), ('Arginine', 'no label'), ('Propionylcarnitine', 'no label'), ('Phe', 'no label'), ('R ≈ -0.600 To -0.830', 'no label'), ('E.G., Phenylpyruvic Acid', 'no label'), ('Phenylacetylglutamine', 'no label'), ('Tyr', 'no label'), ('Cresol Sulfate', 'no label'), ('Phenylsulfate', 'no label'), ('Carnitine', 'no label'), ('Folic Acid', 'no label'), ('Vitamin B12', 'no label'), ('Phe', 'no label'), ('Imidazole Lactic Acid', 'no label'), ('Nutritional Deficiencies', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Urine', 'no label'), ('Blood Specimens', 'no label'), ('Plasma', 'no label'), ('Urine Metabolome', 'no label'), ('Patients', 'no label'), ('Injection-Capillary Electrophoresis-Mass Spectrometry', 'no label'), ('Plasma Phe', 'no label'), ('Tyrosine', 'no label'), ('Patients', 'no label'), ('Amino Acid', 'no label'), ('Blood Phe', 'no label'), ('Plasma', 'no label'), ('Patients', 'no label'), ('Lower Circulating', 'no label'), ('Tyr', 'no label'), ('Arginine', 'no label'), ('2-Aminobutyric Acid', 'no label'), ('Propionylcarnitine', 'no label'), ('Phe (R ≈', 'no label'), ('Patients', 'no label'), ('Catabolites', 'no label'), ('Phe', 'no label'), ('Phenylacetylglutamine', 'no label'), ('Hydroxyphenylacetic Acid', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Tyr', 'no label'), ('Microbiota', 'no label'), ('Cresol Sulfate', 'no label'), ('Carnitine', 'no label'), ('B Vitamin', 'no label'), ('Folic Acid', 'no label'), ('Vitamin B12', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Imidazole Lactic Acid', 'no label'), ('Urine', 'no label')]
phenylketonuria|pubmed~31937333|Inherited Metabolic Diseases (Imds) Are A Group Of Individually Rare Single-Gene Diseases. For Many Imds, There Is A Paucity Of High-Quality Evidence That Evaluates The Effectiveness Of Clinical Interventions. Clinical Effectiveness Trials Of Imd Interventions Could Be Supported Through The Development Of Core Outcome Sets (Coss), A Recommended Minimum Set Of Standardized, High-Quality Outcomes And Associated Outcome Measurement Instruments To Be Incorporated By All Trials In An Area Of Study. We Began The Process Of Establishing Pediatric Coss For Two Imds, Medium-Chain Acyl-Coa Dehydrogenase (Mcad) Deficiency And Phenylketonuria (Pku), By Reviewing Published Literature To Describe Outcomes Reported By Authors, Identify Heterogeneity In Outcomes Across Studies, And Assemble A Candidate List Of Outcomes. We Used A Comprehensive Search Strategy To Identify Primary Studies And Guidelines Relevant To Children With Mcad Deficiency And Pku, Extracting Study Characteristics And Outcome Information From Eligible Studies Including Outcome Measurement Instruments For Select Outcomes. Informed By An Established Framework And A Previously Published Pediatric Cos, Outcomes Were Grouped Into Five, Mutually-Exclusive, A Priori Core Areas: Growth And Development, Life Impact, Pathophysiological Manifestations, Resource Use, And Death. For Mcad Deficiency, We Identified 83 Outcomes From 52 Articles. The Most Frequently Represented Core Area Was Pathophysiological Manifestations, With 33 Outcomes Reported In 29/52 Articles (56%). Death Was The Most Frequently Reported Outcome. One-Third Of Outcomes Were Reported By A Single Study. The Most Diversely Measured Outcome Was Cognition And Intelligence/Iq For Which Eight Unique Measurement Instruments Were Reported Among 14 Articles. For Pku, We Identified 97 Outcomes From 343 Articles. The Most Frequently Represented Core Area Was Pathophysiological Manifestations With 31 Outcomes Reported In 281/343 Articles (82%). Phenylalanine Concentration Was The Most Frequently Reported Outcome. Sixteen Percent Of Outcomes Were Reported By A Single Study. Similar To Mcad Deficiency, The Most Diversely Measured Pku Outcome Was Cognition And Intelligence/Iq With 39 Different Instruments Reported Among 82 Articles. Heterogeneity Of Reported Outcomes And Outcome Measurement Instruments Across Published Studies For Both Mcad Deficiency And Pku Highlights The Need For Coss For These Diseases, To Promote The Use Of Meaningful Outcomes And Facilitate Comparisons Across Studies.|[('Inherited', 'no label'), ('Metabolic Diseases', 'no label'), ('Imds', 'no label'), ('Group', 'no label'), ('Single-Gene Diseases', 'no label'), ('Imds', 'no label'), ('High-Quality', 'no label'), ('Evidence', 'no label'), ('Evaluates', 'no label'), ('Effectiveness', 'no label'), ('Clinical Interventions', 'no label'), ('Clinical Effectiveness Trials', 'no label'), ('Imd Interventions', 'no label'), ('Supported', 'no label'), ('Development', 'no label'), ('Core Outcome Sets', 'no label'), ('Coss', 'no label'), ('Recommended Minimum Set', 'no label'), ('Standardized', 'no label'), ('High-Quality', 'no label'), ('Outcomes', 'no label'), ('Trials', 'no label'), ('Area', 'no label'), ('Study', 'no label'), ('Began', 'no label'), ('Process', 'no label'), ('Pediatric Coss', 'no label'), ('Imds', 'no label'), ('Medium-Chain Acyl-Coa Dehydrogenase', 'no label'), ('Mcad', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Published Literature', 'no label'), ('Outcomes', 'no label'), ('Authors', 'no label'), ('Heterogeneity', 'no label'), ('Outcomes', 'no label'), ('Studies', 'no label'), ('Assemble A Candidate List', 'no label'), ('Outcomes', 'no label'), ('Comprehensive', 'no label'), ('Primary Studies', 'no label'), ('Guidelines', 'no label'), ('Relevant', 'no label'), ('Children', 'no label'), ('Mcad Deficiency', 'no label'), ('Characteristics', 'no label'), ('Outcome Information', 'no label'), ('Studies', 'no label'), ('Outcome Measurement Instruments', 'no label'), ('Select Outcomes', 'no label'), ('Established Framework', 'no label'), ('Pediatric', 'no label'), ('Outcomes', 'no label'), ('Grouped', 'no label'), ('Mutually-Exclusive', 'no label'), ('Core Areas', 'no label'), ('Growth', 'no label'), ('Life Impact', 'no label'), ('Pathophysiological', 'no label'), ('Manifestations', 'no label'), ('Resource Use', 'no label'), ('Death', 'no label'), ('Mcad Deficiency', 'no label'), ('Outcomes', 'no label'), ('Articles', 'no label'), ('Represented', 'no label'), ('Core Area', 'no label'), ('Pathophysiological', 'no label'), ('Manifestations', 'no label'), ('Outcomes', 'no label'), ('Reported', 'no label'), ('Articles', 'no label'), ('Death', 'no label'), ('Outcome', 'no label'), ('One-Third', 'no label'), ('Outcomes', 'no label'), ('Single Study', 'no label'), ('Diversely Measured Outcome', 'no label'), ('Intelligence/Iq', 'no label'), ('Measurement Instruments', 'no label'), ('Articles', 'no label'), ('Outcomes', 'no label'), ('Articles', 'no label'), ('Represented', 'no label'), ('Core Area', 'no label'), ('Pathophysiological', 'no label'), ('Manifestations', 'no label'), ('Outcomes', 'no label'), ('Reported', 'no label'), ('Articles', 'no label'), ('Phenylalanine Concentration', 'no label'), ('Outcome', 'no label'), ('Outcomes', 'no label'), ('Single Study', 'no label'), ('Mcad Deficiency', 'no label'), ('Diversely Measured Pku Outcome', 'no label'), ('Intelligence/Iq', 'no label'), ('Instruments', 'no label'), ('Reported', 'no label'), ('Articles', 'no label'), ('Heterogeneity', 'no label'), ('Outcomes', 'no label'), ('Outcome Measurement Instruments', 'no label'), ('Published Studies', 'no label'), ('Mcad Deficiency', 'no label'), ('Pku Highlights', 'no label'), ('Diseases', 'no label'), ('Promote', 'no label'), ('Meaningful', 'no label'), ('Outcomes', 'no label'), ('Comparisons', 'no label'), ('Studies', 'no label')]|[('Mcad', 'no label'), ('Mcad', 'no label'), ('Mcad', 'no label'), ('Phenylalanine', 'no label'), ('Mcad', 'no label'), ('Diversely', 'no label'), ('Mcad', 'no label')]|[('Imd', 'no label'), ('Medium-Chain Acyl-Coa Dehydrogenase', 'no label'), ('Intelligence/Iq', 'no label'), ('Intelligence/Iq', 'no label')]|[('Metabolic Diseases', 'no label'), ('Medium-Chain', 'no label'), ('Mcad', 'no label'), ('Phenylketonuria', 'no label'), ('Mcad', 'no label'), ('Death', 'no label'), ('Mcad', 'no label'), ('Death', 'no label'), ('Phenylalanine', 'no label'), ('Mcad', 'no label'), ('Mcad', 'no label')]|[('A', 'no label'), ('Imds', 'no label'), ('Imd', 'no label'), ('Imds', 'no label'), ('Medium-Chain Acyl-Coa Dehydrogenase', 'no label'), ('Mcad', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Mcad', 'no label'), ('Cos', 'no label'), ('Mcad', 'no label'), ('Intelligence/Iq', 'no label'), ('Phenylalanine', 'no label'), ('Mcad', 'no label'), ('Intelligence/Iq', 'no label'), ('Mcad', 'no label')]
phenylketonuria|pubmed~26061925|To Determine Verbal Intelligence And Spoken Language Of Children With Phenylketonuria And To Study The Effect Of Age At Diagnosis And Phenylalanine Plasma Level On These Abilities. Cross-Sectional. Children With Phenylketonuria Were Recruited From Pediatric Hospitals In 2012. Normal Control Subjects Were Recruited From Kindergartens In Tehran. 30 Phenylketonuria And 42 Control Subjects Aged 4-6.5 Years. Skills Were Compared Between 3 Phenylketonuria Groups Categorized By Age At Diagnosis/Treatment, And Between The Phenylketonuria And Control Groups. Scores On Wechsler Preschool And Primary Scale Of Intelligence For Verbal And Total Intelligence, And Test Of Language Development-Primary, Third Edition For Spoken Language, Listening, Speaking, Semantics, Syntax, And Organization. The Performance Of Control Subjects Was Significantly Better Than That Of Early-Treated Subjects For All Composite Quotients From Test Of Language Development And Verbal Intelligence (P<0.001). Early-Treated Subjects Scored Significantly Higher Than The Two Groups Of Late-Treated Subjects For Spoken Language (P=0.01), Speaking (P=0.04), Syntax (P=0.02), And Verbal Intelligence (P=0.019). There Was A Negative Correlation Between Phenylalanine Level And Verbal Intelligence (R=-0.79) In Early-Treated Subjects And Between Phenylalanine Level And Spoken Language (R=-0.71), Organization (R=-0.82) And Semantics (R=-0.82) For Late-Treated Subjects Diagnosed Before The Age One Year. The Study Confirmed That Diagnosis Of Newborns And Control Of Blood Phenylalanine Concentration Improves Verbal Intelligence And Spoken Language Scores In Phenylketonuria Subjects.|[('Verbal Intelligence And Spoken Language', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Study', 'no label'), ('Effect', 'no label'), ('Age', 'no label'), ('Diagnosis', 'no label'), ('Phenylalanine', 'no label'), ('Plasma', 'no label'), ('Level', 'no label'), ('Abilities', 'no label'), ('Cross-Sectional', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Pediatric Hospitals', 'no label'), ('Normal Control Subjects', 'no label'), ('Kindergartens', 'no label'), ('Tehran', 'no label'), ('Phenylketonuria', 'no label'), ('Control Subjects', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Skills', 'no label'), ('Phenylketonuria', 'no label'), ('Groups', 'no label'), ('Categorized', 'no label'), ('Age', 'no label'), ('Diagnosis/Treatment', 'no label'), ('Phenylketonuria', 'no label'), ('Control Groups', 'no label'), ('Scores', 'no label'), ('Wechsler Preschool', 'no label'), ('Primary Scale', 'no label'), ('Verbal', 'no label'), ('Total Intelligence', 'no label'), ('Test', 'no label'), ('Development-Primary', 'no label'), ('Spoken Language', 'no label'), ('Listening', 'no label'), ('Speaking', 'no label'), ('Semantics', 'no label'), ('Syntax', 'no label'), ('Organization', 'no label'), ('Performance', 'no label'), ('Control Subjects', 'no label'), ('Than', 'no label'), ('Early-Treated Subjects', 'no label'), ('Composite Quotients', 'no label'), ('Test', 'no label'), ('Language Development', 'no label'), ('Verbal Intelligence', 'no label'), ('Early-Treated Subjects', 'no label'), ('Scored', 'no label'), ('Groups', 'no label'), ('Late-Treated Subjects', 'no label'), ('Spoken Language', 'no label'), ('Speaking', 'no label'), ('Syntax', 'no label'), ('Verbal Intelligence', 'no label'), ('Was A', 'no label'), ('Negative', 'no label'), ('Correlation', 'no label'), ('Phenylalanine', 'no label'), ('Level', 'no label'), ('Early-Treated Subjects', 'no label'), ('Phenylalanine', 'no label'), ('Organization', 'no label'), ('Late-Treated Subjects', 'no label'), ('Diagnosed', 'no label'), ('Age', 'no label'), ('Study', 'no label'), ('Confirmed', 'no label'), ('Diagnosis', 'no label'), ('Newborns', 'no label'), ('Control', 'no label'), ('Blood Phenylalanine Concentration', 'no label'), ('Verbal Intelligence And Spoken Language', 'no label'), ('Phenylketonuria', 'no label'), ('Subjects', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label')]|[('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine Plasma', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Verbal', 'no label'), ('Verbal Intelligence', 'no label'), ('Verbal Intelligence', 'no label'), ('Phenylalanine', 'no label'), ('Verbal Intelligence', 'no label'), ('Phenylalanine', 'no label'), ('Newborns', 'no label'), ('Blood Phenylalanine', 'no label'), ('Verbal', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~29353259|Phenylketonuria (Pku) Is A Common Metabolic Disorder Caused Predominately By Mutations In The Phenylalanine Hydroxylase (<I>Pah</I>) Gene. The Aim Of The Study Was To Design And Validate The Performance Of A Non-Invasive Prenatal Test (Nipt) For Pku Using Circulating Single Molecule Amplification And Resequencing Technology (Csmart). A Total Of 18 Couples At Genetic Risk For Having A Child With Pku Were Recruited To The Study. Gold Standard Invasive Prenatal Diagnosis (Ipd) Was Performed On Amniocyte Or Villus Cell Dna By Sanger Sequencing, Targeting The Known Parental <I>Pah</I> Mutations. Retrospectively, Nipt Was Also Performed On Stored Maternal Plasma Samples From The 18 Pregnancies By A Multiplex Csmart Assay Designed To Target All Known Dna Variants In The <I>Pah</I> Gene. Benchmarking Against Ipd Results, Nipt Correctly Genotyped All Fetuses, Including Six Compound Heterozygotes With Pku, Four Normal Non-Carriers Of Pku And Eight Heterozygote Carriers Of Pku Comprising Five Cases Of A Maternally Inherited Mutation And Three Cases Of A Paternally Inherited Mutation. The Nipt Csmart Pku Assay Was Highly Sensitive And Specific For Mutation Detection And Correct Assignment Of Fetal Genotypes. Based On Comprehensive Mutation Coverage Across The <I>Pah</I> Gene, The Assay May Initially Have Clinical Utility As A Pregnancy Screening Test For High-Risk Carrier Couples.|[('Phenylketonuria', 'no label'), ('Common', 'no label'), ('Metabolic Disorder', 'no label'), ('Caused Predominately By Mutations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('<I>Pah</I>) Gene', 'no label'), ('Study', 'no label'), ('Validate', 'no label'), ('Performance', 'no label'), ('Non-Invasive Prenatal Test', 'no label'), ('Nipt', 'no label'), ('Circulating Single Molecule Amplification', 'no label'), ('Resequencing Technology', 'no label'), ('Csmart', 'no label'), ('Couples', 'no label'), ('Genetic Risk', 'no label'), ('Child', 'no label'), ('Study', 'no label'), ('Gold', 'no label'), ('Standard', 'no label'), ('Invasive', 'no label'), ('Prenatal Diagnosis', 'no label'), ('Ipd', 'no label'), ('Performed', 'no label'), ('Amniocyte', 'no label'), ('Villus Cell Dna', 'no label'), ('Sanger Sequencing', 'no label'), ('Targeting', 'no label'), ('Parental', 'no label'), ('Mutations', 'no label'), ('Retrospectively', 'no label'), ('Nipt', 'no label'), ('Performed', 'no label'), ('Stored', 'no label'), ('Maternal', 'no label'), ('Plasma', 'no label'), ('Samples', 'no label'), ('Pregnancies', 'no label'), ('Multiplex Csmart Assay', 'no label'), ('Target', 'no label'), ('Dna Variants', 'no label'), ('<I>Pah</I> Gene', 'no label'), ('Against Ipd Results', 'no label'), ('Nipt Correctly', 'no label'), ('Genotyped', 'no label'), ('Fetuses', 'no label'), ('Compound', 'no label'), ('Heterozygotes', 'no label'), ('Pku', 'no label'), ('Non-Carriers', 'no label'), ('Heterozygote Carriers', 'no label'), ('Pku Comprising', 'no label'), ('Cases', 'no label'), ('Maternally Inherited', 'no label'), ('Cases', 'no label'), ('Paternally Inherited', 'no label'), ('Mutation', 'no label'), ('Nipt Csmart Pku Assay', 'no label'), ('Sensitive', 'no label'), ('Mutation Detection', 'no label'), ('Correct', 'no label'), ('Assignment', 'no label'), ('Fetal Genotypes', 'no label'), ('Comprehensive', 'no label'), ('Mutation Coverage', 'no label'), ('<I>Pah</I> Gene', 'no label'), ('Assay', 'no label'), ('Clinical', 'no label'), ('Pregnancy Screening Test', 'no label'), ('High-Risk Carrier', 'no label'), ('Couples', 'no label')]|[('Mutations', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Gene', 'no label'), ('Genetic', 'no label'), ('Amniocyte', 'no label'), ('Cell Dna', 'no label'), ('Mutations', 'no label'), ('Known Dna Variants', 'no label'), ('Gene', 'no label'), ('Mutation', 'no label'), ('Mutation', 'no label'), ('Mutation', 'no label'), ('Genotypes', 'no label'), ('Mutation', 'no label'), ('Gene', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Circulating Single Molecule', 'no label'), ('Or Villus Cell Dna', 'no label'), ('Dna Variants', 'no label')]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Technology', 'no label'), ('Amniocyte', 'no label'), ('Villus Cell', 'no label'), ('Nipt', 'no label'), ('Plasma', 'no label'), ('Pregnancies', 'no label'), ('Dna', 'no label'), ('Fetuses', 'no label'), ('Nipt Csmart Pku', 'no label'), ('Fetal', 'no label'), ('Carrier', 'no label')]
phenylketonuria|pubmed~34266901|Evidence To Guide Treatment Of Pediatric Medium-Chain Acyl-Coenzyme A Dehydrogenase (Mcad) Deficiency And Phenylketonuria (Pku) Is Fragmented Because Of Large Variability In Outcome Selection And Measurement. Our Goal Was To Develop Core Outcome Sets (Coss) For These Diseases To Facilitate Meaningful Future Evidence Generation And Enhance The Capacity To Compare And Synthesize Findings Across Studies. Parents And/Or Caregivers, Health Professionals, And Health Policy Advisors Completed A Delphi Survey And Participated In A Consensus Workshop To Select Core Outcomes From Candidate Lists Of Outcomes For Mcad Deficiency And Pku. Delphi Participants Rated The Importance Of Outcomes On A Nine-Point Scale (1-3: Not Important, 4-6: Important But Not Critical, 7-9: Critical). Candidate Outcomes Were Progressively Narrowed Down Over 3 Survey Rounds. At The Workshop, Participants Evaluated The Remaining Candidate Outcomes Using An Adapted Nominal Technique, Open Discussion, And Voting. After The Workshop, We Finalized The Coss And Recommended Measurement Instruments For Each Outcome. There Were 85, 61, And 53 Participants Across 3 Delphi Rounds, Respectively. The Candidate Core Outcome Lists Were Narrowed Down To 20 Outcomes Per Disease To Be Discussed At The Consensus Workshop. Voting By 18 Workshop Participants Led To Coss Composed Of 8 And 9 Outcomes For Mcad Deficiency And Pku, Respectively, With Measurement Recommendations. These Are The First Known Pediatric Coss For Mcad Deficiency And Pku. Adoption In Future Studies Will Help To Ensure Best Use Of Limited Research Resources To Ultimately Improve Care For Children With These Rare Diseases.|[('Evidence', 'no label'), ('Guide Treatment', 'no label'), ('Pediatric', 'no label'), ('Medium-Chain Acyl-Coenzyme A Dehydrogenase', 'no label'), ('Mcad', 'no label'), ('Phenylketonuria', 'no label'), ('Fragmented', 'no label'), ('Variability', 'no label'), ('Outcome Selection', 'no label'), ('Measurement', 'no label'), ('Goal', 'no label'), ('Core Outcome Sets', 'no label'), ('Diseases', 'no label'), ('Meaningful', 'no label'), ('Evidence', 'no label'), ('Generation', 'no label'), ('Enhance', 'no label'), ('Capacity', 'no label'), ('Compare', 'no label'), ('Synthesize', 'no label'), ('Findings', 'no label'), ('Studies', 'no label'), ('Parents', 'no label'), ('And/Or', 'no label'), ('Caregivers', 'no label'), ('Health Professionals', 'no label'), ('Health Policy Advisors', 'no label'), ('Completed A Delphi Survey', 'no label'), ('Consensus Workshop', 'no label'), ('Core Outcomes', 'no label'), ('Candidate Lists', 'no label'), ('Outcomes', 'no label'), ('Mcad Deficiency', 'no label'), ('Outcomes', 'no label'), ('Nine-Point Scale', 'no label'), ('Not Important', 'no label'), ('Critical', 'no label'), ('Candidate Outcomes', 'no label'), ('Narrowed', 'no label'), ('Down', 'no label'), ('Workshop', 'no label'), ('Participants', 'no label'), ('Evaluated', 'no label'), ('Outcomes', 'no label'), ('Adapted Nominal Technique', 'no label'), ('Open Discussion', 'no label'), ('Voting', 'no label'), ('Workshop', 'no label'), ('Coss And Recommended Measurement Instruments', 'no label'), ('Outcome', 'no label'), ('Participants', 'no label'), ('Delphi Rounds', 'no label'), ('Core Outcome Lists', 'no label'), ('Narrowed', 'no label'), ('Down', 'no label'), ('Outcomes Per Disease', 'no label'), ('Consensus Workshop', 'no label'), ('Workshop Participants', 'no label'), ('Outcomes', 'no label'), ('Mcad Deficiency', 'no label'), ('Measurement', 'no label'), ('Recommendations', 'no label'), ('Pediatric Coss', 'no label'), ('Mcad Deficiency', 'no label'), ('Adoption', 'no label'), ('Studies', 'no label'), ('Will Help', 'no label'), ('Best', 'no label'), ('Limited Research Resources', 'no label'), ('Children', 'no label'), ('Rare', 'no label'), ('Diseases', 'no label')]|[('Acyl-Coenzyme A Dehydrogenase (Mcad', 'no label'), ('Mcad', 'no label'), ('Mcad', 'no label'), ('Mcad', 'no label')]|[('Per', 'no label')]|[('Mcad', 'no label'), ('Phenylketonuria', 'no label'), ('And/Or', 'no label'), ('Mcad', 'no label'), ('Be', 'no label'), ('Mcad', 'no label')]|[('Medium-Chain Acyl-Coenzyme A Dehydrogenase', 'no label'), ('Mcad', 'no label'), ('Phenylketonuria', 'no label'), ('And/Or', 'no label'), ('Mcad', 'no label'), ('7-9', 'no label'), ('Mcad', 'no label'), ('Mcad', 'no label'), ('Ensure', 'no label'), ('Children', 'no label')]
phenylketonuria|pubmed~29777816|The Genetic Disorder Phenylketonuria (Pku) Is The Inability To Metabolize Phenylalanine Because Of A Lack Of The Enzyme Phenylalanine Hydroxylase. Phenylalanine Is Used To Biochemically Form Proteins, Coded For By Dna. The Development Of An Apta-Assay For Detection Of L-Phenylalanine Is Presented In This Work. A Highly Specific Dna-Aptamer, Selected To L-Phenylalanine Was Immobilized Onto A Gold Nanostructure And Electrochemical Measurements Were Performed In A Solution Containing The Phosphate Buffer Solution With Physiological Ph. We Have Constructed An Aptamer Immobilized Gold Nanostructure Mediated, Ultrasensitive Electrochemical Biosensor (Apt/Aunss/Au Electrode) For L-Phenylalanine Detection Without Any Additional Signal Amplification Strategy. The Aptamer Assemble Onto The Aunss Makes Apt/Aunss/Au Electrode An Excellent Platform For The L-Phenylalanine Detection In Physiological Like Condition. Differential Pulse Voltammetry Were Used For The Quantitative L-Phenylalanine Detection. The Apt/Aunss/Au Electrode Offers An Ultrasensitive And Selective Detection Of L-Phenylalanine Down To 0.23 Μm Level With A Wide Dynamic Range From 0.72 Μm-6 Mm. The Aptasensor Exhibited Excellent Selectivity And Stability. The Real Sample Analysis Was Performed By Spiking The Unprocessed Human Serum Samples With Various Concentration Of L-Phenylalanine And Obtained Recovery Within 2% Error Value. The Sensor Is Found To Be More Sensitive Than Most Of The Literature Reports. The Simple And Easy Way Of Construction Of This Apta-Assay Provides An Efficient And Promising Diagnosis Of Phenylketonuria.|[('Genetic Disorder Phenylketonuria', 'no label'), ('Metabolize Phenylalanine', 'no label'), ('Lack', 'no label'), ('Enzyme Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Biochemically Form Proteins', 'no label'), ('Dna', 'no label'), ('Development', 'no label'), ('Apta-Assay', 'no label'), ('Detection', 'no label'), ('L-Phenylalanine', 'no label'), ('Work', 'no label'), ('Dna-Aptamer', 'no label'), ('L-Phenylalanine', 'no label'), ('Immobilized', 'no label'), ('Onto A', 'no label'), ('Gold', 'no label'), ('Nanostructure', 'no label'), ('Electrochemical Measurements', 'no label'), ('Performed', 'no label'), ('Solution', 'no label'), ('Containing', 'no label'), ('Phosphate Buffer', 'no label'), ('Solution', 'no label'), ('Physiological', 'no label'), ('Constructed', 'no label'), ('Aptamer', 'no label'), ('Immobilized', 'no label'), ('Gold', 'no label'), ('Nanostructure', 'no label'), ('Mediated', 'no label'), ('Ultrasensitive Electrochemical Biosensor', 'no label'), ('L-Phenylalanine Detection', 'no label'), ('Signal Amplification', 'no label'), ('Strategy', 'no label'), ('Aptamer Assemble Onto', 'no label'), ('Aunss', 'no label'), ('L-Phenylalanine Detection', 'no label'), ('Physiological', 'no label'), ('Condition', 'no label'), ('Pulse Voltammetry', 'no label'), ('Quantitative L-Phenylalanine Detection', 'no label'), ('Apt/Aunss/Au Electrode', 'no label'), ('Ultrasensitive', 'no label'), ('Detection', 'no label'), ('L-Phenylalanine Down', 'no label'), ('Wide Dynamic Range', 'no label'), ('Aptasensor', 'no label'), ('Excellent', 'no label'), ('Selectivity', 'no label'), ('Stability', 'no label'), ('Real Sample Analysis', 'no label'), ('Performed By Spiking', 'no label'), ('Unprocessed', 'no label'), ('Concentration', 'no label'), ('L-Phenylalanine', 'no label'), ('Recovery', 'no label'), ('Error Value', 'no label'), ('Sensor', 'no label'), ('Sensitive', 'no label'), ('Literature Reports', 'no label'), ('Construction', 'no label'), ('Apta-Assay Provides', 'no label'), ('Efficient', 'no label'), ('Diagnosis', 'no label'), ('Phenylketonuria', 'no label')]|[('Genetic', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('Gold', 'no label'), ('Phosphate', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('Unprocessed Human', 'no label'), ('L-Phenylalanine', 'no label')]|[]|[('Disorder Phenylketonuria', 'no label'), ('Metabolize Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('Phosphate', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phenylalanine Down', 'no label'), ('L-Phenylalanine', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Dna', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('Onto', 'no label'), ('Aunss', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phenylalanine', 'no label'), ('Human Serum Samples', 'no label'), ('L-Phenylalanine', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~29433755|Strict Low-Phenylalanine Diet Is Associated With An Increased Risk Of Developing Micronutrient Deficiencies In Patients With Phenylketonuria (Pku). The Primary Objective Of This Single-Center, Case-Control Study Was To Assess The Nutritional Parameters Of Patients With Pku On Strict Low-Phenylalanine Diet Without Vitamin And Mineral Supplementation Compared To A Healthy Control Group. Secondary Objective Was To Identify The Adequacy Of Vitamin/Mineral Supplementation In Phenylalanine-Free (Phe-Free) Amino Acid Formulas. A Total Of 112 Age- And Sex-Matched Patients With Pku And 36 Controls Who Did Not Take Vitamin Or Mineral Supplementation At Least For The Last 6 Months Were Enrolled In The Study. Biochemical And Hematological Markers Including Hemoglobin, Serum Vitamin B12, Folic Acid, Iron, Ferritin, Transferrin Saturation, Copper, Prealbumin, Albumin, Total Protein, Phosphorus, Calcium, 25-Hydroxy Vitamin D, Zinc, Vitamin A And Vitamin E Levels Were Screened From Fasting Morning Blood Samples. One Hundred And Twelve Patients With Classical Pku (53 Females, 47.3%) And 36 Healthy Controls (18 Females, 50.0%) Were Enrolled In The Study. The Mean Age Of Patients With Pku Was 136.8 ± 82.1 Months (18-377). Median Serum Vitamin B12 Level Of Patients With Pku Was Found To Be Higher Than The Control Group (P = 0.002). Vitamin B12 Deficiency Was 15.2% And 30.6% In Patients With Pku And Healthy Controls, Respectively (P = 0.040). Mean Serum Folic Acid Level Was Higher In Patients With Pku Than The Control Group (P < 0.0001). In 55.4% Of Patients With Pku, And 2.8% Of The Control Group, Serum Folic Acid Level Was Above The Reference Range (P < 0.0001). The Frequency Of Ferritin And Prealbumin Values Above The Reference Range Was Found To Be Higher In Patients With Pku Compared To The Control Group (44.4% Vs 16.9%, P = 0.001; 38.8% Vs 22.1%, P = 0.020, Respectively). 25-Hydroxy Vitamin D Deficiency Was Detected In 53.6% And 47.2% Of Patients With Pku And The Control Group, Respectively. Mean Serum Copper Level Was Higher In The Well-Controlled (114.3 ± 26.7 Μg/Dl) Group Than The Poorly Controlled Group (101.0 ± 29.1 Μg/Dl) (P = 0.022). Phe-Free Amino Acid Formulas Provide Adequate Vitamin A And Zinc Levels In Patients With Pku, And Result In Excess Folic Acid, Vitamin B12, Copper And Vitamin E Values That Are Higher Than Required Levels. Our Results Demonstrate A High Percentage Of Vitamin D Deficiency In Patients With Classical Pku And Also In Healthy Controls In Turkey.|[('Low-Phenylalanine', 'no label'), ('Diet', 'no label'), ('Associated With', 'no label'), ('Increased', 'no label'), ('Risk', 'no label'), ('Micronutrient Deficiencies', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Objective', 'no label'), ('Single-Center', 'no label'), ('Case-Control Study', 'no label'), ('Assess', 'no label'), ('Nutritional', 'no label'), ('Parameters', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Low-Phenylalanine', 'no label'), ('Diet', 'no label'), ('Vitamin', 'no label'), ('Mineral Supplementation', 'no label'), ('Healthy', 'no label'), ('Control Group', 'no label'), ('Secondary Objective', 'no label'), ('Adequacy', 'no label'), ('Vitamin/Mineral', 'no label'), ('Supplementation', 'no label'), ('Phenylalanine-Free (Phe-Free) Amino Acid', 'no label'), ('Formulas', 'no label'), ('Age- And', 'no label'), ('Sex-Matched', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Controls', 'no label'), ('Vitamin', 'no label'), ('Mineral Supplementation', 'no label'), ('Months', 'no label'), ('Study', 'no label'), ('Biochemical', 'no label'), ('Hematological', 'no label'), ('Markers', 'no label'), ('Hemoglobin', 'no label'), ('Serum Vitamin B12', 'no label'), ('Folic Acid', 'no label'), ('Iron', 'no label'), ('Ferritin', 'no label'), ('Transferrin', 'no label'), ('Saturation', 'no label'), ('Copper', 'no label'), ('Prealbumin', 'no label'), ('Albumin', 'no label'), ('Total Protein', 'no label'), ('Phosphorus', 'no label'), ('Calcium', 'no label'), ('25-Hydroxy Vitamin D', 'no label'), ('Zinc', 'no label'), ('Vitamin A', 'no label'), ('Vitamin E Levels', 'no label'), ('Screened', 'no label'), ('Fasting', 'no label'), ('Morning', 'no label'), ('Blood Samples', 'no label'), ('Patients', 'no label'), ('Classical Pku', 'no label'), ('Females', 'no label'), ('Healthy Controls', 'no label'), ('Females', 'no label'), ('Study', 'no label'), ('Mean Age', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Months', 'no label'), ('Median', 'no label'), ('Serum', 'no label'), ('Vitamin B12', 'no label'), ('Level', 'no label'), ('Patients', 'no label'), ('Pku Was', 'no label'), ('Higher', 'no label'), ('Control Group', 'no label'), ('Vitamin B12 Deficiency', 'no label'), ('Patients', 'no label'), ('Pku And Healthy Controls', 'no label'), ('Serum Folic Acid', 'no label'), ('Level', 'no label'), ('Patients', 'no label'), ('Pku Than', 'no label'), ('Control Group', 'no label'), ('P\xa0<\xa00.0001', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Control Group', 'no label'), ('Serum Folic Acid', 'no label'), ('Level', 'no label'), ('Reference Range', 'no label'), ('Frequency', 'no label'), ('Ferritin', 'no label'), ('Prealbumin', 'no label'), ('Reference Range', 'no label'), ('Higher', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Control Group', 'no label'), ('25-Hydroxy Vitamin D Deficiency', 'no label'), ('Detected', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Control Group', 'no label'), ('Serum', 'no label'), ('Level', 'no label'), ('Well-Controlled', 'no label'), ('Group', 'no label'), ('Poorly Controlled Group', 'no label'), ('Phe-Free', 'no label'), ('Amino Acid', 'no label'), ('Formulas', 'no label'), ('Provide', 'no label'), ('Adequate', 'no label'), ('Vitamin A', 'no label'), ('Zinc Levels', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Excess', 'no label'), ('Folic Acid', 'no label'), ('Vitamin B12', 'no label'), ('Copper', 'no label'), ('Vitamin E', 'no label'), ('Values', 'no label'), ('Higher', 'no label'), ('Than Required', 'no label'), ('Levels', 'no label'), ('Results', 'no label'), ('Demonstrate', 'no label'), ('Percentage', 'no label'), ('Vitamin D Deficiency', 'no label'), ('Patients', 'no label'), ('Classical Pku', 'no label'), ('Healthy Controls', 'no label'), ('Turkey', 'no label')]|[('Vitamin', 'no label'), ('Mineral', 'no label'), ('Amino Acid', 'no label'), ('Vitamin', 'no label'), ('Mineral', 'no label'), ('Hemoglobin', 'no label'), ('Vitamin', 'no label'), ('Folic Acid', 'no label'), ('Iron', 'no label'), ('Ferritin', 'no label'), ('Transferrin', 'no label'), ('Copper', 'no label'), ('Prealbumin', 'no label'), ('Albumin', 'no label'), ('Protein', 'no label'), ('Phosphorus', 'no label'), ('Calcium', 'no label'), ('Vitamin D', 'no label'), ('Zinc', 'no label'), ('Vitamin A', 'no label'), ('Vitamin', 'no label'), ('Ferritin', 'no label'), ('Prealbumin', 'no label'), ('Vitamin', 'no label'), ('Copper', 'no label'), ('Vitamin A', 'no label'), ('Zinc', 'no label'), ('Vitamin B12', 'no label'), ('Copper', 'no label')]|[('Phenylalanine-Free', 'no label'), ('Who Did', 'no label'), ('Hemoglobin', 'no label'), ('Transferrin', 'no label'), ('Prealbumin', 'no label')]|[('Micronutrient Deficiencies', 'no label'), ('Phenylketonuria', 'no label'), ('Vitamin And Mineral Supplementation', 'no label'), ('Amino Acid', 'no label'), ('Vitamin Or Mineral Supplementation', 'no label'), ('Vitamin B12', 'no label'), ('Folic Acid', 'no label'), ('Iron', 'no label'), ('Copper', 'no label'), ('Calcium', 'no label'), ('25-Hydroxy Vitamin D', 'no label'), ('Vitamin A', 'no label'), ('Vitamin E', 'no label'), ('Vitamin B12', 'no label'), ('Vitamin B12', 'no label'), ('Folic Acid', 'no label'), ('Folic Acid', 'no label'), ('25-Hydroxy Vitamin D Deficiency', 'no label'), ('Amino Acid Formulas Provide', 'no label'), ('Vitamin A', 'no label'), ('Zinc', 'no label'), ('Folic Acid', 'no label'), ('Vitamin B12', 'no label'), ('Copper', 'no label'), ('Vitamin E', 'no label'), ('Vitamin D Deficiency', 'no label')]|[('Low-Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Low-Phenylalanine', 'no label'), ('Vitamin', 'no label'), ('Mineral', 'no label'), ('Vitamin/Mineral', 'no label'), ('Phenylalanine-Free', 'no label'), ('Phe-Free', 'no label'), ('Amino Acid', 'no label'), ('Sex-Matched Patients', 'no label'), ('Pku And 36', 'no label'), ('Vitamin', 'no label'), ('Mineral', 'no label'), ('Last 6', 'no label'), ('Hemoglobin', 'no label'), ('Serum Vitamin B12', 'no label'), ('Folic Acid', 'no label'), ('Iron', 'no label'), ('Ferritin', 'no label'), ('Transferrin', 'no label'), ('Copper', 'no label'), ('Prealbumin', 'no label'), ('Albumin', 'no label'), ('Phosphorus', 'no label'), ('Calcium', 'no label'), ('25-Hydroxy Vitamin D', 'no label'), ('Zinc', 'no label'), ('Vitamin A', 'no label'), ('Vitamin E', 'no label'), ('Blood Samples', 'no label'), ('Patients', 'no label'), ('Pku (53', 'no label'), ('Patients', 'no label'), ('Pku Was 136.8', 'no label'), ('Serum Vitamin B12', 'no label'), ('Patients', 'no label'), ('Pku Was Found', 'no label'), ('Vitamin B12', 'no label'), ('Patients', 'no label'), ('Serum Folic Acid', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Serum Folic Acid', 'no label'), ('Ferritin', 'no label'), ('Prealbumin', 'no label'), ('Patients', 'no label'), ('Vitamin D', 'no label'), ('Patients', 'no label'), ('Serum Copper', 'no label'), ('Phe-Free Amino', 'no label'), ('Vitamin', 'no label'), ('Patients', 'no label'), ('Folic Acid', 'no label'), ('Vitamin B12', 'no label'), ('Copper', 'no label'), ('Vitamin E', 'no label'), ('Vitamin D', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31433494|Analysis Of Blood Phenylalanine Is Central To The Monitoring Of Patients With Phenylketonuria (Pku) And Age-Related Phenylalanine Target Treatment-Ranges (0-12 Years; 120-360 Μmol/L, And >12 Years; 120-600 Μmol/L) Are Recommended In Order To Prevent Adverse Neurological Outcomes. These Target Treatment-Ranges Are Based Upon Plasma Phenylalanine Concentrations. However, Patients Are Routinely Monitored Using Dried Bloodspot (Dbs) Specimens Due To The Convenience Of Collection. Significant Differences Exist Between Phenylalanine Concentrations In Plasma And Dbs, With Phenylalanine Concentrations In Dbs Specimens Analyzed By Flow-Injection Analysis Tandem Mass Spectrometry Reported To Be 18% To 28% Lower Than Paired Plasma Concentrations Analyzed Using Ion-Exchange Chromatography. Dbs Specimens With Phenylalanine Concentrations Of 360 And 600 Μmol/L, At The Critical Upper-Target Treatment-Range Thresholds Would Be Plasma Equivalents Of 461 And 768 Μmol/L, Respectively, When A Reported Difference Of 28% Is Taken Into Account. Furthermore, Analytical Test Imprecision And Bias In Conjunction With Pre-Analytical Factors Such As Volume And Quality Of Blood Applied To Filter Paper Collection Devices To Produce Dbs Specimens Affect The Final Test Results. Reporting Of Inaccurate Patient Results When Comparing Dbs Results To Target Treatment-Ranges Based On Plasma Concentrations, Together With Inter-Laboratory Imprecision Could Have A Significant Impact On Patient Management Resulting In Inappropriate Dietary Change And Potentially Adverse Patient Outcomes. This Review Is Intended To Provide Perspective On The Issues Related To The Measurement Of Phenylalanine In Blood Specimens And To Provide Direction For The Future Needs Of Pku Patients To Ensure Reliable Monitoring Of Metabolic Control Using The Target Treatment-Ranges.|[('Analysis', 'no label'), ('Blood Phenylalanine', 'no label'), ('Monitoring', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Age-Related', 'no label'), ('Phenylalanine', 'no label'), ('Treatment-Ranges', 'no label'), ('Recommended', 'no label'), ('Order', 'no label'), ('Neurological Outcomes', 'no label'), ('Target', 'no label'), ('Treatment-Ranges', 'no label'), ('Plasma', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Patients', 'no label'), ('Dried Bloodspot (Dbs) Specimens', 'no label'), ('Convenience', 'no label'), ('Collection', 'no label'), ('Exist', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Plasma', 'no label'), ('Dbs', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Dbs Specimens', 'no label'), ('Analyzed', 'no label'), ('Flow-Injection Analysis Tandem Mass Spectrometry', 'no label'), ('Paired', 'no label'), ('Plasma', 'no label'), ('Concentrations', 'no label'), ('Analyzed', 'no label'), ('Ion-Exchange Chromatography', 'no label'), ('Dbs Specimens', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Critical Upper-Target Treatment-Range Thresholds', 'no label'), ('Plasma Equivalents', 'no label'), ('Analytical Test', 'no label'), ('Imprecision', 'no label'), ('Bias', 'no label'), ('Conjunction', 'no label'), ('Pre-Analytical Factors', 'no label'), ('Volume', 'no label'), ('Quality', 'no label'), ('Blood Applied', 'no label'), ('Filter Paper Collection Devices', 'no label'), ('Dbs', 'no label'), ('Affect', 'no label'), ('Final Test Results', 'no label'), ('Reporting', 'no label'), ('Inaccurate', 'no label'), ('Patient Results', 'no label'), ('Dbs', 'no label'), ('Results', 'no label'), ('Target', 'no label'), ('Treatment-Ranges', 'no label'), ('Plasma', 'no label'), ('Concentrations', 'no label'), ('Inter-Laboratory Imprecision', 'no label'), ('Significant', 'no label'), ('Impact', 'no label'), ('Patient Management', 'no label'), ('Resulting', 'no label'), ('Inappropriate', 'no label'), ('Dietary Change', 'no label'), ('Patient', 'no label'), ('Outcomes', 'no label'), ('Review', 'no label'), ('Issues', 'no label'), ('Measurement', 'no label'), ('Phenylalanine', 'no label'), ('Blood Specimens', 'no label'), ('Needs', 'no label'), ('Pku Patients', 'no label'), ('Ensure', 'no label'), ('Monitoring', 'no label'), ('Metabolic Control', 'no label'), ('Target', 'no label'), ('Treatment-Ranges', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Dbs', 'no label'), ('Dbs', 'no label'), ('Dbs', 'no label'), ('Dbs', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Blood Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Plasma Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Plasma', 'no label'), ('Dbs', 'no label'), ('Phenylalanine', 'no label'), ('Dbs', 'no label'), ('Be 18', 'no label'), ('Plasma', 'no label'), ('Ion-Exchange', 'no label'), ('Phenylalanine', 'no label'), ('Plasma Equivalents Of', 'no label'), ('Blood', 'no label'), ('Patient', 'no label'), ('Plasma', 'no label'), ('Patient', 'no label'), ('Patient', 'no label'), ('Phenylalanine', 'no label'), ('Blood Specimens', 'no label'), ('Patients', 'no label'), ('Ensure', 'no label')]
phenylketonuria|pubmed~31373030|In Phenylketonuria (Pku) Patients, Early Diagnosis By Neonatal Screening And Immediate Institution Of A Phenylalanine-Restricted Diet Can Prevent Severe Intellectual Impairment. Nevertheless, Outcome Remains Suboptimal In Some Patients Asking For Additional Treatment Strategies. Tetrahydrobiopterin (Bh<Sub>4</Sub> ) Could Be One Of Those Treatment Options, As It May Not Only Increase Residual Phenylalanine Hydroxylase Activity In Bh<Sub>4</Sub> -Responsive Pku Patients, But Possibly Also Directly Improves Neurocognitive Functioning In Both Bh<Sub>4</Sub> -Responsive And Bh<Sub>4</Sub> -Unresponsive Pku Patients. In The Present Review, We Aim To Further Define The Theoretical Working Mechanisms By Which Bh<Sub>4</Sub> Might Directly Influence Neurocognitive Functioning In Pku Having Passed The Blood-Brain Barrier. Further Research Should Investigate Which Of These Mechanisms Are Actually Involved, And Should Contribute To The Development Of An Optimal Bh<Sub>4</Sub> Treatment Regimen To Directly Improve Neurocognitive Functioning In Pku. Such Possible Repurposing Approach Of Bh<Sub>4</Sub> Treatment In Pku May Improve Neuropsychological Outcome And Mental Health In Both Bh<Sub>4</Sub> -Responsive And Bh<Sub>4</Sub> -Unresponsive Pku Patients.|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Early Diagnosis', 'no label'), ('Neonatal', 'no label'), ('Screening', 'no label'), ('Immediate Institution', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Prevent Severe', 'no label'), ('Intellectual Impairment', 'no label'), ('Outcome Remains', 'no label'), ('Suboptimal', 'no label'), ('Patients', 'no label'), ('Treatment', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Treatment Options', 'no label'), ('Increase', 'no label'), ('Residual', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Activity', 'no label'), ('Bh<Sub>4</Sub> -Responsive Pku', 'no label'), ('Patients', 'no label'), ('Neurocognitive Functioning', 'no label'), ('Bh<Sub>4</Sub> -Responsive And Bh<Sub>4</Sub> -Unresponsive Pku', 'no label'), ('Patients', 'no label'), ('Review', 'no label'), ('Theoretical', 'no label'), ('Working Mechanisms', 'no label'), ('Bh<Sub>4</Sub> Might Directly', 'no label'), ('Influence', 'no label'), ('Neurocognitive Functioning', 'no label'), ('Blood-Brain Barrier', 'no label'), ('Research', 'no label'), ('Investigate', 'no label'), ('Mechanisms', 'no label'), ('Contribute', 'no label'), ('Development', 'no label'), ('Optimal', 'no label'), ('Bh<Sub>4</Sub> Treatment Regimen', 'no label'), ('Neurocognitive Functioning', 'no label'), ('Repurposing Approach', 'no label'), ('Bh<Sub>4</Sub> Treatment', 'no label'), ('Pku May Improve Neuropsychological Outcome', 'no label'), ('Bh<Sub>4</Sub> -Responsive And Bh<Sub>4</Sub> -Unresponsive Pku', 'no label'), ('Patients', 'no label')]|[('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label')]|[('Tetrahydrobiopterin', 'no label')]|[('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~33342489||[]|[]|[]|[]|[]
phenylketonuria|pubmed~28552082|Phenylketonuria (Pku), A Genetic Metabolic Disorder That Is Characterized By The Inability To Convert Phenylalanine To Tyrosine, Leads To Severe Intellectual Disability And Other Cerebral Complications If Left Untreated. Dietary Treatment, Initiated Soon After Birth, Prevents Most Brain-Related Complications. A Leading Hypothesis Postulates That A Shortage Of Brain Monoamines May Be Associated With Neurocognitive Deficits That Are Observable Even In Early-Treated Pku. However, There Is A Paucity Of Evidence As Yet For This Hypothesis. We Therefore Assessed In Vivo Striatal Dopamine D2/3 Receptor (D2/3R) Availability And Plasma Monoamine Metabolite Levels Together With Measures Of Impulsivity And Executive Functioning In 18 Adults With Pku And Average Intellect (31.2 ± 7.4 Years, Nine Females), Most Of Whom Were Early And Continuously Treated. Comparison Data From 12 Healthy Controls That Did Not Differ In Gender And Age Were Available. Mean D2/3R Availability Was Significantly Higher (13%; P = 0.032) In The Pku Group (N = 15) Than In The Controls, Which May Reflect Reduced Synaptic Brain Dopamine Levels In Pku. The Pku Group Had Lower Plasma Levels Of Homovanillic Acid (P < 0.001) And 3-Methoxy-4-Hydroxy-Phenylglycol (P < 0.0001), The Predominant Metabolites Of Dopamine And Norepinephrine, Respectively. Self-Reported Impulsivity Levels Were Significantly Higher In The Pku Group Compared With Healthy Controls (P = 0.033). Within The Pku Group, D2/3R Availability Showed A Positive Correlation With Both Impulsivity (R = 0.72, P = 0.003) And The Error Rate During A Cognitive Flexibility Task (R = 0.59, P = 0.020). These Findings Provide Further Support For The Hypothesis That Executive Functioning Deficits In Treated Adult Pku May Be Associated With Cerebral Dopamine Deficiency.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Genetic Metabolic Disorder', 'no label'), ('Characterized', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Leads', 'no label'), ('Severe', 'no label'), ('Intellectual Disability', 'no label'), ('Cerebral Complications', 'no label'), ('Left Untreated', 'no label'), ('Dietary Treatment', 'no label'), ('Birth', 'no label'), ('Prevents', 'no label'), ('Brain-Related', 'no label'), ('Complications', 'no label'), ('Leading Hypothesis', 'no label'), ('Postulates', 'no label'), ('Shortage', 'no label'), ('Brain Monoamines', 'no label'), ('Associated With', 'no label'), ('Neurocognitive Deficits', 'no label'), ('Early-Treated Pku', 'no label'), ('Evidence', 'no label'), ('Hypothesis', 'no label'), ('Assessed', 'no label'), ('In Vivo', 'no label'), ('Striatal', 'no label'), ('Dopamine D2/3 Receptor', 'no label'), ('D2/3R', 'no label'), ('Availability', 'no label'), ('Plasma', 'no label'), ('Monoamine Metabolite', 'no label'), ('Levels', 'no label'), ('Measures', 'no label'), ('Impulsivity', 'no label'), ('Executive Functioning', 'no label'), ('Adults', 'no label'), ('Pku', 'no label'), ('Years', 'no label'), ('Females', 'no label'), ('Early', 'no label'), ('Continuously', 'no label'), ('Treated', 'no label'), ('Comparison', 'no label'), ('Data', 'no label'), ('Healthy Controls', 'no label'), ('Differ', 'no label'), ('Gender', 'no label'), ('Age', 'no label'), ('D2/3R', 'no label'), ('Availability', 'no label'), ('Pku Group', 'no label'), ('Controls', 'no label'), ('Reduced', 'no label'), ('Synaptic', 'no label'), ('Brain', 'no label'), ('Dopamine', 'no label'), ('Levels', 'no label'), ('Pku Group', 'no label'), ('Plasma', 'no label'), ('Levels', 'no label'), ('Homovanillic Acid', 'no label'), ('Predominant Metabolites', 'no label'), ('Dopamine', 'no label'), ('Norepinephrine', 'no label'), ('Self-Reported Impulsivity', 'no label'), ('Levels', 'no label'), ('Pku Group', 'no label'), ('Healthy Controls', 'no label'), ('Pku Group', 'no label'), ('D2/3R', 'no label'), ('Showed', 'no label'), ('Positive', 'no label'), ('Correlation', 'no label'), ('Impulsivity', 'no label'), ('Error Rate', 'no label'), ('Cognitive Flexibility Task', 'no label'), ('Findings', 'no label'), ('Hypothesis', 'no label'), ('Executive Functioning Deficits', 'no label'), ('Treated Adult', 'no label'), ('Pku May', 'no label'), ('Associated With', 'no label'), ('Cerebral Dopamine Deficiency', 'no label')]|[('Genetic', 'no label'), ('Phenylalanine', 'no label'), ('Monoamines', 'no label'), ('Monoamine', 'no label'), ('Dopamine', 'no label'), ('Homovanillic Acid', 'no label'), ('Dopamine', 'no label'), ('Dopamine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Cerebral Complications', 'no label'), ('Monoamines', 'no label'), ('Neurocognitive Deficits', 'no label'), ('Dopamine', 'no label'), ('Impulsivity', 'no label'), ('Dopamine', 'no label'), ('Homovanillic Acid', 'no label'), ('Dopamine', 'no label'), ('Norepinephrine', 'no label'), ('Cerebral Dopamine', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Tyrosine', 'no label'), ('Cerebral Complications', 'no label'), ('Brain Monoamines', 'no label'), ('Striatal Dopamine D2/3 Receptor', 'no label'), ('D2/3R', 'no label'), ('Plasma Monoamine', 'no label'), ('D2/3R', 'no label'), ('Synaptic Brain Dopamine', 'no label'), ('Plasma', 'no label'), ('Homovanillic Acid', 'no label'), ('Dopamine', 'no label'), ('Norepinephrine', 'no label'), ('D2/3R', 'no label'), ('Cerebral Dopamine', 'no label')]
phenylketonuria|pubmed~31439512|"Phenylketonuria (Pku) Is Caused By Phenylalanine Hydroxylase (Pah) Deficiency, Resulting In High Blood And Brain Phenylalanine (Phe) Concentrations That Can Lead To Impaired Brain Development And Function. Standard Treatment Involves A Phe-Restricted Diet Alone Or In Conjunction With Sapropterin Dihydrochloride In Responsive Patients. The Food And Drug Administration Approved Pegvaliase Enzyme Substitution Therapy For Adults With Blood Phe >600 Μmol/L In The Us. Recently, The European Commission Also Approved Pegvaliase For Treatment Of Pku Patients Aged 16 Years Or Older With Blood Phe >600 Μmol/L. The Analyses Presented Below Were Conducted To Provide Comparative Evidence On Long-Term Treatment Effectiveness Of Pegvaliase Versus Standard Of Care In Adults With Pku. Adult Patients (≥18 Years) With Baseline Blood Phe >600 Μmol/L Who Had Enrolled In The Pegvaliase Phase 2 And Phase 3 Clinical Trials Were Propensity Score-Matched To Historical Cohorts Of Patients Treated With ""Sapropterin + Diet"" Or With ""Diet Alone"". These Cohorts Were Derived From The Pku Demographics, Outcome And Safety (Pkudos) Registry And Compared For Clinical Outcomes Including Blood Phe Concentration And Natural Intact Protein Intake After 1 And 2 Years. Propensity Scores Were Estimated Using Logistic Regression With Probability Of Treatment As Outcome (I.E. Pegvaliase, ""Sapropterin + Diet"", Or ""Diet Alone"") And Patient Demographic And Disease Severity Covariates As Predictors. An Additional Analysis In Adult Pku Patients With Baseline Blood Phe ≤600 Μmol/L Comparing Non-Matched Patient Groups ""Sapropterin + Diet"" To ""Diet Alone"" Using Pkudos Registry Data Only Was Also Conducted. The Analyses In Patients With Baseline Blood Phe >600 Μmol Comparing Pegvaliase With ""Sapropterin + Diet"" (N = 64 Matched Pairs) Showed Lower Mean Blood Phe Concentrations After 1 And 2 Years With Pegvaliase (505 And 427 Μmol/L) Versus ""Sapropterin + Diet"" (807 And 891 Μmol/L); Mean Natural Intact Protein Intake After 1 And 2 Years Was 49 And 57 G/Day Respectively With Pegvaliase Versus 23 And 28 G/Day With ""Sapropterin + Diet"". The Analysis Comparing Pegvaliase With ""Diet Alone"" (N = 120 Matched Pairs) Showed Lower Mean Blood Phe At 1 And 2 Years With Pegvaliase (473 And 302 Μmol/L) Versus ""Diet Alone"" (1022 And 965 Μmol/L); Mean Natural Intact Protein Intake After 1 And 2 Years Was 47 And 57 G/Day With Pegvaliase And 27 And 22 G/Day With ""Diet Alone"". Considerably More Patients Achieved Blood Phe ≤600, ≤360, And ≤120 Μmol/L And Reductions From Baseline Of ≥20%, ≥30%, And ≥50% In Blood Phe After 1 And 2 Years Of Pegvaliase Versus Standard Treatments. The Analysis In Patients With Baseline Blood Phe ≤600 Μmol/L Showed Lower Blood Phe After 1 And 2 Years With ""Sapropterin + Diet"" (240 And 324 Μmol/L) Versus ""Diet Alone"" (580 And 549 Μmol/L) And Greater Percentages Of Patients Achieving Blood Phe Targets ≤600, ≤360, And ≤120 Μmol/L And Reductions From Baseline Of ≥20%, ≥30%, And ≥50% In Blood Phe. These Results Support Pegvaliase As The More Effective Treatment Option To Lower Phe Levels In Adults With Pku Who Have Difficulty Keeping Blood Phe ≤600 Μmol/L With ""Diet Alone"". For Patients With Blood Phe ≤600 Μmol/L, Adding Sapropterin To Dietary Management Is An Appropriate Treatment Option, For Those Responsive To The Treatment."|"[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('High Blood', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Lead', 'no label'), ('Impaired', 'no label'), ('Brain Development', 'no label'), ('Function', 'no label'), ('Standard', 'no label'), ('Treatment Involves', 'no label'), ('Phe-Restricted Diet Alone', 'no label'), ('Conjunction', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Responsive', 'no label'), ('Patients', 'no label'), ('Food And Drug Administration Approved', 'no label'), ('Pegvaliase Enzyme Substitution Therapy', 'no label'), ('Adults', 'no label'), ('Blood Phe >600\u202fΜmol/L In The Us', 'no label'), ('European Commission Also Approved Pegvaliase', 'no label'), ('Treatment', 'no label'), ('Pku Patients', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Blood Phe >600\u202fΜmol/L. The Analyses', 'no label'), ('Comparative Evidence', 'no label'), ('Long-Term Treatment Effectiveness', 'no label'), ('Pegvaliase', 'no label'), ('Standard Of Care', 'no label'), ('Adults', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Baseline', 'no label'), ('Blood Phe >600\u202fΜmol/L Who', 'no label'), ('Pegvaliase Phase 2', 'no label'), ('Phase 3', 'no label'), ('Clinical Trials', 'no label'), ('Propensity Score-Matched', 'no label'), ('Cohorts', 'no label'), ('Patients', 'no label'), ('Treated With', 'no label'), ('Sapropterin + Diet', 'no label'), ('""Diet Alone', 'no label'), ('Cohorts', 'no label'), ('Pku Demographics', 'no label'), ('Outcome And Safety', 'no label'), ('Clinical Outcomes', 'no label'), ('Blood Phe Concentration', 'no label'), ('Natural Intact Protein Intake', 'no label'), ('Years', 'no label'), ('Propensity Scores', 'no label'), ('Estimated', 'no label'), ('Logistic Regression', 'no label'), ('Probability', 'no label'), ('Treatment', 'no label'), ('Outcome', 'no label'), ('Pegvaliase', 'no label'), ('Sapropterin + Diet', 'no label'), ('Patient Demographic And Disease', 'no label'), ('Covariates', 'no label'), ('Predictors', 'no label'), ('Analysis', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Baseline', 'no label'), ('Blood Phe', 'no label'), ('Non-Matched Patient Groups', 'no label'), ('Diet', 'no label'), ('Pkudos Registry', 'no label'), ('Data', 'no label'), ('Analyses', 'no label'), ('Patients', 'no label'), ('Baseline', 'no label'), ('Blood Phe >600\u202fΜmol', 'no label'), ('Comparing', 'no label'), ('Pegvaliase', 'no label'), ('Sapropterin + Diet', 'no label'), ('Matched', 'no label'), ('Pairs', 'no label'), ('Mean', 'no label'), ('Blood Phe Concentrations', 'no label'), ('Years', 'no label'), ('Pegvaliase', 'no label'), ('Diet', 'no label'), ('Mean Natural Intact Protein Intake', 'no label'), ('Years', 'no label'), ('G/Day', 'no label'), ('Pegvaliase', 'no label'), ('G/Day', 'no label'), ('Sapropterin + Diet', 'no label'), ('Analysis', 'no label'), ('Pegvaliase', 'no label'), ('""Diet Alone', 'no label'), ('Pairs', 'no label'), ('Blood Phe', 'no label'), ('Years', 'no label'), ('Pegvaliase', 'no label'), ('""Diet Alone', 'no label'), ('Mean Natural Intact Protein Intake', 'no label'), ('Years', 'no label'), ('G/Day', 'no label'), ('Pegvaliase', 'no label'), ('G/Day', 'no label'), ('""Diet Alone', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Reductions', 'no label'), ('Baseline', 'no label'), ('Blood Phe', 'no label'), ('Years', 'no label'), ('Pegvaliase', 'no label'), ('Standard', 'no label'), ('Treatments', 'no label'), ('Analysis', 'no label'), ('Patients', 'no label'), ('Baseline', 'no label'), ('Blood Phe', 'no label'), ('Lower Blood Phe', 'no label'), ('Years', 'no label'), ('Sapropterin + Diet', 'no label'), ('""Diet Alone', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Targets', 'no label'), ('Reductions', 'no label'), ('Baseline', 'no label'), ('Blood Phe', 'no label'), ('Results', 'no label'), ('Support Pegvaliase', 'no label'), ('Effective', 'no label'), ('Treatment Option', 'no label'), ('Phe', 'no label'), ('Levels', 'no label'), ('Adults', 'no label'), ('Pku Who', 'no label'), ('Difficulty Keeping', 'no label'), ('Blood Phe', 'no label'), ('""Diet Alone', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Sapropterin', 'no label'), ('Dietary Management', 'no label'), ('Appropriate', 'no label'), ('Treatment', 'no label'), ('Responsive', 'no label'), ('Treatment', 'no label')]"|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Lead', 'no label'), ('Dihydrochloride', 'no label'), ('Food', 'no label'), ('Drug', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Phe', 'no label'), ('Protein', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Phe', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Blood', 'no label'), ('Brain Phenylalanine', 'no label'), ('Phe', 'no label'), ('Brain', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Pegvaliase', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Pegvaliase Phase 2', 'no label'), ('Cohorts', 'no label'), ('Patients', 'no label'), ('Sapropterin +', 'no label'), ('Blood Phe', 'no label'), ('Natural Intact', 'no label'), ('Sapropterin +', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Non-Matched Patient Groups', 'no label'), ('Sapropterin +', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Pegvaliase', 'no label'), ('Sapropterin +', 'no label'), ('Blood Phe', 'no label'), ('Pegvaliase', 'no label'), ('Sapropterin +', 'no label'), ('Pegvaliase Versus 23', 'no label'), ('Sapropterin +', 'no label'), ('Pegvaliase', 'no label'), ('Blood Phe At', 'no label'), ('Pegvaliase And 27', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Blood Phe', 'no label'), ('Pegvaliase', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Sapropterin +', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Blood', 'no label'), ('Lower Phe', 'no label'), ('Blood Phe', 'no label'), ('Patients', 'no label'), ('Blood Phe', 'no label'), ('Sapropterin', 'no label')]
phenylketonuria|pubmed~31375398|To Provide Recommendations For Managing Hypersensitivity Adverse Events (Haes) To An Injectable Enzyme Substitution Therapy (Pegvaliase, A Pegylated Phenylalanine Ammonia Lyase Enzyme) In Adult Patients With Phenylketonuria (Pku). Eight European Academic Immunology Experts With A Broad Range Of Experience In Hypersensitivity, Anaphylaxis, And/Or Drug Reactions, And Two Geneticists From The Usa With Pegvaliase Experience Convened For Two Advisory Board Meetings. Efficacy, Safety, And Immunological Profile Of Pegvaliase Were Discussed With The Objective Of Developing Recommendations For The Clinical Management Of Haes Associated With Pegvaliase Treatment. Based On Available Immunogenicity Data, It Was Concluded That Pegvaliase Induces A Type Iii Hypersensitivity Reaction, Causing Haes With Peak Event Rates During Induction/Titration And A Decline Over Time During Maintenance Therapy. The Decline In Haes With Longer Duration Of Therapy Was Considered To Likely Be Driven By Anti-Drug Antibody Affinity Maturation, Reduced Immune Complex Formation, And Decreased Complement Activation Over Time. Immunology And Pku Experts Unanimously Supported That The Use Of An Induction, Titration, And Maintenance Dosing Regimen And Implementation Of Several Risk Mitigation Strategies Contributed To The Improvement Of Tolerability Over Time. Key Risk Mitigation Strategies Utilized In The Phase 3 Clinical Trials Such As Premedication With H1-Receptor Antagonists, Allowance For A Longer Titration Period After An Hae, Patient Education, And Requirement To Carry Auto-Injectable Adrenaline (Epinephrine) Should Be Continued In Clinical Practice. A Tool For Administration Of Auto-Injectable Adrenaline In Patients Using Pegvaliase Was Suggested. It Was Added That After The Occurrence Of A Severe Hae A Temporary Dose Reduction Is More Likely To Improve Tolerability Than Treatment Interruption. Overall, It Was Agreed That Pegvaliase Has A Generally Tolerable Safety Profile In Adults With Pku. Importantly, The Risk Mitigation Strategies Utilized In The Clinical Trials Were Considered To Support The Continued Use Of Key Strategies For Management In The Commercial Setting, Such As A Slow Induction/Titration Dosing Paradigm And Premedication With H1-Receptor Antagonists. However, Physicians And Patients Need To Be Aware Of The Risk Of Haes Associated With Pegvaliase; Presence Of A Trained Observer During Early Treatment May Be Beneficial In Certain Circumstances, And A Requirement To Carry Auto-Injectable Adrenaline Is Recommended. Because Pegvaliase Offers The Possibility To Normalize Diet, While Maintaining Blood Phenylalanine Within The Recommended Therapeutic Range, Safe Use Of This Medication In The Clinical Setting Is Important. Ongoing Monitoring Of Long-Term Clinical Safety Of Patients On Pegvaliase Treatment In The Commercial Setting Was Recommended.|[('Recommendations', 'no label'), ('Managing', 'no label'), ('Hypersensitivity Adverse Events', 'no label'), ('Haes', 'no label'), ('Injectable', 'no label'), ('Pegvaliase', 'no label'), ('Pegylated', 'no label'), ('Phenylalanine', 'no label'), ('Ammonia Lyase', 'no label'), ('Enzyme', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('European Academic Immunology', 'no label'), ('Broad Range', 'no label'), ('Experience', 'no label'), ('Hypersensitivity', 'no label'), ('Anaphylaxis', 'no label'), ('And/Or Drug Reactions', 'no label'), ('Geneticists', 'no label'), ('Usa', 'no label'), ('Pegvaliase', 'no label'), ('Advisory Board Meetings', 'no label'), ('Efficacy', 'no label'), ('Safety', 'no label'), ('Immunological', 'no label'), ('Profile', 'no label'), ('Pegvaliase', 'no label'), ('Recommendations', 'no label'), ('Clinical Management', 'no label'), ('Haes', 'no label'), ('Associated With', 'no label'), ('Pegvaliase', 'no label'), ('Treatment', 'no label'), ('Immunogenicity', 'no label'), ('Data', 'no label'), ('Pegvaliase', 'no label'), ('Induces', 'no label'), ('Type Iii Hypersensitivity Reaction', 'no label'), ('Causing', 'no label'), ('Peak Event Rates', 'no label'), ('Induction/Titration', 'no label'), ('Decline', 'no label'), ('Therapy', 'no label'), ('Decline', 'no label'), ('Longer Duration', 'no label'), ('Therapy', 'no label'), ('Driven', 'no label'), ('Anti-Drug Antibody', 'no label'), ('Affinity', 'no label'), ('Maturation', 'no label'), ('Reduced', 'no label'), ('Immune Complex', 'no label'), ('Formation', 'no label'), ('Decreased', 'no label'), ('Complement Activation', 'no label'), ('Time', 'no label'), ('Immunology', 'no label'), ('Pku Experts Unanimously Supported', 'no label'), ('Induction', 'no label'), ('Titration', 'no label'), ('Maintenance', 'no label'), ('Dosing', 'no label'), ('Regimen', 'no label'), ('Implementation', 'no label'), ('Risk Mitigation', 'no label'), ('Strategies', 'no label'), ('Contributed', 'no label'), ('Improvement', 'no label'), ('Tolerability', 'no label'), ('Time', 'no label'), ('Key Risk', 'no label'), ('Mitigation', 'no label'), ('Strategies', 'no label'), ('Phase 3 Clinical Trials', 'no label'), ('Premedication', 'no label'), ('H1-Receptor Antagonists', 'no label'), ('Allowance', 'no label'), ('Titration', 'no label'), ('Period', 'no label'), ('Hae', 'no label'), ('Patient Education', 'no label'), ('Auto-Injectable Adrenaline', 'no label'), ('Epinephrine', 'no label'), ('Clinical Practice', 'no label'), ('Tool', 'no label'), ('Administration', 'no label'), ('Auto-Injectable Adrenaline', 'no label'), ('Patients', 'no label'), ('Pegvaliase', 'no label'), ('Added', 'no label'), ('Severe', 'no label'), ('Hae A Temporary', 'no label'), ('Dose', 'no label'), ('Reduction', 'no label'), ('Improve', 'no label'), ('Tolerability', 'no label'), ('Treatment', 'no label'), ('Interruption', 'no label'), ('Agreed', 'no label'), ('Pegvaliase', 'no label'), ('Tolerable Safety Profile', 'no label'), ('Adults', 'no label'), ('Risk Mitigation', 'no label'), ('Strategies', 'no label'), ('Clinical Trials', 'no label'), ('Key Strategies', 'no label'), ('Management', 'no label'), ('Commercial Setting', 'no label'), ('Slow Induction/Titration', 'no label'), ('Dosing', 'no label'), ('Paradigm', 'no label'), ('Premedication', 'no label'), ('H1-Receptor Antagonists', 'no label'), ('Physicians', 'no label'), ('Patients', 'no label'), ('Need', 'no label'), ('Risk', 'no label'), ('Haes', 'no label'), ('Associated With', 'no label'), ('Pegvaliase', 'no label'), ('Presence', 'no label'), ('Trained Observer', 'no label'), ('Early Treatment', 'no label'), ('Beneficial', 'no label'), ('Circumstances', 'no label'), ('Requirement', 'no label'), ('Auto-Injectable', 'no label'), ('Adrenaline', 'no label'), ('Recommended', 'no label'), ('Pegvaliase', 'no label'), ('Possibility', 'no label'), ('Normalize Diet', 'no label'), ('Blood Phenylalanine', 'no label'), ('Therapeutic Range', 'no label'), ('Medication', 'no label'), ('Clinical Setting', 'no label'), ('Monitoring', 'no label'), ('Long-Term Clinical Safety', 'no label'), ('Patients', 'no label'), ('Pegvaliase', 'no label'), ('Treatment', 'no label'), ('Commercial Setting', 'no label'), ('Recommended', 'no label')]|[('Enzyme Substitution', 'no label'), ('Ammonia', 'no label'), ('Drug', 'no label'), ('Antibody', 'no label'), ('Adrenaline', 'no label'), ('Epinephrine', 'no label'), ('Adrenaline', 'no label'), ('Adrenaline', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Hypersensitivity', 'no label'), ('Phenylketonuria', 'no label'), ('Hypersensitivity', 'no label'), ('Anaphylaxis', 'no label'), ('Adrenaline', 'no label'), ('Epinephrine', 'no label'), ('Adrenaline', 'no label'), ('Adrenaline', 'no label'), ('Phenylalanine', 'no label')]|[('Pegylated Phenylalanine Ammonia Lyase', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Experience', 'no label'), ('And/Or', 'no label'), ('Pegvaliase', 'no label'), ('A Type Iii', 'no label'), ('Immune Complex', 'no label'), ('H1-Receptor Antagonists', 'no label'), ('Adrenaline', 'no label'), ('Epinephrine', 'no label'), ('Adrenaline', 'no label'), ('Patients', 'no label'), ('Pegvaliase', 'no label'), ('Pegvaliase Has', 'no label'), ('H1-Receptor Antagonists', 'no label'), ('Patients', 'no label'), ('Adrenaline', 'no label'), ('Pegvaliase', 'no label'), ('Blood Phenylalanine', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31242484|The Standard, Lifelong Therapy Of Phenylketonuria (Pku) Is A Natural Protein-Restricted Diet Complemented With Phenylalanine (Phe)-Free L-Amino Acid Mixtures That Provide The Daily Necessary Micronutrients. To Assess Thyroid Function And Structure And The Iodine Status Of Early-Treated Adult Pku (Etpku) Patients In Hungary. Sixty-Nine Pku Patients (Aged 18-41 Years) And 50 Healthy Controls Were Enrolled In The Study. Thyroid Hormones, Serum Thyroglobulin, Thyroid Antibodies, Urinary Iodine, And Selenium Concentrations Were Measured, And Thyroid Ultrasound Was Performed. The Incidence Of Thyroid Dysfunction Was Infrequent (N = 2). Blood Phe Was Negatively Correlated With Thyroid-Stimulating Hormone (Tsh), And Pku Patients Had Higher Free Thyroxine And Lower Tsh Levels Than Healthy Controls. Although Optimal Iodine Status Was Found In The Entire Pku Population, By Dividing The Patients According To Their Therapy Compliance, We Observed That Lower Therapy Adherence Was Associated With Mild Iodine Deficiency And Lower Urinary Selenium Levels. The Results Of This Study Suggest That Iodine Status Is Strongly Influenced By The Adherence To Therapy In Etpku Patients. No Or Not Enough Medical Food Consumption Combined With A Low-Phe Diet Can Lead To Subclinical Iodine Deficiency.|[('Standard', 'no label'), ('Lifelong Therapy', 'no label'), ('Phenylketonuria', 'no label'), ('Natural Protein-Restricted Diet Complemented', 'no label'), ('Phenylalanine (Phe)-Free L-Amino Acid Mixtures', 'no label'), ('Daily', 'no label'), ('Necessary', 'no label'), ('Micronutrients', 'no label'), ('Assess', 'no label'), ('Thyroid Function', 'no label'), ('Structure', 'no label'), ('Iodine Status', 'no label'), ('Early-Treated Adult Pku (Etpku)', 'no label'), ('Patients', 'no label'), ('Hungary', 'no label'), ('Sixty-Nine Pku Patients', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Healthy Controls', 'no label'), ('Study', 'no label'), ('Thyroid Hormones', 'no label'), ('Serum Thyroglobulin', 'no label'), ('Thyroid Antibodies', 'no label'), ('Urinary Iodine', 'no label'), ('Selenium', 'no label'), ('Concentrations', 'no label'), ('Measured', 'no label'), ('Thyroid Ultrasound', 'no label'), ('Incidence', 'no label'), ('Thyroid Dysfunction', 'no label'), ('Infrequent', 'no label'), ('Blood Phe', 'no label'), ('Correlated', 'no label'), ('Thyroid-Stimulating Hormone', 'no label'), ('Tsh', 'no label'), ('Patients', 'no label'), ('Higher', 'no label'), ('Free Thyroxine', 'no label'), ('Tsh', 'no label'), ('Healthy Controls', 'no label'), ('Optimal', 'no label'), ('Iodine Status', 'no label'), ('Entire Pku Population', 'no label'), ('Patients', 'no label'), ('Therapy', 'no label'), ('Compliance', 'no label'), ('Observed', 'no label'), ('Lower Therapy', 'no label'), ('Adherence', 'no label'), ('Associated With', 'no label'), ('Mild Iodine Deficiency', 'no label'), ('Urinary', 'no label'), ('Selenium', 'no label'), ('Levels', 'no label'), ('Study Suggest', 'no label'), ('Iodine Status', 'no label'), ('Influenced', 'no label'), ('Adherence', 'no label'), ('Therapy', 'no label'), ('Etpku', 'no label'), ('Patients', 'no label'), ('Medical Food Consumption', 'no label'), ('Low-Phe Diet', 'no label'), ('Lead', 'no label'), ('Subclinical Iodine Deficiency', 'no label')]|[('Micronutrients', 'no label'), ('Antibodies', 'no label'), ('Selenium', 'no label'), ('Thyroid-Stimulating Hormone', 'no label'), ('Tsh', 'no label'), ('Thyroxine', 'no label'), ('Tsh', 'no label'), ('Selenium', 'no label'), ('Food', 'no label'), ('Iodine', 'no label')]|[('Thyroid Antibodies', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Sixty-Nine', 'no label'), ('Selenium', 'no label'), ('Thyroid Dysfunction', 'no label'), ('Thyroxine', 'no label'), ('Iodine Deficiency', 'no label'), ('Selenium', 'no label'), ('Iodine Deficiency', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine (Phe)-Free', 'no label'), ('L-Amino Acid', 'no label'), ('Thyroid', 'no label'), ('Iodine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Thyroid', 'no label'), ('Serum Thyroglobulin', 'no label'), ('Thyroid Antibodies', 'no label'), ('Urinary Iodine', 'no label'), ('Selenium', 'no label'), ('Thyroid', 'no label'), ('Thyroid', 'no label'), ('Tsh', 'no label'), ('Patients', 'no label'), ('Thyroxine', 'no label'), ('Iodine', 'no label'), ('Entire', 'no label'), ('Patients', 'no label'), ('Iodine', 'no label'), ('Lower Urinary Selenium', 'no label'), ('Iodine', 'no label'), ('Patients', 'no label'), ('Iodine', 'no label')]
phenylketonuria|pubmed~32591341||[]|[]|[]|[]|[]
phenylketonuria|pubmed~28982351|Phenylketonuria (Pku), Which Primarily Results From A Deficiency Of Phenylalanine Hydroxylase (Pah), Is One Of The Most Common Inherited Inborn Errors Of Metabolism That Impairs Postnatal Cognitive Development. The Incidence Of Various Pah Variations Differs By Race And Ethnicity. The Aim Of The Present Study Was To Characterize The Pah Gene Variants Of A Han Population From Northern China. In Total, 655 Pku Patients And Their Families Were Recruited For This Study; Each Proband Was Diagnosed Both Clinically And Biochemically With Phenylketonuria. Subjects Were Sequentially Screened For Single-Base Variants And Exon Deletions Or Duplications Within Pah Via Direct Sanger Sequencing And Multiplex Ligation-Dependent Probe Amplification (Mlpa). A Spectrum Of 174 Distinct Pah Variants Was Identified: 152 Previously Documented Variants And 22 Novel Variants. While Single-Base Variants Were Distributed Throughout The 13 Exons, They Were Particularly Concentrated In Exons 7 (33.3%), 11 (14.2%), 6 (13.2%), 12 (11.0%), 3 (10.4%), And 5 (4.4%). The Predominant Variant Was P.Arg243Gln (17.7%), Followed By Ex6-96A > G (8.3%), P.Val399 = (6.4%), P.Arg53His (4.7%), P.Tyr356* (4.7%), P.Arg241Cys (4.6%), P.Arg413Pro (4.6%), P.Arg111* (4.4%), And C.442-1G > A (3.4%). Notably, Two Patients Were Also Identified As Carrying De Novo Variants. The Composition Of Pah Gene Variants In This Han Population From Northern China Was Distinct From Those Of Other Ethnic Groups. As Such, The Construction Of A Pah Gene Variant Database For Northern China Is Necessary To Lay A Foundation For Genetic-Based Diagnoses, Prenatal Diagnoses, And Population Screening.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Deficiency', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Inherited Inborn Errors', 'no label'), ('Metabolism', 'no label'), ('Impairs', 'no label'), ('Postnatal', 'no label'), ('Cognitive Development', 'no label'), ('Incidence', 'no label'), ('Variations', 'no label'), ('Differs', 'no label'), ('Race', 'no label'), ('Ethnicity', 'no label'), ('Study', 'no label'), ('Characterize', 'no label'), ('Pah Gene', 'no label'), ('Han Population', 'no label'), ('Northern China', 'no label'), ('Pku Patients', 'no label'), ('Families', 'no label'), ('Study', 'no label'), ('Proband', 'no label'), ('Diagnosed', 'no label'), ('Clinically', 'no label'), ('Phenylketonuria', 'no label'), ('Subjects', 'no label'), ('Screened', 'no label'), ('Single-Base Variants', 'no label'), ('Exon Deletions', 'no label'), ('Duplications', 'no label'), ('Direct Sanger Sequencing', 'no label'), ('Mlpa', 'no label'), ('Spectrum', 'no label'), ('Variants', 'no label'), ('Documented', 'no label'), ('Variants', 'no label'), ('Novel', 'no label'), ('Variants', 'no label'), ('Single-Base Variants', 'no label'), ('Exons', 'no label'), ('Concentrated', 'no label'), ('Predominant', 'no label'), ('Ex6-96A\xa0>\xa0G', 'no label'), ('P.Val399\xa0', 'no label'), ('P.Arg53His', 'no label'), ('P.Tyr356* (', 'no label'), ('P.Arg241Cys', 'no label'), ('P.Arg413Pro', 'no label'), ('P.Arg111*', 'no label'), ('C.442-1G\xa0>\xa0A', 'no label'), ('Patients', 'no label'), ('Carrying', 'no label'), ('De Novo', 'no label'), ('Variants', 'no label'), ('Composition', 'no label'), ('Pah Gene', 'no label'), ('Variants', 'no label'), ('Han Population', 'no label'), ('Northern China', 'no label'), ('Ethnic Groups', 'no label'), ('Construction', 'no label'), ('Pah Gene Variant Database', 'no label'), ('Northern China', 'no label'), ('Lay A Foundation', 'no label'), ('Genetic-Based Diagnoses', 'no label'), ('Prenatal Diagnoses', 'no label'), ('Population Screening', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Gene', 'no label'), ('Variants', 'no label'), ('Exon Deletions', 'no label'), ('Probe', 'no label'), ('Variants', 'no label'), ('Exons', 'no label'), ('Ex6', 'no label'), ('Gene', 'no label'), ('Gene Variant', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Pah Gene Variants', 'no label'), ('Exon Deletions', 'no label'), ('Pah', 'no label'), ('13 Exons', 'no label'), ('Exons 7', 'no label'), ('P.Arg53His', 'no label'), ('P.Arg413Pro', 'no label'), ('Pah Gene Variants', 'no label'), ('Pah Gene', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Common Inherited Inborn Errors', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Pah', 'no label'), ('Concentrated', 'no label'), ('Ex6', 'no label'), ('C.442-1G', 'no label'), ('Patients', 'no label'), ('Pah Gene', 'no label'), ('A Pah Gene', 'no label')]
phenylketonuria|pubmed~27269713|Patients With Phenylketonuria Have Been Reported To Be Deficient In Long-Chain Polyunsaturated Fatty Acids (Lcpufas). It Has Been Postulated That Good Compliance With The Dietary Regimen Negatively Influences Lcpufa Status. In 36 Patients With Phenylketonuria And 18 Age-Matched Healthy Control Subjects Lcpufa-Levels In Plasma Phospholipids And Cholesteryl Esters, Erythrocyte Phosphatidylcholine And Phosphatidylethanolamine Were Evaluated. Eicosapentaenoic Acid (Epa) And Docosahexaenoic Acid (Dha) Levels Did Not Differ Significantly Between Patients And Control Subjects In Plasma And Erythrocyte Fractions. There Was A Significant Negative Correlation Between Sds (Standard Deviation) Scores Of Dha-Levels In Erythrocyte Parameters From The Respective Age-Matched Control Group And Patients' Concurrent And Long-Term Phenylalanine Levels For Erythrocyte Phosphatidylethanolamine And Erythrocyte Phosphatidylcholine. Patients With Lower (Higher) Phenylalanine Levels Had Positive (Negative) Dha-Sds. In Contrast To Previous Reports We Did Not Find Lower Lcpufa-Levels In Patients With Phenylketonuria Compared To Age-Matched Healthy Control Subjects. Good Dietary Control Was Associated With Better Lcpufa Status.|"[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Deficient', 'no label'), ('Long-Chain Polyunsaturated Fatty Acids', 'no label'), ('Lcpufas', 'no label'), ('Good', 'no label'), ('Compliance', 'no label'), ('Dietary Regimen', 'no label'), ('Negatively', 'no label'), ('Influences', 'no label'), ('Lcpufa Status', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Healthy Control Subjects', 'no label'), ('Lcpufa-Levels', 'no label'), ('Plasma', 'no label'), ('Phospholipids', 'no label'), ('Cholesteryl Esters', 'no label'), ('Erythrocyte Phosphatidylcholine', 'no label'), ('Phosphatidylethanolamine', 'no label'), ('Evaluated', 'no label'), ('Eicosapentaenoic Acid', 'no label'), ('Epa', 'no label'), ('Docosahexaenoic Acid', 'no label'), ('Dha', 'no label'), ('Levels', 'no label'), ('Differ', 'no label'), ('Patients', 'no label'), ('Control Subjects', 'no label'), ('Plasma', 'no label'), ('Erythrocyte Fractions', 'no label'), ('Significant', 'no label'), ('Negative', 'no label'), ('Correlation', 'no label'), ('Standard Deviation', 'no label'), ('Scores', 'no label'), ('Dha-Levels', 'no label'), ('Erythrocyte', 'no label'), ('Parameters', 'no label'), ('Age-Matched', 'no label'), ('Control Group', 'no label'), (""Patients'"", 'no label'), ('Concurrent', 'no label'), ('Long-Term', 'no label'), ('Phenylalanine', 'no label'), ('Levels', 'no label'), ('Erythrocyte', 'no label'), ('Phosphatidylethanolamine', 'no label'), ('Erythrocyte', 'no label'), ('Phosphatidylcholine', 'no label'), ('Patients', 'no label'), ('Lower', 'no label'), ('Phenylalanine Levels', 'no label'), ('Dha-Sds', 'no label'), ('Contrast', 'no label'), ('Reports', 'no label'), ('Lcpufa-Levels', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Compared', 'no label'), ('Healthy Control Subjects', 'no label'), ('Dietary Control', 'no label'), ('Associated With', 'no label'), ('Lcpufa Status', 'no label')]"|[('Fatty Acids', 'no label'), ('Phospholipids', 'no label'), ('Cholesteryl', 'no label'), ('Erythrocyte Phosphatidylcholine', 'no label'), ('Phosphatidylethanolamine', 'no label'), ('Docosahexaenoic Acid', 'no label'), ('Dha-Levels', 'no label'), ('Phenylalanine', 'no label'), ('Erythrocyte Phosphatidylethanolamine', 'no label'), ('Erythrocyte Phosphatidylcholine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Long-Chain Polyunsaturated Fatty Acids', 'no label'), ('Phenylketonuria', 'no label'), ('Phospholipids', 'no label'), ('Cholesteryl', 'no label'), ('Phosphatidylcholine', 'no label'), ('Phosphatidylethanolamine', 'no label'), ('Eicosapentaenoic Acid', 'no label'), ('Docosahexaenoic Acid', 'no label'), ('Dha', 'no label'), ('Phenylalanine', 'no label'), ('Phosphatidylethanolamine', 'no label'), ('Phosphatidylcholine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label')]|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Long-Chain Polyunsaturated Fatty Acids', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Plasma Phospholipids', 'no label'), ('Cholesteryl', 'no label'), ('Erythrocyte Phosphatidylcholine', 'no label'), ('Phosphatidylethanolamine', 'no label'), ('Eicosapentaenoic Acid', 'no label'), ('Docosahexaenoic Acid', 'no label'), ('Patients', 'no label'), ('Plasma', 'no label'), ('Erythrocyte', 'no label'), ('Erythrocyte', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Erythrocyte Phosphatidylethanolamine', 'no label'), ('Erythrocyte Phosphatidylcholine', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~29176022|This Study Aims To Investigate The Spectrum And Frequency Of Phenylalanine Hydroxylase (Pah) Gene Mutations And The Power To Prenatally Diagnose Phenylketonuria (Pku) Patients In Shaanxi, China. Polymerase Chain Reaction (Pcr) And Dna Sequencing Analyses Were Performed To Examine The Pah Gene In 33 Pku Patients And Seven Amniotic Fluid Samples. Thirty-Four Pathogenic Variants Were Indicated In All 63 Alleles, In Which Two Probands Carried Three Variants. Pedigree Analysis Suggested That The [C.158G>A([P.R53H)][Ivs7+2T>A] Mutation Was Located At The Same Chromatid. However, There Was A Controversial Viewpoint That Thought The C.158G>A(P.R53H) Variant Was A Polymorphism In The Chinese. We Also Found One Novel Indel Mutation And Identified The C.59_60Delaginscc Mutation Of The Pah Gene For The Very First Time. The Spectrum Of The Pah Mutations In Shaanxi Province Were Similar To That Among China'S Population. Based On The Results Of Pah Gene Analysis, We Further Performed Prenatal Genetic Diagnoses For Seven Pku Families. All Foetuses Were Definitively Diagnosed, And Their Parents Were Provided With Genetic Counselling. Pah Gene Analysis Is A Crucial Method For Pku Diagnosis And Prenatal Genetic Prognosis, Even Though Many Uncommon Mutations Would Affect The Analysis And Diagnosis Of Genetic Abnormalities.|"[('Study', 'no label'), ('Investigate', 'no label'), ('Spectrum', 'no label'), ('Frequency', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Gene Mutations', 'no label'), ('Power', 'no label'), ('Prenatally Diagnose Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Shaanxi', 'no label'), ('China', 'no label'), ('Polymerase Chain Reaction', 'no label'), ('Pcr', 'no label'), ('Dna Sequencing Analyses', 'no label'), ('Performed', 'no label'), ('Pah Gene', 'no label'), ('Patients', 'no label'), ('Amniotic Fluid', 'no label'), ('Samples', 'no label'), ('Pathogenic', 'no label'), ('Variants', 'no label'), ('Alleles', 'no label'), ('Probands', 'no label'), ('Variants', 'no label'), ('Pedigree Analysis', 'no label'), ('C.158G>A([P.R53H)][Ivs7+2T>A] Mutation', 'no label'), ('Chromatid', 'no label'), ('C.158G>A(P.R53H) Variant', 'no label'), ('Was A', 'no label'), ('Polymorphism', 'no label'), ('Chinese', 'no label'), ('Indel', 'no label'), ('Mutation', 'no label'), ('C.59_60Delaginscc Mutation', 'no label'), ('Pah Gene', 'no label'), ('Very First Time', 'no label'), ('Spectrum', 'no label'), ('Pah Mutations', 'no label'), ('Shaanxi Province', 'no label'), (""China'S"", 'no label'), ('Population', 'no label'), ('Pah Gene Analysis', 'no label'), ('Performed', 'no label'), ('Prenatal', 'no label'), ('Genetic Diagnoses', 'no label'), ('Pku Families', 'no label'), ('Foetuses', 'no label'), ('Definitively', 'no label'), ('Diagnosed', 'no label'), ('Parents', 'no label'), ('Genetic Counselling', 'no label'), ('Gene Analysis', 'no label'), ('Pku Diagnosis', 'no label'), ('Prenatal', 'no label'), ('Genetic Prognosis', 'no label'), ('Mutations', 'no label'), ('Analysis', 'no label'), ('Diagnosis', 'no label'), ('Genetic Abnormalities', 'no label')]"|[('Phenylalanine Hydroxylase', 'no label'), ('Gene Mutations', 'no label'), ('Dna', 'no label'), ('Gene', 'no label'), ('Mutation', 'no label'), ('Variant', 'no label'), ('Polymorphism', 'no label'), ('Mutation', 'no label'), ('Mutation', 'no label'), ('Gene', 'no label'), ('Mutations', 'no label'), ('Gene', 'no label'), ('Genetic', 'no label'), ('Genetic', 'no label'), ('Gene', 'no label'), ('Genetic', 'no label'), ('Mutations', 'no label'), ('Genetic', 'no label')]|[('Pah Gene', 'no label'), ('Pah Gene', 'no label'), ('Pah Mutations', 'no label'), ('Pah Gene', 'no label'), ('Pah Gene', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Pcr', 'no label'), ('Dna', 'no label'), ('Pah Gene', 'no label'), ('Patients', 'no label'), ('Amniotic Fluid Samples', 'no label'), ('C.59_60Delaginscc', 'no label'), ('Pah Gene', 'no label'), ('Pah', 'no label'), ('Pah Gene', 'no label'), ('Foetuses', 'no label')]
phenylketonuria|pubmed~28645531|"Phenylketonuria (Pku) And Less Severe Hyperphenylalaninemia (Hpa) Constitute The Most Common Inborn Error Of Amino Acid Metabolism, And Is Most Often Caused By Defects In Phenylalanine Hydroxylase (Pah) Function Resulting In Accumulation Of Phe To Neurotoxic Levels. Despite The Success Of Dietary Intervention In Preventing Permanent Neurological Damage, Individuals Living With Pku Clamor For Additional Non-Dietary Therapies. The Bulk Of Disease-Associated Mutations Are Pah Missense Variants, Which Occur Throughout The Entire 452 Amino Acid Human Pah Protein. While Some Disease-Associated Mutations Affect Protein Structure (E.G. Truncations) And Others Encode Catalytically Dead Variants, Most Have Been Viewed As Defective In Protein Folding/Stability. Here We Refine This View To Address How Pku-Associated Missense Variants Can Perturb The Equilibrium Among Alternate Native Pah Structures (Resting-State Pah And Activated Pah), Thus Shifting The Tipping Point Of This Equilibrium To A Neurotoxic Phe Concentration. This Refined View Of Pku Introduces Opportunities For The Design Or Discovery Of Therapeutic Pharmacological Chaperones That Can Help Restore The Tipping Point To Healthy Phe Levels And How Such A Therapeutic Might Work With Or Without The Inhibitory Pharmacological Chaperone Bh<Sub>4</Sub>. Dysregulation Of An Equilibrium Of Architecturally Distinct Native Pah Structures Departs From The Concept Of ""Misfolding"", Provides An Updated Understanding Of Pku, And Presents An Enhanced Foundation For Understanding Genotype/Phenotype Relationships."|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Hpa', 'no label'), ('Constitute', 'no label'), ('Inborn Error', 'no label'), ('Amino Acid Metabolism', 'no label'), ('Defects', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Resulting', 'no label'), ('Accumulation', 'no label'), ('Phe', 'no label'), ('Neurotoxic', 'no label'), ('Levels', 'no label'), ('Success', 'no label'), ('Dietary Intervention', 'no label'), ('Preventing', 'no label'), ('Permanent', 'no label'), ('Neurological Damage', 'no label'), ('Individuals', 'no label'), ('Pku Clamor', 'no label'), ('Non-Dietary Therapies', 'no label'), ('Disease-Associated Mutations', 'no label'), ('Missense Variants', 'no label'), ('Occur', 'no label'), ('Entire', 'no label'), ('Amino Acid', 'no label'), ('Human Pah Protein', 'no label'), ('Disease-Associated Mutations', 'no label'), ('Protein Structure', 'no label'), ('Truncations', 'no label'), ('Encode', 'no label'), ('Catalytically', 'no label'), ('Dead Variants', 'no label'), ('Defective', 'no label'), ('Protein Folding/Stability', 'no label'), ('Refine', 'no label'), ('Pku-Associated', 'no label'), ('Missense Variants', 'no label'), ('Equilibrium', 'no label'), ('Alternate Native Pah Structures', 'no label'), ('Tipping Point', 'no label'), ('Equilibrium', 'no label'), ('Neurotoxic', 'no label'), ('Phe', 'no label'), ('Concentration', 'no label'), ('Refined View', 'no label'), ('Pku Introduces Opportunities', 'no label'), ('Design', 'no label'), ('Therapeutic', 'no label'), ('Pharmacological', 'no label'), ('Chaperones', 'no label'), ('Restore', 'no label'), ('Tipping Point', 'no label'), ('Healthy', 'no label'), ('Phe Levels', 'no label'), ('Therapeutic', 'no label'), ('Inhibitory', 'no label'), ('Pharmacological', 'no label'), ('Chaperone', 'no label'), ('Bh<Sub>4</Sub>. Dysregulation', 'no label'), ('Equilibrium', 'no label'), ('Architecturally', 'no label'), ('Native', 'no label'), ('Structures Departs', 'no label'), ('Concept', 'no label'), ('Provides', 'no label'), ('Enhanced', 'no label'), ('Foundation', 'no label'), ('Genotype/Phenotype Relationships', 'no label')]|[('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Neurotoxic', 'no label'), ('Individuals', 'no label'), ('Mutations', 'no label'), ('Amino Acid Human', 'no label'), ('Protein', 'no label'), ('Mutations', 'no label'), ('Protein', 'no label'), ('Truncations', 'no label'), ('Protein', 'no label'), ('Variants', 'no label'), ('Neurotoxic Phe', 'no label'), ('Phe', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Neurotoxic', 'no label'), ('Neurological Damage', 'no label'), ('Amino Acid Human Pah Protein', 'no label'), ('Neurotoxic', 'no label')]|[('Phenylketonuria', 'no label'), ('Error', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phe', 'no label'), ('Clamor', 'no label'), ('Pah', 'no label'), ('Amino Acid', 'no label'), ('Human Pah', 'no label'), ('E.G.', 'no label'), ('Phe', 'no label'), ('Chaperones', 'no label'), ('Phe', 'no label'), ('Chaperone', 'no label'), ('Sub>4</Sub>.', 'no label')]
phenylketonuria|pubmed~29468336|Phenylketonuria (Pku) Is A Rare Inherited Metabolic Disorder Which Can Cause Neurological Damage If Left Untreated. Pku Is Identified Through Newborn Screening In Developed Countries, And Treatment Begins Immediately To Prevent These Severe Consequences. When A Child Is Diagnosed, Parents Must Assume Immediate Responsibility For The Management Of Pku And Prevention Of Neurological Damage. Quantitative Studies Have Identified Significant Psychosocial Stressors For Parents, But Little Is Known About How The Parents Experience This Process. This Study Aimed To Explore The Experiences Of Parents Of Children With Pku Under The Age Of Two. It Is The First Study To Examine These Experiences In This Way. Seven Parents Were Interviewed About Their Experiences, And Interpretative Phenomenological Analysis Was Used To Analyse The Data. Three Main Themes Were Identified: Control, Striving For Normality And Acceptance Of Pku As A Continuum. Links Between The Themes And Processes Underpinning The Results Were Explored With Relation To Existing Literature And Theories From A Clinical Psychology Perspective. The Role Of Acceptance Of Pku Was Central To The Parent'S Experiences. Clinical Implications And Suggestions For Further Research Are Discussed.|"[('Phenylketonuria', 'no label'), ('Rare', 'no label'), ('Inherited', 'no label'), ('Metabolic Disorder', 'no label'), ('Neurological Damage', 'no label'), ('Left Untreated', 'no label'), ('Identified', 'no label'), ('Newborn', 'no label'), ('Screening', 'no label'), ('Developed Countries', 'no label'), ('Treatment Begins', 'no label'), ('Prevent', 'no label'), ('Severe', 'no label'), ('Consequences', 'no label'), ('Child', 'no label'), ('Diagnosed', 'no label'), ('Parents', 'no label'), ('Immediate Responsibility', 'no label'), ('Management', 'no label'), ('Pku And Prevention', 'no label'), ('Neurological Damage', 'no label'), ('Quantitative Studies', 'no label'), ('Psychosocial', 'no label'), ('Stressors', 'no label'), ('Parents', 'no label'), ('Parents', 'no label'), ('Experience', 'no label'), ('Process', 'no label'), ('Study', 'no label'), ('Experiences', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Age', 'no label'), ('First Study', 'no label'), ('Experiences', 'no label'), ('Parents', 'no label'), ('Experiences', 'no label'), ('Interpretative Phenomenological Analysis', 'no label'), ('Data', 'no label'), ('Themes', 'no label'), ('Identified', 'no label'), ('Control', 'no label'), ('Striving', 'no label'), ('Normality', 'no label'), ('Acceptance', 'no label'), ('Continuum', 'no label'), ('Themes', 'no label'), ('Processes', 'no label'), ('Results', 'no label'), ('Relation', 'no label'), ('Literature', 'no label'), ('Theories', 'no label'), ('Clinical Psychology Perspective', 'no label'), ('Acceptance', 'no label'), ('Pku Was Central', 'no label'), (""Parent'S"", 'no label'), ('Experiences', 'no label'), ('Clinical Implications', 'no label'), ('Suggestions', 'no label'), ('Research', 'no label')]"|[]|[]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Neurological Damage', 'no label'), ('Neurological Damage', 'no label')]|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Children', 'no label'), ('Pku As A', 'no label'), ('Pku', 'no label')]
phenylketonuria|pubmed~30453665|In Phenylketonuria (Pku), Synthetic Protein Derived From L-Amino Acids (Aas) Is Essential In A Low-Phenylalanine (Phe) Diet. Glycomacropeptide (Gmp), An Intact Protein, Is Very Low In Phe In Its Native Form. It Has Been Modified And Adapted For Pku To Provide An Alternative Protein Source Through Supplementation With Rate-Limiting Amino Acids (Gmp-Aas), Although It Still Contains Residual Phe. This Review Aims To Systematically Evaluate Published Intervention Studies On The Use Of Gmp-Aas In Pku By Considering Its Impact On Blood Phe Control (Primary Aim) And Changes In Tyrosine Control, Nutritional Biomarkers, And Patient Acceptability Or Palatability (Secondary Aims). Four Electronic Databases Were Searched For Articles Published From 2007 To June 2018. Of The 274 Studies Identified, Only Eight Were Included. Bias Risk Was Assessed And A Quality Appraisal Of The Body Of Evidence Was Completed. A Meta-Analysis Was Performed With Two Studies With Adequate Comparable Methodology Which Showed No Differences Between Gmp-Aas And Aas For Any Of The Interventions Analysed. This Work Underlines The Scarcity And Nature Of Studies With Gmp-Aas Interventions. All Were Short-Term With Small Sample Sizes. There Is A Need For Better-Designed Studies To Provide The Best Evidence-Based Recommendations.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Synthetic Protein', 'no label'), ('L-Amino Acids', 'no label'), ('Low-Phenylalanine (Phe) Diet', 'no label'), ('Glycomacropeptide', 'no label'), ('Gmp', 'no label'), ('Intact Protein', 'no label'), ('Phe', 'no label'), ('Native Form', 'no label'), ('Modified', 'no label'), ('Supplementation', 'no label'), ('Rate-Limiting Amino Acids', 'no label'), ('Gmp-Aas', 'no label'), ('Residual', 'no label'), ('Phe', 'no label'), ('Review', 'no label'), ('Systematically Evaluate', 'no label'), ('Published Intervention Studies', 'no label'), ('Gmp-Aas', 'no label'), ('Impact', 'no label'), ('Blood Phe Control', 'no label'), ('Changes', 'no label'), ('Tyrosine Control', 'no label'), ('Nutritional Biomarkers', 'no label'), ('Patient', 'no label'), ('Acceptability', 'no label'), ('Palatability', 'no label'), ('Secondary Aims', 'no label'), ('Electronic Databases', 'no label'), ('Searched', 'no label'), ('Articles', 'no label'), ('Published', 'no label'), ('Studies', 'no label'), ('Identified', 'no label'), ('Bias Risk', 'no label'), ('Assessed', 'no label'), ('Quality', 'no label'), ('Appraisal', 'no label'), ('Body', 'no label'), ('Evidence', 'no label'), ('Was Completed', 'no label'), ('Meta-Analysis', 'no label'), ('Performed', 'no label'), ('Studies', 'no label'), ('Adequate', 'no label'), ('Methodology', 'no label'), ('Gmp-Aas', 'no label'), ('Interventions', 'no label'), ('Analysed', 'no label'), ('Work Underlines', 'no label'), ('Scarcity', 'no label'), ('Nature', 'no label'), ('Studies', 'no label'), ('Gmp-Aas', 'no label'), ('Interventions', 'no label'), ('Short-Term With', 'no label'), ('Small Sample Sizes', 'no label'), ('Need', 'no label'), ('Better-Designed Studies', 'no label'), ('Best', 'no label'), ('Evidence-Based', 'no label'), ('Recommendations', 'no label')]|[('Synthetic Protein', 'no label'), ('L-Amino Acids', 'no label'), ('Phe', 'no label'), ('Glycomacropeptide', 'no label'), ('Gmp', 'no label'), ('Protein', 'no label'), ('Phe', 'no label'), ('Protein', 'no label'), ('Amino Acids', 'no label'), ('Tyrosine', 'no label')]|[('Gmp-Aas', 'no label'), ('Gmp-Aas', 'no label'), ('Gmp-Aas', 'no label')]|[('Phenylketonuria', 'no label'), ('Phe', 'no label'), ('Glycomacropeptide', 'no label'), ('Gmp', 'no label'), ('Phe', 'no label'), ('Amino Acids', 'no label'), ('Tyrosine', 'no label')]|[('Phenylketonuria', 'no label'), ('L-Amino Acids', 'no label'), ('Low-Phenylalanine', 'no label'), ('Phe', 'no label'), ('Glycomacropeptide', 'no label'), ('Gmp', 'no label'), ('Phe', 'no label'), ('Amino Acids', 'no label'), ('Phe', 'no label'), ('Pku', 'no label'), ('Blood Phe', 'no label'), ('Tyrosine', 'no label'), ('Body', 'no label')]
phenylketonuria|pubmed~23737086|Phenylketonuria Is An Inherited Disease For Which The Main Treatment Is The Dietary Restriction Of The Amino Acid Phenylalanine. The Diet Has To Be Initiated In The Neonatal Period To Prevent Or Reduce Mental Handicap. However, The Diet Is Very Restrictive And Unpalatable And Can Be Difficult To Follow. A Deficiency Of The Amino Acid Tyrosine Has Been Suggested As A Cause Of Some Of The Neuropsychological Problems Exhibited In Phenylketonuria. Therefore, This Review Aims To Assess The Efficacy Of Tyrosine Supplementation For Phenylketonuria. To Assess The Effects Of Tyrosine Supplementation Alongside Or Instead Of A Phenylalanine-Restricted Diet For People With Phenylketonuria, Who Commenced On Diet At Diagnosis And Either Continued On The Diet Or Relaxed The Diet Later In Life. To Assess The Evidence That Tyrosine Supplementation Alongside, Or Instead Of A Phenylalanine-Restricted Diet Improves Intelligence, Neuropsychological Performance, Growth And Nutritional Status, Mortality Rate And Quality Of Life. We Searched The Cochrane Cystic Fibrosis And Genetic Disorders Group'S Trials Register Which Is Comprised Of References Identified From Comprehensive Electronic Database Searches, Handsearches Of Relevant Journals And Abstract Books Of Conference Proceedings. Additional Studies Were Identified From Handsearches Of The Journal Of Inherited Metabolic Disease (From Inception In 1978 To 1998). The Manufacturers Of Prescribable Dietary Products Used In The Treatment Of Phenylketonuria Were Also Contacted For Further References.Date Of The Most Recent Search Of The Group'S Inborn Errors Of Metabolism Trials Register: 28 June 2012. All Randomised Or Quasi-Randomised Trials Investigating The Use Of Tyrosine Supplementation Versus Placebo In People With Phenylketonuria In Addition To, Or Instead Of, A Phenylalanine-Restricted Diet. People Treated For Maternal Phenylketonuria Were Excluded. Two Authors Independently Assessed The Trial Eligibility, Methodological Quality And Extracted The Data. Six Trials Were Found, Of Which Three Trials Reporting The Results Of A Total Of 56 Participants, Were Suitable For Inclusion In The Review. The Blood Tyrosine Concentrations Were Significantly Higher In The Participants Receiving Tyrosine Supplements Than Those In The Placebo Group, Mean Difference 23.46 (95% Confidence Interval 12.87 To 34.05). No Significant Differences Were Found Between Any Of The Other Outcomes Measured. From The Available Evidence No Recommendations Can Be Made About Whether Tyrosine Supplementation Should Be Introduced Into Routine Clinical Practice. Further Randomised Controlled Studies Are Required To Provide More Evidence.|"[('Phenylketonuria', 'no label'), ('Inherited Disease', 'no label'), ('Main Treatment', 'no label'), ('Dietary Restriction', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Diet', 'no label'), ('Initiated', 'no label'), ('Neonatal', 'no label'), ('Period', 'no label'), ('Prevent', 'no label'), ('Reduce', 'no label'), ('Mental Handicap', 'no label'), ('Diet', 'no label'), ('Unpalatable', 'no label'), ('Deficiency', 'no label'), ('Amino Acid Tyrosine', 'no label'), ('Cause', 'no label'), ('Neuropsychological Problems Exhibited', 'no label'), ('Phenylketonuria', 'no label'), ('Review Aims', 'no label'), ('Efficacy', 'no label'), ('Tyrosine', 'no label'), ('Supplementation', 'no label'), ('Phenylketonuria', 'no label'), ('Assess', 'no label'), ('Effects', 'no label'), ('Tyrosine', 'no label'), ('Supplementation', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Commenced', 'no label'), ('Diet', 'no label'), ('Diagnosis', 'no label'), ('Continued', 'no label'), ('Diet', 'no label'), ('Diet', 'no label'), ('Assess', 'no label'), ('Evidence', 'no label'), ('Tyrosine', 'no label'), ('Supplementation', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Intelligence', 'no label'), ('Neuropsychological Performance', 'no label'), ('Growth', 'no label'), ('Nutritional Status', 'no label'), ('Mortality Rate', 'no label'), ('Cochrane Cystic Fibrosis', 'no label'), ('Genetic Disorders', 'no label'), (""Group'S Trials"", 'no label'), ('References', 'no label'), ('Identified', 'no label'), ('Comprehensive Electronic Database Searches', 'no label'), ('Handsearches', 'no label'), ('Relevant', 'no label'), ('Journals', 'no label'), ('Proceedings', 'no label'), ('Studies', 'no label'), ('Identified', 'no label'), ('Handsearches', 'no label'), ('Metabolic Disease', 'no label'), ('Inception', 'no label'), ('Manufacturers', 'no label'), ('Prescribable', 'no label'), ('Dietary Products', 'no label'), ('Treatment', 'no label'), ('Phenylketonuria', 'no label'), ('Contacted', 'no label'), ('References', 'no label'), (""Group'S"", 'no label'), ('Inborn Errors', 'no label'), ('Metabolism Trials Register', 'no label'), ('Randomised Or Quasi-Randomised Trials', 'no label'), ('Investigating', 'no label'), ('Tyrosine Supplementation', 'no label'), ('Placebo', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('People', 'no label'), ('Treated', 'no label'), ('Maternal', 'no label'), ('Phenylketonuria', 'no label'), ('Assessed', 'no label'), ('Trial', 'no label'), ('Eligibility', 'no label'), ('Methodological Quality', 'no label'), ('Data', 'no label'), ('Trials', 'no label'), ('Trials Reporting', 'no label'), ('Participants', 'no label'), ('Inclusion', 'no label'), ('Review', 'no label'), ('Blood Tyrosine', 'no label'), ('Concentrations', 'no label'), ('Participants', 'no label'), ('Tyrosine Supplements', 'no label'), ('Placebo Group', 'no label'), ('Mean Difference', 'no label'), ('Confidence Interval', 'no label'), ('No Significant', 'no label'), ('Differences', 'no label'), ('Outcomes', 'no label'), ('Measured', 'no label'), ('Available', 'no label'), ('Evidence', 'no label'), ('Recommendations', 'no label'), ('Tyrosine', 'no label'), ('Supplementation', 'no label'), ('Introduced', 'no label'), ('Routine', 'no label'), ('Clinical Practice', 'no label'), ('Randomised Controlled Studies', 'no label'), ('Evidence', 'no label')]"|[('Amino Acid Phenylalanine', 'no label'), ('Amino Acid Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Genetic', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Inherited Disease', 'no label'), ('Amino Acid Phenylalanine', 'no label'), ('Amino Acid Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Fibrosis', 'no label'), ('Metabolic Disease', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label')]|[('Phenylketonuria', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Amino Acid', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('Phenylketonuria', 'no label'), ('Tyrosine', 'no label'), ('People', 'no label'), ('Phenylketonuria', 'no label'), ('Blood Tyrosine', 'no label'), ('Tyrosine', 'no label'), ('Tyrosine', 'no label')]
phenylketonuria|pubmed~32883979|Phenylalanine Hydroxylase (Pah) Deficiency Leads To Phenylalanine Accumulation And Results In Phenylketonuria (Pku). Phenylketonuria Can Contribute To Severe Inability Such As Mental Impairment. Early Diagnosis And Dietary Intervention Can Have Beneficial Effects On Maintaining Normal Neural And Cognitive Function In Patients With Pku. However, A Long-Term Low Phenylalanine Diet May Put Children At Risk Of Malnutrition. A Food Supplement Was Therefore Used For Children With Pku Under Dietician Supervision According To Dietary Reference Intakes (Dris). In This Cross-Sectional Study, We Enrolled Patients With Pku And Age-Matched Controls To Compare Their Anthropometry Data [Weight, Height, Body Mass Index (Bmi), And Body Composition Using Bioelectrical Impedance Analysis (Bia)], And Correlated It With Their Dietary Intake Based On 24-H Dietary Recall. For Continuous Parameters, The Data Were Expressed As Median ± Standard Deviation (Sd), And The Mann-Whitney U Test Was Used To Test The Difference Among The Groups. Correlation By Natural Proteins, Body Fat, And Fat-Free Mass Were Evaluated Using The Pearson Correlation Coefficient. Twenty-Two Participants Diagnosed With Pku (Ages 8-27 Years; Mean 15.23 ± 5.23) And A Control Group Of 22 Non-Pku Participants (Ages 8-39 Years; Mean 19.73 ± 10.6) Were Recruited For This Study. Between The Two Groups Of Participants, No Significant Difference Was Found In Height, Weight, Bmi, Muscle Mass, Or Fat Mass. The Percentage Of Natural Protein Has No Effect On Body Composition. We Found A Significant Positive Correlation Between The Total Protein Intake Percentage Of Dris And Muscle Mass (R = 0.491, P = 0.020) And A Significant Negative Correlation In The Total Protein Intake Percentage Of Dris And Fat Mass (R = -0.475, P = 0.025) In Participants With Pku. There Were No Significant Differences In Body Composition And Nutrition Intake Between Patients With Pku (Under Metabolic Control) And Healthy Subjects. Thus, Giving Proper Nutrition Treatment May Have Beneficial Effects On Body Growth And Nutrition Status In Patients With Pku In Taiwan.|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Accumulation', 'no label'), ('Results', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Contribute', 'no label'), ('Severe', 'no label'), ('Inability', 'no label'), ('Mental Impairment', 'no label'), ('Early Diagnosis', 'no label'), ('Dietary Intervention', 'no label'), ('Beneficial', 'no label'), ('Effects', 'no label'), ('Normal Neural', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Long-Term', 'no label'), ('Phenylalanine Diet', 'no label'), ('Children', 'no label'), ('Risk', 'no label'), ('Malnutrition', 'no label'), ('Food Supplement', 'no label'), ('Children', 'no label'), ('Pku Under Dietician Supervision', 'no label'), ('Dietary Reference Intakes', 'no label'), ('Dris', 'no label'), ('Cross-Sectional Study', 'no label'), ('Patients', 'no label'), ('Pku And Age-Matched Controls', 'no label'), ('Compare', 'no label'), ('Anthropometry Data', 'no label'), ('Weight', 'no label'), ('Height', 'no label'), ('Body Mass Index', 'no label'), ('Bmi', 'no label'), ('Body Composition', 'no label'), ('Bioelectrical Impedance Analysis', 'no label'), ('Bia', 'no label'), ('Correlated', 'no label'), ('Dietary Intake', 'no label'), ('Dietary Recall', 'no label'), ('Continuous Parameters', 'no label'), ('Data', 'no label'), ('Expressed', 'no label'), ('Sd', 'no label'), ('Mann-Whitney U Test', 'no label'), ('Difference', 'no label'), ('Groups', 'no label'), ('Correlation', 'no label'), ('Natural Proteins', 'no label'), ('Body Fat', 'no label'), ('Fat-Free Mass', 'no label'), ('Pearson Correlation Coefficient', 'no label'), ('Participants', 'no label'), ('Diagnosed', 'no label'), ('Pku', 'no label'), ('Control Group', 'no label'), ('Non-Pku Participants', 'no label'), ('Ages', 'no label'), ('Study', 'no label'), ('Groups', 'no label'), ('Participants', 'no label'), ('No Significant Difference', 'no label'), ('Height', 'no label'), ('Weight', 'no label'), ('Bmi', 'no label'), ('Muscle Mass', 'no label'), ('Fat Mass.', 'no label'), ('Percentage', 'no label'), ('Natural Protein', 'no label'), ('Effect', 'no label'), ('Body Composition', 'no label'), ('Significant', 'no label'), ('Positive', 'no label'), ('Correlation', 'no label'), ('Total Protein Intake', 'no label'), ('Percentage', 'no label'), ('Dris', 'no label'), ('Significant', 'no label'), ('Negative', 'no label'), ('Correlation', 'no label'), ('Total Protein Intake', 'no label'), ('Percentage', 'no label'), ('Dris', 'no label'), ('Participants', 'no label'), ('Pku', 'no label'), ('No Significant', 'no label'), ('Differences', 'no label'), ('Body Composition', 'no label'), ('Nutrition Intake', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Metabolic Control', 'no label'), ('Healthy Subjects', 'no label'), ('Nutrition Treatment', 'no label'), ('Beneficial Effects', 'no label'), ('Body Growth', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Taiwan', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Food', 'no label'), ('Bmi', 'no label'), ('Bmi', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label')]|[]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Malnutrition', 'no label'), ('Muscle Mass (R\u2009=\u20090.491, P\u2009=\u20090.020)', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Long-Term', 'no label'), ('Phenylalanine', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Patients', 'no label'), ('Pku And', 'no label'), ('Bmi', 'no label'), ('Body', 'no label'), ('U Test', 'no label'), ('Fat-Free', 'no label'), ('Pku (Ages 8', 'no label'), ('Bmi', 'no label'), ('Muscle', 'no label'), ('Fat Mass.', 'no label'), ('Body', 'no label'), ('Muscle', 'no label'), ('Fat', 'no label'), ('Body', 'no label'), ('Patients', 'no label'), ('Pku (', 'no label'), ('Body', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~29909188|Phenylketonuria (Pku) Is A Prevalent Inherited Metabolic Disorder Caused By A Phenylalanine Hydroxylase (Pah) Or Tetrahydrobiopterin (Bh4) Deficiency, Which Leads To The Accumulation Of Phenylalanine (Phe). High Blood Levels Of Phe Have A Toxic Effect On The Brain And Are Associated With Several Neurological Signs. Most Cases Of Pku Are Identified During Infancy, And Diagnosis Of Pku In Adult Is Rare. Here, We Describe A 29-Year-Old Patient With Progressive Dementia And Muscular Weakness Mimicking X-Linked Adrenoleukodystrophy. Haematological Tests Revealed High Phe Levels (966.67 Μmol/ L, Normal 20.00-120.00 Μmol/L) And His Gene Test Showed Compound Heterozygosity For C.740 G > T And C.728 G > A Of Pah Gene Mutations, Suggesting A Diagnosis Of Pku. His Condition Had Controlled Partly But Not Significantly Improved With Appropriate Treatment. Our Patient Is The First Case Of Late-Diagnosed Pku With Definite Heterozygous Pah Gene Mutations Reported In China Albeit He Had Milder Symptoms Than The Previous Reported Cases Around World. Although Late-Diagnosed Pku Is Rare, This Diagnosis Should Be Considered For Patients Presenting With Leukoencephalopathy Accompanied By Common Neurological Signs.|[('Phenylketonuria', 'no label'), ('Prevalent', 'no label'), ('Inherited', 'no label'), ('Metabolic Disorder', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Deficiency', 'no label'), ('Leads', 'no label'), ('Accumulation', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Blood Levels', 'no label'), ('Phe', 'no label'), ('Toxic Effect', 'no label'), ('Brain', 'no label'), ('Associated With', 'no label'), ('Neurological Signs', 'no label'), ('Cases', 'no label'), ('Pku Are Identified', 'no label'), ('Infancy', 'no label'), ('Diagnosis', 'no label'), ('Pku In Adult', 'no label'), ('Rare', 'no label'), ('29-Year-Old', 'no label'), ('Patient', 'no label'), ('Progressive Dementia', 'no label'), ('Muscular Weakness', 'no label'), ('X-Linked Adrenoleukodystrophy', 'no label'), ('Haematological Tests', 'no label'), ('Revealed', 'no label'), ('Phe Levels', 'no label'), ('Normal', 'no label'), ('His Gene Test', 'no label'), ('Compound Heterozygosity', 'no label'), ('C.740\u202fG\u202f>\u202fT', 'no label'), ('C.728\u202fG\u202f>\u202fA', 'no label'), ('Gene Mutations', 'no label'), ('Suggesting', 'no label'), ('Diagnosis', 'no label'), ('Condition', 'no label'), ('Controlled', 'no label'), ('Appropriate', 'no label'), ('Treatment', 'no label'), ('Patient', 'no label'), ('Heterozygous Pah Gene', 'no label'), ('Reported', 'no label'), ('China', 'no label'), ('Milder', 'no label'), ('Symptoms', 'no label'), ('Cases', 'no label'), ('World', 'no label'), ('Late-Diagnosed Pku', 'no label'), ('Diagnosis', 'no label'), ('Patients', 'no label'), ('Leukoencephalopathy', 'no label'), ('Accompanied', 'no label'), ('Neurological Signs', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Toxic', 'no label'), ('Phe', 'no label'), ('His Gene', 'no label'), ('Gene Mutations', 'no label'), ('His', 'no label'), ('Gene Mutations', 'no label')]|[('Pah Gene', 'no label'), ('His', 'no label'), ('Pah Gene Mutations', 'no label')]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Bh4', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Dementia', 'no label'), ('Muscular Weakness', 'no label'), ('Adrenoleukodystrophy', 'no label'), ('Phe', 'no label'), ('966.67', 'no label'), ('Leukoencephalopathy', 'no label')]|[('Phenylketonuria', 'no label'), ('A Phenylalanine Hydroxylase', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Blood', 'no label'), ('Phe', 'no label'), ('Brain', 'no label'), ('Pku', 'no label'), ('Pku', 'no label'), ('Patient', 'no label'), ('Muscular Weakness Mimicking', 'no label'), ('Pah Gene', 'no label'), ('Patient', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~33618142||[]|[]|[]|[]|[]
phenylketonuria|pubmed~30078395||[]|[]|[]|[]|[]
phenylketonuria|pubmed~28489557|Phenylketonuria (Pku) Is An Autosomal Recessive Metabolic Disorder. Dietary Control Of Classic Pku Needs Restriction Of Natural Proteins. The Diet Results In Unbalanced Nutrition, Which Might Affect The Physical Development Of The Patients. Our Aim Was To Evaluate Bone Mineral Density (Bmd) In Children With Pku. To Investigate The Bmd Of Children With Pku, 41 Children With Pku And 64 Healthy Controls Were Recruited (All 3-4 Years Of Age). Body Weight And Height, Bmd, Phe Blood Levels, Thyroid Function, Calcium, Phosphorus, Iron Metabolism Markers, And Vitamin D3 Were Measured. Body Height And Bmd Of Patients Were Lower Than In Controls. The Bmd Of Controls Was Positively Associated With Age, Body Weight And Height. In Patients, Bmd Was Positively Associated With Body Weight. There Was No Correlation Between Phe Blood Levels And Bmd In Patients. Blood Levels Of Alkaline Phosphatase Were Higher In Patients Compared To Controls. Blood Calcium Levels Were Higher In 4-Year-Old Patients, While The Body Weight Was Lower Compared To Controls. Thyroid Function, Iron Metabolism Markers, Vitamin D3 Levels And Igf-1 Levels Were Normal. Reduced Bmd Was Observed In Children With Phenylketonuria, But The Exact Reasons For This Remain To Be Elucidated.|[('Phenylketonuria', 'no label'), ('Autosomal Recessive Metabolic Disorder', 'no label'), ('Dietary Control', 'no label'), ('Pku Needs Restriction', 'no label'), ('Natural Proteins', 'no label'), ('Diet Results', 'no label'), ('Nutrition', 'no label'), ('Physical Development', 'no label'), ('Patients', 'no label'), ('Evaluate', 'no label'), ('Bone Mineral Density', 'no label'), ('Bmd', 'no label'), ('Children', 'no label'), ('Investigate', 'no label'), ('Bmd', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Healthy Controls', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Body Weight', 'no label'), ('Height', 'no label'), ('Bmd', 'no label'), ('Phe Blood Levels', 'no label'), ('Thyroid Function', 'no label'), ('Calcium', 'no label'), ('Phosphorus', 'no label'), ('Iron Metabolism', 'no label'), ('Markers', 'no label'), ('Vitamin D3', 'no label'), ('Measured', 'no label'), ('Body Height', 'no label'), ('Bmd', 'no label'), ('Patients', 'no label'), ('Lower Than', 'no label'), ('Controls', 'no label'), ('Bmd', 'no label'), ('Controls', 'no label'), ('Positively', 'no label'), ('Associated With', 'no label'), ('Age', 'no label'), ('Body Weight', 'no label'), ('Height', 'no label'), ('Patients', 'no label'), ('Bmd', 'no label'), ('Associated With', 'no label'), ('Body Weight', 'no label'), ('Correlation', 'no label'), ('Phe Blood Levels', 'no label'), ('Bmd', 'no label'), ('Patients', 'no label'), ('Blood Levels', 'no label'), ('Alkaline Phosphatase', 'no label'), ('Higher', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Blood Calcium Levels', 'no label'), ('Higher', 'no label'), ('Patients', 'no label'), ('Body Weight', 'no label'), ('Controls', 'no label'), ('Thyroid Function', 'no label'), ('Iron Metabolism', 'no label'), ('Markers', 'no label'), ('Vitamin D3', 'no label'), ('Levels', 'no label'), ('Igf-1', 'no label'), ('Levels', 'no label'), ('Normal', 'no label'), ('Reduced', 'no label'), ('Bmd', 'no label'), ('Observed', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Exact Reasons', 'no label'), ('Remain', 'no label')]|[('Mineral', 'no label'), ('Phe', 'no label'), ('Calcium', 'no label'), ('Phosphorus', 'no label'), ('Iron', 'no label'), ('Phe', 'no label'), ('Alkaline', 'no label'), ('Calcium', 'no label'), ('Iron', 'no label')]|[('Igf-1', 'no label')]|[('Phenylketonuria', 'no label'), ('Autosomal Recessive Metabolic Disorder', 'no label'), ('Calcium', 'no label'), ('Phosphorus, Iron Metabolism Markers', 'no label'), ('Vitamin D3', 'no label'), ('Phe', 'no label'), ('Calcium', 'no label'), ('Iron', 'no label'), ('Vitamin D3', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Children', 'no label'), ('Bmd', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Bmd', 'no label'), ('Blood', 'no label'), ('Thyroid', 'no label'), ('Calcium', 'no label'), ('Phosphorus', 'no label'), ('Iron', 'no label'), ('Vitamin D3', 'no label'), ('Bmd', 'no label'), ('Patients', 'no label'), ('Bmd', 'no label'), ('Body Weight', 'no label'), ('Patients', 'no label'), ('Bmd Was', 'no label'), ('Body', 'no label'), ('Blood', 'no label'), ('Bmd', 'no label'), ('Patients', 'no label'), ('Blood', 'no label'), ('Alkaline Phosphatase', 'no label'), ('Patients', 'no label'), ('Blood Calcium', 'no label'), ('Patients', 'no label'), ('Body Weight', 'no label'), ('Iron', 'no label'), ('Vitamin D3', 'no label'), ('Igf-1', 'no label'), ('Bmd', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~32545860|This Is The First Study To Evaluate Vitamin K Status In Relation To Dietary Intake And Phenylalanine Dietary Compliance In Patients With Phenylketonuria (Pku). The Dietary And Pku Formula Intake Of Vitamin K Was Calculated In 34 Pku Patients, With Vitamin K Status Determined By The Measurement Of Prothrombin Induced By Vitamin K Absence (Pivka-Ii). Blood Phenylalanine Concentrations In The Preceding 12 Months Were Considered. There Were Significantly More Phenylalanine Results Exceeding 6 Mg/Dl In Patients With Normal Pivka-Ii Concentrations Than In Those With Abnormal Pivka-Ii Levels (<I>P</I> = 0.035). Similarly, A Higher Total Intake Of Vitamin K And Dietary Vitamin Intake Expressed As Μg/Day (<I>P</I> = 0.033 For Both) And %Rda (<I>P</I> = 0.0002 And <I>P</I> = 0.003, Respectively) Was Observed In Patients With Normal Pivka-Ii Levels. Abnormal Pivka-Ii Concentrations Were Associated With A Lower Or (0.1607; 95%Ci: 0.0273-0.9445, <I>P</I> = 0.043) Of Having A Median Phenylalanine Concentration Higher Than 6 Mg/Dl. In Conclusion, Vitamin K Deficiency Is Not Uncommon In Phenylketonuria And May Also Occur In Patients With Adequate Vitamin K Intake. Pku Patients With Better Dietary Compliance Have A Higher Risk Of Vitamin K Deficiency. The Present Findings Highlight The Need For Further Studies To Re-Evaluate Dietary Recommendations Regarding Vitamin K Intake, Both Concerning Formula-Based And Dietary Consumption Of Natural Products.|[('First Study', 'no label'), ('Evaluate', 'no label'), ('Vitamin K Status', 'no label'), ('Dietary Intake', 'no label'), ('Phenylalanine', 'no label'), ('Dietary', 'no label'), ('Compliance', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Dietary', 'no label'), ('Pku Formula Intake', 'no label'), ('Vitamin K', 'no label'), ('Patients', 'no label'), ('Vitamin K Status', 'no label'), ('Measurement', 'no label'), ('Prothrombin', 'no label'), ('Induced', 'no label'), ('Vitamin K', 'no label'), ('Absence', 'no label'), ('Pivka-Ii', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Months', 'no label'), ('Phenylalanine Results', 'no label'), ('Mg/Dl', 'no label'), ('Patients', 'no label'), ('Normal Pivka-Ii', 'no label'), ('Concentrations', 'no label'), ('Than', 'no label'), ('Abnormal Pivka-Ii', 'no label'), ('Levels', 'no label'), ('<I>P</I>', 'no label'), ('Total Intake', 'no label'), ('Vitamin K', 'no label'), ('Dietary Vitamin Intake', 'no label'), ('Expressed', 'no label'), ('<I>P</I>', 'no label'), ('%Rda', 'no label'), ('<I>P</I>', 'no label'), ('Observed', 'no label'), ('Patients', 'no label'), ('Normal Pivka-Ii Levels', 'no label'), ('Abnormal', 'no label'), ('Pivka-Ii', 'no label'), ('Concentrations', 'no label'), ('Associated With', 'no label'), ('Lower', 'no label'), ('<I>P</I> = 0.043)', 'no label'), ('Median', 'no label'), ('Phenylalanine', 'no label'), ('Concentration', 'no label'), ('Higher', 'no label'), ('Than 6', 'no label'), ('Mg/Dl', 'no label'), ('Vitamin K Deficiency', 'no label'), ('Phenylketonuria', 'no label'), ('Occur', 'no label'), ('Patients', 'no label'), ('Adequate', 'no label'), ('Vitamin K', 'no label'), ('Intake', 'no label'), ('Patients', 'no label'), ('Dietary Compliance', 'no label'), ('Higher', 'no label'), ('Risk', 'no label'), ('Vitamin K Deficiency', 'no label'), ('Findings', 'no label'), ('Studies', 'no label'), ('Re-Evaluate', 'no label'), ('Dietary', 'no label'), ('Recommendations', 'no label'), ('Vitamin K', 'no label'), ('Intake', 'no label'), ('Formula-Based', 'no label'), ('Dietary Consumption', 'no label'), ('Natural Products', 'no label')]|[('Vitamin', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Vitamin', 'no label'), ('Phenylalanine', 'no label'), ('Vitamin', 'no label')]|[('Prothrombin', 'no label'), ('Pivka-Ii', 'no label'), ('Pivka-Ii', 'no label'), ('Pivka-Ii', 'no label')]|[('Vitamin K', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Vitamin K', 'no label'), ('Vitamin K', 'no label'), ('Vitamin K', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Vitamin K', 'no label'), ('Vitamin Intake', 'no label'), ('Phenylalanine', 'no label'), ('Vitamin K', 'no label'), ('Phenylketonuria', 'no label'), ('Vitamin K', 'no label'), ('Vitamin K', 'no label'), ('Vitamin K', 'no label')]|[('Vitamin K', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Pku Formula', 'no label'), ('Vitamin K', 'no label'), ('Vitamin K', 'no label'), ('Prothrombin', 'no label'), ('Vitamin K', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Vitamin K', 'no label'), ('Vitamin', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Vitamin K', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Vitamin K', 'no label'), ('Patients', 'no label'), ('Vitamin K', 'no label'), ('Vitamin K', 'no label')]
phenylketonuria|pubmed~35015767|Management Of Phenylketonuria (Pku) Is Mainly Achieved Through Dietary Control With Limited Intake Of Phenylalanine (Phe) From Food, Supplemented With Low Protein (Lp) Food And A Mixture Of Free Synthetic (Fs) Amino Acids (Aa) (Fsaa). Casein Glycomacropeptide (Cgmp) Is A Natural Peptide Released In Whey During Cheese Making By The Action Of The Enzyme Chymosin. Because Cgmp In Its Pure Form Does Not Contain Phe, It Is Nutritionally Suitable As A Supplement In The Diet For Pku When Enriched With Specific Aas. Lacprodan® Cgmp-20 (= Cgmp) Used In This Study Contained Only Trace Amounts Of Phe Due To Minor Presence Of Other Proteins/Peptides. The Aims Were To Address The Following Questions In A Classical Pku Mouse Model: Study 1, Off Diet: Can Pure Cgmp Or Cgmp Supplemented With Large Neutral Amino Acids (Lnaa) As A Supplement To Normal Diet Significantly Lower The Content Of Phe In The Brain Compared To A Control Group On Normal Diet, And Does Supplementation Of Selected Lnaa Results In Significant Lower Brain Phe Level?. Study 2, On Diet: Does A Combination Of Cgmp, Essential (Non-Phe) Eaas And Lp Diet, Provide Similar Plasma And Brain Phe Levels, Growth And Behavioral Skills As A Formula Which Alone Consist Of Fsaa, With A Similar Composition?. 45 Female Mice Homozygous For The Pahenu2 Mutation Were Treated For 12 Weeks In Five Different Groups; G1(N-Cgmp), Fed On Normal (N) Casein Diet (75%) In Combination With Cgmp (25%); G2 (N-Cgmp-Lnaa), Fed On Normal (N) Casein Diet (75%) In Combination With Cgmp (19,7%) And Selected Lnaa (5,3% Leu, Tyr And Trp); G3 (N), Fed On Normal Casein Diet (100%); G4 (Cgmp-Eaa-Lp), Fed On Cgmp (70,4%) In Combination With Essential Aa (19,6%) And Lp Diet; G5 (Fsaa-Lp), Fed On Fsaa (100%) And Lp Diet. The Following Parameters Were Measured During The Treatment Period: Plasma Aa Profiles Including Phe And Tyr, Growth, Food And Water Intake And Number Of Teeth Cut. At The End Of The Treatment Period, A Body Scan (Fat And Lean Body Mass) And A Behavioral Test (Barnes Maze) Were Performed. Finally, The Brains Were Examined For Content Of Phe, Tyr, Trp, Dopamine (Da), 3,4-Dihydroxyphenylacetic Acid (Dopac), Serotonin (5-Ht) And 5-Hydroxyindole-Acetic Acid (5-Hiaa), And The Bone Density And Bone Mineral Content Were Determined By Dual-Energy X-Ray Absorptiometry. Study 1: Mice Off Diet Supplemented With Cgmp (G1 (N-Cgmp)) Or Supplemented With Cgmp In Combination With Lnaa (G2 (N-Cgmp-Lnaa)) Had Significantly Lower Phe In Plasma And In The Brain Compared To Mice Fed Only Casein (G3 (N)). Extra Lnaa (Tyr, Trp And Leu) To Cgmp Did Not Have Any Significant Impact On Phe Levels In The Plasma And Brain, But An Increase In Serotonin Was Measured In The Brain Of G2 Mice Compared To G1. Study 2: Pku Mice Fed With Mixture Of Cgmp And Eaa As Supplement To Lp Diet (G4 (Cgmp-Eaa-Lp)) Demonstrated Lower Plasma-Phe Levels But Similar Brain- Phe Levels And Growth As Mice Fed On An Almost Identical Combination Of Fsaa (G5 (Fsaa-Lp)). Cgmp Can Be A Relevant Supplement For The Treatment Of Pku.|[('Management', 'no label'), ('Phenylketonuria', 'no label'), ('Achieved', 'no label'), ('Dietary Control', 'no label'), ('Limited Intake', 'no label'), ('Phenylalanine (Phe)', 'no label'), ('Food', 'no label'), ('Supplemented', 'no label'), ('Low Protein', 'no label'), ('Free Synthetic (Fs) Amino Acids', 'no label'), ('Aa', 'no label'), ('Fsaa', 'no label'), ('Casein Glycomacropeptide', 'no label'), ('Cgmp', 'no label'), ('Natural Peptide', 'no label'), ('Released', 'no label'), ('Whey', 'no label'), ('Cheese Making', 'no label'), ('Action', 'no label'), ('Enzyme Chymosin', 'no label'), ('Cgmp', 'no label'), ('Pure Form', 'no label'), ('Not Contain', 'no label'), ('Phe', 'no label'), ('Nutritionally', 'no label'), ('Diet', 'no label'), ('Lacprodan® Cgmp-20 (= Cgmp', 'no label'), ('Study', 'no label'), ('Trace', 'no label'), ('Amounts', 'no label'), ('Phe', 'no label'), ('Minor', 'no label'), ('Presence', 'no label'), ('Proteins/Peptides', 'no label'), ('Questions', 'no label'), ('Classical Pku Mouse Model', 'no label'), ('Study 1', 'no label'), ('Off Diet', 'no label'), ('Cgmp Or', 'no label'), ('Supplemented', 'no label'), ('Neutral Amino Acids', 'no label'), ('Lnaa', 'no label'), ('Normal Diet', 'no label'), ('Content', 'no label'), ('Phe', 'no label'), ('Brain', 'no label'), ('Compared', 'no label'), ('Control Group', 'no label'), ('Normal Diet', 'no label'), ('Supplementation', 'no label'), ('Lnaa Results', 'no label'), ('Brain', 'no label'), ('Phe Level', 'no label'), ('Study', 'no label'), ('Diet', 'no label'), ('Combination', 'no label'), ('Cgmp', 'no label'), ('Eaas', 'no label'), ('Lp Diet', 'no label'), ('Plasma', 'no label'), ('Brain', 'no label'), ('Phe Levels', 'no label'), ('Growth', 'no label'), ('Behavioral Skills', 'no label'), ('Formula', 'no label'), ('Consist', 'no label'), ('Fsaa', 'no label'), ('Composition', 'no label'), ('Female', 'no label'), ('Homozygous', 'no label'), ('Pahenu2', 'no label'), ('Mutation', 'no label'), ('Treated', 'no label'), ('Weeks', 'no label'), ('Groups', 'no label'), ('Fed', 'no label'), ('Normal (N) Casein Diet', 'no label'), ('Combination', 'no label'), ('Cgmp', 'no label'), ('G2', 'no label'), ('N-Cgmp-Lnaa', 'no label'), ('Fed', 'no label'), ('Normal (N) Casein Diet', 'no label'), ('Combination', 'no label'), ('Cgmp', 'no label'), ('Lnaa', 'no label'), ('Leu', 'no label'), ('Tyr And Trp', 'no label'), ('N', 'no label'), ('Fed', 'no label'), ('Normal Casein Diet', 'no label'), ('G4', 'no label'), ('Cgmp-Eaa-Lp', 'no label'), ('Fed', 'no label'), ('Cgmp', 'no label'), ('Combination', 'no label'), ('Essential Aa', 'no label'), ('Lp Diet', 'no label'), ('G5', 'no label'), ('Fsaa-Lp', 'no label'), ('Fed', 'no label'), ('Fsaa', 'no label'), ('Lp Diet', 'no label'), ('Parameters', 'no label'), ('Measured', 'no label'), ('Treatment', 'no label'), ('Period', 'no label'), ('Plasma', 'no label'), ('Aa', 'no label'), ('Profiles', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Growth', 'no label'), ('Food And Water Intake', 'no label'), ('Teeth Cut', 'no label'), ('Treatment', 'no label'), ('Body Scan', 'no label'), ('Fat And Lean Body Mass', 'no label'), ('Behavioral Test', 'no label'), ('Performed', 'no label'), ('Brains', 'no label'), ('Content', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Dopamine (Da)', 'no label'), ('3,4-Dihydroxyphenylacetic Acid', 'no label'), ('Dopac', 'no label'), ('Serotonin (5-Ht)', 'no label'), ('Bone Density', 'no label'), ('Bone Mineral Content', 'no label'), ('Dual-Energy X-Ray Absorptiometry', 'no label'), ('Study', 'no label'), ('Mice', 'no label'), ('Off Diet', 'no label'), ('Supplemented', 'no label'), ('Cgmp (G1 (N-Cgmp)', 'no label'), ('Supplemented', 'no label'), ('Cgmp', 'no label'), ('Combination', 'no label'), ('Lnaa', 'no label'), ('G2', 'no label'), ('N-Cgmp-Lnaa', 'no label'), ('Phe', 'no label'), ('Plasma', 'no label'), ('Brain', 'no label'), ('Mice', 'no label'), ('Fed', 'no label'), ('Casein', 'no label'), ('Extra Lnaa', 'no label'), ('Tyr', 'no label'), ('Trp And Leu', 'no label'), ('Cgmp', 'no label'), ('Significant', 'no label'), ('Impact', 'no label'), ('Phe', 'no label'), ('Levels', 'no label'), ('Plasma', 'no label'), ('Brain', 'no label'), ('Increase', 'no label'), ('Serotonin', 'no label'), ('Measured', 'no label'), ('Brain', 'no label'), ('G2 Mice', 'no label'), ('G1', 'no label'), ('Study', 'no label'), ('Pku Mice', 'no label'), ('Fed', 'no label'), ('Cgmp And Eaa', 'no label'), ('Lp Diet', 'no label'), ('G4', 'no label'), ('Cgmp-Eaa-Lp', 'no label'), ('Levels', 'no label'), ('Brain- Phe Levels', 'no label'), ('Growth', 'no label'), ('Mice', 'no label'), ('Fed', 'no label'), ('Combination', 'no label'), ('Fsaa', 'no label'), ('G5', 'no label'), ('Fsaa-Lp', 'no label'), ('Cgmp Can Be A', 'no label'), ('Relevant', 'no label'), ('Supplement', 'no label'), ('Treatment', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Food', 'no label'), ('Protein', 'no label'), ('Food', 'no label'), ('Amino Acids', 'no label'), ('Glycomacropeptide', 'no label'), ('Cgmp', 'no label'), ('Cgmp', 'no label'), ('Phe', 'no label'), ('Cgmp', 'no label'), ('Phe', 'no label'), ('Mouse', 'no label'), ('Cgmp', 'no label'), ('Cgmp', 'no label'), ('Amino Acids', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Cgmp', 'no label'), ('Phe', 'no label'), ('Mice', 'no label'), ('Mutation', 'no label'), ('Cgmp', 'no label'), ('Cgmp', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Cgmp', 'no label'), ('Fsaa', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Food', 'no label'), ('Water', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Dopamine', 'no label'), ('3,4-Dihydroxyphenylacetic Acid', 'no label'), ('Dopac', 'no label'), ('Serotonin (5-Ht', 'no label'), ('Mineral', 'no label'), ('Mice', 'no label'), ('Cgmp', 'no label'), ('Cgmp', 'no label'), ('Phe', 'no label'), ('Mice', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Phe', 'no label'), ('Serotonin Was', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Cgmp', 'no label'), ('Phe', 'no label'), ('Mice', 'no label'), ('Fsaa', 'no label'), ('Cgmp', 'no label')]|[('Lp', 'no label'), ('Teeth Cut', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Amino Acids', 'no label'), ('Glycomacropeptide', 'no label'), ('Cgmp', 'no label'), ('Chymosin', 'no label'), ('Cgmp', 'no label'), ('(= Cgmp', 'no label'), ('Phe', 'no label'), ('Cgmp', 'no label'), ('Cgmp', 'no label'), ('Amino Acids', 'no label'), ('Phe', 'no label'), ('Cgmp', 'no label'), ('Cgmp', 'no label'), ('Cgmp', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Cgmp', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Barnes', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Dopamine', 'no label'), ('3,4-Dihydroxyphenylacetic Acid', 'no label'), ('Dopac', 'no label'), ('Serotonin', 'no label'), ('5-Ht', 'no label'), ('Dual-Energy X-Ray Absorptiometry.', 'no label'), ('Cgmp', 'no label'), ('Cgmp', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Cgmp', 'no label'), ('Phe', 'no label'), ('Serotonin', 'no label'), ('Cgmp', 'no label'), ('Phe', 'no label'), ('Cgmp', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Free', 'no label'), ('Amino Acids', 'no label'), ('Glycomacropeptide', 'no label'), ('Cgmp', 'no label'), ('Whey', 'no label'), ('Cgmp', 'no label'), ('Phe', 'no label'), ('Cgmp', 'no label'), ('Phe', 'no label'), ('Mouse', 'no label'), ('Pure Cgmp', 'no label'), ('Cgmp', 'no label'), ('Amino Acids', 'no label'), ('Phe', 'no label'), ('Brain', 'no label'), ('Lnaa', 'no label'), ('Cgmp', 'no label'), ('Lp Diet', 'no label'), ('Plasma', 'no label'), ('Brain Phe', 'no label'), ('Formula', 'no label'), ('Fsaa', 'no label'), ('Mice', 'no label'), ('Pahenu2', 'no label'), ('Cgmp', 'no label'), ('Cgmp', 'no label'), ('Lnaa', 'no label'), ('Trp', 'no label'), ('Casein', 'no label'), ('Cgmp', 'no label'), ('Plasma Aa', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Teeth', 'no label'), ('Fat', 'no label'), ('Lean Body', 'no label'), ('Brains', 'no label'), ('Phe', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Dopamine', 'no label'), ('3,4-Dihydroxyphenylacetic Acid', 'no label'), ('Dopac', 'no label'), ('Serotonin', 'no label'), ('5-Ht', 'no label'), ('Bone', 'no label'), ('Bone Mineral', 'no label'), ('Mice', 'no label'), ('Cgmp', 'no label'), ('Cgmp', 'no label'), ('Lnaa (G2 (', 'no label'), ('Phe', 'no label'), ('Plasma', 'no label'), ('Brain', 'no label'), ('Mice', 'no label'), ('Casein', 'no label'), ('Tyr', 'no label'), ('Trp', 'no label'), ('Cgmp', 'no label'), ('Phe', 'no label'), ('Plasma', 'no label'), ('Brain', 'no label'), ('Serotonin', 'no label'), ('Brain', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Cgmp', 'no label'), ('Eaa', 'no label'), ('Brain-', 'no label'), ('Mice', 'no label'), ('Fsaa (G5', 'no label'), ('Cgmp', 'no label'), ('Be A', 'no label')]
phenylketonuria|pubmed~28504493|Although With Early Treatment Phenylketonuria Patients May Have Average Intelligence Levels, It Is Important To Optimize The Nutritional Management To Maintain Adequate Phenylalanine Levels, So That Patients Can Develop Their Intellectal Potential Free Of Abnormalities In Their Daily Activities Due To Deficits Of Cognitive Executive Functions. This Study Presents A Series Of 26 Patients, Diagnosed And Treated Early, Who Underwent A Psychometric Evaluation Together With Phenylalanine Determinations Along Their Lives, And At The Time Of Doing The Tests. A Trend Is Observed Towards A Reverse Relationship Between Iq And Concurrent Phenylalanine Concentration, Phenylalanine Median And Phenylalanine/Tyrosine Ratio. Likewise, A Trend Towards A Negative Relationship Is Observed Between Executive Functions And Concurrent Phenylalanine Values Along Patients' Lives.|"[('Early Treatment', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Average Intelligence', 'no label'), ('Levels', 'no label'), ('Optimize', 'no label'), ('Nutritional Management', 'no label'), ('Adequate', 'no label'), ('Phenylalanine Levels', 'no label'), ('Patients', 'no label'), ('Intellectal', 'no label'), ('Free', 'no label'), ('Abnormalities', 'no label'), ('Daily Activities', 'no label'), ('Deficits', 'no label'), ('Cognitive Executive Functions', 'no label'), ('Study', 'no label'), ('Presents', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Treated', 'no label'), ('Early', 'no label'), ('Psychometric', 'no label'), ('Phenylalanine', 'no label'), ('Determinations', 'no label'), ('Lives', 'no label'), ('Time', 'no label'), ('Tests', 'no label'), ('Trend', 'no label'), ('Relationship', 'no label'), ('Iq', 'no label'), ('Concurrent', 'no label'), ('Phenylalanine', 'no label'), ('Concentration', 'no label'), ('Phenylalanine', 'no label'), ('Median', 'no label'), ('Phenylalanine/Tyrosine Ratio', 'no label'), ('Trend Towards A Negative', 'no label'), ('Relationship', 'no label'), ('Observed', 'no label'), ('Executive Functions', 'no label'), ('Concurrent', 'no label'), ('Phenylalanine', 'no label'), (""Patients'"", 'no label'), ('Lives', 'no label')]"|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Deficits Of Cognitive Executive Functions.', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria Patients', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~25596310|In Phenylketonuria, Genetic Heterogeneity, Frequent Compound Heterozygosity, And The Lack Of Functional Data For Phenylalanine Hydroxylase Genotypes Hamper Reliable Phenotype Prediction And Individualised Treatment. A Literature Search Revealed 690 Different Phenylalanine Hydroxylase Genotypes In 3066 Phenylketonuria Patients From Europe And The Middle East. We Determined Phenylalanine Hydroxylase Function Of 30 Frequent Homozygous And Compound Heterozygous Genotypes Covering 55% Of The Study Population, Generated Activity Landscapes, And Assessed The Phenylalanine Hydroxylase Working Range In The Metabolic (Phenylalanine) And Therapeutic (Tetrahydrobiopterin) Space. Shared Patterns In Genotype-Specific Functional Landscapes Were Linked To Biochemical And Pharmacological Phenotypes, Where (1) Residual Activity Below 3.5% Was Associated With Classical Phenylketonuria Unresponsive To Pharmacological Treatment; (2) Lack Of Defined Peak Activity Induced Loss Of Response To Tetrahydrobiopterin; (3) A Higher Cofactor Need Was Linked To Inconsistent Clinical Phenotypes And Low Rates Of Tetrahydrobiopterin Response; And (4) Residual Activity Above 5%, A Defined Peak Of Activity, And A Normal Cofactor Need Were Associated With Pharmacologically Treatable Mild Phenotypes. In Addition, We Provide A Web Application For Retrieving Country-Specific Information On Genotypes And Genotype-Specific Phenylalanine Hydroxylase Function That Warrants Continuous Extension, Updates, And Research On Demand. The Combination Of Genotype-Specific Functional Analyses With Biochemical, Clinical, And Therapeutic Data Of Individual Patients May Serve As A Powerful Tool To Enable Phenotype Prediction And To Establish Personalised Medicine Strategies For Dietary Regimens And Pharmacological Treatment In Phenylketonuria.|[('Phenylketonuria', 'no label'), ('Genetic Heterogeneity', 'no label'), ('Frequent', 'no label'), ('Compound', 'no label'), ('Heterozygosity', 'no label'), ('Lack', 'no label'), ('Functional Data', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Genotypes', 'no label'), ('Phenotype', 'no label'), ('Prediction', 'no label'), ('Individualised', 'no label'), ('Treatment', 'no label'), ('Literature', 'no label'), ('Revealed', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Genotypes', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Europe', 'no label'), ('Middle East', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Function', 'no label'), ('Frequent', 'no label'), ('Homozygous', 'no label'), ('Compound', 'no label'), ('Covering', 'no label'), ('Study Population', 'no label'), ('Activity', 'no label'), ('Landscapes', 'no label'), ('Assessed', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Working Range', 'no label'), ('Metabolic', 'no label'), ('Phenylalanine', 'no label'), ('Therapeutic', 'no label'), ('Shared Patterns', 'no label'), ('Genotype-Specific Functional Landscapes', 'no label'), ('Biochemical', 'no label'), ('Pharmacological', 'no label'), ('Phenotypes', 'no label'), ('Residual', 'no label'), ('Activity', 'no label'), ('Associated With', 'no label'), ('Classical Phenylketonuria', 'no label'), ('Unresponsive', 'no label'), ('Pharmacological Treatment', 'no label'), ('Lack', 'no label'), ('Peak Activity', 'no label'), ('Loss', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Higher', 'no label'), ('Cofactor', 'no label'), ('Need', 'no label'), ('Clinical Phenotypes', 'no label'), ('Rates', 'no label'), ('Tetrahydrobiopterin Response', 'no label'), ('Residual', 'no label'), ('Activity', 'no label'), ('Activity', 'no label'), ('Normal Cofactor Need', 'no label'), ('Associated With', 'no label'), ('Pharmacologically', 'no label'), ('Mild', 'no label'), ('Phenotypes', 'no label'), ('Web Application', 'no label'), ('Country-Specific Information', 'no label'), ('Genotypes', 'no label'), ('Genotype-Specific Phenylalanine Hydroxylase', 'no label'), ('Function', 'no label'), ('Warrants', 'no label'), ('Continuous Extension', 'no label'), ('Updates', 'no label'), ('Research', 'no label'), ('Combination', 'no label'), ('Genotype-Specific Functional Analyses', 'no label'), ('Biochemical', 'no label'), ('Clinical', 'no label'), ('Therapeutic Data', 'no label'), ('Patients', 'no label'), ('Enable', 'no label'), ('Phenotype', 'no label'), ('Prediction', 'no label'), ('Establish Personalised Medicine', 'no label'), ('Strategies', 'no label'), ('Dietary Regimens', 'no label'), ('Pharmacological Treatment', 'no label'), ('Phenylketonuria', 'no label')]|[('Genetic', 'no label'), ('Phenylalanine', 'no label'), ('Genotypes', 'no label'), ('Phenylalanine', 'no label'), ('Genotypes', 'no label'), ('Phenylalanine', 'no label'), ('Genotypes', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Genotypes', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylalanine Hydroxylase Genotypes Hamper', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Heterozygous', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylketonuria Patients', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Phenylketonuria', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('Cofactor Need', 'no label'), ('Tetrahydrobiopterin', 'no label'), ('A Normal Cofactor Need', 'no label'), ('Phenylalanine Hydroxylase', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label')]
phenylketonuria|pubmed~29465562|Phenylketonuria (Pku) Is A Metabolic Disorder, Which Manifests A Progressive Irreversible Neurological Impairment During Infancy And Childhood. Hyperhomocysteinemia Also Showed That It Might Be Involved In Pathophysiology Of Many Neuropsychiatric Disorders. The Late-Onset Clinical Manifestations Of These 2 Diseases Have Not Been Reported Elsewhere. We Speculated That The Late-Onset Pku Is Caused By 2 Kinds Of Metabolic Dysfunction Synergistically, Especially A Short Period Of Irregular Diet Directly Caused Clinical Symptoms. A 21-Year Old Asian Male Patient Demonstrated Subacute Leukodystrophy And Visual-Spatial Disorders Of Late Onset In Adulthood. Phenylketonuria Combined With Homocysteinmia, Who Presented With Heterozygous Mutations In Gene Encoding Pah P.G247R (C.739G>C) And P.Y204C (C.611A>G), Along With Homozygous Mutation Of Gene Encoding Mthfr C.677C>T. The Patient Was Treated With Cobalamine (500 Μg/Day), Vitamin B6 (30 Mg/Day), Folate (5 Mg/Day) And Encouraged To Follow A Protein-Restricted Diet. Visual Disorientation And Cognitive Function Showed Improvement. Head Mr Showed Similar Resolution With The Original Lesion. Serum Homocysteine And Folate Analysis Were Normal With Decreased Phenylalanine Level. This Case Suggests That Neurological Involvement Of Progressive Nervous System Dysfunction Could Be Caused By More Than One Kind Of Inherited Metabolic Disturbances, And Each One Can Induce Or Deteriorate The Manifestations Of Another Metabolic Disorders.|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Manifests', 'no label'), ('Progressive', 'no label'), ('Neurological Impairment', 'no label'), ('Infancy', 'no label'), ('Childhood', 'no label'), ('Hyperhomocysteinemia', 'no label'), ('Pathophysiology', 'no label'), ('Neuropsychiatric Disorders', 'no label'), ('Late-Onset', 'no label'), ('Clinical', 'no label'), ('Diseases', 'no label'), ('Have Not', 'no label'), ('Late-Onset', 'no label'), ('Kinds', 'no label'), ('Metabolic Dysfunction', 'no label'), ('Synergistically', 'no label'), ('Short Period', 'no label'), ('Irregular Diet', 'no label'), ('Clinical Symptoms', 'no label'), ('Old Asian', 'no label'), ('Male', 'no label'), ('Patient', 'no label'), ('Subacute Leukodystrophy', 'no label'), ('Late Onset', 'no label'), ('Phenylketonuria', 'no label'), ('Homocysteinmia', 'no label'), ('Heterozygous Mutations', 'no label'), ('Gene Encoding', 'no label'), ('C.739G>C', 'no label'), ('P.Y204C', 'no label'), ('C.611A>G', 'no label'), ('Homozygous Mutation', 'no label'), ('Gene Encoding', 'no label'), ('Mthfr', 'no label'), ('C.677C>T. The', 'no label'), ('Patient', 'no label'), ('Treated With', 'no label'), ('Cobalamine', 'no label'), ('Vitamin B6', 'no label'), ('Folate', 'no label'), ('Protein-Restricted Diet', 'no label'), ('Visual Disorientation', 'no label'), ('Cognitive Function', 'no label'), ('Improvement', 'no label'), ('Head Mr', 'no label'), ('Resolution', 'no label'), ('Original Lesion', 'no label'), ('Serum', 'no label'), ('Homocysteine', 'no label'), ('Folate Analysis', 'no label'), ('Decreased', 'no label'), ('Phenylalanine', 'no label'), ('Level', 'no label'), ('Case Suggests', 'no label'), ('Neurological', 'no label'), ('Involvement', 'no label'), ('Progressive Nervous System Dysfunction', 'no label'), ('Inherited', 'no label'), ('Metabolic Disturbances', 'no label'), ('Induce', 'no label'), ('Deteriorate', 'no label'), ('Manifestations', 'no label'), ('Metabolic Disorders', 'no label')]|[('Mutations', 'no label'), ('Gene', 'no label'), ('Mutation', 'no label'), ('Gene', 'no label'), ('Cobalamine', 'no label'), ('Vitamin', 'no label'), ('Folate', 'no label'), ('Folate', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Neurological Impairment', 'no label'), ('Hyperhomocysteinemia', 'no label'), ('Neuropsychiatric Disorders', 'no label'), ('Metabolic Dysfunction', 'no label'), ('Phenylketonuria', 'no label'), ('Homocysteinmia', 'no label'), ('Heterozygous', 'no label'), ('C.739G', 'no label'), ('Cobalamine', 'no label'), ('Vitamin B6', 'no label'), ('Folate', 'no label'), ('Visual Disorientation', 'no label'), ('Homocysteine', 'no label'), ('Folate', 'no label'), ('Phenylalanine', 'no label'), ('Nervous System Dysfunction', 'no label'), ('Metabolic Disturbances', 'no label'), ('Metabolic Disorders', 'no label')]|[('Phenylketonuria', 'no label'), ('Patient', 'no label'), ('Visual-Spatial', 'no label'), ('Pah P.G247R', 'no label'), ('Patient', 'no label'), ('Cobalamine', 'no label'), ('Vitamin B6', 'no label'), ('Folate', 'no label'), ('Head Mr', 'no label'), ('Serum Homocysteine', 'no label'), ('Folate', 'no label'), ('Phenylalanine', 'no label'), ('Kind', 'no label')]
phenylketonuria|pubmed~28656971|Phenylketonuria (Pku) And Several Other Inherited Metabolic Diseases (Imd) Require A Lifelong Low-Protein Diet (Lpd), Otherwise They Lead To Many Health Complications. Lpds, However, Carry A Significant Economic Burden For Patients And Their Families. The Objective Of This Study Was To Explore The Costs Of Low-Protein Foods (Lpfs) Necessary For Lpd As Well As Dietary Patterns And Compliance Towards An Lpd. A Detailed Questionnaire Was Created In Cooperation With National Association Of Pku And Other Imd (Nspku), And Consequently Sent To All Nspku Members Treated With An Lpd (N=303). A Total Of 184 Respondents From The Czech Republic Were Included In The Study (174 Had Pku, 10 Had Other Imd). The Average Daily Consumption Of Lpf Was Equal To 411.7 G (Pku) And 345.6 G (Other Imd), Which Corresponds To Energy Value Of 5558 Kj And 4438 Kj, Respectively, Per Patient Per Day. Patients Mostly Consumed Low-Protein Flour (≈30% Of Energy Intake), Pasta (≈18%), Basic Pastry (≈15%) And Sweets (≈10%). The Average Monthly Costs Of Lpds Were Equal To [Euro ]130 (Pku) And [Euro ]129 (Other Imd) Per Patient Per Month. The Compliance With Lpd Was Decreasing With Increasing Age (P<0.0001). This Is The Largest Study Examining Costs And Dietary Patterns Of Lpds In Patients With Pku And The First Study Of This Kind In Other Imd Patients Requiring An Lpd. The Study Clearly Showed That An Lpd Carries A Very High Economic Burden For Families, Which May Lead To Less Lpd Compliance And Potential Severe Health Consequences.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Inherited', 'no label'), ('Metabolic Diseases', 'no label'), ('Imd', 'no label'), ('Require', 'no label'), ('Lifelong Low-Protein Diet', 'no label'), ('Lpd', 'no label'), ('Lead', 'no label'), ('Health Complications', 'no label'), ('Lpds', 'no label'), ('Carry A', 'no label'), ('Significant', 'no label'), ('Economic Burden', 'no label'), ('Patients', 'no label'), ('Families', 'no label'), ('Study', 'no label'), ('Costs', 'no label'), ('Low-Protein Foods', 'no label'), ('Lpfs', 'no label'), ('Lpd', 'no label'), ('Dietary Patterns', 'no label'), ('Compliance', 'no label'), ('Lpd', 'no label'), ('Cooperation', 'no label'), ('National Association', 'no label'), ('Imd', 'no label'), ('Nspku', 'no label'), ('Sent', 'no label'), ('Nspku Members', 'no label'), ('Treated', 'no label'), ('Lpd (N=303)', 'no label'), ('Respondents', 'no label'), ('Czech Republic', 'no label'), ('Study', 'no label'), ('Imd', 'no label'), ('Daily', 'no label'), ('Consumption', 'no label'), ('Lpf', 'no label'), ('Equal', 'no label'), ('Imd', 'no label'), ('Corresponds', 'no label'), ('Energy Value', 'no label'), ('Per Patient', 'no label'), ('Per Day', 'no label'), ('Patients', 'no label'), ('Consumed', 'no label'), ('Low-Protein Flour', 'no label'), ('Energy Intake', 'no label'), ('Pasta', 'no label'), ('Basic Pastry', 'no label'), ('Sweets', 'no label'), ('Average', 'no label'), ('Monthly', 'no label'), ('Costs', 'no label'), ('Lpds', 'no label'), ('Equal', 'no label'), ('Euro', 'no label'), ('Euro', 'no label'), ('Imd', 'no label'), ('Patient', 'no label'), ('Month', 'no label'), ('Compliance', 'no label'), ('Lpd', 'no label'), ('Decreasing', 'no label'), ('Increasing', 'no label'), ('Age', 'no label'), ('Study', 'no label'), ('Costs', 'no label'), ('Dietary Patterns', 'no label'), ('Lpds', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('First Study', 'no label'), ('Kind', 'no label'), ('Imd', 'no label'), ('Patients', 'no label'), ('Lpd', 'no label'), ('Study', 'no label'), ('Lpd Carries', 'no label'), ('Economic Burden', 'no label'), ('Families', 'no label'), ('Lead', 'no label'), ('Lpd', 'no label'), ('Compliance', 'no label'), ('Potential', 'no label'), ('Severe', 'no label'), ('Health', 'no label'), ('Consequences', 'no label')]|[('Lead', 'no label'), ('Foods', 'no label'), ('Lead', 'no label')]|[('Lpd', 'no label'), ('Imd', 'no label'), ('Per', 'no label'), ('Lpds', 'no label'), ('Per', 'no label'), ('Lpd', 'no label'), ('Lpds', 'no label'), ('Imd', 'no label')]|[('Phenylketonuria', 'no label'), ('Metabolic Diseases', 'no label')]|[('Phenylketonuria', 'no label'), ('Lpd', 'no label'), ('Patients', 'no label'), ('Lpd', 'no label'), ('Lpd', 'no label'), ('Pku', 'no label'), ('Imd', 'no label'), ('Lpd', 'no label'), ('Imd', 'no label'), ('Lpf', 'no label'), ('Imd', 'no label'), ('Patients', 'no label'), ('Pasta (', 'no label'), ('Sweets', 'no label'), ('Lpds', 'no label'), ('[Euro ]130', 'no label'), ('[Euro ]129', 'no label'), ('Patient', 'no label'), ('Lpd', 'no label'), ('Lpds', 'no label'), ('Patients', 'no label'), ('Kind', 'no label'), ('Patients', 'no label'), ('Lpd', 'no label'), ('Lpd', 'no label'), ('Lpd', 'no label')]
phenylketonuria|pubmed~28850634|"Insufficient Treatment Adherence After Early Childhood Is Frequently Observed In Patients With Phenylketonuria. Assessment Of These Individuals' Long-Term Metabolic Control Could Enable Early Detection Of The Risk Of Intellectual Deterioration Resulting From High Blood Phenylalanine Concentration. However, The Predictive Value Of Specific Parameters Related To Individual Dynamics Of Hyperphenylalaninemia Is Not Clear. Here, We Assessed The Impact Of Blood Phenylalanine Fluctuations During The First 12 Years Of Life On Cognitive Outcome In Early And Continuously Treated Teenagers With Phenylketonuria. We Have Analyzed A Total Of 5141 Results Of Blood Phenylalanine Measurements In 32 Patients. The Phenylalanine Levels Of These Patients Were Usually Acceptable During Their Early Childhood, But The Control Of Hyperphenylalaninemia Worsened And The Average Treatment Adherence Dropped To 40% During The Late Primary School. Our Analysis Revealed A Strong Association Between The Wechsler Intelligence Verbal Scores And The Mean Of The Yearly Means Of Phenylalanine Concentrations (R=-0.62). The Correlations Of Iq Scores With Median Phenylalanine Concentrations And The Variability Of Blood Phenylalanine Levels Gave Weaker Associations. The Wechsler Verbal Scores Were Also Strongly Correlated With The Treatment Adherence Level During Preschool And Late Primary School (R=0.61 And 0.72). The Mean Of The Yearly Means Of Blood Phenylalanine Concentrations Appears To Be A Better Predictor Of Cognitive Outcome In Children With Phenylketonuria Than Other Parameters Related To Phenylalanine Fluctuations. The Percentage Of Acceptable Phenylalanine Levels Below 50-60% Should Be Regarded As A ""Red Flag"" Due To The Risk Of Intellectual Deterioration In Patients."|"[('Insufficient', 'no label'), ('Treatment Adherence', 'no label'), ('Early Childhood', 'no label'), ('Observed', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Assessment', 'no label'), (""Individuals'"", 'no label'), ('Long-Term', 'no label'), ('Metabolic Control', 'no label'), ('Early', 'no label'), ('Detection', 'no label'), ('Risk', 'no label'), ('Intellectual Deterioration', 'no label'), ('Resulting', 'no label'), ('High Blood', 'no label'), ('Phenylalanine', 'no label'), ('Concentration', 'no label'), ('Predictive Value', 'no label'), ('Parameters', 'no label'), ('Dynamics', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Not Clear', 'no label'), ('Assessed', 'no label'), ('Impact', 'no label'), ('Blood Phenylalanine', 'no label'), ('Fluctuations', 'no label'), ('Years', 'no label'), ('Cognitive Outcome', 'no label'), ('Early', 'no label'), ('Continuously', 'no label'), ('Treated', 'no label'), ('Teenagers', 'no label'), ('Phenylketonuria', 'no label'), ('Analyzed', 'no label'), ('Results', 'no label'), ('Blood Phenylalanine Measurements', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Levels', 'no label'), ('Patients', 'no label'), ('Acceptable', 'no label'), ('Early Childhood', 'no label'), ('Control', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Worsened', 'no label'), ('Average', 'no label'), ('Treatment', 'no label'), ('Dropped', 'no label'), ('Late Primary School', 'no label'), ('Analysis', 'no label'), ('Revealed', 'no label'), ('Association', 'no label'), ('Wechsler Intelligence Verbal Scores', 'no label'), ('Means', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Correlations', 'no label'), ('Scores', 'no label'), ('Median', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Variability', 'no label'), ('Blood Phenylalanine Levels Gave', 'no label'), ('Weaker', 'no label'), ('Associations', 'no label'), ('Wechsler Verbal Scores', 'no label'), ('Correlated', 'no label'), ('Treatment', 'no label'), ('Adherence', 'no label'), ('Level', 'no label'), ('Preschool', 'no label'), ('Means', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Appears', 'no label'), ('Better', 'no label'), ('Predictor', 'no label'), ('Cognitive Outcome', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Parameters', 'no label'), ('Phenylalanine', 'no label'), ('Fluctuations', 'no label'), ('Percentage', 'no label'), ('Acceptable', 'no label'), ('Phenylalanine', 'no label'), ('Levels', 'no label'), ('""Red Flag', 'no label'), ('Risk', 'no label'), ('Intellectual Deterioration', 'no label'), ('Patients', 'no label')]"|[('Individuals', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Blood Phenylalanine', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Blood Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Verbal', 'no label'), ('Phenylalanine', 'no label'), ('Iq', 'no label'), ('Phenylalanine', 'no label'), ('Blood Phenylalanine', 'no label'), ('Blood Phenylalanine', 'no label'), ('Be A', 'no label'), ('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~34521668|Phenylketonuria (Pku) Is A Disorder Of Protein Metabolism Resulting In An Accumulation Of Phenylalanine In The Body. Dietary Management Consists Of Altering The Sources Of Ingested Protein To Limit Phenylalanine Intake. Current Dietary Protein Guidelines For Pku Are Based On Limited Scientific Evidence, Thus It Remains Unclear Whether Current Practice Leads To Optimal Protein Status In People With Pku. To Date, No Attempt Has Been Made To Systematically Evaluate The Protein Status Of People With Pku, Using A Combination Of Validated Anthropometric, Biochemical And Functional Measurement Tools. Furthermore, Factors Known To Influence Protein Status In The General Population Warrant Consideration When Determining Protein Status In Individuals With Pku, Alongside Factors Unique To Pku Such As The Type Of Protein Substitute Consumed. Understanding The Impact Of These Variables On Protein Status Is Crucial To Developing A Personalised Approach To Protein Recommendations For Optimising Health And Functional Outcomes In People With Pku. Therefore, The Aim Of This Scoping Review Is To Examine Existing Evidence Regarding The Protein Status Of People With Pku, And To Investigate The Nutritional And Lifestyle Variables That Influence Protein Status. This Review Will Be Guided By Arksey And O'Malley'S Framework, Along With Guidance From Levac <I>Et Al</I>, Pawliuk <I>Et Al</I> And The Joanna Briggs Institute. The Following Databases Will Be Searched: Medline (Ovid), Embase, Central, Web Of Science And Scopus, Alongside Grey Literature. Identified Literature Will Be Assessed By Two Independent Reviewers For Inclusion. Descriptive Numerical Analysis Will Be Performed And A Narrative Summary Will Accompany The Tabulated Results Describing How Study Findings Relate To The Review Questions. This Review Protocol Does Not Require Ethical Approval. Findings Will Be Disseminated Through Peer-Reviewed Publication, Presented At Relevant Conferences, And Shared With A Patient Research Advisory Group To Inform Discussions On Future Research.|"[('Phenylketonuria', 'no label'), ('Disorder', 'no label'), ('Protein Metabolism', 'no label'), ('Resulting', 'no label'), ('Accumulation', 'no label'), ('Phenylalanine', 'no label'), ('Body', 'no label'), ('Dietary Management', 'no label'), ('Consists', 'no label'), ('Altering', 'no label'), ('Sources', 'no label'), ('Ingested Protein', 'no label'), ('Phenylalanine Intake', 'no label'), ('Dietary Protein', 'no label'), ('Limited Scientific Evidence', 'no label'), ('Practice Leads', 'no label'), ('Optimal', 'no label'), ('Protein Status', 'no label'), ('People', 'no label'), ('Pku', 'no label'), ('No Attempt', 'no label'), ('Systematically Evaluate', 'no label'), ('Protein Status', 'no label'), ('People', 'no label'), ('Pku', 'no label'), ('Combination', 'no label'), ('Validated Anthropometric', 'no label'), ('Biochemical', 'no label'), ('Functional Measurement Tools', 'no label'), ('Factors', 'no label'), ('Influence', 'no label'), ('Protein Status', 'no label'), ('General Population Warrant', 'no label'), ('Protein Status', 'no label'), ('Individuals', 'no label'), ('Pku', 'no label'), ('Factors', 'no label'), ('Protein Substitute', 'no label'), ('Consumed', 'no label'), ('Impact', 'no label'), ('Variables', 'no label'), ('Protein Status', 'no label'), ('Personalised Approach', 'no label'), ('Protein Recommendations', 'no label'), ('Optimising', 'no label'), ('People', 'no label'), ('Pku', 'no label'), ('Scoping Review', 'no label'), ('Evidence', 'no label'), ('Protein Status', 'no label'), ('People', 'no label'), ('Pku', 'no label'), ('Investigate', 'no label'), ('Nutritional', 'no label'), ('Lifestyle', 'no label'), ('Variables', 'no label'), ('Influence', 'no label'), ('Protein Status', 'no label'), ('Review', 'no label'), (""O'Malley'S Framework"", 'no label'), ('Guidance', 'no label'), ('Levac', 'no label'), ('Pawliuk', 'no label'), ('Joanna Briggs Institute', 'no label'), ('Databases', 'no label'), ('Searched', 'no label'), ('Medline', 'no label'), ('Embase', 'no label'), ('Central', 'no label'), ('Web Of Science And Scopus', 'no label'), ('Grey Literature', 'no label'), ('Assessed', 'no label'), ('Independent Reviewers', 'no label'), ('Inclusion', 'no label'), ('Descriptive Numerical Analysis', 'no label'), ('Performed', 'no label'), ('Narrative', 'no label'), ('Will Accompany', 'no label'), ('Study', 'no label'), ('Findings', 'no label'), ('Review', 'no label'), ('Questions', 'no label'), ('Review Protocol', 'no label'), ('Ethical Approval', 'no label'), ('Findings', 'no label'), ('Disseminated', 'no label'), ('Relevant', 'no label'), ('Conferences', 'no label'), ('Patient', 'no label'), ('Advisory Group', 'no label'), ('Inform Discussions', 'no label'), ('Future', 'no label'), ('Research', 'no label')]"|[('Protein', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Individuals', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Body.', 'no label'), ('Phenylalanine', 'no label'), ('People', 'no label'), ('People', 'no label'), ('Type Of Protein', 'no label'), ('People', 'no label'), ('People', 'no label')]
phenylketonuria|pubmed~31546852|Many Phenylketonuria (Pku) Patients Cannot Adhere To The Severe Dietary Restrictions As Advised By The European Pku Guidelines, Which Can Be Accompanied By Aggravated Neuropsychological Impairments That, At Least In Part, Have Been Attributed To Brain Monoaminergic Neurotransmitter Deficiencies. Supplementation Of Large Neutral Amino Acids (Lnaa) To An Unrestricted Diet Has Previously Been Shown To Effectively Improve Brain Monoamines In Pku Mice Of Various Ages. To Determine The Additive Value Of Lnaa Supplementation To A Liberalized Phenylalanine-Restricted Diet, Brain And Plasma Monoamine And Amino Acid Concentrations In 10 To 16-Month-Old Adult C57Bl/6 Pku Mice On A Less Severe Phenylalanine-Restricted Diet With Lnaa Supplementation Were Compared To Those On A Non-Supplemented Severe Or Less Severe Phenylalanine-Restricted Diet. Lnaa Supplementation To A Less Severe Phenylalanine-Restricted Diet Was Found To Improve Both Brain Monoamine And Phenylalanine Concentrations. Compared To A Severe Phenylalanine-Restricted Diet, It Was Equally Effective To Restore Brain Norepinephrine And Serotonin Even Though Being Less Effective To Reduce Brain Phenylalanine Concentrations. These Results In Adult Pku Mice Support The Idea That Lnaa Supplementation May Enhance The Effect Of A Less Severe Phenylalanine-Restricted Diet And Suggest That Cerebral Outcome Of Pku Patients Treated With A Less Severe Phenylalanine-Restricted Diet May Be Helped By Additional Lnaa Treatment.|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Severe', 'no label'), ('Dietary', 'no label'), ('Restrictions', 'no label'), ('European Pku Guidelines', 'no label'), ('Accompanied', 'no label'), ('Aggravated', 'no label'), ('Neuropsychological Impairments', 'no label'), ('Brain Monoaminergic', 'no label'), ('Neurotransmitter Deficiencies', 'no label'), ('Supplementation', 'no label'), ('Neutral Amino Acids', 'no label'), ('Lnaa', 'no label'), ('Unrestricted Diet', 'no label'), ('Brain Monoamines', 'no label'), ('Pku Mice', 'no label'), ('Ages', 'no label'), ('Additive Value', 'no label'), ('Lnaa Supplementation', 'no label'), ('Liberalized Phenylalanine-Restricted Diet', 'no label'), ('Brain', 'no label'), ('Plasma', 'no label'), ('Monoamine', 'no label'), ('Amino Acid', 'no label'), ('Concentrations', 'no label'), ('Adult', 'no label'), ('C57Bl/6 Pku Mice', 'no label'), ('Severe', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Lnaa Supplementation', 'no label'), ('Non-Supplemented Severe', 'no label'), ('Severe', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Supplementation', 'no label'), ('Severe', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Brain Monoamine', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Severe', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Effective', 'no label'), ('Restore Brain', 'no label'), ('Norepinephrine', 'no label'), ('Serotonin', 'no label'), ('Effective', 'no label'), ('Brain', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Results', 'no label'), ('Adult', 'no label'), ('Pku Mice Support', 'no label'), ('Lnaa', 'no label'), ('Supplementation', 'no label'), ('Enhance', 'no label'), ('Effect', 'no label'), ('Severe', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Suggest', 'no label'), ('Cerebral Outcome', 'no label'), ('Pku Patients', 'no label'), ('Treated With', 'no label'), ('Severe', 'no label'), ('Phenylalanine-Restricted Diet', 'no label'), ('Helped', 'no label'), ('Lnaa Treatment', 'no label')]|[('Monoaminergic Neurotransmitter', 'no label'), ('Amino Acids', 'no label'), ('Monoamines', 'no label'), ('Mice', 'no label'), ('Monoamine', 'no label'), ('Amino Acid', 'no label'), ('Mice', 'no label'), ('Monoamine', 'no label'), ('Phenylalanine', 'no label'), ('Norepinephrine', 'no label'), ('Phenylalanine', 'no label'), ('Mice', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Aggravated Neuropsychological Impairments', 'no label'), ('Amino Acids', 'no label'), ('Amino Acid', 'no label'), ('Phenylalanine', 'no label'), ('Norepinephrine', 'no label'), ('Serotonin', 'no label'), ('Phenylalanine', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Brain Monoaminergic Neurotransmitter', 'no label'), ('Amino Acids', 'no label'), ('Brain Monoamines', 'no label'), ('Mice', 'no label'), ('Lnaa', 'no label'), ('Brain', 'no label'), ('Plasma Monoamine', 'no label'), ('Amino Acid', 'no label'), ('C57Bl/6 Pku Mice', 'no label'), ('Lnaa', 'no label'), ('Brain Monoamine', 'no label'), ('Phenylalanine', 'no label'), ('Serotonin', 'no label'), ('Brain Phenylalanine', 'no label'), ('Mice', 'no label'), ('Lnaa', 'no label'), ('Cerebral', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~31484352|"There Is An Ongoing Debate Regarding The Impact Of Phenylketonuria (Pku) And Its Treatment On Growth. To Date, Evidence From Studies Is Inconsistent, And Data On The Whole Developmental Period Is Limited. The Primary Aim Of This Systematic Review Was To Investigate The Effects Of A Phenylalanine (Phe)-Restricted Diet On Long-Term Growth In Patients With Pku. Four Electronic Databases Were Searched For Articles Published Until September 2018. A Total Of 887 Results Were Found, But Only 13 Articles Met Eligibility Criteria. Only Three Studies Had An Adequate Methodology For Meta-Analysis. Although The Results Indicate Normal Growth At Birth And During Infancy, Children With Pku Were Significantly Shorter And Had Lower Weight For Age Than Reference Populations During The First Four Years Of Life. Impaired Linear Growth Was Observed Until The End Of Adolescence In Pku. In Contrast, Growth Impairment Was Not Reported In Patients With Mild Hyperphenylalaninemia, Not Requiring Dietary Restriction. Current Evidence Indicates That Even With Advances In Dietary Treatments, ""Optimal"" Growth Outcomes Are Not Attained In Pku. The Majority Of Studies Include Children Born Before 1990S, So Further Research Is Needed To Show The Effects Of Recent Dietary Practices On Growth In Pku."|[('Impact', 'no label'), ('Phenylketonuria', 'no label'), ('Treatment', 'no label'), ('Growth', 'no label'), ('Evidence', 'no label'), ('Studies', 'no label'), ('Inconsistent', 'no label'), ('Data', 'no label'), ('Whole Developmental Period', 'no label'), ('Systematic Review', 'no label'), ('Investigate', 'no label'), ('Effects', 'no label'), ('Phenylalanine (Phe)-Restricted', 'no label'), ('Diet', 'no label'), ('Long-Term Growth', 'no label'), ('Patients', 'no label'), ('Electronic Databases', 'no label'), ('Searched', 'no label'), ('Articles', 'no label'), ('Published', 'no label'), ('Results', 'no label'), ('Articles', 'no label'), ('Met', 'no label'), ('Studies', 'no label'), ('Adequate Methodology', 'no label'), ('Meta-Analysis', 'no label'), ('Results', 'no label'), ('Indicate', 'no label'), ('Normal Growth', 'no label'), ('Birth', 'no label'), ('Infancy', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), ('Shorter', 'no label'), ('Lower Weight', 'no label'), ('Age Than', 'no label'), ('Years', 'no label'), ('Life', 'no label'), ('Impaired', 'no label'), ('Linear Growth', 'no label'), ('Observed', 'no label'), ('Adolescence', 'no label'), ('Contrast', 'no label'), ('Growth Impairment', 'no label'), ('Patients', 'no label'), ('Mild Hyperphenylalaninemia', 'no label'), ('Dietary Restriction', 'no label'), ('Evidence', 'no label'), ('Indicates', 'no label'), ('Advances', 'no label'), ('Dietary Treatments', 'no label'), ('Optimal', 'no label'), ('Growth Outcomes', 'no label'), ('Not Attained', 'no label'), ('Studies', 'no label'), ('Children', 'no label'), ('Research', 'no label'), ('Effects', 'no label'), ('Dietary Practices', 'no label'), ('Growth', 'no label')]|[('Phenylalanine', 'no label'), ('Met', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Hyperphenylalaninemia', 'no label')]|[('Phenylketonuria', 'no label'), ('A Phenylalanine', 'no label'), ('Long-Term', 'no label'), ('Patients', 'no label'), ('Met', 'no label'), ('Children', 'no label'), ('Lower Weight', 'no label'), ('Patients', 'no label'), ('Children', 'no label')]
phenylketonuria|pubmed~30598390|The Long-Term Prognosis Of Early Treated Phenylketonuria (Pku) Is Still Under Discussion. Aim Of This Controlled Long-Term Study Was To Assess The Neurological And Neuropsychological Outcome In Adult Patients With Early-Treated Pku. We Investigated 35 Patients With Early-Treated Classical Pku Aged 29 To 51 Years (Mean Age 41 Years) And 18 Healthy Controls Matched For Age And Socioeconomic Status. Patients And Controls Were Assessed For Their Intelligence Quotient (Iq), Attention And Information-Processing Abilities. Magnetic Resonance Imaging (Mri) Of The Brain Was Performed In All Patients. Neuropsychological Assessments And Mri Were Repeated At A Five-Year And A Ten-Year Follow-Up. In The Entire Interval Iq, Information Processing And Attention Of Patients And Controls Remained Constant. At Both Follow-Up Assessment Times The Iq Scores Were Significantly Lower In Patients Compared To Controls. Older Adult Patients (> 42 Years) Showed Poorer Information Processing And Attention At Both Assessment Times Compared To Young Adult Patients (< 42 Years) And Controls. Iq, Information Processing And Attention Showed No Correlation To Imaging Results. Iq, However, Was Significantly Correlated To Blood Phenylalanine (Phe) Levels In Patients´ Childhood And Adolescence, And Phe Levels Had Been Higher In The Adolescent Years Of Older Adult Patients. Cognitive Performance In Adult Patients With Early-Treated Pku Does Not Seem To Deteriorate In A Ten-Year Interval. Neuropsychological Assessment In Adults With Pku Revealed Neurocognitive Impairment Particularly In Older Adult Patients. This Seems To Refer To An Early Relaxation Of Diet That Was Recommended When The Older Patients Were Adolescents. Results Indicate A Benefit Of Dietary Control During Adolescence In Pku.|[('Long-Term Prognosis', 'no label'), ('Early', 'no label'), ('Treated', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Controlled Long-Term Study', 'no label'), ('Neurological', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Early-Treated Pku', 'no label'), ('Investigated', 'no label'), ('Patients', 'no label'), ('Early-Treated Classical Pku', 'no label'), ('Years', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Healthy Controls', 'no label'), ('Matched', 'no label'), ('Age', 'no label'), ('Socioeconomic Status', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Assessed', 'no label'), ('Intelligence Quotient', 'no label'), ('Attention', 'no label'), ('Magnetic Resonance Imaging', 'no label'), ('Mri', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('Neuropsychological Assessments', 'no label'), ('Mri', 'no label'), ('Repeated', 'no label'), ('Ten-Year Follow-Up', 'no label'), ('Entire Interval Iq, Information Processing', 'no label'), ('Attention', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Remained Constant', 'no label'), ('Follow-Up Assessment Times', 'no label'), ('Iq Scores', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Older Adult', 'no label'), ('Patients', 'no label'), ('Poorer Information Processing', 'no label'), ('Attention', 'no label'), ('Assessment Times', 'no label'), ('Young Adult', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Information Processing', 'no label'), ('Attention', 'no label'), ('Correlation', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Levels', 'no label'), ('Patients´ Childhood', 'no label'), ('Adolescence', 'no label'), ('Phe', 'no label'), ('Levels', 'no label'), ('Adolescent', 'no label'), ('Years', 'no label'), ('Older Adult', 'no label'), ('Patients', 'no label'), ('Cognitive Performance', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Early-Treated Pku', 'no label'), ('Deteriorate', 'no label'), ('Ten-Year Interval', 'no label'), ('Neuropsychological Assessment', 'no label'), ('Adults', 'no label'), ('Pku Revealed Neurocognitive Impairment', 'no label'), ('Older Adult', 'no label'), ('Patients', 'no label'), ('Early', 'no label'), ('Relaxation', 'no label'), ('Diet', 'no label'), ('Older Patients', 'no label'), ('Adolescents', 'no label'), ('Results', 'no label'), ('Indicate', 'no label'), ('Benefit', 'no label'), ('Dietary Control', 'no label'), ('Adolescence', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Iq Scores', 'no label')]|[('Prognosis', 'no label'), ('Treated Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Neurocognitive Impairment', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('Entire Interval Iq', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Blood Phenylalanine', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Seem', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~32359754|Considering That Phenylalanine-Poor Diets May Be Monotonous And Compromise The Development And Nutritional Status Of Children And Adolescents With Phenylketonuria, The Aim Of This Study Was To Evaluate The Anthropometric And Biochemical Characteristics Of Children And Adolescents With This Condition. Retrospective Study With Anthropometric And Biochemical Data Collection From Patients With Phenylketonuria In The Age Group 2-19.9 Years. Nutritional Status Was Classified According To The World Health Organization. Biochemical Tests Were Compared To Current Recommendations. A Total Of 84 Patients (71.8%) Were Eligible, With A Median Age Of 10.7 Years (2.4-19.9 Years). There Was Predominance Of Adequate (N = 58, 69%) With Presence Of Overweight And Obesity In 24 (28.5%) Patients. The Biochemical Tests Revealed Hyperphosphatemia In 46 (55%), Hypertriglyceridemia In 27 (50%), Vitamin B12 Elevated In 34 (41.2%), Selenium Deficiency In 10 (13.7%), Insufficient Zinc In 7 (8.9%), Low Globulin In 21 (26.9%), Low Hdl In 35 (59.3%) And Elevated Phenylalanine Level In 28 (34.5%) Patients In The Sample. Overweight And Obesity Were Correlated With Low Hdl (P = 0.04) And Lowest Adequate Frequency Of Ldl (P = 0.09). Higher Phosphorus Values Were Associated With Lower Body Weight (R = -0.72) And Age (R = -0.75), As Well As Vitamin B12 In The Same Parameters (R = -0.67 And R = -0, 68). A Positive Correlation Of Phenylalanine With Body Weight And Age (R = 0.62 And R = 0.66) Was Observed. Most Patients Presented Adequate According To Anthropometric Parameters And Appropriate Biochemical Tests, Except Hdl, And Moderate Metabolic Control Of The Disease. However, Attention Should Be Paid To The Presence Of Overweight And Need For Biochemical Monitoring Of Triglycerides, Selenium, Zinc, Hdl, And Phenylalanine.|[('Phenylalanine-Poor Diets May', 'no label'), ('Monotonous', 'no label'), ('Development', 'no label'), ('Nutritional Status', 'no label'), ('Children', 'no label'), ('Adolescents', 'no label'), ('Phenylketonuria', 'no label'), ('Study', 'no label'), ('Evaluate', 'no label'), ('Anthropometric', 'no label'), ('Biochemical', 'no label'), ('Characteristics', 'no label'), ('Children', 'no label'), ('Adolescents', 'no label'), ('Condition', 'no label'), ('Retrospective Study', 'no label'), ('Anthropometric', 'no label'), ('Biochemical', 'no label'), ('Data Collection', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Age Group', 'no label'), ('Years', 'no label'), ('Nutritional Status', 'no label'), ('World Health Organization', 'no label'), ('Biochemical Tests', 'no label'), ('Recommendations', 'no label'), ('Patients', 'no label'), ('Median Age', 'no label'), ('Years', 'no label'), ('Years', 'no label'), ('Predominance', 'no label'), ('Adequate', 'no label'), ('Presence', 'no label'), ('Overweight', 'no label'), ('Obesity', 'no label'), ('Patients', 'no label'), ('Biochemical Tests', 'no label'), ('Hyperphosphatemia', 'no label'), ('Hypertriglyceridemia', 'no label'), ('Vitamin B12', 'no label'), ('Elevated', 'no label'), ('Selenium Deficiency', 'no label'), ('Insufficient', 'no label'), ('Zinc', 'no label'), ('Low', 'no label'), ('Globulin', 'no label'), ('Hdl', 'no label'), ('Elevated', 'no label'), ('Phenylalanine', 'no label'), ('Level', 'no label'), ('Patients', 'no label'), ('Sample', 'no label'), ('Overweight', 'no label'), ('Obesity', 'no label'), ('Correlated', 'no label'), ('Hdl', 'no label'), ('Lowest', 'no label'), ('Adequate', 'no label'), ('Frequency', 'no label'), ('Ldl (P\xa0', 'no label'), ('Higher', 'no label'), ('Phosphorus', 'no label'), ('Associated With', 'no label'), ('Lower Body Weight', 'no label'), ('Age', 'no label'), ('R\xa0', 'no label'), ('Vitamin B12', 'no label'), ('Parameters', 'no label'), ('R\xa0', 'no label'), ('Positive', 'no label'), ('Correlation', 'no label'), ('Phenylalanine', 'no label'), ('Body Weight', 'no label'), ('R\xa0', 'no label'), ('R\xa0', 'no label'), ('Observed', 'no label'), ('Patients', 'no label'), ('Adequate', 'no label'), ('Anthropometric Parameters', 'no label'), ('Appropriate', 'no label'), ('Biochemical Tests', 'no label'), ('Hdl', 'no label'), ('Moderate', 'no label'), ('Metabolic Control', 'no label'), ('Disease', 'no label'), ('Attention', 'no label'), ('Paid', 'no label'), ('Overweight', 'no label'), ('Biochemical', 'no label'), ('Monitoring', 'no label'), ('Triglycerides', 'no label'), ('Selenium', 'no label'), ('Zinc', 'no label'), ('Hdl', 'no label'), ('Phenylalanine', 'no label')]|[('Vitamin', 'no label'), ('Selenium', 'no label'), ('Zinc', 'no label'), ('Globulin', 'no label'), ('Hdl', 'no label'), ('Phenylalanine', 'no label'), ('Hdl', 'no label'), ('Phosphorus', 'no label'), ('Vitamin', 'no label'), ('Phenylalanine', 'no label'), ('Triglycerides', 'no label'), ('Selenium', 'no label'), ('Zinc', 'no label'), ('Hdl', 'no label'), ('Phenylalanine', 'no label')]|[('Vitamin B12', 'no label'), ('Hdl', 'no label'), ('Hdl', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylketonuria', 'no label'), ('N\xa0=\xa0', 'no label'), ('Obesity', 'no label'), ('Hyperphosphatemia', 'no label'), ('Hypertriglyceridemia', 'no label'), ('Vitamin B12', 'no label'), ('Selenium', 'no label'), ('Phenylalanine', 'no label'), ('Obesity', 'no label'), ('Vitamin B12', 'no label'), ('Phenylalanine', 'no label'), ('Selenium', 'no label'), ('Phenylalanine', 'no label')]|[('Children', 'no label'), ('Phenylketonuria', 'no label'), ('Children', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Vitamin B12', 'no label'), ('Selenium', 'no label'), ('Zinc', 'no label'), ('Globulin', 'no label'), ('21', 'no label'), ('Hdl', 'no label'), ('Phenylalanine', 'no label'), ('Patients', 'no label'), ('Hdl', 'no label'), ('Ldl (P\xa0', 'no label'), ('Phosphorus', 'no label'), ('Vitamin B12', 'no label'), ('Phenylalanine', 'no label'), ('Body Weight', 'no label'), ('Patients', 'no label'), ('Hdl', 'no label'), ('Triglycerides', 'no label'), ('Selenium', 'no label'), ('Zinc', 'no label'), ('Hdl', 'no label'), ('Phenylalanine', 'no label')]
phenylketonuria|pubmed~28235150|Sapropterin Causes Reductions In Blood Phenylalanine Concentrations In Sensitive Patients With Phenylketonuria (Pku). We Examined Whether The Subsequent Relaxation Of Dietary Restrictions Influenced The Quality Of Life (Qol) Of Patients And Parents. The Study Cohort Comprised 112 Patients With Pku Followed At The Metabolic Centre At Münster University Children'S Hospital, Germany, From 2012 To 2015. A Sapropterin Response Was Defined As A ≥30% Reduction In Blood Phenylalanine Levels. The Qol Of 38 Children And Adolescents From The Study Cohort, With A Mean Age Of 12.4 (Range 6.6-18.7) Years, Was Assessed In An Outpatient Setting And 49 Parents Of Children With Pku Also Commented On Their Child'S Qol And Their Own. The Participants' Qol Was Assessed Before The Start Of Therapy, And Again After Six Months, Using Self-Report Questionnaires. After Six Months Of Continuous Therapy Or Diet, Qol Was Largely Unchanged In The Patients, According To Their Self-Reports And The Parental Reports. Qol Also Remained Unchanged In The Parents. Sapropterin Did Not Seem To Improve Qol In Pku Patients And Their Parents. Patients With Pku Had Already Reached High Levels Of Qol Following Classic Diets, And These Levels Were Not Easily Improved By Sapropterin.|"[('Sapropterin', 'no label'), ('Causes', 'no label'), ('Reductions', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Sensitive', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Relaxation', 'no label'), ('Dietary Restrictions', 'no label'), ('Influenced', 'no label'), ('Quality Of Life (Qol)', 'no label'), ('Patients', 'no label'), ('Parents', 'no label'), ('Study Cohort Comprised', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Metabolic Centre', 'no label'), ('Münster University', 'no label'), (""Children'S Hospital"", 'no label'), ('Germany', 'no label'), ('Sapropterin Response', 'no label'), ('Reduction', 'no label'), ('Blood Phenylalanine Levels', 'no label'), ('Qol', 'no label'), ('Children', 'no label'), ('Adolescents', 'no label'), ('Study', 'no label'), ('Cohort', 'no label'), ('Mean Age', 'no label'), ('Range', 'no label'), ('Years', 'no label'), ('Assessed', 'no label'), ('Outpatient Setting', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Pku', 'no label'), (""Child'S"", 'no label'), ('Qol', 'no label'), ('Own', 'no label'), (""Participants'"", 'no label'), ('Qol', 'no label'), ('Assessed', 'no label'), ('Therapy', 'no label'), ('Months', 'no label'), ('Self-Report Questionnaires', 'no label'), ('Months', 'no label'), ('Continuous Therapy', 'no label'), ('Diet', 'no label'), ('Qol', 'no label'), ('Unchanged', 'no label'), ('Patients', 'no label'), ('Self-Reports', 'no label'), ('Parental Reports', 'no label'), ('Qol', 'no label'), ('Remained', 'no label'), ('Unchanged', 'no label'), ('Parents', 'no label'), ('Sapropterin', 'no label'), ('Qol', 'no label'), ('Pku Patients', 'no label'), ('Parents', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Levels', 'no label'), ('Qol', 'no label'), ('Classic Diets', 'no label'), ('Levels', 'no label'), ('Sapropterin', 'no label')]"|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label')]|[]|[('Sapropterin', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Sapropterin', 'no label'), ('Reduction In Blood Phenylalanine', 'no label'), ('Sapropterin', 'no label'), ('Sapropterin', 'no label')]|[('Sapropterin', 'no label'), ('Blood Phenylalanine', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Children', 'no label'), ('Sapropterin', 'no label'), ('Blood Phenylalanine', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Patients', 'no label'), ('Sapropterin', 'no label'), ('Seem', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Sapropterin', 'no label')]
phenylketonuria|pubmed~27922243|Phenylketonuria, Previously A Common Cause Of Severe Intellectual Disability, Is A Metabolic Disorder Now Promptly Diagnosed And Effectively Treated Thanks To Newborn Screening Programs. Here, We Report A Male Patient Presenting With Dyslexia And Attention-Deficit Hyperactivity Disorder, Who Was Diagnosed With Mild Phenylketonuria At Eight Years Of Age. Earlier Recognition And Treatment Before The Establishment Of Irreversible Brain Damage Would Have Resulted In Better Neurobehavioural Outcomes. Classical Phenylketonuria And Milder Phenotypes Of Phenylalanine Hydroxylase Deficiency Need To Be Considered In The Differential Diagnosis Of All Cognitive And Behavioural Problems Of Unknown Cause.|[('Phenylketonuria', 'no label'), ('Common', 'no label'), ('Cause', 'no label'), ('Severe', 'no label'), ('Intellectual Disability', 'no label'), ('Metabolic Disorder', 'no label'), ('Promptly Diagnosed', 'no label'), ('Treated', 'no label'), ('Newborn Screening Programs', 'no label'), ('Report', 'no label'), ('Male', 'no label'), ('Presenting', 'no label'), ('Dyslexia', 'no label'), ('Attention-Deficit Hyperactivity Disorder', 'no label'), ('Diagnosed', 'no label'), ('Mild Phenylketonuria', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Recognition', 'no label'), ('Treatment', 'no label'), ('Irreversible', 'no label'), ('Brain Damage', 'no label'), ('Resulted', 'no label'), ('Neurobehavioural Outcomes', 'no label'), ('Phenylketonuria', 'no label'), ('Milder', 'no label'), ('Phenotypes', 'no label'), ('Phenylalanine Hydroxylase Deficiency', 'no label'), ('Need', 'no label'), ('Differential Diagnosis', 'no label'), ('Cognitive', 'no label'), ('Behavioural Problems', 'no label'), ('Unknown Cause', 'no label')]|[('Phenylalanine Hydroxylase', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Metabolic Disorder', 'no label'), ('Phenylketonuria', 'no label'), ('Brain Damage', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label')]|[('Patient', 'no label'), ('Attention-Deficit Hyperactivity', 'no label'), ('Brain', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine Hydroxylase', 'no label')]
phenylketonuria|pubmed~28266201|Phenylketonuria Is One Of The Most Prevalent Autosomal Recessive Hereditary Disorders In Turkey. If Untreated, It Results In Severe Brain Damage And Can Also Be Associated With Autism In Certain Patients. We Present A Three-Year Old Boy Who Exhibited The Symptoms Of Autism And Was Subsequently Diagnosed With Phenylketonuria. This Case Illustrates That Because The Majority Of Autism Cases Are Idiopathic, An Occasional Patient With A Metabolic Disorder Might Be Overlooked Especially In The Era Of Newborn Screening. We Also Discuss The Possible Pathogenetic Processes Leading To Autistic Symptoms In Phenylketonuria, And Wish To Draw Attention To The Possibility Of Cases Missed In The Screening Program Because Of Less Than 100% Coverage Or Insufficient Food Intake Before Blood Sampling. Clinicians Should Keep In Mind The Possibility Of Treatable Disorders In Children With Autism Even When Such Disorders Appear Unlikely.|[('Phenylketonuria', 'no label'), ('Prevalent', 'no label'), ('Autosomal Recessive Hereditary Disorders', 'no label'), ('Turkey', 'no label'), ('Untreated', 'no label'), ('Severe', 'no label'), ('Brain Damage', 'no label'), ('Associated With', 'no label'), ('Autism', 'no label'), ('Patients', 'no label'), ('Three-Year Old Boy', 'no label'), ('Exhibited', 'no label'), ('Symptoms', 'no label'), ('Autism', 'no label'), ('Diagnosed', 'no label'), ('Phenylketonuria', 'no label'), ('Case', 'no label'), ('Autism', 'no label'), ('Cases', 'no label'), ('Idiopathic', 'no label'), ('Occasional Patient', 'no label'), ('Metabolic Disorder', 'no label'), ('Overlooked', 'no label'), ('Newborn', 'no label'), ('Screening', 'no label'), ('Pathogenetic Processes', 'no label'), ('Autistic Symptoms', 'no label'), ('Phenylketonuria', 'no label'), ('Wish To Draw Attention', 'no label'), ('Possibility', 'no label'), ('Cases', 'no label'), ('Missed', 'no label'), ('Screening Program', 'no label'), ('Coverage', 'no label'), ('Insufficient', 'no label'), ('Food Intake', 'no label'), ('Blood Sampling', 'no label'), ('Clinicians', 'no label'), ('Keep In Mind', 'no label'), ('Possibility', 'no label'), ('Treatable Disorders', 'no label'), ('Children', 'no label'), ('Autism', 'no label'), ('Appear', 'no label')]|[('Food', 'no label')]|[('Three-Year Old Boy Who', 'no label')]|[('Phenylketonuria', 'no label'), ('Hereditary Disorders', 'no label'), ('Brain Damage', 'no label'), ('Autism', 'no label'), ('Autism', 'no label'), ('Phenylketonuria', 'no label'), ('Autism', 'no label'), ('Metabolic Disorder', 'no label'), ('Autistic', 'no label'), ('Phenylketonuria', 'no label'), ('Autism', 'no label')]|[('Phenylketonuria', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('Phenylketonuria', 'no label'), ('Patient', 'no label'), ('Phenylketonuria', 'no label'), ('Blood', 'no label'), ('Children', 'no label')]
phenylketonuria|pubmed~31444193|This Study Examines The Incidence And Spatial Clustering Of Phenylketonuria (Pku) In China Between 2013 And 2017. Data From The Chinese Newborn Screening Information System Were Analysed To Assess Pku Incidence With 95% Cis By Province, Region And Disease Severity. Spatial Clustering Of Pku Cases Was Analysed Using Global And Local Spatial Autocorrelation Analysis In The Geographic Information System. The Database Contained 4925 Neonates With Confirmed Pku During The Study Period, Corresponding To An Incidence Of 6.28 (95% Ci: 6.11 To 6.46) Per 100 000 Neonates Screened. Incidence Was Highest In The Provinces Of Gansu, Ningxia And Qinghai, Where It Ranged From 19.00 To 28.63 Per 100 000 Neonates Screened. Overall Incidence Was Higher In The Northern Part Of The Country, Where Classical Disease Predominated, Than In The Southern Part, Where Mild Disease Predominated. Pku Cases Clustered Spatially (Global Moran'S I=0.3603, <I>Z</I>=5.3097, P<0.001), And Local Spatial Autocorrelation Identified Four Northern Provinces As High-High Clusters (Gansu, Qinghai, Ningxia And Shanxi). China Shows An Intermediate Pku Incidence Among Countries, And Incidence Differs Substantially Among Chinese Provinces And Between Northern And Southern Regions. Our Results Suggest The Need To Focus Efforts On Screening, Diagnosing And Treating Pku In High-Incidence Provinces.|"[('Study Examines', 'no label'), ('Incidence', 'no label'), ('Spatial Clustering', 'no label'), ('Phenylketonuria', 'no label'), ('China', 'no label'), ('Data', 'no label'), ('Chinese Newborn Screening Information System', 'no label'), ('Analysed', 'no label'), ('Assess', 'no label'), ('Incidence', 'no label'), ('Cis', 'no label'), ('Province', 'no label'), ('Region', 'no label'), ('Disease Severity', 'no label'), ('Spatial Clustering', 'no label'), ('Pku Cases', 'no label'), ('Analysed', 'no label'), ('Global', 'no label'), ('Local', 'no label'), ('Spatial Autocorrelation Analysis', 'no label'), ('Geographic Information System', 'no label'), ('Database', 'no label'), ('Neonates', 'no label'), ('Confirmed Pku', 'no label'), ('Study', 'no label'), ('Period', 'no label'), ('Incidence', 'no label'), ('Ci', 'no label'), ('Neonates', 'no label'), ('Screened', 'no label'), ('Incidence', 'no label'), ('Highest', 'no label'), ('Provinces', 'no label'), ('Gansu', 'no label'), ('Ningxia', 'no label'), ('Qinghai', 'no label'), ('Ranged', 'no label'), ('Neonates', 'no label'), ('Screened', 'no label'), ('Incidence', 'no label'), ('Higher', 'no label'), ('Northern', 'no label'), ('Country', 'no label'), ('Classical Disease', 'no label'), ('Predominated', 'no label'), ('Southern Part', 'no label'), ('Mild Disease', 'no label'), ('Predominated', 'no label'), ('Cases', 'no label'), ('Clustered', 'no label'), (""Spatially (Global Moran'S I=0.3603"", 'no label'), ('Local', 'no label'), ('Spatial Autocorrelation', 'no label'), ('Northern', 'no label'), ('Provinces', 'no label'), ('High-High Clusters', 'no label'), ('Gansu', 'no label'), ('Qinghai', 'no label'), ('Ningxia', 'no label'), ('Shanxi', 'no label'), ('China', 'no label'), ('Incidence', 'no label'), ('Countries', 'no label'), ('Incidence Differs', 'no label'), ('Chinese', 'no label'), ('Provinces', 'no label'), ('Northern', 'no label'), ('Southern Regions', 'no label'), ('Results', 'no label'), ('Suggest', 'no label'), ('Need', 'no label'), ('Screening', 'no label'), ('Diagnosing', 'no label'), ('Treating', 'no label'), ('Pku In High-Incidence Provinces', 'no label')]"|[('Cis', 'no label'), ('Region', 'no label')]|[('Per', 'no label'), ('Per', 'no label')]|[('Phenylketonuria', 'no label'), ('Cis', 'no label'), ('Classical Disease', 'no label')]|[('Phenylketonuria', 'no label'), ('Cis', 'no label'), ('28.63 Per 100', 'no label')]
phenylketonuria|pubmed~34216350|Although Phenylalanine (Phe) Is Known To Be Neurotoxic In Phenylketonuria (Pku), Its Exact Pathogenetic Mechanisms Of Brain Damage Are Still Poorly Known. Furthermore, Much Less Is Known About The Role Of The Phe Derivatives Phenylacetic (Paa), Phenyllactic (Pla) And Phenylpyruvic (Ppa) Acids That Also Accumulate In This This Disorder On Pku Neuropathology. Previous In Vitro And In Vivo Studies Have Shown That Phe Elicits Oxidative Stress In Brain Of Rodents And That This Deleterious Process Also Occurs In Peripheral Tissues Of Phenylketonuric Patients. In The Present Study, We Investigated Whether Phe And Its Derivatives Paa, Pla And Ppa Separately Or In Combination Could Induce Reactive Oxygen Species (Ros) Formation And Provoke Dna Damage In C6 Glial Cells. We Also Tested The Role Of L-Carnitine (L-Car), Which Has Been Recently Considered An Antioxidant Agent And Easily Cross The Blood Brain Barrier On The Alterations Of C6 Redox Status Provoked By Phe And Its Metabolites. We First Observed That Cell Viability Was Not Changed By Phe And Its Metabolites. Furthermore, Phe, Paa, Pla And Ppa, At Concentrations Found In Plasma Of Pku Patients, Provoked Marked Dna Damage In The Glial Cells Separately And When Combined. Of Note, These Effects Were Totally Prevented (Phe, Paa And Ppa) Or Attenuated (Pla) By L-Car Pre-Treatment. In Addition, A Potent Ros Formation Also Induced By Phe And Paa, Whereas Only Moderate Increases Of Ros Were Caused By Ppa And Pla. Pre-Treatment With L-Car Also Prevented Phe- And Paa-Induced Ros Generation, But Not That Provoked By Pla And Ppa. Thus, Our Data Show That Phe And Its Major Metabolites Accumulated In Pku Provoke Extensive Dna Damage In Glial Cells Probably By Ros Formation And That L-Car May Potentially Represent An Adjuvant Therapeutic Agent In Pku Treatment.|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Neurotoxic', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Exact Pathogenetic Mechanisms', 'no label'), ('Brain Damage', 'no label'), ('Phe Derivatives', 'no label'), ('Paa', 'no label'), ('Phenyllactic', 'no label'), ('Pla', 'no label'), ('Phenylpyruvic', 'no label'), ('Accumulate', 'no label'), ('Disorder', 'no label'), ('Pku Neuropathology', 'no label'), ('In Vitro', 'no label'), ('In Vivo', 'no label'), ('Studies', 'no label'), ('Phe', 'no label'), ('Elicits', 'no label'), ('Oxidative Stress', 'no label'), ('Brain', 'no label'), ('Rodents', 'no label'), ('Deleterious Process', 'no label'), ('Occurs', 'no label'), ('Peripheral Tissues', 'no label'), ('Phenylketonuric', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Investigated', 'no label'), ('Phe', 'no label'), ('Paa', 'no label'), ('Pla', 'no label'), ('Ppa', 'no label'), ('Combination', 'no label'), ('Induce', 'no label'), ('Reactive Oxygen Species', 'no label'), ('Formation', 'no label'), ('Provoke', 'no label'), ('Dna Damage', 'no label'), ('C6 Glial Cells', 'no label'), ('Tested', 'no label'), ('L-Carnitine', 'no label'), ('L-Car', 'no label'), ('Antioxidant Agent', 'no label'), ('Easily Cross', 'no label'), ('Blood Brain Barrier', 'no label'), ('Alterations', 'no label'), ('C6 Redox Status', 'no label'), ('Provoked', 'no label'), ('Phe', 'no label'), ('Metabolites', 'no label'), ('Observed', 'no label'), ('Cell Viability', 'no label'), ('Changed', 'no label'), ('Phe', 'no label'), ('Metabolites', 'no label'), ('Phe', 'no label'), ('Paa', 'no label'), ('Pla', 'no label'), ('Ppa', 'no label'), ('Concentrations', 'no label'), ('Found', 'no label'), ('Plasma', 'no label'), ('Pku Patients', 'no label'), ('Provoked', 'no label'), ('Dna Damage', 'no label'), ('Glial Cells', 'no label'), ('Combined', 'no label'), ('Effects', 'no label'), ('Prevented', 'no label'), ('Phe', 'no label'), ('Paa', 'no label'), ('Ppa', 'no label'), ('Attenuated', 'no label'), ('Pla', 'no label'), ('L-Car', 'no label'), ('Pre-Treatment', 'no label'), ('Addition', 'no label'), ('Ros', 'no label'), ('Formation', 'no label'), ('Induced', 'no label'), ('Phe', 'no label'), ('Paa', 'no label'), ('Moderate', 'no label'), ('Increases', 'no label'), ('Ros', 'no label'), ('Ppa', 'no label'), ('Pla', 'no label'), ('Pre-Treatment', 'no label'), ('L-Car', 'no label'), ('Prevented', 'no label'), ('Phe-', 'no label'), ('Generation', 'no label'), ('Provoked', 'no label'), ('Pla', 'no label'), ('Ppa', 'no label'), ('Data', 'no label'), ('Phe', 'no label'), ('Metabolites', 'no label'), ('Accumulated', 'no label'), ('Extensive', 'no label'), ('Dna Damage', 'no label'), ('Glial Cells', 'no label'), ('Ros Formation', 'no label'), ('L-Car', 'no label'), ('Represent', 'no label'), ('Adjuvant Therapeutic Agent', 'no label'), ('Pku Treatment', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Neurotoxic', 'no label'), ('Phe', 'no label'), ('Phenylacetic', 'no label'), ('Paa', 'no label'), ('Phenyllactic', 'no label'), ('Acids', 'no label'), ('Rodents', 'no label'), ('Phe', 'no label'), ('Oxygen Species', 'no label'), ('Dna', 'no label'), ('Glial Cells', 'no label'), ('L-Carnitine', 'no label'), ('L-Car', 'no label'), ('Cell', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Paa', 'no label'), ('Glial Cells', 'no label'), ('Phe', 'no label'), ('Paa', 'no label'), ('L-Car', 'no label'), ('Phe', 'no label'), ('L-Car', 'no label'), ('Phe-', 'no label'), ('Phe', 'no label'), ('Metabolites', 'no label'), ('Dna', 'no label'), ('Glial Cells', 'no label'), ('L-Car', 'no label')]|[('Pla', 'no label'), ('C6 Glial Cells', 'no label'), ('Pla', 'no label'), ('Glial Cells', 'no label'), ('Pla', 'no label'), ('Pla', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Neurotoxic', 'no label'), ('Phenylketonuria', 'no label'), ('Brain Damage', 'no label'), ('Phe Derivatives Phenylacetic (Paa), Phenyllactic (Pla) And Phenylpyruvic (Ppa) Acids', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Oxygen', 'no label'), ('L-Carnitine', 'no label'), ('L-Car', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('L-Car', 'no label'), ('Phe', 'no label'), ('Ros', 'no label'), ('Ppa', 'no label'), ('L-Car', 'no label'), ('Pla', 'no label'), ('Phe', 'no label'), ('L-Car', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Brain', 'no label'), ('Phe Derivatives Phenylacetic', 'no label'), ('Phe', 'no label'), ('Stress', 'no label'), ('Brain Of', 'no label'), ('Peripheral Tissues', 'no label'), ('Patients', 'no label'), ('Phe', 'no label'), ('Its Derivatives', 'no label'), ('Dna', 'no label'), ('C6 Glial Cells', 'no label'), ('L-Carnitine', 'no label'), ('L-Car', 'no label'), ('Blood Brain', 'no label'), ('C6', 'no label'), ('Phe', 'no label'), ('Cell', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Plasma', 'no label'), ('Dna', 'no label'), ('Glial Cells', 'no label'), ('Phe', 'no label'), ('L-Car', 'no label'), ('Ros', 'no label'), ('Phe', 'no label'), ('Ros', 'no label'), ('L-Car', 'no label'), ('Ros', 'no label'), ('Dna', 'no label'), ('Glial Cells', 'no label'), ('Ros', 'no label'), ('L-Car', 'no label')]
phenylketonuria|pubmed~30864096|Phenylalanine Hydroxylase (Pah) Deficiency Is An Inborn Error Of Metabolism That Results In Elevated Phenylalanine Levels In Blood. The Classical Form Of The Disease With Phenylalanine Level > 1200 Μmol/L In Blood Is Called Phenylketonuria (Pku) And Is Associated With Severe Intellectual Disability When Untreated. In Addition, Phenylalanine Levels Above The Therapeutic Range In Pregnant Female Patients Lead To Adverse Fetal Effects. Lowering The Plasma Phenylalanine Level Prevents Intellectual Disability, Maintaining The Level In The Therapeutic Range Of 120-360 Μmol/L Is Associated With Good Outcome For Patients As Well As Their Pregnancies. Patient Phenotypes Are On A Continuous Spectrum From Mild Hyperphenylalaninemia To Mild Pku, Moderate Pku, And Severe Classic Pku. There Is A Good Correlation Between The Biochemical Phenotype And The Patient'S Genotype. For Over Four Decades The Only Available Treatment Was A Very Restrictive Low Phenylalanine Diet. This Changed In 2007 With The Approval Of Cofactor Therapy Which Is Effective In Up To 55% Of Patients Depending On The Population. Cofactor Therapy Typically Is More Effective In Patients With Milder Forms Of The Disease And Less Effective In Classical Pku. A New Therapy Has Just Been Approved That Can Be Effective In All Patients With Pah Deficiency Regardless Of Their Degree Of Enzyme Deficiency Or The Severity Of Their Phenotype. This Article Reviews The Mainstay Therapy, Adjunct Enzyme Cofactor Therapy, And The Newly Available Enzyme Substitution Therapy For Hyperphenylalaninemia. It Also Provides An Outlook On Emerging Approaches For Hyperphenylalaninemia Treatment Such As Recruiting The Microbiome Into The Therapeutic Endeavor As Well As Therapies Under Development Such As Gene Therapy.|"[('Phenylalanine Hydroxylase', 'no label'), ('Inborn Error', 'no label'), ('Metabolism', 'no label'), ('Results', 'no label'), ('Elevated', 'no label'), ('Phenylalanine', 'no label'), ('Levels', 'no label'), ('Blood', 'no label'), ('Classical Form', 'no label'), ('Disease', 'no label'), ('Phenylalanine', 'no label'), ('Level', 'no label'), ('Blood', 'no label'), ('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Associated With', 'no label'), ('Severe', 'no label'), ('Intellectual Disability', 'no label'), ('Untreated', 'no label'), ('Addition', 'no label'), ('Phenylalanine Levels Above', 'no label'), ('Therapeutic Range', 'no label'), ('Pregnant Female', 'no label'), ('Patients', 'no label'), ('Lead', 'no label'), ('Adverse Fetal', 'no label'), ('Plasma', 'no label'), ('Phenylalanine', 'no label'), ('Prevents', 'no label'), ('Intellectual Disability', 'no label'), ('Level', 'no label'), ('Therapeutic Range', 'no label'), ('Associated With', 'no label'), ('Good Outcome', 'no label'), ('Patients', 'no label'), ('Pregnancies', 'no label'), ('Patient', 'no label'), ('Phenotypes', 'no label'), ('Continuous Spectrum', 'no label'), ('Mild Hyperphenylalaninemia', 'no label'), ('Mild Pku', 'no label'), ('Moderate Pku', 'no label'), ('Severe', 'no label'), ('Classic Pku', 'no label'), ('Correlation', 'no label'), ('Biochemical', 'no label'), ('Phenotype', 'no label'), (""Patient'S"", 'no label'), ('Genotype', 'no label'), ('Decades', 'no label'), ('Available Treatment', 'no label'), ('Very Restrictive', 'no label'), ('Phenylalanine Diet', 'no label'), ('Changed', 'no label'), ('Approval', 'no label'), ('Cofactor Therapy', 'no label'), ('Effective', 'no label'), ('Patients', 'no label'), ('Population', 'no label'), ('Cofactor Therapy', 'no label'), ('Effective', 'no label'), ('Patients', 'no label'), ('Milder', 'no label'), ('Disease', 'no label'), ('Effective', 'no label'), ('Classical Pku', 'no label'), ('New Therapy', 'no label'), ('Effective', 'no label'), ('Patients', 'no label'), ('Pah Deficiency', 'no label'), ('Degree', 'no label'), ('Enzyme Deficiency', 'no label'), ('Severity', 'no label'), ('Phenotype', 'no label'), ('Article Reviews', 'no label'), ('Mainstay Therapy', 'no label'), ('Adjunct Enzyme Cofactor Therapy', 'no label'), ('Enzyme Substitution Therapy', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Provides', 'no label'), ('Outlook', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Treatment', 'no label'), ('Microbiome', 'no label'), ('Therapeutic Endeavor', 'no label'), ('Therapies', 'no label'), ('Gene Therapy', 'no label')]"|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Lead', 'no label'), ('Phenylalanine', 'no label'), ('Genotype', 'no label'), ('Phenylalanine', 'no label'), ('Enzyme', 'no label'), ('Enzyme', 'no label'), ('Enzyme Substitution', 'no label'), ('Gene', 'no label')]|[]|[('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phenylalanine', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Hyperphenylalaninemia', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Error', 'no label'), ('Phenylalanine', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Patients Lead', 'no label'), ('Plasma Phenylalanine', 'no label'), ('Patients', 'no label'), ('Patient', 'no label'), ('Phenylalanine', 'no label'), ('Cofactor', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Pah', 'no label')]
phenylketonuria|pubmed~32679806|A Delicate Intracellular Balance Among Protein Synthesis, Folding, And Degradation Is Essential To Maintaining Protein Homeostasis Or Proteostasis, And It Is Challenged By Genetic And Environmental Factors. Molecular Chaperones And The Ubiquitin Proteasome System (Ups) Play A Vital Role In Proteostasis For Normal Cellular Function. As Part Of Protein Quality Control, Molecular Chaperones Recognize Misfolded Proteins And Assist In Their Refolding. Proteins That Are Beyond Repair Or Refolding Undergo Degradation, Which Is Largely Mediated By The Ups. The Importance Of Protein Quality Control Is Becoming Ever Clearer, But It Can Also Be A Disease-Causing Mechanism. Diseases Such As Phenylketonuria (Pku) And Hereditary Tyrosinemia-I (Ht1) Are Caused Due To Mutations In <I>Pah</I> And <I>Fah</I> Gene, Resulting In Reduced Protein Stability, Misfolding, Accelerated Degradation, And Deficiency In Functional Proteins. Misfolded Or Partially Unfolded Proteins Do Not Necessarily Lose Their Functional Activity Completely. Thus, Partially Functional Proteins Can Be Rescued From Degradation By Molecular Chaperones And Deubiquitinating Enzymes (Dubs). Deubiquitination Is An Important Mechanism Of The Ups That Can Reverse The Degradation Of A Substrate Protein By Covalently Removing Its Attached Ubiquitin Molecule. In This Review, We Discuss The Importance Of Molecular Chaperones And Dubs In Reducing The Severity Of Pku And Ht1 By Stabilizing And Rescuing Mutant Proteins.|[('Delicate Intracellular', 'no label'), ('Balance', 'no label'), ('Protein Synthesis', 'no label'), ('Folding', 'no label'), ('Degradation', 'no label'), ('Protein Homeostasis', 'no label'), ('Proteostasis', 'no label'), ('Genetic', 'no label'), ('Environmental Factors', 'no label'), ('Molecular Chaperones', 'no label'), ('Ubiquitin Proteasome System', 'no label'), ('Play A', 'no label'), ('Proteostasis', 'no label'), ('Normal Cellular Function', 'no label'), ('Protein Quality Control', 'no label'), ('Molecular Chaperones', 'no label'), ('Misfolded Proteins', 'no label'), ('Assist', 'no label'), ('Refolding', 'no label'), ('Proteins', 'no label'), ('Repair', 'no label'), ('Refolding', 'no label'), ('Degradation', 'no label'), ('Ups', 'no label'), ('Protein Quality Control', 'no label'), ('Becoming', 'no label'), ('Clearer', 'no label'), ('Disease-Causing', 'no label'), ('Mechanism', 'no label'), ('Diseases', 'no label'), ('Phenylketonuria', 'no label'), ('Hereditary Tyrosinemia-I', 'no label'), ('Ht1', 'no label'), ('Mutations', 'no label'), ('<I>Pah</I> And <I>Fah</I> Gene', 'no label'), ('Reduced', 'no label'), ('Protein Stability', 'no label'), ('Misfolding', 'no label'), ('Accelerated', 'no label'), ('Degradation', 'no label'), ('Deficiency', 'no label'), ('Functional Proteins', 'no label'), ('Misfolded', 'no label'), ('Partially', 'no label'), ('Proteins', 'no label'), ('Do Not', 'no label'), ('Lose Their', 'no label'), ('Functional Activity', 'no label'), ('Partially Functional Proteins', 'no label'), ('Rescued', 'no label'), ('Degradation', 'no label'), ('Molecular Chaperones', 'no label'), ('Deubiquitinating', 'no label'), ('Enzymes', 'no label'), ('Dubs', 'no label'), ('Deubiquitination', 'no label'), ('Mechanism', 'no label'), ('Ups', 'no label'), ('Degradation', 'no label'), ('Substrate Protein', 'no label'), ('Covalently Removing', 'no label'), ('Attached Ubiquitin Molecule', 'no label'), ('Review', 'no label'), ('Molecular Chaperones', 'no label'), ('Dubs', 'no label'), ('Severity', 'no label'), ('Pku And Ht1 By Stabilizing', 'no label'), ('Rescuing', 'no label'), ('Mutant Proteins', 'no label')]|[('Intracellular', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Genetic', 'no label'), ('Molecular', 'no label'), ('Proteasome', 'no label'), ('Cellular', 'no label'), ('Protein', 'no label'), ('Molecular', 'no label'), ('Proteins', 'no label'), ('Assist', 'no label'), ('Proteins', 'no label'), ('Protein', 'no label'), ('Gene', 'no label'), ('Protein', 'no label'), ('Proteins', 'no label'), ('Proteins', 'no label'), ('Proteins', 'no label'), ('Molecular', 'no label'), ('Enzymes', 'no label'), ('Dubs', 'no label'), ('Protein', 'no label'), ('Molecular', 'no label'), ('Dubs', 'no label'), ('Ht1', 'no label'), ('Mutant Proteins', 'no label')]|[('Misfolded Proteins', 'no label'), ('Dubs', 'no label'), ('Ups', 'no label'), ('Ubiquitin Molecule', 'no label'), ('Dubs', 'no label')]|[('Phenylketonuria', 'no label')]|[('Intracellular', 'no label'), ('Chaperones', 'no label'), ('Ubiquitin', 'no label'), ('Normal Cellular', 'no label'), ('Phenylketonuria', 'no label'), ('Proteins', 'no label'), ('Deubiquitinating Enzymes', 'no label'), ('Dubs', 'no label'), ('Ubiquitin', 'no label'), ('Dubs', 'no label'), ('Pku And', 'no label')]
phenylketonuria|pubmed~31790339|<B>Introduction</B>: Mental Health, Physical Health, And Cognitive Skills Have Been Scarcely Investigated In The Same Sample Of Adults With Pku (Awpku). This Is Striking Since Emotional Difficulties May Potentially Contribute To Cognitive Impairments And Vice-Versa. Here We Aim To Fill This Gap.<B>Method</B>: Thirty-Six Early-Treated Awpku And 40 Controls Were Given An Extensive Battery Of Cognitive Tasks Assessing Complex Executive Functions, Inhibitory Control, Short-Term Memory, Sustained Attention, Visuospatial Attention, Language Production (Reading And Naming), Visuomotor Coordination, Spoken Language And Orthographic Processing. In Addition, Participants Were Given Tasks Tapping Emotion Recognition And Completed Questionnaires To Assess Depression (Bdi-Ii), Empathy (Iri) And Mental/Physical Health-Related Quality Of Life (Sf-36).<B>Results</B>: As A Group, Awpku Performed Significantly Worse Than Controls Especially In Tasks Tapping Complex Executive Functions And Across Tasks When Speed Was Measured But Did Not Differ For Emotional-Health And Physical Health. In The Pku Group, Cognitive Measures And Measures Of Physical Health-Related Quality Of Life Were Inter-Correlated (Differently Than In The Control Group), And Both Measures Were Associated With Metabolic Control: Better Metabolic Control, Better Cognition, And Better Physical Health. Instead, Cognitive Measures And Measures Of Emotional-Health/Mental-Health-Related Quality Of Life Did Not Correlate With One Another And Better Metabolic Control Was Not Associated With Better Emotional Health. Instead, Some Negative Correlations Were Found. Better Metabolic Control Was Associated With Worse Perspective Taking And More Distress In Socially Stressful Situations. Furthermore, Difficulties In Keeping The Diet Were Associated With Less Emotional Well-Being.<B>Conclusions</B>: Taken Together, These Results Indicate The Advantages, But Also Possible Emotional Difficulties Related To Maintain A Pku Diet, Suggesting The Importance Of Developing Alternative Therapy Options.|[('Mental Health', 'no label'), ('Physical Health', 'no label'), ('Cognitive Skills', 'no label'), ('Investigated', 'no label'), ('Sample', 'no label'), ('Adults', 'no label'), ('Pku (Awpku)', 'no label'), ('Striking', 'no label'), ('Emotional Difficulties', 'no label'), ('Contribute', 'no label'), ('Cognitive Impairments', 'no label'), ('Fill', 'no label'), ('Gap.<B', 'no label'), ('Method</B>', 'no label'), ('Early-Treated Awpku', 'no label'), ('Controls', 'no label'), ('Extensive Battery', 'no label'), ('Cognitive Tasks Assessing', 'no label'), ('Complex', 'no label'), ('Executive Functions', 'no label'), ('Inhibitory Control', 'no label'), ('Short-Term Memory', 'no label'), ('Sustained', 'no label'), ('Attention', 'no label'), ('Visuospatial Attention', 'no label'), ('Language Production', 'no label'), ('Visuomotor Coordination', 'no label'), ('Spoken Language', 'no label'), ('Orthographic Processing', 'no label'), ('Addition', 'no label'), ('Participants', 'no label'), ('Tasks Tapping', 'no label'), ('Emotion', 'no label'), ('Recognition', 'no label'), ('Completed Questionnaires', 'no label'), ('Assess Depression', 'no label'), ('Bdi-Ii', 'no label'), ('Empathy', 'no label'), ('Iri', 'no label'), ('Mental/Physical Health-Related Quality Of Life (Sf-36).<B>Results</B>', 'no label'), ('Group', 'no label'), ('Awpku Performed', 'no label'), ('Worse', 'no label'), ('Than Controls', 'no label'), ('Tasks Tapping', 'no label'), ('Executive Functions', 'no label'), ('Tasks', 'no label'), ('Speed', 'no label'), ('Measured', 'no label'), ('Differ', 'no label'), ('Emotional-Health', 'no label'), ('Physical Health', 'no label'), ('Pku Group', 'no label'), ('Cognitive Measures', 'no label'), ('Measures', 'no label'), ('Physical Health-Related Quality Of Life Were Inter-Correlated', 'no label'), ('Control Group', 'no label'), ('Measures', 'no label'), ('Associated With', 'no label'), ('Metabolic Control', 'no label'), ('Better', 'no label'), ('Metabolic Control', 'no label'), ('Better Cognition', 'no label'), ('Physical Health', 'no label'), ('Cognitive Measures', 'no label'), ('Measures', 'no label'), ('Emotional-Health/Mental-Health-Related Quality Of Life', 'no label'), ('Did Not Correlate', 'no label'), ('Better', 'no label'), ('Metabolic Control', 'no label'), ('Was Not', 'no label'), ('Associated With', 'no label'), ('Emotional Health', 'no label'), ('Negative', 'no label'), ('Correlations', 'no label'), ('Metabolic Control', 'no label'), ('Associated With', 'no label'), ('Worse', 'no label'), ('Distress', 'no label'), ('Socially Stressful', 'no label'), ('Situations', 'no label'), ('Difficulties', 'no label'), ('Diet', 'no label'), ('Associated With', 'no label'), ('Emotional Well-Being.<B>Conclusions</B>', 'no label'), ('Results', 'no label'), ('Indicate', 'no label'), ('Advantages', 'no label'), ('Emotional Difficulties', 'no label'), ('Maintain', 'no label'), ('Pku Diet', 'no label'), ('Suggesting', 'no label'), ('Therapy', 'no label'), ('Options', 'no label')]|[]|[]|[('Cognitive Impairments', 'no label'), ('Depression', 'no label'), ('Iri', 'no label'), ('Emotional Difficulties', 'no label')]|[('B', 'no label'), ('Fill', 'no label'), ('Iri', 'no label'), ('A', 'no label')]
phenylketonuria|pubmed~31331350|Phenylketonuria (Pku) Is An Inherited Deficiency In The Enzyme Phenylalanine Hydroxylase (Pah), Which, When Poorly-Managed, Is Associated With Clinical Features Including Deficient Growth, Microcephaly, Seizures, And Intellectual Impairment. The Management Of Pku Should Start As Soon As Possible After Diagnosis To Prevent Irreversible Damage And Be Maintained Throughout Life. The Aim Of This Study Was To Assess The Burden Of Illness In Pku Patients In General And In Pku Patients Born Before And After The Introduction Of Newborn Screening In Germany. This Retrospective Matched Cohort Analysis Used The Institut Für Angewandte Gesundheitsforschung Berlin (Ingef) Research Database Containing Anonymized Healthcare Claims Of Approximately 4 Million Covered Lives. Pku Patients Were Compared With Matched Controls From The General Population Within The Same Database (1:10 Ratio Via Direct, Exact Matching On Age And Gender Without Replacement). Pku Patients Were Included If They Were Aged ≥18 Years On 01/01/15 And Were Continuously Enrolled From 01/01/10 To 31/12/15. The 50 Most Commonly Reported Comorbidities And 50 Most Commonly Prescribed Medications In The Pku Population Were Analyzed. Differences Between Groups Were Tested Using 95% Confidence Interval (Ci) Of Prevalence Ratio (Pr) Values. The Analysis Included 377 Adult Pku Patients (< 5 Of Which Were Receiving Sapropterin Dihydrochloride) And 3,770 Matched Controls. Of The 50 Most Common Comorbidities In The Pku Population, Those With A Statistically Significant Pr > 1.5 Vs Controls Included Major Depressive Disorders (Pr = 2.3), Chronic Ischemic Heart Disease (Pr = 1.7), Asthma (Pr = 1.7), Dizziness And Giddiness (Pr = 1.8), Unspecified Diabetes Mellitus (Pr = 1.7), Infectious Gastroenteritis And Colitis (Pr = 1.7), And Reaction To Severe Stress And Adjustment Disorders (Pr = 1.6). The Most Commonly Prescribed Anatomical Therapeutic Chemical (Atc) Subcodes Among Pku Patients (Vs The Control Population) Are For Systemic Antibacterials (34.7% Vs 32.8%), Anti-Inflammatory And Antirheumatic (29.4% Vs 27.5%), Renin-Angiotensin Agents (30.0% Vs 27.0%), Acid-Related Disorders (29.4% Vs 20.2%), And Beta-Blockers (24.9% Vs 19.9%). The Overall Clinical Burden On Patients With Pku Is Exacerbated By A Significantly Higher Risk Of Numerous Comorbidities And Hence, Prescribing Of The Requisite Medication, Both For Recognized (E.G. Major Depressive Disorders) And More Unexpected Comorbidities (E.G. Ischemic Heart Disease).|[('Phenylketonuria', 'no label'), ('Inherited Deficiency', 'no label'), ('Enzyme Phenylalanine Hydroxylase', 'no label'), ('Poorly-Managed', 'no label'), ('Associated With', 'no label'), ('Clinical Features', 'no label'), ('Deficient', 'no label'), ('Growth', 'no label'), ('Microcephaly', 'no label'), ('Seizures', 'no label'), ('Intellectual Impairment', 'no label'), ('Management', 'no label'), ('Pku Should Start', 'no label'), ('Diagnosis', 'no label'), ('Irreversible', 'no label'), ('Damage', 'no label'), ('Life', 'no label'), ('Study', 'no label'), ('Assess', 'no label'), ('Burden', 'no label'), ('Illness', 'no label'), ('Pku Patients', 'no label'), ('General', 'no label'), ('Pku Patients', 'no label'), ('Newborn Screening', 'no label'), ('Germany', 'no label'), ('Retrospective Matched Cohort Analysis', 'no label'), ('Institut Für Angewandte Gesundheitsforschung Berlin', 'no label'), ('Healthcare', 'no label'), ('Claims', 'no label'), ('Covered Lives', 'no label'), ('Patients', 'no label'), ('Matched Controls', 'no label'), ('General Population', 'no label'), ('Same Database', 'no label'), ('Ratio', 'no label'), ('Direct', 'no label'), ('Exact Matching', 'no label'), ('Age', 'no label'), ('Gender', 'no label'), ('Replacement', 'no label'), ('Pku Patients', 'no label'), ('Aged', 'no label'), ('Continuously', 'no label'), ('Reported', 'no label'), ('Comorbidities', 'no label'), ('Prescribed', 'no label'), ('Medications', 'no label'), ('Pku Population', 'no label'), ('Analyzed', 'no label'), ('Groups', 'no label'), ('Tested', 'no label'), ('Confidence Interval', 'no label'), ('Ci', 'no label'), ('Prevalence Ratio', 'no label'), ('Analysis', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Receiving', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Matched Controls', 'no label'), ('Common', 'no label'), ('Comorbidities', 'no label'), ('Pku Population', 'no label'), ('Statistically Significant', 'no label'), ('Controls', 'no label'), ('Major Depressive Disorders', 'no label'), ('Chronic Ischemic Heart Disease', 'no label'), ('Asthma', 'no label'), ('Dizziness', 'no label'), ('Giddiness', 'no label'), ('Unspecified Diabetes Mellitus', 'no label'), ('Infectious Gastroenteritis', 'no label'), ('Colitis', 'no label'), ('Reaction', 'no label'), ('Severe', 'no label'), ('Stress', 'no label'), ('Prescribed', 'no label'), ('Anatomical Therapeutic Chemical', 'no label'), ('Atc', 'no label'), ('Subcodes', 'no label'), ('Pku Patients', 'no label'), ('Control Population', 'no label'), ('Systemic Antibacterials', 'no label'), ('Anti-Inflammatory And Antirheumatic', 'no label'), ('Renin-Angiotensin Agents', 'no label'), ('Acid-Related Disorders', 'no label'), ('Beta-Blockers', 'no label'), ('Clinical Burden', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Exacerbated', 'no label'), ('Risk', 'no label'), ('Numerous', 'no label'), ('Comorbidities', 'no label'), ('Requisite Medication', 'no label'), ('Recognized', 'no label'), ('Unexpected', 'no label'), ('Comorbidities', 'no label')]|[('Million', 'no label'), ('Replacement', 'no label'), ('Dihydrochloride', 'no label'), ('Chemical', 'no label'), ('Atc', 'no label'), ('Antibacterials', 'no label')]|[('Enzyme Phenylalanine Hydroxylase', 'no label')]|[('Phenylketonuria', 'no label'), ('Inherited Deficiency', 'no label'), ('Phenylalanine', 'no label'), ('Microcephaly', 'no label'), ('Seizures', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Depressive Disorders', 'no label'), ('Chronic Ischemic Heart Disease', 'no label'), ('Pr', 'no label'), ('Dizziness', 'no label'), ('Giddiness', 'no label'), ('Diabetes Mellitus', 'no label'), ('Infectious Gastroenteritis', 'no label'), ('Colitis', 'no label'), ('Pr', 'no label'), ('Depressive Disorders', 'no label'), ('E.G. Ischemic Heart Disease', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Sapropterin Dihydrochloride', 'no label'), ('Heart', 'no label'), ('Giddiness (', 'no label'), ('Mellitus', 'no label'), ('Colitis (', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('E.G.', 'no label'), ('Heart', 'no label')]
phenylketonuria|pubmed~31194686|Breastfeeding Replacement Is The Only Treatment For Galactosemia (Gal) And Phenylketonuria (Pku) During Infancy. We Aimed To Evaluate The Stress Degree In Mothers Who Were Obliged To Replace Breastfeeding With Special Formulas As The Only Treatment For The Diseased Newborns. Thirty-Two Mothers With Gal Newborns, 19 On Breastfeeding Only And 13 On Breastfeeding Plus Formula, Participated In This Study. Additionally, 54 Mothers With Pku Infants, 32 Offered Breastfeeding Only And 22 Breastfeeding Plus Formula, Participated In The Study. Stress Degree Was Evaluated In Both Groups: Gal And Pku. Mothers On Breastfeeding Only Experienced The Highest Degree Of Stress Than Those Who Were On Breastfeeding Plus Formula. After 1 Month Of Psychological Support, Most Mothers Were Ameliorated: Mothers On Breastfeeding Only Felt Better As Compared To Those On Breastfeeding Plus Formula. Conversely, In Mothers On Breastfeeding Plus Formulas, Symptoms And Signs Of Stress Almost Disappeared. In Conclusion, Gal Or Pku Mothers With Breastfeeding Only Experienced The Highest Degree Of Stress When Asked For Breastfeeding Replacement. Psychological Support Made All The Studied Groups To Feel Better Or Free Of Symptoms And Signs Of Stress.|[('Breastfeeding', 'no label'), ('Replacement', 'no label'), ('Treatment', 'no label'), ('Galactosemia', 'no label'), ('Gal', 'no label'), ('Phenylketonuria', 'no label'), ('Infancy', 'no label'), ('Evaluate', 'no label'), ('Stress', 'no label'), ('Degree', 'no label'), ('Mothers', 'no label'), ('Obliged', 'no label'), ('Replace Breastfeeding', 'no label'), ('Special Formulas', 'no label'), ('Treatment', 'no label'), ('Diseased', 'no label'), ('Newborns', 'no label'), ('Thirty-Two', 'no label'), ('Mothers', 'no label'), ('Gal Newborns', 'no label'), ('Breastfeeding', 'no label'), ('Breastfeeding Plus Formula', 'no label'), ('Study', 'no label'), ('Mothers', 'no label'), ('Pku Infants', 'no label'), ('Offered Breastfeeding', 'no label'), ('Breastfeeding Plus Formula', 'no label'), ('Study', 'no label'), ('Stress', 'no label'), ('Groups', 'no label'), ('Gal', 'no label'), ('Pku.', 'no label'), ('Mothers', 'no label'), ('Breastfeeding', 'no label'), ('Experienced', 'no label'), ('Highest', 'no label'), ('Degree', 'no label'), ('Breastfeeding Plus', 'no label'), ('Month', 'no label'), ('Psychological Support', 'no label'), ('Mothers', 'no label'), ('Ameliorated', 'no label'), ('Mothers', 'no label'), ('Breastfeeding', 'no label'), ('Breastfeeding Plus', 'no label'), ('Mothers', 'no label'), ('Breastfeeding Plus', 'no label'), ('Formulas', 'no label'), ('Symptoms', 'no label'), ('Signs', 'no label'), ('Stress', 'no label'), ('Disappeared', 'no label'), ('Gal', 'no label'), ('Pku Mothers', 'no label'), ('Breastfeeding', 'no label'), ('Experienced', 'no label'), ('Highest', 'no label'), ('Degree', 'no label'), ('Stress', 'no label'), ('Breastfeeding', 'no label'), ('Replacement', 'no label'), ('Psychological Support', 'no label'), ('Studied Groups', 'no label'), ('Feel Better', 'no label'), ('Free', 'no label'), ('Symptoms', 'no label'), ('Signs', 'no label'), ('Stress', 'no label')]|[('Replacement', 'no label')]|[('Who', 'no label')]|[('Galactosemia', 'no label'), ('Phenylketonuria', 'no label'), ('Diseased', 'no label')]|[('Galactosemia', 'no label'), ('Phenylketonuria', 'no label'), ('Gal Newborns, 19', 'no label'), ('Gal', 'no label'), ('Stress', 'no label'), ('Stress', 'no label'), ('Gal', 'no label'), ('Pku', 'no label')]
phenylketonuria|pubmed~34420302|In The Present Contribution, On The Basis Of A Spectroscopic And Microscopic Investigation, The Characterization And Photophysics Of Various Assemblies Of Oleic Acid/Oleate Solution At Three Ph Values, Namely, 8.28, 9.72, And 11.77, Were Explored. The Variation In The Dynamic Response Of Aqua Molecules In And Around The Assemblies Has Been Interrogated By A Picoseconds Solvation Dynamics Experiment Using A Time-Correlated Single-Photon Counting Setup Employing Coumarin-153 As A Probe. On The One Hand, The Time-Resolved Fluorescence Anisotropy Measurement Along With The Fluorescence Correlation Spectroscopy Experiment Was Executed To Extract Information Regarding The Comparison Of The Extent Of The Internal Restricted Confinement Of These Assemblies. On The Other Hand, An Effort To Investigate The Cross-Interaction Between The Self-Assembled Architectures Of L-Phenylalanine (L-Phe), Responsible For Phenylketonuria (Pku) Disorder, And The Oleic Acid At The Vesicle-Forming Ph Established That The L-Phe Fibrillar Morphologies Strongly Alter The Dynamic Properties Of The Vesicle Membrane Formed By The Oleic Acid. Specifically, The Interaction Of The L-Phe Assemblies With The Oleic Acid Vesicle Membrane Is Found To Introduce The Flexibility Of The Vesicle Membrane And Alter The Hydration Properties Of The Membrane. To Track The Fibril-Induced Alterations Of The Oleic Acid Vesicle Properties, Various Spectroscopic And Microscopic Investigations Were Performed. The Mutual Reconciliation Of The Experimental Outputs, Therefore, Portrays The State Of The Art, Which Accounts For The Fibril-Induced Alterations Of The Properties Of The Oleic Acid Vesicle Membrane, The Mimicking Setup Of The Cellular Membrane, Thereby Informing Us That Alterations Of Such A Property Of The Membrane Should Be Taken Into Active Consideration During The Rational Development Of Therapeutic Modulators Against Disorders Like Pku.|[('Contribution', 'no label'), ('Spectroscopic And Microscopic Investigation', 'no label'), ('Characterization', 'no label'), ('Photophysics', 'no label'), ('Assemblies', 'no label'), ('Oleic Acid/Oleate', 'no label'), ('Solution', 'no label'), ('Ph Values', 'no label'), ('Variation', 'no label'), ('Dynamic Response', 'no label'), ('Aqua Molecules', 'no label'), ('Assemblies', 'no label'), ('Picoseconds', 'no label'), ('Time-Correlated Single-Photon Counting', 'no label'), ('Coumarin-153', 'no label'), ('Probe', 'no label'), ('Time-Resolved Fluorescence Anisotropy', 'no label'), ('Measurement', 'no label'), ('Fluorescence Correlation Spectroscopy', 'no label'), ('Experiment', 'no label'), ('Extract Information', 'no label'), ('Comparison', 'no label'), ('Internal Restricted Confinement', 'no label'), ('Assemblies', 'no label'), ('Effort', 'no label'), ('Investigate', 'no label'), ('Cross-Interaction', 'no label'), ('Self-Assembled Architectures', 'no label'), ('L-Phenylalanine (L-Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Pku) Disorder', 'no label'), ('Oleic Acid', 'no label'), ('Vesicle-Forming Ph', 'no label'), ('Established', 'no label'), ('L-Phe', 'no label'), ('Fibrillar Morphologies', 'no label'), ('Dynamic', 'no label'), ('Properties', 'no label'), ('Vesicle Membrane', 'no label'), ('Oleic Acid', 'no label'), ('Interaction', 'no label'), ('L-Phe Assemblies', 'no label'), ('Oleic Acid', 'no label'), ('Vesicle Membrane', 'no label'), ('Flexibility', 'no label'), ('Vesicle Membrane', 'no label'), ('Alter', 'no label'), ('Hydration', 'no label'), ('Properties', 'no label'), ('Membrane', 'no label'), ('Track', 'no label'), ('Fibril-Induced', 'no label'), ('Alterations', 'no label'), ('Oleic Acid', 'no label'), ('Vesicle', 'no label'), ('Properties', 'no label'), ('Spectroscopic', 'no label'), ('Microscopic Investigations', 'no label'), ('Performed', 'no label'), ('Mutual Reconciliation', 'no label'), ('Experimental', 'no label'), ('Outputs', 'no label'), ('Portrays', 'no label'), ('State', 'no label'), ('Art', 'no label'), ('Accounts', 'no label'), ('Fibril-Induced', 'no label'), ('Alterations', 'no label'), ('Properties', 'no label'), ('Oleic Acid', 'no label'), ('Vesicle Membrane', 'no label'), ('Mimicking', 'no label'), ('Setup', 'no label'), ('Cellular Membrane', 'no label'), ('Informing', 'no label'), ('Alterations', 'no label'), ('Property', 'no label'), ('Membrane', 'no label'), ('Active', 'no label'), ('Rational Development', 'no label'), ('Therapeutic Modulators', 'no label')]|[('Spectroscopic', 'no label'), ('Oleic', 'no label'), ('Molecules', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phe', 'no label'), ('Oleic Acid', 'no label'), ('L-Phe', 'no label'), ('Oleic Acid Vesicle Membrane', 'no label'), ('Oleic Acid Vesicle Membrane', 'no label'), ('Cellular Membrane', 'no label'), ('Membrane', 'no label')]|[]|[('Oleic', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Oleic Acid', 'no label'), ('L-Phe', 'no label'), ('Oleic Acid', 'no label'), ('L-Phe', 'no label'), ('Oleic Acid', 'no label'), ('Oleic Acid Vesicle', 'no label'), ('Oleic Acid', 'no label')]|[('Oleic', 'no label'), ('Extract', 'no label'), ('L-Phenylalanine', 'no label'), ('L-Phe', 'no label'), ('Phenylketonuria', 'no label'), ('Oleic Acid', 'no label'), ('L-Phe Fibrillar', 'no label'), ('Vesicle Membrane', 'no label'), ('Oleic', 'no label'), ('L-Phe', 'no label'), ('Oleic Acid', 'no label'), ('Vesicle Membrane', 'no label'), ('Vesicle Membrane', 'no label'), ('Membrane', 'no label'), ('Oleic Acid', 'no label'), ('Vesicle', 'no label'), ('Oleic Acid', 'no label'), ('Vesicle Membrane', 'no label'), ('Cellular Membrane', 'no label'), ('Membrane', 'no label')]
phenylketonuria|pubmed~31208951|Phenylketonuria (Pku) Is Due To The Deficit Of The Enzyme Phenylalanine Hydroxylase, The First Step Of Dopamine Synthesis. If Not Early Treated The Disease Results In Severe Neurological Impairment. Minor Neurological Signs Have Been Reported In Early Treated Pku (Etpku) Subjects. Prolactin Level Is Affected By (And Reflects) Brain Dopamine Availability. Object Of The Study Was To Assess The Occurrence, Age At Onset, Distribution, Associated Neurological Signs, And Possible Pathogenetic Biomarkers Of Tremor In Etpku. Fifty-Nine Etpku And 43 Control Subjects (Age Range 7-54) Underwent Individual And Familiar Tremor History, Clinical Assessment Of Tremor By Means Of The Fahn-Tolosa-Marin Tremor Rating Scale, And Iq Evaluation. Historical And Concomitant Biochemical Data (Blood Levels Of Phe) And Serum Prolactin Were Included In The Analysis. Thirty-Two Percent Of Etpku Patients Were Affected By Postural And Kinetic Tremor. We Found A Significant Correlation Between Severity Of Tremor And: Prolactin Level At The Day Of Examination (Part A: R<Sub>S</Sub> = 0.320; P = .014; Part C: R<Sub>S</Sub> = 0.319; P = .014), Phe Fluctuations From 12 Years Onwards (Part B: R<Sub>S</Sub> = 0.300; P = .036). We Also Found A Significant Correlation Between Prolactin (18.2 ± 9.6 Ng/Ml) And Phe Levels (852 ± 472 Μmol/L) On The Day Of Assessment (R<Sub>S</Sub> = 0.470; P < .001). The Main Clinical Features Of Tremor In Etpku Evoke Those Of Essential Tremor, Although With A Higher Prevalence And An Earlier Onset Than In General Population. The Severity Of Tremor Was Related To Concomitant Prolactin Rather Than Phe Levels. This Pattern Suggests That Metabolic Alterations Associated With Pku May Result In An Anticipation Of The Tremor Onset In Subjects Who Are Possibly Prone To This Disorder.|[('Phenylketonuria', 'no label'), ('Deficit', 'no label'), ('Enzyme Phenylalanine Hydroxylase', 'no label'), ('Dopamine Synthesis', 'no label'), ('Treated', 'no label'), ('Disease Results', 'no label'), ('Severe', 'no label'), ('Neurological Impairment', 'no label'), ('Neurological Signs', 'no label'), ('Early Treated', 'no label'), ('Pku (Etpku) Subjects', 'no label'), ('Prolactin', 'no label'), ('Level', 'no label'), ('Affected', 'no label'), ('Reflects', 'no label'), ('Brain', 'no label'), ('Dopamine', 'no label'), ('Object', 'no label'), ('Study', 'no label'), ('Occurrence', 'no label'), ('Age', 'no label'), ('Onset', 'no label'), ('Distribution', 'no label'), ('Neurological Signs', 'no label'), ('Pathogenetic Biomarkers', 'no label'), ('Tremor', 'no label'), ('Etpku', 'no label'), ('Fifty-Nine', 'no label'), ('Etpku', 'no label'), ('Control Subjects', 'no label'), ('Age Range', 'no label'), ('Individual', 'no label'), ('Familiar Tremor History', 'no label'), ('Clinical Assessment', 'no label'), ('Tremor', 'no label'), ('Means', 'no label'), ('Fahn-Tolosa-Marin Tremor Rating Scale', 'no label'), ('Evaluation', 'no label'), ('Historical', 'no label'), ('Concomitant', 'no label'), ('Biochemical', 'no label'), ('Data', 'no label'), ('Blood Levels', 'no label'), ('Phe', 'no label'), ('Serum Prolactin', 'no label'), ('Analysis', 'no label'), ('Etpku Patients', 'no label'), ('Affected', 'no label'), ('Postural', 'no label'), ('Kinetic Tremor', 'no label'), ('Correlation', 'no label'), ('Severity', 'no label'), ('Tremor', 'no label'), ('Prolactin', 'no label'), ('Level', 'no label'), ('Day', 'no label'), ('Examination', 'no label'), ('Part A', 'no label'), ('Part C', 'no label'), ('Phe', 'no label'), ('Fluctuations', 'no label'), ('Onwards', 'no label'), ('Part B', 'no label'), ('Correlation', 'no label'), ('Prolactin', 'no label'), ('Phe Levels', 'no label'), ('Day', 'no label'), ('Clinical Features', 'no label'), ('Tremor', 'no label'), ('Etpku Evoke', 'no label'), ('Essential Tremor', 'no label'), ('Higher', 'no label'), ('Prevalence', 'no label'), ('Onset Than', 'no label'), ('General Population', 'no label'), ('Severity', 'no label'), ('Tremor', 'no label'), ('Concomitant', 'no label'), ('Prolactin', 'no label'), ('Phe', 'no label'), ('Levels', 'no label'), ('Pattern Suggests', 'no label'), ('Metabolic', 'no label'), ('Alterations', 'no label'), ('Associated With', 'no label'), ('Pku May', 'no label'), ('Result', 'no label'), ('Anticipation', 'no label'), ('Tremor', 'no label'), ('Onset', 'no label'), ('Subjects', 'no label'), ('Prone', 'no label'), ('Disorder', 'no label')]|[('Dopamine', 'no label'), ('Dopamine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Prolactin', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Iq', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Dopamine', 'no label'), ('Neurological Impairment', 'no label'), ('Dopamine', 'no label'), ('Tremor', 'no label'), ('Tremor', 'no label'), ('Tremor', 'no label'), ('Tremor', 'no label'), ('Phe', 'no label'), ('Tremor', 'no label'), ('Tremor', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Tremor', 'no label'), ('Tremor', 'no label'), ('Tremor', 'no label'), ('Phe', 'no label'), ('Tremor', 'no label')]|[('Phenylketonuria', 'no label'), ('Deficit', 'no label'), ('Dopamine', 'no label'), ('Prolactin', 'no label'), ('Brain Dopamine', 'no label'), ('Tremor', 'no label'), ('Fifty-Nine', 'no label'), ('Tremor', 'no label'), ('Blood', 'no label'), ('Phe', 'no label'), ('Serum Prolactin', 'no label'), ('Patients', 'no label'), ('Tremor', 'no label'), ('Prolactin', 'no label'), ('Part C', 'no label'), ('Phe', 'no label'), ('Part B', 'no label'), ('Prolactin', 'no label'), ('Phe', 'no label'), ('Tremor', 'no label'), ('Tremor', 'no label'), ('Prolactin', 'no label')]
phenylketonuria|pubmed~30668579|Phenylalanine Hydroxylase (Pah) Deficiency Is Responsible For Most Cases Of Phenylketonuria (Pku). Furthermore, Numerous Studies On Bh4-Sensitive Pah Deficiency Have Been Conducted. To Date, Bh4, A Cofactor Of Pah, Has Not Been Used To Treat Pku In Russia.Genotype Data Of Patients With Pku Can Be Used To Predict Their Sensitivity To Bh4 Therapy. A Cohort Of 2579 Patients With Pku From Russia Was Analyzed For 25 Common Pah Gene Mutations Using Custom Allele-Specific Multiplex Ligation-Dependent Probe Amplification-Based Technology. A Mutation Detection Rate Of 84.1% Chromosomes Was Accomplished. Both Pathogenic Alleles Were Identified In 73.1% Of Patients. The Most Frequent Pathogenic Variants Were P.Arg408Trp (50.9%), P.Arg261Gln (5.3%), P.Pro281Leu (3.5%), Ivs12+1G>A (3.1%), Ivs10-11G>A (2.6%), And P.Arg158Leu (2.4%). The Exact Boundaries Of A Pah Exon 5 Deletion Were Defined As Ex5Del4154Ins268 (C.442-2913_509+1173Del4154Ins268). Severe Phenotypes Prevailed In The Cohort, And Classical Pku Was Observed In 71.8% Cases. Due To The Genotype-Based Prediction, 55.9% Of The Probands Were Non-Responders To The Bh4-Treatment, And 20.2% Were Potential Responders. Analysis Of Genotype Data Is Useful To Predict Bh4 Response In Pku Patients. The High Rate Of Non-Responders Among Russian Patients Was Due To The High Allele Frequency Of Severe Pah Mutations.|[('Phenylalanine Hydroxylase', 'no label'), ('Cases', 'no label'), ('Phenylketonuria', 'no label'), ('Studies', 'no label'), ('Bh4-Sensitive Pah Deficiency', 'no label'), ('Date', 'no label'), ('Bh4', 'no label'), ('Cofactor', 'no label'), ('Has Not', 'no label'), ('Treat', 'no label'), ('Russia', 'no label'), ('Genotype', 'no label'), ('Data', 'no label'), ('Patients', 'no label'), ('Pku Can Be', 'no label'), ('Sensitivity', 'no label'), ('Bh4 Therapy', 'no label'), ('Cohort', 'no label'), ('Patients', 'no label'), ('Pku', 'no label'), ('Russia', 'no label'), ('Analyzed', 'no label'), ('Pah Gene', 'no label'), ('Custom Allele-Specific Multiplex Ligation-Dependent Probe Amplification-Based Technology', 'no label'), ('Mutation Detection', 'no label'), ('Chromosomes', 'no label'), ('Pathogenic Alleles', 'no label'), ('Identified', 'no label'), ('Patients', 'no label'), ('Frequent', 'no label'), ('Pathogenic Variants', 'no label'), ('P.Arg261Gln', 'no label'), ('P.Pro281Leu', 'no label'), ('Ivs12+1G>A', 'no label'), ('Ivs10-11G>A', 'no label'), ('P.Arg158Leu', 'no label'), ('Exact Boundaries', 'no label'), ('Deletion', 'no label'), ('Ex5Del4154Ins268', 'no label'), ('C.442-2913_509+1173Del4154Ins268', 'no label'), ('Severe', 'no label'), ('Phenotypes', 'no label'), ('Cohort', 'no label'), ('Classical Pku', 'no label'), ('Observed', 'no label'), ('Cases', 'no label'), ('Genotype-Based Prediction', 'no label'), ('Probands', 'no label'), ('Non-Responders', 'no label'), ('Bh4-Treatment', 'no label'), ('Potential', 'no label'), ('Responders', 'no label'), ('Analysis', 'no label'), ('Genotype', 'no label'), ('Data', 'no label'), ('Predict', 'no label'), ('Bh4', 'no label'), ('Response', 'no label'), ('Patients', 'no label'), ('High Rate', 'no label'), ('Non-Responders', 'no label'), ('Russian', 'no label'), ('Patients', 'no label'), ('High', 'no label'), ('Allele Frequency', 'no label'), ('Severe', 'no label'), ('Pah Mutations', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Genotype', 'no label'), ('Gene Mutations', 'no label'), ('Probe', 'no label'), ('Mutation', 'no label'), ('Chromosomes', 'no label'), ('Alleles', 'no label'), ('Ivs10', 'no label'), ('Boundaries', 'no label'), ('Exon', 'no label'), ('Deletion', 'no label'), ('Genotype', 'no label'), ('Allele', 'no label'), ('Mutations', 'no label')]|[('Pah Gene', 'no label'), ('Pah Exon 5 Deletion', 'no label')]|[('Phenylalanine', 'no label'), ('Phenylketonuria', 'no label')]|[('Phenylalanine Hydroxylase', 'no label'), ('Phenylketonuria', 'no label'), ('Bh4, A Cofactor', 'no label'), ('Pah', 'no label'), ('Patients', 'no label'), ('Pku Can', 'no label'), ('Bh4', 'no label'), ('Patients', 'no label'), ('Chromosomes', 'no label'), ('Patients', 'no label'), ('Ivs12+1G', 'no label'), ('Ivs10-11G', 'no label'), ('A Pah Exon', 'no label'), ('Bh4 Response', 'no label'), ('Pku Patients', 'no label'), ('Patients', 'no label')]
phenylketonuria|pubmed~29270710|The Role Of Oxidative Stress In The Pathogenesis Of Phenylketonuria (Pku)-Associated Disorders Has Been Implicated. Ischemia Modified Albumin (Ima) Is A Modified Form Of Serum Albumin, Which Is Produced Under The Conditions Of Oxidative Stress. The Aim Of This Study Was To Measure The Serum Level Of Ima In The Pku Patients And To Investigate Its Ability In Predicting The Status Of Oxidative Stress In These Patients. Fifty Treated-Pku Patients And Fifty Age- And Sex-Matched Healthy Subjects Were Included In The Study. The Blood Samples Were Obtained And The Serum Level Of Phenylalanine (Phe) Was Measured Using Reverse Phase Hplc Method. The Levels Of Ima, Malondialdehyde (Mda), Gamma-Glutamyl Transferase (Ggt) Activity, And Uric Acid (Ua) Were Determined Using Colorimetric Methods. The Levels Of Serum Phe, Ima, And Mda Were Significantly Higher (P < 0.001) And The Level Of Ua (P < 0.05) Was Lower In The Pku Patients Compared To Control Group. Serum Ima Level Was Positively Correlated With Mda (R = 0.585, P < 0.001) And Ua (R = 0.6, P < 0.001). An Inverse Relationship Was Observed Between The Serum Level Of Ima And Phe (R = - 0.410, P < 0. 01). Results Of The Present Study Suggest That Serum Ima Level Could Be Used As A Novel Marker For The Evaluation Of Oxidative Stress In The Pku Patients.|[('Oxidative Stress', 'no label'), ('Pathogenesis', 'no label'), ('Phenylketonuria', 'no label'), ('Ischemia', 'no label'), ('Modified Form', 'no label'), ('Serum Albumin', 'no label'), ('Conditions', 'no label'), ('Oxidative Stress', 'no label'), ('Study', 'no label'), ('Measure', 'no label'), ('Serum', 'no label'), ('Level', 'no label'), ('Pku Patients', 'no label'), ('Investigate', 'no label'), ('Ability', 'no label'), ('Predicting', 'no label'), ('Status', 'no label'), ('Oxidative Stress', 'no label'), ('Patients', 'no label'), ('Treated-Pku', 'no label'), ('Patients', 'no label'), ('Age- And', 'no label'), ('Sex-Matched', 'no label'), ('Healthy Subjects', 'no label'), ('Study', 'no label'), ('Blood Samples', 'no label'), ('Obtained', 'no label'), ('Serum', 'no label'), ('Level', 'no label'), ('Phenylalanine (Phe)', 'no label'), ('Measured', 'no label'), ('Reverse Phase Hplc Method', 'no label'), ('Levels', 'no label'), ('Malondialdehyde', 'no label'), ('Mda', 'no label'), ('Gamma-Glutamyl Transferase', 'no label'), ('Uric Acid', 'no label'), ('Ua', 'no label'), ('Colorimetric Methods', 'no label'), ('Levels', 'no label'), ('Serum Phe', 'no label'), ('Mda', 'no label'), ('Level', 'no label'), ('Pku Patients', 'no label'), ('Control Group', 'no label'), ('Serum Ima Level', 'no label'), ('Positively', 'no label'), ('Mda', 'no label'), ('Ua', 'no label'), ('Inverse Relationship', 'no label'), ('Observed', 'no label'), ('Serum', 'no label'), ('Level', 'no label'), ('Phe', 'no label'), ('Study', 'no label'), ('Suggest', 'no label'), ('Serum Ima Level', 'no label'), ('Novel', 'no label'), ('Marker', 'no label'), ('Evaluation', 'no label'), ('Oxidative Stress', 'no label'), ('Pku Patients', 'no label')]|[('Modified Albumin', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Malondialdehyde', 'no label'), ('Gamma-Glutamyl Transferase', 'no label'), ('Uric Acid', 'no label'), ('Mda', 'no label'), ('Mda', 'no label')]|[('Gamma-Glutamyl Transferase', 'no label')]|[('Pathogenesis', 'no label'), ('Phenylketonuria', 'no label'), ('Ischemia', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Malondialdehyde', 'no label'), ('Uric Acid', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Albumin', 'no label'), ('Im', 'no label'), ('Serum Albumin', 'no label'), ('Serum', 'no label'), ('Im', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Blood Samples', 'no label'), ('Serum', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Im', 'no label'), ('Malondialdehyde', 'no label'), ('Gamma-Glutamyl Transferase', 'no label'), ('Uric Acid', 'no label'), ('Serum Phe, Im', 'no label'), ('Patients', 'no label'), ('Serum I', 'no label'), ('Mda (R\u2009', 'no label'), ('Serum', 'no label'), ('Im', 'no label'), ('Phe (R\u2009', 'no label'), ('Serum I', 'no label')]
phenylketonuria|pubmed~28940742|In Phenylketonuria (Pku), During Weaning, It Is Necessary To Introduce A Second Stage Phenylalanine (Phe)-Free Protein Substitute (Ps) To Help Meet Non-Phe Protein Requirements. Semi-Solid Weaning Phe-Free Ps Have Been Available For >15 Years, Although No Long-Term Studies Have Reported Their Efficacy. Retrospective Data From 31 Children With Pku Who Commenced A Weaning Ps Were Collected From Clinical Records From Age Of Weaning To 2 Years, On: Gender; Birth Order; Weaning Age; Anthropometry; Blood Phe Levels; Age Commenced And Dosage Of Weaning Ps And Phe-Free Infant L-Amino Acid Formula; Natural Protein Intake; And Issues With Administration Of Ps Or Food. Median Commencement Age For Weaning Was 17 Weeks (Range 12-25 Weeks) And, For Weaning Ps, 20 Weeks (Range 13-37 Weeks). Median Natural Protein Was 4 G Day<Sup>-1</Sup> (Range 3-11 G Day<Sup>-1</Sup> ) And Total Protein Intake Was >2 G Kg<Sup>-1</Sup> Day<Sup>-1</Sup> From Weaning To 2 Years Of Age. Children Started On 2-4 G Day<Sup>-1</Sup> Protein Equivalent (5-10 G Day<Sup>-1</Sup> Of Powder) From Weaning Ps, Increasing By 0.2 G Kg<Sup>-1</Sup> Day<Sup>-1</Sup> (2 G Day<Sup>-1</Sup> ) Monthly To 12 Months Of Age. Teething And Illness Adversely Affected The Administration Of Weaning Ps And The Acceptance Of Solid Foods. Altogether, 32% Of Children Had Delayed Introduction Of More Textured Foods, Associated With Birth Order (Firstborn 80% Versus 38%; P = 0.05) And Food Refusal When Teething (80% Versus 29%; P = 0.02). Timing Of Introduction Of Solid Foods And Weaning Ps, Progression Onto More Textured Foods And Consistent Feeding Routines Were Important In Aiding Their Acceptance. Any Negative Behaviour With Weaning Ps Was Mainly Associated With Food Refusal, Teething And Illness. Parental Approach Influenced The Acceptance Of Weaning Ps.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Weaning', 'no label'), ('Second Stage Phenylalanine (Phe)-Free Protein Substitute', 'no label'), ('Meet Non-Phe Protein Requirements', 'no label'), ('Semi-Solid Weaning', 'no label'), ('Ps', 'no label'), ('Years', 'no label'), ('No Long-Term Studies', 'no label'), ('Efficacy', 'no label'), ('Retrospective Data', 'no label'), ('Children', 'no label'), ('Pku Who Commenced A Weaning', 'no label'), ('Ps Were', 'no label'), ('Collected', 'no label'), ('Clinical Records', 'no label'), ('Age', 'no label'), ('Weaning', 'no label'), ('Years', 'no label'), ('Gender', 'no label'), ('Birth Order', 'no label'), ('Weaning Age', 'no label'), ('Anthropometry', 'no label'), ('Blood Phe Levels', 'no label'), ('Age Commenced', 'no label'), ('Dosage', 'no label'), ('Weaning', 'no label'), ('Ps And Phe-Free Infant', 'no label'), ('L-Amino Acid Formula', 'no label'), ('Natural Protein Intake', 'no label'), ('Issues', 'no label'), ('Administration', 'no label'), ('Ps Or Food', 'no label'), ('Median Commencement Age', 'no label'), ('Weaning', 'no label'), ('Weeks', 'no label'), ('Range', 'no label'), ('Weeks', 'no label'), ('Weaning Ps', 'no label'), ('Weeks', 'no label'), ('Range', 'no label'), ('Weeks', 'no label'), ('Median Natural Protein', 'no label'), ('Total Protein Intake', 'no label'), ('Weaning', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Children', 'no label'), ('Sup>-1</Sup> Protein', 'no label'), ('Equivalent', 'no label'), ('Powder', 'no label'), ('Weaning Ps', 'no label'), ('Increasing', 'no label'), ('Monthly', 'no label'), ('Months', 'no label'), ('Age', 'no label'), ('Teething', 'no label'), ('Illness', 'no label'), ('Adversely', 'no label'), ('Affected', 'no label'), ('Administration', 'no label'), ('Weaning', 'no label'), ('Acceptance', 'no label'), ('Solid Foods', 'no label'), ('Children', 'no label'), ('Delayed', 'no label'), ('Textured Foods', 'no label'), ('Associated With', 'no label'), ('Birth Order', 'no label'), ('Firstborn', 'no label'), ('Food Refusal', 'no label'), ('Teething', 'no label'), ('Timing', 'no label'), ('Solid Foods And Weaning Ps', 'no label'), ('Progression', 'no label'), ('Textured Foods', 'no label'), ('Feeding', 'no label'), ('Routines', 'no label'), ('Aiding', 'no label'), ('Acceptance', 'no label'), ('Negative Behaviour With', 'no label'), ('Associated With', 'no label'), ('Food Refusal', 'no label'), ('Teething', 'no label'), ('Illness', 'no label'), ('Parental Approach', 'no label'), ('Influenced', 'no label'), ('Acceptance', 'no label'), ('Weaning', 'no label')]|[('Phenylalanine', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Phe', 'no label'), ('Protein', 'no label'), ('Food', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Protein', 'no label'), ('Foods', 'no label'), ('Food', 'no label'), ('Foods', 'no label'), ('Food', 'no label')]|[('Ps', 'no label'), ('Natural Protein', 'no label')]|[('Phenylketonuria', 'no label'), ('Teething And Illness Adversely Affected The Administration Of Weaning Ps And The Acceptance Of Solid Foods', 'no label')]|[('Phenylketonuria', 'no label'), ('Phe-Free', 'no label'), ('Children', 'no label'), ('Blood Phe', 'no label'), ('Phe-Free', 'no label'), ('L-Amino Acid', 'no label'), ('Ps', 'no label'), ('Children', 'no label'), ('5-10', 'no label'), ('Solid Foods', 'no label'), ('Children', 'no label'), ('Solid Foods', 'no label')]
phenylketonuria|pubmed~30875376|In Phenylketonuria (Pku), A Gene Mutation In The Phenylalanine Metabolic Pathway Causes Accumulation Of Phenylalanine (Phe) In Blood And Brain. Although Early Introduction Of A Phe-Restricted Diet Can Prevent Severe Symptoms From Developing, Patients Who Are Diagnosed And Treated Early Still Experience Deficits In Cognitive Functioning Indicating Shortcomings Of Current Treatment. In The Search For New And/Or Additional Treatment Strategies, A Specific Nutrient Combination (Snc) Was Postulated To Improve Brain Function In Pku. In This Study, A Long-Term Dietary Intervention With A Low-Phe Diet, A Specific Combination Of Nutrients Designed To Improve Brain Function, Or Both Concepts Together Was Investigated In Male And Female Btbr Pku And Wt Mice. 48 Homozygous Wild-Types (Wt, +/+) And 96 Pku Btbrpah2 (-/-) Male And Female Mice Received Dietary Interventions From Postnatal Day 31 Till 10 Months Of Age And Were Distributed In The Following Six Groups: High Phe Diet (Wt C-Hp, Pku C-Hp), High Phe Plus Specific Nutrient Combination (Wt Snc-Hp, Pku Snc-Hp), Pku Low-Phe Diet (Pku C-Lp), And Pku Low-Phe Diet Plus Specific Nutrient Combination (Pku Snc- Lp). Memory And Motor Function Were Tested At Time Points 3, 6, And 9 Months After Treatment Initiation In The Open Field (Of), Novel Object Recognition Test (Nor), Spatial Object Recognition Test (Sor), And The Balance Beam (Bb). At The End Of The Experiments, Brain Neurotransmitter Concentrations Were Determined. In The Nor, We Found That Pku Mice, Despite Being Subjected To High Phe Conditions, Could Master The Task On All Three Time Points When Supplemented With Snc. Under Low Phe Conditions, Pku Mice On Control Diet Could Master The Nor At All Three Time Points, While Pku Mice On The Snc Supplemented Diet Could Master The Task At Time Points 6 And 9 Months. Snc Supplementation Did Not Consistently Influence The Performance In The Of, Sor Or Bb In Pku Mice. The Low Phe Diet Was Able To Normalize Concentrations Of Norepinephrine And Serotonin; However, These Neurotransmitters Were Not Influenced By Snc Supplementation. This Study Demonstrates That Both A Long-Lasting Low Phe Diet, The Diet Enriched With Snc, As Well As The Combined Diet Was Able To Ameliorate Some, But Not All Of These Pku-Induced Abnormalities. Specifically, This Study Is The First Long-Term Intervention Study In Btbr Pku Mice That Shows That Snc Supplementation Can Specifically Improve Novel Object Recognition.|[('Phenylketonuria', 'no label'), ('Pku', 'no label'), ('Gene Mutation', 'no label'), ('Phenylalanine Metabolic Pathway', 'no label'), ('Causes', 'no label'), ('Accumulation', 'no label'), ('Phenylalanine (Phe)', 'no label'), ('Blood', 'no label'), ('Brain', 'no label'), ('Early Introduction', 'no label'), ('Phe-Restricted Diet', 'no label'), ('Prevent Severe', 'no label'), ('Symptoms', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Treated', 'no label'), ('Early', 'no label'), ('Experience Deficits', 'no label'), ('Cognitive Functioning', 'no label'), ('Shortcomings', 'no label'), ('Current', 'no label'), ('Treatment', 'no label'), ('And/Or', 'no label'), ('Additional', 'no label'), ('Treatment', 'no label'), ('Nutrient', 'no label'), ('Combination', 'no label'), ('Snc', 'no label'), ('Brain Function', 'no label'), ('Study', 'no label'), ('Long-Term', 'no label'), ('Dietary Intervention', 'no label'), ('Low-Phe Diet', 'no label'), ('Combination', 'no label'), ('Nutrients', 'no label'), ('Brain Function', 'no label'), ('Concepts', 'no label'), ('Investigated', 'no label'), ('Male', 'no label'), ('Female Btbr', 'no label'), ('Pku And Wt Mice', 'no label'), ('Homozygous Wild-Types (Wt, +/+)', 'no label'), ('Pku Btbrpah2', 'no label'), ('Male', 'no label'), ('Received', 'no label'), ('Dietary Interventions', 'no label'), ('Postnatal', 'no label'), ('Day', 'no label'), ('Months', 'no label'), ('Age', 'no label'), ('Groups', 'no label'), ('High Phe Diet', 'no label'), ('Wt C-Hp, Pku C-Hp)', 'no label'), ('High Phe Plus', 'no label'), ('Specific', 'no label'), ('Nutrient', 'no label'), ('Combination', 'no label'), ('Snc-Hp', 'no label'), ('Pku Snc-Hp', 'no label'), ('Pku Low-Phe Diet', 'no label'), ('Pku C-Lp', 'no label'), ('Pku Low-Phe Diet Plus', 'no label'), ('Specific', 'no label'), ('Nutrient', 'no label'), ('Combination', 'no label'), ('Pku Snc- Lp)', 'no label'), ('Memory', 'no label'), ('Motor Function', 'no label'), ('Tested', 'no label'), ('Time Points', 'no label'), ('Months', 'no label'), ('Treatment Initiation', 'no label'), ('Open Field', 'no label'), ('Novel', 'no label'), ('Object Recognition Test', 'no label'), ('Spatial Object Recognition Test', 'no label'), ('Sor', 'no label'), ('Balance Beam (Bb)', 'no label'), ('Experiments', 'no label'), ('Brain', 'no label'), ('Neurotransmitter', 'no label'), ('Concentrations', 'no label'), ('Pku Mice', 'no label'), ('Being', 'no label'), ('Phe', 'no label'), ('Conditions', 'no label'), ('Task', 'no label'), ('Time Points', 'no label'), ('Supplemented', 'no label'), ('Snc', 'no label'), ('Low', 'no label'), ('Phe', 'no label'), ('Conditions', 'no label'), ('Pku Mice', 'no label'), ('Control Diet', 'no label'), ('Time Points', 'no label'), ('Pku Mice', 'no label'), ('Snc', 'no label'), ('Task', 'no label'), ('Months', 'no label'), ('Snc', 'no label'), ('Supplementation', 'no label'), ('Influence', 'no label'), ('Performance', 'no label'), ('Pku Mice', 'no label'), ('Low Phe Diet', 'no label'), ('Normalize', 'no label'), ('Concentrations', 'no label'), ('Norepinephrine', 'no label'), ('Serotonin', 'no label'), ('Neurotransmitters', 'no label'), ('Influenced', 'no label'), ('Snc', 'no label'), ('Supplementation', 'no label'), ('Study', 'no label'), ('Demonstrates', 'no label'), ('Long-Lasting', 'no label'), ('Low', 'no label'), ('Phe Diet', 'no label'), ('Diet', 'no label'), ('Snc', 'no label'), ('Combined Diet', 'no label'), ('Pku-Induced Abnormalities', 'no label'), ('Study', 'no label'), ('Long-Term Intervention Study', 'no label'), ('Btbr', 'no label'), ('Snc', 'no label'), ('Supplementation', 'no label'), ('Novel', 'no label'), ('Object Recognition', 'no label')]|[('Gene Mutation', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe-Restricted', 'no label'), ('Nutrient', 'no label'), ('Snc', 'no label'), ('Nutrients', 'no label'), ('Wt Mice', 'no label'), ('Wt', 'no label'), ('Mice', 'no label'), ('Phe', 'no label'), ('Wt', 'no label'), ('Phe', 'no label'), ('Nutrient', 'no label'), ('Wt', 'no label'), ('Nutrient', 'no label'), ('Mice', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Phe', 'no label'), ('Norepinephrine', 'no label'), ('Neurotransmitters', 'no label'), ('Phe', 'no label'), ('Pku-Induced', 'no label'), ('Mice', 'no label')]|[('Open Field', 'no label'), ('Snc', 'no label'), ('Snc', 'no label'), ('Snc', 'no label'), ('Snc', 'no label'), ('Snc', 'no label'), ('Snc', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Deficits In Cognitive Functioning Indicating Shortcomings Of Current Treatment', 'no label'), ('And/Or', 'no label'), ('Phe', 'no label'), ('Norepinephrine', 'no label'), ('Serotonin', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Blood', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('And/Or', 'no label'), ('Snc', 'no label'), ('Brain', 'no label'), ('Brain', 'no label'), ('Mice', 'no label'), ('Btbrpah2', 'no label'), ('Mice', 'no label'), ('C-Hp', 'no label'), ('Pku C-Hp', 'no label'), ('Pku Snc-Hp', 'no label'), ('Pku Snc- Lp', 'no label'), ('Brain Neurotransmitter', 'no label'), ('Mice', 'no label'), ('Snc', 'no label'), ('Phe', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Snc', 'no label'), ('Snc', 'no label'), ('Phe', 'no label'), ('Norepinephrine', 'no label'), ('Serotonin', 'no label'), ('Neurotransmitters', 'no label'), ('Snc', 'no label'), ('Phe', 'no label'), ('Snc', 'no label'), ('Mice', 'no label'), ('Snc', 'no label')]
phenylketonuria|pubmed~30504004|Phenylketonuria (Pku) Is An Autosomal Recessive Inborn Error Of Phenylalanine (Phe) Metabolism Caused By A Deficiency In The Enzyme Phenylalanine Hydroxylase That Converts Phe Into Tyrosine. If Left Untreated, Pku Results In Increased Phe Concentrations In The Blood And In The Brain, Which Cause Severe Intellectual Disability, Epilepsy, And Behavioral Problems. These Disorders Can Be Prevented If A Diet Low In Phe Is Introduced. This Report Focuses On A Preterm Newborn (Gestational Age 29 Wk) With Adequate Weight (1290 G) And No Family History Of Pku. His Parents Had Not Received Metabolic Neonatal Screening. A Blood Sample At 16 D Of Age And A Weight Of 1430 G Showed Phe 420 Μmol/L, Compatible With Mild Pku. Mixed Feeding Was Initiated With A Formula Free Of Phe (X-Phe), And Breastfeeding Was Fortified With A Contribution Of 3.5 G/Kg Daily (2.5 G X-Phe And 1 G Of High-Value Biological Proteins). The Next Measurements Of Amino Acid Levels In The Blood And Urine Were Normal, And The Progenitors Study For Pku Was Negative. Normal Feeding Was Reintroduced With Normal Neurologic And Metabolic Later Evolution. The Disorders Of The Metabolism Of Phe, In Most Cases, Are Due To A Genetic Condition. However, There Are Infrequent Cases Of Transient Hyperphenylalaninemia Secondary To Delayed Maturation Of The Hydroxylation Enzyme System. They Are Especially Significant In Premature Infants. Although These Forms Have Not Been Shown To Cause Sequelae, In View Of High Levels Of Phe In The Blood, Phe Consumption Must Be Restricted.|[('Phenylketonuria', 'no label'), ('Autosomal', 'no label'), ('Recessive Inborn Error', 'no label'), ('Phenylalanine (Phe) Metabolism', 'no label'), ('Deficiency', 'no label'), ('Enzyme Phenylalanine Hydroxylase', 'no label'), ('Converts', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Left Untreated', 'no label'), ('Increased', 'no label'), ('Phe', 'no label'), ('Concentrations', 'no label'), ('Blood', 'no label'), ('Brain', 'no label'), ('Cause Severe', 'no label'), ('Intellectual Disability', 'no label'), ('Epilepsy', 'no label'), ('Behavioral Problems', 'no label'), ('Disorders', 'no label'), ('Diet', 'no label'), ('Low', 'no label'), ('Phe', 'no label'), ('Report', 'no label'), ('Focuses', 'no label'), ('Preterm Newborn', 'no label'), ('Gestational Age', 'no label'), ('Adequate Weight', 'no label'), ('No Family History', 'no label'), ('Parents', 'no label'), ('Metabolic Neonatal', 'no label'), ('Screening', 'no label'), ('Blood Sample', 'no label'), ('Age', 'no label'), ('Phe', 'no label'), ('Mild Pku', 'no label'), ('Mixed Feeding', 'no label'), ('Formula Free', 'no label'), ('X-Phe', 'no label'), ('Breastfeeding', 'no label'), ('Fortified', 'no label'), ('Contribution', 'no label'), ('G/Kg', 'no label'), ('Daily', 'no label'), ('Biological Proteins', 'no label'), ('Measurements', 'no label'), ('Amino Acid', 'no label'), ('Levels', 'no label'), ('Blood', 'no label'), ('Urine', 'no label'), ('Normal', 'no label'), ('Progenitors', 'no label'), ('Study', 'no label'), ('Pku Was Negative', 'no label'), ('Normal Feeding', 'no label'), ('Normal Neurologic', 'no label'), ('Metabolic', 'no label'), ('Evolution', 'no label'), ('Metabolism', 'no label'), ('Phe', 'no label'), ('Cases', 'no label'), ('Genetic Condition', 'no label'), ('Infrequent', 'no label'), ('Cases', 'no label'), ('Transient', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Secondary', 'no label'), ('Delayed', 'no label'), ('Maturation', 'no label'), ('Hydroxylation Enzyme System', 'no label'), ('Significant', 'no label'), ('Premature Infants', 'no label'), ('Forms', 'no label'), ('Cause Sequelae', 'no label'), ('Levels', 'no label'), ('Phe', 'no label'), ('Blood', 'no label'), ('Phe', 'no label'), ('Consumption', 'no label'), ('Restricted', 'no label')]|[('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('His', 'no label'), ('Phe', 'no label'), ('X-Phe', 'no label'), ('Proteins', 'no label'), ('Amino Acid', 'no label'), ('Phe', 'no label'), ('Genetic', 'no label'), ('Enzyme', 'no label'), ('Phe', 'no label'), ('Phe', 'no label')]|[('Enzyme Phenylalanine Hydroxylase', 'no label'), ('His', 'no label')]|[('Phenylketonuria', 'no label'), ('Autosomal Recessive Inborn', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Phe', 'no label'), ('Epilepsy', 'no label'), ('Phe', 'no label'), ('G Showed Phe 420 Μmol/L', 'no label'), ('Phe', 'no label'), ('Amino Acid', 'no label'), ('Phe', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phe', 'no label')]|[('Phenylketonuria', 'no label'), ('Phenylalanine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Tyrosine', 'no label'), ('Phe', 'no label'), ('Blood', 'no label'), ('Brain', 'no label'), ('Phe', 'no label'), ('Blood', 'no label'), ('Phe', 'no label'), ('A Formula', 'no label'), ('Phe', 'no label'), ('G X-Phe And 1', 'no label'), ('Amino Acid', 'no label'), ('Blood', 'no label'), ('Urine', 'no label'), ('Phe', 'no label'), ('Phe', 'no label'), ('Blood', 'no label'), ('Phe', 'no label')]
phenylketonuria|pubmed~31688717|Phenylketonuria (Pku) And Mild Hyperphenylalaninemia (Hpa) Are Characterized By Increased Blood Phenylalanine Concentrations Varying From Mild To Severe. Management Of Pku Was Reported To Be Time Consuming And Burdensome For Caregivers. This Study Intended To Explore The Experiences Of Families Caring For A Child With Pku/Hpa In A Country With A High Pku Rate. The Aim Of This Study Was To Compare Parental Well-Being Between Parents Of Children With And Without Dietary Restrictions And To Explore The Factors Associated With Parental Psychological Well-Being. Participants Were Interviewed About Their Experiences, Concerns, And Challenges Related To The Disease By Using A Semistructured Questionnaire. After The Interview, Parents Filled Out The Beck Depression Inventory And State-Trait Anxiety Inventory-Trait. This Study Highlighted The Adverse Psychological, Financial, And Social Effects Of The Diagnosis And Management Of The Disease Regarding The Lives Of The Families Of Children With Pku/Hpa. Although Parental Anxiety Scores Of Children With And Without Dietary Restrictions Were Similar, Depressive Symptom Scores Were Higher In Parents Of Children With Dietary Restrictions. However, In Multiple Regression Analysis, Lower Household Income And Absence Of Perceived Social Support Were Found To Be Independent Factors Associated With Higher Depressive Symptom Scores. Having A Daughter Diagnosed With Pku/Hpa And Lower Household Income Were Found To Be Factors Associated With Higher Anxiety Scores. This Study Revealed That Income Level, Perceived Social Support, And Gender Of The Child Were Factors Associated With Psychological Well-Being Of Parents Caring For Children With Pku/Hpa. Health Care Professionals Should Identify The Challenges Faced By Families And Should Be Aware Of Risk Factors Associated With Lower Parental Well-Being To Achieve Better Family Adjustment And Better Health Outcomes.|[('Phenylketonuria', 'no label'), ('Mild Hyperphenylalaninemia', 'no label'), ('Hpa', 'no label'), ('Characterized', 'no label'), ('Increased', 'no label'), ('Blood', 'no label'), ('Phenylalanine', 'no label'), ('Concentrations', 'no label'), ('Mild To Severe', 'no label'), ('Management', 'no label'), ('Pku Was', 'no label'), ('Time Consuming', 'no label'), ('Burdensome', 'no label'), ('Caregivers', 'no label'), ('Study', 'no label'), ('Experiences', 'no label'), ('Families', 'no label'), ('Caring', 'no label'), ('Child', 'no label'), ('Pku/Hpa', 'no label'), ('Country', 'no label'), ('High Pku Rate', 'no label'), ('Study', 'no label'), ('Compare', 'no label'), ('Parental Well-Being', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Dietary', 'no label'), ('Restrictions', 'no label'), ('Factors', 'no label'), ('Associated With', 'no label'), ('Parental Psychological Well-Being', 'no label'), ('Participants', 'no label'), ('Experiences', 'no label'), ('Concerns', 'no label'), ('Challenges', 'no label'), ('Disease', 'no label'), ('Semistructured Questionnaire', 'no label'), ('Interview', 'no label'), ('Parents', 'no label'), ('Beck Depression Inventory', 'no label'), ('Study', 'no label'), ('Adverse Psychological', 'no label'), ('Financial', 'no label'), ('Social Effects', 'no label'), ('Diagnosis', 'no label'), ('Management', 'no label'), ('Disease', 'no label'), ('Lives', 'no label'), ('Families', 'no label'), ('Children', 'no label'), ('Pku/Hpa', 'no label'), ('Parental Anxiety Scores', 'no label'), ('Children', 'no label'), ('Dietary', 'no label'), ('Restrictions', 'no label'), ('Depressive Symptom Scores', 'no label'), ('Higher', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Dietary', 'no label'), ('Restrictions', 'no label'), ('Multiple Regression Analysis', 'no label'), ('Lower Household Income', 'no label'), ('Absence', 'no label'), ('Perceived', 'no label'), ('Social Support', 'no label'), ('Independent Factors', 'no label'), ('Associated With', 'no label'), ('Higher', 'no label'), ('Depressive Symptom Scores', 'no label'), ('Daughter', 'no label'), ('Diagnosed', 'no label'), ('Pku/Hpa', 'no label'), ('Lower Household Income', 'no label'), ('Factors', 'no label'), ('Associated With', 'no label'), ('Higher Anxiety Scores', 'no label'), ('Study', 'no label'), ('Revealed', 'no label'), ('Income Level', 'no label'), ('Perceived', 'no label'), ('Social Support', 'no label'), ('Gender', 'no label'), ('Child Were Factors', 'no label'), ('Associated With', 'no label'), ('Psychological Well-Being', 'no label'), ('Parents', 'no label'), ('Caring', 'no label'), ('Children', 'no label'), ('Pku/Hpa', 'no label'), ('Health Care Professionals', 'no label'), ('Challenges', 'no label'), ('Families', 'no label'), ('Aware', 'no label'), ('Risk Factors', 'no label'), ('Associated With', 'no label'), ('Lower Parental Well-Being', 'no label'), ('Better', 'no label'), ('Family Adjustment', 'no label'), ('Better', 'no label'), ('Health Outcomes', 'no label')]|[('Phenylalanine', 'no label')]|[]|[('Phenylketonuria', 'no label'), ('Hyperphenylalaninemia', 'no label'), ('Phenylalanine', 'no label'), ('Depression', 'no label'), ('Anxiety Inventory-Trait', 'no label'), ('Anxiety', 'no label'), ('Depressive', 'no label'), ('Depressive', 'no label'), ('Anxiety', 'no label')]|[('Phenylketonuria', 'no label'), ('Blood Phenylalanine', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Parents', 'no label'), ('Children', 'no label'), ('Be Factors', 'no label'), ('Children', 'no label')]
phenylketonuria|pubmed~32681775|"Objectives Self-Esteem Is The Degree To Which The Qualities And Characteristics Contained In One'S Self-Concept Are Perceived To Be Positive. The Aim Of This Study Was To Evaluate The Self-Esteem Scores In Phenylketonuria (Pku) Patients On ""Strict"", ""Loos"" And ""Off Diet"". Sixty Pku Patients Were Divided In Three Equal Groups. Methods Group A: ""On Strict"", Group B: ""On Loos"" And Group C: ""Off Diet"". A Special Questionnaire For Self-Esteem Scores Was Created For These Patients. Results Before Psychological Support, Group A Patients Demonstrated 6/20 (30%) Very High Self-Esteem, 9/20 (45%) High And 5/25 (25%) Moderate. After Support 14/20 (70%) Were Turned To Very High, 5/20 (25%) Represented High Except One Whose Degrees Remained An Altered. Group B 4/20 (20%) Were Very High, 7/20 (35%) Were High, 3/20 (15%) Moderate And The Rest Of Them Showed Low Self-Esteem Degrees, After Support, 10/20 (50%) Showed Very High, 5/20 (25%) Became High, 3/20 (15%) Turned To Moderate And 2/20 (10%) Remained Unaltered. Group C, 1/20 (5%) Were Very High Self-Esteemed, 7/20 (35%) Were High, 6/20 (30%) Were Moderate And 6/20 (30%) With Low Self-Esteemed, At The End Of Support, 6/20 (30%) Become Very High, 8/20 (40%) With High, 4/20 (20.0%), Moderate Self-Esteem Whereas The Rest Were Unaltered. Conclusions Very High And High Self-Esteem Degrees Were Demonstrated In Patients Who Follow Their Pku Diet. Moderate And Low Self-Esteem Degrees Were Predominantly Found In Patients On Loos And Or Off Diet. Psychological Supports Commonly Result In Amelioration Of Self-Esteem Degrees."|"[('Objectives', 'no label'), ('Degree', 'no label'), ('Qualities', 'no label'), ('Characteristics', 'no label'), ('Contained', 'no label'), ('Self-Concept', 'no label'), ('Perceived', 'no label'), ('Positive', 'no label'), ('Study', 'no label'), ('Evaluate', 'no label'), ('Self-Esteem Scores', 'no label'), ('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Pku Patients', 'no label'), ('Equal Groups', 'no label'), ('Group A', 'no label'), ('Group B', 'no label'), ('Group', 'no label'), ('""Off Diet', 'no label'), ('Special Questionnaire', 'no label'), ('Patients', 'no label'), ('Psychological Support', 'no label'), ('Group', 'no label'), ('Patients', 'no label'), ('Moderate', 'no label'), ('Degrees', 'no label'), ('Altered', 'no label'), ('Group B', 'no label'), ('High', 'no label'), ('Moderate', 'no label'), ('Rest', 'no label'), ('Low Self-Esteem Degrees', 'no label'), ('Support', 'no label'), ('Very High', 'no label'), ('High', 'no label'), ('Moderate', 'no label'), ('Remained', 'no label'), ('Unaltered', 'no label'), ('Group C', 'no label'), ('Self-Esteemed', 'no label'), ('High', 'no label'), ('Moderate', 'no label'), ('Low', 'no label'), ('Self-Esteemed', 'no label'), ('Support', 'no label'), ('High', 'no label'), ('Moderate Self-Esteem', 'no label'), ('Rest', 'no label'), ('Unaltered', 'no label'), ('High Self-Esteem Degrees', 'no label'), ('Patients', 'no label'), ('Pku Diet', 'no label'), ('Moderate', 'no label'), ('Low Self-Esteem Degrees', 'no label'), ('Patients', 'no label'), ('Psychological Supports', 'no label'), ('Result', 'no label'), ('Amelioration', 'no label'), ('Self-Esteem Degrees', 'no label')]"|[]|[]|[('Phenylketonuria', 'no label')]|[('Phenylketonuria', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Loos', 'no label')]
tako-tsubo cardiomyopathy|pubmed~31262719|Tako-Tsubo Cardiomyopathy (Ttc) Is A Transient Myocardial Dysfunction Mainly Affecting The Left Ventricle, Mimicking An Acute Coronary Syndrome. This Condition Can Be Precipitated Either By Psychological/Physical Stressful Events Or By A Number Of Medical Conditions Among Which Are Seizures And Status Epilepticus (Se). The Evolution Is Mostly Favourable But Sometimes Ttc Can Evolve Into Life-Threatening Conditions. We Searched For Cases Of Ttc Among All Consecutive Se Episodes Observed At Our Department During The Period 2013-2018. In Addition, We Searched Medline (Accessed Through Pubmed From Inception To August 31, 2018) To Identify Reports Of Patients With Ttc Associated With An Se Episode. Three Ttc Cases Among 392 Se Episodes Were Identified. Adding Our Cases To Those Previously Reported, Overall, We Identified 45 Cases Of Ttc Induced By Se. The Majority Were Females Of Around 60 Years Of Age Experiencing A First Episode Of Se With Prominent Motor Phenomena, Mostly In The Context Of Remote Aetiology. The Most Frequent Presenting Symptom Was Mild Hypotension But Cases With A Severe Presentation Were Also Reported. The Overall Evolution Was Positive In All Cases But Some Severe Complications Such As Pulmonary Oedema, Cardiogenic Shock, Ventricular Fibrillation, And A Giant Apical Thrombus Were Also Reported (19%). Ttc May Be A Rare Potentially Life-Threatening Consequence Of Se. It Is Frequently Unrecognized, And Therefore Underdiagnosed. Clinicians Dealing With Se Should Be Aware Of This Entity.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Transient Myocardial Dysfunction', 'no label'), ('Affecting', 'no label'), ('Left Ventricle', 'no label'), ('Mimicking', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Condition', 'no label'), ('Psychological/Physical Stressful Events', 'no label'), ('Medical Conditions', 'no label'), ('Seizures', 'no label'), ('Status Epilepticus', 'no label'), ('Se', 'no label'), ('Evolution', 'no label'), ('Favourable', 'no label'), ('Ttc', 'no label'), ('Evolve Into', 'no label'), ('Conditions', 'no label'), ('Cases', 'no label'), ('Ttc', 'no label'), ('Consecutive', 'no label'), ('Se', 'no label'), ('Episodes', 'no label'), ('Observed', 'no label'), ('Department', 'no label'), ('Period', 'no label'), ('Searched Medline', 'no label'), ('Pubmed', 'no label'), ('Inception', 'no label'), ('Reports', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Associated With', 'no label'), ('Se Episode', 'no label'), ('Ttc', 'no label'), ('Cases', 'no label'), ('Se', 'no label'), ('Episodes', 'no label'), ('Identified', 'no label'), ('Cases', 'no label'), ('Identified', 'no label'), ('Cases', 'no label'), ('Ttc', 'no label'), ('Induced', 'no label'), ('Se', 'no label'), ('Majority', 'no label'), ('Females', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Experiencing A First', 'no label'), ('Episode', 'no label'), ('Se', 'no label'), ('Motor Phenomena', 'no label'), ('Context', 'no label'), ('Remote Aetiology', 'no label'), ('Frequent', 'no label'), ('Presenting Symptom', 'no label'), ('Mild Hypotension', 'no label'), ('Cases', 'no label'), ('Severe', 'no label'), ('Presentation', 'no label'), ('Evolution', 'no label'), ('Positive', 'no label'), ('Cases', 'no label'), ('Severe', 'no label'), ('Complications', 'no label'), ('Pulmonary Oedema', 'no label'), ('Cardiogenic Shock', 'no label'), ('Ventricular Fibrillation', 'no label'), ('Giant Apical Thrombus', 'no label'), ('Ttc', 'no label'), ('Rare', 'no label'), ('Life-Threatening', 'no label'), ('Consequence', 'no label'), ('Se', 'no label'), ('Unrecognized', 'no label'), ('Underdiagnosed', 'no label'), ('Clinicians', 'no label'), ('Se', 'no label'), ('Aware', 'no label'), ('Entity', 'no label')]|[('Se', 'no label'), ('Se', 'no label'), ('Se', 'no label'), ('Se', 'no label'), ('Se', 'no label'), ('Se', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Myocardial Dysfunction', 'no label'), ('Left Ventricle', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Seizures', 'no label'), ('Status Epilepticus', 'no label'), ('Se', 'no label'), ('Se', 'no label'), ('Se', 'no label'), ('Hypotension', 'no label'), ('Pulmonary Oedema', 'no label'), ('Cardiogenic Shock', 'no label'), ('Ventricular Fibrillation', 'no label'), ('Thrombus', 'no label'), ('Se', 'no label')]|[('Myocardial', 'no label'), ('Left Ventricle', 'no label'), ('Se', 'no label'), ('Se', 'no label'), ('Patients', 'no label'), ('Se', 'no label'), ('Se', 'no label'), ('Se', 'no label'), ('Se', 'no label'), ('Pulmonary Oedema', 'no label'), ('Ventricular', 'no label'), ('Thrombus', 'no label'), ('Se', 'no label'), ('Se', 'no label')]
tako-tsubo cardiomyopathy|pubmed~31673849|Tako-Tsubo Cardiomyopathy (Ttc) Is Characterized By The Presence Of Transient Left Ventricular (Lv) Dysfunction. Whether Left Atrial (La) Function Is Also Impaired In This Setting Is Unclear. To Assess Prospectively La Peak Systolic Longitudinal Strain (Las) By Two-Dimensional Strain At The Acute Phase Of Ttc And After Recovery And Its Association With In-Hospital Complications. 40 Patients With Typical Ttc (Mean Age 79.5 ± 10 Years) Underwent Transthoracic-Doppler Echocardiography At The Acute Phase And At Follow-Up (32 ± 18 Days Later), Including The Measurement Of The Las (Mean Of Maximal Strain From The 4-2 Chamber Views). A Control Group Of 15 Patients (75 ± 7 Years, 13 Women) Without Overt Cardiovascular Disease Served As A Comparative Group. In-Hospital Complication Was A Composite Of Death, Heart Failure, Cardiogenic Shock, Lv Thrombus, And Sustained Ventricular Arrhythmia. In The Ttc Group, Las Improved Significantly Between The Two Examinations From 15 ± 5.5% To 27 ± 8% (P < 0.01) Whereas La Volume Did Not Change (P = Ns). In The Control Group Las Was 30 ± 4% (P < 0.01 Vs. Ttc Acute Phase, P = Ns Vs. Ttc Follow-Up). In Ttc, At The Acute Phase Las Was Independently Correlated To Lv Global Longitudinal Strain (Lvgls), And After Recovery To E/E', And The Change Of Las Was Independently Correlated To The Change Of The Lvgls (All, P < 0.01). Furthermore Las Was Independently Correlated To In-Hospital Complications (P < 0.01). La Function (Reservoir) Is Transiently Impaired In Ttc And Associated To In-Hospital Complications. Furthermore, The Improvement Of Las Parallel The Dynamic Improvement Of Lvgls Suggests That Ttc Induces A Transient Global Left Heart Dysfunction.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Characterized', 'no label'), ('Transient Left Ventricular (Lv) Dysfunction', 'no label'), ('Left Atrial (La) Function', 'no label'), ('Impaired', 'no label'), ('Peak Systolic Longitudinal Strain (Las)', 'no label'), ('Two-Dimensional Strain', 'no label'), ('Acute Phase', 'no label'), ('Ttc', 'no label'), ('Recovery', 'no label'), ('In-Hospital', 'no label'), ('Complications', 'no label'), ('Patients', 'no label'), ('Typical Ttc', 'no label'), ('Mean Age', 'no label'), ('Transthoracic-Doppler Echocardiography', 'no label'), ('Acute Phase', 'no label'), ('Follow-Up', 'no label'), ('Days', 'no label'), ('Measurement', 'no label'), ('Las', 'no label'), ('Maximal Strain', 'no label'), ('Views', 'no label'), ('Control Group', 'no label'), ('Patients', 'no label'), ('Years', 'no label'), ('Women', 'no label'), ('Overt Cardiovascular Disease Served', 'no label'), ('Comparative Group', 'no label'), ('In-Hospital', 'no label'), ('Complication', 'no label'), ('Composite', 'no label'), ('Death', 'no label'), ('Heart Failure', 'no label'), ('Cardiogenic Shock', 'no label'), ('Lv Thrombus', 'no label'), ('Sustained', 'no label'), ('Ventricular Arrhythmia', 'no label'), ('Ttc Group', 'no label'), ('Las', 'no label'), ('Examinations', 'no label'), ('La Volume', 'no label'), ('Did Not Change', 'no label'), ('Control Group Las', 'no label'), ('Ttc Acute Phase', 'no label'), ('Ttc Follow-Up', 'no label'), ('Ttc', 'no label'), ('Acute Phase Las', 'no label'), ('Correlated', 'no label'), ('Lv Global Longitudinal Strain (Lvgls)', 'no label'), ('Recovery', 'no label'), ('E/E', 'no label'), ('Change', 'no label'), ('Las', 'no label'), ('Correlated', 'no label'), ('Lvgls', 'no label'), ('Correlated', 'no label'), ('In-Hospital', 'no label'), ('Complications', 'no label'), ('La Function', 'no label'), ('Reservoir', 'no label'), ('Transiently Impaired', 'no label'), ('Ttc', 'no label'), ('Complications', 'no label'), ('Improvement', 'no label'), ('Las Parallel', 'no label'), ('Dynamic', 'no label'), ('Improvement', 'no label'), ('Lvgls Suggests', 'no label'), ('Ttc', 'no label'), ('Induces', 'no label'), ('Transient', 'no label')]|[('Transthoracic-Doppler', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Left Ventricular (Lv) Dysfunction', 'no label'), ('Cardiovascular Disease', 'no label'), ('Death', 'no label'), ('Heart Failure', 'no label'), ('Cardiogenic Shock', 'no label'), ('Thrombus', 'no label'), ('Ventricular Arrhythmia', 'no label'), ('Left Heart Dysfunction', 'no label')]|[('Left Ventricular', 'no label'), ('Left Atrial (La)', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cardiovascular Disease', 'no label'), ('Heart', 'no label'), ('Ventricular Arrhythmia.', 'no label'), ('Lv', 'no label'), ('Heart', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25544669|The Etiology And Epidemiology Of Tako-Tsubo Cardiomyopathy Remain Uncertain. The Symptoms Of This Condition Are Often Similar To Those Of Myocardial Infarction And, Although It Usually Has A Good Prognosis, It Is Not Without Complications. Our Aim Was To Characterize This Disease In Our Setting Using A Dedicated Registry (Spanish Registry For Takotsubo Cardiomyopathy). The Prospective Registry Included 202 Incident Patients In 23 Hospitals From 2012 To 2013. The Patients' Clinical Characteristics And Analytical, Echocardiographic, And Imaging Results Were Recorded, As Were The Events During Follow-Up. Patients Were Included When The Attending Physician Considered The Case Proven, And Incidence Was Calculated Relative To The Catheterizations Requested For A Presumptive Diagnosis Of Acute Coronary Syndrome. The Patients Were Predominantly Women (90%), With A Mean Age Of 70 Years, And Many Had Cardiovascular Risk Factors, Such As Hypertension (67%), Dyslipidemia (41%), Diabetes Mellitus (15%), And Smoking (15%). The Incidence Of Tako-Tsubo Cardiomyopathy Was 1.2%, And There Was No Clear Weekly Or Seasonal Distribution Pattern. Chest Pain Was The Predominant Symptom, A Triggering Factor (Emotional, Physical, Or Both) Was Present In 72%, And Most Patients Consulted Within The First 6H After Symptom Onset. The Median Duration Of Hospitalization Was 7 Days. There Were Heart Failure Symptoms In 34.0%, Arrhythmia In 26.7%, And 2.4% Of Patients Died. The Incidence Of Tako-Tsubo Cardiomyopathy Is Low. This Disease Primarily Affects Postmenopausal Women, And Occurs After A Situation Of Emotional Stress In More Than Half Of Affected Individuals. It Is Characterized By Anginal Pain, Shows No Seasonal Distribution, And Has A Good Prognosis, Although It Is Not Without Morbidity And Mortality.|"[('Etiology', 'no label'), ('Epidemiology', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Remain', 'no label'), ('Uncertain', 'no label'), ('Symptoms', 'no label'), ('Condition', 'no label'), ('Myocardial Infarction', 'no label'), ('Good Prognosis', 'no label'), ('Complications', 'no label'), ('Characterize', 'no label'), ('Disease', 'no label'), ('Dedicated Registry', 'no label'), ('Spanish Registry', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Prospective Registry', 'no label'), ('Incident', 'no label'), ('Patients', 'no label'), ('Hospitals', 'no label'), (""Patients'"", 'no label'), ('Clinical Characteristics', 'no label'), ('Analytical', 'no label'), ('Echocardiographic', 'no label'), ('Imaging Results', 'no label'), ('Events', 'no label'), ('Follow-Up', 'no label'), ('Patients', 'no label'), ('Attending', 'no label'), ('Physician', 'no label'), ('Case Proven', 'no label'), ('Incidence', 'no label'), ('Catheterizations', 'no label'), ('Presumptive Diagnosis', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Cardiovascular', 'no label'), ('Risk Factors', 'no label'), ('Hypertension', 'no label'), ('Dyslipidemia', 'no label'), ('Diabetes Mellitus', 'no label'), ('Smoking', 'no label'), ('Incidence', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Weekly', 'no label'), ('Seasonal', 'no label'), ('Distribution', 'no label'), ('Chest Pain', 'no label'), ('Predominant Symptom', 'no label'), ('Triggering Factor', 'no label'), ('Emotional', 'no label'), ('Physical', 'no label'), ('Patients', 'no label'), ('Consulted', 'no label'), ('Median Duration', 'no label'), ('Hospitalization', 'no label'), ('Days', 'no label'), ('Heart Failure', 'no label'), ('Symptoms', 'no label'), ('Arrhythmia', 'no label'), ('Patients', 'no label'), ('Died', 'no label'), ('Incidence', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Disease', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Occurs', 'no label'), ('Situation', 'no label'), ('Emotional Stress', 'no label'), ('Affected', 'no label'), ('Individuals', 'no label'), ('Characterized', 'no label'), ('Anginal Pain', 'no label'), ('No Seasonal', 'no label'), ('Distribution', 'no label'), ('Has A', 'no label'), ('Good Prognosis', 'no label'), ('Morbidity', 'no label'), ('Mortality', 'no label')]"|[('Individuals', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Myocardial Infarction', 'no label'), ('Prognosis', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Hypertension', 'no label'), ('Dyslipidemia', 'no label'), ('Diabetes Mellitus', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Chest Pain', 'no label'), ('Heart Failure Symptoms', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Anginal Pain', 'no label'), ('Prognosis', 'no label')]|[('Myocardial', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Acute Coronary', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Cardiovascular', 'no label'), ('Mellitus', 'no label'), ('A Triggering Factor', 'no label'), ('Patients', 'no label'), ('Heart', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~32815793|Tako-Tsubo Cardiomyopathy (Tc) Is Characterized By Acute But Transient Ventricular Dysfunction Without Obstructive Coronary Artery Disease, Generally Precipitated By Emotional And Physical Triggers. We Describe This Syndrome In A 76-Year-Old Woman Who Was Admitted With Thoracic Pain Secondary To Tc As Shown By Echocardiographic Assessment, With A Concurrent Diagnosis Of Giant Ascending Aortic Aneurism. Surgical Intervention Was Delayed To Allow Ventricular Recovery And Then To Perform Ascending Aorta Replacement. An Individualized Perioperative Approach Was Applied To Avoid A Possible Tc Recurrence With An Uneventful Postoperative Course.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tc', 'no label'), ('Characterized', 'no label'), ('Acute', 'no label'), ('Transient Ventricular Dysfunction', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Precipitated', 'no label'), ('Emotional And Physical Triggers', 'no label'), ('Syndrome', 'no label'), ('76-Year-Old Woman Who', 'no label'), ('Admitted With', 'no label'), ('Thoracic Pain', 'no label'), ('Secondary', 'no label'), ('Tc', 'no label'), ('Echocardiographic Assessment', 'no label'), ('Concurrent', 'no label'), ('Diagnosis', 'no label'), ('Giant Ascending Aortic Aneurism', 'no label'), ('Surgical Intervention', 'no label'), ('Delayed', 'no label'), ('Ventricular Recovery', 'no label'), ('Perform', 'no label'), ('Ascending Aorta', 'no label'), ('Replacement', 'no label'), ('Individualized', 'no label'), ('Perioperative', 'no label'), ('Tc', 'no label'), ('Recurrence', 'no label'), ('Uneventful Postoperative Course', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Thoracic Pain', 'no label')]|[('Ventricular', 'no label'), ('Coronary Artery', 'no label')]
tako-tsubo cardiomyopathy|pubmed~29027587|Takotsubo Cardiomyopathy (Ttc) Is Characterized By Transient Systolic Ventricular Dysfunction. It Is Supposed To Be Caused By A Cathecolaminergic Wave Which Leads To Myocardial Stunning Through A Massive Action On Beta2-Adrenoreceptor. Moreover, Beta2-Receptor Hyperactivity Negatively Influences Endothelial Function. It Can Be Detected By Brachial Flow Mediated Dilation (B-Fmd) Which Assesses Endothelium Regulated Vasomotility. The Study Aim Is To Analyze The B-Fmd Variability During Hospitalization In 50 Patients Admitted With Ttc. In Addition, We Investigated A Possible Correlation Between B-Fmd At Admission And Both Length Of Hospital Stay (Lohs) And Troponin I Peak. We Detected B-Fmd By Measuring The Hypoxic Induced Vasoreactivity Through Assessing Brachial Artery Dilation After 5 Min Of Iatrogenic Ischemia Obtained By Inflating A Sphygmomanometer Cuff. Artery Diameter Modifications Were Assessed By High-Resolution Ultrasound, And A Dedicated Software Calculated Accurately The Percentage Of Dilation After Ischemia By Comparing It To The Basal. These Values Were Measured At Admission And On Discharge. The Obtained Values Were Compared For Each Patient To Explore Their Variability During Hospitalization. Moreover, The Correlation Between The B-Fmd At Admission And Both The Troponin I Peak And The Lohs Was Investigated. There Was A Statistical Significant Difference Between Mean Fmd Measured At Admission And At Discharge (Respectively 1.54 ± 0.34 And 8.92 ± 2.48%; P < 0.001). Moreover, We Found A Significant Negative Correlation Between Troponin I Peak And Fmd Values At Admission (R = - 0.7645; P < 0.001) And A Significant Inverse Correlation Between Fmd At Admission And Lohs (R = - 0.7543; P < 0.001). There Is A Significant Improvement Of B-Fmd During Hospitalization In Patients Admitted For Tako-Tsubo Cardiomyopathy. Moreover, For The First Time, A Direct Correlation Among B-Fmd, Troponin I Peak And Lohs Has Been Detected.|[('Takotsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Characterized', 'no label'), ('Transient Systolic Ventricular Dysfunction', 'no label'), ('Supposed', 'no label'), ('Cathecolaminergic Wave', 'no label'), ('Myocardial Stunning', 'no label'), ('Massive Action', 'no label'), ('Beta2-Adrenoreceptor', 'no label'), ('Beta2-Receptor Hyperactivity', 'no label'), ('Influences', 'no label'), ('Endothelial Function', 'no label'), ('Detected', 'no label'), ('Brachial Flow Mediated Dilation', 'no label'), ('B-Fmd', 'no label'), ('Assesses', 'no label'), ('Endothelium', 'no label'), ('Regulated Vasomotility', 'no label'), ('Study', 'no label'), ('Analyze', 'no label'), ('B-Fmd', 'no label'), ('Variability', 'no label'), ('Hospitalization', 'no label'), ('Patients', 'no label'), ('Admitted With', 'no label'), ('Ttc', 'no label'), ('Investigated', 'no label'), ('Correlation', 'no label'), ('B-Fmd', 'no label'), ('Admission', 'no label'), ('Length Of Hospital Stay', 'no label'), ('Lohs', 'no label'), ('Troponin I', 'no label'), ('Peak', 'no label'), ('Detected', 'no label'), ('Measuring', 'no label'), ('Hypoxic', 'no label'), ('Induced', 'no label'), ('Vasoreactivity', 'no label'), ('Brachial Artery', 'no label'), ('Dilation', 'no label'), ('Min', 'no label'), ('Iatrogenic', 'no label'), ('Ischemia', 'no label'), ('Obtained', 'no label'), ('Inflating A', 'no label'), ('Sphygmomanometer Cuff', 'no label'), ('Artery Diameter Modifications', 'no label'), ('Assessed', 'no label'), ('High-Resolution Ultrasound', 'no label'), ('Percentage', 'no label'), ('Dilation', 'no label'), ('Ischemia', 'no label'), ('Basal', 'no label'), ('Values', 'no label'), ('Measured', 'no label'), ('Admission', 'no label'), ('Discharge', 'no label'), ('Values', 'no label'), ('Patient', 'no label'), ('Variability', 'no label'), ('Hospitalization', 'no label'), ('Correlation', 'no label'), ('B-Fmd', 'no label'), ('Admission', 'no label'), ('Troponin I', 'no label'), ('Peak', 'no label'), ('Lohs Was', 'no label'), ('Investigated', 'no label'), ('Statistical Significant Difference', 'no label'), ('Mean', 'no label'), ('Fmd', 'no label'), ('Measured', 'no label'), ('Admission', 'no label'), ('Discharge', 'no label'), ('Significant', 'no label'), ('Negative', 'no label'), ('Correlation', 'no label'), ('Troponin I', 'no label'), ('Peak', 'no label'), ('Fmd', 'no label'), ('Values', 'no label'), ('Admission', 'no label'), ('Significant', 'no label'), ('Inverse', 'no label'), ('Correlation', 'no label'), ('Fmd', 'no label'), ('Admission', 'no label'), ('Significant', 'no label'), ('Improvement', 'no label'), ('B-Fmd', 'no label'), ('Hospitalization', 'no label'), ('Patients', 'no label'), ('Admitted', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('First Time', 'no label'), ('Correlation', 'no label'), ('B-Fmd', 'no label'), ('Troponin I', 'no label'), ('Peak', 'no label'), ('Detected', 'no label')]|[('Cathecolaminergic', 'no label'), ('B-Fmd', 'no label'), ('Fmd', 'no label'), ('Fmd', 'no label'), ('Fmd', 'no label'), ('Troponin I', 'no label')]|[('B-Fmd', 'no label'), ('Troponin I', 'no label'), ('B-Fmd', 'no label'), ('B-Fmd', 'no label'), ('Troponin I', 'no label'), ('Troponin I', 'no label'), ('B-Fmd', 'no label'), ('Troponin I', 'no label')]|[('Takotsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Myocardial Stunning', 'no label'), ('Hyperactivity', 'no label'), ('Ischemia', 'no label'), ('Ischemia', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Wave', 'no label'), ('Myocardial', 'no label'), ('Beta2-Receptor Hyperactivity', 'no label'), ('Endothelial', 'no label'), ('Endothelium', 'no label'), ('Patients', 'no label'), ('Troponin I', 'no label'), ('Brachial Artery Dilation', 'no label'), ('Troponin I', 'no label'), ('Fmd', 'no label'), ('Troponin I', 'no label'), ('Fmd', 'no label'), ('Fmd', 'no label'), ('Patients', 'no label'), ('Troponin I', 'no label')]
tako-tsubo cardiomyopathy|pubmed~27060130|Tako-Tsubo Cardiomyopathy (Ttc) Is A Syndrome Characterized By Acute Transient Ventricular Dysfunction In The Absence Of Obstructive Coronary Artery Disease And Is Predominantly Associated With Exposure To Sudden Emotional Or Physical Stress. Patients With Ttc May Develop Serious In-Hospital Complications, Including Ventricular Arrhythmias. However, Triggering Of Ttc After An Electrical Storm Has Not Previously Been Described. We Present Two Cases Of Ttc Induced By Multiple Shocks In The Setting Of An Electrical Storm Due To Pharmacologically Induced Long Qt Syndrome.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Syndrome', 'no label'), ('Characterized', 'no label'), ('Acute Transient Ventricular Dysfunction', 'no label'), ('Absence', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Associated With', 'no label'), ('Exposure To', 'no label'), ('Sudden', 'no label'), ('Emotional Or Physical Stress', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Serious In-Hospital', 'no label'), ('Complications', 'no label'), ('Ventricular Arrhythmias', 'no label'), ('Triggering', 'no label'), ('Ttc', 'no label'), ('Electrical Storm', 'no label'), ('Cases', 'no label'), ('Ttc', 'no label'), ('Induced', 'no label'), ('Multiple Shocks', 'no label'), ('Electrical Storm', 'no label'), ('Pharmacologically', 'no label'), ('Induced', 'no label'), ('Long Qt Syndrome', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Ventricular Arrhythmias', 'no label'), ('Long Qt Syndrome', 'no label')]|[('Ventricular', 'no label'), ('Coronary Artery', 'no label'), ('Patients', 'no label'), ('Ventricular', 'no label')]
tako-tsubo cardiomyopathy|pubmed~26958041|To Report A Case Of Tako-Tsubo Cardiomyopathy In A Blind Woman. We Report A Confirmed Case Of Tako-Tsubo Cardiomyopathy In A 55-Year-Old Blind Woman With Past Medical History Of Ocular Trauma. The Patient Suffered From Sudden Chest Pain After A Quarrel. Transthoracic Echocardiogram (Tte) Showed Regional Wall Motion Abnormalities. Coronary Angiogram Showed No Significant Coronary Stenosis, But Ventriculogram Demonstrated Apical Ballooning Akinesis And Hypercontraction In The Basal Segments. The Follow-Up Tte Revealed A Recovery Of Systolic Function 6 Weeks Later. We Report A Case Of Tako-Tsubo Cardiomyopathy After A Quarrel, Implicating That Severe Emotional Or Physical Stress Could Trigger Myocardial Stunning.|[('Report', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Blind', 'no label'), ('Woman', 'no label'), ('Report', 'no label'), ('Confirmed', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Blind', 'no label'), ('Woman', 'no label'), ('Past Medical History', 'no label'), ('Ocular Trauma', 'no label'), ('Patient', 'no label'), ('Suffered', 'no label'), ('Sudden Chest Pain', 'no label'), ('Quarrel', 'no label'), ('Transthoracic Echocardiogram', 'no label'), ('Tte', 'no label'), ('Regional Wall Motion Abnormalities', 'no label'), ('Coronary Angiogram', 'no label'), ('No Significant', 'no label'), ('Coronary Stenosis', 'no label'), ('Ventriculogram', 'no label'), ('Apical Ballooning', 'no label'), ('Akinesis', 'no label'), ('Hypercontraction', 'no label'), ('Basal Segments', 'no label'), ('Follow-Up', 'no label'), ('Tte', 'no label'), ('Revealed', 'no label'), ('Recovery', 'no label'), ('Systolic Function', 'no label'), ('Weeks', 'no label'), ('Report', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Quarrel', 'no label'), ('Implicating', 'no label'), ('Severe', 'no label'), ('Emotional Or Physical Stress', 'no label'), ('Myocardial', 'no label'), ('Stunning', 'no label')]|[('Apical', 'no label'), ('Tte', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ocular Trauma', 'no label'), ('Chest Pain', 'no label'), ('Coronary Stenosis', 'no label'), ('Ventriculogram', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Myocardial Stunning', 'no label')]|[('Ocular Trauma', 'no label'), ('Wall', 'no label'), ('Apical', 'no label'), ('Basal Segments.', 'no label'), ('Follow-Up Tte', 'no label'), ('Myocardial', 'no label')]
tako-tsubo cardiomyopathy|pubmed~27863368|To Jointly Describe Clinical Characteristics, Ecg And Echocardiographic Findings, And Adverse Cardiovascular Events In Patients With Tako-Tsubo Cardiomyopathy (Tc) In The Long-Term. Longitudinal Multicenter Study Including Retrospective Analysis Of Clinical And Ecg Data, And Follow-Up Evaluation With Clinical Interview, Electrocardiogram And Echocardiogram. Data From 66 Cases Of Tc Were Available For Analysis Of Clinical And Adverse Cardiovascular Events, And 56 Of Them Completed The Follow-Up Visit Including Electrocardiogram And Echocardiogram. Most Patients (97%) Were Asymptomatic Or Oligosymptomatic (Nyha I [58%] Or Ii [39%], Respectively) At Follow-Up (Median Time: 3.7 [1.8-6.6] Years). The Vast Majority Of Individual Qrs Complex And Repolarization Abnormalities Had Disappeared (87% With No Ecg Abnormalities At Follow-Up). On Echocardiography, Left Ventricular Ejection Fraction Was ≥50% In All Patients (Mean: 63±6%). Wall Motion Abnormalities Were Observed In 4 Patients (7%; 3 With Apical Wall Motion Abnormalities And 1 With Mild Global Hypokinesia). Long-Term Outcomes Were As Follows: 4 Deaths (6%), 2 Cardiovascular And 2 Non-Cardiovascular; No Atrial Fibrillation Development; No Stroke Events; 5 Acute Recurrence Events Of Tc (8%). Globally, 57 Patients (86%) Had A Clinical Course Free From Adverse Cardiovascular Events. After A Long Period Following The Admission Event, Patients Discharged From Tc Remain Asymptomatic Or Minimally Symptomatic, And Feature A Low Prevalence Of Both Ecg And Left Ventricular Wall Motion Abnormalities; Moreover, The Latter Lead To A Very Mild Impairment Of Ejection Fraction. Among Cardiovascular Adverse Events, Recurrence Of The Tc Event Appears To Play The Most Significant Role.|[('Jointly', 'no label'), ('Clinical Characteristics', 'no label'), ('Ecg', 'no label'), ('Echocardiographic Findings', 'no label'), ('Adverse', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tc', 'no label'), ('Long-Term', 'no label'), ('Longitudinal Multicenter Study', 'no label'), ('Retrospective Analysis', 'no label'), ('Clinical And Ecg Data', 'no label'), ('Follow-Up', 'no label'), ('Evaluation', 'no label'), ('Clinical Interview', 'no label'), ('Electrocardiogram', 'no label'), ('Echocardiogram', 'no label'), ('Data', 'no label'), ('Cases', 'no label'), ('Tc', 'no label'), ('Available', 'no label'), ('Analysis', 'no label'), ('Clinical And Adverse', 'no label'), ('Completed', 'no label'), ('Follow-Up Visit', 'no label'), ('Electrocardiogram', 'no label'), ('Echocardiogram', 'no label'), ('Patients', 'no label'), ('Asymptomatic', 'no label'), ('Oligosymptomatic', 'no label'), ('Nyha I', 'no label'), ('Follow-Up', 'no label'), ('Median Time', 'no label'), ('Years', 'no label'), ('Qrs Complex', 'no label'), ('Repolarization Abnormalities', 'no label'), ('Disappeared', 'no label'), ('No Ecg Abnormalities', 'no label'), ('Follow-Up', 'no label'), ('Echocardiography', 'no label'), ('Left Ventricular Ejection Fraction', 'no label'), ('Patients', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Observed', 'no label'), ('Patients', 'no label'), ('Apical Wall Motion Abnormalities', 'no label'), ('Mild Global Hypokinesia', 'no label'), ('Long-Term Outcomes', 'no label'), ('Deaths', 'no label'), ('Cardiovascular', 'no label'), ('Atrial Fibrillation Development', 'no label'), ('No Stroke Events', 'no label'), ('Acute Recurrence Events', 'no label'), ('Tc', 'no label'), ('Patients', 'no label'), ('Clinical Course', 'no label'), ('Free', 'no label'), ('Adverse Cardiovascular Events', 'no label'), ('Long Period', 'no label'), ('Admission Event', 'no label'), ('Patients', 'no label'), ('Tc', 'no label'), ('Remain', 'no label'), ('Asymptomatic', 'no label'), ('Minimally', 'no label'), ('Symptomatic', 'no label'), ('Feature A', 'no label'), ('Low', 'no label'), ('Prevalence', 'no label'), ('Ecg', 'no label'), ('Left Ventricular Wall Motion Abnormalities', 'no label'), ('Latter Lead', 'no label'), ('Very Mild Impairment', 'no label'), ('Ejection Fraction', 'no label'), ('Cardiovascular Adverse Events', 'no label'), ('Recurrence', 'no label'), ('Tc', 'no label'), ('Event', 'no label'), ('Appears', 'no label'), ('Significant', 'no label')]|[('Ii', 'no label'), ('Lead To', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Repolarization Abnormalities', 'no label'), ('Disappeared', 'no label'), ('Left Ventricular Ejection Fraction Was ≥50% In All Patients (Mean: 63±6%).', 'no label'), ('Hypokinesia', 'no label'), ('Deaths', 'no label'), ('Atrial Fibrillation', 'no label'), ('Stroke', 'no label'), ('Ventricular Wall Motion Abnormalities', 'no label'), ('Cardiovascular Adverse Events, Recurrence Of The Tc Event Appears To Play The Most Significant Role.', 'no label')]|[('Cardiovascular', 'no label'), ('Patients', 'no label'), ('Cardiovascular', 'no label'), ('Patients', 'no label'), ('Nyha I', 'no label'), ('Ecg Abnormalities', 'no label'), ('Left Ventricular', 'no label'), ('Patients', 'no label'), ('Wall', 'no label'), ('Patients', 'no label'), ('Wall', 'no label'), ('Tc (8', 'no label'), ('Patients', 'no label'), ('Cardiovascular', 'no label'), ('Patients', 'no label'), ('Ecg', 'no label'), ('Left Ventricular Wall', 'no label'), ('A', 'no label'), ('Cardiovascular', 'no label')]
tako-tsubo cardiomyopathy|pubmed~30554740|An Association Between Tako-Tsubo Cardiomyopathy (Ttc) And Underlying Malignancies Has Been Observed, Suggesting That Ttc Might Be The Consequence Of Paraneoplastic Phenomena. This Study Investigates The Presence Of Autoantibodies Against Cardiomyocytes As Well As Adrenergic (Β<Sub>1</Sub>, Β<Sub>2</Sub>) And Muscarinic (M2) Receptors In Patients With Ttc. Serum From 20 Ttc Patients And 20 Controls With Ischemic Heart Disease Was Obtained. Indirect Immunofluorescence Testing For Intracellular Autoantibodies Against Cardiomyocytes Showed A Homogenous Distribution, As In Both Groups 9 Of 20 Sera Displayed A Characteristic Binding Pattern Of Antibodies Including Vascular Walls And Intracellular Structures. Flow Cytometry Analysis Revealed No Difference Between Ttc And Controls In The Binding Of Autoantibodies To The Surface Antigens Of Cardiomyocyte Hl-1 Cells (P = 0.569, T-Test). Flow Cytometry Analysis Of Nontransfected Wild Type Cells (P = 0.633, T-Test), M2 Receptor-Transfected Cells (P = 0.687, T-Test), Β<Sub>1</Sub> Receptor-Transfected Cells (P = 0.444, T-Test) And Β<Sub>2</Sub> Receptor-Transfected Cells (P = 0.632, T-Test) Showed Similar Results For Control And Ttc Sera. Likewise, The Binding Pattern Of Ttc Patients With A History Of Neoplasia Compared To Those Without Or To Controls Did Not Differ Significantly (P > 0.05, U-Test). Findings Suggest That The Presumed Paraneoplastic Etiology Of Ttc Cannot Be Attributed To The Formation Of These Antibodies.|[('Association', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Malignancies', 'no label'), ('Observed', 'no label'), ('Suggesting', 'no label'), ('Ttc', 'no label'), ('Consequence', 'no label'), ('Paraneoplastic Phenomena', 'no label'), ('Study Investigates', 'no label'), ('Presence', 'no label'), ('Autoantibodies', 'no label'), ('Against', 'no label'), ('Cardiomyocytes', 'no label'), ('Adrenergic', 'no label'), ('Muscarinic (M2) Receptors', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Serum', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Ischemic Heart Disease', 'no label'), ('Indirect Immunofluorescence Testing', 'no label'), ('Intracellular', 'no label'), ('Autoantibodies', 'no label'), ('Cardiomyocytes', 'no label'), ('Homogenous', 'no label'), ('Distribution', 'no label'), ('Groups', 'no label'), ('Sera', 'no label'), ('Characteristic', 'no label'), ('Binding Pattern', 'no label'), ('Antibodies', 'no label'), ('Vascular Walls', 'no label'), ('Intracellular', 'no label'), ('Structures', 'no label'), ('Flow Cytometry Analysis', 'no label'), ('Revealed', 'no label'), ('No Difference', 'no label'), ('Ttc', 'no label'), ('Controls', 'no label'), ('Binding', 'no label'), ('Autoantibodies', 'no label'), ('Surface Antigens', 'no label'), ('Cardiomyocyte Hl-1 Cells', 'no label'), ('T-Test', 'no label'), ('Flow Cytometry Analysis', 'no label'), ('Nontransfected', 'no label'), ('Wild Type Cells', 'no label'), ('T-Test', 'no label'), ('M2 Receptor-Transfected Cells', 'no label'), ('T-Test', 'no label'), ('Β<Sub>1</Sub> Receptor-Transfected Cells', 'no label'), ('T-Test', 'no label'), ('Β<Sub>2</Sub> Receptor-Transfected Cells', 'no label'), ('T-Test', 'no label'), ('Control', 'no label'), ('Ttc', 'no label'), ('Sera', 'no label'), ('Binding Pattern', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('History', 'no label'), ('Neoplasia', 'no label'), ('Controls', 'no label'), ('Differ', 'no label'), ('U-Test', 'no label'), ('Findings', 'no label'), ('Suggest', 'no label'), ('Paraneoplastic Etiology', 'no label'), ('Ttc', 'no label'), ('Attributed', 'no label'), ('Formation', 'no label'), ('Antibodies', 'no label')]|[('Autoantibodies', 'no label'), ('Cardiomyocytes', 'no label'), ('Intracellular Autoantibodies', 'no label'), ('Cardiomyocytes', 'no label'), ('Antibodies', 'no label'), ('Intracellular', 'no label'), ('Cardiomyocyte', 'no label'), ('Cells', 'no label'), ('Wild Type Cells', 'no label'), ('Cells', 'no label'), ('Cells', 'no label'), ('Cells', 'no label'), ('Antibodies', 'no label')]|[('Intracellular Autoantibodies', 'no label'), ('Autoantibodies', 'no label'), ('Surface Antigens', 'no label'), ('Cardiomyocyte Hl-1 Cells', 'no label'), ('M2 Receptor-Transfected Cells', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Malignancies', 'no label'), ('Paraneoplastic', 'no label'), ('Ischemic Heart Disease', 'no label'), ('Neoplasia', 'no label'), ('Paraneoplastic Etiology', 'no label'), ('Ttc', 'no label')]|[('Malignancies', 'no label'), ('Paraneoplastic', 'no label'), ('Autoantibodies', 'no label'), ('Cardiomyocytes', 'no label'), ('Adrenergic', 'no label'), ('Muscarinic (M2)', 'no label'), ('Patients', 'no label'), ('Serum', 'no label'), ('Patients', 'no label'), ('Heart', 'no label'), ('Intracellular Autoantibodies Against Cardiomyocytes Showed A Homogenous Distribution, As In Both Groups 9 Of', 'no label'), ('Sera', 'no label'), ('Vascular Walls', 'no label'), ('Intracellular Structures.', 'no label'), ('Surface Antigens', 'no label'), ('Cardiomyocyte Hl-1 Cells', 'no label'), ('Wild Type Cells', 'no label'), ('Cells', 'no label'), ('Cells', 'no label'), ('Cells', 'no label'), ('Ttc Sera', 'no label'), ('Patients', 'no label'), ('Neoplasia', 'no label')]
tako-tsubo cardiomyopathy|pubmed~30704132|<B>Background</B>. Though Several Studies About Prevalence, Etiology, Clinical Characteristics, Preceding Events, Clinical Management, And Outcome Of Tako-Tsubo Cardiomyopathy (Ttc) Exist, The Current Knowledge Of Ttc Remains Limited. <B>Objective</B>. In 2006, Ttc Was Classified Among The Acquired Forms Of Cardiomyopathy. On The Basis Of Pathophysiological Implications, We Analyzed Whether The Presence Of St-Segment Elevation In Lead -Avr (I.E., St-Segment Depression In Avr) And The Simultaneous Absence Of St-Segment Elevation In Lead V1 Allow A Reliable Differentiation Of Ttc From Acute Anterior St-Segment Elevation Myocardial Infarction (Stemi). A Further Investigative Feature Is The Seasonal Variation Of Ttc. Since Acute Cardiovascular Events Exhibit Definite Chronobiological Patterns, Various Small Studies Have Tried To Evaluate Whether This Is Also The Case For Ttc. Because Results Are Conflicting, We Also Conducted A Multicenter Study And Analyzed The Findings In Context With A Systematic Overview Of Available Studies. <B>Methods</B>. We Compared The Ecg Patterns Of 115 Patients With Ttc, Who Were Admitted To Five Large Acute Cardiac Care Centers Associated With University Hospitals In Southwestern Germany Between January 2001 And June 2011, With Those Of 100 Patients With Acute Anterior St-Segment Elevation Myocardial Infarction (Stemi) Treated In One Of These Centers. In Addition, We Performed A Computer-Assisted Medline Search Of The Literature From January 2000 To September 2011 And Analyzed The Chronobiological Patterns Of Available Ttc Cases, Including Our Ttc Cohort. <B>Results</B>. Testing The Predefined Diagnostic Criteria Was Superior To Any Other Electrocardiographic Finding And Differentiated Ttc From Anterior Stemi With A Sensitivity Of 73%, A Specificity Of 84%, A Positive Predictive Value Of 63%, And A Negative Predictive Value Of 89%. Beyond That, The Onset Of Ttc Showed A Clear Variation As A Function Of Season And Month. While Events Occurred Most Frequently During Summer (38.4%, <I>P</I> < 0.01), The Event Rate Was The Lowest In Autumn (16.4%) And Winter (21.9%). Chronobiological Analyses On A Monthly Basis Identified A Significant Annual Rhythmic Pattern In Ttc, Which Peaked In August (11.9%; <I>P</I> < 0.01) And Had Its Nadir In November (6.3%). <B>Conclusions</B>. Our Data Illustrate That The St-Segment Changes In Leads Avr And V1 Represent A Simple And Accurate Ecg Criterion To Differentiate Ttc From Anterior Stemi In Patients Who Are Admitted Within 12 H Of Symptom Onset. Similarly, The Results Of Our Seasonal Analysis Indicate A Distinct Chronobiological Variation In Ttc Occurrence. Ttc, Thereby, Differs From Major Acute Cardiovascular Diseases, Especially Acute Myocardial Infarction (Ami), Which Is Characterized By Winter Peaks And Troughs In Summer. If These Results Are Confirmed In Large Independent Cohorts, They May Yield Diagnostic Implications, Changing The Regular Invasive Ami Management In Ttc Patients.|[('Studies', 'no label'), ('Prevalence', 'no label'), ('Etiology', 'no label'), ('Clinical Characteristics', 'no label'), ('Preceding Events', 'no label'), ('Clinical Management', 'no label'), ('Outcome', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Exist', 'no label'), ('Knowledge', 'no label'), ('Ttc', 'no label'), ('Ttc', 'no label'), ('Acquired Forms', 'no label'), ('Cardiomyopathy', 'no label'), ('Pathophysiological', 'no label'), ('Implications', 'no label'), ('Analyzed', 'no label'), ('Presence', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Lead', 'no label'), ('St-Segment', 'no label'), ('Depression', 'no label'), ('Avr', 'no label'), ('Simultaneous', 'no label'), ('Absence', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Lead V1', 'no label'), ('Allow A', 'no label'), ('Differentiation', 'no label'), ('Ttc', 'no label'), ('Acute Anterior St-Segment Elevation Myocardial Infarction', 'no label'), ('Stemi', 'no label'), ('Seasonal Variation', 'no label'), ('Ttc', 'no label'), ('Acute Cardiovascular Events', 'no label'), ('Chronobiological Patterns', 'no label'), ('Small Studies', 'no label'), ('Evaluate', 'no label'), ('Ttc', 'no label'), ('Results', 'no label'), ('Conflicting', 'no label'), ('Multicenter Study', 'no label'), ('Analyzed', 'no label'), ('Findings', 'no label'), ('Context', 'no label'), ('Systematic Overview', 'no label'), ('Available Studies', 'no label'), ('Ecg Patterns', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Admitted', 'no label'), ('Acute Cardiac Care', 'no label'), ('Associated With', 'no label'), ('University Hospitals', 'no label'), ('Southwestern Germany', 'no label'), ('January', 'no label'), ('Patients', 'no label'), ('Acute Anterior St-Segment Elevation Myocardial Infarction', 'no label'), ('Stemi', 'no label'), ('Treated', 'no label'), ('Centers', 'no label'), ('Performed', 'no label'), ('Computer-Assisted Medline', 'no label'), ('Literature', 'no label'), ('Analyzed', 'no label'), ('Chronobiological Patterns', 'no label'), ('Available Ttc', 'no label'), ('Cases', 'no label'), ('Ttc', 'no label'), ('Cohort', 'no label'), ('Testing', 'no label'), ('Predefined Diagnostic Criteria', 'no label'), ('Electrocardiographic Finding', 'no label'), ('Differentiated Ttc', 'no label'), ('Anterior Stemi With A', 'no label'), ('Sensitivity', 'no label'), ('Specificity', 'no label'), ('Positive Predictive Value', 'no label'), ('Negative Predictive Value', 'no label'), ('Ttc', 'no label'), ('Variation', 'no label'), ('Function', 'no label'), ('Season', 'no label'), ('Month', 'no label'), ('Events', 'no label'), ('Summer', 'no label'), ('Event Rate', 'no label'), ('Lowest', 'no label'), ('Autumn', 'no label'), ('Winter', 'no label'), ('Chronobiological Analyses', 'no label'), ('Monthly', 'no label'), ('Basis', 'no label'), ('Identified', 'no label'), ('Significant', 'no label'), ('Annual', 'no label'), ('Rhythmic Pattern', 'no label'), ('Ttc', 'no label'), ('Peaked', 'no label'), ('Nadir', 'no label'), ('Data Illustrate', 'no label'), ('St-Segment', 'no label'), ('Changes', 'no label'), ('Leads Avr', 'no label'), ('Represent', 'no label'), ('Accurate', 'no label'), ('Ecg Criterion', 'no label'), ('Differentiate Ttc', 'no label'), ('Anterior Stemi', 'no label'), ('Patients', 'no label'), ('Admitted', 'no label'), ('Seasonal Analysis', 'no label'), ('Indicate', 'no label'), ('Chronobiological', 'no label'), ('Variation', 'no label'), ('Ttc', 'no label'), ('Ttc', 'no label'), ('Differs', 'no label'), ('Acute Cardiovascular Diseases', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Characterized', 'no label'), ('Winter', 'no label'), ('Peaks', 'no label'), ('Troughs', 'no label'), ('Summer', 'no label'), ('Results', 'no label'), ('Confirmed', 'no label'), ('Independent', 'no label'), ('Cohorts', 'no label'), ('Yield Diagnostic', 'no label'), ('Implications', 'no label'), ('Regular Invasive Ami', 'no label'), ('Management', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label')]|[('Lead', 'no label'), ('St-Segment Depression In Avr', 'no label')]|[('V1', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Cardiomyopathy', 'no label'), ('St-Segment Depression', 'no label'), ('Myocardial Infarction', 'no label'), ('Myocardial Infarction', 'no label'), ('Acute Cardiovascular Diseases', 'no label'), ('Myocardial Infarction', 'no label')]|[('B', 'no label'), ('Background</B>.', 'no label'), ('B', 'no label'), ('Lead -Avr', 'no label'), ('Avr', 'no label'), ('Lead V1', 'no label'), ('Myocardial', 'no label'), ('Acute Cardiovascular', 'no label'), ('B', 'no label'), ('Patients', 'no label'), ('Acute Cardiac Care Centers', 'no label'), ('Patients', 'no label'), ('Acute Anterior St-Segment', 'no label'), ('Myocardial', 'no label'), ('B', 'no label'), ('B', 'no label'), ('Avr And V1', 'no label'), ('Patients', 'no label'), ('Acute Cardiovascular', 'no label'), ('Myocardial', 'no label'), ('Regular Invasive Ami', 'no label'), ('Ttc Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~34998160|Myocardial Dysfunction Is A Known Complication In Patients Who Experience Severe Stressful Events, Such As Traumatic Brain Injuries (Tbi). One Common Manifestation Is Takotsubo Cardiomyopathy (Tc) Which Can Appear Concomitantly In Patients With Haemorrhagic Brain Injuries. There Is Often A Management Dilemma When Two Conditions With Conflicting Treatment Regimens Arise In The Same Individual. Previous Systematic Review Had Highlighted The Importance Of Accurate Diagnosis But There Is No Algorithm To Aid Decision-Making In An Emergency Trauma Setting. A Systematic Review Was Performed With The Aim Of Establishing A New Algorithm To Aid In The Diagnosis And Management Of Tc Patients With Concurrent Tbi. We Performed A Comprehensive Search Of Pubmed, Google Scholar, Embase And Cochrane Databases Using Keywords 'Traumatic Brain Injury' And 'Head Injury' Associated With Keywords Of 'Takotsubo Cardiomyopathy,' 'Tako-Tsubo Cardiomyopathy,' 'Stress Cardiomyopathy,' 'Stunned Myocardium,' 'Transient-Left-Ventricular Ballooning Syndrome,' 'Apical Ballooning Syndrome,' 'Myocardial Dysfunction' Or 'Heart Failure'. Non Traumatic Brain Injury, Blunt Cardiac Injury Or Cardiac Events From Chest Trauma Were Excluded. The Search Was Done Between 1St To 4Th October 2020 And Only Articles Published After The Year 2000 In English Were Included. Articles Were Then Analysed In-Depth. No Articles Were Excluded After Analysis To Remove Reporting Bias. A Total Of 11 Case Reports And 7 Cohort Studies Were Analysed, Giving A Total Number Of 382 Patients, With 36% Of The Patients Analysed Presenting With Subdural Haematoma, 27% With Subarachnoid Haemorrhage And 5% With Extradural Haematoma. Of The Patients Who Underwent Surgical Interventions For Traumatic Brain Injuries, 75% Survived. 9% Of Patients In Total Were Reported To Have An Ef Of Less Than 55% Whereas 51% Had An Ef Of Equal To Or More Than 55%. Tte Details Were Not Reported In A Total Of 35% Of Patients. All Case Reports Which Had Followed Up On Their Patient'S Cardiac Status With Repeated Echocardiography Had Demonstrated A Resolution Of Cardiac Function Independent Of Cardiac Intervention. Our Analysis Was Limited By The Fact That Not All Papers Analysed Had Reported The Parameters We Required. However, Based On Our Review, We Conclude That Most Patients With Tc Demonstrate A Resolution Of Cardiac Function Independent Of Cardiac Interventions From As Fast As A Few Hours To As Long As 6-12 Weeks. Therefore, Despite High Cardiac Risks, If Neurosurgical Intervention Is Needed, It Should Be Offered To Improve The Chance Of Survival As Transient Cardiomyopathy Can Be Supported With Inotropes. We Have Developed A New Algorithm For Management Of Cases Of Concurrent Tbi And Tc.|"[('Myocardial Dysfunction', 'no label'), ('Complication', 'no label'), ('Patients', 'no label'), ('Experience Severe Stressful Events', 'no label'), ('Traumatic Brain Injuries', 'no label'), ('Tbi', 'no label'), ('Manifestation', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Tc', 'no label'), ('Patients', 'no label'), ('Haemorrhagic Brain Injuries', 'no label'), ('Management', 'no label'), ('Conditions', 'no label'), ('Conflicting Treatment', 'no label'), ('Arise', 'no label'), ('Individual', 'no label'), ('Systematic Review', 'no label'), ('Accurate', 'no label'), ('Diagnosis', 'no label'), ('No Algorithm', 'no label'), ('Emergency Trauma Setting', 'no label'), ('Systematic Review', 'no label'), ('Performed', 'no label'), ('New Algorithm', 'no label'), ('Diagnosis', 'no label'), ('Management', 'no label'), ('Tc', 'no label'), ('Patients', 'no label'), ('Concurrent', 'no label'), ('Tbi', 'no label'), ('Performed', 'no label'), ('Comprehensive', 'no label'), ('Search', 'no label'), ('Pubmed', 'no label'), ('Google Scholar', 'no label'), ('Embase', 'no label'), ('Cochrane Databases', 'no label'), ('Keywords', 'no label'), ('Traumatic Brain Injury', 'no label'), ('Associated With', 'no label'), ('Keywords', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Stunned', 'no label'), ('Transient-Left-Ventricular Ballooning Syndrome', 'no label'), ('Apical Ballooning Syndrome', 'no label'), ('Myocardial Dysfunction', 'no label'), ('Non Traumatic Brain Injury', 'no label'), ('Blunt Cardiac Injury', 'no label'), ('Cardiac Events', 'no label'), ('Chest Trauma', 'no label'), ('Search', 'no label'), ('Articles', 'no label'), ('Published', 'no label'), ('Year', 'no label'), ('English', 'no label'), ('Articles', 'no label'), ('Analysed', 'no label'), ('No Articles', 'no label'), ('Analysis', 'no label'), ('Remove Reporting', 'no label'), ('Bias', 'no label'), ('Case Reports', 'no label'), ('Cohort Studies', 'no label'), ('Analysed', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Analysed', 'no label'), ('Subdural Haematoma', 'no label'), ('Subarachnoid Haemorrhage', 'no label'), ('Extradural Haematoma', 'no label'), ('Patients', 'no label'), ('Surgical Interventions', 'no label'), ('Traumatic Brain Injuries', 'no label'), ('Survived', 'no label'), ('Patients', 'no label'), ('Ef', 'no label'), ('Ef', 'no label'), ('Equal', 'no label'), ('Tte', 'no label'), ('Details', 'no label'), ('Patients', 'no label'), ('Case Reports', 'no label'), ('Followed Up', 'no label'), (""Patient'S"", 'no label'), ('Cardiac Status', 'no label'), ('Repeated', 'no label'), ('Echocardiography', 'no label'), ('Resolution', 'no label'), ('Cardiac Function', 'no label'), ('Independent', 'no label'), ('Cardiac Intervention', 'no label'), ('Analysis', 'no label'), ('Fact', 'no label'), ('Papers', 'no label'), ('Analysed', 'no label'), ('Parameters', 'no label'), ('Review', 'no label'), ('Conclude', 'no label'), ('Patients', 'no label'), ('Tc', 'no label'), ('Demonstrate', 'no label'), ('Resolution', 'no label'), ('Cardiac Function', 'no label'), ('Independent', 'no label'), ('Cardiac Interventions', 'no label'), ('Fast', 'no label'), ('Weeks', 'no label'), ('Cardiac', 'no label'), ('Risks', 'no label'), ('Neurosurgical Intervention', 'no label'), ('Chance', 'no label'), ('Survival', 'no label'), ('Transient Cardiomyopathy', 'no label'), ('Inotropes', 'no label'), ('New Algorithm', 'no label'), ('Management', 'no label'), ('Cases', 'no label'), ('Concurrent', 'no label'), ('Tbi', 'no label'), ('Tc', 'no label')]"|[]|[('Tte', 'no label')]|"[('Myocardial Dysfunction', 'no label'), ('Traumatic Brain Injuries', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Brain Injuries', 'no label'), ('Trauma', 'no label'), (""Traumatic Brain Injury' And 'Head Injury'"", 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Cardiomyopathy', 'no label'), ('Ballooning Syndrome', 'no label'), ('Ballooning Syndrome', 'no label'), ('Myocardial Dysfunction', 'no label'), ('Heart Failure', 'no label'), ('Traumatic Brain Injury', 'no label'), ('Cardiac Injury Or Cardiac Events', 'no label'), ('Chest Trauma', 'no label'), ('Subdural Haematoma', 'no label'), ('Subarachnoid Haemorrhage', 'no label'), ('Extradural Haematoma', 'no label'), ('Traumatic Brain Injuries', 'no label'), ('Echocardiography', 'no label'), ('Cardiomyopathy', 'no label')]"|[('Myocardial', 'no label'), ('Patients', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('Brain', 'no label'), ('Head Injury', 'no label'), ('Myocardial', 'no label'), ('Heart', 'no label'), ('Brain', 'no label'), ('Cardiac', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Subdural', 'no label'), ('Subarachnoid', 'no label'), ('Extradural Haematoma', 'no label'), ('Patients', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cardiac', 'no label'), ('Cardiac', 'no label'), ('Cardiac', 'no label'), ('Conclude', 'no label'), ('Patients', 'no label'), ('Tc Demonstrate A', 'no label'), ('Cardiac', 'no label'), ('Cardiac', 'no label'), ('Cardiac', 'no label')]
tako-tsubo cardiomyopathy|pubmed~28648424|In Clinical Practice, Dynamic Left Ventricular Outflow Tract Obstruction (Lvoto) In The Setting Of Tako-Tsubo Cardiomyopathy (Ttc) Has Been Regarded As An Early-Onset Complication Typically Emerging In Accordance With Wall Motion Abnormalities. However, Dynamic Lvoto Has, Very Rarely, Been Reported As A Late-Onset Phenomenon In The Setting Of Ttc As Well (Arising In The Late Stage Or After Recovery). Accordingly, The Present Paper Aims To Highlight Clinical Relevance And Potential Implications Of Late-Onset Lvoto In The Setting Of Ttc.|[('Clinical Practice', 'no label'), ('Dynamic Left Ventricular Outflow Tract Obstruction', 'no label'), ('Lvoto', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Early-Onset', 'no label'), ('Complication', 'no label'), ('Accordance', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Dynamic Lvoto', 'no label'), ('Very Rarely', 'no label'), ('Late-Onset', 'no label'), ('Phenomenon', 'no label'), ('Ttc', 'no label'), ('Late Stage', 'no label'), ('Recovery', 'no label'), ('Present Paper', 'no label'), ('Clinical', 'no label'), ('Relevance', 'no label'), ('Late-Onset', 'no label'), ('Lvoto', 'no label'), ('Ttc', 'no label')]|[]|[]|[('Left Ventricular Outflow Tract Obstruction', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label')]|[('Left Ventricular Outflow', 'no label'), ('Wall', 'no label')]
tako-tsubo cardiomyopathy|pubmed~28079765|: We Report The Case Of Early Recurrence Of Tako-Tsubo Cardiomyopathy In An Elderly Woman With Amyotrophic Lateral Sclerosis Triggered By Different Stressors. A First Episode With Typical Apical Ballooning Was Anticipated By An Emotional Stress; A Second, Characterized By Systolic Anterior Motion Of The Mitral Valve Associated With Mitral Regurgitation And Severe Intra-Ventricular Gradient, Was Precipitated By Surgical Stress And Hypovolemia. We Therefore Hypothesize Both A Possible Link Between Amyotrophic Lateral Sclerosis And Tako-Tsubo Cardiomyopathy, And Between Different Stressors And Different Tako-Tsubo Patterns.|[('Early', 'no label'), ('Recurrence', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Elderly Woman', 'no label'), ('Amyotrophic Lateral Sclerosis', 'no label'), ('Triggered', 'no label'), ('Stressors', 'no label'), ('Episode', 'no label'), ('Typical', 'no label'), ('Apical Ballooning', 'no label'), ('Anticipated', 'no label'), ('Emotional Stress', 'no label'), ('Characterized', 'no label'), ('Systolic Anterior', 'no label'), ('Motion', 'no label'), ('Mitral Valve', 'no label'), ('Associated With', 'no label'), ('Mitral Regurgitation', 'no label'), ('Severe', 'no label'), ('Intra-Ventricular', 'no label'), ('Gradient', 'no label'), ('Precipitated', 'no label'), ('Surgical Stress', 'no label'), ('Hypovolemia', 'no label'), ('Hypothesize', 'no label'), ('Amyotrophic Lateral Sclerosis And Tako-Tsubo Cardiomyopathy', 'no label'), ('Stressors', 'no label'), ('Tako-Tsubo Patterns', 'no label')]|[('Apical', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Mitral Regurgitation', 'no label'), ('Hypovolemia', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo', 'no label')]|[('Apical', 'no label'), ('Mitral Valve', 'no label'), ('Mitral', 'no label'), ('Link', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23079608|To Describe The Actual Incidence, Prevalence Among Acute Coronary Syndrome Patients And Rate Of Recurrences Of Tako-Tsubo Cardiomyopathy In An Emergency Department Of A Community Hospital. We Report The In-Hospital And Long-Term Clinical Course (7.5 Years Follow-Up) Of 25 Consecutive Tako-Tsubo Cardiomyopathy Patients (Mean Age 66.8 ± 11.76 Years; F/M: 21/4) Admitted To A Community Hospital (Referring Population: 97,000 Inhabitants). The Incidence Rate Of Tako-Tsubo Cardiomyopathy Was 0.03 Cases Per 1000 Person-Years; The Prevalence Was 3.0% Among Those With Acute Coronary Syndrome And 7.6% Among St Elevation Myocardial Infarction Patients. Clinical Presentations Included Mainly Chest Pain (N = 16, 64%) And Dyspnea (N = 3, 12%). Precipitating Conditions Were Emotional (N = 10, 40%), Physical Stress (N = 5, 20%) Or Both (N = 1, 4%); No Stressors Were Recorded In Nine Patients (36%). Two Patients Died During Hospitalization (8%). At The End Of Follow-Up (Mean Time: 960.24 ± 724.34 Days), All Patients (N = 23) Were Alive And No Major Cardiovascular Events Were Observed. Five Patients Had Recurrences (22%). The Mean Time Of Recurrence Was 105.4 ± 82.92 Days And The Clinical Presentation Was Less Severe Compared With The First Event: Ecg Had Less St Involvement, Ejection Fraction Was Higher And Cardiac Injury Biomarkers Were Lower. In Our Population Incidence And Prevalence Of Tako-Tsubo Cardiomyopathy Among Acute Coronary Syndrome Patients, As Well As The Recurrence Rate Of Tako-Tsubo Cardiomyopathy, Were Higher Than Previously Reported, Suggesting That Probably This Syndrome Often Passes Undiagnosed.|[('Actual', 'no label'), ('Incidence', 'no label'), ('Prevalence', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Patients', 'no label'), ('Rate', 'no label'), ('Recurrences', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Emergency Department', 'no label'), ('Community Hospital', 'no label'), ('In-Hospital', 'no label'), ('Long-Term Clinical Course', 'no label'), ('Years Follow-Up', 'no label'), ('Consecutive', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Patients', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Community Hospital', 'no label'), ('Population', 'no label'), ('Inhabitants', 'no label'), ('Incidence Rate', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Cases', 'no label'), ('Prevalence', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('St Elevation Myocardial Infarction', 'no label'), ('Patients', 'no label'), ('Clinical Presentations', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Precipitating Conditions', 'no label'), ('Emotional (N = 10', 'no label'), ('Physical Stress', 'no label'), ('No Stressors', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Died', 'no label'), ('Hospitalization', 'no label'), ('Follow-Up', 'no label'), ('Mean Time', 'no label'), ('Days', 'no label'), ('Patients', 'no label'), ('Alive', 'no label'), ('Cardiovascular Events', 'no label'), ('Observed', 'no label'), ('Patients', 'no label'), ('Recurrences', 'no label'), ('Mean Time', 'no label'), ('Recurrence', 'no label'), ('Days', 'no label'), ('Clinical Presentation', 'no label'), ('Severe', 'no label'), ('First Event', 'no label'), ('Ecg', 'no label'), ('St', 'no label'), ('Involvement', 'no label'), ('Ejection Fraction', 'no label'), ('Cardiac Injury', 'no label'), ('Biomarkers', 'no label'), ('Population', 'no label'), ('Incidence', 'no label'), ('Prevalence', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Patients', 'no label'), ('Recurrence Rate', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Higher', 'no label'), ('Suggesting', 'no label'), ('Syndrome', 'no label'), ('Undiagnosed', 'no label')]|[]|[('724.34', 'no label')]|[('Acute Coronary Syndrome', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Myocardial Infarction', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Alive', 'no label'), ('Cardiac Injury', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Acute Coronary Syndrome Patients', 'no label'), ('Patients', 'no label'), ('Acute Coronary', 'no label'), ('St Elevation Myocardial Infarction Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cardiovascular', 'no label'), ('Patients', 'no label'), ('Cardiac', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25380951|The Etiology Of Tako-Tsubo Cardiomyopathy, Defined As A Transient Left Ventricular Dysfunction In The Absence Of Significant Coronary Artery Stenosis, Still Remains Unclear. This Syndrome Mainly Occurs In Postmenopausal Women And Is Often Associated With Emotional Stress Or Miscellaneous Diagnostic And Therapeutic Procedures. Estimated Prevalence Of Tako-Tsubo Cardiomyopathy Is Found In 1% To 2% Of Patients Presenting With Suspected Acute Coronary Syndrome. So Far There Has Been Only One Case Report Of Tako-Tsubo Cardiomyopathy In A Renal Transplant Recipient. We Describe The Case Of A 68-Year-Old Woman With A History Of Coronary Artery Disease And Coronary Artery Bypass Grafting In Whom Unspecific Transient Chest Pain And Hypotension Were Observed On The First Day After Renal Transplantation. After Transplantation, The Patient Was Anuric With Pulmonary Congestion And Toxic Tacrolimus Concentrations Were Observed. Electrocardiogram Showed Sinus Rhythm With Left Bundle Branch Block (Lbbb) That Has Not Been Described Before. Plasma Cardiac Necrosis Markers Troponin I And Creatine Kinase Mb Were Mildly Elevated. Echocardiography Showed Severe Left Ventricular Function Impairment With Characteristic Shape Of Left Ventricle. Subsequent Cardiac Catheterization Revealed The Absence Of Angiographic Evidence Of Acute Plaque Rupture Within Both Coronary Arteries And Bypass Grafts. During The Next Few Days There Was Marked Clinical Improvement With Resolution Of Lbbb And Full Recovery Of All Biochemical Parameters. On Discharge, Full Functional Recovery Of The Left Ventricle In Echocardiography Was Observed. Postulated Mechanisms Of Tako-Tsubo Cardiomyopathy Include Catecholamine Excess, Coronary Artery Spasm, And Microvascular Dysfunction. On The Other Hand Calcineurin Inhibitors Are Known Factors Causing Coronary Epicardial Endothelial Dysfunction And Negatively Affecting Vasomotor Function. Tako-Tsubo Cardiomyopathy In Patients After Renal Transplantation May Be At Least In Part A Manifestation Of Calcineurin Inhibitor Cardiotoxicity.|[('Etiology', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Transient', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Absence', 'no label'), ('Significant', 'no label'), ('Coronary Artery Stenosis', 'no label'), ('Syndrome', 'no label'), ('Occurs', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Associated With', 'no label'), ('Emotional Stress', 'no label'), ('Diagnostic', 'no label'), ('Therapeutic Procedures', 'no label'), ('Estimated Prevalence', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Patients', 'no label'), ('Suspected', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Case Report', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Renal Transplant', 'no label'), ('Recipient', 'no label'), ('History', 'no label'), ('Coronary Artery Disease', 'no label'), ('Coronary Artery', 'no label'), ('Bypass Grafting', 'no label'), ('Unspecific', 'no label'), ('Transient Chest Pain', 'no label'), ('Hypotension', 'no label'), ('Observed', 'no label'), ('Day', 'no label'), ('Renal Transplantation', 'no label'), ('Transplantation', 'no label'), ('Patient', 'no label'), ('Anuric', 'no label'), ('Pulmonary Congestion', 'no label'), ('Toxic', 'no label'), ('Tacrolimus', 'no label'), ('Concentrations', 'no label'), ('Observed', 'no label'), ('Electrocardiogram', 'no label'), ('Sinus Rhythm', 'no label'), ('Left Bundle Branch Block', 'no label'), ('Lbbb', 'no label'), ('Plasma', 'no label'), ('Cardiac Necrosis', 'no label'), ('Markers', 'no label'), ('Troponin I', 'no label'), ('Creatine Kinase', 'no label'), ('Mildly Elevated', 'no label'), ('Echocardiography', 'no label'), ('Severe', 'no label'), ('Left Ventricular Function', 'no label'), ('Characteristic', 'no label'), ('Shape', 'no label'), ('Left Ventricle', 'no label'), ('Cardiac Catheterization', 'no label'), ('Revealed', 'no label'), ('Absence', 'no label'), ('Angiographic Evidence', 'no label'), ('Acute Plaque', 'no label'), ('Rupture', 'no label'), ('Coronary Arteries', 'no label'), ('Bypass Grafts', 'no label'), ('Days', 'no label'), ('Clinical Improvement', 'no label'), ('Resolution', 'no label'), ('Lbbb', 'no label'), ('Recovery', 'no label'), ('Biochemical', 'no label'), ('Parameters', 'no label'), ('Discharge', 'no label'), ('Functional', 'no label'), ('Recovery', 'no label'), ('Left Ventricle', 'no label'), ('Echocardiography', 'no label'), ('Observed', 'no label'), ('Mechanisms', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Catecholamine', 'no label'), ('Excess', 'no label'), ('Coronary Artery Spasm', 'no label'), ('Microvascular Dysfunction', 'no label'), ('Hand Calcineurin Inhibitors', 'no label'), ('Factors', 'no label'), ('Causing', 'no label'), ('Coronary Epicardial Endothelial Dysfunction', 'no label'), ('Affecting', 'no label'), ('Vasomotor Function', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Patients', 'no label'), ('Renal Transplantation', 'no label'), ('Manifestation', 'no label'), ('Calcineurin Inhibitor', 'no label'), ('Cardiotoxicity', 'no label')]|[('Toxic Tacrolimus', 'no label'), ('Troponin I', 'no label'), ('Catecholamine', 'no label'), ('Inhibitors', 'no label'), ('Inhibitor', 'no label')]|[('Plasma Cardiac Necrosis Markers Troponin I', 'no label'), ('Calcineurin', 'no label'), ('Calcineurin', 'no label')]|[('Etiology Of', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Coronary Artery Stenosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Coronary Artery Disease And Coronary Artery Bypass Grafting In Whom Unspecific Transient', 'no label'), ('Chest Pain', 'no label'), ('Hypotension', 'no label'), ('Pulmonary Congestion', 'no label'), ('Tacrolimus', 'no label'), ('Left Bundle Branch Block', 'no label'), ('Cardiac Necrosis', 'no label'), ('Creatine', 'no label'), ('Left Ventricular Function Impairment With', 'no label'), ('Left Ventricle', 'no label'), ('Left Ventricle', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Catecholamine', 'no label'), ('Coronary Artery Spasm', 'no label'), ('Microvascular Dysfunction', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Cardiotoxicity', 'no label')]|[('Left Ventricular', 'no label'), ('Women', 'no label'), ('Patients', 'no label'), ('Acute Coronary', 'no label'), ('Far', 'no label'), ('Coronary Artery', 'no label'), ('Coronary Artery', 'no label'), ('Patient', 'no label'), ('Pulmonary', 'no label'), ('Tacrolimus', 'no label'), ('Left Bundle Branch', 'no label'), ('Cardiac', 'no label'), ('Troponin I', 'no label'), ('Creatine Kinase', 'no label'), ('Left Ventricular', 'no label'), ('Cardiac', 'no label'), ('Coronary Arteries', 'no label'), ('Grafts', 'no label'), ('Left Ventricle', 'no label'), ('Catecholamine', 'no label'), ('Coronary Artery', 'no label'), ('Microvascular', 'no label'), ('Patients', 'no label'), ('Calcineurin Inhibitor', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25821406|Tako-Tsubo Cardiomyopathy (Ttc) Is A Rare Disorder With High Relevance For Anaesthesia. It Is An Acute Cardiac Syndrome Characterized By An Acute Onset Of Reversible Left Ventricular Dysfunction Associated With Emotional And Physical Stress. This Is The Only Case Published Of A Patient Having Five Severe Tako-Tsubo Incidents In Five Consecutive General Anaesthesia Procedures Within One Year. A 61 Years Old Female Patient (Height 1.65 M; Weight 70 Kg) Presented With A Haemorrhagic Pituitary Adenoma With Compression Of The Optic Chiasm And Was Scheduled For Transnasal Endoscopic Tumour Resection. We Report A Case Series With Five Consecutive Anaesthesia Procedures In The Same Patient For Neurosurgery. This Case Series Is Remarkable Since The Severe Symptoms Occurred During Every Anaesthesia Procedure. The Female Patient Was Resuscitated Two Times Including Therapeutic Hypothermia, But Fortunately No Neurological Or Cognitive Deficit Was Detectable. Ttc May Initially Present In The Perioperative Period With Pulmonary Oedema, Electrocardiographic (Ecg) Changes, Elevation Of Cardiac Enzymes, And Cardiogenic Shock Or Cardiac Arrest. Since The Risk Of Recurrence Is Considered To Be Low In Ttc, This Case Report Is Of High Interest. In Each Procedure Similar Clinical Signs Were Found Which Resulted In Severe Haemodynamic Derangements In Every Manifestation And Cardiac Arrest In Two Of The Manifestations. Despite Cardiopulmonary Resuscitation Twice, The Patient Survived Without Any Neurological Deficiency.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Rare', 'no label'), ('Disorder', 'no label'), ('Relevance', 'no label'), ('Anaesthesia', 'no label'), ('Acute Cardiac Syndrome', 'no label'), ('Characterized', 'no label'), ('Acute Onset', 'no label'), ('Reversible', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Associated With', 'no label'), ('Emotional And Physical Stress', 'no label'), ('Case Published', 'no label'), ('Patient', 'no label'), ('Severe', 'no label'), ('Tako-Tsubo Incidents', 'no label'), ('Consecutive', 'no label'), ('General Anaesthesia', 'no label'), ('Procedures', 'no label'), ('Year', 'no label'), ('Old Female', 'no label'), ('Height', 'no label'), ('Weight', 'no label'), ('Haemorrhagic Pituitary Adenoma', 'no label'), ('Compression', 'no label'), ('Optic Chiasm', 'no label'), ('Transnasal Endoscopic Tumour Resection', 'no label'), ('Report', 'no label'), ('Case Series', 'no label'), ('Consecutive', 'no label'), ('Anaesthesia', 'no label'), ('Procedures', 'no label'), ('Patient', 'no label'), ('Neurosurgery', 'no label'), ('Case Series', 'no label'), ('Severe', 'no label'), ('Symptoms', 'no label'), ('Anaesthesia', 'no label'), ('Procedure', 'no label'), ('Female Patient', 'no label'), ('Resuscitated', 'no label'), ('Therapeutic', 'no label'), ('Hypothermia', 'no label'), ('Neurological Or Cognitive Deficit', 'no label'), ('Detectable', 'no label'), ('Ttc', 'no label'), ('Present', 'no label'), ('Perioperative', 'no label'), ('Period', 'no label'), ('Pulmonary Oedema', 'no label'), ('Electrocardiographic (Ecg) Changes', 'no label'), ('Elevation', 'no label'), ('Cardiac Enzymes', 'no label'), ('Cardiogenic Shock', 'no label'), ('Cardiac Arrest', 'no label'), ('Risk', 'no label'), ('Recurrence', 'no label'), ('Low', 'no label'), ('Ttc', 'no label'), ('Case Report', 'no label'), ('Procedure', 'no label'), ('Clinical Signs', 'no label'), ('Resulted', 'no label'), ('Severe', 'no label'), ('Haemodynamic Derangements', 'no label'), ('Manifestation', 'no label'), ('Cardiac Arrest', 'no label'), ('Manifestations', 'no label'), ('Cardiopulmonary Resuscitation', 'no label'), ('Patient', 'no label'), ('Survived', 'no label'), ('Neurological Deficiency', 'no label')]|[('Enzymes', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Disorder', 'no label'), ('Acute Cardiac Syndrome', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Tako-Tsubo Incidents', 'no label'), ('Pituitary Adenoma', 'no label'), ('Optic Chiasm', 'no label'), ('Tumour', 'no label'), ('Hypothermia', 'no label'), ('Neurological Or Cognitive Deficit', 'no label'), ('Pulmonary Oedema', 'no label'), ('Cardiogenic Shock', 'no label'), ('Cardiac Arrest', 'no label'), ('Cardiac Arrest', 'no label'), ('Neurological Deficiency', 'no label')]|[('Acute Cardiac', 'no label'), ('Left Ventricular', 'no label'), ('Patient', 'no label'), ('Haemorrhagic Pituitary Adenoma', 'no label'), ('Optic Chiasm', 'no label'), ('Transnasal Endoscopic Tumour', 'no label'), ('Patient', 'no label'), ('Pulmonary Oedema', 'no label'), ('Cardiac', 'no label'), ('Cardiac', 'no label'), ('Cardiac', 'no label'), ('Cardiopulmonary Resuscitation', 'no label'), ('Patient', 'no label')]
tako-tsubo cardiomyopathy|pubmed~30371194|Background There Are Limited Data On The Presentation Of Takotsubo Cardiomyopathy ( Ttc ) In Severe Sepsis. Methods And Results This Was A Retrospective Cohort Study Using The National Inpatient Sample Database (2007-2013) Of All Adults With Severe Sepsis. Ttc Was Identified In Patients With Severe Sepsis Using Previously Validated Administrative Codes. The Primary Outcome Was In-Hospital Mortality, And Secondary Outcomes Included Resource Utilization And Discharge Disposition. Regression Analysis Was Performed For The Entire Cohort And A Propensity-Matched Sample. An Exploratory Analysis Was Performed For Predictors Of Ttc Incidence And Mortality In Ttc . During This 7-Year Period, In 7.1-Million Hospitalizations For Severe Sepsis, Ttc Was Diagnosed In 10 746 (0.15%) Admissions. Ttc Was Noted More Commonly In Whites, Females, And Among 65- To 79-Year-Old Individuals. Ttc Was Independently Associated With Lower In-Hospital Mortality In Severe Sepsis (Odds Ratio, 0.58; 95% Confidence Interval, 0.51-0.65). This Association Was More Prominent In Females (Odds Ratio, 0.51; 95% Confidence Interval, 0.44-0.59]) Compared With Males (Odds Ratio, 0.69; 95% Confidence Interval, 0.55-0.85]). Presentation In Later Years Of The Study Period, Middle-Age, Female Sex, And White Race Were Independent Predictors For The Diagnosis Of Ttc . Age ≥80 Years, Black Race, Greater Comorbidity, And Multiorgan Dysfunction Were Independently Associated With Higher In-Hospital Mortality Among Ttc Admissions. Conclusions Ttc Is Observed With Increasing Frequency In Severe Sepsis And Was Associated With A Significantly Lower In-Hospital Mortality Compared With Patients Without Ttc . Presentation In Later Years Of The Study Period, Middle Age, Female Sex, And White Race Were Independent Predictors For The Diagnosis Of Ttc In Severe Sepsis.|[('Limited Data', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Severe', 'no label'), ('Sepsis', 'no label'), ('Was A', 'no label'), ('Retrospective Cohort Study', 'no label'), ('National Inpatient Sample Database', 'no label'), ('Adults', 'no label'), ('Severe', 'no label'), ('Sepsis', 'no label'), ('Ttc', 'no label'), ('Identified', 'no label'), ('Patients', 'no label'), ('Severe', 'no label'), ('Sepsis', 'no label'), ('Validated Administrative Codes', 'no label'), ('Primary Outcome', 'no label'), ('Mortality', 'no label'), ('Secondary Outcomes', 'no label'), ('Resource Utilization', 'no label'), ('Discharge Disposition', 'no label'), ('Regression Analysis', 'no label'), ('Performed', 'no label'), ('Entire Cohort', 'no label'), ('Propensity-Matched Sample', 'no label'), ('Exploratory Analysis', 'no label'), ('Performed', 'no label'), ('Predictors', 'no label'), ('Ttc', 'no label'), ('Incidence', 'no label'), ('Mortality', 'no label'), ('Ttc', 'no label'), ('Period', 'no label'), ('7.1-Million', 'no label'), ('Hospitalizations', 'no label'), ('Severe', 'no label'), ('Sepsis', 'no label'), ('Ttc', 'no label'), ('Diagnosed', 'no label'), ('Admissions', 'no label'), ('Ttc', 'no label'), ('Noted', 'no label'), ('Whites', 'no label'), ('Females', 'no label'), ('79-Year-Old', 'no label'), ('Individuals', 'no label'), ('Ttc', 'no label'), ('Associated With', 'no label'), ('Lower In-Hospital', 'no label'), ('Mortality', 'no label'), ('Severe', 'no label'), ('Sepsis', 'no label'), ('Odds Ratio', 'no label'), ('Confidence Interval', 'no label'), ('Association', 'no label'), ('Females', 'no label'), ('Odds Ratio', 'no label'), ('Confidence Interval', 'no label'), ('Males', 'no label'), ('Odds Ratio', 'no label'), ('Confidence Interval', 'no label'), ('Years', 'no label'), ('Study', 'no label'), ('Period', 'no label'), ('Middle-Age', 'no label'), ('Female Sex', 'no label'), ('White Race', 'no label'), ('Independent Predictors', 'no label'), ('Diagnosis', 'no label'), ('Ttc', 'no label'), ('Age', 'no label'), ('Black Race', 'no label'), ('Greater', 'no label'), ('Comorbidity', 'no label'), ('Multiorgan Dysfunction', 'no label'), ('Associated With', 'no label'), ('Higher', 'no label'), ('In-Hospital', 'no label'), ('Mortality', 'no label'), ('Ttc Admissions', 'no label'), ('Ttc', 'no label'), ('Increasing', 'no label'), ('Frequency', 'no label'), ('Severe', 'no label'), ('Sepsis', 'no label'), ('Associated With', 'no label'), ('Mortality', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Years', 'no label'), ('Study', 'no label'), ('Period', 'no label'), ('Middle Age', 'no label'), ('Female Sex', 'no label'), ('White Race', 'no label'), ('Independent Predictors', 'no label'), ('Diagnosis', 'no label'), ('Ttc', 'no label'), ('Severe', 'no label'), ('Sepsis', 'no label')]|[('Individuals', 'no label')]|[]|[('Takotsubo Cardiomyopathy', 'no label'), ('Sepsis', 'no label'), ('Sepsis', 'no label'), ('Sepsis', 'no label'), ('Sepsis', 'no label'), ('Sepsis', 'no label'), ('Comorbidity', 'no label'), ('Multiorgan Dysfunction', 'no label'), ('Sepsis', 'no label'), ('Ttc', 'no label'), ('Sepsis', 'no label')]|[('Patients', 'no label'), ('Ttc', 'no label'), ('Lower In-Hospital', 'no label'), ('Middle-Age', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~24412188|The Purpose Of This Study Was To Determine Clinical And Echocardiographic Correlates Of Acute Heart Failure, Cardiogenic Shock And In-Hospital Mortality In A Large Cohort Of Tako-Tsubo Cardiomyopathy (Ttc) Patients. Despite Good Long-Term Prognosis, Life-Threatening Complications Due To Hemodynamic Instability Can Occur Early In Ttc Patients. The Study Population Consisted Of 227 Patients (66.2 ± 12.2 Years Of Age; Females, 90.3%) Enrolled In The Tako-Tsubo Italian Network, Undergoing Transthoracic Two-Dimensional Echocardiography On Admission And At Short-Term Follow-Up (4.3 [4 To 6] Weeks). Patients Were Divided Into Two Groups According To The Presence Or Absence Of Major Adverse Events, A Composite Of Acute Heart Failure, Cardiogenic Shock, And In-Hospital Mortality. Major Adverse Events Occurred In 59 Patients (25.9%). The Variables For Elderly Patients ≥ 75 Years Of Age (42.4% Vs. 23.8%; P = 0.011): Left Ventricular (Lv) Ejection Fraction (35.1 ± 5.9% Vs. 38.4 ± 4.6%, P < 0.001), Wall Motion Score Index (1.9 ± 0.2 Vs. 1.7 ± 0.2, P < 0.001), E/E' Ratio (13.5 ± 4.3 Vs. 9.9 ± 3.3 [Where E/E' Is Ratio Of Mitral E Peak Velocity And Averaged E' Velocity], P < 0.001), Lv Outflow Tract Obstruction (23.7 Vs. 8.9%, P = 0.006), Pulmonary Artery Systolic Pressure (47.4 ± 12.3 Mm Hg Vs. 38.0 ± 9.2 Mm Hg; P < 0.001), Right Ventricular Involvement (28.8 Vs. 9.5%; P < 0.001), And Reversible Moderate-To-Severe Mitral Regurgitation (49.1 Vs. 11.9%; P < 0.001), Were Significantly Different Between Groups And Were Associated With Adverse Events. At Multivariate Analysis, Lv Ejection Fraction (Hr: 0.92; 95% Ci: 0.89 To 0.95; P < 0.001), E/E' Ratio (Hr: 1.13; 95% Ci: 1.02 To 1.24; P = 0.011), Reversible Moderate To Severe Mitral Regurgitation (Hr: 3.25; 95% Ci: 1.16 To 9.10; P = 0.025), And Age ≥ 75 Years (Hr: 2.81; 95% Ci: 1.05 To 7.52; P = 0.039) Were Independent Correlates Of Major Adverse Events. Echocardiographic Parameters Provide Additional Information Compared To Other Variables Routinely Used In Clinical Practice To Identify Patients At Higher Risk Of Hemodynamic Deterioration And Poor In-Hospital Outcome, Allowing Prompt Institution Of Appropriate Pharmacological Treatment And Adequate Mechanical Support.|"[('Study', 'no label'), ('Clinical', 'no label'), ('Echocardiographic', 'no label'), ('Correlates', 'no label'), ('Acute Heart Failure', 'no label'), ('Cardiogenic Shock', 'no label'), ('In-Hospital', 'no label'), ('Mortality', 'no label'), ('Cohort', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Long-Term', 'no label'), ('Life-Threatening', 'no label'), ('Complications', 'no label'), ('Hemodynamic Instability', 'no label'), ('Occur', 'no label'), ('Early', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Study Population', 'no label'), ('Patients', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Females', 'no label'), ('Tako-Tsubo Italian', 'no label'), ('Network', 'no label'), ('Transthoracic Two-Dimensional Echocardiography', 'no label'), ('Admission', 'no label'), ('Short-Term Follow-Up', 'no label'), ('Weeks', 'no label'), ('Patients', 'no label'), ('Divided', 'no label'), ('Groups', 'no label'), ('Presence', 'no label'), ('Absence', 'no label'), ('Major Adverse Events', 'no label'), ('Composite', 'no label'), ('Acute Heart Failure', 'no label'), ('Cardiogenic Shock', 'no label'), ('In-Hospital', 'no label'), ('Mortality', 'no label'), ('Major Adverse Events', 'no label'), ('Occurred', 'no label'), ('Patients', 'no label'), ('Variables', 'no label'), ('Elderly', 'no label'), ('Patients', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Left Ventricular (Lv) Ejection Fraction', 'no label'), ('Wall Motion Score Index', 'no label'), (""E/E' Ratio"", 'no label'), ('Ratio', 'no label'), ('Mitral E Peak Velocity', 'no label'), ('Averaged', 'no label'), (""E' Velocity"", 'no label'), ('Lv Outflow Tract Obstruction', 'no label'), ('Pulmonary Artery Systolic Pressure', 'no label'), ('Mm Hg Vs', 'no label'), ('Mm Hg', 'no label'), ('Right Ventricular Involvement', 'no label'), ('Reversible', 'no label'), ('Mitral Regurgitation', 'no label'), ('Groups', 'no label'), ('Associated With', 'no label'), ('Adverse Events', 'no label'), ('Multivariate Analysis', 'no label'), ('Lv Ejection Fraction', 'no label'), ('Hr', 'no label'), ('Ci', 'no label'), (""E/E' Ratio"", 'no label'), ('Hr', 'no label'), ('Ci', 'no label'), ('Reversible', 'no label'), ('Moderate', 'no label'), ('Severe', 'no label'), ('Mitral Regurgitation', 'no label'), ('Hr', 'no label'), ('Ci', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('Hr', 'no label'), ('Ci', 'no label'), ('Independent', 'no label'), ('Correlates', 'no label'), ('Major Adverse Events', 'no label'), ('Echocardiographic', 'no label'), ('Parameters', 'no label'), ('Information', 'no label'), ('Variables', 'no label'), ('Clinical Practice', 'no label'), ('Patients', 'no label'), ('Higher', 'no label'), ('Risk', 'no label'), ('Hemodynamic Deterioration', 'no label'), ('Poor In-Hospital Outcome', 'no label'), ('Prompt Institution', 'no label'), ('Pharmacological', 'no label'), ('Treatment', 'no label'), ('Adequate', 'no label'), ('Mechanical Support', 'no label')]"|[('Hg', 'no label')]|[]|[('Acute Heart Failure', 'no label'), ('Cardiogenic Shock', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Prognosis', 'no label'), ('Tako-Tsubo', 'no label'), ('Acute Heart Failure', 'no label'), ('Cardiogenic Shock', 'no label'), ('Left Ventricular (Lv) Ejection Fraction (35.1 ±', 'no label'), ('Outflow Tract Obstruction', 'no label'), ('Mitral Regurgitation', 'no label'), ('Mitral Regurgitation', 'no label')]|[('Heart', 'no label'), ('Ttc Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Heart', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Left Ventricular', 'no label'), ('Wall', 'no label'), ('Mitral E Peak', 'no label'), ('Lv Outflow Tract', 'no label'), ('Pulmonary Artery', 'no label'), ('Mm', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~35295724|Tako-Tsubo Stress Cardiomyopathy Is A Clinical Syndrome Marked By Transient Reduction Of Left Ventricular Function In The Setting Of Emotional Or Physical Stress And In The Absence Of Obstructive Coronary Artery Disease. We Describe A Case Of An Atypical Variant Of Tako-Tsubo In A Male Patient Following An Elective Direct Current Cardioversion (Dccv). A 78-Year-Old Male Whose Atrial Fibrillation Persisted After Earlier Unsuccessful Direct Current Dccv And Radiofrequency Ablations Presented To The Emergency Department For Acutely Worsening Dyspnoea And Orthopnoea 12 H Following His Most Recent Dccv. Previously, He Was Known To Have Non-Obstructive Coronary Artery Disease. Evaluation Was Notable For Troponin I 0.019 Ng/Ml (Negative <0.050 Ng/Ml), Pro-Brain Natriuretic Peptide 2321 Pg/Ml (Reference Range 0.0-900 Pg/Ml). There Were No Acute Electrocardiogram Abnormalities. He Required Bilevel Positive Airway Pressure But Was Weaned Off Eventually To Room Air. Transthoracic Echocardiogram Revealed Newly Reduced Left Ventricular Ejection Fraction Of 45-50%, Associated With Hypokinesis Of The Basal Anteroseptal Segment, As Well As Akinesis Of Mid-Inferoseptal And Mid-Anteroseptal Segments. Apical Contractility Was Preserved. On Day 5 Of Hospitalization, Diagnostic Left Heart Catheterization Again Revealed Benign Coronary Anatomy, And He Was Discharged Home The Following Day. Only Five Other Cases Of Cardioversion Mediated Tako-Tsubo Cardiomyopathy Have Been Reported In The Literature. To Our Knowledge, This Is The First Case Of Dccv-Induced Atypical Tako-Tsubo Cardiomyopathy. Although Overall Prognosis Is Favourable, Some Have Been Observed To Require Advanced Support Therapy. Given Risk For Life-Threatening Complications, Patients Undergoing Cardioversion Should Be Educated On Symptoms Of Congestive Cardiomyopathy.|[('Tako-Tsubo Stress Cardiomyopathy', 'no label'), ('Clinical Syndrome', 'no label'), ('Transient', 'no label'), ('Reduction', 'no label'), ('Left Ventricular Function', 'no label'), ('Emotional Or Physical Stress', 'no label'), ('Absence', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Atypical Variant', 'no label'), ('Tako-Tsubo', 'no label'), ('Male', 'no label'), ('Patient', 'no label'), ('Elective Direct Current Cardioversion', 'no label'), ('Dccv', 'no label'), ('Male', 'no label'), ('Atrial Fibrillation', 'no label'), ('Persisted', 'no label'), ('Direct Current Dccv', 'no label'), ('Radiofrequency Ablations', 'no label'), ('Emergency Department', 'no label'), ('Acutely', 'no label'), ('Dyspnoea', 'no label'), ('Orthopnoea 12\u2009H', 'no label'), ('Non-Obstructive', 'no label'), ('Coronary Artery Disease', 'no label'), ('Evaluation', 'no label'), ('Troponin I', 'no label'), ('Negative', 'no label'), ('Pro-Brain Natriuretic Peptide', 'no label'), ('Reference Range', 'no label'), ('Acute Electrocardiogram Abnormalities', 'no label'), ('Bilevel', 'no label'), ('Airway Pressure', 'no label'), ('Weaned', 'no label'), ('Room Air', 'no label'), ('Transthoracic Echocardiogram', 'no label'), ('Revealed', 'no label'), ('Reduced', 'no label'), ('Left Ventricular Ejection Fraction', 'no label'), ('Associated With', 'no label'), ('Hypokinesis', 'no label'), ('Basal Anteroseptal Segment', 'no label'), ('Akinesis', 'no label'), ('Mid-Inferoseptal', 'no label'), ('Mid-Anteroseptal', 'no label'), ('Segments', 'no label'), ('Apical', 'no label'), ('Hospitalization', 'no label'), ('Diagnostic Left Heart Catheterization', 'no label'), ('Revealed', 'no label'), ('Benign Coronary Anatomy', 'no label'), ('Day', 'no label'), ('Cases', 'no label'), ('Cardioversion', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Literature', 'no label'), ('Knowledge', 'no label'), ('Atypical', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Prognosis', 'no label'), ('Favourable', 'no label'), ('Observed', 'no label'), ('Require', 'no label'), ('Advanced', 'no label'), ('Support Therapy', 'no label'), ('Risk', 'no label'), ('Life-Threatening', 'no label'), ('Complications', 'no label'), ('Patients', 'no label'), ('Cardioversion', 'no label'), ('Educated', 'no label'), ('Symptoms', 'no label'), ('Congestive Cardiomyopathy', 'no label')]|[('Variant', 'no label'), ('Tako-Tsubo', 'no label'), ('His', 'no label'), ('Troponin I', 'no label'), ('Natriuretic Peptide', 'no label'), ('Mid-Inferoseptal', 'no label'), ('Mid-Anteroseptal Segments', 'no label')]|[('His', 'no label'), ('Troponin I', 'no label')]|[('Tako-Tsubo Stress Cardiomyopathy', 'no label'), ('Left Ventricular Function', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Tako-Tsubo', 'no label'), ('Atrial Fibrillation Persisted', 'no label'), ('Dyspnoea', 'no label'), ('Orthopnoea', 'no label'), ('Coronary Artery Disease', 'no label'), ('Electrocardiogram Abnormalities', 'no label'), ('Hypokinesis Of The Basal Anteroseptal Segment, As Well As Akinesis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Atypical Tako-Tsubo Cardiomyopathy', 'no label'), ('Prognosis', 'no label'), ('Congestive Cardiomyopathy', 'no label')]|[('Left Ventricular', 'no label'), ('Coronary Artery', 'no label'), ('A Case', 'no label'), ('Patient', 'no label'), ('Non-Obstructive', 'no label'), ('Troponin I', 'no label'), ('Pg/Ml', 'no label'), ('Pg/Ml', 'no label'), ('Acute Electrocardiogram Abnormalities', 'no label'), ('Left Ventricular', 'no label'), ('Basal Anteroseptal', 'no label'), ('Mid-Inferoseptal', 'no label'), ('Heart', 'no label'), ('Patients', 'no label'), ('Congestive', 'no label')]
tako-tsubo cardiomyopathy|pubmed~30441985|Severe Carbon Monoxide Intoxication May Cause Tissue Injury By Hypoxemia And Histotoxicity. The Affection Of The Heart Muscle Often Leads To Transient Global Or Regional Systolic Dysfunction Of Left Ventricle Or Both Ventricles And Increased Occurences Of Malignant Arrhytmias. On The Contrary, Stress-Induced Cardiomyopathy Is Described As Temporary Segmental Loss Of Contractility, Mostly In Apical Segments Of The Left Ventricle With Mid- And Basal Sparing And Less Common Hypokinesias In Mid- Or Basal Parts, Or Affection Of Both Ventricles. This Case Report Is Dedicated To A 34-Years Old Male, Who Was Admitted To The Department Of Emergency Medicine After Suicide Attempt By Carbon Monoxide Poisoning. Echocardiography At Admission Showed Akinesias Of Midsegments Of Left Ventricle And Severe Hypokinesias Of Apical And Basal Segments. Despite Severe Cardiogenic Shock, Adequate Therapeutic Management Including Mechanical Ventilation, Normobaric Oxygenotherapy And Catecholamine Treatment Led To A Complete Somatic Recovery After 2 Weeks, And Without Any Permanent Hypoxemic Brain Injury. Our Case Might Be A Coincidence Of Toxic Cardiomyopathy, Caused By Carbon Monoxide Poisoning, And Takotsubo Cardiomyopathy As A Result Of Long Term Exposition To Combined Stress Factors That May Lead Even To A Suicide Attempt. Both Types Of Cardiomyopathies Often Occure Simultaneously Due To Similar Pathophysiologic Mechanisms. Both Tako-Tsubo And Toxic Cardiomypathy Have Good Prognosis After Overcoming The Acute Phase. Key Words: Carbon Monoxide - Cardiogennic Shock - Cardiomyopathy - Suicide - Tako-Tsubo Cardiomypathy.|[('Severe', 'no label'), ('Carbon Monoxide Intoxication', 'no label'), ('Cause Tissue Injury', 'no label'), ('Hypoxemia', 'no label'), ('Histotoxicity', 'no label'), ('Affection', 'no label'), ('Heart Muscle', 'no label'), ('Transient', 'no label'), ('Global', 'no label'), ('Regional Systolic Dysfunction', 'no label'), ('Left Ventricle', 'no label'), ('Ventricles', 'no label'), ('Increased', 'no label'), ('Occurences', 'no label'), ('Malignant Arrhytmias', 'no label'), ('Stress-Induced Cardiomyopathy', 'no label'), ('Temporary', 'no label'), ('Segmental Loss', 'no label'), ('Contractility', 'no label'), ('Apical Segments', 'no label'), ('Left Ventricle', 'no label'), ('Mid-', 'no label'), ('Basal Sparing', 'no label'), ('Hypokinesias', 'no label'), ('Basal Parts', 'no label'), ('Affection', 'no label'), ('Ventricles', 'no label'), ('Case Report', 'no label'), ('Male', 'no label'), ('Department', 'no label'), ('Emergency Medicine', 'no label'), ('Suicide Attempt', 'no label'), ('Carbon Monoxide Poisoning', 'no label'), ('Echocardiography', 'no label'), ('Admission', 'no label'), ('Akinesias', 'no label'), ('Midsegments', 'no label'), ('Left Ventricle', 'no label'), ('Severe', 'no label'), ('Apical', 'no label'), ('Basal', 'no label'), ('Severe', 'no label'), ('Cardiogenic Shock', 'no label'), ('Adequate', 'no label'), ('Therapeutic Management', 'no label'), ('Mechanical Ventilation', 'no label'), ('Normobaric Oxygenotherapy', 'no label'), ('Catecholamine Treatment', 'no label'), ('Somatic', 'no label'), ('Recovery', 'no label'), ('Weeks', 'no label'), ('Permanent', 'no label'), ('Hypoxemic Brain Injury', 'no label'), ('Case', 'no label'), ('Coincidence', 'no label'), ('Toxic Cardiomyopathy', 'no label'), ('Carbon Monoxide Poisoning', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Result', 'no label'), ('Long Term Exposition', 'no label'), ('Stress Factors', 'no label'), ('Lead', 'no label'), ('Suicide Attempt', 'no label'), ('Cardiomyopathies', 'no label'), ('Occure', 'no label'), ('Simultaneously', 'no label'), ('Pathophysiologic', 'no label'), ('Mechanisms', 'no label'), ('Tako-Tsubo', 'no label'), ('Toxic Cardiomypathy', 'no label'), ('Good Prognosis', 'no label'), ('Acute Phase', 'no label'), ('Cardiogennic Shock\xa0', 'no label'), ('Cardiomyopathy', 'no label'), ('Suicide', 'no label'), ('Tako-Tsubo', 'no label'), ('Cardiomypathy', 'no label')]|[('Apical Segments', 'no label'), ('Monoxide', 'no label'), ('Midsegments', 'no label'), ('Apical', 'no label'), ('Catecholamine', 'no label'), ('Toxic', 'no label'), ('Monoxide', 'no label'), ('Lead', 'no label'), ('Toxic Cardiomypathy', 'no label'), ('Carbon Monoxide', 'no label')]|[]|[('Carbon Monoxide Intoxication', 'no label'), ('Hypoxemia', 'no label'), ('Heart Muscle', 'no label'), ('Left Ventricle', 'no label'), ('Cardiomyopathy', 'no label'), ('Temporary Segmental Loss', 'no label'), ('Left Ventricle', 'no label'), ('Hypokinesias', 'no label'), ('Carbon Monoxide Poisoning', 'no label'), ('Echocardiography', 'no label'), ('Akinesias', 'no label'), ('Left Ventricle And Severe', 'no label'), ('Hypokinesias', 'no label'), ('Cardiogenic Shock', 'no label'), ('Catecholamine', 'no label'), ('Hypoxemic Brain Injury', 'no label'), ('Toxic Cardiomyopathy', 'no label'), ('Carbon Monoxide Poisoning', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Cardiomyopathies', 'no label'), ('Tako-Tsubo And Toxic Cardiomypathy', 'no label'), ('Prognosis', 'no label'), ('Carbon Monoxide', 'no label'), ('Shock', 'no label'), ('Cardiomyopathy', 'no label')]|[('Carbon Monoxide', 'no label'), ('Tissue', 'no label'), ('Heart Muscle', 'no label'), ('Malignant Arrhytmias', 'no label'), ('Left Ventricle', 'no label'), ('Basal', 'no label'), ('Carbon Monoxide', 'no label'), ('Midsegments', 'no label'), ('Apical', 'no label'), ('Catecholamine', 'no label'), ('Brain', 'no label'), ('Carbon Monoxide', 'no label'), ('Cardiomyopathies Often', 'no label'), ('Carbon Monoxide', 'no label')]
tako-tsubo cardiomyopathy|pubmed~32962968||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~22222065|Tako-Tsubo Cardiomyopathy, First Described In 1990 By Sato In Japan, Has Recently Gained Increasing Consideration When Reported In Non-Japanese Patients, Including The United States And Europe. Typical Presentation Mimics Acute Coronary Syndrome, With Acute Chest Pain And/Or Dyspnoea, Associated To Electrocardiographic Changes And Moderate Cardiac Biomarkers Release, But In Which Coronary Angiography Reveals No Coronary Arteries Lesions And Echocardiography Or Left Ventriculography Shows A Reversible Left Ventricle Systolic Dysfunction. Prognosis Is Good, In Contrast To Acute Coronary Syndrome, Provided That The Patients Survive The Possible Life-Threatening Acute Presentation, With Correction Of The Left Ventricle Systolic Dysfunction Within Several Days Or Weeks. As Noted In Several Reviews, 3.5% To 10% Of The Patients Have A Recurrence During The First Few Years After The Initial Presentation. Here, We Described A Case Of A 60-Year-Old Female Who Had Three Episodes Of Tako-Tsubo Always Preceded By Severe Emotional Stress Suggesting A Potential Common Etiopathogenesis. |[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Japan', 'no label'), ('Gained', 'no label'), ('Increasing', 'no label'), ('Non-Japanese', 'no label'), ('Patients', 'no label'), ('United States And Europe', 'no label'), ('Mimics', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Acute Chest Pain And/Or', 'no label'), ('Dyspnoea', 'no label'), ('Electrocardiographic Changes', 'no label'), ('Moderate', 'no label'), ('Cardiac Biomarkers', 'no label'), ('Release', 'no label'), ('Coronary Angiography', 'no label'), ('Reveals', 'no label'), ('Coronary Arteries', 'no label'), ('Lesions', 'no label'), ('Echocardiography', 'no label'), ('Left Ventriculography', 'no label'), ('Shows A', 'no label'), ('Reversible', 'no label'), ('Left Ventricle Systolic Dysfunction', 'no label'), ('Prognosis', 'no label'), ('Good', 'no label'), ('Contrast', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Patients', 'no label'), ('Survive', 'no label'), ('Acute Presentation', 'no label'), ('Correction', 'no label'), ('Left Ventricle Systolic Dysfunction', 'no label'), ('Days', 'no label'), ('Weeks', 'no label'), ('Noted', 'no label'), ('Reviews', 'no label'), ('Patients', 'no label'), ('Recurrence', 'no label'), ('Years', 'no label'), ('Initial', 'no label'), ('Presentation', 'no label'), ('60-Year-Old', 'no label'), ('Female', 'no label'), ('Episodes', 'no label'), ('Tako-Tsubo Always', 'no label'), ('Preceded', 'no label'), ('Severe', 'no label'), ('Emotional Stress Suggesting', 'no label'), ('Etiopathogenesis', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Chest Pain And/Or Dyspnoea', 'no label'), ('Left Ventricle Systolic Dysfunction', 'no label'), ('Prognosis', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Left Ventricle Systolic Dysfunction', 'no label'), ('Tako-Tsubo', 'no label')]|[('Sato', 'no label'), ('Patients', 'no label'), ('Acute Coronary', 'no label'), ('Acute Chest', 'no label'), ('And/Or', 'no label'), ('Cardiac', 'no label'), ('Left', 'no label'), ('Acute Coronary', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~26782339|Acute Stress-Induced (Tako-Tsubo) Cardiomyopathy Is An Increasingly Recognized But Insufficiently Characterized Syndrome. Here, We Investigate The Pathophysiology Of Right Ventricular (Rv) Involvement In Tako-Tsubo And Its Recovery Time Course. We Prospectively Recruited 31 Patients With Tako-Tsubo With Predominantly St-Elevation Electrocardiogram And 18 Controls Of Similar Gender, Age, And Co-Morbidity Distribution. Patients Underwent Echocardiography And Cardiac Magnetic Resonance (Cmr) Imaging On A 3T Philips Scanner In The Acute Phase (Day 0 To 3 After Presentation) And At 4-Months Follow-Up. Visually, Echocardiography Was Able To Identify Only 52% Of Patients Who Showed Rv Wall Motion Abnormalities On Cmr. Only Cmr-Derived Rv Ejection Fraction (P = 0.01) And Echocardiography-Estimated Pulmonary Artery Pressure (P = 0.01) Identify Rv Functional Involvement In The Acute Phase. Although Rv Ejection Fraction Normalizes In Most Patients By 4 Months, Acutely There Is Rv Myocardial Edema In Both Functioning And Malfunctioning Segments, As Measured By Prolonged Native T1 Mapping (P = 0.02 For Both Vs Controls), And This Persists At 4 Months In The Acutely Malfunctioning Segments (P = 0.002 Vs Controls). The Extracellular Volume Fraction Was Significantly Increased Acutely In All Rv Segments And Remained Increased At Follow-Up Compared With Controls (P = 0.004 For All). In Conclusion, In A Tako-Tsubo Population Presenting Predominantly With St-Elevation Electrocardiogram, We Demonstrate That Although Rv Functional Involvement Is Seen In Only Half Of The Patients, Rv Myocardial Edema Is Present Acutely Throughout The Rv Myocardium In All Patients And Results In Microscopic Fibrosis At 4-Month Follow-Up.|[('Acute Stress-Induced (Tako-Tsubo) Cardiomyopathy', 'no label'), ('Recognized', 'no label'), ('Insufficiently Characterized Syndrome', 'no label'), ('Investigate', 'no label'), ('Pathophysiology', 'no label'), ('Right Ventricular (Rv)', 'no label'), ('Involvement', 'no label'), ('Tako-Tsubo', 'no label'), ('Recovery', 'no label'), ('Time Course', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo With', 'no label'), ('St-Elevation', 'no label'), ('Electrocardiogram', 'no label'), ('Controls', 'no label'), ('Gender', 'no label'), ('Age', 'no label'), ('Co-Morbidity', 'no label'), ('Distribution', 'no label'), ('Patients', 'no label'), ('Echocardiography', 'no label'), ('Cardiac Magnetic Resonance', 'no label'), ('Acute Phase', 'no label'), ('Presentation', 'no label'), ('4-Months', 'no label'), ('Follow-Up', 'no label'), ('Visually', 'no label'), ('Echocardiography', 'no label'), ('Patients', 'no label'), ('Rv Wall Motion Abnormalities', 'no label'), ('Cmr', 'no label'), ('Rv Ejection Fraction', 'no label'), ('Echocardiography-Estimated Pulmonary Artery Pressure', 'no label'), ('Rv Functional Involvement', 'no label'), ('Acute Phase', 'no label'), ('Rv Ejection Fraction', 'no label'), ('Normalizes', 'no label'), ('Patients', 'no label'), ('Months', 'no label'), ('Acutely', 'no label'), ('Rv Myocardial Edema', 'no label'), ('Functioning', 'no label'), ('Malfunctioning', 'no label'), ('Segments', 'no label'), ('Measured', 'no label'), ('Prolonged', 'no label'), ('Native T1', 'no label'), ('Mapping', 'no label'), ('Vs Controls', 'no label'), ('Persists', 'no label'), ('Months', 'no label'), ('Acutely', 'no label'), ('Malfunctioning', 'no label'), ('Segments', 'no label'), ('Controls', 'no label'), ('Extracellular Volume Fraction', 'no label'), ('Increased', 'no label'), ('Acutely', 'no label'), ('Rv Segments', 'no label'), ('Remained', 'no label'), ('Increased', 'no label'), ('Follow-Up', 'no label'), ('Controls', 'no label'), ('Tako-Tsubo Population', 'no label'), ('St-Elevation', 'no label'), ('Electrocardiogram', 'no label'), ('Demonstrate', 'no label'), ('Rv Functional Involvement', 'no label'), ('Patients', 'no label'), ('Rv Myocardial Edema', 'no label'), ('Acutely', 'no label'), ('Rv Myocardium', 'no label'), ('Patients', 'no label'), ('Results', 'no label'), ('Microscopic Fibrosis', 'no label'), ('4-Month Follow-Up', 'no label')]|[('Cmr', 'no label'), ('Cmr-Derived Rv', 'no label'), ('Extracellular', 'no label')]|[('T1', 'no label')]|[('Tako-Tsubo', 'no label'), ('Cardiomyopathy', 'no label'), ('Right Ventricular', 'no label'), ('Tako-Tsubo', 'no label'), ('Tako-Tsubo', 'no label'), ('Co-Morbidity', 'no label'), ('Myocardial Edema', 'no label'), ('Tako-Tsubo', 'no label'), ('Myocardial Edema', 'no label'), ('Fibrosis', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('Cardiac', 'no label'), ('A 3T', 'no label'), ('Acute Phase', 'no label'), ('Patients', 'no label'), ('Pulmonary', 'no label'), ('Patients', 'no label'), ('Rv Myocardial Edema', 'no label'), ('Extracellular Volume', 'no label'), ('Rv Segments', 'no label'), ('Patients', 'no label'), ('Rv Myocardial Edema', 'no label'), ('Rv Myocardium', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~26993120|Clinically Isolated Syndromes Affecting The Brainstem May Present With Rare Manifestations Such As Neurogenic Pulmonary Oedema (Npo). We Present The Case Of A 23 Year-Old Man With Npo Caused By Tako-Tsubo Cardiomyopathy (Ttc) As A First Manifestation Of Multiple Sclerosis (Ms). A Brain Magnetic Resonance Imaging Scan At Admission Showed Multiple Supra And Infratentorial White Matter Inflammatory Demyelinating Lesions. This Examination Was Repeated 2 And 4 Weeks After Symptoms Onset And Active Lesions Showing Contrast Uptake Were Identified, Two Of Them Involving The Pons And The Medulla Oblongata, Probably Affecting The Solitary Tract Nucleus. Cerebrospinal Fluid Oligoclonal Bands Were Detected. The Patient Was Treated With A 3-Day Course Of 1G Intravenous Methylprednisolone Presenting A Significant And Progressive Improvement. The Proposed Underlying Physiopathology Is An Excessive Secretion Of Catecholamines Resulting In Myocardial Stunning And Ventricular Failure. Two Months Later He Developed Optic Neuritis And Disease-Modifying Treatment Was Initiated. Clinicians Should Consider A Possible Neurological Origin Of Ttc, And According To The Clinical Characteristics Of The Patient, Ms May Be Suspected.|[('Clinically Isolated Syndromes', 'no label'), ('Affecting', 'no label'), ('Brainstem', 'no label'), ('Rare', 'no label'), ('Manifestations', 'no label'), ('Neurogenic Pulmonary Oedema', 'no label'), ('Npo', 'no label'), ('Year-Old Man', 'no label'), ('Npo', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Manifestation', 'no label'), ('Multiple Sclerosis', 'no label'), ('Brain Magnetic Resonance Imaging Scan', 'no label'), ('Admission', 'no label'), ('Inflammatory', 'no label'), ('Demyelinating Lesions', 'no label'), ('Examination', 'no label'), ('Repeated', 'no label'), ('Weeks', 'no label'), ('Symptoms', 'no label'), ('Onset', 'no label'), ('Active Lesions', 'no label'), ('Contrast', 'no label'), ('Uptake', 'no label'), ('Identified', 'no label'), ('Medulla Oblongata', 'no label'), ('Affecting', 'no label'), ('Solitary Tract Nucleus', 'no label'), ('Cerebrospinal Fluid', 'no label'), ('Oligoclonal Bands', 'no label'), ('Detected', 'no label'), ('Patient', 'no label'), ('Treated With', 'no label'), ('3-Day Course', 'no label'), ('Intravenous', 'no label'), ('Methylprednisolone', 'no label'), ('Presenting', 'no label'), ('Significant', 'no label'), ('Progressive', 'no label'), ('Improvement', 'no label'), ('Physiopathology', 'no label'), ('Excessive', 'no label'), ('Secretion', 'no label'), ('Catecholamines', 'no label'), ('Resulting', 'no label'), ('Myocardial Stunning', 'no label'), ('Ventricular Failure', 'no label'), ('Months', 'no label'), ('Optic Neuritis', 'no label'), ('Disease-Modifying Treatment', 'no label'), ('Clinicians', 'no label'), ('Neurological Origin', 'no label'), ('Ttc', 'no label'), ('Clinical Characteristics', 'no label'), ('Patient', 'no label'), ('Suspected', 'no label')]|[('Catecholamines', 'no label')]|[('Npo', 'no label')]|[('Neurogenic Pulmonary Oedema', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Demyelinating Lesions', 'no label'), ('Methylprednisolone', 'no label'), ('Catecholamines', 'no label'), ('Myocardial Stunning', 'no label'), ('Ventricular Failure', 'no label'), ('Optic Neuritis', 'no label')]|[('Brainstem', 'no label'), ('Pulmonary Oedema', 'no label'), ('Case Of A 23', 'no label'), ('Brain', 'no label'), ('Lesions', 'no label'), ('Pons', 'no label'), ('Medulla Oblongata', 'no label'), ('Patient', 'no label'), ('Intravenous Methylprednisolone', 'no label'), ('Catecholamines', 'no label'), ('Myocardial', 'no label'), ('Ventricular', 'no label'), ('Optic', 'no label')]
tako-tsubo cardiomyopathy|pubmed~34059953||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~23561588|The Investigators Describe The Occurrence Of An Episode Of Acute Tako-Tsubo Cardiomyopathy In A 51-Year-Old Woman, Which Was Followed, Only Days Later, By An Episode Of Acute Tako-Tsubo Cardiomyopathy In Her 74-Year-Old Mother. The Mother And Daughter Had Distinctly Different Left Ventricular Contraction Patterns, Yet The Left Anterior Descending Coronary Artery Distribution Was Similar, Extending Beyond The Left Ventricular Apex In Both Women. In Conclusion, This Unusual Scenario Suggests A Familial Predisposition To Tako-Tsubo Cardiomyopathy. Furthermore, The Daughter'S Event May Have Contributed To (Or Triggered) The Tako-Tsubo Episode In Her Mother.|"[('Investigators', 'no label'), ('Episode', 'no label'), ('Acute Tako-Tsubo Cardiomyopathy', 'no label'), ('Woman', 'no label'), ('Followed', 'no label'), ('Days', 'no label'), ('Episode', 'no label'), ('Acute Tako-Tsubo Cardiomyopathy', 'no label'), ('Mother', 'no label'), ('Mother And Daughter', 'no label'), ('Left Ventricular Contraction', 'no label'), ('Patterns', 'no label'), ('Left Anterior Descending Coronary Artery', 'no label'), ('Distribution', 'no label'), ('Left Ventricular Apex', 'no label'), ('Women', 'no label'), ('Scenario Suggests', 'no label'), ('Familial Predisposition', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), (""Daughter'S Event"", 'no label'), ('Triggered', 'no label'), ('Tako-Tsubo Episode', 'no label'), ('Mother', 'no label')]"|[]|[('Mother And Daughter', 'no label')]|[('Acute Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricular Contraction', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo', 'no label')]|[('Acute Tako-Tsubo', 'no label'), ('Acute Tako-Tsubo', 'no label'), ('Left Ventricular', 'no label'), ('Left Anterior Descending Coronary Artery', 'no label'), ('Left Ventricular Apex', 'no label'), ('Women', 'no label')]
tako-tsubo cardiomyopathy|pubmed~29720346|Embolic Stroke Is A Complication Of Tako-Tsubo-Cardiomyopathy (Ttc), Transient Left Ventricular Dysfunction Mimicking Myocardial Infarction Without Coronary Culprit Lesion Explaining The Whole Left Ventricular Dysfunction. Transient Global Amnesia (Tga) Is Characterized By Sudden Onset Of Anterograde Amnesia Without Compromise Of Other Neurologic Functions. A 57 Years Old Female Was Admitted Because Of Sudden Confusion And Loss Of Her Memory After Emotional Stress. Tga Was Diagnosed. Because Of Chest Pain And Laboratory Tests Indicating Myocardial Ischemia, She Underwent Coronary Angiography Which Was Normal. Within The Following 24H Her Memory Improved. She Complained About Severe Vertigo And Cerebral Magnetic Resonance Imaging Showed A Recent Ischemia In The Left Cerebellum. Tga Is Not A Disease For The Neurologists Exclusively But Also Cardiac Comorbidities Have To Be Considered And Cardiologists Should Be Involved In The Acute Care Of These Patients In Order Not To Overlook Life-Threatening Diseases.|[('Embolic Stroke', 'no label'), ('Complication', 'no label'), ('Tako-Tsubo-Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Transient Left Ventricular Dysfunction', 'no label'), ('Myocardial Infarction', 'no label'), ('Coronary Culprit', 'no label'), ('Lesion', 'no label'), ('Whole Left Ventricular Dysfunction', 'no label'), ('Transient Global Amnesia', 'no label'), ('Tga', 'no label'), ('Characterized', 'no label'), ('Sudden', 'no label'), ('Anterograde Amnesia', 'no label'), ('Neurologic Functions', 'no label'), ('Years', 'no label'), ('Admitted', 'no label'), ('Sudden Confusion', 'no label'), ('Loss', 'no label'), ('Memory', 'no label'), ('Emotional Stress', 'no label'), ('Tga', 'no label'), ('Diagnosed', 'no label'), ('Chest Pain', 'no label'), ('Laboratory Tests', 'no label'), ('Myocardial Ischemia', 'no label'), ('Coronary Angiography', 'no label'), ('Normal', 'no label'), ('24H Her Memory', 'no label'), ('Improved', 'no label'), ('Complained', 'no label'), ('Severe', 'no label'), ('Vertigo', 'no label'), ('Cerebral Magnetic Resonance Imaging', 'no label'), ('Showed A', 'no label'), ('Ischemia', 'no label'), ('Left Cerebellum', 'no label'), ('Tga', 'no label'), ('Not A Disease', 'no label'), ('Neurologists', 'no label'), ('Exclusively', 'no label'), ('Cardiac Comorbidities', 'no label'), ('Considered', 'no label'), ('Cardiologists', 'no label'), ('Acute Care', 'no label'), ('Patients', 'no label'), ('Order', 'no label'), ('Overlook', 'no label')]|[]|[('Tga', 'no label'), ('Tga', 'no label')]|[('Embolic Stroke', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Myocardial Infarction', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Amnesia', 'no label'), ('Amnesia', 'no label'), ('Sudden Confusion', 'no label'), ('Chest Pain', 'no label'), ('Myocardial Ischemia', 'no label'), ('Vertigo', 'no label'), ('Ischemia', 'no label')]|[('Left Ventricular', 'no label'), ('Myocardial', 'no label'), ('Culprit', 'no label'), ('Myocardial', 'no label'), ('Cerebral', 'no label'), ('Cardiac', 'no label'), ('Acute Care', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~26482629|We Present A Case Which Developed A Typical Tako-Tsubo-Like Cardiomyopathy (Ttc) During Dobutamine Stress Echocardiography (Dse). Its Originality Is Related To Several Findings, Which Have Never Been Described Simultaneously In The Same Patient. This 63-Year-Old Woman With Normal Coronary Angiography And No Evidence Of Coronary Vasospasm Had A Biphasic Response To Dse, A Finding Which Usually Occurs In Coronary Artery Disease. Moreover, The Symmetric Extensive Wall Motion Abnormalities (Wma) Occurred Simultaneously With The Development Of A Systolic Anterior Motion Of The Mitral Valve (Sam) And Left Ventricular Obstruction, And Was Clinically Asymptomatic. Although In Ttc The Stunning Usually Occurs For Several Days, Wma And Sam Resolved Within Few Minutes After Cessation Of Dobutamine And Administration Of A Beta-Blocker. And Finally, Exercise Echo Performed At The Same Target Heart Rate Few Days Later Did Not Induce Neither A Sam Nor Wma, Which Suggests That Left Ventricular Obstruction Could Have Played A Role In The Pathogenesis Of This Case By Supply-Demand Mismatch. Concomitant Coronary Microvascular Dysfunction Was Also Demonstrated By A Reduction Of The Non-Invasive Coronary Flow Reserve In The Distal Part Of The Left Anterior Descending Artery.|[('Case', 'no label'), ('Typical Tako-Tsubo-Like Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Dobutamine Stress Echocardiography', 'no label'), ('Dse', 'no label'), ('Originality', 'no label'), ('Findings', 'no label'), ('Simultaneously', 'no label'), ('Patient', 'no label'), ('Woman', 'no label'), ('Normal Coronary Angiography', 'no label'), ('No Evidence', 'no label'), ('Coronary Vasospasm', 'no label'), ('Biphasic Response', 'no label'), ('Dse', 'no label'), ('Finding', 'no label'), ('Occurs', 'no label'), ('Coronary Artery Disease', 'no label'), ('Symmetric Extensive Wall Motion Abnormalities', 'no label'), ('Wma', 'no label'), ('Development', 'no label'), ('Systolic Anterior', 'no label'), ('Motion', 'no label'), ('Mitral Valve (Sam)', 'no label'), ('Left Ventricular Obstruction', 'no label'), ('Clinically Asymptomatic', 'no label'), ('Ttc', 'no label'), ('Stunning', 'no label'), ('Occurs', 'no label'), ('Days', 'no label'), ('Wma And Sam', 'no label'), ('Resolved', 'no label'), ('Cessation', 'no label'), ('Dobutamine', 'no label'), ('Administration', 'no label'), ('Beta-Blocker', 'no label'), ('Exercise Echo Performed', 'no label'), ('Target Heart Rate', 'no label'), ('Days', 'no label'), ('Did Not', 'no label'), ('Induce', 'no label'), ('Suggests', 'no label'), ('Left Ventricular Obstruction', 'no label'), ('Played', 'no label'), ('Pathogenesis', 'no label'), ('Mismatch', 'no label'), ('Concomitant', 'no label'), ('Coronary Microvascular Dysfunction', 'no label'), ('Reduction', 'no label'), ('Non-Invasive', 'no label'), ('Coronary Flow Reserve', 'no label'), ('Distal Part', 'no label'), ('Left Anterior Descending Artery', 'no label')]|[]|[]|[('Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Dobutamine', 'no label'), ('Coronary Vasospasm', 'no label'), ('Coronary Artery Disease', 'no label'), ('Left Ventricular Obstruction', 'no label'), ('Dobutamine', 'no label'), ('Left Ventricular Obstruction', 'no label'), ('Pathogenesis', 'no label'), ('Coronary Microvascular Dysfunction', 'no label')]|[('Coronary Vasospasm', 'no label'), ('A Biphasic Response', 'no label'), ('Dse', 'no label'), ('Coronary Artery', 'no label'), ('Wall', 'no label'), ('Mitral Valve', 'no label'), ('Left Ventricular', 'no label'), ('Dobutamine', 'no label'), ('Heart', 'no label'), ('Left Ventricular', 'no label'), ('Microvascular', 'no label'), ('Left Anterior Descending', 'no label')]
tako-tsubo cardiomyopathy|pubmed~30407769|Tako-Tsubo Cardiomyopathy (Tcm) Is Being Recognized More Frequently; And A Familial Form Of This Diagnosis Has Been Suspected But Is Less Well-Established. A 75-Year-Old Patient With A Family History Of Tcm Was Admitted With Suspected St-Segment Elevation Myocardial Infarction. Transthoracic Echocardiography Showed Apical Dyskinesis With Hyperdynamic Basal Walls And A Left Ventricular Ejection Fraction (Lvef) Of 25%. Repeat Echocardiography Showed Normal Lvef Of 60% Ejection Fraction. Cardiac Catheterization Showed No Significant Stenosis. Tcm Is Characterized By Transient Systolic Left Ventricular Dysfunction. A Few Cases Of Familial Tcm Have Been Reported In The Literature And A Genetic Component Is Suspected. Although There Has Been A Paucity Of Data, Familial Cases Of Tcm Have Been Reported. This Case Study Addresses Tcm And The Familial Occurrence Of The Syndrome, Which May Have A Genetic Basis.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tcm', 'no label'), ('Being', 'no label'), ('Recognized', 'no label'), ('Familial Form', 'no label'), ('Diagnosis', 'no label'), ('Suspected', 'no label'), ('75-Year-Old', 'no label'), ('Patient', 'no label'), ('Family History', 'no label'), ('Tcm', 'no label'), ('Admitted With', 'no label'), ('Suspected', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Myocardial Infarction', 'no label'), ('Transthoracic Echocardiography', 'no label'), ('Apical Dyskinesis', 'no label'), ('Hyperdynamic Basal Walls', 'no label'), ('Left Ventricular Ejection Fraction', 'no label'), ('Lvef', 'no label'), ('Echocardiography', 'no label'), ('Lvef', 'no label'), ('Ejection Fraction', 'no label'), ('Cardiac Catheterization', 'no label'), ('No Significant', 'no label'), ('Stenosis', 'no label'), ('Tcm', 'no label'), ('Characterized', 'no label'), ('Transient Systolic Left Ventricular Dysfunction', 'no label'), ('Cases', 'no label'), ('Familial', 'no label'), ('Literature', 'no label'), ('Genetic Component', 'no label'), ('Suspected', 'no label'), ('Data', 'no label'), ('Familial Cases', 'no label'), ('Tcm', 'no label'), ('Case Study', 'no label'), ('Addresses', 'no label'), ('Tcm', 'no label'), ('Familial', 'no label'), ('Occurrence', 'no label'), ('Syndrome', 'no label'), ('Genetic Basis', 'no label')]|[('Basal Walls', 'no label'), ('Repeat', 'no label'), ('Genetic', 'no label'), ('Genetic', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Myocardial Infarction', 'no label'), ('Ventricular Ejection Fraction (Lvef) Of 25%', 'no label'), ('Stenosis', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Familial Tcm Have Been Reported In The Literature And A Genetic Component Is Suspected', 'no label')]|[('Tcm', 'no label'), ('Myocardial', 'no label'), ('Apical', 'no label'), ('Hyperdynamic Basal Walls', 'no label'), ('A Left Ventricular', 'no label'), ('Cardiac', 'no label'), ('Tcm', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23415891|Tako-Tsubo Cardiomyopathy Was First Described In Japan In 1990. The Clinical Presentation Of Tako-Tsubo Cardiomyopathy (Tcm) Is Similar To An Acute Myocardial Infarction With Patients Having Chest Pain, St Segment Elevations On Ekg And Elevated Cardiac Biomarkers. In Tcm, However, The Elevation In Cardiac Enzymes Is Usually Mild. We Report A Case Of Tcm Where The Patient Had Troponin I Elevation Up To 42.3 Ng/Ml. To The Best Of Our Knowledge, This Is The First Case In Which Such High Troponins Have Been Reported In A Patient With Tako-Tsubo Cardiomyopathy.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Japan', 'no label'), ('Clinical Presentation', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tcm', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Patients', 'no label'), ('Chest Pain', 'no label'), ('St Segment Elevations', 'no label'), ('Ekg', 'no label'), ('Elevated', 'no label'), ('Cardiac Biomarkers', 'no label'), ('Tcm', 'no label'), ('Elevation', 'no label'), ('Cardiac Enzymes', 'no label'), ('Mild', 'no label'), ('Report', 'no label'), ('Tcm', 'no label'), ('Patient', 'no label'), ('Troponin I', 'no label'), ('Elevation', 'no label'), ('Knowledge', 'no label'), ('High', 'no label'), ('Troponins', 'no label'), ('Patient', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Enzymes', 'no label'), ('Troponin', 'no label'), ('Troponins', 'no label')]|[('Tcm', 'no label'), ('Troponin I', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Chest Pain', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Myocardial', 'no label'), ('Patients', 'no label'), ('Cardiac', 'no label'), ('Tcm', 'no label'), ('Cardiac', 'no label'), ('Patient', 'no label'), ('Troponin I', 'no label'), ('Troponins', 'no label')]
tako-tsubo cardiomyopathy|pubmed~30889079||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~23765730|Tako-Tsubo Cardiomyopathy Is A Transient Left Ventricular Apical Ballooning Syndrome Also Known As Stress-Induced Cardiomyopathy. This Reversible Cardiomyopathy Without Epicardial Coronary Artery Disease Mimics Acute Myocardial Infarction. Right Ventricular Involvement, Which Has Been Infrequently Reported, Is Present In About A Quarter Of Cases Of Tako-Tsubo Cardiomyopathy And Is Associated With A More Severe Clinical Outcome. We Report The Case Of A 55-Year-Old Postmenopausal Woman With Transient Biventricular Apical Ballooning. She Recently Had Acute Exacerbation Of Multiple Sclerosis. Regional And Global Function Of Both Ventricles Was Estimated Using Two-Dimensional Speckle Tracking Strain Echocardiography.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Transient', 'no label'), ('Left Ventricular Apical Ballooning Syndrome', 'no label'), ('Stress-Induced Cardiomyopathy', 'no label'), ('Reversible Cardiomyopathy', 'no label'), ('Epicardial Coronary Artery Disease', 'no label'), ('Right Ventricular Involvement', 'no label'), ('Quarter', 'no label'), ('Cases', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Associated With', 'no label'), ('Severe', 'no label'), ('Clinical Outcome', 'no label'), ('Postmenopausal Woman', 'no label'), ('Transient', 'no label'), ('Biventricular Apical Ballooning', 'no label'), ('Acute Exacerbation', 'no label'), ('Multiple Sclerosis', 'no label'), ('Regional', 'no label'), ('Global Function', 'no label'), ('Ventricles', 'no label'), ('Estimated', 'no label'), ('Two-Dimensional Speckle Tracking Strain Echocardiography', 'no label')]|[('Apical', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricular Apical Ballooning Syndrome', 'no label'), ('Cardiomyopathy', 'no label'), ('Cardiomyopathy', 'no label'), ('Epicardial Coronary Artery Disease', 'no label'), ('Myocardial Infarction', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Left Ventricular', 'no label'), ('Epicardial Coronary', 'no label'), ('Acute Myocardial', 'no label'), ('Biventricular Apical Ballooning', 'no label'), ('Ventricles', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22652494|The Name 'Tako-Tsubo' Cardiomyopathy Was Initially Used To Describe A Unique 'Short-Neck Round-Flask'-Shaped Form Of Left Ventricular Apical Ballooning, Resembling A Japanese Tako-Tsubo, A Jar (Tsubo) Used For Capturing Octopus (Tako). Tako-Tsubo Cardiomyopathy Exhibits Acute Onset, Transient Left Ventricular Apical Wall Motion Abnormalities With Chest Symptoms And Minimal Myocardial Enzymatic Release, Mimicking Acute Myocardial Infarction In Patients Without Angiographic Stenosis On Coronary Angiography. There Have Been Few Case Reports On Tako-Tsubo Cardiomyopathy, And This Disorder Is Especially Rare In Pregnant Women. A 30-Year-Old Woman Who Was Pregnant With Triplets, And Had Been Treated With Ritodrine Hydrochloride For 12 Weeks For Threatened Premature Delivery, Underwent Cesarean Section With Spinal Anesthesia At 30 Weeks' Gestation. Three Hours Later, She Complained Of Acute Chest Pain, Dyspnea And Episodes Of Unconsciousness. She Was Transferred To The Intensive Care Unit And Intubated For Ventilatory Support. We Diagnosed Heart Failure Due To Tako-Tsubo Cardiomyopathy Based On Heart Ultrasonography, Blood Tests, Chest X-Ray, Electrocardiogram And Myocardial Scintigraphy. She Was Extubated From The Ventilator After 3 Days Of Catecholamine, Furosemide And Carperitide Administration. She Was Discharged From The Hospital On Day 53 Without Symptoms.|"[('Cardiomyopathy', 'no label'), ('Unique', 'no label'), ('Short-Neck', 'no label'), (""Round-Flask'-Shaped Form"", 'no label'), ('Left Ventricular Apical Ballooning', 'no label'), ('Resembling', 'no label'), ('Japanese', 'no label'), ('Tako-Tsubo', 'no label'), ('Jar', 'no label'), ('Capturing Octopus', 'no label'), ('Tako', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Onset', 'no label'), ('Transient Left Ventricular Apical Wall Motion Abnormalities', 'no label'), ('Chest Symptoms', 'no label'), ('Myocardial Enzymatic Release', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Patients', 'no label'), ('Angiographic Stenosis', 'no label'), ('Coronary Angiography', 'no label'), ('Case Reports', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Disorder', 'no label'), ('Pregnant Women', 'no label'), ('Pregnant', 'no label'), ('Triplets', 'no label'), ('Treated With', 'no label'), ('Ritodrine Hydrochloride', 'no label'), ('Weeks', 'no label'), ('Threatened Premature', 'no label'), ('Cesarean Section', 'no label'), ('Spinal Anesthesia', 'no label'), ('Gestation', 'no label'), ('Hours', 'no label'), ('Complained', 'no label'), ('Acute Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Episodes', 'no label'), ('Unconsciousness', 'no label'), ('Transferred', 'no label'), ('Intensive Care Unit', 'no label'), ('Intubated', 'no label'), ('Ventilatory Support', 'no label'), ('Diagnosed Heart Failure', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Heart Ultrasonography', 'no label'), ('Blood Tests', 'no label'), ('Chest X-Ray', 'no label'), ('Electrocardiogram', 'no label'), ('Myocardial Scintigraphy', 'no label'), ('Extubated', 'no label'), ('Ventilator', 'no label'), ('Days', 'no label'), ('Catecholamine', 'no label'), ('Furosemide', 'no label'), ('Carperitide', 'no label'), ('Administration', 'no label'), ('Hospital', 'no label'), ('Symptoms', 'no label')]"|[('Apical', 'no label'), ('Apical', 'no label'), ('Hydrochloride', 'no label'), ('Catecholamine', 'no label'), ('Carperitide', 'no label')]|"[(""Name 'Tako-Tsubo' Cardiomyopathy"", 'no label'), ('Jar', 'no label')]"|"[(""Tako-Tsubo' Cardiomyopathy"", 'no label'), ('Left Ventricular Apical Ballooning', 'no label'), ('Tako-Tsubo', 'no label'), ('Tako', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Chest Symptoms', 'no label'), ('Myocardial Infarction', 'no label'), ('Angiographic Stenosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Disorder', 'no label'), ('Ritodrine Hydrochloride', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Heart Failure', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Chest X-Ray, Electrocardiogram And Myocardial Scintigraphy', 'no label'), ('Catecholamine', 'no label'), ('Furosemide', 'no label'), ('Carperitide', 'no label')]"|[('Left Ventricular', 'no label'), ('A Jar', 'no label'), ('Left Ventricular', 'no label'), ('Myocardial', 'no label'), ('Myocardial', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Ritodrine Hydrochloride For', 'no label'), ('Cesarean', 'no label'), ('Heart', 'no label'), ('Heart', 'no label'), ('Blood', 'no label'), ('Myocardial', 'no label'), ('Catecholamine', 'no label'), ('Furosemide', 'no label'), ('Carperitide', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25049018|This Study Evaluated The Frequency, Severity And Outcome Of Complications In The Clinical Course Of Tako-Tsubo Cardiomyopathy (Ttc). Ttc Is Regarded As A Benign Disease Since Left Ventricular (Lv) Function Returns To Normal Within A Short Time. However, Severe Complications Have Been Reported In Selected Patients. From 37 Hospitals, 209 Patients (189 Female, Age 69 ± 12 Years) Were Prospectively Included In A Ttc Registry. Complications Developed In 108/209 Patients (52%); 23 (11%) Had >2 Complications. Complications Occurred Median 1 Day After Symptom Onset, And 77% Were Seen Within 3 Days. Arrhythmias Were Documented In 45/209 Patients (22%) Including Atrial Fibrillation In 32 (15%) And Ventricular Tachycardia In 17 (8%). Of 8 Patients Resuscitated (4%), 6 Survived. Additional Complications Were Right Ventricular Involvement (24%), Pulmonary Edema (13%), Cardiogenic Shock (7%), Transient Intraventricular Pressure Gradients (5%), Lv Thrombi (3%) And Stroke (1%). During Hospitalization, 5/209 Patients (2.5%) Died. Patients With Complications Were Older (70 ± 13 Vs 67 ± 10 Years, P=0.012), Had A Higher Heart Rate (91 ± 26 Vs 83 ± 19/Min, P=0.025), More Frequently Q\ Waves On The Admission Ecg (36% Vs 21%, P=0.019) And A Lower Lv Ejection Fraction (47 ± 15 Vs 54 ± 14%, P = 0.002). Multivariate Regression Analysis Identified Q-Waves On Admission (Or 2.49, 95% Ci 1.23-5.05, P=0.021) And Ejection Fraction ≤ 30% (Or 4.03, 95% Ci 1.04-15.67, P=0.022) As Independent Predictors For Complications. Ttc May Be Associated With Severe Complications In Half Of The Patients. Since The Majority Of Complications Occur Up To Day 3, Monitoring Is Advisable For This Time Period.|[('Study Evaluated', 'no label'), ('Frequency', 'no label'), ('Severity', 'no label'), ('Outcome', 'no label'), ('Complications', 'no label'), ('Clinical Course', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Ttc', 'no label'), ('Benign Disease', 'no label'), ('Left Ventricular', 'no label'), ('Short Time', 'no label'), ('Severe', 'no label'), ('Complications', 'no label'), ('Patients', 'no label'), ('Hospitals', 'no label'), ('Patients', 'no label'), ('Female', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('Ttc Registry', 'no label'), ('Complications', 'no label'), ('Patients', 'no label'), ('Complications', 'no label'), ('Complications', 'no label'), ('Day', 'no label'), ('Days', 'no label'), ('Arrhythmias', 'no label'), ('Documented', 'no label'), ('Patients', 'no label'), ('Atrial Fibrillation', 'no label'), ('Ventricular Tachycardia', 'no label'), ('Patients', 'no label'), ('Resuscitated', 'no label'), ('Survived', 'no label'), ('Complications', 'no label'), ('Right Ventricular Involvement', 'no label'), ('Pulmonary Edema', 'no label'), ('Cardiogenic Shock', 'no label'), ('Transient Intraventricular Pressure Gradients', 'no label'), ('Lv Thrombi', 'no label'), ('Stroke', 'no label'), ('Hospitalization', 'no label'), ('Patients', 'no label'), ('Died', 'no label'), ('Patients', 'no label'), ('Complications', 'no label'), ('Years', 'no label'), ('Higher Heart Rate', 'no label'), ('Q\\ Waves', 'no label'), ('Admission Ecg', 'no label'), ('Lower Lv Ejection Fraction', 'no label'), ('Multivariate Regression Analysis', 'no label'), ('Q-Waves On Admission', 'no label'), ('Ci', 'no label'), ('Ejection Fraction', 'no label'), ('Ci', 'no label'), ('Independent Predictors', 'no label'), ('Complications', 'no label'), ('Ttc', 'no label'), ('Associated With', 'no label'), ('Severe', 'no label'), ('Complications', 'no label'), ('Patients', 'no label'), ('Complications', 'no label'), ('Occur', 'no label'), ('Monitoring', 'no label'), ('Advisable', 'no label'), ('Time Period', 'no label')]|[]|[('Q-Waves', 'no label'), ('≤', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Left Ventricular (Lv) Function Returns To Normal Within A Short Time', 'no label'), ('Arrhythmias', 'no label'), ('Atrial Fibrillation', 'no label'), ('Ventricular Tachycardia', 'no label'), ('Right Ventricular Involvement (24%),', 'no label'), ('Pulmonary Edema', 'no label'), ('Cardiogenic Shock', 'no label'), ('Thrombi', 'no label'), ('Stroke', 'no label'), ('≤', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Pulmonary Edema', 'no label'), ('Lv Thrombi', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Heart', 'no label'), ('Lower Lv', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~32381325||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25202025|Stress Cardiomyopathy (Sc) Is A Transient Ventricular Dysfunction Rarely Described In The Critical Care Setting. To Evaluate The Mechanisms, Incidence, Treatment And Prognosis Of Sc. This Is A Retrospective Observational Study Of Every Critically-Ill Patient Admitted To The Icu Over A Period Of Two Years. Among 1314 Patients Admitted In The Icu, 20 Patients (1.5%) Were Diagnosed With Sc. A Total Of 249 Patients Experienced Cardiogenic Shock, Whereas 8% Were Suffering From Sc. Sc Was Suspected Because Of Hemodynamic Impairment (80% Of Cases), Ecg Modifications (15%) And/Or Dyspnea (15%). Sc Was Apical (Typical Tako-Tsubo) In 90% And Atypical In 10% Of Cases. Several Mechanisms Or Conditions May Explain The Occurrence Of Sc And Are May Be Combined: Catecholamine Toxicity (45%), Psychological Stress, Seizures Or Neurological Impairment (35%), Non-Epicardial Coronary Ischemia (20%) And Left Ventricular Outflow Track (Lvot) Obstruction (10%). Sc Could Have Indirectly Caused Death By Worsening Heart Failure In Three Patients And Arrhythmias Were Seen In 40% Of Patients. Saps2, Renal Impairment, Malnutrition, Norepinephrine Infusion And Thrombocytopenia Were Associated With Death In The Univariate Analysis. Catecholamines Were Required In 85% And Intra-Aortic Balloon Pump In 20% Of Patients. Sc Is A Rare Reversible Cardiac Impairment In The Critically-Ill Patient That Can Induce Arrhythmias And Cardiogenic Shock. The Likely Mechanisms Are Combined: Catecholamine Toxicity, Stress Or Neurological Involvement And Less Frequently Ischemia Or Lvot Obstruction.|[('Stress Cardiomyopathy', 'no label'), ('Sc', 'no label'), ('Transient Ventricular Dysfunction', 'no label'), ('Critical Care Setting', 'no label'), ('Evaluate', 'no label'), ('Mechanisms', 'no label'), ('Incidence', 'no label'), ('Treatment', 'no label'), ('Prognosis', 'no label'), ('Retrospective Observational Study', 'no label'), ('Critically-Ill', 'no label'), ('Patient', 'no label'), ('Admitted', 'no label'), ('Icu', 'no label'), ('Period', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Admitted', 'no label'), ('Icu', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Sc', 'no label'), ('Patients', 'no label'), ('Cardiogenic Shock', 'no label'), ('Suffering', 'no label'), ('Suspected', 'no label'), ('Hemodynamic Impairment', 'no label'), ('Cases', 'no label'), ('Ecg Modifications', 'no label'), ('Dyspnea', 'no label'), ('Sc Was Apical', 'no label'), ('Tako-Tsubo', 'no label'), ('Atypical', 'no label'), ('Cases', 'no label'), ('Mechanisms', 'no label'), ('Conditions', 'no label'), ('Explain', 'no label'), ('Sc', 'no label'), ('May', 'no label'), ('Combined', 'no label'), ('Catecholamine', 'no label'), ('Toxicity', 'no label'), ('Psychological Stress', 'no label'), ('Seizures', 'no label'), ('Neurological Impairment', 'no label'), ('Non-Epicardial Coronary Ischemia', 'no label'), ('Sc', 'no label'), ('Worsening', 'no label'), ('Heart Failure', 'no label'), ('Patients', 'no label'), ('Arrhythmias', 'no label'), ('Patients', 'no label'), ('Saps2', 'no label'), ('Renal Impairment', 'no label'), ('Malnutrition', 'no label'), ('Norepinephrine Infusion', 'no label'), ('Thrombocytopenia', 'no label'), ('Associated With', 'no label'), ('Death', 'no label'), ('Univariate Analysis', 'no label'), ('Catecholamines', 'no label'), ('Intra-Aortic Balloon Pump', 'no label'), ('Patients', 'no label'), ('Sc', 'no label'), ('Rare', 'no label'), ('Reversible Cardiac Impairment', 'no label'), ('Critically-Ill Patient', 'no label'), ('Induce', 'no label'), ('Arrhythmias', 'no label'), ('Cardiogenic Shock', 'no label'), ('Mechanisms', 'no label'), ('Catecholamine', 'no label'), ('Toxicity', 'no label'), ('Stress', 'no label'), ('Neurological', 'no label'), ('Involvement', 'no label'), ('Ischemia', 'no label'), ('Lvot Obstruction', 'no label')]|[('Apical', 'no label'), ('Catecholamine', 'no label'), ('Norepinephrine', 'no label'), ('Catecholamines', 'no label'), ('Catecholamine', 'no label')]|[('Sc', 'no label'), ('Sc And Are May Be', 'no label'), ('Sc', 'no label'), ('Sc', 'no label')]|[('Stress Cardiomyopathy', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Cardiogenic Shock', 'no label'), ('Dyspnea', 'no label'), ('Tako-Tsubo', 'no label'), ('Catecholamine Toxicity', 'no label'), ('Seizures', 'no label'), ('Neurological Impairment', 'no label'), ('Coronary Ischemia', 'no label'), ('Death', 'no label'), ('Worsening Heart Failure', 'no label'), ('Arrhythmias', 'no label'), ('Renal Impairment', 'no label'), ('Malnutrition', 'no label'), ('Norepinephrine', 'no label'), ('Thrombocytopenia', 'no label'), ('Death', 'no label'), ('Catecholamines', 'no label'), ('Cardiac Impairment', 'no label'), ('Arrhythmias', 'no label'), ('Cardiogenic Shock', 'no label'), ('Catecholamine Toxicity', 'no label'), ('Ischemia', 'no label'), ('Lvot Obstruction', 'no label')]|[('Ventricular', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('And/Or', 'no label'), ('Apical', 'no label'), ('Catecholamine', 'no label'), ('Heart', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Renal', 'no label'), ('Norepinephrine', 'no label'), ('Catecholamines', 'no label'), ('Patients', 'no label'), ('Cardiac', 'no label'), ('Patient', 'no label'), ('Catecholamine', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23830846|A 32 Year Old Parturient With A History Of Tako-Tsubo Cardiomyopathy, Who Suffered From Postpartum Hemorrhage For Which Sulprostone Was Administered Without Any Adverse Events, Is Reported. Anesthetic Considerations Related To The Management Of Patient With A History Of Tako-Tsubo Cardiomyopathy, Especially Triggers That May Cause A Recurrence, Are Described. The Potential Deleterious Effects Of Sulprostone In A Patient With A History Of Tako-Tsubo Cardiomyopathy Are Discussed. |[('Year', 'no label'), ('History', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Suffered', 'no label'), ('Postpartum Hemorrhage', 'no label'), ('Sulprostone', 'no label'), ('Administered', 'no label'), ('Adverse Events', 'no label'), ('Anesthetic Considerations', 'no label'), ('Management', 'no label'), ('Patient', 'no label'), ('History', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Triggers', 'no label'), ('Cause A', 'no label'), ('Recurrence', 'no label'), ('Deleterious Effects', 'no label'), ('Sulprostone', 'no label'), ('Patient', 'no label'), ('History', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Postpartum Hemorrhage', 'no label'), ('Sulprostone', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Sulprostone', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Postpartum', 'no label'), ('Sulprostone', 'no label'), ('Patient', 'no label'), ('Sulprostone', 'no label')]
tako-tsubo cardiomyopathy|pubmed~28079764|: We Report A Case Of Paroxysmal Supraventricular Tachycardia Complicating Tako-Tsubo Cardiomyopathy. We Hypothesize That Increased Adrenergic Tone Supposedly Underlying Transient Apical Ballooning Syndrome May Facilitate The Onset Of Paroxysmal Supraventricular Tachycardias In Predisposed Patients.|[('Report', 'no label'), ('Paroxysmal Supraventricular Tachycardia', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Hypothesize', 'no label'), ('Increased', 'no label'), ('Adrenergic', 'no label'), ('Tone', 'no label'), ('Transient', 'no label'), ('Apical Ballooning Syndrome', 'no label'), ('Paroxysmal Supraventricular Tachycardias', 'no label'), ('Predisposed', 'no label'), ('Patients', 'no label')]|[('Adrenergic Tone', 'no label'), ('Apical', 'no label')]|[]|[('Paroxysmal Supraventricular Tachycardia', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Paroxysmal Supraventricular Tachycardias', 'no label')]|[('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~31698474||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~27529592||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~31175069||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~27756491||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25910524|Tako-Tsubo Cardiomyopathy (Ttc) Is Characterized By Apical Ballooning Of The Left Ventricle And Symptoms And Signs Mimicking Acute Myocardial Infarction. The High Catecholamine Levels In The Acute Phase Of Ttc And Common Emotional Triggers Suggest A Dysregulated Stress Response System. This Study Examined Whether Patients With Ttc Show Exaggerated Emotional, Neurohormonal, And Hemodynamic Responses To Mental Stress. Patients With Ttc (N = 18; Mean Age 68.3 ± 11.7, 78% Women) And 2 Comparison Groups (Healthy Controls, N = 19; Mean Age 60.0 ± 7.6, 68% Women; Chronic Heart Failure, N = 19; Mean Age 68.8 ± 10.1, 68% Women) Performed A Structured Mental Stress Task (Anger Recall And Mental Arithmetic) And Low-Grade Exercise With Repeated Assessments Of Negative Emotions, Neurohormones (Catecholamines: Norepinephrine, Epinephrine, Dopamine, Hypothalamic-Pituitary-Adrenal Axis Hormones: Adrenocorticotropic Hormone [Acth], Cortisol), Echocardiography, Blood Pressure, And Heart Rate. Ttc Was Associated With Higher Norepinephrine (520.7 ± 125.5 Vs 407.9 ± 155.3 Pg/Ml, P = 0.021) And Dopamine (16.2 ± 10.3 Vs 10.3 ± 3.9 Pg/Ml, P = 0.027) Levels During Mental Stress And Relatively Low Emotional Arousal (P <0.05) Compared With Healthy Controls. During Exercise, Norepinephrine (511.3 ± 167.1 Vs 394.4 ± 124.3 Pg/Ml, P = 0.037) And Dopamine (17.3 ± 10.0 Vs 10.8 ± 4.1 Pg/Ml, P = 0.017) Levels Were Also Significantly Higher In Patients With Ttc Compared With Healthy Controls. In Conclusion, Catecholamine Levels During Mental Stress And Exercise Were Elevated In Ttc Compared With Healthy Controls. No Evidence Was Found For A Dysregulated Hypothalamic-Pituitary-Adrenal Axis Or Hemodynamic Responses. Patients With Ttc Showed Blunted Emotional Arousal To Mental Stress. This Study Suggests That Catecholamine Hyper-Reactivity And Not Emotional Hyper-Reactivity To Stress Is Likely To Play A Role In Myocardial Vulnerability In Ttc. |[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Characterized', 'no label'), ('Apical Ballooning', 'no label'), ('Left Ventricle', 'no label'), ('Symptoms', 'no label'), ('Signs Mimicking', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Catecholamine Levels', 'no label'), ('Acute Phase', 'no label'), ('Ttc', 'no label'), ('Emotional Triggers', 'no label'), ('Suggest', 'no label'), ('Dysregulated Stress Response System', 'no label'), ('Study', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Exaggerated', 'no label'), ('Emotional', 'no label'), ('Neurohormonal', 'no label'), ('Hemodynamic Responses', 'no label'), ('Mental Stress', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('N\xa0', 'no label'), ('Mean Age', 'no label'), ('Women', 'no label'), ('Comparison', 'no label'), ('Groups', 'no label'), ('Healthy Controls', 'no label'), ('Mean Age', 'no label'), ('Women', 'no label'), ('Chronic Heart Failure', 'no label'), ('N\xa0', 'no label'), ('Mean Age', 'no label'), ('Women', 'no label'), ('Performed A', 'no label'), ('Structured Mental Stress Task', 'no label'), ('Anger Recall And Mental Arithmetic', 'no label'), ('Low-Grade', 'no label'), ('Exercise', 'no label'), ('Repeated Assessments', 'no label'), ('Negative', 'no label'), ('Emotions', 'no label'), ('Neurohormones', 'no label'), ('Catecholamines', 'no label'), ('Norepinephrine', 'no label'), ('Epinephrine', 'no label'), ('Dopamine', 'no label'), ('Hypothalamic-Pituitary-Adrenal Axis Hormones', 'no label'), ('Adrenocorticotropic Hormone', 'no label'), ('Acth', 'no label'), ('Cortisol', 'no label'), ('Echocardiography', 'no label'), ('Blood Pressure', 'no label'), ('Heart Rate', 'no label'), ('Ttc', 'no label'), ('Associated With', 'no label'), ('Higher', 'no label'), ('Norepinephrine', 'no label'), ('Dopamine', 'no label'), ('Levels', 'no label'), ('Mental Stress', 'no label'), ('Low', 'no label'), ('Emotional Arousal', 'no label'), ('Healthy Controls', 'no label'), ('Exercise', 'no label'), ('Norepinephrine', 'no label'), ('Dopamine', 'no label'), ('Levels', 'no label'), ('Higher', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Healthy Controls', 'no label'), ('Catecholamine Levels', 'no label'), ('Mental Stress', 'no label'), ('Exercise', 'no label'), ('Elevated', 'no label'), ('Ttc', 'no label'), ('Healthy Controls', 'no label'), ('Dysregulated', 'no label'), ('Hypothalamic-Pituitary-Adrenal Axis', 'no label'), ('Hemodynamic Responses', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Blunted', 'no label'), ('Emotional Arousal To Mental Stress', 'no label'), ('Study', 'no label'), ('Suggests', 'no label'), ('Catecholamine Hyper-Reactivity', 'no label'), ('Not Emotional', 'no label'), ('Stress', 'no label'), ('Play A', 'no label'), ('Myocardial Vulnerability', 'no label'), ('Ttc', 'no label')]|[('Catecholamine', 'no label'), ('Catecholamines', 'no label'), ('Norepinephrine', 'no label'), ('Epinephrine', 'no label'), ('Dopamine', 'no label'), ('Hormone', 'no label'), ('Cortisol', 'no label'), ('Norepinephrine', 'no label'), ('Dopamine', 'no label'), ('Norepinephrine', 'no label'), ('Dopamine', 'no label'), ('Catecholamine', 'no label'), ('Catecholamine', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Left Ventricle And Symptoms And Signs Mimicking Acute Myocardial Infarction', 'no label'), ('Catecholamine', 'no label'), ('N\xa0= 18; Mean Age 68.3 ±', 'no label'), ('Heart Failure', 'no label'), ('N\xa0= 19; Mean Age 68.8 ±', 'no label'), ('Catecholamines', 'no label'), ('Norepinephrine', 'no label'), ('Epinephrine', 'no label'), ('Dopamine', 'no label'), ('Hypothalamic-Pituitary-Adrenal Axis', 'no label'), ('Cortisol', 'no label'), ('Echocardiography', 'no label'), ('Norepinephrine', 'no label'), ('Dopamine', 'no label'), ('Norepinephrine', 'no label'), ('Dopamine', 'no label'), ('Catecholamine', 'no label'), ('Catecholamine', 'no label')]|[('Apical', 'no label'), ('Left Ventricle', 'no label'), ('Myocardial', 'no label'), ('Catecholamine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Ttc (N\xa0', 'no label'), ('Women', 'no label'), ('Heart', 'no label'), ('Low-Grade', 'no label'), ('Neurohormones', 'no label'), ('Catecholamines', 'no label'), ('Norepinephrine', 'no label'), ('Epinephrine', 'no label'), ('Dopamine', 'no label'), ('Hypothalamic-Pituitary-Adrenal Axis', 'no label'), ('Acth', 'no label'), ('Blood', 'no label'), ('Heart', 'no label'), ('Norepinephrine', 'no label'), ('Pg/Ml', 'no label'), ('Dopamine (16.2 ± 10.3 Vs 10.3', 'no label'), ('Pg/Ml', 'no label'), ('Norepinephrine', 'no label'), ('511.3 ± 167.1', 'no label'), ('Pg/Ml', 'no label'), ('Dopamine', 'no label'), ('Pg/Ml', 'no label'), ('Patients', 'no label'), ('Catecholamine', 'no label'), ('Hypothalamic-Pituitary-Adrenal Axis', 'no label'), ('Patients', 'no label'), ('Catecholamine', 'no label'), ('Myocardial', 'no label')]
tako-tsubo cardiomyopathy|pubmed~24296394|Tako-Tsubo Cardiomyopathy Is An Entity Of Unknown Etiology Characterized By Transient Apical Dyskinesia In Patients With Angiographically Normal Coronary Arteries. However, Atypical Forms Of Tako-Tsubo Cardiomyopathy May Also Occur, Affecting Other Myocardial Segments. Optical Coherence Tomography Has A Unique Resolution And May Detect Angiographically Silent Atherosclerotic Coronary Artery Disease. In This Report, We Describe Optical Coherence Tomography Findings In A Patient With Atypical Tako-Tsubo Cardiomyopathy Presenting As Transient Mid-Ventricular Ballooning.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Entity', 'no label'), ('Unknown Etiology', 'no label'), ('Characterized', 'no label'), ('Transient Apical Dyskinesia', 'no label'), ('Patients', 'no label'), ('Angiographically Normal Coronary Arteries', 'no label'), ('Atypical', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Occur', 'no label'), ('Affecting', 'no label'), ('Myocardial Segments', 'no label'), ('Optical Coherence Tomography', 'no label'), ('Unique', 'no label'), ('Resolution', 'no label'), ('Detect', 'no label'), ('Angiographically', 'no label'), ('Atherosclerotic', 'no label'), ('Coronary Artery Disease', 'no label'), ('Report', 'no label'), ('Optical Coherence Tomography', 'no label'), ('Findings', 'no label'), ('Patient', 'no label'), ('Atypical', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Presenting', 'no label'), ('Transient', 'no label'), ('Mid-Ventricular Ballooning', 'no label')]|[('Apical Dyskinesia', 'no label'), ('Mid-Ventricular', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Dyskinesia', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Silent Atherosclerotic Coronary Artery Disease', 'no label'), ('Atypical Tako-Tsubo Cardiomyopathy', 'no label')]|[('Patients', 'no label'), ('Myocardial Segments.', 'no label'), ('Mid-Ventricular', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23863780|In The Medical Literature, Several Cases Of Tako-Tsubo Cardiomyopathy (Ttc) With Coronary Artery Disease (Cad) Have Been Reported, And In Clinical Practice, Several Typical Ttc Cases Show Relevant Stenoses Of The Coronary Arteries Spatially Unrelated To The Dysfunctional Myocardium. This Study Aimed To Evaluate The Prevalence, Clinical Characteristics, And Outcome Of Patients With Ttc And Relevant Cad In A Large Multicenter Database. In 26 Centers, 450 Patients Admitted With A Diagnosis Of Ttc Underwent Coronary Angiography Within 48 H Of Hospital Admission And Were Included Prospectively In The Tako-Tsubo Italian Network Registry. Overall, 43 (9.6%) Patients Had At Least One Relevant (≥50%) Coronary Stenosis Not Supplying The Dysfunctional Myocardium, Whereas 407 Patients (90.4%) Had Irrelevant Stenosis Or Angiographically Normal Coronary Arteries. Ttc Patients With Relevant Cad Were More Likely To Be Older In Age, To Have Diabetes, A Familial History Of Cad, And Acute Functional Mitral Regurgitation Compared With Those Without Relevant Cad. At The 6-Month Follow-Up, The Incidence Of Death, Ttc Recurrence, And Rehospitalization Rates In Patients With And Without Relevant Cad Were Similar. On Multivariable Cox Analysis, An Independent Predictor Of Death Was The Charlson Comorbidity Index, Whereas The Presence Of Cad Did Not Influence The Mid-Term Outcome Significantly. The Presence Of Cad Is A Rather Common Finding In A Large Proportion Of Patients With Ttc. Thus, When The Stenotic Artery Does Not Supply The Dysfunctional Myocardium Or When The Extent Of Dysfunctional Myocardium Is Wider Than The Territory Of Distribution Supplied By A Single Stenotic Coronary Artery, The Presence Of Angiographically Relevant Cad Should Not Be Considered An Exclusion Criterion For Ttc.|[('Medical Literature', 'no label'), ('Cases', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Coronary Artery Disease', 'no label'), ('Cad', 'no label'), ('Clinical Practice', 'no label'), ('Typical', 'no label'), ('Ttc', 'no label'), ('Cases', 'no label'), ('Relevant', 'no label'), ('Stenoses', 'no label'), ('Coronary Arteries', 'no label'), ('Spatially Unrelated', 'no label'), ('Dysfunctional Myocardium', 'no label'), ('Study', 'no label'), ('Evaluate', 'no label'), ('Prevalence', 'no label'), ('Clinical Characteristics', 'no label'), ('Outcome', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Relevant', 'no label'), ('Cad', 'no label'), ('Multicenter Database', 'no label'), ('Centers', 'no label'), ('Patients', 'no label'), ('Admitted With A Diagnosis', 'no label'), ('Ttc', 'no label'), ('Coronary Angiography', 'no label'), ('Hospital Admission', 'no label'), ('Tako-Tsubo Italian Network Registry', 'no label'), ('Patients', 'no label'), ('Relevant', 'no label'), ('Coronary Stenosis', 'no label'), ('Not Supplying', 'no label'), ('Dysfunctional Myocardium', 'no label'), ('Patients', 'no label'), ('Irrelevant Stenosis', 'no label'), ('Angiographically', 'no label'), ('Normal Coronary Arteries', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Relevant', 'no label'), ('Cad', 'no label'), ('Older', 'no label'), ('Age', 'no label'), ('Diabetes', 'no label'), ('Familial History', 'no label'), ('Cad', 'no label'), ('Acute Functional Mitral Regurgitation', 'no label'), ('Relevant', 'no label'), ('Cad', 'no label'), ('Follow-Up', 'no label'), ('Incidence', 'no label'), ('Death', 'no label'), ('Ttc', 'no label'), ('Recurrence', 'no label'), ('Rehospitalization Rates', 'no label'), ('Patients', 'no label'), ('Relevant', 'no label'), ('Cad', 'no label'), ('Multivariable Cox Analysis', 'no label'), ('Independent Predictor', 'no label'), ('Death', 'no label'), ('Charlson Comorbidity Index', 'no label'), ('Presence', 'no label'), ('Cad', 'no label'), ('Did Not', 'no label'), ('Influence', 'no label'), ('Mid-Term', 'no label'), ('Outcome', 'no label'), ('Cad', 'no label'), ('Finding', 'no label'), ('Proportion', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Stenotic Artery', 'no label'), ('Dysfunctional', 'no label'), ('Myocardium', 'no label'), ('Extent', 'no label'), ('Dysfunctional', 'no label'), ('Wider Than', 'no label'), ('Territory', 'no label'), ('Distribution Supplied', 'no label'), ('Single Stenotic Coronary Artery', 'no label'), ('Angiographically', 'no label'), ('Relevant', 'no label'), ('Cad', 'no label'), ('Exclusion Criterion', 'no label'), ('Ttc', 'no label')]|[('Cox', 'no label'), ('Territory', 'no label')]|[('Cad', 'no label'), ('Cad', 'no label'), ('Cad', 'no label'), ('Cad', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Coronary Artery Disease', 'no label'), ('Tako-Tsubo', 'no label'), ('Coronary Stenosis', 'no label'), ('Irrelevant Stenosis', 'no label'), ('Diabetes', 'no label'), ('Acute Functional Mitral Regurgitation', 'no label'), ('Death', 'no label'), ('Death', 'no label'), ('Comorbidity', 'no label')]|[('Coronary Artery Disease', 'no label'), ('Cad', 'no label'), ('Coronary Arteries', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Cad', 'no label'), ('Mitral', 'no label'), ('Cad', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Cad', 'no label'), ('Cad Is A', 'no label'), ('Patients', 'no label'), ('Stenotic Artery', 'no label'), ('Myocardium', 'no label'), ('Myocardium', 'no label'), ('Cad', 'no label')]
tako-tsubo cardiomyopathy|pubmed~24944763|"To Investigate The Possible Association Between Tako-Tsubo Cardiomyopathy (Ttc)-A Reversible Clinical Condition Mimicking An Acute Myocardial Infarction Characterized By Multifactorial Pathophysiologic Mechanisms- And Respiratory System Diseases. We Systematically Searched Pubmed And Embase Medical Information Sources, To Identify The Different Triggering Causes, Limiting Our Search To Articles In English. The Search Keywords Were: ""Tako-Tsubo Cardiomyopathy"", ""Takotsubo"", ""Takotsubo Cardiomyopathy"", ""Broken Heart Syndrome"", ""Stress-Induced Cardiomyopathy"", ""Apical Ballooning Syndrome"", And ""Ampulla Cardiomyopathy In Combination With Respiratory Diseases, Lung, Pulmonary Disease. For Each Kind Of Disease, We Registered: Author, Year And Country Of Study, Patient Sex, Age, Concurring Situation, And Outcome. Out Of A Total Of 1725 Articles Found, We Selected 37 Papers Reporting A Total Of 38 Patients. As Expected, Most Patients Were Women (81.6%), Mean Age Was 65 ± 10 Years. Outcome Was Favorable In 100% Of Cases, And All The Patients Have Been Discharged Uneventfully In A Few Days. An Association Between Respiratory Diseases And Ttc Is Likely To Exist. Patients With Severe Respiratory Diseases, Due To The High Dosages Of Β2-Agonists Used Or To The Need Of Invasive Procedures, Are Highly Exposed To The Risk Of Developing Ttc."|[('Investigate', 'no label'), ('Association', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Reversible', 'no label'), ('Clinical Condition', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Characterized', 'no label'), ('Pathophysiologic Mechanisms-', 'no label'), ('Respiratory System Diseases', 'no label'), ('Systematically Searched Pubmed', 'no label'), ('Sources', 'no label'), ('Triggering', 'no label'), ('Causes', 'no label'), ('Articles', 'no label'), ('English', 'no label'), ('Search', 'no label'), ('Keywords', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Stress-Induced Cardiomyopathy', 'no label'), ('Apical Ballooning Syndrome', 'no label'), ('Ampulla Cardiomyopathy', 'no label'), ('Combination', 'no label'), ('Respiratory Diseases', 'no label'), ('Lung', 'no label'), ('Pulmonary Disease', 'no label'), ('Kind Of Disease', 'no label'), ('Author', 'no label'), ('Year', 'no label'), ('Country', 'no label'), ('Study', 'no label'), ('Patient Sex', 'no label'), ('Age', 'no label'), ('Concurring Situation', 'no label'), ('Outcome', 'no label'), ('Articles', 'no label'), ('Papers Reporting A', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Outcome', 'no label'), ('Favorable', 'no label'), ('Cases', 'no label'), ('Patients', 'no label'), ('Uneventfully', 'no label'), ('Days', 'no label'), ('Association', 'no label'), ('Respiratory Diseases', 'no label'), ('Ttc', 'no label'), ('Exist', 'no label'), ('Patients', 'no label'), ('Severe Respiratory Diseases', 'no label'), ('Dosages', 'no label'), ('Need', 'no label'), ('Invasive Procedures', 'no label'), ('Exposed', 'no label'), ('Risk', 'no label'), ('Developing Ttc', 'no label')]|[('Apical', 'no label'), ('Β2-Agonists', 'no label')]|[('Mechanisms-', 'no label'), ('Β2-Agonists', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Heart Syndrome', 'no label'), ('Cardiomyopathy', 'no label'), ('Ballooning Syndrome', 'no label'), ('Ampulla Cardiomyopathy', 'no label'), ('Respiratory Diseases', 'no label'), ('Pulmonary Disease', 'no label'), ('Respiratory Diseases', 'no label'), ('Respiratory Diseases', 'no label')]|[('Myocardial', 'no label'), ('Respiratory System', 'no label'), ('Broken Heart', 'no label'), ('Apical', 'no label'), ('Ampulla', 'no label'), ('Respiratory', 'no label'), ('Lung', 'no label'), ('Pulmonary', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Patients', 'no label'), ('Respiratory', 'no label'), ('Patients', 'no label'), ('Respiratory', 'no label'), ('Β2-Agonists', 'no label'), ('Need', 'no label')]
tako-tsubo cardiomyopathy|pubmed~28490198|The Most Plausible Hypothesis For Takotsubo Cardiomyopathy (Tcm) Is A Catecholamine Surge. Direct Administration Of Catecholamines Or Medications Causing Catecholamine Surge Is Frequently Used In Clinical Practice. A Medline/Pubmed Database Search Was Conducted For Case Reports Or Series Of Drug-Induced Tcm. All Reported Cases Of Drug-Induced Tcm Were Systemically Identified And Analyzed. We Identified 157 Cases Of Drug-Induced Tcm. Fifty-Seven (36.3%) Cases Were Related To The Administration Of Exogenous Catecholamines. In 50 (31.9%) Other Cases, There Was Potential Adrenergic Effect. This Included Drugs With Adrenergic Vasoconstriction Properties (3.2%), Hyperadrenergic State Due To Alcohol Or Opioid Withdrawal (7.7%), Inhibitors Of Catecholamine Reuptake (14.7%), Anaphylactic Reaction That Is Accompanied By Catecholamine Release (3.2%), And Psychological Or Somatic Stress Coinciding With The Administration Of A Drug That Was Thought To Be The Culprit (3.2%). Overall, 68.2% Of These Drug-Induced Tcm Cases Were Catecholamine Related. In 14 (8.9%) Cases, The Likely Etiology Of Cardiomyopathy Was Chemotherapy-Induced Coronary Vasospasm. Our Systematic Review Showed That Over Two-Thirds Of Drug-Induced Tcm Cases Were Due To Direct Or Indirect Catecholamine Stimulation. The Lowest Effective Dose And Shortest Duration Of Catecholamines Should Be Utilized, And Alternative Therapies Should Be Considered If Feasible.|[('Hypothesis', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Tcm', 'no label'), ('Catecholamine Surge', 'no label'), ('Direct Administration', 'no label'), ('Catecholamines', 'no label'), ('Medications', 'no label'), ('Causing', 'no label'), ('Catecholamine Surge', 'no label'), ('Clinical Practice', 'no label'), ('Medline/Pubmed Database', 'no label'), ('Search', 'no label'), ('Case Reports', 'no label'), ('Cases', 'no label'), ('Drug-Induced Tcm', 'no label'), ('Systemically', 'no label'), ('Identified', 'no label'), ('Analyzed', 'no label'), ('Cases', 'no label'), ('Drug-Induced Tcm', 'no label'), ('Fifty-Seven', 'no label'), ('Cases', 'no label'), ('Administration', 'no label'), ('Exogenous', 'no label'), ('Catecholamines', 'no label'), ('Cases', 'no label'), ('Adrenergic', 'no label'), ('Effect', 'no label'), ('Drugs', 'no label'), ('Adrenergic Vasoconstriction', 'no label'), ('Properties', 'no label'), ('Hyperadrenergic State', 'no label'), ('Alcohol Or Opioid Withdrawal', 'no label'), ('Inhibitors', 'no label'), ('Catecholamine Reuptake', 'no label'), ('Anaphylactic Reaction', 'no label'), ('Catecholamine Release', 'no label'), ('Psychological', 'no label'), ('Somatic Stress', 'no label'), ('Administration', 'no label'), ('Drug', 'no label'), ('Culprit', 'no label'), ('Drug-Induced', 'no label'), ('Tcm', 'no label'), ('Cases', 'no label'), ('Catecholamine', 'no label'), ('Cases', 'no label'), ('Etiology', 'no label'), ('Cardiomyopathy', 'no label'), ('Chemotherapy-Induced', 'no label'), ('Coronary Vasospasm', 'no label'), ('Systematic Review', 'no label'), ('Two-Thirds', 'no label'), ('Drug-Induced Tcm', 'no label'), ('Cases', 'no label'), ('Indirect', 'no label'), ('Catecholamine Stimulation', 'no label'), ('Effective', 'no label'), ('Dose', 'no label'), ('Shortest', 'no label'), ('Duration', 'no label'), ('Catecholamines', 'no label'), ('Alternative Therapies', 'no label')]|[('Catecholamine', 'no label'), ('Catecholamines', 'no label'), ('Catecholamine', 'no label'), ('Catecholamines', 'no label'), ('Alcohol', 'no label'), ('Inhibitors', 'no label'), ('Catecholamine', 'no label'), ('Catecholamine', 'no label'), ('Drug', 'no label'), ('Catecholamine', 'no label'), ('Catecholamine', 'no label'), ('Catecholamines', 'no label')]|[('Medline/Pubmed Database', 'no label'), ('Tcm', 'no label')]|[('Takotsubo Cardiomyopathy', 'no label'), ('Catecholamine', 'no label'), ('Catecholamines', 'no label'), ('Catecholamine', 'no label'), ('Drug-Induced Tcm', 'no label'), ('Catecholamines', 'no label'), ('Alcohol', 'no label'), ('Catecholamine', 'no label'), ('Anaphylactic Reaction', 'no label'), ('Catecholamine', 'no label'), ('Culprit', 'no label'), ('Catecholamine', 'no label'), ('Cardiomyopathy', 'no label'), ('Vasospasm', 'no label'), ('Catecholamine', 'no label'), ('Catecholamines', 'no label')]|[('Catecholamine', 'no label'), ('Catecholamines', 'no label'), ('Catecholamine', 'no label'), ('Catecholamines', 'no label'), ('Alcohol', 'no label'), ('Opioid', 'no label'), ('Catecholamine Reuptake', 'no label'), ('Catecholamine', 'no label'), ('Culprit', 'no label'), ('Catecholamine', 'no label'), ('Catecholamine', 'no label'), ('Catecholamines', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23078863|Since Dr Sato At Hiroshima City Hospital First Recognized And Reported The Concept Of Tako-Tsubo Cardiomyopathy In 1990, This Disorder Has Become Accepted Worldwide As A Distinct Clinical Entity. Tako-Tsubo Cardiomyopathy Is An Important Disorder As A Differential Diagnosis Of Acute Myocardial Infarction. This Disorder Usually Occurs In Postmenopausal Women Of An Advanced Age, And Is Characterized By Transient Left Ventricular Apical Wall Motion Abnormalities Associated With Emotional Or Physical Stress. Typically, Left Ventricular Apical Wall Motion Abnormalities Are Transient And Resolve During A Period Of Days To Weeks. The Prognosis Is Generally Favorable. However, Several Acute Complications Have Been Reported Such As Congestive Heart Failure, Cardiac Rupture, Hypotension, Left Ventricular Apical Thrombosis, Or Torsade De Pointes. Several Possible Mechanisms Such As Multivessel Coronary Artery Spasm, Coronary Microvascular Dysfunction, Myocarditis, Or Catecholamine Toxicity Have Been Proposed To Explain Tako-Tsubo Cardiomyopathy, But Its Pathophysiology Is Not Well Understood.|[('Hiroshima City Hospital', 'no label'), ('Recognized', 'no label'), ('Concept', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Disorder', 'no label'), ('Accepted', 'no label'), ('Worldwide', 'no label'), ('Clinical Entity', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Disorder', 'no label'), ('Differential Diagnosis', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Disorder', 'no label'), ('Occurs', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Advanced Age', 'no label'), ('Characterized', 'no label'), ('Transient', 'no label'), ('Left Ventricular Apical Wall Motion Abnormalities', 'no label'), ('Associated With', 'no label'), ('Emotional Or Physical Stress', 'no label'), ('Left Ventricular Apical Wall Motion Abnormalities', 'no label'), ('Transient And Resolve', 'no label'), ('Period', 'no label'), ('Days', 'no label'), ('Weeks', 'no label'), ('Prognosis', 'no label'), ('Favorable', 'no label'), ('Acute', 'no label'), ('Complications', 'no label'), ('Congestive Heart Failure', 'no label'), ('Cardiac Rupture', 'no label'), ('Hypotension', 'no label'), ('Left Ventricular Apical Thrombosis', 'no label'), ('Torsade', 'no label'), ('De Pointes', 'no label'), ('Mechanisms', 'no label'), ('Multivessel Coronary Artery Spasm', 'no label'), ('Coronary Microvascular Dysfunction', 'no label'), ('Myocarditis', 'no label'), ('Catecholamine', 'no label'), ('Toxicity', 'no label'), ('Explain', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Pathophysiology', 'no label')]|[('Apical', 'no label'), ('Apical', 'no label'), ('Catecholamine', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Disorder', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Prognosis', 'no label'), ('Congestive Heart Failure', 'no label'), ('Cardiac Rupture', 'no label'), ('Hypotension', 'no label'), ('Left Ventricular Apical Thrombosis', 'no label'), ('Torsade De Pointes', 'no label'), ('Multivessel Coronary Artery Spasm', 'no label'), ('Coronary Microvascular Dysfunction', 'no label'), ('Myocarditis', 'no label'), ('Catecholamine Toxicity', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Sato', 'no label'), ('Acute Myocardial', 'no label'), ('Women', 'no label'), ('Left Ventricular', 'no label'), ('Acute Complications', 'no label'), ('Heart', 'no label'), ('Cardiac', 'no label'), ('Left Ventricular', 'no label'), ('Microvascular', 'no label'), ('Catecholamine', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25412594|Symptoms Of A Post-Traumatic Stress Disorder Can Follow Tako-Tsubo Cardiomyopathy. This Vignette Describes Such A Linkage And Exemplifies The Risk That These Symptoms May Remain Undetected. After A Skiing Accident That Had Evoked Existential Fear Of Suffocation, A Post-Menopausal Woman Was Diagnosed With Tako-Tsubo Syndrome And Myocardial Contusion. Symptoms Of Post-Traumatic Stress Disorder Appeared 2 Weeks After Remission Of The Cardiomyopathy. Two Months Later, A Psychological Assessment Was Conducted During Cardiac Rehabilitation. A Post-Traumatic Stress Disorder Was Diagnosed And Successfully Treated By Narrative Exposure. This Case Report Suggests That These Patients Should Be Informed During The Initial Hospital Stay That Post-Traumatic Stress Symptoms Could Appear. It Also Suggests Including A Screening For Post-Traumatic Stress Disorder In The Follow-Up Of These Patients.|[('Symptoms', 'no label'), ('Post-Traumatic Stress Disorder', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Vignette Describes', 'no label'), ('Linkage', 'no label'), ('Exemplifies', 'no label'), ('Risk', 'no label'), ('Symptoms', 'no label'), ('Undetected', 'no label'), ('Skiing Accident', 'no label'), ('Evoked', 'no label'), ('Existential', 'no label'), ('Fear', 'no label'), ('Suffocation', 'no label'), ('Post-Menopausal Woman', 'no label'), ('Diagnosed', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Myocardial Contusion', 'no label'), ('Symptoms', 'no label'), ('Post-Traumatic Stress Disorder', 'no label'), ('Appeared 2 Weeks', 'no label'), ('Remission', 'no label'), ('Cardiomyopathy', 'no label'), ('Months', 'no label'), ('Psychological Assessment', 'no label'), ('Cardiac Rehabilitation', 'no label'), ('Post-Traumatic Stress Disorder', 'no label'), ('Diagnosed', 'no label'), ('Successfully', 'no label'), ('Treated', 'no label'), ('Narrative', 'no label'), ('Exposure', 'no label'), ('Case Report', 'no label'), ('Suggests', 'no label'), ('Patients', 'no label'), ('Initial', 'no label'), ('Hospital Stay', 'no label'), ('Post-Traumatic Stress Symptoms', 'no label'), ('Appear', 'no label'), ('Screening', 'no label'), ('Post-Traumatic Stress Disorder', 'no label'), ('Follow-Up', 'no label'), ('Patients', 'no label')]|[]|[]|[('Stress Disorder', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Suffocation', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Myocardial Contusion', 'no label'), ('Post-Traumatic Stress Disorder', 'no label'), ('Cardiomyopathy', 'no label'), ('Cardiac Rehabilitation', 'no label'), ('Stress Disorder', 'no label'), ('Stress Disorder', 'no label')]|[('Myocardial', 'no label'), ('Stress', 'no label'), ('Cardiac', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23608401|Tako-Tsubo Cardiomyopathy (Ttc), Is Defined As A Fully Reversible Acute Deterioration Of Left-Ventricular (Lv) Function, Which Is Mainly Found In Women After An Episode Of Emotional Or Physical Stress (E.G. Psychosocial Stress, Sepsis, Surgery). The Underlying Mechanisms Remain Unclear. There Is Evidence Suggesting A Possible Link Between Neurological Disease And Ttc. The Pathophysiology Of The Several Neurologic Diseases Has Been Reviewed Searching For Possible Mechanisms That Could Lead To Ttc In These Patients. |[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Acute Deterioration', 'no label'), ('Left-Ventricular', 'no label'), ('Women', 'no label'), ('Episode', 'no label'), ('Emotional Or Physical Stress', 'no label'), ('E.G. Psychosocial Stress', 'no label'), ('Sepsis', 'no label'), ('Surgery', 'no label'), ('Mechanisms', 'no label'), ('Remain Unclear', 'no label'), ('Evidence', 'no label'), ('Suggesting', 'no label'), ('Neurological Disease', 'no label'), ('Ttc', 'no label'), ('Pathophysiology', 'no label'), ('Neurologic Diseases', 'no label'), ('Reviewed', 'no label'), ('Mechanisms', 'no label'), ('Lead', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label')]|[('Lead To', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Acute Deterioration Of Left-Ventricular (Lv) Function', 'no label'), ('Sepsis', 'no label'), ('Neurological Disease', 'no label'), ('Neurologic Diseases', 'no label')]|[('Left-Ventricular', 'no label'), ('Women', 'no label'), ('E.G.', 'no label'), ('Link', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~26249047|Takotsubo Cardiomyopathy, Also Known As Transient Left Ventricular Ballooning And Stress Myocardiopathy, Has Been Diagnosed Increasingly More Over The Last Decade. The Takotsubo Syndrome Mimics Acute Myocardial Infarction In Symptoms And In Electrocardiographic Findings. There Are Two Major Types Of Takotsubo Cardiomyopathy: The Classical Type With Left Ventricular Apical Ballooning And A Type With Midventricular Ballooning. Both Types Show Different Electrocardiographic Patterns At Presentation. The Present Article Describes Classical Electrocardiographic Findings Of The Acute And Subacute Phases Of Takotsubo Cardiomyopathy. |[('Takotsubo Cardiomyopathy', 'no label'), ('Transient', 'no label'), ('Left Ventricular Ballooning', 'no label'), ('Stress Myocardiopathy', 'no label'), ('Diagnosed', 'no label'), ('Takotsubo Syndrome', 'no label'), ('Mimics Acute Myocardial Infarction', 'no label'), ('Symptoms', 'no label'), ('Electrocardiographic Findings', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Classical Type', 'no label'), ('Left Ventricular Apical Ballooning', 'no label'), ('Midventricular Ballooning', 'no label'), ('Electrocardiographic Patterns', 'no label'), ('Presentation', 'no label'), ('Article', 'no label'), ('Describes', 'no label'), ('Electrocardiographic Findings', 'no label'), ('Acute', 'no label'), ('Subacute', 'no label'), ('Phases', 'no label'), ('Takotsubo Cardiomyopathy', 'no label')]|[('Apical', 'no label')]|[]|[('Takotsubo Cardiomyopathy', 'no label'), ('Ventricular Ballooning', 'no label'), ('Takotsubo Syndrome', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Left Ventricular Apical Ballooning And A Type With Midventricular Ballooning', 'no label'), ('Takotsubo Cardiomyopathy', 'no label')]|[('Left Ventricular', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Left Ventricular', 'no label'), ('A Type', 'no label'), ('Midventricular', 'no label'), ('Acute And Subacute Phases', 'no label')]
tako-tsubo cardiomyopathy|pubmed~24746945|We Report The Case Of A Middle Age Patient Presenting With Tako-Tsubo Cardiomyopathy (Ttc) Complicated By Cardiogenic Shock That Was Successfully Handled With Milrinone. A 64-Year Old Man Presented With Cardiogenic Shock After Benzodiazepine And Alcohol Intoxication. A Slight Elevation Of Troponin And Typical Left Ventricular Ballooning Without Coronary Lesions Suggested Ttc. Within A Few Hours Milrinone Infusion Normalized The Cardiac Index. Ttc Is Responsible For Severe Transient Left Ventricular Dysfunction Occurring After Physical Or Psychological Stress. The Major Pathophysiological Mechanism Involved Is Disproportionate Catecholamine Secretion, Which May Stun The Myocardium. We Considered If Treatment Of This Unique Physiopathology With Catecholamines Could Be Dangerous In These Patients And If Alternative Inotropes Such As Milrinone Should Be Preferred. |[('Report', 'no label'), ('Middle Age', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Complicated', 'no label'), ('Cardiogenic Shock', 'no label'), ('Successfully', 'no label'), ('Handled', 'no label'), ('Milrinone', 'no label'), ('64-Year Old Man', 'no label'), ('Cardiogenic Shock', 'no label'), ('Benzodiazepine', 'no label'), ('Alcohol Intoxication', 'no label'), ('Elevation', 'no label'), ('Troponin', 'no label'), ('Typical', 'no label'), ('Left Ventricular Ballooning', 'no label'), ('Coronary Lesions', 'no label'), ('Suggested Ttc', 'no label'), ('Hours', 'no label'), ('Milrinone', 'no label'), ('Infusion', 'no label'), ('Cardiac Index', 'no label'), ('Ttc', 'no label'), ('Severe', 'no label'), ('Transient', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Physical Or', 'no label'), ('Psychological Stress', 'no label'), ('Pathophysiological', 'no label'), ('Mechanism', 'no label'), ('Disproportionate', 'no label'), ('Catecholamine Secretion', 'no label'), ('Stun', 'no label'), ('Myocardium', 'no label'), ('Treatment', 'no label'), ('Physiopathology', 'no label'), ('Catecholamines', 'no label'), ('Dangerous', 'no label'), ('Patients', 'no label'), ('Alternative Inotropes', 'no label'), ('Milrinone', 'no label')]|[('Benzodiazepine', 'no label'), ('Alcohol', 'no label'), ('Troponin', 'no label'), ('Catecholamine', 'no label'), ('Catecholamines', 'no label')]|[('Troponin', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Cardiogenic Shock', 'no label'), ('Milrinone', 'no label'), ('Cardiogenic Shock', 'no label'), ('Benzodiazepine', 'no label'), ('Alcohol Intoxication', 'no label'), ('Left Ventricular Ballooning', 'no label'), ('Milrinone', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Catecholamine', 'no label'), ('Catecholamines', 'no label'), ('Milrinone', 'no label')]|[('Case Of A', 'no label'), ('Patient', 'no label'), ('Handled', 'no label'), ('Milrinone', 'no label'), ('Benzodiazepine', 'no label'), ('Alcohol', 'no label'), ('Troponin', 'no label'), ('Left Ventricular', 'no label'), ('Coronary Lesions', 'no label'), ('Milrinone', 'no label'), ('Cardiac', 'no label'), ('Left Ventricular', 'no label'), ('Catecholamine', 'no label'), ('Myocardium.', 'no label'), ('Catecholamines', 'no label'), ('Patients', 'no label'), ('Milrinone', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25620641||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~30664537||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25885754||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~26397404||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~26144453|Although Tako-Tsubo Cardiomyopathy (Ttc) Is Regarded As A Reversible Condition With Favorable Outcome, A Malignant Clinical Course Evolves In Some Subjects. In This Single-Institution Experience, We Describe The Clinical Profile Of Patients With Adverse Ttc Outcome. A Cohort Of 249 Consecutive Patients With Ttc Was Interrogated For Those With Acute Unstable Presentation During The First 24 Hours. Forty-Seven Patients (19%) Experienced Early Complicated Clinical Course With Cardiac Arrest In 9 (Ventricular Fibrillation, N = 4, Pulseless Electrical Activity, N = 3, And Asystole, N = 2) Or Marked Hypotension In 38 (Systolic Blood Pressure ≤90 Mm Hg Requiring Vasopressors And/Or Balloon Pump). Of The 47 Patients, Killip Class Iii To Iv Heart Failure Was Present In 30 (64%). Despite Treatment, 8 Patients (3%; All Women) Died Inhospital Due To Respiratory Failure, Cardiogenic Shock, Or Anoxic Brain Injury. All 8 Inhospital Deaths Occurred Among The 47 Patients With Unstable Presentation, Including 2 After Cardiac Arrest And 6 With Marked Hypotension. Post-Ttc Event Mortality For A Period Of 4.7 ± 3.4 Years Significantly Exceeded That In A Matched General Us Population (Standardized Mortality Ratio 1.4; 95% Confidence Interval 1.1 To 1.9; P = 0.005) Largely Due To Noncardiac Co-Morbidities. In Conclusion, Contrary To Widespread Perception, Ttc Is Not An Entirely Benign And Reversible Condition. Among This Large Cohort, A High-Risk Subgroup Was Identified With Cardiac Arrest Or Hemodynamic Instability, Accounting For All Hospital Deaths. Hospital Nonsurvivors Had A Variety Of Irreversible Co-Morbid Conditions With The Potential To Compromise Clinical Status And Adversely Affect Short-Term Survival. Long-Term Survival After Hospital Discharge Was Also Reduced Compared With The General Population Because Of Noncardiac Co-Morbidities. |[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Reversible', 'no label'), ('Condition', 'no label'), ('Favorable Outcome', 'no label'), ('Malignant Clinical Course', 'no label'), ('Evolves', 'no label'), ('Subjects', 'no label'), ('Single-Institution', 'no label'), ('Experience', 'no label'), ('Clinical Profile', 'no label'), ('Patients', 'no label'), ('Adverse Ttc', 'no label'), ('Outcome', 'no label'), ('Cohort', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Acute Unstable Presentation', 'no label'), ('Patients', 'no label'), ('Experienced', 'no label'), ('Early', 'no label'), ('Complicated', 'no label'), ('Clinical Course', 'no label'), ('Cardiac Arrest', 'no label'), ('Ventricular Fibrillation', 'no label'), ('Pulseless', 'no label'), ('Electrical Activity', 'no label'), ('Asystole', 'no label'), ('N\xa0', 'no label'), ('Hypotension', 'no label'), ('Systolic Blood Pressure', 'no label'), ('Vasopressors And/Or', 'no label'), ('Balloon Pump', 'no label'), ('Patients', 'no label'), ('Killip Class Iii', 'no label'), ('Iv Heart Failure', 'no label'), ('Treatment', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Died Inhospital', 'no label'), ('Respiratory Failure', 'no label'), ('Cardiogenic Shock', 'no label'), ('Anoxic', 'no label'), ('Brain Injury', 'no label'), ('Inhospital Deaths', 'no label'), ('Occurred', 'no label'), ('Patients', 'no label'), ('Unstable', 'no label'), ('Presentation', 'no label'), ('Cardiac Arrest', 'no label'), ('Hypotension', 'no label'), ('Post-Ttc Event', 'no label'), ('Mortality', 'no label'), ('Period', 'no label'), ('Years', 'no label'), ('Exceeded', 'no label'), ('Matched', 'no label'), ('General Us Population', 'no label'), ('Standardized Mortality Ratio', 'no label'), ('Confidence Interval', 'no label'), ('Noncardiac', 'no label'), ('Co-Morbidities', 'no label'), ('Widespread', 'no label'), ('Perception', 'no label'), ('Ttc', 'no label'), ('Benign', 'no label'), ('Reversible', 'no label'), ('Condition', 'no label'), ('Cohort', 'no label'), ('High-Risk Subgroup', 'no label'), ('Cardiac Arrest', 'no label'), ('Hemodynamic Instability', 'no label'), ('Accounting', 'no label'), ('Hospital Deaths', 'no label'), ('Hospital', 'no label'), ('Nonsurvivors', 'no label'), ('Irreversible', 'no label'), ('Co-Morbid', 'no label'), ('Conditions', 'no label'), ('Potential', 'no label'), ('Compromise Clinical Status', 'no label'), ('Affect', 'no label'), ('Short-Term', 'no label'), ('Survival', 'no label'), ('Long-Term Survival', 'no label'), ('Hospital Discharge', 'no label'), ('Reduced', 'no label'), ('General Population', 'no label'), ('Noncardiac', 'no label'), ('Co-Morbidities', 'no label')]|[('Hg', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Cardiac Arrest', 'no label'), ('Ventricular Fibrillation', 'no label'), ('N\xa0= 4, Pulseless Electrical Activity, N\xa0= 3, And', 'no label'), ('Asystole', 'no label'), ('N\xa0= 2)', 'no label'), ('Hypotension', 'no label'), ('And/Or', 'no label'), ('Heart Failure', 'no label'), ('Respiratory Failure', 'no label'), ('Cardiogenic Shock', 'no label'), ('Anoxic Brain Injury', 'no label'), ('Deaths', 'no label'), ('Cardiac Arrest', 'no label'), ('Hypotension', 'no label'), ('Noncardiac Co-Morbidities', 'no label'), ('Cardiac Arrest', 'no label'), ('Deaths', 'no label'), ('Nonsurvivors', 'no label'), ('Noncardiac Co-Morbidities', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cardiac', 'no label'), ('Ventricular', 'no label'), ('Blood', 'no label'), ('Mm', 'no label'), ('And/Or', 'no label'), ('Patients', 'no label'), ('Killip Class', 'no label'), ('Heart', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Respiratory', 'no label'), ('Brain', 'no label'), ('Patients', 'no label'), ('Cardiac', 'no label'), ('Cardiac', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25889440||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25822333|Tako-Tsubo Cardiomyopathy (Ttc) Is An Acute Cardiomyopathy Mimicking Acute Myocardial Infarction. The Aim Of Our Study Was To Define Clinical And Instrumental Features Of An Italian Population Of Patients With Ttc And To Report Their Short And Mid-Term Outcome. We Retrospectively Evaluated 42 Patients Admitted To Our Department With Diagnosis Of Ttc (100% Women, Age 67 ± 11 Years) Using Mayo Clinic-Modified Criteria. In This Population, We Analyzed The Stressful Event (If Present), The Clinical Presentation, The Ecg And Echocardiogram At Admission And The Markers Of Myocardial Cytonecrosis, Such As Troponin I, At Admission And During The Hospitalization. All The Patients Have Been Clinically Evaluated After 6 Months And 1 Year Of Follow-Up. In This Population, A Stressful Event Before Ttc Has Been Detected In 59% Of Patients. The Most Common Clinical Presentation Was Chest Pain (81%) And The Major Sign Was Dyspnea (17%). Ecg Showed Negative T Waves And St Elevation, Respectively, In 45 And 38%. Only 10% Had A St Depression And 7% Developed A Newly Acquired Complete Left Bundle Branch Block. All Of These Abnormalities Disappeared Within 1.8 ± 0.9 Days. The Mean Ejection Fraction At Admission Was 35 ± 7% Associated With Apical (40%), Mid-Apical (56%) And Mid-Ventricular (4%) Wall Motion Abnormalities. The Recovery Of These Abnormalities Occurred Within 10 ± 3 Days. At 6-Month And 1-Year Follow-Up, No Patients Had Ttc Recurrence, And 10 Patients At 6 Months And 20 Patients At 1 Year Were Re-Hospitalized For A Non-Cardiac Cause. Our Data Describe The Characteristics Of Ttc In A Small Italian Population, Which Are Similarly Described In Japanese And North American People. Ttc Was Related To A Very Low Mortality, Both In The Short And Mid Term, But The Risk Of Acute Heart Failure In The Acute Phase Could Not Be Neglected.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Acute Cardiomyopathy', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Study', 'no label'), ('Clinical', 'no label'), ('Instrumental', 'no label'), ('Features', 'no label'), ('Italian', 'no label'), ('Population', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Short', 'no label'), ('Outcome', 'no label'), ('Retrospectively Evaluated', 'no label'), ('Patients', 'no label'), ('Admitted', 'no label'), ('Department', 'no label'), ('Diagnosis', 'no label'), ('Ttc', 'no label'), ('Women', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('Mayo Clinic-Modified Criteria', 'no label'), ('Population', 'no label'), ('Analyzed', 'no label'), ('Stressful Event', 'no label'), ('Clinical Presentation', 'no label'), ('Ecg And Echocardiogram', 'no label'), ('Admission', 'no label'), ('Markers', 'no label'), ('Myocardial', 'no label'), ('Cytonecrosis', 'no label'), ('Troponin I', 'no label'), ('Admission', 'no label'), ('Hospitalization', 'no label'), ('Patients', 'no label'), ('Clinically Evaluated', 'no label'), ('Months', 'no label'), ('Year', 'no label'), ('Follow-Up', 'no label'), ('Population', 'no label'), ('Stressful Event', 'no label'), ('Ttc', 'no label'), ('Detected', 'no label'), ('Patients', 'no label'), ('Clinical Presentation', 'no label'), ('Major Sign Was Dyspnea', 'no label'), ('Ecg Showed Negative T Waves', 'no label'), ('St', 'no label'), ('Elevation', 'no label'), ('St Depression', 'no label'), ('Left Bundle Branch Block', 'no label'), ('Abnormalities', 'no label'), ('Disappeared', 'no label'), ('Days', 'no label'), ('Mean Ejection Fraction', 'no label'), ('Admission', 'no label'), ('Associated With', 'no label'), ('Apical', 'no label'), ('Mid-Apical', 'no label'), ('Mid-Ventricular', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Recovery', 'no label'), ('Abnormalities', 'no label'), ('Occurred', 'no label'), ('Days', 'no label'), ('1-Year Follow-Up', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Recurrence', 'no label'), ('Patients', 'no label'), ('Months', 'no label'), ('Patients', 'no label'), ('Year', 'no label'), ('Re-Hospitalized', 'no label'), ('Non-Cardiac', 'no label'), ('Cause', 'no label'), ('Data', 'no label'), ('Characteristics', 'no label'), ('Ttc', 'no label'), ('Population', 'no label'), ('Japanese', 'no label'), ('North American', 'no label'), ('People', 'no label'), ('Ttc', 'no label'), ('Low', 'no label'), ('Mortality', 'no label'), ('Short', 'no label'), ('Risk', 'no label'), ('Acute Heart Failure', 'no label'), ('Acute Phase', 'no label'), ('Neglected', 'no label')]|[('Troponin I', 'no label'), ('±', 'no label'), ('Mid-Ventricular', 'no label'), ('±', 'no label')]|[('Troponin I', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Cardiomyopathy', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Depression', 'no label'), ('Bundle Branch Block', 'no label'), ('Abnormalities Disappeared', 'no label'), ('Acute Heart Failure', 'no label')]|[('Myocardial', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Myocardial', 'no label'), ('Troponin I', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Mid-Ventricular (4', 'no label'), ('Wall', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('A Non-Cardiac', 'no label'), ('Ttc In A Small', 'no label'), ('Heart', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23027688|Tako-Tsubo Cardiomyopathy (Ttc) Is Typically Triggered By An Acute Emotional Or Physical Stress Event. The Aim Of This Study Was To Investigate The Impact Of Stressor Patterns On Clinical Features, Laboratory Parameters, And Electrocardiographic And Echocardiographic Findings In Patients With Ttc. Clinical Features Are Different According To Stressor Patterns. Of 137 Patients Enrolled From The Ttc Registry Database, 14 Patients Had Emotional Triggers (E Group), 96 Had Physical Triggers (P Group), And 27 Had No Triggers (N Group). Most Clinical Presentations And In-Hospital Courses Were Similar Among The Groups. However, The E Group Had A Higher Prevalence Of Chest Pain (P = 0.006) And Palpitation (P = 0.006), Whereas The P Group Had A Higher Prevalence Of Cardiogenic Shock (P = 0.040), Than Other Groups. The P Group Had A Significantly Higher Heart Rate (P = 0.001); Higher High-Sensitivity C-Reactive Protein (P = 0.006), Creatine Kinase Mb Fraction (P = 0.045), And N Terminal-Probrain Natriuretic Peptide (P = 0.036) Levels; Higher Left Ventricular End-Diastolic Pressure (P = 0.019) And Left Ventricular End-Systolic Diameter (P = 0.002); But Lower Left Ventricular Ejection Fraction (P = 0.018). The E Group Had Lesser Prevalence Of Apical Ballooning Pattern (P = 0.038) Than Other Groups. The P Group Required More Frequent Use Of Inotropics (P = 0.041) And Diuretics (P = 0.047) And Had Significantly Longer Intensive Care Unit (P = 0.014) And In-Hospital Stays (P = 0.001). The Clinical Features Of Ttc Are Different According To Preceding Stressor Patterns. The Ttc Group With Preceding Physical Stressors Was Less Likely To Have Preserved Cardiovascular Reserve And More Likely To Require Hemodynamic Support Than Other Groups. The Overall Prognosis Of Ttc Is Excellent, Regardless Of Triggering Stressors.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Triggered', 'no label'), ('Acute Emotional Or Physical Stress Event', 'no label'), ('Study', 'no label'), ('Investigate', 'no label'), ('Impact', 'no label'), ('Stressor', 'no label'), ('Patterns', 'no label'), ('Clinical Features', 'no label'), ('Laboratory Parameters', 'no label'), ('Electrocardiographic', 'no label'), ('Echocardiographic', 'no label'), ('Findings', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Clinical Features', 'no label'), ('Stressor', 'no label'), ('Patterns', 'no label'), ('Patients', 'no label'), ('Ttc Registry Database', 'no label'), ('Patients', 'no label'), ('Emotional Triggers', 'no label'), ('E Group', 'no label'), ('Physical Triggers', 'no label'), ('Group', 'no label'), ('Triggers', 'no label'), ('N Group', 'no label'), ('Clinical Presentations', 'no label'), ('In-Hospital', 'no label'), ('Courses', 'no label'), ('Groups', 'no label'), ('E Group', 'no label'), ('Higher', 'no label'), ('Prevalence', 'no label'), ('Chest Pain', 'no label'), ('Palpitation', 'no label'), ('Group', 'no label'), ('Higher', 'no label'), ('Prevalence', 'no label'), ('Cardiogenic Shock', 'no label'), ('Groups', 'no label'), ('P Group', 'no label'), ('Heart Rate', 'no label'), ('Higher', 'no label'), ('High-Sensitivity C-Reactive Protein', 'no label'), ('Creatine Kinase', 'no label'), ('Fraction', 'no label'), ('N Terminal-Probrain Natriuretic Peptide', 'no label'), ('Levels', 'no label'), ('Higher', 'no label'), ('Left Ventricular End-Diastolic Pressure', 'no label'), ('Left Ventricular End-Systolic Diameter', 'no label'), ('Left Ventricular Ejection Fraction', 'no label'), ('E Group', 'no label'), ('Lesser', 'no label'), ('Prevalence', 'no label'), ('Apical Ballooning Pattern', 'no label'), ('Groups', 'no label'), ('P Group', 'no label'), ('Frequent', 'no label'), ('Inotropics', 'no label'), ('Diuretics', 'no label'), ('Intensive Care Unit', 'no label'), ('Clinical Features', 'no label'), ('Ttc', 'no label'), ('Stressor', 'no label'), ('Patterns', 'no label'), ('Ttc Group', 'no label'), ('Preceding', 'no label'), ('Physical Stressors', 'no label'), ('Cardiovascular Reserve', 'no label'), ('Hemodynamic Support', 'no label'), ('Groups', 'no label'), ('Prognosis', 'no label'), ('Ttc', 'no label'), ('Excellent', 'no label'), ('Triggering', 'no label'), ('Stressors', 'no label')]|[('Protein', 'no label'), ('Creatine', 'no label'), ('Terminal-Probrain Natriuretic Peptide', 'no label'), ('Diuretics', 'no label')]|[('E Group', 'no label'), ('Higher High-Sensitivity C-Reactive Protein', 'no label'), ('Creatine Kinase Mb Fraction', 'no label'), ('E Group', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Chest Pain', 'no label'), ('Palpitation', 'no label'), ('Cardiogenic Shock', 'no label'), ('Creatine', 'no label'), ('N Terminal-Probrain Natriuretic Peptide (P = 0.036', 'no label'), ('Left Ventricular End-Diastolic Pressure (P = 0.019) And Left Ventricular End-Systolic Diameter (P = 0.002)', 'no label'), ('Prognosis', 'no label'), ('Ttc', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Heart', 'no label'), ('Creatine Kinase Mb', 'no label'), ('Left Ventricular End-Diastolic', 'no label'), ('Left Ventricular End-Systolic Diameter', 'no label'), ('Apical', 'no label'), ('Inotropics', 'no label'), ('Diuretics', 'no label'), ('Cardiovascular Reserve', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21074123|Tako-Tsubo Cardiomyopathy Is A Clinical Entity Mimicking Acute Coronary Syndrome. Assessment Of Left Ventricular Function May Be Difficult Using Conventional Echocardiography. To Characterize Left Ventricular Systolic Function Using Contrast Echocardiography In Tako-Tsubo Cardiomyopathy. We Prospectively Studied 63 Consecutive Women Admitted For Suspected Acute Coronary Syndrome Who Underwent Coronary Arteriography, Biplane Left Ventricular Angiography And Conventional And Contrast Echocardiography; 25 Women Had Tako-Tsubo Cardiomyopathy (Group 1), 25 Women Had Proven Coronary Artery Disease (Group 2) And 13 Women Had No Significant Coronary Lesion (Group 3). Echocardiographic Interpretation Was Performed By Two Observers: A Physician Trainee (Observer 1) And An Experienced Investigator (Observer 2). Left Ventricular Segments Were Assessed For Wall Motion Abnormalities, Which Were Present In 70 And 88% (Observer 1) And In 91 And 99% (Observer 2), Using Conventional And Contrast Echocardiography, Respectively (P<0.0001). Accuracy For The Diagnosis Of Tako-Tsubo Cardiomyopathy Was Improved Significantly For Both Observers Using Contrast Echocardiography: For Observer 1, Sensitivity Was 56 And 88%, Respectively, Using Conventional And Contrast Echocardiography (P=0.01), Whereas For Observer 2, Sensitivity Was 72 And 96%, Respectively (P=0.04). Interobserver Agreement Was Excellent Using Contrast Agent (Kappa=0.85 Vs 0.34 Using Conventional Echocardiography). The Blinded Review Of Left Ventriculograms Distinguished Tako-Tsubo Cardiomyopathy From Coronary Artery Disease Correctly In 96% Of Cases. Contrast Echocardiography Could Be Used In Routine Practice To Replace Left Ventricular Angiography In Tako-Tsubo Cardiomyopathy.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Clinical Entity', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Assessment', 'no label'), ('Left Ventricular Function May', 'no label'), ('Difficult', 'no label'), ('Conventional Echocardiography', 'no label'), ('Characterize', 'no label'), ('Left Ventricular Systolic Function', 'no label'), ('Contrast Echocardiography', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Consecutive', 'no label'), ('Women', 'no label'), ('Admitted', 'no label'), ('Suspected', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Coronary Arteriography', 'no label'), ('Biplane Left Ventricular Angiography', 'no label'), ('Conventional And Contrast Echocardiography', 'no label'), ('Women', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Group', 'no label'), ('Women', 'no label'), ('Proven', 'no label'), ('Coronary Artery Disease', 'no label'), ('Group', 'no label'), ('Women', 'no label'), ('No Significant', 'no label'), ('Coronary Lesion', 'no label'), ('Group', 'no label'), ('Echocardiographic', 'no label'), ('Interpretation', 'no label'), ('Performed', 'no label'), ('Observers', 'no label'), ('Physician', 'no label'), ('Trainee', 'no label'), ('Experienced Investigator', 'no label'), ('Left Ventricular Segments', 'no label'), ('Assessed', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Observer 2', 'no label'), ('Conventional And Contrast Echocardiography', 'no label'), ('Accuracy', 'no label'), ('Diagnosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Observers', 'no label'), ('Contrast Echocardiography', 'no label'), ('Observer 1', 'no label'), ('Sensitivity', 'no label'), ('Conventional And Contrast Echocardiography', 'no label'), ('Observer 2', 'no label'), ('Sensitivity', 'no label'), ('Interobserver Agreement', 'no label'), ('Excellent', 'no label'), ('Contrast Agent', 'no label'), ('Conventional Echocardiography', 'no label'), ('Blinded Review', 'no label'), ('Left Ventriculograms Distinguished', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Coronary Artery Disease', 'no label'), ('Cases', 'no label'), ('Contrast Echocardiography', 'no label'), ('Routine Practice', 'no label'), ('Left Ventricular Angiography', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Left Ventricular Function', 'no label'), ('Left Ventricular Systolic Function', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Coronary Syndrome Who', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Proven Coronary Artery Disease', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Coronary Artery Disease Correctly In 96', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Left Ventricular', 'no label'), ('Left Ventricular Systolic', 'no label'), ('Women', 'no label'), ('Acute Coronary', 'no label'), ('Left Ventricular', 'no label'), ('Women', 'no label'), ('Women', 'no label'), ('Women', 'no label'), ('Wall', 'no label'), ('Contrast', 'no label'), ('Kappa=0.85', 'no label')]
tako-tsubo cardiomyopathy|pubmed~24464623|Tako-Tsubo Cardiomyopathy (Tcm) Is An Increasingly Recognized Clinical Syndrome Characterized By Acute Reversible Apical Ventricular Dysfunction, Commonly Preceded By Exposure To Severe Physical Or Emotional Stress. In This Review, We Give A Short Overview On Clinical Presentation And Treatment Of Tcm And Discuss The Possible Pathophysiological Mechanisms Of Tcm And The Role Of Various Non-Invasive Imaging Modalities In Tcm With A Focus On The Potential Role Of (123)I-Meta-Iodobenzylguanidine (Mibg) Scintigraphy. Currently, The Dominating Hypothesis On The Pathophysiology Of Tcm Postulates That High Levels Of The Neurotransmitter Epinephrine May Trigger A Change In Intracellular Signaling In Ventricular Myocytes. More Specific, Epinephrine Stimulates G-Protein Coupled Β2 Adenoreceptors (Β2Ar) Which Are Located On Ventricular Myocytes. Normal Levels Of This Neurotransmitter Predominantly Stimulate The Intracellular G-Protein, And Induce A Positive Inotropic Effect. However, With Significant Increasing Levels Of Epinephrine, The Predominance Of Stimulation Is Shifted From G-Stimulating To The G-Inhibitor Protein Coupling, Which Leads To A Negative Inotropic Effect. Interestingly, This Negative Inotropic Effect Is The Largest In The Apical Myocardium Where The Β2Ar:Β1Ar Ratio Is The Highest Within The Heart. Echocardiography And Ventriculography Are Essential To Diagnose Tcm, But New Imaging Tools Are Promising To Diagnose Tcm And To Evaluate Therapeutic Efficacy. Cardiovascular Magnetic Resonance Can Be Used To Differentiate Tcm From Other Myocardial Diseases, Such As Myocarditis. (123)I-Meta-Iodobenzylguanidine ((123)I-Mibg) Scintigraphy Can Be Used To Assess Ventricular Adrenergic Activity And May Guide Optimization Of Individual (Pharmacological) Therapy. These New Insights Into The Possible Pathophysiological Mechanisms And Novel Diagnostic Imaging Modalities Can Be Used As Starting Point For The Development Of International Guidelines Of Tcm Which May Increase The Awareness, And Optimize The Treatment Of Tcm.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tcm', 'no label'), ('Clinical Syndrome', 'no label'), ('Characterized', 'no label'), ('Acute Reversible Apical Ventricular Dysfunction', 'no label'), ('Preceded', 'no label'), ('Exposure To', 'no label'), ('Severe', 'no label'), ('Physical Or', 'no label'), ('Emotional Stress', 'no label'), ('Review', 'no label'), ('Short Overview', 'no label'), ('Clinical Presentation', 'no label'), ('Treatment', 'no label'), ('Tcm', 'no label'), ('Pathophysiological', 'no label'), ('Mechanisms', 'no label'), ('Tcm', 'no label'), ('Non-Invasive', 'no label'), ('Imaging', 'no label'), ('Modalities', 'no label'), ('Tcm', 'no label'), ('Focus', 'no label'), ('(123)I-Meta-Iodobenzylguanidine', 'no label'), ('Mibg', 'no label'), ('Scintigraphy', 'no label'), ('Dominating Hypothesis', 'no label'), ('Pathophysiology', 'no label'), ('Tcm', 'no label'), ('Postulates', 'no label'), ('Levels', 'no label'), ('Neurotransmitter Epinephrine', 'no label'), ('Trigger', 'no label'), ('Change', 'no label'), ('Intracellular', 'no label'), ('Signaling', 'no label'), ('Ventricular Myocytes', 'no label'), ('Epinephrine', 'no label'), ('Stimulates', 'no label'), ('G-Protein Coupled Β2', 'no label'), ('Adenoreceptors', 'no label'), ('Ventricular Myocytes', 'no label'), ('Normal Levels', 'no label'), ('Neurotransmitter', 'no label'), ('Stimulate', 'no label'), ('Intracellular', 'no label'), ('G-Protein', 'no label'), ('Induce', 'no label'), ('Positive', 'no label'), ('Inotropic Effect', 'no label'), ('Increasing', 'no label'), ('Levels', 'no label'), ('Epinephrine', 'no label'), ('Predominance', 'no label'), ('Stimulation', 'no label'), ('G-Inhibitor Protein Coupling', 'no label'), ('Leads', 'no label'), ('Negative', 'no label'), ('Inotropic Effect', 'no label'), ('Negative', 'no label'), ('Inotropic Effect', 'no label'), ('Largest', 'no label'), ('Apical Myocardium', 'no label'), ('Β2Ar:Β1Ar Ratio', 'no label'), ('Heart', 'no label'), ('Echocardiography', 'no label'), ('Ventriculography', 'no label'), ('Tcm', 'no label'), ('New Imaging Tools', 'no label'), ('Diagnose', 'no label'), ('Tcm', 'no label'), ('Evaluate', 'no label'), ('Therapeutic Efficacy', 'no label'), ('Cardiovascular Magnetic Resonance', 'no label'), ('Differentiate', 'no label'), ('Tcm', 'no label'), ('Myocardial Diseases', 'no label'), ('Myocarditis', 'no label'), ('(123)I-Meta-Iodobenzylguanidine', 'no label'), ('Assess', 'no label'), ('Ventricular Adrenergic Activity', 'no label'), ('Optimization', 'no label'), ('Individual', 'no label'), ('Pharmacological', 'no label'), ('Pathophysiological', 'no label'), ('Mechanisms', 'no label'), ('Novel', 'no label'), ('Diagnostic Imaging Modalities', 'no label'), ('Development', 'no label'), ('International Guidelines', 'no label'), ('Tcm', 'no label'), ('Increase', 'no label'), ('Awareness', 'no label'), ('Optimize', 'no label'), ('Treatment', 'no label'), ('Tcm', 'no label')]|[('Intracellular', 'no label'), ('Epinephrine', 'no label'), ('Neurotransmitter', 'no label'), ('Intracellular', 'no label'), ('Epinephrine', 'no label'), ('Protein', 'no label'), ('Adrenergic', 'no label')]|[('Tcm', 'no label'), ('Β2 Adenoreceptors', 'no label'), ('G-Inhibitor Protein', 'no label'), ('Β1Ar', 'no label'), ('Tcm', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ventricular Dysfunction', 'no label'), ('(123)I-Meta-Iodobenzylguanidine', 'no label'), ('Epinephrine', 'no label'), ('Epinephrine', 'no label'), ('Β2 Adenoreceptors', 'no label'), ('Epinephrine', 'no label'), ('Myocardial Diseases', 'no label'), ('Myocarditis', 'no label'), ('(123)I-Meta-Iodobenzylguanidine', 'no label')]|[('Tcm', 'no label'), ('Tcm', 'no label'), ('Tcm With', 'no label'), ('(123)I-Meta-Iodobenzylguanidine', 'no label'), ('Neurotransmitter Epinephrine', 'no label'), ('Intracellular Signaling In Ventricular Myocytes.', 'no label'), ('Epinephrine', 'no label'), ('Neurotransmitter', 'no label'), ('Intracellular', 'no label'), ('Epinephrine', 'no label'), ('Heart', 'no label'), ('Myocardial', 'no label'), ('Ventricular Adrenergic', 'no label'), ('Tcm', 'no label'), ('Tcm', 'no label')]
tako-tsubo cardiomyopathy|pubmed~30082205||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25074559||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~20063291|Recent Studies Have Demonstrated That Stress-Induced Tako-Tsubo Cardiomyopathy Is Likely To Occur In Elderly Female Patients. The Purpose Of This Study Was To Evaluate Gender Differences In The Clinical Characteristics Of Patients With Tako-Tsubo Cardiomyopathy. This Study Consisted Of 102 Patients With Tako-Tsubo Cardiomyopathy. It Was Characterized By Akinesia/Hypokinesia Of The Mid-To-Distal Portion Of The Left Ventricular Chamber, With Normokinesia/Hyperkinesia Of The Basal Portion With An Ejection Fraction Of Less Than 50% On Transthoracic Echocardiography. There Were 13 Male And 89 Female Patients. In 10 Male Patients (77%), Tako-Tsubo Cardiomyopathy Occurred During Or Immediately After Receiving Medical Treatment Or Examination For An Underlying Disease. In 9 Male Patients (69%), Objective Symptoms Such As Abnormality Of Monitoring Or Low Blood Pressure, But Not Subjective Symptoms Increased The Chance Of The Patient Being Diagnosed With Tako-Tsubo Cardiomyopathy. There Was No Significant Difference In Age, Body Weight, Hypertension, Or Diabetes Except For Height Between Male And Female Patients. The Incidence Of In-Hospital Onset Was Significantly Higher In Male Patients Than In Female Patients (77% Vs 17%, P < 0.01). There Was No Significant Difference In In-Hospital Mortality (15% Vs 6%, P = Not Significant). These Results Suggested That Physical Stress Might Have More To Do With The Occurrence Of Tako-Tsubo In Male Than Female Patients.|[('Studies', 'no label'), ('Stress-Induced', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Occur', 'no label'), ('Elderly', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Evaluate', 'no label'), ('Gender', 'no label'), ('Differences', 'no label'), ('Clinical Characteristics', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Study', 'no label'), ('Consisted', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Characterized', 'no label'), ('Mid-To-Distal Portion', 'no label'), ('Left Ventricular Chamber', 'no label'), ('Normokinesia/Hyperkinesia', 'no label'), ('Basal Portion', 'no label'), ('Ejection Fraction', 'no label'), ('Transthoracic Echocardiography', 'no label'), ('Male', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Male', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Medical Treatment', 'no label'), ('Underlying Disease', 'no label'), ('Male', 'no label'), ('Patients', 'no label'), ('Objective Symptoms', 'no label'), ('Abnormality', 'no label'), ('Monitoring', 'no label'), ('Low Blood Pressure', 'no label'), ('Subjective Symptoms', 'no label'), ('Increased', 'no label'), ('Chance', 'no label'), ('Patient Being', 'no label'), ('Diagnosed', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('No Significant Difference', 'no label'), ('Age', 'no label'), ('Body Weight', 'no label'), ('Hypertension', 'no label'), ('Diabetes', 'no label'), ('Except For Height', 'no label'), ('Male', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Incidence', 'no label'), ('In-Hospital Onset', 'no label'), ('Higher', 'no label'), ('Male', 'no label'), ('Patients', 'no label'), ('Than', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('No Significant Difference', 'no label'), ('In-Hospital', 'no label'), ('Mortality', 'no label'), ('Not Significant', 'no label'), ('Results', 'no label'), ('Physical Stress', 'no label'), ('Tako-Tsubo', 'no label'), ('Male Than', 'no label'), ('Female', 'no label'), ('Patients', 'no label')]|[('Tako-Tsubo', 'no label')]|[('Mid-To-Distal Portion', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Hypertension', 'no label'), ('Diabetes', 'no label'), ('Tako-Tsubo', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Left Ventricular', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Blood', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23810239|Tako-Tsubo Cardiomyopathy (Ttc) Is Characterized By Symptoms, Ecg Changes With Elevated Cardiac Markers Mimicking Acute Myocardial Infarction, Left Ventricular (Lv) Wall Motion Abnormalities In The Apical Region With Preserved Function Of Base, And Normal Coronary Arteries. Usual Ecg Anomalies Heralding Ttc Are St-Elevation In Anterior Leads, Qt Prolongation And Negative T-Waves. We Report The Unusual Case Of Ttc With An Uncommon Ecg Presentation: J Wave In Inferior Leads Followed By Diffuse St-Elevation. An 82-Year-Old Woman Was Admitted For Dyspnea And Chest Pain Following Exacerbation Of Chronic Obstructive Pulmonary Disease. Ecg Showed J-Wave In Inferior Leads Followed By Diffuse St-Elevation. The Patient Was Monitored In Intensive Care Unit And Treated With Diuretics. Both Ecg And Echocardiography Anomalies Gradually Recovered. Diffuse St-Elevation Following J-Waves May Be Considered As A Possible Ecg Pattern Of Presentation In Case Of Ttc.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Characterized', 'no label'), ('Symptoms', 'no label'), ('Ecg Changes', 'no label'), ('Elevated', 'no label'), ('Cardiac Markers', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Left Ventricular (Lv) Wall Motion Abnormalities', 'no label'), ('Apical Region', 'no label'), ('Preserved Function', 'no label'), ('Base', 'no label'), ('Normal Coronary Arteries', 'no label'), ('Usual Ecg Anomalies', 'no label'), ('Heralding Ttc', 'no label'), ('St-Elevation', 'no label'), ('Anterior Leads', 'no label'), ('Qt', 'no label'), ('Prolongation', 'no label'), ('Negative', 'no label'), ('Unusual', 'no label'), ('Ttc', 'no label'), ('Uncommon Ecg Presentation', 'no label'), ('Inferior Leads', 'no label'), ('St-Elevation', 'no label'), ('Exacerbation', 'no label'), ('Chronic Obstructive Pulmonary Disease', 'no label'), ('Inferior Leads', 'no label'), ('St-Elevation', 'no label'), ('Patient', 'no label'), ('Monitored', 'no label'), ('Intensive Care Unit', 'no label'), ('Treated With', 'no label'), ('Diuretics', 'no label'), ('Ecg', 'no label'), ('Echocardiography', 'no label'), ('Gradually Recovered', 'no label'), ('Diffuse', 'no label'), ('St-Elevation', 'no label'), ('Ecg Pattern', 'no label'), ('Presentation', 'no label'), ('Ttc', 'no label')]|[('Diuretics', 'no label')]|[('J-Wave', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Myocardial Infarction', 'no label'), ('Left Ventricular', 'no label'), ('Anomalies Heralding Ttc', 'no label'), ('Dyspnea', 'no label'), ('Chest Pain', 'no label'), ('Obstructive Pulmonary Disease', 'no label'), ('Echocardiography Anomalies', 'no label')]|[('Cardiac', 'no label'), ('Myocardial', 'no label'), ('Apical', 'no label'), ('Base', 'no label'), ('Normal Coronary', 'no label'), ('Ecg Anomalies', 'no label'), ('Wave', 'no label'), ('Pulmonary', 'no label'), ('J-Wave', 'no label'), ('Patient', 'no label'), ('Ecg', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23623669|Tako-Tsubo Cardiomyopathy (Ttc) Is A Recently Described Medical Entity And The Incidence Of Ttc In A Global Population Is Still Uncertain. We Sought To Prospectively Assess The Incidence Of Ttc In A Large Urban Area. We Included All Consecutive Patients Referred For Coronary Angiography In Three Hospitals Located In Paris And Its Suburbs. We Prospectively Estimated The Percentage Of Ttc Among Patients Referred For Coronary Angiography And Extrapolated The Number Of Cases Of Ttc In The Greater Paris Area (11,598,866 Inhabitants) According To The Cardio-Arhif Registry (Government Agency). Among 2547 Patients (2972 Coronary Angiographies) Including 815 Acute Coronary Syndromes, 20 Patients Presented With Ttc (19 Women, Mean Age 66 ± 13 Years). The Percentage Of Ttc Among Suspected Acute Coronary Syndromes Was 2.5% (8.2% In Women Versus 0.2% In Men, P<0.001). In The Cardio-Arhif Registry, We Individualized 51,403 Coronary Angiographies Performed In All Catheterization Laboratories In One Year (13,820 Women And 10,246 Women ≥ 60 Years). In This Region, The Yearly Number Of Ttc Cases Is Estimated To Be 346 (95% Ci: 216-520). The Annual Incidence Of Ttc Is Estimated To Be 29.8 Per 1,000,000 Inhabitants (95% Ci: 18.6-44.9), 48.2 Per 1,000,000 Inhabitants (95% Ci: 29.7-73.0) Among Women And 187.4 Per 1,000,000 Inhabitants (95% Ci: 103.3-307.2) Among Women ≥ 60 Years. Within A Large Urban Agglomeration, The Incidence Of Ttc Is High In Women ≥ 60 Years. The Current Rate Of This Recently Described Cardiomyopathy Has Been Underestimated In Previous Retrospective Studies And Will Probably Rise With The Increase Of Life Expectancy.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Medical Entity', 'no label'), ('Incidence', 'no label'), ('Ttc', 'no label'), ('Global Population', 'no label'), ('Incidence', 'no label'), ('Ttc', 'no label'), ('Urban Area', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Referred', 'no label'), ('Coronary Angiography', 'no label'), ('Hospitals', 'no label'), ('Paris', 'no label'), ('Suburbs', 'no label'), ('Estimated', 'no label'), ('Percentage', 'no label'), ('Ttc', 'no label'), ('Patients Referred', 'no label'), ('Coronary Angiography', 'no label'), ('Cases', 'no label'), ('Ttc', 'no label'), ('Greater Paris Area', 'no label'), ('Inhabitants', 'no label'), ('Cardio-Arhif Registry', 'no label'), ('Patients', 'no label'), ('Coronary Angiographies', 'no label'), ('Acute Coronary Syndromes', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Women', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Percentage', 'no label'), ('Ttc', 'no label'), ('Suspected', 'no label'), ('Acute Coronary Syndromes', 'no label'), ('Women', 'no label'), ('Men', 'no label'), ('Cardio-Arhif Registry', 'no label'), ('Individualized', 'no label'), ('Coronary Angiographies', 'no label'), ('Performed', 'no label'), ('Catheterization Laboratories', 'no label'), ('Year', 'no label'), ('Women', 'no label'), ('Women', 'no label'), ('Years', 'no label'), ('Region', 'no label'), ('Ttc', 'no label'), ('Cases', 'no label'), ('Ci', 'no label'), ('Annual', 'no label'), ('Incidence', 'no label'), ('Ttc', 'no label'), ('Inhabitants', 'no label'), ('Ci', 'no label'), ('Inhabitants', 'no label'), ('Ci', 'no label'), ('Women', 'no label'), ('Inhabitants', 'no label'), ('Ci', 'no label'), ('Women', 'no label'), ('Years', 'no label'), ('Urban', 'no label'), ('Agglomeration', 'no label'), ('Incidence', 'no label'), ('Ttc', 'no label'), ('Women', 'no label'), ('Years', 'no label'), ('Current', 'no label'), ('Rate', 'no label'), ('Cardiomyopathy', 'no label'), ('Underestimated', 'no label'), ('Retrospective Studies', 'no label'), ('Increase', 'no label'), ('Life Expectancy', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Referred', 'no label'), ('Referred', 'no label'), ('Ttc', 'no label'), ('Urban Agglomeration', 'no label'), ('Cardiomyopathy', 'no label')]|[('Ttc In A', 'no label'), ('Ttc In A', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cardio-Arhif', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Acute Coronary', 'no label'), ('Women', 'no label'), ('Cardio-Arhif', 'no label'), ('Women', 'no label'), ('Women', 'no label'), ('Women', 'no label'), ('Women', 'no label'), ('Women', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25774733|"A 42-Year Old Female Patient Was Admitted In Cardiogenic Shock With Pulmonary Edema Requiring Prehospital Intubation And Mechanical Ventilation. | Emergency Cardiac Catheterization Because Of Suspected Acute Coronary Syndrome Excluded Coronary Artery Disease. Ventriculography And Echocardiography Suggested An Inverse Tako-Tsubo Cardiomyopathy With Akinesia Of The Basal Left Ventricular Myocardium And Only Apical Preserved Wall Motion. Under Intensive Care Therapy With Mechanical Ventilation, Inotropic Support, Infusion Of Saline And Intraaortal Balloon Pumping, Left Ventricular Function Improved. After Discontinuation Of Mechanical Ventilation And Discharge From Icu, The Patient Repeatedly Suffered From Panic Attacks. She Was Therefore Transferred To A Psychosomatic Center. There She Exhibited Repeated Hypertensive Crisis. Ultrasound Of The Kidney Showed An Adrenal Mass. Together With Elevated Plasma Catecholamines, The Diagnosis Of Pheochromocytoma Was Suspected. This Could Be Proved By Magnetic Resonance Imaging. After Surgical Removement Of The Adrenal Mass, The Patient Was Free Of Symptoms."|[('42-Year Old Female', 'no label'), ('Admitted', 'no label'), ('Cardiogenic Shock', 'no label'), ('Pulmonary Edema', 'no label'), ('Prehospital Intubation', 'no label'), ('Mechanical Ventilation', 'no label'), ('Emergency', 'no label'), ('Cardiac Catheterization', 'no label'), ('Suspected', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Coronary Artery Disease', 'no label'), ('Ventriculography', 'no label'), ('Echocardiography', 'no label'), ('Inverse', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Akinesia', 'no label'), ('Basal Left Ventricular Myocardium', 'no label'), ('Apical Preserved Wall Motion', 'no label'), ('Intensive Care Therapy', 'no label'), ('Mechanical Ventilation', 'no label'), ('Inotropic Support', 'no label'), ('Infusion', 'no label'), ('Saline', 'no label'), ('Intraaortal', 'no label'), ('Pumping', 'no label'), ('Left Ventricular Function', 'no label'), ('Discontinuation', 'no label'), ('Mechanical Ventilation', 'no label'), ('Discharge', 'no label'), ('Icu', 'no label'), ('Patient', 'no label'), ('Suffered', 'no label'), ('Panic Attacks', 'no label'), ('Transferred', 'no label'), ('Psychosomatic Center', 'no label'), ('Repeated', 'no label'), ('Hypertensive Crisis', 'no label'), ('Ultrasound', 'no label'), ('Kidney', 'no label'), ('Adrenal Mass.', 'no label'), ('Elevated', 'no label'), ('Plasma', 'no label'), ('Catecholamines', 'no label'), ('Diagnosis', 'no label'), ('Pheochromocytoma', 'no label'), ('Suspected', 'no label'), ('Proved', 'no label'), ('Magnetic Resonance Imaging', 'no label'), ('Surgical Removement', 'no label'), ('Adrenal Mass', 'no label'), ('Patient', 'no label'), ('Free', 'no label'), ('Symptoms', 'no label')]|[('Catecholamines', 'no label')]|[]|[('Cardiogenic Shock', 'no label'), ('Pulmonary Edema', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Coronary Artery Disease', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Akinesia', 'no label'), ('Left Ventricular Function Improved.', 'no label'), ('Panic', 'no label'), ('Hypertensive', 'no label'), ('Catecholamines', 'no label'), ('Pheochromocytoma', 'no label')]|[('Patient', 'no label'), ('Cardiogenic Shock', 'no label'), ('Pulmonary Edema', 'no label'), ('Cardiac', 'no label'), ('Acute Coronary', 'no label'), ('Coronary Artery', 'no label'), ('Basal Left Ventricular Myocardium And', 'no label'), ('Wall', 'no label'), ('Saline', 'no label'), ('Left Ventricular', 'no label'), ('Patient', 'no label'), ('Kidney', 'no label'), ('Adrenal Mass.', 'no label'), ('Plasma Catecholamines', 'no label'), ('Pheochromocytoma', 'no label'), ('Adrenal', 'no label'), ('Patient', 'no label'), ('Free', 'no label')]
tako-tsubo cardiomyopathy|pubmed~18499288|Tako-Tsubo Cardiomyopathy Has Been Gradually Recognized Worldwide. However, Medications For The Prevention Remain Not To Be Investigated In Part Because The Precise Mechanism Is Unclear. We Sought To Examine Medications Before The Onset Of Tako-Tsubo Cardiomyopathy, And To Prove The Limitation Of These Medications For The Prevention. This Study Consisted Of 21 Patients With Tako-Tsubo Cardiomyopathy Who Received One Or More Medications For Hypertension Or Suspected Angina Pectoris. Each Patient Was Assessed With History, Medications, Coronary Angiography And Left Ventriculography. All Patients But 1 Were Female, And Age Ranged 41 To 87 Years (73+/-11 Years). Twelve Patients Received Calcium Channel Blockers, 7 Patients Received Nitrates, And One Patient Received Beta Blocker. Three Patients Received Angiotensin Coverting Enzyme Inhibitors, And 4 Patients Received Angiotensin Ii Receptor Blockers. One Patient Died Of Serious Pneumonia, But There Was No Patient Who Died Of Tako-Tsubo Cardiomyopathy Itself. During The 3 Year Follow-Up, One Patient Receiving Angiotensin Receptor Blocker Had The Recurrence Of Tako-Tsubo Cardiomyopathy Due To Recurrent Epileptic Seizure. Tako-Tsubo Cardiomyopathy Can Occur Despite Treatment With Calcium Channel Blockers, Nitrates Or Beta-Blockers, Suggesting Limitation Of These Medications To Prevent Tako-Tsubo Cardiomyopathy.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Worldwide', 'no label'), ('Medications', 'no label'), ('Prevention', 'no label'), ('Remain', 'no label'), ('Investigated', 'no label'), ('Mechanism', 'no label'), ('Examine', 'no label'), ('Medications', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Limitation', 'no label'), ('Medications', 'no label'), ('Prevention', 'no label'), ('Study', 'no label'), ('Consisted', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Medications', 'no label'), ('Hypertension', 'no label'), ('Suspected Angina Pectoris', 'no label'), ('Patient', 'no label'), ('Assessed', 'no label'), ('History', 'no label'), ('Medications', 'no label'), ('Coronary Angiography', 'no label'), ('Left Ventriculography', 'no label'), ('Patients', 'no label'), ('Female', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Calcium Channel Blockers', 'no label'), ('Patients', 'no label'), ('Nitrates', 'no label'), ('Patient', 'no label'), ('Received', 'no label'), ('Beta Blocker', 'no label'), ('Patients', 'no label'), ('Angiotensin Coverting', 'no label'), ('Enzyme Inhibitors', 'no label'), ('Patients', 'no label'), ('Angiotensin Ii Receptor', 'no label'), ('Blockers', 'no label'), ('Patient', 'no label'), ('Died', 'no label'), ('Pneumonia', 'no label'), ('Patient', 'no label'), ('Died', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Patient', 'no label'), ('Angiotensin Receptor', 'no label'), ('Blocker', 'no label'), ('Recurrence', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Recurrent', 'no label'), ('Epileptic Seizure', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Occur', 'no label'), ('Treatment', 'no label'), ('Calcium Channel Blockers', 'no label'), ('Nitrates', 'no label'), ('Beta-Blockers', 'no label'), ('Suggesting', 'no label'), ('Limitation', 'no label'), ('Medications', 'no label'), ('Prevent', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Calcium', 'no label'), ('Blockers', 'no label'), ('Nitrates', 'no label'), ('Calcium', 'no label'), ('Blockers', 'no label'), ('Nitrates', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Hypertension', 'no label'), ('Suspected Angina Pectoris', 'no label'), ('Calcium', 'no label'), ('Nitrates', 'no label'), ('Angiotensin', 'no label'), ('Angiotensin Ii', 'no label'), ('Pneumonia', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Angiotensin', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Epileptic Seizure', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Calcium', 'no label'), ('Nitrates', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Patients', 'no label'), ('Left', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Calcium', 'no label'), ('Patients', 'no label'), ('Nitrates', 'no label'), ('Patient', 'no label'), ('Beta', 'no label'), ('Patients', 'no label'), ('Angiotensin', 'no label'), ('Patients', 'no label'), ('Angiotensin Ii', 'no label'), ('Patient', 'no label'), ('Patient', 'no label'), ('Angiotensin Receptor', 'no label'), ('Calcium Channel Blockers', 'no label'), ('Nitrates', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25355779|Tako-Tsubo Cardiomyopathy Is Characterized By Reversible Left Ventricular Dysfunction Following Emotional Or Surgical Stress. Unlike The Well-Known Complications Of Catheter Ablation (Ca) Of Atrial Fibrillation (Af), Tako-Tsubo Cardiomyopathy Has Been Rarely Reported So Far. We Report A Case Of Acute Reversible Left Heart Failure Following Successful Ca Of Paroxysmal Af In A Patient With A History Of Panic Disorder. |[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Characterized', 'no label'), ('Reversible', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Emotional Or', 'no label'), ('Surgical Stress', 'no label'), ('Well-Known', 'no label'), ('Complications', 'no label'), ('Catheter Ablation', 'no label'), ('Ca', 'no label'), ('Atrial Fibrillation', 'no label'), ('Af', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Reported', 'no label'), ('Report', 'no label'), ('Acute Reversible Left Heart Failure', 'no label'), ('Ca', 'no label'), ('Paroxysmal Af', 'no label'), ('Patient', 'no label'), ('History', 'no label'), ('Panic Disorder', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Ca', 'no label'), ('Atrial Fibrillation', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Heart Failure', 'no label'), ('Ca', 'no label'), ('Panic Disorder', 'no label')]|[('Atrial Fibrillation', 'no label'), ('Acute Reversible Left Heart Failure', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23582148|Tako-Tsubo Cardiomyopathy Usually Mimics An Acute Coronary Syndrome And Is Defined As A Transient Left Ventricular Systolic Dysfunction. Stress Is Frequently Present, But Is Not Systematically Found. Diagnosis Is Based On The Criteria Of The Mayo-Clinic. Tako-Tsubo Cardiomyopathy Preferentially Affects Postmenopausal Women. Several Explorations Are Performed To Confirm The Diagnosis: Electrocardiogram, Biomarkers, Echocardiography, Coronary Angiography And Left Ventricular Angiography, And Mri. Left Ventricular Dysfunction Is Pathognomonic, With Circular Akinesia Regarding The Different Mid And Apical Segments Of The Left Ventricle In Its Typical Form. Complications May Occur In The Acute Phase And Should Be Systematically Assessed. The Complete Recovery Of Left Ventricular Systolic Dysfunction Is The Rule And Must Be Assessed, Allowing To Confirm The Diagnosis Of Tako-Tsubo Cardiomyopathy.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Mimics', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Transient', 'no label'), ('Left Ventricular Systolic Dysfunction', 'no label'), ('Stress', 'no label'), ('Diagnosis', 'no label'), ('Criteria', 'no label'), ('Mayo-Clinic', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Explorations', 'no label'), ('Performed', 'no label'), ('Confirm', 'no label'), ('Diagnosis', 'no label'), ('Electrocardiogram', 'no label'), ('Biomarkers', 'no label'), ('Echocardiography', 'no label'), ('Coronary Angiography', 'no label'), ('Left Ventricular Angiography', 'no label'), ('Mri', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Pathognomonic', 'no label'), ('Circular Akinesia', 'no label'), ('Mid', 'no label'), ('Apical Segments', 'no label'), ('Left Ventricle', 'no label'), ('Typical Form', 'no label'), ('Complications', 'no label'), ('Occur', 'no label'), ('Acute Phase', 'no label'), ('Systematically', 'no label'), ('Assessed', 'no label'), ('Complete', 'no label'), ('Recovery', 'no label'), ('Left Ventricular Systolic Dysfunction', 'no label'), ('Assessed', 'no label'), ('Confirm', 'no label'), ('Diagnosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Apical Segments', 'no label')]|[('Mid And Apical Segments', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Left Ventricular Systolic Dysfunction', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Akinesia', 'no label'), ('Left Ventricle In Its Typical Form.', 'no label'), ('Left Ventricular Systolic Dysfunction', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Left Ventricular', 'no label'), ('Left Ventricle', 'no label'), ('Left Ventricular Systolic', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25304075||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~29844005||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25127963||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~22987076|Recent Retrospective Studies Suggest That Psychiatric Disorders Could Be A Predisposing Risk Factor For Tako-Tsubo Cardiomyopathy (Ttc). The Aim Of The Present Study Was To Characterize The Prevalence Of Anxiodepressive Disorders (Add) And Chronic Psychological Stress (Cps) In Patients With Ttc Or Acute Coronary Syndrome (Acs). Between January 2010 And December 2011, 45 Consecutive Patients With Ttc Were Prospectively Screened By Systematic Interview With The Mini International Neuropsychiatric Interview. Cps Was Systematically Recorded. During The Same Period, 50 Patients Admitted For Acs With Troponin Elevation And Matched For Age And Sex Were Prospectively Included As A Control Group. An Acute Stressful Event Within 72 H Before Presentation Was Identified In 35 Patients (78%) With Ttc Vs. 9 (18%) With Acs (P<0.001). Thirty-Five Patients (78%) And 13 (26%) Had Add In The Ttc And Acs Groups, Respectively (P<0.001). Cps Was Found In 20 Patients (44%) And In 9 (18%) With Ttc And Acs, Respectively (P=0.005). Cps And/Or Add Were Found In 35 Patients (78%) And In 18 (36%) With Ttc And Acs, Respectively (P<0.001). Add And Cps Are Common In Patients With Ttc And More Frequent Than In Patients With Acs. This Finding Suggests That Systemic Effects Of Add And Cps Could Participate In The Pathophysiology Of Ttc.|[('Retrospective Studies', 'no label'), ('Suggest', 'no label'), ('Psychiatric Disorders', 'no label'), ('Predisposing Risk Factor', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Study', 'no label'), ('Characterize', 'no label'), ('Prevalence', 'no label'), ('Anxiodepressive Disorders', 'no label'), ('Chronic Psychological Stress', 'no label'), ('Cps', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Acs', 'no label'), ('January', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Prospectively Screened', 'no label'), ('Systematic Interview', 'no label'), ('Mini International Neuropsychiatric Interview', 'no label'), ('Period', 'no label'), ('Patients', 'no label'), ('Admitted', 'no label'), ('Acs', 'no label'), ('Troponin', 'no label'), ('Elevation', 'no label'), ('Matched', 'no label'), ('Age', 'no label'), ('Sex', 'no label'), ('Control Group', 'no label'), ('Acute Stressful Event', 'no label'), ('Presentation', 'no label'), ('Identified', 'no label'), ('Patients', 'no label'), ('Ttc Vs', 'no label'), ('Acs', 'no label'), ('Thirty-Five', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Acs Groups', 'no label'), ('Cps', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Acs', 'no label'), ('Cps And/Or Add Were Found', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Acs', 'no label'), ('Cps', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Frequent', 'no label'), ('Than', 'no label'), ('Patients', 'no label'), ('Acs', 'no label'), ('Suggests', 'no label'), ('Systemic', 'no label'), ('Effects', 'no label'), ('Cps', 'no label'), ('Participate', 'no label'), ('Pathophysiology', 'no label'), ('Ttc', 'no label')]|[('Acs', 'no label'), ('Acs', 'no label'), ('Troponin', 'no label'), ('Acs', 'no label'), ('Acs', 'no label'), ('Acs', 'no label'), ('Cps And/Or', 'no label'), ('Acs', 'no label'), ('Acs', 'no label')]|[('Mini International Neuropsychiatric Interview', 'no label'), ('Troponin', 'no label'), ('Sex', 'no label')]|[('Psychiatric Disorders', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Acs', 'no label'), ('Acs', 'no label'), ('And/Or', 'no label')]|[('Cps', 'no label'), ('Patients', 'no label'), ('Ttc Or Acute Coronary Syndrome', 'no label'), ('Acs', 'no label'), ('Patients', 'no label'), ('Mini', 'no label'), ('Patients', 'no label'), ('Acs', 'no label'), ('Troponin', 'no label'), ('Patients', 'no label'), ('Acs', 'no label'), ('Patients', 'no label'), ('Acs', 'no label'), ('Patients', 'no label'), ('Acs', 'no label'), ('And/Or', 'no label'), ('Patients', 'no label'), ('Acs', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Acs', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25392722|Tako-Tsubo Syndrome Is Very Rare In Male Patients, Often Overlooked By Practitioners In Its Atypical Form Painless, And Who Did Not Always A Good Prognostic, Often Revealed In A Context Of Acute Stress At Any Time In The Hospital Or Outside, Its Pathophysiology Remains To Discuss, The Diagnosis Is Greatly Facilitated By Imaging Including Echocardiography With Apical Ballooning. We Relate This Clinical Case Of A Patient Admitted To The Icu For A Liver Contusion With A Diagnosis Incidentally This Syndrome. |[('Tako-Tsubo Syndrome', 'no label'), ('Male', 'no label'), ('Patients', 'no label'), ('Overlooked', 'no label'), ('Practitioners', 'no label'), ('Atypical Form', 'no label'), ('Prognostic', 'no label'), ('Revealed', 'no label'), ('Context', 'no label'), ('Acute Stress', 'no label'), ('Hospital', 'no label'), ('Pathophysiology Remains', 'no label'), ('Discuss', 'no label'), ('Diagnosis', 'no label'), ('Greatly Facilitated', 'no label'), ('Imaging', 'no label'), ('Echocardiography', 'no label'), ('Apical Ballooning', 'no label'), ('Clinical Case', 'no label'), ('Patient', 'no label'), ('Admitted', 'no label'), ('Liver Contusion', 'no label'), ('Diagnosis', 'no label'), ('Syndrome', 'no label')]|[('Tako-Tsubo Syndrome', 'no label')]|[]|[('Tako-Tsubo Syndrome', 'no label'), ('Liver Contusion', 'no label')]|[('Patients', 'no label'), ('Apical', 'no label'), ('Liver', 'no label')]
tako-tsubo cardiomyopathy|pubmed~26201689||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~23954006||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~23932038||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25851794|Tako-Tsubo Cardiomyopathy (Tc) Is A Novel Form Of Acute Heart Failure, Characterized By Regional Left Ventricular Dysfunction Without Coronary Artery Obstruction, And Usually Triggered By A Stressful Event. Excessive Circulating Catecholamines Have Been Implicated In The Pathophysiology Of This Condition. This Report Documents The Unusual Occurrence Of Acute Tc Events In 2 Male Subjects Of Disparate Ages, 16 And 66 Years, For Whom Subsequent Investigation In Both Led To The Unexpected Discovery Of Catecholamine-Producing Pheochromocytoma. Marked Elevation Of Plasma Catecholamines (Epinephrine, Norepinephrine, And Dopamine) Was Present In Both Subjects And Were Remarkably Similar To Those Previously Reported In Female Patients With Tc Triggered By Emotional Stress. These Observations Show A Common Link Between Tc Occurrence And Elevated Catecholamine Levels In Both Male And Female Patients And, Therefore, Support The Hypothesis That Excessive Levels Of Catecholamines May Be Involved In The Pathophysiology Of Tc Independent Of Age Or Gender. |[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tc', 'no label'), ('Novel', 'no label'), ('Form', 'no label'), ('Acute Heart Failure', 'no label'), ('Characterized', 'no label'), ('Regional', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Coronary Artery Obstruction', 'no label'), ('Triggered', 'no label'), ('Stressful Event', 'no label'), ('Excessive', 'no label'), ('Circulating', 'no label'), ('Catecholamines', 'no label'), ('Pathophysiology', 'no label'), ('Condition', 'no label'), ('Report Documents', 'no label'), ('Acute Tc Events', 'no label'), ('Male Subjects', 'no label'), ('Disparate Ages', 'no label'), ('Years', 'no label'), ('Investigation', 'no label'), ('Led', 'no label'), ('Discovery', 'no label'), ('Catecholamine-Producing Pheochromocytoma', 'no label'), ('Elevation', 'no label'), ('Plasma', 'no label'), ('Catecholamines', 'no label'), ('Epinephrine', 'no label'), ('Norepinephrine', 'no label'), ('Dopamine', 'no label'), ('Subjects', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Tc', 'no label'), ('Triggered By', 'no label'), ('Emotional Stress', 'no label'), ('Observations', 'no label'), ('Show A', 'no label'), ('Tc', 'no label'), ('Occurrence', 'no label'), ('Elevated', 'no label'), ('Catecholamine Levels', 'no label'), ('Male', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Support', 'no label'), ('Hypothesis', 'no label'), ('Excessive', 'no label'), ('Levels', 'no label'), ('Catecholamines', 'no label'), ('Pathophysiology', 'no label'), ('Tc', 'no label'), ('Independent Of Age', 'no label'), ('Gender', 'no label')]|[('Catecholamines', 'no label'), ('Catecholamines', 'no label'), ('Epinephrine', 'no label'), ('Norepinephrine', 'no label'), ('Dopamine', 'no label'), ('Catecholamine', 'no label'), ('Catecholamines', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Heart Failure', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Coronary Artery Obstruction', 'no label'), ('Catecholamines', 'no label'), ('Pheochromocytoma', 'no label'), ('Catecholamines', 'no label'), ('Epinephrine', 'no label'), ('Norepinephrine', 'no label'), ('Dopamine', 'no label'), ('Catecholamine', 'no label'), ('Catecholamines', 'no label')]|[('Heart', 'no label'), ('Coronary Artery', 'no label'), ('Circulating Catecholamines', 'no label'), ('Acute Tc Events In 2', 'no label'), ('Pheochromocytoma', 'no label'), ('Plasma Catecholamines', 'no label'), ('Epinephrine', 'no label'), ('Norepinephrine', 'no label'), ('Dopamine', 'no label'), ('Patients', 'no label'), ('Catecholamine', 'no label'), ('Patients', 'no label'), ('Catecholamines', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23628296||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~23093396|A 69-Year-Old Female Patient Who Had Been Physically And Mentally Healthy Was Admitted To Our Emergency Department Because Of Acute Onset Of Amnesia. Inconspicuous Diagnostic Findings Led To The Diagnosis Of Transient Global Amnesia (Tga). Furthermore Bradycardia And Elevated Troponins Were Detected. Because Of These Findings A Cardiologic Workup Was Performed Resulting In The Diagnosis Of Tako-Tsubo Cardiomyopathy. The Patient Recovered Completely From Tga As Well As From The Slight Reduction Of The Left-Ventricular Ejection Fraction As Part Of The Tako-Tsubo Cardiomyopathy. There Are Similarities Of The Two Diseases Tako-Tsubo Cardiomyopathy And Tga Concerning Triggers As Well As Reversibility. Patients Presenting With Symptoms Suggestive For Tga Should Be Considered To Undergo Additional Cardiologic Evaluation.|[('69-Year-Old', 'no label'), ('Female', 'no label'), ('Patient', 'no label'), ('Physically', 'no label'), ('Mentally Healthy', 'no label'), ('Emergency Department', 'no label'), ('Acute Onset', 'no label'), ('Amnesia', 'no label'), ('Inconspicuous Diagnostic Findings', 'no label'), ('Diagnosis', 'no label'), ('Transient Global Amnesia', 'no label'), ('Tga', 'no label'), ('Bradycardia', 'no label'), ('Elevated', 'no label'), ('Troponins', 'no label'), ('Detected', 'no label'), ('Findings', 'no label'), ('Cardiologic Workup', 'no label'), ('Performed', 'no label'), ('Resulting', 'no label'), ('Diagnosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Patient', 'no label'), ('Completely', 'no label'), ('Tga', 'no label'), ('Reduction', 'no label'), ('Left-Ventricular Ejection Fraction', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Similarities', 'no label'), ('Diseases', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tga', 'no label'), ('Triggers', 'no label'), ('Reversibility', 'no label'), ('Patients', 'no label'), ('Symptoms', 'no label'), ('Suggestive', 'no label'), ('Tga', 'no label'), ('Cardiologic', 'no label'), ('Evaluation', 'no label')]|[('Troponins', 'no label')]|[('Troponins', 'no label'), ('Tga', 'no label'), ('Tga', 'no label'), ('Tga', 'no label')]|[('Amnesia', 'no label'), ('Amnesia', 'no label'), ('Bradycardia', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Diseases Tako-Tsubo Cardiomyopathy', 'no label')]|[('Patient', 'no label'), ('Troponins', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Tga', 'no label')]
tako-tsubo cardiomyopathy|pubmed~31752657|Takotsubo Cardiomyopathy (Ttc) Is An Uncommon Cause Of Acute Reversible Ventricular Systolic Dysfunction In The Absence Of Obstructive Coronary Artery Disease (Cad). Typically Manifesting As Apical Wall Ballooning, Ttc Can Rarely Present Atypically With Apical Wall Sparing. A 62-Year-Old Female Presented With Complaints Of Chest Pain And Features Mimicking Acute Coronary Syndrome. Coronary Angiogram Revealed No Obstructive Cad And Left Ventriculogram Showed Reduced Ejection Fraction, Normal Left Ventricular Apex And Hypokinetic Mid-Ventricles Consistent With Atypical Ttc. The Patient Was Discharged Home On Heart Failure Medications And A Follow-Up Transthoracic Echocardiogram Demonstrated Improved Left Ventricular Function With No Wall Motion Abnormality. This Case Report Provides An Insight Into The Diagnosis And Management Of Ttc In The Absence Of Pathognomic Features.|[('Takotsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Cause', 'no label'), ('Acute Reversible Ventricular Systolic Dysfunction', 'no label'), ('Absence', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Cad', 'no label'), ('Manifesting', 'no label'), ('Apical Wall', 'no label'), ('Ballooning', 'no label'), ('Ttc', 'no label'), ('Rarely', 'no label'), ('Apical Wall', 'no label'), ('Sparing', 'no label'), ('Female', 'no label'), ('Complaints', 'no label'), ('Chest Pain', 'no label'), ('Features', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Coronary Angiogram', 'no label'), ('Revealed', 'no label'), ('Obstructive Cad', 'no label'), ('Left Ventriculogram', 'no label'), ('Reduced', 'no label'), ('Ejection Fraction', 'no label'), ('Normal Left Ventricular Apex', 'no label'), ('Hypokinetic', 'no label'), ('Mid-Ventricles', 'no label'), ('Atypical Ttc', 'no label'), ('Patient', 'no label'), ('Medications', 'no label'), ('Transthoracic Echocardiogram', 'no label'), ('Left Ventricular Function', 'no label'), ('Wall Motion Abnormality', 'no label'), ('Case Report', 'no label'), ('Provides', 'no label'), ('Diagnosis', 'no label'), ('Management', 'no label'), ('Ttc', 'no label'), ('Absence', 'no label'), ('Pathognomic Features', 'no label')]|[('Mid-Ventricles', 'no label')]|[]|[('Takotsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Ventricular Systolic Dysfunction', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Chest Pain', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Ventriculogram', 'no label'), ('Heart Failure', 'no label')]|[('Acute Reversible Ventricular Systolic', 'no label'), ('Coronary Artery', 'no label'), ('Cad', 'no label'), ('Wall', 'no label'), ('Wall', 'no label'), ('Cad', 'no label'), ('Left Ventriculogram', 'no label'), ('Patient', 'no label'), ('Heart', 'no label'), ('A Follow-Up Transthoracic', 'no label'), ('Left Ventricular', 'no label'), ('Wall', 'no label'), ('Pathognomic', 'no label')]
tako-tsubo cardiomyopathy|pubmed~26878476||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~24524742||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25137200|We Report The Case Of A Patient Who Suffered A Serious Subarachnoid Hemorrhage With A Cardialaffection And Development Of An Inverted Tako-Tsubo-Cardiomyopathy. To Avoid Apparent Cerebral Ischemia Due To Severe Cerebral Vasospasm After Exhaustion Of Conservative Therapeutic Options A Temporarily Endovascular Therapy With Continuous Intra-Arterial Application Of Nimodipine Was Necessary. In The Overall Protracted And Complicated Course The Special Challenge Were The Therapeutic Efforts To Avoid Apparent Cerebral Ischemia In Context To The Significant Cardial Affection.|[('Report', 'no label'), ('Patient', 'no label'), ('Suffered A', 'no label'), ('Serious', 'no label'), ('Subarachnoid Hemorrhage', 'no label'), ('Cardialaffection', 'no label'), ('Development', 'no label'), ('Inverted Tako-Tsubo-Cardiomyopathy', 'no label'), ('Apparent Cerebral Ischemia', 'no label'), ('Severe', 'no label'), ('Cerebral Vasospasm', 'no label'), ('Exhaustion', 'no label'), ('Conservative Therapeutic Options', 'no label'), ('Endovascular Therapy', 'no label'), ('Continuous Intra-Arterial Application', 'no label'), ('Nimodipine', 'no label'), ('Protracted', 'no label'), ('Complicated Course', 'no label'), ('Special Challenge', 'no label'), ('Therapeutic', 'no label'), ('Apparent Cerebral Ischemia', 'no label'), ('Context', 'no label'), ('Significant', 'no label'), ('Cardial Affection', 'no label')]|[('Nimodipine', 'no label')]|[]|[('Subarachnoid Hemorrhage', 'no label'), ('Cerebral Ischemia', 'no label'), ('Cerebral Vasospasm', 'no label'), ('Nimodipine', 'no label'), ('Cerebral Ischemia', 'no label')]|[('Patient', 'no label'), ('Cerebral Ischemia', 'no label'), ('Cerebral', 'no label'), ('Nimodipine', 'no label'), ('Cerebral Ischemia', 'no label')]
tako-tsubo cardiomyopathy|pubmed~24187769|An 83-Year-Old Woman With A Possible History Of Myocardial Infarction Presented With Acute Chest Pain And Dyspnoea. The Electrocardiogram Showed No Signs Of Acute Coronary Syndrome, But Q Waves In The Anteroseptal Leads. The Blood Tests Showed An Important Elevation Of Troponin T Level. Emergency Coronary Angiography Revealed Normal Epicardial Arteries, But The Left Ventriculogram Demonstrated Anterior Akinesis And Ballooning With Normal Apical And Basal Function. An Atypical Takotsubo Cardiomyopathy Was Suspected And The Patient Received Beta Blocker And Ace Inhibitor Treatment. Two Days Later The Echocardiogram Evolved To A Classical Pattern Of Apical Ballooning With Normalization On The Follow-Up Examination 5 Weeks From The Acute Episode. To Our Knowledge, This Is The First Case Report Describing An Evolving Pattern Of Wall Motion Abnormality From An Anterior Wall Ballooning To An Apical Form.|[('History', 'no label'), ('Myocardial Infarction', 'no label'), ('Acute Chest Pain', 'no label'), ('Dyspnoea', 'no label'), ('Electrocardiogram', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Q Waves', 'no label'), ('Anteroseptal Leads', 'no label'), ('Blood Tests', 'no label'), ('Elevation', 'no label'), ('Troponin T', 'no label'), ('Level', 'no label'), ('Emergency', 'no label'), ('Coronary Angiography', 'no label'), ('Revealed', 'no label'), ('Normal Epicardial Arteries', 'no label'), ('Left Ventriculogram', 'no label'), ('Demonstrated Anterior Akinesis', 'no label'), ('Ballooning', 'no label'), ('Normal Apical And Basal Function', 'no label'), ('Atypical Takotsubo Cardiomyopathy', 'no label'), ('Suspected', 'no label'), ('Patient', 'no label'), ('Received', 'no label'), ('Beta Blocker', 'no label'), ('Ace Inhibitor', 'no label'), ('Treatment', 'no label'), ('Days', 'no label'), ('Echocardiogram', 'no label'), ('Evolved', 'no label'), ('Classical Pattern', 'no label'), ('Apical Ballooning', 'no label'), ('Normalization', 'no label'), ('Follow-Up Examination', 'no label'), ('Weeks', 'no label'), ('Acute Episode', 'no label'), ('Knowledge', 'no label'), ('First Case Report', 'no label'), ('Evolving Pattern', 'no label'), ('Wall Motion Abnormality', 'no label'), ('Anterior Wall Ballooning', 'no label'), ('Apical Form', 'no label')]|[('Troponin', 'no label'), ('Apical', 'no label'), ('Inhibitor', 'no label'), ('Apical', 'no label')]|[]|[('Myocardial Infarction', 'no label'), ('Chest Pain', 'no label'), ('Dyspnoea', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Ventriculogram', 'no label'), ('Atypical Takotsubo Cardiomyopathy', 'no label')]|[('Myocardial', 'no label'), ('Acute Chest', 'no label'), ('Acute Coronary', 'no label'), ('Anteroseptal', 'no label'), ('Blood', 'no label'), ('Troponin T', 'no label'), ('Epicardial Arteries', 'no label'), ('Left Ventriculogram', 'no label'), ('Normal Apical', 'no label'), ('Patient', 'no label'), ('Beta Blocker', 'no label'), ('Ace Inhibitor', 'no label'), ('Apical', 'no label'), ('Wall', 'no label'), ('Wall', 'no label')]
tako-tsubo cardiomyopathy|pubmed~18582968|Tako-Tsubo Cardiomyopathy, Also Called Transient Left Ventricular Apical Ballooning, Is A Clinical Entity First Described In Japan. This Syndrome Is Triggered By Emotional Or Physical Stress And Mimics An Acute Coronary Syndrome, Although The Coronary Arteries Are Essentially Normal. Recently, Several Reports Have Described Variant Forms Of Tako-Tsubo Cardiomyopathy, Such As Inverted Tako-Tsubo And Mid-Ventricular Ballooning Cardiomyopathy. We Describe A Case Herein Of An 87-Year-Old Woman Who Presented A Variant Form Of Tako-Tsubo Cardiomyopathy Complicated By Syncope. Our Findings May Contribute To An Elucidation Of The Mechanism Underlying Tako-Tsubo Cardiomyopathy.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Transient', 'no label'), ('Left Ventricular Apical Ballooning', 'no label'), ('Clinical Entity', 'no label'), ('Japan', 'no label'), ('Syndrome', 'no label'), ('Triggered', 'no label'), ('Emotional Or Physical Stress', 'no label'), ('Mimics', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Coronary Arteries', 'no label'), ('Normal', 'no label'), ('Reports', 'no label'), ('Described', 'no label'), ('Variant Forms', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo', 'no label'), ('Mid-Ventricular Ballooning Cardiomyopathy', 'no label'), ('Case', 'no label'), ('Variant Form', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Complicated', 'no label'), ('Syncope', 'no label'), ('Findings', 'no label'), ('Contribute', 'no label'), ('Elucidation', 'no label'), ('Mechanism', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Apical', 'no label'), ('Mid-Ventricular', 'no label'), ('Variant', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricular Apical Ballooning', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Syncope', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Left Ventricular', 'no label'), ('Coronary Arteries', 'no label'), ('Mid-Ventricular', 'no label'), ('A Case', 'no label')]
tako-tsubo cardiomyopathy|pubmed~26476987||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~23871350||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25499374||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25828111||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~26296044||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25037469|After Acute-Anterior Myocardial Infarction (Ami), Left Ventricular (Lv) Viable Myocardial Segments Show Some Degree Of Active Deformation (Longitudinal Shortening) Despite Wall Motion Abnormalities (Wma). Tako-Tsubo Cardiomyopathy (Ttc) Is Characterized By Myocardial Stunning; However, It Is Unclear Whether In Ttc The Strain Pattern Mimics Ami. To Compare The Strain-Pattern In Ttc And Ami Using The 2D-Longitudinal Strain By Speckle-Tracking In Segments With Wma, And Its Relationship With Recovery Of Function At Follow-Up. 21 Consecutive Patients With Typical Ttc And 21 Age-Matched Ami Patients Treated By Primary Angioplasty Had An Analysis Of Lv-Longitudinal Strain At The Acute-Phase And At Follow-Up (1 And 6 Months Later For Ttc And Ami Respectively). The Recovery Of A Segment Was Defined As Normal Wall Motion At Follow-Up. Among The 706 Analyzable Lv-Segments At The Acute-Phase, 406 Had Wma (Ttc 229, Ami 177). At Follow-Up, Total Recovery Was Observed For 45 % Segments In Ami And 100 % In Ttc, (P < 0.01). At The Acute Phase, Systolic Lengthening Duration (47 ± 43 Vs. 18 ± 33 %) And Amplitude (0.25 ± 0.29 Vs. 0.09 ± 0.19) And Post Systolic Shortening (67 ± 53 Vs. 39 ± 38 %) Were Higher In Ttc, When Compared To Ami-Recovery (All, P < 0.01). In Ami, Systolic Lengthening Duration Was An Independent Predictor Of Poor Recovery In Multivariate Analysis, Linked To Segmental Longitudinal Strain At Follow-Up (All, P ≤ 0.01). Furthermore, Among The 57 % Of Segments Exhibiting Any Systolic Lengthening Duration In Ami, Only ¼ Recovered, Versus 62 % Of Such Segments In Ttc With 100 % Recovery (P < 0.001). The Systolic Passive Motion Which Is Closely And Inversely Linked To Recovery In Ami Is Paradoxically Frequent And Severe In Ttc. This Suggests That Myocardial Stunning In Ttc And Ami Is Different According To Longitudinal Strain.|[('Acute-Anterior Myocardial Infarction', 'no label'), ('Left Ventricular (Lv)', 'no label'), ('Myocardial Segments', 'no label'), ('Degree', 'no label'), ('Deformation', 'no label'), ('Longitudinal Shortening', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Wma', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Characterized', 'no label'), ('Myocardial', 'no label'), ('Ttc', 'no label'), ('Strain Pattern Mimics Ami', 'no label'), ('Compare', 'no label'), ('Strain-Pattern', 'no label'), ('Ttc', 'no label'), ('2D-Longitudinal Strain By Speckle-Tracking', 'no label'), ('Segments', 'no label'), ('Wma', 'no label'), ('Relationship', 'no label'), ('Recovery', 'no label'), ('Function', 'no label'), ('Follow-Up', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Typical Ttc', 'no label'), ('Patients', 'no label'), ('Treated', 'no label'), ('Primary Angioplasty', 'no label'), ('Analysis', 'no label'), ('Lv-Longitudinal', 'no label'), ('Strain', 'no label'), ('Acute-Phase', 'no label'), ('Follow-Up', 'no label'), ('Months', 'no label'), ('Ttc', 'no label'), ('Recovery', 'no label'), ('Normal Wall Motion', 'no label'), ('Follow-Up', 'no label'), ('Lv-Segments', 'no label'), ('Acute-Phase', 'no label'), ('Wma', 'no label'), ('Ttc', 'no label'), ('Follow-Up', 'no label'), ('Total Recovery', 'no label'), ('Observed', 'no label'), ('Segments', 'no label'), ('Ttc', 'no label'), ('Acute Phase', 'no label'), ('Systolic Lengthening Duration', 'no label'), ('Vs', 'no label'), ('Amplitude', 'no label'), ('Post Systolic Shortening', 'no label'), ('Higher', 'no label'), ('Ttc', 'no label'), ('Ami-Recovery', 'no label'), ('Systolic Lengthening Duration', 'no label'), ('Independent Predictor', 'no label'), ('Poor Recovery', 'no label'), ('Multivariate Analysis', 'no label'), ('Segmental', 'no label'), ('Follow-Up', 'no label'), ('Segments', 'no label'), ('Exhibiting', 'no label'), ('Systolic', 'no label'), ('Lengthening', 'no label'), ('Duration', 'no label'), ('¼', 'no label'), ('Recovered', 'no label'), ('Segments', 'no label'), ('Ttc', 'no label'), ('Recovery', 'no label'), ('Systolic Passive Motion', 'no label'), ('Inversely', 'no label'), ('Recovery', 'no label'), ('Frequent', 'no label'), ('Severe', 'no label'), ('Ttc', 'no label'), ('Suggests', 'no label'), ('Myocardial Stunning', 'no label'), ('Ttc', 'no label'), ('Longitudinal Strain', 'no label')]|[('Segment', 'no label')]|[('Lv-Segments', 'no label'), ('Wma', 'no label'), ('Ami 177', 'no label'), ('Ami', 'no label')]|[('Myocardial Infarction', 'no label'), ('Left Ventricular (Lv) Viable Myocardial', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Myocardial Stunning', 'no label'), ('≤', 'no label'), ('Myocardial Stunning', 'no label')]|[('Myocardial', 'no label'), ('Myocardial Segments', 'no label'), ('Wall', 'no label'), ('Myocardial', 'no label'), ('Strain-Pattern', 'no label'), ('Segments', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Follow-Up (1 And 6', 'no label'), ('Wall', 'no label'), ('Segments', 'no label'), ('Ami-Recovery', 'no label'), ('Segments', 'no label'), ('Segments', 'no label'), ('Myocardial', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23152070|A 70-Year-Old Woman Complained Of Persistent Angina Pectoris And Exertional Dyspnoea After A Fierce Row With A Dog Owner. Five Days After The Conflict She Visited Our Clinic. The Ecg Showed T-Wave Inversions Across The Inferior And Anterior Leads As Well As A Prolonged Qtc Interval (490 Ms). Ntprobnp Was Elevated (6733 Ng/L) While Troponin T Was Normal. Echocardiography And Ventriculography During Cardiac Catheterisation Demonstrated An Impaired Left Ventricular Function (Ef 55 %) With Apical Akinesia. Coronary Artery Disease Was Ruled Out By Coronary Angiography. Based On These Findings Stress-Related Cardiomyopathy (Tako-Tsubo Syndrome) Was Diagnosed. Guideline-Based Therapy Of Heart Failure Was Performed. At Control Examination 13 Days After The Initial Event Left Ventricular Function Had Improved But Now A New Left Ventricular Apical Thrombus Was Detected. Therefore, Oral Anticoagulation Therapy Was Started. In Cases Of Tako-Tsubo Cardiomyopathy With Apical Akinesia It Should Be Noted That A Left Ventricular Thrombus Can Develope Within Few Days.|[('Woman', 'no label'), ('Complained', 'no label'), ('Persistent Angina Pectoris', 'no label'), ('Exertional Dyspnoea', 'no label'), ('Fierce Row With', 'no label'), ('Dog', 'no label'), ('Days', 'no label'), ('Conflict She Visited', 'no label'), ('Clinic', 'no label'), ('Ecg Showed T-Wave Inversions', 'no label'), ('Inferior', 'no label'), ('Anterior Leads', 'no label'), ('Prolonged Qtc Interval', 'no label'), ('Ntprobnp', 'no label'), ('Elevated', 'no label'), ('Troponin T', 'no label'), ('Echocardiography', 'no label'), ('Ventriculography', 'no label'), ('Cardiac Catheterisation', 'no label'), ('Impaired', 'no label'), ('Left Ventricular Function', 'no label'), ('Apical Akinesia', 'no label'), ('Coronary Artery Disease', 'no label'), ('Coronary Angiography', 'no label'), ('Findings', 'no label'), ('Stress-Related Cardiomyopathy', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Diagnosed', 'no label'), ('Guideline-Based Therapy', 'no label'), ('Heart Failure', 'no label'), ('Control Examination 13 Days', 'no label'), ('Initial Event', 'no label'), ('Left Ventricular Function', 'no label'), ('New Left Ventricular', 'no label'), ('Apical Thrombus', 'no label'), ('Detected', 'no label'), ('Oral Anticoagulation Therapy', 'no label'), ('Cases', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Apical Akinesia', 'no label'), ('Noted', 'no label'), ('Left Ventricular Thrombus', 'no label'), ('Develope', 'no label'), ('Days', 'no label')]|[('Dog', 'no label'), ('Troponin', 'no label')]|[('Ecg Showed T-Wave Inversions', 'no label'), ('Troponin T', 'no label')]|[('Angina Pectoris', 'no label'), ('Exertional Dyspnoea', 'no label'), ('Impaired Left Ventricular Function', 'no label'), ('Akinesia', 'no label'), ('Coronary Artery Disease', 'no label'), ('Cardiomyopathy', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Heart Failure', 'no label'), ('Left Ventricular Apical Thrombus', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Akinesia', 'no label'), ('Ventricular Thrombus', 'no label')]|[('Troponin T', 'no label'), ('Cardiac', 'no label'), ('Left Ventricular', 'no label'), ('Heart', 'no label'), ('A New Left Ventricular', 'no label'), ('Thrombus', 'no label'), ('Oral', 'no label'), ('Left Ventricular Thrombus', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25920403||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~24768388||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~20884730|Stress-Induced Or Tako-Tsubo Cardiomyopathy (Ttc) Is A Rare Acute Cardiac Syndrome Characterized By Transient Left Ventricular (Lv) Dysfunction Of Uncertain Cause And Outcome. This Study Sought To Assess The Long-Term Outcome Of Patients With Ttc. One-Hundred Sixteen Consecutive Patients Were Prospectively Included In The Study And Observed At Long-Term Follow-Up. Primary End Points Were Death, Ttc Recurrence, And Hospitalization From Any Cause. Mean Initial Lv Ejection Fraction (Lvef) At Admission Was 36% ± 9%. Two Patients Died Of Refractory Heart Failure During Hospitalization. Of The Patients Who Were Discharged Alive All Except One Showed Complete Lv Functional Recovery. At Follow-Up (2.0 ± 1.3 Years), Only 64 (55%) Patients Were Asymptomatic. Rehospitalization Rate Was High (25%), With Chest Pain (N = 6) And Dyspnea (N = 5) As The Most Common Causes. Only Two Patients Had A Recurrence Of Ttc. Eleven Patients Died (Seven From Cardiovascular Cause). There Was No Significant Difference In Mortality (12% Vs 7%; P = .284) And In The Other Clinical Events Between Patients With And Without Severe Lv Dysfunction At Presentation (Lvef ≤ 35%). Mortality Observed In Patients With Ttc Was Compared With Age And Sex-Specific Mortality Of The General Population Using The Standardized Mortality Ratio (Smr) Method. The Smr Was 3.40 (95% Ci, 1.83-6.34) In The Ttc Population. The Only Independent Predictor Of Death At Cox Analysis Was Charlson Comorbidity Index (Hazard Ratio, 1.786; P = .0001), But The Degree Of Initial Lv Dysfunction Was Not An Independent Predictor Of Death. The Recurrence Of Ttc Is Rare, But Recurrences Of Chest Pain Or Dyspnea Are Common In Patients With Ttc And Frequently Lead To Hospital Readmission. Long-Term Mortality Is Higher As Compared With The Control General Population And At Least In Part Related To Patients' Comorbidities. Initial Lv Dysfunction Severity Does Not Seem To Impact Long-Term Event Rates.|"[('Stress-Induced', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Rare', 'no label'), ('Acute Cardiac Syndrome', 'no label'), ('Characterized', 'no label'), ('Transient Left Ventricular (Lv) Dysfunction', 'no label'), ('Uncertain Cause', 'no label'), ('Outcome', 'no label'), ('Study', 'no label'), ('Assess', 'no label'), ('Long-Term Outcome', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Observed', 'no label'), ('Long-Term Follow-Up', 'no label'), ('Primary End Points', 'no label'), ('Death', 'no label'), ('Ttc', 'no label'), ('Recurrence', 'no label'), ('Hospitalization', 'no label'), ('Cause', 'no label'), ('Lv Ejection Fraction', 'no label'), ('Lvef', 'no label'), ('Admission', 'no label'), ('Patients', 'no label'), ('Died', 'no label'), ('Refractory Heart Failure', 'no label'), ('Hospitalization', 'no label'), ('Patients', 'no label'), ('Lv Functional Recovery', 'no label'), ('Follow-Up', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Asymptomatic', 'no label'), ('Rehospitalization Rate', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Causes', 'no label'), ('Patients', 'no label'), ('Recurrence', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Died', 'no label'), ('Cardiovascular Cause', 'no label'), ('No Significant Difference', 'no label'), ('Mortality', 'no label'), ('Clinical Events', 'no label'), ('Patients', 'no label'), ('Severe', 'no label'), ('Lv Dysfunction', 'no label'), ('Presentation', 'no label'), ('Lvef', 'no label'), ('Mortality', 'no label'), ('Observed', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Age', 'no label'), ('Sex-Specific', 'no label'), ('Mortality', 'no label'), ('General Population', 'no label'), ('Standardized Mortality Ratio', 'no label'), ('Smr', 'no label'), ('Ci', 'no label'), ('Ttc', 'no label'), ('Population', 'no label'), ('Independent Predictor', 'no label'), ('Death', 'no label'), ('Cox Analysis', 'no label'), ('Charlson Comorbidity Index', 'no label'), ('Hazard Ratio', 'no label'), ('Degree', 'no label'), ('Initial', 'no label'), ('Lv Dysfunction', 'no label'), ('Independent Predictor', 'no label'), ('Death', 'no label'), ('Recurrence', 'no label'), ('Ttc', 'no label'), ('Rare', 'no label'), ('Recurrences', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Lead', 'no label'), ('Hospital', 'no label'), ('Readmission', 'no label'), ('Long-Term', 'no label'), ('Mortality', 'no label'), ('Control', 'no label'), ('General Population', 'no label'), (""Patients'"", 'no label'), ('Comorbidities', 'no label'), ('Initial', 'no label'), ('Lv Dysfunction Severity', 'no label'), ('Impact', 'no label'), ('Long-Term Event', 'no label'), ('Rates', 'no label')]"|[('±', 'no label'), ('Smr', 'no label'), ('Smr', 'no label'), ('Cox', 'no label'), ('Lead', 'no label')]|[('Smr', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Cardiac Syndrome', 'no label'), ('Uncertain', 'no label'), ('Death', 'no label'), ('Heart Failure', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Cardiovascular Cause', 'no label'), ('≤', 'no label'), ('Death', 'no label'), ('Comorbidity', 'no label'), ('Death', 'no label'), ('Ttc', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label')]|[('Rare Acute Cardiac', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lv', 'no label'), ('Patients', 'no label'), ('Heart', 'no label'), ('Patients', 'no label'), ('Lv', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cardiovascular', 'no label'), ('Patients', 'no label'), ('Lv', 'no label'), ('Patients', 'no label'), ('Smr Was 3.40', 'no label'), ('Lv', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lv', 'no label'), ('Seem', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25743177||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~21477336|The Cause Of Tako Tsubo Cardiomyopathy Remains Unclear. We Used A Multidisciplinary Approach To Investigate If A Common Pathophysiological Denominator Could Be Outlined. Within 3 Days Following Symptom Presentation And Again After 3 Months We Investigated All Patients Coming To Our Institution And Diagnosed With Tako-Tsubo Cardiomyopathy. Patients Underwent Extensive Biochemical Screening. Left Ventricular Function Was Evaluated By Echocardiography And Contrast-Enhanced Cardiac Magnetic Resonance Imaging. Cardiac Autonomic Function Was Studied By Heart Rate Variability And Signal-Averaged Electrocardiogram And Posttraumatic Stress And Depression Were Investigated By Questionnaires (The Posttraumatic Stress Syndrome 10-Questions Inventory, Ptss-10 And The Montgomery-Åsberg Depression Rating Scale, Self Rated Version, Madrs-S). During 2 Years, 13 Consecutive Patients Were Included. Markers Of Myocardial Damage And Heart Failure Were Slightly To Moderately Elevated And Ejection Fraction (Echocardiography And Mri) Was Moderately Reduced At Hospitalization And Improved To Normal Values In All Patients. Signal Averaged Ecg Demonstrated A Statistically Significant Shorter Duration Of The Filtered Qrs Complex In The Acute Phase As Compared To Follow-Up. In Heart Rate Variability Analysis, Sdnn And Sdann Were Shorter Acutely Compared To Follow-Up. Two Patients Fulfilled Criteria For Posttraumatic Stress Syndrome While 7 Patients Were In The Borderline Zone. There Was A Statistically Significant Inverse Correlation Between Ptss-10 Score And Qrs Duration In The Signal-Averaged Ecg (R = -0.66, P = 0.01). Patients With Tako Tsubo Cardiomyopathy Have Altered Cardiac Autonomic Function And A High Incidence Rate Of Borderline Or Definite Posttraumatic Stress Syndrome Acutely. This Is In Line With Findings In Patients With Myocardial Infarction And Does Not Allow Conclusions On Cause And Effect.|[('Cause', 'no label'), ('Tako Tsubo Cardiomyopathy', 'no label'), ('Remains', 'no label'), ('Multidisciplinary Approach', 'no label'), ('Investigate', 'no label'), ('Pathophysiological', 'no label'), ('Days', 'no label'), ('Symptom Presentation', 'no label'), ('Months', 'no label'), ('Investigated', 'no label'), ('Patients', 'no label'), ('Institution', 'no label'), ('Diagnosed', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Patients', 'no label'), ('Extensive', 'no label'), ('Biochemical', 'no label'), ('Screening', 'no label'), ('Left Ventricular Function', 'no label'), ('Echocardiography', 'no label'), ('Contrast-Enhanced Cardiac Magnetic Resonance Imaging', 'no label'), ('Cardiac Autonomic Function', 'no label'), ('Heart Rate Variability', 'no label'), ('Signal-Averaged Electrocardiogram', 'no label'), ('Posttraumatic Stress', 'no label'), ('Depression', 'no label'), ('Investigated', 'no label'), ('Questionnaires', 'no label'), ('Posttraumatic Stress Syndrome 10-Questions Inventory', 'no label'), ('Ptss-10', 'no label'), ('Montgomery-Åsberg Depression Rating Scale', 'no label'), ('Self Rated Version', 'no label'), ('Madrs-S', 'no label'), ('Years', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Markers', 'no label'), ('Myocardial Damage', 'no label'), ('Heart Failure', 'no label'), ('Elevated', 'no label'), ('Ejection Fraction', 'no label'), ('Echocardiography', 'no label'), ('Mri', 'no label'), ('Reduced', 'no label'), ('Hospitalization', 'no label'), ('Normal Values', 'no label'), ('Patients', 'no label'), ('Signal Averaged Ecg Demonstrated A', 'no label'), ('Statistically Significant', 'no label'), ('Shorter Duration', 'no label'), ('Filtered Qrs Complex', 'no label'), ('Acute Phase', 'no label'), ('Follow-Up', 'no label'), ('Heart Rate Variability Analysis', 'no label'), ('Sdnn', 'no label'), ('Sdann', 'no label'), ('Shorter', 'no label'), ('Acutely', 'no label'), ('Follow-Up', 'no label'), ('Patients', 'no label'), ('Criteria', 'no label'), ('Posttraumatic Stress Syndrome', 'no label'), ('Patients', 'no label'), ('Borderline Zone', 'no label'), ('Statistically Significant', 'no label'), ('Inverse', 'no label'), ('Correlation', 'no label'), ('Ptss-10', 'no label'), ('Score', 'no label'), ('Qrs Duration', 'no label'), ('Signal-Averaged Ecg', 'no label'), ('Patients', 'no label'), ('Tako Tsubo Cardiomyopathy', 'no label'), ('Altered', 'no label'), ('Cardiac Autonomic Function', 'no label'), ('High Incidence Rate', 'no label'), ('Borderline', 'no label'), ('Definite', 'no label'), ('Posttraumatic Stress Syndrome', 'no label'), ('Acutely', 'no label'), ('Findings', 'no label'), ('Patients', 'no label'), ('Myocardial Infarction', 'no label'), ('Conclusions', 'no label'), ('Cause', 'no label'), ('Effect', 'no label')]|[]|[('Ptss-10', 'no label'), ('Sdnn', 'no label')]|[('Tako', 'no label'), ('Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Depression', 'no label'), ('Stress Syndrome 10-Questions Inventory', 'no label'), ('Myocardial Damage', 'no label'), ('Heart Failure', 'no label'), ('Posttraumatic Stress Syndrome', 'no label'), ('Tako', 'no label'), ('Cardiomyopathy', 'no label'), ('Posttraumatic Stress Syndrome', 'no label'), ('Myocardial Infarction', 'no label')]|[('Tako', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Left Ventricular', 'no label'), ('Cardiac', 'no label'), ('Cardiac Autonomic', 'no label'), ('Heart', 'no label'), ('Patients', 'no label'), ('Myocardial', 'no label'), ('Heart', 'no label'), ('Patients', 'no label'), ('Heart', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Borderline Zone', 'no label'), ('Patients', 'no label'), ('Cardiac Autonomic', 'no label'), ('Borderline Or', 'no label'), ('Line', 'no label'), ('Patients', 'no label'), ('Myocardial', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23642827||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~23582692||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~23243944|Tako-Tsubo Cardiomyopathy Is A Clinical Syndrome Induced By A Strong Mental Or Physical Stress, Characterized By A Transient Hypokinesia, Akinesia Or Dyskinesia Middle Segments Of The Left Ventricle And Apical, With Associated Electrocardiographic Changes Of St-T Segment Like In Acute Coronary Syndrome, With No Significant Changes In Coronary Arteries In Coronary Angiography. Tako-Tsubo Cardiomyopathy Is Mainly Found In Women In The Sixth And Seventh Decade Of Life And Represents 1-2% Of Cases Originally Diagnosed As Acute Coronary Syndrome. We Present A Case Of Tako-Tsubo Syndrome In The Course Of Carbon Monoxide Poisoning In A 56-Year-Old Patient, With A Positive History Of Ischemic Heart Disease And Hypertension. Moreover, The Reasons For Its Occurrence Were Considered Based On Clinical Course, Laboratory Tests And Imaging, And Available Literature.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Clinical Syndrome', 'no label'), ('Induced', 'no label'), ('Strong', 'no label'), ('Physical Stress', 'no label'), ('Characterized', 'no label'), ('Transient Hypokinesia', 'no label'), ('Akinesia', 'no label'), ('Dyskinesia', 'no label'), ('Segments', 'no label'), ('Left Ventricle', 'no label'), ('Apical', 'no label'), ('Electrocardiographic Changes', 'no label'), ('St-T Segment', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('No Significant', 'no label'), ('Changes', 'no label'), ('Coronary Arteries', 'no label'), ('Coronary Angiography', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Women', 'no label'), ('Cases', 'no label'), ('Diagnosed', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Case', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Course', 'no label'), ('Carbon Monoxide Poisoning', 'no label'), ('56-Year-Old', 'no label'), ('Patient', 'no label'), ('Positive History', 'no label'), ('Ischemic Heart Disease', 'no label'), ('Hypertension', 'no label'), ('Occurrence', 'no label'), ('Clinical Course', 'no label'), ('Laboratory Tests', 'no label'), ('Imaging', 'no label'), ('Available Literature', 'no label')]|[('Monoxide', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Hypokinesia', 'no label'), ('Akinesia', 'no label'), ('Dyskinesia', 'no label'), ('Left Ventricle And Apical,', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Carbon Monoxide Poisoning', 'no label'), ('Ischemic Heart Disease', 'no label'), ('Hypertension', 'no label')]|[('Segments', 'no label'), ('Left Ventricle', 'no label'), ('Acute Coronary', 'no label'), ('Coronary Arteries', 'no label'), ('Women', 'no label'), ('Acute Coronary', 'no label'), ('Carbon Monoxide', 'no label'), ('Heart', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25601763|"""Tako-Tsubo Cardiomyopathy"" (Ttc) Is A Syndrome Characterized By Left Ventricular (Lv) Wall Motion Abnormalities, Usually Without Coronary Artery Disease, Mimicking The Diagnosis Of Acute Coronary Syndrome. It Most Often Affects Post-Menopausal Women And Ttc Tends To Run A Benign Course With Very Low Rates Of Recurrence, Complications Or Mortality. The Condition Is Also Called ""Stress-Induced Cardiomyopathy"" Because Acute Physical Or Emotional Stress Appears To Be Frequently Related To Its Onset. The Pathogenic Role Of Premorbid Or Comorbid Psychiatric Illnesses Has Been Discussed Controversially. For The First Time, We Present A Case Of Fourfold Recurrent Ttc With Severe Complications In A Pre-Menopausal Woman. Furthermore, A Long History Of Flaring Posttraumatic Stress Symptoms Anteceded The First Event. A 43-Year Old, Pre-Menopausal Caucasian Woman Was Hospitalized With Symptoms Of Acute Coronary Syndrome. Clinical Examination Revealed Hypokinetic Wall Motion In The Apical Ventricular Region With No Signs Of Coronary Artery Disease And Diagnosis Of Ttc Was Established. She Experienced Recurrence Three Times Within The Following Ten Months, Which Led To Thrombembolism And Myocardial Scarring Among Others. The Circumstances Of Chronic Distress Were Striking. 16 Years Ago She Miscarried After Having Removed A Myoma According To Her Doctor'S Suggestion. Since Then, She Has Suffered From Symptoms Of Posttraumatic Distress Which Peaked Annually At The Day Of Abortion. Chronic Distress Became Even More Pronounced After The Premature Birth Of A Daughter Some Years Later. The First Event Of Ttc Occurred After A Family Dispute About Parenting. This Is The First Case Report Of Fourfold Ttc In A Pre-Menopausal Woman. From Somatic Perspectives, The Course Of The Disease With Recurrences And Complications Underlines The Fact That Ttc Is Not Entirely Benign. Furthermore, It Is The First Case Report Of Long Lasting Symptoms Of Traumatic Stress Anteceding Ttc. Close Connections Between Adrenergic Signaling And Late Onset Of Clinical Stress Symptoms Are Well Known In The Psychopathology Of Traumatization. Although Larger Clinical Trials Are Needed To Elucidate Possible Interactions Of Premorbid Psychiatric Illnesses And Ttc, Cardiologists Should Be Vigilant Especially In Cases Of Recurrent Ttc."|"[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Syndrome', 'no label'), ('Characterized', 'no label'), ('Left Ventricular (Lv) Wall Motion Abnormalities', 'no label'), ('Coronary Artery Disease', 'no label'), ('Mimicking', 'no label'), ('Diagnosis', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Affects', 'no label'), ('Post-Menopausal', 'no label'), ('Women', 'no label'), ('Ttc', 'no label'), ('Tends', 'no label'), ('Benign Course', 'no label'), ('Rates', 'no label'), ('Recurrence', 'no label'), ('Complications', 'no label'), ('Mortality', 'no label'), ('Condition', 'no label'), ('Stress-Induced Cardiomyopathy', 'no label'), ('Acute Physical Or', 'no label'), ('Emotional Stress Appears', 'no label'), ('Pathogenic', 'no label'), ('Premorbid', 'no label'), ('Comorbid', 'no label'), ('Psychiatric Illnesses', 'no label'), ('First Time', 'no label'), ('Recurrent Ttc', 'no label'), ('Severe', 'no label'), ('Complications', 'no label'), ('Pre-Menopausal Woman', 'no label'), ('Long History', 'no label'), ('Flaring', 'no label'), ('Posttraumatic Stress Symptoms', 'no label'), ('Anteceded', 'no label'), ('First Event', 'no label'), ('43-Year Old', 'no label'), ('Pre-Menopausal', 'no label'), ('Caucasian', 'no label'), ('Woman', 'no label'), ('Symptoms', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Clinical Examination', 'no label'), ('Hypokinetic Wall Motion', 'no label'), ('Apical Ventricular Region', 'no label'), ('Coronary Artery Disease', 'no label'), ('Diagnosis', 'no label'), ('Ttc', 'no label'), ('Established', 'no label'), ('Experienced', 'no label'), ('Recurrence', 'no label'), ('Times', 'no label'), ('Months', 'no label'), ('Thrombembolism', 'no label'), ('Myocardial Scarring', 'no label'), ('Circumstances', 'no label'), ('Chronic Distress', 'no label'), ('Striking', 'no label'), ('Years', 'no label'), ('Ago', 'no label'), ('Miscarried', 'no label'), ('Removed', 'no label'), ('Myoma', 'no label'), (""Doctor'S"", 'no label'), ('Suggestion', 'no label'), ('Suffered', 'no label'), ('Symptoms', 'no label'), ('Posttraumatic Distress', 'no label'), ('Peaked', 'no label'), ('Annually', 'no label'), ('Day', 'no label'), ('Abortion', 'no label'), ('Chronic Distress', 'no label'), ('Premature Birth', 'no label'), ('Daughter', 'no label'), ('Years', 'no label'), ('First Event', 'no label'), ('Ttc', 'no label'), ('Family Dispute', 'no label'), ('Parenting', 'no label'), ('First Case Report', 'no label'), ('Ttc', 'no label'), ('Pre-Menopausal Woman', 'no label'), ('Somatic Perspectives', 'no label'), ('Course', 'no label'), ('Disease', 'no label'), ('Recurrences', 'no label'), ('Complications', 'no label'), ('Underlines', 'no label'), ('Fact', 'no label'), ('Ttc', 'no label'), ('Benign', 'no label'), ('First Case Report', 'no label'), ('Long Lasting Symptoms', 'no label'), ('Traumatic Stress Anteceding', 'no label'), ('Ttc', 'no label'), ('Connections', 'no label'), ('Adrenergic Signaling', 'no label'), ('Late Onset', 'no label'), ('Clinical Stress Symptoms', 'no label'), ('Psychopathology', 'no label'), ('Traumatization', 'no label'), ('Clinical Trials', 'no label'), ('Interactions', 'no label'), ('Premorbid', 'no label'), ('Psychiatric Illnesses', 'no label'), ('Ttc', 'no label'), ('Cardiologists', 'no label'), ('Vigilant', 'no label'), ('Cases', 'no label'), ('Recurrent Ttc', 'no label')]"|[('Pathogenic', 'no label'), ('Pre-Menopausal', 'no label'), ('Region', 'no label'), ('Ago', 'no label'), ('Adrenergic', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricular (Lv) Wall Motion Abnormalities, Usually Without Coronary Artery Disease', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Cardiomyopathy', 'no label'), ('Psychiatric', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Coronary Artery Disease', 'no label'), ('Ttc', 'no label'), ('Thrombembolism', 'no label'), ('Myoma', 'no label'), ('Posttraumatic Distress', 'no label'), ('Abortion', 'no label'), ('Traumatic', 'no label')]|[('Left Ventricular', 'no label'), ('Coronary Artery', 'no label'), ('Acute Coronary', 'no label'), ('Women', 'no label'), ('Acute Physical Or', 'no label'), ('Stress', 'no label'), ('Acute Coronary', 'no label'), ('Wall', 'no label'), ('Coronary Artery', 'no label'), ('Myocardial', 'no label'), ('Ago', 'no label'), ('Myoma', 'no label'), ('Long', 'no label'), ('Adrenergic Signaling', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25711840||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~18372055|St-Segment Elevation In Lead Avr In Patients With Angina At Rest Can Be Related To Transmural Ischemia Of The Basal Part Of The Interventricular Septum, Frequently Due To Left Main Or Multivessel Coronary Disease. However, This Electrocardiographic (Ecg) Sign May Also Occur In Other Clinical Conditions Manifesting By Acute Chest Pain. We Present A Case Of A 76-Year-Old Caucasian Woman With Transient St-Segment Elevation In Lead Avr Associated With Tako-Tsubo Cardiomyopathy. Our Report Seems To Confirm The Hypothesis About The Role Of Reversible Myocardial Ischemia Involving The Basal Part Of The Interventricular Septum In The Pathogenesis Of Tako-Tsubo Cardiomyopathy. In Conclusion, St-Segment Elevation In Lead Avr In Patients With A Clinical Presentation Of Acute Coronary Syndrome May Be Not Related To Coronary Artery Disease. Tako-Tsubo Cardiomyopathy Should Be Considered Among The Causes Of St-Segment Elevation In Lead Avr In Patients With Angina At Rest. Further Studies Are Needed To Evaluate The Occurrence And Importance Of This Ecg Sign In Patients With Tako-Tsubo Cardiomyopathy.|[('St-Segment', 'no label'), ('Elevation', 'no label'), ('Lead Avr', 'no label'), ('Patients', 'no label'), ('Angina', 'no label'), ('Rest', 'no label'), ('Transmural Ischemia', 'no label'), ('Basal Part', 'no label'), ('Interventricular Septum', 'no label'), ('Multivessel Coronary Disease', 'no label'), ('Electrocardiographic (Ecg) Sign', 'no label'), ('Occur', 'no label'), ('Clinical Conditions', 'no label'), ('Manifesting', 'no label'), ('Acute Chest Pain', 'no label'), ('Caucasian', 'no label'), ('Woman', 'no label'), ('Transient', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Lead Avr', 'no label'), ('Associated With', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Report', 'no label'), ('Confirm', 'no label'), ('Hypothesis', 'no label'), ('Reversible', 'no label'), ('Myocardial Ischemia', 'no label'), ('Basal Part', 'no label'), ('Interventricular Septum', 'no label'), ('Pathogenesis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Lead Avr', 'no label'), ('Patients', 'no label'), ('Clinical Presentation', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Not Related', 'no label'), ('Coronary Artery Disease', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Causes', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Lead Avr', 'no label'), ('Patients', 'no label'), ('Angina', 'no label'), ('Studies', 'no label'), ('Occurrence', 'no label'), ('Ecg Sign', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('St-Segment', 'no label'), ('Lead Avr', 'no label'), ('Lead Avr', 'no label'), ('Lead Avr', 'no label'), ('Lead Avr', 'no label')]|[]|[('Angina', 'no label'), ('Ischemia', 'no label'), ('Interventricular Septum', 'no label'), ('Multivessel Coronary Disease', 'no label'), ('Chest Pain', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Myocardial Ischemia', 'no label'), ('Pathogenesis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Coronary Artery Disease', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Angina', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Lead Avr', 'no label'), ('Patients', 'no label'), ('Transmural', 'no label'), ('Basal Part', 'no label'), ('Interventricular Septum, Frequently Due To Left Main Or Multivessel Coronary Disease.', 'no label'), ('Lead Avr', 'no label'), ('Myocardial', 'no label'), ('Basal Part', 'no label'), ('Interventricular Septum In The Pathogenesis Of Tako-Tsubo Cardiomyopathy.', 'no label'), ('Lead Avr', 'no label'), ('Patients', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Coronary Artery', 'no label'), ('Lead Avr', 'no label'), ('Patients', 'no label'), ('Ecg Sign', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~24508496||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~23002215|Typical Tako-Tsubo Cardiomyopathy (Ttc) Mimics Acute Anterior Myocardial Infarction (Ami) And The Differential Diagnosis Is Challenging Before Coronary Angiography (Ca) Is Performed; It Demonstrates Reduced Or Absent Antegrade Flow In The Left Anterior Descending Artery (Lad) In Ami, Whereas There Is No Such Flow Limiting In Ttc. At The Acute Phase, We Tested The Usefulness Of The Distal Lad Flow Visualization By Transthoracic Doppler Echocardiography (Tde) To Distinguish Between These Two Diseases. For This Purpose, We Prospectively Enrolled 28 Consecutive Patients With Ttc (75 ± 10 Years, 93% Females) Who Were Compared With 28 Consecutive Patients With Ami Treated Successfully By Primary Angioplasty (66 ± 12 Years, 79% Females). All The Patients Underwent The Assessment Of The Distal Lad Flow Just Before Ca, Using Colour And Pulsed-Wave Tde. In Addition, The Symmetric Involvement Of Wall Motion Abnormalities (Wmas) Based On The Extent Of The Disease Far Beyond One Coronary Territory In Ttc Was Searched By Tde. Non-Invasive Coronary Flow Reserve (Cfr) By Tde, In The Distal Lad, Was Also Performed Within 1 Day After Admission. Before Ca, The Distal Lad Flow Was Visible In 38 Of 56 Cases (68%) In The Whole Population, In All Cases With Ttc And In 10 Cases With Ami (36%). The Sensitivity (Se) And Specificity (Sp) Of The Lad Flow Visualization For The Diagnosis Of Ttc Were 100 And 64%, Respectively, With A Diagnostic Accuracy Of 82%. In Comparison, The Pattern Of Wma Yielded A Se Of 75% And Sp Of 86%, And A Diagnostic Accuracy Of 80%. With The Combination Of Both Tools, The Se And Sp To Detect Ttc Were 75 And 96% Respectively, With A Diagnostic Accuracy Of 86%. After Ca, The Acute Cfr Was Less Severely Impaired In The Ttc Group When Compared With The Ami Group (2.2 ± 0.5 Vs. 1.7 ± 0.6, P < 0.01) Despite A Worse Lv Systolic Dysfunction. Non-Invasive Evaluation Of The Distal Lad Flow Could Be Helpful To Differentiate Ttc From Ami, And Its Combination With The Pattern Of Wma Improved Slightly Its Diagnostic Accuracy. Furthermore, The Acute Cfr Is Less Severely Impaired In Ttc Compared With Ami Despite Poorer Lv Systolic Dysfunction, Suggesting That Other Mechanisms Than Direct Microcirculatory Damage Are Also Involved In The Pathogenesis Of Wmas In Ttc.|[('Typical', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Mimics', 'no label'), ('Acute Anterior Myocardial Infarction', 'no label'), ('Differential Diagnosis', 'no label'), ('Coronary Angiography', 'no label'), ('Ca', 'no label'), ('Performed', 'no label'), ('Demonstrates', 'no label'), ('Reduced', 'no label'), ('Absent Antegrade Flow', 'no label'), ('Left Anterior Descending Artery', 'no label'), ('Flow', 'no label'), ('Ttc', 'no label'), ('Acute Phase', 'no label'), ('Tested', 'no label'), ('Usefulness', 'no label'), ('Distal Lad Flow Visualization', 'no label'), ('Transthoracic Doppler Echocardiography', 'no label'), ('Tde', 'no label'), ('Distinguish', 'no label'), ('Diseases', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Years', 'no label'), ('Females', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Ami Treated', 'no label'), ('Successfully', 'no label'), ('Primary Angioplasty', 'no label'), ('Years', 'no label'), ('Females', 'no label'), ('Patients', 'no label'), ('Assessment', 'no label'), ('Distal Lad Flow', 'no label'), ('Ca', 'no label'), ('Colour', 'no label'), ('Pulsed-Wave', 'no label'), ('Symmetric Involvement', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Wmas', 'no label'), ('Disease', 'no label'), ('Coronary Territory', 'no label'), ('Ttc', 'no label'), ('Searched', 'no label'), ('Non-Invasive', 'no label'), ('Coronary Flow Reserve', 'no label'), ('Cfr', 'no label'), ('Distal', 'no label'), ('Performed', 'no label'), ('Day', 'no label'), ('Admission', 'no label'), ('Ca', 'no label'), ('Distal Lad Flow', 'no label'), ('Cases', 'no label'), ('Whole Population', 'no label'), ('Cases', 'no label'), ('Ttc', 'no label'), ('Cases', 'no label'), ('Ami', 'no label'), ('Sensitivity', 'no label'), ('Se', 'no label'), ('Specificity', 'no label'), ('Sp', 'no label'), ('Lad Flow Visualization', 'no label'), ('Diagnosis', 'no label'), ('Ttc', 'no label'), ('Diagnostic Accuracy', 'no label'), ('Comparison', 'no label'), ('Pattern', 'no label'), ('Wma Yielded A', 'no label'), ('Se', 'no label'), ('Diagnostic Accuracy', 'no label'), ('Combination', 'no label'), ('Tools', 'no label'), ('Se', 'no label'), ('Detect Ttc', 'no label'), ('Diagnostic Accuracy', 'no label'), ('Ca', 'no label'), ('Acute Cfr', 'no label'), ('Severely Impaired', 'no label'), ('Ttc', 'no label'), ('Group', 'no label'), ('Ami Group', 'no label'), ('Worse', 'no label'), ('Lv Systolic Dysfunction', 'no label'), ('Evaluation', 'no label'), ('Distal Lad Flow', 'no label'), ('Differentiate Ttc', 'no label'), ('Combination', 'no label'), ('Pattern', 'no label'), ('Wma', 'no label'), ('Diagnostic Accuracy', 'no label'), ('Acute Cfr', 'no label'), ('Severely Impaired', 'no label'), ('Ttc', 'no label'), ('Poorer', 'no label'), ('Lv Systolic Dysfunction', 'no label'), ('Suggesting', 'no label'), ('Mechanisms', 'no label'), ('Direct', 'no label'), ('Microcirculatory Damage', 'no label'), ('Pathogenesis', 'no label'), ('Wmas', 'no label'), ('Ttc', 'no label')]|[('Territory', 'no label'), ('Se', 'no label'), ('Se', 'no label'), ('Se', 'no label')]|[('Sp', 'no label'), ('Sp', 'no label'), ('Ami Group (2.2 ± 0.5', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Myocardial Infarction', 'no label'), ('Ca', 'no label'), ('Ca', 'no label'), ('Ca', 'no label'), ('Se', 'no label'), ('Se', 'no label'), ('Ca', 'no label'), ('Cfr', 'no label'), ('Systolic Dysfunction', 'no label'), ('Cfr', 'no label'), ('Systolic Dysfunction', 'no label'), ('Microcirculatory Damage', 'no label'), ('Pathogenesis', 'no label')]|[('Acute Anterior Myocardial Infarction (', 'no label'), ('Left Anterior Descending', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Colour', 'no label'), ('Wall', 'no label'), ('Se', 'no label'), ('Ttc Were 100', 'no label'), ('Se', 'no label'), ('Sp Of', 'no label'), ('Se', 'no label'), ('Lv Systolic', 'no label'), ('Lv Systolic', 'no label'), ('Microcirculatory', 'no label'), ('Wmas', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23583150|We Present A Case Of A 15 Year Old Girl Who Developed Transient Left Ventricular Apical Ballooning Syndrome, Tako-Tsubo Cardiomyopathy, After A Significant Motor Vehicle Accident. On Post-Trauma Day Three She Developed Heart Failure With Mid-To-Apical Left Ventricular Wall Dysfunction With An Ef Of 10%-15%. The Patient Eventually Regained Full Cardiac Function By Post-Trauma Day Seven. Here We Present The First Case Report Of Trauma Induced Left Ventricular Apical Ballooning Syndrome In Pediatrics.|[('Old Girl Who', 'no label'), ('Left Ventricular Apical Ballooning Syndrome', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Significant', 'no label'), ('Motor Vehicle Accident', 'no label'), ('Post-Trauma Day', 'no label'), ('Developed Heart Failure', 'no label'), ('Mid-To-Apical', 'no label'), ('Left Ventricular Wall Dysfunction', 'no label'), ('Patient', 'no label'), ('Regained', 'no label'), ('Cardiac Function', 'no label'), ('Day', 'no label'), ('First Case Report', 'no label'), ('Trauma', 'no label'), ('Induced', 'no label'), ('Left Ventricular Apical Ballooning Syndrome', 'no label'), ('Pediatrics', 'no label')]|[('Apical', 'no label'), ('Apical', 'no label')]|[]|[('Left Ventricular Apical Ballooning Syndrome', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Heart Failure', 'no label'), ('Left Ventricular Wall Dysfunction', 'no label'), ('Trauma', 'no label'), ('Left Ventricular Apical Ballooning Syndrome', 'no label')]|[('Left Ventricular', 'no label'), ('Heart', 'no label'), ('Left Ventricular Wall', 'no label'), ('Patient', 'no label'), ('Cardiac', 'no label'), ('Left Ventricular', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23871341||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~24175304|There Is No Data About The Serotonergic Activity During The Acute Phase Of Tako-Tsubo Cardiomyopathy (Ttc). The Objective Of Our Study Was To Investigate Evidence Of Serotonin Release From Patients With Ttc In Comparison With Patients With St Elevation Myocardial Infarction (Stemi) And Healthy Control Subjects (Hcs). Plasma Serotonin Levels In 14 Consecutive Patients With Ttc Were Compared With Those In 14 Patients With Stemi And 14 Hcs. Plasma Serotonin Levels At Admission Were Markedly Higher In Patients With Ttc And Stemi As Compared To Hcs (3.9 ± 4.6, P = 0.02 Versus Control; 5.7 ± 5.6, P = 0.001 Versus Control; And 1 ± 0.4 Ng/Ml, Resp.). There Was No Difference In Serotonin Levels Between Patients With Ttc And Those With Stemi (P = 0.33). This Finding Suggests That Serotonin Could Participate To The Pathophysiology Of Ttc.|[('Data', 'no label'), ('Serotonergic Activity', 'no label'), ('Acute Phase', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Study', 'no label'), ('Investigate', 'no label'), ('Evidence', 'no label'), ('Serotonin Release', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Comparison', 'no label'), ('Patients', 'no label'), ('St Elevation Myocardial Infarction', 'no label'), ('Stemi', 'no label'), ('Healthy Control Subjects', 'no label'), ('Hcs', 'no label'), ('Plasma', 'no label'), ('Serotonin', 'no label'), ('Levels', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Stemi', 'no label'), ('Hcs', 'no label'), ('Plasma', 'no label'), ('Serotonin Levels', 'no label'), ('Admission', 'no label'), ('Markedly', 'no label'), ('Higher', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Hcs', 'no label'), ('Control', 'no label'), ('Control', 'no label'), ('Resp', 'no label'), ('No Difference', 'no label'), ('Serotonin Levels', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Stemi', 'no label'), ('Suggests', 'no label'), ('Serotonin', 'no label'), ('Participate', 'no label'), ('Pathophysiology', 'no label'), ('Ttc', 'no label')]|[('Serotonin', 'no label'), ('Serotonin', 'no label'), ('Serotonin', 'no label'), ('Serotonin', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Serotonin', 'no label'), ('Myocardial Infarction', 'no label'), ('Serotonin', 'no label'), ('Serotonin', 'no label'), ('Serotonin', 'no label'), ('Serotonin', 'no label')]|[('Serotonin', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('St', 'no label'), ('Myocardial', 'no label'), ('Plasma Serotonin', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Plasma Serotonin', 'no label'), ('Patients', 'no label'), ('Serotonin', 'no label'), ('Patients', 'no label'), ('Serotonin', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20558930|"We Report The Case Of A 57-Year-Old Woman With Anorexia Nervosa Showing Evidence Of ""Tako-Tsubo"" Cardiomyopathy Complicated By Several Syncopes Due To Recurrent Episodes Of Torsades De Pointes. Prolongation Of Qt Interval And Qt Dispersion Have Been Reported Both In The ""Tako-Tsubo"" Cardiomyopathy And In Anorexia Nervosa. The Qt Prolongation And The Qt Dispersion Has Been Linked As Risk Indicators For Sudden Cardiac Death. The Combination Of ""Tako-Tsubo"" Cardiomyopathy With A Condition Associated With The Prolongation Of Qt And/Or With An Increase Of Qt Dispersion, Such As Anorexia Nervosa, Makes The Acute And Subacute Prognosis Of This Disease Much More Severe Than Usual."|"[('Report', 'no label'), ('57-Year-Old', 'no label'), ('Woman', 'no label'), ('Anorexia Nervosa', 'no label'), ('Showing Evidence', 'no label'), ('Cardiomyopathy', 'no label'), ('Complicated', 'no label'), ('Syncopes', 'no label'), ('Recurrent', 'no label'), ('Episodes', 'no label'), ('Torsades', 'no label'), ('De Pointes', 'no label'), ('Prolongation', 'no label'), ('Qt Interval', 'no label'), ('Qt Dispersion', 'no label'), ('Anorexia Nervosa', 'no label'), ('Qt', 'no label'), ('Prolongation', 'no label'), ('Qt Dispersion', 'no label'), ('Risk Indicators', 'no label'), ('Sudden Cardiac Death', 'no label'), ('Combination', 'no label'), ('Tako-Tsubo"" Cardiomyopathy', 'no label'), ('Condition', 'no label'), ('Associated With', 'no label'), ('Prolongation', 'no label'), ('Qt And/Or', 'no label'), ('Increase', 'no label'), ('Qt Dispersion', 'no label'), ('Anorexia Nervosa', 'no label'), ('Acute', 'no label'), ('Subacute', 'no label'), ('Prognosis', 'no label'), ('Disease', 'no label'), ('Severe', 'no label'), ('Than Usual', 'no label')]"|[]|[]|[('Anorexia Nervosa', 'no label'), ('Cardiomyopathy', 'no label'), ('Torsades De Pointes', 'no label'), ('Cardiomyopathy', 'no label'), ('Anorexia Nervosa', 'no label'), ('Sudden Cardiac Death', 'no label'), ('Cardiomyopathy', 'no label'), ('And/Or', 'no label'), ('Anorexia Nervosa', 'no label')]|[('Cardiac', 'no label'), ('And/Or', 'no label'), ('Nervosa', 'no label')]
tako-tsubo cardiomyopathy|pubmed~28034461||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25838229||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~33243478|Stress-Induced Cardiomyopathy, Also Known By Various Names Such As Tako-Tsubo Cardiomyopathy (Ttc), Is A Cardiomyopathy That Presents Different Types Of Transient Left Ventricular Dysfunction. We Present Two Cases Of Reverse Ttc Occurring In Two Young Men After Amphetamine Use And Complicated By Cardiogenic Shock Necessitating Venoarterial Extra-Corporeal Membrane Oxygenation (Va-Ecmo). Levosimendan Was Used In One Case To Prevent Subsequent Aggravation Of Left Ventricular Function Provoked By The Use Of Catecholamine In This Context. In Both Cases, Myocardial Function Recovered Rapidly. Amphetamine Use Can Lead To Reverse Ttc Requiring Transient Mechanical Assistance And Inotropic Support.|[('Stress-Induced Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Cardiomyopathy', 'no label'), ('Presents', 'no label'), ('Transient', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Cases', 'no label'), ('Reverse Ttc', 'no label'), ('Occurring', 'no label'), ('Young Men', 'no label'), ('Amphetamine Use', 'no label'), ('Complicated', 'no label'), ('Cardiogenic Shock Necessitating', 'no label'), ('Venoarterial Extra-Corporeal Membrane Oxygenation', 'no label'), ('Va-Ecmo', 'no label'), ('Levosimendan', 'no label'), ('Prevent', 'no label'), ('Aggravation', 'no label'), ('Left Ventricular Function Provoked', 'no label'), ('Catecholamine', 'no label'), ('Context', 'no label'), ('Cases', 'no label'), ('Myocardial Function Recovered Rapidly', 'no label'), ('Amphetamine', 'no label'), ('Reverse Ttc', 'no label'), ('Transient', 'no label'), ('Mechanical Assistance', 'no label'), ('Inotropic Support', 'no label')]|[('Amphetamine', 'no label'), ('Membrane', 'no label'), ('Catecholamine', 'no label'), ('Amphetamine', 'no label')]|[]|[('Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Cardiomyopathy', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Amphetamine', 'no label'), ('Cardiogenic Shock', 'no label'), ('Levosimendan', 'no label'), ('Left Ventricular Function Provoked By The Use Of', 'no label'), ('Catecholamine', 'no label'), ('Amphetamine', 'no label')]|[('Left Ventricular', 'no label'), ('Amphetamine', 'no label'), ('Venoarterial Extra-Corporeal Membrane', 'no label'), ('Levosimendan', 'no label'), ('Left Ventricular', 'no label'), ('Catecholamine', 'no label'), ('Myocardial', 'no label'), ('Amphetamine', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22298173|A 57 Year-Old Woman With No History Of Cardiac Disease Presented To The Emergency Department With Confusion And Seizures Secondary To Alcohol Withdrawal. Elevated Troponin Levels And An Electrocardiogram Demonstrating Global T-Wave Inversions Prompted Coronary Angiography, Which Revealed Coronary Vessels Free Of Significant Disease. An Echocardiogram Showed Both Hypokinesis Of The Left-Ventricular Mid-Segments With Apical Involvement And A Hyperkinetic Base Consistent With Tako-Tsubo Cardiomyopathy (Tcm). Several Clinical Conditions Have Been Reported As Triggers Of Tcm. We Report A Case Of Tcm In A Post-Menopausal Woman That Was Precipitated By Alcohol Withdrawal.|[('Year-Old Woman', 'no label'), ('No History', 'no label'), ('Cardiac Disease', 'no label'), ('Emergency Department', 'no label'), ('Confusion', 'no label'), ('Seizures', 'no label'), ('Secondary To Alcohol Withdrawal', 'no label'), ('Elevated', 'no label'), ('Troponin', 'no label'), ('Levels', 'no label'), ('Electrocardiogram', 'no label'), ('Global T-Wave Inversions', 'no label'), ('Coronary Angiography', 'no label'), ('Revealed', 'no label'), ('Coronary Vessels', 'no label'), ('Disease', 'no label'), ('Echocardiogram', 'no label'), ('Hypokinesis', 'no label'), ('Left-Ventricular', 'no label'), ('Mid-Segments', 'no label'), ('Apical', 'no label'), ('Hyperkinetic Base', 'no label'), ('Consistent With', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tcm', 'no label'), ('Clinical Conditions', 'no label'), ('Triggers', 'no label'), ('Tcm', 'no label'), ('Report', 'no label'), ('Tcm', 'no label'), ('Post-Menopausal Woman', 'no label'), ('Precipitated', 'no label'), ('Alcohol Withdrawal', 'no label')]|[('Alcohol', 'no label'), ('Troponin', 'no label'), ('Mid-Segments', 'no label'), ('Apical', 'no label'), ('Alcohol', 'no label')]|[('Troponin', 'no label'), ('Tcm', 'no label')]|[('Cardiac Disease', 'no label'), ('Confusion', 'no label'), ('Seizures', 'no label'), ('Alcohol', 'no label'), ('Hypokinesis Of The Left-Ventricular Mid-Segments With Apical Involvement And A', 'no label'), ('Hyperkinetic', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Alcohol', 'no label')]|[('Cardiac', 'no label'), ('Alcohol', 'no label'), ('Troponin', 'no label'), ('Left-Ventricular Mid-Segments', 'no label'), ('Apical', 'no label'), ('A Hyperkinetic Base', 'no label'), ('Tcm In A', 'no label'), ('Alcohol', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21082291|"The Occurrence Of Major Cardiovascular Events Is Not Randomly Distributed Over Time, But Exhibits Chronobiological Patterns, I.E., Circadian, Weekly, Or Seasonal. No Systematic Studies On The Temporal Preference Of Onset Of Tako-Tsubo Cardiomyopathy (Ttc) Are Known. We Performed A Computer-Assisted Search Of The Literature (From 2000 To January 2010), With The Following Search Terms: Transient Left Ventricular Apical Ballooning Syndrome, Takotsubo-Like Left Ventricular Dysfunction, Ampulla Cardiomyopathy, Tako-Tsubo Or Takotsubo Cardiomyopathy, Tako-Tsubo, Apical Ballooning. Criteria For Publication Inclusion Were (A) Reporting Of Original Data, (B) Inclusion Of At Least 30 Or More Cases, (C) Adherence To The Requested Diagnostic Criteria For Ttc. We Focused On Studies Including In Their Purposes The ""Time Of Onset"" Of Events. Out Of The 19 Studies Found, 7 (4 From Europe, 1 Each From Asia, Australia And Usa) Specifically Addressed This Aspect. A Circadian (Morning) And A Seasonal (Summer) Higher Frequency Of Events Was Found. Ttc Seems To Exhibit A Temporal Variation Of Onset, With Preferred Peaks During Morning And Summer. Stress And Catecholamines, Also According To Their Temporal Organization, Might Play A Pivotal Role. The Demonstration Of Time Frames Characterized By Highest Frequency Of Occurrence Might Help To Try To Ensure Maximal Protection During Particularly Vulnerable Periods."|[('Cardiovascular', 'no label'), ('Chronobiological Patterns', 'no label'), ('I.E.', 'no label'), ('Circadian', 'no label'), ('Weekly', 'no label'), ('Seasonal', 'no label'), ('Systematic Studies', 'no label'), ('Temporal', 'no label'), ('Preference', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Performed', 'no label'), ('Literature', 'no label'), ('Transient', 'no label'), ('Left Ventricular Apical Ballooning Syndrome', 'no label'), ('Takotsubo-Like Left Ventricular Dysfunction', 'no label'), ('Ampulla Cardiomyopathy', 'no label'), ('Tako-Tsubo Or Takotsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo', 'no label'), ('Apical Ballooning', 'no label'), ('Criteria', 'no label'), ('Publication', 'no label'), ('Original Data', 'no label'), ('Cases', 'no label'), ('Adherence', 'no label'), ('Requested Diagnostic Criteria', 'no label'), ('Ttc', 'no label'), ('Focused', 'no label'), ('Studies', 'no label'), ('Purposes', 'no label'), ('Events', 'no label'), ('Studies', 'no label'), ('Europe', 'no label'), ('Asia', 'no label'), ('Australia', 'no label'), ('Usa', 'no label'), ('Aspect', 'no label'), ('Circadian', 'no label'), ('Morning', 'no label'), ('Seasonal', 'no label'), ('Frequency', 'no label'), ('Events', 'no label'), ('Ttc', 'no label'), ('Exhibit', 'no label'), ('Temporal', 'no label'), ('Variation', 'no label'), ('Onset', 'no label'), ('Preferred Peaks', 'no label'), ('Morning', 'no label'), ('Summer', 'no label'), ('Stress', 'no label'), ('Catecholamines', 'no label'), ('Temporal Organization', 'no label'), ('Play A', 'no label'), ('Pivotal', 'no label'), ('Demonstration', 'no label'), ('Time Frames', 'no label'), ('Characterized', 'no label'), ('Frequency', 'no label'), ('Occurrence', 'no label'), ('Ensure', 'no label'), ('Maximal Protection', 'no label'), ('Vulnerable Periods', 'no label')]|[('Apical', 'no label'), ('Apical', 'no label'), ('Catecholamines', 'no label'), ('Protection', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Takotsubo-Like Left Ventricular Dysfunction', 'no label'), ('Ampulla Cardiomyopathy', 'no label'), ('Tako-Tsubo', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo', 'no label'), ('Catecholamines', 'no label')]|[('Cardiovascular', 'no label'), ('Left Ventricular', 'no label'), ('Takotsubo-Like Left Ventricular', 'no label'), ('Ampulla', 'no label'), ('Apical', 'no label'), ('B', 'no label'), ('Asia', 'no label'), ('Catecholamines', 'no label'), ('Ensure', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20009955|Tako-Tsubo Syndrome Is A Transient Cardiomyopathy Usually Precipitated By An Acute Emotional Or Physiological Stress. Our Study Objectives Were To Review And Analyze The Impact Of Emotional Stress On Clinical Variables, Echocardiographic Characteristics, And Short-Term Outcomes In Patients With Tako-Tsubo Syndrome. Retrospective Chart Review. Eleven Patients Presented With Tako-Tsubo Syndrome (1 Man And 10 Women) During The 8-Year Period (January 2000 To January 2008). The Patients Were Split Into 2 Groups, Defined By Presenting Either After Emotional Stress (6/11, 54.5%) Or After Idiopathic/Physical Stress (5/11, 45.5%). The Mean Age Was 53.8 (12.6) Years. The Mean Peak Troponin T Level Was 0.54 Ng/Ml (Range, 0.03-2.06 Ng/Ml), And The Mean Left Ventricular End-Diastolic Pressure Was 15.8 (8.1) Mm Hg. Emotional Stress Was Associated With Younger Age (P = 0.024), A Lower Left Ventricular End-Diastolic Pressure (P < 0.05), More St Segment Changes On Electrocardiogram (66.7% Vs 40%), And A Higher Ejection Fraction (P = 0.012). The Patients In The Idiopathic/Physical Stress Group Required More Frequent Hemodynamic Support. We Conclude That Clinical, Echocardiographic, And Outcome Characteristics Can Differentiate Tako-Tsubo Patients Presenting With Emotional Stress From Those With Idiopathic/Physical Stress Into 2 Distinct Clinical Phenotypes. Clinicians Should Monitor Idiopathic/Physically Stressed Tako-Tsubo Patients Carefully For Hemodynamic Compromise.|[('Tako-Tsubo Syndrome', 'no label'), ('Transient Cardiomyopathy', 'no label'), ('Precipitated', 'no label'), ('Acute Emotional Or', 'no label'), ('Physiological Stress', 'no label'), ('Study Objectives', 'no label'), ('Review', 'no label'), ('Analyze', 'no label'), ('Impact', 'no label'), ('Emotional Stress', 'no label'), ('Clinical Variables', 'no label'), ('Echocardiographic Characteristics', 'no label'), ('Short-Term', 'no label'), ('Outcomes', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Retrospective Chart Review', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Women', 'no label'), ('Period', 'no label'), ('Patients', 'no label'), ('Split Into 2 Groups', 'no label'), ('Emotional Stress', 'no label'), ('Idiopathic/Physical Stress', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Peak Troponin T', 'no label'), ('Level', 'no label'), ('Range', 'no label'), ('Mean', 'no label'), ('Left Ventricular End-Diastolic Pressure', 'no label'), ('Emotional Stress', 'no label'), ('Associated With', 'no label'), ('Younger Age', 'no label'), ('Lower Left Ventricular End-Diastolic Pressure', 'no label'), ('St Segment', 'no label'), ('Changes', 'no label'), ('Electrocardiogram', 'no label'), ('Patients', 'no label'), ('Idiopathic/Physical Stress Group', 'no label'), ('Frequent', 'no label'), ('Hemodynamic Support', 'no label'), ('Conclude', 'no label'), ('Clinical', 'no label'), ('Echocardiographic', 'no label'), ('Outcome Characteristics', 'no label'), ('Differentiate', 'no label'), ('Tako-Tsubo Patients', 'no label'), ('Emotional Stress', 'no label'), ('Idiopathic/Physical Stress', 'no label'), ('Clinical', 'no label'), ('Phenotypes', 'no label'), ('Clinicians', 'no label'), ('Tako-Tsubo Patients', 'no label'), ('Hemodynamic', 'no label'), ('Compromise', 'no label')]|[('Tako-Tsubo Syndrome Is A', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Troponin', 'no label')]|[('2.06', 'no label')]|[('Tako-Tsubo Syndrome', 'no label'), ('Cardiomyopathy', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Ventricular End-Diastolic', 'no label'), ('Left Ventricular End-Diastolic Pressure (P < 0.05)', 'no label'), ('Tako-Tsubo', 'no label'), ('Tako-Tsubo', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Troponin T', 'no label'), ('St Segment', 'no label'), ('Patients', 'no label'), ('Conclude', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22350855|Severe Subarachnoid Hemorrhage May Be Associated With Regional Wall Motion Abnormalities (Rwma) In The Absence Of Epicardial Coronary Occlusion. The Rwma Extends Beyond The Distribution Of A Single Coronary Artery And May Present In A Typical Tako-Tsubo Cardiomyopathy Pattern. Other Variants Have Also Been Recognized, Including An Inverted Tako-Tsubo Pattern Of Severe Basal Hypokinesis That Spares The Apex. The Mechanism Of This Cardiomyopathy Is Not Well Understood But Likely Involves Catecholamine Excess. While Classic Tako-Tsubo Cardiomyopathy From Emotional Stress Carries A Favorable Prognosis, Cardiac Dysfunction From Subarachnoid Hemorrhage Is A Marker Of Overall Poor Prognosis. We Collected Cases Over A Period Of 4 Years At A Large Teaching Hospital. The Cases Represent Cardiac Dysfunction In The Setting Of Subarachnoid Hemorrhage In The Unusual Distribution Of Basal Hypokinesis With Relative Sparing Of The Apex (Inverted Tako-Tsubo Pattern). A Total Of Four Cases Were Identified. All Cases Were Female Between The Ages 43-67 Years And Had Echocardiographic Evidence Of Basal Hypokinesis After Suffering From An Intracranial Hemorrhage. The Typical And Inverted Patterns May Represent A Spectrum Within The Same Disease Process Or Distinct Clinical Entities With Dramatically Different Prognostic Implications. Larger Studies Comparing The Two Presentations Will Help Elucidate This Further.|[('Severe', 'no label'), ('Subarachnoid Hemorrhage', 'no label'), ('May', 'no label'), ('Associated With', 'no label'), ('Regional Wall Motion Abnormalities', 'no label'), ('Rwma', 'no label'), ('Absence', 'no label'), ('Epicardial Coronary Occlusion', 'no label'), ('Rwma', 'no label'), ('Extends', 'no label'), ('Distribution', 'no label'), ('Single Coronary Artery', 'no label'), ('Typical', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Pattern', 'no label'), ('Variants', 'no label'), ('Recognized', 'no label'), ('Inverted', 'no label'), ('Tako-Tsubo Pattern', 'no label'), ('Severe', 'no label'), ('Basal Hypokinesis', 'no label'), ('Spares', 'no label'), ('Apex', 'no label'), ('Mechanism', 'no label'), ('Cardiomyopathy', 'no label'), ('Involves', 'no label'), ('Catecholamine', 'no label'), ('Excess', 'no label'), ('Classic Tako-Tsubo Cardiomyopathy', 'no label'), ('Emotional Stress Carries', 'no label'), ('Favorable Prognosis', 'no label'), ('Cardiac Dysfunction', 'no label'), ('Subarachnoid Hemorrhage', 'no label'), ('Marker', 'no label'), ('Poor Prognosis', 'no label'), ('Collected Cases', 'no label'), ('Period', 'no label'), ('Years', 'no label'), ('Large Teaching Hospital', 'no label'), ('Cases', 'no label'), ('Represent', 'no label'), ('Cardiac Dysfunction', 'no label'), ('Subarachnoid Hemorrhage', 'no label'), ('Unusual', 'no label'), ('Distribution', 'no label'), ('Basal Hypokinesis', 'no label'), ('Relative Sparing', 'no label'), ('Apex', 'no label'), ('Inverted Tako-Tsubo Pattern', 'no label'), ('Cases', 'no label'), ('Identified', 'no label'), ('Cases', 'no label'), ('Female', 'no label'), ('Ages', 'no label'), ('Years', 'no label'), ('Echocardiographic', 'no label'), ('Evidence', 'no label'), ('Basal Hypokinesis', 'no label'), ('Suffering', 'no label'), ('Intracranial Hemorrhage', 'no label'), ('Typical', 'no label'), ('Represent', 'no label'), ('Spectrum', 'no label'), ('Same Disease', 'no label'), ('Clinical Entities', 'no label'), ('Prognostic', 'no label'), ('Studies', 'no label'), ('Comparing', 'no label'), ('Presentations', 'no label'), ('Will Help', 'no label'), ('Elucidate', 'no label')]|[('Catecholamine', 'no label')]|[('Ages 43-67 Years And', 'no label')]|[('Subarachnoid Hemorrhage', 'no label'), ('Epicardial Coronary Occlusion', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Cardiomyopathy', 'no label'), ('Catecholamine', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Prognosis', 'no label'), ('Cardiac Dysfunction', 'no label'), ('Subarachnoid Hemorrhage', 'no label'), ('Cardiac Dysfunction', 'no label'), ('Subarachnoid Hemorrhage', 'no label'), ('Intracranial Hemorrhage', 'no label')]|[('Subarachnoid', 'no label'), ('Wall', 'no label'), ('Epicardial Coronary', 'no label'), ('Rwma', 'no label'), ('Catecholamine', 'no label'), ('Cardiac', 'no label'), ('Subarachnoid', 'no label'), ('Cardiac', 'no label'), ('Subarachnoid', 'no label'), ('Basal', 'no label'), ('Apex', 'no label'), ('Basal', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21947995|We Report The Case Of A 69 Year-Old Chinese Lady With Pheochromocytoma Who Developed Chest Pain And Acute St-Segment Elevation In The Anterior Leads On Electrocardiography. She Was Given Intravenous Phenoxybenzamine For Alpha-Blockade Before Undergoing Urgent Coronary Angiography. This Revealed Minor Coronary Artery Disease. Left Ventriculogram Demonstrated Akinesis In The Apex With Hypercontraction Of The Basal Segments. The Tako-Tsubo Cardiomyopathy Eventually Resolved With Surgical Removal Of The Pheochromocytoma. This Case Highlights The Challenging Management Of Suspected Acute Myocardial Infarction In Pheochromocytoma Crisis And Also Reinforces The Notion That Tako-Tsubo Cardiomyopathy Is Likely Precipitated By Catecholamine Excess.|[('Report', 'no label'), ('Year-Old Chinese Lady', 'no label'), ('Pheochromocytoma', 'no label'), ('Acute St-Segment', 'no label'), ('Elevation', 'no label'), ('Anterior Leads', 'no label'), ('Electrocardiography', 'no label'), ('Intravenous Phenoxybenzamine', 'no label'), ('Alpha-Blockade', 'no label'), ('Urgent', 'no label'), ('Coronary Angiography', 'no label'), ('Revealed', 'no label'), ('Coronary Artery Disease', 'no label'), ('Left Ventriculogram', 'no label'), ('Demonstrated Akinesis', 'no label'), ('Apex', 'no label'), ('Hypercontraction', 'no label'), ('Basal Segments', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Resolved', 'no label'), ('Surgical Removal', 'no label'), ('Pheochromocytoma', 'no label'), ('Management', 'no label'), ('Suspected', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Pheochromocytoma Crisis', 'no label'), ('Reinforces', 'no label'), ('Notion', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Precipitated', 'no label'), ('Catecholamine', 'no label'), ('Excess', 'no label')]|[('Intravenous Phenoxybenzamine', 'no label'), ('Catecholamine', 'no label')]|[]|[('Pheochromocytoma', 'no label'), ('Chest Pain', 'no label'), ('Phenoxybenzamine', 'no label'), ('Coronary Artery Disease', 'no label'), ('Ventriculogram', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Pheochromocytoma', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Pheochromocytoma', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Catecholamine', 'no label')]|[('Case Of A 69', 'no label'), ('Pheochromocytoma', 'no label'), ('Intravenous Phenoxybenzamine', 'no label'), ('Apex', 'no label'), ('Basal Segments.', 'no label'), ('Pheochromocytoma', 'no label'), ('Acute Myocardial Infarction In', 'no label'), ('Pheochromocytoma', 'no label'), ('Catecholamine', 'no label')]
tako-tsubo cardiomyopathy|pubmed~35145772|A Literature Review Shows Scarce Reports Of Myasthenic Crises (Mc) Complicated By Takotsubo Cardiomyopathy (Tc). This Patient Cohort (0.11%) Has Higher All-Cause Mortality And Prolonged In-Hospital Course. We Present A Rare Case Of A 72-Year-Old Man Who Developed Cardiogenic Shock Post-Plasmapheresis For Myasthenia Crisis. He Became Hemodynamically Unstable And Developed Acute Respiratory Failure Requiring Intubation 30 Minutes After Completion Of Plasma Exchange. Serum Troponin Peaked At 3.19 Ng/Ml While An Emergent 12-Lead Electrocardiogram (Ekg) Showed New-Onset Diffuse St-Segment Elevation. Hypokinesis Of The Entire Apex, Anterior Septum, Mid-And Apical Inferior Septum, And Mid-And Apical Inferior Wall Consistent With Takotsubo Cardiomyopathy Was Seen On Bedside Echocardiogram. The Patient Received A Continuous Infusion Of Norepinephrine And Vasopressin. The Hospital Course Was Complicated By Multiorgan Failure And Eventual Demise. This Case Highlights Mc And The Potential Of Plasma Exchange Therapy To Induce Tc.|[('Literature Review', 'no label'), ('Myasthenic Crises', 'no label'), ('Complicated', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Tc', 'no label'), ('Patient Cohort', 'no label'), ('Higher', 'no label'), ('All-Cause', 'no label'), ('Mortality', 'no label'), ('Prolonged In-Hospital', 'no label'), ('Course', 'no label'), ('Rare', 'no label'), ('Case', 'no label'), ('Cardiogenic Shock', 'no label'), ('Post-Plasmapheresis', 'no label'), ('Myasthenia Crisis', 'no label'), ('Hemodynamically Unstable', 'no label'), ('Acute Respiratory Failure', 'no label'), ('Intubation', 'no label'), ('Completion', 'no label'), ('Plasma Exchange', 'no label'), ('Serum', 'no label'), ('Troponin', 'no label'), ('Peaked', 'no label'), ('Emergent 12-Lead Electrocardiogram', 'no label'), ('Ekg', 'no label'), ('Diffuse St-Segment', 'no label'), ('Elevation', 'no label'), ('Hypokinesis', 'no label'), ('Entire Apex', 'no label'), ('Anterior Septum', 'no label'), ('Mid-And Apical Inferior Septum', 'no label'), ('Mid-And', 'no label'), ('Apical Inferior Wall', 'no label'), ('Consistent With', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Bedside Echocardiogram', 'no label'), ('Patient', 'no label'), ('Received', 'no label'), ('Continuous Infusion', 'no label'), ('Norepinephrine', 'no label'), ('Vasopressin', 'no label'), ('Hospital Course', 'no label'), ('Complicated', 'no label'), ('Multiorgan Failure', 'no label'), ('Eventual', 'no label'), ('Demise', 'no label'), ('Case Highlights Mc', 'no label'), ('Plasma Exchange Therapy', 'no label'), ('Induce', 'no label'), ('Tc', 'no label')]|[('Norepinephrine', 'no label')]|[]|[('Takotsubo Cardiomyopathy', 'no label'), ('Cardiogenic Shock', 'no label'), ('Myasthenia', 'no label'), ('Respiratory Failure', 'no label'), ('Inferior Septum', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Norepinephrine', 'no label'), ('Vasopressin', 'no label'), ('Multiorgan Failure', 'no label')]|[('Patient', 'no label'), ('A 72-Year-Old Man', 'no label'), ('Plasma', 'no label'), ('Serum Troponin', 'no label'), ('Entire Apex', 'no label'), ('Patient', 'no label'), ('Norepinephrine', 'no label'), ('Multiorgan', 'no label'), ('Plasma', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25910498||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~19389788|Tako-Tsubo Cardiomyopathy Is Characterized By Transient Contractile Dysfunction After Emotional Or Physical Stress. Only Few Patients Show Late Gadolinium Enhancement (Lge) In Cardiovascular Magnetic Resonance Imaging (Mri). It Was The Purpose Of This Study To Elucidate The Histological Basis Of This Phenomenon. The Study Included 15 Patients. Tako-Tsubo Cardiomyopathy Was Diagnosed By Coronary Angiography And Ventriculography. Cardiac Mri Was Performed Within 24 H Of Admission. Endomyocardial Biopsies Were Taken During The Acute Phase And After Recovery. The Content Of Fibrosis Was Determined By Immunohistochemical Staining Of Collagen-1. In The Acute Phase, Cardiac Mri Revealed Lge In Five Patients. This Was Completely Reversed At Follow-Up [14, Inter-Quartile Range (Iqr) 11-14.5 Days]. All Patients Showed A Significant Increase Of Collagen-1 Compared With Control Tissue. Moreover, The Amount Of Collagen-1 Was Significantly Higher In Lge Positive Patients (Lge Positive: 18.84, Iqr 13.82-19.75 Au/Microm(2); Lge Negative: 7.57, Iqr 5.41-9.19 Au/Microm(2), P = 0.001). The Presence Of Lge Was Not Associated With Poorer Left Ventricular Function. The Presence Of Lge Cannot Rule Out Tako-Tsubo Cardiomyopathy. Instead It Defines A Special Subgroup Of Patients With A Disproportionate Increase Of Extracellular Matrix.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Characterized', 'no label'), ('Transient', 'no label'), ('Contractile Dysfunction', 'no label'), ('Emotional Or Physical Stress', 'no label'), ('Patients', 'no label'), ('Late Gadolinium Enhancement', 'no label'), ('Cardiovascular Magnetic Resonance Imaging', 'no label'), ('Mri', 'no label'), ('Study', 'no label'), ('Histological Basis', 'no label'), ('Phenomenon', 'no label'), ('Study', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Diagnosed', 'no label'), ('Coronary Angiography', 'no label'), ('Ventriculography', 'no label'), ('Cardiac Mri', 'no label'), ('Admission', 'no label'), ('Endomyocardial Biopsies', 'no label'), ('Acute Phase', 'no label'), ('Recovery', 'no label'), ('Content', 'no label'), ('Fibrosis', 'no label'), ('Immunohistochemical Staining', 'no label'), ('Collagen-1', 'no label'), ('Acute Phase', 'no label'), ('Cardiac Mri', 'no label'), ('Patients', 'no label'), ('Was Completely Reversed At Follow-Up', 'no label'), ('Inter-Quartile Range', 'no label'), ('Iqr', 'no label'), ('Days', 'no label'), ('Patients', 'no label'), ('Increase', 'no label'), ('Collagen-1', 'no label'), ('Control', 'no label'), ('Tissue', 'no label'), ('Amount', 'no label'), ('Collagen-1', 'no label'), ('Higher', 'no label'), ('Lge Positive', 'no label'), ('Patients', 'no label'), ('Lge Positive', 'no label'), ('Iqr', 'no label'), ('Lge Negative', 'no label'), ('Iqr', 'no label'), ('Lge Was', 'no label'), ('Associated With', 'no label'), ('Poorer', 'no label'), ('Left Ventricular Function', 'no label'), ('Lge Cannot Rule', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Defines', 'no label'), ('Special', 'no label'), ('Subgroup', 'no label'), ('Patients', 'no label'), ('Disproportionate Increase', 'no label'), ('Extracellular Matrix', 'no label')]|[('Collagen-1', 'no label'), ('Collagen-1', 'no label'), ('Collagen-1', 'no label'), ('Extracellular Matrix', 'no label')]|[('Collagen-1', 'no label'), ('Collagen-1', 'no label'), ('Collagen-1', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Fibrosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Patients', 'no label'), ('Cardiovascular', 'no label'), ('Patients', 'no label'), ('Cardiac', 'no label'), ('Collagen-1', 'no label'), ('Cardiac', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Collagen-1', 'no label'), ('Tissue', 'no label'), ('Collagen-1', 'no label'), ('Patients', 'no label'), ('Left Ventricular', 'no label'), ('Patients', 'no label'), ('Extracellular Matrix', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22192296|This Study Evaluated If There Are Gender Differences In The Manifestation Of Tako-Tsubo Cardiomyopathy (Ttc). Ttc Predominantly Occurs In Elderly Females And Mimics Acute Myocardial Infarction (Ami) Where Men And Women Are Known To Have A Different Clinical Profile. 324 Patients From 37 Hospitals Were Prospectively Included In A Ttc Registry. Clinical, Electrocardiographic, Angiographic And Outcome Data From Male And Female Patients Were Compared. Of 324 Patients 296 (91%) Were Female And 28 (9%) Male. Mean Age (68 ± 12 Vs 66 ± 12 Years) And Prehospital Delay Were Similar. A Triggering Event Preceded Ttc Onset In 76% Of Women And 86% Of Men. Physical Stress Was More Frequent In Men (30% Vs 57%, P=0.005) Whereas More Women Experienced Emotional Or No Stress. The Prevalence Of Angina And Dyspnea Did Not Differ. Fewer Females Were Admitted In Cardiogenic Shock And/Or After Out Of Hospital Cardiac Arrest (1% Vs 14%, P=0.0006), And Cardiac Troponin Was Lower (Median 7.2 Vs 10.7 Times The Upper Limit Of Normal, P=0.03). The Qtc Interval Was Longer In Females Than In Males Only On The Day Of Admission (468 ± 52 Vs 441 ± 51 Ms, P=0.047). Overall, Complications During The Acute Course (53% Vs 40%) Were Comparable In Both Sexes. In This Large Ttc Registry, Males And Females Showed A Similar Clinical Profile. In Males, Physical Stress As A Trigger Event And Shock Or Cardiac Arrest As Presenting Symptoms Were More Frequent. The Qtc Interval Was Longer In Females Only On Admission But Similar In Males And Females During The Following Days.|[('Study', 'no label'), ('Evaluated', 'no label'), ('Gender', 'no label'), ('Differences', 'no label'), ('Manifestation', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Ttc', 'no label'), ('Occurs', 'no label'), ('Elderly', 'no label'), ('Females', 'no label'), ('Mimics Acute Myocardial Infarction', 'no label'), ('Men', 'no label'), ('Women', 'no label'), ('Clinical Profile', 'no label'), ('Patients', 'no label'), ('Hospitals', 'no label'), ('Ttc Registry', 'no label'), ('Clinical', 'no label'), ('Electrocardiographic', 'no label'), ('Angiographic', 'no label'), ('Outcome', 'no label'), ('Male', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Female', 'no label'), ('Male', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Prehospital Delay', 'no label'), ('Triggering Event', 'no label'), ('Preceded Ttc', 'no label'), ('Women', 'no label'), ('Men', 'no label'), ('Physical Stress', 'no label'), ('Frequent', 'no label'), ('Men', 'no label'), ('Women', 'no label'), ('Experienced', 'no label'), ('Emotional', 'no label'), ('No Stress', 'no label'), ('Prevalence', 'no label'), ('Angina', 'no label'), ('Dyspnea', 'no label'), ('Did Not Differ', 'no label'), ('Females', 'no label'), ('Admitted', 'no label'), ('Cardiogenic Shock And/Or', 'no label'), ('Hospital Cardiac Arrest', 'no label'), ('Cardiac Troponin', 'no label'), ('Median', 'no label'), ('Times', 'no label'), ('Upper Limit', 'no label'), ('Normal', 'no label'), ('Qtc Interval', 'no label'), ('Longer', 'no label'), ('Females', 'no label'), ('Than', 'no label'), ('Males', 'no label'), ('Day', 'no label'), ('Admission', 'no label'), ('Complications', 'no label'), ('Acute Course', 'no label'), ('Sexes', 'no label'), ('Ttc Registry', 'no label'), ('Males', 'no label'), ('Females', 'no label'), ('Clinical Profile', 'no label'), ('Males', 'no label'), ('Physical Stress', 'no label'), ('Trigger Event', 'no label'), ('Shock', 'no label'), ('Cardiac Arrest', 'no label'), ('Presenting Symptoms', 'no label'), ('Frequent', 'no label'), ('Qtc Interval', 'no label'), ('Longer', 'no label'), ('Females', 'no label'), ('Admission', 'no label'), ('Males', 'no label'), ('Females', 'no label'), ('Days', 'no label')]|[('Troponin', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Myocardial Infarction', 'no label'), ('Angina', 'no label'), ('Dyspnea', 'no label'), ('Cardiogenic Shock', 'no label'), ('Cardiac Arrest', 'no label'), ('Shock', 'no label'), ('Cardiac Arrest', 'no label')]|[('Acute Myocardial Infarction (', 'no label'), ('Women', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Men', 'no label'), ('Women', 'no label'), ('Cardiogenic Shock And/Or', 'no label'), ('Cardiac', 'no label'), ('Cardiac Troponin', 'no label'), ('Cardiac', 'no label')]
tako-tsubo cardiomyopathy|pubmed~18562025|Tako-Tsubo Cardiomyopathy Is A Stress-Related Cardiomyopathy Which Occurs In Postmenopausal Women After Severe Emotional Stress. Although No Evidence Supporting Specific Treatment With Tako-Tsubo Cardiomyopathy Has Been Established, The Prognosis Is Considered Favorable With Normalization Of Wall Motion Abnormalities Within Weeks. In Addition, Recurrence Of This Syndrome Seems To Be Rare. Now, We Report A Recurrent Case Of Tako-Tsubo Cardiomyopathy Complicated By Cardiogenic Shock After Repeated Emotional Stress.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Stress-Related Cardiomyopathy', 'no label'), ('Occurs', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Severe', 'no label'), ('Emotional Stress', 'no label'), ('No Evidence', 'no label'), ('Specific', 'no label'), ('Treatment', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Established', 'no label'), ('Prognosis', 'no label'), ('Favorable', 'no label'), ('Normalization', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Weeks', 'no label'), ('Recurrence', 'no label'), ('Syndrome Seems To Be Rare', 'no label'), ('Report', 'no label'), ('Recurrent', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Complicated', 'no label'), ('Cardiogenic Shock', 'no label'), ('Repeated Emotional Stress', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Prognosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Cardiogenic Shock', 'no label')]|[('Wall', 'no label')]
tako-tsubo cardiomyopathy|pubmed~30351809|A 73 Year-Old Female Patient Was Scheduled For Lumbar Peritoneal Shunt Three Weeks After Subarachnoid Hemorrhage. Before Induction Of General Anesthesia, Her Ecg Showed Ventricular Tachycardia (Vt) Without Any Complaints. Administration Of Lidocaine And Direct Current Shocks Were Ineffective And Vt Continued. Operation Was Postponed And Transthoracic Echocardiography Revealed Diffuse Hypokinesis. Emergent Angiogram Revealed Midventricular Ballooning With Slight Hypoki- Nesis In Basal And Apical Regions Without Significant Coronary Artery Lesion. Atypical Takotsubo Cardiomyopathy Was Diagnosed. Intra Aortic Balloon Pumping And Continuous Infusion Of Amiodaron And Catecholamines Were Started, But Her Ventricular Motion Decreased. She Died Next Morning. In This Case, The Physical/Psychological Stress Before Operation Was Con- Sidered To Be A Trigger Of The Event. Although Tako- Tsubo Cardiomyopathy Is Usually A Transient Disease, It Must Be Kept In Mind That An Acute And Lethal Case With No Response To Any Treatment Like Ours Exists.|[('Year-Old', 'no label'), ('Female', 'no label'), ('Lumbar Peritoneal Shunt', 'no label'), ('Weeks', 'no label'), ('Subarachnoid Hemorrhage', 'no label'), ('Induction', 'no label'), ('General Anesthesia', 'no label'), ('Ecg Showed Ventricular Tachycardia', 'no label'), ('Vt', 'no label'), ('Complaints', 'no label'), ('Administration', 'no label'), ('Lidocaine', 'no label'), ('Direct Current', 'no label'), ('Shocks', 'no label'), ('Ineffective', 'no label'), ('Vt', 'no label'), ('Continued', 'no label'), ('Operation', 'no label'), ('Transthoracic Echocardiography', 'no label'), ('Revealed', 'no label'), ('Diffuse', 'no label'), ('Hypokinesis', 'no label'), ('Emergent', 'no label'), ('Angiogram', 'no label'), ('Revealed', 'no label'), ('Midventricular Ballooning', 'no label'), ('Slight Hypoki-', 'no label'), ('Nesis', 'no label'), ('Basal', 'no label'), ('Apical Regions', 'no label'), ('Significant', 'no label'), ('Coronary Artery', 'no label'), ('Lesion', 'no label'), ('Atypical Takotsubo Cardiomyopathy', 'no label'), ('Diagnosed', 'no label'), ('Intra Aortic Balloon Pumping', 'no label'), ('Continuous Infusion', 'no label'), ('Amiodaron', 'no label'), ('Catecholamines', 'no label'), ('Started', 'no label'), ('Ventricular Motion', 'no label'), ('Decreased', 'no label'), ('Died Next Morning', 'no label'), ('Case', 'no label'), ('Physical/Psychological Stress', 'no label'), ('Operation', 'no label'), ('Trigger', 'no label'), ('Event', 'no label'), ('Tako- Tsubo Cardiomyopathy', 'no label'), ('Transient Disease', 'no label'), ('Mind', 'no label'), ('Acute And Lethal Case', 'no label'), ('No Response', 'no label'), ('Treatment', 'no label'), ('Ours Exists', 'no label')]|[('Lidocaine', 'no label'), ('Apical Regions', 'no label'), ('Amiodaron', 'no label'), ('Catecholamines', 'no label')]|[]|[('Subarachnoid Hemorrhage', 'no label'), ('Ventricular Tachycardia', 'no label'), ('Lidocaine', 'no label'), ('Coronary Artery Lesion', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Amiodaron', 'no label'), ('Catecholamines', 'no label'), ('Cardiomyopathy', 'no label')]|[('Patient', 'no label'), ('Peritoneal', 'no label'), ('Subarachnoid', 'no label'), ('Ventricular Tachycardia', 'no label'), ('Lidocaine', 'no label'), ('Midventricular', 'no label'), ('Basal', 'no label'), ('Amiodaron', 'no label'), ('Catecholamines', 'no label'), ('Be A', 'no label'), ('Lethal Case', 'no label')]
tako-tsubo cardiomyopathy|pubmed~24739134||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~20451358|To Describe A Case Of Tako Tsubo Cardiomyopathy [Ttc] In A Patient After An Overdose Of The Serotonin-Norepinephrine Reuptake Inhibitor [Snri] Venlafaxine. We Present A Case Study Including Clinical And Laboratory Data. Current Relevant Literature Is Reviewed And Summarized In Regard To Tako Tsubo Syndrome And Snri. A 43Year-Old Woman Was Admitted With Acute Angina Pectoris After Accidentally Taking An Overdose On Venlafaxine In Order To Treat Major Depression. Because Of The Ecg-T-Wave-Inversions In The Precordial Leads, The Slightly Increased Troponin/Creatine Kinase Levels And The Apical Systolic Dysfunction Of The Left Ventricle In Echocardiogram A Cardiac Catheterization Was Performed. Coronary Artery Disease Could Be Excluded By Coronary Angiography. The Followed Laevocardiography And Cardiac Mri Scan Showed Apical Akinesis And Basal Hypercontractibility Typical For Apical Ballooning (Tako Tsubo Cardiomyopathy). Urine Analysis Revealed Elevated Normetanephrine Level Potentially Caused By Venlafaxine. Six Weeks After The First Admission The Echocardiogram Showed A Complete Recovery To Normal Left Ventricular Function. To Our Knowledge This Is The First Reported Case Of An Overdose Of Venlafaxine (Snri) Associated Tako Tsubo Cardiomyopathy.|[('Case', 'no label'), ('Tako Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Patient', 'no label'), ('Overdose', 'no label'), ('Serotonin-Norepinephrine Reuptake Inhibitor', 'no label'), ('Snri] Venlafaxine', 'no label'), ('Case Study', 'no label'), ('Clinical And Laboratory', 'no label'), ('Relevant', 'no label'), ('Literature', 'no label'), ('Reviewed', 'no label'), ('Regard', 'no label'), ('Tako Tsubo Syndrome', 'no label'), ('Snri', 'no label'), ('Woman', 'no label'), ('Admitted With', 'no label'), ('Acute Angina Pectoris', 'no label'), ('Accidentally', 'no label'), ('Overdose', 'no label'), ('Venlafaxine', 'no label'), ('Order', 'no label'), ('Major Depression', 'no label'), ('Ecg-T-Wave-Inversions', 'no label'), ('Precordial Leads', 'no label'), ('Increased', 'no label'), ('Troponin/Creatine', 'no label'), ('Kinase', 'no label'), ('Levels', 'no label'), ('Apical Systolic Dysfunction', 'no label'), ('Left Ventricle', 'no label'), ('Echocardiogram A', 'no label'), ('Cardiac Catheterization', 'no label'), ('Coronary Artery Disease', 'no label'), ('Coronary Angiography', 'no label'), ('Laevocardiography', 'no label'), ('Cardiac Mri Scan', 'no label'), ('Apical Akinesis', 'no label'), ('Basal Hypercontractibility', 'no label'), ('Apical Ballooning', 'no label'), ('Tako Tsubo Cardiomyopathy', 'no label'), ('Urine Analysis', 'no label'), ('Revealed', 'no label'), ('Elevated', 'no label'), ('Normetanephrine', 'no label'), ('Level', 'no label'), ('Venlafaxine', 'no label'), ('Weeks', 'no label'), ('First Admission', 'no label'), ('Echocardiogram', 'no label'), ('Complete', 'no label'), ('Recovery', 'no label'), ('Normal Left Ventricular Function', 'no label'), ('Knowledge', 'no label'), ('Overdose', 'no label'), ('Venlafaxine', 'no label'), ('Snri', 'no label'), ('Tako Tsubo Cardiomyopathy', 'no label')]|[('Serotonin-Norepinephrine', 'no label'), ('Inhibitor', 'no label'), ('Ecg-T-Wave-Inversions', 'no label'), ('Apical', 'no label')]|[]|[('Tako', 'no label'), ('Cardiomyopathy', 'no label'), ('Overdose', 'no label'), ('Serotonin-Norepinephrine Reuptake Inhibitor [Snri] Venlafaxine', 'no label'), ('Tako Tsubo Syndrome', 'no label'), ('Acute Angina Pectoris', 'no label'), ('Overdose', 'no label'), ('Venlafaxine', 'no label'), ('Depression', 'no label'), ('Troponin/Creatine', 'no label'), ('Systolic Dysfunction', 'no label'), ('Left Ventricle In Echocardiogram A Cardiac Catheterization', 'no label'), ('Coronary Artery Disease', 'no label'), ('Tako', 'no label'), ('Cardiomyopathy', 'no label'), ('Normetanephrine', 'no label'), ('Venlafaxine', 'no label'), ('Overdose', 'no label'), ('Venlafaxine', 'no label'), ('Tako', 'no label'), ('Cardiomyopathy', 'no label')]|[('A Case', 'no label'), ('Tako', 'no label'), ('Serotonin-Norepinephrine Reuptake Inhibitor', 'no label'), ('Venlafaxine', 'no label'), ('Tako', 'no label'), ('Venlafaxine', 'no label'), ('Precordial', 'no label'), ('Troponin/Creatine', 'no label'), ('Left Ventricle', 'no label'), ('Echocardiogram A Cardiac', 'no label'), ('Cardiac', 'no label'), ('Apical', 'no label'), ('Basal Hypercontractibility', 'no label'), ('Apical', 'no label'), ('Urine', 'no label'), ('Normetanephrine', 'no label'), ('Venlafaxine', 'no label'), ('Normal Left Ventricular', 'no label'), ('Venlafaxine', 'no label')]
tako-tsubo cardiomyopathy|pubmed~26897678||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~22991810|An 85-Year-Old Woman Recieved Emergency Repair Of Left Obturator Hernia Under General Anesthesia. The Surgery Was Completed Uneventfully. Shortly After The Admission To The Recovery Unit, Blood Pressure Dropped To 80Mmhg And Ecg Showed Negative T Wave. Hypotension Was Successfully Treated With Colloid Infusion And Dopamine Administration, But Negative T Wave Was Unchanged By Nitrate Infusion. The Serum Ck-Mb Examination Indicated No Cardiomyogenic Problems. On Postoperative Day 13, She Received Emergency Colostomy Under General Anesthesia. Large Negative T Wave Still Persisted. Immediately After Induction Of Anesthesia, She Showed Hypotension, Which Recovered By Fluid Infusion And Intravenous Ephedrine. The Ucg After Surgery Showed Hypokinesis Of The Apex Of Left Ventricle. She Was Diagnosed As Tako-Tsubo Myocardiopathy. One Month After The Second Surgery, She Received Closure Of Colostomy Under General Anesthesia Combined With Continuous Epidural Anesthesia, When Negative T Wave Was Seen On The Ecg. Negative T Wave Returned To Normal 10 Weeks After The First Surgery. When Unknown Tachycardia And Negative T Waves Are Seen, Tako-Tsubo Cardiomyopathy Should Be Considered.|[('Left Obturator Hernia', 'no label'), ('General Anesthesia', 'no label'), ('Surgery', 'no label'), ('Uneventfully', 'no label'), ('Admission', 'no label'), ('Recovery Unit', 'no label'), ('Blood Pressure Dropped', 'no label'), ('Ecg Showed Negative T Wave', 'no label'), ('Hypotension', 'no label'), ('Successfully', 'no label'), ('Treated', 'no label'), ('Colloid Infusion', 'no label'), ('Dopamine Administration', 'no label'), ('Negative T Wave', 'no label'), ('Unchanged', 'no label'), ('Nitrate', 'no label'), ('Infusion', 'no label'), ('Serum Ck-Mb Examination', 'no label'), ('Cardiomyogenic Problems', 'no label'), ('Postoperative Day', 'no label'), ('Emergency', 'no label'), ('Colostomy', 'no label'), ('General Anesthesia', 'no label'), ('T Wave', 'no label'), ('Persisted', 'no label'), ('Induction', 'no label'), ('Anesthesia', 'no label'), ('Hypotension', 'no label'), ('Recovered', 'no label'), ('Fluid Infusion', 'no label'), ('Intravenous', 'no label'), ('Ephedrine', 'no label'), ('Surgery', 'no label'), ('Hypokinesis', 'no label'), ('Apex', 'no label'), ('Left Ventricle', 'no label'), ('Diagnosed', 'no label'), ('Tako-Tsubo Myocardiopathy', 'no label'), ('Month', 'no label'), ('Second Surgery', 'no label'), ('Closure', 'no label'), ('Colostomy', 'no label'), ('General Anesthesia', 'no label'), ('Continuous Epidural Anesthesia', 'no label'), ('Negative T Wave', 'no label'), ('Ecg', 'no label'), ('T Wave', 'no label'), ('Returned', 'no label'), ('Weeks', 'no label'), ('First Surgery', 'no label'), ('Unknown Tachycardia', 'no label'), ('T Waves', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Dopamine', 'no label'), ('Nitrate', 'no label')]|[('Ucg', 'no label')]|[('Left Obturator Hernia', 'no label'), ('Hypotension', 'no label'), ('Dopamine', 'no label'), ('Nitrate', 'no label'), ('Hypotension', 'no label'), ('Ephedrine', 'no label'), ('Left Ventricle', 'no label'), ('Tako-Tsubo Myocardiopathy', 'no label'), ('Tachycardia', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Left Obturator', 'no label'), ('Blood', 'no label'), ('Colloid', 'no label'), ('Dopamine', 'no label'), ('Serum', 'no label'), ('Fluid', 'no label'), ('Intravenous Ephedrine.', 'no label'), ('Apex', 'no label'), ('Left Ventricle', 'no label'), ('Epidural', 'no label'), ('T Wave', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20549172|Tako-Tsubo Cardiomyopathy (Tk) Is An Acutely Appearing Myocardial Disease Leading To Impaired Cardiac Function, Which Can Barely Be Distinguished Clinically From An Acute Myocardial Infarction. It Occurs Mainly In Postmenopausal Women And Usually Has A Good Prognosis. The Pathophysiology Of Tk Still Remains To Be Elucidated But The Favoured Hypothesis Is Myocardial Damage Induced By Catecholamine Excess. Various Acute Diseases, Emotional Stress, Surgical Procedures And Anaesthesia Have Been Described As Possible Causes For Tk. Little Is Known About The Optimal Therapy, However, There Might Be Potential Differences In The Therapy Of Tk Compared To Contemporary Therapy Algorithms For Heart Failure. Knowledge Of Tk As A Differential Diagnosis For Acute Myocardial Infarction Is Necessary To Avoid Incorrect Treatment.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tk', 'no label'), ('Acutely Appearing', 'no label'), ('Myocardial Disease', 'no label'), ('Impaired', 'no label'), ('Cardiac Function', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Has A', 'no label'), ('Good Prognosis', 'no label'), ('Pathophysiology', 'no label'), ('Tk', 'no label'), ('Favoured Hypothesis', 'no label'), ('Myocardial Damage', 'no label'), ('Induced', 'no label'), ('Catecholamine', 'no label'), ('Excess', 'no label'), ('Acute Diseases', 'no label'), ('Emotional Stress', 'no label'), ('Surgical Procedures', 'no label'), ('Anaesthesia', 'no label'), ('Causes', 'no label'), ('Tk', 'no label'), ('Optimal Therapy', 'no label'), ('Potential', 'no label'), ('Therapy', 'no label'), ('Tk', 'no label'), ('Contemporary Therapy', 'no label'), ('Algorithms', 'no label'), ('Heart Failure', 'no label'), ('Tk', 'no label'), ('Differential Diagnosis', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Incorrect', 'no label'), ('Treatment', 'no label')]|[('Catecholamine', 'no label')]|[('Tk', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Myocardial Disease', 'no label'), ('Impaired Cardiac Function', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Prognosis', 'no label'), ('Myocardial Damage', 'no label'), ('Catecholamine', 'no label'), ('Diseases, Emotional Stress, Surgical Procedures And Anaesthesia', 'no label'), ('Heart Failure', 'no label'), ('Myocardial Infarction', 'no label')]|[('Myocardial', 'no label'), ('Cardiac', 'no label'), ('Myocardial', 'no label'), ('Women', 'no label'), ('Myocardial', 'no label'), ('Catecholamine', 'no label'), ('Heart', 'no label'), ('Acute Myocardial Infarction', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19318927|Earlier Studies Have Often Required The Absence Of Obstructive Coronary Artery Disease (Cad) As The Criteria. However, It Is Probable That Patients With Tako-Tsubo Cardiomyopathy Have An Incidental Cad Because Most Patients Are Elderly. We Assessed The Prevalence Of Incidental Cad. We Reviewed Coronary Angiograms Of 97 Japanese Patients With Tako-Tsubo Cardiomyopathy. A Wrapped Left Anterior Descending Artery (Lad) Was Defined As A Lad That Perfused At Least One-Quarter Of The Inferior Wall Of The Left Ventricle In The 30 Degrees Right Anterior Oblique Projection. Ten Patients (10%) Had Definitively Incidental Cad Defined As Greater Than 75% Reduction In The Luminal Diameter Of The Major Epicardial Coronary Artery. All Patients Had St-Segment Elevation, And Five Patients Had T-Wave Inversion On Admission. Nine Patients Had Single Vessel Disease, And One Patient Had Double Vessel Disease. Six Patients Had Cad In The Nonwrapped Lad, And They Were Judged To Be Definitively Incidental. Three Patients Had Cad In The Left Circumflex Artery, And Two Patients Had Cad In The Right Coronary Artery. This Study Showed That Incidental Cad Was Found In 10% Of Japanese Patients With Tako-Tsubo Cardiomyopathy. In Patients With Cad In The Lad, It Should Be Carefully Judged Whether The Cad Causes Left Ventricular Apical Ballooning To Avoid Performing Coronary Revascularization Unnecessarily.|[('Absence', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Cad', 'no label'), ('Criteria', 'no label'), ('Probable', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Incidental', 'no label'), ('Cad', 'no label'), ('Patients', 'no label'), ('Elderly', 'no label'), ('Assessed', 'no label'), ('Prevalence', 'no label'), ('Incidental', 'no label'), ('Cad', 'no label'), ('Reviewed', 'no label'), ('Coronary Angiograms', 'no label'), ('Japanese', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Wrapped Left Anterior Descending Artery', 'no label'), ('Perfused', 'no label'), ('Inferior Wall', 'no label'), ('Left Ventricle', 'no label'), ('Degrees Right Anterior Oblique Projection', 'no label'), ('Patients', 'no label'), ('Definitively', 'no label'), ('Incidental', 'no label'), ('Cad', 'no label'), ('Reduction', 'no label'), ('Luminal Diameter', 'no label'), ('Epicardial', 'no label'), ('Coronary Artery', 'no label'), ('Patients', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Patients', 'no label'), ('T-Wave Inversion', 'no label'), ('Admission', 'no label'), ('Patients', 'no label'), ('Single Vessel Disease', 'no label'), ('Patient', 'no label'), ('Double Vessel Disease', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Nonwrapped Lad', 'no label'), ('Definitively Incidental', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Left Circumflex Artery', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Right Coronary Artery', 'no label'), ('Study', 'no label'), ('Incidental', 'no label'), ('Cad', 'no label'), ('Japanese', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Cad', 'no label'), ('Causes', 'no label'), ('Left Ventricular Apical Ballooning', 'no label'), ('Coronary Revascularization', 'no label')]|[('St-Segment', 'no label'), ('Apical', 'no label')]|[('Cad', 'no label'), ('Cad', 'no label'), ('Cad', 'no label'), ('Cad', 'no label'), ('Cad', 'no label')]|[('Obstructive Coronary Artery Disease', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricle In The 30 Degrees Right Anterior Oblique Projection', 'no label'), ('Luminal', 'no label'), ('Vessel Disease', 'no label'), ('Vessel Disease', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricular Apical Ballooning To Avoid Performing Coronary Revascularization', 'no label')]|[('Coronary Artery', 'no label'), ('Cad', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Patients', 'no label'), ('Wall', 'no label'), ('Left Ventricle', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Luminal', 'no label'), ('Epicardial Coronary', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('T-Wave', 'no label'), ('Patients', 'no label'), ('Vessel', 'no label'), ('Patient', 'no label'), ('Vessel', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Left Circumflex', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Right Coronary', 'no label'), ('Cad', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Cad', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22326519|Copeptin, In Addition To Troponin, Has Recently Been Suggested For Non-Invasive Differentiation Between Tako-Tsubo Cardiomyopathy (Ttc) And Acute Myocardial Infarction (Ami). In Order To Test This Hypothesis, We Investigated Release Patterns Of Pituitary Copeptin And Cardiac Troponin In 49 Patients With Ttc And 49 Age-, Gender-, And Ecg-Matched Control Patients With Ami. Elevated Copeptin Levels (I.E. >12 Pmol/L) At Cardiac Catheterization Were Found In 23/49 (47%) Ttc Patients And 25/49 (51%) Ami Patients. Of These, Median Copeptin Levels Were Almost Identical In Both Cohorts (34.1 Vs. 35.4 Pmol/L). Subgroup Analysis According To Ecg Changes Revealed That Ami Patients With St-Segment Elevation Had 3.6-Fold Higher Copeptin Levels Than Ami Patients Without St-Segment Elevation (P<0.05). Furthermore, In Patients With Ttc And Atypical (Midventricular) Ballooning On Left Ventricular Angiography, Copeptin Levels Were 5.7-Fold Higher Than In Ttc Patients With A Typical (Apical) Type Of Ballooning (P<0.01). Elevated Troponin T Levels (I.E. >0.01 Μg/L) At Catheterization Were Detectable In 47/49 (96%) Ttc Patients And 45/49 (92%) Ami Patients; However, Peak Levels Did Not Differ Significantly Between Both Cohorts (Median 0.35 Vs. 0.27 Μg/L). Subgroup Analysis According To Ecg Changes Revealed 2-Fold Higher Peak Troponin T Levels In Ttc Patients Presenting With St-Segment Elevation Than Non-St-Segment Elevation (P<0.05). In Conclusion, Copeptin Does Not Seem To Significantly Increase Non-Invasive Differentiation Between Ttc And Ami. At Present, Coronary Angiography, Specifically In Patients With St-Segment Elevation At Presentation Remains Absolutely Mandatory.|[('Copeptin', 'no label'), ('Troponin', 'no label'), ('Non-Invasive', 'no label'), ('Differentiation', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Hypothesis', 'no label'), ('Investigated', 'no label'), ('Release', 'no label'), ('Patterns', 'no label'), ('Pituitary Copeptin', 'no label'), ('Cardiac Troponin', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Gender-', 'no label'), ('Ecg-Matched', 'no label'), ('Patients', 'no label'), ('Elevated', 'no label'), ('Copeptin Levels', 'no label'), ('Cardiac Catheterization', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Median', 'no label'), ('Copeptin Levels', 'no label'), ('Cohorts', 'no label'), ('Subgroup', 'no label'), ('Analysis', 'no label'), ('Ecg Changes', 'no label'), ('Revealed', 'no label'), ('Patients', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Higher', 'no label'), ('Copeptin', 'no label'), ('Patients', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Atypical', 'no label'), ('Midventricular', 'no label'), ('Ballooning', 'no label'), ('Left Ventricular Angiography', 'no label'), ('Copeptin Levels', 'no label'), ('Higher', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Typical (Apical) Type', 'no label'), ('Ballooning', 'no label'), ('Elevated', 'no label'), ('Troponin T Levels', 'no label'), ('Catheterization', 'no label'), ('Detectable', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Peak Levels', 'no label'), ('Differ', 'no label'), ('Cohorts', 'no label'), ('Median', 'no label'), ('Subgroup', 'no label'), ('Analysis', 'no label'), ('Ecg Changes', 'no label'), ('Revealed', 'no label'), ('Higher', 'no label'), ('Peak Troponin T Levels', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Non-St-Segment', 'no label'), ('Elevation', 'no label'), ('Copeptin', 'no label'), ('Increase', 'no label'), ('Non-Invasive', 'no label'), ('Differentiation', 'no label'), ('Ttc', 'no label'), ('Present', 'no label'), ('Coronary Angiography', 'no label'), ('Patients', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Presentation Remains', 'no label'), ('Absolutely', 'no label'), ('Mandatory', 'no label')]|[('Copeptin', 'no label'), ('Copeptin', 'no label'), ('Troponin', 'no label'), ('Copeptin', 'no label'), ('Copeptin', 'no label'), ('Copeptin', 'no label'), ('Copeptin', 'no label'), ('5.7-Fold', 'no label'), ('Troponin T', 'no label'), ('Copeptin', 'no label')]|[('Copeptin', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Myocardial Infarction', 'no label')]|[('Copeptin', 'no label'), ('Troponin', 'no label'), ('Myocardial', 'no label'), ('Pituitary Copeptin', 'no label'), ('Cardiac Troponin In', 'no label'), ('Patients', 'no label'), ('Ecg-Matched', 'no label'), ('Patients', 'no label'), ('Copeptin', 'no label'), ('Cardiac', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Copeptin', 'no label'), ('Patients', 'no label'), ('Copeptin', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Midventricular', 'no label'), ('Left Ventricular', 'no label'), ('Copeptin', 'no label'), ('Ttc Patients', 'no label'), ('Troponin T', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Troponin T', 'no label'), ('Patients', 'no label'), ('Copeptin', 'no label'), ('Seem', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23415170|It Is Not Clarified Whether The Transient, Regional Left Ventricular Dysfunction (Trlvd) Associated With Several Neurological Disorders Shares The Same Pathophysiology With The Classical Tako-Tsubo Cardiomyopathy Occurring Without Overt Neurological Disease, And Whether It Is Appropriate To Include These Patients In A Single Stress Cardiomyopathy (Scm) Condition. In February 2012, We Systematically Explored Major Electronic Medical Information Sources To Identify Cases Of Trlvd Triggered By Neurological Disorders. The 81 Selected Papers Reported A Total Of 124 Patients, Suffering From Neurological Disorders, In Whom Trlvd Occurred: 117 With Central Nervous System Diseases, 6 With Peripheral Nervous System Diseases And 1 With Both Systems Involved. Most Patients Were Females (N=102), Mean Age Was 63 ± 15 Years, And The Majority Presented With An Apex-Involving Pattern. The Most Common Disease Described Was Subarachnoid Hemorrhage (N=52), Followed By Stroke/Transient Ischemic Attack (N=24), And Seizures (N=18). Trlvd In Neurological Patients Was Often Associated With Need Of Inotropic Support, Orotracheal Intubation, Cerebrovascular Spasm And Delayed Surgery. Trlvd Is A Complication Of Neurological Diseases, In Particular In Female Patients In Post-Menopausal Phase. The Predilection For Neurological Damage At Or Close To The Insular Cortex Highlights The Pivotal Role Of Sympathetic Over-Activation. Many Other Similarities With Tako-Tsubo Support The Inclusion In A Single Scm Category.|[('Clarified', 'no label'), ('Transient', 'no label'), ('Regional Left Ventricular Dysfunction', 'no label'), ('Trlvd', 'no label'), ('Associated With', 'no label'), ('Neurological Disorders', 'no label'), ('Shares', 'no label'), ('Pathophysiology', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Occurring', 'no label'), ('Overt Neurological Disease', 'no label'), ('Patients', 'no label'), ('Single Stress Cardiomyopathy', 'no label'), ('Scm', 'no label'), ('Condition', 'no label'), ('Systematically', 'no label'), ('Explored Major', 'no label'), ('Electronic Medical Information', 'no label'), ('Sources', 'no label'), ('Cases', 'no label'), ('Trlvd Triggered By Neurological Disorders', 'no label'), ('Papers', 'no label'), ('Reported', 'no label'), ('Patients', 'no label'), ('Suffering', 'no label'), ('Neurological Disorders', 'no label'), ('Trlvd', 'no label'), ('Central Nervous System Diseases', 'no label'), ('Peripheral Nervous System Diseases', 'no label'), ('Systems', 'no label'), ('Involved', 'no label'), ('Patients', 'no label'), ('Females', 'no label'), ('N=102', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Apex-Involving Pattern', 'no label'), ('Common Disease', 'no label'), ('Subarachnoid Hemorrhage', 'no label'), ('Stroke/Transient Ischemic Attack', 'no label'), ('Seizures', 'no label'), ('Trlvd', 'no label'), ('Neurological Patients', 'no label'), ('Associated With', 'no label'), ('Need', 'no label'), ('Inotropic Support', 'no label'), ('Orotracheal Intubation', 'no label'), ('Cerebrovascular Spasm', 'no label'), ('Delayed Surgery', 'no label'), ('Trlvd', 'no label'), ('Complication', 'no label'), ('Neurological Diseases', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Post-Menopausal Phase', 'no label'), ('Predilection', 'no label'), ('Neurological Damage', 'no label'), ('Insular Cortex', 'no label'), ('Sympathetic', 'no label'), ('Over-Activation', 'no label'), ('Similarities', 'no label'), ('Tako-Tsubo Support', 'no label'), ('Inclusion', 'no label'), ('Single Scm Category', 'no label')]|[('Scm', 'no label')]|[('Scm', 'no label')]|[('Ventricular Dysfunction', 'no label'), ('Trlvd', 'no label'), ('Neurological Disorders Shares The Same Pathophysiology', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Neurological Disease', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Trlvd', 'no label'), ('Neurological Disorders', 'no label'), ('Neurological Disorders', 'no label'), ('Central Nervous System Diseases', 'no label'), ('Peripheral Nervous System Diseases And 1 With Both Systems Involved', 'no label'), ('Subarachnoid Hemorrhage', 'no label'), ('N=52', 'no label'), ('Seizures', 'no label'), ('Cerebrovascular Spasm', 'no label'), ('Neurological Diseases', 'no label'), ('Neurological Damage', 'no label'), ('Tako-Tsubo', 'no label')]|[('Clarified', 'no label'), ('Left Ventricular', 'no label'), ('Patients', 'no label'), ('Scm', 'no label'), ('Patients', 'no label'), ('Peripheral Nervous System', 'no label'), ('Patients', 'no label'), ('Subarachnoid', 'no label'), ('Patients', 'no label'), ('Need', 'no label'), ('Orotracheal', 'no label'), ('Cerebrovascular Spasm', 'no label'), ('Patients', 'no label'), ('Insular Cortex', 'no label'), ('Sympathetic', 'no label'), ('Scm', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25762213||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~24383066||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~22306383|Tako-Tsubo Transient Cardiomyopathy (Tcm) Is A Syndrome Of Specific Myocardial Wall Motion Abnormalities That Appear In Response To Extreme Physiological Or Emotional Stress. The Patients Have Normal Coronary Arteries And Usually Present As New-Onset Heart Failure Or Acute Coronary Syndrome. We Report On A 48-Year-Old Woman With Post-Community Cardiac Arrest Presenting As An Acute Myocardial Infarction. An Emergency Physician–Performed Echocardiogram Showed Significant Wall Motion Abnormalities, Suggesting Myocardial Infarction. Cardiac Catheterization Revealed Patent Epicoronary Circulation, And Ventriculography Demonstrated A Rare And Only Recently Described Variant Of Tcm:“Reverse” Tcm. The Patient Subsequently Died From A Subarachnoid Hemorrhage.|[('Tako-Tsubo Transient Cardiomyopathy', 'no label'), ('Tcm', 'no label'), ('Myocardial Wall Motion Abnormalities', 'no label'), ('Appear', 'no label'), ('Response', 'no label'), ('Physiological', 'no label'), ('Emotional Stress', 'no label'), ('Patients', 'no label'), ('Normal Coronary Arteries', 'no label'), ('New-Onset Heart Failure', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Report', 'no label'), ('Woman', 'no label'), ('Post-Community Cardiac Arrest', 'no label'), ('Presenting', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Emergency Physician–Performed Echocardiogram', 'no label'), ('Significant', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Suggesting', 'no label'), ('Myocardial Infarction', 'no label'), ('Cardiac Catheterization', 'no label'), ('Patent Epicoronary', 'no label'), ('Circulation', 'no label'), ('Ventriculography', 'no label'), ('Demonstrated A Rare', 'no label'), ('Variant', 'no label'), ('Tcm:“Reverse” Tcm', 'no label'), ('Patient', 'no label'), ('Died', 'no label'), ('Subarachnoid Hemorrhage', 'no label')]|[('Variant', 'no label')]|[]|[('Tako-Tsubo Transient Cardiomyopathy', 'no label'), ('Heart Failure Or Acute Coronary Syndrome', 'no label'), ('Cardiac Arrest', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Myocardial Infarction', 'no label'), ('Subarachnoid Hemorrhage', 'no label')]|[('Myocardial Wall', 'no label'), ('Patients', 'no label'), ('Heart', 'no label'), ('Cardiac', 'no label'), ('Myocardial', 'no label'), ('Wall', 'no label'), ('Myocardial', 'no label'), ('Cardiac', 'no label'), ('Patient', 'no label'), ('Subarachnoid', 'no label')]
tako-tsubo cardiomyopathy|pubmed~24049031|Atypical Form Of Tako-Tsubo Cardiomyopathy (Ttc) Is Associated With Regional Wall Motion Abnormalities In Basal And/Or Middle Segments Or Only Middle Segments With Sparing Of Apical Segments Or Apical And Basal Segments. We Described A Case Of47-Year-Old Female With Atypical Form Of Ttc Due To Fast Atrial Fibrillation That Converted Into Ventricular Fibrillation In Wpw Syndrome. The Echocardiogram Made After Direct Current Cardioversion Revealed Decreased Left Ventricular Ejection Fraction (Lvef 35%) With Akinesis Of Inferior And Posterior Walls And Anterior Part Of Interventricular Septum In The Middle And The Basal Segments With Hyperkinesis Of Apical Segments. The Biochemistry Blood Samples Revealed Elevated Both Troponin T- 0.35 Ng/Ml And Nt-Probnp - 3550 Pg/Ml Plasma Level. The Ecg Showed Sinus Rhythm 62 Bpm, Shortened Pq Interval 100 Ms, Widened Qrs Duration - 115 Ms With Delta Wave, Prolonged Qt Interval - 520 Ms, Qs In Leads: Ii, Iii, Avf. Negativet Waves In Leads: I, Avl And Positive, Symmetrical T Waves In Leads V1-V6. The Coronarography Revealed Normal Coronaryarteries. The Control Echocardiography After 10 Days Showed Normal Lvef 70%, Without Any Wall Motion Abnormalities. Ttc Was Recognised Based On: History Of Sudden Stress Situation Before, Ischaemic Ecg Changes, Positive Markers Of Myocardial Injury, Transient Segmental Wall Motion Abnormalities And Normal Coronary Arteries. The Ablation Of Right Postero-Septal Accessory Pathway Was Successfully Performed. |[('Atypical Form', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Associated With', 'no label'), ('Regional Wall Motion Abnormalities', 'no label'), ('Basal And/Or', 'no label'), ('Middle Segments', 'no label'), ('Middle Segments', 'no label'), ('Sparing', 'no label'), ('Apical Segments', 'no label'), ('Apical', 'no label'), ('Basal', 'no label'), ('Female', 'no label'), ('Atypical Form', 'no label'), ('Ttc', 'no label'), ('Fast Atrial Fibrillation', 'no label'), ('Converted Into', 'no label'), ('Ventricular Fibrillation', 'no label'), ('Echocardiogram', 'no label'), ('Direct Current Cardioversion', 'no label'), ('Decreased', 'no label'), ('Left Ventricular Ejection Fraction', 'no label'), ('Akinesis', 'no label'), ('Inferior And Posterior Walls', 'no label'), ('Anterior', 'no label'), ('Interventricular Septum', 'no label'), ('Middle', 'no label'), ('Basal Segments', 'no label'), ('Hyperkinesis', 'no label'), ('Apical Segments', 'no label'), ('Biochemistry Blood Samples', 'no label'), ('Revealed', 'no label'), ('Elevated', 'no label'), ('Troponin', 'no label'), ('T-', 'no label'), ('Nt-Probnp', 'no label'), ('Plasma', 'no label'), ('Level', 'no label'), ('Ecg Showed Sinus Rhythm', 'no label'), ('Bpm', 'no label'), ('Pq Interval', 'no label'), ('Widened Qrs Duration', 'no label'), ('Prolonged', 'no label'), ('Qt Interval', 'no label'), ('Qs', 'no label'), ('Leads', 'no label'), ('Avf', 'no label'), ('Negativet Waves', 'no label'), ('Leads', 'no label'), ('I', 'no label'), ('Avl', 'no label'), ('Positive', 'no label'), ('Symmetrical T Waves', 'no label'), ('Leads V1-V6', 'no label'), ('Coronarography', 'no label'), ('Revealed', 'no label'), ('Normal Coronaryarteries', 'no label'), ('Control Echocardiography', 'no label'), ('Days', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Ttc', 'no label'), ('Recognised', 'no label'), ('History Of Sudden Stress Situation', 'no label'), ('Ischaemic Ecg Changes', 'no label'), ('Positive Markers', 'no label'), ('Myocardial Injury', 'no label'), ('Transient Segmental Wall Motion Abnormalities', 'no label'), ('Normal Coronary Arteries', 'no label'), ('Ablation', 'no label'), ('Right Postero-Septal Accessory Pathway', 'no label')]|[('Apical Segments', 'no label'), ('Apical', 'no label'), ('Lvef 35', 'no label'), ('Apical Segments', 'no label'), ('Troponin', 'no label'), ('Avl', 'no label')]|[('Nt-Probnp', 'no label'), ('Delta', 'no label'), ('Ii', 'no label'), ('Avl', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('And/Or', 'no label'), ('Atrial Fibrillation', 'no label'), ('Ventricular Fibrillation', 'no label'), ('Decreased Left Ventricular Ejection Fraction (Lvef 35%) With', 'no label'), ('Akinesis Of Inferior And Posterior Walls And Anterior Part Of Interventricular Septum', 'no label'), ('Myocardial Injury', 'no label'), ('Transient Segmental Wall Motion Abnormalities And Normal Coronary Arteries', 'no label')]|[('Wall', 'no label'), ('Basal And/Or', 'no label'), ('Left Ventricular', 'no label'), ('Walls', 'no label'), ('Anterior Part', 'no label'), ('Interventricular Septum In The', 'no label'), ('Basal Segments', 'no label'), ('Blood Samples', 'no label'), ('Troponin T- 0.35', 'no label'), ('Nt-Probnp', 'no label'), ('Delta Wave', 'no label'), ('Ii', 'no label'), ('I', 'no label'), ('Avl', 'no label'), ('Symmetrical T', 'no label'), ('Wall', 'no label'), ('Stress', 'no label'), ('Myocardial', 'no label'), ('Right Postero-Septal', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22322473|Tako-Tsubo (Stress) Cardiomyopathy (Ttc) Is A Recently Described Acute Cardiac Syndrome That Mimics St-Segment Elevation Myocardial Infarction. The Ttc Tuscany Registry Is An Observational Prospective Multicenter Registry Established To Define The Prevalence, Epidemiology And Prognosis Of Ttc In The Tuscany Area. From January 1 To December 31, 2009, 105 Consecutive Patients Hospitalized In The 14 Cardiology Units Of The Tuscany Region With A Diagnosis Of Ttc, Were Enrolled In The Registry. Ttc Diagnosis Was Made Using The Mayo Clinic Modified Criteria. Clinical, Instrumental, Laboratory And 6-Month Follow-Up Data Were Collected. Results. Ttc Represented 1.2% Of All Myocardial Infarctions In The Tuscany Region During 2009, And It Was Diagnosed In 0.6% Of The Angiographic Exams Performed During The Same Year. The Data Collected Showed That Ttc Affects Mainly The Female Gender (91%) In The Post-Menopausal Period (70 ± 11 Years), Though 5% Of Patients Were ≤50 Years Old. An Antecedent Stressful Event Was Frequently Detected (74%). The Main Clinical Presentation Was Chest Pain (86%), Associated With St-Segment Elevation (59%). Mean Left Ventricular Ejection Fraction On Admission Was 40 ± 9%, And Was Associated With Apical (37%), Midapical (49%) Or Midventricular (5%) Wall Motion Abnormalities. Left Ventricular Ejection Fraction Recovered To 51 ± 9% In 7 ± 9 Days. Heart Failure Was The Most Common Complication In The Acute Phase (14%), And 4 Patients Presented With Cardiogenic Shock. No Patient Died During The Index Hospitalization. At 6-Month Follow-Up, No Patient Had Ttc Recurrence, 9 Patients Were Rehospitalized (7 For Noncardiac Disease) And 2 Patients Died Of Noncardiac Causes. Our Data, Which Represent The Largest Prospective Series Of Patients With A Diagnosis Of Ttc, Show That The Prevalence Of Ttc In Tuscany Is Similar That Described In Other National And International Studies. Moreover, The Data Highlight That Ttc May Occur Also In Male Patients And In Patients Aged <50 Years. The Mid-Term Prognosis Is Good, But The Risk Of Acute Complications Related To Heart Failure Cannot Be Neglected.|[('Tako-Tsubo (Stress) Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Acute Cardiac Syndrome', 'no label'), ('Mimics', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Myocardial Infarction', 'no label'), ('Ttc Tuscany Registry', 'no label'), ('Observational Prospective Multicenter Registry', 'no label'), ('Prevalence', 'no label'), ('Epidemiology', 'no label'), ('Prognosis', 'no label'), ('Ttc', 'no label'), ('Tuscany Area', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Hospitalized', 'no label'), ('Cardiology', 'no label'), ('Tuscany Region', 'no label'), ('Diagnosis', 'no label'), ('Ttc', 'no label'), ('Registry', 'no label'), ('Ttc Diagnosis', 'no label'), ('Mayo Clinic', 'no label'), ('Clinical', 'no label'), ('Instrumental', 'no label'), ('Laboratory', 'no label'), ('Follow-Up', 'no label'), ('Data', 'no label'), ('Collected', 'no label'), ('Ttc', 'no label'), ('Myocardial Infarctions', 'no label'), ('Tuscany Region', 'no label'), ('Diagnosed', 'no label'), ('Angiographic Exams', 'no label'), ('Year', 'no label'), ('Data Collected', 'no label'), ('Ttc', 'no label'), ('Female Gender', 'no label'), ('Post-Menopausal Period', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Years Old', 'no label'), ('Antecedent Stressful Event', 'no label'), ('Detected', 'no label'), ('Main Clinical Presentation', 'no label'), ('Associated With', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Left Ventricular Ejection Fraction', 'no label'), ('Admission', 'no label'), ('Associated With', 'no label'), ('Apical', 'no label'), ('Midapical', 'no label'), ('Midventricular', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Left Ventricular Ejection Fraction', 'no label'), ('Days', 'no label'), ('Heart Failure', 'no label'), ('Complication', 'no label'), ('Acute Phase', 'no label'), ('Patients', 'no label'), ('Cardiogenic Shock', 'no label'), ('Patient', 'no label'), ('Died', 'no label'), ('Hospitalization', 'no label'), ('Follow-Up', 'no label'), ('Patient', 'no label'), ('Ttc', 'no label'), ('Recurrence', 'no label'), ('Patients', 'no label'), ('Rehospitalized', 'no label'), ('Noncardiac Disease', 'no label'), ('Patients', 'no label'), ('Died', 'no label'), ('Noncardiac Causes', 'no label'), ('Data', 'no label'), ('Represent', 'no label'), ('Prospective Series', 'no label'), ('Patients', 'no label'), ('Diagnosis', 'no label'), ('Ttc', 'no label'), ('Prevalence', 'no label'), ('Ttc', 'no label'), ('Tuscany', 'no label'), ('National And International Studies', 'no label'), ('Data Highlight', 'no label'), ('Ttc', 'no label'), ('Occur', 'no label'), ('Male', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Aged', 'no label'), ('Years', 'no label'), ('Mid-Term', 'no label'), ('Prognosis', 'no label'), ('Good', 'no label'), ('Risk', 'no label'), ('Acute Complications', 'no label'), ('Heart Failure', 'no label'), ('Neglected', 'no label')]|[('Region', 'no label'), ('Region', 'no label'), ('±', 'no label'), ('±', 'no label'), ('±', 'no label')]|[('Post-Menopausal Period (70 ± 11', 'no label')]|[('Tako-Tsubo', 'no label'), ('Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Cardiac Syndrome', 'no label'), ('Myocardial Infarction', 'no label'), ('Ttc', 'no label'), ('Ttc', 'no label'), ('Myocardial Infarctions', 'no label'), ('Chest Pain', 'no label'), ('Heart Failure', 'no label'), ('Cardiogenic Shock', 'no label'), ('Noncardiac Disease', 'no label'), ('Ttc', 'no label'), ('Prognosis', 'no label'), ('Heart Failure', 'no label')]|[('Cardiac', 'no label'), ('Myocardial', 'no label'), ('Patients', 'no label'), ('Myocardial Infarctions', 'no label'), ('Patients', 'no label'), ('Left Ventricular', 'no label'), ('Wall', 'no label'), ('Heart', 'no label'), ('Acute Phase (', 'no label'), ('Patients', 'no label'), ('Patient', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Noncardiac Disease', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Acute Complications', 'no label'), ('Heart', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22293805|A 68-Year-Old Woman Was Admitted To Our Hospital Due To Sudden Onset Of Dyspnea. On Admission, Electrocardiogram (Ecg) Showed T-Wave Inversion And Qrs Prolongation (120 Msec) That Were Not Found In Her Previous Ecg. Chest X-Ray Showed Pulmonary Edema And Cardiac Enlargement. Left Ventriculogram Showed Akinesis Of The Left Ventricle Except In The Basal Region. No Significant Coronary Stenosis Was Found On Angiogram. She Was Diagnosed As Having Tako-Tsubo Cardiomyopathy Complicated By Qrs Prolongation. Intraaortic Balloon Pumping (Iabp) Was Subsequently Initiated For The Treatment Of Acute Heart Failure. Qrs Prolongation Was Resolved Immediately After The Initiation Of Iabp, And Left Ventricular Dysfunction Was Resolved Within 9 Days. She Was Discharged 14 Days Later.|[('Hospital', 'no label'), ('Sudden', 'no label'), ('Onset', 'no label'), ('Dyspnea', 'no label'), ('Admission', 'no label'), ('Electrocardiogram', 'no label'), ('Qrs', 'no label'), ('Prolongation', 'no label'), ('Ecg', 'no label'), ('Chest X-Ray', 'no label'), ('Pulmonary Edema', 'no label'), ('Cardiac Enlargement', 'no label'), ('Left Ventriculogram', 'no label'), ('Akinesis', 'no label'), ('Left Ventricle', 'no label'), ('Basal Region', 'no label'), ('No Significant', 'no label'), ('Coronary Stenosis', 'no label'), ('Angiogram', 'no label'), ('Diagnosed', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Complicated', 'no label'), ('Qrs', 'no label'), ('Prolongation', 'no label'), ('Intraaortic Balloon Pumping', 'no label'), ('Iabp', 'no label'), ('Initiated', 'no label'), ('Treatment', 'no label'), ('Acute Heart Failure', 'no label'), ('Qrs Prolongation', 'no label'), ('Resolved', 'no label'), ('Initiation', 'no label'), ('Iabp', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Resolved', 'no label'), ('Days', 'no label'), ('Days', 'no label')]|[]|[]|[('Dyspnea', 'no label'), ('Chest X-Ray Showed Pulmonary Edema', 'no label'), ('Cardiac Enlargement', 'no label'), ('Ventriculogram', 'no label'), ('Coronary Stenosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Heart Failure', 'no label'), ('Ventricular Dysfunction', 'no label')]|[('T-Wave', 'no label'), ('Pulmonary Edema', 'no label'), ('Cardiac Enlargement.', 'no label'), ('Left Ventricle', 'no label'), ('Heart', 'no label'), ('Iabp', 'no label'), ('Left Ventricular', 'no label'), ('Resolved Within 9', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19185360|Tako-Tsubo Cardiomyopathy Is Characterized By A Transient And Reversible Left Ventricular Dysfunction Possibly Due To A Catecholamine-Mediated Myocardial Stunning. This Form Of Cardiomyopathy Is Rarely Associated With Cardiogenic Shock. Here We Report On A Patient With Tako-Tsubo Cardiomyopathy Induced Low Output Failure In Which Blood Flow Disturbances In The Thoracic Aorta Mimicked An Acute Type A Aortic Dissection.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Characterized', 'no label'), ('Transient', 'no label'), ('Reversible', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Catecholamine-Mediated Myocardial', 'no label'), ('Stunning', 'no label'), ('Form', 'no label'), ('Cardiomyopathy', 'no label'), ('Rarely', 'no label'), ('Associated With', 'no label'), ('Cardiogenic Shock', 'no label'), ('Report', 'no label'), ('Patient', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Induced', 'no label'), ('Output', 'no label'), ('Failure', 'no label'), ('Blood Flow', 'no label'), ('Disturbances', 'no label'), ('Thoracic Aorta Mimicked', 'no label'), ('Acute Type A Aortic Dissection', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Myocardial Stunning', 'no label'), ('Cardiomyopathy', 'no label'), ('Cardiogenic Shock', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Low Output Failure', 'no label')]|[('Myocardial', 'no label'), ('Blood Flow', 'no label'), ('Acute Type A Aortic', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20371531|We Describe A Case Of Tako-Tsubo Cardiomyopathy In An Elderly Woman With A Permanent Pacemaker Admitted To The Ed With Chest Pain And Dyspnea. Coronary Angiography Revealed Normal Coronary Arteries. Typical Left Ventricular Apical Ballooning Was Demonstrated On Contrast Ventriculography. Left And Right Ventricular Ballooning With Pulmonary Artery Systolic Hypertension Was Detected By Transthoracic Echocardiography. Velocity Vector Imaging And Strain Analysis Showed A Typical Pattern Of Regional Myocardial Apical Right Ventricular Contraction Characterized By Paradoxical Positive Longitudinal Systolic Strain. Biventricular Involvement Was Associated With Hemodynamic Instability, Signs Of Pulmonary Vascular Congestion, And Bilateral Basal Pleural Effusion. The Patient'S Clinical Condition Gradually Improved, And She Was Discharged After Prolonged Hospitalization. Predischarge Echocardiography Showed Substantial Recovery Of Left And Right Systolic Function Along With Normalization Of Pulmonary Artery Systolic Pressure. Right Ventricular Function Should Be Carefully Evaluated In Patients With Tako-Tsubo Cardiomyopathy, Especially In The Acute Phase.|"[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Elderly Woman With A Permanent', 'no label'), ('Pacemaker', 'no label'), ('Admitted', 'no label'), ('Ed With Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Coronary Angiography', 'no label'), ('Revealed', 'no label'), ('Normal Coronary Arteries', 'no label'), ('Left Ventricular Apical Ballooning', 'no label'), ('Contrast Ventriculography', 'no label'), ('Left And Right Ventricular Ballooning', 'no label'), ('Pulmonary Artery', 'no label'), ('Systolic Hypertension', 'no label'), ('Detected', 'no label'), ('Transthoracic Echocardiography', 'no label'), ('Velocity Vector Imaging', 'no label'), ('Strain Analysis', 'no label'), ('Typical', 'no label'), ('Pattern', 'no label'), ('Regional Myocardial Apical Right', 'no label'), ('Ventricular Contraction', 'no label'), ('Characterized', 'no label'), ('Paradoxical Positive Longitudinal Systolic Strain', 'no label'), ('Biventricular', 'no label'), ('Involvement', 'no label'), ('Associated With', 'no label'), ('Hemodynamic Instability', 'no label'), ('Signs Of Pulmonary Vascular Congestion', 'no label'), ('Bilateral', 'no label'), ('Basal Pleural Effusion', 'no label'), (""Patient'S"", 'no label'), ('Clinical', 'no label'), ('Improved', 'no label'), ('Prolonged', 'no label'), ('Hospitalization', 'no label'), ('Predischarge Echocardiography', 'no label'), ('Recovery', 'no label'), ('Left And Right Systolic Function', 'no label'), ('Normalization', 'no label'), ('Pulmonary Artery Systolic Pressure', 'no label'), ('Right Ventricular Function', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Phase', 'no label')]"|[('Apical', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Left Ventricular Apical Ballooning', 'no label'), ('Ventricular Ballooning', 'no label'), ('Pulmonary Artery Systolic Hypertension', 'no label'), ('Regional Myocardial Apical Right Ventricular Contraction', 'no label'), ('Pulmonary Vascular Congestion', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('A Case', 'no label'), ('Left Ventricular', 'no label'), ('Contrast', 'no label'), ('Pulmonary', 'no label'), ('Myocardial Apical Right Ventricular', 'no label'), ('Pulmonary Vascular', 'no label'), ('Bilateral Basal Pleural Effusion', 'no label'), ('Left', 'no label'), ('Pulmonary', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23602299||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~27049039|"In 2011 A List Of 20 Drugs Linked To Drug-Induced Tako-Tsubo Cardiomyopathy (Tcm) Was Published. Thus, The Objectives Were Both To Identify Cases Of Drug-Induced Tcm, And Update The 2011 List Of Drugs As Possible Triggers Of This Cardiomyopathy. As The 2011 Report Of Drug-Induced Tcm, Case Reports Of Drug-Induced Tcm Were Identified By A Comprehensive Search In Medline/Pubmed Database. From December 2010 To March 2015 Search Terms Were Takotsubo Cardiomyopathy, Takotsubo Cardiomyopathy, Stress Cardiomyopathy, Transient-Left-Ventricular Ballooning Syndrome, Ampulla Cardiomyopathy, Apical Ballooning Syndrome, Or Broken Heart Syndrome; Together With ""Iatrogenic"", ""Drug-Induced"", Or ""Induced By"". Publications Limited To English, Spanish, And French, In Humans, And With Full Texts Were Retrieved. Articles That Recognized Any Drug As A Possible Trigger Of Tcm Were Selected. Overall, 405 Different References Were Retrieved And 67 Were Selected (62 Case Reports And 5 Case Series) Involving 78 Patient Cases With Tcm Possibly Associated To Drugs Were Reviewed. At Total Of 44 Drugs Were Recognized As Possible Drug-Induced Tcm, Mainly With Sympathetic Effect, And 37 (84.1%) Were Different To Those 20 Identified In The 2011 Review; Therefore, A List Of 57 Drugs Associated To Tcm Was Obtained. There Are New Case Reports That Linked Drug-Use With The Development Of Tcm. The List Of 57 Drugs Obtained Is Principally Integrated By Drugs That Generate Sympathetic Overstimulation. Consequently, The Recommendation ""Drug-Induced Tcm Would Be Considered In Patients With Tcm, Particularly Those In Which No Clear Emotional Or Stress Trigger Could Be Identified"" Is Endorsed."|"[('Drugs', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tcm', 'no label'), ('Published', 'no label'), ('Objectives', 'no label'), ('Cases', 'no label'), ('Drug-Induced Tcm', 'no label'), ('Update', 'no label'), ('Drugs', 'no label'), ('Triggers', 'no label'), ('Cardiomyopathy', 'no label'), ('Report', 'no label'), ('Drug-Induced Tcm', 'no label'), ('Case Reports', 'no label'), ('Drug-Induced Tcm', 'no label'), ('Comprehensive', 'no label'), ('Search', 'no label'), ('Medline/Pubmed Database', 'no label'), ('Terms', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Transient-Left-Ventricular Ballooning Syndrome', 'no label'), ('Ampulla Cardiomyopathy', 'no label'), ('Apical Ballooning Syndrome', 'no label'), ('Broken Heart Syndrome', 'no label'), ('Iatrogenic', 'no label'), ('Induced', 'no label'), ('Publications', 'no label'), ('Limited', 'no label'), ('English', 'no label'), ('Spanish', 'no label'), ('French', 'no label'), ('Humans', 'no label'), ('Texts', 'no label'), ('Articles', 'no label'), ('Recognized', 'no label'), ('Drug', 'no label'), ('Trigger', 'no label'), ('Tcm', 'no label'), ('References', 'no label'), ('Case Reports', 'no label'), ('Case Series', 'no label'), ('Patient', 'no label'), ('Cases', 'no label'), ('Tcm', 'no label'), ('Drugs', 'no label'), ('Reviewed', 'no label'), ('Drugs', 'no label'), ('Drug-Induced', 'no label'), ('Tcm', 'no label'), ('Sympathetic Effect', 'no label'), ('Identified', 'no label'), ('Review', 'no label'), ('Drugs', 'no label'), ('Tcm', 'no label'), ('New Case Reports', 'no label'), ('Drug-Use', 'no label'), ('Development', 'no label'), ('Tcm', 'no label'), ('Drugs', 'no label'), ('Obtained', 'no label'), ('Drugs', 'no label'), ('Sympathetic', 'no label'), ('Overstimulation', 'no label'), ('Recommendation ""Drug-Induced Tcm', 'no label'), ('Patients', 'no label'), ('Tcm', 'no label'), ('Emotional', 'no label'), ('Stress', 'no label'), ('Identified', 'no label'), ('Endorsed', 'no label')]"|[('Apical', 'no label'), ('Humans', 'no label'), ('Drug', 'no label')]|[('Tcm', 'no label'), ('Tcm', 'no label'), ('67', 'no label'), ('Tcm', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Cardiomyopathy', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Transient-Left-Ventricular Ballooning Syndrome', 'no label'), ('Ampulla Cardiomyopathy', 'no label'), ('Ballooning Syndrome', 'no label'), ('Heart Syndrome', 'no label')]|[('Ampulla', 'no label'), ('Broken Heart', 'no label'), ('Humans', 'no label'), ('Tcm', 'no label'), ('Patient', 'no label'), ('Tcm', 'no label'), ('New Case', 'no label'), ('Patients', 'no label'), ('Tcm', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22092251|To Describe The Clinical Characteristics And In-Hospital Outcomes Of Older Adults With Tako-Tsubo Cardiomyopathy (Ttc). Partially Retrospective, Partially Prospective Observational Study. Eleven Italian Referral Cardiac Centers Included In The Tako-Tsubo Italian Network. One Hundred Ninety Consecutive Individuals With Ttc (92.1% Female, Mean Age 66) Were Divided Into Three Groups According To Age (<65, N = 78; 65-74, N = 61; ≥75, N = 51). Clinical Findings And In-Hospital Outcomes Were Evaluated In Each Group. Participants Aged 65 And Older Had A Greater Prevalence Of Hypertension (P = .001) And A Lower Glomerular Filtration Rate (P < .001), And Those Aged 65 To 74 Had A Greater Prevalence Of Psychiatric Disorders (P = .01), St-Segment Elevation On Admission (P = .01) And A Cerebrovascular Disease (P = .003) Than Those Younger Than 65. Despite Similar Left Ventricular Ejection Fraction (Lvef) On Admission (P = .26), The Oldest Group Had A Lower Lvef At Discharge (P = .03). Inotropic Agents Were Used More Frequently In Older Adults (P = .03). In-Hospital Composite Adverse Events (All-Cause Death, Acute Heart Failure, Life-Threatening Arrhythmias, Stroke, And Cardiogenic Shock; P = .03) And Overall Complications (P = .004) Were More Common In Participants Aged 75 And Older. Overall In-Hospital Mortality Was Low (2.8%) But Was More Prevalent In Participants Aged 75 And Older (6.3%). On Multivariate Analysis, Age Of 75 And Older (Hazard Ratio (Hr) = 2.45, 95% Confidence Interval (Ci) = 1.28-5.82, P = .04) And Lvef On Admission (Hr = 0.874, 95% Ci = 0.81-0.95, P < .001) Were The Only Independent Predictors Of In-Hospital Adverse Events. The Clinical Profile Of Participants Aged 75 And Older With Ttc Was Different From That Of Those Younger Than 75 With Ttc, And They Had A Higher In-Hospital Complication Rate.|[('Clinical Characteristics', 'no label'), ('In-Hospital', 'no label'), ('Outcomes', 'no label'), ('Older Adults', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Partially Retrospective', 'no label'), ('Partially Prospective Observational Study', 'no label'), ('Italian', 'no label'), ('Referral Cardiac Centers', 'no label'), ('Tako-Tsubo Italian', 'no label'), ('Network', 'no label'), ('Consecutive', 'no label'), ('Individuals', 'no label'), ('Ttc', 'no label'), ('Female', 'no label'), ('Mean Age 66) Were Divided', 'no label'), ('Groups', 'no label'), ('Age', 'no label'), ('N\xa0', 'no label'), ('N\xa0', 'no label'), ('Clinical Findings', 'no label'), ('In-Hospital', 'no label'), ('Outcomes', 'no label'), ('Evaluated', 'no label'), ('Group', 'no label'), ('Participants', 'no label'), ('Aged', 'no label'), ('Older', 'no label'), ('Greater Prevalence', 'no label'), ('Hypertension', 'no label'), ('Lower Glomerular Filtration Rate', 'no label'), ('P\xa0<\xa0.001', 'no label'), ('Greater Prevalence', 'no label'), ('Psychiatric Disorders', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Admission', 'no label'), ('Cerebrovascular Disease', 'no label'), ('Younger Than', 'no label'), ('Left Ventricular Ejection Fraction', 'no label'), ('Lvef', 'no label'), ('Admission', 'no label'), ('Oldest Group', 'no label'), ('Lvef', 'no label'), ('Discharge', 'no label'), ('Inotropic Agents', 'no label'), ('Older Adults', 'no label'), ('Composite Adverse Events', 'no label'), ('All-Cause Death', 'no label'), ('Acute Heart Failure', 'no label'), ('Life-Threatening Arrhythmias', 'no label'), ('Stroke', 'no label'), ('Cardiogenic Shock', 'no label'), ('Complications', 'no label'), ('Participants', 'no label'), ('Aged', 'no label'), ('Older', 'no label'), ('In-Hospital', 'no label'), ('Mortality', 'no label'), ('Low', 'no label'), ('Prevalent', 'no label'), ('Participants', 'no label'), ('Aged', 'no label'), ('Older', 'no label'), ('Multivariate Analysis', 'no label'), ('Age', 'no label'), ('Older', 'no label'), ('Hazard Ratio', 'no label'), ('Hr', 'no label'), ('Confidence Interval', 'no label'), ('Ci', 'no label'), ('Lvef', 'no label'), ('Hr\xa0', 'no label'), ('Ci\xa0', 'no label'), ('P\xa0<\xa0.001', 'no label'), ('Independent', 'no label'), ('Predictors', 'no label'), ('In-Hospital Adverse Events', 'no label'), ('Clinical Profile', 'no label'), ('Participants', 'no label'), ('Aged', 'no label'), ('Ttc', 'no label'), ('Younger Than', 'no label'), ('Ttc', 'no label'), ('Higher', 'no label'), ('Complication Rate', 'no label')]|[('Individuals', 'no label'), ('Lvef', 'no label'), ('Agents', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Tako-Tsubo', 'no label'), ('≥75', 'no label'), ('N\xa0=\xa0', 'no label'), ('Hypertension', 'no label'), ('Psychiatric Disorders', 'no label'), ('Cerebrovascular Disease', 'no label'), ('Left Ventricular Ejection Fraction (Lvef)', 'no label'), ('Death', 'no label'), ('Acute Heart Failure', 'no label'), ('Arrhythmias', 'no label'), ('Stroke', 'no label'), ('Cardiogenic Shock', 'no label')]|[('Cerebrovascular Disease', 'no label'), ('Left Ventricular', 'no label'), ('Heart', 'no label'), ('Hr', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25012104||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~28041712|"The Cardiac Impact Of Psychological Stress Historically And Socially Understood As Boundary Experiences Of Human Life Has Long Since Become An Icon. From The Aching Heart To The Sudden Death Provoked By Awe, Horror, Grief, Anger, And Humiliation On One Side And Extreme Enchantment, Enthusiasm, And Excitement On The Other, The Broken Heart Has Become A Globally Recognized And Powerful Metaphor Present From Folklore To Popular Culture To High Literature And Back To Everyday Communication. In Medicine, The ""Broken Heart Syndrome"" Is Described As A Relatively New Nosological Entity That Has Been Used Synonymously With The Term Tako-Tsubo Or Stress Cardiomyopathy. Among Those Three Terms, However, The Broken Heart Most Vividly Draws The Connection Between Conditions Under Which Lived Experience Triggers Cardiac Damage And Conversely, Cardiovascular Death Occurs. According To Hassan And Yamasaki (2013) [1] And Quite Apart From The General Perception Medical Notions Of The Broken Heart Indeed Go Back To At Least 1967, When Rees And Lutkins Studied The Death Rate Among 903 Relatives Of Patients Who Died In Wales. They Found That 4.8% Of Bereaved Close Relatives Died Within A Year Of Bereavement Compared With 0.68% Of A Non-Bereaved Control Group. Among Widows And Widowers, The Mortality Rate Was Even 10 Times Greater Than That Of The Matched Controls. After The First Year Of Bereavement, However, Mortality Rates Of Relatives Of A Deceased Person Did Not Differ Significantly From The Control Group Rees And Lutkins (1967) [2]. Similar Findings Were Published By Parkes Et Al. (1969) [3] Following Up On 4486 Widowers At The Age Of 55 For 9Years Following The Death Of Their Wives In 1957. During The First Six Months After The Spouse Had Died, The Mortality Rate Of The Widowers Was 40% Above The Rate Of Married Men Of The Same Age. While It Seems Plausible To Accept The Etiological Role And Pathogenic Impact Of Personal Loss, The Pathogenic Processes Causing Death Remained Relatively Blurred. We Will Explain, Why Inaccurately Stressing The Fact That The Broken Heart And/Or Tako-Tsubo Syndrome Would Be A Relatively New Way Of Looking At Stress-Related Cardiomyopathy As Outlined By Yoshikawa (2015) [4] And Why Attaching Stress-Related Cardiomyopathy To Culturally Powerful Yet Value-Laden Metaphors, Might Obstruct Pathways To A Better Understanding, Prevention And Clinical Management Of The Disease. By Looking At Narrative Understandings And Clinical Representations Of The Broken Heart, We Aim To Highlight The Need For A More Contextualised View Of The Broken Heart Syndrome In Order To Facilitate Multi- And Transdisciplinary Approaches Aiming At Its Prediction, Prevention, And Treatment."|[('Cardiac Impact', 'no label'), ('Psychological Stress', 'no label'), ('Socially', 'no label'), ('Boundary', 'no label'), ('Experiences', 'no label'), ('Human Life', 'no label'), ('Aching Heart', 'no label'), ('Sudden Death', 'no label'), ('Provoked', 'no label'), ('Horror', 'no label'), ('Grief', 'no label'), ('Anger', 'no label'), ('Humiliation', 'no label'), ('Extreme Enchantment', 'no label'), ('Enthusiasm', 'no label'), ('Excitement', 'no label'), ('Broken Heart', 'no label'), ('Recognized', 'no label'), ('Metaphor', 'no label'), ('Present', 'no label'), ('Folklore', 'no label'), ('Popular Culture', 'no label'), ('Literature', 'no label'), ('Back', 'no label'), ('Everyday', 'no label'), ('Communication', 'no label'), ('Medicine', 'no label'), ('Nosological Entity', 'no label'), ('Synonymously', 'no label'), ('Term', 'no label'), ('Tako-Tsubo Or Stress Cardiomyopathy', 'no label'), ('Terms', 'no label'), ('Broken Heart', 'no label'), ('Vividly Draws', 'no label'), ('Connection', 'no label'), ('Conditions', 'no label'), ('Lived', 'no label'), ('Triggers', 'no label'), ('Cardiac Damage', 'no label'), ('Cardiovascular Death', 'no label'), ('Occurs', 'no label'), ('Hassan And Yamasaki', 'no label'), ('General Perception Medical', 'no label'), ('Notions', 'no label'), ('Broken Heart Indeed', 'no label'), ('Rees', 'no label'), ('Lutkins', 'no label'), ('Studied', 'no label'), ('Death', 'no label'), ('Rate', 'no label'), ('Relatives', 'no label'), ('Patients', 'no label'), ('Died', 'no label'), ('Wales', 'no label'), ('Bereaved', 'no label'), ('Relatives', 'no label'), ('Died', 'no label'), ('Year', 'no label'), ('Bereavement', 'no label'), ('Control Group', 'no label'), ('Widows', 'no label'), ('Widowers', 'no label'), ('Mortality Rate', 'no label'), ('Matched Controls', 'no label'), ('Year', 'no label'), ('Bereavement', 'no label'), ('Mortality Rates', 'no label'), ('Relatives', 'no label'), ('Deceased', 'no label'), ('Person', 'no label'), ('Differ', 'no label'), ('Control Group Rees And Lutkins', 'no label'), ('Findings', 'no label'), ('Published', 'no label'), ('Parkes Et Al', 'no label'), ('Widowers', 'no label'), ('Age', 'no label'), ('Death', 'no label'), ('Wives', 'no label'), ('Months', 'no label'), ('Spouse', 'no label'), ('Died', 'no label'), ('Mortality Rate', 'no label'), ('Widowers', 'no label'), ('Rate', 'no label'), ('Married', 'no label'), ('Men', 'no label'), ('Same Age', 'no label'), ('Accept', 'no label'), ('Etiological Role', 'no label'), ('Pathogenic', 'no label'), ('Impact', 'no label'), ('Personal Loss', 'no label'), ('Pathogenic Processes', 'no label'), ('Causing Death', 'no label'), ('Remained', 'no label'), ('Blurred', 'no label'), ('Explain', 'no label'), ('Stressing', 'no label'), ('Fact', 'no label'), ('Broken Heart And/Or Tako-Tsubo Syndrome', 'no label'), ('Stress-Related Cardiomyopathy', 'no label'), ('Attaching', 'no label'), ('Stress-Related Cardiomyopathy', 'no label'), ('Culturally', 'no label'), ('Value-Laden Metaphors', 'no label'), ('Obstruct Pathways', 'no label'), ('Prevention', 'no label'), ('Clinical Management', 'no label'), ('Disease', 'no label'), ('Narrative', 'no label'), ('Understandings', 'no label'), ('Clinical Representations', 'no label'), ('Broken Heart', 'no label'), ('Need', 'no label'), ('Contextualised View', 'no label'), ('Broken Heart Syndrome', 'no label'), ('Transdisciplinary', 'no label'), ('Approaches', 'no label'), ('Prediction', 'no label'), ('Prevention', 'no label'), ('Treatment', 'no label')]|[('Human', 'no label'), ('Pathogenic', 'no label'), ('Pathogenic', 'no label')]|[]|[('Sudden Death', 'no label'), ('Anger', 'no label'), ('Heart Syndrome', 'no label'), ('Tako-Tsubo Or Stress Cardiomyopathy', 'no label'), ('Cardiac Damage', 'no label'), ('Cardiovascular Death', 'no label'), ('Death', 'no label'), ('Widows', 'no label'), ('Death', 'no label'), ('Personal Loss', 'no label'), ('Death', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Cardiomyopathy', 'no label'), ('Cardiomyopathy', 'no label'), ('Heart Syndrome', 'no label')]|[('Cardiac', 'no label'), ('Boundary Experiences', 'no label'), ('Human Life', 'no label'), ('Heart', 'no label'), ('Broken Heart', 'no label'), ('Broken Heart', 'no label'), ('Broken Heart', 'no label'), ('Cardiac', 'no label'), ('Cardiovascular', 'no label'), ('Broken Heart', 'no label'), ('Rees And', 'no label'), ('Patients', 'no label'), ('Lutkins (1967) [2', 'no label'), ('Al', 'no label'), ('Broken Heart And/Or', 'no label'), ('Be A', 'no label'), ('Broken Heart', 'no label'), ('Broken Heart', 'no label')]
tako-tsubo cardiomyopathy|pubmed~18063149|Tako-Tsubo Cardiomyopathy Is A Rare, Stress-Related Cardiomyopathy That Occurs In Postmenopausal Women After Emotional Or Physiological Stressors. The Prognosis Is Favorable With Normalization Of Wall Motion Abnormalities Within Weeks. We Report A Rare Case Of Tako-Tsubo Cardiomyopathy Complicated By A Left Thrombus. Coronary Angiography Showed Normal Coronary Arteries, Although The Echocardiography Demonstrated The Ballooning Of The Apex With Hyperkinesis Of The Base In Addition To A Left Ventricular Thrombus. It Is Thought That This Thrombus May Have Been Caused By Left Ventricular Dyskinesis. After Short-Term Anticoagulant Therapy, Echocardiography Revealed Complete Resolution Of The Left Ventricular Thrombus.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Rare', 'no label'), ('Stress-Related Cardiomyopathy', 'no label'), ('Occurs', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Emotional', 'no label'), ('Physiological', 'no label'), ('Stressors', 'no label'), ('Prognosis', 'no label'), ('Favorable', 'no label'), ('Normalization', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Weeks', 'no label'), ('Report', 'no label'), ('Rare', 'no label'), ('Case', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Complicated', 'no label'), ('Left Thrombus', 'no label'), ('Coronary Angiography', 'no label'), ('Normal Coronary Arteries', 'no label'), ('Echocardiography', 'no label'), ('Ballooning', 'no label'), ('Apex', 'no label'), ('Hyperkinesis', 'no label'), ('Base', 'no label'), ('Left Ventricular Thrombus', 'no label'), ('Thrombus', 'no label'), ('Left Ventricular Dyskinesis', 'no label'), ('Short-Term', 'no label'), ('Anticoagulant Therapy', 'no label'), ('Echocardiography', 'no label'), ('Revealed', 'no label'), ('Resolution', 'no label'), ('Left Ventricular Thrombus', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Cardiomyopathy', 'no label'), ('Prognosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Thrombus', 'no label'), ('Ventricular Thrombus', 'no label'), ('Thrombus', 'no label'), ('Left Ventricular Dyskinesis', 'no label'), ('Ventricular Thrombus', 'no label')]|[('Wall', 'no label'), ('Apex', 'no label'), ('A Left Ventricular Thrombus', 'no label'), ('Thrombus', 'no label'), ('Left Ventricular', 'no label'), ('Left Ventricular Thrombus', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25034928||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25034926||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25499134||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~23553664||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25034929||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~25034927||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~23218574||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~18599133|Acute Coronary Syndromes Are Not Uncommon In Medical Intensive Care Units. Multiple Molecular, Pharmacologic, And Hemodynamic Mechanisms May Contribute To The Pathogenesis Resulting In Increased Mortality In This Setting. Tako-Tsubo Cardiomyopathy Is A Recently Defined Uncommon Cardiac Syndrome With Characteristic Features Often Encountered In Patients With Hyperadrenergic Situations Such As Emotional Stress. Although Myocardial Depression In Sepsis Can Be Expected In Previously Healthy Individuals; Tako-Tsubo Cardiomyopathy Is Rarely Reported In Septic Patients. In This Case Report We Present A 52 Year-Old Man With Sepsis Secondary To Pseudomonas Pneumonia Who Developed Significant Segmental Wall Motion Abnormalities During The Disease Course. The Patient'S Myocardial Function Recovered Completely Soon After The Sepsis Resolved. Clinical, Echocardiographic, And Coronary Angiographic Findings Suggested The Diagnosis Of Tako-Tsubo Cardiomyopathy In This Patient.|"[('Acute Coronary Syndromes', 'no label'), ('Uncommon', 'no label'), ('Medical Intensive Care Units', 'no label'), ('Molecular', 'no label'), ('Pharmacologic', 'no label'), ('Hemodynamic Mechanisms', 'no label'), ('Contribute', 'no label'), ('Pathogenesis', 'no label'), ('Resulting', 'no label'), ('Increased', 'no label'), ('Mortality', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Uncommon Cardiac Syndrome', 'no label'), ('Characteristic Features', 'no label'), ('Encountered', 'no label'), ('Patients', 'no label'), ('Hyperadrenergic Situations', 'no label'), ('Emotional Stress', 'no label'), ('Myocardial Depression', 'no label'), ('Sepsis', 'no label'), ('Expected', 'no label'), ('Healthy', 'no label'), ('Individuals', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Septic', 'no label'), ('Patients', 'no label'), ('Case Report', 'no label'), ('Sepsis', 'no label'), ('Secondary', 'no label'), ('Pseudomonas Pneumonia', 'no label'), ('Segmental Wall Motion Abnormalities', 'no label'), ('Disease Course', 'no label'), (""Patient'S"", 'no label'), ('Myocardial Function', 'no label'), ('Sepsis', 'no label'), ('Resolved', 'no label'), ('Clinical', 'no label'), ('Echocardiographic', 'no label'), ('Coronary Angiographic Findings', 'no label'), ('Diagnosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Patient', 'no label')]"|[('Molecular', 'no label'), ('Individuals', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Cardiac Syndrome', 'no label'), ('Hyperadrenergic Situations', 'no label'), ('Myocardial Depression', 'no label'), ('Sepsis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Septic', 'no label'), ('Sepsis', 'no label'), ('Pneumonia', 'no label'), ('Sepsis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Cardiac', 'no label'), ('Patients', 'no label'), ('Myocardial', 'no label'), ('Patients', 'no label'), ('Patient', 'no label'), ('Myocardial', 'no label')]
tako-tsubo cardiomyopathy|pubmed~18757105|We Present The Case Of A Patient With Tako-Tsubo Cardiomyopathy Whose Initial Diagnosis, Based On The Location Of Shoulder And Chest Pain And Electrocardiographic (Ecg) Changes, Suggested That She Was Suffering From Pericarditis. However, 24 H After Admission, Evolutionary Changes Of Ecg And The Echocardiogram Performed Suggested A Tako-Tsubo Cardiomyopathy. In This Context, We Review The Literature To Discuss The Clinical Presentation And Evolutionary Ecg Changes Associated With Tako-Tsubo Cardiomyopathy.|[('Patient', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Initial', 'no label'), ('Diagnosis', 'no label'), ('Location', 'no label'), ('Shoulder And Chest Pain', 'no label'), ('Electrocardiographic (Ecg) Changes', 'no label'), ('Suggested', 'no label'), ('Suffering', 'no label'), ('Pericarditis', 'no label'), ('Admission', 'no label'), ('Evolutionary Changes', 'no label'), ('Ecg', 'no label'), ('Echocardiogram', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Context', 'no label'), ('Review', 'no label'), ('Literature', 'no label'), ('Clinical Presentation', 'no label'), ('Evolutionary', 'no label'), ('Associated With', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Chest Pain', 'no label'), ('Pericarditis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Patient', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20432510|A 69-Year-Old Woman And A 29-Year-Old Man Were Admitted To Our Hospital After Successful Resuscitation Of Out-Of Hospital Cardiac Arrest. In The First Case, Electrocardiogram Showed Mild St-Segment Elevation In Leads V3-V5. Coronary Angiography Did Not Show Any Obstructive Coronary Artery Disease, And Left Ventriculography Showed Apical Ballooning Of The Left Ventricular Chamber. She Was Diagnosed As Having The Classic Form Of Tako-Tsubo Cardiomyopathy. In The Second Case, Electrocardiogram Did Not Show St-Segment Elevation In Any Lead. Coronary Angiography Showed No Coronary Artery Disease And Left Ventriculography Showed Basal Ballooning Of The Left Ventricular Chamber. He Was Diagnosed As Having The Variant Form Of Tako-Tsubo Cardiomyopathy. In Both Cases, Left Ventricular Function Returned To Normal, But They Died Of Multiple Organ Failure. In Conclusion, Cardiologists Should Recognize That Takotsubo Cardiomyopathy Can Occur Even After Successful Resuscitation Of Cardiac Arrest. Early Diagnosis And Appropriate Intensive Care Are Essential In These Critically Ill Patients.|[('69-Year-Old Woman', 'no label'), ('Hospital', 'no label'), ('Resuscitation', 'no label'), ('Out-Of', 'no label'), ('Hospital Cardiac Arrest', 'no label'), ('First Case', 'no label'), ('Electrocardiogram', 'no label'), ('Mild', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Leads V3-V5', 'no label'), ('Coronary Angiography', 'no label'), ('Did Not', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Left Ventriculography', 'no label'), ('Apical Ballooning', 'no label'), ('Left Ventricular Chamber', 'no label'), ('Diagnosed', 'no label'), ('Classic Form', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Electrocardiogram', 'no label'), ('Did Not', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Lead', 'no label'), ('Coronary Angiography', 'no label'), ('Coronary Artery Disease', 'no label'), ('Left Ventriculography', 'no label'), ('Basal Ballooning', 'no label'), ('Left Ventricular Chamber', 'no label'), ('Diagnosed', 'no label'), ('Variant Form', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Cases', 'no label'), ('Left Ventricular Function', 'no label'), ('Returned To Normal', 'no label'), ('Died', 'no label'), ('Multiple Organ Failure', 'no label'), ('Cardiologists', 'no label'), ('Recognize', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Occur', 'no label'), ('Resuscitation', 'no label'), ('Cardiac Arrest', 'no label'), ('Early Diagnosis', 'no label'), ('Appropriate', 'no label'), ('Intensive Care', 'no label'), ('Critically Ill', 'no label'), ('Patients', 'no label')]|[('Lead', 'no label')]|[]|[('Cardiac Arrest', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Left Ventricular Chamber', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Coronary Artery Disease', 'no label'), ('Left Ventricular Chamber', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricular Function', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Cardiac Arrest', 'no label')]|[('A 29-Year-Old Man', 'no label'), ('Cardiac', 'no label'), ('Left', 'no label'), ('Left Ventricular', 'no label'), ('Coronary Artery', 'no label'), ('Left Ventricular', 'no label'), ('Left Ventricular', 'no label'), ('Cardiac', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~24945041|Mansencal Nicolas Discussed The Latest Evidence At The International Conference On Heart And Brain.|[('Mansencal', 'no label'), ('Nicolas', 'no label'), ('Evidence', 'no label'), ('International Conference On Heart And Brain', 'no label')]|[]|[]|[]|[('Heart', 'no label'), ('Brain', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21938986|In This Report, We Describe A Case Of Tako-Tsubo Cardiomyopathy (Ttc)--Also Called 'Apical Ballooning' Syndrome--In Which Transient Left Ventricular Outflow Tract (Lvot) Obstruction And Mitral Regurgitation Led To Haemodynamic Instability. Patients With Hypotension Should Undergo Urgent Echocardiography To Determine If Lvot Obstruction Is Present. This Complication Has Been Described In 10-25% Of All Ttc Patients. In Patients With Hypotension And Moderate-To-Severe Lvot Obstruction, Inotropic Agents Should Not Be Used Because They Can Worsen The Degree Of Obstruction. Instead, It Is Suggested To Use Beta-Blockers, Which Can Improve Haemodynamics By Causing Resolution Of The Obstruction. The Fact That Some Patients Do Not Survive Their Acute Ttc Event Only Underscores The Importance Of Prompt Recognition And Targeted Management Of Dynamic Lvot Obstruction.|[('Report', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Transient', 'no label'), ('Left Ventricular Outflow Tract', 'no label'), ('Mitral Regurgitation', 'no label'), ('Haemodynamic Instability', 'no label'), ('Patients', 'no label'), ('Hypotension', 'no label'), ('Urgent Echocardiography', 'no label'), ('Lvot Obstruction', 'no label'), ('Complication', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Hypotension', 'no label'), ('Lvot Obstruction', 'no label'), ('Inotropic Agents', 'no label'), ('Worsen', 'no label'), ('Degree', 'no label'), ('Obstruction', 'no label'), ('Beta-Blockers', 'no label'), ('Haemodynamics', 'no label'), ('Causing', 'no label'), ('Resolution', 'no label'), ('Obstruction', 'no label'), ('Fact', 'no label'), ('Patients', 'no label'), ('Survive', 'no label'), ('Acute Ttc', 'no label'), ('Prompt Recognition', 'no label'), ('Targeted Management', 'no label'), ('Dynamic Lvot Obstruction', 'no label')]|[('Apical', 'no label')]|[]|"[('Tako-Tsubo Cardiomyopathy', 'no label'), (""Ballooning' Syndrome"", 'no label'), ('Left Ventricular Outflow Tract', 'no label'), ('Obstruction And Mitral Regurgitation', 'no label'), ('Hypotension', 'no label'), ('Hypotension', 'no label'), ('Obstruction', 'no label')]"|[('A Case', 'no label'), ('Apical', 'no label'), ('Left Ventricular Outflow', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~27303068|Takotsubo Cardiomyopathy (Ttc) Is Characterized By A Systolic Dysfunction Localized In The Apical And Medial Aspect Of The Left Ventricle. It Is Usually Related To Physical Or Emotional Stress. Recent Evidence Highlighting The Role Of Infection Led Us To Analyze The Links Between Ttc And Sepsis. A Systematic Review Of The Literature Was Undertaken To Assess Any Trends In Clinical Findings, Diagnosis, And Outcomes In Such Patients. We Identified 23 Selected Papers Reporting A Total Of 26 Patients, Having Sepsis, In Whom Ttc Occurred. For Each Case, We Collected Data Identifying Population Characteristics, Source Of Sepsis, Clinical Disease Description, And The Results Of Cardiovascular Investigations. The Majority Of Patients Were Females (N = 16), Mean Age Was 62.8 (14.0 Standard Deviation) Years, And Clinical Outcome Was Favorable In 92.3% Of The Cases Once The Management Of Sepsis Was Initiated. A Better Understanding Of The Mechanisms Of Sepsis-Associated Ttc May Generate Novel Strategies To Treat The Complications Of This Cardiomyopathy And May Even Help Predict And Prevent Its Occurrence.|[('Takotsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Characterized', 'no label'), ('Systolic Dysfunction', 'no label'), ('Localized', 'no label'), ('Apical', 'no label'), ('Medial Aspect', 'no label'), ('Left Ventricle', 'no label'), ('Physical', 'no label'), ('Emotional Stress', 'no label'), ('Evidence', 'no label'), ('Infection', 'no label'), ('Led', 'no label'), ('Analyze', 'no label'), ('Ttc', 'no label'), ('Sepsis', 'no label'), ('Systematic Review', 'no label'), ('Literature', 'no label'), ('Trends', 'no label'), ('Clinical Findings', 'no label'), ('Diagnosis', 'no label'), ('Outcomes', 'no label'), ('Patients', 'no label'), ('Papers Reporting A', 'no label'), ('Patients', 'no label'), ('Sepsis', 'no label'), ('Ttc', 'no label'), ('Case', 'no label'), ('Collected', 'no label'), ('Data', 'no label'), ('Population', 'no label'), ('Characteristics', 'no label'), ('Source', 'no label'), ('Sepsis', 'no label'), ('Clinical Disease', 'no label'), ('Description', 'no label'), ('Results', 'no label'), ('Cardiovascular Investigations', 'no label'), ('Patients', 'no label'), ('Females', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Clinical Outcome', 'no label'), ('Favorable', 'no label'), ('Cases', 'no label'), ('Management', 'no label'), ('Sepsis', 'no label'), ('Mechanisms', 'no label'), ('Sepsis-Associated Ttc', 'no label'), ('Strategies', 'no label'), ('Treat', 'no label'), ('Complications', 'no label'), ('Cardiomyopathy', 'no label'), ('Help', 'no label'), ('Predict', 'no label'), ('Prevent', 'no label')]|[('Apical', 'no label')]|[]|[('Takotsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Left Ventricle', 'no label'), ('Infection', 'no label'), ('Sepsis', 'no label'), ('Sepsis', 'no label'), ('Sepsis', 'no label'), ('Sepsis', 'no label'), ('Cardiomyopathy', 'no label')]|[('Apical', 'no label'), ('Left Ventricle', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cardiovascular', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20859840|Tako-Tsubo Cardiomyopathy (Ttc) Was First Described In 1990 In Japan. A Ttc Registry Was Initiated By The Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (Alkk) In Order To Evaluate The Clinical Spectrum And The Management Of Patients With This Syndrome In Germany. Patients From 37 Hospitals Were Included In The Registry If They Fulfilled The Following Criteria: 1. Acute Chest Symptoms Or Syncope, 2. New Ischemic Ecg Changes With St-Segment Elevation ± T-Wave Inversion, 3. Reversible Left Ventricular Regional Wall Motion Abnormality Not Corresponding To A Single Coronary Artery Territory, 4. Absence Of Significant Coronary Artery Stenoses. 296 Of The 324 Patients (Age 68 ±  12) Were Women (91 %) And 28 Men (9 %). Leading Symptoms Were Angina Pectoris (72 %), Dyspnoea (16 %), Syncope (3 %) Or Resuscitation/Cardiogenic Shock (2 %). An Antecedent Trigger Was Found In 77  %. Time From Symptom Onset To Hospital Admission Was 7,6  ±  6,9 Hours. An Acute Coronary Syndrome (Acs) Was Clinically Suspected In 87 %. The Ecg Showed St-Segment Elevation In 85 %. Cardiac Troponin Was Elevated In More Than 90 % Of Patients. Left Ventricular Ejection Fraction By Angiography Was Reduced To 49 ± 14 %. Initial Medical Treatment Corresponded To The Working Diagnosis Of An Acs. Catecholamines Or An Intraaortic Balloon Pump Were Necessary In 5 % And 1 %, Respectively. Seven Patients (2.2 %) Died In Hospital. Ttc Afflicts Mainly Women And Presents Clinically As An Acs In 87 %. Hospital Mortality Is Low With Symptomatic Therapy.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Japan', 'no label'), ('Ttc Registry', 'no label'), ('Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte', 'no label'), ('Alkk', 'no label'), ('Order', 'no label'), ('Evaluate', 'no label'), ('Clinical Spectrum', 'no label'), ('Management', 'no label'), ('Patients', 'no label'), ('Syndrome', 'no label'), ('Germany', 'no label'), ('Patients', 'no label'), ('Hospitals', 'no label'), ('Registry', 'no label'), ('Criteria', 'no label'), ('Acute Chest Symptoms', 'no label'), ('Syncope', 'no label'), ('Ischemic Ecg', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('T-Wave', 'no label'), ('Reversible', 'no label'), ('Left Ventricular Regional Wall Motion', 'no label'), ('Single Coronary Artery', 'no label'), ('Absence', 'no label'), ('Significant', 'no label'), ('Coronary Artery', 'no label'), ('Stenoses', 'no label'), ('Patients', 'no label'), ('Age', 'no label'), ('Women', 'no label'), ('Men', 'no label'), ('Leading Symptoms', 'no label'), ('Angina Pectoris', 'no label'), ('Dyspnoea', 'no label'), ('Syncope', 'no label'), ('Resuscitation/Cardiogenic Shock', 'no label'), ('Antecedent', 'no label'), ('Trigger', 'no label'), ('Symptom Onset To Hospital Admission', 'no label'), ('Hours', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Acs', 'no label'), ('Clinically Suspected', 'no label'), ('Ecg', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Cardiac Troponin', 'no label'), ('Elevated', 'no label'), ('Patients', 'no label'), ('Left Ventricular Ejection Fraction', 'no label'), ('Angiography', 'no label'), ('Reduced', 'no label'), ('Medical Treatment', 'no label'), ('Working Diagnosis', 'no label'), ('Acs', 'no label'), ('Catecholamines', 'no label'), ('Intraaortic Balloon Pump', 'no label'), ('Patients', 'no label'), ('Died', 'no label'), ('Hospital', 'no label'), ('Ttc Afflicts', 'no label'), ('Women', 'no label'), ('Presents', 'no label'), ('Clinically', 'no label'), ('Acs', 'no label'), ('Hospital Mortality', 'no label'), ('Symptomatic Therapy', 'no label')]|[('±', 'no label'), ('Acs', 'no label'), ('Troponin', 'no label'), ('Acs', 'no label'), ('Catecholamines', 'no label'), ('Acs', 'no label')]|[('St-Segment Elevation ± T-Wave', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Syncope', 'no label'), ('Left Ventricular Regional Wall Motion Abnormality Not Corresponding To A Single Coronary Artery Territory, 4.', 'no label'), ('Angina Pectoris', 'no label'), ('Dyspnoea', 'no label'), ('Syncope', 'no label'), ('Shock', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Acs', 'no label'), ('Left Ventricular Ejection Fraction By Angiography Was Reduced To 49 ± 14 %.', 'no label'), ('Acs', 'no label'), ('Catecholamines', 'no label'), ('Acs', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('Wall', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Syncope (3 %', 'no label'), ('Acs', 'no label'), ('Patients', 'no label'), ('Left Ventricular', 'no label'), ('Acs', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Acs', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21606714|"We Report The Case Of A 68-Year-Old Woman In Whom The Use Of Duloxetine, A Potent Serotonin And Norepinephrine Reuptake Inhibitor, Was Associated With ""Tako-Tsubo"" Cardiomyopathy (Ttc). Although Several Pathophysiological Mechanisms For Ttc Have Been Proposed, Available Evidence Suggests That An Excess Of Catecholamines May Play A Major Role. Our Patient Had A History Of Myocardial Infarction With Normal Coronary Arteries, Probably The First Manifestation Of Ttc. We Speculate That Duloxetine May Have Precipitated Ttc By Increasing Plasma Catecholamine Concentration In A Predisposed Patient."|"[('Report', 'no label'), ('Woman', 'no label'), ('Duloxetine', 'no label'), ('Serotonin', 'no label'), ('Norepinephrine Reuptake Inhibitor', 'no label'), ('Associated With', 'no label'), ('Tako-Tsubo"" Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Pathophysiological', 'no label'), ('Mechanisms', 'no label'), ('Ttc', 'no label'), ('Available Evidence', 'no label'), ('Suggests', 'no label'), ('Excess', 'no label'), ('Catecholamines', 'no label'), ('Play A', 'no label'), ('Patient', 'no label'), ('History', 'no label'), ('Myocardial Infarction', 'no label'), ('Normal Coronary Arteries', 'no label'), ('Manifestation', 'no label'), ('Ttc', 'no label'), ('Speculate', 'no label'), ('Duloxetine', 'no label'), ('May', 'no label'), ('Precipitated Ttc', 'no label'), ('Increasing', 'no label'), ('Plasma', 'no label'), ('Catecholamine Concentration', 'no label'), ('Predisposed', 'no label'), ('Patient', 'no label')]"|[('Duloxetine', 'no label'), ('Serotonin And', 'no label'), ('Norepinephrine', 'no label'), ('Catecholamines', 'no label'), ('Duloxetine', 'no label'), ('Catecholamine', 'no label')]|[]|"[('Duloxetine', 'no label'), ('Serotonin', 'no label'), ('Norepinephrine Reuptake Inhibitor, Was Associated With ""Tako-Tsubo', 'no label'), ('Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Catecholamines', 'no label'), ('Myocardial Infarction', 'no label'), ('Duloxetine', 'no label'), ('Catecholamine', 'no label')]"|[('Case Of A 68-Year-Old Woman', 'no label'), ('Duloxetine', 'no label'), ('Serotonin', 'no label'), ('Norepinephrine Reuptake Inhibitor', 'no label'), ('Catecholamines', 'no label'), ('Patient', 'no label'), ('Myocardial', 'no label'), ('Normal Coronary', 'no label'), ('Duloxetine', 'no label'), ('Plasma Catecholamine', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20418161|"Tako Tsubo Or ""Stress"" Cardiomyopathy And Its Variants Are Well Recognised As Potential Causes Of Acute Coronary Presentations, With Manifestations Including Chest Pain, Cardiac Failure And Arrhythmia. Similarly, Subarachnoid Haemorrhage May Be Associated With Cardiac Abnormalities. Tako Tsubo Cardiomyopathy Is A Diagnosis Of Exclusion With Typical Left Ventricular Dysfunction In The Absence Of Epicardial Coronary Disease, But Importantly Also After Exclusion Of An Intracerebral Insult. We Describe A Case Of Unrecognised Intracerebral Haemorrhage With Left Ventricular Dysfunction Consistent With Both Variant Tako Tsubo Cardiomyopathy And Subarachnoid Haemorrhage In A Patient Treated With Intra-Aortic Balloon Pump Counterpulsation And Associated Heparinisation."|[('Tako Tsubo', 'no label'), ('Cardiomyopathy', 'no label'), ('Variants', 'no label'), ('Recognised', 'no label'), ('Causes', 'no label'), ('Acute Coronary Presentations', 'no label'), ('Manifestations', 'no label'), ('Chest Pain', 'no label'), ('Cardiac Failure', 'no label'), ('Arrhythmia', 'no label'), ('Subarachnoid Haemorrhage', 'no label'), ('Associated With', 'no label'), ('Cardiac Abnormalities', 'no label'), ('Tako Tsubo Cardiomyopathy', 'no label'), ('Diagnosis', 'no label'), ('Typical', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Absence', 'no label'), ('Epicardial Coronary Disease', 'no label'), ('Intracerebral Insult', 'no label'), ('Unrecognised', 'no label'), ('Intracerebral Haemorrhage', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Variant Tako Tsubo Cardiomyopathy', 'no label'), ('Subarachnoid Haemorrhage', 'no label'), ('Patient', 'no label'), ('Treated With', 'no label'), ('Intra-Aortic Balloon Pump', 'no label'), ('Counterpulsation', 'no label'), ('Heparinisation', 'no label')]|[('Variant', 'no label')]|[]|[('Tako', 'no label'), ('Cardiomyopathy', 'no label'), ('Chest Pain', 'no label'), ('Cardiac Failure', 'no label'), ('Subarachnoid Haemorrhage', 'no label'), ('Cardiac Abnormalities', 'no label'), ('Tako', 'no label'), ('Cardiomyopathy', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Epicardial Coronary Disease', 'no label'), ('Intracerebral Insult', 'no label'), ('Intracerebral Haemorrhage', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Tako', 'no label'), ('Cardiomyopathy', 'no label'), ('Subarachnoid Haemorrhage', 'no label')]|[('Acute Coronary', 'no label'), ('Cardiac', 'no label'), ('Subarachnoid', 'no label'), ('Cardiac Abnormalities.', 'no label'), ('Left Ventricular', 'no label'), ('Epicardial Coronary', 'no label'), ('A Case', 'no label'), ('Left Ventricular', 'no label'), ('Subarachnoid', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22285074|Tako-Tsubo Cardiomyopathy (Ttc) Occurs Particularly In Post-Menopausal Women, Being Precipitated In Many Cases By Severe Emotional Stress. We Describe Six Patients In Whom Ttc Occurred In Association With Therapeutic Ingestion Or Overdose Of The Serotonin/Noradrenaline Reuptake Inhibitor Venlafaxine, Or Its Metabolite Desvenlafaxine. Importantly, Two Of The Six Cases Were Not Post-Menopausal Women. An Increased Risk Of Ttc May Account For Some Of The Reported Cardiovascular Adverse Effects Of Venlafaxine And Similar Agents.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Occurs', 'no label'), ('Post-Menopausal', 'no label'), ('Women', 'no label'), ('Being', 'no label'), ('Precipitated', 'no label'), ('Cases', 'no label'), ('Severe', 'no label'), ('Emotional Stress', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Occurred', 'no label'), ('Association', 'no label'), ('Therapeutic Ingestion', 'no label'), ('Overdose', 'no label'), ('Serotonin/Noradrenaline', 'no label'), ('Reuptake Inhibitor', 'no label'), ('Venlafaxine', 'no label'), ('Metabolite', 'no label'), ('Desvenlafaxine', 'no label'), ('Cases', 'no label'), ('Women', 'no label'), ('Increased', 'no label'), ('Risk', 'no label'), ('Ttc', 'no label'), ('Cardiovascular', 'no label'), ('Adverse Effects', 'no label'), ('Venlafaxine', 'no label'), ('Agents', 'no label')]|[('Inhibitor Venlafaxine', 'no label'), ('Desvenlafaxine', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Overdose', 'no label'), ('Venlafaxine', 'no label'), ('Desvenlafaxine', 'no label'), ('Venlafaxine', 'no label')]|[('Patients', 'no label'), ('Serotonin/Noradrenaline Reuptake', 'no label'), ('Venlafaxine', 'no label'), ('Desvenlafaxine', 'no label'), ('Cardiovascular', 'no label'), ('Venlafaxine', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19708132|Tako-Tsubo Cardiomyopathy (Ttc) Is A Recently Described Clinical Condition That May Mimic Acute Myocardial Infarction. The Presence Or New Onset Of Left Bundle Branch Block (Lbbb) Is Associated With Adverse Outcome In Patients With Acute Myocardial Infarction. We Sought To Assess The Incidence, Clinical Profile, And Outcome Of Patients With Ttc And Lbbb At Presentation. From July 2003 To December 2006, 84 Consecutive Patients Met The Diagnostic Criteria For Ttc. Lbbb Was Present In Eight (9%) Patients At Presentation. Patients With Lbbb Tended To Be Older (77 +/- 11 Years Versus 72 +/- 10 Years; P=0.186), And With A More Frequent, But Not Statistically Significant, History Of Hypertension (75 Versus 53%; P=0.227), And Chronic Renal Failure (25 Versus 8%, P=0.117). Moreover, Patients With Lbbb Showed A Higher Peak Creatine Kinase-Mb Value (76 +/- 32 U/I Versus 21 +/- 31 U/I; P=0.005), And A Lower, But Not Significantly, Baseline Left Ventricular Ejection Fraction (30 +/- 13% Versus 36 +/- 9%; P=0.107), As Compared With Patients Without Lbbb. Follow-Up Length Was 12 +/- 10 Months. The Mortality Rate Was Higher In Patients With Lbbb As Compared With Those Without (25 And 3%; P=0.005). However, At Cox Analysis The Only Independent Predictor Of Death Was Age (P=0.042). Lbbb Was Documented At Presentation In 9% Of Ttc Patients. At Long-Term Follow-Up, Ttc Patients With Lbbb Showed Increased Unadjusted Mortality. However, When Adjusted For Age, Baseline Characteristics, And Concomitant Diseases, Lbbb Did Not Appear To Be An Independent Predictor Of Poor Outcome In Patients With Ttc.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Clinical Condition', 'no label'), ('Mimic Acute Myocardial Infarction', 'no label'), ('Presence', 'no label'), ('Left Bundle Branch Block', 'no label'), ('Lbbb', 'no label'), ('Associated With', 'no label'), ('Adverse Outcome', 'no label'), ('Patients', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Assess', 'no label'), ('Incidence', 'no label'), ('Clinical Profile', 'no label'), ('Outcome', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Lbbb', 'no label'), ('Presentation', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Met', 'no label'), ('Diagnostic Criteria', 'no label'), ('Ttc', 'no label'), ('Lbbb', 'no label'), ('Patients', 'no label'), ('Presentation', 'no label'), ('Patients', 'no label'), ('Lbbb', 'no label'), ('Tended', 'no label'), ('Older', 'no label'), ('Years', 'no label'), ('Years', 'no label'), ('Frequent', 'no label'), ('Statistically Significant', 'no label'), ('History', 'no label'), ('Hypertension', 'no label'), ('Chronic Renal Failure', 'no label'), ('Patients', 'no label'), ('Lbbb', 'no label'), ('Higher', 'no label'), ('Peak Creatine Kinase-Mb Value', 'no label'), ('Lower', 'no label'), ('Baseline', 'no label'), ('Left Ventricular Ejection Fraction', 'no label'), ('Patients', 'no label'), ('Lbbb', 'no label'), ('Follow-Up', 'no label'), ('Length', 'no label'), ('Months', 'no label'), ('Mortality Rate', 'no label'), ('Patients', 'no label'), ('Lbbb', 'no label'), ('Cox Analysis', 'no label'), ('Independent Predictor', 'no label'), ('Death', 'no label'), ('Age', 'no label'), ('Lbbb', 'no label'), ('Documented', 'no label'), ('Presentation', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Long-Term Follow-Up', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Lbbb', 'no label'), ('Increased', 'no label'), ('Unadjusted', 'no label'), ('Mortality', 'no label'), ('Adjusted', 'no label'), ('Age', 'no label'), ('Baseline', 'no label'), ('Characteristics', 'no label'), ('Concomitant', 'no label'), ('Diseases', 'no label'), ('Lbbb', 'no label'), ('Independent Predictor', 'no label'), ('Poor Outcome', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label')]|[('Met', 'no label'), ('Lbbb', 'no label'), ('Creatine', 'no label'), ('Cox', 'no label'), ('Lbbb', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Myocardial Infarction', 'no label'), ('Left Bundle Branch Block', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Hypertension', 'no label'), ('Chronic Renal Failure', 'no label'), ('Creatine', 'no label'), ('Death', 'no label')]|[('Myocardial', 'no label'), ('Left Bundle Branch', 'no label'), ('Patients', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Patients', 'no label'), ('Patients Met', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Renal', 'no label'), ('Patients', 'no label'), ('Creatine Kinase-Mb', 'no label'), ('21', 'no label'), ('Left Ventricular', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Ttc Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21413433|The Tako-Tsubo Syndrome Is Characterized By A Transient Left Ventricular Dysfunction In The Absence Of Obstructive Coronary Disease, Typically Precipitated By Severe Emotional Or Physical Stress. It Is Characterized By A Balloon-Like Left Ventricular Appearance On Angiography, Ecg Changes, And Elevated Cardiac Biomarkers. We Describe A Case, Where Tako-Tsubo Cardiomyopathy Was Diagnosed In A Patient With Subarachnoid Haemorrhage. A 57-Year-Old Man Was Brought To The Hospital After Cardiac Arrest And Successful Resuscitation. After Admission, Echocardiography Was Performed That Revealed Marked Impairment Of Contractility Of The Left Ventricle With Akinesis Of The Apex, Interventricular Septum, And Anterior Wall. Subsequent Coronary Angiography Revealed Neither Coronary Pathology Nor Pulmonary Embolism; However, Ventriculography Showed Typical Dynamics Of The Tako-Tsubo Syndrome. Because Of A Deep Cerebral Coma (Gsg 3), A Ct-Scan Was Performed That Revealed Subarachnoid Haemorrhage With A Haemotoma In The Left Temporal Lobe, Together With Symptoms Of Massive Cerebral Oedema. The Patient Died Eight Days Later Despite Vigorous Intensive Care. During The Autopsy, A Ruptured Aneurysm Of The Left Central Cerebral Artery Was Found. The Tako-Tsubo Syndrome May Occur Not Only During Serious Stress But Also After Resuscitation Of Cardiac Arrest Following Cerebral Bleeding.|[('Tako-Tsubo Syndrome', 'no label'), ('Characterized', 'no label'), ('Transient', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Absence', 'no label'), ('Obstructive Coronary Disease', 'no label'), ('Precipitated', 'no label'), ('Severe', 'no label'), ('Emotional Or Physical Stress', 'no label'), ('Characterized', 'no label'), ('Balloon-Like Left Ventricular Appearance', 'no label'), ('Angiography', 'no label'), ('Ecg Changes', 'no label'), ('Elevated', 'no label'), ('Cardiac Biomarkers', 'no label'), ('Case', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Diagnosed', 'no label'), ('Patient', 'no label'), ('Subarachnoid Haemorrhage', 'no label'), ('Hospital', 'no label'), ('Cardiac Arrest', 'no label'), ('Resuscitation', 'no label'), ('Admission', 'no label'), ('Echocardiography', 'no label'), ('Performed', 'no label'), ('Revealed', 'no label'), ('Marked Impairment', 'no label'), ('Contractility', 'no label'), ('Left Ventricle', 'no label'), ('Akinesis', 'no label'), ('Apex', 'no label'), ('Interventricular Septum', 'no label'), ('Anterior Wall', 'no label'), ('Coronary Angiography', 'no label'), ('Revealed', 'no label'), ('Coronary Pathology', 'no label'), ('Pulmonary Embolism', 'no label'), ('Ventriculography', 'no label'), ('Typical Dynamics', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Deep Cerebral Coma', 'no label'), ('Gsg 3', 'no label'), ('Ct-Scan', 'no label'), ('Performed', 'no label'), ('Revealed', 'no label'), ('Subarachnoid Haemorrhage', 'no label'), ('Haemotoma', 'no label'), ('Left Temporal Lobe', 'no label'), ('Symptoms', 'no label'), ('Massive Cerebral Oedema', 'no label'), ('Patient', 'no label'), ('Days', 'no label'), ('Vigorous Intensive Care', 'no label'), ('Autopsy', 'no label'), ('Ruptured', 'no label'), ('Aneurysm', 'no label'), ('Left Central Cerebral Artery', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Occur', 'no label'), ('Serious Stress', 'no label'), ('Resuscitation', 'no label'), ('Cardiac Arrest', 'no label'), ('Cerebral Bleeding', 'no label')]|[('Tako-Tsubo Syndrome', 'no label'), ('Tako-Tsubo', 'no label'), ('Tako-Tsubo Syndrome', 'no label')]|[]|[('Tako-Tsubo Syndrome', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Obstructive Coronary Disease', 'no label'), ('Left Ventricular Appearance On Angiography, Ecg Changes, And Elevated Cardiac Biomarkers', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Subarachnoid Haemorrhage', 'no label'), ('Cardiac Arrest', 'no label'), ('Left Ventricle', 'no label'), ('Interventricular Septum', 'no label'), ('Pulmonary Embolism', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Cerebral Coma', 'no label'), ('Subarachnoid Haemorrhage', 'no label'), ('Haemotoma', 'no label'), ('Cerebral Oedema', 'no label'), ('Aneurysm', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Cardiac Arrest', 'no label'), ('Cerebral Bleeding', 'no label')]|[('Left Ventricular', 'no label'), ('A Balloon-Like Left Ventricular', 'no label'), ('Cardiac', 'no label'), ('A Case', 'no label'), ('Subarachnoid', 'no label'), ('Cardiac', 'no label'), ('Left Ventricle', 'no label'), ('Apex', 'no label'), ('Interventricular Septum', 'no label'), ('Wall', 'no label'), ('Pulmonary', 'no label'), ('A Deep Cerebral Coma', 'no label'), ('Subarachnoid', 'no label'), ('Haemotoma', 'no label'), ('Left Temporal Lobe', 'no label'), ('Cerebral Oedema', 'no label'), ('Patient', 'no label'), ('Left Central', 'no label'), ('Cerebral Artery', 'no label'), ('Cardiac', 'no label'), ('Cerebral', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22975421|Tako-Tsubo Cardiomyopathy (Ttc) Presents With Chest Pain, St-Segment Elevation Followed By T-Wave Inversion And Qt Interval Prolongation (Wellens' Electrocardiographic [Ecg] Pattern), And Left Ventricular Dysfunction, Which May Mimic An Acute Coronary Syndrome. To Assess The Pathophysiologic Basis Of The Wellens' Ecg Pattern In Ttc By Characterization Of Underlying Myocardial Changes By Using Cardiac Magnetic Resonance (Cmr). The Study Population Included 20 Consecutive Patients With Ttc (95% Women; Mean Age 65.3 ± 10.4 Years) Who Underwent Cmr Studies Both In The Initial Phase And After 3-Month Follow-Up By Using A Protocol That Included Cine Images, T2-Weighted Sequences For Myocardial Edema, And Post-Contrast Sequences For Late Gadolinium Enhancement. Quantitative Ecg Indices Of Repolarization, Such As Maximal Amplitude Of Negative T Waves, Sum Of The Amplitudes Of Negative T Waves, And Maximum Corrected Qt Interval (Qtc Max), Were Correlated To Cmr Findings. At The Time Of Initial Cmr Study, There Was A Significant Linear Correlation Between The Apicobasal Ratio Of T2-Weighted Signal Intensity For Myocardial Edema And The Maximal Amplitude Of Negative T Waves (Ρ = 0.498; P = .02), Sum Of The Amplitudes Of Negative T Waves (Ρ = 0.483; P = .03), And Maximum Corrected Qt Interval (Ρ = 0.520; P = .02). Repolarization Indices Were Unrelated To Either Late Gadolinium Enhancement Or Quantitative Cine Parameters. Wellens' Ecg Abnormalities And Myocardial Edema Showed A Parallel Time Course Of Development And Resolution On Initial And Follow-Up Cmr Studies. Our Study Results Show That The Ischemic-Like Wellens' Ecg Pattern In Ttc Coincides And Quantitatively Correlates With The Apicobasal Gradient Of Myocardial Edema As Evidenced By Using Cmr. Dynamic Negative T Waves And Qtc Prolongation Are Likely To Reflect The Edema-Induced Transient Inhomogeneity And Dispersion Of Repolarization Between Apical And Basal Left Ventricular Regions.|"[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Chest Pain', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('T-Wave Inversion', 'no label'), ('Qt Interval', 'no label'), (""Wellens'"", 'no label'), ('Pattern', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Mimic', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Pathophysiologic', 'no label'), (""Wellens'"", 'no label'), ('Ecg Pattern', 'no label'), ('Ttc', 'no label'), ('Characterization', 'no label'), ('Myocardial', 'no label'), ('Changes', 'no label'), ('Cardiac Magnetic Resonance', 'no label'), ('Cmr', 'no label'), ('Study Population', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Women', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Cmr Studies', 'no label'), ('Initial', 'no label'), ('Phase', 'no label'), ('3-Month Follow-Up', 'no label'), ('Protocol', 'no label'), ('Cine Images', 'no label'), ('T2-Weighted Sequences', 'no label'), ('Myocardial Edema', 'no label'), ('Post-Contrast Sequences', 'no label'), ('Late Gadolinium Enhancement', 'no label'), ('Quantitative Ecg Indices', 'no label'), ('Repolarization', 'no label'), ('Maximal', 'no label'), ('Amplitude', 'no label'), ('T Waves', 'no label'), ('Sum', 'no label'), ('Amplitudes', 'no label'), ('Negative', 'no label'), ('T Waves', 'no label'), ('Maximum', 'no label'), ('Corrected Qt Interval', 'no label'), ('Qtc Max', 'no label'), ('Cmr', 'no label'), ('Findings', 'no label'), ('Cmr Study', 'no label'), ('Significant', 'no label'), ('Linear Correlation', 'no label'), ('Apicobasal Ratio', 'no label'), ('T2-Weighted Signal Intensity', 'no label'), ('Myocardial Edema', 'no label'), ('Maximal Amplitude', 'no label'), ('T Waves', 'no label'), ('Sum', 'no label'), ('Amplitudes', 'no label'), ('T Waves', 'no label'), ('Maximum', 'no label'), ('Corrected Qt Interval', 'no label'), ('Repolarization Indices', 'no label'), ('Unrelated', 'no label'), ('Late Gadolinium Enhancement', 'no label'), ('Quantitative Cine Parameters', 'no label'), (""Wellens'"", 'no label'), ('Ecg Abnormalities', 'no label'), ('Myocardial Edema', 'no label'), ('Parallel Time Course', 'no label'), ('Development', 'no label'), ('Resolution', 'no label'), ('Initial', 'no label'), ('Follow-Up', 'no label'), ('Cmr Studies', 'no label'), ('Study Results', 'no label'), (""Ischemic-Like Wellens' Ecg Pattern"", 'no label'), ('Ttc', 'no label'), ('Coincides', 'no label'), ('Quantitatively', 'no label'), ('Correlates', 'no label'), ('Apicobasal', 'no label'), ('Gradient', 'no label'), ('Myocardial Edema', 'no label'), ('Cmr', 'no label'), ('Dynamic Negative T Waves', 'no label'), ('Qtc', 'no label'), ('Prolongation', 'no label'), ('Edema-Induced Transient Inhomogeneity', 'no label'), ('Dispersion', 'no label'), ('Repolarization', 'no label'), ('Apical', 'no label'), ('Basal Left Ventricular Regions', 'no label')]"|[('Cmr', 'no label'), ('Cmr', 'no label'), ('Sequences', 'no label'), ('Sequences', 'no label'), ('Cmr', 'no label'), ('Cmr', 'no label')]|[('T2-Weighted Sequences', 'no label')]|"[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Chest Pain', 'no label'), (""Wellens' Electrocardiographic [Ecg] Pattern)"", 'no label'), ('Ventricular Dysfunction', 'no label'), ('Acute Coronary Syndrome', 'no label'), (""Wellens' Ecg Pattern In Ttc By Characterization Of Underlying Myocardial Changes By Using Cardiac Magnetic Resonance (Cmr)"", 'no label'), ('Myocardial Edema', 'no label'), ('Myocardial Edema', 'no label'), (""Wellens' Ecg Abnormalities"", 'no label'), ('Myocardial Edema', 'no label'), (""Wellens' Ecg Pattern In Ttc"", 'no label'), ('Myocardial Edema', 'no label')]"|[('T-Wave', 'no label'), ('Left Ventricular', 'no label'), ('Myocardial', 'no label'), ('Cardiac', 'no label'), ('Patients', 'no label'), ('Ttc (95', 'no label'), ('Women', 'no label'), ('Myocardial Edema', 'no label'), ('T2-Weighted Signal', 'no label'), ('Myocardial Edema', 'no label'), ('Ecg', 'no label'), ('Myocardial Edema', 'no label'), ('Myocardial Edema', 'no label'), ('Apical', 'no label'), ('Basal Left Ventricular', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19681838|We Report A Possible New Therapeutic Strategy, Using Extracorporeal Cardiopulmonary Support (Ecls), For Severe Refractory Cardiogenic Shock (Srcs) In A Patient With Tako-Tsubo Cardiomyopathy (Tc). Tc Is A Syndrome Characterized By Left Ventricular Wall Motion Abnormalities, Without Coronary Artery Disease, Mimicking The Diagnosis Of Acute Coronary Syndrome. This Ventricular Dysfunction Can Be Reversible; However, It Can Progress Into Refractory Cardiogenic Shock With Limited Therapeutic Options Available. For The First Time In A Tako-Tsubo Patient With Refractory Cardiogenic Shock, We Used Ecls Treatment In Order To Rest The Heart, Sustain Circulation And End-Organ Perfusion, And Promote Potential Ventricular Recovery. Ecls Might Be The Selected Treatment For Srcs In Patients With Tc, And Seems To Be An Effective And Useful Ultimate Therapeutic Strategy For Preventing Death.|[('Report', 'no label'), ('Therapeutic Strategy', 'no label'), ('Extracorporeal Cardiopulmonary Support', 'no label'), ('Ecls', 'no label'), ('Severe', 'no label'), ('Cardiogenic Shock', 'no label'), ('Srcs', 'no label'), ('Patient', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tc', 'no label'), ('Tc', 'no label'), ('Syndrome', 'no label'), ('Characterized', 'no label'), ('Left Ventricular Wall Motion Abnormalities', 'no label'), ('Coronary Artery Disease', 'no label'), ('Mimicking', 'no label'), ('Diagnosis', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Reversible', 'no label'), ('Progress', 'no label'), ('Refractory', 'no label'), ('Cardiogenic Shock', 'no label'), ('Therapeutic Options', 'no label'), ('Available', 'no label'), ('First Time', 'no label'), ('Tako-Tsubo Patient', 'no label'), ('Refractory', 'no label'), ('Cardiogenic Shock', 'no label'), ('Ecls Treatment', 'no label'), ('Order', 'no label'), ('Heart', 'no label'), ('Sustain Circulation', 'no label'), ('End-Organ', 'no label'), ('Perfusion', 'no label'), ('Promote', 'no label'), ('Potential', 'no label'), ('Ventricular Recovery', 'no label'), ('Ecls', 'no label'), ('Treatment', 'no label'), ('Srcs', 'no label'), ('Patients', 'no label'), ('Tc', 'no label'), ('Effective', 'no label'), ('Therapeutic Strategy', 'no label'), ('Preventing Death', 'no label')]|[('Tc', 'no label')]|[]|[('Cardiogenic Shock', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricular Wall Motion Abnormalities, Without Coronary Artery Disease', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Cardiogenic Shock', 'no label'), ('Tako-Tsubo', 'no label'), ('Cardiogenic Shock', 'no label'), ('Death', 'no label')]|[('Left Ventricular Wall', 'no label'), ('Coronary Artery', 'no label'), ('Acute Coronary', 'no label'), ('Ventricular', 'no label'), ('Heart', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19217178|We Report A Case Of Tako-Tsubo Cardiomyopathy (Ttc) Occurring After Colonoscopy. A 60-Year-Old Post Menopausal Female With Syncope Following An Acute Abdominal Syndrome Underwent Diagnostic Colonoscopy. Anginal Chest Pain With Marked St Segment Elevation Occurred The Day Following The Procedure. Coronary Angiogram Was Entirely Normal, But Left Ventriculography Showed Marked Reduction In Systolic Function Along With Mid Ventricular And Apical Akinesis. The Patient'S Symptoms Completely Improved With Eventual Normalization Of Ventricular Function. The Occurrence In This Patient Of Initial Vagal Syndrome Followed By Sympathetic Stimulation Preceding Ttc Is Compared To Prior Reports With Similar Provocateurs And Implications For Pathogenesis Discussed.|"[('Report', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Occurring', 'no label'), ('Colonoscopy', 'no label'), ('60-Year-Old', 'no label'), ('Post', 'no label'), ('Menopausal', 'no label'), ('Female', 'no label'), ('Syncope', 'no label'), ('Acute Abdominal Syndrome Underwent Diagnostic', 'no label'), ('Colonoscopy', 'no label'), ('Anginal Chest Pain', 'no label'), ('St Segment Elevation', 'no label'), ('Day', 'no label'), ('Procedure', 'no label'), ('Coronary Angiogram', 'no label'), ('Normal', 'no label'), ('Left Ventriculography', 'no label'), ('Reduction', 'no label'), ('Systolic Function', 'no label'), ('Mid Ventricular', 'no label'), ('Apical Akinesis', 'no label'), (""Patient'S"", 'no label'), ('Symptoms', 'no label'), ('Completely', 'no label'), ('Improved', 'no label'), ('Eventual', 'no label'), ('Normalization', 'no label'), ('Ventricular Function', 'no label'), ('Patient', 'no label'), ('Initial', 'no label'), ('Vagal Syndrome', 'no label'), ('Followed', 'no label'), ('Sympathetic Stimulation', 'no label'), ('Ttc', 'no label'), ('Reports', 'no label'), ('Provocateurs', 'no label'), ('Pathogenesis', 'no label')]"|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Syncope', 'no label'), ('Acute Abdominal Syndrome', 'no label'), ('Chest Pain', 'no label'), ('Ventricular Function', 'no label'), ('Pathogenesis', 'no label')]|[('Syncope', 'no label'), ('Patient', 'no label'), ('Ventricular', 'no label'), ('Patient', 'no label'), ('Vagal', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23083536|There Have Been Few Data To Review And Analyze The Temporal Preference Of The Onset Of Tako-Tsubo Cardiomyopathy (Ttc). Aim Of This Study Was To Investigate Chronobiological Variations In The Occurrence Of Ttc And Changes Of These Variations According To Age And Gender. One Hundred And Thirty-Seven Patients Were Enrolled From Our Ttc Registry Database From January 2004 To December 2010 In Korea. The Median Age Of The Entire Study Population Was 59 Years (Inter-Quartile Range 53-72 Years). The Majority Of Patients Were Women (N = 101, 74%). The Onset Of Ttc Differed As A Function Of Season (P = .001), With The Peak In July And The Nadir In March. Events Were Most Frequent In Summer (N = 53%, 38.7%) And Least So In Winter (N = 26, 19%, Chi-Square = 13.92, P = .003). Ttc Was Most Frequent In The Morning (N = 56, 40.9%) And Least So At Night (N = 22, 16.1%, Chi-Square = 21.98, P = .001). Also, Ttc Was Most Frequent On Monday (N = 34, 24.8%) And Least So On Saturday (N = 7, 5.1%, Chi-Square = 30.44, P = .001). Stressor Pattern, Age And Gender Do Not Influence These Increases Of Occurrence In Summer, On Monday, And In The Morning Of Ttc. Ttc Seems To Exhibit A Temporal Variation Of Occurrence With Preferred Peaks During Morning, Monday, And Summer. Stressor Pattern, Age And Gender Do Not Influence These Temporal Patterns Of The Occurrence Of Ttc. Further Studies Are Needed To Investigate The Potential Link Between Chronobiological Variations Of Ttc Onset And Underlying Pathophysiologic Mechanisms.|[('Data', 'no label'), ('Review', 'no label'), ('Analyze', 'no label'), ('Temporal', 'no label'), ('Preference', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Study', 'no label'), ('Investigate', 'no label'), ('Chronobiological Variations', 'no label'), ('Ttc', 'no label'), ('Changes', 'no label'), ('Variations', 'no label'), ('Age', 'no label'), ('Gender', 'no label'), ('Thirty-Seven Patients', 'no label'), ('Ttc Registry Database', 'no label'), ('Korea', 'no label'), ('Median Age', 'no label'), ('Entire Study', 'no label'), ('Years', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Ttc', 'no label'), ('Differed', 'no label'), ('Function', 'no label'), ('Season', 'no label'), ('Nadir', 'no label'), ('Events', 'no label'), ('Frequent', 'no label'), ('Summer', 'no label'), ('Winter', 'no label'), ('Chi-Square\xa0', 'no label'), ('Ttc', 'no label'), ('Frequent', 'no label'), ('Morning', 'no label'), ('Night', 'no label'), ('Chi-Square\xa0', 'no label'), ('Ttc', 'no label'), ('Frequent', 'no label'), ('Monday', 'no label'), ('Saturday', 'no label'), ('N\xa0', 'no label'), ('Chi-Square\xa0', 'no label'), ('Stressor', 'no label'), ('Pattern', 'no label'), ('Age', 'no label'), ('Gender', 'no label'), ('Do Not', 'no label'), ('Influence', 'no label'), ('Increases', 'no label'), ('Summer', 'no label'), ('Monday', 'no label'), ('Morning', 'no label'), ('Ttc', 'no label'), ('Ttc', 'no label'), ('Exhibit', 'no label'), ('Temporal', 'no label'), ('Variation', 'no label'), ('Preferred Peaks', 'no label'), ('Morning', 'no label'), ('Monday', 'no label'), ('Summer', 'no label'), ('Stressor', 'no label'), ('Pattern', 'no label'), ('Age', 'no label'), ('Gender', 'no label'), ('Do Not', 'no label'), ('Influence', 'no label'), ('Temporal Patterns', 'no label'), ('Ttc', 'no label'), ('Studies', 'no label'), ('Investigate', 'no label'), ('Potential', 'no label'), ('Link', 'no label'), ('Chronobiological Variations', 'no label'), ('Ttc', 'no label'), ('Pathophysiologic', 'no label'), ('Mechanisms', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('N\xa0=\xa0101, 74%', 'no label'), ('N\xa0=\xa0', 'no label'), ('N\xa0=\xa0', 'no label'), ('N\xa0=\xa0', 'no label'), ('N\xa0=\xa07, 5.1%, Chi-Square\xa0=\xa030.44, P\xa0=\xa0.001)', 'no label')]|[('Patients', 'no label'), ('Entire', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Link', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22651882|Tako-Tsubo Cardiomyopathy (Ttc) Is An Acute Reversible Cardiac Condition Usually Triggered By Stressful Events, With A Predilection For Older Women And Clinical Presentation Often Confused With Acute Coronary Syndrome. Definition Of The Diurnal Hourly Pattern Of Ttc Events May Contribute To Understanding The Pathogenesis Of This Complex Entity. We Prospectively Enrolled 186 Consecutive Patients With Ttc (68 ± 14 Years Old, 95% Women) And, For Comparison, 2,975 Patients With St-Segment Elevation Myocardial Infarction (Stemi) At The Minneapolis Heart Institute Over The Same Period. Circadian Periodicity Was Analyzed For Hourly Occurrence Of Events Throughout The Day And For Days Of The Week And Months Of The Year. Occurrence Of Ttc Showed A Nonuniform Distribution With A Distinctive Afternoon Peak From 12:00 (Noon) To 4:00 P.M., Comprising 28% (N = 52) Of All Events, And With The Nadir At 12 To 4 A.M. (Chi-Square 25.6, P <0.001). Patients With Events Within The Peak Were Older (73 ± 13 Years) Than Other Patients (66 ± 13 Years, P = 0.0025). Events Were Uniformly Distributed Over Days Of The Week And Months (P = 0.2 And 0.47, Respectively). In Contrast, Patients With Stemi Showed Peak Occurrence In The Early Morning Hours, 8:00 A.M. To 12:00 P.M., Comprising 24% Of All Events (Chi-Square 248, P <0.001). In Conclusion, Ttc Events Occurred In A Circadian Pattern With A Peak In The Afternoon Hours, Distinctive From The Predilection Of Stemi For Morning Hours. This Timing Of Ttc Events Is Most Consistent With Mechanisms Underlying Stressful Life Situations That Usually Trigger This Condition.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Acute Reversible Cardiac Condition', 'no label'), ('Triggered By Stressful Events', 'no label'), ('Predilection', 'no label'), ('Older Women', 'no label'), ('Clinical Presentation', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Definition', 'no label'), ('Diurnal', 'no label'), ('Hourly', 'no label'), ('Pattern', 'no label'), ('Ttc', 'no label'), ('Contribute', 'no label'), ('Pathogenesis', 'no label'), ('Complex', 'no label'), ('Entity', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Years Old', 'no label'), ('Women', 'no label'), ('Comparison', 'no label'), ('Patients', 'no label'), ('St-Segment', 'no label'), ('Elevation Myocardial Infarction', 'no label'), ('Stemi', 'no label'), ('Minneapolis Heart Institute', 'no label'), ('Period', 'no label'), ('Circadian Periodicity', 'no label'), ('Analyzed', 'no label'), ('Hourly', 'no label'), ('Events', 'no label'), ('Day', 'no label'), ('Days', 'no label'), ('Week', 'no label'), ('Months', 'no label'), ('Year', 'no label'), ('Ttc', 'no label'), ('Nonuniform', 'no label'), ('Distribution', 'no label'), ('Distinctive Afternoon', 'no label'), ('Peak', 'no label'), ('Comprising', 'no label'), ('Events', 'no label'), ('Nadir', 'no label'), ('Chi-Square', 'no label'), ('Patients', 'no label'), ('Events', 'no label'), ('Peak Were Older', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Years', 'no label'), ('Events', 'no label'), ('Uniformly Distributed', 'no label'), ('Days', 'no label'), ('Week', 'no label'), ('Months', 'no label'), ('Contrast', 'no label'), ('Patients', 'no label'), ('Stemi', 'no label'), ('Occurrence', 'no label'), ('Early Morning', 'no label'), ('Comprising', 'no label'), ('Events', 'no label'), ('Ttc', 'no label'), ('Occurred', 'no label'), ('Circadian', 'no label'), ('Afternoon Hours', 'no label'), ('Predilection', 'no label'), ('Stemi', 'no label'), ('Timing', 'no label'), ('Ttc', 'no label'), ('Events', 'no label'), ('Consistent With', 'no label'), ('Mechanisms', 'no label'), ('Stressful Life Situations', 'no label'), ('Trigger', 'no label'), ('Condition', 'no label')]|[('±', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Myocardial Infarction', 'no label')]|[('Cardiac', 'no label'), ('Women', 'no label'), ('Acute Coronary', 'no label'), ('Complex', 'no label'), ('Patients', 'no label'), ('Ttc (68 ± 14', 'no label'), ('Patients', 'no label'), ('Myocardial', 'no label'), ('Heart', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~24276117||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~29771705|"""Tako-Tsubo"" Cardiomyopathy, Also Known As ""Broken Heart Syndrome,"" Is One Of The Rarest Types Of Stress-Induced Cardiomyopathy. It Frequently Mimics Acute Coronary Syndrome, Characterized By Transient Left Ventricular Dysfunction, Electrocardiographic Changes, And Release Of Myocardial Enzymes. After Treatment, The Patients Are Cured In Most Cases Without Sequelae. Tako-Tsubo Syndrome Is Rarely Considered As A Reason For Consultation In The Forensic Department.Herein, We Report A Case Of A 68-Year-Old Woman Who Was Assaulted By Her Police Officer Neighbor. The Latter Punched Her In The Arms And Kneed Her In The Gut Without Causing Any Intrathoracic Or Abdominal Injury. The Victim Was Urgently Hospitalized In The Cardiology Department For Chest Pain And Dyspnea Accompanied By St-Segment Elevation And High Troponin Level.Tako-Tsubo Cardiomyopathy Diagnosis Was Based On Clinical Findings, Echocardiography, Coronary Angiography, And Magnetic Resonance Imaging Findings. A Forensic Medicine Consult Was Initially Solicited For The Drafting Of An Initial Medical Certificate And For Evaluating The Total Transitory Disability Rate. A Second Consultation Was Then Sought To Evaluate The Permanent Partial Disability.We Report This Work To Discuss The Conduct Of The Forensic Pathologist And To Prove The Causality Relationship Between The Assault And The Physical Injuries."|[('Cardiomyopathy', 'no label'), ('Broken Heart Syndrome', 'no label'), ('Rarest', 'no label'), ('Stress-Induced Cardiomyopathy', 'no label'), ('Mimics', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Characterized', 'no label'), ('Transient', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Electrocardiographic Changes', 'no label'), ('Release', 'no label'), ('Myocardial Enzymes', 'no label'), ('Treatment', 'no label'), ('Patients', 'no label'), ('Cured', 'no label'), ('Cases', 'no label'), ('Sequelae', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Reason', 'no label'), ('Consultation', 'no label'), ('Forensic Department', 'no label'), ('Report', 'no label'), ('Was Assaulted', 'no label'), ('Police Officer', 'no label'), ('Neighbor', 'no label'), ('Latter Punched', 'no label'), ('Kneed', 'no label'), ('Gut', 'no label'), ('Causing', 'no label'), ('Intrathoracic', 'no label'), ('Abdominal Injury', 'no label'), ('Victim Was Urgently', 'no label'), ('Hospitalized', 'no label'), ('Cardiology Department', 'no label'), ('Dyspnea', 'no label'), ('Accompanied', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('High', 'no label'), ('Troponin', 'no label'), ('Level', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Diagnosis', 'no label'), ('Clinical Findings', 'no label'), ('Echocardiography', 'no label'), ('Coronary Angiography', 'no label'), ('Magnetic Resonance Imaging', 'no label'), ('Findings', 'no label'), ('Forensic Medicine Consult', 'no label'), ('Solicited', 'no label'), ('Drafting', 'no label'), ('Initial', 'no label'), ('Medical Certificate', 'no label'), ('Evaluating', 'no label'), ('Total Transitory Disability Rate', 'no label'), ('Consultation', 'no label'), ('Evaluate', 'no label'), ('Permanent Partial Disability', 'no label'), ('Work', 'no label'), ('Conduct', 'no label'), ('Forensic Pathologist', 'no label'), ('Causality', 'no label'), ('Relationship', 'no label'), ('Assault', 'no label'), ('Physical Injuries', 'no label')]|[('Troponin', 'no label')]|[]|[('Cardiomyopathy', 'no label'), ('Heart Syndrome', 'no label'), ('Cardiomyopathy', 'no label'), ('Coronary Syndrome', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Abdominal Injury', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Transitory Disability Rate. A Second Consultation Was Then Sought To Evaluate The Permanent Partial Disability', 'no label')]|[('Broken Heart', 'no label'), ('Acute Coronary', 'no label'), ('Left Ventricular', 'no label'), ('Myocardial', 'no label'), ('Patients', 'no label'), ('Troponin', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23042318|Tako-Tsubo Cardiomyopathy, Known Since 1990, Is Described As Hypo/Akinesis Of Apical Heart Segments With The Hyperkinesis Of The Basis Of The Heart Which Mimics The Shape Of A Traditional Japanese Octopus Trap.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Hypo/Akinesis', 'no label'), ('Apical Heart Segments', 'no label'), ('Hyperkinesis', 'no label'), ('Heart Which Mimics', 'no label'), ('Shape', 'no label'), ('Traditional', 'no label'), ('Japanese', 'no label'), ('Octopus Trap', 'no label')]|[('Apical', 'no label'), ('Trap', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Hypo/Akinesis', 'no label')]|[('Heart', 'no label'), ('Heart', 'no label'), ('Trap', 'no label')]
tako-tsubo cardiomyopathy|pubmed~25555558||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~20455042|Tako-Tsubo Cardiomyopathy Is Characterized By A Transient And Reversible Left Ventricular Dysfunction And Shows Clinical Similarities With The Acute Coronary Syndrome. Here, The Authors Report And Discuss A Case Of A Patient With Tako-Tsubo Cardiomyopathy Triggered By Adrenaline Injection After A Wasp Sting.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Characterized', 'no label'), ('Transient', 'no label'), ('Reversible', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Shows Clinical', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Report', 'no label'), ('Discuss A', 'no label'), ('Patient', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Triggered', 'no label'), ('Adrenaline Injection', 'no label'), ('Wasp Sting', 'no label')]|[('Adrenaline', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Adrenaline', 'no label')]|[('Acute Coronary', 'no label'), ('Patient', 'no label'), ('Adrenaline', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21965053|To Assess Left Ventricular (Lv) Twist Mechanics In Patients With Tako-Tsubo Cardiomyopathy (Ttc). Two-Dimensional Strain And Lv Twist By Speckle-Tracking Echocardiography Was Performed In 17 Consecutive Patients With Typical Ttc According To The Mayo Clinic Criteria [78 ± 8 Years, 88% Women, And Mean Left Ventricular Ejection Fraction (Lvef) 45 ± 10%], At The Acute Phase (Within 24 H After Admission) And After Recovery (1 Month Later). Seventeen Control (C) Patients Matched For Age And Sex (Mean Lvef 70 ± 7%), And 17 Patients With Acute Anterior Myocardial Infarction (Mi) Treated By Successful Primary Angioplasty 24 H Before, Matched For Lvef, Age, And Sex, Were Compared With Ttc Patients. Lv Twist Was Assessed Using The Parasternal Basal And Apical Short-Axis Planes, And Defined As The Net Difference In Degrees Of Apical (Ar) And Basal Rotation (Br). Peak Systolic And Early Diastolic, Apical (As And Ad) And Basal (Bs And Bd) Rotation Rate, And Lv Twisting Rate (Tr) And Untwisting Rate (Ur) (In °/S) Were Derived From Rotational And Twist Curves. The Time Sequences Were Normalized To The Percentage Of Systolic Duration. At The Acute Phase, Ar, As, Ad, Bs, Lv Twist (10 ± 9° Vs. 23 ± 6°), Lv Tr, And Lv Ur Were Significantly Impaired In Patients With Ttc When Compared With Controls (All, P < 0.05). Patients With Mi Displayed Intermediate Values (P = Ns Vs. Ttc, And P < 0.05 Vs. C). However, In The Subgroup Of Patients With Electrocardiogram St-Segment Elevation At Presentation (N = 12 Ttc And 17 Mi), Several Lv Twist Mechanics Parameters Were Significantly Reduced In Ttc Patients When Compared With Mi Patients, Lv Twist, And Lv Tr Being The Most Significant Factors (All, P≤ 0.01). Abnormal Reversed Ar (Clockwise When Seen From The Apex) Was Seen In Three Patients (18%) With Ttc Vs. None In The Other Groups. A Significant Correlation Between Lv Twist And Lvef, Lv Volumes, Wall Motion Score Index, And Plasma Nt-Pro Bnp Was Observed In The Ttc Group (All, P < 0.05). At Follow-Up, Lv Twist Mechanics Improved Significantly In Ttc Patients (All, P < 0.05 Vs. Acute Phase), Who Had Final Values Similar To C (All, P = Ns), Whereas The Magnitude Of Improvement Was Lower In Mi Patients (P ≤ 0.05 Vs. Ttc). Lv Twist Mechanics Is Significantly Impaired In Patients With Ttc Mainly Due To A Severe Reduction In Apical Function And Is Entirely Reversible. Furthermore, In The Subgroup Of Patients With St-Segment Elevation, The Early Post-Admission Evaluation Of Lv Twist Mechanics Is More Severely Impaired In Ttc When Compared With Mi.|[('Assess', 'no label'), ('Left Ventricular (Lv) Twist', 'no label'), ('Mechanics', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Two-Dimensional Strain And Lv Twist By Speckle-Tracking Echocardiography', 'no label'), ('Performed', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Typical Ttc', 'no label'), ('Mayo Clinic Criteria', 'no label'), ('Years', 'no label'), ('Women', 'no label'), ('Mean', 'no label'), ('Left Ventricular Ejection Fraction', 'no label'), ('Lvef', 'no label'), ('Acute Phase', 'no label'), ('Admission', 'no label'), ('Recovery', 'no label'), ('Month', 'no label'), ('Control (C) Patients', 'no label'), ('Age', 'no label'), ('Sex', 'no label'), ('Patients', 'no label'), ('Acute Anterior Myocardial Infarction', 'no label'), ('Treated', 'no label'), ('Primary Angioplasty', 'no label'), ('Matched', 'no label'), ('Lvef', 'no label'), ('Age', 'no label'), ('Sex', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Assessed', 'no label'), ('Parasternal Basal', 'no label'), ('Apical Short-Axis Planes', 'no label'), ('Difference', 'no label'), ('Degrees', 'no label'), ('Apical (Ar)', 'no label'), ('Basal Rotation', 'no label'), ('Br', 'no label'), ('Peak Systolic', 'no label'), ('Early Diastolic', 'no label'), ('Apical', 'no label'), ('Ad', 'no label'), ('Basal', 'no label'), ('Rotation Rate', 'no label'), ('Lv Twisting Rate', 'no label'), ('Tr', 'no label'), ('Untwisting Rate', 'no label'), ('Rotational', 'no label'), ('Twist Curves', 'no label'), ('Time Sequences', 'no label'), ('Percentage', 'no label'), ('Systolic Duration', 'no label'), ('Acute Phase', 'no label'), ('Ar', 'no label'), ('Ad', 'no label'), ('Bs', 'no label'), ('Lv Twist', 'no label'), ('Lv Tr', 'no label'), ('Lv Ur', 'no label'), ('Impaired', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Controls', 'no label'), ('Patients', 'no label'), ('Intermediate Values', 'no label'), ('Ttc', 'no label'), ('Subgroup', 'no label'), ('Patients', 'no label'), ('Electrocardiogram St-Segment', 'no label'), ('Elevation', 'no label'), ('Presentation', 'no label'), ('Ttc', 'no label'), ('Twist', 'no label'), ('Mechanics Parameters', 'no label'), ('Reduced', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Mi', 'no label'), ('Patients', 'no label'), ('Lv Twist', 'no label'), ('Lv Tr Being', 'no label'), ('Significant', 'no label'), ('Factors', 'no label'), ('Abnormal Reversed Ar', 'no label'), ('Apex', 'no label'), ('Patients', 'no label'), ('Ttc Vs', 'no label'), ('Groups', 'no label'), ('Correlation', 'no label'), ('Lv Twist And Lvef, Lv Volumes', 'no label'), ('Wall Motion Score Index', 'no label'), ('Plasma', 'no label'), ('Nt-Pro', 'no label'), ('Bnp', 'no label'), ('Observed', 'no label'), ('Ttc Group', 'no label'), ('Follow-Up', 'no label'), ('Lv Twist Mechanics', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Acute Phase', 'no label'), ('Final Values', 'no label'), ('Magnitude', 'no label'), ('Improvement', 'no label'), ('Mi', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Twist', 'no label'), ('Mechanics', 'no label'), ('Impaired', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Severe', 'no label'), ('Reduction', 'no label'), ('Apical Function', 'no label'), ('Reversible', 'no label'), ('Subgroup', 'no label'), ('Patients', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Early Post-Admission', 'no label'), ('Evaluation', 'no label'), ('Lv Twist Mechanics', 'no label'), ('Severely Impaired', 'no label'), ('Ttc', 'no label'), ('Mi', 'no label')]|[('Twist', 'no label'), ('Twist', 'no label'), ('±', 'no label'), ('±', 'no label'), ('Twist', 'no label'), ('Ar', 'no label'), ('Twist', 'no label'), ('Sequences', 'no label'), ('Ar', 'no label'), ('Twist', 'no label'), ('±', 'no label'), ('±', 'no label'), ('Twist', 'no label'), ('Twist', 'no label'), ('Ar', 'no label'), ('Twist', 'no label'), ('Bnp', 'no label'), ('Twist', 'no label'), ('Twist', 'no label'), ('Apical', 'no label'), ('Twist', 'no label')]|[('Sex', 'no label'), ('Twist', 'no label')]|[('Left Ventricular (Lv) Twist Mechanics In Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Acute Anterior Myocardial Infarction', 'no label'), ('≤', 'no label')]|[('Left Ventricular', 'no label'), ('Patients', 'no label'), ('Lv Twist', 'no label'), ('Patients', 'no label'), ('Acute Phase', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Acute Anterior Myocardial Infarction', 'no label'), ('Patients', 'no label'), ('Twist', 'no label'), ('Parasternal Basal', 'no label'), ('Apical', 'no label'), ('Bs', 'no label'), ('Lv', 'no label'), ('Twist', 'no label'), ('Ad', 'no label'), ('Bs', 'no label'), ('Lv Twist', 'no label'), ('Lv Tr', 'no label'), ('Lv Ur', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Electrocardiogram St-Segment', 'no label'), ('Lv Twist', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lv Twist', 'no label'), ('Lv Tr', 'no label'), ('P≤', 'no label'), ('Patients', 'no label'), ('Lv Twist', 'no label'), ('Lv Volumes', 'no label'), ('Wall', 'no label'), ('Plasma Nt-Pro', 'no label'), ('Bnp', 'no label'), ('Lv Twist', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Twist', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lv Twist', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20117439|This Study Was Designed To Define More Completely The Clinical Spectrum And Consequences Of Stress Cardiomyopathy (Sc) Beyond The Acute Event. Stress Cardiomyopathy Is A Recently Recognized Condition Characterized By Transient Cardiac Dysfunction With Ventricular Ballooning. Clinical Profile And Outcome Were Prospectively Assessed In 136 Consecutive Sc Patients. Patients Were Predominantly Women (N = 130; 96%), But 6 Were Men (4%). Ages Were 32 To 94 Years (Mean Age 68 +/- 13 Years); 13 (10%) Were <Or=50 Years Of Age. In 121 Patients (89%), Sc Was Precipitated By Intensely Stressful Emotional (N = 64) Or Physical (N = 57) Events, Including 22 Associated With Sympathomimetic Drugs Or Medical/Surgical Procedures; 15 Other Patients (11%) Had No Evident Stress Trigger. Twenty-Five Patients (18%) Were Taking Beta-Blockers At The Time Of Sc Events. Three Diverse Ventricular Contraction Patterns Were Defined By Cardiovascular Magnetic Resonance (Cmr) Imaging, Usually With Rapid Return To Normal Systolic Function, Although Delayed >2 Months In 5%. Right And/Or Left Ventricular Thrombi Were Identified In 5 Patients (Predominantly By Cmr Imaging), Including 2 With Embolic Events. Three Patients (2%) Died In-Hospital And 116 (85%) Have Survived, Including 5% With Nonfatal Recurrent Sc Events. All-Cause Mortality During Follow-Up Exceeded A Matched General Population (P = 0.016) With Most Deaths Occurring In The First Year. In This Large Sc Cohort, The Clinical Spectrum Was Heterogeneous With About One-Third Either Male, <Or=50 Years Of Age, Without A Stress Trigger, Or With In-Hospital Death, Nonfatal Recurrence, Embolic Stroke, Or Delayed Normalization Of Ejection Fraction. Beta-Blocking Drugs Were Not Absolutely Protective And Sc Was A Marker For Increased Noncardiac Mortality. These Data Support Expanded Management And Surveillance Strategies Including Cmr Imaging And Consideration For Anticoagulation.|[('Study', 'no label'), ('Completely', 'no label'), ('Clinical Spectrum', 'no label'), ('Consequences', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Acute Event', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Recognized', 'no label'), ('Condition', 'no label'), ('Characterized', 'no label'), ('Transient Cardiac Dysfunction', 'no label'), ('Ventricular Ballooning', 'no label'), ('Clinical Profile', 'no label'), ('Outcome', 'no label'), ('Assessed', 'no label'), ('Consecutive', 'no label'), ('Sc', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Men', 'no label'), ('Ages', 'no label'), ('Years', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Patients', 'no label'), ('Sc', 'no label'), ('Precipitated', 'no label'), ('Intensely Stressful', 'no label'), ('Emotional (N = 64) Or Physical (N = 57) Events', 'no label'), ('Associated With', 'no label'), ('Sympathomimetic Drugs', 'no label'), ('Medical/Surgical Procedures', 'no label'), ('Patients', 'no label'), ('No Evident', 'no label'), ('Stress', 'no label'), ('Trigger', 'no label'), ('Patients', 'no label'), ('Beta-Blockers', 'no label'), ('Sc Events', 'no label'), ('Diverse', 'no label'), ('Ventricular Contraction', 'no label'), ('Patterns', 'no label'), ('Cardiovascular Magnetic Resonance', 'no label'), ('Rapid', 'no label'), ('Return To Normal Systolic Function', 'no label'), ('Delayed', 'no label'), ('Months', 'no label'), ('Right And/Or Left Ventricular Thrombi', 'no label'), ('Patients', 'no label'), ('Cmr Imaging', 'no label'), ('Embolic Events', 'no label'), ('Patients', 'no label'), ('Died In-Hospital', 'no label'), ('Survived', 'no label'), ('Nonfatal Recurrent', 'no label'), ('Sc Events', 'no label'), ('Mortality', 'no label'), ('Follow-Up', 'no label'), ('Exceeded A Matched', 'no label'), ('General Population', 'no label'), ('Deaths', 'no label'), ('Occurring', 'no label'), ('First Year', 'no label'), ('Sc', 'no label'), ('Cohort', 'no label'), ('Clinical Spectrum', 'no label'), ('Heterogeneous', 'no label'), ('One-Third', 'no label'), ('Male', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Stress Trigger', 'no label'), ('In-Hospital Death', 'no label'), ('Nonfatal', 'no label'), ('Recurrence', 'no label'), ('Embolic Stroke', 'no label'), ('Delayed', 'no label'), ('Normalization', 'no label'), ('Ejection Fraction', 'no label'), ('Beta-Blocking Drugs', 'no label'), ('Not Absolutely', 'no label'), ('Protective', 'no label'), ('Marker', 'no label'), ('Increased', 'no label'), ('Noncardiac', 'no label'), ('Mortality', 'no label'), ('Data Support', 'no label'), ('Expanded Management', 'no label'), ('Surveillance Strategies', 'no label'), ('Cmr Imaging', 'no label'), ('Anticoagulation', 'no label')]|[('Cmr', 'no label'), ('Cmr', 'no label'), ('Cmr', 'no label')]|[('Sc', 'no label'), ('Or=50', 'no label'), ('Sc', 'no label')]|[('Stress Cardiomyopathy', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Cardiac Dysfunction', 'no label'), ('Ventricular Ballooning', 'no label'), ('Ventricular Thrombi', 'no label'), ('Embolic Events', 'no label'), ('Deaths', 'no label'), ('Death', 'no label'), ('Embolic Stroke', 'no label')]|[('Stress', 'no label'), ('Cardiac', 'no label'), ('Ventricular', 'no label'), ('Sc Patients', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cardiovascular', 'no label'), ('Normal Systolic', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~18657330|Tako-Tsubo Cardiomyopathy (Ttc) Which Is Usually Precipitated By Profound Emotional And Physical Stress Has Been Widely Reported In The Past. In This Case We Report A Young Female Patient Who Developed Sudden Dyspnea And Palpitation After An Profound Stress (Fierce Argument).The Patient Had Characteristic Feature Of Progressive Pulmonary Edema. Her Symptom Worsened Gradually Leading To Cardiopulmonary Arrest In A Few Hours From The Onset. After Resuscitation An Immediately Performed Echocardiography Showed A Severe Mitral Regurgitation Due To Rupture Of Antromedial Papillary Muscle. Left Ventricular Function Showed Akinetic Mid-To-Distal Portion Of The Left Ventricular Chamber And Hyperkinetic In Basal Segment. Inotrop Infusion And Aortic Balloon Pump Placement Was Done Because Of Unstable Homodynamics. Semi-Elective Surgical Valve Replacement Was Performed. One Year After The Acute Event The Patient Remained Asymptomatic. Clinicians Should Recognize That Tako-Tsubo Cardiomyopathy Is One Etiology Of Acute Pulmonary Edema With Normal Coronary Artery Finding.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Precipitated', 'no label'), ('Profound Emotional And Physical Stress', 'no label'), ('Case', 'no label'), ('Report', 'no label'), ('Young Female', 'no label'), ('Developed Sudden Dyspnea', 'no label'), ('Palpitation', 'no label'), ('Profound Stress', 'no label'), ('Fierce Argument).The', 'no label'), ('Patient', 'no label'), ('Characteristic Feature', 'no label'), ('Progressive Pulmonary Edema', 'no label'), ('Symptom Worsened', 'no label'), ('Gradually', 'no label'), ('Cardiopulmonary Arrest', 'no label'), ('Hours', 'no label'), ('Onset', 'no label'), ('Resuscitation', 'no label'), ('Performed Echocardiography', 'no label'), ('Showed A', 'no label'), ('Severe', 'no label'), ('Mitral Regurgitation', 'no label'), ('Rupture', 'no label'), ('Antromedial Papillary Muscle', 'no label'), ('Left Ventricular Function', 'no label'), ('Akinetic Mid-To-Distal Portion', 'no label'), ('Left Ventricular Chamber', 'no label'), ('Hyperkinetic', 'no label'), ('Basal Segment', 'no label'), ('Inotrop Infusion', 'no label'), ('Aortic Balloon Pump', 'no label'), ('Placement', 'no label'), ('Homodynamics', 'no label'), ('Semi-Elective Surgical Valve Replacement', 'no label'), ('Year', 'no label'), ('Acute Event', 'no label'), ('Patient', 'no label'), ('Asymptomatic', 'no label'), ('Clinicians', 'no label'), ('Recognize', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Etiology', 'no label'), ('Acute Pulmonary Edema', 'no label'), ('Normal Coronary Artery', 'no label'), ('Finding', 'no label')]|[('Inotrop', 'no label'), ('Replacement', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Sudden Dyspnea', 'no label'), ('Palpitation', 'no label'), ('Pulmonary Edema', 'no label'), ('Cardiopulmonary Arrest', 'no label'), ('Mitral Regurgitation', 'no label'), ('Rupture', 'no label'), ('Antromedial Papillary Muscle', 'no label'), ('Akinetic', 'no label'), ('Hyperkinetic', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Etiology Of Acute Pulmonary Edema', 'no label')]|[('Patient', 'no label'), ('Patient', 'no label'), ('Pulmonary', 'no label'), ('Cardiopulmonary', 'no label'), ('Antromedial Papillary Muscle.', 'no label'), ('Left Ventricular', 'no label'), ('Basal Segment', 'no label'), ('Acute Event', 'no label'), ('Patient', 'no label'), ('Acute Pulmonary Edema', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23008472||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~20226426|Several Patterns Of Tako-Tsubo Cardiomyopathy (Ttc) Have Been Described Recently. To Assess The Prevalence And Characteristics Of An Apical-Sparing Variant Of Ttc. This Study Included Consecutive Patients Admitted To Our Catheterization Laboratory For Suspected Acute Coronary Syndrome (Acs). All Patients Underwent Coronary And Left Ventricular Angiography Systematically If No Significant Coronary Lesions Were Found. Among 2893 Patients With A Suspected Acs, 38 Had Confirmed Ttc. Nine Patients Presented With The Apical-Sparing Variant, Resulting In A 24% Prevalence In Our Ttc Population. At Admission, Mean Left Ventricular Ejection Fraction (Lvef) Was Significantly Higher In Patients With Apical-Sparing Ttc (45+/-4% Vs 35+/-7%, P=0.01). Patients With Classic Ttc Were Significantly Older (74+/-10 Years Vs 63+/-14 Years, P=0.01) And Had A Significantly Higher Mean Heart Rate And New York Heart Association Functional Class (P=0.04 And P=0.002, Respectively). Surgical Or Disease-Related Stress Was Found More Frequently Among Patients With The Apical-Sparing Variant (P=0.02). At Day 7, Mean Lvef Was Significantly Higher In Patients With Apical-Sparing Ttc (55+/-6% Vs 48+/-6%, P=0.04). At 1-Month And 1-Year Follow-Up, No Significant Difference In Lvef Was Observed Between The Two Patterns Of Ttc (P=0.60 And P=0.46, Respectively). The Apical-Sparing Variant Of Ttc Is Not Rare And Differs In Several Ways From The Classic Pattern Of Ttc. Physicians Should Be Aware Of And Recognize This Partial Pattern Of Ttc.|[('Patterns', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Assess', 'no label'), ('Prevalence', 'no label'), ('Characteristics', 'no label'), ('Apical-Sparing Variant', 'no label'), ('Ttc', 'no label'), ('Study', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Admitted', 'no label'), ('Catheterization Laboratory', 'no label'), ('Suspected', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Acs', 'no label'), ('Patients', 'no label'), ('Coronary', 'no label'), ('Left Ventricular Angiography', 'no label'), ('Systematically', 'no label'), ('Coronary Lesions', 'no label'), ('Patients', 'no label'), ('Suspected', 'no label'), ('Acs', 'no label'), ('Confirmed Ttc', 'no label'), ('Patients', 'no label'), ('Apical-Sparing Variant', 'no label'), ('Prevalence', 'no label'), ('Ttc Population', 'no label'), ('Admission', 'no label'), ('Mean Left Ventricular Ejection Fraction', 'no label'), ('Lvef', 'no label'), ('Patients', 'no label'), ('Apical-Sparing Ttc', 'no label'), ('Patients', 'no label'), ('Classic Ttc', 'no label'), ('Years', 'no label'), ('Years', 'no label'), ('Mean Heart Rate', 'no label'), ('New York Heart Association Functional Class', 'no label'), ('Surgical', 'no label'), ('Disease-Related Stress', 'no label'), ('Patients', 'no label'), ('Apical-Sparing Variant', 'no label'), ('Lvef', 'no label'), ('Patients', 'no label'), ('Apical-Sparing Ttc', 'no label'), ('1-Year Follow-Up', 'no label'), ('No Significant Difference', 'no label'), ('Lvef', 'no label'), ('Observed', 'no label'), ('Patterns', 'no label'), ('Ttc', 'no label'), ('Apical-Sparing Variant', 'no label'), ('Ttc', 'no label'), ('Not Rare', 'no label'), ('Differs', 'no label'), ('Classic Pattern', 'no label'), ('Ttc', 'no label'), ('Physicians', 'no label'), ('Aware', 'no label'), ('Recognize', 'no label'), ('Partial', 'no label'), ('Pattern', 'no label'), ('Ttc', 'no label')]|[('Variant', 'no label'), ('Acs', 'no label'), ('Variant', 'no label'), ('Lvef', 'no label'), ('Variant', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Acs', 'no label'), ('55+/-6', 'no label')]|[('Patients', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Acs', 'no label'), ('Patients', 'no label'), ('Left Ventricular', 'no label'), ('Patients', 'no label'), ('Acs', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Heart', 'no label'), ('Heart', 'no label'), ('Class', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23612894||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~21570911|Tako-Tsubo Cardiomyopathy (Ttc), Also Known As Transient Left Ventricular (Lv) Ballooning Syndrome Or Stress-Induced Cardiomyopathy, Is Characterised By Transient Lv Dysfunction In The Absence Of Significant Angiographic Coronary Stenoses, Frequently Provoked By An Episode Of Emotional Or Physical Stress. In Ttc, Typically Transient Akinesis Or Dyskinesis Of The Lv Apical Segments With Normal Or Hypercontractile Basal Wall Motions Is Observed. Recently, Several Cases Of Atypical Or Inverted Transient Ttc Sparing The Lv Apex Have Been Reported. We Report A Case Of Inverted Ttc Showing Akinesis Of The Basal And Mid-Ventricular Segments Of The Lv With Apical Hyperkinesia Triggered By Bronchoscopy With Bronchoalveolar Lavage.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Transient', 'no label'), ('Left Ventricular (Lv) Ballooning Syndrome', 'no label'), ('Stress-Induced Cardiomyopathy', 'no label'), ('Characterised', 'no label'), ('Transient Lv Dysfunction', 'no label'), ('Absence', 'no label'), ('Significant', 'no label'), ('Angiographic', 'no label'), ('Coronary Stenoses', 'no label'), ('Provoked', 'no label'), ('Episode', 'no label'), ('Emotional Or Physical Stress', 'no label'), ('Ttc', 'no label'), ('Transient Akinesis', 'no label'), ('Dyskinesis', 'no label'), ('Lv Apical Segments', 'no label'), ('Normal', 'no label'), ('Hypercontractile', 'no label'), ('Basal Wall Motions', 'no label'), ('Observed', 'no label'), ('Cases', 'no label'), ('Atypical', 'no label'), ('Inverted', 'no label'), ('Transient Ttc', 'no label'), ('Sparing', 'no label'), ('Lv Apex', 'no label'), ('Report', 'no label'), ('Inverted Ttc', 'no label'), ('Akinesis', 'no label'), ('Basal', 'no label'), ('Mid-Ventricular Segments', 'no label'), ('Apical Hyperkinesia', 'no label'), ('Triggered By', 'no label'), ('Bronchoscopy', 'no label'), ('Bronchoalveolar Lavage', 'no label')]|[('Apical Segments', 'no label')]|[('Lv Apical Segments', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Cardiomyopathy', 'no label'), ('Hyperkinesia', 'no label')]|[('Left Ventricular', 'no label'), ('Lv', 'no label'), ('Lv Apical', 'no label'), ('Lv Apex', 'no label'), ('Basal', 'no label'), ('Mid-Ventricular Segments', 'no label'), ('Lv', 'no label'), ('Bronchoscopy With Bronchoalveolar Lavage', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21444938|Tako Tsubo Cardiomyopathy Is A Serious Condition That Is Caused By Heart Failure Due To Inordinate Stress. We Here Present A Case Of A Young Woman With This Disorder In Association With Anorexia Nervosa. We Postulate A Pathophysiological Relationship And Discuss The Management Of Tako Tsubo Cardiomyopathy.|[('Tako Tsubo Cardiomyopathy', 'no label'), ('Serious', 'no label'), ('Condition', 'no label'), ('Heart Failure', 'no label'), ('Inordinate Stress', 'no label'), ('Young Woman', 'no label'), ('Disorder', 'no label'), ('Association', 'no label'), ('Anorexia Nervosa', 'no label'), ('Postulate', 'no label'), ('Pathophysiological', 'no label'), ('Relationship', 'no label'), ('Discuss', 'no label'), ('Management', 'no label'), ('Tako Tsubo Cardiomyopathy', 'no label')]|[]|[]|[('Tako', 'no label'), ('Cardiomyopathy', 'no label'), ('Heart Failure', 'no label'), ('Anorexia Nervosa', 'no label'), ('Tako', 'no label'), ('Cardiomyopathy', 'no label')]|[('Heart', 'no label')]
tako-tsubo cardiomyopathy|pubmed~24924856||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~22364781||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~22225762||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~22119264||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~21456480|Tako-Tsubo Cardiomyopathy Is A Rapidly Reversible Form Of Acute Heart Failure Triggered By Stressful Events That Occur More Frequently In Postmenopausal Women. A Central Role Is Supposed To Be Played By Catecholamines And The Association With Pheocromocytoma Is Rare. We Describe A Patient Admitted For Abdominal Pain And Suffering Of Hypertension Pharmacologically Treated. During Hospitalization The Patient Presented Cephalea And Precordial Pain With Nausea And Profuse Sweating. Ecg Showed St Elevation And Deep Negative T Wave. Blood Tests Were Moderately Elevated. Echo-Cardiography Reported A Left Ventricular Apex Akynesia And Hyperkynesia Of The Base While Coronarography Was Negative. As Hypertension Persisted The Suspicion Of Pheocromocytoma Arose. Urinary And Blood Catecholamines Were Mildly Elevated And Echography And Magnetic Resonance Revealed A Left Adrenal Gland Mass. The Diagnosis Of Pheocromocytoma Was Thus Confirmed Left Laparoscopic Adrenalectomy Was Performed After Adequate Stabilization And Preoperative Pharmacological Preparation By Hydration, A-And F-Blockers. Intraoperatively Blood Pressure Was Controlled By Nitroprussiate, Rapid Half Life Beta-Blockers (Esmolol Cloridrate). Post-Operative Course Was Uneventful And Arterial Pressure Returned To Normal As Well As Catecholamines Values. Patient Was Discharged On The 5Th Post-Operative Day Five Months Afterwards The Patient Had Normal Arterial Pressure Without Anti-Hypertensive Therapy And Symptom Free. The Case Confirmed That Tako-Tsubo Cardiomyopathy Could Be The First Manifestation Of Tumors Secreting Catecholamines And That Pheocromocytoma Should Be Considered In Patients With Hypertension And Acute Stress-Induced Cardiomiopathy Without Evidence Of Acute Coronary Disease And With Negative Coronarography.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Heart Failure', 'no label'), ('Triggered By Stressful Events', 'no label'), ('Occur', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Central Role', 'no label'), ('Supposed', 'no label'), ('Played', 'no label'), ('Catecholamines', 'no label'), ('Association', 'no label'), ('Pheocromocytoma', 'no label'), ('Rare', 'no label'), ('Patient', 'no label'), ('Admitted', 'no label'), ('Abdominal Pain', 'no label'), ('Suffering', 'no label'), ('Hypertension', 'no label'), ('Pharmacologically', 'no label'), ('Treated', 'no label'), ('Hospitalization', 'no label'), ('Patient', 'no label'), ('Cephalea', 'no label'), ('Precordial Pain', 'no label'), ('Nausea', 'no label'), ('Profuse Sweating', 'no label'), ('Ecg Showed St', 'no label'), ('Elevation', 'no label'), ('Deep Negative T', 'no label'), ('Blood Tests', 'no label'), ('Elevated', 'no label'), ('Echo-Cardiography', 'no label'), ('Left Ventricular Apex Akynesia', 'no label'), ('Hyperkynesia', 'no label'), ('Base', 'no label'), ('Coronarography', 'no label'), ('Negative', 'no label'), ('Hypertension', 'no label'), ('Persisted', 'no label'), ('Suspicion', 'no label'), ('Pheocromocytoma Arose', 'no label'), ('Urinary', 'no label'), ('Blood Catecholamines', 'no label'), ('Mildly Elevated', 'no label'), ('Echography', 'no label'), ('Magnetic Resonance Revealed', 'no label'), ('Left Adrenal Gland', 'no label'), ('Diagnosis', 'no label'), ('Pheocromocytoma', 'no label'), ('Confirmed', 'no label'), ('Left Laparoscopic Adrenalectomy', 'no label'), ('Performed', 'no label'), ('Adequate', 'no label'), ('Stabilization', 'no label'), ('Preoperative', 'no label'), ('Pharmacological', 'no label'), ('Preparation', 'no label'), ('Hydration', 'no label'), ('A-And', 'no label'), ('F-Blockers', 'no label'), ('Intraoperatively Blood Pressure', 'no label'), ('Was Controlled By Nitroprussiate', 'no label'), ('Rapid Half Life Beta-Blockers', 'no label'), ('Esmolol Cloridrate', 'no label'), ('Post-Operative Course', 'no label'), ('Uneventful', 'no label'), ('Arterial Pressure', 'no label'), ('Returned', 'no label'), ('Catecholamines', 'no label'), ('Values', 'no label'), ('Patient', 'no label'), ('Months', 'no label'), ('Patient', 'no label'), ('Normal Arterial Pressure', 'no label'), ('Anti-Hypertensive Therapy', 'no label'), ('Symptom Free', 'no label'), ('Case Confirmed', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Manifestation', 'no label'), ('Tumors', 'no label'), ('Secreting Catecholamines', 'no label'), ('Pheocromocytoma', 'no label'), ('Patients', 'no label'), ('Hypertension', 'no label'), ('Acute', 'no label'), ('Stress-Induced Cardiomiopathy', 'no label'), ('Evidence', 'no label'), ('Acute Coronary Disease', 'no label'), ('Negative', 'no label'), ('Coronarography', 'no label')]|[('Catecholamines', 'no label'), ('Hyperkynesia', 'no label'), ('Catecholamines', 'no label'), ('Catecholamines', 'no label'), ('Catecholamines', 'no label')]|[('5Th Post-Operative Day Five Months Afterwards The', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Heart Failure', 'no label'), ('Catecholamines', 'no label'), ('Abdominal Pain', 'no label'), ('Hypertension', 'no label'), ('Cephalea', 'no label'), ('Precordial Pain', 'no label'), ('Nausea', 'no label'), ('Hypertension', 'no label'), ('Catecholamines', 'no label'), ('Nitroprussiate', 'no label'), ('Esmolol', 'no label'), ('Catecholamines', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tumors', 'no label'), ('Catecholamines', 'no label'), ('Hypertension', 'no label'), ('Cardiomiopathy', 'no label'), ('Acute Coronary Disease', 'no label')]|[('Heart', 'no label'), ('Catecholamines', 'no label'), ('Pheocromocytoma', 'no label'), ('Patient', 'no label'), ('Profuse', 'no label'), ('Blood', 'no label'), ('Left Ventricular', 'no label'), ('Pheocromocytoma', 'no label'), ('Blood Catecholamines', 'no label'), ('Left Adrenal', 'no label'), ('Mass.', 'no label'), ('Pheocromocytoma', 'no label'), ('Left Laparoscopic', 'no label'), ('A-And', 'no label'), ('Blood', 'no label'), ('Esmolol', 'no label'), ('Arterial', 'no label'), ('Catecholamines', 'no label'), ('Patient', 'no label'), ('Arterial', 'no label'), ('Tumors Secreting Catecholamines', 'no label'), ('Pheocromocytoma', 'no label'), ('Patients', 'no label'), ('Acute Coronary Disease', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22791656|Tako-Tsubo Cardiomyopathy (Ttc) Is Associated With Regional Left Ventricular Dysfunction, Independent Of The Presence Of Fixed Coronary Artery Disease. Previous Studies Have Used T2-Weighted Cardiac Mri To Demonstrate The Presence Of Periapical Oedema. The Authors Sought To Determine The Distribution, Resolution And Correlates Of Oedema In Ttc. 32 Patients With Ttc Were Evaluated At A Median Of 2 Days After Presentation, Along With 10 Age-Matched Female Controls. Extent Of Oedema Was Quantified Both Regionally And Globally; Scanning Was Repeated In Patients With Ttc After 3 Months. Correlations Were Sought Between Oedema And The Extent Of Hypokinesis, Catecholamine Release, Release Of N-Terminal Prohormone Of B-Type Natriuretic Peptide (Nt-Probnp), And Markers Of Systemic Inflammatory Activation (High-Sensitivity C-Reactive Protein And Platelet Response To Nitric Oxide). In The Acute Phase Of Ttc, T2-Weighted Signal Intensity Was Greater At The Apex Than At The Base (P<0.0001) But Was Nevertheless Significantly Elevated At The Base (P<0.0001), Relative To Control Values. Over 3 Months, T2-Weighted Signal Decreased Substantially, But Remained Abnormally Elevated (P<0.02). The Regional Extent Of Oedema Correlated Inversely With Radial Myocardial Strain (Except At The Apex). There Were Also Direct Correlations Between Global T2-Weighted Signal And (1) Plasma Normetanephrine (R=0.39, P=0.04) And (2) Peak Nt-Probnp (R=0.39, P=0.03), But Not With Systemic Inflammatory Markers. Ttc Is Associated With Slowly Resolving Global Myocardial Oedema, The Acute Extent Of Which Correlates With Regional Contractile Disturbance And Acute Release Of Both Catecholamines And Nt-Probnp.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Associated With', 'no label'), ('Regional Left Ventricular Dysfunction', 'no label'), ('Presence', 'no label'), ('Fixed Coronary Artery Disease', 'no label'), ('Studies', 'no label'), ('T2-Weighted Cardiac Mri', 'no label'), ('Periapical Oedema', 'no label'), ('Distribution', 'no label'), ('Resolution', 'no label'), ('Correlates', 'no label'), ('Oedema', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Evaluated', 'no label'), ('Median', 'no label'), ('Days', 'no label'), ('Presentation', 'no label'), ('Age-Matched', 'no label'), ('Female Controls', 'no label'), ('Oedema', 'no label'), ('Quantified', 'no label'), ('Regionally', 'no label'), ('Scanning', 'no label'), ('Repeated', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Months', 'no label'), ('Correlations', 'no label'), ('Oedema', 'no label'), ('Hypokinesis', 'no label'), ('Catecholamine Release', 'no label'), ('Release', 'no label'), ('N-Terminal Prohormone', 'no label'), ('B-Type Natriuretic Peptide', 'no label'), ('Nt-Probnp', 'no label'), ('Markers', 'no label'), ('Systemic Inflammatory Activation', 'no label'), ('High-Sensitivity C-Reactive Protein', 'no label'), ('Platelet Response', 'no label'), ('Nitric Oxide', 'no label'), ('Acute Phase', 'no label'), ('Ttc', 'no label'), ('T2-Weighted Signal Intensity', 'no label'), ('Apex Than', 'no label'), ('Base', 'no label'), ('Elevated', 'no label'), ('Base', 'no label'), ('Control Values', 'no label'), ('Months', 'no label'), ('T2-Weighted Signal', 'no label'), ('Decreased', 'no label'), ('Remained Abnormally Elevated', 'no label'), ('Regional', 'no label'), ('Extent', 'no label'), ('Oedema', 'no label'), ('Correlated', 'no label'), ('Inversely', 'no label'), ('Radial Myocardial Strain', 'no label'), ('Apex', 'no label'), ('Correlations', 'no label'), ('Global T2-Weighted Signal And (1)', 'no label'), ('Plasma', 'no label'), ('Normetanephrine', 'no label'), ('Peak Nt-Probnp', 'no label'), ('Systemic Inflammatory', 'no label'), ('Markers', 'no label'), ('Ttc', 'no label'), ('Associated With', 'no label'), ('Slowly Resolving Global Myocardial Oedema', 'no label'), ('Acute', 'no label'), ('Extent', 'no label'), ('Correlates', 'no label'), ('Regional Contractile Disturbance', 'no label'), ('Acute Release', 'no label'), ('Catecholamines', 'no label'), ('Nt-Probnp', 'no label')]|[('Catecholamine', 'no label'), ('B-Type Natriuretic Peptide', 'no label'), ('Protein', 'no label'), ('Platelet', 'no label'), ('Normetanephrine', 'no label'), ('Catecholamines', 'no label')]|[('High-Sensitivity C-Reactive Protein', 'no label'), ('Nt-Probnp', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Ventricular Dysfunction', 'no label'), ('Coronary Artery Disease', 'no label'), ('Periapical Oedema', 'no label'), ('Oedema', 'no label'), ('Oedema', 'no label'), ('Oedema', 'no label'), ('Hypokinesis', 'no label'), ('Catecholamine', 'no label'), ('Nitric Oxide', 'no label'), ('Oedema', 'no label'), ('Normetanephrine', 'no label'), ('Myocardial Oedema', 'no label'), ('Catecholamines', 'no label')]|[('Left Ventricular', 'no label'), ('Cardiac', 'no label'), ('Periapical Oedema', 'no label'), ('Oedema', 'no label'), ('Patients', 'no label'), ('Oedema', 'no label'), ('Patients', 'no label'), ('Oedema', 'no label'), ('Catecholamine', 'no label'), ('B-Type Natriuretic Peptide', 'no label'), ('Platelet Response', 'no label'), ('Nitric Oxide', 'no label'), ('Oedema', 'no label'), ('Myocardial', 'no label'), ('Apex', 'no label'), ('Plasma Normetanephrine', 'no label'), ('Myocardial Oedema', 'no label'), ('Catecholamines', 'no label'), ('Nt-Probnp', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23608394||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~20513218|"Inverted Tako-Tsubo Cardiomyopathy (Ttc) Is A Variation Of Stress Cardiomyopathy. It Features Transient Myocardial Dysfunction Characterised By A Typical Contractile Abnormality Consisting Of Extensive Left Ventricular Circumferential Dyskinesia Or Akinesia With A Hyperkinetic Apex. Endogenous Catecholamine Surges Are Believed To Be The Mediators Of This Potentially Life-Threatening Condition. We Describe A Patient Who Received An Inadvertent Bolus Of Noradrenaline And Developed Significant Haemodynamic Instability Associated With Electrocardiographic And Cardiac Biomarkers Indicative Of Diffuse Myocardial Injury And Echocardiography Findings Of An ""Inverted"" Ttc. The Patient Made A Full Recovery. Our Case Highlights That A Reversible Inverted Ttc May Result From An Exogenous Catecholamine Surge."|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Variation', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Transient', 'no label'), ('Myocardial Dysfunction', 'no label'), ('Characterised', 'no label'), ('Contractile Abnormality', 'no label'), ('Consisting', 'no label'), ('Extensive', 'no label'), ('Left Ventricular Circumferential Dyskinesia', 'no label'), ('Akinesia', 'no label'), ('Hyperkinetic Apex', 'no label'), ('Endogenous', 'no label'), ('Catecholamine Surges', 'no label'), ('Believed', 'no label'), ('Mediators', 'no label'), ('Condition', 'no label'), ('Patient', 'no label'), ('Bolus', 'no label'), ('Noradrenaline', 'no label'), ('Haemodynamic', 'no label'), ('Instability', 'no label'), ('Associated With', 'no label'), ('Electrocardiographic', 'no label'), ('Cardiac Biomarkers', 'no label'), ('Diffuse Myocardial Injury', 'no label'), ('Echocardiography', 'no label'), ('Findings', 'no label'), ('Ttc', 'no label'), ('Patient', 'no label'), ('Recovery', 'no label'), ('Case Highlights', 'no label'), ('Reversible Inverted Ttc', 'no label'), ('Result', 'no label'), ('Exogenous', 'no label'), ('Catecholamine Surge', 'no label')]|[('Catecholamine', 'no label'), ('Catecholamine', 'no label')]|[('Who', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Myocardial Dysfunction', 'no label'), ('Left Ventricular Circumferential Dyskinesia', 'no label'), ('Akinesia', 'no label'), ('Hyperkinetic', 'no label'), ('Catecholamine', 'no label'), ('Noradrenaline', 'no label'), ('Myocardial Injury', 'no label'), ('Catecholamine', 'no label')]|[('Myocardial', 'no label'), ('Contractile', 'no label'), ('Left Ventricular Circumferential Dyskinesia', 'no label'), ('Akinesia', 'no label'), ('Catecholamine', 'no label'), ('Mediators', 'no label'), ('Patient', 'no label'), ('Noradrenaline', 'no label'), ('Cardiac', 'no label'), ('Myocardial', 'no label'), ('Patient', 'no label'), ('Catecholamine', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20655278|Current Data Suggest An Excellent Outcome For Patients With Tako-Tsubo Cardiomyopathy (Tc). The Objectives Of This Study Were To Evaluate The Long-Term Outcome And The Prognostic Implication Of Thrombolysis In Myocardial Infarction Myocardial Perfusion Grade (Tmpg) In Patients With Tc. Retrospective Analysis Of All Patients Diagnosed With Tc At Our Hospital Between 2003 And 2008. During The Five-Year Period, We Identified 27 Patients With Tc Out Of 1374 Cases Of Emergent Left Heart Catheterisation (2%). Mean Follow-Up Was 27 ± 16 Months. The Majority Were Caucasian (81%) Female (96%), Postmenopausal (96%), With A Mean Age Of 68 ± 14 Years. A Precipitating Stressor Event Was Found In 74% Of The Patients, 30% Being Gastrointestinal Triggers. Fourteen Patients (52%) Reached A Combined End Point Of All Cause Death, Cardiogenic Shock, Sudden Cardiac Death And Rehospitalisation For Cardiac Reasons. Tmpg Was Abnormal In 37% Cases With No Correlation With The Outcome. The Long-Term Outcome Of Patients With Tc Is Worse Than Previously Reported. Tmpg Does Not Correlate With The Outcome In Tc.|[('Current', 'no label'), ('Data Suggest', 'no label'), ('Excellent Outcome', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tc', 'no label'), ('Study', 'no label'), ('Evaluate', 'no label'), ('Long-Term Outcome', 'no label'), ('Prognostic', 'no label'), ('Implication', 'no label'), ('Thrombolysis', 'no label'), ('Myocardial Infarction', 'no label'), ('Myocardial Perfusion Grade', 'no label'), ('Tmpg', 'no label'), ('Patients', 'no label'), ('Tc', 'no label'), ('Retrospective Analysis', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Tc', 'no label'), ('Hospital', 'no label'), ('Period', 'no label'), ('Patients', 'no label'), ('Tc', 'no label'), ('Cases', 'no label'), ('Emergent', 'no label'), ('Left Heart Catheterisation', 'no label'), ('Mean Follow-Up', 'no label'), ('Months', 'no label'), ('Majority', 'no label'), ('Caucasian', 'no label'), ('Female', 'no label'), ('Postmenopausal', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Precipitating Stressor Event', 'no label'), ('Patients', 'no label'), ('Gastrointestinal Triggers', 'no label'), ('Patients', 'no label'), ('Reached A', 'no label'), ('Cause Death', 'no label'), ('Cardiogenic Shock', 'no label'), ('Sudden Cardiac Death', 'no label'), ('Rehospitalisation', 'no label'), ('Cardiac Reasons', 'no label'), ('Tmpg', 'no label'), ('Abnormal', 'no label'), ('Cases', 'no label'), ('Correlation', 'no label'), ('Outcome', 'no label'), ('Long-Term Outcome', 'no label'), ('Patients', 'no label'), ('Tc', 'no label'), ('Worse', 'no label'), ('Tmpg', 'no label'), ('Outcome', 'no label'), ('Tc', 'no label')]|[('±', 'no label')]|[('End Point', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Thrombolysis', 'no label'), ('Myocardial Infarction Myocardial Perfusion Grade (Tmpg)', 'no label'), ('Death', 'no label'), ('Cardiogenic Shock', 'no label'), ('Sudden Cardiac Death', 'no label')]|[('Patients', 'no label'), ('Myocardial', 'no label'), ('Myocardial', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Heart', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cardiac', 'no label'), ('Cardiac', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~29997970|Although Morphological Abnormalities Of The Heart Appear To Be Remarkable, Most Patients With Tako-Tsubo Cardiomyopathy (Ttc) Remain Clinically Stable. We Investigate Real Time Changes In The Left Ventricular (Lv) And Right Ventricular (Rv) Mechanics And Function To Explore The Mechanism To Preserve Hemodynamics. With Deformation And Doppler Echocardiography, We Evaluated Myocardial Mechanics And Ventricular Function/Hemodynamics Simultaneously In 103 Consecutive Ttc Patients Admitted From 01/01/2008 Through 12/31/2015. The Coronary Angiography And Left Ventriculography Were Performed To Rule Out Culprit Coronary Artery Stenosis (Cas). We Included 66 Patients In A Control Group With Matched Age, Sex, And Risk Factors For Coronary Artery Disease (Cad), And 41 Patients In A Group Of Myocardial Infarction Induced Cardiogenic Shock, Who Required Circulatory Supporting Devices To Maintain Hemodynamic Stability. Although Systolic Myocardial Strain In Most Of The Lv Segments Was Significantly Impaired, 4 Basal Lv Segments Remained Functionally Active During Acute Stage Of Ttc. The Impairment In The Myocardial Strain Of The Rv Apex Could Extend To The Middle Segments, But Basal Rv Systolic Strain Was Also Preserved. Despites Comparable Apical To Basal Strain Gradients, Lv And Rv Displayed Discrepant Functional/Hemodynamic Status. In Contrast To Lv, Rv Functional/Hemodynamic Parameters Appeared To Be Hyper-Dynamic. This Unique Rv Strain Pattern Remained Unchanged In Patients With Atypical (Mid-Lv Cavity) Ttc. In 41 Patients With Myocardial Infarction Induced Cardiogenic Shock, Rv Exhibited Comparable Mechanic And Functional Features With Those In Ttc Patients. The Identified Lv And Rv Mechanic Changes Appear To Support Interventricular Hemodynamic Dependence During Ttc, Which May Represent A Universal Rescue Mechanism In A Jeopardized Or Injured Heart.|[('Morphological Abnormalities', 'no label'), ('Heart Appear', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Clinically Stable', 'no label'), ('Investigate', 'no label'), ('Real Time', 'no label'), ('Left Ventricular (Lv) And Right Ventricular (Rv) Mechanics', 'no label'), ('Function', 'no label'), ('Mechanism', 'no label'), ('Preserve', 'no label'), ('Hemodynamics', 'no label'), ('Deformation', 'no label'), ('Doppler Echocardiography', 'no label'), ('Myocardial Mechanics', 'no label'), ('Ventricular Function/Hemodynamics', 'no label'), ('Simultaneously', 'no label'), ('Consecutive', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Admitted', 'no label'), ('Coronary Angiography', 'no label'), ('Left Ventriculography', 'no label'), ('Performed', 'no label'), ('Culprit', 'no label'), ('Coronary Artery Stenosis', 'no label'), ('Cas', 'no label'), ('Patients', 'no label'), ('Control Group', 'no label'), ('Matched Age', 'no label'), ('Sex', 'no label'), ('Risk Factors', 'no label'), ('Coronary Artery Disease', 'no label'), ('Cad', 'no label'), ('Patients', 'no label'), ('Group', 'no label'), ('Myocardial Infarction', 'no label'), ('Cardiogenic Shock', 'no label'), ('Circulatory', 'no label'), ('Maintain', 'no label'), ('Hemodynamic Stability', 'no label'), ('Systolic Myocardial Strain', 'no label'), ('Lv Segments', 'no label'), ('Basal Lv Segments', 'no label'), ('Functionally Active', 'no label'), ('Acute Stage', 'no label'), ('Ttc', 'no label'), ('Impairment', 'no label'), ('Myocardial Strain', 'no label'), ('Rv Apex Could Extend', 'no label'), ('Middle Segments', 'no label'), ('Basal Rv Systolic Strain', 'no label'), ('Despites', 'no label'), ('Apical', 'no label'), ('Basal Strain Gradients', 'no label'), ('Lv And Rv', 'no label'), ('Functional/Hemodynamic Status', 'no label'), ('Contrast', 'no label'), ('Rv Functional/Hemodynamic', 'no label'), ('Parameters', 'no label'), ('Appeared', 'no label'), ('Rv Strain Pattern', 'no label'), ('Unchanged', 'no label'), ('Patients', 'no label'), ('Atypical', 'no label'), ('Mid-Lv', 'no label'), ('Cavity', 'no label'), ('Patients', 'no label'), ('Myocardial Infarction', 'no label'), ('Cardiogenic Shock', 'no label'), ('Mechanic', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Lv And Rv Mechanic', 'no label'), ('Interventricular Hemodynamic Dependence', 'no label'), ('Ttc', 'no label'), ('Represent', 'no label'), ('Universal Rescue', 'no label'), ('Mechanism', 'no label'), ('Jeopardized', 'no label'), ('Injured', 'no label'), ('Heart', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Left Ventricular (Lv) And Right Ventricular', 'no label'), ('Culprit Coronary Artery Stenosis', 'no label'), ('Coronary Artery Disease', 'no label'), ('Myocardial Infarction', 'no label'), ('Cardiogenic Shock', 'no label'), ('Myocardial Infarction', 'no label'), ('Cardiogenic Shock', 'no label')]|[('Heart', 'no label'), ('Patients', 'no label'), ('Left Ventricular', 'no label'), ('Myocardial', 'no label'), ('Ventricular Function/Hemodynamics Simultaneously In', 'no label'), ('Patients', 'no label'), ('Left', 'no label'), ('Culprit Coronary', 'no label'), ('Cas', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Patients', 'no label'), ('Myocardial', 'no label'), ('Lv Segments', 'no label'), ('Acute Stage', 'no label'), ('Myocardial', 'no label'), ('Rv Apex', 'no label'), ('Basal Rv Systolic', 'no label'), ('Lv', 'no label'), ('Lv', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Myocardial', 'no label'), ('Ttc Patients', 'no label'), ('Lv', 'no label'), ('Interventricular', 'no label'), ('Heart', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20582389|The Prognosis Of Patients Presenting With Tako-Tsubo Cardiomyopathy (Ttc) Is Generally Considered To Be Favorable. However, In The Acute Phase Of The Disorder Complications Are Not Infrequent And, Therefore, Continuous Monitoring And Consistent Therapy In An Intensive Care Unit Is Essential. Typical Complications In Patients With Ttc Are Cardiogenic Shock, Obstruction Of The Left Ventricular Outflow Tract (Lvot), Occasionally Accompanied By Acute Mitral Regurgitation, Arrhythmias, Predominantly Torsade De Pointes Tachycardias Due To Qt Prolongation, Left Ventricular (Lv) Thrombus Formation With Or Without Consecutive Thromboembolic Events, And Lv Rupture. After Confirmation Of Ttc By Coronary Angiography, Repeat Echocardiography Should Be Performed. A Standardized Therapy For Patients With Ttc Has So Far Not Been Established. Recommendations For The Acute Phase Include The Administration Of Anxiolytic Agents For Patients Who Present With Preceding Emotional Stress, Consistent Therapy Of Physical Stressors (Such As Pain Or Asthma) And Avoidance Of Catecholamine Therapy. Shock Due To Lvot Obstruction Is Treated By Administration Of Volume And Β-Blockers. With Respect To The Occurrence Of Torsade De Pointes Tachycardias, Drugs Which Might Cause Qt Prolongation Should Not Be Given. The Notable Incidence Of Lv Thrombus Formation Justifies Therapeutic Anticoagulation. Systematic Studies And Treatment Recommendations For The Prophylaxis Of Recurrent Ttc Do Not Exist. The Recently Reported Association Between Ttc And Malignant Disorders Should Prompt Tumor Screening And Subsequent Preventive Medical Checkups In Patients Affected By Ttc.|[('Prognosis', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Favorable', 'no label'), ('Acute Phase', 'no label'), ('Disorder', 'no label'), ('Complications', 'no label'), ('Infrequent', 'no label'), ('Continuous Monitoring', 'no label'), ('Therapy', 'no label'), ('Intensive Care Unit', 'no label'), ('Complications', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Cardiogenic Shock', 'no label'), ('Obstruction', 'no label'), ('Left Ventricular Outflow Tract', 'no label'), ('Lvot', 'no label'), ('Accompanied', 'no label'), ('Acute Mitral Regurgitation', 'no label'), ('Arrhythmias', 'no label'), ('Torsade', 'no label'), ('De Pointes Tachycardias', 'no label'), ('Qt', 'no label'), ('Prolongation', 'no label'), ('Left Ventricular (Lv) Thrombus', 'no label'), ('Formation', 'no label'), ('Consecutive', 'no label'), ('Thromboembolic Events', 'no label'), ('Lv Rupture', 'no label'), ('Ttc', 'no label'), ('Coronary Angiography', 'no label'), ('Echocardiography', 'no label'), ('Performed', 'no label'), ('Standardized Therapy', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Far', 'no label'), ('Established', 'no label'), ('Recommendations', 'no label'), ('Acute Phase Include', 'no label'), ('Administration', 'no label'), ('Anxiolytic Agents', 'no label'), ('Patients', 'no label'), ('Preceding', 'no label'), ('Emotional Stress', 'no label'), ('Therapy', 'no label'), ('Physical Stressors', 'no label'), ('Pain', 'no label'), ('Asthma', 'no label'), ('Avoidance', 'no label'), ('Catecholamine Therapy', 'no label'), ('Shock', 'no label'), ('Lvot Obstruction', 'no label'), ('Treated By Administration', 'no label'), ('Volume', 'no label'), ('Respect', 'no label'), ('Torsade', 'no label'), ('De Pointes Tachycardias', 'no label'), ('Drugs', 'no label'), ('Cause', 'no label'), ('Prolongation', 'no label'), ('Incidence', 'no label'), ('Lv Thrombus', 'no label'), ('Formation', 'no label'), ('Justifies', 'no label'), ('Therapeutic Anticoagulation', 'no label'), ('Systematic Studies', 'no label'), ('Treatment', 'no label'), ('Recommendations', 'no label'), ('Prophylaxis', 'no label'), ('Recurrent Ttc', 'no label'), ('Exist', 'no label'), ('Association', 'no label'), ('Ttc', 'no label'), ('Malignant Disorders', 'no label'), ('Prompt', 'no label'), ('Tumor Screening', 'no label'), ('Preventive Medical Checkups', 'no label'), ('Patients', 'no label'), ('Affected', 'no label'), ('Ttc', 'no label')]|[('Repeat', 'no label'), ('Catecholamine', 'no label')]|[]|[('Prognosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Disorder Complications', 'no label'), ('Cardiogenic Shock', 'no label'), ('Left Ventricular Outflow Tract', 'no label'), ('Acute Mitral Regurgitation', 'no label'), ('Arrhythmias', 'no label'), ('Torsade De Pointes Tachycardias', 'no label'), ('Left Ventricular', 'no label'), ('Thrombus', 'no label'), ('Thromboembolic', 'no label'), ('Pain', 'no label'), ('Catecholamine', 'no label'), ('Shock', 'no label'), ('Obstruction', 'no label'), ('Torsade De Pointes Tachycardias', 'no label'), ('Thrombus', 'no label'), ('Malignant Disorders', 'no label'), ('Tumor', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('Left Ventricular Outflow', 'no label'), ('Left Ventricular', 'no label'), ('Thrombus', 'no label'), ('Lv', 'no label'), ('Patients', 'no label'), ('Far', 'no label'), ('Patients', 'no label'), ('Catecholamine', 'no label'), ('Lv Thrombus', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21391994|As The Clinical, Electrocardiographic And Laboratory Presentation Of Tako-Tsubo Cardiomyopathy (Ttc) And Acute Myocardial Infarction (Ami) Is Similar, Both Entities Are In General Only Distinguishable By Coronary Angiography. The Purpose Of This Study Was To Examine The Endogenous Stress Response At Presentation, Quantified By The Copeptin Level, Of Patients With Ttc And Patients With Ami, As Copeptin May Be Useful In The Non-Invasive Differentiation Between Both Diseases. We Compared The Endogenous Stress Response At Initial Presentation, Quantified By The Plasma Copeptin Levels, In 21 Consecutive Patients Finally Diagnosed With Ttc And 21 Patients Finally Diagnosed With Ami Matched For Sex And Time Since Chest Pain Onset. The Prevalence Of Cardiovascular Risk Factors And Initial Cardiac Troponin T Levels Were Comparable In Ttc And Ami. Copeptin Levels Were Significantly Lower In Patients With Ttc When Compared To Patients With Ami (Median 4·8 [Interquartile Range, Iqr 3·5-13·5] Pm Vs. 25·6 [Iqr 12·1-63·9] Pm, P = 0·002). The Accuracy For Diagnosing Ttc As Quantified By The Area Under The Receiver Operating Characteristics Curve Was Significantly Higher For Copeptin Than For Cardiac Troponin T (0·782 Vs. 0·549, P = 0·031). The Optimal Cut-Off Value For Differentiation Between Ttc And Ami Was Found At A Copeptin Level Of 7·8 Pm (Sensitivity 67% At A Specificity Of 86%, Negative Predictive Value 72%, Positive Predictive Value 82%). The Endogenous Stress Response, Quantified By A Novel Sensitive Biomarker, Seems To Be Different In Patients With Ttc And Ami. Copeptin Levels May Be Helpful In The Non-Invasive Differentiation Between Ttc And Ami.|[('Clinical', 'no label'), ('Electrocardiographic And Laboratory', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Entities', 'no label'), ('Coronary Angiography', 'no label'), ('Study', 'no label'), ('Endogenous', 'no label'), ('Stress Response', 'no label'), ('Presentation', 'no label'), ('Quantified', 'no label'), ('Copeptin', 'no label'), ('Level', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Ami', 'no label'), ('Copeptin', 'no label'), ('Non-Invasive Differentiation', 'no label'), ('Diseases', 'no label'), ('Endogenous', 'no label'), ('Stress Response', 'no label'), ('Initial', 'no label'), ('Presentation', 'no label'), ('Quantified', 'no label'), ('Plasma', 'no label'), ('Copeptin', 'no label'), ('Levels', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Matched', 'no label'), ('Sex', 'no label'), ('Time', 'no label'), ('Chest Pain', 'no label'), ('Prevalence', 'no label'), ('Cardiovascular Risk Factors', 'no label'), ('Initial', 'no label'), ('Cardiac Troponin T', 'no label'), ('Levels', 'no label'), ('Ttc', 'no label'), ('Copeptin', 'no label'), ('Levels', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Ami', 'no label'), ('Median', 'no label'), ('Interquartile Range', 'no label'), ('Iqr 3·5-13·5] Pm Vs', 'no label'), ('Iqr', 'no label'), ('Accuracy', 'no label'), ('Diagnosing Ttc', 'no label'), ('Quantified', 'no label'), ('Area', 'no label'), ('Receiver Operating Characteristics Curve', 'no label'), ('Copeptin Than', 'no label'), ('Cardiac Troponin T', 'no label'), ('Optimal', 'no label'), ('Cut-Off Value', 'no label'), ('Differentiation', 'no label'), ('Ttc', 'no label'), ('Copeptin', 'no label'), ('Level', 'no label'), ('Pm', 'no label'), ('Sensitivity', 'no label'), ('Specificity', 'no label'), ('Negative Predictive Value', 'no label'), ('Positive Predictive Value', 'no label'), ('Endogenous', 'no label'), ('Stress Response', 'no label'), ('Quantified', 'no label'), ('Sensitive', 'no label'), ('Biomarker', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Copeptin Levels May', 'no label'), ('Non-Invasive Differentiation', 'no label'), ('Ttc', 'no label')]|[('Copeptin', 'no label'), ('Copeptin', 'no label'), ('Copeptin', 'no label'), ('Troponin T', 'no label'), ('Copeptin', 'no label'), ('Copeptin', 'no label'), ('Troponin T', 'no label'), ('Copeptin', 'no label'), ('Copeptin', 'no label')]|[('Sex', 'no label'), ('Copeptin', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Myocardial Infarction', 'no label'), ('Chest Pain', 'no label'), ('Cardiac Troponin T', 'no label'), ('Cardiac Troponin T', 'no label')]|[('Myocardial', 'no label'), ('Copeptin', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Copeptin', 'no label'), ('Plasma Copeptin', 'no label'), ('21', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cardiovascular', 'no label'), ('Cardiac Troponin T', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('3·5-13·5] Pm', 'no label'), ('Copeptin', 'no label'), ('Cardiac Troponin T', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~34429107|Cardiovascular Complications Of Severe Acute Respiratory Distress Syndrome Coronavirus 2 (Sars-Cov2) Are Known To Be Associated With Poor Outcome. A Small Number Of Case Series And Reports Have Described Cases Of Myocarditis And Ischaemic Events, However, Knowledge On The Aetiology Of Acute Cardiac Failure In Sars-Cov2 Remains Limited. We Describe The Occurrence And Risk Stratification Imaging Correlates Of 'Takotsubo' Stress Cardiomyopathy Presenting In A Patient With Coronavirus Disease 2019 (Covid-19) In The Intensive Care Unit. An Intubated 53-Year Old Patient With Covid19 Suffered Acute Haemodynamic Collapse In The Intensive Care Unit, And Was Thus Investigated With Transthoracic Echocardiography (Tte), 12-Lead Electrocardiograms (Ecg) And Serial Troponins And Blood Tests, And Eventually Coronary Angiography Due To Clinical Suspicion Of Ischaemic Aetiology. Echocardiography Revealed A Reduced Ejection Fraction, With Evident Extensive Apical Akinesia Spanning Multiple Coronary Territories. Troponins And Nt-Probnp Were Elevated, And Ecg Revealed St Elevation: Coronary Angiography Was Thus Performed. This Revealed No Significant Coronary Stenosis. Repeat Echocardiography Performed Within The Following Week Revealed A Substantial Recovery Of Ejection Fraction And Wall Motion Abnormalities. Despite Requirement Of A Prolonged Icu Stay, The Patient Now Remains Clinically Stable, And Is On Spontaneous Breathing. This Case Report Presents A Case Of Takotsubo Stress Cardiomyopathy Occurring In A Critically Unwell Patient With Covid19 In The Intensive Care Setting. Stress Cardiomyopathy May Be An Acute Cardiovascular Complication Of Covid-19 Infection. In The Covid19 Critical Care Setting, Urgent Bedside Echocardiography Is An Important Tool For Initial Clinical Assessment Of Patients Suffering Haemodynamic Compromise.|"[('Cardiovascular', 'no label'), ('Complications', 'no label'), ('Severe', 'no label'), ('Acute Respiratory Distress Syndrome', 'no label'), ('Coronavirus 2', 'no label'), ('Sars-Cov2', 'no label'), ('Associated With', 'no label'), ('Poor Outcome', 'no label'), ('Case Series', 'no label'), ('Reports', 'no label'), ('Cases', 'no label'), ('Myocarditis', 'no label'), ('Ischaemic Events', 'no label'), ('Knowledge', 'no label'), ('Aetiology', 'no label'), ('Acute Cardiac Failure', 'no label'), ('Sars-Cov2', 'no label'), ('Remains', 'no label'), ('Limited', 'no label'), ('Occurrence', 'no label'), ('Risk', 'no label'), ('Stratification Imaging', 'no label'), ('Correlates', 'no label'), (""Takotsubo' Stress Cardiomyopathy"", 'no label'), ('Presenting', 'no label'), ('Patient', 'no label'), ('Coronavirus Disease', 'no label'), ('Covid-19', 'no label'), ('Intensive Care Unit', 'no label'), ('Intubated 53-Year Old Patient', 'no label'), ('Covid19 Suffered Acute', 'no label'), ('Haemodynamic', 'no label'), ('Collapse', 'no label'), ('Intensive Care Unit', 'no label'), ('Investigated', 'no label'), ('Transthoracic Echocardiography', 'no label'), ('Tte', 'no label'), ('12-Lead Electrocardiograms (Ecg)', 'no label'), ('Serial', 'no label'), ('Troponins', 'no label'), ('Blood Tests', 'no label'), ('Coronary Angiography', 'no label'), ('Clinical Suspicion', 'no label'), ('Ischaemic Aetiology', 'no label'), ('Echocardiography', 'no label'), ('Revealed', 'no label'), ('Reduced', 'no label'), ('Apical Akinesia', 'no label'), ('Multiple', 'no label'), ('Coronary Territories', 'no label'), ('Troponins', 'no label'), ('Nt-Probnp', 'no label'), ('Elevated', 'no label'), ('Ecg Revealed', 'no label'), ('Elevation', 'no label'), ('Coronary Angiography', 'no label'), ('Performed', 'no label'), ('Revealed', 'no label'), ('No Significant', 'no label'), ('Coronary Stenosis', 'no label'), ('Echocardiography', 'no label'), ('Performed', 'no label'), ('Week', 'no label'), ('Revealed', 'no label'), ('Recovery', 'no label'), ('Ejection Fraction', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Requirement', 'no label'), ('Prolonged', 'no label'), ('Patient', 'no label'), ('Clinically Stable', 'no label'), ('Spontaneous', 'no label'), ('Breathing', 'no label'), ('Case Report', 'no label'), ('Presents A', 'no label'), ('Case', 'no label'), ('Takotsubo Stress Cardiomyopathy', 'no label'), ('Occurring', 'no label'), ('Critically Unwell', 'no label'), ('Patient', 'no label'), ('Covid19', 'no label'), ('Intensive Care Setting', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Acute Cardiovascular Complication', 'no label'), ('Covid-19', 'no label'), ('Infection', 'no label'), ('Covid19 Critical Care Setting', 'no label'), ('Urgent Bedside Echocardiography', 'no label'), ('Initial', 'no label'), ('Clinical Assessment', 'no label'), ('Patients', 'no label'), ('Suffering', 'no label'), ('Haemodynamic', 'no label'), ('Compromise', 'no label')]"|[('Coronavirus', 'no label'), ('Coronavirus', 'no label'), ('Repeat', 'no label')]|[('Serial Troponins', 'no label'), ('Troponins', 'no label'), ('Nt-Probnp', 'no label')]|"[('Cardiovascular Complications', 'no label'), ('Respiratory Distress Syndrome Coronavirus 2 (Sars-Cov2)', 'no label'), ('Myocarditis', 'no label'), ('Acute Cardiac Failure', 'no label'), (""Takotsubo' Stress Cardiomyopathy"", 'no label'), ('Coronavirus Disease', 'no label'), ('Ischaemic Aetiology', 'no label'), ('Coronary Stenosis', 'no label'), ('Takotsubo Stress Cardiomyopathy', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Acute Cardiovascular Complication', 'no label'), ('Covid-19 Infection', 'no label')]"|[('Cardiovascular Complications', 'no label'), ('Coronavirus 2', 'no label'), ('Acute Cardiac Failure In', 'no label'), ('Coronavirus Disease 2019', 'no label'), ('Patient', 'no label'), ('Covid19 Suffered Acute', 'no label'), ('Tte', 'no label'), ('Blood', 'no label'), ('Nt-Probnp', 'no label'), ('Wall', 'no label'), ('Patient', 'no label'), ('Patient', 'no label'), ('Covid19', 'no label'), ('Cardiovascular', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23796841|Takotsubo Cardiomyopathy Is An Acute Syndrome Characterized By Cardiac Failure From Disturbances In The Contractility Of The Left Ventricle. It Is Presumably Caused By Sympathetic Over Stimulation. We Describe A Case Of Postoperatively Developed Takotsubo Cardiomyopathy In A 69-Year-Old Female. The Syndrome Developed In Connection With Awareness During Complete Residual Paralysis. The Literature On This Syndrome Is Reviewed And Implications For Anaesthesia Described.|[('Takotsubo Cardiomyopathy', 'no label'), ('Acute Syndrome', 'no label'), ('Characterized', 'no label'), ('Cardiac Failure', 'no label'), ('Disturbances', 'no label'), ('Contractility', 'no label'), ('Left Ventricle', 'no label'), ('Sympathetic', 'no label'), ('Stimulation', 'no label'), ('Case', 'no label'), ('Postoperatively Developed', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('69-Year-Old', 'no label'), ('Female', 'no label'), ('Syndrome', 'no label'), ('Connection', 'no label'), ('Awareness', 'no label'), ('Complete', 'no label'), ('Residual', 'no label'), ('Paralysis', 'no label'), ('Literature', 'no label'), ('Syndrome', 'no label'), ('Reviewed', 'no label'), ('Anaesthesia', 'no label'), ('Described', 'no label')]|[]|[]|[('Takotsubo Cardiomyopathy', 'no label'), ('Acute Syndrome', 'no label'), ('Cardiac Failure', 'no label'), ('Left Ventricle', 'no label'), ('Takotsubo Cardiomyopathy', 'no label')]|[('Cardiac', 'no label'), ('Left Ventricle', 'no label'), ('A Case', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21606046|The Aim Of This Study Was To Assess The Echocardiographic Distribution Of Regional Wall Motion Abnormalities (Rwma) In Patients With Tako-Tsubo Cardiomyopathy (Ttc) Compared With Anterior St-Elevation Myocardial Infarction (Ant-Stemi). Thirty-Seven Ttc And 37 Ant-Stemi Patients Underwent Standard Echocardiographic Examination At The Time Of Hospital Admission. Rwma And The Involvement Of The Left Ventricular Territories Supplied By Each Coronary Artery According To The American Society Of Echocardiography Classification Were Reported. Ttc Patients Showed A Lower Left Ventricular Ejection Fraction (37.6 ± 5.1 Vs. 40.9 ± 3.7%; P = 0.002) And A Higher Wall Motion Score Index (Wmsi; 1.98 ± 0.2 Vs. 1.51 ± 0.14; P < 0.001) Compared With Ant-Stemi Patients. No Significant Differences Were Observed Between Groups With Regard To Detection Of Rwma In The Territory Supplied By The Left Anterior Descending Coronary Artery (Lad) (37 Vs. 37; P = 1). Conversely, In Ttc Patients, The Territories Supplied By The Lad/Left Circumflex Coronary Artery (Lcx) (37 Vs. 31; P = 0.011), Lad/Right Coronary Artery (Rca) (34 Vs. 13; P < 0.001), Rca (33 Vs. 5; P < 0.001), And Rca/Lcx (31 Vs. 2; P < 0.001) Were More Frequently Involved. A Cut-Off Value Of Wmsi ≥1.75 (Area Under The Curve 0.956) And For The Number Of Territories With Rwma ≥4 (Auc = 0.928) Predicted Ttc With A Sensitivity Of 83 And 84% And A Specificity Of 100 And 97%, Respectively. Echocardiography Revealed A Distinctive Pattern Of Contractility In Ttc Patients, Characterized By Symmetrical Rwma Extending Equally Into The Territory Of Distribution Of All Coronary Arteries.|[('Study', 'no label'), ('Echocardiographic', 'no label'), ('Distribution', 'no label'), ('Regional Wall Motion Abnormalities', 'no label'), ('Rwma', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Anterior', 'no label'), ('Myocardial Infarction', 'no label'), ('Ant-Stemi', 'no label'), ('Thirty-Seven Ttc', 'no label'), ('Ant-Stemi', 'no label'), ('Patients', 'no label'), ('Echocardiographic Examination', 'no label'), ('Time', 'no label'), ('Hospital Admission', 'no label'), ('Rwma', 'no label'), ('Involvement', 'no label'), ('Left Ventricular Territories', 'no label'), ('Coronary Artery', 'no label'), ('American Society', 'no label'), ('Echocardiography', 'no label'), ('Classification', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Lower Left Ventricular Ejection Fraction', 'no label'), ('Wall Motion Score Index', 'no label'), ('Ant-Stemi', 'no label'), ('Patients', 'no label'), ('No Significant', 'no label'), ('Differences', 'no label'), ('Observed', 'no label'), ('Groups', 'no label'), ('Regard', 'no label'), ('Detection', 'no label'), ('Rwma', 'no label'), ('Territory', 'no label'), ('Left Anterior Descending Coronary Artery', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Territories', 'no label'), ('Lad/Left', 'no label'), ('Circumflex', 'no label'), ('Coronary Artery', 'no label'), ('Lcx', 'no label'), ('Coronary Artery', 'no label'), ('Rca', 'no label'), ('Rca', 'no label'), ('Rca/Lcx', 'no label'), ('Cut-Off Value', 'no label'), ('Wmsi ≥1.75', 'no label'), ('Area Under The Curve', 'no label'), ('Territories', 'no label'), ('Rwma', 'no label'), ('Predicted Ttc', 'no label'), ('Sensitivity', 'no label'), ('Specificity', 'no label'), ('Echocardiography', 'no label'), ('Revealed', 'no label'), ('Distinctive Pattern', 'no label'), ('Contractility', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Characterized', 'no label'), ('Symmetrical Rwma', 'no label'), ('Territory', 'no label'), ('Distribution', 'no label'), ('Coronary Arteries', 'no label')]|[('Territory', 'no label'), ('Rca', 'no label'), ('Territory', 'no label')]|[('Rwma', 'no label'), ('Lad/Left Circumflex Coronary Artery (Lcx) (37 Vs. 31; P = 0.011', 'no label'), ('Rca', 'no label'), ('Wmsi ≥1.75', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Myocardial Infarction', 'no label'), ('Left Ventricular Ejection Fraction', 'no label')]|[('Wall', 'no label'), ('Patients', 'no label'), ('Myocardial', 'no label'), ('Patients', 'no label'), ('Left Ventricular', 'no label'), ('Patients', 'no label'), ('Wall', 'no label'), ('Patients', 'no label'), ('Rwma', 'no label'), ('Left Anterior Descending Coronary Artery', 'no label'), ('Ttc Patients', 'no label'), ('Rca', 'no label'), ('Rwma ≥4', 'no label'), ('Patients', 'no label'), ('Symmetrical Rwma', 'no label'), ('Coronary Arteries', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20124311|The Frequent Occurrence Of A Reversible Left Ventricular Dysfunction Complicating Subarachnoid Haemorrhage Raises A Number Of Issues About The Clinical And Pathophysiological Similarities With The Transient Left Ventricular Apical Ballooning Syndrome (Tlvabs) Or Tako-Tsubo Cardiomyopathy (Ttc). Given The Latest Clinical And Pathophysiological Evidence About Neurogenic Cardiomyopathies, The Diagnosis Of Ttc Should Not Be Ruled Out In Patients Experiencing Acute Brain Injury And Cerebrovascular Events. Each Type Of Reversible Left Ventricular Dysfunction Mediated By The Central Nervous System And Initiated By Acute Brain Injury, Both Physical, Such As Intracranial Bleeding Or Head Traumas, And Psychological, Such As Sudden Emotional Stress, Could Be Encompassed In A Single Definition With Larger Inclusion Criteria, Such As 'Acute Ballooning Cardiomyopathy' (Abc), That Is Likely To Be More Representative Of The Real Needs In The Clinical Setting.|"[('Frequent', 'no label'), ('Reversible', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Subarachnoid Haemorrhage', 'no label'), ('Raises', 'no label'), ('Issues', 'no label'), ('Clinical', 'no label'), ('Pathophysiological', 'no label'), ('Similarities', 'no label'), ('Transient', 'no label'), ('Left Ventricular Apical Ballooning Syndrome', 'no label'), ('Tlvabs', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Clinical', 'no label'), ('Pathophysiological', 'no label'), ('Evidence', 'no label'), ('Neurogenic Cardiomyopathies', 'no label'), ('Diagnosis', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Acute Brain Injury', 'no label'), ('Cerebrovascular Events', 'no label'), ('Reversible', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Central Nervous System', 'no label'), ('Initiated', 'no label'), ('Acute Brain Injury', 'no label'), ('Physical', 'no label'), ('Intracranial Bleeding', 'no label'), ('Head Traumas', 'no label'), ('Psychological', 'no label'), ('Sudden Emotional Stress', 'no label'), ('Encompassed', 'no label'), ('Definition', 'no label'), ('Larger Inclusion Criteria', 'no label'), (""Acute Ballooning Cardiomyopathy' (Abc)"", 'no label'), ('Representative', 'no label'), ('Real Needs', 'no label'), ('Clinical Setting', 'no label')]"|[('Apical', 'no label')]|[]|[('Left Ventricular Dysfunction', 'no label'), ('Subarachnoid Haemorrhage', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Neurogenic Cardiomyopathies', 'no label'), ('Brain Injury And Cerebrovascular Events', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Acute Brain Injury', 'no label'), ('Intracranial Bleeding', 'no label'), ('Head Traumas', 'no label'), ('Sudden Emotional Stress, Could Be Encompassed In A Single Definition', 'no label'), ('Cardiomyopathy', 'no label')]|[('A Reversible Left Ventricular', 'no label'), ('Subarachnoid', 'no label'), ('Patients', 'no label'), ('Acute Brain', 'no label'), ('Cerebrovascular', 'no label'), ('Left Ventricular', 'no label'), ('Acute Brain', 'no label'), ('Intracranial', 'no label'), ('Head Traumas', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22430419|A 74 Year-Old Patient Was Admitted To Invasive Cardiology Department. Non-St Elevation Myocardial Infarction Was Suspected.  Patient Has Typical Chest Pain After Strong Stress. The Normal Coronary Artery Was Found In Coroangiography. The Apical  Ballooning And Almost Closure In ½ Of Left Ventricle Cavity Were Found In Ventriculography. The Echocardiography Shown  Asymmetric Hypertrophy Of Heart Walls And Left Ventricle Outflow Obstruction. The Cardiac Magnetic Resonance Was Performed  Because Of Heart Tumour Was Suspected.|[('Year-Old', 'no label'), ('Patient', 'no label'), ('Admitted', 'no label'), ('Non-St Elevation Myocardial Infarction', 'no label'), ('Suspected', 'no label'), ('Patient', 'no label'), ('Typical Chest Pain', 'no label'), ('Strong', 'no label'), ('Stress', 'no label'), ('Normal Coronary Artery', 'no label'), ('Coroangiography', 'no label'), ('Apical', 'no label'), ('Ballooning', 'no label'), ('Closure', 'no label'), ('In ½', 'no label'), ('Left Ventricle Cavity', 'no label'), ('Ventriculography', 'no label'), ('Echocardiography', 'no label'), ('Heart Walls', 'no label'), ('Left Ventricle', 'no label'), ('Outflow Obstruction', 'no label'), ('Cardiac Magnetic Resonance', 'no label'), ('Performed', 'no label'), ('Heart Tumour', 'no label'), ('Suspected', 'no label')]|[]|[('Non-St', 'no label')]|[('Myocardial Infarction', 'no label'), ('Chest Pain', 'no label'), ('Left Ventricle Cavity Were Found In Ventriculography.', 'no label'), ('Heart Walls And Left Ventricle Outflow Obstruction', 'no label'), ('Heart Tumour', 'no label')]|[('Myocardial', 'no label'), ('Normal Coronary', 'no label'), ('Heart Walls', 'no label'), ('Cardiac', 'no label'), ('Heart Tumour', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20058057|Takotsubo Cardiomyopathy Was Described For The First Time In Japan In The 1990S. It Is Very Similar To The Ischemic Cardiopathy Both For Clinical And Instrumental Characteristics. His Peculiarity Is An Alteration Of The Ventricular Contraction Mechanism With Hypo-Akinesis Of The Apex And Lateral Segments Of The Left Ventricle, Associated With Hyper-Kinesis Of The Heart Base Which Is Responsible For The Typical Echocardiographic Aspect Of A Cruet During The Systole. However, The Etiology Of This Cardiomyopathy Is Still Unknown Despite The Fact That Numerous Hypothesis Have Been Made. A Single Study Of 16 Patients Proved Multivasal Damage By A Blash Score Analysis Of The Coronary Radiography. In Our Study, Performed On 24 Patients, We Intended To Assess The Actual Implication Of The Microcirculation By Analyzing The Timi Frame Count (Tfc), So As Reporting Correlations Between Alterations Of Each Single Artery And Its Respective Myocardial Area. Six Cardiology Centres Performed An International Multi-Centre Collection Of A Consecutive Series Of 24 Patients, Of Which 20 Were Women And Four Men. The Average Age Was 67.4 Years. All Patients Admitted To One Of The Cardiology Divisions Were Previously Listed For Symptoms And Signs Of Takotsubo Cardiomyopathy. An Electrocardiographic (Ecg), Echocardio-Gram And A Hemodynamic Study Were Carried Out On Each Patient. The Patients Were Evaluated With A Follow Up Lasting 7 Weeks. On The Coronary Radiography Film, The Microcirculation Was Examined By An Analysis Of The Tfc According To The Gibson Technique. The Value Obtained Was Considered Pathological If It Was >30 Frames. The Evaluation Of The Microcirculation By The Tfc Analysis Showed That In 23 Of The 24 Patients There Was A Pathological Slow Down Of The Flow In The Coronary Micro- Circulation. By Analysing The Number Of Involved Vessels It Was Noted That Nine Patients Had A Slowdown Of The General Flow In All Three Vessels, Six Patients In Only Two Vessels And The Remaining Nine In One Vessel. In Particular: In 14 Patients There Was An Abnormal Tfc In Left Anterior Descending Coronary Artery (Lad), 16 In The Right Coronary Artery (Rca) And 18 In The Left Circumflex Coronary Artery (Lcx), While In One Patient The Picture Quality In The Acute Phase Did Not Allow An Evaluation Of The Score In The Rca And In Another Patient In The Lda. None Of The Explored Vessels That Was Responsible For The Disorder Of The Microcirculation Showed Any Stenosis. From The Data Evaluated By Us, Microcirculatory Dysfunction Seems To Be Present Very Often During Acute Phases Of Takotsubo Illness, But It Is Not The Only Determining Factor Of The Illness.|[('Takotsubo Cardiomyopathy', 'no label'), ('First Time', 'no label'), ('Japan', 'no label'), ('Ischemic Cardiopathy', 'no label'), ('Clinical And Instrumental', 'no label'), ('Characteristics', 'no label'), ('Peculiarity', 'no label'), ('Alteration', 'no label'), ('Ventricular Contraction', 'no label'), ('Mechanism', 'no label'), ('Hypo-Akinesis', 'no label'), ('Apex', 'no label'), ('Lateral Segments', 'no label'), ('Left Ventricle', 'no label'), ('Associated With', 'no label'), ('Hyper-Kinesis', 'no label'), ('Heart Base', 'no label'), ('Echocardiographic Aspect', 'no label'), ('Cruet', 'no label'), ('Systole', 'no label'), ('Etiology', 'no label'), ('Cardiomyopathy', 'no label'), ('Fact', 'no label'), ('Hypothesis', 'no label'), ('Patients', 'no label'), ('Proved', 'no label'), ('Multivasal Damage', 'no label'), ('Blash Score Analysis', 'no label'), ('Coronary Radiography', 'no label'), ('Study', 'no label'), ('Performed', 'no label'), ('Patients', 'no label'), ('Intended', 'no label'), ('Actual', 'no label'), ('Implication', 'no label'), ('Microcirculation', 'no label'), ('Timi Frame Count', 'no label'), ('Tfc', 'no label'), ('Reporting', 'no label'), ('Correlations', 'no label'), ('Alterations', 'no label'), ('Single Artery', 'no label'), ('Myocardial Area', 'no label'), ('Cardiology Centres', 'no label'), ('Performed', 'no label'), ('International Multi-Centre Collection', 'no label'), ('Consecutive', 'no label'), ('Series', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Men', 'no label'), ('Average Age', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Admitted', 'no label'), ('Cardiology Divisions', 'no label'), ('Symptoms', 'no label'), ('Signs', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Electrocardiographic (Ecg)', 'no label'), ('Echocardio-Gram', 'no label'), ('Hemodynamic Study', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Evaluated', 'no label'), ('Follow Up', 'no label'), ('Weeks', 'no label'), ('Coronary Radiography', 'no label'), ('Microcirculation', 'no label'), ('Analysis', 'no label'), ('Tfc', 'no label'), ('Gibson Technique', 'no label'), ('Value', 'no label'), ('Pathological', 'no label'), ('Frames', 'no label'), ('Evaluation', 'no label'), ('Microcirculation', 'no label'), ('Tfc Analysis', 'no label'), ('Patients', 'no label'), ('Was A', 'no label'), ('Pathological', 'no label'), ('Slow Down', 'no label'), ('Flow', 'no label'), ('Coronary Micro- Circulation', 'no label'), ('Vessels', 'no label'), ('Noted', 'no label'), ('Patients', 'no label'), ('Slowdown', 'no label'), ('General Flow', 'no label'), ('Vessels', 'no label'), ('Patients', 'no label'), ('Vessels', 'no label'), ('Vessel', 'no label'), ('Patients', 'no label'), ('Abnormal', 'no label'), ('Tfc', 'no label'), ('Left Anterior Descending Coronary Artery', 'no label'), ('Right Coronary Artery', 'no label'), ('Rca', 'no label'), ('Left Circumflex Coronary Artery', 'no label'), ('Lcx', 'no label'), ('Patient', 'no label'), ('Picture Quality', 'no label'), ('Acute Phase', 'no label'), ('Evaluation', 'no label'), ('Score', 'no label'), ('Rca', 'no label'), ('Patient', 'no label'), ('Explored Vessels', 'no label'), ('Disorder', 'no label'), ('Microcirculation', 'no label'), ('Showed', 'no label'), ('Stenosis', 'no label'), ('Data Evaluated', 'no label'), ('Microcirculatory Dysfunction', 'no label'), ('Acute Phases', 'no label'), ('Takotsubo Illness', 'no label'), ('Factor', 'no label'), ('Illness', 'no label')]|[('His', 'no label'), ('Rca', 'no label')]|[('His', 'no label'), ('Rca', 'no label')]|[('Takotsubo Cardiomyopathy', 'no label'), ('Ischemic Cardiopathy', 'no label'), ('Left Ventricle', 'no label'), ('Etiology Of This Cardiomyopathy', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Disorder', 'no label'), ('Stenosis', 'no label'), ('Microcirculatory Dysfunction', 'no label'), ('Takotsubo Illness', 'no label')]|[('Ventricular', 'no label'), ('Apex', 'no label'), ('Lateral Segments', 'no label'), ('Left Ventricle', 'no label'), ('Heart Base', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Myocardial', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Vessels', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Vessels', 'no label'), ('Vessel', 'no label'), ('Patients', 'no label'), ('Left Anterior', 'no label'), ('Right Coronary Artery', 'no label'), ('Rca', 'no label'), ('Left Circumflex', 'no label'), ('Picture', 'no label'), ('Acute Phase', 'no label'), ('Rca', 'no label'), ('Patient', 'no label'), ('Acute Phases', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22974729||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~21437701|A 50-Year-Old Woman With Arterial Hypertension Suffered From Recurrent Syncope. On Admission, Recurrent Torsades De Pointes Tachycardia, Ventricular Flutter, And Ventricular Fibrillation With The Necessity Of Cardiopulmonary Resuscitation Were Documented. After Administration Of Β-Blocking Agents, Amiodarone, And Magnesium, Heart Rhythm Was Stabilized. Coronary Angiography Excluded Coronary Artery Disease. Echocardiography Revealed Apical Ballooning With Reduced Ventricular Function. The Ecg Showed Left Bundle-Branch Block And Profound Qt Prolongation. A Wcd (Wearable Cardioverter-Defibrillator) Lifevest Was Prescribed For The Patient, And, Thereafter, No Arrhythmias Were Experienced. The Ecg Gradually Normalized; Echocardiography Revealed Slight Anteroapical Hypokinesia With Overall Normal Left Ventricular Function. After A Period Of 3 Months, The Patient Was No Longer Asked To Wear The Lifevest; 6 Months Later The Patient Is Without Any Complaints.|[('Woman', 'no label'), ('Arterial Hypertension', 'no label'), ('Suffered', 'no label'), ('Recurrent Syncope', 'no label'), ('Admission', 'no label'), ('Recurrent', 'no label'), ('Torsades', 'no label'), ('De Pointes Tachycardia', 'no label'), ('Ventricular Flutter', 'no label'), ('Ventricular Fibrillation', 'no label'), ('Necessity', 'no label'), ('Cardiopulmonary Resuscitation', 'no label'), ('Documented', 'no label'), ('Administration', 'no label'), ('Β-Blocking Agents', 'no label'), ('Amiodarone', 'no label'), ('Magnesium', 'no label'), ('Heart Rhythm', 'no label'), ('Stabilized', 'no label'), ('Coronary Angiography', 'no label'), ('Coronary Artery Disease', 'no label'), ('Echocardiography', 'no label'), ('Revealed', 'no label'), ('Apical Ballooning', 'no label'), ('Reduced', 'no label'), ('Ventricular Function', 'no label'), ('Ecg Showed', 'no label'), ('Left Bundle-Branch Block', 'no label'), ('Qt', 'no label'), ('Prolongation', 'no label'), ('Wcd', 'no label'), ('Wearable Cardioverter-Defibrillator', 'no label'), ('Patient', 'no label'), ('Arrhythmias', 'no label'), ('Experienced', 'no label'), ('Ecg Gradually Normalized', 'no label'), ('Echocardiography', 'no label'), ('Revealed', 'no label'), ('Anteroapical Hypokinesia', 'no label'), ('Left Ventricular Function', 'no label'), ('Period', 'no label'), ('Months', 'no label'), ('Patient', 'no label'), ('Wear', 'no label'), ('Lifevest', 'no label'), ('Months', 'no label'), ('Patient', 'no label'), ('Complaints', 'no label')]|[('Amiodarone', 'no label'), ('Magnesium', 'no label'), ('Apical', 'no label')]|[]|[('Hypertension', 'no label'), ('Syncope', 'no label'), ('Torsades De Pointes Tachycardia', 'no label'), ('Ventricular Flutter', 'no label'), ('Ventricular Fibrillation', 'no label'), ('Amiodarone', 'no label'), ('Magnesium', 'no label'), ('Coronary Artery Disease', 'no label'), ('Left Bundle-Branch Block And Profound Qt Prolongation', 'no label'), ('Arrhythmias', 'no label'), ('Anteroapical Hypokinesia', 'no label')]|[('Arterial', 'no label'), ('Ventricular Flutter', 'no label'), ('Ventricular', 'no label'), ('Cardiopulmonary Resuscitation', 'no label'), ('Amiodarone', 'no label'), ('Magnesium', 'no label'), ('Heart', 'no label'), ('Coronary Artery', 'no label'), ('Ventricular', 'no label'), ('Ecg', 'no label'), ('Left Bundle-Branch Block', 'no label'), ('Left Ventricular', 'no label'), ('Patient', 'no label'), ('Patient', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20963467|Tako-Tsubo-Like Cardiomyopathy (Ttc) Is Much More Common Than Originally Thought. The Exact Pathophysiology Of Ttc Is Unclear. The Most Accepted Theory Proposes Myocardial Stunning Of Neurogenic Origin, Supported By The Frequent Antecedent Of Emotional Or Physical Stress, Suggesting A Catecholamine-Mediated Mechanism. We Present A Patient With This Syndrome And Bilateral Damage Of The Dorsal Medulla Oblongata Likely Affecting Both Solitary Tract Nuclei. Our Case Points To A Link Between Baroreflex Failure And Ttc, Highlighting The Important Role Of Sympathetic Discharge In The Pathophysiology Of Ttc.|[('Tako-Tsubo-Like Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Than Originally Thought', 'no label'), ('Exact Pathophysiology', 'no label'), ('Ttc', 'no label'), ('Accepted', 'no label'), ('Theory Proposes', 'no label'), ('Myocardial Stunning', 'no label'), ('Neurogenic Origin', 'no label'), ('Frequent', 'no label'), ('Antecedent', 'no label'), ('Emotional Or Physical Stress', 'no label'), ('Suggesting', 'no label'), ('Catecholamine-Mediated Mechanism', 'no label'), ('Patient', 'no label'), ('Syndrome', 'no label'), ('Bilateral', 'no label'), ('Damage', 'no label'), ('Dorsal Medulla Oblongata', 'no label'), ('Solitary Tract Nuclei', 'no label'), ('Case Points', 'no label'), ('Baroreflex', 'no label'), ('Failure', 'no label'), ('Ttc', 'no label'), ('Sympathetic Discharge', 'no label'), ('Pathophysiology', 'no label'), ('Ttc', 'no label')]|[]|[]|[('Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Myocardial Stunning', 'no label'), ('Baroreflex Failure', 'no label')]|[('Myocardial', 'no label'), ('Patient', 'no label'), ('Dorsal Medulla Oblongata', 'no label'), ('Solitary Tract Nuclei', 'no label'), ('Link', 'no label'), ('Baroreflex', 'no label'), ('Sympathetic Discharge', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23392545||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~19348350|Tako-Tsubo Cardiomyopathy Is Still En Entity Of Unknown Etiology And Pathophysiology Which Clinically Manifests With Sudden, Severe Chest Pain And/Or Dyspnea. It Is Generally Triggered By Emotional Or Physical Stress And Most Cases Are Reported In Postmenopausal Women. Electrocardiographic Changes Are Similar To Acute Myocardial Infarction With St-Elevation, Laboratory Markers Of Myocardial Lesion Are Usually Mild To Moderately High, And Coronary Angiography Shows No Significant Pathomorphological Changes Of Epicardial Coronary Arteries. Ventriculography And Echocardiography Show Reversible Akinesis And Ballooning Of The Left Ventricular Apex With Reduced Ejection Fraction Which Is Usually Normalized Within 2-4 Weeks. Generally, Tako-Tsubo Cardiomyopathy Has A Good Prognosis, In-Hospital Mortality Rate Is About 1%. In This Article, We Present A Review About Todays Knowledge On Tako-Tsubo Cardiomyopathy.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Entity', 'no label'), ('Unknown Etiology', 'no label'), ('Pathophysiology', 'no label'), ('Clinically Manifests', 'no label'), ('Sudden', 'no label'), ('Severe Chest Pain And/Or', 'no label'), ('Dyspnea', 'no label'), ('Triggered', 'no label'), ('Emotional Or Physical Stress', 'no label'), ('Cases', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Electrocardiographic Changes', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('St-Elevation', 'no label'), ('Laboratory Markers', 'no label'), ('Myocardial Lesion', 'no label'), ('Coronary Angiography', 'no label'), ('Pathomorphological', 'no label'), ('Changes', 'no label'), ('Epicardial Coronary Arteries', 'no label'), ('Ventriculography', 'no label'), ('Echocardiography', 'no label'), ('Reversible Akinesis', 'no label'), ('Ballooning', 'no label'), ('Left Ventricular Apex', 'no label'), ('Reduced Ejection Fraction', 'no label'), ('Weeks', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Has A', 'no label'), ('Good Prognosis', 'no label'), ('In-Hospital', 'no label'), ('Mortality Rate', 'no label'), ('Article', 'no label'), ('Review', 'no label'), ('Knowledge', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Unknown Etiology', 'no label'), ('Chest Pain And/Or Dyspnea', 'no label'), ('Myocardial Infarction', 'no label'), ('Myocardial Lesion', 'no label'), ('Akinesis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Prognosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('And/Or', 'no label'), ('Acute Myocardial', 'no label'), ('Myocardial', 'no label'), ('Epicardial Coronary', 'no label'), ('Left Ventricular Apex', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21316777||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~32459199||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~20582391|Tako-Tsubo Cardiomyopathy (Ttc) Is A Reversible Cardiomyopathy With A Clinical Presentation Indistinguishable From Myocardial Infarction. Ttc Is Estimated To Represent 1%-2% Of Patients Presenting With Acute Myocardial Infarction. It Most Commonly Occurs In Postmenopausal Women And Is Frequently Precipitated By A Stressful Event. Chest Pain And Dyspnea Are The Typical Presenting Symptoms. Transient St-Segment Elevation On Ecg And A Small Rise In Cardiac Biomarkers Are Common. Characteristic Wall Motion Abnormalities Extend Beyond The Territory Of A Single Epicardial Coronary Artery In The Absence Of Obstructive Coronary Lesions. Supportive Treatment Leads To Spontaneous Rapid Recovery In Nearly All Patients. The Prognosis Is Excellent, And Recurrence Occurs In < 10% Of Patients. In This Article, We Review The Clinical Features Of Ttc That Form The Basis Of The Mayo Clinic Diagnostic Criteria, As Well As The Long-Term Prognosis For This Type Of Cardiomyopathy.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Reversible Cardiomyopathy', 'no label'), ('Clinical Presentation', 'no label'), ('Myocardial Infarction', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Occurs', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Precipitated', 'no label'), ('Stressful Event', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Presenting Symptoms', 'no label'), ('Transient', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Cardiac Biomarkers', 'no label'), ('Wall Motion Abnormalities', 'no label'), ('Extend', 'no label'), ('Territory', 'no label'), ('Single Epicardial Coronary Artery', 'no label'), ('Absence', 'no label'), ('Obstructive', 'no label'), ('Coronary Lesions', 'no label'), ('Supportive Treatment Leads', 'no label'), ('Spontaneous', 'no label'), ('Rapid', 'no label'), ('Recovery', 'no label'), ('Patients', 'no label'), ('Prognosis', 'no label'), ('Excellent', 'no label'), ('Recurrence', 'no label'), ('Occurs', 'no label'), ('Patients', 'no label'), ('Article', 'no label'), ('Review', 'no label'), ('Clinical Features', 'no label'), ('Ttc', 'no label'), ('Mayo Clinic Diagnostic Criteria', 'no label'), ('Long-Term Prognosis', 'no label'), ('Cardiomyopathy', 'no label')]|[('Territory', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Cardiomyopathy', 'no label'), ('Myocardial Infarction', 'no label'), ('Myocardial Infarction', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Obstructive Coronary Lesions', 'no label'), ('Prognosis', 'no label'), ('Prognosis', 'no label'), ('Cardiomyopathy', 'no label')]|[('Myocardial', 'no label'), ('Patients', 'no label'), ('Acute Myocardial', 'no label'), ('Women', 'no label'), ('Cardiac', 'no label'), ('Wall', 'no label'), ('Coronary Lesions', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Type', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19800075|"From The Electrocardiographic (Ecg) Point Of View, The Tako-Tsubo Cardiomyopathy (Ttc) Behaves Like An Acute Subepicardial Circumferential Ischemic Syndrome. The Electrical Manifestations Are Significantly Different From Those Of Acute Transmural Segmental Ischemia, In Which The Ecg Primarily Expresses The Electrophysiologic And Metabolic Changes Occurring In The Subepicardial Layer. In Comparison With Transmural Anterior Ischemia And Despite Acute Contraction Impairment (Circumferential Middle And Apical Dyskinesis And Basal Hyperkinesis), In Ttc There Is Typically Only Moderate St Elevation In The Precordial Leads. This Paradox Can Be Understood By Taking Into Consideration The Molecular Biology And Basic Electrophysiology. In The Senescent Female With Hypoestrogenemia, The Subepicardium Is Almost Totally Unprotected Against ""Adrenergic Storm."" In The Fertile Female, Estrogen Plays The Pivotal Role Of Protecting The Myocardium At Many Levels Of The Metabolic Cascade, Such As In The Regulation Of The Presynaptic Release Of Adrenergic Substances And By Increasing The Release Of Adenosine. There Is Consequential Increase Of The Adenosine Triphosphate (Atp)-Sensitive K+ Channels, Thus Regulating The Inward Flow Of Ca2+ Toward The Sarcoplasmic Reticulum. The Atp-Sensitive K+ Channels Hyperpolarize The Subepicardial Cells During Extremely Aggressive Situations Such As Ischemia And Adrenergic Storm. The Hyperpolarization Of The Subepicardium Is Manifested In The Ecg By Tall, Peaked T Waves, Indicating An Increase Of The Repolarization Gradient Between The Subendocardial And Subepicardial Layers. In The Absence Of Estrogen, There Are Severe Decreases In The Concentration Of Adenosine And In The Density Of The Atp-Sensitive K+ Channels. The Subepicardial Myocytes Cannot Be Hyperpolarized, And The Adrenergic Storm Is Manifested By Moderate St-T Elevation. Furthermore, The Very Rapid Appearance And Disappearance Of A Q Wave Are ""Against The Rules."" This Is A Classical Example Of Electrical Stunning, That Disappears Before Mechanical Stunning In Which Contraction Is Typically Recovered Only After 1 Week."|[('Electrocardiographic (Ecg) Point', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Behaves', 'no label'), ('Acute', 'no label'), ('Subepicardial Circumferential Ischemic Syndrome', 'no label'), ('Electrical Manifestations', 'no label'), ('Acute Transmural Segmental Ischemia', 'no label'), ('Ecg Primarily Expresses', 'no label'), ('Electrophysiologic', 'no label'), ('Metabolic', 'no label'), ('Changes', 'no label'), ('Occurring', 'no label'), ('Subepicardial Layer', 'no label'), ('Comparison', 'no label'), ('Transmural Anterior Ischemia', 'no label'), ('Acute Contraction Impairment', 'no label'), ('Circumferential Middle', 'no label'), ('Apical Dyskinesis', 'no label'), ('Basal Hyperkinesis', 'no label'), ('Ttc', 'no label'), ('Moderate', 'no label'), ('St', 'no label'), ('Elevation', 'no label'), ('Precordial Leads', 'no label'), ('Molecular Biology', 'no label'), ('Senescent', 'no label'), ('Female', 'no label'), ('Hypoestrogenemia', 'no label'), ('Subepicardium', 'no label'), ('Unprotected', 'no label'), ('Adrenergic Storm', 'no label'), ('Fertile', 'no label'), ('Female', 'no label'), ('Estrogen Plays', 'no label'), ('Pivotal', 'no label'), ('Myocardium', 'no label'), ('Levels', 'no label'), ('Metabolic Cascade', 'no label'), ('Regulation', 'no label'), ('Presynaptic', 'no label'), ('Release', 'no label'), ('Adrenergic Substances', 'no label'), ('Increasing', 'no label'), ('Release', 'no label'), ('Adenosine', 'no label'), ('Consequential', 'no label'), ('Increase', 'no label'), ('Adenosine Triphosphate (Atp)-Sensitive K+ Channels', 'no label'), ('Regulating', 'no label'), ('Inward Flow', 'no label'), ('Ca2+', 'no label'), ('Toward', 'no label'), ('Sarcoplasmic Reticulum', 'no label'), ('Atp-Sensitive K+ Channels', 'no label'), ('Hyperpolarize', 'no label'), ('Subepicardial Cells', 'no label'), ('Aggressive Situations', 'no label'), ('Ischemia', 'no label'), ('Adrenergic Storm', 'no label'), ('Hyperpolarization', 'no label'), ('Subepicardium', 'no label'), ('Manifested', 'no label'), ('Peaked T Waves', 'no label'), ('Increase', 'no label'), ('Repolarization', 'no label'), ('Gradient', 'no label'), ('Subendocardial', 'no label'), ('Subepicardial Layers', 'no label'), ('Absence', 'no label'), ('Estrogen', 'no label'), ('Severe', 'no label'), ('Decreases', 'no label'), ('Concentration', 'no label'), ('Adenosine', 'no label'), ('Density', 'no label'), ('Atp-Sensitive K+ Channels', 'no label'), ('Subepicardial Myocytes', 'no label'), ('Hyperpolarized', 'no label'), ('Adrenergic Storm', 'no label'), ('Manifested', 'no label'), ('Moderate St-T Elevation', 'no label'), ('Rapid', 'no label'), ('Appearance', 'no label'), ('Disappearance', 'no label'), ('Q Wave', 'no label'), ('Rules', 'no label'), ('Electrical Stunning', 'no label'), ('Disappears', 'no label'), ('Mechanical Stunning', 'no label'), ('Contraction', 'no label'), ('Recovered', 'no label'), ('Week', 'no label')]|[('Electrophysiologic', 'no label'), ('Molecular', 'no label'), ('Subepicardium', 'no label'), ('Adrenergic Substances', 'no label'), ('Adenosine', 'no label'), ('Adenosine Triphosphate', 'no label'), ('K+', 'no label'), ('Ca2+', 'no label'), ('Sarcoplasmic', 'no label'), ('Subepicardial Cells', 'no label'), ('Subepicardium', 'no label'), ('Adenosine', 'no label')]|[('Adenosine Triphosphate (Atp)-Sensitive K+ Channels', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Circumferential Ischemic Syndrome', 'no label'), ('Ischemia', 'no label'), ('Ischemia', 'no label'), ('Hypoestrogenemia', 'no label'), ('Subepicardium', 'no label'), ('Adenosine', 'no label'), ('Adenosine Triphosphate', 'no label'), ('K+', 'no label'), ('Ischemia', 'no label'), ('Subepicardium', 'no label'), ('Estrogen', 'no label'), ('Adenosine', 'no label')]|[('Acute Transmural Segmental', 'no label'), ('Subepicardial Layer', 'no label'), ('Transmural Anterior', 'no label'), ('Circumferential', 'no label'), ('Apical', 'no label'), ('St', 'no label'), ('Subepicardium', 'no label'), ('Estrogen', 'no label'), ('Myocardium', 'no label'), ('Presynaptic', 'no label'), ('Adenosine', 'no label'), ('Adenosine Triphosphate', 'no label'), ('K+', 'no label'), ('Ca2+', 'no label'), ('Sarcoplasmic', 'no label'), ('Subepicardial Cells', 'no label'), ('Subepicardium', 'no label'), ('Ecg', 'no label'), ('Subendocardial', 'no label'), ('Estrogen', 'no label'), ('Adenosine', 'no label'), ('Subepicardial Myocytes', 'no label'), ('A Q Wave', 'no label')]
tako-tsubo cardiomyopathy|pubmed~33722401|Licensed Independent Practitioners In Emergency Clinical Practice Are Tasked With Differentiating Acute Cardiac Presentations. Despite Its Similarity In Clinical Presentation To Acute Coronary Syndrome, Takotsubo Cardiomyopathy Is A Unique Cardiac Disorder Characterized By A Stress-Induced Ballooning Of The Myocardium. Also Known As The Broken Heart Syndrome, Takotsubo Cardiomyopathy Most Frequently Occurs After An Overwhelming Emotional Or Physical Stressor. The Subsequent Impaired Contractility Of The Heart Places The Patient At Risk Of Complications, Including Acute Heart Failure, Cardiogenic Shock, Thromboembolism, Arrhythmias, And Left Ventricular Outflow Obstruction. Takotsubo Cardiomyopathy Is Similar In Presentation To Other Cardiac Disorders; Therefore, Clinicians In Emergency Settings Must Be Efficient And Effective In Their Diagnosis Of This Disorder On The Basis Of Its Distinct Criteria. The Current Article Uses Most Recent Evidence To Describe The Etiology, Pathophysiology, Diagnosis, And Recommended Treatment For Takotsubo Cardiomyopathy To Support Licensed Independent Practitioners In Emergency Departments In Improving Patient Outcomes And Reducing Morbidity.|[('Licensed', 'no label'), ('Emergency Clinical Practice', 'no label'), ('Differentiating', 'no label'), ('Acute Cardiac Presentations', 'no label'), ('Similarity', 'no label'), ('Clinical Presentation', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Unique', 'no label'), ('Cardiac Disorder', 'no label'), ('Characterized', 'no label'), ('Stress-Induced', 'no label'), ('Myocardium', 'no label'), ('Broken Heart Syndrome', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Occurs', 'no label'), ('Emotional Or Physical Stressor', 'no label'), ('Impaired', 'no label'), ('Contractility', 'no label'), ('Heart Places', 'no label'), ('Patient', 'no label'), ('Risk', 'no label'), ('Complications', 'no label'), ('Acute Heart Failure', 'no label'), ('Cardiogenic Shock', 'no label'), ('Thromboembolism', 'no label'), ('Arrhythmias', 'no label'), ('Left Ventricular Outflow Obstruction', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Cardiac Disorders', 'no label'), ('Clinicians', 'no label'), ('Emergency', 'no label'), ('Efficient', 'no label'), ('Effective', 'no label'), ('Diagnosis', 'no label'), ('Disorder', 'no label'), ('Criteria', 'no label'), ('Article', 'no label'), ('Evidence', 'no label'), ('Etiology', 'no label'), ('Pathophysiology', 'no label'), ('Diagnosis', 'no label'), ('Recommended Treatment', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Support Licensed', 'no label'), ('Emergency Departments', 'no label'), ('Improving', 'no label'), ('Patient', 'no label'), ('Outcomes', 'no label'), ('Reducing', 'no label'), ('Morbidity', 'no label')]|[]|[]|[('Acute Coronary Syndrome', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Cardiac Disorder', 'no label'), ('Heart Syndrome', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Acute Heart Failure', 'no label'), ('Cardiogenic Shock', 'no label'), ('Thromboembolism', 'no label'), ('Arrhythmias', 'no label'), ('Left Ventricular Outflow Obstruction', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Cardiac Disorders', 'no label'), ('Disorder', 'no label'), ('Etiology', 'no label'), ('Takotsubo Cardiomyopathy', 'no label')]|[('Cardiac', 'no label'), ('Acute Coronary', 'no label'), ('Cardiac', 'no label'), ('Myocardium.', 'no label'), ('Broken Heart', 'no label'), ('Heart', 'no label'), ('Patient', 'no label'), ('Heart', 'no label'), ('Left Ventricular Outflow', 'no label'), ('Cardiac', 'no label'), ('Patient', 'no label')]
tako-tsubo cardiomyopathy|pubmed~35122776|Takotsubo Cardiomyopathy (Tc) Or Stress-Induced Cardiomyopathy Is A Transient Heart Condition That Clinically Resembles An Acute Coronary Syndrome. This Study Aims To Assess The Incidence Of Life-Threatening Arrhythmias In Patients With Takotsubo Cardiomyopathy And Evaluate The Outcomes Of Patients With Life-Threatening Arrhythmias (Ltas) In Takotsubo Cardiomyopathy Compared With Those Without Lta. We Comprehensively Searched The Pubmed, Google Scholar, And Embase Databases From Inception To February 2021. The Primary Aim Of The Study Was To Determine The Incidence Of Ltas In Tc Patients. Other Outcomes Of Interest Were The Odds Of In-Hospital, Long-Term Mortality, And Cardiogenic Shock (Cs) In Tc Patients With Ltas Versus Those Without Ltas. For All Statistical Analyses, Reviewmanager And Medcalc Were Used. Eighteen Studies Were Included In This Study Involving 55,557 Participants (2,185 With Ltas And 53,372 Without Ltas). The Pooled Incidence Of Ltas In The Patients Of Tc Was Found To Be 6.29% (Ci: 4.70-8.08%; I2 = 94.67%). There Was A Statistically Significant Increased Risk Of In-Hospital Mortality (Or = 4.74; Ci: 2.24-10.04; I2 = 77%, P < 0.0001) And Cardiogenic Shock (Or = 5.60; Ci: 3.51-8.95; I2 = 0%, P < 0.00001) In The Lta Group Versus The Non-Lta Group. Lta Was Not Associated With Long-Term Mortality (Or = 2.23; Ci: 0.94-5.28; I2 = 53%, P = 0.07). The Pooled Incidence Of Life-Threatening Arrhythmias In The Patients Of Tc Was Found To Be 6.29%. In The Group Of Tc Patients With Ltas, The Odds Of In-Hospital Mortality And Cs, Was Higher Than In The Tc Patients Without Ltas.|[('Takotsubo Cardiomyopathy', 'no label'), ('Tc', 'no label'), ('Stress-Induced Cardiomyopathy', 'no label'), ('Transient Heart Condition', 'no label'), ('Clinically Resembles', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Study', 'no label'), ('Assess', 'no label'), ('Incidence', 'no label'), ('Life-Threatening Arrhythmias', 'no label'), ('Patients', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Evaluate', 'no label'), ('Outcomes', 'no label'), ('Patients', 'no label'), ('Life-Threatening Arrhythmias', 'no label'), ('Ltas', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Lta', 'no label'), ('Comprehensively Searched', 'no label'), ('Pubmed', 'no label'), ('Google Scholar', 'no label'), ('Embase Databases', 'no label'), ('Inception', 'no label'), ('Study', 'no label'), ('Incidence', 'no label'), ('Ltas', 'no label'), ('Tc', 'no label'), ('Patients', 'no label'), ('Outcomes', 'no label'), ('Odds', 'no label'), ('In-Hospital', 'no label'), ('Long-Term', 'no label'), ('Mortality', 'no label'), ('Cardiogenic Shock', 'no label'), ('Cs', 'no label'), ('Tc', 'no label'), ('Patients', 'no label'), ('Ltas', 'no label'), ('Ltas', 'no label'), ('Statistical Analyses', 'no label'), ('Reviewmanager', 'no label'), ('Medcalc', 'no label'), ('Studies', 'no label'), ('Study', 'no label'), ('Participants', 'no label'), ('Ltas', 'no label'), ('Ltas', 'no label'), ('Pooled', 'no label'), ('Incidence', 'no label'), ('Ltas', 'no label'), ('Patients', 'no label'), ('Tc', 'no label'), ('Ci', 'no label'), ('Statistically Significant', 'no label'), ('Increased', 'no label'), ('Risk', 'no label'), ('In-Hospital', 'no label'), ('Mortality', 'no label'), ('Ci', 'no label'), ('P\xa0<\xa00.0001', 'no label'), ('Cardiogenic Shock', 'no label'), ('Ci', 'no label'), ('P\xa0<\xa00.00001', 'no label'), ('Lta Group', 'no label'), ('Non-Lta', 'no label'), ('Group', 'no label'), ('Lta', 'no label'), ('Associated With', 'no label'), ('Long-Term Mortality', 'no label'), ('Ci', 'no label'), ('Pooled', 'no label'), ('Incidence', 'no label'), ('Life-Threatening Arrhythmias', 'no label'), ('Patients', 'no label'), ('Tc', 'no label'), ('Group', 'no label'), ('Tc', 'no label'), ('Patients', 'no label'), ('Ltas', 'no label'), ('Odds', 'no label'), ('In-Hospital', 'no label'), ('Mortality', 'no label'), ('Cs', 'no label'), ('Tc', 'no label'), ('Patients', 'no label'), ('Ltas', 'no label')]|[('Tc', 'no label'), ('Lta', 'no label'), ('Tc', 'no label')]|[('Lta', 'no label'), ('Non-Lta Group', 'no label'), ('Lta', 'no label')]|[('Takotsubo Cardiomyopathy', 'no label'), ('Cardiomyopathy', 'no label'), ('Acute Coronary Syndrome', 'no label'), ('Arrhythmias', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Arrhythmias', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Cardiogenic Shock', 'no label'), ('Cardiogenic Shock', 'no label'), ('Arrhythmias', 'no label')]|[('Heart', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lta', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Tc Was Found', 'no label'), ('I2', 'no label'), ('Lta', 'no label'), ('Non-Lta', 'no label'), ('Lta', 'no label'), ('Patients', 'no label'), ('Tc Was Found', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22456259||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~20965597||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~22114832|Tako-Tsubo Cardiomyopathy (Ttc) Is A Heart Syndrome Associated With Transient Myocardial Contractile Dysfunction. The Pathogenesis Of Ttc Remains Unclear. The Purpose Of This Study Was To Investigate Brachial Artery Flow-Mediated Dilation (Fmd) In Patients With Ttc. The Results Of Fmd Tests Of 4 Women With Ttc Were Compared With The Results From 18 Women With St-Elevation Acute Myocardial Infarction (Stemi) And From 26 Healthy Female Volunteers. Fmd Tests In All Patients Were Performed Within 24 Hours Of Admission And Again At 1-3 Weeks As A Follow-Up. The Fmd Levels Were Significantly Lower At The Acute Phase In Patients With Ttc Than In Patients With Stemi And In Healthy Volunteers (P <.01). After 1-3 Weeks, The Fmd Test Results Of Patients With Ttc Had Greatly Increased, And No Significant Differences Were Found Between These Results And The Results From Patients With Stemi (P >.05). Also, There Were No Significant Differences In The Fmd Test Results Between The Group Of Patients With Ttc And The Group Of Healthy Volunteers (P >.05). There Is A Pronounced And Reversible Endothelial Dysfunction In Patients With Ttc, Which Can Impair Myocardial Perfusion.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Heart Syndrome', 'no label'), ('Associated With', 'no label'), ('Transient', 'no label'), ('Myocardial Contractile Dysfunction', 'no label'), ('Pathogenesis', 'no label'), ('Ttc', 'no label'), ('Study', 'no label'), ('Investigate', 'no label'), ('Brachial Artery', 'no label'), ('Flow-Mediated Dilation', 'no label'), ('Fmd', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Fmd', 'no label'), ('Tests', 'no label'), ('Women', 'no label'), ('Ttc', 'no label'), ('Results', 'no label'), ('Women', 'no label'), ('St-Elevation', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Stemi', 'no label'), ('Healthy Female Volunteers', 'no label'), ('Fmd', 'no label'), ('Tests', 'no label'), ('Patients', 'no label'), ('Performed', 'no label'), ('Hours', 'no label'), ('Admission', 'no label'), ('Weeks', 'no label'), ('Follow-Up', 'no label'), ('Fmd', 'no label'), ('Levels', 'no label'), ('Acute Phase', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Stemi', 'no label'), ('Healthy Volunteers', 'no label'), ('Weeks', 'no label'), ('Fmd Test', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Increased', 'no label'), ('Differences', 'no label'), ('Results', 'no label'), ('Results', 'no label'), ('Patients', 'no label'), ('Stemi', 'no label'), ('No Significant', 'no label'), ('Fmd Test', 'no label'), ('Group', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Group', 'no label'), ('Healthy Volunteers', 'no label'), ('Reversible', 'no label'), ('Endothelial Dysfunction', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Impair', 'no label'), ('Myocardial Perfusion', 'no label')]|[('Fmd', 'no label'), ('Fmd', 'no label'), ('Fmd', 'no label'), ('Fmd', 'no label'), ('Fmd', 'no label'), ('Fmd', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Heart Syndrome', 'no label'), ('Myocardial Contractile Dysfunction', 'no label'), ('Pathogenesis', 'no label'), ('Fmd', 'no label'), ('Myocardial Infarction', 'no label'), ('Endothelial Dysfunction', 'no label')]|[('Heart', 'no label'), ('Myocardial Contractile', 'no label'), ('Fmd', 'no label'), ('Patients', 'no label'), ('Fmd', 'no label'), ('Women', 'no label'), ('Women', 'no label'), ('St-Elevation Acute Myocardial Infarction', 'no label'), ('Fmd', 'no label'), ('Patients', 'no label'), ('Fmd', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Fmd', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Fmd', 'no label'), ('Patients', 'no label'), ('Endothelial', 'no label'), ('Patients', 'no label'), ('Myocardial', 'no label')]
tako-tsubo cardiomyopathy|pubmed~18353465|We Report A Rare Case Of An 83-Year-Old Woman With Tako-Tsubo Cardiomyopathy, Who Presented With Variable Forms Of Left Ventricular Dysfunction During Her Clinical Course. The Distribution Regional Wall-Motion Abnormalities Of The Left Ventricle On Echocardiography Had Changed From A Mid-Ventricular Ballooning Type To The Apical Ballooning Type 3 Days From The Onset. We Suggest That These Findings May Indicate A New Or Variant Entity Of Tako-Tsubo Cardiomyopathy.|[('Report', 'no label'), ('Rare', 'no label'), ('Case', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Variable Forms', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Clinical Course', 'no label'), ('Distribution Regional Wall-Motion Abnormalities', 'no label'), ('Left Ventricle', 'no label'), ('Echocardiography', 'no label'), ('Changed', 'no label'), ('Mid-Ventricular Ballooning Type', 'no label'), ('Apical Ballooning Type 3 Days', 'no label'), ('Onset', 'no label'), ('Suggest', 'no label'), ('Findings', 'no label'), ('Indicate', 'no label'), ('Variant', 'no label'), ('Entity', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Mid-Ventricular', 'no label'), ('Apical', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Left Ventricle', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Left Ventricular', 'no label'), ('Left Ventricle', 'no label'), ('Mid-Ventricular', 'no label'), ('Type 3', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22542482||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~22483623||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~33481183|This Case Report Describes A 65-Year-Old Female With Iatrogenic Opioid Use Disorder For Chronic Lower Back Pain, Who Developed Takotsubo Cardiomyopathy On Multiple Occasions Following Buprenorphine Induction. This Patient Had Three Opioid Transfers To Buprenorphine, Over 4 Years, Two Of Which Were Complicated By Takotsubo Cardiomyopathy. In The Transfer Where She Did Not Develop Takotsubo Cardiomyopathy, She Was Treated With High Doses Of The Centrally Acting Agonist, Clonidine (Three Times A Day, Total Of 600 Mcg/Day), Up To And Including The Day Of Her Transfer. This Case Highlights The Potential Consequences Of A Precipitated Withdrawal With Buprenorphine In An Opioid Transfer And Its Possible Prevention With Clonidine. To Our Knowledge, This Is The First Description Of The Recurrent Takotsubo Cardiomyopathy In An Opioid Transfer Setting. Given That Buprenorphine Is A Partial Agonist, In The Presence Of A Full Opioid Agonist, It Can Precipitate Withdrawal Within Minutes To Hours Of Its Administration. Opioid Withdrawal Can Result In A Sympathetic Overdrive. Although Complications Of Opioid Withdrawal Are Extensively Documented, Cardiotoxicity Is Uncommon. As The Use Of Buprenorphine And Its New Injectable Formulations Rise, It Is Important For Prescribers To Be Aware Of This Life Threatening Complication. The Prophylactic Administration Of Clonidine Can Be Considered To Reduce The Risk Of Cardiotoxicity, As Well As Manage Opioid Withdrawal Symptoms.|[('Case Report', 'no label'), ('Describes', 'no label'), ('65-Year-Old', 'no label'), ('Female', 'no label'), ('Iatrogenic', 'no label'), ('Opioid Use Disorder', 'no label'), ('Chronic Lower Back Pain', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Multiple', 'no label'), ('Occasions', 'no label'), ('Buprenorphine', 'no label'), ('Induction', 'no label'), ('Patient', 'no label'), ('Opioid Transfers', 'no label'), ('Buprenorphine', 'no label'), ('Years', 'no label'), ('Complicated', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Transfer', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Treated', 'no label'), ('High Doses', 'no label'), ('Centrally Acting Agonist', 'no label'), ('Clonidine', 'no label'), ('Day', 'no label'), ('Mcg/Day', 'no label'), ('Day', 'no label'), ('Transfer', 'no label'), ('Potential', 'no label'), ('Consequences', 'no label'), ('Precipitated Withdrawal', 'no label'), ('Buprenorphine', 'no label'), ('Opioid Transfer', 'no label'), ('Prevention', 'no label'), ('Clonidine', 'no label'), ('Knowledge', 'no label'), ('Description', 'no label'), ('Recurrent Takotsubo Cardiomyopathy', 'no label'), ('Opioid Transfer Setting', 'no label'), ('Buprenorphine', 'no label'), ('Partial Agonist', 'no label'), ('Opioid Agonist', 'no label'), ('Precipitate', 'no label'), ('Withdrawal', 'no label'), ('Administration', 'no label'), ('Opioid Withdrawal', 'no label'), ('Sympathetic', 'no label'), ('Overdrive', 'no label'), ('Complications', 'no label'), ('Opioid Withdrawal', 'no label'), ('Extensively Documented', 'no label'), ('Cardiotoxicity', 'no label'), ('Uncommon', 'no label'), ('Buprenorphine', 'no label'), ('Prescribers', 'no label'), ('Life Threatening Complication', 'no label'), ('Prophylactic Administration', 'no label'), ('Clonidine', 'no label'), ('Reduce', 'no label'), ('Risk', 'no label'), ('Cardiotoxicity', 'no label'), ('Manage', 'no label'), ('Opioid Withdrawal', 'no label'), ('Symptoms', 'no label')]|[('Agonist', 'no label')]|[]|[('Lower Back Pain', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Buprenorphine', 'no label'), ('Buprenorphine', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Clonidine', 'no label'), ('Buprenorphine', 'no label'), ('Clonidine', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Buprenorphine', 'no label'), ('Cardiotoxicity', 'no label'), ('Buprenorphine', 'no label'), ('Clonidine', 'no label'), ('Cardiotoxicity', 'no label')]|[('Opioid', 'no label'), ('Buprenorphine', 'no label'), ('Patient', 'no label'), ('Opioid', 'no label'), ('Buprenorphine', 'no label'), ('Clonidine', 'no label'), ('Buprenorphine', 'no label'), ('Clonidine', 'no label'), ('Buprenorphine', 'no label'), ('A Full Opioid', 'no label'), ('Opioid', 'no label'), ('Buprenorphine', 'no label'), ('Clonidine', 'no label'), ('Opioid', 'no label')]
tako-tsubo cardiomyopathy|pubmed~28819491|Stress Cardiomyopathy Or Tako Tsubo Cardiomyopathy Is A Cardiac Pathology Evoking Acute Coronary Syndrome Characterized By Electrocardiographic Signs, Cardiac Enzyme Elevation And No Obstructive Coronary Lesions. It Generally Affects Postmenopausal Women And It Usually Occurs After Periods Of Intense Stress. Disease Onset Is Widely Variable, Ranging From Anginal Pain (Most Common) To Cardiogenic Shock. Exact Pathophysiological Mechanism Continues To Be Debated. Various Hypotheses Have Been Posited. Abrupt Elevation Of Adrenaline Levels Appears To Be The Most Credible. In Particular, There Is No Consensus On Treatment And Prevention. Questions May Then Be Asked About The Existence Of An Underlying Psychiatric Pathology Or A Personality Predisposition And, Therefore, About The Role Of The Psychiatrist In The Management Of This Condition.|[('Stress Cardiomyopathy', 'no label'), ('Tako Tsubo Cardiomyopathy', 'no label'), ('Cardiac Pathology', 'no label'), ('Evoking Acute Coronary Syndrome', 'no label'), ('Characterized', 'no label'), ('Electrocardiographic Signs', 'no label'), ('Cardiac Enzyme', 'no label'), ('Elevation', 'no label'), ('Obstructive', 'no label'), ('Coronary Lesions', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Occurs', 'no label'), ('Periods', 'no label'), ('Intense Stress', 'no label'), ('Variable', 'no label'), ('Ranging', 'no label'), ('Anginal Pain', 'no label'), ('Cardiogenic Shock', 'no label'), ('Pathophysiological', 'no label'), ('Mechanism', 'no label'), ('Debated', 'no label'), ('Hypotheses', 'no label'), ('Posited', 'no label'), ('Abrupt Elevation', 'no label'), ('Adrenaline', 'no label'), ('Appears', 'no label'), ('Credible', 'no label'), ('Consensus', 'no label'), ('Treatment', 'no label'), ('Prevention', 'no label'), ('Existence', 'no label'), ('Psychiatric Pathology', 'no label'), ('Personality', 'no label'), ('Management', 'no label'), ('Condition', 'no label')]|[('Enzyme', 'no label'), ('Adrenaline', 'no label')]|[]|[('Stress Cardiomyopathy', 'no label'), ('Tako', 'no label'), ('Cardiomyopathy', 'no label'), ('Coronary Syndrome', 'no label'), ('Obstructive Coronary Lesions', 'no label'), ('Anginal Pain', 'no label'), ('Cardiogenic Shock', 'no label'), ('Adrenaline', 'no label')]|[('Cardiac Pathology', 'no label'), ('Cardiac', 'no label'), ('Women', 'no label'), ('Adrenaline', 'no label')]
tako-tsubo cardiomyopathy|pubmed~34426937|This Case Report Describes A 31-Year-Old Man With 10 Years Of Cocaine And Cannabis Dependence Who Developed Reverse Takotsubo Cardiomyopathy (Rtc), A Rare Variant Of Takotsubo Cardiomyopathy. He Presented To The Emergency Department (Ed) With Severe Left Temporal Headache And Vomiting Which Began Whilst Smoking Cannabis And Several Hours After Smoking Methamphetamine And Using Cocaine Via Insufflation. Computed Tomography And Angiography Of The Brain Was Normal, And The Headache Resolved With Analgesia. Urine Drug Screen Was Positive For Benzodiazepines, Cannabinoids, Cocaine, Opiates (Attributed To Morphine Administered In Ed) And Amphetamines. Three Hours Later He Had A Seizure And Within 10 Min Developed Cardiogenic Shock With Antero-Inferior St Segment Depression On Electrocardiogram And Troponin-T Rise To 126 Ng/L. Coronary Angiography Demonstrated Normal Coronary Arteries. Transthoracic Echocardiogram Demonstrated Severely Impaired Left Ventricular (Lv) Systolic Function With Ejection Fraction 15-20% And Hypokinesis Sparing The Apex. Thyrotoxicosis, Nutritional, Vasculitic, Autoimmune And Viral Screens Were Negative. Cardiac Magnetic Resonance Imaging Demonstrated Severe Lv Functional Impairment With Dilated And Hypocontractile Basal Segments, And T2 Hyperintensity Consistent With Myocardial Oedema And Rtc. He Received Supportive Management. Proposed Mechanisms Of Rtc Include Catecholamine Cardiotoxicity And Coronary Artery Vasospasm. In This Case, Multiple Insults Including Severe Headache, Cannabis Hyperemesis And Cocaine And Methamphetamine-Induced Serotonin Toxicity Culminated In A Drug-Induced Seizure Which Led To Catecholamine Cardiotoxicity Resulting In Rtc. Clinicians Should Be Cognizant Of Stress Cardiomyopathy As A Differential Diagnosis In Patients With Substance Use Disorders.|[('Case Report', 'no label'), ('Describes', 'no label'), ('Years', 'no label'), ('Cocaine', 'no label'), ('Cannabis Dependence', 'no label'), ('Reverse Takotsubo Cardiomyopathy', 'no label'), ('Rtc', 'no label'), ('Rare', 'no label'), ('Variant', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Emergency Department', 'no label'), ('Severe', 'no label'), ('Left Temporal Headache', 'no label'), ('Vomiting', 'no label'), ('Began', 'no label'), ('Smoking', 'no label'), ('Cannabis', 'no label'), ('Hours', 'no label'), ('Smoking', 'no label'), ('Methamphetamine', 'no label'), ('Cocaine', 'no label'), ('Insufflation', 'no label'), ('Computed Tomography', 'no label'), ('Angiography', 'no label'), ('Brain', 'no label'), ('Headache Resolved With', 'no label'), ('Analgesia', 'no label'), ('Urine Drug Screen', 'no label'), ('Benzodiazepines', 'no label'), ('Cannabinoids', 'no label'), ('Cocaine', 'no label'), ('Opiates', 'no label'), ('Morphine', 'no label'), ('Amphetamines', 'no label'), ('Hours', 'no label'), ('Seizure', 'no label'), ('Cardiogenic Shock', 'no label'), ('Antero-Inferior St Segment Depression', 'no label'), ('Electrocardiogram', 'no label'), ('Troponin-T', 'no label'), ('Ng/L. Coronary Angiography', 'no label'), ('Normal Coronary Arteries', 'no label'), ('Transthoracic Echocardiogram', 'no label'), ('Demonstrated Severely Impaired', 'no label'), ('Left Ventricular (Lv) Systolic Function', 'no label'), ('Ejection Fraction', 'no label'), ('Hypokinesis', 'no label'), ('Sparing', 'no label'), ('Apex', 'no label'), ('Thyrotoxicosis', 'no label'), ('Nutritional', 'no label'), ('Vasculitic', 'no label'), ('Autoimmune And Viral Screens', 'no label'), ('Cardiac Magnetic Resonance Imaging', 'no label'), ('Demonstrated Severe Lv Functional Impairment', 'no label'), ('Dilated', 'no label'), ('Hypocontractile', 'no label'), ('Basal Segments', 'no label'), ('T2', 'no label'), ('Hyperintensity', 'no label'), ('Consistent With', 'no label'), ('Myocardial Oedema', 'no label'), ('Rtc', 'no label'), ('Supportive Management', 'no label'), ('Mechanisms', 'no label'), ('Rtc', 'no label'), ('Catecholamine Cardiotoxicity', 'no label'), ('Coronary Artery', 'no label'), ('Vasospasm', 'no label'), ('Case', 'no label'), ('Multiple Insults', 'no label'), ('Severe Headache', 'no label'), ('Cannabis Hyperemesis', 'no label'), ('Cocaine', 'no label'), ('Methamphetamine-Induced', 'no label'), ('Serotonin', 'no label'), ('Toxicity', 'no label'), ('Culminated', 'no label'), ('Drug-Induced Seizure', 'no label'), ('Catecholamine', 'no label'), ('Cardiotoxicity', 'no label'), ('Resulting', 'no label'), ('Rtc', 'no label'), ('Clinicians', 'no label'), ('Cognizant', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Differential Diagnosis', 'no label'), ('Patients', 'no label'), ('Substance Use Disorders', 'no label')]|[('Rtc', 'no label'), ('Cannabis', 'no label'), ('Drug', 'no label'), ('Benzodiazepines', 'no label'), ('Cannabinoids', 'no label'), ('Morphine', 'no label'), ('Segment', 'no label'), ('Viral', 'no label'), ('Rtc', 'no label'), ('Rtc', 'no label'), ('Catecholamine', 'no label'), ('Cannabis', 'no label'), ('Serotonin', 'no label'), ('Catecholamine', 'no label'), ('Rtc', 'no label'), ('Substance', 'no label')]|[('Ng/L.', 'no label')]|[('Cocaine', 'no label'), ('Cannabis', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Rtc', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Headache', 'no label'), ('Vomiting', 'no label'), ('Cannabis', 'no label'), ('Methamphetamine', 'no label'), ('Cocaine', 'no label'), ('Headache', 'no label'), ('Benzodiazepines', 'no label'), ('Cannabinoids', 'no label'), ('Cocaine', 'no label'), ('Morphine Administered', 'no label'), ('Amphetamines', 'no label'), ('Seizure', 'no label'), ('Cardiogenic Shock', 'no label'), ('Segment Depression', 'no label'), ('Troponin-T', 'no label'), ('Left Ventricular', 'no label'), ('Thyrotoxicosis', 'no label'), ('Functional Impairment', 'no label'), ('Dilated And Hypocontractile Basal Segments, And T2 Hyperintensity', 'no label'), ('Myocardial Oedema', 'no label'), ('Rtc', 'no label'), ('Rtc', 'no label'), ('Catecholamine Cardiotoxicity', 'no label'), ('Coronary Artery Vasospasm', 'no label'), ('Headache', 'no label'), ('Cannabis Hyperemesis', 'no label'), ('Cocaine', 'no label'), ('Serotonin Toxicity', 'no label'), ('Seizure', 'no label'), ('Catecholamine Cardiotoxicity', 'no label'), ('Rtc', 'no label'), ('Stress Cardiomyopathy', 'no label')]|[('Cocaine', 'no label'), ('Cannabis Dependence', 'no label'), ('Rtc', 'no label'), ('Methamphetamine', 'no label'), ('Cocaine', 'no label'), ('Brain', 'no label'), ('Urine', 'no label'), ('Benzodiazepines', 'no label'), ('Cannabinoids', 'no label'), ('Cocaine', 'no label'), ('Opiates', 'no label'), ('Morphine', 'no label'), ('Amphetamines', 'no label'), ('Troponin-T', 'no label'), ('Left Ventricular', 'no label'), ('Cardiac', 'no label'), ('Lv', 'no label'), ('Hypocontractile Basal Segments', 'no label'), ('T2 Hyperintensity', 'no label'), ('Myocardial Oedema', 'no label'), ('Rtc', 'no label'), ('Rtc', 'no label'), ('Catecholamine', 'no label'), ('Coronary Artery', 'no label'), ('Case', 'no label'), ('Cocaine', 'no label'), ('Serotonin', 'no label'), ('Catecholamine', 'no label'), ('Rtc', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~20091403|Tako-Tsubo Cardiomyopathy Is A Form Of Reversible Left Ventricular Dysfunction, With A Clinical And Electrocardiographic Picture Of Acute Myocardial Infarction In The Absence Of Significant Coronary Disease. The Precise Clinical Features And Etiologic Basis Of This Syndrome Remain Unclear, Although An Association With Emotional Or Stressful Triggers Has Been Recognized. We Describe The First Case Of This Syndrome Complicated With A Ventricular Septal Perforation And Dissection.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Reversible', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Clinical And Electrocardiographic Picture', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Absence', 'no label'), ('Significant', 'no label'), ('Coronary Disease', 'no label'), ('Clinical Features', 'no label'), ('Etiologic Basis', 'no label'), ('Syndrome Remain Unclear', 'no label'), ('Association', 'no label'), ('Emotional', 'no label'), ('Stressful', 'no label'), ('Triggers', 'no label'), ('Recognized', 'no label'), ('Syndrome', 'no label'), ('Complicated With', 'no label'), ('Ventricular Septal Perforation', 'no label'), ('Dissection', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Left Ventricular Dysfunction', 'no label'), ('Myocardial Infarction', 'no label'), ('Coronary Disease', 'no label'), ('Ventricular Septal Perforation', 'no label')]|[('Left Ventricular', 'no label'), ('Acute Myocardial Infarction In', 'no label'), ('Ventricular Septal', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19801564|We Report The Case Of A 71-Year-Old Woman, With A Dual Chamber Pacemaker (Pm), In Whom A Pm Syndrome, Due To Loss Of Atrial Sensing And Pacing, Was Associated With A Tako-Tsubo Cardiomyopathy (Ttc). The Repositioning Of The Atrial Lead Immediately Improved Symptoms, Whereas Complete Regression Of Left Ventricular Wall Motion Abnormalities Occurred After 1 Month. We Hypothesize That Haemodynamic And Hormonal Responses Associated With A Pm Syndrome, Such As Increased Levels Of Catecholamines, May Account For Ttc In Our Patient.|[('Report', 'no label'), ('Woman', 'no label'), ('Dual Chamber Pacemaker', 'no label'), ('Pm', 'no label'), ('Pm Syndrome', 'no label'), ('Atrial Sensing', 'no label'), ('Pacing', 'no label'), ('Associated With', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Atrial Lead', 'no label'), ('Improved', 'no label'), ('Symptoms', 'no label'), ('Complete Regression', 'no label'), ('Left Ventricular Wall Motion Abnormalities', 'no label'), ('Month', 'no label'), ('Hypothesize', 'no label'), ('Haemodynamic', 'no label'), ('Hormonal Responses', 'no label'), ('Associated With', 'no label'), ('A Pm Syndrome', 'no label'), ('Increased', 'no label'), ('Levels', 'no label'), ('Catecholamines', 'no label'), ('Ttc', 'no label'), ('Patient', 'no label')]|[('Lead', 'no label'), ('Catecholamines', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Left Ventricular Wall Motion Abnormalities Occurred After 1 Month.', 'no label'), ('Catecholamines', 'no label')]|[('Case Of A', 'no label'), ('Atrial', 'no label'), ('Atrial Lead', 'no label'), ('Left Ventricular Wall', 'no label'), ('Catecholamines', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19100634|Tako-Tsubo Cardiomyopathy (Ttc) Is Characterized By The Sudden Onset Of Severe Left Ventricular Contractile Dysfunction Following Profound Emotional Or Physical Stress. The Underlying Pathomechanism Still Remains To Be Elucidated. In This Case We Present A, To Date, Unique Case Of A Female Patient Suffering From An Episode Of Major Depression Who Shows Characteristic Features Of Ttc.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Characterized', 'no label'), ('Sudden', 'no label'), ('Severe', 'no label'), ('Left Ventricular Contractile Dysfunction', 'no label'), ('Profound Emotional Or Physical Stress', 'no label'), ('Pathomechanism', 'no label'), ('Female', 'no label'), ('Suffering', 'no label'), ('Episode', 'no label'), ('Major Depression', 'no label'), ('Ttc', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Left Ventricular Contractile Dysfunction', 'no label'), ('Depression', 'no label')]|[('Left Ventricular', 'no label'), ('Patient', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22421505|Tako-Tsubo Cardiomyopathy Is A Relatively Recently Recognized Clinical Entity, Which Presents Similar To An Acute Myocardial Infarction But There Is No Evidence Of Obstructive Coronary Artery Disease On Cardiac Catheterization. It Mostly Affects Postmenopausal Women And An Episode Of Acute Illness Or Stress Can Often Be Identified Preceding The Presentation. Tako-Tsubo Cardiomyopathy (Tcm) Usually Has A Favorable Outcome And An Excellent Prognosis But, In Rare Instances, It Can Be Associated With Life Threatening Complications. We Report A Unique Case Of Tcm Where The Patient Presented With A Transient Complete Heart Block.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Clinical Entity', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Cardiac Catheterization', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Episode', 'no label'), ('Acute Illness Or Stress', 'no label'), ('Identified', 'no label'), ('Preceding', 'no label'), ('Presentation', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tcm', 'no label'), ('Has A', 'no label'), ('Favorable Outcome', 'no label'), ('Excellent Prognosis', 'no label'), ('Rare', 'no label'), ('Instances', 'no label'), ('Associated With', 'no label'), ('Life Threatening', 'no label'), ('Complications', 'no label'), ('Report', 'no label'), ('Unique', 'no label'), ('Case', 'no label'), ('Tcm', 'no label'), ('Patient', 'no label'), ('Transient Complete Heart Block', 'no label')]|[]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Acute Illness Or Stress Can Often Be Identified Preceding The Presentation', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Heart Block', 'no label')]|[('Myocardial', 'no label'), ('Coronary Artery', 'no label'), ('Cardiac', 'no label'), ('Women', 'no label'), ('Acute Illness', 'no label'), ('Stress', 'no label'), ('Patient', 'no label'), ('Heart', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19430344|A 70-Year-Old Woman With Extensive Psychiatric History, Including Depression And Bipolar Disorder, And Past Medical History Of Mitral Valve Prolapse Repair (3 Years Ago) Was Brought In From The Psychiatry Ward To The Emergency Department For Evaluation Of Ecg Changes Following Electroconvulsive Therapy (Ect). Ecg Done After The Procedure Showed St Elevations In V2-V3 And New T-Wave Inversions In The Precordial Leads. Troponin Level Was 0.23 Ng/Ml. An Echocardiogram Revealed Apical Akinesis With Segmental Wall Motion Abnormalities And A Decreased Ejection Fraction Of 30-35%. Cardiac Catheterization Revealed Clean Coronaries. A Repeat Echocardiogram 6 Weeks After The Event Showed A Normal Ejection Fraction. A Diagnosis Of Tako-Tsubo Cardiomyopathy Was Made. Ect Causes A Significant Increase In Bigeminy, Trigeminy, And Supraventricular Tachycardia. Ect Is Associated With A Low Mortality Rate; In The Range Of 0.01-0.1% And 75% Of These Are Attributable To Cardiovascular Causes. To Our Knowledge, This Is The First Reported Case Of Tako-Tsubo Syndrome Immediately Following Electroconvulsive Therapy.|[('Woman', 'no label'), ('Psychiatric History', 'no label'), ('Depression', 'no label'), ('Bipolar Disorder', 'no label'), ('Past Medical History', 'no label'), ('Mitral Valve Prolapse Repair', 'no label'), ('Ago', 'no label'), ('Psychiatry Ward', 'no label'), ('Emergency Department', 'no label'), ('Evaluation', 'no label'), ('Ecg Changes', 'no label'), ('Electroconvulsive Therapy', 'no label'), ('Ect', 'no label'), ('Ecg Done', 'no label'), ('Procedure Showed St', 'no label'), ('Elevations', 'no label'), ('New T-Wave', 'no label'), ('Inversions', 'no label'), ('Precordial Leads', 'no label'), ('Troponin', 'no label'), ('Level', 'no label'), ('Echocardiogram', 'no label'), ('Revealed', 'no label'), ('Apical Akinesis', 'no label'), ('Segmental Wall Motion Abnormalities', 'no label'), ('Decreased Ejection Fraction', 'no label'), ('Cardiac Catheterization', 'no label'), ('Revealed', 'no label'), ('Clean Coronaries', 'no label'), ('Echocardiogram', 'no label'), ('Weeks', 'no label'), ('Event', 'no label'), ('Normal Ejection Fraction', 'no label'), ('Diagnosis', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ect', 'no label'), ('Causes', 'no label'), ('Increase', 'no label'), ('Bigeminy', 'no label'), ('Trigeminy', 'no label'), ('Supraventricular Tachycardia', 'no label'), ('Ect', 'no label'), ('Associated With', 'no label'), ('Low', 'no label'), ('Mortality Rate', 'no label'), ('Range', 'no label'), ('Attributable', 'no label'), ('Cardiovascular Causes', 'no label'), ('Knowledge', 'no label'), ('Case', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Electroconvulsive Therapy', 'no label')]|[('Apical', 'no label'), ('Repeat', 'no label')]|[('Ect', 'no label'), ('Ect', 'no label')]|[('Depression', 'no label'), ('Bipolar Disorder', 'no label'), ('Mitral Valve Prolapse Repair', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Bigeminy', 'no label'), ('Trigeminy', 'no label'), ('Supraventricular Tachycardia', 'no label'), ('Tako-Tsubo Syndrome', 'no label')]|[('Mitral Valve Prolapse', 'no label'), ('Ecg', 'no label'), ('Ect', 'no label'), ('St Elevations', 'no label'), ('Precordial', 'no label'), ('Troponin', 'no label'), ('Apical', 'no label'), ('Cardiac', 'no label'), ('Trigeminy', 'no label'), ('Supraventricular Tachycardia', 'no label'), ('Cardiovascular', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22523255||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~22056476||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~18404003|We Report A Case Of Transient Tako-Tsubo Cardiomyopathy Characterized By An Unusual Trigger In A Woman Victim Of Near-Drowning Syndrome. After 24 H, Electrocardiogram Changes And A Typical Echocardiographic Pattern Of Apical Ballooning With A Mild Increase Of Serum Troponin Level Induced The Suspicion Of Tako-Tsubo Cardiomyopathy Despite The Absence Of Chest Pain. Left Ventriculography Confirmed The Apical Ballooning, And Coronary Angiography Revealed Normal Coronary Arteries. Electrocardiogram Changes And Apical Contraction Abnormalities Were Reversed Within 1 Month. In Conclusion, We Hypothesize That Hypoxemia Related To Near-Drowning Syndrome Could Have Induced Transient Myocardial Dysfunction Mediated By A Sympathetic Nerve Activation.|[('Report', 'no label'), ('Transient', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Characterized', 'no label'), ('Unusual', 'no label'), ('Trigger', 'no label'), ('Woman', 'no label'), ('Victim', 'no label'), ('Electrocardiogram Changes', 'no label'), ('Echocardiographic', 'no label'), ('Apical Ballooning With A Mild', 'no label'), ('Increase', 'no label'), ('Serum', 'no label'), ('Troponin', 'no label'), ('Level', 'no label'), ('Induced', 'no label'), ('Suspicion', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Absence', 'no label'), ('Chest Pain', 'no label'), ('Left Ventriculography', 'no label'), ('Confirmed', 'no label'), ('Apical Ballooning', 'no label'), ('Coronary Angiography', 'no label'), ('Revealed', 'no label'), ('Normal Coronary Arteries', 'no label'), ('Electrocardiogram Changes', 'no label'), ('Apical Contraction', 'no label'), ('Month', 'no label'), ('Hypothesize', 'no label'), ('Hypoxemia', 'no label'), ('Induced', 'no label'), ('Transient', 'no label'), ('Myocardial Dysfunction', 'no label'), ('Sympathetic Nerve', 'no label'), ('Activation', 'no label')]|[('Apical', 'no label'), ('Apical', 'no label')]|[]|[('Transient Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Chest Pain', 'no label'), ('Hypoxemia', 'no label'), ('Myocardial Dysfunction', 'no label')]|[('Apical', 'no label'), ('Serum Troponin Level', 'no label'), ('Apical', 'no label'), ('Myocardial', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19816866|The Exact Pathophysiology Of Tako-Tsubo Cardiomyopathy (Ttc) Is Unclear. A Nonapical Form Of Ttc Precipitated By Emotional Stress Is Presented. Findings On 12 Lead Ecg And Coronary Angiogram Are Discussed. The Role Of Specialized Investigations Such As Cardiac Mri And Tissue Doppler Imaging Are Reviewed. We Then Examine The Probable Molecular Explanations For This Condition And Suggest A Probable Molecular Mechanism Based On Animal Studies. Future Therapeutic Options Are Also Briefly Discussed.|[('Exact Pathophysiology', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Nonapical Form', 'no label'), ('Ttc', 'no label'), ('Precipitated', 'no label'), ('Emotional Stress', 'no label'), ('Findings', 'no label'), ('Lead Ecg', 'no label'), ('Coronary Angiogram', 'no label'), ('Specialized Investigations', 'no label'), ('Cardiac Mri', 'no label'), ('Tissue Doppler Imaging', 'no label'), ('Reviewed', 'no label'), ('Examine', 'no label'), ('Probable', 'no label'), ('Molecular', 'no label'), ('Condition', 'no label'), ('Suggest', 'no label'), ('Probable', 'no label'), ('Molecular Mechanism', 'no label'), ('Animal Studies', 'no label'), ('Therapeutic Options', 'no label'), ('Briefly', 'no label')]|[('Lead', 'no label'), ('Molecular', 'no label'), ('Molecular', 'no label'), ('Animal', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label')]|[('Cardiac', 'no label'), ('Tissue', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23064630|A 94-Year-Old Woman Was Admitted To Our Hospital Because Of Altered Mental Status And Cerebellar Ataxia Of Left Upper And Lower Extremities. A Brain Ct Scan Revealed A Right Cerebellar Hemorrhage Approximately 15 Cc. Plasma Brain Natriuretic Peptide (Bnp) Value On Admission Was 1,064.6 Pg/Ml. Twelve-Lead Ecg Revealed Negative T-Wave In V3-V5. Transthoracic Echocardiology Confirmed An Ejection Fraction Of 35%, And Left Ventricular Apical Akinesia And Basal Hyperkinesis Were Seen. Plasma Bnp Value Was Dramatically Declined In The Subacute Phase Of Cerebellar Hemorrhage. On The 14Th Day, Echocardiography Showed Completely Improvement Of The Left Ventricular Wall Abnormalities. Therefore, We Diagnosed Having As A Tako-Tsubo Cardiomyopathy. Tako-Tsubo Cardiomyopathy Is A Rare Complication Of Acute Intracerebral Hemorrhage. In The Present Case, Plasma Bnp Was Effective As A Screening Marker Of Tako-Tsubo Cardiomyopathy And Serial Measurement Of Bnp Was Made Helpful To Know Cardiac Status.|[('Hospital', 'no label'), ('Altered Mental Status', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Left Upper', 'no label'), ('Lower Extremities', 'no label'), ('Brain Ct Scan', 'no label'), ('Revealed', 'no label'), ('Right Cerebellar Hemorrhage', 'no label'), ('Cc', 'no label'), ('Plasma', 'no label'), ('Brain Natriuretic Peptide', 'no label'), ('Admission', 'no label'), ('Twelve-Lead', 'no label'), ('Ecg Revealed', 'no label'), ('Negative T-Wave', 'no label'), ('V3-V5', 'no label'), ('Transthoracic Echocardiology', 'no label'), ('Confirmed', 'no label'), ('Ejection Fraction', 'no label'), ('Left Ventricular Apical Akinesia', 'no label'), ('Basal Hyperkinesis', 'no label'), ('Plasma', 'no label'), ('Bnp Value', 'no label'), ('Declined', 'no label'), ('Subacute Phase', 'no label'), ('Cerebellar Hemorrhage', 'no label'), ('Echocardiography', 'no label'), ('Completely Improvement', 'no label'), ('Left Ventricular Wall Abnormalities', 'no label'), ('Diagnosed', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Rare', 'no label'), ('Complication', 'no label'), ('Acute Intracerebral Hemorrhage', 'no label'), ('Case', 'no label'), ('Plasma', 'no label'), ('Bnp', 'no label'), ('Screening Marker', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Serial Measurement', 'no label'), ('Bnp', 'no label'), ('Know Cardiac Status', 'no label')]|[('Bnp', 'no label'), ('Apical', 'no label'), ('Bnp', 'no label'), ('Bnp', 'no label'), ('Bnp', 'no label')]|[('Ct', 'no label')]|[('Cerebellar Ataxia', 'no label'), ('Cerebellar Hemorrhage', 'no label'), ('Left Ventricular Apical Akinesia And Basal Hyperkinesis Were Seen.', 'no label'), ('Cerebellar Hemorrhage', 'no label'), ('Ventricular Wall Abnormalities', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Acute Intracerebral Hemorrhage', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Cerebellar', 'no label'), ('Left Upper', 'no label'), ('Brain', 'no label'), ('Right Cerebellar', 'no label'), ('Bnp', 'no label'), ('T-Wave', 'no label'), ('Left Ventricular', 'no label'), ('Cerebellar', 'no label'), ('Left Ventricular Wall', 'no label'), ('Acute Intracerebral', 'no label'), ('Plasma Bnp', 'no label'), ('Bnp', 'no label'), ('Cardiac', 'no label')]
tako-tsubo cardiomyopathy|pubmed~29122513|Tako-Tsubo Syndrome Is A Potentially Serious Disease During The Acute Phase. It Mimics Myocardial Infarction, But With No Potentially Causative Coronary Lesions. The Aim Of This Study Was To Analyze The Clinical Course And Outcome Of Patients With Tako-Tsubo Syndrome By Sex. We Analyzed The Characteristics Of Patients Included In The Retako Registry From 2003 To 2015, A Multicenter Registry With Participation Of 32 Spanish Hospitals. Of 562 Patients Included, 493 (87.7%) Were Women. Chest Pain Was Less Frequent As An Initial Symptom In Men Than In Women (43 [66.2%] Vs 390 [82.8%]; P < .01). The Prognosis Was Worse In Men, With Higher In-Hospital Mortality (3 [4.4%] Vs 1 [0.2%]; P < .01), Longer Intensive Care Stay (4.2 ± 3.7 Vs 3.2 ± 3.2 Days; P = .03) And A Higher Frequency Of Severe Heart Failure (22 [33.3%] Vs 95 [20.3%]; P = .02). However, Dynamic Obstruction At The Left-Ventricular Outflow Tract Occurred Exclusively In Women (39 [7.9%] Vs 0 [0.0%]; P = .02). The Incidence Of Functional Mitral Regurgitation Was Also Higher In Women (52 [10.6%] Vs 2 [2.9%]; P = .04). Tako-Tsubo Syndrome Shows Wide Differences By Sex In Terms Of Its Incidence, Presentation, And Outcomes. Prognosis Is Worse In Men.|[('Tako-Tsubo Syndrome', 'no label'), ('Serious Disease', 'no label'), ('Acute Phase', 'no label'), ('Mimics', 'no label'), ('Myocardial Infarction', 'no label'), ('Causative', 'no label'), ('Coronary Lesions', 'no label'), ('Study', 'no label'), ('Analyze', 'no label'), ('Clinical Course', 'no label'), ('Outcome', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Sex', 'no label'), ('Analyzed', 'no label'), ('Characteristics', 'no label'), ('Patients', 'no label'), ('Retako Registry', 'no label'), ('Multicenter Registry', 'no label'), ('Participation', 'no label'), ('Spanish', 'no label'), ('Hospitals', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Chest Pain', 'no label'), ('Frequent', 'no label'), ('Initial Symptom', 'no label'), ('Men Than', 'no label'), ('Women', 'no label'), ('Prognosis', 'no label'), ('Worse', 'no label'), ('Men', 'no label'), ('Higher', 'no label'), ('In-Hospital', 'no label'), ('Mortality', 'no label'), ('Longer Intensive Care', 'no label'), ('Days', 'no label'), ('Higher', 'no label'), ('Frequency', 'no label'), ('Severe Heart Failure', 'no label'), ('Dynamic Obstruction', 'no label'), ('Left-Ventricular Outflow Tract Occurred', 'no label'), ('Exclusively', 'no label'), ('Women', 'no label'), ('Incidence', 'no label'), ('Functional Mitral Regurgitation', 'no label'), ('Higher', 'no label'), ('Women', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Shows Wide', 'no label'), ('Sex', 'no label'), ('Incidence', 'no label'), ('Presentation', 'no label'), ('Outcomes', 'no label'), ('Prognosis', 'no label'), ('Worse', 'no label'), ('Men', 'no label')]|[('Tako-Tsubo Syndrome Is A', 'no label')]|[('Sex', 'no label')]|[('Tako-Tsubo Syndrome', 'no label'), ('Myocardial Infarction', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Chest Pain', 'no label'), ('Prognosis', 'no label'), ('Heart Failure', 'no label'), ('Functional Mitral Regurgitation', 'no label'), ('Tako-Tsubo Syndrome', 'no label'), ('Prognosis', 'no label')]|[('Myocardial', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Retako', 'no label'), ('562 Patients', 'no label'), ('Women', 'no label'), ('Heart', 'no label'), ('Left-Ventricular Outflow', 'no label'), ('Women', 'no label'), ('Mitral', 'no label'), ('Women', 'no label')]
tako-tsubo cardiomyopathy|pubmed~32843113|To Explore The Epidemiology And Outcomes Of Takotsubo Cardiomyopathy In Children. A Retrospective Analysis Of The Healthcare Cost And Utilization 2012 And 2016 Kids' Inpatient Database Was Performed. Patients Admitted With The Diagnosis Of Takotsubo Cardiomyopathy In The Age Group Of 1 Month-20 Years Were Identified Using International Classification Of Diseases (Icd)-9 Code 429.83 And Icd-10 Code I51.81. Among A Total Of 4,860,859 Discharges, There Were 153 With The Diagnosis Of Takotsubo Cardiomyopathy (3.1 Per 100,000 Discharges). Among Patients With Takotsubo Cardiomyopathy, 55.0% Were Male, 62.4% Were White, And 16.7% Were Black. Eighty-Nine Percent Of Patients Were Between 12 And 20 Years. Psychiatric Diagnosis Was Documented In 46% And Substance Use Disorder In 36.2%. Sepsis Was Documented In 22.8% Of Patients. The Median Length Of Stay Was 5 Days (Interquartile Range: 2.7-15), And Median Total Charges Were $75,080 (Interquartile Range: 32,176-198,336). The Overall Mortality For Takotsubo Cardiomyopathy Was 7%. On Multivariable Regression Analysis, Mortality Was Higher In The Presence Of Anoxic Injury (Odds Ratio = 34.42, 95% Confidence Interval: 4.85-320.11, P = 0.00). Takotsubo Cardiomyopathy Is Uncommon In Children And Carries A Mortality Rate Of 7%. Most Children With Takotsubo Cardiomyopathy Are Adolescent Males, Many Of Whom Have Psychiatric Disorder Or Substance Use Disorder Or Both. Takotsubo Cardiomyopathy Should Be Considered In The Differential Diagnosis For Patients Who Present With Cardiac Dysfunction And Have Underlying Psychiatric Disorders Or Drug Abuse.|"[('Epidemiology', 'no label'), ('Outcomes', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Children', 'no label'), ('Retrospective Analysis', 'no label'), ('Healthcare Cost', 'no label'), ('Utilization', 'no label'), (""Kids' Inpatient Database"", 'no label'), ('Patients', 'no label'), ('Admitted With', 'no label'), ('Diagnosis', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Age Group', 'no label'), ('Years', 'no label'), ('International Classification Of Diseases (Icd)-9 Code', 'no label'), ('Icd-10', 'no label'), ('Code', 'no label'), ('Discharges', 'no label'), ('Diagnosis', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Discharges', 'no label'), ('Patients', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Male', 'no label'), ('White', 'no label'), ('Black', 'no label'), ('Eighty-Nine', 'no label'), ('Patients', 'no label'), ('Years', 'no label'), ('Psychiatric Diagnosis', 'no label'), ('Documented', 'no label'), ('Substance Use Disorder', 'no label'), ('Sepsis', 'no label'), ('Documented', 'no label'), ('Patients', 'no label'), ('Median Length Of Stay', 'no label'), ('Days', 'no label'), ('Interquartile Range', 'no label'), ('Median', 'no label'), ('Total Charges', 'no label'), ('Interquartile Range', 'no label'), ('Mortality', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Multivariable Regression Analysis', 'no label'), ('Mortality', 'no label'), ('Anoxic Injury', 'no label'), ('Odds Ratio', 'no label'), ('Confidence Interval', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Children', 'no label'), ('Carries', 'no label'), ('Mortality Rate', 'no label'), ('Children', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Adolescent', 'no label'), ('Males', 'no label'), ('Psychiatric Disorder', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Differential Diagnosis', 'no label'), ('Patients', 'no label'), ('Cardiac Dysfunction', 'no label'), ('Psychiatric Disorders', 'no label'), ('Drug Abuse', 'no label')]"|[('Substance', 'no label'), ('Substance', 'no label'), ('Drug', 'no label')]|[]|[('Takotsubo Cardiomyopathy', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Diseases (Icd)-9 Code 429.83 And Icd-10 Code', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Psychiatric Diagnosis', 'no label'), ('Sepsis', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Anoxic Injury', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Psychiatric Disorder', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Cardiac Dysfunction', 'no label'), ('Psychiatric Disorders Or Drug Abuse', 'no label')]|[('Children', 'no label'), ('Patients', 'no label'), ('Code I51.81', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Children', 'no label'), ('Children', 'no label'), ('Patients', 'no label'), ('Cardiac', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19785378|Tako-Tsubo Cardiomyopathy Is New Clinical Syndrome Which Mimic Acute Myocardial Infarction. The Main Characteristic Is Apical Ballooning Of The Left Ventricular Wall During Systole And Normal Findings On Coronary Arteries. Pathophysiology Is Not Known, Very Important Is Definitively The Role Of Catecholamines. The Electrocardiography, Echocardiography, Left Ventricular Angiography And Coronary Angiography Are Methods Used In Diagnosis Of This Syndrome. The Therapy Is Only Symptomatic, In Cases With Severe Complications Mechanical Support Of Circulation Should Be Used.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('New Clinical Syndrome', 'no label'), ('Mimic Acute', 'no label'), ('Myocardial Infarction', 'no label'), ('Characteristic', 'no label'), ('Apical Ballooning', 'no label'), ('Left Ventricular Wall', 'no label'), ('Systole', 'no label'), ('Normal Findings', 'no label'), ('Coronary Arteries', 'no label'), ('Pathophysiology', 'no label'), ('Catecholamines', 'no label'), ('Electrocardiography', 'no label'), ('Echocardiography', 'no label'), ('Left Ventricular Angiography', 'no label'), ('Coronary Angiography', 'no label'), ('Diagnosis', 'no label'), ('Syndrome', 'no label'), ('Therapy', 'no label'), ('Symptomatic', 'no label'), ('Cases', 'no label'), ('Severe', 'no label'), ('Complications', 'no label'), ('Mechanical Support', 'no label'), ('Circulation', 'no label')]|[('Catecholamines', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Myocardial Infarction', 'no label'), ('Catecholamines', 'no label')]|[('Myocardial', 'no label'), ('Left Ventricular Wall', 'no label'), ('Catecholamines', 'no label'), ('Left Ventricular', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22086475|Tako-Tsubo Cardiomyopathy (Ttc, Stress Cardiomyopathy) Is More Common In Elderly Women And Its Symptoms Can Be Deceptively Similar To Those Of Acute Myocardial Infarction. Although Coronary Arteries Appear Normal On Coronary Angiograms, A Shape Like A Tako-Tsubo (A Japanese Fishing Pot For Trapping Octopuses) Can Be Observed On Left Ventriculogram. Ttc Is Generally Considered To Be A Trigger For Sudden Cardiac Death. The Onset Mechanism Of Ttc Is Still Controversial. Catecholamine Cardiotoxicity And/Or Coronary Circulation Disturbance Due To Coronary Microvascular Spasm And/Or Neurogenic Stunned Myocardium As A Result Of Autonomic Imbalance Are Considered To Be The Most Likely Causes. In This Review, We Assess The Usefulness Of Myocardial Scintigraphic Imaging In Ttc Patients On The Basis Of The Results Obtained From Earlier Studies And Case Reports In Order To Establish A Deeper Understanding Of The Pathophysiological Mechanism Of This Syndrome.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Elderly', 'no label'), ('Women', 'no label'), ('Symptoms', 'no label'), ('Deceptively', 'no label'), ('Acute Myocardial Infarction', 'no label'), ('Coronary Arteries Appear', 'no label'), ('Normal', 'no label'), ('Coronary Angiograms', 'no label'), ('Shape', 'no label'), ('Tako-Tsubo', 'no label'), ('Japanese', 'no label'), ('Fishing', 'no label'), ('Pot', 'no label'), ('Trapping', 'no label'), ('Octopuses', 'no label'), ('Observed', 'no label'), ('Left Ventriculogram', 'no label'), ('Ttc', 'no label'), ('Trigger', 'no label'), ('Sudden Cardiac Death', 'no label'), ('Onset Mechanism', 'no label'), ('Ttc', 'no label'), ('Catecholamine Cardiotoxicity And/Or', 'no label'), ('Coronary Circulation Disturbance', 'no label'), ('Coronary Microvascular Spasm', 'no label'), ('Neurogenic', 'no label'), ('Stunned', 'no label'), ('Autonomic Imbalance', 'no label'), ('Causes', 'no label'), ('Review', 'no label'), ('Assess', 'no label'), ('Usefulness', 'no label'), ('Myocardial Scintigraphic Imaging', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Results', 'no label'), ('Studies', 'no label'), ('Case Reports', 'no label'), ('Order', 'no label'), ('Establish', 'no label'), ('Pathophysiological', 'no label'), ('Mechanism', 'no label'), ('Syndrome', 'no label')]|[('Catecholamine', 'no label')]|[('Pot', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Myocardial Infarction', 'no label'), ('Tako-Tsubo', 'no label'), ('Ventriculogram', 'no label'), ('Sudden Cardiac Death', 'no label'), ('Catecholamine Cardiotoxicity And/Or Coronary Circulation Disturbance Due To Coronary Microvascular Spasm And/Or Neurogenic Stunned Myocardium As A', 'no label')]|[('Women', 'no label'), ('Acute Myocardial', 'no label'), ('Coronary Arteries', 'no label'), ('Be A', 'no label'), ('Cardiac', 'no label'), ('Catecholamine', 'no label'), ('And/Or', 'no label'), ('Microvascular', 'no label'), ('And/Or', 'no label'), ('Myocardial', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19996500|The Aim Of Our Study Was To Assess If The Analysis Of Precatheterisation Initial 12-Lead Ecg Could Reliably Differentiate Between Taco-Tsubo Cardiomyopathy (Ttc) And St-Segment Elevation Myocardial Infarction (Stemi), Two Conditions With A Similar Clinical Presentation. Of The 320 Patients With Suspected Stemi Who Underwent Angiography Over A 2-Year Period We Identified 23 (7.2%) Patients Without Significant Coronary Artery Disease. 6 (26.1%) Of Whom Met The Diagnostic Criteria For Tako-Tsubo Cardiomyopathy (6 Females, Median Age 70 (65-83) Years). Ttc Patients Were Compared With The Remaining 297 Patients With Angiographic Evidence Of Cad. There Was No Significant Difference In Regard With Heart Rate, Pr Interval, Qrs Duration, And Corrected Qt Interval, But Qt Dispersion Was Less In Ttc Patients Compared To Stemi Group (34.1+/-9.7 Vs. 43.9+/-16.2 P=0.046). Distribution Of St-Segment Elevation Was Similar In Both Groups, But The Sum Of The Level Of St-Segment Elevation Was Significantly Smaller (0,6+/-0.14 [0,4-0,8] Mv Vs. 0.95+/-0.17 [0,8-1,4] Mv; P =0.002 ) And Concurrent St-Segment Depression Was Rare Finding In Ttc Patients (16.6% Vs. 65.7 % P=0.022). Careful Analysis Of Initial Ecg In Combination With Complex Analysis Of Initial Cardiac Markers And Presence Of Preceding Stressful Event Could Be Informative Tool In Differentiating Of Ttc From Stemi.|[('Study', 'no label'), ('Assess', 'no label'), ('Analysis', 'no label'), ('Precatheterisation', 'no label'), ('Initial', 'no label'), ('12-Lead Ecg', 'no label'), ('Differentiate', 'no label'), ('Taco-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('St-Segment', 'no label'), ('Elevation Myocardial Infarction', 'no label'), ('Stemi', 'no label'), ('Clinical Presentation', 'no label'), ('Patients', 'no label'), ('Suspected', 'no label'), ('Stemi Who Underwent Angiography', 'no label'), ('Period', 'no label'), ('Patients', 'no label'), ('Significant', 'no label'), ('Coronary Artery Disease', 'no label'), ('Met', 'no label'), ('Diagnostic Criteria', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Females', 'no label'), ('Median Age 70', 'no label'), ('Years', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Angiographic Evidence', 'no label'), ('Cad', 'no label'), ('No Significant Difference', 'no label'), ('Heart Rate', 'no label'), ('Pr Interval', 'no label'), ('Qrs Duration', 'no label'), ('Corrected Qt Interval', 'no label'), ('Qt Dispersion', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Stemi Group', 'no label'), ('Distribution', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Groups', 'no label'), ('Sum', 'no label'), ('Level', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Concurrent', 'no label'), ('St-Segment', 'no label'), ('Depression', 'no label'), ('Finding', 'no label'), ('Ttc', 'no label'), ('Patients', 'no label'), ('Analysis', 'no label'), ('Initial', 'no label'), ('Ecg', 'no label'), ('Combination', 'no label'), ('Complex', 'no label'), ('Analysis', 'no label'), ('Initial', 'no label'), ('Cardiac Markers', 'no label'), ('Stressful Event', 'no label'), ('Informative Tool', 'no label'), ('Ttc', 'no label'), ('Stemi', 'no label')]|[('Met', 'no label')]|[('Pr', 'no label')]|[('Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Myocardial Infarction', 'no label'), ('Coronary Artery Disease', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('St-Segment Depression', 'no label')]|[('Myocardial', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Met', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Heart', 'no label'), ('Pr Interval', 'no label'), ('Ttc Patients', 'no label'), ('Patients', 'no label'), ('Cardiac', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21462531||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~17395287|We Report A Rare Case Of Tako-Tsubo Cardiomyopathy Developed After Excision Of Left Atrial Myxoma And Adrenaline Infusion Given For Blood Pressure Augmentation In A 56-Year-Old Lady. Although The Risk For Developing Tako-Tsubo Cardiomyopathy Associated With Adrenaline Use Has Not Been Established, Caution Is Still Warranted.|[('Report', 'no label'), ('Rare', 'no label'), ('Case', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Excision', 'no label'), ('Left Atrial Myxoma', 'no label'), ('Adrenaline', 'no label'), ('Infusion', 'no label'), ('Blood Pressure', 'no label'), ('Augmentation', 'no label'), ('Risk', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Associated With', 'no label'), ('Adrenaline', 'no label'), ('Has Not', 'no label'), ('Established', 'no label'), ('Caution', 'no label')]|[('Adrenaline', 'no label'), ('Adrenaline', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Atrial Myxoma', 'no label'), ('Adrenaline', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Adrenaline', 'no label')]|[('Left Atrial', 'no label'), ('Adrenaline', 'no label'), ('Blood Pressure', 'no label'), ('Adrenaline', 'no label')]
tako-tsubo cardiomyopathy|pubmed~19581037|Tako Tsubo Cardiomyopathy Has Been Described In A Variety Of Stress Situations, Including Several Critical Illness Settings. We Report The First Case Of This Syndrome In A Patient With Multiple Trauma. Tako Tsubo Is An Unusual Cause Of Circulatory Failure In Such Patients, To Be Distinguished From Myocardial Contusion And Myocardial Infarction. Prolonged St Segment Elevation On Ekg, Minor Troponin Release, And Transient Left Ventricular Apical Ballooning On Transthoracic Echocardiography Are Among The Features To Be Recognized. Full Recovery Occurs Spontaneously Within Several Weeks.|[('Tako Tsubo Cardiomyopathy', 'no label'), ('Stress Situations', 'no label'), ('Critical Illness', 'no label'), ('Syndrome', 'no label'), ('Patient', 'no label'), ('Multiple Trauma', 'no label'), ('Tako Tsubo', 'no label'), ('Unusual', 'no label'), ('Cause', 'no label'), ('Circulatory Failure', 'no label'), ('Patients', 'no label'), ('Distinguished', 'no label'), ('Myocardial Contusion', 'no label'), ('Myocardial Infarction', 'no label'), ('Prolonged', 'no label'), ('St Segment Elevation', 'no label'), ('Ekg', 'no label'), ('Minor', 'no label'), ('Troponin', 'no label'), ('Release', 'no label'), ('Transient', 'no label'), ('Left Ventricular Apical Ballooning', 'no label'), ('Transthoracic Echocardiography', 'no label'), ('Features', 'no label'), ('Recognized', 'no label'), ('Recovery', 'no label'), ('Occurs', 'no label'), ('Spontaneously', 'no label'), ('Weeks', 'no label')]|[('Troponin', 'no label'), ('Apical', 'no label')]|[('Troponin', 'no label')]|[('Tako', 'no label'), ('Cardiomyopathy', 'no label'), ('Stress Situations', 'no label'), ('Critical Illness', 'no label'), ('Trauma', 'no label'), ('Tako', 'no label'), ('Circulatory Failure', 'no label'), ('Myocardial Contusion', 'no label'), ('Myocardial Infarction', 'no label')]|[('Stress', 'no label'), ('Circulatory Failure', 'no label'), ('Patients', 'no label'), ('Myocardial Contusion', 'no label'), ('Myocardial', 'no label'), ('Troponin', 'no label'), ('Left Ventricular', 'no label')]
tako-tsubo cardiomyopathy|pubmed~22086476|Tako-Tsubo Cardiomyopathy (Ttc) Predominantly Affects Elderly People With A High Prevalence Of Cardiovascular Risk Factors. Therefore, One Would Expect To Encounter Incidental Coronary Artery Disease In A Significant Number Of Cases. In Fact, The Prevalence Of Mild Coronary Artery Disease (Cad), By Angiography, Has Been Reported To Be In The Range Of 30%-60%. Similarly, More Severe Stenotic Lesions In At Least One Coronary Vessel Were Incidentally Found In 10%-35% Of Patients With The Disease. Using Intravascular Ultrasound In A Series Of 10 Patients With Ttc, Coronary Atherosclerosis Was Demonstrable In All Patients, Although Five Patients Had Normal Coronary Angiograms. Therefore, Ttc And Cad Are Not Mutually Exclusive Disease Entities. The Incidental Finding Of Coronary Lesions, Even If Significant, Should Not Automatically Lead To A Dismissal Of The Diagnosis Of Ttc. Rather, A Case-By-Case Approach Using Additional Imaging Modalities Should Be Endorsed.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Elderly People', 'no label'), ('High Prevalence', 'no label'), ('Cardiovascular Risk Factors', 'no label'), ('Encounter Incidental', 'no label'), ('Coronary Artery Disease', 'no label'), ('Cases', 'no label'), ('Prevalence', 'no label'), ('Mild Coronary Artery Disease', 'no label'), ('Cad', 'no label'), ('Angiography', 'no label'), ('Range', 'no label'), ('Severe', 'no label'), ('Stenotic Lesions', 'no label'), ('Coronary Vessel', 'no label'), ('Patients', 'no label'), ('Disease', 'no label'), ('Intravascular Ultrasound', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Coronary Atherosclerosis', 'no label'), ('Demonstrable', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Normal Coronary Angiograms', 'no label'), ('Ttc', 'no label'), ('Cad', 'no label'), ('Entities', 'no label'), ('Incidental', 'no label'), ('Coronary Lesions', 'no label'), ('Significant', 'no label'), ('Not Automatically Lead', 'no label'), ('Dismissal', 'no label'), ('Diagnosis', 'no label'), ('Ttc', 'no label'), ('Case-By-Case', 'no label'), ('Imaging Modalities', 'no label'), ('Endorsed', 'no label')]|[('Lead To', 'no label')]|[('Cad', 'no label'), ('Case-By-Case', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Coronary Artery Disease', 'no label'), ('Coronary Artery Disease', 'no label'), ('Atherosclerosis', 'no label')]|[('People', 'no label'), ('Cardiovascular', 'no label'), ('Coronary Artery', 'no label'), ('Cad', 'no label'), ('Stenotic Lesions', 'no label'), ('Vessel', 'no label'), ('Patients', 'no label'), ('Intravascular', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cad', 'no label'), ('Coronary Lesions', 'no label'), ('Modalities', 'no label')]
tako-tsubo cardiomyopathy|pubmed~34001727|Many Antitumoral Drugs Have Been Linked To Takotsubo Cardiomyopathy, With No Clear Pathogenetic Mechanisms. Data About This Condition Are Lacking In Literature. The Aim Of This Meta-Summary Is To Summarize The Characteristics Of Patients With Antitumoral Drug-Induced Takotsubo Cardiomyopathy, Described In Case Reports Available In Literature. We Searched For Published Case Reports In Pubmed, Google Scholar, Embase, And Scopus From 2009 About Stress Cardiomyopathy And Antiblastic Drugs. We Selected 41 Case Reports. All Cases Underwent Chemotherapy/Immunotherapy For Different Types Of Cancer. The Median Age Was 58 Years, And 61% Of Them Were Women. The Most Common Comorbidities Were Hypertension (12.2%) And Dyslipidemia (4.9%), But Most Of The Population Had No Cardiological Clinical History. Takotsubo Cardiomyopathy Is Associated To The 5-Fluorouracil (36.5%), Capecitabine (9.7%), Trastuzumab (9.7%), And Immune Check Point Inhibitor (9.7%) Treatment. The Median Time Of Onset Was 2 Days (1-150). Cardiogenic Shock Was The First Manifestation In 11 Patients (26.8%). Left Ventricle Ejection Fraction Recovery Was Showed In 33 Patients (89%) With Mean Ejection Fraction 57.7 ± 7%, After A Median Of 30-Day (4-300) Follow-Up. Patients With Cancer Experienced Takotsubo Cardiomyopathy Within Few Days From The Beginning Of Therapy, And The Most Of Them Normalized The Heart Function In Few Weeks. Cardiogenic Shock Showed High Prevalence In This Setting Of Patients. Larger Studies Are Needed To Better Understand The Pathological Mechanisms Of Antiblastic Drug-Induced Stress Cardiomyopathy, To Find Risk Factors Associated And Preventive Strategies For Limit This Type Of Cardiotoxicities.|[('Antitumoral Drugs', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Pathogenetic Mechanisms', 'no label'), ('Data', 'no label'), ('Condition', 'no label'), ('Lacking', 'no label'), ('Literature', 'no label'), ('Meta-Summary', 'no label'), ('Characteristics', 'no label'), ('Patients', 'no label'), ('Antitumoral Drug-Induced Takotsubo Cardiomyopathy', 'no label'), ('Case Reports', 'no label'), ('Available', 'no label'), ('Literature', 'no label'), ('Published Case Reports', 'no label'), ('Pubmed', 'no label'), ('Google Scholar', 'no label'), ('Embase', 'no label'), ('Scopus', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Antiblastic Drugs', 'no label'), ('Case Reports', 'no label'), ('Cases', 'no label'), ('Chemotherapy/Immunotherapy', 'no label'), ('Cancer', 'no label'), ('Median Age', 'no label'), ('Years', 'no label'), ('Women', 'no label'), ('Common', 'no label'), ('Comorbidities', 'no label'), ('Hypertension', 'no label'), ('Dyslipidemia', 'no label'), ('Population', 'no label'), ('Cardiological Clinical History', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('5-Fluorouracil', 'no label'), ('Capecitabine', 'no label'), ('Trastuzumab', 'no label'), ('Immune Check Point Inhibitor', 'no label'), ('Treatment', 'no label'), ('Median Time', 'no label'), ('Days', 'no label'), ('Cardiogenic Shock', 'no label'), ('Manifestation', 'no label'), ('Patients', 'no label'), ('Left Ventricle Ejection Fraction', 'no label'), ('Recovery', 'no label'), ('Patients', 'no label'), ('Mean Ejection Fraction', 'no label'), ('Median', 'no label'), ('Follow-Up', 'no label'), ('Patients', 'no label'), ('Cancer', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Days', 'no label'), ('Therapy', 'no label'), ('Heart Function', 'no label'), ('Weeks', 'no label'), ('Cardiogenic Shock', 'no label'), ('High Prevalence', 'no label'), ('Patients', 'no label'), ('Studies', 'no label'), ('Pathological Mechanisms', 'no label'), ('Antiblastic Drug-Induced Stress Cardiomyopathy', 'no label'), ('Risk Factors', 'no label'), ('Associated And', 'no label'), ('Preventive Strategies', 'no label'), ('Limit', 'no label'), ('Cardiotoxicities', 'no label')]|[('Trastuzumab', 'no label'), ('±', 'no label'), ('Cardiotoxicities', 'no label')]|[]|[('Takotsubo Cardiomyopathy', 'no label'), ('Clear Pathogenetic Mechanisms', 'no label'), ('Antitumoral Drug-Induced Takotsubo Cardiomyopathy', 'no label'), ('Stress Cardiomyopathy', 'no label'), ('Cancer', 'no label'), ('Hypertension', 'no label'), ('Dyslipidemia', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('5-Fluorouracil', 'no label'), ('Capecitabine', 'no label'), ('Trastuzumab', 'no label'), ('Cardiogenic Shock', 'no label'), ('Left Ventricle Ejection Fraction Recovery Was Showed In 33 Patients (89%) With Mean Ejection Fraction 57.7 ±', 'no label'), ('Cancer', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Cardiogenic Shock', 'no label'), ('Antiblastic Drug-Induced Stress Cardiomyopathy', 'no label')]|[('Antitumoral', 'no label'), ('Patients', 'no label'), ('Antitumoral', 'no label'), ('Cancer', 'no label'), ('5-Fluorouracil', 'no label'), ('Capecitabine', 'no label'), ('Trastuzumab', 'no label'), ('Immune Check Point Inhibitor', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cancer', 'no label'), ('Heart', 'no label'), ('Patients', 'no label'), ('Type', 'no label')]
tako-tsubo cardiomyopathy|pubmed~30532873|Tako-Tsubo Cardiomyopathy Is Characterized By Transient Left Ventricular Contractile Dysfunction. The Precise Etiology Of Tako-Tsubo Cardiomyopathy Remains To Be Elucidated. We Performed Coronary Angiography In Two Patients With Tako-Tsubo Cardiomyopathy And Evaluated The Coronary Microcirculation By Digital Subtraction Angiography (Dsa). In The Acute Phase Of Tako-Tsubo Cardiomyopathy, Coronary Dsa Demonstrated Severely Reduced Perfusion In The Apex. Follow-Up Dsa Showed The Restoration Of Normal Myocardial Perfusion In The Apex. Coronary Dsa Can Simultaneously Depict The Coronary Vessels And Myocardial Perfusion Abnormalities. Furthermore, Dsa Can Also Show The Relationship Between The Perfusion Territory Of The Coronary Arteries And The Region Of Impaired Myocardial Perfusion. This Technique Might Support The Central Role Of Microcirculation Disturbance In Tako-Tsubo Cardiomyopathy.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Characterized', 'no label'), ('Transient', 'no label'), ('Left Ventricular Contractile Dysfunction', 'no label'), ('Etiology', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Remains', 'no label'), ('Performed', 'no label'), ('Coronary Angiography', 'no label'), ('Patients', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Evaluated', 'no label'), ('Coronary Microcirculation', 'no label'), ('Digital Subtraction Angiography', 'no label'), ('Dsa', 'no label'), ('Acute Phase', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Coronary Dsa', 'no label'), ('Reduced', 'no label'), ('Perfusion', 'no label'), ('Apex.', 'no label'), ('Restoration', 'no label'), ('Normal Myocardial', 'no label'), ('Perfusion', 'no label'), ('Apex', 'no label'), ('Coronary Dsa', 'no label'), ('Depict', 'no label'), ('Coronary Vessels', 'no label'), ('Myocardial Perfusion', 'no label'), ('Dsa', 'no label'), ('Relationship', 'no label'), ('Perfusion', 'no label'), ('Territory', 'no label'), ('Coronary Arteries', 'no label'), ('Region', 'no label'), ('Impaired', 'no label'), ('Myocardial Perfusion', 'no label'), ('Technique', 'no label'), ('Microcirculation', 'no label'), ('Disturbance', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Territory', 'no label'), ('Region', 'no label')]|[]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ventricular Contractile Dysfunction', 'no label'), ('Etiology', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Impaired Myocardial', 'no label'), ('Microcirculation Disturbance', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label')]|[('Patients', 'no label'), ('Apex.', 'no label'), ('Myocardial', 'no label'), ('Apex.', 'no label'), ('Myocardial', 'no label'), ('Coronary Arteries', 'no label'), ('Myocardial', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23375254||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~19660615|Tako-Tsubo Cardiomyopathy (Ttc) Is Increasingly Diagnosed In The United States, Especially In The Caucasian Population. To Evaluate The Clinical Features And Outcome Of Patients With Ttc, We Evaluated 34 Patients (32 Women And 2 Men) 22 To 88 Years Of Age (Mean 66 +/- 14) Who Fulfilled The Following Criteria: (1) Akinesia Or Dyskinesia Of The Apical And/Or Midventricular Segments Of The Left Ventricle With Regional Wall Motion Abnormalities That Extended Beyond The Distribution Of A Single Epicardial Vessel And (2) Absence Of Obstructive Coronary Artery Disease. Twenty-Five Patients (74%) Presented With Chest Pain, 20 Patients (59%) Presented With Dyspnea, And 8 Patients (24%) Presented With Cardiogenic Shock. Twenty-Two Patients (65%) Had St-Segment Elevation And 14 Patients (41%) Had T-Wave Inversion On Presentation. Twenty-Five Patients (74%) Reported A Preceding Stressful Event. Cardiac Biomarkers Were Often Mildly Increased, With A Mean Troponin I (Peak) Of 13.9 +/- 24. Mean +/- Sd Left Ventricular Ejection Fractions Were 28 +/- 10% At Time Of Presentation And 51 +/- 14 At Time Of Follow-Up (P <0.0001). Two Patients (6%) Died During The Hospital Stay. Average Duration Of Hospital Stay Was 6.6 +/- 6.2 Days. In Conclusion, Ttc Is Common In Postmenopausal Women With Preceding Physical Or Emotional Stress. It Predominantly Involves The Apical Portion Of The Left Ventricle And Patients With This Condition Have A Favorable Outcome With Appropriate Medical Management. The Precise Cause Remains Unclear.|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Diagnosed', 'no label'), ('United States', 'no label'), ('Caucasian', 'no label'), ('Population', 'no label'), ('Evaluate', 'no label'), ('Clinical Features', 'no label'), ('Outcome', 'no label'), ('Patients', 'no label'), ('Ttc', 'no label'), ('Evaluated', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Men', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Criteria', 'no label'), ('Akinesia', 'no label'), ('Dyskinesia', 'no label'), ('Apical And/Or', 'no label'), ('Midventricular Segments', 'no label'), ('Left Ventricle', 'no label'), ('Regional Wall Motion Abnormalities', 'no label'), ('Extended', 'no label'), ('Distribution', 'no label'), ('Single Epicardial Vessel', 'no label'), ('Absence', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Patients', 'no label'), ('Chest Pain', 'no label'), ('Patients', 'no label'), ('Dyspnea', 'no label'), ('Patients', 'no label'), ('Cardiogenic Shock', 'no label'), ('Patients', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Patients', 'no label'), ('T-Wave Inversion', 'no label'), ('Presentation', 'no label'), ('Patients', 'no label'), ('Preceding', 'no label'), ('Stressful Event', 'no label'), ('Cardiac Biomarkers', 'no label'), ('Mildly', 'no label'), ('Increased', 'no label'), ('Mean', 'no label'), ('Troponin I', 'no label'), ('Peak', 'no label'), ('Left Ventricular Ejection Fractions', 'no label'), ('Time', 'no label'), ('Presentation', 'no label'), ('Follow-Up', 'no label'), ('Patients', 'no label'), ('Hospital Stay', 'no label'), ('Duration', 'no label'), ('Days', 'no label'), ('Ttc', 'no label'), ('Postmenopausal', 'no label'), ('Women', 'no label'), ('Physical', 'no label'), ('Emotional Stress', 'no label'), ('Apical Portion', 'no label'), ('Left Ventricle', 'no label'), ('Patients', 'no label'), ('Condition', 'no label'), ('Favorable Outcome', 'no label'), ('Medical Management', 'no label'), ('Cause Remains', 'no label')]|[('St-Segment', 'no label')]|[('Troponin I', 'no label')]|[('Tako-Tsubo Cardiomyopathy', 'no label'), ('Ttc', 'no label'), ('Akinesia', 'no label'), ('Dyskinesia', 'no label'), ('Left Ventricle With Regional Wall Motion Abnormalities That Extended Beyond The Distribution Of A Single Epicardial Vessel And (2) Absence Of', 'no label'), ('Obstructive Coronary Artery Disease', 'no label'), ('Chest Pain', 'no label'), ('Dyspnea', 'no label'), ('Cardiogenic Shock', 'no label'), ('Twenty-Two', 'no label'), ('Left Ventricular Ejection', 'no label'), ('Left Ventricle', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Left Ventricle', 'no label'), ('Wall', 'no label'), ('Coronary Artery', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('T-Wave', 'no label'), ('Patients', 'no label'), ('Cardiac', 'no label'), ('Troponin I', 'no label'), ('Patients', 'no label'), ('Apical', 'no label'), ('Left Ventricle', 'no label'), ('Patients', 'no label')]
tako-tsubo cardiomyopathy|pubmed~21739207|"The Syndrome Of ""Left Ventricular Ballooning"" Summarizes An Acute Onset Of Transient Extensive Akinesia Of Several Segments (Apical, Mid-Ventricular) Of The Left Ventricle, Without Significant Lesions On The Coronary Angiogram, Accompanied By Chest Symptoms, Electrocardiographic Changes, And Limited Release Of Cardiac Markers Disproportionate To The Extent Of Akinesia. Initially, The Vast Majority Of Cases Has Been Reported Among Japanese Population. Emotional Or Physical Stress Or Other Preceding Triggering Factors Might Play A Key Role In This Reversible Form Of Cardiomyopathy, But The Precise Etiology Remains Unknown. We Describe A Case Of A 52-Year-Old Woman With Posttraumatic Stress Disorder After Cerebral Bleeding Presenting With An Atypical Form Of Left Ventricular Ballooning (""Midventricular Ballooning"") Syndrome."|[('Syndrome', 'no label'), ('Left Ventricular Ballooning', 'no label'), ('Summarizes', 'no label'), ('Acute Onset', 'no label'), ('Transient', 'no label'), ('Extensive Akinesia', 'no label'), ('Segments', 'no label'), ('Apical', 'no label'), ('Mid-Ventricular', 'no label'), ('Left Ventricle', 'no label'), ('Significant', 'no label'), ('Lesions', 'no label'), ('Coronary Angiogram', 'no label'), ('Chest Symptoms', 'no label'), ('Electrocardiographic Changes', 'no label'), ('Limited Release', 'no label'), ('Cardiac Markers', 'no label'), ('Disproportionate', 'no label'), ('Akinesia', 'no label'), ('Cases', 'no label'), ('Japanese', 'no label'), ('Population', 'no label'), ('Emotional Or Physical Stress', 'no label'), ('Triggering Factors', 'no label'), ('Play A', 'no label'), ('Reversible Form', 'no label'), ('Cardiomyopathy', 'no label'), ('Etiology', 'no label'), ('Remains', 'no label'), ('Unknown', 'no label'), ('Woman', 'no label'), ('Posttraumatic Stress Disorder', 'no label'), ('Cerebral Bleeding', 'no label'), ('Presenting With', 'no label'), ('Atypical Form', 'no label'), ('Left Ventricular Ballooning', 'no label')]|[]|[]|[('Ventricular Ballooning', 'no label'), ('Akinesia', 'no label'), ('Left Ventricle', 'no label'), ('Chest Symptoms', 'no label'), ('Akinesia', 'no label'), ('Cardiomyopathy', 'no label'), ('Posttraumatic Stress Disorder', 'no label'), ('Cerebral Bleeding', 'no label'), ('Left Ventricular Ballooning', 'no label')]|[('Left Ventricular', 'no label'), ('Segments', 'no label'), ('Mid-Ventricular', 'no label'), ('Left Ventricle', 'no label'), ('Cardiac', 'no label'), ('A Case', 'no label'), ('Stress', 'no label'), ('Cerebral Bleeding', 'no label'), ('Left Ventricular', 'no label'), ('Midventricular', 'no label')]
tako-tsubo cardiomyopathy|pubmed~18038119|A 71-Year-Old Female Patient Developed Acute Myocardial Failure Immediately After Cataract Surgery Under General Anesthesia. Subsequently Performed Laevocardiography Demonstrated A Basal Ballooning Of The Left Ventricle Characteristic Of Basal Tako-Tsubo Cardiomyopathy. The Basal Tako-Tsubo Cardiomyopathy Was Induced By A Previously Asymptomatic Pheochromocytoma. The Left Ventricular Function Recovered Completely Within 4 Days Without Specific Treatment.|[('Female', 'no label'), ('Patient', 'no label'), ('Acute Myocardial Failure', 'no label'), ('Cataract Surgery', 'no label'), ('General Anesthesia', 'no label'), ('Performed', 'no label'), ('Laevocardiography', 'no label'), ('Basal Ballooning', 'no label'), ('Left Ventricle', 'no label'), ('Characteristic', 'no label'), ('Basal Tako-Tsubo Cardiomyopathy', 'no label'), ('Basal Tako-Tsubo Cardiomyopathy', 'no label'), ('Induced', 'no label'), ('Asymptomatic', 'no label'), ('Pheochromocytoma', 'no label'), ('Left Ventricular Function', 'no label'), ('Completely', 'no label'), ('Days', 'no label'), ('Specific', 'no label'), ('Treatment', 'no label')]|[]|[]|[('Myocardial Failure', 'no label'), ('Cataract', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Tako-Tsubo Cardiomyopathy', 'no label'), ('Pheochromocytoma', 'no label')]|[('Patient', 'no label'), ('Myocardial', 'no label'), ('Left Ventricle', 'no label'), ('Basal Tako-Tsubo', 'no label'), ('Basal Tako-Tsubo', 'no label'), ('Pheochromocytoma', 'no label'), ('Left Ventricular', 'no label')]
tako-tsubo cardiomyopathy|pubmed~23178291||[]|[]|[]|[]|[]
tako-tsubo cardiomyopathy|pubmed~32693809|Takotsubo Cardiomyopathy Is Characterized By Transient Dysfunction Of The Medial To Apical Segment Of The Left Ventricle. Recurrence Within A Few Months Or Years Has Been Reported And Serious Complications, Including Arrhythmia, Acute Cardiac Shock And Cardiac Rupture, Can Arise; However, Recurrence Is Rare And Takotsubo Cardiomyopathy Is Typically A Reversible Functional Disorder. A 91-Year-Old Japanese Woman With A Past Medical History Of Angina Pectoris, Hypertension And Uterine Carcinoma Noted Bilateral Axillary Pain And Presented Herself To An Emergency Room. Although The Pain Improved And She Went Home, There Were Several Subsequent Episodes Of Recurrent Chest Pain. At Approximately 1 Week After The Onset, She Was Hospitalized As Her Symptom Worsened. Electrocardiography Showed Low Voltage In Limb And Chest Leads, And St-Segment Elevation In Leads Ii, Iii, Avf And V3 To V6. Echocardiography Revealed Medial To Apical Dyskinesia And Basal Hypercontractility Of The Left Ventricle, And Cardiac Tamponade. Pericardiocentesis Improved The Symptom, But Not Her Cardiac Dysfunction. At 3 Days After Her Admission, Cardiopulmonary Resuscitation Was Performed Due To Ventricular Fibrillation. She Died On The 5Th Day Of Admission (2 Weeks After The Onset). At Autopsy, The Left Ventricle Was Dilatated And The Apical Ventricular Wall Was Thin. On Microscopy, Remarkable Wavy Change And Thinning Of Myocardium Were Diffusely Observed, Especially At The Apex And The Anterior To Lateral Wall Of The Left Ventricle, Interventricular Septum And Right Ventricle, Intermingled With Interstitial Fibrosis, Hemorrhage And Neutrophil Infiltration. Contraction Band Necrosis Was Mainly Observed On The Posterior To Inferior Wall Of The Left Ventricle. Our Case Showed Severe Morphological Myocardial Change After Several Chest Pain Episodes That Were Considered To Be Takotsubo Cardiomyopathy. This Notable Case Suggests That The Frequent Recurrence Of Serious Takotsubo Cardiomyopathy Is Life Threatening And Can Lead To Irreversible Serious Myocardial Degeneration.|[('Takotsubo Cardiomyopathy', 'no label'), ('Characterized', 'no label'), ('Transient Dysfunction', 'no label'), ('Medial', 'no label'), ('Apical Segment', 'no label'), ('Left Ventricle', 'no label'), ('Recurrence', 'no label'), ('Months', 'no label'), ('Years', 'no label'), ('Reported', 'no label'), ('Serious', 'no label'), ('Complications', 'no label'), ('Arrhythmia', 'no label'), ('Acute Cardiac Shock', 'no label'), ('Cardiac Rupture', 'no label'), ('Arise', 'no label'), ('Recurrence', 'no label'), ('Rare', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Reversible Functional Disorder', 'no label'), ('Japanese', 'no label'), ('Woman', 'no label'), ('Past Medical History', 'no label'), ('Angina Pectoris', 'no label'), ('Hypertension', 'no label'), ('Uterine Carcinoma', 'no label'), ('Noted', 'no label'), ('Bilateral', 'no label'), ('Axillary Pain', 'no label'), ('Herself', 'no label'), ('Emergency Room', 'no label'), ('Pain', 'no label'), ('Improved', 'no label'), ('Episodes', 'no label'), ('Recurrent Chest Pain', 'no label'), ('Week', 'no label'), ('Onset', 'no label'), ('Symptom Worsened', 'no label'), ('Electrocardiography', 'no label'), ('Low', 'no label'), ('Voltage', 'no label'), ('Limb', 'no label'), ('Chest Leads', 'no label'), ('St-Segment', 'no label'), ('Elevation', 'no label'), ('Avf', 'no label'), ('Echocardiography', 'no label'), ('Revealed', 'no label'), ('Medial', 'no label'), ('Apical Dyskinesia', 'no label'), ('Basal Hypercontractility', 'no label'), ('Left Ventricle', 'no label'), ('Cardiac Tamponade', 'no label'), ('Pericardiocentesis', 'no label'), ('Symptom', 'no label'), ('Cardiac Dysfunction', 'no label'), ('Days', 'no label'), ('Admission', 'no label'), ('Cardiopulmonary Resuscitation', 'no label'), ('Ventricular Fibrillation', 'no label'), ('Died', 'no label'), ('Day', 'no label'), ('Admission', 'no label'), ('Weeks', 'no label'), ('Onset', 'no label'), ('Autopsy', 'no label'), ('Left Ventricle', 'no label'), ('Dilatated', 'no label'), ('Apical Ventricular Wall Was Thin', 'no label'), ('Microscopy', 'no label'), ('Wavy Change', 'no label'), ('Thinning', 'no label'), ('Myocardium', 'no label'), ('Diffusely', 'no label'), ('Observed', 'no label'), ('Apex', 'no label'), ('Anterior', 'no label'), ('Lateral Wall', 'no label'), ('Left Ventricle', 'no label'), ('Interventricular Septum', 'no label'), ('Right Ventricle', 'no label'), ('Interstitial Fibrosis', 'no label'), ('Hemorrhage', 'no label'), ('Neutrophil', 'no label'), ('Infiltration', 'no label'), ('Contraction Band Necrosis', 'no label'), ('Observed', 'no label'), ('Posterior', 'no label'), ('Inferior Wall', 'no label'), ('Left Ventricle', 'no label'), ('Case Showed', 'no label'), ('Severe', 'no label'), ('Morphological', 'no label'), ('Myocardial Change', 'no label'), ('Chest Pain', 'no label'), ('Episodes', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Case Suggests', 'no label'), ('Frequent', 'no label'), ('Recurrence', 'no label'), ('Serious Takotsubo Cardiomyopathy', 'no label'), ('Life Threatening', 'no label'), ('Irreversible', 'no label'), ('Myocardial Degeneration', 'no label')]|[('Apical Segment', 'no label'), ('Ii', 'no label'), ('Neutrophil', 'no label')]|[('V3', 'no label'), ('Neutrophil', 'no label')]|[('Takotsubo Cardiomyopathy', 'no label'), ('Transient Dysfunction', 'no label'), ('Left Ventricle', 'no label'), ('Cardiac Shock', 'no label'), ('Cardiac Rupture', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Functional Disorder', 'no label'), ('Angina Pectoris', 'no label'), ('Hypertension', 'no label'), ('Uterine Carcinoma', 'no label'), ('Pain', 'no label'), ('Pain', 'no label'), ('Chest Pain', 'no label'), ('Chest', 'no label'), ('Dyskinesia', 'no label'), ('Left Ventricle', 'no label'), ('Cardiac Tamponade', 'no label'), ('Cardiac Dysfunction', 'no label'), ('Ventricular Fibrillation', 'no label'), ('Left Ventricle', 'no label'), ('Left Ventricle, Interventricular Septum And Right Ventricle', 'no label'), ('Interstitial Fibrosis', 'no label'), ('Hemorrhage', 'no label'), ('Necrosis', 'no label'), ('Left Ventricle', 'no label'), ('Chest Pain', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Takotsubo Cardiomyopathy', 'no label'), ('Myocardial Degeneration', 'no label')]|[('Apical', 'no label'), ('Left Ventricle', 'no label'), ('Arrhythmia', 'no label'), ('Cardiac', 'no label'), ('Cardiac', 'no label'), ('Uterine Carcinoma', 'no label'), ('Limb', 'no label'), ('Ii', 'no label'), ('Left Ventricle', 'no label'), ('Cardiac Tamponade.', 'no label'), ('Cardiac', 'no label'), ('Cardiopulmonary Resuscitation', 'no label'), ('Ventricular', 'no label'), ('Myocardium Were', 'no label'), ('Apex', 'no label'), ('Lateral Wall', 'no label'), ('Left Ventricle', 'no label'), ('Interventricular Septum And Right Ventricle,', 'no label'), ('Interstitial', 'no label'), ('Neutrophil', 'no label'), ('Band Necrosis', 'no label'), ('Wall', 'no label'), ('Left Ventricle', 'no label'), ('Myocardial', 'no label'), ('Myocardial', 'no label')]
lambert eaton syndrome|pubmed~35305594|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Type Of Paraneoplastic Syndrome That May Initially Manifest Itself With Proximal Weakness And Gait Abnormalities. Approximately Up To 50% Of Lems Patients Have A Primary Autonomic Dysfunction. We Present Here A Case Of A 75-Year-Old Male With Symmetric Proximal Muscle Weakness, Dry Mouth And Constipation. The Cutaneous Response To Scratch And Upright Tilt-Table Testing Were Positive. A Repetitive Nerve Stimulation Test Showed That There Was A Decremental Response Of Compound Muscle Action Potential (Cmap) Amplitude At 3 Hz While An Incremental Response At 20 Hz. The Presence Of Antibodies Against Voltage-Gated Calcium Channels (Vgcc) Confirmed The Diagnosis. Because Of The Prominent Symptom Of Autonomic Disorder, The Patient Further Underwent The Test Of Skin Sympathetic Response (Ssr). Lower Amplitude And Longer Response Duration Were Found In Palms, While It Evoked No Response In Soles. In This Case, We Present The Detailed Results Of Ssr Test On A Patient Suffering Lems With Autonomic Disorder. Since Autonomic Dysfunction Has A Significant Impact On Clinical Management And Ssr Test Is An Effective Detection Method, We Recommend That Ssr Test Be Performed On Patients With Lems Regularly.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Initially Manifest Itself', 'no label'), ('Proximal Weakness', 'no label'), ('Gait Abnormalities', 'no label'), ('Lems Patients', 'no label'), ('Primary Autonomic Dysfunction', 'no label'), ('75-Year-Old', 'no label'), ('Male', 'no label'), ('Symmetric Proximal Muscle Weakness', 'no label'), ('Dry Mouth', 'no label'), ('Constipation', 'no label'), ('Cutaneous Response', 'no label'), ('Scratch', 'no label'), ('Tilt-Table Testing', 'no label'), ('Positive', 'no label'), ('Repetitive Nerve Stimulation Test', 'no label'), ('Decremental Response', 'no label'), ('Compound Muscle', 'no label'), ('Cmap', 'no label'), ('Incremental Response', 'no label'), ('Presence', 'no label'), ('Antibodies', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Vgcc', 'no label'), ('Confirmed', 'no label'), ('Diagnosis', 'no label'), ('Prominent Symptom', 'no label'), ('Autonomic Disorder', 'no label'), ('Patient', 'no label'), ('Test', 'no label'), ('Skin Sympathetic Response', 'no label'), ('Ssr', 'no label'), ('Lower Amplitude', 'no label'), ('Longer Response Duration', 'no label'), ('Palms', 'no label'), ('Soles', 'no label'), ('Case', 'no label'), ('Results', 'no label'), ('Ssr Test', 'no label'), ('Patient', 'no label'), ('Autonomic Disorder', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Significant', 'no label'), ('Impact', 'no label'), ('Clinical Management', 'no label'), ('Ssr Test', 'no label'), ('Effective', 'no label'), ('Detection Method', 'no label'), ('Recommend', 'no label'), ('Performed', 'no label'), ('Patients', 'no label'), ('Lems', 'no label')]|[('Antibodies', 'no label'), ('Calcium', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Manifest', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Muscle Weakness', 'no label'), ('Dry Mouth', 'no label'), ('Constipation', 'no label'), ('Calcium', 'no label'), ('Autonomic Disorder', 'no label'), ('Autonomic Disorder', 'no label'), ('Autonomic Dysfunction', 'no label')]|[('A Type', 'no label'), ('Lems Patients Have A Primary Autonomic', 'no label'), ('Muscle', 'no label'), ('Scratch', 'no label'), ('Muscle', 'no label'), ('Calcium', 'no label'), ('Patient', 'no label'), ('Skin Sympathetic', 'no label'), ('Palms', 'no label'), ('Case', 'no label'), ('Lems', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~31236596|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disease Of The Neuromuscular Junction Caused By Autoantibodies Binding To P/Q-Type Voltage-Gated Calcium Channels. Breakdown Of The Blood-Brain Barrier And Diffusion Of Cerebellar Granule/Purkinje Cell-Reactive Autoantibodies Into The Cns Are Critical For The Pathogenesis Of Paraneoplastic Cerebellar Degeneration (Pcd) With Lambert-Eaton Myasthenic Syndrome. We Recently Found Evidence That Glucose-Regulated Protein 78 (Grp78) Autoantibodies In The Plasma Of Patients With Neuromyelitis Optica Promote The Cns Access Of Aqp4 Autoantibodies. In The Present Study, We Investigated Whether The Grp78 Autoantibodies In Pcd-Lems Igg Boost The Brain Uptake Of Cerebellar Cell-Reactive Antibodies Across The Blood-Brain Barrier And Facilitate Cerebellar Dysfunction. We First Evaluated The Effects Of Purified Igg From Pcd-Lems Or Pcd Patients On The Blood-Brain Barrier Function In Human Brain Microvascular Endothelial Cells Using A High Content Imaging System With Nuclear Factor Κb P65 And Intracellular Adhesion Molecule 1 (Icam1) Immunostaining. Next, We Identified Grp78 Autoantibodies Causing Blood-Brain Barrier Permeability In Pcd-Lems Igg By Co-Immunoprecipitation And The Living Cell-Based Antibody Binding Assays. Exposure Of Brain Microvascular Endothelial Cells To Igg From Pcd-Lems Patients Induced Nuclear Factor Κb P65 Nuclear Translocation, Icam1 Upregulation, Reduced Claudin-5 Expression, Increased Permeability And Increased Autocrine Il-1Β And Il-8 Secretion; The Igg From Patients With Lambert-Eaton Myasthenic Syndrome Did Not Have These Effects. We Detected Grp78 Autoantibodies In The Igg Of Lems-Pcd (83.3%, N = 18), But Observed Fewer In Patients With Lems (6.6%, N = 15) And None Were Observed In The Control Subjects (N = 8). The Depletion Of Grp78 Autoantibodies Reduced The Biological Effect Of Lems-Pcd Igg On Brain Microvascular Endothelial Cells. These Findings Suggest That Grp78 Autoantibodies Play A Role Beyond Neuromyelitis Optica And That They Have Direct Implications In The Phenotypic Differences Between Pcd-Lems And Lems.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disease', 'no label'), ('Neuromuscular Junction', 'no label'), ('Autoantibodies', 'no label'), ('Binding', 'no label'), ('P/Q-Type Voltage-Gated', 'no label'), ('Calcium Channels', 'no label'), ('Blood-Brain Barrier', 'no label'), ('Diffusion', 'no label'), ('Cerebellar', 'no label'), ('Granule/Purkinje', 'no label'), ('Cell-Reactive Autoantibodies', 'no label'), ('Cns', 'no label'), ('Pathogenesis', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Evidence', 'no label'), ('Glucose-Regulated Protein 78', 'no label'), ('Autoantibodies', 'no label'), ('Plasma', 'no label'), ('Patients', 'no label'), ('Neuromyelitis Optica', 'no label'), ('Promote', 'no label'), ('Cns Access', 'no label'), ('Aqp4', 'no label'), ('Autoantibodies', 'no label'), ('Study', 'no label'), ('Investigated', 'no label'), ('Grp78 Autoantibodies', 'no label'), ('Pcd-Lems Igg Boost', 'no label'), ('Brain', 'no label'), ('Uptake', 'no label'), ('Cerebellar', 'no label'), ('Cell-Reactive Antibodies', 'no label'), ('Blood-Brain Barrier', 'no label'), ('Facilitate', 'no label'), ('Cerebellar Dysfunction', 'no label'), ('Evaluated', 'no label'), ('Effects', 'no label'), ('Purified Igg', 'no label'), ('Pcd-Lems', 'no label'), ('Pcd Patients', 'no label'), ('Blood-Brain Barrier', 'no label'), ('Function', 'no label'), ('Human', 'no label'), ('Brain', 'no label'), ('Microvascular', 'no label'), ('Endothelial Cells', 'no label'), ('High Content Imaging System', 'no label'), ('Nuclear Factor Κb P65', 'no label'), ('Intracellular', 'no label'), ('Adhesion Molecule 1', 'no label'), ('Icam1', 'no label'), ('Immunostaining', 'no label'), ('Grp78 Autoantibodies', 'no label'), ('Causing', 'no label'), ('Blood-Brain Barrier', 'no label'), ('Permeability', 'no label'), ('Pcd-Lems Igg', 'no label'), ('Co-Immunoprecipitation', 'no label'), ('Living', 'no label'), ('Antibody', 'no label'), ('Binding Assays', 'no label'), ('Exposure', 'no label'), ('Brain', 'no label'), ('Microvascular', 'no label'), ('Endothelial Cells', 'no label'), ('Igg', 'no label'), ('Pcd-Lems', 'no label'), ('Patients', 'no label'), ('Nuclear Factor Κb P65', 'no label'), ('Nuclear Translocation', 'no label'), ('Icam1', 'no label'), ('Upregulation', 'no label'), ('Reduced', 'no label'), ('Claudin-5', 'no label'), ('Expression', 'no label'), ('Increased', 'no label'), ('Permeability', 'no label'), ('Increased', 'no label'), ('Autocrine', 'no label'), ('Il-1Β', 'no label'), ('Il-8 Secretion', 'no label'), ('Igg', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Did Not', 'no label'), ('Effects', 'no label'), ('Grp78 Autoantibodies', 'no label'), ('Igg', 'no label'), ('Lems-Pcd', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Observed', 'no label'), ('Control Subjects', 'no label'), ('Depletion', 'no label'), ('Grp78 Autoantibodies', 'no label'), ('Reduced', 'no label'), ('Biological Effect', 'no label'), ('Lems-Pcd Igg', 'no label'), ('Brain', 'no label'), ('Microvascular', 'no label'), ('Endothelial Cells', 'no label'), ('Findings', 'no label'), ('Suggest', 'no label'), ('Grp78 Autoantibodies', 'no label'), ('Play A', 'no label'), ('Neuromyelitis Optica', 'no label'), ('Phenotypic Differences', 'no label'), ('Pcd-Lems', 'no label')]|[('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Glucose-Regulated Protein', 'no label'), ('Grp78', 'no label'), ('Aqp4 Autoantibodies', 'no label'), ('Grp78', 'no label'), ('Antibodies', 'no label'), ('Human', 'no label'), ('Microvascular Endothelial Cells', 'no label'), ('Nuclear', 'no label'), ('P65', 'no label'), ('Intracellular', 'no label'), ('Molecule', 'no label'), ('Icam1', 'no label'), ('Grp78 Autoantibodies', 'no label'), ('Antibody', 'no label'), ('Microvascular Endothelial Cells', 'no label'), ('Nuclear', 'no label'), ('Icam1', 'no label'), ('Claudin-5', 'no label'), ('Grp78', 'no label'), ('Grp78', 'no label'), ('Microvascular Endothelial Cells', 'no label'), ('Grp78', 'no label')]|[('Aqp4 Autoantibodies', 'no label'), ('Grp78 Autoantibodies', 'no label'), ('Pcd-Lems Igg', 'no label'), ('Cerebellar Cell-Reactive Antibodies', 'no label'), ('Purified Igg', 'no label'), ('Nuclear Factor Κb P65 And Intracellular Adhesion Molecule 1 (Icam1) Immunostaining', 'no label'), ('Grp78 Autoantibodies', 'no label'), ('Pcd-Lems Igg', 'no label'), ('Pcd-Lems', 'no label'), ('Nuclear Factor Κb', 'no label'), ('P65', 'no label'), ('Icam1', 'no label'), ('Claudin-5', 'no label'), ('Il-1Β', 'no label'), ('Il-8', 'no label'), ('Igg', 'no label'), ('Grp78 Autoantibodies', 'no label'), ('Igg', 'no label'), ('Grp78 Autoantibodies', 'no label'), ('Brain Microvascular Endothelial Cells', 'no label'), ('Grp78 Autoantibodies', 'no label'), ('Pcd-Lems', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Cerebellar Granule/Purkinje Cell-Reactive Autoantibodies Into The Cns Are Critical For The', 'no label'), ('Pathogenesis', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Neuromyelitis Optica', 'no label'), ('Cerebellar Dysfunction', 'no label'), ('Il-8', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Neuromyelitis Optica', 'no label')]|[('Neuromuscular', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Blood-Brain Barrier', 'no label'), ('Cerebellar Granule/Purkinje', 'no label'), ('Cns', 'no label'), ('Paraneoplastic Cerebellar', 'no label'), ('Glucose-Regulated', 'no label'), ('Grp78', 'no label'), ('Plasma', 'no label'), ('Patients', 'no label'), ('Neuromyelitis Optica', 'no label'), ('Cns', 'no label'), ('Aqp4', 'no label'), ('Grp78', 'no label'), ('Brain Uptake Of', 'no label'), ('Cerebellar Cell-Reactive Antibodies Across', 'no label'), ('Cerebellar', 'no label'), ('Patients', 'no label'), ('Blood-Brain Barrier', 'no label'), ('Human Brain Microvascular Endothelial Cells', 'no label'), ('Nuclear Factor', 'no label'), ('P65', 'no label'), ('Intracellular Adhesion Molecule 1', 'no label'), ('Icam1', 'no label'), ('Grp78', 'no label'), ('Antibody', 'no label'), ('Brain Microvascular Endothelial Cells', 'no label'), ('Igg', 'no label'), ('Patients', 'no label'), ('Nuclear Factor', 'no label'), ('P65', 'no label'), ('Icam1', 'no label'), ('Claudin-5', 'no label'), ('Il-1Β', 'no label'), ('Il-8', 'no label'), ('Igg', 'no label'), ('Patients', 'no label'), ('Grp78', 'no label'), ('Igg', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Grp78', 'no label'), ('Brain Microvascular Endothelial Cells', 'no label'), ('Grp78', 'no label'), ('Neuromyelitis', 'no label')]
lambert eaton syndrome|pubmed~31880403|Paraneoplastic Neurological Syndromes (Pns) Are Rare Disorders Affecting Any Part Of The Central, Peripheral Or Autonomic Nervous System That Occur In Association With Cancer. Among Cancer Patients, Less Than 1% Overall Develop Pns. Anti-Sox1 Antibodies' Positive Paraneoplastic Neurological Disorders Are Rare And Are Usually Associated With Small Cell Lung Cancer (Sclc). Here, We Report A Case Of A 61-Year-Old Male Patient Who Presented With An Unusual Anti-Sox1 Positive Pns. The Right Tibialis Anterior Showed Noticeable Low-Amplitude Motor Unit Potentials And High Amplitude Motor Potentials In Electrodiagnostic Study, Suggesting The Presence Of Lambert-Eaton Myasthenic Syndrome (Lems). Typical Mri And Pet-Ct Found A Hyperintense Lesion With Contrast Enhancement In The Thorax In Front Of 5-6 Centrum Of Vertebrae, And Thoracoscopic Biopsy Revealed Pathological Findings For Sclc. The Patient Underwent Several Lines Of Chemotherapy And Radiotherapy And Survived For 15 Months After The Diagnosis Of Sclc.|[('Paraneoplastic Neurological Syndromes', 'no label'), ('Pns', 'no label'), ('Rare', 'no label'), ('Affecting', 'no label'), ('Central', 'no label'), ('Peripheral', 'no label'), ('Autonomic Nervous System', 'no label'), ('Occur', 'no label'), ('Cancer', 'no label'), ('Cancer', 'no label'), ('Patients', 'no label'), ('Pns', 'no label'), ('Anti-Sox1 Antibodies', 'no label'), ('Positive Paraneoplastic Neurological Disorders', 'no label'), ('Rare', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Report', 'no label'), ('Male', 'no label'), ('Patient', 'no label'), ('Unusual', 'no label'), ('Anti-Sox1', 'no label'), ('Positive Pns', 'no label'), ('Right Tibialis Anterior', 'no label'), ('Low-Amplitude Motor Unit', 'no label'), ('Potentials', 'no label'), ('High Amplitude Motor Potentials', 'no label'), ('Electrodiagnostic Study', 'no label'), ('Suggesting', 'no label'), ('Presence', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Typical', 'no label'), ('Mri', 'no label'), ('Pet-Ct', 'no label'), ('Hyperintense', 'no label'), ('Lesion', 'no label'), ('Contrast Enhancement', 'no label'), ('Thorax', 'no label'), ('Front', 'no label'), ('Centrum', 'no label'), ('Vertebrae', 'no label'), ('Thoracoscopic Biopsy', 'no label'), ('Pathological Findings', 'no label'), ('Sclc', 'no label'), ('Patient', 'no label'), ('Chemotherapy', 'no label'), ('Radiotherapy', 'no label'), ('Months', 'no label'), ('Diagnosis', 'no label'), ('Sclc', 'no label')]|[('Antibodies', 'no label'), ('Cell', 'no label')]|"[(""Anti-Sox1 Antibodies' Positive Paraneoplastic Neurological Disorders Are Rare"", 'no label')]"|[('Paraneoplastic Neurological Syndromes', 'no label'), ('Cancer', 'no label'), ('Cancer', 'no label'), ('Paraneoplastic Neurological Disorders', 'no label'), ('Myasthenic Syndrome', 'no label')]|[('Peripheral', 'no label'), ('Cancer', 'no label'), ('Cancer Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('A 61-Year-Old', 'no label'), ('Patient', 'no label'), ('Right Tibialis', 'no label'), ('Pet-Ct Found A', 'no label'), ('Thorax', 'no label'), ('5-6', 'no label'), ('Vertebrae', 'no label'), ('Biopsy', 'no label'), ('Patient', 'no label'), ('Lines', 'no label')]
lambert eaton syndrome|pubmed~34549392|Paraneoplastic Neurological Disorders Associated With Autoantibodies Are Rare Diseases, Causing Abnormal Manifestations In The Central Or Peripheral Nervous System Separately Or Simultaneously. Early Recognizing The Occurrence Of Paraneoplastic Syndrome Can Lead To Prompt And Effective Management. We Presented A Patient Of Subacute Cerebellar Degeneration With Cachectic And Bed-Ridden Status, Who Was Proven To Have Positive Sox1 Antibody. A Coexisting Lambert-Eaton Myasthenic Syndrome Was Also Documented By Electrophysiological Study. Intensive And Regular Follow Up For An Occult Malignancy Is Crucial In Patients With Sox1 Antibody. Coadministration Of Therapies For Underlying Malignancy And Lems Improve The Functional Disability.|[('Paraneoplastic Neurological Disorders', 'no label'), ('Associated With', 'no label'), ('Autoantibodies', 'no label'), ('Rare', 'no label'), ('Diseases', 'no label'), ('Causing', 'no label'), ('Abnormal', 'no label'), ('Manifestations', 'no label'), ('Central', 'no label'), ('Peripheral Nervous System', 'no label'), ('Early', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Prompt', 'no label'), ('Effective', 'no label'), ('Management', 'no label'), ('Patient', 'no label'), ('Subacute Cerebellar Degeneration', 'no label'), ('Cachectic', 'no label'), ('Bed-Ridden Status', 'no label'), ('Positive', 'no label'), ('Sox1', 'no label'), ('Antibody', 'no label'), ('Coexisting', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Documented', 'no label'), ('Electrophysiological Study', 'no label'), ('Intensive', 'no label'), ('Regular', 'no label'), ('Occult Malignancy', 'no label'), ('Patients', 'no label'), ('Sox1 Antibody', 'no label'), ('Coadministration', 'no label'), ('Therapies', 'no label'), ('Malignancy', 'no label'), ('Lems Improve', 'no label'), ('Functional Disability', 'no label')]|[('Bed-Ridden', 'no label'), ('Sox1 Antibody', 'no label'), ('Sox1 Antibody', 'no label')]|[('Bed-Ridden', 'no label'), ('Sox1', 'no label'), ('Sox1', 'no label')]|[('Paraneoplastic Neurological Disorders', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Cerebellar Degeneration', 'no label'), ('Cachectic And Bed-Ridden Status', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Occult Malignancy', 'no label'), ('Malignancy', 'no label')]|[('Peripheral', 'no label'), ('Patient', 'no label'), ('Cerebellar', 'no label'), ('Sox1', 'no label'), ('Patients', 'no label'), ('Sox1', 'no label')]
lambert eaton syndrome|pubmed~32154996|"Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare Disease Characterized By Involvement Of The Neuromuscular Junction. Most Cases Have An Underlying Malignancy, Especially Small-Cell Lung Cancer (Sclc), While Adenocarcinoma Is Less Common. Here, We Report A Rare Case Of Metastatic Lung Adenocarcinoma Complicated With Lems. In This Case, L858R Mutation Was Detected In The 21St Exon Of The Egfr Gene. First-Line Treatment With Gefitinib Was Given, And The Patient Has Survived For More Than Six Years. Early Diagnosis Of Lems And Timely And Effective Treatment Can Result In A Good Prognosis. We Also Searched For ""Lung Cancer"", Or ""Carcinoma Of Lung"", Or ""Adenocarcinoma Of Lung"", Or ""Lambert-Eaton Myasthenic Syndrome"" In Pubmed Until 1 December 2019. Seven Cases Of Lung Adenocarcinoma Complicated With Lems Were Found, Most Of Which Had A Poor Prognosis. Key Points: This Article Reports A Rare Case Of Metastatic Lung Adenocarcinoma With Egfr Mutation, Complicated With Lems. Gefitinib Was Given As First-Line Treatment, And Resulted In A Good Prognosis."|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Characterized', 'no label'), ('Involvement', 'no label'), ('Neuromuscular Junction', 'no label'), ('Cases', 'no label'), ('Underlying Malignancy', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Adenocarcinoma', 'no label'), ('Report', 'no label'), ('Rare', 'no label'), ('Case', 'no label'), ('Metastatic Lung Adenocarcinoma', 'no label'), ('Complicated', 'no label'), ('Lems', 'no label'), ('Case', 'no label'), ('L858R Mutation', 'no label'), ('Detected', 'no label'), ('Exon', 'no label'), ('Egfr Gene', 'no label'), ('First-Line Treatment', 'no label'), ('Gefitinib', 'no label'), ('Patient', 'no label'), ('Survived', 'no label'), ('Years', 'no label'), ('Early Diagnosis', 'no label'), ('Lems', 'no label'), ('Timely', 'no label'), ('Effective', 'no label'), ('Treatment', 'no label'), ('Good Prognosis', 'no label'), ('Searched', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Pubmed', 'no label'), ('Cases', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Complicated', 'no label'), ('Lems', 'no label'), ('Poor Prognosis', 'no label'), ('Key Points', 'no label'), ('Article Reports', 'no label'), ('Rare', 'no label'), ('Case', 'no label'), ('Metastatic Lung Adenocarcinoma', 'no label'), ('Egfr Mutation', 'no label'), ('Complicated', 'no label'), ('Lems', 'no label'), ('Gefitinib', 'no label'), ('First-Line Treatment', 'no label'), ('Resulted', 'no label'), ('Good Prognosis', 'no label')]|[('Mutation', 'no label'), ('Exon', 'no label'), ('Gefitinib', 'no label'), ('Mutation', 'no label'), ('Gefitinib', 'no label')]|[('21St Exon', 'no label'), ('Egfr Gene', 'no label'), ('Egfr', 'no label')]|"[('Myasthenic Syndrome', 'no label'), ('Malignancy', 'no label'), ('Lung Cancer', 'no label'), ('Adenocarcinoma', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('L858R', 'no label'), ('Gefitinib', 'no label'), ('Prognosis', 'no label'), ('Lung Cancer', 'no label'), ('Carcinoma', 'no label'), ('Adenocarcinoma Of Lung""', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Prognosis', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Gefitinib', 'no label'), ('Prognosis', 'no label')]"|[('Neuromuscular', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Adenocarcinoma', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Case', 'no label'), ('Egfr', 'no label'), ('Gefitinib', 'no label'), ('Patient', 'no label'), ('Lems', 'no label'), ('Lung Cancer', 'no label'), ('Carcinoma', 'no label'), ('Lung', 'no label'), ('Adenocarcinoma', 'no label'), ('Lung', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Lems', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Egfr', 'no label'), ('Gefitinib', 'no label')]
lambert eaton syndrome|pubmed~32893358|When Performing Postexercise Facilitation (Pef) As Part Of The Repetitive Nerve Stimulation (Rns) Test In Lambert-Eaton Myasthenic Syndrome (Lems), It Is Important To Avoid Any Influence Of The Previous Exercise Or Rns Test On The Compound Muscle Action Potential (Cmap) Amplitude. To Measure The Cmap Amplitude Return Time (Art) To That At Rest, A Single Cmap Was Obtained Every 30 Seconds Until The Amplitude Was Within 5% Of That At Rest In Three Exercise Periods (10, 20, And 30 Seconds) And In 10-Second Postexercise (Pe) 3-Hz Rns Testing With 17 Tests In 10 Lems Patients. Adequate Art Between Tests Is 150 Seconds For 10-Second Exercise (Ex) And 10-Second Pe 3-Hz Rns Test, 120 Seconds For 20-Second Ex, And 90 Seconds For 30-Second Ex. We Recommend 150 Seconds As Adequate Art Between The Pef Test And The Next Test When Performing Rns Test In Lems.|[('Postexercise Facilitation', 'no label'), ('Pef', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Influence', 'no label'), ('Exercise', 'no label'), ('Compound Muscle Action Potential', 'no label'), ('Cmap', 'no label'), ('Measure', 'no label'), ('Cmap Amplitude Return Time', 'no label'), ('Art', 'no label'), ('Rest', 'no label'), ('Single Cmap', 'no label'), ('Amplitude', 'no label'), ('Rest', 'no label'), ('Exercise Periods', 'no label'), ('Postexercise (Pe) 3-Hz Rns Testing', 'no label'), ('Tests', 'no label'), ('Lems Patients', 'no label'), ('Adequate', 'no label'), ('Art', 'no label'), ('Tests', 'no label'), ('Exercise', 'no label'), ('Adequate', 'no label'), ('Art', 'no label'), ('Pef Test', 'no label'), ('Next Test', 'no label'), ('Rns Test', 'no label')]|[]|[]|[('Pef', 'no label'), ('Myasthenic Syndrome', 'no label')]|[('Postexercise', 'no label'), ('Pef', 'no label'), ('Nerve', 'no label'), ('Rns', 'no label'), ('Postexercise', 'no label'), ('Patients', 'no label'), ('Rns Test', 'no label'), ('Pef', 'no label'), ('Rns Test', 'no label')]
lambert eaton syndrome|pubmed~31639317|<B>Introduction</B>: Lambert-Eaton Myasthenic Syndrome Is An Autoimmune Disease Of The Neuromuscular Junction Characterized By A Presynaptic Defect Of Neuromuscular Transmission Resulting In Muscle Weakness And Fatigability. Diagnostic Features Are Specific Neurophysiological Alterations And Autoantibody Detection. The Present Review Is Focused On The Use Of Amifampridine Phosphate To Treat Lems Patients.<B>Areas Covered</B>: Medline Search From 1990 To 2019 Was Examined Using The Free Subject Terms: Lambert-Eaton Myasthenic Syndrome, Lems, Amifampridine, 3,4-Diaminopyridine, Which Were Then Combined With Treatment, Therapy, Clinical Trial, Controlled Clinical Trial, Randomized Clinical Trial And Cochrane Review. The Author Has Done A Supervised Analysis Of The Retrieved Articles And Focused On Those Subjectively Evaluated As Most Relevant.<B>Expert Commentary</B>: Data From Randomized Clinical Trials And Case Series Have Demonstrated That Lambert-Eaton Myasthenic Syndrome Symptoms Were Successfully Treated By Amifampridine Phosphate. Hence, The Drug Represents A Substantial Step Forward In The Symptomatic Treatment Of The Disease Due To Its Efficacy, Safety And Reliable Gmp Formulation. As Amifampridine Phosphate Works By Enhancing The Release Of Acetylcholine At The Neuromuscular Junction By Blocking K+ Efflux At The Pre-Synaptic Membrane, It Is Also Conceivable To Use It For Other Diseases Of The Neuromuscular Junction In Which Such An Effect Is Searched For.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('Neuromuscular Junction', 'no label'), ('Characterized', 'no label'), ('Presynaptic Defect', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Resulting', 'no label'), ('Muscle Weakness', 'no label'), ('Fatigability', 'no label'), ('Diagnostic Features', 'no label'), ('Neurophysiological', 'no label'), ('Alterations', 'no label'), ('Autoantibody Detection', 'no label'), ('Present Review', 'no label'), ('Focused', 'no label'), ('Amifampridine Phosphate', 'no label'), ('Patients.<B>Areas', 'no label'), ('Covered</B>', 'no label'), ('Medline', 'no label'), ('Search', 'no label'), ('Free Subject Terms', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Amifampridine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Treatment', 'no label'), ('Therapy', 'no label'), ('Clinical Trial', 'no label'), ('Controlled Clinical Trial', 'no label'), ('Randomized Clinical Trial', 'no label'), ('Cochrane Review', 'no label'), ('Author', 'no label'), ('Supervised Analysis', 'no label'), ('Articles', 'no label'), ('Focused', 'no label'), ('Subjectively Evaluated', 'no label'), ('Relevant.<B>Expert Commentary</B>', 'no label'), ('Data', 'no label'), ('Randomized Clinical Trials', 'no label'), ('Case Series', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Symptoms', 'no label'), ('Successfully', 'no label'), ('Treated', 'no label'), ('Amifampridine Phosphate', 'no label'), ('Drug Represents A Substantial Step Forward', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Disease', 'no label'), ('Efficacy', 'no label'), ('Safety', 'no label'), ('Gmp Formulation', 'no label'), ('Amifampridine Phosphate Works', 'no label'), ('Enhancing', 'no label'), ('Release', 'no label'), ('Acetylcholine', 'no label'), ('Neuromuscular Junction', 'no label'), ('Blocking', 'no label'), ('K+', 'no label'), ('Efflux', 'no label'), ('Pre-Synaptic Membrane', 'no label'), ('Diseases', 'no label'), ('Neuromuscular Junction', 'no label'), ('Effect', 'no label'), ('Searched', 'no label')]|[('Autoantibody', 'no label'), ('Amifampridine Phosphate', 'no label'), ('Amifampridine Phosphate', 'no label'), ('Drug', 'no label'), ('Gmp', 'no label'), ('Amifampridine Phosphate', 'no label'), ('Acetylcholine', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('Muscle Weakness', 'no label'), ('Amifampridine', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Amifampridine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Amifampridine', 'no label'), ('Gmp', 'no label'), ('Amifampridine', 'no label'), ('Acetylcholine', 'no label'), ('K+', 'no label')]|[('B', 'no label'), ('Neuromuscular', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular', 'no label'), ('Muscle', 'no label'), ('Autoantibody', 'no label'), ('Amifampridine', 'no label'), ('Amifampridine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Amifampridine', 'no label'), ('Gmp', 'no label'), ('Amifampridine', 'no label'), ('Acetylcholine', 'no label'), ('Neuromuscular', 'no label'), ('Membrane', 'no label'), ('Neuromuscular', 'no label')]
lambert eaton syndrome|pubmed~33328403|A 69-Year-Old Man Was Admitted To Our Hospital For Progressive Muscle Weakness In Both Lower Limbs And Limb Ataxia (Day 0). Nerve Conduction Studies Showed Low Compound Muscle Action Potential Amplitudes At Rest And Increased Amplitudes After Maximum Voluntary Contraction. Blood Testing Revealed Sox-1 Antibodies. He Was Diagnosed With Paraneoplastic Cerebellar Degeneration And Lambert-Eaton Myasthenic Syndrome (Pcd-Lems). He Died From Aspiration Pneumonia On Day 9. Small-Cell Lung Carcinoma (Sclc), Which Had Not Been Obvious On Computed Tomography, Was Found During The Autopsy. Patients With Pcd-Lems Who Test Positive For Sox-1 Antibodies Should Be Carefully Evaluated For Sclc.|[('69-Year-Old Man', 'no label'), ('Hospital', 'no label'), ('Progressive Muscle Weakness', 'no label'), ('Lower Limbs', 'no label'), ('Limb Ataxia', 'no label'), ('Nerve Conduction Studies', 'no label'), ('Low', 'no label'), ('Compound Muscle', 'no label'), ('Amplitudes', 'no label'), ('Rest', 'no label'), ('Increased', 'no label'), ('Amplitudes', 'no label'), ('Maximum', 'no label'), ('Voluntary Contraction', 'no label'), ('Blood Testing', 'no label'), ('Revealed', 'no label'), ('Sox-1 Antibodies', 'no label'), ('Diagnosed', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Pcd-Lems', 'no label'), ('Died', 'no label'), ('Aspiration Pneumonia', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Obvious', 'no label'), ('Computed Tomography', 'no label'), ('Autopsy', 'no label'), ('Patients', 'no label'), ('Pcd-Lems Who Test', 'no label'), ('Positive', 'no label'), ('Sox-1 Antibodies', 'no label'), ('Sclc', 'no label')]|[('Sox-1 Antibodies', 'no label'), ('Sox-1 Antibodies', 'no label')]|[('Sox-1 Antibodies', 'no label'), ('Sox-1 Antibodies', 'no label')]|[('Muscle Weakness', 'no label'), ('Ataxia', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Pneumonia', 'no label'), ('Lung Carcinoma', 'no label')]|[('Muscle', 'no label'), ('Lower Limbs', 'no label'), ('Blood', 'no label'), ('Sox-1', 'no label'), ('Paraneoplastic Cerebellar', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Patients', 'no label'), ('Sox-1', 'no label')]
lambert eaton syndrome|pubmed~31586614|Thymic Small Cell Cancer Is A Very Rare Type Of Thymic Epithelial Tumor. Lambert-Eaton Myasthenic Syndrome Is A Rare Paraneoplastic Syndrome Associated With Thymic Epithelial Tumors. We Report An Extremely Rare Case Of Lambert-Eaton Myasthenic Syndrome Associated With Thymic Small Cell Carcinoma. A 71-Year-Old Man Was Referred To Our Institution For A Mediastinal Tumor And A 2-Month History Of Ptosis, Fatigue, And Gait Disorder. Based On Radiologic Findings Thymoma Associated With Lambert-Eaton Myasthenic Syndrome Was Diagnosed, And Extended Thymectomy Was Performed. After Surgery The Patient'S Symptoms Had Not Improved. Anticholinesterase Treatment Alleviated His Symptoms.|"[('Thymic Small Cell Cancer', 'no label'), ('Thymic Epithelial Tumor', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Rare', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Associated With', 'no label'), ('Thymic Epithelial Tumors', 'no label'), ('Rare', 'no label'), ('Case', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Associated With', 'no label'), ('Thymic Small Cell Carcinoma', 'no label'), ('Institution', 'no label'), ('Mediastinal Tumor', 'no label'), ('History', 'no label'), ('Ptosis', 'no label'), ('Fatigue', 'no label'), ('Gait Disorder', 'no label'), ('Radiologic Findings', 'no label'), ('Thymoma', 'no label'), ('Associated With', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Diagnosed', 'no label'), ('Extended', 'no label'), ('Thymectomy', 'no label'), ('Performed', 'no label'), ('Surgery', 'no label'), (""Patient'S"", 'no label'), ('Symptoms', 'no label'), ('Anticholinesterase Treatment', 'no label'), ('Alleviated His Symptoms', 'no label')]"|[('Thymic Small Cell', 'no label'), ('Cell', 'no label'), ('His', 'no label')]|[('Thymic Small Cell Cancer', 'no label'), ('Mediastinal Tumor And A 2-Month History Of', 'no label'), ('His', 'no label')]|[('Cancer', 'no label'), ('Epithelial Tumor', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Thymic Epithelial Tumors', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Thymic Small Cell Carcinoma', 'no label'), ('Tumor', 'no label'), ('Fatigue', 'no label'), ('Thymoma', 'no label'), ('Myasthenic Syndrome', 'no label')]|[('Thymic Small Cell Cancer', 'no label'), ('Thymic Epithelial Tumor', 'no label'), ('Thymic Epithelial Tumors', 'no label'), ('Thymic Small Cell Carcinoma.', 'no label'), ('A Mediastinal Tumor', 'no label'), ('A 2-Month', 'no label'), ('Thymoma', 'no label')]
lambert eaton syndrome|pubmed~33223079|Myasthenia Gravis (Mg) And Lambert-Eaton Myasthenic Syndrome (Lems) Are The Most Common Disorders Of Neuromuscular Transmission In Clinical Practice. Disorders Of The Neuromuscular Junction (Nmj) Are Characterized By Fluctuating And Fatigable Weakness And Include Autoimmune, Toxic, And Genetic Conditions. Adults With Nmj Disorders Are Most Often Antibody Mediated, With Mg Being The Most Common, Having A Prevalence Of Approximately 1 In 10,000, And With Women Being Affected About Twice As Often As Men. This Article Focuses On Advances In Management Of Autoimmune Mg And Lems.|[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Clinical Practice', 'no label'), ('Neuromuscular Junction', 'no label'), ('Characterized', 'no label'), ('Fluctuating', 'no label'), ('Fatigable Weakness', 'no label'), ('Autoimmune', 'no label'), ('Toxic', 'no label'), ('Genetic Conditions', 'no label'), ('Adults', 'no label'), ('Nmj Disorders', 'no label'), ('Antibody', 'no label'), ('Mediated', 'no label'), ('Mg Being', 'no label'), ('Common', 'no label'), ('Prevalence', 'no label'), ('Women Being', 'no label'), ('Affected', 'no label'), ('Men', 'no label'), ('Article Focuses', 'no label'), ('Advances', 'no label'), ('Management', 'no label'), ('Autoimmune Mg', 'no label')]|[('Toxic', 'no label'), ('Genetic', 'no label'), ('Antibody', 'no label')]|[]|[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Disorders Of Neuromuscular Transmission', 'no label'), ('Fatigable Weakness', 'no label'), ('Autoimmune, Toxic, And Genetic Conditions.', 'no label'), ('Mg', 'no label'), ('Mg', 'no label')]|[('Neuromuscular', 'no label'), ('Neuromuscular', 'no label'), ('Mg', 'no label'), ('Women', 'no label'), ('Mg', 'no label')]
lambert eaton syndrome|pubmed~34544947|We Herein Report Two P/Q-Type Voltage-Gated Calcium Channel (Vgcc) Antibody-Positive Lambert-Eaton Myasthenic Syndrome (Lems) Patients Who Responded Dramatically To Cholinesterase Inhibitors. Patient 1, A 76-Year-Old Man, Had Small-Cell Lung Cancer And Developed Lems During Chemotherapy. When Symptomatic Treatment Was Started With Pyridostigmine, Gait Disturbance Was Ameliorated, And His Modified Rankin Scale Decreased From 4 Points To 3 Points. Patient 2, A 68-Year-Old Man, Had Cancer-Free Lems. Distigmine Bromide Was Very Effective And Ameliorated Not Only His Gait Disturbance But Also Autonomic Symptoms, And His Modified Rankin Scale Decreased From 2 Points To 1 Point. Cholinesterase Inhibitors Alone May Be Effective In A Small Portion Of Lems Patients.|[('Voltage-Gated Calcium Channel', 'no label'), ('Vgcc', 'no label'), ('Antibody-Positive Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Cholinesterase Inhibitors', 'no label'), ('Patient', 'no label'), ('76-Year-Old Man', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Chemotherapy', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Pyridostigmine', 'no label'), ('Gait Disturbance', 'no label'), ('Ameliorated', 'no label'), ('Decreased', 'no label'), ('Points', 'no label'), ('Patient 2', 'no label'), ('Distigmine Bromide', 'no label'), ('Effective', 'no label'), ('Ameliorated', 'no label'), ('His Gait Disturbance', 'no label'), ('Autonomic Symptoms', 'no label'), ('Decreased', 'no label'), ('Point', 'no label'), ('Cholinesterase Inhibitors', 'no label'), ('Effective', 'no label'), ('Lems Patients', 'no label')]|[('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('His', 'no label'), ('Distigmine Bromide', 'no label'), ('His', 'no label'), ('His', 'no label'), ('Inhibitors', 'no label')]|[('His', 'no label'), ('His', 'no label')]|[('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Lung Cancer', 'no label'), ('Pyridostigmine', 'no label'), ('Distigmine Bromide', 'no label')]|[('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Patients', 'no label'), ('Cholinesterase', 'no label'), ('A 76-Year-Old', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Pyridostigmine', 'no label'), ('Patient', 'no label'), ('Distigmine Bromide', 'no label'), ('Lems Patients', 'no label')]
lambert eaton syndrome|pubmed~33845932||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~34450126|Anti-Sry-Like High Mobility Group Box 1 (Anti Sox-1) Proteins Are Rare Onconeural Antibodies Associated With Paraneoplastic Lambert-Eaton Myasthenic Syndrome (Lems). Few Patients With Anti-Sox-1 Antibodies And Negative Anti-Glial Nuclear Antibody Reactivity Have Been Described To Date. Our Case Involves A 72-Year-Old Female Patient With Progressive Girdle Weakness, Sensation Of Heaviness In The Lower Limbs, Predominantly Distal And Associated With Circulatory Problems Together With Instability When Walking, With A High Suspicion Of An Autoimmune Myopathic Disorder. Immunoblot Test For Autoimmune Myopathies Antibodies Detection Were All Negative. Onconeuronal Antibodies Were Determined In Serum By Indirect Immunofluorescence Being Negative As Well. Given The High Suspicion, We Also Checked For The Presence Of Other Antineuronal Antibodies Whose Patterns Are Not Visible By Iif. Onconeuronal Antibodies By Immunoblot For The Following Antibodies: Hu, Ri, Yo, Zic4, Tr, Pca-2, Ma-Ta, Cv2, Gad65, Zic4, Titin, Sox1, Recoverin And Amp, Revealed An Unexpected Clear Band In Sox-1, Which Are Highly Suggestive Of Paraneoplastic Lems. We Hypothesize That Discordant Onconeuronal Antibodies Results Were Due To The Fact That Positivity In Iif Is Associated With Other Sox-B Group Proteins (Normally Related To Cases Of Non-Paraneoplastic Neuropathy), While Negativity In Iif And Subsequent Confirmed Presence Of Specific Sox1 Antibody By Immunoblot Could Indicate An Underlying Tumor.|[('Anti-Sry-Like High Mobility Group Box 1', 'no label'), ('Anti Sox-1) Proteins', 'no label'), ('Rare', 'no label'), ('Onconeural Antibodies', 'no label'), ('Associated With', 'no label'), ('Paraneoplastic Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Anti-Sox-1 Antibodies', 'no label'), ('Negative', 'no label'), ('Anti-Glial Nuclear Antibody', 'no label'), ('Reactivity', 'no label'), ('Case Involves', 'no label'), ('Female', 'no label'), ('Patient', 'no label'), ('Progressive', 'no label'), ('Girdle Weakness', 'no label'), ('Sensation', 'no label'), ('Heaviness', 'no label'), ('Lower Limbs', 'no label'), ('Distal', 'no label'), ('Associated With', 'no label'), ('Circulatory', 'no label'), ('Problems', 'no label'), ('Instability', 'no label'), ('Walking', 'no label'), ('Suspicion', 'no label'), ('Autoimmune Myopathic Disorder', 'no label'), ('Immunoblot Test', 'no label'), ('Antibodies', 'no label'), ('Detection', 'no label'), ('Negative', 'no label'), ('Onconeuronal Antibodies', 'no label'), ('Serum', 'no label'), ('Indirect Immunofluorescence Being', 'no label'), ('Negative', 'no label'), ('Suspicion', 'no label'), ('Presence', 'no label'), ('Antineuronal Antibodies', 'no label'), ('Patterns', 'no label'), ('Onconeuronal Antibodies', 'no label'), ('Immunoblot', 'no label'), ('Antibodies', 'no label'), ('Ri', 'no label'), ('Yo', 'no label'), ('Zic4', 'no label'), ('Tr', 'no label'), ('Pca-2', 'no label'), ('Ma-Ta', 'no label'), ('Cv2', 'no label'), ('Gad65', 'no label'), ('Zic4', 'no label'), ('Titin', 'no label'), ('Sox1', 'no label'), ('Recoverin', 'no label'), ('Amp', 'no label'), ('Revealed', 'no label'), ('Sox-1', 'no label'), ('Suggestive', 'no label'), ('Paraneoplastic Lems', 'no label'), ('Hypothesize', 'no label'), ('Discordant', 'no label'), ('Onconeuronal Antibodies', 'no label'), ('Results', 'no label'), ('Fact', 'no label'), ('Positivity', 'no label'), ('Iif', 'no label'), ('Associated With', 'no label'), ('Sox-B', 'no label'), ('Group Proteins', 'no label'), ('Cases', 'no label'), ('Non-Paraneoplastic Neuropathy', 'no label'), ('Negativity', 'no label'), ('Iif', 'no label'), ('Confirmed', 'no label'), ('Presence', 'no label'), ('Sox1', 'no label'), ('Antibody', 'no label'), ('Immunoblot', 'no label'), ('Tumor', 'no label')]|[('Proteins', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Zic4', 'no label'), ('Cv2', 'no label'), ('Gad65', 'no label'), ('Zic4', 'no label'), ('Titin', 'no label'), ('Sox1', 'no label'), ('Recoverin', 'no label'), ('Sox-1', 'no label'), ('Antibodies', 'no label'), ('Proteins', 'no label'), ('Sox1 Antibody', 'no label')]|[('Anti Sox-1', 'no label'), ('Anti-Sox-1 Antibodies', 'no label'), ('Negative Anti-Glial Nuclear Antibody', 'no label'), ('Antineuronal Antibodies', 'no label'), ('Hu', 'no label'), ('Zic4', 'no label'), ('Sox1', 'no label'), ('Recoverin', 'no label'), ('Sox-1', 'no label'), ('Sox1 Antibody', 'no label')]|[('Paraneoplastic Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Girdle Weakness', 'no label'), ('Autoimmune Myopathic Disorder', 'no label'), ('Paraneoplastic', 'no label'), ('Neuropathy', 'no label'), ('Tumor', 'no label')]|[('Sox-1', 'no label'), ('Paraneoplastic Lambert-Eaton', 'no label'), ('Patients', 'no label'), ('Anti-Glial Nuclear', 'no label'), ('Patient', 'no label'), ('Heaviness', 'no label'), ('Lower Limbs', 'no label'), ('Serum', 'no label'), ('Antineuronal Antibodies', 'no label'), ('Yo', 'no label'), ('Zic4', 'no label'), ('Tr,', 'no label'), ('Cv2', 'no label'), ('Gad65', 'no label'), ('Zic4', 'no label'), ('Titin', 'no label'), ('Sox1', 'no label'), ('Recoverin', 'no label'), ('Sox-1', 'no label'), ('Sox-B Group Proteins', 'no label'), ('Sox1', 'no label'), ('Tumor', 'no label')]
lambert eaton syndrome|pubmed~29681644|Neurological Paraneoplastic Syndromes Are Rare, Occur In 0.01% Of All Cancer Patients; Like Part Of Them, The Lambert-Eaton Syndrome Is An Autoimmune Presynaptic Disorder Of Neuromuscular Transmission Characterized By Muscle Weakness And Neurovegetative Dysfunction, And Often Associated With Small Cell Lung Cancer. A 72 Years Old Female With A Family History Of Lung Cancer And Leukemia, With 7 Months Of Dry Cough And 3 Months With Waist And Pelvic Muscle Weakness, Oropharyngeal Dysphagia, Dry Mouth, Chronic Constipation And Weight Loss Of 10 Kg. Physical Examination: Patient Prostrated; Clinical Muscle Examination: Pelvic Muscles Waist -3/5 And -4/5 The Rest; Diminished Reflexes. Laboratory Normal Parathormone And Hypercalcemia. With Electrophysiological Study And Positive Anti-Voltage-Gated Calcium Channel Antibodies, Confirming Lambert-Eaton Syndrome And Imaging Studies With Neoplastic Condition In Brain, Liver And Kidney, With Unspecified Primary Origin.|[('Neurological Paraneoplastic Syndromes', 'no label'), ('Rare', 'no label'), ('Occur', 'no label'), ('Cancer', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Autoimmune Presynaptic Disorder', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Characterized', 'no label'), ('Muscle Weakness', 'no label'), ('Neurovegetative Dysfunction', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Years', 'no label'), ('Family History', 'no label'), ('Lung Cancer', 'no label'), ('Leukemia', 'no label'), ('Months', 'no label'), ('Dry Cough', 'no label'), ('Months', 'no label'), ('Waist And Pelvic Muscle Weakness', 'no label'), ('Oropharyngeal Dysphagia', 'no label'), ('Dry Mouth', 'no label'), ('Chronic Constipation', 'no label'), ('Weight Loss', 'no label'), ('Physical Examination', 'no label'), ('Patient', 'no label'), ('Prostrated', 'no label'), ('Clinical Muscle Examination', 'no label'), ('Pelvic Muscles', 'no label'), ('Waist -3/5 And -4/5 The Rest', 'no label'), ('Diminished', 'no label'), ('Reflexes', 'no label'), ('Laboratory Normal Parathormone', 'no label'), ('Hypercalcemia', 'no label'), ('Electrophysiological Study', 'no label'), ('Positive', 'no label'), ('Anti-Voltage-Gated', 'no label'), ('Calcium Channel Antibodies', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Neoplastic Condition', 'no label'), ('Brain', 'no label'), ('Liver', 'no label'), ('Kidney', 'no label')]|[('Cell', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label')]|[('-4/5', 'no label')]|[('Neurological Paraneoplastic Syndromes', 'no label'), ('Cancer', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Autoimmune Presynaptic Disorder Of Neuromuscular Transmission', 'no label'), ('Muscle Weakness', 'no label'), ('Neurovegetative Dysfunction', 'no label'), ('Lung Cancer', 'no label'), ('Leukemia', 'no label'), ('Cough', 'no label'), ('Pelvic Muscle Weakness', 'no label'), ('Oropharyngeal Dysphagia', 'no label'), ('Dry Mouth', 'no label'), ('Chronic Constipation', 'no label'), ('Weight Loss', 'no label'), ('Hypercalcemia', 'no label'), ('Calcium', 'no label'), ('Lambert-Eaton Syndrome', 'no label')]|[('Cancer Patients', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular', 'no label'), ('Muscle', 'no label'), ('Small Cell Lung Cancer.', 'no label'), ('Lung Cancer', 'no label'), ('Muscle', 'no label'), ('Oropharyngeal', 'no label'), ('Patient', 'no label'), ('Muscle', 'no label'), ('-4/5', 'no label'), ('Calcium', 'no label'), ('Neoplastic', 'no label'), ('Brain', 'no label'), ('Liver', 'no label')]
lambert eaton syndrome|pubmed~33185628|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Presynaptic Autoimmune Disabling Neuromuscular Disease Caused By Antibodies Against Presynaptic Voltage-Gated Calcium Channels. It Reduces The Quantal Release Of Acetylcholine (Ach), Causing Muscle Weakness, Reduced Or Absent Reflex And Dysautonomia. About Half Of Lems Patients Have Associated Small Cell Lung Cancer. For Symptomatic Treatment, Amifampridine (3,4-Diaminopyridine [3,4-Dap]) Is Ideal Because It Increases The Release Of Ach At The Presynaptic Membrane. Since The First Use Of 3,4-Dap In Lems Patients In The 1980S, 136 Lems Patients Were Treated With Amifampridines In The Open-Label Studies And 208 Patients In The Eight Randomized Studies. These Studies Showed That Amifampridine Is The Most Effective Drug For Symptomatic Treatment In Lems. Now, 3,4-Dapp (3,4-Dap Phosphate) Is Approved For Adult Lems Patients And 3,4-Dap For Pediatric Patients. The Recommended Dose Is 80 Mg A Day, Divided 3 Or 4 Times A Day. Side Effects Are Usually Mild, And The Most Frequently Reported Are Paresthesia.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Presynaptic Autoimmune', 'no label'), ('Neuromuscular Disease', 'no label'), ('Antibodies', 'no label'), ('Presynaptic Voltage-Gated', 'no label'), ('Reduces', 'no label'), ('Quantal Release', 'no label'), ('Acetylcholine (', 'no label'), ('Ach', 'no label'), ('Causing Muscle Weakness', 'no label'), ('Reduced', 'no label'), ('Absent Reflex', 'no label'), ('Dysautonomia', 'no label'), ('Lems Patients', 'no label'), ('Associated Small Cell', 'no label'), ('Lung Cancer', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Amifampridine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Ideal', 'no label'), ('Increases', 'no label'), ('Release', 'no label'), ('Ach', 'no label'), ('Presynaptic Membrane', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Lems Patients', 'no label'), ('Treated', 'no label'), ('Amifampridines', 'no label'), ('Open-Label Studies', 'no label'), ('Patients', 'no label'), ('Randomized Studies', 'no label'), ('Studies', 'no label'), ('Amifampridine', 'no label'), ('Effective', 'no label'), ('Drug', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Phosphate', 'no label'), ('Adult', 'no label'), ('Patients', 'no label'), ('Pediatric', 'no label'), ('Patients', 'no label'), ('Recommended Dose', 'no label'), ('Mg A Day', 'no label'), ('Day', 'no label'), ('Side Effects', 'no label'), ('Mild', 'no label'), ('Reported', 'no label'), ('Paresthesia', 'no label')]|[('Antibodies', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Cell', 'no label'), ('Amifampridine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Amifampridine', 'no label'), ('Drug', 'no label'), ('Phosphate', 'no label'), ('Dose Is 80 Mg A', 'no label')]|[('Ach', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disabling Neuromuscular Disease', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Ach', 'no label'), ('Muscle Weakness', 'no label'), ('Dysautonomia', 'no label'), ('Amifampridine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Ach', 'no label'), ('Amifampridines', 'no label'), ('Amifampridine', 'no label'), ('Phosphate', 'no label'), ('Mg', 'no label'), ('Paresthesia', 'no label')]|[('Presynaptic', 'no label'), ('Neuromuscular', 'no label'), ('Presynaptic', 'no label'), ('Calcium', 'no label'), ('Quantal', 'no label'), ('Acetylcholine', 'no label'), ('Ach', 'no label'), ('Muscle', 'no label'), ('Lems Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Amifampridine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Ach', 'no label'), ('Presynaptic Membrane', 'no label'), ('Lems Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Amifampridine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Divided 3', 'no label'), ('Paresthesia', 'no label')]
lambert eaton syndrome|pubmed~32291768|Increment Of Compound Muscle Action Potential Amplitude Is A Diagnostic Hallmark Of Lambert-Eaton Myasthenic Syndrome (Lems). Making A Diagnosis Can Be Challenging, Therefore, A Proper Cutoff For Abnormal Increment Is Highly Relevant For Improved Recognition Of This Rare Disease. We Determined The Sensitivity And Specificity Of 60% And 100% Cutoff Values In All Consecutive Patients Who Underwent Increment Testing In Our Hospital From 1999 To 2016. We Included 156 Patients, 63 With Lems And 93 Without Lems. Sensitivity Of A 60% Cutoff For Increment Testing Was 77.8% (95% Confidence Interval 65.5%-87.3%) And 58.7% (45.6%-71.0%) For 100%. Specificity Was 98.9% (94.2%-100%) And 100% (96.1%-100%) Using A Threshold Of 60% And 100%, Respectively. Lowering The Cutoff Value For Abnormal Increment To 60% Greatly Increases Sensitivity To Diagnose Lems Without An Overt Loss In Specificity.|[('Increment', 'no label'), ('Compound Muscle', 'no label'), ('Diagnostic Hallmark', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Making A', 'no label'), ('Diagnosis', 'no label'), ('Challenging', 'no label'), ('Cutoff', 'no label'), ('Abnormal Increment', 'no label'), ('Relevant', 'no label'), ('Recognition', 'no label'), ('Rare Disease', 'no label'), ('Sensitivity', 'no label'), ('Specificity', 'no label'), ('Cutoff Values', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Increment Testing', 'no label'), ('Hospital', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Lems', 'no label'), ('Sensitivity', 'no label'), ('Cutoff', 'no label'), ('Increment Testing', 'no label'), ('Confidence Interval', 'no label'), ('Specificity', 'no label'), ('Threshold', 'no label'), ('Cutoff Value', 'no label'), ('Abnormal Increment', 'no label'), ('Increases', 'no label'), ('Sensitivity', 'no label'), ('Overt Loss', 'no label'), ('Specificity', 'no label')]|[]|[]|[('Myasthenic Syndrome', 'no label'), ('Overt Loss', 'no label')]|[('Muscle', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lems And', 'no label')]
lambert eaton syndrome|pubmed~34563155|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare Autoimmune Disorder Of Neuromuscular Transmission. The Objective Was To Examine The Efficacy And Safety Of 3,4-Diaminopyridine (3,4-Dap) In Patients With Lems. We Searched Several Databases To Identify Relevant Studies, Including Pubmed, Embase, Web Of Science, Medline, Cochrane Neuromuscular Disease Group Specialized Register And The Cochrane Central Register Of Controlled Trials(Central). The Primary Outcome, Quantitative Myasthenia Gravis (Qmg) Score And The Secondary Outcome, Compound Muscle Action Potentials (Cmap) Amplitude Were Pooled By Meta-Analysis. Six Randomised Controlled Trials (Rcts) Involving 115 Patients With Lems Were Included. Qmg Score Showed A Significant Decrease (Improvement) Of 2.76 Points (95 % Ci, -4.08 To -1.45, P < 0.001) After Treatment With 3, 4-Dap. Moreover, The Overall Mean Cmap Amplitude Improved Significantly In Lems Patients With 3, 4-Dap Treatment, Compared With Placebo Treatment (Mean Difference 1.34 Mv, 95 % Ci, 0.98 To 1.70, P < 0.001). The Overall Assessment Of All Included Trials Showed A Low Risk Of Bias And Low Heterogeneity. The Pooled Results Of Rcts Demonsrated With Moderate To High Evidence That 3,4-Dap Has A Significant Effect On Lems Treatment, With Improvements In Muscle Strength Score And Cmap Amplitude.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Autoimmune Disorder', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Objective', 'no label'), ('Efficacy', 'no label'), ('Safety', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Databases', 'no label'), ('Relevant', 'no label'), ('Studies', 'no label'), ('Pubmed', 'no label'), ('Embase', 'no label'), ('Web Of Science', 'no label'), ('Medline', 'no label'), ('Cochrane Neuromuscular Disease Group', 'no label'), ('Specialized Register', 'no label'), ('Cochrane Central Register', 'no label'), ('Primary Outcome', 'no label'), ('Quantitative Myasthenia Gravis', 'no label'), ('Secondary Outcome', 'no label'), ('Compound Muscle Action Potentials', 'no label'), ('Cmap', 'no label'), ('Pooled', 'no label'), ('Meta-Analysis', 'no label'), ('Randomised Controlled Trials', 'no label'), ('Rcts', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Qmg Score', 'no label'), ('Showed A', 'no label'), ('Significant', 'no label'), ('Decrease', 'no label'), ('Improvement', 'no label'), ('Points', 'no label'), ('Ci', 'no label'), ('Treatment', 'no label'), ('4-Dap', 'no label'), ('Cmap', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('4-Dap Treatment', 'no label'), ('Placebo Treatment', 'no label'), ('Mean Difference', 'no label'), ('Ci', 'no label'), ('Assessment', 'no label'), ('Trials', 'no label'), ('Low', 'no label'), ('Risk', 'no label'), ('Bias', 'no label'), ('Low', 'no label'), ('Heterogeneity', 'no label'), ('Pooled Results', 'no label'), ('Rcts Demonsrated', 'no label'), ('Moderate', 'no label'), ('Evidence', 'no label'), ('Significant', 'no label'), ('Effect', 'no label'), ('Lems Treatment', 'no label'), ('Improvements', 'no label'), ('Muscle Strength Score', 'no label'), ('Cmap', 'no label')]|[]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Neuromuscular Disease', 'no label'), ('Myasthenia Gravis', 'no label')]|[('Neuromuscular', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Lems Patients', 'no label'), ('Rcts', 'no label'), ('Lems', 'no label'), ('Muscle', 'no label')]
lambert eaton syndrome|pubmed~33983073|This Current Report Describes A Rare Clinical Case Of Neuroendocrine Carcinoma (Nec) Of The Larynx With Associated Lambert-Eaton Myasthenic Paraneoplastic Syndrome (Lems). A 68-Year-Old Male Patient Presented With Severe Dysphonia And Dysphagia. He Underwent A Total Laryngectomy And The Excised Lesion Was Extremely Large. A Pathological Examination Demonstrated 'Morphological Findings Of A Poorly Differentiated Carcinoma (G3) With Aspects Of Neuroendocrine Differentiation' (I.E. A Poorly Differentiated Neuroendocrine Carcinomas [Pd-Nec]). Based On The Patient'S Medical History And The Immunohistochemical Findings, He Was Treated With Three Cycles Of Neoadjuvant Chemotherapy (Cisplatin-Etoposide) And Then Radiotherapy With A Total Dose Of 70 Gy. Of The 10 Cases Of Paraneoplastic Syndrome (Pns) Related To Laryngeal Nec Reported In The Literature, Nine Of These Syndromes Were Of An Endocrine Type. Only One Case Of Pns Associated With Laryngeal Cancer Had A Neurological Manifestation, Which Was Lems. To The Best Of Our Knowledge, This Current Case Has Only One Similar Precedent In The Literature And It Is The Second Report Of An Association Between A Pd-Nec And Lems. Laryngeal Necs Are Rare Lesions With Different Prognostic Characteristics. The Diagnosis Should Be Made Using An Endocrinological, Neurological, Radiological And Histological Multidisciplinary Approach. A Radical Surgical Approach Is Recommended.|"[('Report', 'no label'), ('Describes', 'no label'), ('Rare', 'no label'), ('Clinical Case', 'no label'), ('Neuroendocrine Carcinoma', 'no label'), ('Nec', 'no label'), ('Larynx', 'no label'), ('Lambert-Eaton Myasthenic Paraneoplastic Syndrome', 'no label'), ('Lems', 'no label'), ('Male', 'no label'), ('Patient', 'no label'), ('Severe', 'no label'), ('Dysphonia', 'no label'), ('Dysphagia', 'no label'), ('Total Laryngectomy', 'no label'), ('Excised Lesion', 'no label'), ('Large', 'no label'), ('Pathological Examination', 'no label'), ('Morphological', 'no label'), ('Findings', 'no label'), ('Poorly Differentiated Carcinoma', 'no label'), (""Neuroendocrine Differentiation'"", 'no label'), ('Poorly', 'no label'), ('Differentiated', 'no label'), ('Neuroendocrine Carcinomas', 'no label'), (""Patient'S"", 'no label'), ('Medical History', 'no label'), ('Immunohistochemical Findings', 'no label'), ('Treated', 'no label'), ('Neoadjuvant Chemotherapy', 'no label'), ('Cisplatin-Etoposide', 'no label'), ('Radiotherapy', 'no label'), ('Total Dose', 'no label'), ('Cases', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Laryngeal', 'no label'), ('Nec', 'no label'), ('Literature', 'no label'), ('Syndromes', 'no label'), ('Endocrine Type', 'no label'), ('Associated With', 'no label'), ('Laryngeal Cancer', 'no label'), ('Neurological Manifestation', 'no label'), ('Knowledge', 'no label'), ('Case', 'no label'), ('Precedent', 'no label'), ('Literature', 'no label'), ('Association', 'no label'), ('Pd-Nec', 'no label'), ('Lems', 'no label'), ('Laryngeal Necs', 'no label'), ('Rare', 'no label'), ('Lesions', 'no label'), ('Prognostic Characteristics', 'no label'), ('Diagnosis', 'no label'), ('Endocrinological', 'no label'), ('Neurological', 'no label'), ('Radiological', 'no label'), ('Histological', 'no label'), ('Radical Surgical Approach', 'no label'), ('Recommended', 'no label')]"|[]|[]|[('Neuroendocrine Carcinoma', 'no label'), ('Nec', 'no label'), ('Myasthenic Paraneoplastic Syndrome', 'no label'), ('Dysphonia', 'no label'), ('Dysphagia', 'no label'), ('Carcinoma', 'no label'), ('Neuroendocrine Carcinomas', 'no label'), ('Cisplatin-Etoposide', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Nec', 'no label'), ('Laryngeal Cancer', 'no label'), ('Neurological Manifestation', 'no label')]|[('Neuroendocrine Carcinoma', 'no label'), ('Nec', 'no label'), ('Larynx', 'no label'), ('Patient', 'no label'), ('Carcinoma', 'no label'), ('Neuroendocrine', 'no label'), ('Neuroendocrine Carcinomas [', 'no label'), ('Laryngeal', 'no label'), ('Endocrine Type', 'no label'), ('Pns', 'no label'), ('Laryngeal Cancer', 'no label'), ('Laryngeal Necs', 'no label'), ('Rare Lesions', 'no label')]
lambert eaton syndrome|pubmed~33290581||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~31951874|Since Approximately 50% Of Patients With Lambert-Eaton Myasthenic Syndrome (Lems) Subsequently Develop Small-Cell Lung Cancer (Sclc), It Is Important To Be Able To Predict Cancer Occurrence In These Patients At Neurological Presentation. We Aimed To Determine Whether Circulating Biomarkers Were Effective And Objective Predictors Of Cancer Development In Lems. We Found That The Presence Of Either Sox2, N-Type Voltage Gated Calcium Channel Or Gabab Antibodies At Lems Diagnosis Was Highly Sensitive (84%) And Specific (87%) For The Detection Of Sclc. Screening For Sox2 And Neuronal Antibodies Is A Useful Adjunct To Clinical Predictive Scoring Tools In Predicting Sclc In Lems.|[('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Cancer', 'no label'), ('Occurrence', 'no label'), ('Patients', 'no label'), ('Neurological Presentation', 'no label'), ('Circulating', 'no label'), ('Biomarkers', 'no label'), ('Effective', 'no label'), ('Objective', 'no label'), ('Predictors', 'no label'), ('Cancer Development', 'no label'), ('Presence', 'no label'), ('Sox2', 'no label'), ('N-Type Voltage Gated', 'no label'), ('Calcium Channel', 'no label'), ('Gabab Antibodies', 'no label'), ('Lems Diagnosis', 'no label'), ('Sensitive', 'no label'), ('Detection', 'no label'), ('Sclc', 'no label'), ('Screening', 'no label'), ('Sox2', 'no label'), ('Neuronal Antibodies', 'no label'), ('Clinical Predictive Scoring Tools', 'no label'), ('Sclc', 'no label')]|[('Sox2', 'no label'), ('N-Type', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('Sox2', 'no label'), ('Neuronal Antibodies', 'no label')]|[('Sox2', 'no label'), ('Sox2', 'no label'), ('Neuronal Antibodies', 'no label')]|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lung Cancer', 'no label'), ('Cancer', 'no label'), ('Cancer', 'no label'), ('Calcium', 'no label')]|[('Patients', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Cancer', 'no label'), ('Patients', 'no label'), ('Cancer', 'no label'), ('Sox2', 'no label'), ('N-Type Voltage', 'no label'), ('Calcium', 'no label'), ('Gabab Antibodies', 'no label'), ('Lems', 'no label'), ('Sox2', 'no label'), ('Neuronal Antibodies', 'no label')]
lambert eaton syndrome|pubmed~31831596|To Study Survival And To Characterize Long-Term Functional Impairments And Health-Related Quality Of Life (Hrqol) Of Patients With Lambert-Eaton Myasthenic Syndrome (Lems). In This Observational Study, Survival Of Patients With Lems, Separately For Nontumor (Nt) And Small Cell Lung Cancer (Sclc), Was Compared To That Of The Dutch General Population And Patients With Sclc. Disease Course In Patients With Lems Was Recorded Retrospectively. Several Scales For Functional Impairments And Health-Related Quality Of Life Were Assessed. We Included 150 Patients With Lems. Survival Was Similar To That Of The General Population In 65 Patients With Nt-Lems. Tumor Survival Was Significantly Longer In 81 Patients With Sclc-Lems Compared To Patients With Non-Lems Sclc (Overall Median Survival 17 Vs 7.0 Months, <I>P</I> < 0.0001). At Diagnosis, 39 (62%) Of 63 Patients With Complete Follow-Up Data Were Independent For Activities Of Daily Living, Improving To 85% At The 1-Year Follow-Up. The Physical Hrqol Composite Score (55.9) Was Significantly Lower Than In The General Population (76.3, <I>P</I> < 0.0001) And Comparable To That Of Patients With Myasthenia Gravis (60.5). The Mental Hrqol Composite Score Was 71.8 In Patients With Lems, Comparable To That Of The General Population (77.9, <I>P</I> = 0.19) And Patients With Myasthenia Gravis (70.3). This Study Shows That Patients With Nt-Lems Have Normal Survival. Patients With Sclc-Lems Have An Improved Tumor Survival, Even After Correction For Tumor Stage. A Majority Of Patients With Lems Report A Stable Disease Course And Remain Or Become Independent For Self-Care After Treatment.|[('Study Survival', 'no label'), ('Characterize', 'no label'), ('Long-Term', 'no label'), ('Functional Impairments', 'no label'), ('Health-Related Quality Of Life', 'no label'), ('Hrqol', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Observational Study', 'no label'), ('Survival', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Nontumor', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Dutch General Population', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Disease Course', 'no label'), ('Patients', 'no label'), ('Lems Was Recorded', 'no label'), ('Retrospectively', 'no label'), ('Scales', 'no label'), ('Functional Impairments', 'no label'), ('Health-Related Quality Of Life', 'no label'), ('Assessed', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Survival', 'no label'), ('General Population', 'no label'), ('Patients', 'no label'), ('Nt-Lems.', 'no label'), ('Tumor Survival', 'no label'), ('Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Patients', 'no label'), ('Non-Lems', 'no label'), ('Sclc', 'no label'), ('Median Survival', 'no label'), ('Diagnosis', 'no label'), ('Patients', 'no label'), ('Complete Follow-Up', 'no label'), ('Data', 'no label'), ('Independent', 'no label'), ('Activities', 'no label'), ('Improving', 'no label'), ('1-Year Follow-Up', 'no label'), ('Physical Hrqol Composite Score', 'no label'), ('General Population', 'no label'), ('<I>P</I> < 0.0001)', 'no label'), ('Patients', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mental Hrqol Composite Score', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('General Population', 'no label'), ('<I>P</I> = 0.19) And Patients', 'no label'), ('Myasthenia Gravis', 'no label'), ('Study', 'no label'), ('Patients', 'no label'), ('Nt-Lems', 'no label'), ('Normal Survival', 'no label'), ('Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Tumor Survival', 'no label'), ('Correction', 'no label'), ('Tumor Stage', 'no label'), ('Patients', 'no label'), ('Lems Report', 'no label'), ('Stable Disease Course', 'no label'), ('Remain', 'no label'), ('Independent', 'no label'), ('Self-Care', 'no label'), ('Treatment', 'no label')]|[('Cell', 'no label'), ('Sclc-Lems', 'no label')]|[('Non-Lems', 'no label'), ('Physical Hrqol Composite Score (55.9) Was', 'no label'), ('Mental Hrqol Composite', 'no label')]|[('Functional Impairments', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Tumor', 'no label'), ('Myasthenia Gravis', 'no label'), ('Myasthenia Gravis', 'no label'), ('Tumor', 'no label'), ('Tumor', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('Nontumor', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Patients', 'no label'), ('Non-Lems', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Tumor', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~31319693|<B>Objective:</B> The Purpose Of This Article Is To Review The Literature For Both 3,4-Diaminopyridine (3,4-Dap) And Amifampridine For The Treatment Of Lambert-Eaton Myasthenic Syndrome (Lems). Amifampridine (Firdapse) Is The Salt Form Of 3,4-Dap And Was Approved By The Food And Drug Administration For The Treatment Of Lems. <B>Data Sources:</B> Pubmed, Trip Database, And Embase Searches Were Conducted Without A Back Date (Current To June 2019) Utilizing The Following Search Terms: <I>Amifampridine, 3,4-Diaminopyridine</I>, And <I>Lambert-Eaton Myasthenic Syndrome</I>. Completed Trials Were Also Reviewed At Clinicaltrials.Gov. <B>Study Selection And Data Extraction:</B> Criteria For Article Inclusion Consisted Of Human Subjects, Age ≥18 Years, Phase Ii Or Iii Clinical Trials, And English Language For Both Drugs. Observational And Pharmacokinetic Studies For Amifampridine Were Also Included. <B>Data Synthesis:</B> Prior To The Approval Of Amifampridine, 3,4-Dap Was First-Line For The Management Of Lems Symptoms. Two Phase Iii Trials Have Evaluated Amifampridine To Confirm Efficacy, Both Showing Superiority Over Placebo In The Management Of Lems Symptoms, With Minimal Adverse Effects. A Significant Improvement In Both Quantitative Myasthenia Gravis Scores And Subjective Global Impression Scores Was Established At Days 4 And 14. <B>Relevance To Patient Care And Clinical Practice:</B> With An Improved Stability Profile And Decreased Dose Variability, Amifampridine Will Likely Assume The Role Of First-Line Management Of Lems. <B>Conclusions:</B> Amifampridine Has Been Shown To Improve Symptoms Of Lems And Is Generally Well Tolerated.|[('Objective:</B', 'no label'), ('Article', 'no label'), ('Review', 'no label'), ('Literature', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Amifampridine', 'no label'), ('Treatment', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Amifampridine', 'no label'), ('Firdapse', 'no label'), ('Salt Form', 'no label'), ('Food And Drug Administration', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label'), ('Pubmed', 'no label'), ('Trip Database', 'no label'), ('Embase Searches', 'no label'), ('Back Date', 'no label'), ('Amifampridine', 'no label'), ('Myasthenic Syndrome</I>.', 'no label'), ('Completed Trials', 'no label'), ('Reviewed', 'no label'), ('Clinicaltrials', 'no label'), ('Selection', 'no label'), ('Data', 'no label'), ('Extraction:</B', 'no label'), ('Criteria', 'no label'), ('Article Inclusion Consisted', 'no label'), ('Human Subjects', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('Phase Ii Or Iii Clinical Trials', 'no label'), ('English Language', 'no label'), ('Drugs', 'no label'), ('Observational', 'no label'), ('Pharmacokinetic Studies', 'no label'), ('Amifampridine', 'no label'), ('Synthesis:</B', 'no label'), ('Approval', 'no label'), ('Amifampridine', 'no label'), ('First-Line', 'no label'), ('Management', 'no label'), ('Lems Symptoms', 'no label'), ('Phase Iii Trials', 'no label'), ('Evaluated', 'no label'), ('Amifampridine', 'no label'), ('Confirm Efficacy', 'no label'), ('Superiority', 'no label'), ('Placebo', 'no label'), ('Management', 'no label'), ('Lems Symptoms', 'no label'), ('Minimal', 'no label'), ('Adverse Effects', 'no label'), ('Significant', 'no label'), ('Improvement', 'no label'), ('Quantitative Myasthenia Gravis', 'no label'), ('Scores', 'no label'), ('Subjective Global Impression Scores', 'no label'), ('Days', 'no label'), ('Relevance', 'no label'), ('Patient Care', 'no label'), ('Clinical', 'no label'), ('Improved', 'no label'), ('Stability', 'no label'), ('Profile', 'no label'), ('Decreased', 'no label'), ('Dose', 'no label'), ('Variability', 'no label'), ('Amifampridine', 'no label'), ('First-Line Management', 'no label'), ('Lems', 'no label'), ('Conclusions:</B', 'no label'), ('Amifampridine', 'no label'), ('Improve', 'no label'), ('Symptoms', 'no label'), ('Lems', 'no label'), ('Tolerated', 'no label')]|[('Amifampridine', 'no label'), ('Amifampridine', 'no label'), ('Salt', 'no label'), ('Food', 'no label'), ('Drug', 'no label'), ('Amifampridine', 'no label'), ('Human', 'no label'), ('Ii', 'no label'), ('Amifampridine', 'no label'), ('Amifampridine', 'no label'), ('Amifampridine', 'no label'), ('Amifampridine', 'no label')]|[]|[('3,4-Diaminopyridine', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Amifampridine', 'no label'), ('Amifampridine', 'no label'), ('Amifampridine', 'no label'), ('Myasthenia Gravis', 'no label'), ('Amifampridine', 'no label'), ('Amifampridine', 'no label')]|[('B', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Salt Form', 'no label'), ('B', 'no label'), ('B', 'no label'), ('Human', 'no label'), ('Amifampridine', 'no label'), ('B', 'no label'), ('Amifampridine', 'no label'), ('Lems', 'no label'), ('Lems', 'no label'), ('B', 'no label'), ('Patient', 'no label'), ('Amifampridine', 'no label'), ('B', 'no label'), ('Conclusions:</B', 'no label'), ('Amifampridine', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~34210541|Disorders Of The Neuromuscular Junction (Nmj) Comprise A Spectrum Of Rare Diseases Causing Muscle Fatigability And Weakness, Leading To Life-Long Effects On Quality Of Life. We Established The Dutch-Belgian Registry For Nmj Disorders, Based On A Unique Combination Of Patient- And Physician-Reported Information. Information On Natural Course, Disease Burden, Prevalence Of Complications And Comorbidity Is Collected Through Patient-Reported Standardized Questionnaires And Verified Using Medical Documentation. Currently, The Registry Contains Information Of 565 Myasthenia Gravis (Mg) Patients And 38 Lambert-Eaton Myasthenic Syndrome (Lems) Patients, Constituting Approximately 25% (Mg) And 80% (Lems) Of Patients In The Netherlands. This Is A Very Large Registry, With The Highest Participation Rate Per Capita. In Addition To Confirming Many Disease Characteristics Previously Described In The Literature, This Registry Provides Several Novel Insights. The Reported Rate Of Potentially Corticosteroid-Related Comorbidity, Including Hypertension, Heart Disease, Osteoporosis And Type 2 Diabetes Was High, Emphasizing The Need To Commence Corticosteroid-Sparing Immune Suppressive Treatment As Soon As Possible. The Reported Rate Of Other Auto-Immune Diseases Is Far Higher Than Previously Expected: 27% Of Mg And 38% Of Lems Patients, And A Surprisingly High Number Of Mg Patients (47%) Is Unaware Of Their Antibody Status. In Conclusion, This Registry Provides A Valuable Collection Of Information Regarding Mg And Lems Disease Course. Continuous Collection Of Annual Follow-Up Data Will Provide Further Longitudinal Insights In Disease Burden, Course And Treatment Effect.|[('Neuromuscular Junction', 'no label'), ('Comprise A', 'no label'), ('Spectrum', 'no label'), ('Rare', 'no label'), ('Diseases', 'no label'), ('Causing', 'no label'), ('Muscle Fatigability', 'no label'), ('Weakness', 'no label'), ('Life-Long Effects', 'no label'), ('Quality Of Life', 'no label'), ('Dutch-Belgian Registry', 'no label'), ('Nmj Disorders', 'no label'), ('Combination', 'no label'), ('Patient- And Physician-Reported', 'no label'), ('Information', 'no label'), ('Natural Course', 'no label'), ('Disease Burden', 'no label'), ('Prevalence', 'no label'), ('Complications', 'no label'), ('Comorbidity', 'no label'), ('Collected', 'no label'), ('Patient-Reported Standardized Questionnaires', 'no label'), ('Medical Documentation', 'no label'), ('Registry', 'no label'), ('Contains Information', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Constituting', 'no label'), ('Mg', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Netherlands', 'no label'), ('Registry', 'no label'), ('Highest', 'no label'), ('Participation Rate', 'no label'), ('Per Capita', 'no label'), ('Disease Characteristics', 'no label'), ('Literature', 'no label'), ('Registry', 'no label'), ('Provides', 'no label'), ('Insights', 'no label'), ('Rate', 'no label'), ('Corticosteroid-Related Comorbidity', 'no label'), ('Hypertension', 'no label'), ('Heart Disease', 'no label'), ('Osteoporosis', 'no label'), ('Type 2 Diabetes', 'no label'), ('Need', 'no label'), ('Corticosteroid-Sparing', 'no label'), ('Immune', 'no label'), ('Suppressive Treatment', 'no label'), ('Rate', 'no label'), ('Auto-Immune Diseases', 'no label'), ('Mg', 'no label'), ('Lems Patients', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Unaware', 'no label'), ('Antibody Status', 'no label'), ('Registry', 'no label'), ('Provides', 'no label'), ('Information', 'no label'), ('Mg', 'no label'), ('Lems Disease Course', 'no label'), ('Continuous Collection', 'no label'), ('Annual Follow-Up', 'no label'), ('Data', 'no label'), ('Longitudinal Insights In Disease', 'no label'), ('Burden', 'no label'), ('Course', 'no label'), ('Treatment Effect', 'no label')]|[('Antibody', 'no label')]|[]|[('Weakness', 'no label'), ('Comorbidity', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Mg', 'no label'), ('Comorbidity', 'no label'), ('Hypertension', 'no label'), ('Heart Disease', 'no label'), ('Osteoporosis', 'no label'), ('Diabetes', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label')]|[('Neuromuscular', 'no label'), ('Muscle', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Heart', 'no label'), ('Type 2', 'no label'), ('Immune', 'no label'), ('Far', 'no label'), ('Mg', 'no label'), ('Lems Patients', 'no label'), ('Mg Patients', 'no label'), ('Mg', 'no label')]
lambert eaton syndrome|pubmed~29489969|This Historical Review Describes The Contribution Of Drs. Lee M. Eaton And Edward H. Lambert To The Diagnosis Of Myasthenic Syndrome On The 60Th Anniversary Of Their Pioneering Article (Jama 1957) On The Disease. There Are Important Landmarks In Their Article On A Disorder Of The Neuromuscular Junction Associated With Thoracic Neoplasm And The Electrophysiological Criteria For Lambert-Eaton Myasthenic Syndrome (Lems). After 60 Years, The Main Electrophysiological Criteria Described In Eaton And Lambert'S Pioneering Article Are Still Currently Useful In The Diagnosis Of Lems.|"[('Historical Review', 'no label'), ('Describes', 'no label'), ('Contribution', 'no label'), ('Diagnosis', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Pioneering', 'no label'), ('Article', 'no label'), ('Disease', 'no label'), ('Landmarks', 'no label'), ('Article', 'no label'), ('Disorder', 'no label'), ('Neuromuscular Junction', 'no label'), ('Associated With', 'no label'), ('Thoracic Neoplasm', 'no label'), ('Electrophysiological Criteria', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Years', 'no label'), ('Main Electrophysiological Criteria', 'no label'), (""Eaton And Lambert'S Pioneering"", 'no label'), ('Article', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label')]"|[]|[]|[('Myasthenic Syndrome', 'no label'), ('Thoracic Neoplasm', 'no label'), ('Myasthenic Syndrome', 'no label')]|[('60Th', 'no label'), ('Neuromuscular', 'no label'), ('Thoracic Neoplasm', 'no label')]
lambert eaton syndrome|pubmed~33290573||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~28608304|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare Autoimmune Neuromuscular Junction Disorder That Is Related To The Loss Of Functional P/Q-Type Voltage-Gated Calcium Channels (Vgccs) On Presynaptic Nerve Terminals. Up To 60% Of Cases Occur As A Paraneoplastic Disorder (Sclc-Lems), Most Commonly In Association With Small Cell Lung Cancer. The Remaining Cases Have An Idiopathic Non-Tumor Etiology But Are Associated With Underlying Autoimmune Disease (Nt-Lems). Patients With Lems Invariably Experience Progressive Proximal Muscle Weakness, Often Accompanied By General Fatigue And Autonomic Symptoms. Some Lems Clinical Symptoms Overlap With Those Of Other Myasthenic Syndromes, Most Commonly Myasthenia Gravis, Which Can Contribute To Misdiagnosis Or Delayed Diagnosis. Prognosis Is Related To The Presence Of Cancer Or Autoimmune Disease And The Severity/Distribution Of Muscle Weakness. Cause Of Death In Patients With Sclc-Lems Is Typically Tumor Progression, Whereas Nt-Lems Does Not Reduce Life Expectancy. Lems Diagnosis Is Supported By A Threefold Approach: Clinical Features, Electromyography, And Anti-Vgcc Antibody Serology. Lems Is A Clinically Important Early Indicator Of Possible Cancer; Therefore, A Lems Diagnosis Should Immediately Prompt Rigorous Oncological Screening And Surveillance. Symptomatic Treatment Of Lems Typically Involves Medications That Improve Neurotransmission (E.G., The Potassium Channel Blocker Amifampridine [3,4-Diaminopyridine]), With Addition Of Immunosuppressants/Modulators (E.G., Prednisone Plus Azathioprine) In Individuals With Persistent Symptoms. Where A Tumor Is Identified, Oncological Treatment Should Take Priority. It Should Be Remembered, However, That Lems Has A Significant Impact On A Patient'S Quality Of Life And Ability To Perform Daily Activities, And Therefore Warrants Timely Diagnosis And Appropriate Treatment In And Of Itself.|"[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Autoimmune Neuromuscular Junction Disorder', 'no label'), ('Loss', 'no label'), ('Functional', 'no label'), ('Vgccs', 'no label'), ('Presynaptic Nerve', 'no label'), ('Terminals', 'no label'), ('Cases', 'no label'), ('Occur', 'no label'), ('Paraneoplastic Disorder', 'no label'), ('Sclc-Lems', 'no label'), ('Association', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Cases', 'no label'), ('Idiopathic Non-Tumor', 'no label'), ('Etiology', 'no label'), ('Associated With', 'no label'), ('Autoimmune Disease', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Experience', 'no label'), ('Progressive Proximal Muscle Weakness', 'no label'), ('General Fatigue', 'no label'), ('Autonomic Symptoms', 'no label'), ('Lems Clinical Symptoms', 'no label'), ('Overlap', 'no label'), ('Myasthenic Syndromes', 'no label'), ('Myasthenia Gravis', 'no label'), ('Contribute', 'no label'), ('Misdiagnosis', 'no label'), ('Delayed Diagnosis', 'no label'), ('Prognosis', 'no label'), ('Presence', 'no label'), ('Cancer', 'no label'), ('Severity/Distribution', 'no label'), ('Muscle Weakness', 'no label'), ('Death', 'no label'), ('Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Tumor Progression', 'no label'), ('Not Reduce', 'no label'), ('Life Expectancy', 'no label'), ('Lems Diagnosis', 'no label'), ('Clinical Features', 'no label'), ('Electromyography', 'no label'), ('Anti-Vgcc', 'no label'), ('Antibody', 'no label'), ('Serology', 'no label'), ('Lems', 'no label'), ('Clinically Important', 'no label'), ('Early Indicator', 'no label'), ('Cancer', 'no label'), ('Lems Diagnosis', 'no label'), ('Prompt', 'no label'), ('Oncological Screening', 'no label'), ('Surveillance', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label'), ('Medications', 'no label'), ('Improve', 'no label'), ('Neurotransmission', 'no label'), ('Potassium Channel Blocker', 'no label'), ('Amifampridine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Addition', 'no label'), ('Immunosuppressants/Modulators', 'no label'), ('E.G.', 'no label'), ('Prednisone Plus', 'no label'), ('Azathioprine', 'no label'), ('Individuals', 'no label'), ('Persistent Symptoms', 'no label'), ('Tumor', 'no label'), ('Identified', 'no label'), ('Oncological Treatment', 'no label'), ('Take Priority', 'no label'), ('Remembered', 'no label'), ('Lems', 'no label'), ('Significant', 'no label'), ('Impact', 'no label'), (""Patient'S"", 'no label'), ('Quality Of Life', 'no label'), ('Perform', 'no label'), ('Daily Activities', 'no label'), ('Warrants', 'no label'), ('Timely', 'no label'), ('Diagnosis', 'no label'), ('Appropriate', 'no label'), ('Treatment', 'no label')]"|[('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Nerve Terminals', 'no label'), ('Cell', 'no label'), ('Sclc-Lems', 'no label'), ('Anti-Vgcc Antibody', 'no label'), ('Potassium', 'no label'), ('Amifampridine', 'no label'), ('Azathioprine', 'no label'), ('Individuals', 'no label')]|[('Sclc-Lems', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Neuromuscular Junction Disorder', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Paraneoplastic Disorder', 'no label'), ('Idiopathic Non-Tumor Etiology', 'no label'), ('Autoimmune Disease', 'no label'), ('Muscle Weakness', 'no label'), ('Fatigue', 'no label'), ('Myasthenic Syndromes', 'no label'), ('Myasthenia Gravis', 'no label'), ('Misdiagnosis', 'no label'), ('Delayed Diagnosis', 'no label'), ('Prognosis', 'no label'), ('Cancer', 'no label'), ('Autoimmune Disease', 'no label'), ('Muscle Weakness', 'no label'), ('Death', 'no label'), ('Tumor', 'no label'), ('Cancer', 'no label'), ('Potassium', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('E.G.', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label'), ('Tumor', 'no label')]|[('Neuromuscular', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Presynaptic Nerve', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Non-Tumor', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Muscle', 'no label'), ('Lems', 'no label'), ('Cancer', 'no label'), ('Muscle', 'no label'), ('Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Tumor', 'no label'), ('Anti-Vgcc Antibody', 'no label'), ('Cancer', 'no label'), ('Lems', 'no label'), ('Amifampridine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label'), ('Tumor', 'no label'), ('Lems', 'no label'), ('Life', 'no label')]
lambert eaton syndrome|pubmed~27816328|Tubular Aggregates Are Accumulations Of Densely Packed Tubules In Muscle Fibers, Occurring In Distinct Hereditary And Acquired Disorders. We Present A Patient With Tubular Aggregates And Autoimmune Lambert-Eaton Myasthenic Syndrome. Initially, He Showed Mild Proximal Weakness, Borderline Decrement On 3 Hz Stimulation, And Slightly Elevated Creatine Kinase. Muscle Biopsy Revealed Tubular Aggregates In Type Ii Fibers. Due To A Good Response To Pyridostigmine, A Limb-Girdle Myasthenia With Tubular Aggregates Was Suspected, But Genetic Analyses Of Gfpt1, Dpgat1, And Alg2 Were Normal. Two Years Later, The Patient Presented With Progressive Weakness And Autonomic Dysfunction. 17% Decrement On 3 Hz Stimulation And 100% Increment After Brief Exercise Were Revealed. Autoantibodies To Voltage-Gated Calcium-Channels Confirmed The Diagnosis Of Lambert-Eaton Myasthenic Syndrome. Steroids, Azathioprine, And 3,4-Diaminopyridine Significantly Improved Symptoms. No Tumor Was Found During Follow-Up. This Is The First Report About Tubular Aggregates Associated With An Acquired Myasthenic Syndrome. Our Findings Are Important Because Of The Therapeutic Implications.|[('Tubular Aggregates', 'no label'), ('Accumulations', 'no label'), ('Packed Tubules', 'no label'), ('Muscle Fibers', 'no label'), ('Occurring', 'no label'), ('Hereditary', 'no label'), ('Patient', 'no label'), ('Tubular Aggregates', 'no label'), ('Autoimmune Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Mild Proximal Weakness', 'no label'), ('Borderline Decrement', 'no label'), ('Stimulation', 'no label'), ('Elevated', 'no label'), ('Creatine Kinase', 'no label'), ('Muscle Biopsy', 'no label'), ('Tubular Aggregates', 'no label'), ('Type Ii Fibers', 'no label'), ('Good Response', 'no label'), ('Pyridostigmine', 'no label'), ('Limb-Girdle Myasthenia', 'no label'), ('Tubular Aggregates', 'no label'), ('Suspected', 'no label'), ('Genetic Analyses', 'no label'), ('Gfpt1', 'no label'), ('Dpgat1', 'no label'), ('Alg2', 'no label'), ('Normal', 'no label'), ('Years', 'no label'), ('Patient', 'no label'), ('Progressive Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Decrement', 'no label'), ('Stimulation', 'no label'), ('Increment', 'no label'), ('Brief Exercise', 'no label'), ('Revealed', 'no label'), ('Autoantibodies', 'no label'), ('Voltage-Gated Calcium-Channels', 'no label'), ('Confirmed', 'no label'), ('Diagnosis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Steroids', 'no label'), ('Azathioprine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Symptoms', 'no label'), ('Tumor', 'no label'), ('Follow-Up', 'no label'), ('First Report', 'no label'), ('Tubular Aggregates', 'no label'), ('Associated With', 'no label'), ('Acquired Myasthenic Syndrome', 'no label'), ('Findings', 'no label'), ('Therapeutic', 'no label'), ('Implications', 'no label')]|[('Creatine', 'no label'), ('Genetic', 'no label'), ('Gfpt1', 'no label'), ('Dpgat1', 'no label'), ('Alg2', 'no label'), ('Azathioprine', 'no label')]|[('Creatine Kinase', 'no label'), ('Type Ii Fibers', 'no label'), ('Alg2', 'no label'), ('Autoantibodies', 'no label')]|[('Hereditary', 'no label'), ('Autoimmune Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Weakness', 'no label'), ('Creatine', 'no label'), ('Type Ii', 'no label'), ('Pyridostigmine', 'no label'), ('Limb-Girdle Myasthenia', 'no label'), ('Weakness And Autonomic Dysfunction', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Steroids', 'no label'), ('Azathioprine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Tumor', 'no label'), ('Acquired Myasthenic Syndrome', 'no label')]|[('Tubular Aggregates', 'no label'), ('Tubules', 'no label'), ('Muscle Fibers', 'no label'), ('Patient', 'no label'), ('Tubular Aggregates', 'no label'), ('Creatine Kinase', 'no label'), ('Tubular Aggregates', 'no label'), ('Type Ii', 'no label'), ('Pyridostigmine', 'no label'), ('Tubular Aggregates', 'no label'), ('Gfpt1', 'no label'), ('Alg2', 'no label'), ('Patient', 'no label'), ('Steroids', 'no label'), ('Azathioprine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Tumor', 'no label'), ('Tubular Aggregates', 'no label')]
lambert eaton syndrome|pubmed~34291446|Early Diagnosis Based On Clinical Findings, Neurophysiological Studies And Serum Antibody Titres Allows Early Initiation Of Symptomatic Treatment And Oncological Screening. Reports Of Patients With Lems In Latin America Are Scarce. This Article Aims To Describe The Characteristics Of Patients With Lems From A Private Centre In Buenos Aires, Argentina, And To Compare Them With Those Of Other Series That Have Been Published. The Medical Records Of 13 Patients With Lems With Clinical Findings, Compatible Electromyogram And/Or Positive Antibodies Were Reviewed. Follow-Up Was Performed Until Associated Neoplasia Was Ruled Out Or Confirmed According To The Recommended Algorithms. Four Patients Were Diagnosed With T-Lems, Two Of Them With Small-Cell Lung Carcinoma. Of The Nine Patients With Nt-Lems, Five Had A Delta-P Score Of 3 And 4. Nine Patients Presented With The Classic Clinical Triad From The Onset Of The Disease. All Patients Had Electromyogram Findings Compatible With Presynaptic Neuromuscular Plaque Defect. Of The Total, 70% Improved Symptomatically With Pyridostigmine. The Clinical Findings, Together With Compatible Neurophysiological Studies, Are Sufficient For The Diagnosis Of Lems. The Relationship Between The Delta-P Score And The Risk Of Small-Cell Lung Carcinoma Could Not Be Replicated. Symptomatic Treatment With Pyridostigmine Represents An Effective Therapeutic Alternative.|[('Early Diagnosis', 'no label'), ('Clinical Findings', 'no label'), ('Neurophysiological Studies', 'no label'), ('Serum', 'no label'), ('Antibody', 'no label'), ('Titres', 'no label'), ('Early Initiation', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Oncological Screening', 'no label'), ('Reports', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Latin America', 'no label'), ('Article Aims', 'no label'), ('Characteristics', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Private Centre', 'no label'), ('Buenos Aires', 'no label'), ('Argentina', 'no label'), ('Compare', 'no label'), ('Series', 'no label'), ('Published', 'no label'), ('Medical Records', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Clinical Findings', 'no label'), ('Compatible', 'no label'), ('Electromyogram', 'no label'), ('And/Or', 'no label'), ('Positive Antibodies', 'no label'), ('Reviewed', 'no label'), ('Follow-Up', 'no label'), ('Performed', 'no label'), ('Associated Neoplasia', 'no label'), ('Confirmed', 'no label'), ('Recommended Algorithms', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('T-Lems', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Patients', 'no label'), ('Nt-Lems', 'no label'), ('Delta-P', 'no label'), ('Score', 'no label'), ('Patients', 'no label'), ('Classic Clinical Triad', 'no label'), ('Disease', 'no label'), ('Patients', 'no label'), ('Electromyogram', 'no label'), ('Findings', 'no label'), ('Compatible', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular Plaque', 'no label'), ('Defect', 'no label'), ('Symptomatically', 'no label'), ('Pyridostigmine', 'no label'), ('Clinical Findings', 'no label'), ('Compatible', 'no label'), ('Neurophysiological Studies', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Relationship', 'no label'), ('Delta-P', 'no label'), ('Score', 'no label'), ('Risk', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Replicated', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Pyridostigmine', 'no label'), ('Represents', 'no label'), ('Effective', 'no label'), ('Therapeutic Alternative', 'no label')]|[('Antibody', 'no label'), ('Antibodies', 'no label'), ('Pyridostigmine', 'no label')]|[]|[('And/Or', 'no label'), ('Neoplasia', 'no label'), ('Lung Carcinoma', 'no label'), ('Pyridostigmine', 'no label'), ('Lung Carcinoma', 'no label'), ('Pyridostigmine', 'no label')]|[('Serum Antibody Titres', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Neoplasia', 'no label'), ('Patients', 'no label'), ('T-Lems', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Patients', 'no label'), ('A Delta-P', 'no label'), ('Patients', 'no label'), ('Triad', 'no label'), ('Patients', 'no label'), ('Electromyogram', 'no label'), ('Pyridostigmine', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Pyridostigmine', 'no label')]
lambert eaton syndrome|pubmed~30951047|Neurological Paraneoplastic Syndromes Are Rare, Occur In 0.01% Of All Cancer Patients; Like Part Of Them, The Lambert-Eaton Syndrome Is An Autoimmune Presynaptic Disorder Of Neuromuscular Transmission Characterized By Muscle Weakness And Neurovegetative Dysfunction, And Often Associated With Small Cell Lung Cancer. A 72 Years Old Female With A Family History Of Lung Cancer And Leukemia, With 7 Months Of Dry Cough And 3 Months With Waist And Pelvic Muscle Weakness, Oropharyngeal Dysphagia, Dry Mouth, Chronic Constipation And Weight Loss Of 10 Kg. Patient Prostrated; Clinical Muscle Examination: Pelvic Muscles Waist -3/5 And -4/5 The Rest; Diminished Reflexes. Laboratory Normal Parathormone And Hypercalcemia. With Electrophysiological Study And Positive Anti-Voltage-Gated Calcium Channel Antibodies, Confirming Lambert-Eaton Syndrome And Imaging Studies With Neoplastic Condition In Brain, Liver And Kidney, With Unspecified Primary Origin.|[('Neurological Paraneoplastic Syndromes', 'no label'), ('Rare', 'no label'), ('Occur', 'no label'), ('Cancer', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Autoimmune Presynaptic Disorder', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Characterized', 'no label'), ('Muscle Weakness', 'no label'), ('Neurovegetative Dysfunction', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Years', 'no label'), ('Family History', 'no label'), ('Lung Cancer', 'no label'), ('Leukemia', 'no label'), ('Months', 'no label'), ('Dry Cough', 'no label'), ('Months', 'no label'), ('Waist And Pelvic Muscle Weakness', 'no label'), ('Oropharyngeal Dysphagia', 'no label'), ('Dry Mouth', 'no label'), ('Chronic Constipation', 'no label'), ('Weight Loss', 'no label'), ('Patient', 'no label'), ('Prostrated', 'no label'), ('Clinical Muscle Examination', 'no label'), ('Pelvic Muscles', 'no label'), ('Waist -3/5 And -4/5 The Rest', 'no label'), ('Diminished', 'no label'), ('Reflexes', 'no label'), ('Laboratory Normal Parathormone', 'no label'), ('Hypercalcemia', 'no label'), ('Electrophysiological Study', 'no label'), ('Positive', 'no label'), ('Anti-Voltage-Gated', 'no label'), ('Calcium Channel Antibodies', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Neoplastic Condition', 'no label'), ('Brain', 'no label'), ('Liver', 'no label'), ('Kidney', 'no label')]|[('Cell', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label')]|[('-4/5', 'no label')]|[('Neurological Paraneoplastic Syndromes', 'no label'), ('Cancer', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Autoimmune Presynaptic Disorder Of Neuromuscular Transmission', 'no label'), ('Muscle Weakness', 'no label'), ('Neurovegetative Dysfunction', 'no label'), ('Lung Cancer', 'no label'), ('Leukemia', 'no label'), ('Cough', 'no label'), ('Pelvic Muscle Weakness', 'no label'), ('Oropharyngeal Dysphagia', 'no label'), ('Dry Mouth', 'no label'), ('Chronic Constipation', 'no label'), ('Weight Loss', 'no label'), ('Hypercalcemia', 'no label'), ('Calcium', 'no label'), ('Lambert-Eaton Syndrome', 'no label')]|[('Cancer Patients', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular', 'no label'), ('Muscle', 'no label'), ('Small Cell Lung Cancer.', 'no label'), ('Lung Cancer', 'no label'), ('Muscle', 'no label'), ('Oropharyngeal', 'no label'), ('Muscle', 'no label'), ('-4/5', 'no label'), ('Calcium', 'no label'), ('Neoplastic', 'no label'), ('Brain', 'no label'), ('Liver', 'no label')]
lambert eaton syndrome|pubmed~31794471|This Article Reviews The Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, And Treatment Of Lambert-Eaton Myasthenic Syndrome (Lems) And Of Botulism, And Immune-Related Myasthenia Gravis (Mg) Occurring In The Context Of Immune Checkpoint Inhibitor Therapy For Cancer. The Suspicion That Lems Is Rare But Also Likely Underdiagnosed Is Supported By Recent Epidemiologic Data. A Validated, Lems-Specific Scale Now Exists To Assess And Monitor Disease, And Symptomatic And Immunomodulatory Treatments Are Available. As Presynaptic Disorders Of Neuromuscular Transmission, Lems And Botulism Share Electrodiagnostic Abnormalities But Have Important Distinguishing Features. Knowledge Of The Clinical Features Of Botulism Is Needed, Particularly With Continued Cases Of Infant Botulism, The Opioid Epidemic Increasing The Incidence Of Wound Botulism, And Medical Use Of Botulinum Toxin, Which May Cause Iatrogenic Botulism. Foodborne Botulism Remains Rare. Prompt Recognition Of Botulism And Administration Of Antitoxin Can Improve Outcomes. Mg May Be Exacerbated Or May Present De Novo In The Context Of Immune Activation From Immune Checkpoint Inhibitor Therapies For Cancer. Immune-Related Mg Commonly Overlaps With Myositis And Myocarditis. Corticosteroids Typically Result In Improvement. However, Immune-Related Mg Can Be More Fulminant Than Its Idiopathic Counterpart And May Cause Permanent Disability Or Death. The Diagnosis Of Lems, Botulism, Or Immune-Related Mg Can Generally Be Made From The Patient'S History, Supplemented With Directed Questions, A Physical Examination Designed To Demonstrate Abnormalities, And Laboratory And Electrodiagnostic Testing. Early Diagnosis And Carefully Selected Treatment Not Only Improve Outcomes Of The Neuromuscular Disease But Can Affect The Prognosis Of Underlying Malignancy, When Present.|"[('Article Reviews', 'no label'), ('Pathophysiology', 'no label'), ('Epidemiology', 'no label'), ('Clinical Presentation', 'no label'), ('Diagnosis', 'no label'), ('Treatment', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Botulism', 'no label'), ('Immune-Related Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Occurring', 'no label'), ('Context', 'no label'), ('Immune Checkpoint Inhibitor Therapy', 'no label'), ('Cancer', 'no label'), ('Suspicion', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Underdiagnosed', 'no label'), ('Epidemiologic Data', 'no label'), ('Validated', 'no label'), ('Lems-Specific Scale', 'no label'), ('Symptomatic', 'no label'), ('Immunomodulatory Treatments', 'no label'), ('Presynaptic Disorders', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Lems', 'no label'), ('Botulism', 'no label'), ('Share', 'no label'), ('Electrodiagnostic Abnormalities', 'no label'), ('Features', 'no label'), ('Clinical Features', 'no label'), ('Botulism', 'no label'), ('Cases', 'no label'), ('Infant Botulism', 'no label'), ('Opioid Epidemic', 'no label'), ('Increasing', 'no label'), ('Incidence', 'no label'), ('Wound Botulism', 'no label'), ('Medical Use', 'no label'), ('Botulinum Toxin', 'no label'), ('Iatrogenic', 'no label'), ('Botulism', 'no label'), ('Foodborne', 'no label'), ('Botulism', 'no label'), ('Rare', 'no label'), ('Prompt', 'no label'), ('Recognition', 'no label'), ('Botulism', 'no label'), ('Administration', 'no label'), ('Antitoxin', 'no label'), ('Outcomes', 'no label'), ('Exacerbated', 'no label'), ('De Novo', 'no label'), ('Context', 'no label'), ('Immune Activation', 'no label'), ('Immune Checkpoint Inhibitor Therapies', 'no label'), ('Cancer', 'no label'), ('Myositis', 'no label'), ('Myocarditis', 'no label'), ('Corticosteroids', 'no label'), ('Result', 'no label'), ('Improvement', 'no label'), ('Immune-Related Mg', 'no label'), ('Fulminant', 'no label'), ('Than Its Idiopathic', 'no label'), ('May', 'no label'), ('Cause Permanent Disability Or Death', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Botulism', 'no label'), ('Immune-Related Mg', 'no label'), (""Patient'S History"", 'no label'), ('Supplemented', 'no label'), ('Directed Questions', 'no label'), ('Physical Examination', 'no label'), ('Demonstrate Abnormalities', 'no label'), ('Laboratory', 'no label'), ('Electrodiagnostic Testing', 'no label'), ('Early Diagnosis', 'no label'), ('Treatment', 'no label'), ('Improve', 'no label'), ('Outcomes', 'no label'), ('Neuromuscular Disease', 'no label'), ('Prognosis', 'no label'), ('Malignancy', 'no label')]"|[('Inhibitor', 'no label'), ('Toxin', 'no label'), ('Antitoxin', 'no label'), ('Inhibitor', 'no label')]|[]|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Botulism', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Cancer', 'no label'), ('Disorders Of Neuromuscular Transmission', 'no label'), ('Botulism', 'no label'), ('Wound Botulism', 'no label'), ('Botulism', 'no label'), ('Botulism', 'no label'), ('Botulism', 'no label'), ('Mg', 'no label'), ('Cancer', 'no label'), ('Mg', 'no label'), ('Myositis', 'no label'), ('Myocarditis', 'no label'), ('Mg', 'no label'), ('Death', 'no label'), ('Botulism', 'no label'), ('Mg', 'no label'), ('Neuromuscular Disease', 'no label'), ('Prognosis', 'no label'), ('Malignancy', 'no label')]|[('Immune Checkpoint Inhibitor', 'no label'), ('Cancer', 'no label'), ('Lems', 'no label'), ('Lems-Specific', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular', 'no label'), ('Opioid', 'no label'), ('Wound', 'no label'), ('Botulinum Toxin', 'no label'), ('Antitoxin', 'no label'), ('Immune', 'no label'), ('Immune Checkpoint Inhibitor Therapies', 'no label'), ('Cancer', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Neuromuscular', 'no label')]
lambert eaton syndrome|pubmed~29125190|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disorder Caused By Antibodies Directed Against The Voltage-Gated Calcium Channels That Provide The Calcium Ion Flux That Triggers Acetylcholine Release At The Neuromuscular Junction. To Study The Pathophysiology Of Lems And Test Candidate Therapeutic Strategies, A Passive-Transfer Animal Model Has Been Developed In Mice, Which Can Be Created By Daily Intraperitoneal Injections Of Lems Patient Serum Or Igg Into Mice For 2-4 Weeks. Results From Studies Of The Mouse Neuromuscular Junction Have Revealed That Each Synapse Has Hundreds Of Transmitter Release Sites But That The Probability For Release At Each One Is Likely To Be Low. Lems Further Reduces This Low Probability Such That Transmission Is No Longer Effective At Triggering A Muscle Contraction. The Lems-Mediated Attack Reduces The Number Of Presynaptic Calcium Channels, Disorganizes Transmitter Release Sites, And Results In The Homeostatic Upregulation Of Other Calcium Channel Types. Symptomatic Treatment Is Focused On Increasing The Probability Of Release From Dysfunctional Release Sites. Current Treatment Uses The Potassium Channel Blocker 3,4-Diaminopyridine (Dap) To Broaden The Presynaptic Action Potential, Providing More Time For Calcium Channels To Open. Current Research Is Focused On Testing New Calcium Channel Gating Modifiers That Work Synergistically With Dap.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disorder', 'no label'), ('Antibodies', 'no label'), ('Directed', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Calcium Ion Flux', 'no label'), ('Triggers', 'no label'), ('Acetylcholine Release', 'no label'), ('Neuromuscular Junction', 'no label'), ('Study', 'no label'), ('Pathophysiology', 'no label'), ('Lems And Test', 'no label'), ('Therapeutic Strategies', 'no label'), ('Passive-Transfer Animal Model', 'no label'), ('Mice', 'no label'), ('Lems Patient Serum', 'no label'), ('Mice', 'no label'), ('Weeks', 'no label'), ('Studies', 'no label'), ('Mouse', 'no label'), ('Neuromuscular Junction', 'no label'), ('Revealed', 'no label'), ('Synapse', 'no label'), ('Transmitter Release', 'no label'), ('Probability', 'no label'), ('Release', 'no label'), ('Reduces', 'no label'), ('Low', 'no label'), ('Probability', 'no label'), ('Transmission', 'no label'), ('Effective', 'no label'), ('Triggering A', 'no label'), ('Muscle Contraction', 'no label'), ('Lems-Mediated Attack Reduces', 'no label'), ('Presynaptic Calcium Channels', 'no label'), ('Disorganizes Transmitter Release Sites', 'no label'), ('Results', 'no label'), ('Homeostatic', 'no label'), ('Upregulation', 'no label'), ('Calcium Channel', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Focused', 'no label'), ('Increasing', 'no label'), ('Probability', 'no label'), ('Release', 'no label'), ('Dysfunctional Release Sites', 'no label'), ('Current', 'no label'), ('Treatment', 'no label'), ('Potassium Channel Blocker 3,4-Diaminopyridine', 'no label'), ('Dap', 'no label'), ('Broaden', 'no label'), ('Presynaptic Action', 'no label'), ('Potential', 'no label'), ('Calcium Channels', 'no label'), ('Current', 'no label'), ('Research', 'no label'), ('Focused', 'no label'), ('Testing', 'no label'), ('New Calcium Channel Gating Modifiers', 'no label'), ('Work', 'no label'), ('Synergistically', 'no label'), ('Dap', 'no label')]|[('Antibodies', 'no label'), ('Calcium', 'no label'), ('Calcium Ion', 'no label'), ('Acetylcholine', 'no label'), ('Animal', 'no label'), ('Mice', 'no label'), ('Mice', 'no label'), ('Mouse', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Potassium', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label')]|[('Transmitter Release Sites', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Potassium', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Dap', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label')]|[('Calcium', 'no label'), ('Calcium Ion', 'no label'), ('Acetylcholine', 'no label'), ('Neuromuscular', 'no label'), ('Lems', 'no label'), ('Mice', 'no label'), ('Intraperitoneal', 'no label'), ('Lems Patient Serum', 'no label'), ('Igg', 'no label'), ('Mice', 'no label'), ('Mouse Neuromuscular', 'no label'), ('Muscle', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Dap', 'no label'), ('Presynaptic', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Dap', 'no label')]
lambert eaton syndrome|pubmed~29987589|As Testing For Neuronal Antibodies Become More Readily Available, The Spectrum Of Conditions Potentially Associated With These Autoantibodies Has Been Widening. Voltage-Gated Calcium Channel Antibodies (Vgcc-Ab) Are No Exception To This Trend. The Significance Of An Elevated Vgcc-Ab Titer Beyond Its Original Clinicopathological Correlate, Lambert-Eaton Myasthenic Syndrome (Lems) Remains Undetermined. We Sought To Determine The Diagnostic Significance Of An Elevated Serum Vgcc-Ab Titer In A Large Single-Center Cohort Of 100 Patients. The Majority Of Patients (58%) With Elevated Vgcc-Ab Levels Lacked An Inflammatory Or Autoimmune Etiology Of Their Neurologic Diagnosis. Only Six Cases (6%) Of Lems And Two Cases (2%) Of Sclc (Without Lems) Were Identified. No Significant Differences In Antibody Titers Were Seen Between The Autoimmune And Non-Autoimmune Groups. These Findings Support The Notions That: (A) Elevated Vgcc-Ab Titers Without Clinical Correlation Must Be Interpreted With Caution, And (B) The Clinical And Electrodiagnostic Criteria For Lems Should Remain The Mainstay In The Diagnosis Of Lems.|[('Testing', 'no label'), ('Neuronal Antibodies', 'no label'), ('Readily Available', 'no label'), ('Spectrum', 'no label'), ('Associated With', 'no label'), ('Autoantibodies', 'no label'), ('Widening', 'no label'), ('Voltage-Gated Calcium Channel Antibodies', 'no label'), ('Vgcc-Ab', 'no label'), ('No Exception', 'no label'), ('Trend', 'no label'), ('Significance', 'no label'), ('Elevated', 'no label'), ('Titer', 'no label'), ('Clinicopathological Correlate', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Undetermined', 'no label'), ('Diagnostic Significance', 'no label'), ('Elevated Serum', 'no label'), ('Single-Center Cohort', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Elevated', 'no label'), ('Levels', 'no label'), ('Inflammatory', 'no label'), ('Autoimmune Etiology', 'no label'), ('Neurologic Diagnosis', 'no label'), ('Cases', 'no label'), ('Lems', 'no label'), ('Cases', 'no label'), ('Sclc', 'no label'), ('Identified', 'no label'), ('Antibody', 'no label'), ('Titers', 'no label'), ('Autoimmune And Non-Autoimmune Groups', 'no label'), ('Findings', 'no label'), ('Notions', 'no label'), ('Elevated', 'no label'), ('Titers', 'no label'), ('Clinical', 'no label'), ('Caution', 'no label'), ('B', 'no label'), ('Clinical', 'no label'), ('Electrodiagnostic Criteria', 'no label'), ('Lems', 'no label'), ('Mainstay', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label')]|[('Neuronal Antibodies', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('Vgcc-Ab', 'no label'), ('Vgcc-Ab', 'no label'), ('Antibody', 'no label')]|[('Neuronal Antibodies', 'no label')]|[('Calcium', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Autoimmune Etiology', 'no label'), ('Neurologic Diagnosis', 'no label')]|[('Neuronal', 'no label'), ('Calcium Channel Antibodies', 'no label'), ('Serum', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~28562525|The Lambert-Eaton Myasthenic Syndrome (Lems) Is A Neuromuscular Disease; Its Unique Symptoms Of Lems Include Dry Mouth With A Metallic Taste, Constipation, And Erectile Dysfunction. As It Is Quite Rare, Isolated Ocular Muscle Impairment Associated With Lems East To Ignore. A 65-Year-Old Man Presented With Alternating Ptosis And Diplopia. Isolated Ocular Muscle Impairment Had Lasted For 6 Years, And The Patient Was Initially Diagnosed With Ocular Myasthenia Gravis (Mg). Treatment With Azathioprine Only Slightly Improved Symptoms Over The First 2 Months; Long-Term Treatment Was Not Effective. Dynamic Observation Of Chest Computed Tomography Images Revealed A Slowly Progressing Nodule In The Lower Lobe Of The Left Lung. The Subsequent Pathologic Examination Following Mass Resection Confirmed A Diagnosis Of Lung Adenocarcinoma. The Patient Was Ultimately Diagnosed With The Lambert-Eaton Myasthenic Syndrome Associated With Pulmonary Adenocarcinoma. Resection Of The Lung Tumor Relieved All Symptoms. Other Causes Of Ocular Mg Symptoms Should Be Considered When Standard Mg Therapy Is Ineffective, Especially The Lambert-Eaton Myasthenic Syndrome.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Neuromuscular Disease', 'no label'), ('Symptoms', 'no label'), ('Lems Include Dry Mouth', 'no label'), ('Metallic Taste', 'no label'), ('Constipation', 'no label'), ('Erectile Dysfunction', 'no label'), ('Quite Rare', 'no label'), ('Isolated Ocular Muscle Impairment', 'no label'), ('Associated With', 'no label'), ('Lems East', 'no label'), ('Ignore', 'no label'), ('65-Year-Old Man', 'no label'), ('Alternating', 'no label'), ('Ptosis', 'no label'), ('Diplopia', 'no label'), ('Isolated', 'no label'), ('Ocular Muscle Impairment', 'no label'), ('Years', 'no label'), ('Patient', 'no label'), ('Diagnosed', 'no label'), ('Ocular Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Treatment', 'no label'), ('Azathioprine', 'no label'), ('Improved', 'no label'), ('Symptoms', 'no label'), ('First 2 Months', 'no label'), ('Long-Term Treatment', 'no label'), ('Effective', 'no label'), ('Dynamic Observation Of Chest Computed Tomography Images', 'no label'), ('Revealed', 'no label'), ('Slowly Progressing', 'no label'), ('Nodule', 'no label'), ('Lower Lobe', 'no label'), ('Left Lung', 'no label'), ('Pathologic Examination', 'no label'), ('Mass Resection', 'no label'), ('Confirmed A', 'no label'), ('Diagnosis', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Patient', 'no label'), ('Diagnosed', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Associated With', 'no label'), ('Pulmonary Adenocarcinoma', 'no label'), ('Resection', 'no label'), ('Lung Tumor', 'no label'), ('Symptoms', 'no label'), ('Causes', 'no label'), ('Ocular Mg', 'no label'), ('Symptoms', 'no label'), ('Standard', 'no label'), ('Mg Therapy', 'no label'), ('Ineffective', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label')]|[]|[]|[('Myasthenic Syndrome', 'no label'), ('Neuromuscular Disease', 'no label'), ('Constipation', 'no label'), ('Erectile Dysfunction', 'no label'), ('Ocular Muscle Impairment', 'no label'), ('Diplopia', 'no label'), ('Ocular Muscle Impairment', 'no label'), ('Ocular Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Azathioprine', 'no label'), ('Chest', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Pulmonary Adenocarcinoma', 'no label'), ('Tumor', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label')]|[('Neuromuscular', 'no label'), ('Lems', 'no label'), ('Ocular Muscle', 'no label'), ('Lems East', 'no label'), ('Ignore.', 'no label'), ('Ocular Muscle', 'no label'), ('Patient', 'no label'), ('Ocular Myasthenia', 'no label'), ('Azathioprine', 'no label'), ('Left Lung.', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Patient', 'no label'), ('Pulmonary Adenocarcinoma', 'no label'), ('Lung Tumor', 'no label'), ('Ocular Mg', 'no label'), ('Mg', 'no label')]
lambert eaton syndrome|pubmed~33596001|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Presynaptic Neuromuscular Junction Disorder, And Dermatomyositis (Dm) Is An Idiopathic Inflammatory Myopathy. Lems And Dm Are Uncommon Conditions That Can Present Similarly And Are Often Associated With Autoantibodies. Concomitant Lems And Dm Have Only Been Reported A Few Times, And Most Of Those Cases Were Paraneoplastic. We Present The First Reported Case Of A Patient With Antivoltage Gated Calcium Channel Antibody Positive Lems Who Subsequently Developed Dm With Antitranscription Intermediary Factor 1-Gamma (Anti-Tif1-Γ) Antibodies. Interestingly, Both Conditions Occurred Without Evidence Of Malignancy. This Diagnosis Of Lems And Dm With Characteristic Clinical, Electrodiagnostic, And Histopathological Evidence Led To A Beneficial Modification Of The Patient'S Therapeutic Regimen. Due To The Fact That Overlapping Concurrent Neuromuscular Conditions Are Rare, A High Clinical Suspicion Is Needed To Identify, Evaluate (Including Appropriate Cancer Screenings), And Appropriately Treat These Patients.|"[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular Junction Disorder', 'no label'), ('Dermatomyositis', 'no label'), ('Dm', 'no label'), ('Idiopathic Inflammatory Myopathy', 'no label'), ('Lems And Dm', 'no label'), ('Conditions', 'no label'), ('Associated With', 'no label'), ('Autoantibodies', 'no label'), ('Concomitant', 'no label'), ('Lems And Dm', 'no label'), ('Times', 'no label'), ('Cases', 'no label'), ('Paraneoplastic', 'no label'), ('Patient', 'no label'), ('Antivoltage', 'no label'), ('Gated', 'no label'), ('Calcium Channel Antibody', 'no label'), ('Developed Dm', 'no label'), ('Antitranscription Intermediary Factor 1-Gamma', 'no label'), ('Conditions', 'no label'), ('Evidence', 'no label'), ('Malignancy', 'no label'), ('Diagnosis', 'no label'), ('Lems And Dm', 'no label'), ('Characteristic Clinical', 'no label'), ('Electrodiagnostic', 'no label'), ('Histopathological', 'no label'), ('Evidence', 'no label'), ('Led', 'no label'), ('Beneficial', 'no label'), ('Modification', 'no label'), (""Patient'S"", 'no label'), ('Therapeutic Regimen', 'no label'), ('Fact', 'no label'), ('Concurrent', 'no label'), ('Neuromuscular', 'no label'), ('Conditions', 'no label'), ('Rare', 'no label'), ('High Clinical Suspicion', 'no label'), ('Evaluate', 'no label'), ('Appropriate Cancer', 'no label'), ('Screenings', 'no label'), ('Treat', 'no label'), ('Patients', 'no label')]"|[('Calcium', 'no label'), ('Antibody', 'no label'), ('Antitranscription Intermediary Factor 1-Gamma', 'no label'), ('Antibodies', 'no label')]|[('Antitranscription Intermediary Factor 1-Gamma (Anti-Tif1-Γ) Antibodies', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Neuromuscular Junction Disorder', 'no label'), ('Dermatomyositis', 'no label'), ('Idiopathic Inflammatory Myopathy', 'no label'), ('Paraneoplastic', 'no label'), ('Calcium', 'no label'), ('Malignancy', 'no label'), ('Cancer', 'no label')]|[('Presynaptic Neuromuscular', 'no label'), ('Patient', 'no label'), ('Calcium', 'no label'), ('Intermediary Factor 1-Gamma', 'no label'), ('Lems', 'no label'), ('Neuromuscular', 'no label'), ('Cancer', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~29526952|Lambert-Eaton Myasthenic Syndrome (Lems) Is Most Commonly Associated With Small Cell Lung Carcinoma, While It Is Rarely Associated With Gynecological And Breast Carcinoma. We Herein Report A Case Of Lems Associated With Synchronous Double Cancer, Which Was A Combination Of Small Cell Carcinoma Of The Cervix And Breast Carcinoma. The Early Diagnosis And Treatment Of Lems Are Important For Achieving A Good Outcome. The Possibility Of Accompanying Paraneoplastic Neurological Syndrome Must Be Sufficiently Considered In Gynecology And Breast Cancer Patients. To Our Knowledge, This Is The First Report Of Lems Associated With Synchronous Double Cancer.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Rarely', 'no label'), ('Associated With', 'no label'), ('Gynecological', 'no label'), ('Breast Carcinoma', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Synchronous Double Cancer', 'no label'), ('Combination', 'no label'), ('Small Cell Carcinoma', 'no label'), ('Cervix', 'no label'), ('Breast Carcinoma', 'no label'), ('Early Diagnosis', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label'), ('Good Outcome', 'no label'), ('Possibility', 'no label'), ('Paraneoplastic Neurological Syndrome', 'no label'), ('Gynecology', 'no label'), ('Patients', 'no label'), ('Knowledge', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Synchronous Double Cancer', 'no label')]|[('Cell', 'no label'), ('Cell', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Breast Carcinoma', 'no label'), ('Cancer', 'no label'), ('Carcinoma Of The Cervix', 'no label'), ('Breast Carcinoma', 'no label'), ('Paraneoplastic Neurological Syndrome', 'no label'), ('Breast Cancer', 'no label'), ('Cancer', 'no label')]|[('Small Cell Lung Carcinoma', 'no label'), ('Breast Carcinoma', 'no label'), ('Lems', 'no label'), ('Synchronous Double Cancer', 'no label'), ('Small Cell Carcinoma', 'no label'), ('Cervix', 'no label'), ('Breast Carcinoma', 'no label'), ('Lems', 'no label'), ('Gynecology', 'no label'), ('Breast Cancer Patients', 'no label'), ('Lems', 'no label'), ('Synchronous Double Cancer', 'no label')]
lambert eaton syndrome|pubmed~26323934|To Further Evaluate The Clinical Characteristics Of Small Cell Lung Cancer (Sclc) With Lambert-Eaton Syndrome. We Reviewed The Patient Database Of Our Hospital From 2001 To 2013 To Evaluate And Analyze The Patients Of Sclc With Lambert-Eaton Syndrome. The Clinical Characteristics And Prognosis Of The Patients Were Analyzed In This Retrospective Study. From Reviewing Our Hospital Database, We Included 5 Sclc Patients With Lambert-Eaton Syndrome From 202 Sclc Subjects With An Incidence Rate Of 2.5%. The Median Age Of The 5 Patients Was 52 (41-71) With 4 Male And 1 Female. The Myasthenia Symptom Can Be Detected In 2-20 Months Before The Pathology Confirmation For Small Cell Lung Carcinoma. The General Electromyography Characteristics Of Lambert-Eaton Syndrome Was Reduction In Action Potential Amplitude After Repetitive Peripheral Never Stimulation At Low Frequency And Increased Amplitude At High Frequency. Lambert-Eaton Syndrome Was Sometimes Found In Patients With Sclc Which Was Useful For Diagnosis Of Non-Small Cell Lung Carcinoma In A Relatively Early Stage.|[('Evaluate', 'no label'), ('Clinical Characteristics', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Reviewed', 'no label'), ('Patient Database', 'no label'), ('Hospital', 'no label'), ('Evaluate', 'no label'), ('Analyze', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Clinical Characteristics', 'no label'), ('Prognosis', 'no label'), ('Patients', 'no label'), ('Analyzed', 'no label'), ('Retrospective Study', 'no label'), ('Hospital Database', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Sclc', 'no label'), ('Subjects', 'no label'), ('Incidence Rate', 'no label'), ('Median Age', 'no label'), ('Patients', 'no label'), ('Male', 'no label'), ('Female', 'no label'), ('Myasthenia Symptom', 'no label'), ('Detected', 'no label'), ('Months', 'no label'), ('Pathology', 'no label'), ('Confirmation', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('General Electromyography', 'no label'), ('Characteristics', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Reduction', 'no label'), ('Action Potential Amplitude', 'no label'), ('Repetitive Peripheral Never Stimulation', 'no label'), ('Low Frequency', 'no label'), ('Increased', 'no label'), ('Amplitude', 'no label'), ('High Frequency', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Diagnosis', 'no label'), ('Non-Small Cell', 'no label'), ('Lung Carcinoma', 'no label'), ('Early Stage', 'no label')]|[('Cell', 'no label'), ('Cell', 'no label'), ('Cell', 'no label')]|[]|[('Lambert-Eaton Syndrome', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Myasthenia', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Lung Carcinoma', 'no label')]|[('Small Cell Lung Cancer', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Peripheral', 'no label'), ('Patients', 'no label'), ('Non-Small Cell Lung Carcinoma', 'no label')]
lambert eaton syndrome|pubmed~24114606|Lambert-Eaton Myasthenic Syndrome Is A Neuromuscular Junction Disorder Characterized By Proximal Limb Muscle Weakness, Fatigability, Decreased Deep-Tendon Reflexes, And Autonomic Symptoms. There Are 2 Forms Of Lambert-Eaton Myasthenic Syndrome: One Most Frequently Associated With Small-Cell Lung Cancer (P-Lambert-Eaton Myasthenic Syndrome) And The Other That Is A Pure Autoimmune Form (Np-Lambert-Eaton Myasthenic Syndrome). Lambert-Eaton Myasthenic Syndrome Is A Very Rare Disorder In Children Younger Than Age 12 Years. Herein, We Report A 25-Year-Old Man With Np-Lambert-Eaton Myasthenic Syndrome, Which Onset Was At The Age Of 10 Years. To Date, This Is The Most Long-Term Follow-Up Of Np-Lambert-Eaton Myasthenic Syndrome In Childhood. In Our Patient, The Only Symptomatic Treatment With 3,4-Diaminopyridine Phosphate Has Been Sufficient To Guarantee Him A Good Quality Of Life. Our Data Remind Physicians To Keep In Mind The Diagnosis Of Lambert-Eaton Myasthenic Syndrome In Children With A Proximal Myopathic Pattern And They Confirm The Specificity Of Compound Muscle Action Potential Incremental Pattern After Brief Maximal Effort In Lambert-Eaton Myasthenic Syndrome. |[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Neuromuscular Junction Disorder', 'no label'), ('Characterized', 'no label'), ('Proximal Limb Muscle Weakness', 'no label'), ('Fatigability', 'no label'), ('Decreased', 'no label'), ('Reflexes', 'no label'), ('Autonomic Symptoms', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Associated With', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('P-Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Pure Autoimmune Form', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Very Rare Disorder', 'no label'), ('Children', 'no label'), ('Younger Than Age', 'no label'), ('Years', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('Long-Term Follow-Up', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Childhood', 'no label'), ('Patient', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('3,4-Diaminopyridine Phosphate', 'no label'), ('Guarantee', 'no label'), ('Him A Good Quality Of Life', 'no label'), ('Data Remind Physicians', 'no label'), ('Keep In Mind', 'no label'), ('Diagnosis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Children', 'no label'), ('Proximal', 'no label'), ('Myopathic Pattern', 'no label'), ('Confirm', 'no label'), ('Specificity', 'no label'), ('Compound Muscle', 'no label'), ('Brief Maximal Effort', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label')]|[('Phosphate', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Neuromuscular Junction Disorder', 'no label'), ('Muscle Weakness', 'no label'), ('Fatigability', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lung Cancer', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Disorder', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenic Syndrome', 'no label'), ('3,4-Diaminopyridine Phosphate', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenic Syndrome', 'no label')]|[('Small-Cell Lung Cancer', 'no label'), ('Children', 'no label'), ('3,4-Diaminopyridine Phosphate Has', 'no label'), ('Children', 'no label')]
lambert eaton syndrome|pubmed~28638036|The Authors Studied Two Patients With Lambert-Eaton Myasthenic Syndrome (Lems) In Whom The Repeated Examination Did Not Find Specific Of Lems P/Q Type Voltage-Gates Calcium Channel Autoantibodies. The Results Of Clinical Testing And Electrophysiological Examination Showed The Typical Character Of Movement Disorders With The Absence Of Tendon Reflexes And Signs Of Disautonomia As Well As A Decrease In M-Response Amplitude And Phenomena Of Decrement With Low Frequency- And Increment With High Frequency Stimulation. Both Patients Revealed No Signs Of Paraneoplastic Process. Autoimmune Character Of The Damage Was Confirmed By The Effectiveness Of Treatment With Glucocorticoid Hormones.|[('Authors', 'no label'), ('Studied', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Repeated Examination', 'no label'), ('Lems P/Q Type Voltage-Gates Calcium Channel Autoantibodies', 'no label'), ('Clinical Testing', 'no label'), ('Electrophysiological Examination', 'no label'), ('Typical Character', 'no label'), ('Absence', 'no label'), ('Tendon Reflexes', 'no label'), ('Signs', 'no label'), ('Disautonomia', 'no label'), ('Decrease', 'no label'), ('M-Response Amplitude', 'no label'), ('Phenomena', 'no label'), ('Decrement', 'no label'), ('Low Frequency- And Increment', 'no label'), ('High Frequency Stimulation', 'no label'), ('Patients', 'no label'), ('Revealed', 'no label'), ('No Signs', 'no label'), ('Paraneoplastic Process', 'no label'), ('Autoimmune Character', 'no label'), ('Damage', 'no label'), ('Confirmed', 'no label'), ('Effectiveness', 'no label'), ('Treatment', 'no label'), ('Glucocorticoid Hormones', 'no label')]|[('Calcium', 'no label')]|[]|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Calcium', 'no label'), ('Movement Disorders', 'no label'), ('Disautonomia', 'no label'), ('Paraneoplastic', 'no label')]|[('Patients', 'no label'), ('Lems P/Q Type Voltage-Gates Calcium Channel Autoantibodies.', 'no label'), ('Tendon Reflexes', 'no label'), ('Patients', 'no label'), ('Paraneoplastic', 'no label'), ('Glucocorticoid Hormones', 'no label')]
lambert eaton syndrome|pubmed~29655456|Lambert-Eaton Myasthenic Syndrome Is A Paraneoplastic Or Primary Autoimmune Neuromuscular Junction Disorder Characterized By Proximal Weakness, Autonomic Dysfunction And Ariflexia. The Characteristic Symptoms Are Thought To Be Caused By Antibodies Generated Against The P/Q-Type Voltage-Gated Calcium Channels Present On Presynaptic Nerve Terminals And By Diminished Release Of Acetylcholine. More Than Half Of Lambert-Eaton Myasthenic Syndrome Cases Are Associated With Small Cell Lung Carcinoma. Diagnosis Is Confirmed By Serologic Testing And Electrophysiologic Studies. 3,4-Diaminopyridine Is Effective Symptomatic Treatment Of Lems.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Paraneoplastic', 'no label'), ('Primary', 'no label'), ('Neuromuscular Junction Disorder', 'no label'), ('Characterized', 'no label'), ('Proximal Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Ariflexia', 'no label'), ('Characteristic Symptoms', 'no label'), ('Antibodies', 'no label'), ('P/Q-Type Voltage-Gated', 'no label'), ('Calcium Channels', 'no label'), ('Present', 'no label'), ('Presynaptic Nerve', 'no label'), ('Terminals', 'no label'), ('Diminished', 'no label'), ('Acetylcholine', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Cases', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Diagnosis', 'no label'), ('Confirmed', 'no label'), ('Serologic Testing', 'no label'), ('Electrophysiologic Studies', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Effective', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label')]|[('Antibodies', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Nerve Terminals', 'no label'), ('Cell', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Or Primary Autoimmune Neuromuscular Junction Disorder', 'no label'), ('Autonomic Dysfunction', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Diagnosis', 'no label'), ('3,4-Diaminopyridine', 'no label')]|[('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Presynaptic Nerve', 'no label'), ('Acetylcholine', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('3,4-Diaminopyridine', 'no label')]
lambert eaton syndrome|pubmed~31533480|<B>Introduction</B>: The Present Status Of Amifampridine (Afp) For The Treatment Of Lambert-Eaton Myasthenic Syndrome (Lems) Is Reviewed. <B>Areas Covered</B>: All Relevant Literature Identified Through A Pubmed Search Under Treatment Of Lems, Aminopyridine, And Amifampridine Are Reviewed. An Expert Opinion On Afp Was Formulated. <B>Expert Opinion</B>: Afps, 3,4-Dap And 3,4-Dapp, Are The Most Studied Drugs In Neuromuscular Diseases. Randomized And Non-Randomized Studies Showed The Most Effective Drug As Symptomatic Medication For Lems. Afps Are Safe And Tolerable. Thus, Afps Should Be The Drug Of Choice For The Symptomatic Treatment In Lems. As Long As The Daily Dose Is Less Than 80 Mg A Day, There Is No Concern For The Serious Side-Reaction, Seizure. Because Of Short-Acting Drug Effects, It Should Be Given Three Or Four Times A Day. Peri-Oral And Finger Paresthesia, The Most Common Side-Reaction, Is Accepted As A Sign Of Drug-Intake By Many Patients. Gastro-Intestinal Side Reactions, The Next Common Side-Reaction Of Afps, Are Tolerable. Afps Are Also The Drug Of Choice And Life-Saving For Lems Crisis. For The Long-Term Usage, It Is Proven To Be Safe And Afps Can Be Supplemented With Liberal Amount Of Pyridostigmine To Sustain A Symptomatic Improvement Without Any Undue Side-Reaction.|[('Introduction</B', 'no label'), ('Present Status', 'no label'), ('Amifampridine', 'no label'), ('Afp', 'no label'), ('Treatment', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Reviewed', 'no label'), ('Covered</B>', 'no label'), ('Relevant', 'no label'), ('Literature', 'no label'), ('Identified', 'no label'), ('Pubmed', 'no label'), ('Search', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label'), ('Aminopyridine', 'no label'), ('Amifampridine', 'no label'), ('Reviewed', 'no label'), ('Expert Opinion', 'no label'), ('Afp', 'no label'), ('Afps', 'no label'), ('Drugs', 'no label'), ('Neuromuscular Diseases', 'no label'), ('Randomized', 'no label'), ('Effective', 'no label'), ('Drug', 'no label'), ('Symptomatic Medication', 'no label'), ('Lems', 'no label'), ('Afps', 'no label'), ('Safe', 'no label'), ('Tolerable', 'no label'), ('Afps', 'no label'), ('Drug', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Daily Dose', 'no label'), ('Day', 'no label'), ('Serious Side-Reaction', 'no label'), ('Seizure', 'no label'), ('Short-Acting Drug Effects', 'no label'), ('Times', 'no label'), ('Day', 'no label'), ('Peri-Oral', 'no label'), ('Finger', 'no label'), ('Paresthesia', 'no label'), ('Side-Reaction', 'no label'), ('Sign', 'no label'), ('Drug-Intake', 'no label'), ('Patients', 'no label'), ('Gastro-Intestinal Side Reactions', 'no label'), ('Next Common Side-Reaction', 'no label'), ('Afps', 'no label'), ('Tolerable', 'no label'), ('Afps', 'no label'), ('Drug', 'no label'), ('Long-Term Usage', 'no label'), ('Proven', 'no label'), ('Safe And Afps Can Be', 'no label'), ('Supplemented', 'no label'), ('Liberal Amount', 'no label'), ('Pyridostigmine', 'no label'), ('Sustain A', 'no label'), ('Symptomatic', 'no label'), ('Improvement', 'no label'), ('Undue Side-Reaction', 'no label')]|[('Amifampridine', 'no label'), ('Afp', 'no label'), ('Aminopyridine', 'no label'), ('Amifampridine', 'no label'), ('Afp', 'no label'), ('Drug', 'no label'), ('Drug', 'no label'), ('Drug', 'no label'), ('Drug', 'no label'), ('Pyridostigmine', 'no label')]|[('Afp', 'no label'), ('Peri-Oral', 'no label')]|[('Amifampridine', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Aminopyridine', 'no label'), ('Neuromuscular Diseases', 'no label'), ('Mg', 'no label'), ('Seizure', 'no label'), ('Paresthesia', 'no label'), ('Pyridostigmine', 'no label')]|[('B', 'no label'), ('Amifampridine', 'no label'), ('Afp', 'no label'), ('B', 'no label'), ('Aminopyridine', 'no label'), ('Amifampridine', 'no label'), ('Afp', 'no label'), ('B', 'no label'), ('Afps', 'no label'), ('Neuromuscular', 'no label'), ('Afps', 'no label'), ('Afps', 'no label'), ('Sign', 'no label'), ('Patients', 'no label'), ('Afps', 'no label'), ('Lems', 'no label'), ('Afps', 'no label'), ('Pyridostigmine', 'no label')]
lambert eaton syndrome|pubmed~29696584|Congenital Myasthenic Syndromes (Cms) Are Heterogeneous Genetic Diseases In Which Neuromuscular Transmission Is Compromised. Cms Resembling The Lambert-Eaton Myasthenic Syndrome (Cms-Lems) Are Emerging As A Rare Group Of Distinct Presynaptic Cms That Share The Same Electrophysiological Features. They Have Low Compound Muscular Action Potential Amplitude That Increment After Brief Exercise (Facilitation) Or High-Frequency Repetitive Nerve Stimulation. Although Clinical Signs Similar To Lems Can Be Present, The Main Hallmark Is The Electrophysiological Findings, Which Are Identical To Autoimmune Lems. Cms-Lems Occurs Due To Deficits In Acetylcholine Vesicle Release Caused By Dysfunction Of Different Components In Its Pathway. To Date, The Genes That Have Been Associated With Cms-Lems Are Agrn, Syt2, Munc13-1, Vamp1, And Lama5. Clinicians Should Keep In Mind These Newest Subtypes Of Cms-Lems To Achieve The Correct Diagnosis And Therapy. We Believe That Cms-Lems Must Be Included As An Important Diagnostic Clue To Genetic Investigation In The Diagnostic Algorithms To Cms. We Briefly Review The Main Features Of Cms-Lems.|[('Congenital Myasthenic Syndromes', 'no label'), ('Cms', 'no label'), ('Heterogeneous Genetic Diseases', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Cms Resembling', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Cms-Lems', 'no label'), ('Rare', 'no label'), ('Group', 'no label'), ('Presynaptic', 'no label'), ('Cms', 'no label'), ('Electrophysiological Features', 'no label'), ('Low', 'no label'), ('Compound Muscular Action Potential Amplitude', 'no label'), ('Increment', 'no label'), ('Brief Exercise', 'no label'), ('Facilitation', 'no label'), ('High-Frequency', 'no label'), ('Repetitive Nerve', 'no label'), ('Stimulation', 'no label'), ('Clinical Signs', 'no label'), ('Lems', 'no label'), ('Main Hallmark', 'no label'), ('Electrophysiological Findings', 'no label'), ('Autoimmune Lems', 'no label'), ('Cms-Lems', 'no label'), ('Occurs', 'no label'), ('Deficits', 'no label'), ('Acetylcholine Vesicle', 'no label'), ('Release', 'no label'), ('Dysfunction', 'no label'), ('Components', 'no label'), ('Pathway', 'no label'), ('Genes', 'no label'), ('Associated With', 'no label'), ('Cms-Lems', 'no label'), ('Agrn', 'no label'), ('Syt2', 'no label'), ('Munc13-1', 'no label'), ('Vamp1', 'no label'), ('Lama5', 'no label'), ('Clinicians', 'no label'), ('Keep In Mind', 'no label'), ('Newest', 'no label'), ('Subtypes', 'no label'), ('Cms-Lems', 'no label'), ('Correct', 'no label'), ('Diagnosis', 'no label'), ('Therapy', 'no label'), ('Cms-Lems', 'no label'), ('Diagnostic Clue', 'no label'), ('Genetic Investigation', 'no label'), ('Diagnostic Algorithms', 'no label'), ('Cms', 'no label'), ('Briefly Review', 'no label'), ('Cms-Lems', 'no label')]|[('Genetic', 'no label'), ('Acetylcholine Vesicle', 'no label'), ('Genes', 'no label'), ('Agrn', 'no label'), ('Syt2', 'no label'), ('Munc13', 'no label'), ('Vamp1', 'no label'), ('Lama5', 'no label'), ('Genetic', 'no label')]|[('Cms', 'no label'), ('Cms-Lems', 'no label'), ('Cms-Lems', 'no label'), ('Lama5', 'no label'), ('Cms-Lems', 'no label'), ('Cms-Lems', 'no label')]|[('Congenital Myasthenic Syndromes', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Cms-Lems', 'no label'), ('Acetylcholine', 'no label')]|[('Neuromuscular', 'no label'), ('Presynaptic', 'no label'), ('Compound Muscular', 'no label'), ('Nerve', 'no label'), ('Lems', 'no label'), ('Acetylcholine Vesicle', 'no label'), ('Agrn', 'no label'), ('Syt2', 'no label'), ('Munc13-1', 'no label'), ('Lama5', 'no label'), ('Cms', 'no label')]
lambert eaton syndrome|pubmed~29879051|Myasthenia Gravis (Mg) And Lambert-Eaton Myasthenic Syndrome (Lems) Are Both Neuromuscular Junction Diseases, And Some Controversy Exists Whether The 2 Diseases Occur At The Same Time. We Report A Case That A Patient With Presentation Of Acetylcholine Receptor (Achr) Antibody Positive Mg And Lems Associated With Small Cell Lung Cancer (Sclc). The Patient Firstly Suffered From Fluctuant Symptoms, Including Slurred Speech, Double Eyelid Ptosis, And Weakness Of Limbs. His Clinical Characteristics Were Consistent With The Diagnosis Of Mg And Were Effective With The Treatment Of Pyridostigmine Bromide And Corticosteroids. After 8 Months, The Performance Of Repeated Electrical Stimulation Suggested Presynaptic Lesion, Which Supported The Patient With Lems. After Further Examination, Malignant Tumors Were Found In The Liver And Right Lung, And The Pathology Proved Small Cell Carcinoma. His Clinical Characteristics Were Effective With The Treatment Of Pyridostigmine Bromide And Corticosteroids. Right Hilar Lesion And Multiple Metastatic Tumors In Liver Shrunk After Chemotherapy. The Patient'S Condition Improved Gradually. He Was Followed Up For 17 Months Without Tumor Progression. The Case Report Illustrates That Mg And Lems May Be Coexisted In The Same Patient. In Mg And Lems, Clinicians Should Consider The Possibility Of Malignant Tumors As Early Detection And Treatment May Significantly Improve The Patient'S Prognosis.|"[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Neuromuscular Junction Diseases', 'no label'), ('Controversy', 'no label'), ('Exists', 'no label'), ('Diseases', 'no label'), ('Occur', 'no label'), ('Report', 'no label'), ('Case', 'no label'), ('Patient', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Achr', 'no label'), ('Antibody', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Patient', 'no label'), ('Suffered', 'no label'), ('Fluctuant Symptoms', 'no label'), ('Slurred Speech', 'no label'), ('Double Eyelid Ptosis', 'no label'), ('Weakness', 'no label'), ('Limbs', 'no label'), ('Clinical Characteristics', 'no label'), ('Consistent With', 'no label'), ('Diagnosis', 'no label'), ('Mg', 'no label'), ('Effective', 'no label'), ('Treatment', 'no label'), ('Pyridostigmine Bromide', 'no label'), ('Corticosteroids', 'no label'), ('Months', 'no label'), ('Performance', 'no label'), ('Electrical Stimulation', 'no label'), ('Presynaptic', 'no label'), ('Lesion', 'no label'), ('Patient', 'no label'), ('Lems', 'no label'), ('Examination', 'no label'), ('Malignant Tumors', 'no label'), ('Liver', 'no label'), ('Right Lung', 'no label'), ('Pathology Proved Small Cell Carcinoma', 'no label'), ('Clinical Characteristics', 'no label'), ('Effective', 'no label'), ('Treatment', 'no label'), ('Pyridostigmine Bromide', 'no label'), ('Corticosteroids', 'no label'), ('Hilar Lesion', 'no label'), ('Multiple', 'no label'), ('Metastatic Tumors', 'no label'), ('Liver Shrunk', 'no label'), ('Chemotherapy', 'no label'), (""Patient'S"", 'no label'), ('Condition', 'no label'), ('Months', 'no label'), ('Tumor', 'no label'), ('Progression', 'no label'), ('Case Report', 'no label'), ('Mg', 'no label'), ('Coexisted', 'no label'), ('Patient', 'no label'), ('Mg', 'no label'), ('Lems', 'no label'), ('Clinicians', 'no label'), ('Possibility', 'no label'), ('Malignant Tumors', 'no label'), ('Early Detection', 'no label'), ('Treatment', 'no label'), ('Significantly Improve', 'no label'), (""Patient'S"", 'no label'), ('Prognosis', 'no label')]"|[('Acetylcholine Receptor', 'no label'), ('Antibody', 'no label'), ('Cell', 'no label'), ('His', 'no label'), ('Pyridostigmine Bromide', 'no label'), ('Cell', 'no label'), ('His', 'no label'), ('Pyridostigmine Bromide', 'no label')]|[('Acetylcholine Receptor', 'no label'), ('His', 'no label'), ('His', 'no label')]|[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Neuromuscular Junction Diseases', 'no label'), ('Acetylcholine', 'no label'), ('Mg', 'no label'), ('Eyelid Ptosis', 'no label'), ('Mg', 'no label'), ('Pyridostigmine Bromide', 'no label'), ('Malignant Tumors', 'no label'), ('Carcinoma', 'no label'), ('Pyridostigmine Bromide', 'no label'), ('Tumors', 'no label'), ('Tumor', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Malignant Tumors', 'no label'), ('Prognosis', 'no label')]|[('Neuromuscular', 'no label'), ('Patient', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Patient', 'no label'), ('Eyelid', 'no label'), ('Mg', 'no label'), ('Pyridostigmine Bromide', 'no label'), ('Corticosteroids', 'no label'), ('Presynaptic', 'no label'), ('Patient', 'no label'), ('Malignant Tumors', 'no label'), ('Liver', 'no label'), ('Lung', 'no label'), ('Pathology Proved', 'no label'), ('Pyridostigmine Bromide', 'no label'), ('Corticosteroids', 'no label'), ('Hilar', 'no label'), ('Tumors', 'no label'), ('Liver Shrunk', 'no label'), ('Tumor', 'no label'), ('Mg', 'no label'), ('Lems', 'no label'), ('Mg', 'no label'), ('Malignant Tumors', 'no label')]
lambert eaton syndrome|pubmed~33846760||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~29742721|Autoimmune Encephalitis And Lambert-Eaton Myasthenic Syndrome Are Classic Paraneoplastic Neurological Conditions Common In Patients With Small Cell Lung Cancer. The Patient Complained Of Tiredness, Fluctuating Recent Memory Loss, And Inability To Find His Home. His Family Members Reported A Change In Character, Irritability, And Paranoia. One Month Later, The Patient Had 1 Grand Mal Seizure Lasting 5 Minutes. The Patient Was Diagnosed With Limbic Encephalitis Combined With Lambert-Eaton Myasthenic Syndrome. The Gamma-Aminobutyric Acid B (Gabab) Receptor And Collapsin Response Mediator Protein 5 (Crmp5, Also Called Cv2) Antibody Test Results Were Positive. Nine Months After The Onset Of Symptoms, The Patient Was Diagnosed With Small Cell Lung Cancer. The Patient Was Administered Intravenous Immunoglobulin For 5 Days. He Was Then Treated With 60 Mg Prednisone Once Per Day. The Prednisone Dose Was Gradually Reduced By 1 Tablet Every 2 Weeks. After The Diagnosis, The Patient Underwent 6 Courses Of Chemotherapy With Cisplatin Combined With Sequential Chemoradiation Therapy. The Patient Was Able To Take Care Of Himself. Neurological Examination Revealed A Lower Limb Proximal Muscle Strength Level Of 4 And A Reduced Limb Tendon Reflex. The Patient Had Deficits In Short-Term Memory, A Mini-Mental State Examination Score Of 26, Montreal Cognitive Assessment Score Of 24, Self-Rating Depression Scale Score Of 54 (Mild Depression), And Self-Rating Anxiety Scale Score Of 42 (Normal). Autoimmune Diseases Of The Peripheral And Central Nervous Systems Can Be Observed At The Same Time In Patients With Small Cell Lung Cancer, Even When Magnetic Resonance Imaging Findings Are Negative And Immune Therapy Is Effective.|[('Autoimmune Encephalitis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Paraneoplastic Neurological', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Patient', 'no label'), ('Complained', 'no label'), ('Tiredness', 'no label'), ('Fluctuating Recent Memory Loss', 'no label'), ('Family Members', 'no label'), ('Change', 'no label'), ('Character', 'no label'), ('Irritability', 'no label'), ('Paranoia', 'no label'), ('Month', 'no label'), ('Patient', 'no label'), ('Mal Seizure', 'no label'), ('Lasting 5\u200aMinutes', 'no label'), ('Patient', 'no label'), ('Diagnosed', 'no label'), ('Limbic Encephalitis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Gamma-Aminobutyric Acid B', 'no label'), ('Collapsin', 'no label'), ('Mediator Protein 5', 'no label'), ('Crmp5', 'no label'), ('Cv2', 'no label'), ('Antibody Test', 'no label'), ('Positive', 'no label'), ('Months', 'no label'), ('Symptoms', 'no label'), ('Patient', 'no label'), ('Diagnosed', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Patient', 'no label'), ('Administered', 'no label'), ('Intravenous Immunoglobulin', 'no label'), ('Days', 'no label'), ('Treated', 'no label'), ('Prednisone', 'no label'), ('Per Day', 'no label'), ('Prednisone', 'no label'), ('Dose', 'no label'), ('Reduced', 'no label'), ('Tablet', 'no label'), ('Weeks', 'no label'), ('Diagnosis', 'no label'), ('Patient', 'no label'), ('Courses', 'no label'), ('Chemotherapy', 'no label'), ('Cisplatin', 'no label'), ('Sequential', 'no label'), ('Chemoradiation Therapy', 'no label'), ('Patient', 'no label'), ('Himself', 'no label'), ('Neurological Examination', 'no label'), ('Revealed', 'no label'), ('Lower Limb Proximal Muscle', 'no label'), ('Level', 'no label'), ('Reduced', 'no label'), ('Limb Tendon Reflex', 'no label'), ('Patient', 'no label'), ('Deficits', 'no label'), ('Short-Term', 'no label'), ('Memory', 'no label'), ('Mini-Mental State Examination Score', 'no label'), ('Montreal Cognitive Assessment Score', 'no label'), ('Self-Rating Depression Scale Score', 'no label'), ('Mild Depression', 'no label'), ('Self-Rating Anxiety Scale Score', 'no label'), ('Normal', 'no label'), ('Autoimmune Diseases', 'no label'), ('Peripheral', 'no label'), ('Central Nervous Systems', 'no label'), ('Observed', 'no label'), ('Time', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Magnetic Resonance Imaging', 'no label'), ('Findings', 'no label'), ('Negative', 'no label'), ('Immune Therapy', 'no label'), ('Effective', 'no label')]|[('Cell', 'no label'), ('His', 'no label'), ('His', 'no label'), ('Acid', 'no label'), ('Collapsin', 'no label'), ('Mediator Protein 5', 'no label'), ('Crmp5', 'no label'), ('Cv2', 'no label'), ('Antibody', 'no label'), ('Cell', 'no label'), ('Cisplatin', 'no label'), ('Cell', 'no label')]|[('His', 'no label'), ('Gamma-Aminobutyric Acid B', 'no label'), ('Collapsin Response Mediator Protein 5', 'no label'), ('Per', 'no label')]|[('Autoimmune Encephalitis', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Neurological Conditions Common', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Tiredness', 'no label'), ('Memory Loss', 'no label'), ('Seizure', 'no label'), ('Limbic Encephalitis', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Gamma-Aminobutyric Acid B', 'no label'), ('Mg Prednisone', 'no label'), ('Prednisone', 'no label'), ('Cisplatin', 'no label'), ('Depression', 'no label'), ('Small Cell Lung Cancer', 'no label')]|[('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Patient', 'no label'), ('Patient', 'no label'), ('Patient', 'no label'), ('Limbic Encephalitis', 'no label'), ('Gamma-Aminobutyric Acid B', 'no label'), ('Collapsin Response', 'no label'), ('Mediator Protein 5', 'no label'), ('Cv2', 'no label'), ('Patient', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Patient', 'no label'), ('Intravenous Immunoglobulin', 'no label'), ('Mg Prednisone', 'no label'), ('Prednisone', 'no label'), ('Patient', 'no label'), ('Cisplatin', 'no label'), ('Patient', 'no label'), ('Lower Limb', 'no label'), ('Muscle', 'no label'), ('Patient', 'no label'), ('Peripheral', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Immune', 'no label')]
lambert eaton syndrome|pubmed~32247193||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~29093415|Paraneoplastic Cerebellar Degeneration And Lambert-Eaton Myasthenic Syndrome (Pcd-Lems) Are Usually Associated With Small-Cell Lung Carcinoma (Sclc). Pcd-Lems With Extrapulmonary Non-Sclc Tumors; However, Has Not Been Previously Reported. A 78-Year-Old Man Presented With Dysarthria, Dysphagia, Staggering Gait, And Lower Extremity Muscle Fatigue. He Was Diagnosed With Pcd-Lems Associated With Neuroendocrine Carcinoma Of The Oropharynx, Based On The Histological Findings Of The Biopsy, The Existence Of Antibodies Against P/Q-Type Voltage-Gated Calcium Channels, And An Incremental Response Of The Compound Muscle Action Potentials During Repetitive Nerve Stimulation Tests. Thus, Pcd-Lems Should Be Included In The Differential Diagnosis Of Neurological Dysfunction, Even In Extrapulmonary Non-Sclc Patients.|[('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Pcd-Lems', 'no label'), ('Associated With', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Pcd-Lems', 'no label'), ('Extrapulmonary Non-Sclc', 'no label'), ('Tumors', 'no label'), ('Dysarthria', 'no label'), ('Dysphagia', 'no label'), ('Staggering Gait', 'no label'), ('Lower Extremity Muscle', 'no label'), ('Fatigue', 'no label'), ('Diagnosed', 'no label'), ('Pcd-Lems', 'no label'), ('Associated With', 'no label'), ('Neuroendocrine Carcinoma', 'no label'), ('Oropharynx', 'no label'), ('Histological Findings', 'no label'), ('Biopsy', 'no label'), ('Existence', 'no label'), ('Antibodies', 'no label'), ('P/Q-Type Voltage-Gated', 'no label'), ('Calcium Channels', 'no label'), ('Incremental Response', 'no label'), ('Compound Muscle', 'no label'), ('Repetitive Nerve Stimulation Tests', 'no label'), ('Pcd-Lems', 'no label'), ('Differential Diagnosis', 'no label'), ('Neurological Dysfunction', 'no label'), ('Extrapulmonary', 'no label'), ('Patients', 'no label')]|[('Antibodies', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label')]|[('Pcd-Lems', 'no label'), ('Pcd-Lems', 'no label'), ('Pcd-Lems', 'no label')]|[('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Lung Carcinoma', 'no label'), ('Tumors', 'no label'), ('Dysarthria', 'no label'), ('Dysphagia', 'no label'), ('Neuroendocrine Carcinoma', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Neurological Dysfunction', 'no label')]|[('Small-Cell Lung Carcinoma', 'no label'), ('Extrapulmonary Non-Sclc Tumors', 'no label'), ('Muscle', 'no label'), ('Neuroendocrine Carcinoma', 'no label'), ('Oropharynx', 'no label'), ('Biopsy', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Extrapulmonary Non-Sclc Patients', 'no label')]
lambert eaton syndrome|pubmed~35228217|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Neuromuscular Junction Defect That Results In Weakness. It Is Rarely Seen In Children And Most Commonly Is Associated With Small-Cell Lung Cancer. Diagnosis Of Lems Requires Characteristic Electromyogram (Emg) Findings And The Detection Of Antibodies Directed Against Voltage-Gated Calcium Channels. We Report The Case Of An 8-Year-Old Female Child Who Presented With Profound Weakness Found To Have Emg Evidence Of A Neuromuscular Junction Defect And Detectable Antivoltage-Gated Calcium Channel Antibodies. She Received Plasma Exchange Electrophoresis, Intravenous Immunoglobulin, Oral Steroids And Amifampridine With Some Clinical Improvement. We Present A Case Of A Child With A Demonstrated Autoimmune Propensity And No Evidence Of Malignancy, Thereby Adding To The 12 Previously Reported Cases Of Lems In Children.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Neuromuscular Junction Defect', 'no label'), ('Results', 'no label'), ('Weakness', 'no label'), ('Children', 'no label'), ('Associated With', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Diagnosis', 'no label'), ('Lems Requires Characteristic Electromyogram', 'no label'), ('Emg', 'no label'), ('Findings', 'no label'), ('Detection', 'no label'), ('Antibodies', 'no label'), ('Directed Against', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Female', 'no label'), ('Profound Weakness', 'no label'), ('Emg', 'no label'), ('Evidence', 'no label'), ('Neuromuscular Junction Defect', 'no label'), ('Detectable', 'no label'), ('Antivoltage-Gated Calcium Channel Antibodies', 'no label'), ('Plasma', 'no label'), ('Exchange Electrophoresis', 'no label'), ('Intravenous Immunoglobulin', 'no label'), ('Oral Steroids', 'no label'), ('Amifampridine', 'no label'), ('Clinical Improvement', 'no label'), ('Demonstrated Autoimmune Propensity', 'no label'), ('No Evidence', 'no label'), ('Malignancy', 'no label'), ('Cases', 'no label'), ('Lems', 'no label'), ('Children', 'no label')]|[('Antibodies', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('Amifampridine', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Weakness', 'no label'), ('Lung Cancer', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Steroids', 'no label'), ('Amifampridine', 'no label'), ('Malignancy', 'no label')]|[('Children', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Lems', 'no label'), ('Electromyogram', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Plasma', 'no label'), ('Intravenous Immunoglobulin', 'no label'), ('Oral Steroids', 'no label'), ('Lems', 'no label'), ('Children', 'no label')]
lambert eaton syndrome|pubmed~32324619||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~31743258||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~34039725||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~27997683|One Nationwide Study (The Netherlands) Of Lambert-Eaton Myasthenic Syndrome (Lems) Has Been Published. We Report Lems Epidemiology And Its Therapeutic Response In The United States Veterans Affairs (Va) Population. Medical Records For All Active Patients (12.5 Million) In The Va Health System Were Queried For Relevant Icd-9 Codes For The Period October 1, 1999 To September 30, 2013. Clinical, Electrophysiologic, And Serologic Features Were Evaluated To Confirm Diagnosis; Epidemiologic And Treatment Data Were Collected. Point Prevalence Was Estimated At 2.6 Per 1,000,000 (Confirmed Cases) And 3.3 Per 1,000,000 (Combined Confirmed And Probable Cases). Crude Prevalence Was Similarly Estimated At 9.2 And 10.9 Per 1,000,000 Respectively. A Total Of 18 Of 48 (38%) Patients Received 3,4-Diaminopyridine (3,4-Dap); 14 Of 18 (78%) Improved. This Investigation Was A Large North American Epidemiologic Study Of Lems. Lems Prevalence In The National Va Population Was Found To Be Similar To Previously Published Rates In Other Large International Populations. Most Patients Experienced Improvement With Therapy, Including A Majority With 3,4-Dap. Muscle Nerve 56: 421-426, 2017.|[('Nationwide Study', 'no label'), ('Netherlands', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Published', 'no label'), ('Lems Epidemiology', 'no label'), ('Therapeutic Response', 'no label'), ('United States Veterans Affairs', 'no label'), ('Medical Records', 'no label'), ('Active Patients', 'no label'), ('Million', 'no label'), ('Va Health System', 'no label'), ('Queried', 'no label'), ('Relevant', 'no label'), ('Icd-9 Codes', 'no label'), ('Period', 'no label'), ('Clinical', 'no label'), ('Electrophysiologic', 'no label'), ('Serologic Features', 'no label'), ('Evaluated', 'no label'), ('Diagnosis', 'no label'), ('Epidemiologic', 'no label'), ('Treatment', 'no label'), ('Collected', 'no label'), ('Point Prevalence', 'no label'), ('Estimated', 'no label'), ('Confirmed', 'no label'), ('Cases', 'no label'), ('Probable', 'no label'), ('Cases', 'no label'), ('Crude Prevalence', 'no label'), ('Estimated', 'no label'), ('Patients', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Investigation', 'no label'), ('North American', 'no label'), ('Epidemiologic Study', 'no label'), ('Prevalence', 'no label'), ('National Va Population', 'no label'), ('Published Rates', 'no label'), ('International Populations', 'no label'), ('Patients', 'no label'), ('Improvement', 'no label'), ('Therapy', 'no label'), ('Muscle Nerve', 'no label')]|[]|[('Icd-9', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('3,4-Diaminopyridine', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Patients', 'no label'), ('Muscle Nerve', 'no label')]
lambert eaton syndrome|pubmed~29632282|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disease Of The Neuromuscular Junction. Approximately 50-60% Of Patients With Lems Have A Tumor, Most Often Small Cell Lung Cancer (Sclc), Making Lems A Paraneoplastic Neurological Syndrome. In Japan, The Clinical Picture Is A Male: Female Ratio Of 3:1; Mean Age, 62 Years (17-80 Years); And 61% Of Lems Patients Have Sclc (Sclc-Lems), With The Remainder Of Patients Having No Cancer. Patients With Lems Develop A Unique Set Of Clinical Characteristics, Which Include Proximal Muscle Weakness, Depressed Tendon Reflexes With Post-Tetanic Potentiation, And Autonomic Symptoms. Interestingly, Less Than 10% Of Patients With Lems Have Cerebellar Ataxia (Lems With Paraneoplastic Cerebellar Degeneration). Considering Its Pathomechanisms, Lems Is A Presynaptic Disorder Of Neuromuscular Transmission In Which Quantal Release Of Acetylcholine Is Impaired By Autoantibodies Against P/Q-Type Voltage-Gated Calcium Channels (P/Q-Vgccs) At Active Zones Reducing Quantal Release Of Acetylcholine, Although An Animal Model Using Immunization With Purified P/Q-Vgccs Has Not Yet Been Established. The Diagnosis Can Be Confirmed By Finding A Reduced Compound Muscle Action Potential Amplitude That Increases By Over 60% Following Maximum Voluntary Activation Or 50 Hz Nerve Stimulation. Approximately 90% Of Patients Who Satisfy The Above Electrophysiological Diagnostic Criteria Are Positive For P/Q-Vgcc Antibodies Have Their Diagnosis Confirmed. Specific Tumor Therapy In Sclc-Lems Will Often Improve The Neurologic Deficit. Tumor Removal Is The Primary Treatment For Lems. If Primary Tumor Screening Is Negative, Screening Should Be Repeated After 3-6 Months, Followed By Screening Every 6 Months Until 2 Years Post Diagnosis. Most Patients Benefit From 3,4-Diaminopyridine Being Administered With Pyridostigmine. In Those With Severe Weakness, High-Dose Intravenous Gamma-Globulin (Ivig) Or Plasmapheresis Confers Short-Term Benefits. Prednisone, Alone Or Combined With Immunosuppressive Drugs, Can Achieve Long-Term Control Of The Disorder. The Results Of A Prospective Cohort Study Showed That The Presence Of Lems With Sclc Had A Significant Survival Advantage Independent Of Other Prognostic Factors Including Disease Extent, Age, Sex, Performance Status, And Serum Sodium Values.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disease', 'no label'), ('Neuromuscular Junction', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Have A Tumor', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Making Lems A', 'no label'), ('Paraneoplastic Neurological Syndrome', 'no label'), ('Japan', 'no label'), ('Clinical Picture', 'no label'), ('Male', 'no label'), ('Female', 'no label'), ('Ratio', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Years', 'no label'), ('Lems Patients', 'no label'), ('Sclc', 'no label'), ('Sclc-Lems', 'no label'), ('Patients', 'no label'), ('No Cancer', 'no label'), ('Patients', 'no label'), ('Lems Develop A', 'no label'), ('Clinical Characteristics', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Depressed Tendon Reflexes', 'no label'), ('Post-Tetanic Potentiation', 'no label'), ('Autonomic Symptoms', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Pathomechanisms', 'no label'), ('Lems', 'no label'), ('Presynaptic Disorder', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Quantal Release', 'no label'), ('Acetylcholine', 'no label'), ('Impaired', 'no label'), ('Autoantibodies', 'no label'), ('P/Q-Type Voltage-Gated Calcium Channels', 'no label'), ('P/Q-Vgccs', 'no label'), ('Active Zones', 'no label'), ('Reducing', 'no label'), ('Quantal Release', 'no label'), ('Acetylcholine', 'no label'), ('Animal Model', 'no label'), ('Immunization', 'no label'), ('Purified', 'no label'), ('P/Q-Vgccs', 'no label'), ('Established', 'no label'), ('Diagnosis', 'no label'), ('Confirmed', 'no label'), ('Reduced', 'no label'), ('Compound Muscle', 'no label'), ('Amplitude', 'no label'), ('Increases', 'no label'), ('Maximum', 'no label'), ('Voluntary Activation', 'no label'), ('Stimulation', 'no label'), ('Patients', 'no label'), ('Electrophysiological Diagnostic Criteria', 'no label'), ('Positive', 'no label'), ('Antibodies', 'no label'), ('Diagnosis', 'no label'), ('Confirmed', 'no label'), ('Tumor Therapy', 'no label'), ('Sclc-Lems', 'no label'), ('Neurologic Deficit', 'no label'), ('Tumor Removal', 'no label'), ('Primary Treatment', 'no label'), ('Lems', 'no label'), ('Primary Tumor Screening', 'no label'), ('Negative', 'no label'), ('Screening', 'no label'), ('Repeated', 'no label'), ('Months', 'no label'), ('Screening', 'no label'), ('Months', 'no label'), ('Years', 'no label'), ('Post Diagnosis', 'no label'), ('Patients', 'no label'), ('Benefit', 'no label'), ('3,4-Diaminopyridine Being', 'no label'), ('Administered', 'no label'), ('Pyridostigmine', 'no label'), ('Severe Weakness', 'no label'), ('High-Dose Intravenous Gamma-Globulin', 'no label'), ('Ivig', 'no label'), ('Plasmapheresis', 'no label'), ('Confers', 'no label'), ('Short-Term', 'no label'), ('Benefits', 'no label'), ('Prednisone', 'no label'), ('Alone', 'no label'), ('Immunosuppressive Drugs', 'no label'), ('Long-Term Control', 'no label'), ('Disorder', 'no label'), ('Prospective Cohort Study', 'no label'), ('Presence', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Significant Survival Advantage', 'no label'), ('Prognostic Factors', 'no label'), ('Disease Extent', 'no label'), ('Age', 'no label'), ('Sex', 'no label'), ('Performance Status', 'no label'), ('Serum Sodium Values', 'no label')]|[('Cell', 'no label'), ('Acetylcholine', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Animal', 'no label'), ('Antibodies', 'no label'), ('Sclc-Lems', 'no label'), ('Intravenous Gamma-Globulin', 'no label'), ('Sodium', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('Tumor', 'no label'), ('Neurological Syndrome', 'no label'), ('Cancer', 'no label'), ('Muscle Weakness', 'no label'), ('Depressed', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Disorder Of Neuromuscular Transmission', 'no label'), ('Acetylcholine', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Tumor', 'no label'), ('Neurologic Deficit', 'no label'), ('Tumor', 'no label'), ('Primary Tumor', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Administered', 'no label'), ('Pyridostigmine', 'no label'), ('Weakness', 'no label'), ('Prednisone', 'no label'), ('Disorder', 'no label'), ('Sodium', 'no label')]|[('Neuromuscular', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Tumor', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Lems A', 'no label'), ('Lems Patients Have Sclc', 'no label'), ('Patients', 'no label'), ('Cancer', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Muscle', 'no label'), ('Tendon Reflexes', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Paraneoplastic Cerebellar', 'no label'), ('Lems', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular', 'no label'), ('Acetylcholine', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('P/Q-Vgccs', 'no label'), ('Patients', 'no label'), ('P/Q-Vgcc', 'no label'), ('Tumor', 'no label'), ('Sclc-Lems', 'no label'), ('Tumor', 'no label'), ('Primary Tumor', 'no label'), ('Patients', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label'), ('Intravenous', 'no label'), ('Prednisone', 'no label'), ('Lems', 'no label'), ('Serum', 'no label')]
lambert eaton syndrome|pubmed~31477611||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~34019010||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~33290602||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~32831159|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Kind Of Autoimmune Disease Of The Neuromuscular Junction That Is Often Misdiagnosed As A Peripheral Nerve Disease Or Myopathy. For Some Difficult Cases, Muscle Biopsy Examination Is Useful For Differential Diagnosis. However, Studies About The Pathological Findings Of Lems Patients Are Rare, Especially Of Patients Who Were Diagnosed With Small Cell Lung Carcinoma (Sclc). This Study Aimed To Describe Several Pathological Muscle Features In Patients With Lems Associated With Sclc. The 5 Patients Enrolled In This Study Were Diagnosed With Lems Associated With Sclc By Clinical Manifestation, Electromyography, And Lung Biopsy. Muscle Biopsies Were Performed For The Patients, And Enzyme Histopathology Was Assessed. The Hematoxylin And Eosin (H & E) Stain Showed Different Sizes Of Fibers, And The Shape Of Atrophic Fibers Were Angular Or Polygonal. The Adenosine Triphosphatase (Atpase) Stain Demonstrated That The Majority Of Atrophic Fibers Were Type Ii. Type Ii Fiber Predominance Was Observed In Case 1 And Case 5. Also, Scattered Muscle Fiber Necrosis Was Shown In Case 3. Type Ii Fiber Atrophy And Type Ii Fiber Predominance May Often Be Found In Patients With Lems Associated With Sclc. Also, Scattered Fiber Necrosis May Appear In This Disease.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Kind', 'no label'), ('Autoimmune Disease', 'no label'), ('Neuromuscular Junction', 'no label'), ('Misdiagnosed', 'no label'), ('Peripheral Nerve Disease', 'no label'), ('Myopathy', 'no label'), ('Difficult', 'no label'), ('Cases', 'no label'), ('Muscle Biopsy Examination', 'no label'), ('Differential Diagnosis', 'no label'), ('Studies', 'no label'), ('Pathological Findings', 'no label'), ('Lems Patients', 'no label'), ('Rare', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Study', 'no label'), ('Pathological Muscle', 'no label'), ('Features', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Diagnosed', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Sclc', 'no label'), ('Clinical', 'no label'), ('Electromyography', 'no label'), ('Lung Biopsy', 'no label'), ('Muscle Biopsies', 'no label'), ('Performed', 'no label'), ('Patients', 'no label'), ('Enzyme Histopathology', 'no label'), ('Assessed', 'no label'), ('Hematoxylin And Eosin (H & E) Stain', 'no label'), ('Sizes', 'no label'), ('Fibers', 'no label'), ('Shape', 'no label'), ('Atrophic Fibers', 'no label'), ('Angular', 'no label'), ('Polygonal', 'no label'), ('Adenosine Triphosphatase', 'no label'), ('Atpase', 'no label'), ('Stain', 'no label'), ('Atrophic Fibers', 'no label'), ('Predominance', 'no label'), ('Observed', 'no label'), ('Case 1', 'no label'), ('Scattered Muscle', 'no label'), ('Fiber Necrosis', 'no label'), ('Type Ii Fiber Atrophy', 'no label'), ('Type Ii Fiber', 'no label'), ('Found', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Sclc', 'no label'), ('Fiber Necrosis', 'no label'), ('Appear', 'no label'), ('Disease', 'no label')]|[('Cell', 'no label'), ('Enzyme', 'no label'), ('Adenosine', 'no label')]|[('Adenosine Triphosphatase (Atpase) Stain', 'no label'), ('Type Ii', 'no label'), ('Type Ii Fiber', 'no label'), ('Type Ii Fiber Atrophy And Type Ii Fiber', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('Nerve Disease', 'no label'), ('Myopathy', 'no label'), ('H & E', 'no label'), ('Adenosine', 'no label'), ('Type Ii Fiber Predominance Was Observed In Case 1 And Case 5. Also, Scattered', 'no label'), ('Muscle Fiber Necrosis', 'no label'), ('Atrophy', 'no label'), ('Type Ii Fiber Predominance May Often Be Found', 'no label'), ('Necrosis', 'no label')]|[('Neuromuscular', 'no label'), ('Peripheral Nerve', 'no label'), ('Muscle Biopsy', 'no label'), ('Lems Patients', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Muscle', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Lung Biopsy.', 'no label'), ('Muscle Biopsies', 'no label'), ('Patients', 'no label'), ('Hematoxylin And Eosin (', 'no label'), ('Fibers', 'no label'), ('Fibers', 'no label'), ('Adenosine Triphosphatase', 'no label'), ('Atpase', 'no label'), ('Fibers Were Type Ii', 'no label'), ('Type Ii Fiber', 'no label'), ('Case 1', 'no label'), ('Muscle Fiber', 'no label'), ('Case 3', 'no label'), ('Type Ii Fiber', 'no label'), ('Type Ii Fiber', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Fiber', 'no label')]
lambert eaton syndrome|pubmed~31233589|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Antibody-Mediated Disorder Of The Neuromuscular Junction That Is Most Commonly Diagnosed In Association With Small Cell Lung Carcinoma (Sclc). Small Cell Lung Carcinoma Is Histologically Similar To The Aggressive Cutaneous Neuroendocrine Malignancy Merkel Cell Carcinoma (Mcc). We Provide A Full Report And Longitudinal Clinical Follow-Up Of A Case Of Lems Occurring With Mcc. We Also Review The Literature On Paraneoplastic Syndromes Associated With Mcc And Other Nonpulmonary Small Cell Carcinomas.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Antibody-Mediated Disorder', 'no label'), ('Neuromuscular Junction', 'no label'), ('Diagnosed', 'no label'), ('Association', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Histologically', 'no label'), ('Aggressive Cutaneous', 'no label'), ('Neuroendocrine Malignancy', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Mcc', 'no label'), ('Full Report', 'no label'), ('Longitudinal Clinical Follow-Up', 'no label'), ('Lems Occurring', 'no label'), ('Mcc', 'no label'), ('Review', 'no label'), ('Literature', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Associated With', 'no label'), ('Mcc', 'no label'), ('Nonpulmonary Small Cell Carcinomas', 'no label')]|[('Cell', 'no label'), ('Cell', 'no label'), ('Cell', 'no label'), ('Cell', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Antibody-Mediated Disorder', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Aggressive Cutaneous Neuroendocrine Malignancy Merkel Cell Carcinoma', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Nonpulmonary Small Cell Carcinomas', 'no label')]|[('Neuromuscular', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Cutaneous Neuroendocrine Malignancy Merkel Cell Carcinoma', 'no label'), ('A Case', 'no label'), ('Lems', 'no label'), ('Nonpulmonary Small Cell Carcinomas', 'no label')]
lambert eaton syndrome|pubmed~27370896|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Paraneoplastic Syndrome And Only 3% Of Small Cell Lung Carcinoma (Sclc) Patients Have Lems. Moreover, The Recurrence Of Sclc After A Disease-Free Survival (Dfs) Of More Than 10 Years Is Rare. We Report A Patient Who Had A Recurrence Of Both Sclc And Lems After A 13-Year Dfs Period. A 69-Year-Old Man Was Diagnosed With Lems And Sclc (Ct0N2M0, Stage Iiia) 13 Years Ago. Chemoradiotherapy Was Performed And A Complete Response Was Achieved. With Anticancer Treatment, The Lems Symptoms Was Alleviated. At The Age Of 82 Years, Gait Disturbance Appeared Followed By Left Supraclavicular Lymphadenopathy And Further Examination Revealed The Recurrence Of Sclc. Careful Screening For The Recurrence Of Sclc Might Be Needed When The Patient Has Recurrent Or Secondary Paraneoplastic Neurological Syndrome Even After A Long Dfs Period. |[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Recurrence', 'no label'), ('Sclc', 'no label'), ('Disease-Free Survival', 'no label'), ('Dfs', 'no label'), ('Years', 'no label'), ('Rare', 'no label'), ('Report', 'no label'), ('Patient', 'no label'), ('Recurrence', 'no label'), ('Sclc', 'no label'), ('Dfs', 'no label'), ('Period', 'no label'), ('69-Year-Old Man', 'no label'), ('Diagnosed', 'no label'), ('Lems', 'no label'), ('Ct0N2M0, Stage Iiia', 'no label'), ('Years', 'no label'), ('Ago', 'no label'), ('Chemoradiotherapy', 'no label'), ('Performed', 'no label'), ('Complete Response', 'no label'), ('Anticancer Treatment', 'no label'), ('Lems Symptoms', 'no label'), ('Alleviated', 'no label'), ('Age', 'no label'), ('Gait Disturbance Appeared', 'no label'), ('Left Supraclavicular Lymphadenopathy', 'no label'), ('Examination', 'no label'), ('Revealed', 'no label'), ('Recurrence', 'no label'), ('Sclc', 'no label'), ('Screening', 'no label'), ('Recurrence', 'no label'), ('Sclc', 'no label'), ('Patient', 'no label'), ('Recurrent', 'no label'), ('Secondary Paraneoplastic Neurological Syndrome', 'no label'), ('Long Dfs Period', 'no label')]|[('Cell', 'no label'), ('Dfs', 'no label')]|[('Long Dfs', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Left Supraclavicular Lymphadenopathy', 'no label'), ('Secondary Paraneoplastic Neurological Syndrome', 'no label')]|[('Small Cell Lung Carcinoma', 'no label'), ('Patients', 'no label'), ('Patient', 'no label'), ('Lems', 'no label'), ('Anticancer', 'no label'), ('Lems', 'no label'), ('Left Supraclavicular', 'no label'), ('Patient', 'no label')]
lambert eaton syndrome|pubmed~29402568|"3,4-Diaminopyridine (34Dap) Is A Presynaptic Transmission Enhancer. Its Efficacy For Lambert-Eaton Myasthenic Syndrome (Lems) And Myasthenia Gravis (Mg) Was Demonstrated. However, There Are Cases Sharing The Characteristics Of Both Disease And The Effect Of 34Dap In ""Gray Zone"" Patients Is Sparse. Recently, We Prescribed 34Dap To Five Anti-Acetylcholine Receptor Antibody-Positive Mg Patients With Electrophysiological Lems Patterns And Three Lems Patients, And Carefully Monitored The Responses. Sero-Positive Mg Patients Exhibited More Favorable Responses Than Lems Patients. The Combination Of 34Dap And Pyridostigmine Resulted In The Best Outcomes. No Significant Side Effects Were Recorded During The Follow-Up Period. In Conclusion, This Study Results Provide Evidence That 34Dap Could Be Effective In Sero-Positive Mg Patients With Pre-Synaptic Dysfunction."|[('3,4-Diaminopyridine', 'no label'), ('Presynaptic Transmission Enhancer', 'no label'), ('Efficacy', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Cases', 'no label'), ('Sharing', 'no label'), ('Characteristics', 'no label'), ('Disease', 'no label'), ('Effect', 'no label'), ('Patients', 'no label'), ('Sparse', 'no label'), ('Anti-Acetylcholine Receptor', 'no label'), ('Antibody-Positive Mg', 'no label'), ('Patients', 'no label'), ('Electrophysiological Lems Patterns', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Monitored', 'no label'), ('Responses', 'no label'), ('Sero-Positive Mg', 'no label'), ('Patients', 'no label'), ('Exhibited', 'no label'), ('Favorable Responses', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Combination', 'no label'), ('Pyridostigmine', 'no label'), ('Resulted', 'no label'), ('Best', 'no label'), ('Outcomes', 'no label'), ('Side Effects', 'no label'), ('Follow-Up', 'no label'), ('Period', 'no label'), ('Study Results', 'no label'), ('Provide', 'no label'), ('Evidence', 'no label'), ('Effective', 'no label'), ('Sero-Positive Mg', 'no label'), ('Patients', 'no label'), ('Pre-Synaptic Dysfunction', 'no label')]|[('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label')]|[('Presynaptic Transmission Enhancer', 'no label')]|[('3,4-Diaminopyridine', 'no label'), ('34Dap', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('34Dap', 'no label'), ('Anti-Acetylcholine', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Pyridostigmine', 'no label'), ('Mg', 'no label')]|[('3,4-Diaminopyridine', 'no label'), ('Patients', 'no label'), ('Anti-Acetylcholine Receptor', 'no label'), ('Mg Patients', 'no label'), ('Lems Patients', 'no label'), ('Patients', 'no label'), ('Pyridostigmine', 'no label'), ('Sero-Positive Mg Patients', 'no label')]
lambert eaton syndrome|pubmed~25335449|Paraneoplastic Syndrome Is A Disease Or Symptom That Is The Consequence Of Cancer In The Body But, Unlike Mass Effect, Is Not Due To The Local Presence Of Cancer Cells. An Overlap Of Two Paraneoplastic Syndromes Secondary To Lung Cancer In A Patient Is Very Rare. In Order To Improve The Diagnosis Of Two Paraneoplastic Syndromes Secondary To Lung Cancer, We Reported An Overlap Of Two Paraneoplastic Syndromes Secondary To Lung Squamous Carcinoma In A Patient. We Reported A Case Of A 60-Year-Old Male Smoker Who Presented Multiple Erythematous Lesions For 6 Months With Progressive Proximal Muscular Weakness, And Developed To Dysphonia In 2 Months. His Chest Computed Tomography Showed A Spiculate Pulmonary Nodule Near The Hilar In The Right Upper Lobe And Mediastinal Lymph Nodes Enlargement. Lung Biopsy Showed Squamous Cell Carcinoma. The Patient'S Blood Test Revealed Elevated Creatine Kinase Levels. Electromyography Results Were Consistent With Moderate Myopathy Accompanied With A Pattern Suggestive Of Lambert-Eaton Myasthenic Syndrome. So We Made The Diagnosis Of An Overlap Of Two Paraneoplastic Syndromes (Dermatomyositis And Lambert-Eaton Myasthenic Syndrome) Secondary To Lung Squamous Carcinoma. Recognition Of Paraneoplastic Syndrome Is Crucial For Early Diagnosis Of Lung Cancer Because Up To 80% Of Patients May Present Paraneoplastic Syndromes Before Any Other Direct Indication Of Malignancy. Early Diagnosis And Treatment Of Paraneoplastic Syndrome Is Also Important Because Delayed Diagnosis May Result In Rapid Disease Progression And Irreversible Neurological Damage.|"[('Paraneoplastic Syndrome', 'no label'), ('Symptom', 'no label'), ('Consequence Of Cancer', 'no label'), ('Body', 'no label'), ('Mass Effect', 'no label'), ('Local', 'no label'), ('Presence', 'no label'), ('Cancer Cells', 'no label'), ('Overlap', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Secondary To Lung Cancer', 'no label'), ('Patient', 'no label'), ('Order', 'no label'), ('Diagnosis', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Secondary To Lung Cancer', 'no label'), ('Overlap', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Secondary To Lung Squamous Carcinoma', 'no label'), ('Patient', 'no label'), ('60-Year-Old', 'no label'), ('Male', 'no label'), ('Multiple', 'no label'), ('Erythematous Lesions', 'no label'), ('Months', 'no label'), ('Progressive Proximal', 'no label'), ('Muscular Weakness', 'no label'), ('Dysphonia', 'no label'), ('Months', 'no label'), ('His Chest Computed Tomography', 'no label'), ('Showed A', 'no label'), ('Spiculate Pulmonary Nodule Near', 'no label'), ('Hilar', 'no label'), ('Right Upper Lobe', 'no label'), ('Mediastinal', 'no label'), ('Enlargement', 'no label'), ('Lung Biopsy', 'no label'), ('Squamous Cell Carcinoma', 'no label'), (""Patient'S"", 'no label'), ('Blood Test', 'no label'), ('Revealed', 'no label'), ('Elevated', 'no label'), ('Creatine Kinase', 'no label'), ('Levels', 'no label'), ('Electromyography Results', 'no label'), ('Consistent With', 'no label'), ('Moderate Myopathy', 'no label'), ('Accompanied With', 'no label'), ('Pattern', 'no label'), ('Suggestive', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Diagnosis', 'no label'), ('Overlap', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Dermatomyositis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lung Squamous Carcinoma', 'no label'), ('Recognition', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Early Diagnosis', 'no label'), ('Lung Cancer', 'no label'), ('Patients', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Indication', 'no label'), ('Malignancy', 'no label'), ('Early Diagnosis', 'no label'), ('Treatment', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Delayed Diagnosis', 'no label'), ('Result', 'no label'), ('Disease Progression', 'no label'), ('Irreversible', 'no label'), ('Neurological Damage', 'no label')]"|[('Cells', 'no label'), ('His', 'no label'), ('Squamous Cell', 'no label'), ('Creatine', 'no label')]|[('His', 'no label')]|[('Paraneoplastic Syndrome', 'no label'), ('Cancer', 'no label'), ('Cancer', 'no label'), ('Paraneoplastic Syndromes Secondary To Lung Cancer', 'no label'), ('Paraneoplastic Syndromes Secondary To Lung Cancer', 'no label'), ('Paraneoplastic Syndromes Secondary To Lung Squamous Carcinoma', 'no label'), ('Muscular Weakness', 'no label'), ('Dysphonia', 'no label'), ('Squamous Cell Carcinoma', 'no label'), ('Creatine', 'no label'), ('Myopathy', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Dermatomyositis', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Lung Squamous Carcinoma', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Lung Cancer', 'no label'), ('Paraneoplastic Syndromes Before Any Other Direct', 'no label'), ('Malignancy', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Diagnosis', 'no label'), ('Neurological Damage', 'no label')]|[('Cancer', 'no label'), ('Body', 'no label'), ('Cancer Cells', 'no label'), ('Lung Cancer', 'no label'), ('Lung Cancer', 'no label'), ('Lung Squamous Carcinoma', 'no label'), ('A Case', 'no label'), ('Erythematous Lesions For 6', 'no label'), ('Muscular', 'no label'), ('Pulmonary', 'no label'), ('Hilar', 'no label'), ('Right Upper Lobe', 'no label'), ('Lymph Nodes', 'no label'), ('Lung Biopsy Showed Squamous Cell Carcinoma', 'no label'), ('Patient', 'no label'), ('Blood', 'no label'), ('Creatine Kinase', 'no label'), ('Lung Squamous Carcinoma', 'no label'), ('Lung Cancer', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~29189554|To Characterize Lambert-Eaton Myasthenic Syndrome And Limbic Encephalitis With Coexistent Voltage-Gated Calcium Channel (Vgcc) Antibody And Γ-Aminobutyric Acid (Gaba) B Receptor Antibody. Case Study. A 57-Year-Old Man Presented With 6 Months Of Weakness, Unsteadiness, And Vision Difficulties. Examination Revealed Proximal Weakness And Diminished Reflexes. Electrodiagnostic Study Revealed Low-Amplitude Motor Potentials And Facilitation On High-Frequency Stimulation. Laboratory Evaluation Identified P/Q-Type Vgcc Antibody. Positron Emission Tomography Identified A Mediastinal Lesion, Confirmed As Small-Cell Lung Carcinoma. The Patient Developed Confusion And Seizures. Cerebrospinal Fluid Analysis Identified Antibodies To Gabab Receptor. This Case Describes A Patient With Lambert-Eaton Myasthenic Syndrome, Limbic Encephalitis, And Autoantibodies To Vgcc And Gabab Receptor. Atypical Presentation Of Paraneoplastic Neurological Syndromes Could Indicate The Presence Of A Second Antibody That May Have Significant Impact On Therapy.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Limbic Encephalitis', 'no label'), ('Coexistent Voltage-Gated Calcium Channel', 'no label'), ('Vgcc', 'no label'), ('Antibody', 'no label'), ('Γ-Aminobutyric Acid', 'no label'), ('Antibody', 'no label'), ('Case Study', 'no label'), ('Months', 'no label'), ('Weakness', 'no label'), ('Unsteadiness', 'no label'), ('Vision Difficulties', 'no label'), ('Examination', 'no label'), ('Proximal Weakness', 'no label'), ('Diminished', 'no label'), ('Reflexes', 'no label'), ('Electrodiagnostic Study', 'no label'), ('Revealed', 'no label'), ('Low-Amplitude Motor Potentials', 'no label'), ('Facilitation', 'no label'), ('High-Frequency Stimulation', 'no label'), ('Laboratory Evaluation', 'no label'), ('Vgcc', 'no label'), ('Antibody', 'no label'), ('Positron Emission Tomography', 'no label'), ('Identified', 'no label'), ('Mediastinal', 'no label'), ('Lesion', 'no label'), ('Confirmed As', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Patient Developed Confusion', 'no label'), ('Seizures', 'no label'), ('Cerebrospinal Fluid Analysis', 'no label'), ('Antibodies', 'no label'), ('Gabab Receptor', 'no label'), ('Case Describes', 'no label'), ('Patient', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Limbic Encephalitis', 'no label'), ('Autoantibodies', 'no label'), ('Vgcc', 'no label'), ('Gabab Receptor', 'no label'), ('Atypical', 'no label'), ('Presentation', 'no label'), ('Paraneoplastic Neurological Syndromes', 'no label'), ('Presence', 'no label'), ('Antibody', 'no label'), ('May', 'no label'), ('Significant', 'no label'), ('Impact', 'no label'), ('Therapy', 'no label')]|[('Calcium', 'no label'), ('Antibody', 'no label'), ('Antibody', 'no label'), ('P/Q-Type', 'no label'), ('Antibody', 'no label'), ('Antibodies', 'no label'), ('Autoantibodies', 'no label'), ('Antibody', 'no label')]|[('Antibodies', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Limbic Encephalitis', 'no label'), ('Calcium', 'no label'), ('Weakness', 'no label'), ('Unsteadiness', 'no label'), ('Vision Difficulties', 'no label'), ('Lung Carcinoma', 'no label'), ('Confusion', 'no label'), ('Seizures', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Limbic Encephalitis', 'no label'), ('Paraneoplastic Neurological Syndromes', 'no label')]|[('Calcium', 'no label'), ('P/Q-Type Vgcc Antibody', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Patient', 'no label'), ('Gabab Receptor', 'no label'), ('Patient', 'no label'), ('Vgcc', 'no label'), ('Gabab Receptor', 'no label')]
lambert eaton syndrome|pubmed~30718446|A 63-Year-Old Female Who Developed Dizziness, Diplopia And Subsequent Gait Disturbance From September X-1 Year Was Analyzed. The First Neurological Findings In May X Year Revealed Cerebellar Ataxia, Weakness In The Proximal Limbs, Decreased Tendon Reflexes, And Autonomic Symptoms (Adl:Mrs 3). Furthermore, An Incremental Phenomenon Was Observed In The Repetitive Nerve Stimulation Test, And She Was Diagnosed With Lambert-Eaton Myasthenic Syndrome (Lems) Based On The Serum P/Q-Type Calcium Channel (Vgcc) Antibody Positivity. In Addition, Small Cell Lung Cancer Was Detected By Chest Ct And Bronchoscopy, And Her Cerebellar Ataxia Was Diagnosed As Paraneoplastic Cerebellar Degeneration (Pcd). Therefore, The Patient Underwent Chemotherapy And Radiotherapy From June In X Year. Six Months After Initiation Of Treatment, Her Cerebellar Ataxia Had Almost Disappeared And She Could Walk Without Assistance (Adl:Mrs 1). The P/Q-Type Vgcc Antibodies Were Also Negative At That Time. Cases Wherein Cerebellar Ataxia Resolved Almost Completely In Parallel With Disappearance Of The Serum P/Q-Type Vgcc Antibodies Are Of Great Interest. We Conducted A Systematic Literature Review Of Pcd-Lems Cases In Japan Reported Since P/Q-Type Calcium Channel Antibody Measurement Was Reported In 1995. As A Result, 13 Cases (Including Our Study) That Concurrently Displayed Cerebellar Ataxia And Lems Were Selected. The Average Age Of The 13 Patients (10 Males And 3 Females) Was 61.5 Years. Small Cell Carcinoma Was Complicated In 11 Patients (10 In The Lung And 1 In The Oropharynx); In The Other 2 Patients, Cancer Was Not Found At The Time Of Reporting (The Observation Period Was As Short As 1-2 Months). The Time From Onset To Treatment Ranged Between 1 Week And 10 Months. While 1 Of The 13 Patients Developed Cerebellar Ataxia During The Subsequent Course Of The Treatment, The Remaining 12 Had Already Developed Cerebellar Ataxia And Lems Symptoms, Although Their Main Neurologic Finding Was Cerebellar Ataxia And They Were Subsequently Diagnosed With Lems After Electrophysiological Testing And Autoantibody Detection. Small Cell Carcinoma Was Found In 11 Patients. We Define The Pathology Following Such A Certain Clinical Course As Pcd-Lems. The P/Q-Type Vgcc Antibodies Were Positive In 11 Of The 13 Cases, Although Their Antibody Titers Were Not Necessarily Very High. Treatment For The Associated Small Cell Carcinoma Might Have Improved The Neurological Findings In 9 Of The 11 Pcd-Lems Patients. The P/Q-Type Vgcc Antibodies Were Measured Before And After The Treatment. The Pcd-Lems Symptoms Improved In All Patients And Their Antibody Titers Decreased. These Findings Indicate That P/Q-Type Vgcc Antibodies Are Involved In The Pathology Of Pcd-Lems. Appropriate And Timely Treatment, At Least In Pcd-Lems Patients In Japan, That Actively Treats Any Associated Cancer Can Be Expected To Improve Not Only Life Prognosis But Also Cerebellar Ataxia. (Received October 15, 2018; Accepted November 5, 2018; Published January 1, 2019).|[('63-Year-Old', 'no label'), ('Female', 'no label'), ('Diplopia', 'no label'), ('Gait Disturbance', 'no label'), ('X-1 Year', 'no label'), ('Analyzed', 'no label'), ('Neurological Findings', 'no label'), ('May X', 'no label'), ('Revealed', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Weakness', 'no label'), ('Proximal Limbs', 'no label'), ('Decreased', 'no label'), ('Tendon Reflexes', 'no label'), ('Autonomic Symptoms', 'no label'), ('Incremental Phenomenon', 'no label'), ('Observed', 'no label'), ('Repetitive Nerve Stimulation Test', 'no label'), ('Diagnosed', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Serum P/Q-Type Calcium Channel', 'no label'), ('Vgcc', 'no label'), ('Antibody', 'no label'), ('Positivity', 'no label'), ('Addition', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Chest Ct', 'no label'), ('Bronchoscopy', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Diagnosed', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Pcd', 'no label'), ('Patient', 'no label'), ('Chemotherapy', 'no label'), ('Radiotherapy', 'no label'), ('X Year', 'no label'), ('Months', 'no label'), ('Initiation', 'no label'), ('Treatment', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Disappeared', 'no label'), ('Walk', 'no label'), ('Assistance', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Negative', 'no label'), ('Cases', 'no label'), ('Wherein Cerebellar Ataxia', 'no label'), ('Resolved', 'no label'), ('Completely', 'no label'), ('Disappearance', 'no label'), ('Serum P/Q-Type Vgcc Antibodies', 'no label'), ('Great Interest', 'no label'), ('Systematic Literature Review', 'no label'), ('Pcd-Lems', 'no label'), ('Cases', 'no label'), ('Japan', 'no label'), ('Reported', 'no label'), ('P/Q-Type Calcium Channel', 'no label'), ('Antibody', 'no label'), ('Measurement', 'no label'), ('Result', 'no label'), ('Cases', 'no label'), ('Study', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Average', 'no label'), ('Age', 'no label'), ('Patients', 'no label'), ('Males', 'no label'), ('Females', 'no label'), ('Years', 'no label'), ('Small Cell Carcinoma', 'no label'), ('Complicated', 'no label'), ('Patients', 'no label'), ('Lung', 'no label'), ('Oropharynx', 'no label'), ('Patients', 'no label'), ('Cancer', 'no label'), ('Was Not', 'no label'), ('Reporting', 'no label'), ('Observation Period', 'no label'), ('Time', 'no label'), ('Treatment', 'no label'), ('Week', 'no label'), ('Months', 'no label'), ('Patients', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Course', 'no label'), ('Treatment', 'no label'), ('Developed', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Lems Symptoms', 'no label'), ('Neurologic', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Diagnosed', 'no label'), ('Lems', 'no label'), ('Electrophysiological Testing', 'no label'), ('Autoantibody Detection', 'no label'), ('Small Cell Carcinoma', 'no label'), ('Patients', 'no label'), ('Pathology', 'no label'), ('Clinical Course', 'no label'), ('Pcd-Lems', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Positive', 'no label'), ('Cases', 'no label'), ('Antibody', 'no label'), ('Titers', 'no label'), ('Treatment', 'no label'), ('Associated Small Cell Carcinoma', 'no label'), ('Neurological Findings', 'no label'), ('Pcd-Lems', 'no label'), ('Patients', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Measured', 'no label'), ('Treatment', 'no label'), ('Pcd-Lems', 'no label'), ('Symptoms', 'no label'), ('Improved', 'no label'), ('Patients', 'no label'), ('Antibody', 'no label'), ('Titers', 'no label'), ('Decreased', 'no label'), ('Findings', 'no label'), ('Indicate', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Pathology', 'no label'), ('Pcd-Lems', 'no label'), ('Appropriate', 'no label'), ('Timely', 'no label'), ('Treatment', 'no label'), ('Pcd-Lems', 'no label'), ('Patients', 'no label'), ('Japan', 'no label'), ('Treats', 'no label'), ('Associated Cancer', 'no label'), ('Expected', 'no label'), ('Life Prognosis', 'no label'), ('Cerebellar Ataxia', 'no label')]|[('Serum P/Q-Type Calcium', 'no label'), ('Antibody', 'no label'), ('Cell', 'no label'), ('P/Q-Type', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('P/Q-Type Calcium', 'no label'), ('Antibody', 'no label'), ('Cell', 'no label'), ('Autoantibody', 'no label'), ('Cell', 'no label'), ('P/Q-Type', 'no label'), ('Antibodies', 'no label'), ('Antibody', 'no label'), ('Cell', 'no label'), ('P/Q-Type', 'no label'), ('Antibodies', 'no label'), ('Antibody', 'no label'), ('P/Q-Type', 'no label'), ('Antibodies', 'no label')]|[('X-1', 'no label'), ('Ct', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Serum P/Q-Type Vgcc Antibodies', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Pcd-Lems', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Pcd-Lems', 'no label')]|[('Dizziness', 'no label'), ('Diplopia', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Weakness', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Calcium', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Disappeared', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Calcium', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Carcinoma', 'no label'), ('Cancer', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Carcinoma', 'no label'), ('Carcinoma', 'no label'), ('Cancer', 'no label'), ('Prognosis', 'no label'), ('Cerebellar Ataxia', 'no label')]|[('X', 'no label'), ('Cerebellar', 'no label'), ('Tendon', 'no label'), ('Serum P/Q-Type Calcium Channel', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Cerebellar', 'no label'), ('Paraneoplastic Cerebellar', 'no label'), ('Patient', 'no label'), ('X', 'no label'), ('Cerebellar', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Cerebellar', 'no label'), ('Serum P/Q-Type Vgcc Antibodies', 'no label'), ('P/Q-Type Calcium Channel', 'no label'), ('Cerebellar', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lung', 'no label'), ('Patients', 'no label'), ('Cancer', 'no label'), ('Patients', 'no label'), ('Cerebellar', 'no label'), ('Cerebellar', 'no label'), ('Lems', 'no label'), ('Cerebellar', 'no label'), ('Patients', 'no label'), ('Pathology', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Small Cell Carcinoma', 'no label'), ('Patients', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Patients', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Pathology', 'no label'), ('Patients', 'no label'), ('Cancer', 'no label'), ('Cerebellar', 'no label')]
lambert eaton syndrome|pubmed~29386498|In This Independent Clinical Study, We Analyzed Retrospectively The Clinical Features Of 9 Cases (6 Male And 3 Female) Of Lambert-Eaton Myasthenic Syndrome That Were Administered 3,4-Diaminopyridine (3,4-Dap). Four Cases Showed No Cancer And 5 Cases Had Small Cell Lung Carcinoma. Seven Cases Were Positive For Anti Voltage-Gated Calcium Channel Antibodies. Activities Of Daily Living (Adl) Were Improved By 3,4-Dap In 8 Cases That Showed Mainly Weakness Of The Extremities, But Did Not Improve Adl In 1 Case With Cerebellar Ataxia Of Paraneoplastic Cerebellar Degeneration (Pcd). Seven Cases Showed Autonomic Symptoms, And 6 Cases Were Improved With 3,4-Dap. The Maintenance Dose Varied Widely Among Individuals, With A Single Dose Ranging From 10 To 40 Mg. Each Patient Was Prescribed A Maintenance Dose 3 To 7 Times A Day. The Daily Dosage Ranged From 36 To 100 Mg. Two Cases Showed Adverse Effects To The Treatment. Of Those 2 Cases, 1 Case Treated At 45 Mg/Day Discontinued Treatment, But Another Case Treated At 100 Mg/Day Reduced The Dosage And Continued Treatment. The Administration Period Was 1 To 149 Months. Three Cases Have Continued 3,4-Dap For More Than 10 Years. Four Cases Have Discontinued 3,4-Dap, With 2 Cases Discontinuing Due To Death, 1 Case Discontinuing Due To Progression Of Cancer, And 1 Case Discontinuing Due To An Adverse Reaction. Our Results Suggest That 3,4-Dap Treatment Is Effective For Weakness And Autonomic Symptoms, But May Be Ineffective For Ataxia Of Pcd. Treatment With 3,4-Dap Can Be Tolerated For A Long Period, But The Optimal Dosage Varies Widely Among Individuals.|[('Independent Clinical Study', 'no label'), ('Analyzed', 'no label'), ('Retrospectively', 'no label'), ('Clinical Features', 'no label'), ('Cases', 'no label'), ('Male', 'no label'), ('Female', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Administered', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Cases', 'no label'), ('No Cancer', 'no label'), ('Cases', 'no label'), ('Small Cell', 'no label'), ('Lung Carcinoma', 'no label'), ('Cases', 'no label'), ('Positive', 'no label'), ('Anti Voltage-Gated Calcium Channel Antibodies', 'no label'), ('Activities', 'no label'), ('Cases', 'no label'), ('Weakness', 'no label'), ('Extremities', 'no label'), ('Not Improve', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Pcd', 'no label'), ('Cases', 'no label'), ('Autonomic Symptoms', 'no label'), ('Cases', 'no label'), ('Maintenance', 'no label'), ('Dose', 'no label'), ('Individuals', 'no label'), ('Single Dose Ranging', 'no label'), ('Patient', 'no label'), ('Prescribed', 'no label'), ('Maintenance', 'no label'), ('Dose', 'no label'), ('Times', 'no label'), ('Day', 'no label'), ('Daily Dosage', 'no label'), ('Ranged', 'no label'), ('Cases', 'no label'), ('Showed', 'no label'), ('Adverse Effects', 'no label'), ('Treatment', 'no label'), ('Cases', 'no label'), ('Case Treated', 'no label'), ('Discontinued', 'no label'), ('Treatment', 'no label'), ('Case Treated', 'no label'), ('Reduced', 'no label'), ('Dosage', 'no label'), ('Continued', 'no label'), ('Treatment', 'no label'), ('Administration Period', 'no label'), ('Months', 'no label'), ('Cases', 'no label'), ('Years', 'no label'), ('Cases', 'no label'), ('Discontinued', 'no label'), ('Cases', 'no label'), ('Discontinuing', 'no label'), ('Death', 'no label'), ('Case Discontinuing', 'no label'), ('Progression', 'no label'), ('Cancer', 'no label'), ('Case Discontinuing', 'no label'), ('Adverse Reaction', 'no label'), ('Suggest', 'no label'), ('Treatment', 'no label'), ('Effective', 'no label'), ('Weakness', 'no label'), ('Autonomic Symptoms', 'no label'), ('Ineffective', 'no label'), ('Ataxia', 'no label'), ('Treatment', 'no label'), ('Tolerated', 'no label'), ('Long Period', 'no label'), ('Optimal', 'no label'), ('Dosage', 'no label'), ('Varies', 'no label'), ('Individuals', 'no label')]|[('Cell', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('Individuals', 'no label'), ('Individuals', 'no label')]|[('Anti', 'no label'), ('Mg/Day', 'no label'), ('Mg/Day', 'no label')]|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Administered 3,4-Diaminopyridine', 'no label'), ('Cancer', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Calcium', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Death', 'no label'), ('Cancer', 'no label'), ('Weakness And Autonomic Symptoms', 'no label'), ('Ataxia', 'no label')]|[('3,4-Diaminopyridine', 'no label'), ('Cancer', 'no label'), ('Small Cell Lung Carcinoma.', 'no label'), ('Calcium Channel Antibodies', 'no label'), ('Cerebellar Ataxia Of', 'no label'), ('Cerebellar', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Cancer', 'no label')]
lambert eaton syndrome|pubmed~27016366|Myasthenia Gravis (Mg) Is An Autoimmune Postsynaptic Disorder Of Neuromuscular Transmission Caused, In Most Patients, By Antibodies Against Postsynaptic Acetylcholine Receptors. Lambert-Eaton Myasthenic Syndrome (Lems) Is A Presynaptic Autoimmune Disease In Which There Is A Reduction In Ca<Sup>2+</Sup> Entry With Each Impulse Due To The Action Of Antibodies Against Ca<Sup>2+</Sup> Channels. These Diseases Have A Distinct Pattern Of Response To Low-Frequency Repetitive Nerve Stimulation Which Allows Its Recognition In A Particular Subject. Nevertheless, The Physiologic Basis Of This Response Is Not Entirely Known. A Model Of The Time-Course Of Release Probability Of Neuromuscular Junctions That Incorporates Facilitation And A Depression-Recovery Mechanism Has Been Developed With The Aim To Investigate These Response Patterns. When The Basal Value Of Release Probability Was In The Physiologic Range, As In Mg, Release Probability Showed An Increment After Its Initial Decrease Only If The Recovery From Depression Was Accelerated By Presynaptic Residual Ca<Sup>2+</Sup>. Otherwise, When The Basal Release Probability Was Low, As In Lems, A Progressive Reduction In The Release Probability Without Any Late Increase Was Only Obtained If The Efficacy Of Facilitation And Ca<Sup>2+</Sup>-Dependent Recovery From Depression Were Reduced.|[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Autoimmune Postsynaptic Disorder', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Patients', 'no label'), ('Antibodies', 'no label'), ('Postsynaptic Acetylcholine Receptors', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Presynaptic Autoimmune Disease', 'no label'), ('Reduction', 'no label'), ('Ca<Sup>2+</Sup> Entry', 'no label'), ('Impulse', 'no label'), ('Action', 'no label'), ('Antibodies', 'no label'), ('Ca<Sup>2+</Sup> Channels', 'no label'), ('Diseases', 'no label'), ('Pattern', 'no label'), ('Response', 'no label'), ('Low-Frequency', 'no label'), ('Repetitive Nerve', 'no label'), ('Stimulation', 'no label'), ('Recognition', 'no label'), ('Physiologic Basis', 'no label'), ('Response', 'no label'), ('Model', 'no label'), ('Time-Course', 'no label'), ('Probability', 'no label'), ('Neuromuscular Junctions', 'no label'), ('Facilitation', 'no label'), ('Depression-Recovery', 'no label'), ('Mechanism', 'no label'), ('Investigate', 'no label'), ('Response Patterns', 'no label'), ('Basal Value', 'no label'), ('Release', 'no label'), ('Probability', 'no label'), ('Physiologic Range', 'no label'), ('Release Probability', 'no label'), ('Increment', 'no label'), ('Initial', 'no label'), ('Decrease', 'no label'), ('Recovery', 'no label'), ('Depression', 'no label'), ('Accelerated', 'no label'), ('Presynaptic', 'no label'), ('Residual', 'no label'), ('Ca<Sup>2+</Sup>.', 'no label'), ('Basal Release', 'no label'), ('Probability', 'no label'), ('Low', 'no label'), ('Progressive', 'no label'), ('Reduction', 'no label'), ('Release', 'no label'), ('Probability', 'no label'), ('Late Increase', 'no label'), ('Efficacy', 'no label'), ('Facilitation', 'no label'), ('Ca<Sup>2+</Sup>-Dependent', 'no label'), ('Recovery', 'no label'), ('Depression', 'no label'), ('Reduced', 'no label')]|[('Antibodies', 'no label'), ('Postsynaptic Acetylcholine Receptors', 'no label'), ('Antibodies', 'no label')]|[('Postsynaptic Acetylcholine Receptors', 'no label')]|[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Autoimmune Postsynaptic Disorder', 'no label'), ('Acetylcholine', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('Ca', 'no label'), ('Ca', 'no label'), ('Mg', 'no label'), ('Depression', 'no label'), ('Ca', 'no label'), ('Ca', 'no label'), ('Depression', 'no label')]|[('Postsynaptic', 'no label'), ('Neuromuscular', 'no label'), ('Patients', 'no label'), ('Acetylcholine', 'no label'), ('Presynaptic', 'no label'), ('Ca', 'no label'), ('Neuromuscular', 'no label'), ('Basal Value Of', 'no label'), ('Mg', 'no label'), ('Presynaptic', 'no label')]
lambert eaton syndrome|pubmed~30518000||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~32601396|To Evaluate The Dutch-English Lambert-Eaton Myasthenic Syndrome (Lems) Tumour Association Prediction (Delta-P) Score In A Prospective Cohort Of Patients With Newly Diagnosed Lems To Assess The Clinical Validity Of This Tool In A Real-World Setting. Clinical Features From 87 Patients With Lems, Occurring Within Three Months From Disease Onset, Were Collated To Produce A Delta-P Score For Each Patient. Lung Cancer Was Detected In 44/87 (51%) Lems Patients. Weight Loss ≥ 5%, Tobacco Use At Lems Onset And Age At Onset ≥ 50 Years Were Independent Predictors For The Development Of Small-Cell Lung Cancer (Sclc) In Lems Patients In Multivariable Analysis. Median Delta-P Scores Were Significantly Higher In Sclc-Lems Patients (3.5, 95% Ci 3 To 4) Compared To Non-Tumour-Lems (2, 95% Ci 1 To 2) (P < 0.0001). Higher Delta-P Scores Increased The Risk Of Sclc Stepwise (Score 0 = 0%, 1 = 18.8%, 2 = 45%, 3 = 55.5%, 4 = 85.7%, 5 = 87.5%, 6 = 100%). The Area Under The Curve Of The Receiver Operating Curve Was 82.5% (95% Ci 73.9% To 91%). The Delta-P Cancer Prediction Score, Calculated At The Time Of Lems Diagnosis, Is An Effective Tool For Cancer Screening In An Independent, Prospective Study Setting.|[('Evaluate', 'no label'), ('Dutch-English Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Delta-P', 'no label'), ('Prospective Cohort', 'no label'), ('Patients', 'no label'), ('Newly Diagnosed Lems', 'no label'), ('Clinical Validity', 'no label'), ('Tool', 'no label'), ('Real-World Setting', 'no label'), ('Clinical Features', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Occurring', 'no label'), ('Months', 'no label'), ('Disease Onset', 'no label'), ('Produce', 'no label'), ('Delta-P', 'no label'), ('Score', 'no label'), ('Patient', 'no label'), ('Lung Cancer', 'no label'), ('Detected', 'no label'), ('Patients', 'no label'), ('Weight Loss\u2009≥\u20095%', 'no label'), ('Tobacco Use', 'no label'), ('Lems Onset And Age', 'no label'), ('Years', 'no label'), ('Predictors', 'no label'), ('Development', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Lems Patients', 'no label'), ('Multivariable Analysis', 'no label'), ('Median', 'no label'), ('Delta-P', 'no label'), ('Scores', 'no label'), ('Sclc-Lems', 'no label'), ('Patients', 'no label'), ('Ci 3', 'no label'), ('Non-Tumour-Lems', 'no label'), ('Ci 1', 'no label'), ('Delta-P', 'no label'), ('Scores', 'no label'), ('Increased', 'no label'), ('Risk', 'no label'), ('Sclc', 'no label'), ('Stepwise (Score 0\u2009=\u20090%', 'no label'), ('Area', 'no label'), ('Receiver Operating Curve', 'no label'), ('Ci', 'no label'), ('Delta-P Cancer', 'no label'), ('Prediction Score', 'no label'), ('Calculated', 'no label'), ('Time', 'no label'), ('Lems Diagnosis', 'no label'), ('Effective Tool For Cancer', 'no label'), ('Screening', 'no label'), ('Independent, Prospective Study Setting', 'no label')]|[('Sclc-Lems', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Tumour', 'no label'), ('Lung Cancer', 'no label'), ('Weight Loss', 'no label'), ('Lung Cancer', 'no label'), ('Cancer', 'no label'), ('Cancer', 'no label')]|[('Tumour', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Lung Cancer', 'no label'), ('Patients', 'no label'), ('Tobacco', 'no label'), ('Lems', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Lems Patients', 'no label'), ('Sclc-Lems Patients', 'no label'), ('Ci 3', 'no label'), ('Ci 1', 'no label'), ('Delta-P Cancer', 'no label'), ('Lems', 'no label'), ('Cancer', 'no label')]
lambert eaton syndrome|pubmed~24704152|Lambert-Eaton Myasthenic Syndrome Is A Paraneoplastic Phenomenon Associated With Neuroendocrine Tumours, Most Frequently Small Cell Lung Carcinoma. Merkel Cell Carcinoma Is A Rare Cause Of Lambert-Eaton Myasthenic Syndrome. A 70-Year Old Gentleman Was Referred With Metastatic Axillary Nodal Disease From A Previously Resected Merkel Cell Carcinoma Of The Left Arm. Pre-Operatively, The Patient Was Wheelchair-Bound From Lambert-Eaton Myasthenic Syndrome. Level I-Iii Left Axillary Node Clearance Was Performed And Within 6 Months, He Had Experienced Full Recovery Of Muscle Power And Mobility. We Describe A Case Of Complete Cure Of Lambert-Eaton Myasthenic Syndrome Following Axillary Nodal Clearance In A Patient With Metastatic Merkel Cell Carcinoma. |[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Paraneoplastic Phenomenon', 'no label'), ('Associated With', 'no label'), ('Neuroendocrine Tumours', 'no label'), ('Small Cell', 'no label'), ('Lung Carcinoma', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Rare', 'no label'), ('Cause', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('70-Year Old Gentleman', 'no label'), ('Referred', 'no label'), ('Metastatic Axillary Nodal Disease', 'no label'), ('Resected', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Left Arm', 'no label'), ('Patient', 'no label'), ('Wheelchair-Bound', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Left Axillary Node', 'no label'), ('Clearance', 'no label'), ('Performed', 'no label'), ('Months', 'no label'), ('Experienced', 'no label'), ('Recovery', 'no label'), ('Muscle Power', 'no label'), ('Mobility', 'no label'), ('Complete Cure', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Axillary', 'no label'), ('Nodal', 'no label'), ('Clearance', 'no label'), ('Patient', 'no label'), ('Metastatic Merkel Cell Carcinoma', 'no label')]|[('Cell', 'no label'), ('Cell', 'no label'), ('Cell', 'no label'), ('Cell', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Paraneoplastic', 'no label'), ('Neuroendocrine Tumours', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Merkel Cell Carcinoma', 'no label')]|[('Neuroendocrine Tumours', 'no label'), ('Small Cell Lung Carcinoma.', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Axillary Nodal', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Left Arm', 'no label'), ('Patient', 'no label'), ('Muscle', 'no label'), ('A Case', 'no label'), ('Axillary Nodal', 'no label'), ('Metastatic Merkel Cell Carcinoma', 'no label')]
lambert eaton syndrome|pubmed~30080186|A 46-Year-Old Woman Suffering From Lower Extremity Weakness, Dysarthria, Dysphagia, Dyspnea, And Dry Mouth Was Suspected Of Having Lambert-Eaton Myasthenic Syndrome Based On The Characteristic Electromyographic Abnormalities Of Right Ulnar Nerve, Which Demonstrated Reduced Resting Compound Muscle Action Potential Amplitude And Greater Than 100% Incremental Change In High-Frequency Repetitive Nerve Stimulation. An F-Fdg Pet/Ct Was Performed To Detect The Underlying Neoplasm And Revealed A Retroperitoneal Soft Tissue Mass With High F-Fdg Avidity In The Left Iliac Fossa. The Patient'S Symptoms Were Prominently Relieved After The Tumor Resection, And The Histopathology Indicated A Small Cell Carcinoma.|"[('46-Year-Old Woman', 'no label'), ('Suffering', 'no label'), ('Lower Extremity Weakness', 'no label'), ('Dysarthria', 'no label'), ('Dysphagia', 'no label'), ('Dyspnea', 'no label'), ('Dry Mouth', 'no label'), ('Suspected', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Characteristic Electromyographic Abnormalities', 'no label'), ('Right Ulnar Nerve', 'no label'), ('Reduced', 'no label'), ('Compound Muscle', 'no label'), ('Amplitude', 'no label'), ('Incremental Change', 'no label'), ('High-Frequency', 'no label'), ('Repetitive Nerve', 'no label'), ('Stimulation', 'no label'), ('F-Fdg', 'no label'), ('Performed', 'no label'), ('Detect', 'no label'), ('Neoplasm', 'no label'), ('Revealed', 'no label'), ('Retroperitoneal', 'no label'), ('Soft Tissue', 'no label'), ('Mass', 'no label'), ('High', 'no label'), ('F-Fdg', 'no label'), ('Avidity', 'no label'), ('Left Iliac Fossa', 'no label'), (""Patient'S"", 'no label'), ('Symptoms', 'no label'), ('Prominently', 'no label'), ('Tumor Resection', 'no label'), ('Histopathology', 'no label'), ('Small Cell Carcinoma', 'no label')]"|[('Cell', 'no label')]|[('F-Fdg', 'no label'), ('F-Fdg', 'no label')]|[('Lower Extremity Weakness', 'no label'), ('Dysarthria', 'no label'), ('Dysphagia', 'no label'), ('Dyspnea', 'no label'), ('Dry Mouth', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Right Ulnar Nerve', 'no label'), ('Neoplasm', 'no label'), ('Tumor', 'no label'), ('Carcinoma', 'no label')]|[('Right Ulnar Nerve', 'no label'), ('Nerve', 'no label'), ('Neoplasm', 'no label'), ('Retroperitoneal Soft Tissue', 'no label'), ('High F-Fdg Avidity', 'no label'), ('Left Iliac', 'no label'), ('Patient', 'no label'), ('Prominently', 'no label'), ('Tumor', 'no label'), ('A Small Cell Carcinoma', 'no label')]
lambert eaton syndrome|pubmed~31735997||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~34707051|We Herein Report A 74-Year-Old Man Who Developed Lambert-Eaton Myasthenic Syndrome (Lems) During Atezolizumab Treatment For Extensive-Stage Small-Cell Lung Cancer. He Was Started On Maintenance Immunotherapy With Atezolizumab Every Three Weeks After Four Cycles Of Atezolizumab Plus Carboplatin Plus Etoposide Combination Therapy. After 13 Cycles Of Maintenance Atezolizumab Therapy, He Complained Of Muscular Weakness And Fatigue. Findings From A Nerve Conduction Study And Positive Findings For Anti-P/Q-Type Voltage-Gated Calcium Channel Antibody Resulted In A Diagnosis Of Lems. This Was A Rare Case Of Lems As A Neurological Immune-Related Adverse Event Induced By Atezolizumab Therapy.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Atezolizumab Treatment', 'no label'), ('Extensive-Stage Small-Cell Lung Cancer', 'no label'), ('Maintenance', 'no label'), ('Immunotherapy', 'no label'), ('Atezolizumab', 'no label'), ('Weeks', 'no label'), ('Cycles', 'no label'), ('Atezolizumab Plus Carboplatin Plus', 'no label'), ('Etoposide', 'no label'), ('Combination Therapy', 'no label'), ('Cycles', 'no label'), ('Maintenance', 'no label'), ('Atezolizumab Therapy', 'no label'), ('Muscular Weakness', 'no label'), ('Fatigue', 'no label'), ('Findings', 'no label'), ('Nerve Conduction Study', 'no label'), ('Positive Findings', 'no label'), ('Voltage-Gated Calcium Channel', 'no label'), ('Antibody', 'no label'), ('Resulted', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Case', 'no label'), ('Neurological Immune-Related Adverse Event', 'no label'), ('Induced', 'no label'), ('Atezolizumab Therapy', 'no label')]|[('Carboplatin', 'no label'), ('Calcium', 'no label'), ('Antibody', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Lung Cancer', 'no label'), ('Carboplatin', 'no label'), ('Etoposide', 'no label'), ('Muscular Weakness', 'no label'), ('Fatigue', 'no label'), ('Calcium', 'no label')]|[('Extensive-Stage Small-Cell Lung Cancer', 'no label'), ('Carboplatin', 'no label'), ('Etoposide', 'no label'), ('Muscular Weakness', 'no label'), ('Calcium', 'no label'), ('A Rare Case', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~24929678|Antibodies (Abs) To The Gabab Receptor Have Been Recently Found To Be Responsible For Immune-Mediated Encephalitis With Dominant Seizures. They Are In Approximately 50% Of Cases Associated With Small-Cell Lung Cancer (Sclc). Gabab Receptors Are Mainly Located In The Hippocampus, Thalamus And Cerebellum In The Presynaptic And Postsynaptic Regions Of Synapses. The Main Function Of These Receptors Is To Reduce Activity States Of Neurons. In Some Instances, Gabab Receptor Abs In These Patients Were Accompanied By Other Antibodies, Among Them Vgcc Abs (Lancaster Et Al., 2010, Boronat Et Al., 2011). Vgcc Abs Cause Paraneoplastic Lambert Eaton Myasthenic Syndrome (Lems) By Reduction Of Presynaptic Vgccs (Titulaer Et Al., 2011). In The Domain Of Cns Disease, Vgcc Abs Have Been Found In Association With Paraneoplastic Cerebellar Ataxia (Mason Et Al., 1997) And Rarely And At Low Titres Also In Other Paraneoplastic Encephalopathies Together With Hu Abs (Lennon Et Al., 1995). It Has Been A Long-Standing Debate If Abs In Paraneoplastic Conditions Associate Rather With The Neurological Syndrome Or The Tumour. Here, We Describe The Conjoint Occurrence Of Abs To The Gabab Receptor And To The Vgcc In A Patient With Sclc Presenting Only Symptoms Of The Peripheral Nervous System Giving Another Example Of The Latter Hypothesis.|[('Antibodies', 'no label'), ('Abs', 'no label'), ('Gabab Receptor', 'no label'), ('Immune-Mediated Encephalitis', 'no label'), ('Dominant Seizures', 'no label'), ('Cases', 'no label'), ('Associated With', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Gabab Receptors', 'no label'), ('Hippocampus', 'no label'), ('Thalamus', 'no label'), ('Cerebellum', 'no label'), ('Presynaptic', 'no label'), ('Postsynaptic Regions', 'no label'), ('Synapses', 'no label'), ('Main Function', 'no label'), ('Receptors', 'no label'), ('Reduce', 'no label'), ('Activity States', 'no label'), ('Neurons', 'no label'), ('Instances', 'no label'), ('Gabab Receptor Abs', 'no label'), ('Patients', 'no label'), ('Antibodies', 'no label'), ('Vgcc Abs', 'no label'), ('Lancaster Et Al', 'no label'), ('Boronat Et Al', 'no label'), ('Vgcc', 'no label'), ('Abs', 'no label'), ('Paraneoplastic Lambert Eaton Myasthenic Syndrome', 'no label'), ('Reduction', 'no label'), ('Presynaptic Vgccs', 'no label'), ('Titulaer Et Al', 'no label'), ('Domain', 'no label'), ('Cns Disease', 'no label'), ('Vgcc', 'no label'), ('Abs', 'no label'), ('Association', 'no label'), ('Paraneoplastic Cerebellar Ataxia', 'no label'), ('Mason Et Al', 'no label'), ('Rarely', 'no label'), ('Low', 'no label'), ('Titres', 'no label'), ('Paraneoplastic Encephalopathies', 'no label'), ('Hu Abs', 'no label'), ('Lennon Et Al', 'no label'), ('Long-Standing Debate', 'no label'), ('Abs', 'no label'), ('Paraneoplastic Conditions Associate', 'no label'), ('Neurological Syndrome', 'no label'), ('Tumour', 'no label'), ('Conjoint', 'no label'), ('Occurrence', 'no label'), ('Abs', 'no label'), ('Gabab Receptor', 'no label'), ('Vgcc', 'no label'), ('Patient', 'no label'), ('Sclc', 'no label'), ('Presenting', 'no label'), ('Symptoms', 'no label'), ('Peripheral Nervous System', 'no label'), ('Latter Hypothesis', 'no label')]|[('Antibodies', 'no label'), ('Neurons', 'no label'), ('Antibodies', 'no label'), ('Domain', 'no label'), ('Abs', 'no label')]|[('Gabab Receptors', 'no label'), ('Presynaptic And Postsynaptic Regions', 'no label'), ('Gabab Receptor Abs', 'no label'), ('Them Vgcc Abs', 'no label'), ('Hu Abs', 'no label'), ('Abs', 'no label')]|[('Encephalitis', 'no label'), ('Dominant Seizures', 'no label'), ('Lung Cancer', 'no label'), ('Boronat Et Al', 'no label'), ('Lambert Eaton Myasthenic Syndrome', 'no label'), ('Paraneoplastic Cerebellar Ataxia', 'no label'), ('Mason Et Al', 'no label'), ('Paraneoplastic Encephalopathies', 'no label'), ('Neurological Syndrome', 'no label'), ('Tumour', 'no label')]|[('Gabab Receptor', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Thalamus', 'no label'), ('Cerebellum', 'no label'), ('Presynaptic', 'no label'), ('Postsynaptic', 'no label'), ('Synapses', 'no label'), ('Neurons', 'no label'), ('Gabab Receptor Abs', 'no label'), ('Patients', 'no label'), ('Vgcc', 'no label'), ('Al', 'no label'), ('Boronat Et Al', 'no label'), ('Presynaptic Vgccs', 'no label'), ('Al', 'no label'), ('Cns Disease', 'no label'), ('Vgcc Abs', 'no label'), ('Paraneoplastic Cerebellar Ataxia', 'no label'), ('Al', 'no label'), ('Hu Abs', 'no label'), ('Lennon Et', 'no label'), ('Al', 'no label'), ('Tumour', 'no label'), ('Gabab Receptor', 'no label'), ('Vgcc', 'no label'), ('Peripheral Nervous System', 'no label')]
lambert eaton syndrome|pubmed~34605270|We Report A Very Rare Case Of Ct1N0M0 Lung Adenocarcinoma Reveling Lambert-Eaton Myasthenic Syndrome (Lems). A 69-Year-Old Nonsmoking Woman, With Several Comorbidities Consulted For Cough And Dyspnea. Chest Radiograph And Ct Scanning Detected A Left Lower Lobe Mass; Needle Biopsy Confirmed Differentiated Adenocarcinoma; 18Fdg-Pet Scan And Brain Mri Eliminated Metastatic Disease Dissemination. Our Patient Underwent A Left Lower Lobectomy With Mediastinal Lymphadenectomy (Pt1N0M0), No Adjuvant Chemotherapy Was Administrated. One Month Later Patient Present A Muscle Weakness In Both Lower Limbs And Fatigability Followed By An Inability To Walk. The Diagnosis Of Lems Was Made From The Distinctive Electromyogram (Emg) Findings And A Treatment With Amifampridine (3, 4-Diaminopyridine Phosphate [3, 4-Dap]) Was Prescribed With Evident Efficacy For Symptoms.|[('Report', 'no label'), ('Case', 'no label'), ('Ct1N0M0', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Reveling Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('69-Year-Old Nonsmoking', 'no label'), ('Comorbidities Consulted', 'no label'), ('Detected', 'no label'), ('Left Lower Lobe Mass', 'no label'), ('Needle Biopsy', 'no label'), ('Differentiated Adenocarcinoma', 'no label'), ('Scan', 'no label'), ('Brain', 'no label'), ('Metastatic Disease', 'no label'), ('Dissemination', 'no label'), ('Patient', 'no label'), ('Left Lower Lobectomy', 'no label'), ('Mediastinal Lymphadenectomy', 'no label'), ('Pt1N0M0', 'no label'), ('Adjuvant Chemotherapy', 'no label'), ('Administrated', 'no label'), ('Month', 'no label'), ('Patient', 'no label'), ('Present', 'no label'), ('Muscle Weakness', 'no label'), ('Lower Limbs', 'no label'), ('Fatigability', 'no label'), ('Walk', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Distinctive Electromyogram', 'no label'), ('Emg', 'no label'), ('Findings', 'no label'), ('Treatment', 'no label'), ('Amifampridine', 'no label'), ('4-Diaminopyridine', 'no label'), ('Phosphate', 'no label'), ('4-Dap])', 'no label'), ('Prescribed', 'no label'), ('Efficacy', 'no label'), ('Symptoms', 'no label')]|[('Pt1N0M0', 'no label'), ('Amifampridine', 'no label'), ('Phosphate', 'no label')]|[]|[('Ct1N0M0 Lung Adenocarcinoma Reveling Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Cough', 'no label'), ('Dyspnea', 'no label'), ('Chest', 'no label'), ('Differentiated Adenocarcinoma', 'no label'), ('Muscle Weakness', 'no label'), ('Amifampridine', 'no label'), ('3, 4-Diaminopyridine Phosphate', 'no label')]|[('Lung Adenocarcinoma', 'no label'), ('Needle Biopsy Confirmed Differentiated Adenocarcinoma; 18Fdg-Pet', 'no label'), ('Brain', 'no label'), ('Patient', 'no label'), ('Mediastinal Lymphadenectomy', 'no label'), ('Muscle', 'no label'), ('Lower Limbs', 'no label'), ('Lems', 'no label'), ('Electromyogram', 'no label'), ('Amifampridine (3,', 'no label'), ('4-Diaminopyridine Phosphate [3', 'no label')]
lambert eaton syndrome|pubmed~34661104|Lambert-Eaton Syndrome Is A Rare Paraneoplastic Disorder Of The Neuromuscular Junction, Characterized By Impaired Release Of Acetylcholine, Which Causes Proximal Muscle Weakness, Depressed Tendon Reflexes, And Autonomic Changes. Most Cases Of Lambert-Eaton Syndrome Present In Small-Cell Lung Carcinoma, And Only A Few Cases Have Been Reported In Other Lung Subtypes. Herein, We Report A Case Of 69 Years Old Male Patient With Lambert-Eaton Syndrome As A Rare Association With A Pulmonary Large-Cell Neuroendocrine Carcinoma, Which Presented 5 Months Before Neoplasm Diagnosis. A Lobectomy Was Auspiciously Performed. A Review Of The Literature Is Also Presented.|[('Lambert-Eaton Syndrome', 'no label'), ('Rare', 'no label'), ('Paraneoplastic Disorder', 'no label'), ('Neuromuscular Junction', 'no label'), ('Characterized', 'no label'), ('Impaired', 'no label'), ('Release', 'no label'), ('Acetylcholine', 'no label'), ('Causes', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Depressed Tendon Reflexes', 'no label'), ('Autonomic Changes', 'no label'), ('Cases', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Present', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Cases', 'no label'), ('Lung', 'no label'), ('Subtypes', 'no label'), ('Report', 'no label'), ('Male', 'no label'), ('Patient', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Rare', 'no label'), ('Pulmonary Large-Cell', 'no label'), ('Neuroendocrine Carcinoma', 'no label'), ('Months', 'no label'), ('Neoplasm Diagnosis', 'no label'), ('Lobectomy', 'no label'), ('Review', 'no label'), ('Literature', 'no label')]|[]|[]|[('Paraneoplastic Disorder', 'no label'), ('Acetylcholine', 'no label'), ('Muscle Weakness', 'no label'), ('Depressed', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Lung Carcinoma', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Pulmonary Large-Cell Neuroendocrine Carcinoma', 'no label'), ('Neoplasm', 'no label')]|[('Neuromuscular', 'no label'), ('Acetylcholine', 'no label'), ('Muscle', 'no label'), ('Tendon', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Lung', 'no label'), ('Patient', 'no label'), ('Pulmonary Large-Cell Neuroendocrine Carcinoma', 'no label'), ('Neoplasm', 'no label')]
lambert eaton syndrome|pubmed~24138947|Lambert-Eaton Myasthenic Syndrome, A Presynaptic Neuromuscular Junction Autoimmune Disorder, Rarely Occurs In Children. Patients Typically Present With Proximal Lower Extremity Weakness With Areflexia. We Report Three Children Presenting Between Ages 9 And 10 Years Diagnosed With Lambert-Eaton Myasthenic Syndrome 2 Years, 1 Year, And 5 Months Later, Respectively. Their Clinical Attributes Are Correlated With Nine Other Pediatric Lambert-Eaton Myasthenic Syndrome Patients Found In Our Literature Review. These Patients Were Identified As Having Lambert-Eaton Myasthenic Syndrome During Their Evaluation For Proximal Weakness. Low-Amplitude Compound Muscle Action Potentials Classically Facilitating >100% With Voluntary Exercise And/Or 50 Hz Stimulation Were Essential To Diagnosis. Three Of The 12 Children Had Associated Malignancies, Two Of Them Had Lymphoproliferative Disorders With Onset Of Symptoms More Rapid Than The Rest, And The Third Had Neuroblastoma. The Nine Nonparaneoplastic Lambert-Eaton Myasthenic Syndrome Patients Responded To Immunomodulatory Therapy With Close Return To Their Baseline Function. Complete Remission No Longer Necessitating Medication Was Reported In Two Patients. Follow-Up Up To 17 Years Was Available On Two Patients Previously Reported. Lambert-Eaton Myasthenic Syndrome Is A Diagnosis That Must Be Considered In Children Presenting With Unidentified Proximal Muscle Weakness. In Most Children, Lambert-Eaton Myasthenic Syndrome Is A Primary Autoimmune Disorder That Is Treatable. Nevertheless, A Search For Malignancy Is Recommended.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular Junction', 'no label'), ('Autoimmune Disorder', 'no label'), ('Occurs', 'no label'), ('Children', 'no label'), ('Patients', 'no label'), ('Proximal Lower Extremity Weakness', 'no label'), ('Areflexia', 'no label'), ('Children', 'no label'), ('Presenting', 'no label'), ('Ages', 'no label'), ('Years', 'no label'), ('Diagnosed', 'no label'), ('Lambert-Eaton Myasthenic Syndrome 2 Years', 'no label'), ('Year', 'no label'), ('Months', 'no label'), ('Clinical Attributes', 'no label'), ('Correlated', 'no label'), ('Pediatric', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Patients', 'no label'), ('Literature Review', 'no label'), ('Patients', 'no label'), ('Identified', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Evaluation', 'no label'), ('Proximal Weakness', 'no label'), ('Low-Amplitude Compound Muscle', 'no label'), ('Action Potentials', 'no label'), ('Voluntary Exercise And/Or 50 Hz Stimulation', 'no label'), ('Diagnosis', 'no label'), ('Children', 'no label'), ('Malignancies', 'no label'), ('Lymphoproliferative Disorders', 'no label'), ('Symptoms', 'no label'), ('Rest', 'no label'), ('Neuroblastoma', 'no label'), ('Nonparaneoplastic Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Patients', 'no label'), ('Immunomodulatory Therapy', 'no label'), ('Return To', 'no label'), ('Baseline Function', 'no label'), ('Remission', 'no label'), ('Longer Necessitating', 'no label'), ('Medication', 'no label'), ('Patients', 'no label'), ('Follow-Up', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Diagnosis', 'no label'), ('Children', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Children', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Primary Autoimmune Disorder', 'no label'), ('Treatable', 'no label'), ('Malignancy', 'no label'), ('Recommended', 'no label')]|[]|[]|[('Myasthenic Syndrome', 'no label'), ('Neuromuscular Junction Autoimmune Disorder', 'no label'), ('Lower Extremity Weakness', 'no label'), ('Areflexia', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Weakness', 'no label'), ('And/Or', 'no label'), ('Malignancies', 'no label'), ('Lymphoproliferative Disorders', 'no label'), ('Neuroblastoma', 'no label'), ('Nonparaneoplastic Lambert-Eaton', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Muscle Weakness', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Malignancy', 'no label')]|[('Children', 'no label'), ('Patients', 'no label'), ('Children', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Voluntary Exercise And/Or', 'no label'), ('Children', 'no label'), ('Malignancies', 'no label'), ('Neuroblastoma', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Children', 'no label'), ('Muscle', 'no label'), ('Children', 'no label')]
lambert eaton syndrome|pubmed~24259319|All Descriptions Of The Lambert-Eaton Syndrome Are Based On Symptomatic Patients. We Incidentally Encountered Electromyographic Evidence Of This Syndrome In A Patient Being Studied For Another Reason. The Patient Had Controlled Hypothyroidism And Smoked For 9 Pack-Years But Never Had Symptoms Of Weakness Or Had Evidence Of Cancer. Detailed Electrophysiological And Serological Evaluations Were Undertaken In This Study. Neuromuscular Transmission Tests Were Consistent With A Presynaptic Disorder. Autoantibodies Specific For P/Q-Type Voltage-Gated Calcium Channels (Vgcc) Were Detected In The Serum And Persisted Throughout 7 Years Of Follow-Up. Multiple Igg Markers Of Thyrogastric Autoimmunity Also Were Detected. This Demonstration Of Asymptomatic Lambert-Eaton Syndrome Persisting For 8 Years Provided Novel Insight Into The Natural History Of The Disorder. It Is Plausible That Patients With A Subclinical Syndrome Would Have Abrupt Neuromuscular Decompensation When Challenged With Medications That Compromise The Safety Factor For Synaptic Transmission.|[('Descriptions', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Symptomatic', 'no label'), ('Patients', 'no label'), ('Encountered', 'no label'), ('Electromyographic Evidence', 'no label'), ('Syndrome', 'no label'), ('Patient Being', 'no label'), ('Studied', 'no label'), ('Reason', 'no label'), ('Patient', 'no label'), ('Controlled Hypothyroidism', 'no label'), ('Smoked', 'no label'), ('Pack-Years', 'no label'), ('Never', 'no label'), ('Symptoms', 'no label'), ('Weakness', 'no label'), ('Evidence', 'no label'), ('Cancer', 'no label'), ('Electrophysiological', 'no label'), ('Serological Evaluations', 'no label'), ('Study', 'no label'), ('Neuromuscular Transmission Tests', 'no label'), ('Consistent With', 'no label'), ('Presynaptic Disorder', 'no label'), ('Autoantibodies', 'no label'), ('P/Q-Type Voltage-Gated Calcium Channels', 'no label'), ('Vgcc', 'no label'), ('Detected', 'no label'), ('Serum', 'no label'), ('Persisted', 'no label'), ('Years', 'no label'), ('Follow-Up', 'no label'), ('Multiple', 'no label'), ('Igg', 'no label'), ('Markers', 'no label'), ('Thyrogastric Autoimmunity', 'no label'), ('Detected', 'no label'), ('Demonstration', 'no label'), ('Asymptomatic', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Persisting', 'no label'), ('Years', 'no label'), ('Natural History', 'no label'), ('Disorder', 'no label'), ('Patients', 'no label'), ('Subclinical Syndrome', 'no label'), ('Abrupt', 'no label'), ('Neuromuscular Decompensation', 'no label'), ('Challenged', 'no label'), ('Medications', 'no label'), ('Compromise The Safety Factor', 'no label'), ('Synaptic Transmission', 'no label')]|[('P/Q-Type', 'no label'), ('Calcium', 'no label')]|[]|[('Hypothyroidism', 'no label'), ('Weakness', 'no label'), ('Cancer', 'no label'), ('Disorder', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Thyrogastric Autoimmunity', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Disorder', 'no label'), ('Syndrome', 'no label'), ('Neuromuscular Decompensation', 'no label')]|[('Patients', 'no label'), ('Patient', 'no label'), ('Cancer', 'no label'), ('Presynaptic', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Serum', 'no label'), ('Thyrogastric', 'no label'), ('Patients', 'no label'), ('Neuromuscular', 'no label'), ('Synaptic', 'no label')]
lambert eaton syndrome|pubmed~29189551|To Reappraise The Distinguishing Features Of The Repetitive Nerve Stimulation (Rns) Tests In The Abductor Digiti Quinti Muscle Between Myasthenia Gravis (Mg) And Lambert-Eaton Myasthenic Syndrome (Lems) 50 Years After The 1965'S Lambert Seminal Paper. The Various Parameters Of The Rns Test Were Compared Between 34 Patients With Lems And 140 Patients With Mg To Assess Their Diagnostic Sensitivity. Rns Test Was Abnormal In All (100%) Patients With Lems And 76 (54%) Patients With Mg. The Diagnostic Hallmark Of Lems, ≥60% Increment At High-Rate Stimulation Or Postexercise Facilitation, Was Present In 33 (97%) Of Patients. The Diagnostic Hallmark Of Mg, Decrement At Low-Rate Stimulation (Lrs), Was Present In 65 (46%) Of Patients With Mg. The Most Prominent Difference In The Various Parameters Of Rns Tests Was Noted Between Lems Versus Mg And Normal Controls. Distinguishing Features Of The Rns Test In Lems And Mg Are Confirmed In This Direct Comparison Study: The Low Compound Muscle Action Potential Amplitude, Decrement At Lrs, And Increment At High-Rate Stimulation Or Postexercise Facilitation For Lems And Normal Compound Muscle Action Potential Amplitude And Decrement At Lrs For Mg.|[('Reappraise', 'no label'), ('Features', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Abductor Digiti', 'no label'), ('Quinti Muscle', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Years', 'no label'), ('Lambert Seminal Paper', 'no label'), ('Parameters', 'no label'), ('Rns Test', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Assess', 'no label'), ('Diagnostic Sensitivity', 'no label'), ('Abnormal', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Diagnostic Hallmark', 'no label'), ('Lems', 'no label'), ('Increment', 'no label'), ('High-Rate Stimulation', 'no label'), ('Postexercise Facilitation', 'no label'), ('Patients', 'no label'), ('Diagnostic Hallmark', 'no label'), ('Mg', 'no label'), ('Decrement', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Parameters', 'no label'), ('Rns Tests', 'no label'), ('Noted', 'no label'), ('Lems', 'no label'), ('Mg', 'no label'), ('Normal Controls', 'no label'), ('Features', 'no label'), ('Rns Test', 'no label'), ('Confirmed', 'no label'), ('Compound Muscle', 'no label'), ('Amplitude', 'no label'), ('Decrement', 'no label'), ('Increment', 'no label'), ('High-Rate Stimulation', 'no label'), ('Postexercise Facilitation', 'no label'), ('Lems', 'no label'), ('Compound Muscle', 'no label'), ('Action Potential Amplitude And Decrement', 'no label'), ('Mg', 'no label')]|[('Rns', 'no label')]|[('Rns Tests', 'no label')]|[('Abductor Digiti Quinti Muscle Between Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label')]|[('Nerve', 'no label'), ('Abductor Digiti', 'no label'), ('Muscle', 'no label'), ('Lambert Seminal', 'no label'), ('Rns Test', 'no label'), ('Patients', 'no label'), ('Lems And', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('High-Rate', 'no label'), ('Postexercise', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Rns Tests', 'no label'), ('Lems', 'no label'), ('Mg', 'no label'), ('Rns Test', 'no label'), ('Lems', 'no label'), ('Mg', 'no label'), ('High-Rate', 'no label'), ('Postexercise', 'no label'), ('Lems', 'no label'), ('Mg', 'no label')]
lambert eaton syndrome|pubmed~29191521|Pharmaceutical Compounding Preparations, Produced By (Hospital) Pharmacies, Usually Do Not Have Marketing Authorization. As A Consequence, Some Of These Pharmaceutical Compounding Preparations Can Be Picked-Up By A Pharmaceutical Company To Obtain Marketing Authorization, Often Leading To Price Increases. An Example Is The 3,4-Diaminopyridine Slow Release (3,4-Dap Sr) Tablets For Lambert-Eaton Myasthenic Syndrome (Lems). In 2009 Marketing Authorization Was Given For The Commercial Immediate Release Phosphate Salt Of The Drug, Including A Fifty-Fold Price Increase Compared To The Pharmaceutical Compounding Preparation. Obtaining Marketing Authorization For 3,4-Dap Sr By Academia Might Have Been A Solution To Prevent This Price Increase. To Determine Whether The Available Data Of A Pharmaceutical Compounding Preparation With Long-Term Experience In Regular Care Are Adequate To Obtain Marketing Authorization, 3,4-Dap Sr Is Used As A Case Study. A Retrospective Qualitative Case-Study Was Performed. Initially, Document Analysis Was Executed By Collecting The Required Data For Marketing Authorization In General And Whether Data Of Firdapse® And 3,4-Dap Sr Met These Requirements. Secondly, The (Non-) Available Data Of The Two Formulations Were Compared With Each Other To Determine The Differences In Availability. At The Time Of Approval, Almost All Data Were Available For Both Firdapse® And 3,4-Dap Sr. Conversely, Much Of The Data Used For The Approval Of Firdapse® Originated From The 3,4-Dap Immediate Release (3,4-Dap Ir) Formulation. Only Two Bioequivalence Studies And One Pharmacology Safety Study Was Performed With Firdapse® Before Marketing Authorization Application. In Conclusion, At Time Firdapse® Obtained Approval, The Data Available Did Not Differ Substantially From 3,4-Dap Sr, Indicating That Approval With 3,4-Dap Sr Would Have Been Possible. We Make A Plea For Approval Of Orphan Medicinal Products Developed And Manufactured By Academic Institutions As To Keep Utilization Of These Products Affordable.|[('Pharmaceutical', 'no label'), ('Preparations', 'no label'), ('Hospital', 'no label'), ('Pharmacies', 'no label'), ('Marketing Authorization', 'no label'), ('Consequence', 'no label'), ('Pharmaceutical Compounding Preparations', 'no label'), ('Picked-Up', 'no label'), ('Pharmaceutical Company', 'no label'), ('Marketing Authorization', 'no label'), ('Price', 'no label'), ('Increases', 'no label'), ('3,4-Diaminopyridine Slow Release', 'no label'), ('Tablets', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Marketing Authorization', 'no label'), ('Commercial', 'no label'), ('Immediate Release', 'no label'), ('Phosphate Salt', 'no label'), ('Drug', 'no label'), ('Fifty-Fold Price', 'no label'), ('Increase', 'no label'), ('Pharmaceutical', 'no label'), ('Preparation', 'no label'), ('Marketing Authorization', 'no label'), ('Solution', 'no label'), ('Prevent', 'no label'), ('Price', 'no label'), ('Increase', 'no label'), ('Available Data', 'no label'), ('Pharmaceutical', 'no label'), ('Preparation', 'no label'), ('Long-Term', 'no label'), ('Experience', 'no label'), ('Regular Care', 'no label'), ('Adequate', 'no label'), ('Marketing Authorization', 'no label'), ('Sr', 'no label'), ('Case Study', 'no label'), ('Retrospective', 'no label'), ('Document Analysis', 'no label'), ('Data', 'no label'), ('Marketing Authorization', 'no label'), ('General', 'no label'), ('Data', 'no label'), ('Firdapse® And 3,4-Dap Sr Met', 'no label'), ('Requirements', 'no label'), ('Data', 'no label'), ('Formulations', 'no label'), ('Differences', 'no label'), ('Availability', 'no label'), ('Time', 'no label'), ('Approval', 'no label'), ('Data', 'no label'), ('Firdapse', 'no label'), ('Data', 'no label'), ('Approval', 'no label'), ('Firdapse® Originated', 'no label'), ('Immediate Release', 'no label'), ('Formulation', 'no label'), ('Bioequivalence Studies', 'no label'), ('Pharmacology Safety Study', 'no label'), ('Performed', 'no label'), ('Firdapse® Before Marketing Authorization Application', 'no label'), ('Time Firdapse® Obtained Approval', 'no label'), ('Data Available', 'no label'), ('Differ', 'no label'), ('Sr', 'no label'), ('Indicating', 'no label'), ('Approval', 'no label'), ('Sr', 'no label'), ('Approval', 'no label'), ('Medicinal Products', 'no label'), ('Developed', 'no label'), ('Manufactured', 'no label'), ('Academic Institutions', 'no label'), ('Utilization', 'no label'), ('Products Affordable', 'no label')]|[('Phosphate Salt', 'no label'), ('Drug', 'no label')]|[('3,4-Dap Sr) Tablets For', 'no label'), ('3,4-Dap Immediate Release', 'no label')]|[('Price', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Sr', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Phosphate', 'no label'), ('Price', 'no label'), ('Sr', 'no label'), ('Price', 'no label'), ('Sr', 'no label'), ('®', 'no label'), ('Sr', 'no label'), ('®', 'no label'), ('Originated', 'no label'), ('Sr', 'no label'), ('Sr', 'no label')]|[('Preparations', 'no label'), ('Preparations', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Tablets', 'no label'), ('Salt', 'no label'), ('Regular Care', 'no label'), ('Sr', 'no label'), ('A Case', 'no label'), ('Formulations', 'no label'), ('Sr', 'no label'), ('Sr', 'no label'), ('Products', 'no label')]
lambert eaton syndrome|pubmed~27922503|This Article Discusses The Pathogenesis, Diagnosis, And Management Of Autoimmune Myasthenia Gravis (Mg) And Lambert-Eaton Myasthenic Syndrome (Lems). Recognition Of New Antigenic Targets And Improved Diagnostic Methods Promise To Improve The Diagnosis Of Mg, Although The Clinical Phenotypes Associated With Newer Antibodies Have Not Yet Been Defined. Future Therapies Might Specifically Target The Aberrant Immune Response. The Apparent Increase In The Prevalence Of Mg Is Not Fully Explained. Results Of A Long-Awaited Trial Of Thymectomy Support The Practice Of Performing A Thymectomy Under Specific Conditions. The Current Treatment Options Are So Effective In Most Patients With Mg Or Lems That In Patients With Refractory Disease The Diagnosis Should Be Reconsidered. The Management Of Mg Is Individualized, And Familiarity With Mechanisms, Adverse Effects, And Strategies To Manage These Commonly Used Treatments Improves Outcome. Patient Education Is Important. Lems, Frequently Associated With An Underlying Small Cell Lung Cancer, Is Uncommon, And The Mainstay Of Treatment Is Symptomatic In Most Patients.|[('Article', 'no label'), ('Discusses', 'no label'), ('Pathogenesis', 'no label'), ('Diagnosis', 'no label'), ('Management', 'no label'), ('Autoimmune Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Recognition', 'no label'), ('Antigenic', 'no label'), ('Targets', 'no label'), ('Diagnostic Methods', 'no label'), ('Diagnosis', 'no label'), ('Mg', 'no label'), ('Clinical Phenotypes', 'no label'), ('Associated With', 'no label'), ('Antibodies', 'no label'), ('Therapies', 'no label'), ('Target', 'no label'), ('Aberrant', 'no label'), ('Immune Response', 'no label'), ('Apparent Increase', 'no label'), ('Prevalence', 'no label'), ('Mg', 'no label'), ('Long-Awaited Trial', 'no label'), ('Thymectomy', 'no label'), ('Practice', 'no label'), ('Performing A', 'no label'), ('Thymectomy', 'no label'), ('Conditions', 'no label'), ('Current', 'no label'), ('Treatment Options', 'no label'), ('Effective', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Refractory Disease', 'no label'), ('Diagnosis', 'no label'), ('Management', 'no label'), ('Mg', 'no label'), ('Individualized', 'no label'), ('Familiarity', 'no label'), ('Mechanisms', 'no label'), ('Adverse Effects', 'no label'), ('Strategies', 'no label'), ('Manage', 'no label'), ('Treatments', 'no label'), ('Outcome', 'no label'), ('Patient Education', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Underlying Small Cell Lung Cancer', 'no label'), ('Uncommon', 'no label'), ('Mainstay', 'no label'), ('Treatment', 'no label'), ('Symptomatic', 'no label'), ('Patients', 'no label')]|[('Antibodies', 'no label'), ('Cell', 'no label')]|[]|[('Autoimmune Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Diagnosis', 'no label'), ('Mg', 'no label')]|[('Autoimmune Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Immune', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~25885033|Lambert-Eaton Myasthenic Syndrome Is A Rare Autoimmune Disorder Of Neuromuscular Transmission Due To The Presence Of Antibodies To Presynaptic P/Q-Type Voltage-Gated Calcium Channels. The Gold Standard Of Therapy Is The Potassium Channel Blocker 3,4-Diaminopyridine. To The Best Of Our Knowledge, No Clinical Reports Have Been Published To Date About Long-Term Follow-Up Outcomes In Patients Who Discontinued 3,4-Diaminopyridine Therapy. In Addition, We Know Of No Recent Articles In Which The Natural History In Patients With Autoimmune-Mediated Lambert-Eaton Myasthenic Syndrome Has Been Addressed. In This Report, We Describe The Cases Of Two Such Patients. Patient 1 Was A Caucasian Man Who Had Been Diagnosed At Age 15 Years With Lambert-Eaton Myasthenic Syndrome With Symptoms Of Fluctuating Muscle Weakness And Easy Fatigability. These Symptoms Stabilized, And His Electrophysiological Parameters Normalized, During Treatment With A Maintenance Dose Of 50Mg/Day Of 3,4-Diaminopyridine. After 5.5 Years, However, He Wished To Discontinue The Treatment. After That Point, His Electrophysiological Parameters And Presynaptic P/Q-Type Voltage-Gated Calcium-Channel Antibody Titer Remained Stable. During The 15-Year Follow-Up Period, Patient 1 Reported Mild Exertion-Induced Complaints But Did Not Feel Restricted In His Occupation And Most Daily Activities. Patient 2 Was A Caucasian Man Diagnosed At 32 Years Of Age With A Moderate Limb Girdle Syndrome. He Was Treated With Up To 80 Mg/Day Of 3,4-Diaminopyridine. Because Of The Drug'S Very Short-Lasting Effect (<1 Hour), However, He Took It Mostly Irregularly (≤ 1 × 20 Mg/Day). During The 14- Year Period Of Observation, His Repetitive Nerve Stimulation Responses And Presynaptic P/Q-Type Voltage-Gated Calcium-Channel Antibody Titer Remained Stable, His Compound Muscle Action Potential Amplitudes Were Decreasing And His Clinical Symptoms Did Not Deteriorate. At His Last Follow-Up Examination, Patient 2 Was Independent In All Of His Daily Activities. Some Patients With Autoimmune-Mediated Lambert-Eaton Myasthenic Syndrome Show A Stable Clinical Long-Term Course Without Treatment. The Benefit Of Each Long-Term Therapy Should Be Critically Assessed During Follow-Up, And Possible Side Effects Should Be Balanced Against The Quality Of Life In These Patients.|"[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Rare', 'no label'), ('Autoimmune Disorder', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Presence', 'no label'), ('Antibodies', 'no label'), ('Presynaptic P/Q-Type Voltage-Gated', 'no label'), ('Calcium Channels', 'no label'), ('Gold Standard', 'no label'), ('Therapy', 'no label'), ('Potassium Channel Blocker', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Knowledge', 'no label'), ('Clinical Reports', 'no label'), ('Published', 'no label'), ('Long-Term Follow-Up', 'no label'), ('Outcomes', 'no label'), ('Patients', 'no label'), ('Discontinued', 'no label'), ('3,4-Diaminopyridine Therapy', 'no label'), ('No Recent Articles', 'no label'), ('Natural History', 'no label'), ('Patients', 'no label'), ('Autoimmune-Mediated Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Report', 'no label'), ('Cases', 'no label'), ('Patients', 'no label'), ('Patient', 'no label'), ('Was A', 'no label'), ('Caucasian', 'no label'), ('Diagnosed', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Symptoms', 'no label'), ('Fluctuating Muscle Weakness', 'no label'), ('Easy Fatigability', 'no label'), ('Symptoms', 'no label'), ('Stabilized', 'no label'), ('Electrophysiological Parameters', 'no label'), ('Treatment', 'no label'), ('Maintenance', 'no label'), ('Dose', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Years', 'no label'), ('Discontinue', 'no label'), ('Treatment', 'no label'), ('Point', 'no label'), ('Electrophysiological Parameters', 'no label'), ('Presynaptic P/Q-Type Voltage-Gated Calcium-Channel Antibody', 'no label'), ('Remained', 'no label'), ('Stable', 'no label'), ('15-Year Follow-Up', 'no label'), ('Period', 'no label'), ('Patient', 'no label'), ('Mild Exertion-Induced', 'no label'), ('Complaints', 'no label'), ('Restricted', 'no label'), ('Occupation', 'no label'), ('Daily Activities', 'no label'), ('Patient 2', 'no label'), ('Caucasian', 'no label'), ('Diagnosed', 'no label'), ('Years', 'no label'), ('Age', 'no label'), ('Moderate Limb', 'no label'), ('Girdle Syndrome', 'no label'), ('Treated', 'no label'), ('Mg/Day', 'no label'), ('3,4-Diaminopyridine', 'no label'), (""Drug'S"", 'no label'), ('Short-Lasting', 'no label'), ('Effect', 'no label'), ('Hour', 'no label'), ('Year', 'no label'), ('Period', 'no label'), ('Observation', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Responses', 'no label'), ('Presynaptic P/Q-Type Voltage-Gated Calcium-Channel Antibody', 'no label'), ('Remained', 'no label'), ('Stable', 'no label'), ('Compound Muscle', 'no label'), ('Amplitudes', 'no label'), ('Decreasing', 'no label'), ('Clinical Symptoms', 'no label'), ('Did Not Deteriorate', 'no label'), ('His Last Follow-Up Examination', 'no label'), ('Patient 2', 'no label'), ('Independent', 'no label'), ('His Daily Activities', 'no label'), ('Patients', 'no label'), ('Autoimmune-Mediated Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Show A', 'no label'), ('Stable', 'no label'), ('Treatment', 'no label'), ('Benefit', 'no label'), ('Long-Term Therapy', 'no label'), ('Assessed', 'no label'), ('Follow-Up', 'no label'), ('Side Effects', 'no label'), ('Balanced', 'no label'), ('Quality Of Life', 'no label'), ('Patients', 'no label')]"|[('Antibodies', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Potassium', 'no label'), ('His', 'no label'), ('His', 'no label'), ('P/Q-Type', 'no label'), ('Calcium-Channel Antibody', 'no label'), ('His', 'no label'), ('Drug', 'no label'), ('His', 'no label'), ('P/Q-Type', 'no label'), ('Calcium-Channel Antibody', 'no label'), ('His', 'no label'), ('His', 'no label'), ('His', 'no label'), ('His', 'no label')]|[('His', 'no label'), ('His', 'no label'), ('His', 'no label'), ('His', 'no label'), ('His', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Potassium', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Muscle Weakness', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Discontinue', 'no label'), ('P/Q-Type', 'no label'), ('Girdle Syndrome', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('P/Q-Type', 'no label'), ('Myasthenic Syndrome', 'no label')]|[('Neuromuscular', 'no label'), ('Presynaptic P/Q-Type', 'no label'), ('Calcium', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Patients', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Muscle', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Presynaptic P/Q-Type', 'no label'), ('Patient 1', 'no label'), ('Feel', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Nerve', 'no label'), ('Presynaptic P/Q-Type', 'no label'), ('Patient 2', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~27506750|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Uncommon Autoimmune Idiopathic Or Paraneoplastic Syndrome Producing Antibodies Against Voltage Presynaptic Calcium Channels. According To Previous Studies, Many Patients With Lems Experience Remission In Both The Clinical Symptoms Of Muscle Weakness And The Electrophysiologic Abnormalities After Successful Treatment Of Lung Scc. However, Some Patients Might Not Respond To Conventional Therapy And Eventually Require Palliative Care. Hereby, We Reported A Lems Patient With Advanced Lung Malignancy Was Referred For Palliative Care. He Was Benefited From Multidisciplinary Approach Even With Limited Survival. In This Case, Use Of 3,4-Diaminopyridine (3,4-Dap) Had Other Roles Apart From Symptomatic Treatment.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Idiopathic', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Producing', 'no label'), ('Antibodies', 'no label'), ('Voltage', 'no label'), ('Presynaptic', 'no label'), ('Calcium Channels', 'no label'), ('Studies', 'no label'), ('Patients', 'no label'), ('Lems Experience Remission', 'no label'), ('Clinical Symptoms', 'no label'), ('Muscle Weakness', 'no label'), ('Electrophysiologic Abnormalities', 'no label'), ('Successful Treatment', 'no label'), ('Lung Scc', 'no label'), ('Patients', 'no label'), ('Conventional Therapy', 'no label'), ('Palliative Care', 'no label'), ('Lems Patient', 'no label'), ('Advanced', 'no label'), ('Lung Malignancy', 'no label'), ('Referred', 'no label'), ('Palliative Care', 'no label'), ('Was Benefited', 'no label'), ('Multidisciplinary Approach', 'no label'), ('Limited Survival', 'no label'), ('Case', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label')]|[('Antibodies', 'no label'), ('Calcium', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Uncommon Autoimmune Idiopathic', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Calcium', 'no label'), ('Muscle Weakness', 'no label'), ('Lung Malignancy', 'no label'), ('3,4-Diaminopyridine', 'no label')]|[('Calcium', 'no label'), ('Patients', 'no label'), ('Lems Experience', 'no label'), ('Muscle', 'no label'), ('Lung', 'no label'), ('Patients', 'no label'), ('Lung', 'no label'), ('3,4-Diaminopyridine', 'no label')]
lambert eaton syndrome|pubmed~26502758|Lambert-Eaton Myasthenic Syndrome (Lems) And Botulism Are Acquired Presynaptic Nerve Terminal Disorders Of The Neuromuscular Junction. Lambert-Eaton Myasthenic Syndrome Is An Idiopathic Or Paraneoplastic Autoimmune Syndrome In Which Autoantibodies Of The P/Q-Type Voltage-Gated Calcium Channel Play A Role In Decreasing The Release Of Acetylcholine, Resulting In Clinical Symptoms Of Skeletal Muscle Weakness, Diminished Reflexes, And Autonomic Symptoms. Paraneoplastic Lems Is Most Often Associated With Small Cell Lung Cancer. Diagnosis Is Confirmed By Positive Serologic Testing And Electrophysiological Studies, Which Display Characteristic Features Of Low Compound Muscle Action Potentials, A Decrement At 3Hz Repetitive Nerve Stimulation, And Facilitation With Exercise Or High-Frequency Repetitive Stimulation. Treatment Involves Cancer Monitoring And Treatment, 3,4-Diaminopyridine, Immunosuppressive Medications, And Acetylcholinesterase Inhibitors. Botulism Is Another Presynaptic Disorder Of Neuromuscular Transmission. Clinical Features Classically Involve Cranial And Bulbar Palsies Followed By Descending Weakness Of The Limbs, Respiratory Failure, And Autonomic Dysfunction. Electrodiagnostic Testing Is Important In The Evaluation And Diagnosis. Treatment Is Supportive, And Administration Of Antitoxin Is Beneficial In Selected Cases.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Botulism', 'no label'), ('Acquired', 'no label'), ('Presynaptic Nerve', 'no label'), ('Terminal Disorders', 'no label'), ('Neuromuscular Junction', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Idiopathic Or', 'no label'), ('Paraneoplastic Autoimmune Syndrome', 'no label'), ('Autoantibodies', 'no label'), ('P/Q-Type Voltage-Gated Calcium Channel Play A', 'no label'), ('Decreasing', 'no label'), ('Release', 'no label'), ('Acetylcholine', 'no label'), ('Clinical Symptoms', 'no label'), ('Skeletal Muscle Weakness', 'no label'), ('Diminished', 'no label'), ('Reflexes', 'no label'), ('Autonomic Symptoms', 'no label'), ('Paraneoplastic Lems', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Diagnosis', 'no label'), ('Confirmed', 'no label'), ('Serologic Testing', 'no label'), ('Electrophysiological Studies', 'no label'), ('Display', 'no label'), ('Compound Muscle', 'no label'), ('Decrement', 'no label'), ('Repetitive Nerve', 'no label'), ('Facilitation', 'no label'), ('Exercise', 'no label'), ('High-Frequency', 'no label'), ('Repetitive Stimulation', 'no label'), ('Treatment Involves', 'no label'), ('Cancer', 'no label'), ('Monitoring', 'no label'), ('Treatment', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Immunosuppressive Medications', 'no label'), ('Acetylcholinesterase Inhibitors', 'no label'), ('Botulism', 'no label'), ('Presynaptic Disorder', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Clinical Features', 'no label'), ('Cranial', 'no label'), ('Bulbar Palsies', 'no label'), ('Followed', 'no label'), ('Descending Weakness', 'no label'), ('Limbs', 'no label'), ('Respiratory Failure', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Electrodiagnostic Testing', 'no label'), ('Evaluation', 'no label'), ('Diagnosis', 'no label'), ('Treatment', 'no label'), ('Supportive', 'no label'), ('Administration', 'no label'), ('Antitoxin', 'no label'), ('Beneficial', 'no label'), ('Cases', 'no label')]|[('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Cell', 'no label'), ('Acetylcholinesterase Inhibitors', 'no label'), ('Antitoxin', 'no label')]|[('Acetylcholinesterase', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Botulism', 'no label'), ('Acquired Presynaptic Nerve Terminal Disorders Of The Neuromuscular Junction', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Idiopathic Or Paraneoplastic Autoimmune Syndrome', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Skeletal Muscle Weakness', 'no label'), ('Paraneoplastic', 'no label'), ('Diagnosis', 'no label'), ('Cancer', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Botulism', 'no label'), ('Disorder Of Neuromuscular Transmission', 'no label'), ('Descending Weakness', 'no label'), ('Respiratory Failure', 'no label'), ('Autonomic Dysfunction', 'no label')]|[('Neuromuscular', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Skeletal Muscle', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Nerve', 'no label'), ('Cancer', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Acetylcholinesterase', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular', 'no label'), ('Cranial', 'no label'), ('Respiratory', 'no label'), ('Antitoxin', 'no label')]
lambert eaton syndrome|pubmed~25468580|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disorder Of The Neuromuscular Junction That Manifests With Muscle Weakness, Autonomic And Bulbar Dysfunction, And Increased Sensitivity To Neuromuscular Blocking Drugs. The Objective Of This Study Is To Review Perioperative Outcomes On A Series Of Patients With Lems. The Medical Records Of Surgical Patients With Lems From January 1, 1990, To December 31, 2012, Were Retrospectively Reviewed. Major Academic Hospital. Surgical Patients With Lems. Thirty-Seven Patients Underwent 60 Surgeries, With Most Performed To Diagnose Or Treat Lung Malignancy (N = 31; 51.7%). Equal Number Of Patients Had Lems Associated With Small Cell Lung Cancer (N = 16; 43.2%) Or An Autoimmune Process (N = 16; 43.2%), With The Remainder Having Various Malignancies. Neuromuscular Blocking Drug Medications Were Used In 23 (38.3%) Of Cases, Including 8 Patients Who Were Not Treated For Lems Symptoms. Four Patients (11%) Had Respiratory Complications. Interestingly, 3 Patients Were Either Undiagnosed Or Not Treated For Lems At The Time Of Perioperative Complication, And Developed Weakness After Use Of Neuromuscular Blocking Drugs. Patients With Lems Have Increased Sensitivity To Neuromuscular Blocking Drugs. The Risk For The Development Of Prolonged Muscle Weakness Or Postoperative Respiratory Failure After Being Exposed To Neuromuscular Blocking Drugs Is Increased In Patients With Undiagnosed Or Untreated Lems.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disorder', 'no label'), ('Neuromuscular Junction', 'no label'), ('Manifests', 'no label'), ('Muscle Weakness', 'no label'), ('Autonomic And Bulbar Dysfunction', 'no label'), ('Increased', 'no label'), ('Sensitivity', 'no label'), ('Neuromuscular Blocking', 'no label'), ('Drugs', 'no label'), ('Study', 'no label'), ('Review', 'no label'), ('Perioperative', 'no label'), ('Outcomes', 'no label'), ('Series', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Medical Records', 'no label'), ('Surgical Patients', 'no label'), ('Lems', 'no label'), ('Retrospectively', 'no label'), ('Reviewed', 'no label'), ('Academic Hospital', 'no label'), ('Surgical Patients', 'no label'), ('Lems', 'no label'), ('Thirty-Seven Patients', 'no label'), ('Surgeries', 'no label'), ('Performed', 'no label'), ('Diagnose', 'no label'), ('Treat', 'no label'), ('Lung Malignancy', 'no label'), ('Equal Number', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Autoimmune Process', 'no label'), ('Malignancies', 'no label'), ('Neuromuscular Blocking', 'no label'), ('Drug Medications', 'no label'), ('Cases', 'no label'), ('Patients', 'no label'), ('Treated', 'no label'), ('Lems Symptoms', 'no label'), ('Patients', 'no label'), ('Respiratory Complications', 'no label'), ('Patients', 'no label'), ('Undiagnosed', 'no label'), ('Treated', 'no label'), ('Lems', 'no label'), ('Time', 'no label'), ('Perioperative', 'no label'), ('Complication', 'no label'), ('Developed Weakness', 'no label'), ('Neuromuscular Blocking', 'no label'), ('Drugs', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Increased', 'no label'), ('Sensitivity', 'no label'), ('Neuromuscular Blocking', 'no label'), ('Drugs', 'no label'), ('Risk', 'no label'), ('Development', 'no label'), ('Prolonged', 'no label'), ('Muscle Weakness', 'no label'), ('Postoperative', 'no label'), ('Respiratory Failure', 'no label'), ('Being', 'no label'), ('Exposed', 'no label'), ('Neuromuscular', 'no label'), ('Blocking', 'no label'), ('Drugs', 'no label'), ('Increased', 'no label'), ('Patients', 'no label'), ('Undiagnosed', 'no label'), ('Untreated Lems', 'no label')]|[('Cell', 'no label'), ('Drug', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Muscle Weakness', 'no label'), ('Lung Malignancy', 'no label'), ('Respiratory Complications', 'no label'), ('Muscle Weakness Or Postoperative Respiratory Failure', 'no label')]|[('Neuromuscular', 'no label'), ('Muscle', 'no label'), ('Neuromuscular', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lung', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Malignancies', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Respiratory', 'no label'), ('Patients', 'no label'), ('Neuromuscular', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Neuromuscular', 'no label'), ('Muscle', 'no label'), ('Respiratory', 'no label'), ('Neuromuscular', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~25065299|Lambert-Eaton Myasthenic Syndrome (Lems) Describes A Rare Human Autoimmune Disorder Of The Neuromuscular Junction (Nmj). Clinically, Lems Patients Suffer From Characteristic Muscle Weakness That Is Caused By The Presence Of Antibodies Directed Against Their Voltage-Gated Calcium Channels (Vgcc). These Channels Are Localized In The Presynaptic Membrane Of Their Motor Nerve Terminals. Binding Of Autoimmune Antibodies To The Vgccs Leads To Reduced Neuromuscular Transmission. In Approximately 50% Of The Patients, Lems Is Reflected By A Paraneoplastic Manifestation And Most Commonly Associated With A Small Cell Lung Carcinoma (Sclc) Whose Cells Also Express Vgccs In Their Plasma Membrane. Better Understanding Of The Pathophysiological Mechanisms Of Lems Has Helped With The Development Of New Diagnostic Approaches And Has Led To Targeted Symptomatic And Immunosuppressive Therapy. For Lems Patients With An Underlying Malignancy, Tumor Therapy Is The First Choice To Date. |[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Describes', 'no label'), ('Rare', 'no label'), ('Human Autoimmune Disorder', 'no label'), ('Neuromuscular Junction', 'no label'), ('Nmj', 'no label'), ('Clinically', 'no label'), ('Lems Patients', 'no label'), ('Characteristic Muscle Weakness', 'no label'), ('Presence', 'no label'), ('Antibodies', 'no label'), ('Directed', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Vgcc', 'no label'), ('Channels', 'no label'), ('Localized', 'no label'), ('Presynaptic Membrane', 'no label'), ('Motor Nerve', 'no label'), ('Terminals', 'no label'), ('Binding', 'no label'), ('Autoimmune Antibodies', 'no label'), ('Vgccs Leads', 'no label'), ('Reduced', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Paraneoplastic Manifestation', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Cells', 'no label'), ('Express Vgccs', 'no label'), ('Plasma', 'no label'), ('Membrane', 'no label'), ('Pathophysiological', 'no label'), ('Mechanisms', 'no label'), ('Lems', 'no label'), ('Development', 'no label'), ('New Diagnostic Approaches', 'no label'), ('Symptomatic', 'no label'), ('Immunosuppressive Therapy', 'no label'), ('Lems Patients', 'no label'), ('Underlying Malignancy', 'no label'), ('Tumor Therapy', 'no label')]|[('Human', 'no label'), ('Antibodies', 'no label'), ('Calcium', 'no label'), ('Membrane', 'no label'), ('Antibodies', 'no label'), ('Cell', 'no label'), ('Cells', 'no label'), ('Plasma Membrane', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Human Autoimmune Disorder', 'no label'), ('Muscle Weakness', 'no label'), ('Calcium', 'no label'), ('Reduced Neuromuscular Transmission', 'no label'), ('Malignancy', 'no label'), ('Tumor', 'no label')]|[('Human', 'no label'), ('Neuromuscular', 'no label'), ('Lems Patients', 'no label'), ('Muscle', 'no label'), ('Calcium', 'no label'), ('Presynaptic Membrane', 'no label'), ('Vgccs', 'no label'), ('Neuromuscular', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('A Small Cell Lung Carcinoma', 'no label'), ('Cells', 'no label'), ('Vgccs', 'no label'), ('Plasma Membrane', 'no label'), ('Lems', 'no label'), ('Lems Patients', 'no label'), ('Tumor', 'no label')]
lambert eaton syndrome|pubmed~34025312|<I>Introduction:</I> Nutritional Intervention, Such As A Whole-Food Plant-Based (Wfpb) Diet, Is Suggested To Improve Symptoms Of Autoimmune Disorders. Its Effects On Neuromuscular Junction (Nmj) Diseases Are Less Known. <I>Case Description:</I> A 56-Year-Old Female With A Combined Myasthenia Gravis And Lambert-Eaton Myasthenic Syndrome Presented With Persistent Musculoskeletal Weakness And Pain, Fatigue, And Diminished Concentration. <I>Methods:</I> A Wfpb Diet Was Implemented For 5 Months In This Case Study. Functionality, Biometrics, And Quality Of Life Were Assessed At Regular Intervals Via Blood Work, Vital Signs, And Patient Surveys. <I>Results:</I> After 10 Weeks, 2 Medications Were De-Prescribed Due To Improvement In Blood Glucose Levels And Blood Pressure Readings. Neuromuscular Symptoms Lessened As Measured By The Myasthenia Gravis Illness Index. Weight Loss Of 18.7 Pounds Was Achieved. No Deterioration In Physical Activity Was Reported Throughout The 5-Month Trial Of Wfpb Diet. <I>Discussion:</I> Our Results Have Implications That An Individualized Dietary Strategy May Be Considered As One Component Of Management Of Nmj Diseases. The Effects Of Wfpb Diet On Nmj Diseases Remain Inconclusive.|[('Nutritional', 'no label'), ('Intervention', 'no label'), ('Whole-Food Plant-Based', 'no label'), ('Improve', 'no label'), ('Symptoms', 'no label'), ('Autoimmune Disorders', 'no label'), ('Effects', 'no label'), ('Neuromuscular Junction', 'no label'), ('Female', 'no label'), ('Combined', 'no label'), ('Myasthenia Gravis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Persistent Musculoskeletal Weakness', 'no label'), ('Pain', 'no label'), ('Fatigue', 'no label'), ('Diminished', 'no label'), ('Concentration', 'no label'), ('Wfpb Diet', 'no label'), ('Months', 'no label'), ('Case Study', 'no label'), ('Functionality', 'no label'), ('Biometrics', 'no label'), ('Quality Of Life', 'no label'), ('Assessed', 'no label'), ('Regular Intervals', 'no label'), ('Blood Work', 'no label'), ('Vital Signs', 'no label'), ('Patient Surveys', 'no label'), ('Results:</I', 'no label'), ('Weeks', 'no label'), ('Medications', 'no label'), ('De-Prescribed', 'no label'), ('Improvement', 'no label'), ('Blood Glucose Levels', 'no label'), ('Blood Pressure', 'no label'), ('Readings', 'no label'), ('Neuromuscular Symptoms', 'no label'), ('Measured', 'no label'), ('Myasthenia Gravis Illness Index', 'no label'), ('Weight Loss', 'no label'), ('Pounds', 'no label'), ('Deterioration', 'no label'), ('Physical Activity', 'no label'), ('Trial', 'no label'), ('Wfpb Diet', 'no label'), ('Discussion:</I', 'no label'), ('Results', 'no label'), ('Individualized', 'no label'), ('Dietary Strategy', 'no label'), ('Component', 'no label'), ('Management', 'no label'), ('Nmj Diseases', 'no label'), ('Effects', 'no label'), ('Wfpb Diet', 'no label'), ('Nmj Diseases', 'no label'), ('Remain', 'no label')]|[('Glucose', 'no label')]|[]|[('Autoimmune Disorders', 'no label'), ('Myasthenia Gravis', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Pain', 'no label'), ('Fatigue', 'no label'), ('Glucose', 'no label'), ('Myasthenia Gravis Illness', 'no label'), ('Weight Loss', 'no label')]|[('Neuromuscular', 'no label'), ('A Wfpb', 'no label'), ('Biometrics', 'no label'), ('Regular Intervals', 'no label'), ('Blood', 'no label'), ('De-Prescribed', 'no label'), ('Blood Glucose', 'no label'), ('Blood', 'no label'), ('Wfpb', 'no label'), ('Wfpb', 'no label')]
lambert eaton syndrome|pubmed~26109387|Our Aim In This Study Was To Provide An Updated Literature Review Of Electrodiagnostic Testing In Myasthenia Gravis And Lambert-Eaton Myasthenic Syndrome. A Systematic Review Of The Recent Literature Was Performed Using The Following Key Words: Myasthenia Gravis (Mg); Lambert-Eaton Myasthenic Syndrome (Lems); Electromyography (Emg); Repetitive Nerve Stimulation (Rns); Single-Fiber Electromyography (Sfemg); Nerve Conduction Study; And Normative Values. Several Articles Supported Testing Of Facial, Bulbar, And Respiratory Muscles In The Diagnosis Of Neuromuscular Junction (Nmj) Disorders, Including Muscle-Specific Kinase Antibody (Musk)-Seropositive Mg. Several Articles Supported Use Of Concentric Needle Emg As An Alternative To Sfemg Jitter In Disorders Of Neuromuscular Transmission. A Limited Number Of Articles Addressed Measurement Of Area (Vs. Amplitude) Decrement In Rns And Decreasing The Threshold Of Post-Exercise Facilitation. Electrodiagnostic Testing Continues To Be Useful For Diagnosis Of Mg And Lems, Although The Quality Of The Evidence Is Not Great. This Literature Review Summarizes Rns And Jitter Measurement Of Facial And Respiratory Muscles And Use Of Concentric Needle Emg For Sfemg.|[('Study', 'no label'), ('Updated Literature Review', 'no label'), ('Electrodiagnostic Testing', 'no label'), ('Myasthenia Gravis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Systematic Review', 'no label'), ('Literature', 'no label'), ('Performed', 'no label'), ('Key Words', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Electromyography', 'no label'), ('Emg', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Rns', 'no label'), ('Single-Fiber Electromyography', 'no label'), ('Sfemg', 'no label'), ('Nerve Conduction Study', 'no label'), ('Normative Values', 'no label'), ('Articles', 'no label'), ('Supported Testing', 'no label'), ('Facial', 'no label'), ('Bulbar', 'no label'), ('Respiratory Muscles', 'no label'), ('Diagnosis', 'no label'), ('Neuromuscular Junction', 'no label'), ('Muscle-Specific Kinase Antibody', 'no label'), ('Mg', 'no label'), ('Articles', 'no label'), ('Concentric', 'no label'), ('Emg', 'no label'), ('Sfemg', 'no label'), ('Jitter', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Limited Number', 'no label'), ('Articles', 'no label'), ('Measurement', 'no label'), ('Rns', 'no label'), ('Decreasing', 'no label'), ('Threshold', 'no label'), ('Post-Exercise Facilitation', 'no label'), ('Electrodiagnostic Testing Continues', 'no label'), ('Diagnosis', 'no label'), ('Mg', 'no label'), ('Lems', 'no label'), ('Quality', 'no label'), ('Evidence', 'no label'), ('Not Great', 'no label'), ('Literature Review', 'no label'), ('Summarizes Rns', 'no label'), ('Jitter', 'no label'), ('Facial And Respiratory Muscles', 'no label'), ('Concentric', 'no label'), ('Emg', 'no label'), ('Sfemg', 'no label')]|[('Antibody', 'no label'), ('Rns', 'no label'), ('Rns', 'no label')]|[('Muscle-Specific Kinase Antibody', 'no label'), ('Emg', 'no label'), ('Rns', 'no label'), ('Rns', 'no label'), ('Emg', 'no label')]|[('Myasthenia Gravis', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Mg', 'no label'), ('Disorders Of Neuromuscular Transmission', 'no label'), ('Mg', 'no label')]|[('Nerve', 'no label'), ('Single-Fiber Electromyography', 'no label'), ('Nerve Conduction', 'no label'), ('Facial', 'no label'), ('Respiratory Muscles', 'no label'), ('Neuromuscular', 'no label'), ('Muscle-Specific Kinase Antibody', 'no label'), ('Mg', 'no label'), ('Neuromuscular', 'no label'), ('Rns', 'no label'), ('Mg', 'no label'), ('Rns', 'no label'), ('Facial', 'no label')]
lambert eaton syndrome|pubmed~24461257|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disease Of The Presynaptic Neuromuscular Junction, Typically Occurring In Adults As A Paraneoplastic Syndrome. Only Rare Cases Have Been Reported In Childhood. In Most Childhood Cases, Malignancies Have Not Been Detected But A Propensity To Autoimmune Disease Was Noticed. Nevertheless, Little Is Known About Genetic Factors That May Contribute To The Susceptibility Of An Individual To Develop Lems. We Report On A 13-Year-Old Girl, Known With The Xp11.22-P11.23 Duplication Syndrome, Who Presented With Severe Non-Paraneoplastic Lems. The Potential Role Of This Microduplication Syndrome In The Development Of Lems Is Explored. Previous Literature Review Of Twelve Xp11.2 Duplication Syndrome Patients Showed That Three Of Them Suffered From Various Autoimmune Diseases. The Common Duplicated Region In Those Three Patients And The Presented Case Comprises 12 Disease-Associated Genes Including The Foxp3 (Forkhead Box P3) And Was (Wiskott-Aldrich Syndrome) Gene, Both Implicated In Immune Function. However, It Is Unclear Whether Increased Gene Dosage Of One Or Both Of These Genes Can Cause Susceptibility To Autoimmune Diseases. In Conclusion, The Presented Case Emphasizes That Autoimmune Disease Is A Recurrent Feature Of The Xp11.2 Duplication Syndrome, Which Should Be Considered In The Follow-Up Of These Patients. The Exact Mechanism Underlying This Autoimmune Propensity Remains To Be Elucidated. |[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disease', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular Junction', 'no label'), ('Occurring', 'no label'), ('Adults', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Rare', 'no label'), ('Cases', 'no label'), ('Childhood', 'no label'), ('Childhood Cases', 'no label'), ('Malignancies', 'no label'), ('Detected', 'no label'), ('Propensity', 'no label'), ('Autoimmune Disease', 'no label'), ('Genetic Factors', 'no label'), ('Contribute', 'no label'), ('Susceptibility', 'no label'), ('Lems', 'no label'), ('Report', 'no label'), ('Girl', 'no label'), ('Xp11.22-P11.23 Duplication Syndrome', 'no label'), ('Severe', 'no label'), ('Non-Paraneoplastic Lems', 'no label'), ('Microduplication Syndrome', 'no label'), ('Development', 'no label'), ('Lems', 'no label'), ('Literature Review', 'no label'), ('Xp11.2 Duplication Syndrome', 'no label'), ('Patients', 'no label'), ('Suffered', 'no label'), ('Autoimmune Diseases', 'no label'), ('Duplicated Region', 'no label'), ('Patients', 'no label'), ('Case Comprises', 'no label'), ('Disease-Associated Genes', 'no label'), ('Foxp3', 'no label'), ('Forkhead Box P3', 'no label'), ('Immune Function', 'no label'), ('Increased', 'no label'), ('Gene Dosage', 'no label'), ('Genes', 'no label'), ('Cause Susceptibility', 'no label'), ('Autoimmune Diseases', 'no label'), ('Case Emphasizes', 'no label'), ('Autoimmune Disease', 'no label'), ('Recurrent', 'no label'), ('Feature', 'no label'), ('Xp11.2 Duplication Syndrome', 'no label'), ('Follow-Up', 'no label'), ('Patients', 'no label'), ('Exact Mechanism', 'no label'), ('Autoimmune Propensity Remains', 'no label')]|[('Genetic', 'no label'), ('Duplication', 'no label'), ('Region', 'no label'), ('Genes', 'no label'), ('Foxp3', 'no label'), ('Gene', 'no label'), ('Gene', 'no label'), ('Genes', 'no label')]|[('Xp11.2 Duplication', 'no label'), ('Foxp3 (', 'no label'), ('Forkhead Box P3', 'no label'), ('Xp11.2 Duplication', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Malignancies', 'no label'), ('Autoimmune Disease', 'no label'), ('Xp11.2 Duplication Syndrome', 'no label'), ('Wiskott-Aldrich Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('Xp11.2 Duplication Syndrome', 'no label')]|[('Presynaptic Neuromuscular', 'no label'), ('Malignancies', 'no label'), ('Xp11.22-P11.23', 'no label'), ('Lems', 'no label'), ('Xp11.2', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Foxp3', 'no label'), ('Forkhead Box', 'no label'), ('P3', 'no label'), ('Immune', 'no label'), ('Xp11.2', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~25299290|This Article Reviews The Clinical Presentations, Diagnostic Findings, And Treatment Options For Autoimmune Myasthenia Gravis (Mg) And Lambert-Eaton Myasthenic Syndrome. Immunologic Research Is Unraveling The Immunopathology Of Mg And Identifying Targets For Novel Immune-Based Therapy Of This Condition. Mg Patients With Antibodies To Muscle-Specific Tyrosine Kinase (Musk) Frequently Present With Symptoms And Clinical Findings That Suggest Nerve Or Muscle Disease. Early Diagnosis And Treatment Have A Marked Effect On Outcome In These Diseases. In Most Cases, The Diagnosis Of Mg Or Lambert-Eaton Myasthenic Syndrome Can Be Made From The History, Supplemented With Directed Questions, And A Physical Examination Designed To Demonstrate Variable Weakness In Affected Muscle Groups. Appropriate Confirmatory Tests Almost Always Establish The Diagnosis. Although Several Novel Treatment Modalities For Mg Are Under Investigation, Currently Available Therapies Produce Substantial Improvement In Function And Quality Of Life In Most Patients With This Condition. Knowledge About The Dosing, Adverse Effects, And Costs Of Immunomodulatory Therapies Is Essential For The Effective Management Of Patients With Mg And Lambert-Eaton Myasthenic Syndrome.|[('Article Reviews', 'no label'), ('Clinical Presentations', 'no label'), ('Diagnostic Findings', 'no label'), ('Treatment Options', 'no label'), ('Autoimmune Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Immunologic Research', 'no label'), ('Immunopathology', 'no label'), ('Mg', 'no label'), ('Targets', 'no label'), ('Novel', 'no label'), ('Immune-Based Therapy', 'no label'), ('Condition', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Antibodies', 'no label'), ('Muscle-Specific Tyrosine Kinase', 'no label'), ('Musk', 'no label'), ('Symptoms', 'no label'), ('Clinical Findings', 'no label'), ('Suggest Nerve', 'no label'), ('Muscle Disease', 'no label'), ('Early Diagnosis', 'no label'), ('Treatment', 'no label'), ('Marked Effect', 'no label'), ('Outcome', 'no label'), ('Diseases', 'no label'), ('Cases', 'no label'), ('Diagnosis', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('History', 'no label'), ('Supplemented', 'no label'), ('Directed Questions', 'no label'), ('Physical Examination', 'no label'), ('Demonstrate', 'no label'), ('Variable Weakness', 'no label'), ('Affected Muscle', 'no label'), ('Confirmatory Tests', 'no label'), ('Always Establish', 'no label'), ('Diagnosis', 'no label'), ('Novel', 'no label'), ('Treatment', 'no label'), ('Mg', 'no label'), ('Investigation', 'no label'), ('Therapies', 'no label'), ('Produce', 'no label'), ('Substantial Improvement', 'no label'), ('Function', 'no label'), ('Patients', 'no label'), ('Condition', 'no label'), ('Knowledge', 'no label'), ('Dosing', 'no label'), ('Adverse Effects', 'no label'), ('Costs', 'no label'), ('Immunomodulatory Therapies', 'no label'), ('Effective', 'no label'), ('Management', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label')]|[('Antibodies', 'no label'), ('Tyrosine', 'no label')]|[('Muscle-Specific Tyrosine Kinase', 'no label')]|[('Autoimmune Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Tyrosine', 'no label'), ('Muscle Disease', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Weakness', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label')]|[('Mg', 'no label'), ('Patients', 'no label'), ('Muscle-Specific Tyrosine Kinase', 'no label'), ('Musk', 'no label'), ('Nerve', 'no label'), ('Muscle', 'no label'), ('Mg', 'no label'), ('Muscle', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Mg', 'no label')]
lambert eaton syndrome|pubmed~23759215|Lambert-Eaton Myasthenic Syndrome Is A Rare And Autoimmune Presynaptic Disorder Of The Neuromuscular Junction, Due In 85% Of Cases To Autoantibodies Directed Against Voltage-Gated Calcium Channels. It Is A Paraneoplastic Disorder In 50 To 60% Of Cases. Diagnosis Involves A Proximal Muscle Weakness And Areflexia, Associated With A Significant Increment After Post-Exercise Stimulation In Electrophysiological Study. Symptomatic Treatment Is Based On 3,4-Diaminopyridine. No Etiological Treatment Has Proven Its Efficacy In Both Paraneoplastic And Non-Paraneoplastic Lambert-Eaton Myasthenic Syndrome. We Report A 41-Year-Old Man Who Presented With A Seronegative Non-Paraneoplastic Lambert-Eaton Myasthenic Syndrome In Whom Conventional Immunosuppressive Treatments (Corticosteroids, Azathioprine) Failed, And Who Eventually Improved After Treatment With Rituximab. Rituximab Was An Effective And Well-Tolerated Treatment In This Case Of Seronegative Non-Paraneoplastic Lambert-Eaton Myasthenic Syndrome. Its Indication Should Be Discussed When Conventional Immunosuppressive Therapy Fails In Both Seropositive And Seronegative Patients.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Rare', 'no label'), ('Autoimmune Presynaptic Disorder', 'no label'), ('Neuromuscular Junction', 'no label'), ('Cases', 'no label'), ('Autoantibodies', 'no label'), ('Directed Against', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Paraneoplastic Disorder', 'no label'), ('Cases', 'no label'), ('Diagnosis', 'no label'), ('Involves', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Areflexia', 'no label'), ('Associated With', 'no label'), ('Significant', 'no label'), ('Increment', 'no label'), ('Post-Exercise Stimulation', 'no label'), ('Electrophysiological Study', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Etiological Treatment', 'no label'), ('Proven', 'no label'), ('Efficacy', 'no label'), ('Paraneoplastic', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Report', 'no label'), ('Seronegative', 'no label'), ('Non-Paraneoplastic', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Conventional', 'no label'), ('Immunosuppressive Treatments', 'no label'), ('Corticosteroids', 'no label'), ('Azathioprine', 'no label'), ('Failed', 'no label'), ('Improved', 'no label'), ('Treatment', 'no label'), ('Rituximab', 'no label'), ('Rituximab', 'no label'), ('Effective', 'no label'), ('Well-Tolerated Treatment', 'no label'), ('Seronegative', 'no label'), ('Non-Paraneoplastic', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Indication', 'no label'), ('Conventional', 'no label'), ('Immunosuppressive Therapy', 'no label'), ('Fails', 'no label'), ('Seropositive', 'no label'), ('Seronegative', 'no label'), ('Patients', 'no label')]|[('Calcium', 'no label'), ('Rituximab', 'no label'), ('Non-Paraneoplastic', 'no label')]|[('Who', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Presynaptic Disorder Of The Neuromuscular Junction', 'no label'), ('Calcium', 'no label'), ('Paraneoplastic Disorder', 'no label'), ('Muscle Weakness', 'no label'), ('Areflexia', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Paraneoplastic', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Azathioprine', 'no label'), ('Rituximab', 'no label'), ('Rituximab', 'no label'), ('Myasthenic Syndrome', 'no label')]|[('Presynaptic', 'no label'), ('Neuromuscular', 'no label'), ('Autoantibodies', 'no label'), ('Calcium', 'no label'), ('Muscle', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Corticosteroids', 'no label'), ('Azathioprine', 'no label'), ('Rituximab', 'no label'), ('Rituximab', 'no label'), ('Case', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~30384197|Alemtuzumab Administration Is Known To Cause Secondary Autoimmune Disease But Has Not Been Associated With The Development Of Neurologic Autoimmune Conditions. Lambert-Eaton Myasthenic Syndrome (Lems) Is Caused By Autoantibodies Directed Against Calcium Channels On The Neuromuscular Junction. We Report A Case Of A Patient With Relapsing-Remitting Multiple Sclerosis (Rrms) Treated With Alemtuzumab Who Develop Generalized Weakness Initially Attributed To Progression Of Ms But Eventually Determined To Be Due To Lems. Alemtuzumab Treatment Can Result In The Development Of Neurologic Autoimmune Conditions That Could Mimic Ms Progression.|[('Alemtuzumab', 'no label'), ('Administration', 'no label'), ('Secondary Autoimmune Disease', 'no label'), ('Associated With', 'no label'), ('Development', 'no label'), ('Neurologic Autoimmune Conditions', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoantibodies', 'no label'), ('Directed', 'no label'), ('Calcium Channels', 'no label'), ('Neuromuscular Junction', 'no label'), ('Report', 'no label'), ('Patient', 'no label'), ('Relapsing-Remitting Multiple Sclerosis', 'no label'), ('Rrms', 'no label'), ('Treated With', 'no label'), ('Alemtuzumab', 'no label'), ('Generalized Weakness', 'no label'), ('Progression', 'no label'), ('Lems', 'no label'), ('Alemtuzumab', 'no label'), ('Treatment', 'no label'), ('Development', 'no label'), ('Neurologic Autoimmune', 'no label'), ('Mimic', 'no label'), ('Progression', 'no label')]|[('Alemtuzumab', 'no label'), ('Calcium', 'no label'), ('Alemtuzumab', 'no label')]|[]|[('Secondary Autoimmune Disease', 'no label'), ('Neurologic Autoimmune', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Calcium', 'no label'), ('Neurologic Autoimmune Conditions That Could Mimic Ms Progression', 'no label')]|[('Alemtuzumab', 'no label'), ('Calcium', 'no label'), ('Neuromuscular', 'no label'), ('Patient', 'no label'), ('Alemtuzumab', 'no label'), ('Alemtuzumab', 'no label')]
lambert eaton syndrome|pubmed~27412406|Lambert-Eaton Syndrome (Les) Is A Rare Immune-Mediated Disorder Characterized By Proximal Leg Weakness, Autonomic Symptoms And Hypoactive Tendon Reflexes. The Paraneoplastic Form Is Associated With Small-Cell Lung Cancer In 50-60% Of Cases, Whereas The Remaining Cases Are Found In Younger Adults With A Higher Likelihood Of Coexisting Autoimmune Disease. The Early Recognition Of Les Is Crucial For Improving Clinical Outcomes But Remains A Major Challenge. In This Review, We Analyze The Clinical Characteristics And Diagnostic Considerations In Treating Les Through A Series Of Three Case Studies, One Of Which Showed Definitive Response To Pyridostigmine And Corticosteroid Combination Therapy, Followed By Spontaneous Remission. Patients Were Assessed By Image-Based Screening, Serological Testing And Electrophysiological Evaluations, Which Included Respiratory And Autonomic Testing. A Better Understanding Of The Common Pitfalls In The Clinical, Serological And Neurophysiologic Diagnosis Of Les Through Assessment Of Typical Les Dysfunction Throughout The Nervous System Should Enable Improved Recognition And Treatment Of This Syndrome. |[('Lambert-Eaton Syndrome', 'no label'), ('Rare', 'no label'), ('Immune-Mediated Disorder', 'no label'), ('Characterized', 'no label'), ('Proximal Leg Weakness', 'no label'), ('Autonomic Symptoms', 'no label'), ('Hypoactive', 'no label'), ('Tendon Reflexes', 'no label'), ('Paraneoplastic Form', 'no label'), ('Associated With', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Cases', 'no label'), ('Cases', 'no label'), ('Younger Adults', 'no label'), ('Likelihood', 'no label'), ('Coexisting', 'no label'), ('Autoimmune Disease', 'no label'), ('Early Recognition', 'no label'), ('Improving', 'no label'), ('Clinical Outcomes', 'no label'), ('Remains', 'no label'), ('Review', 'no label'), ('Analyze', 'no label'), ('Clinical Characteristics', 'no label'), ('Diagnostic', 'no label'), ('Considerations', 'no label'), ('Treating', 'no label'), ('Case Studies', 'no label'), ('Definitive', 'no label'), ('Response', 'no label'), ('Pyridostigmine', 'no label'), ('Corticosteroid', 'no label'), ('Combination Therapy', 'no label'), ('Spontaneous Remission', 'no label'), ('Patients', 'no label'), ('Assessed', 'no label'), ('Image-Based Screening', 'no label'), ('Serological Testing', 'no label'), ('Electrophysiological Evaluations', 'no label'), ('Respiratory', 'no label'), ('Autonomic Testing', 'no label'), ('Pitfalls', 'no label'), ('Clinical', 'no label'), ('Serological', 'no label'), ('Neurophysiologic Diagnosis', 'no label'), ('Assessment', 'no label'), ('Typical', 'no label'), ('Dysfunction', 'no label'), ('Nervous System', 'no label'), ('Recognition', 'no label'), ('Treatment', 'no label'), ('Syndrome', 'no label')]|[]|[]|[('Disorder', 'no label'), ('Paraneoplastic', 'no label'), ('Lung Cancer', 'no label'), ('Autoimmune Disease', 'no label'), ('Pyridostigmine', 'no label')]|[('Tendon Reflexes', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Pyridostigmine', 'no label'), ('Corticosteroid', 'no label'), ('Patients', 'no label'), ('Respiratory', 'no label'), ('Common Pitfalls', 'no label'), ('Nervous System', 'no label')]
lambert eaton syndrome|pubmed~28251917|To Establish Whether Improved Tumor Survival In Patients With Lambert-Eaton Myasthenic Syndrome (Lems) And Small-Cell Lung Cancer (Sclc) Was Due To Known Prognostic Risk Factors Or An Effect Of Lems Independently, Perhaps As A Result Of Circulating Factors. We Undertook A Prospective Observational Cohort Study Of Patients With Lems Attending Nottingham University Hospitals, Uk, Or Via The British Neurological Surveillance Unit. In Parallel, Patients With A New Diagnosis Of Biopsy-Proven Sclc Were Enrolled, Examined For Neurologic Illness, And Followed Up Until Death Or Study End. Between May 2005 And November 2014, We Recruited 31 Patients With Lems And Sclc And 279 Patients With Sclc Without Neurologic Illness. Allowing For Known Sclc Survival Prognostic Factors Of Disease Extent, Age, Sex, Performance Status, And Sodium Values, Multivariate Cox Regression Analysis Showed That The Presence Of Lems With Sclc Conferred A Significant Survival Advantage Independently Of The Other Prognostic Variables (Hazard Ratio 1.756, 95% Confidence Interval 1.137-2.709, <I>P</I> = 0.011). Improved Sclc Tumor Survival Seen In Patients With Lems And Sclc May Not Be Due Solely To Lead Time Bias, Given That Survival Advantage Remains After Allowing For Other Prognostic Factors And That The Same Degree Of Survival Advantage Is Not Seen In Patients With Paraneoplastic Neurologic Syndromes Other Than Lems Presenting Before Sclc Diagnosis.|[('Establish', 'no label'), ('Tumor Survival', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Prognostic Risk Factors', 'no label'), ('Effect', 'no label'), ('Lems', 'no label'), ('Circulating Factors', 'no label'), ('Undertook A', 'no label'), ('Patients', 'no label'), ('Lems Attending Nottingham University Hospitals', 'no label'), ('Uk', 'no label'), ('British Neurological Surveillance Unit', 'no label'), ('Parallel', 'no label'), ('Patients', 'no label'), ('New Diagnosis', 'no label'), ('Biopsy-Proven Sclc', 'no label'), ('Neurologic Illness', 'no label'), ('Followed Up', 'no label'), ('Death', 'no label'), ('Study', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Neurologic Illness', 'no label'), ('Sclc', 'no label'), ('Survival', 'no label'), ('Prognostic Factors', 'no label'), ('Disease Extent', 'no label'), ('Age', 'no label'), ('Sex', 'no label'), ('Performance Status', 'no label'), ('Sodium Values', 'no label'), ('Multivariate Cox Regression Analysis', 'no label'), ('Presence', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Conferred', 'no label'), ('Significant', 'no label'), ('Prognostic Variables', 'no label'), ('Hazard Ratio', 'no label'), ('Confidence Interval', 'no label'), ('<I>P</I> = 0.011)', 'no label'), ('Sclc', 'no label'), ('Tumor Survival', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('May', 'no label'), ('Lead Time Bias', 'no label'), ('Survival Advantage', 'no label'), ('Prognostic Factors', 'no label'), ('Degree', 'no label'), ('Patients', 'no label'), ('Paraneoplastic Neurologic Syndromes', 'no label'), ('Lems', 'no label'), ('Presenting', 'no label'), ('Sclc', 'no label'), ('Diagnosis', 'no label')]|[('Sodium', 'no label')]|[]|[('Tumor', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lung Cancer', 'no label'), ('Neurologic Illness', 'no label'), ('Death', 'no label'), ('Neurologic Illness', 'no label'), ('Sodium', 'no label'), ('Tumor', 'no label'), ('Paraneoplastic Neurologic Syndromes', 'no label')]|[('Tumor', 'no label'), ('Patients', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Sodium', 'no label'), ('Lems', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~28178777||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~23643575|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare Condition, Which May Mimic Myopathy. A Few Reports Have Described That Emg In Lems May Show Changes Compatible With Myopathy, And Muscle Biopsies Have Been Described With Type Ii As Well As Type I Atrophy. The Emg Results Were, However, Based On Qualitative Emg Examination And The Histopathological Methods Were Not Always Clear. The Objective Of This Study Was To Investigate If The Previous Emg Findings Could Be Confirmed With Quantitative Emg (Qemg) And To Describe Muscle Histology In Lems. Qemg, Nerve Conduction Studies And Muscle Biopsy Were Performed In Four Consecutive Lems Patients. Qemg Showed Significantly Decreased Mean Mup Duration And Muscle Biopsy Showed Marked Type Ii Fiber Atrophy. Emg And Biopsy Abnormalities Mimicking Myopathy May Often Be Found In Patients With Lems. Lems Is A Debilitating, But Treatable Disease, Which Often Precedes Detection Of A Malignancy And It Is Therefore Of Obvious Importance To Diagnose These Patients With Speed And Certainty. Hence It Is Important That Neurophysiologists And Neurologists Are Aware That Emg And Histological Abnormalities Mimicking Myopathy May Be Found In Lems Patients So That These Findings Do Not Prolong Or Misdirect The Diagnostic Process In These Patients.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Condition', 'no label'), ('Mimic Myopathy', 'no label'), ('Reports', 'no label'), ('Emg', 'no label'), ('Changes', 'no label'), ('Compatible', 'no label'), ('Myopathy', 'no label'), ('Muscle Biopsies', 'no label'), ('Type Ii', 'no label'), ('Type I Atrophy', 'no label'), ('Emg Results', 'no label'), ('Qualitative Emg Examination', 'no label'), ('Histopathological', 'no label'), ('Methods', 'no label'), ('Clear', 'no label'), ('Study', 'no label'), ('Investigate', 'no label'), ('Emg Findings', 'no label'), ('Confirmed With', 'no label'), ('Quantitative Emg', 'no label'), ('Qemg', 'no label'), ('Muscle Histology', 'no label'), ('Lems', 'no label'), ('Qemg', 'no label'), ('Nerve Conduction Studies', 'no label'), ('Muscle Biopsy', 'no label'), ('Performed', 'no label'), ('Consecutive', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Qemg', 'no label'), ('Decreased', 'no label'), ('Mean', 'no label'), ('Mup Duration', 'no label'), ('Muscle Biopsy', 'no label'), ('Type Ii Fiber Atrophy', 'no label'), ('Emg', 'no label'), ('Biopsy Abnormalities', 'no label'), ('Mimicking', 'no label'), ('Myopathy', 'no label'), ('Found', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Debilitating', 'no label'), ('Treatable Disease', 'no label'), ('Precedes', 'no label'), ('Detection', 'no label'), ('Malignancy', 'no label'), ('Obvious', 'no label'), ('Diagnose', 'no label'), ('Patients', 'no label'), ('Speed', 'no label'), ('Certainty', 'no label'), ('Neurophysiologists', 'no label'), ('Neurologists', 'no label'), ('Aware', 'no label'), ('Emg', 'no label'), ('Histological Abnormalities', 'no label'), ('Mimicking', 'no label'), ('Myopathy', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Findings', 'no label'), ('Not Prolong', 'no label'), ('Misdirect', 'no label'), ('Diagnostic Process', 'no label'), ('Patients', 'no label')]|[]|[('Emg', 'no label'), ('Type Ii', 'no label'), ('Emg', 'no label'), ('Emg', 'no label'), ('Emg', 'no label'), ('Type Ii Fiber', 'no label'), ('Emg', 'no label'), ('Emg', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Myopathy', 'no label'), ('Myopathy', 'no label'), ('Type Ii', 'no label'), ('Atrophy', 'no label'), ('Type Ii Fiber Atrophy', 'no label'), ('Myopathy', 'no label'), ('Malignancy', 'no label'), ('Myopathy', 'no label')]|[('Lems', 'no label'), ('Muscle Biopsies', 'no label'), ('Type Ii', 'no label'), ('Type I', 'no label'), ('Muscle', 'no label'), ('Nerve Conduction Studies', 'no label'), ('Muscle Biopsy Were', 'no label'), ('Lems Patients', 'no label'), ('Muscle Biopsy Showed', 'no label'), ('Type Ii Fiber', 'no label'), ('Biopsy Abnormalities', 'no label'), ('Patients', 'no label'), ('A Malignancy', 'no label'), ('Patients', 'no label'), ('Lems Patients', 'no label'), ('Prolong', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~29507855|Pure Ocular Presentation Of Lambert-Eaton Syndrome Is Not A Common Phenomenon. Such Presentation Poses Significant Diagnostic Challenges And Requires Conscientious Evaluation. In This Review, We Have Described A Case Of A Patient With Pure Ocular Weakness, Initially Diagnosed As Seronegative Ocular Myasthenia Which On Further Evaluation Was Found To Have Ocular Lambert-Eaton Myasthenic Syndrome (Lems).|[('Ocular', 'no label'), ('Presentation', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Common', 'no label'), ('Phenomenon', 'no label'), ('Presentation Poses', 'no label'), ('Significant', 'no label'), ('Diagnostic Challenges', 'no label'), ('Requires', 'no label'), ('Conscientious', 'no label'), ('Evaluation', 'no label'), ('Review', 'no label'), ('Patient', 'no label'), ('Pure Ocular Weakness', 'no label'), ('Diagnosed', 'no label'), ('Seronegative', 'no label'), ('Ocular Myasthenia', 'no label'), ('Evaluation', 'no label'), ('Ocular Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label')]|[]|[]|[('Ocular Presentation', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Ocular Weakness', 'no label'), ('Ocular Myasthenia', 'no label'), ('Ocular Lambert-Eaton Myasthenic Syndrome', 'no label')]|[('Patient', 'no label'), ('Pure Ocular', 'no label'), ('Ocular Myasthenia', 'no label')]
lambert eaton syndrome|pubmed~31743253|"A Case Of Triple-Negative Myasthenia Gravis Lambert-Eaton Overlap Syndrome With Negative Agrin And Lrp-4 Antibodies. Myasthenia Gravis (Mg) Is An Autoimmune Disorder That Shares Similar Features With Lambert-Eaton Myasthenic Syndrome. The Combined Clinical And Electrophysiological Findings Of Mg And Lambert-Eaton Myasthenic Syndrome Have Been Reported, These Cases Represent The So-Called ""Myasthenia Gravis Lambert-Eaton Overlap Syndrome"" (Mlos). A Total Of 55 Mlos Cases Have Been Identified, 13 Cases Were Reported Before The Acetylcholine Receptor (Achr) Antibody (Ab) Testing Era, 14 During The Achr-Ab Era, 26 During The Voltage-Gated Calcium Channel (Vgcc)-Ab Era, And 2 Cases Have Been Reported During The Muscle-Specific Kinase (Musk)-Ab Era, Of These; Only 1 Patient Tested Negative For All 3 Antibodies. New Immunological Markers Have Been Identified In The Study Of Mg [Agrin And The Low-Density Lipopro-Tein Receptor-Related Protein 4 (Lrp-4)]. We Present A Patient With Mlos Who Tested Negative For All 5 (Achr, Musk, Vgcc, Agrin, And Lrp-4) Serologic Markers."|[('Case', 'no label'), ('Triple-Negative Myasthenia Gravis', 'no label'), ('Overlap Syndrome', 'no label'), ('Negative', 'no label'), ('Agrin', 'no label'), ('Lrp-4 Antibodies', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Autoimmune Disorder', 'no label'), ('Shares', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Clinical', 'no label'), ('Electrophysiological Findings', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Cases', 'no label'), ('Represent', 'no label'), ('Overlap Syndrome', 'no label'), ('Cases', 'no label'), ('Identified', 'no label'), ('Cases', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Achr', 'no label'), ('Achr-Ab Era', 'no label'), ('Voltage-Gated Calcium Channel (Vgcc)-Ab', 'no label'), ('Cases', 'no label'), ('Muscle-Specific Kinase (Musk)-Ab', 'no label'), ('Patient', 'no label'), ('Tested Negative', 'no label'), ('Antibodies', 'no label'), ('Immunological', 'no label'), ('Markers', 'no label'), ('Identified', 'no label'), ('Study', 'no label'), ('Mg', 'no label'), ('Agrin', 'no label'), ('Low-Density Lipopro-Tein Receptor-Related Protein 4', 'no label'), ('Lrp-4', 'no label'), ('Patient', 'no label'), ('Negative', 'no label'), ('Achr', 'no label'), ('Musk', 'no label'), ('Vgcc', 'no label'), ('Agrin', 'no label'), ('Lrp-4) Serologic', 'no label'), ('Markers', 'no label')]|[('Agrin', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Antibody', 'no label'), ('Calcium', 'no label'), ('Agrin', 'no label'), ('Protein', 'no label'), ('Agrin', 'no label')]|[('Lrp-4', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Achr-Ab Era, 26 During', 'no label'), ('Muscle-Specific Kinase', 'no label'), ('Low-Density Lipopro-Tein Receptor-Related Protein 4', 'no label'), ('Mlos Who Tested Negative', 'no label')]|[('Triple-Negative Myasthenia Gravis', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Autoimmune Disorder', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenia Gravis', 'no label'), ('Acetylcholine', 'no label'), ('Calcium', 'no label'), ('Mg', 'no label')]|[('Triple-Negative Myasthenia Gravis', 'no label'), ('Agrin', 'no label'), ('Mg', 'no label'), ('55 Mlos', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Calcium', 'no label'), ('Muscle-Specific Kinase', 'no label'), ('Mg', 'no label'), ('Agrin', 'no label'), ('Musk', 'no label'), ('Vgcc', 'no label'), ('Agrin', 'no label')]
lambert eaton syndrome|pubmed~26480796||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~25195700|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disease That Disrupts The Normally Reliable Neurotransmission At The Neuromuscular Junction (Nmj). This Disruption Is Thought To Result From An Autoantibody-Mediated Removal Of A Subset Of The P/Q-Type Ca(2+) Channels Involved With Neurotransmitter Release. With Less Neurotransmitter Release At The Nmj, Lems Patients Experience Debilitating Muscle Weakness. The Underlying Cause Of Lems In Slightly More Than Half Of All Patients Is Small Cell Lung Cancer, And Cancer Therapy Is The Priority For These Patients. In The Remaining Cases, The Cause Of Lems Is Unknown, And These Patients Often Rely On Symptomatic Treatment Options, As There Is No Cure. However, Current Symptomatic Treatment Options, Such As 3,4-Diaminopyridine (3,4-Dap), Can Have Significant Dose-Limiting Side Effects; Thus, Additional Treatment Approaches Would Benefit Lems Patients. Recent Studies Introduced A Novel Ca(2+) Channel Agonist (Gv-58) As A Potential Therapeutic Alternative For Lems. Additionally, This Work Has Shown That Gv-58 And 3,4-Dap Interact In A Supra-Additive Manner To Completely Restore The Magnitude Of Neurotransmitter Release At The Nmjs Of A Lems Mouse Model. In This Review, We Discuss Synaptic Mechanisms For Reliability At The Nmj And How These Mechanisms Are Disrupted In Lems. We Then Discuss The Current Treatment Options For Lems Patients, While Also Considering Recent Work Demonstrating The Therapeutic Potential Of Gv-58 Alone And In Combination With 3,4-Dap. |[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disease', 'no label'), ('Disrupts', 'no label'), ('Neurotransmission', 'no label'), ('Neuromuscular Junction', 'no label'), ('Nmj', 'no label'), ('Disruption', 'no label'), ('Autoantibody-Mediated', 'no label'), ('Removal', 'no label'), ('Subset', 'no label'), ('P/Q-Type Ca(2+) Channels', 'no label'), ('Neurotransmitter Release', 'no label'), ('Neurotransmitter Release', 'no label'), ('Nmj', 'no label'), ('Lems Patients', 'no label'), ('Experience', 'no label'), ('Debilitating Muscle Weakness', 'no label'), ('Cause', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Cancer Therapy', 'no label'), ('Priority', 'no label'), ('Patients', 'no label'), ('Cases', 'no label'), ('Cause', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Rely', 'no label'), ('Symptomatic', 'no label'), ('Treatment Options', 'no label'), ('Cure', 'no label'), ('Symptomatic', 'no label'), ('Treatment Options', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Significant', 'no label'), ('Dose-Limiting Side Effects', 'no label'), ('Treatment Approaches', 'no label'), ('Patients', 'no label'), ('Studies', 'no label'), ('Introduced', 'no label'), ('Novel', 'no label'), ('Ca(2+) Channel Agonist', 'no label'), ('Gv-58', 'no label'), ('Therapeutic Alternative', 'no label'), ('Lems', 'no label'), ('Work', 'no label'), ('Gv-58', 'no label'), ('Interact', 'no label'), ('Supra-Additive', 'no label'), ('Manner', 'no label'), ('Restore', 'no label'), ('Magnitude', 'no label'), ('Neurotransmitter Release', 'no label'), ('Nmjs', 'no label'), ('Lems Mouse Model', 'no label'), ('Review', 'no label'), ('Synaptic Mechanisms', 'no label'), ('Reliability', 'no label'), ('Nmj', 'no label'), ('Mechanisms', 'no label'), ('Disrupted', 'no label'), ('Lems', 'no label'), ('Discuss', 'no label'), ('Current', 'no label'), ('Treatment Options', 'no label'), ('Lems Patients', 'no label'), ('Work', 'no label'), ('Therapeutic', 'no label'), ('Potential', 'no label'), ('Gv-58 Alone', 'no label'), ('Combination', 'no label')]|[('P/Q-Type', 'no label'), ('Neurotransmitter', 'no label'), ('Neurotransmitter', 'no label'), ('Cell', 'no label'), ('Agonist', 'no label'), ('Neurotransmitter', 'no label'), ('Mouse', 'no label')]|[('Nmj', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('P/Q-Type', 'no label'), ('Muscle Weakness', 'no label'), ('Cancer', 'no label'), ('3,4-Diaminopyridine', 'no label')]|[('Neuromuscular', 'no label'), ('P/Q-Type Ca(2+', 'no label'), ('Neurotransmitter', 'no label'), ('Lems Patients Experience', 'no label'), ('Muscle', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Cancer', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Rely', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Patients', 'no label'), ('Neurotransmitter', 'no label'), ('Lems Mouse', 'no label'), ('Synaptic', 'no label'), ('Lems Patients', 'no label')]
lambert eaton syndrome|pubmed~32496121|We Present The Case Of A 50-Year-Old Male Diagnosed With Myasthenia Gravis, Secondary To Thymoma Or Lambert-Eaton Syndrome During The Study Of Repeated Vomiting. Gastrointestinal Symptoms Persisted Despite The Treatment Of The Thymoma. He Suffered From Sigma Volvulus That Required Sigmoidectomy 9 Years After Diagnosis. Neuromuscular Junction Disorders Are Not Characterized By Gastrointestinal Involvement, As In Our Case. They Have Previously Sporadically Been Related To Intestinal Motility Dysfunction.|[('Male Diagnosed', 'no label'), ('Myasthenia Gravis', 'no label'), ('Secondary', 'no label'), ('Thymoma', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Study', 'no label'), ('Repeated Vomiting', 'no label'), ('Gastrointestinal Symptoms', 'no label'), ('Persisted', 'no label'), ('Treatment', 'no label'), ('Thymoma', 'no label'), ('Suffered', 'no label'), ('Sigma Volvulus', 'no label'), ('Sigmoidectomy', 'no label'), ('Years', 'no label'), ('Diagnosis', 'no label'), ('Neuromuscular Junction Disorders', 'no label'), ('Characterized', 'no label'), ('Gastrointestinal Involvement', 'no label'), ('Case', 'no label'), ('Intestinal Motility', 'no label'), ('Dysfunction', 'no label')]|[]|[]|[('Myasthenia Gravis', 'no label'), ('Thymoma', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Vomiting', 'no label'), ('Thymoma', 'no label'), ('Intestinal Motility Dysfunction', 'no label')]|[('Case Of A', 'no label'), ('Thymoma', 'no label'), ('Thymoma', 'no label'), ('Intestinal', 'no label')]
lambert eaton syndrome|pubmed~31780213||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~31072737|In Order To Describe The Clinical Characteristics, Treatment Response And Long-Term Follow Up In Lambert-Eaton Myasthenic Syndrome (Lems) Patients With And Without Small Cell Lung Cancer (Sclc) In East China, Patients Seen In Huashan Hospital From January 1997 To December 2017 Were Included. Clinical Information Was Collected Retrospectively And Quantitative Mg (Qmg) Score, Manual Muscle Testing (Mmt), Activities Of Daily Living (Adl) Scale Were Evaluated When The Patients Were Followed Up. Of 50 Patients, 23 (46%) Were Sclc-Lems And 20 (40%) Were Nontumor Lems (Nt-Lems). The Median Onset Age Was 55.5 (18-86) Years Old And The Gender Ratio Was About 1.8:1. It Took Less Time To Make The Diagnosis (Median Time: 6 Vs 22.5 Months, P = 0.0003) And There Were More Patients With Other Paraneoplastic Syndromes In Sclc-Lems Group Than In Nt-Lems Group (8/23 Vs 0/20, P = 0.0042). Electrophysiologically, The Peroneal Compound Motor Action Potential (Cmap) Of Rest Showed Difference Between Sclc-Lems And Nt-Lems (0.8 Vs 1.6 Mv, P = 0.0499). The Median Survival Time Of 19 Sclc-Lems Patients Since The Diagnosis Of Sclc Was 30 Months. According To Their Survival Time, Sclc Patients With Lems Showed A More Favorable Prognosis Than Those Without Lems. In The Time Of Follow-Up, Most Nt-Lems Showed Improvement Or Obtained Status Of Csr/Pr/Mm After Immunosuppressive Therapy And No Significant Difference In Proportion Of Achieving Csr/Pr/Mm Was Found Between Sclc-Lems And Nt-Lems Patients (0/5 Vs 6/13, P = 0.114).|[('Order', 'no label'), ('Clinical Characteristics', 'no label'), ('Treatment Response', 'no label'), ('Long-Term', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('East China', 'no label'), ('Patients', 'no label'), ('Huashan Hospital', 'no label'), ('Clinical Information', 'no label'), ('Retrospectively', 'no label'), ('Quantitative Mg', 'no label'), ('Manual Muscle Testing', 'no label'), ('Mmt', 'no label'), ('Activities Of Daily Living', 'no label'), ('Patients', 'no label'), ('Followed Up', 'no label'), ('Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Nontumor Lems', 'no label'), ('Median Onset Age', 'no label'), ('Years Old', 'no label'), ('Gender', 'no label'), ('Ratio', 'no label'), ('Took Less Time', 'no label'), ('Diagnosis', 'no label'), ('Median Time', 'no label'), ('Months', 'no label'), ('Patients', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Sclc-Lems', 'no label'), ('Group', 'no label'), ('Than', 'no label'), ('Nt-Lems Group', 'no label'), ('Electrophysiologically', 'no label'), ('Peroneal Compound Motor Action Potential', 'no label'), ('Cmap', 'no label'), ('Rest Showed Difference', 'no label'), ('Sclc-Lems', 'no label'), ('Nt-Lems', 'no label'), ('Median Survival Time', 'no label'), ('Sclc-Lems', 'no label'), ('Patients', 'no label'), ('Diagnosis', 'no label'), ('Sclc', 'no label'), ('Months', 'no label'), ('Survival Time', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Showed A', 'no label'), ('Favorable', 'no label'), ('Prognosis', 'no label'), ('Lems', 'no label'), ('Time', 'no label'), ('Follow-Up', 'no label'), ('Nt-Lems Showed', 'no label'), ('Improvement', 'no label'), ('Obtained Status', 'no label'), ('Csr/Pr/Mm', 'no label'), ('Immunosuppressive Therapy', 'no label'), ('No Significant Difference', 'no label'), ('Proportion', 'no label'), ('Csr/Pr/Mm', 'no label'), ('Sclc-Lems', 'no label'), ('Nt-Lems', 'no label'), ('Patients', 'no label')]|[('Cell', 'no label'), ('Sclc-Lems', 'no label'), ('Sclc-Lems', 'no label'), ('Sclc-Lems', 'no label'), ('Csr/Pr/Mm', 'no label'), ('Csr/Pr/Mm', 'no label'), ('Sclc-Lems', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Mg', 'no label'), ('Nontumor', 'no label'), ('Paraneoplastic Syndromes In Sclc-Lems Group Than In Nt-Lems Group', 'no label'), ('Prognosis', 'no label')]|[('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Muscle', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Nontumor Lems', 'no label'), ('Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Peroneal Compound', 'no label'), ('Sclc-Lems', 'no label'), ('Sclc-Lems Patients', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Sclc-Lems', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~24862203|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Presynaptic Neuromuscular Disorder. Autoantibodies Against Subunits Of Voltage-Gated Calcium Channels (Vgccs) Associated With Acetylcholine Release Are Thought To Cause Lems. Hek293 Cells Expressing Specific Individual Recombinant Subunits Of Α(1A), Α(1B), Α(1C), And Α(1E); Β(3); And Α(2)Δ Of Human Neuronal Vgccs Were Exposed To Antibodies From 3 Lems Patients, 1 Patient With Small-Cell Lung Carcinoma, And 1 With Myasthenia Gravis. All Lems Patient Antibodies Bound To Cells Containing Any Of The Α(1) Or Β(3) Subunits Alone Or Combined With Α(2)Δ Subunits, But Not Α(2)Δ Alone. Autoantibodies From The Patient With Small-Cell Lung Carcinoma But Not The Myasthenia Gravis Patient Targeted The Same Vgcc Subunits. Autoantibodies From Lems Patients Bind Directly To Multiple Vgcc Α(1) Subunits As Well As The Β(3) Subunit. Thus, Multiple Components Of The Presynaptic Vgcc Complex Are Prospective Targets For Antibodies In Lems.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Presynaptic Neuromuscular Disorder', 'no label'), ('Autoantibodies', 'no label'), ('Subunits', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Vgccs', 'no label'), ('Associated With', 'no label'), ('Acetylcholine Release', 'no label'), ('Hek293 Cells', 'no label'), ('Expressing', 'no label'), ('Recombinant Subunits', 'no label'), ('Α(1B)', 'no label'), ('Α(2)Δ', 'no label'), ('Human Neuronal Vgccs', 'no label'), ('Exposed', 'no label'), ('Antibodies', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Patient', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Myasthenia Gravis', 'no label'), ('Lems Patient Antibodies', 'no label'), ('Bound', 'no label'), ('Cells', 'no label'), ('Containing', 'no label'), ('Α(1)', 'no label'), ('Α(2)Δ Subunits', 'no label'), ('Alone', 'no label'), ('Autoantibodies', 'no label'), ('Patient', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Myasthenia Gravis', 'no label'), ('Patient', 'no label'), ('Vgcc', 'no label'), ('Subunits', 'no label'), ('Autoantibodies', 'no label'), ('Lems Patients', 'no label'), ('Multiple', 'no label'), ('Vgcc', 'no label'), ('Α(1) Subunits', 'no label'), ('Subunit', 'no label'), ('Multiple Components', 'no label'), ('Presynaptic Vgcc Complex', 'no label'), ('Prospective Targets', 'no label'), ('Antibodies', 'no label')]|[('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Cells', 'no label'), ('Human Neuronal Vgccs', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Cells', 'no label'), ('Antibodies', 'no label')]|[('Hek293 Cells', 'no label'), ('Presynaptic Vgcc Complex', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Presynaptic Neuromuscular Disorder', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Lung Carcinoma', 'no label'), ('Myasthenia Gravis', 'no label'), ('Lung Carcinoma', 'no label'), ('Myasthenia Gravis', 'no label')]|[('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Hek293 Cells', 'no label'), ('Human Neuronal Vgccs', 'no label'), ('Patients', 'no label'), ('Patient', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Lems Patient Antibodies', 'no label'), ('Cells', 'no label'), ('Subunits', 'no label'), ('Patient', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Lems Patients', 'no label'), ('Vgcc Α(1', 'no label'), ('Presynaptic Vgcc Complex', 'no label')]
lambert eaton syndrome|pubmed~25444432|We Evaluated The Efficacy Of Intravenous Immunoglobulin (Ivig) In A Patient With Lambert-Eaton Myasthenic Syndrome (Lems). Comprehensive Clinical And Electrophysiological Testing Was Performed On A 34-Year-Old Woman With Progressive Limb Weakness, Before And After Ivig Treatment. Neurological Examination Revealed Muscle Weakness, Predominantly In The Proximal Parts Of The Limbs. Muscle Weakness Improved Following A Short Period Of Maximum Voluntary Muscle Contraction. A Repetitive Low-Rate (3-Hz) Nerve Stimulation Test Of The Abductor Hallucis Was Normal, But High-Rate (20-Hz) Stimulation Induced An Incremental Response. Anti-Presynaptic P/Q-Type Voltage-Gated Calcium Channel (P/Q-Vgcc) Antibodies Were Absent In The Patient'S Serum. Whole Body Computed Tomography Revealed No Tumors. We Diagnosed Seronegative Lems Without Tumor And Treated The Patient With Ivig. Both Clinical And Electrophysiological Indices Improved Gradually After Treatment. This Case Study Indicates That Treatment With Ivig Is Equally Effective For Lems That Is Seronegative Or Seropositive For P/Q-Vgcc Antibodies. |"[('Evaluated', 'no label'), ('Efficacy', 'no label'), ('Intravenous Immunoglobulin', 'no label'), ('Ivig', 'no label'), ('Patient', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Comprehensive', 'no label'), ('Clinical', 'no label'), ('Electrophysiological Testing', 'no label'), ('Performed', 'no label'), ('Progressive Limb Weakness', 'no label'), ('Ivig Treatment', 'no label'), ('Neurological Examination Revealed', 'no label'), ('Muscle Weakness', 'no label'), ('Proximal Parts', 'no label'), ('Limbs', 'no label'), ('Muscle Weakness', 'no label'), ('Short Period', 'no label'), ('Maximum', 'no label'), ('Voluntary Muscle Contraction', 'no label'), ('Repetitive Low-Rate', 'no label'), ('Nerve Stimulation Test', 'no label'), ('Abductor Hallucis', 'no label'), ('High-Rate (20-Hz) Stimulation', 'no label'), ('Incremental Response', 'no label'), ('Anti-Presynaptic P/Q-Type Voltage-Gated Calcium Channel', 'no label'), ('Absent', 'no label'), (""Patient'S"", 'no label'), ('Serum', 'no label'), ('Whole Body Computed Tomography', 'no label'), ('Revealed', 'no label'), ('Tumors', 'no label'), ('Diagnosed', 'no label'), ('Tumor', 'no label'), ('Treated', 'no label'), ('Patient', 'no label'), ('Ivig', 'no label'), ('Clinical', 'no label'), ('Electrophysiological Indices', 'no label'), ('Treatment', 'no label'), ('Case Study Indicates', 'no label'), ('Treatment', 'no label'), ('Ivig', 'no label'), ('Effective', 'no label'), ('Lems', 'no label'), ('Seronegative', 'no label'), ('Seropositive', 'no label'), ('Antibodies', 'no label')]"|[('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Weakness', 'no label'), ('Muscle Weakness', 'no label'), ('Muscle Weakness', 'no label'), ('Voluntary Muscle Contraction', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Tumors', 'no label'), ('Tumor', 'no label')]|[('Intravenous Immunoglobulin', 'no label'), ('Limb', 'no label'), ('Muscle', 'no label'), ('Limbs.', 'no label'), ('Muscle', 'no label'), ('Voluntary Muscle', 'no label'), ('Abductor Hallucis', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Patient', 'no label'), ('Serum', 'no label'), ('Tumors', 'no label'), ('Lems', 'no label'), ('Tumor', 'no label'), ('Patient', 'no label'), ('P/Q-Vgcc', 'no label')]
lambert eaton syndrome|pubmed~30627102|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Representative Paraneoplastic Neurological Syndrome. Recently, Nivolumab, An Anti-Programmed Cell Death 1 Inhibitor, Has Been Approved For Advanced Non-Small-Cell Lung Cancer. Careful Attention Should Be Paid To Immune-Related Adverse Events (Iraes), Including Neurotoxicity. We Herein Report A 73-Year-Old Woman With Lems That Occurred During Nivolumab Treatment For Pulmonary Squamous Cell Carcinoma. After The 20Th Week Of Nivolumab, She Experienced Various Neurological Symptoms Such As Ptosis, Lower Limb Weakness, And Photophobia. Findings From A Nerve Conduction Study And A Positive Anti-P/Q-Type Voltage-Gated Calcium Channel Antibody Made A Diagnosis Of Lems. Pyridostigmine And 3,4-Diaminopyridine Temporarily Improved Her Symptoms. This Was The First Case Of Lems As A Neurological Irae. Lems Should Be Considered As A Possible Neurological Irae.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Representative Paraneoplastic Neurological Syndrome', 'no label'), ('Nivolumab', 'no label'), ('Anti-Programmed Cell Death', 'no label'), ('Inhibitor', 'no label'), ('Non-Small-Cell Lung Cancer', 'no label'), ('Attention', 'no label'), ('Paid', 'no label'), ('Immune-Related Adverse Events', 'no label'), ('Iraes', 'no label'), ('Neurotoxicity', 'no label'), ('Lems', 'no label'), ('Nivolumab', 'no label'), ('Treatment', 'no label'), ('Pulmonary Squamous Cell Carcinoma', 'no label'), ('Week', 'no label'), ('Nivolumab', 'no label'), ('Neurological Symptoms', 'no label'), ('Ptosis', 'no label'), ('Lower Limb Weakness', 'no label'), ('Photophobia', 'no label'), ('Findings', 'no label'), ('Nerve Conduction Study', 'no label'), ('Positive Anti-P/Q-Type Voltage-Gated Calcium Channel Antibody', 'no label'), ('Made A', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Pyridostigmine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Improved', 'no label'), ('Symptoms', 'no label'), ('Neurological Irae', 'no label'), ('Lems', 'no label'), ('Neurological Irae', 'no label')]|[('Cell', 'no label'), ('Squamous Cell', 'no label'), ('Calcium', 'no label'), ('Antibody', 'no label'), ('Pyridostigmine', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Neurological Syndrome', 'no label'), ('Death', 'no label'), ('Non-Small-Cell Lung Cancer', 'no label'), ('Neurotoxicity', 'no label'), ('Pulmonary Squamous Cell Carcinoma', 'no label'), ('Ptosis, Lower Limb Weakness', 'no label'), ('Photophobia', 'no label'), ('Anti-P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Pyridostigmine', 'no label'), ('3,4-Diaminopyridine', 'no label')]|[('Nivolumab', 'no label'), ('Cell', 'no label'), ('Non-Small-Cell Lung Cancer', 'no label'), ('Lems', 'no label'), ('Nivolumab', 'no label'), ('Pulmonary Squamous Cell Carcinoma', 'no label'), ('Nivolumab', 'no label'), ('Lower Limb', 'no label'), ('Calcium', 'no label'), ('Pyridostigmine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~24269050||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~31637147|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune-Mediated Neurological Disorder That Manifests As Muscle Fatigue, Diminished Tendon Reflexes, With Symptoms Of Cholinergic Overactivity. It Can Be Associated With Certain Neoplastic Conditions, The Most Common Being Small Cell Lung Carcinoma (Sclc). The Basic Pathophysiology Involved Is Antibody-Mediated Targeting Of Voltage-Gated Calcium Channels (Vgcc), Which Decreases The Release Of Acetylcholine In The Synaptic Junction. Multiple Treatment Options Have Been Introduced In The Past And, Recently, A New Drug, Amifampridine, Has Been Approved By The Food And Drug Administration (Fda) For The Treatment Of Weakness Associated With These Patients. We Summarize This Newly Introduced Drug With A Brief Description Of Other Treatment Options Available.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune-Mediated Neurological Disorder', 'no label'), ('Muscle Fatigue', 'no label'), ('Diminished', 'no label'), ('Tendon Reflexes', 'no label'), ('Symptoms', 'no label'), ('Cholinergic', 'no label'), ('Overactivity', 'no label'), ('Associated With', 'no label'), ('Neoplastic Conditions', 'no label'), ('Common Being Small Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Pathophysiology', 'no label'), ('Targeting', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Vgcc', 'no label'), ('Decreases', 'no label'), ('Release', 'no label'), ('Acetylcholine', 'no label'), ('Synaptic Junction', 'no label'), ('Multiple Treatment Options', 'no label'), ('New Drug', 'no label'), ('Amifampridine', 'no label'), ('Food And Drug Administration', 'no label'), ('Fda', 'no label'), ('Treatment', 'no label'), ('Weakness', 'no label'), ('Associated With', 'no label'), ('Patients', 'no label'), ('Newly', 'no label'), ('Drug With', 'no label'), ('Brief', 'no label'), ('Description', 'no label'), ('Treatment Options', 'no label'), ('Available', 'no label')]|[('Cell', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Drug', 'no label'), ('Food', 'no label'), ('Drug', 'no label'), ('Drug', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Neurological Disorder', 'no label'), ('Muscle Fatigue', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Weakness', 'no label')]|[('Muscle', 'no label'), ('Cholinergic', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Synaptic', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~28374700|To Investigate The Pattern Of Decrement In The Muscles Of Patients With Myasthenia Gravis (Mg) And Lambert-Eaton Myasthenic Syndrome (Lems). Twenty-Seven Patients With Mg And 39 Patients With Lems Were Studied Using Low Frequency Repetitive Nerve Stimulation (3/ Sec). The Decrease Of Safety Factor Of Neuromuscular Transmission Was Equal In Both Groups. At The Same Time, A Significant Difference In The Decrease Of Pattern Of The Amplitude Compound Of Muscle Action Potential (Cmap) Was Found. In Lems, By Contrast With Mg, Another Sequence Of Amplitude Variability Of Cmap From The Second Stimulus To The First And From The Fifth Stimulus To The Fourth Was Noted. In Lems Patients, Progressive Decrement, Manifesting By Increasing Ratios Of Late A9/A1 To Early A4/A1 Was Found, Whereas The Mg Patients Showed Retrogressive Decrement Expressed By The Reduction In Decrement Ratio (From Late To Early). These Differences Reflect The Mechanisms And Status Of Acetylcholine Mobilization And Release From The Axon Terminal.|[('Investigate', 'no label'), ('Pattern', 'no label'), ('Decrement', 'no label'), ('Muscles', 'no label'), ('Patients', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Low Frequency Repetitive Nerve Stimulation', 'no label'), ('Sec', 'no label'), ('Decrease', 'no label'), ('Safety Factor', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Equal', 'no label'), ('Groups', 'no label'), ('Same Time', 'no label'), ('Decrease', 'no label'), ('Pattern', 'no label'), ('Amplitude Compound', 'no label'), ('Muscle Action Potential', 'no label'), ('Cmap', 'no label'), ('Mg', 'no label'), ('Sequence', 'no label'), ('Amplitude Variability', 'no label'), ('Cmap', 'no label'), ('Stimulus', 'no label'), ('Stimulus', 'no label'), ('Noted', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Progressive Decrement', 'no label'), ('Manifesting', 'no label'), ('Increasing', 'no label'), ('Ratios', 'no label'), ('Late A9/A1', 'no label'), ('Early A4/A1', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Retrogressive Decrement', 'no label'), ('Expressed', 'no label'), ('Reduction', 'no label'), ('Decrement', 'no label'), ('Ratio', 'no label'), ('Early', 'no label'), ('Reflect', 'no label'), ('Mechanisms', 'no label'), ('Status', 'no label'), ('Acetylcholine Mobilization', 'no label'), ('Release', 'no label'), ('Axon Terminal', 'no label')]|[('Sequence', 'no label'), ('Acetylcholine', 'no label')]|[]|[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Acetylcholine', 'no label')]|[('Muscles', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Nerve', 'no label'), ('3/ Sec', 'no label'), ('Neuromuscular', 'no label'), ('Muscle', 'no label'), ('Mg', 'no label'), ('Lems Patients', 'no label'), ('Mg Patients', 'no label'), ('Acetylcholine', 'no label'), ('Axon', 'no label')]
lambert eaton syndrome|pubmed~26263702|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare Autoimmune Disorder Affecting Neuromuscular Junctions. Lems Has Served As A Model Of Paraneoplastic Neurological Syndromes And Antitumoral Immunity, Shedding Light On The Pathological Role Of Autoantibodies Directed Against Synaptic Targets. Autoantibodies Associated With Lems Are Directed Against Voltage-Gated Calcium Channels (Vgcc) Present On Nerve Terminals Of Neuromuscular Synapses. Anti-Vggc Antibodies Play A Direct Pathological Role In Lems By Blocking Vgcc And Calcium Entry During Depolarisation. Nearly Half Of Patients With Lems Have Small-Cell Lung Cancer (Sclc), Which Also Expresses Vgcc. Diagnosis Of Lems Frequently Permits Early Detection And Treatment Of Sclc Knowledge Of This Syndrome Has Led To The Discovery Of A Broad Range Of Cancerous And Non Cancerous Antibody-Mediated Neurological Syndromes, And Led To The Concept Of Autoimmune Synaptopathies.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Autoimmune Disorder', 'no label'), ('Affecting', 'no label'), ('Neuromuscular Junctions', 'no label'), ('Lems', 'no label'), ('Model', 'no label'), ('Paraneoplastic Neurological Syndromes', 'no label'), ('Antitumoral Immunity', 'no label'), ('Shedding Light', 'no label'), ('Pathological Role', 'no label'), ('Autoantibodies', 'no label'), ('Directed', 'no label'), ('Synaptic', 'no label'), ('Targets', 'no label'), ('Autoantibodies', 'no label'), ('Associated With', 'no label'), ('Lems', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Vgcc', 'no label'), ('Present', 'no label'), ('Nerve', 'no label'), ('Terminals', 'no label'), ('Neuromuscular Synapses', 'no label'), ('Anti-Vggc Antibodies', 'no label'), ('Play A', 'no label'), ('Pathological', 'no label'), ('Blocking', 'no label'), ('Vgcc', 'no label'), ('Calcium Entry', 'no label'), ('Depolarisation', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Expresses', 'no label'), ('Vgcc', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Detection', 'no label'), ('Treatment', 'no label'), ('Sclc', 'no label'), ('Knowledge', 'no label'), ('Syndrome', 'no label'), ('Discovery', 'no label'), ('Broad Range', 'no label'), ('Cancerous', 'no label'), ('Non Cancerous Antibody-Mediated Neurological Syndromes', 'no label'), ('Concept', 'no label'), ('Autoimmune Synaptopathies', 'no label')]|[('Calcium', 'no label'), ('Synapses', 'no label'), ('Antibodies', 'no label'), ('Calcium', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Paraneoplastic Neurological Syndromes And Antitumoral Immunity', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Lung Cancer', 'no label'), ('Cancerous Antibody-Mediated Neurological Syndromes', 'no label'), ('Autoimmune Synaptopathies', 'no label')]|[('Neuromuscular', 'no label'), ('Antitumoral', 'no label'), ('Autoantibodies', 'no label'), ('Synaptic', 'no label'), ('Lems', 'no label'), ('Calcium', 'no label'), ('Neuromuscular Synapses', 'no label'), ('Lems', 'no label'), ('Vgcc', 'no label'), ('Calcium', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Lems Frequently', 'no label'), ('Cancerous And Non Cancerous', 'no label')]
lambert eaton syndrome|pubmed~23568992|Antibodies Against The Muscle Acetylcholine Receptor (Achr) Were Recognized As The Cause Of Myasthenia Gravis In The 1970S'. Since Then, Other Neurological Disorders Associated With Autoantibodies Have Been Identified, Each Associated With An Antibody Against A Ligand- Or Voltage-Gated Ion Channel. Autoantibodies Against P/Q-Type Voltage-Gated Calcium Channels (Vgccs) Are Detected In Patients With Lambert-Eaton Myasthenic Syndrome (Lems). These Antibodies Interfere With The Calcium-Dependent Release Of Acetylcholine From The Presynaptic Membrane. Lems Is An Autoimmune Disorder Affecting The Neuromuscular Junction, And Is Characterized By Proximal Muscle Weakness, Reduction Of Tendon Reflex, And Autonomic Dysfunction. Electrophysiological Examinations Show Small-Amplitude Compound Muscle Action Potentials And Increments On Rapid Repetitive Nerve Stimulation. Fifty To Sixty Percent Of Lems Patients Present With Tumors, Mostly Small Cell Lung Carcinoma (Sclc), As A Paraneoplastic Syndrome. Sclc Is A Neuroendocrine Tumor, Which Expresses Neuronal Vgccs. Some Patients Present Cerebellar Ataxia, Which Is Always Accompanied By Sclc. These Patients Tend To Show Higher Titers Of Vgcc Antibodies Than That By Lems Patients With No Ataxia. The Diagnosis Can Be Confirmed By Finding Reduced Compound Muscle Action Potential Amplitudes At Rest That Shows Increments Greater Than 100% With Repetitive Nerve Stimulation And Antibody Detection By Using Radioimmunoprecipitation Assays. The Treatment Options Are Generally Categorized As Anti-Tumor, Immunomodulating, Immunosuppressing, And Symptomatic Treatments. In Cases With Sclc, Effective Treatment Against The Tumor Can Improve Lems. Plasmapheresis And Intravenous Administration Of High-Dose Immunoglobulins Have A Short Effect. Prednisone, Alone Or In Combination With Immunosuppressants Can Achieve Long-Term Control Of The Disorder.|[('Antibodies', 'no label'), ('Muscle Acetylcholine Receptor', 'no label'), ('Achr', 'no label'), ('Cause', 'no label'), ('Myasthenia Gravis', 'no label'), ('Neurological Disorders', 'no label'), ('Associated With', 'no label'), ('Autoantibodies', 'no label'), ('Identified', 'no label'), ('Associated With', 'no label'), ('Antibody', 'no label'), ('Against', 'no label'), ('Ligand- Or Voltage-Gated Ion Channel', 'no label'), ('Autoantibodies', 'no label'), ('P/Q-Type Voltage-Gated Calcium Channels', 'no label'), ('Vgccs', 'no label'), ('Detected', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Antibodies', 'no label'), ('Calcium-Dependent Release', 'no label'), ('Acetylcholine', 'no label'), ('Presynaptic Membrane', 'no label'), ('Lems', 'no label'), ('Autoimmune Disorder', 'no label'), ('Affecting', 'no label'), ('Neuromuscular Junction', 'no label'), ('Characterized', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Reduction', 'no label'), ('Tendon Reflex', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Electrophysiological Examinations', 'no label'), ('Small-Amplitude Compound Muscle', 'no label'), ('Increments', 'no label'), ('Repetitive Nerve', 'no label'), ('Stimulation', 'no label'), ('Lems Patients', 'no label'), ('Tumors', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Sclc', 'no label'), ('Neuroendocrine Tumor', 'no label'), ('Expresses', 'no label'), ('Neuronal Vgccs', 'no label'), ('Patients', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Accompanied', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Tend', 'no label'), ('Higher', 'no label'), ('Titers', 'no label'), ('Vgcc Antibodies', 'no label'), ('Patients', 'no label'), ('Ataxia', 'no label'), ('Diagnosis', 'no label'), ('Confirmed', 'no label'), ('Reduced', 'no label'), ('Compound Muscle', 'no label'), ('Amplitudes', 'no label'), ('Rest', 'no label'), ('Increments', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Antibody', 'no label'), ('Detection', 'no label'), ('Radioimmunoprecipitation Assays', 'no label'), ('Treatment Options', 'no label'), ('Categorized', 'no label'), ('Anti-Tumor', 'no label'), ('Immunomodulating', 'no label'), ('Immunosuppressing', 'no label'), ('Symptomatic', 'no label'), ('Treatments', 'no label'), ('Cases', 'no label'), ('Sclc', 'no label'), ('Effective Treatment Against', 'no label'), ('Tumor', 'no label'), ('Plasmapheresis', 'no label'), ('Intravenous Administration', 'no label'), ('High-Dose Immunoglobulins', 'no label'), ('Short Effect', 'no label'), ('Prednisone', 'no label'), ('Alone', 'no label'), ('Combination', 'no label'), ('Immunosuppressants', 'no label'), ('Long-Term Control', 'no label'), ('Disorder', 'no label')]|[('Antibodies', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Antibody', 'no label'), ('Ion', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('Acetylcholine', 'no label'), ('Cell', 'no label'), ('Neuronal Vgccs', 'no label'), ('Antibodies', 'no label'), ('Antibody', 'no label'), ('Immunoglobulins', 'no label')]|[('Muscle Acetylcholine Receptor', 'no label'), ('High-Dose Immunoglobulins', 'no label')]|[('Acetylcholine', 'no label'), ('Myasthenia Gravis', 'no label'), ('Neurological Disorders', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Acetylcholine', 'no label'), ('Autoimmune Disorder', 'no label'), ('Muscle Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Tumors', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Tumor', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Ataxia', 'no label'), ('Tumor', 'no label'), ('Prednisone', 'no label'), ('Disorder', 'no label')]|[('Muscle Acetylcholine Receptor', 'no label'), ('Ligand-', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Patients', 'no label'), ('Acetylcholine', 'no label'), ('Presynaptic Membrane', 'no label'), ('Neuromuscular', 'no label'), ('Muscle', 'no label'), ('Tendon', 'no label'), ('Nerve', 'no label'), ('Lems Patients', 'no label'), ('Tumors', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Neuroendocrine Tumor', 'no label'), ('Neuronal', 'no label'), ('Patients', 'no label'), ('Cerebellar', 'no label'), ('Patients', 'no label'), ('Vgcc Antibodies', 'no label'), ('Lems Patients', 'no label'), ('Anti-Tumor', 'no label'), ('Tumor', 'no label'), ('Intravenous', 'no label'), ('Prednisone', 'no label')]
lambert eaton syndrome|pubmed~24332471|We Reviewed Our Experience To Determine If The Decremental Pattern During Low Frequency Repetitive Nerve Stimulation (Lf-Rns) Distinguishes Between The Lambert-Eaton Myasthenic Syndrome (Lems) And Myasthenia Gravis (Mg). Lf-Rns Studies Were Reviewed From 34 Lems And 44 Mg Patients, 4 Of Whom Had Antibodies To Muscle Specific Kinase (Musk). In Each Train We Calculated The Ratio Between The Early And The Later Decrement. Receiver-Operator Characteristic Curves Were Calculated To Determine The Ratio That Best Distinguished Between Lems And Mg. The Late Decrement Was More Often Greater In Lems And The Converse Was True In Mg, But With Some Overlap In Values In Individual Patients. A Late Decrement More Than 102% Of The Early Decrement Discriminated Between Lems And Mg In 90% Of Studies. The Decremental Pattern In Mg Patients With Musk Antibodies Resembled That In Lems. When The Decrement Becomes Progressively Greater During Low Frequency Rns, The Patient Is More Likely To Have Lems Than Mg, And In Mg, Is More Likely To Have Musk Antibodies. A Progressive Decrement In Patients Otherwise Felt To Have Mg Should Prompt Further Clinical, Serological And Electrodiagnostic Tests. Further Studies Are Needed To Assess The Decremental Pattern In Musk Mg.|[('Reviewed', 'no label'), ('Decremental Pattern', 'no label'), ('Low Frequency Repetitive Nerve Stimulation', 'no label'), ('Distinguishes', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Lf-Rns Studies', 'no label'), ('Reviewed', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Antibodies', 'no label'), ('Muscle Specific Kinase', 'no label'), ('Musk', 'no label'), ('Train', 'no label'), ('Ratio', 'no label'), ('Early', 'no label'), ('Decrement', 'no label'), ('Receiver-Operator Characteristic Curves', 'no label'), ('Ratio', 'no label'), ('Distinguished', 'no label'), ('Mg', 'no label'), ('Late Decrement', 'no label'), ('Lems', 'no label'), ('Converse Was True', 'no label'), ('Mg', 'no label'), ('Overlap', 'no label'), ('Values', 'no label'), ('Patients', 'no label'), ('Late Decrement', 'no label'), ('Early Decrement Discriminated', 'no label'), ('Lems', 'no label'), ('Studies', 'no label'), ('Decremental Pattern', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Musk Antibodies', 'no label'), ('Resembled', 'no label'), ('Decrement', 'no label'), ('Becomes', 'no label'), ('Low Frequency Rns', 'no label'), ('Patient', 'no label'), ('Lems Than Mg', 'no label'), ('Musk Antibodies', 'no label'), ('Progressive Decrement', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Prompt', 'no label'), ('Clinical', 'no label'), ('Serological', 'no label'), ('Electrodiagnostic Tests', 'no label'), ('Studies', 'no label'), ('Decremental Pattern', 'no label'), ('Musk Mg', 'no label')]|[('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Musk Mg', 'no label')]|[('Lf-Rns', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label')]|[('Decremental Pattern', 'no label'), ('Nerve', 'no label'), ('Lems And', 'no label'), ('Muscle', 'no label'), ('Musk', 'no label'), ('Lems', 'no label'), ('Mg', 'no label'), ('Lems', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Mg', 'no label'), ('Decremental Pattern', 'no label'), ('Mg Patients', 'no label'), ('Musk', 'no label'), ('Rns', 'no label'), ('Patient', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Musk', 'no label'), ('Patients', 'no label'), ('Felt', 'no label'), ('Mg', 'no label'), ('Decremental Pattern', 'no label'), ('Musk Mg', 'no label')]
lambert eaton syndrome|pubmed~24128793|To Study Post-Exercise Exhaustion By Decrement (Pee-D) Systematically In 24 Repetitive Nerve Stimulation (Rns) Tests In 14 Patients With Lambert-Eaton Myasthenic Syndrome (Lems). In The Abductor Digiti Quinti Muscle, The Compound Muscle Action Potential (Cmap) Amplitude And 3Hz Responses For 2S Were Obtained With The Supramaximal Stimulation At Rest, Immediately After (Pe0), 30S After (Pe30S), And At 1, 2, 3, And 4M After 10-S Exercise. There Was A 377% Increment In The Cmap Amplitude At Pe0 And A Mild Increment (+26%) At Pe30S. A Transient But Significant Improvement (-22%) In The Decremental Response Was Observed At Pe0, And A Gradual Worsening Of Decrement In Subsequent Tests, With The Worst Decrement Noted (-50%) At Pe2M. Pee-D Was Found 2M After Exercise In Lems. Pee-D May Be Physiologically Closest To The Reversible Myasthenic Fatigue After Exercise Observed In Lems Patients.|[('Study', 'no label'), ('Exhaustion', 'no label'), ('Decrement', 'no label'), ('Pee-D', 'no label'), ('Systematically', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Abductor Digiti', 'no label'), ('Quinti Muscle', 'no label'), ('Compound Muscle Action Potential', 'no label'), ('Cmap', 'no label'), ('Responses', 'no label'), ('2S', 'no label'), ('Supramaximal Stimulation', 'no label'), ('Rest', 'no label'), ('Pe0', 'no label'), ('30S', 'no label'), ('Pe30S', 'no label'), ('Exercise', 'no label'), ('Increment', 'no label'), ('Cmap', 'no label'), ('Amplitude', 'no label'), ('Pe0', 'no label'), ('Mild Increment', 'no label'), ('Pe30S', 'no label'), ('Transient', 'no label'), ('Significant', 'no label'), ('Improvement', 'no label'), ('Decremental Response', 'no label'), ('Observed', 'no label'), ('Pe0', 'no label'), ('Worsening', 'no label'), ('Decrement', 'no label'), ('Tests', 'no label'), ('Worst Decrement Noted', 'no label'), ('Pe2M', 'no label'), ('Pee-D', 'no label'), ('Exercise', 'no label'), ('Pee-D', 'no label'), ('Physiologically Closest', 'no label'), ('Reversible Myasthenic Fatigue', 'no label'), ('Exercise', 'no label'), ('Observed', 'no label'), ('Lems', 'no label'), ('Patients', 'no label')]|[('Pe0', 'no label'), ('Pe0', 'no label')]|[('2S', 'no label')]|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Abductor Digiti Quinti Muscle', 'no label'), ('Myasthenic Fatigue', 'no label')]|[('Nerve', 'no label'), ('Patients', 'no label'), ('Abductor Digiti', 'no label'), ('Muscle', 'no label'), ('30S', 'no label'), ('Found 2', 'no label'), ('Lems Patients', 'no label')]
lambert eaton syndrome|pubmed~31269226|There Are No Validated, Practical, And Quantitative Measures Of Disease Severity In Lambert-Eaton Myasthenia (Lem). Data From The Effectiveness Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (Dapper) Trial Were Analyzed To Assess Triple Timed Up-And-Go (3Tug) Reproducibility And Relationships Between 3Tug Times And Other Measures Of Lem Severity. The Coverage Probability Technique Showed ≥0.90 Probability For An Acceptable 3Tug Difference Of ≤0.2, Indicating That It Is Reproducible In Lem Patients. The Correlation Between 3Tug Times And Lower Extremity Function Scores Was Significant In Subjects Who Continued And In Those Who Were Withdrawn From 3,4-Diaminopyridine Free Base. Worsening Patient-Reported Weakness Self-Assessment Scale And Investigator Assessment Of Treatment Effect Scores Corresponded With Prolongation Of 3Tug Times. The 3Tug Is Reproducible, Demonstrates Construct Validity For Assessment Of Lower Extremity Function In Lem Patients, And Correlates With Changes In Patient And Physician Assessments. These Findings, Along With Prior Reliability Studies, Indicate 3Tug Is A Valid Measure Of Disease Severity In Lem.|[('Practical', 'no label'), ('Quantitative Measures', 'no label'), ('Disease Severity', 'no label'), ('Lambert-Eaton Myasthenia', 'no label'), ('Data', 'no label'), ('Effectiveness', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Analyzed', 'no label'), ('Triple Timed Up-And-Go', 'no label'), ('Reproducibility', 'no label'), ('Relationships', 'no label'), ('Times', 'no label'), ('Measures', 'no label'), ('Lem Severity', 'no label'), ('Coverage', 'no label'), ('Probability', 'no label'), ('Acceptable', 'no label'), ('Patients', 'no label'), ('Correlation', 'no label'), ('Times', 'no label'), ('Lower Extremity Function Scores', 'no label'), ('Significant', 'no label'), ('Subjects', 'no label'), ('Continued', 'no label'), ('Withdrawn', 'no label'), ('3,4-Diaminopyridine Free Base', 'no label'), ('Worsening', 'no label'), ('Patient-Reported Weakness Self-Assessment Scale And Investigator Assessment', 'no label'), ('Treatment Effect', 'no label'), ('Corresponded', 'no label'), ('Prolongation', 'no label'), ('Times', 'no label'), ('Demonstrates', 'no label'), ('Construct Validity', 'no label'), ('Assessment', 'no label'), ('Lower Extremity Function', 'no label'), ('Patients', 'no label'), ('Changes', 'no label'), ('Patient', 'no label'), ('Physician', 'no label'), ('Assessments', 'no label'), ('Findings', 'no label'), ('Reliability Studies', 'no label'), ('Indicate', 'no label'), ('Valid', 'no label'), ('Disease Severity', 'no label')]|[('Dapper', 'no label')]|[]|[('Lambert-Eaton Myasthenia', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('3,4-Diaminopyridine', 'no label')]|[('3,4-Diaminopyridine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patient', 'no label')]
lambert eaton syndrome|pubmed~24481713|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Pre-Synaptic Disorder Of The Neuromuscular And Autonomic Transmission Mediated By Antibodies To Voltage-Gated Calcium Channels At The Motor Nerve Terminal. Lems Is A Quite Rare And Probably Under-Diagnosed Disease: The Onset May Be Slow And Clinical Signs Are Typically Fluctuating, Thus Adding To The Delay In Diagnosis. Lems Weakness Typically Involves Lower And Upper Limbs And The Proximal Muscles Are Predominantly Affected. A Significant Proportion Of Patients Also Have Dysfunction Of The Autonomic Nervous System That May Include Dry Mouth, Constipation, Blurred Vision, Impaired Sweating, And Orthostatic Hypotension. Lems Recognition Is Based On Clinical, Electrophysiological And Immunological Criteria. Nearly 50-60% Of Patients With Lems Have An Underlying Tumour That, In Almost All Cases, Is A Small-Cell Lung Cancer; The Onset Of Neurological Symptoms Generally Precedes Tumour Detection. A Careful Screening For The Early Detection Of The Possible Associated Cancer Is A Crucial Step For Optimal Disease Management. The Italian Working Group On Myasthenic Syndromes Developed Diagnostic And Therapeutic Algorithms That Could Serve In Routine Clinical Practice As Tools For A Patient-Tailored Approach.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Pre-Synaptic Disorder', 'no label'), ('Neuromuscular', 'no label'), ('Autonomic Transmission', 'no label'), ('Antibodies', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Motor Nerve', 'no label'), ('Under-Diagnosed Disease', 'no label'), ('Onset May', 'no label'), ('Slow', 'no label'), ('Fluctuating', 'no label'), ('Delay', 'no label'), ('Diagnosis', 'no label'), ('Lems Weakness', 'no label'), ('Lower', 'no label'), ('Upper Limbs', 'no label'), ('Proximal Muscles', 'no label'), ('Affected', 'no label'), ('Proportion', 'no label'), ('Patients', 'no label'), ('Dysfunction', 'no label'), ('Autonomic Nervous System', 'no label'), ('Dry Mouth', 'no label'), ('Constipation', 'no label'), ('Blurred Vision', 'no label'), ('Impaired', 'no label'), ('Sweating', 'no label'), ('Orthostatic Hypotension', 'no label'), ('Lems Recognition', 'no label'), ('Clinical', 'no label'), ('Electrophysiological', 'no label'), ('Immunological', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Tumour', 'no label'), ('Cases', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Neurological Symptoms', 'no label'), ('Precedes', 'no label'), ('Tumour Detection', 'no label'), ('Screening', 'no label'), ('Early Detection', 'no label'), ('Associated Cancer', 'no label'), ('Optimal', 'no label'), ('Disease Management', 'no label'), ('Italian', 'no label'), ('Working Group', 'no label'), ('Myasthenic Syndromes Developed Diagnostic', 'no label'), ('Routine', 'no label'), ('Clinical Practice', 'no label'), ('Patient-Tailored Approach', 'no label')]|[('Antibodies', 'no label'), ('Calcium', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Disorder Of The Neuromuscular And Autonomic Transmission', 'no label'), ('Calcium', 'no label'), ('Probably Under-Diagnosed Disease', 'no label'), ('Constipation', 'no label'), ('Blurred Vision', 'no label'), ('Impaired Sweating', 'no label'), ('Orthostatic Hypotension', 'no label'), ('Tumour', 'no label'), ('Lung Cancer', 'no label'), ('Tumour', 'no label'), ('Cancer', 'no label'), ('Myasthenic Syndromes Developed Diagnostic And Therapeutic Algorithms That Could Serve In Routine Clinical Practice As Tools For A Patient-Tailored Approach', 'no label')]|[('Neuromuscular', 'no label'), ('Calcium', 'no label'), ('Patients', 'no label'), ('Autonomic Nervous', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Tumour', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Tumour', 'no label'), ('Cancer', 'no label')]
lambert eaton syndrome|pubmed~28785598|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Paraneoplastic Neuromuscular Junction Disorder. Lems Presents With Muscular Weakness And Fatigability, Mainly Involving The Proximal Lower Limbs. There Are 2 Types Of Lems Depending On The Etiology: Paraneoplastic And Idiopathic. The Paraneoplastic Form, Which Constitutes More Than A Half Of The Cases, Is Mostly Associated With Intrathoracic Neoplasms. Most Cases Are Seen In Patients With Small Cell Lung Cancer; Other Subtypes Of Lung Cancer Are Extremely Rare. In This Article, We Report A Case Of Lems As A Rare Association With Adenocarcinoma Of The Lung.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Paraneoplastic Neuromuscular Junction Disorder', 'no label'), ('Muscular Weakness', 'no label'), ('Fatigability', 'no label'), ('Proximal', 'no label'), ('Lower Limbs', 'no label'), ('Lems', 'no label'), ('Etiology', 'no label'), ('Paraneoplastic', 'no label'), ('Idiopathic', 'no label'), ('Paraneoplastic Form', 'no label'), ('Constitutes', 'no label'), ('Than A', 'no label'), ('Cases', 'no label'), ('Associated With', 'no label'), ('Intrathoracic Neoplasms', 'no label'), ('Cases', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Subtypes', 'no label'), ('Lung Cancer', 'no label'), ('Rare', 'no label'), ('Article', 'no label'), ('Report', 'no label'), ('Rare', 'no label'), ('Association', 'no label'), ('Adenocarcinoma', 'no label'), ('Lung', 'no label')]|[('Cell', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Neuromuscular Junction Disorder', 'no label'), ('Muscular Weakness', 'no label'), ('Etiology', 'no label'), ('Paraneoplastic And Idiopathic', 'no label'), ('Paraneoplastic', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Lung Cancer', 'no label'), ('Adenocarcinoma Of The Lung', 'no label')]|[('Muscular Weakness', 'no label'), ('Lems', 'no label'), ('Intrathoracic Neoplasms', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Lung Cancer', 'no label'), ('Lems', 'no label'), ('Adenocarcinoma', 'no label'), ('Lung', 'no label')]
lambert eaton syndrome|pubmed~25993122|To Evaluate Ocular Signs And Symptoms In Lambert-Eaton Myasthenic Syndrome (Lems) And Determine The Frequency Of Ophthalmic Involvement. A Retrospective Review Of The Medical Records Of All Patients Diagnosed With Lems At The Mayo Clinic In Rochester, Mn, From January, 1976, To December, 2010, Was Performed With Special Attention To Ophthalmic Symptoms And Signs. One Hundred Seventy-Six Patients Met The Inclusion Criteria. Ophthalmic Symptoms Included Ptosis In 41 (23%), Diplopia In 36 (20.5%), Decreased Vision In 24 (14%), And Dry Eye Complaints In 12 (7%). Ophthalmic Signs Included Ptosis In 45 (26%), Abnormal Ocular Motility In 15 (8.5%), Strabismus In 14 (8%), Pupillary Dysfunction In 12 (7%), And Findings Consistent With Dry Eyes In 4 (2%). A Significant Number Of Patients Reported Ophthalmic Symptoms, And Many Had Objective Findings On Clinical Examination Consistent With These Symptoms. To Our Knowledge, This Is The Largest Case Series Of Ophthalmic Findings In Patients With Lems And Indicates That These Patients Warrant A Complete Ophthalmic Examination.|[('Evaluate', 'no label'), ('Ocular', 'no label'), ('Signs And Symptoms', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Determine', 'no label'), ('Frequency', 'no label'), ('Ophthalmic Involvement', 'no label'), ('Retrospective Review', 'no label'), ('Medical Records', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Lems', 'no label'), ('Mayo Clinic', 'no label'), ('Rochester', 'no label'), ('Mn', 'no label'), ('January', 'no label'), ('Performed', 'no label'), ('Special Attention', 'no label'), ('Ophthalmic Symptoms', 'no label'), ('Signs', 'no label'), ('Seventy-Six', 'no label'), ('Patients', 'no label'), ('Met', 'no label'), ('Inclusion Criteria', 'no label'), ('Ophthalmic Symptoms', 'no label'), ('Ptosis', 'no label'), ('Diplopia', 'no label'), ('Decreased Vision', 'no label'), ('Dry Eye', 'no label'), ('Complaints', 'no label'), ('Ophthalmic Signs', 'no label'), ('Ptosis', 'no label'), ('Abnormal Ocular Motility', 'no label'), ('Strabismus', 'no label'), ('Pupillary Dysfunction', 'no label'), ('Findings', 'no label'), ('Consistent With', 'no label'), ('Dry Eyes', 'no label'), ('Patients', 'no label'), ('Ophthalmic Symptoms', 'no label'), ('Findings', 'no label'), ('Clinical Examination', 'no label'), ('Consistent With', 'no label'), ('Symptoms', 'no label'), ('Knowledge', 'no label'), ('Largest', 'no label'), ('Case Series', 'no label'), ('Ophthalmic Findings', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Warrant A Complete Ophthalmic Examination', 'no label')]|[('Mn', 'no label'), ('Met', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Mn', 'no label'), ('Ptosis', 'no label'), ('Diplopia', 'no label'), ('Decreased Vision', 'no label'), ('Dry Eye Complaints', 'no label'), ('Abnormal Ocular Motility', 'no label'), ('Strabismus', 'no label'), ('Pupillary Dysfunction', 'no label')]|[('Ocular Signs', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Mn', 'no label'), ('Met', 'no label'), ('Ocular', 'no label'), ('Pupillary', 'no label'), ('Eyes', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Indicates', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~28930822|To Report Our Experience On 7 Patients (4 Males And 3 Females), Affected By Nonparaneoplastic Lambert-Eaton Myasthenic Syndrome, Treated With 3,4-Diaminopyridine Phosphate (3,4-Dapp) Either Alone Or In Combination With Other Immunosuppressants Or Steroids. Patients Have Been Evaluated At Specific Timepoints (Ie, Baseline And Last 5 Year Follow-Up), With Neurological Examination, Autoantibodies Against Presynaptic Voltage-Gated Cav2.1 (P/Q Type) Calcium Ion Channel (Vgcc) Dosage, Neurophysiological Evaluation Focusing On The Increased Amplitude Of The Compound Muscle Action Potential (Cmap) After Maximum Voluntary Effort, Quantitative Myasthenia Gravis (Qmg) And Activities Of Daily Living Scales, And Autonomic Nervous System Involvement Evaluation. Five Out Of 7 Patients Presented A Clinical Improvement Persisting At Last 5-Year Follow-Up; 2 Out Of Them Improved Taking Only 3,4-Dapp At The Maximal Dosage, Whereas The Remaining Received Concomitant Medications, Such As Prednisone And Azathioprine. However, The Clinical Amelioration Was Not Statistically Significant. No One Of The Patients Reported Severe Adverse Events, Except One, Complaining Of Transient Chin And Perioral Paresthesias. A Significant Association Between Qmg And The Type Of Pharmacological Drugs Therapy (P = .028) Emerged. Indeed, We Observed An Improvement Of The Clinical Condition In All 3 Subjects Treated With 3,4-Dapp And Prednisone. In This Study, We Confirm 3,4-Dapp Treatment Efficacy On Muscle Strength, But Minor Evidence Of Drug Effectiveness Have Been Demonstrated On The Autonomic Nervous System Involvement And On The Deep Tendon Reflexes Reappearance, A Part From Patients Who Received 3,4-Dapp Associated To Prednisone.|[('Experience', 'no label'), ('Patients', 'no label'), ('Males', 'no label'), ('Females', 'no label'), ('Affected', 'no label'), ('Nonparaneoplastic Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Treated With', 'no label'), ('3,4-Diaminopyridine Phosphate', 'no label'), ('Alone', 'no label'), ('Immunosuppressants', 'no label'), ('Steroids', 'no label'), ('Patients', 'no label'), ('Evaluated', 'no label'), ('Timepoints', 'no label'), ('Ie', 'no label'), ('Baseline', 'no label'), ('Neurological Examination', 'no label'), ('Autoantibodies', 'no label'), ('Presynaptic Voltage-Gated Cav2.1', 'no label'), ('Calcium Ion Channel', 'no label'), ('Vgcc', 'no label'), ('Dosage', 'no label'), ('Neurophysiological Evaluation Focusing', 'no label'), ('Increased', 'no label'), ('Amplitude', 'no label'), ('Compound Muscle Action Potential', 'no label'), ('Cmap', 'no label'), ('Maximum', 'no label'), ('Voluntary Effort', 'no label'), ('Quantitative Myasthenia Gravis', 'no label'), ('Qmg', 'no label'), ('Activities', 'no label'), ('Daily Living Scales', 'no label'), ('Autonomic Nervous System', 'no label'), ('Involvement', 'no label'), ('Evaluation', 'no label'), ('Patients', 'no label'), ('Clinical Improvement', 'no label'), ('Persisting', 'no label'), ('Last 5-Year Follow-Up', 'no label'), ('Maximal', 'no label'), ('Dosage', 'no label'), ('Concomitant', 'no label'), ('Medications', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label'), ('Clinical Amelioration', 'no label'), ('Statistically Significant', 'no label'), ('Patients', 'no label'), ('Severe Adverse Events', 'no label'), ('Complaining', 'no label'), ('Transient Chin And Perioral Paresthesias', 'no label'), ('Significant', 'no label'), ('Association', 'no label'), ('Qmg', 'no label'), ('Pharmacological Drugs Therapy', 'no label'), ('P\u200a=\u200a.028) Emerged', 'no label'), ('Observed', 'no label'), ('Improvement', 'no label'), ('Clinical Condition', 'no label'), ('Subjects', 'no label'), ('Treated With', 'no label'), ('Prednisone', 'no label'), ('Study', 'no label'), ('Confirm', 'no label'), ('Treatment Efficacy', 'no label'), ('Muscle Strength', 'no label'), ('Minor Evidence', 'no label'), ('Drug Effectiveness', 'no label'), ('Autonomic Nervous System', 'no label'), ('Involvement', 'no label'), ('Deep Tendon', 'no label'), ('Reflexes', 'no label'), ('Reappearance', 'no label'), ('Patients', 'no label'), ('Prednisone', 'no label')]|[('Phosphate', 'no label'), ('Timepoints', 'no label'), ('Autoantibodies', 'no label'), ('Calcium Ion', 'no label'), ('Drug', 'no label')]|[('Presynaptic Voltage-Gated Cav2.1', 'no label'), ('Qmg', 'no label')]|[('Nonparaneoplastic Lambert-Eaton Myasthenic Syndrome', 'no label'), ('3,4-Diaminopyridine Phosphate', 'no label'), ('Immunosuppressants', 'no label'), ('Steroids', 'no label'), ('Calcium', 'no label'), ('Myasthenia Gravis', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label'), ('Perioral Paresthesias', 'no label'), ('Prednisone', 'no label'), ('Prednisone', 'no label')]|[('Experience On 7 Patients', 'no label'), ('Nonparaneoplastic Lambert-Eaton', 'no label'), ('3,4-Diaminopyridine Phosphate', 'no label'), ('Steroids', 'no label'), ('Patients', 'no label'), ('Cav2.1', 'no label'), ('P/Q Type', 'no label'), ('Calcium Ion Channel', 'no label'), ('Patients', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label'), ('Patients', 'no label'), ('Chin', 'no label'), ('Perioral', 'no label'), ('Type', 'no label'), ('Prednisone', 'no label'), ('Muscle', 'no label'), ('Autonomic Nervous', 'no label'), ('Patients', 'no label'), ('Prednisone', 'no label')]
lambert eaton syndrome|pubmed~25015919|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disorder In Which A Significant Fraction Of The Presynaptic P/Q-Type Ca(2+) Channels Critical To The Triggering Of Neurotransmitter Release At The Neuromuscular Junction (Nmj) Are Thought To Be Removed. There Is No Cure For Lems, And The Current Most Commonly Used Symptomatic Treatment Option Is A Potassium Channel Blocker [3,4-Diaminopyridine (3,4-Dap)] That Does Not Completely Reverse Symptoms And Can Have Dose-Limiting Side-Effects. We Previously Reported The Development Of A Novel Ca(2+) Channel Agonist, Gv-58, As A Possible Alternative Treatment Strategy For Lems. In This Study, We Tested The Hypothesis That The Combination Of Gv-58 And 3,4-Dap Will Elicit A Supra-Additive Increase In Neurotransmitter Release At Lems Model Nmjs. First, We Tested Gv-58 In A Cell Survival Assay To Assess Potential Effects On Cyclin-Dependent Kinases (Cdks) And Showed That Gv-58 Did Not Affect Cell Survival At The Relevant Concentrations For Ca(2+) Channel Effects. Then, We Examined The Voltage Dependence Of Gv-58 Effects On Ca(2+) Channels Using Patch Clamp Techniques; This Showed The Effects Of Gv-58 To Be Dependent Upon Ca(2+) Channel Opening. Based On This Mechanism, We Predicted An Interaction Between 3,4-Dap And Gv-58. We Tested This Hypothesis Using A Mouse Passive Transfer Model Of Lems. Using Intracellular Electrophysiological Ex Vivo Recordings, We Demonstrated That A Combined Application Of 3,4-Dap Plus Gv-58 Had A Supra-Additive Effect That Completely Reversed The Deficit In Neurotransmitter Release Magnitude At Lems Model Nmjs. This Reversal Contrasts With The Less Significant Improvement Observed With Either Compound Alone. Our Data Indicate That A Combination Of 3,4-Dap And Gv-58 Represents A Promising Treatment Option For Lems And Potentially For Other Disorders Of The Nmj. |[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disorder', 'no label'), ('Significant', 'no label'), ('Fraction', 'no label'), ('Presynaptic P/Q-Type Ca(2+) Channels', 'no label'), ('Triggering', 'no label'), ('Neurotransmitter Release', 'no label'), ('Neuromuscular Junction', 'no label'), ('Removed', 'no label'), ('Cure', 'no label'), ('Lems', 'no label'), ('Symptomatic', 'no label'), ('Treatment Option', 'no label'), ('Potassium Channel Blocker', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Reverse Symptoms', 'no label'), ('Development', 'no label'), ('Novel', 'no label'), ('Ca(2+) Channel Agonist', 'no label'), ('Gv-58', 'no label'), ('Alternative Treatment Strategy', 'no label'), ('Lems', 'no label'), ('Study', 'no label'), ('Tested', 'no label'), ('Hypothesis', 'no label'), ('Combination', 'no label'), ('Gv-58', 'no label'), ('Supra-Additive Increase', 'no label'), ('Neurotransmitter Release', 'no label'), ('Lems Model', 'no label'), ('Nmjs', 'no label'), ('Tested', 'no label'), ('Gv-58', 'no label'), ('Cell Survival Assay', 'no label'), ('Assess', 'no label'), ('Potential', 'no label'), ('Effects', 'no label'), ('Cyclin-Dependent Kinases', 'no label'), ('Cdks', 'no label'), ('Gv-58', 'no label'), ('Cell Survival', 'no label'), ('Relevant', 'no label'), ('Concentrations', 'no label'), ('Ca(2+) Channel', 'no label'), ('Voltage', 'no label'), ('Dependence', 'no label'), ('Gv-58', 'no label'), ('Effects', 'no label'), ('Ca(2+) Channels', 'no label'), ('Patch Clamp Techniques', 'no label'), ('Effects', 'no label'), ('Gv-58', 'no label'), ('Dependent', 'no label'), ('Ca(2+) Channel', 'no label'), ('Mechanism', 'no label'), ('Predicted', 'no label'), ('Interaction', 'no label'), ('Gv-58', 'no label'), ('Tested', 'no label'), ('Hypothesis', 'no label'), ('Mouse', 'no label'), ('Passive Transfer Model', 'no label'), ('Lems', 'no label'), ('Intracellular', 'no label'), ('Electrophysiological', 'no label'), ('Ex Vivo', 'no label'), ('Recordings', 'no label'), ('Plus', 'no label'), ('Gv-58', 'no label'), ('Supra-Additive Effect', 'no label'), ('Completely Reversed', 'no label'), ('Deficit', 'no label'), ('Neurotransmitter Release', 'no label'), ('Magnitude', 'no label'), ('Lems Model', 'no label'), ('Nmjs', 'no label'), ('Reversal Contrasts', 'no label'), ('Significant', 'no label'), ('Improvement', 'no label'), ('Observed', 'no label'), ('Compound Alone', 'no label'), ('Data Indicate', 'no label'), ('Combination', 'no label'), ('Represents', 'no label'), ('Treatment Option', 'no label'), ('Lems', 'no label'), ('Nmj', 'no label')]|[('P/Q-Type', 'no label'), ('Neurotransmitter', 'no label'), ('Potassium', 'no label'), ('Agonist', 'no label'), ('Neurotransmitter', 'no label'), ('Cell', 'no label'), ('Cell', 'no label'), ('Mouse', 'no label'), ('Intracellular', 'no label'), ('Neurotransmitter', 'no label')]|[('Cyclin-Dependent Kinases', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Potassium', 'no label'), ('3,4-Diaminopyridine', 'no label')]|[('Presynaptic P/Q-Type', 'no label'), ('Neurotransmitter', 'no label'), ('Neuromuscular', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Neurotransmitter', 'no label'), ('Lems', 'no label'), ('A Cell', 'no label'), ('Cdks', 'no label'), ('Cell', 'no label'), ('Intracellular', 'no label'), ('Deficit', 'no label'), ('Neurotransmitter', 'no label'), ('Lems', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~29264043|This Report Describes The Case Of A 65-Year-Old Male Who Complained Of Muscular Weakness Of The Legs With Easy Fatigability. Blood And Imaging Examinations Showed Positive Anti-Acetylcholine Receptor Antibody And An Anterior Mediastinal Tumor (Probably A Thymic Cyst), Suggesting The Diagnosis Of Myasthenia Gravis (Mg). However, Neurological And Electrophysiological Examinations Suggested The Diagnosis Of Lambert-Eaton Myasthenic Syndrome (Lems). We Searched Repeatedly For Malignant Tumors. Small Cell Lung Cancer (Sclc) Was Found. Chemotherapy Reduced The Sclc And Improved The Patient'S Clinical Symptoms. On The Basis Of An Accurate Diagnosis Of Lems, We Were Able To Detect Sclc And Administer Chemotherapy At An Early Stage. Anti-P/Q-Type Voltage-Gated Calcium Channel Antibody Was Negative. In Our Case, Mg And Lems Overlap Syndrome In Addition To Mg Should Be Differentiated. For The Differentiation, The Strict Electrophysiological Criteria Of Lems Were Useful.|"[('Report', 'no label'), ('Describes', 'no label'), ('65-Year-Old', 'no label'), ('Male', 'no label'), ('Muscular Weakness', 'no label'), ('Legs With Easy Fatigability', 'no label'), ('Blood And Imaging Examinations', 'no label'), ('Positive', 'no label'), ('Anti-Acetylcholine Receptor', 'no label'), ('Antibody', 'no label'), ('Anterior Mediastinal Tumor', 'no label'), ('Thymic Cyst', 'no label'), ('Suggesting', 'no label'), ('Diagnosis', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Neurological', 'no label'), ('Electrophysiological Examinations', 'no label'), ('Diagnosis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Malignant Tumors', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Chemotherapy', 'no label'), ('Reduced', 'no label'), ('Sclc', 'no label'), (""Patient'S"", 'no label'), ('Clinical Symptoms', 'no label'), ('Accurate Diagnosis', 'no label'), ('Lems', 'no label'), ('Detect', 'no label'), ('Sclc', 'no label'), ('Administer Chemotherapy', 'no label'), ('Early Stage', 'no label'), ('Voltage-Gated Calcium Channel Antibody', 'no label'), ('Negative', 'no label'), ('Case', 'no label'), ('Mg', 'no label'), ('Lems Overlap Syndrome', 'no label'), ('Mg', 'no label'), ('Differentiated', 'no label'), ('Differentiation', 'no label'), ('Electrophysiological Criteria', 'no label'), ('Lems', 'no label')]"|[('Antibody', 'no label'), ('Cell', 'no label'), ('Calcium', 'no label'), ('Antibody', 'no label')]|[]|[('Muscular Weakness', 'no label'), ('Anti-Acetylcholine', 'no label'), ('Tumor', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Malignant Tumors', 'no label'), ('Calcium', 'no label'), ('Mg', 'no label'), ('Mg', 'no label')]|[('A 65-Year-Old', 'no label'), ('Muscular Weakness', 'no label'), ('Legs', 'no label'), ('Blood', 'no label'), ('Anterior Mediastinal Tumor', 'no label'), ('Malignant Tumors.', 'no label'), ('Administer', 'no label'), ('Calcium', 'no label'), ('Case', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~29272039|"Neuronal Calcium Channel Antibodies Are A Biomarker Of Lambert-Eaton Syndrome (Les) And Cerebellar Ataxia. We Have Encountered Several Patients With Les And Cerebellar Ataxia Coexisting, And We Sought To Further Define This Association. We Reviewed Records Of Patients At Our Institution With A Diagnosis Of ""Lambert-Eaton Syndrome"" And ""Cerebellar Ataxia."" Seventeen Patients Were Identified With Les And Ataxia. Presenting Symptoms Were Weakness (8), Concurrent Weakness And Ataxia (4), Ataxia (4), And Other (1). Nine Patients Had Small-Cell Lung Carcinoma, 3 Of Whom Had Survival Greater Than 100 Months. Immunotherapy Responses Were Best Among Patients Without Cancer. Nine Of 17 (53%) Patients Were Alive At Last Follow-Up (Median Survival 62 Months; Range, 8-240). Calcium Channel Autoimmunity Should Be Considered In Patients With Coexisting Cerebellar Ataxia And Myasthenic Weakness. Affected Patients May Survive Small-Cell Carcinoma Or Have Immunotherapy-Responsive Neurological Symptoms. Muscle Nerve, 2018."|[('Neuronal', 'no label'), ('Calcium Channel Antibodies', 'no label'), ('Biomarker', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Patients', 'no label'), ('Les', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Coexisting', 'no label'), ('Association', 'no label'), ('Reviewed', 'no label'), ('Records', 'no label'), ('Patients', 'no label'), ('Institution', 'no label'), ('Diagnosis', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Patients', 'no label'), ('Les And Ataxia', 'no label'), ('Presenting Symptoms', 'no label'), ('Weakness', 'no label'), ('Concurrent', 'no label'), ('Weakness', 'no label'), ('Ataxia', 'no label'), ('Ataxia', 'no label'), ('Patients', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Survival', 'no label'), ('Months', 'no label'), ('Immunotherapy', 'no label'), ('Responses', 'no label'), ('Patients', 'no label'), ('Cancer', 'no label'), ('Patients', 'no label'), ('Last Follow-Up', 'no label'), ('Median Survival', 'no label'), ('Months', 'no label'), ('Range', 'no label'), ('Calcium Channel Autoimmunity', 'no label'), ('Patients', 'no label'), ('Coexisting', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Myasthenic Weakness', 'no label'), ('Affected', 'no label'), ('Patients', 'no label'), ('Survive', 'no label'), ('Small-Cell Carcinoma', 'no label'), ('Immunotherapy-Responsive Neurological Symptoms', 'no label'), ('Muscle Nerve', 'no label')]|[('Neuronal Calcium', 'no label'), ('Antibodies', 'no label'), ('Calcium', 'no label')]|[]|[('Calcium', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Ataxia', 'no label'), ('Weakness', 'no label'), ('Concurrent Weakness', 'no label'), ('Ataxia', 'no label'), ('Ataxia', 'no label'), ('Lung Carcinoma', 'no label'), ('Cancer', 'no label'), ('Alive', 'no label'), ('Calcium', 'no label'), ('Autoimmunity', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Myasthenic Weakness', 'no label'), ('Survive Small-Cell Carcinoma', 'no label')]|[('Neuronal Calcium', 'no label'), ('Cerebellar', 'no label'), ('Patients', 'no label'), ('Cerebellar', 'no label'), ('Patients', 'no label'), ('Cerebellar', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Patients', 'no label'), ('Cancer', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Cerebellar', 'no label'), ('Patients', 'no label'), ('Small-Cell Carcinoma Or', 'no label'), ('Muscle Nerve', 'no label')]
lambert eaton syndrome|pubmed~29280483|3,4-Diaminopyridine Has Been Used To Treat Lambert-Eaton Myasthenia (Lem) For 30 Years Despite The Lack Of Conclusive Evidence Of Efficacy. We Conducted A Randomized Double-Blind Placebo-Controlled Withdrawal Study In Patients With Lem Who Had Been On Stable Regimens Of 3,4-Diaminopyridine Base (3,4-Dap) For ≥ 3 Months. The Primary Efficacy Endpoint Was >30% Deterioration In Triple Timed Up-And-Go (3Tug) Times During Tapered Drug Withdrawal. The Secondary Endpoint Was Self-Assessment Of Lem-Related Weakness (W-Sas). Thirty-Two Participants Were Randomized To Continuous 3,4-Dap Or Placebo Groups. None Of The 14 Participants Who Received Continuous 3,4-Dap Had > 30% Deterioration In 3Tug Time Versus 72% Of The 18 Who Tapered To Placebo (P < 0.0001). W-Sas Similarly Demonstrated An Advantage For Continuous Treatment Over Placebo (P < 0.0001). Requirement For Rescue And Adverse Events Were More Common In The Placebo Group. This Trial Provides Significant Evidence Of Efficacy Of 3,4-Dap In The Maintenance Of Strength In Lem. Muscle Nerve 57: 561-568, 2018.|[('3,4-Diaminopyridine', 'no label'), ('Treat', 'no label'), ('Lambert-Eaton Myasthenia', 'no label'), ('Years', 'no label'), ('Lack', 'no label'), ('Conclusive Evidence', 'no label'), ('Efficacy', 'no label'), ('Randomized Double-Blind Placebo-Controlled Withdrawal Study', 'no label'), ('Patients', 'no label'), ('Lem Who', 'no label'), ('Stable Regimens', 'no label'), ('3,4-Diaminopyridine Base', 'no label'), ('Months', 'no label'), ('Primary Efficacy', 'no label'), ('Deterioration', 'no label'), ('Triple', 'no label'), ('Tapered Drug Withdrawal', 'no label'), ('Secondary Endpoint Was Self-Assessment', 'no label'), ('Thirty-Two', 'no label'), ('Participants', 'no label'), ('Randomized', 'no label'), ('Placebo Groups', 'no label'), ('Participants', 'no label'), ('Continuous', 'no label'), ('Deterioration', 'no label'), ('Time', 'no label'), ('Tapered', 'no label'), ('Placebo', 'no label'), ('Advantage', 'no label'), ('Continuous Treatment', 'no label'), ('Placebo', 'no label'), ('Requirement', 'no label'), ('Rescue', 'no label'), ('Adverse Events', 'no label'), ('Placebo Group', 'no label'), ('Trial', 'no label'), ('Provides', 'no label'), ('Evidence', 'no label'), ('Efficacy', 'no label'), ('Maintenance', 'no label'), ('Strength', 'no label'), ('Muscle Nerve', 'no label')]|[('Drug', 'no label')]|[]|[('3,4-Diaminopyridine', 'no label'), ('Lambert-Eaton Myasthenia', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Lem-Related Weakness', 'no label')]|[('3,4-Diaminopyridine', 'no label'), ('Patients', 'no label'), ('3,4-Diaminopyridine Base', 'no label'), ('Muscle Nerve', 'no label')]
lambert eaton syndrome|pubmed~26143177||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~29406572||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~24743528|A 61-Year-Old Male Who Noticed Muscular Weakness Of His Extremities, Diplopia And Slur His Words Was Found To Have A Thymic Tumor On Computed Tomography. The Immunological Examination Showed Incremental Of Anti Acetylcholine Receptor Antibody Titer And Anti P/Q-Type Voltage-Gated Calcium Channels Antibody Titer. Electromyography Showed Decremental Response To Low Frequency Stimulations, And Incremental Response To High Frequency Stimulations. So He Was Diagnosed With Thymic Tumor Combined With Myasthenia Gravis And Lambert-Eaton Myasthenic Syndrome. He Treated With Extended Thymomectomy Resulting In The Improvement Of His Neurological Symptoms. Five Years After Operation, The Patient Is Well Without Any Malignant Diseases.|[('Male', 'no label'), ('Noticed', 'no label'), ('Muscular Weakness', 'no label'), ('His Extremities', 'no label'), ('Diplopia', 'no label'), ('Slur His Words', 'no label'), ('Thymic Tumor', 'no label'), ('Computed Tomography', 'no label'), ('Immunological Examination Showed Incremental', 'no label'), ('Anti Acetylcholine Receptor', 'no label'), ('Antibody Titer', 'no label'), ('Anti P/Q-Type Voltage-Gated', 'no label'), ('Calcium Channels', 'no label'), ('Antibody Titer', 'no label'), ('Electromyography', 'no label'), ('Decremental Response', 'no label'), ('Low Frequency Stimulations', 'no label'), ('Incremental Response', 'no label'), ('Frequency', 'no label'), ('Diagnosed', 'no label'), ('Thymic Tumor', 'no label'), ('Myasthenia Gravis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Treated With', 'no label'), ('Extended', 'no label'), ('Thymomectomy', 'no label'), ('Resulting', 'no label'), ('Improvement', 'no label'), ('Neurological Symptoms', 'no label'), ('Years', 'no label'), ('Operation', 'no label'), ('Patient', 'no label'), ('Malignant Diseases', 'no label')]|[('His', 'no label'), ('His', 'no label'), ('Acetylcholine Receptor Antibody', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Antibody', 'no label'), ('His', 'no label')]|[('His', 'no label'), ('Anti Acetylcholine Receptor Antibody', 'no label')]|[('Muscular Weakness', 'no label'), ('His Extremities', 'no label'), ('Diplopia', 'no label'), ('Tumor', 'no label'), ('Acetylcholine', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Thymic Tumor', 'no label'), ('Myasthenia Gravis', 'no label'), ('Myasthenic Syndrome', 'no label')]|[('Muscular Weakness', 'no label'), ('Have A Thymic Tumor', 'no label'), ('Acetylcholine Receptor Antibody', 'no label'), ('Calcium', 'no label'), ('Thymic Tumor', 'no label'), ('Patient', 'no label')]
lambert eaton syndrome|pubmed~26418033|To Assess Whether A Myasthenia Gravis (Mg) Lambert-Eaton Overlap Syndrome (Mlos) Exists. Case Reports That Met The Universally Accepted Diagnostic Criteria For Mg And Lambert-Eaton Myasthenic Syndrome (Lems) Were Sought Through A Pubmed Search. Fifty-Five Possible Cases Of Mlos Were Identified. Thirty-Nine Cases Met The Diagnostic Criteria For Mg And Lems. Analysis Of Clinical Features Showed That These Patients Have Common Mg And Lems Symptoms: Oculo-Bulbar Paresis And Good Response To Anti-Cholinesterase For Mg And Limb Weakness And Decreased Or Absent Reflexes For Lems. All Had The Classical Lems Pattern In The Repetitive Nerve Stimulation Test: Low Compound Muscle Action Potential Amplitude And Incremental Response > 60% With Brief Exercise Or At High Rate Of Stimulation. Eight Patients Had Combined Positive Acetylcholine Receptor Antibody (Achr-Ab) Or Muscle-Specific Kinase-Ab And Voltage-Gated Calcium Channel- Ab Tests. A Myasthenia Gravis Lambert-Eaton Overlap Syndrome (Mlos) Does Exist.|[('Myasthenia Gravis', 'no label'), ('Case Reports', 'no label'), ('Met', 'no label'), ('Diagnostic Criteria', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Pubmed', 'no label'), ('Search', 'no label'), ('Fifty-Five', 'no label'), ('Cases', 'no label'), ('Thirty-Nine', 'no label'), ('Cases', 'no label'), ('Met', 'no label'), ('Diagnostic Criteria', 'no label'), ('Analysis', 'no label'), ('Clinical Features', 'no label'), ('Patients', 'no label'), ('Common', 'no label'), ('Mg', 'no label'), ('Lems Symptoms', 'no label'), ('Oculo-Bulbar Paresis', 'no label'), ('Good Response', 'no label'), ('Anti-Cholinesterase', 'no label'), ('Mg', 'no label'), ('Limb Weakness', 'no label'), ('Decreased', 'no label'), ('Absent Reflexes', 'no label'), ('Lems', 'no label'), ('Classical Lems', 'no label'), ('Repetitive Nerve Stimulation Test', 'no label'), ('Low', 'no label'), ('Compound Muscle', 'no label'), ('Action Potential Amplitude And Incremental Response', 'no label'), ('Brief Exercise', 'no label'), ('High Rate', 'no label'), ('Stimulation', 'no label'), ('Patients', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Antibody', 'no label'), ('Achr-Ab', 'no label'), ('Muscle-Specific Kinase-Ab', 'no label'), ('Voltage-Gated Calcium Channel- Ab Tests', 'no label'), ('Myasthenia Gravis Lambert-Eaton Overlap Syndrome', 'no label'), ('Exist', 'no label')]|[('Met', 'no label'), ('Met', 'no label'), ('Acetylcholine Receptor Antibody', 'no label'), ('Calcium', 'no label')]|[('Mlos', 'no label'), ('Anti-Cholinesterase', 'no label'), ('Or Muscle-Specific Kinase-Ab', 'no label')]|[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Paresis', 'no label'), ('Mg', 'no label'), ('Weakness', 'no label'), ('Acetylcholine', 'no label'), ('Calcium', 'no label'), ('Myasthenia Gravis', 'no label')]|[('A Myasthenia Gravis', 'no label'), ('Met', 'no label'), ('Mg', 'no label'), ('Met', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Lems', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Muscle-Specific Kinase-Ab', 'no label'), ('Calcium Channel- Ab', 'no label')]
lambert eaton syndrome|pubmed~24464710|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disorder Characterized By Autoantibodies Against Presynaptic Voltage-Gated Calcium Channels That Impair Neuromuscular Transmission. Malignancies, Especially Small Cell Lung Cancer (Sclc), Have Been Associated With Lems And Account For Approximately 60% Of Cases, Making Malignancy Management A Central Step In Lems Therapy. In Addition, Immunosuppressive Therapy Is Also Recommended For Symptomatic Control. Interestingly, Both Pathological And Epidemiological Data Suggest That The Autoimmune Response Can Inhibit Progression Of Tumors In Malignancy-Associated Lems. Thus, Conventional Broad-Spectrum Immunosuppressants May Not Be Effective Agents For Treatment Of Lems, Especially In Those With Malignancy-Associated Lems. Recent Preclinical And Clinical Studies Have Indicated That Proteasome Inhibitors Can Eliminate Antibody-Producing Cells Efficiently, Block Dendritic Cell Maturation, And Have Anti-Tumor Activity. We Hypothesize That Proteasome Inhibitors May Be Promising Agents For Treatment Of Malignancy-Related Lems.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disorder', 'no label'), ('Characterized', 'no label'), ('Autoantibodies', 'no label'), ('Presynaptic Voltage-Gated', 'no label'), ('Calcium Channels', 'no label'), ('Impair', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Malignancies', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Associated With', 'no label'), ('Lems', 'no label'), ('Cases', 'no label'), ('Making Malignancy', 'no label'), ('Management', 'no label'), ('Central', 'no label'), ('Lems Therapy', 'no label'), ('Addition', 'no label'), ('Immunosuppressive Therapy', 'no label'), ('Symptomatic', 'no label'), ('Pathological', 'no label'), ('Epidemiological', 'no label'), ('Data Suggest', 'no label'), ('Autoimmune Response', 'no label'), ('Inhibit', 'no label'), ('Progression', 'no label'), ('Tumors', 'no label'), ('Malignancy-Associated Lems', 'no label'), ('Broad-Spectrum Immunosuppressants', 'no label'), ('Effective Agents', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label'), ('Malignancy-Associated Lems', 'no label'), ('Preclinical', 'no label'), ('Clinical Studies', 'no label'), ('Proteasome Inhibitors', 'no label'), ('Antibody-Producing Cells', 'no label'), ('Efficiently', 'no label'), ('Block Dendritic Cell', 'no label'), ('Maturation', 'no label'), ('Anti-Tumor Activity', 'no label'), ('Hypothesize', 'no label'), ('Proteasome Inhibitors', 'no label'), ('Agents', 'no label'), ('Treatment', 'no label'), ('Malignancy-Related Lems', 'no label')]|[('Calcium', 'no label'), ('Cell', 'no label'), ('Proteasome Inhibitors', 'no label'), ('Cells', 'no label'), ('Dendritic Cell', 'no label'), ('Proteasome Inhibitors', 'no label')]|[('Proteasome', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Calcium', 'no label'), ('Malignancies', 'no label'), ('Malignancy', 'no label'), ('Tumors', 'no label'), ('Immunosuppressants', 'no label')]|[('Presynaptic', 'no label'), ('Calcium', 'no label'), ('Neuromuscular', 'no label'), ('Malignancies', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Lems', 'no label'), ('Lems', 'no label'), ('Tumors', 'no label'), ('Cells', 'no label'), ('Dendritic Cell', 'no label'), ('Proteasome Inhibitors', 'no label')]
lambert eaton syndrome|pubmed~30215026|To Report The Clinical Features And The Neurophysiological Approach Of A Patient With Lambert-Eaton Myasthenic Syndrome (Lems), Highlighting The Diagnostic Role Of The Stimulated Single Fiber Electromyography (Ssfemg). A 60-Year-Old Woman Presenting With The Lems Triad (Proximal And Axial Weakness, Autonomic Dysfunction And Areflexia) Was Evaluated By Neurophysiological Tests (Electroneuromyography, Repetitive Stimulation Test (Tsr), Voluntary And Stimulated Sfemg). We Reported: <I>1</I>) Increase Of Compound Muscle Action Potential (Cmap) Amplitude (>60%) Following Brief Isometric Exercise Compared To The Rest (Baseline); <I>2</I>) Decremental/Incremental Response Of Cmap Amplitude At Low- (3 Hz) And High-Frequency (30 Hz) Repetitive Stimulation Test (Rst), Respectively; <I>3</I>) Increased Neuromuscular Jitter And Blocking At Voluntary Single-Fiber Electromyography (Vsfemg); <I>4</I>) Stimulation Rate-Dependent Reduction Of The Neuromuscular Jitter And Blocking At Ssfemg. Diagnosis Was Confirmed By Serological Demonstration Of Circulating Voltage Gated Calcium Channels (Vgcc) Antibodies. The Present Case Highlights The Role Of The Ssfemg In The Diagnosis Of Lems, Underling The Stimulation Rate-Dependency Of Both Neuromuscular Jitter And Blocks.|[('Clinical Features', 'no label'), ('Neurophysiological Approach', 'no label'), ('Patient', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Diagnostic Role', 'no label'), ('Stimulated Single Fiber Electromyography', 'no label'), ('Ssfemg', 'no label'), ('60-Year-Old Woman', 'no label'), ('Presenting With', 'no label'), ('Lems Triad', 'no label'), ('Proximal', 'no label'), ('Axial Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Areflexia', 'no label'), ('Evaluated', 'no label'), ('Neurophysiological Tests', 'no label'), ('Electroneuromyography', 'no label'), ('Repetitive Stimulation Test', 'no label'), ('Tsr', 'no label'), ('Voluntary', 'no label'), ('Sfemg', 'no label'), ('Increase', 'no label'), ('Compound Muscle', 'no label'), ('Cmap', 'no label'), ('Brief Isometric Exercise', 'no label'), ('Rest', 'no label'), ('Baseline', 'no label'), ('Decremental/Incremental Response', 'no label'), ('Cmap', 'no label'), ('Amplitude', 'no label'), ('High-Frequency', 'no label'), ('Repetitive Stimulation Test', 'no label'), ('Rst', 'no label'), ('Increased', 'no label'), ('Neuromuscular Jitter', 'no label'), ('Blocking', 'no label'), ('Voluntary', 'no label'), ('Vsfemg', 'no label'), ('Stimulation', 'no label'), ('Rate-Dependent', 'no label'), ('Reduction', 'no label'), ('Neuromuscular Jitter', 'no label'), ('Blocking', 'no label'), ('Ssfemg', 'no label'), ('Diagnosis', 'no label'), ('Confirmed', 'no label'), ('Serological Demonstration', 'no label'), ('Circulating', 'no label'), ('Calcium Channels', 'no label'), ('Ssfemg', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Underling', 'no label'), ('Stimulation', 'no label'), ('Rate-Dependency', 'no label'), ('Neuromuscular Jitter', 'no label'), ('Blocks', 'no label')]|[('Calcium', 'no label'), ('Antibodies', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Axial Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Areflexia', 'no label'), ('Calcium', 'no label')]|[('Patient', 'no label'), ('Lems Triad', 'no label'), ('Muscle', 'no label'), ('Isometric', 'no label'), ('Neuromuscular', 'no label'), ('Voluntary Single-Fiber Electromyography', 'no label'), ('Neuromuscular', 'no label'), ('Calcium', 'no label'), ('Neuromuscular', 'no label')]
lambert eaton syndrome|pubmed~25702627||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~25589670|To Determine Whether Immunoglobulin G (Igg) From Patients With Lambert-Eaton Myasthenic Syndrome (Lems) Decreases Action Potential–Evoked Synaptic Vesicle Exocytosis,And Whether The Effect Is Mediated By P/Q-Type Voltage-Gated Calcium Channels (Vgccs). Igg Was Obtained From 4 Patients With Lems (3 Males, 1 Female), Including 2 Patients With Lung Malignancy. Antibodies Against P/Q-Type Vgccs Were Detected In All 4 Patients, And Against N-Type Vgccs In 2. We Incubated Neuronal Cultures With Lems Igg And Determined The Size Of The Total Recycling Pool Of Synaptic Vesicles And The Rate Of Action Potential–Evoked Exocytosis Using Fluorescence Imaging Of The Amphiphilic Dye Synaptored C1. Pooled Igg From Healthy Volunteers Was Used As A Control. We Repeated The Experiments On Synapses Lacking P/Q-Type Calcium Channels From A Cacna1A Knockout Mouse To Determine Whether These Channels Account For The Pathogenic Effect Of Lems Igg. Lems Igg Had No Effect On The Total Recycling Pool Size But Significantly Reduced The Rate Of Action Potential–Evoked Synaptic Exocytosis In Wild-Type Neurons When Compared With Neurons Treated With Control Igg. In Contrast, Lems Igg Had No Effect On The Rate Of Synaptic Vesicle Exocytosis In Neurons Lacking P/Q-Type Channels. These Data Provide Direct Evidence That Lems Igg Inhibits Neurotransmitter Release By Acting On P/Q-Type Vgccs.|[('Immunoglobulin G', 'no label'), ('Igg', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Decreases', 'no label'), ('Action', 'no label'), ('Evoked', 'no label'), ('Synaptic', 'no label'), ('Vesicle', 'no label'), ('Exocytosis', 'no label'), ('Effect', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Vgccs', 'no label'), ('Igg', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Males', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Lung Malignancy', 'no label'), ('Antibodies', 'no label'), ('P/Q-Type Vgccs', 'no label'), ('Detected', 'no label'), ('Patients', 'no label'), ('N-Type Vgccs', 'no label'), ('Incubated', 'no label'), ('Neuronal Cultures', 'no label'), ('Lems Igg', 'no label'), ('Size', 'no label'), ('Total Recycling Pool', 'no label'), ('Synaptic Vesicles', 'no label'), ('Rate', 'no label'), ('Action', 'no label'), ('Exocytosis', 'no label'), ('Fluorescence Imaging', 'no label'), ('Amphiphilic Dye', 'no label'), ('Synaptored C1', 'no label'), ('Pooled', 'no label'), ('Igg', 'no label'), ('Healthy Volunteers', 'no label'), ('Control', 'no label'), ('Experiments', 'no label'), ('Synapses', 'no label'), ('Lacking', 'no label'), ('P/Q-Type Calcium Channels', 'no label'), ('Cacna1A', 'no label'), ('Knockout Mouse', 'no label'), ('Channels', 'no label'), ('Pathogenic', 'no label'), ('Effect', 'no label'), ('Lems Igg', 'no label'), ('Lems Igg', 'no label'), ('No Effect', 'no label'), ('Total Recycling Pool', 'no label'), ('Size', 'no label'), ('Reduced', 'no label'), ('Rate', 'no label'), ('Action', 'no label'), ('Evoked', 'no label'), ('Synaptic Exocytosis', 'no label'), ('Wild-Type Neurons', 'no label'), ('Neurons', 'no label'), ('Treated', 'no label'), ('Control Igg', 'no label'), ('Contrast', 'no label'), ('Lems Igg', 'no label'), ('No Effect', 'no label'), ('Rate', 'no label'), ('Synaptic Vesicle', 'no label'), ('Exocytosis', 'no label'), ('Neurons', 'no label'), ('Lacking', 'no label'), ('P/Q-Type Channels', 'no label'), ('Data', 'no label'), ('Evidence', 'no label'), ('Lems Igg', 'no label'), ('Inhibits', 'no label'), ('Neurotransmitter Release', 'no label'), ('Acting', 'no label'), ('P/Q-Type Vgccs', 'no label')]|[('Synaptic Vesicle', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('P/Q-Type', 'no label'), ('Neuronal', 'no label'), ('Synaptic Vesicles', 'no label'), ('Dye', 'no label'), ('Synapses', 'no label'), ('P/Q-Type Calcium', 'no label'), ('Mouse', 'no label'), ('Pathogenic', 'no label'), ('Wild-Type Neurons', 'no label'), ('Neurons', 'no label'), ('Synaptic Vesicle', 'no label'), ('Neurons', 'no label'), ('P/Q-Type', 'no label'), ('Neurotransmitter', 'no label')]|[('Immunoglobulin G (Igg)', 'no label'), ('Igg', 'no label'), ('N-Type Vgccs', 'no label')]|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Lung Malignancy', 'no label'), ('P/Q-Type', 'no label'), ('Amphiphilic Dye Synaptored C1', 'no label'), ('Calcium', 'no label'), ('P/Q-Type', 'no label')]|[('Immunoglobulin G', 'no label'), ('Patients', 'no label'), ('Synaptic Vesicle', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Patients', 'no label'), ('Lems (3', 'no label'), ('Patients', 'no label'), ('Lung Malignancy.', 'no label'), ('P/Q-Type Vgccs', 'no label'), ('Vgccs', 'no label'), ('Neuronal Cultures', 'no label'), ('Lems Igg', 'no label'), ('Pool', 'no label'), ('Synaptic Vesicles', 'no label'), ('Amphiphilic Dye', 'no label'), ('Synaptored C1', 'no label'), ('Synapses', 'no label'), ('P/Q-Type Calcium', 'no label'), ('Mouse', 'no label'), ('Lems Igg', 'no label'), ('Lems Igg', 'no label'), ('Pool', 'no label'), ('Synaptic', 'no label'), ('Neurons', 'no label'), ('Igg', 'no label'), ('Lems Igg', 'no label'), ('Synaptic Vesicle', 'no label'), ('Neurons', 'no label'), ('P/Q-Type', 'no label'), ('Lems Igg', 'no label'), ('Neurotransmitter', 'no label'), ('P/Q-Type', 'no label')]
lambert eaton syndrome|pubmed~22571392|The Outbreak Of Influenza A (H1N1) Pandemic During The Year 2009 Led To The Development Of Several Vaccinations Against H1N1 Virus. In Finland, 2.6 Million Citizens Were Vaccinated During Pandemic 2009 - 2010 With Adjuvanted Influenza Vaccine, Pandemrix(®) . In This Case Report, We Describe A Patient With Non-Paraneoplastic Lambert-Eaton Myasthenic Syndrome Following Pandemrix(®)  Vaccination. Development Of Various Autoimmune Diseases In Genetically Predisposed Subjects Following Exposure To Certain Environmental Factors, Including Vaccinations, Is A Well-Known Entity. Clinicians Should Be Aware Of The Possibility Of The Induction Of Autoimmune Diseases Following Vaccinations And Actively Ask The Relevant Clinical History In A Newly Diagnosed Patient With An Autoimmune Disorder.|[('Outbreak', 'no label'), ('Influenza A', 'no label'), ('Pandemic', 'no label'), ('Year', 'no label'), ('Development', 'no label'), ('Vaccinations', 'no label'), ('H1N1 Virus', 'no label'), ('Finland', 'no label'), ('Citizens', 'no label'), ('Vaccinated', 'no label'), ('Pandemic', 'no label'), ('Adjuvanted Influenza Vaccine', 'no label'), ('Pandemrix(®)', 'no label'), ('Case Report', 'no label'), ('Patient', 'no label'), ('Non-Paraneoplastic', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Pandemrix(®)  Vaccination', 'no label'), ('Development', 'no label'), ('Autoimmune Diseases', 'no label'), ('Genetically Predisposed', 'no label'), ('Subjects', 'no label'), ('Exposure To', 'no label'), ('Environmental Factors', 'no label'), ('Vaccinations', 'no label'), ('Well-Known Entity', 'no label'), ('Clinicians', 'no label'), ('Aware', 'no label'), ('Possibility', 'no label'), ('Induction', 'no label'), ('Autoimmune Diseases', 'no label'), ('Vaccinations', 'no label'), ('Relevant', 'no label'), ('Clinical History', 'no label'), ('Patient', 'no label'), ('Autoimmune Disorder', 'no label')]|[('Million', 'no label'), ('Genetically', 'no label')]|[]|[('H1N1', 'no label'), ('H1N1', 'no label'), ('Adjuvanted Influenza Vaccine', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Autoimmune Diseases', 'no label'), ('Autoimmune Disorder', 'no label')]|[('Influenza A', 'no label'), ('Influenza Vaccine', 'no label'), ('Patient', 'no label')]
lambert eaton syndrome|pubmed~34427792|Myasthenia Gravis (Mg) Lambert-Eaton (Le) Overlap Syndrome Is A Rare Condition. Here, We Describe The First Case Of Mg-Le Overlap Syndrome Revealed By The Anti-Programmed Cell Death 1 Inhibitor, Nivolumab, In A Patient Treated For Metastatic Melanoma. Three Months After Receiving Nivolumab And 1 Month After Brain Metastasis Radiotherapy, Our Patient Developed Generalized Fatigue With Intermittent Ptosis And Swallowing Difficulty Suggesting A Myasthenic Syndrome. Electromyogram Findings, Anti-Acetylcholine Receptor, And Anti-Calcium Channel Antibodies Levels Were Consistent With An Immune-Related Myasthenic Syndrome With Specific Features For Both Mg And Le Syndromes. Immunotherapy With Nivolumab Was Stopped. Patient Was Treated With Systemic Immunosuppressive And Anti-Cholinesterase Drugs, With Remarkable Improvement Of His Neurological Symptoms. Prolonged Partial Remission Was Obtained For His Metastatic Melanoma Without Need For A Third-Line Treatment. Two Years Later, A Relapse Of Hismyasthenic Symptoms Was Observed Along With New Neurological Symptoms Related To Brain Radiation Necrosis. We Describe The First Case Of Mg-Le Overlap Syndrome Diagnosed After Anti-Pd1 Immunotherapy For Metastatic Melanoma, Which Appeared After Radiation Therapy And Then Relapsed After Brain Radiation Necrosis. We Hypothesized A Role For Brain Inflammation As A Trigger For Mg-Le Onset. Neuro-Muscular Junctions Disease Induced Or Revealed By Checkpoint Inhibitors Can Be Challenging And Requires Long-Term Follow-Up.|[('Myasthenia Gravis', 'no label'), ('Rare', 'no label'), ('Condition', 'no label'), ('First Case\xa0', 'no label'), ('Overlap Syndrome', 'no label'), ('Revealed', 'no label'), ('Anti-Programmed Cell Death', 'no label'), ('Inhibitor', 'no label'), ('Nivolumab', 'no label'), ('Patient', 'no label'), ('Treated', 'no label'), ('Metastatic Melanoma', 'no label'), ('Months', 'no label'), ('Receiving', 'no label'), ('Nivolumab', 'no label'), ('Month', 'no label'), ('Brain Metastasis', 'no label'), ('Radiotherapy', 'no label'), ('Patient', 'no label'), ('Developed\xa0Generalized Fatigue', 'no label'), ('Intermittent Ptosis', 'no label'), ('Swallowing', 'no label'), ('Difficulty Suggesting A Myasthenic Syndrome', 'no label'), ('Electromyogram', 'no label'), ('Findings', 'no label'), ('Anti-Acetylcholine Receptor', 'no label'), ('Anti-Calcium Channel Antibodies', 'no label'), ('Levels', 'no label'), ('Immune-Related Myasthenic Syndrome', 'no label'), ('Features', 'no label'), ('Mg', 'no label'), ('Le Syndromes', 'no label'), ('Nivolumab', 'no label'), ('Stopped', 'no label'), ('Patient', 'no label'), ('Treated', 'no label'), ('Systemic', 'no label'), ('Anti-Cholinesterase\xa0Drugs', 'no label'), ('Improvement', 'no label'), ('Neurological Symptoms', 'no label'), ('Prolonged', 'no label'), ('Partial Remission', 'no label'), ('His Metastatic Melanoma', 'no label'), ('Third-Line', 'no label'), ('Treatment', 'no label'), ('Years', 'no label'), ('Relapse', 'no label'), ('Hismyasthenic Symptoms', 'no label'), ('Observed', 'no label'), ('Neurological Symptoms', 'no label'), ('Brain', 'no label'), ('Radiation Necrosis', 'no label'), ('Overlap Syndrome', 'no label'), ('Diagnosed', 'no label'), ('Anti-Pd1 Immunotherapy', 'no label'), ('Metastatic\xa0Melanoma', 'no label'), ('Appeared', 'no label'), ('Radiation Therapy', 'no label'), ('Relapsed', 'no label'), ('Brain', 'no label'), ('Radiation Necrosis', 'no label'), ('Hypothesized A', 'no label'), ('Brain Inflammation', 'no label'), ('Trigger', 'no label'), ('Mg-Le Onset', 'no label'), ('Neuro-Muscular Junctions Disease', 'no label'), ('Revealed', 'no label'), ('Checkpoint Inhibitors', 'no label'), ('Challenging', 'no label'), ('Requires', 'no label'), ('Long-Term Follow-Up', 'no label')]|[('Cell', 'no label'), ('Antibodies', 'no label'), ('His', 'no label'), ('His', 'no label'), ('Inhibitors', 'no label')]|[('Anti-Programmed Cell Death 1 Inhibitor, Nivolumab, In A Patient Treated', 'no label'), ('His', 'no label')]|[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Death', 'no label'), ('Melanoma', 'no label'), ('Fatigue', 'no label'), ('Intermittent Ptosis And Swallowing Difficulty Suggesting A Myasthenic Syndrome', 'no label'), ('Anti-Acetylcholine', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Mg', 'no label'), ('Melanoma', 'no label'), ('Necrosis', 'no label'), ('Melanoma', 'no label'), ('Relapsed', 'no label'), ('Necrosis', 'no label'), ('Brain Inflammation', 'no label')]|[('Le)', 'no label'), ('Cell', 'no label'), ('Nivolumab', 'no label'), ('Melanoma', 'no label'), ('Brain', 'no label'), ('Patient', 'no label'), ('Electromyogram', 'no label'), ('Anti-Acetylcholine Receptor', 'no label'), ('Mg', 'no label'), ('Le Syndromes.', 'no label'), ('Nivolumab', 'no label'), ('Melanoma', 'no label'), ('Brain', 'no label'), ('Anti-Pd1', 'no label'), ('Melanoma', 'no label'), ('Brain', 'no label'), ('Brain', 'no label')]
lambert eaton syndrome|pubmed~22094130|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Neuromuscular Autoimmune Disease That Has Served As A Model For Autoimmunity And Tumour Immunology. In Lems, The Characteristic Muscle Weakness Is Thought To Be Caused By Pathogenic Autoantibodies Directed Against Voltage-Gated Calcium Channels (Vgcc) Present On The Presynaptic Nerve Terminal. Half Of Patients With Lems Have An Associated Tumour, Small-Cell Lung Carcinoma (Sclc), Which Also Expresses Functional Vgcc. Knowledge Of This Association Led To The Discovery Of A Wide Range Of Paraneoplastic And Non-Tumour-Related Neurological Disorders Of The Peripheral And Central Nervous Systems. Detailed Clinical Studies Have Improved Our Diagnostic Skills And Knowledge Of The Pathophysiological Mechanisms And Association Of Lems With Sclc, And Have Helped With The Development Of A Protocol For Early Tumour Detection.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Neuromuscular Autoimmune Disease', 'no label'), ('Model', 'no label'), ('Autoimmunity', 'no label'), ('Tumour Immunology', 'no label'), ('Characteristic Muscle Weakness', 'no label'), ('Pathogenic Autoantibodies', 'no label'), ('Directed Against', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Vgcc', 'no label'), ('Present', 'no label'), ('Presynaptic Nerve', 'no label'), ('Terminal', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Associated Tumour', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Expresses', 'no label'), ('Functional Vgcc', 'no label'), ('Association', 'no label'), ('Led', 'no label'), ('Discovery', 'no label'), ('Wide Range', 'no label'), ('Paraneoplastic', 'no label'), ('Peripheral', 'no label'), ('Central Nervous Systems', 'no label'), ('Clinical Studies', 'no label'), ('Diagnostic Skills', 'no label'), ('Knowledge', 'no label'), ('Pathophysiological', 'no label'), ('Mechanisms', 'no label'), ('Association', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Development', 'no label'), ('Protocol', 'no label'), ('Early Tumour', 'no label'), ('Detection', 'no label')]|[('Pathogenic Autoantibodies', 'no label'), ('Calcium', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Neuromuscular Autoimmune Disease', 'no label'), ('Autoimmunity', 'no label'), ('Tumour', 'no label'), ('Muscle Weakness', 'no label'), ('Calcium', 'no label'), ('Tumour', 'no label'), ('Lung Carcinoma', 'no label'), ('Paraneoplastic', 'no label'), ('Neurological Disorders', 'no label'), ('Tumour', 'no label')]|[('Neuromuscular', 'no label'), ('Tumour', 'no label'), ('Muscle', 'no label'), ('Calcium', 'no label'), ('Presynaptic Nerve', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Tumour', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Peripheral', 'no label'), ('Lems', 'no label'), ('Tumour', 'no label')]
lambert eaton syndrome|pubmed~23298881|A Patient With Typical Lambert-Eaton Myasthenic Syndrome (Lems) Has A Clinical Manifestation Of Proximal Muscle Weaknesses, A Larger-Than-100% Incremental Change In Repetitive Nerve Stimulation On High-Rate Stimulation Electrophysiological Testing, And A Paraneoplastic Origin From Small Cell Carcinoma Of The Lung. Here, We Present A Patient With An Atypical Myasthenic Syndrome With An Oculobulbar-Predominant Muscle Involvement, A Borderline Incremental Change In Repetitive Nerve Stimulation At High Frequencies, And A Paraneoplastic Origin From Extrapulmonary Mixed Small Cell Carcinoma And Adenocarcinoma. The Purpose Of This Report Is To Emphasize The Importance Of Painstaking Scrutiny In The Examination Of A Patient With A Less-Common Presentation Of Lems.|[('Patient', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Clinical', 'no label'), ('Proximal Muscle', 'no label'), ('Larger-Than-100% Incremental Change', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('High-Rate Stimulation', 'no label'), ('Electrophysiological Testing', 'no label'), ('Paraneoplastic Origin', 'no label'), ('Small Cell Carcinoma', 'no label'), ('Lung', 'no label'), ('Patient', 'no label'), ('Atypical Myasthenic Syndrome', 'no label'), ('Oculobulbar-Predominant Muscle', 'no label'), ('Involvement', 'no label'), ('Borderline Incremental Change', 'no label'), ('Repetitive Nerve', 'no label'), ('Stimulation', 'no label'), ('High Frequencies', 'no label'), ('Paraneoplastic Origin', 'no label'), ('Extrapulmonary Mixed Small Cell Carcinoma', 'no label'), ('Adenocarcinoma', 'no label'), ('Report', 'no label'), ('Emphasize', 'no label'), ('Painstaking Scrutiny', 'no label'), ('Examination', 'no label'), ('Patient', 'no label'), ('Lems', 'no label')]|[('Cell', 'no label'), ('Cell', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Carcinoma Of The Lung.', 'no label'), ('Atypical Myasthenic Syndrome', 'no label'), ('Carcinoma', 'no label'), ('Adenocarcinoma', 'no label')]|[('Patient', 'no label'), ('Muscle', 'no label'), ('Nerve', 'no label'), ('High-Rate', 'no label'), ('Small Cell Carcinoma', 'no label'), ('Lung', 'no label'), ('Muscle', 'no label'), ('Borderline Incremental', 'no label'), ('Nerve', 'no label'), ('Extrapulmonary Mixed Small Cell Carcinoma', 'no label'), ('Adenocarcinoma', 'no label'), ('Patient', 'no label'), ('Less-Common', 'no label')]
lambert eaton syndrome|pubmed~23583364|Lambert-Eaton Myasthenic Syndrome (Lems) Is Characterized By Fluctuating Muscle Weakness And Autonomic Dysfunction. In 90% Of The Lems Patients The Disease Is Associated With Auto-Antibodies Against The Voltage-Gated Calcium Channels (Vgcc). Several Auto-Immune Responses Against Other Antigenic Targets Have Been Described To (Co)-Occur In Lems Patients. To Identify New Lems Associated Small Cell Lung Cancer (Sclc) Markers Immunoprecipitation With A Sclc Cell Line Was Performed. We Discovered Strong Immunoreactivity Against The 120 Kda Large Erc1 Protein In One Tumor-Negative Vgcc-Positive Lems Patient. A Recombinant Elisa Assay And A Cellular Assay Expressing Gfp-Tagged Full Length Erc1 Were Used To Confirm The Presence Of Auto-Antibodies Against Erc1 In This Patient. Additional Testing Of 58 Lems Patients Including 9 Vgcc Auto-Antibody Negative Lems Patients, 48 Myasthenia Gravis Patients, 84 Control Patients With Other Diseases And 12 Healthy Controls Revealed No Other Cases. Erc1 Is Therefore A New, But Rare, Antigen In Lems.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Characterized', 'no label'), ('Fluctuating Muscle Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Lems Patients', 'no label'), ('Disease', 'no label'), ('Associated With', 'no label'), ('Auto-Antibodies', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Vgcc', 'no label'), ('Auto-Immune Responses', 'no label'), ('Antigenic', 'no label'), ('Targets', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('New Lems', 'no label'), ('Sclc', 'no label'), ('Immunoprecipitation', 'no label'), ('Sclc', 'no label'), ('Cell Line', 'no label'), ('Immunoreactivity', 'no label'), ('Erc1', 'no label'), ('Protein', 'no label'), ('Tumor-Negative Vgcc-Positive Lems', 'no label'), ('Patient', 'no label'), ('Recombinant Elisa Assay', 'no label'), ('Cellular Assay', 'no label'), ('Gfp-Tagged', 'no label'), ('Full Length Erc1', 'no label'), ('Confirm', 'no label'), ('Presence', 'no label'), ('Auto-Antibodies', 'no label'), ('Erc1', 'no label'), ('Patient', 'no label'), ('Testing', 'no label'), ('Lems Patients', 'no label'), ('Vgcc', 'no label'), ('Auto-Antibody Negative Lems', 'no label'), ('Patients', 'no label'), ('Myasthenia Gravis', 'no label'), ('Patients', 'no label'), ('Control', 'no label'), ('Patients', 'no label'), ('Diseases', 'no label'), ('Healthy Controls', 'no label'), ('Revealed', 'no label'), ('Cases', 'no label'), ('Erc1', 'no label'), ('Rare', 'no label'), ('Antigen', 'no label')]|[('Auto-Antibodies', 'no label'), ('Calcium', 'no label'), ('Cell', 'no label'), ('Cell', 'no label'), ('Erc1 Protein', 'no label'), ('Cellular', 'no label'), ('Erc1', 'no label'), ('Auto-Antibodies', 'no label'), ('Erc1', 'no label'), ('Erc1', 'no label')]|[('Sclc Cell Line', 'no label'), ('120 Kda', 'no label'), ('Erc1 Protein', 'no label'), ('Gfp-Tagged', 'no label'), ('Erc1', 'no label'), ('Erc1', 'no label'), ('Erc1', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Muscle Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Calcium', 'no label'), ('(Co)-Occur', 'no label'), ('Myasthenia Gravis', 'no label')]|[('Muscle', 'no label'), ('Lems Patients', 'no label'), ('Auto-Antibodies', 'no label'), ('Calcium', 'no label'), ('(Co)-Occur', 'no label'), ('Lems Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('A Sclc Cell Line', 'no label'), ('A Cellular', 'no label'), ('Auto-Antibodies', 'no label'), ('Patients', 'no label'), ('Vgcc Auto-Antibody', 'no label'), ('Lems Patients', 'no label'), ('Patients', 'no label'), ('Antigen', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~25192047|Synaptotagmin 2 Is A Synaptic Vesicle Protein That Functions As A Calcium Sensor For Neurotransmission But Has Not Been Previously Associated With Human Disease. Via Whole-Exome Sequencing, We Identified Heterozygous Missense Mutations In The C2B Calcium-Binding Domain Of The Gene Encoding Synaptotagmin 2 In Two Multigenerational Families Presenting With Peripheral Motor Neuron Syndromes. An Essential Calcium-Binding Aspartate Residue, Asp307Ala, Was Disrupted By A C.920A>C Change In One Family That Presented With An Autosomal-Dominant Presynaptic Neuromuscular Junction Disorder Resembling Lambert-Eaton Myasthenic Syndrome. A C.923C>T Variant Affecting An Adjacent Residue (P.Pro308Leu) Produced A Presynaptic Neuromuscular Junction Defect And A Dominant Hereditary Motor Neuropathy In A Second Family. Characterization Of The Mutation Homologous To The Human C.920A>C Variant In Drosophila Synaptotagmin Revealed A Dominant Disruption Of Synaptic Vesicle Exocytosis Using This Transgenic Model. These Findings Indicate That Synaptotagmin 2 Regulates Neurotransmitter Release At Human Peripheral Motor Nerve Terminals. In Addition, Mutations In The Synaptotagmin 2 C2B Domain Represent An Important Cause Of Presynaptic Congenital Myasthenic Syndromes And Link Them With Hereditary Motor Axonopathies. |[('Synaptotagmin 2', 'no label'), ('Synaptic Vesicle Protein', 'no label'), ('Functions', 'no label'), ('Calcium Sensor', 'no label'), ('Neurotransmission', 'no label'), ('Associated With', 'no label'), ('Human Disease', 'no label'), ('Whole-Exome Sequencing', 'no label'), ('Heterozygous', 'no label'), ('Missense Mutations', 'no label'), ('C2B Calcium-Binding Domain', 'no label'), ('Gene Encoding', 'no label'), ('Synaptotagmin 2', 'no label'), ('Multigenerational Families', 'no label'), ('Peripheral Motor Neuron Syndromes', 'no label'), ('Essential Calcium-Binding', 'no label'), ('Aspartate', 'no label'), ('Residue', 'no label'), ('Asp307Ala', 'no label'), ('Was Disrupted', 'no label'), ('C.920A>C', 'no label'), ('Change', 'no label'), ('Family', 'no label'), ('Autosomal-Dominant Presynaptic', 'no label'), ('Neuromuscular Junction Disorder', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('C.923C>T Variant', 'no label'), ('Affecting', 'no label'), ('Adjacent', 'no label'), ('Residue', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular Junction Defect', 'no label'), ('Dominant', 'no label'), ('Hereditary Motor Neuropathy', 'no label'), ('Family', 'no label'), ('Characterization', 'no label'), ('Mutation Homologous', 'no label'), ('Human', 'no label'), ('C.920A>C Variant', 'no label'), ('Drosophila', 'no label'), ('Synaptotagmin', 'no label'), ('Revealed', 'no label'), ('Dominant', 'no label'), ('Disruption', 'no label'), ('Synaptic', 'no label'), ('Exocytosis', 'no label'), ('Transgenic Model', 'no label'), ('Findings', 'no label'), ('Indicate', 'no label'), ('Synaptotagmin 2', 'no label'), ('Regulates', 'no label'), ('Neurotransmitter Release', 'no label'), ('Human Peripheral Motor Nerve', 'no label'), ('Terminals', 'no label'), ('Mutations', 'no label'), ('Synaptotagmin 2 C2B Domain', 'no label'), ('Represent', 'no label'), ('Cause', 'no label'), ('Presynaptic Congenital Myasthenic Syndromes', 'no label'), ('Hereditary Motor Axonopathies', 'no label')]|[('Synaptotagmin 2', 'no label'), ('Synaptic Vesicle Protein', 'no label'), ('Calcium', 'no label'), ('Human', 'no label'), ('Mutations', 'no label'), ('Domain', 'no label'), ('Gene', 'no label'), ('Synaptotagmin 2', 'no label'), ('Motor Neuron', 'no label'), ('Aspartate Residue', 'no label'), ('Variant', 'no label'), ('Residue', 'no label'), ('Mutation', 'no label'), ('Human', 'no label'), ('Variant', 'no label'), ('Drosophila Synaptotagmin', 'no label'), ('Synaptic Vesicle', 'no label'), ('Transgenic', 'no label'), ('Synaptotagmin 2', 'no label'), ('Neurotransmitter', 'no label'), ('Human Peripheral Motor Nerve Terminals', 'no label'), ('Mutations', 'no label'), ('Synaptotagmin 2', 'no label'), ('Domain', 'no label')]|[('Synaptic Vesicle Protein', 'no label'), ('C2B Calcium-Binding Domain', 'no label'), ('Human C.920A>C Variant', 'no label'), ('Human Peripheral Motor Nerve Terminals', 'no label'), ('Synaptotagmin 2 C2B Domain', 'no label')]|[('Calcium', 'no label'), ('Human Disease', 'no label'), ('Heterozygous', 'no label'), ('Peripheral Motor Neuron Syndromes', 'no label'), ('Aspartate', 'no label'), ('Neuromuscular Junction Disorder', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Hereditary Motor Neuropathy', 'no label'), ('Peripheral Motor Nerve Terminals', 'no label'), ('Congenital Myasthenic Syndromes And Link Them With', 'no label'), ('Hereditary Motor Axonopathies', 'no label')]|[('Synaptotagmin', 'no label'), ('Synaptic Vesicle', 'no label'), ('Calcium', 'no label'), ('Human Disease', 'no label'), ('C2B', 'no label'), ('Synaptotagmin', 'no label'), ('Peripheral', 'no label'), ('Aspartate', 'no label'), ('Human', 'no label'), ('Drosophila Synaptotagmin', 'no label'), ('Synaptic Vesicle', 'no label'), ('Synaptotagmin 2', 'no label'), ('Neurotransmitter', 'no label'), ('Human Peripheral Motor Nerve Terminals', 'no label'), ('Synaptotagmin', 'no label'), ('Presynaptic', 'no label'), ('Link', 'no label')]
lambert eaton syndrome|pubmed~31355029|We Present A Case Of A 59-Year-Old Male With A Confirmed Diagnosis Of Small-Cell Lung Cancer (Sclc). He Had Progressive Disease Even After Four Cycles Of Cisplatin And Etoposide Chemotherapy And 21 Cycles Of Radiation. He Was Therefore Started On Immunotherapy With Nivolumab Every 2 Weeks And Ipilimumab Every 6 Weeks. After 4 Months Of Starting Immunotherapy, He Reported Extreme Fatigue, Muscular Weakness, And Poor Appetite. He Was Diagnosed With Hypothyroidism, Primary Adrenal Insufficiency, And Lambert-Eaton Myasthenic Syndrome (Lems). Lems Can Be Both A Paraneoplastic Syndrome Of Sclc And An Adverse Effect Of Immunotherapy. Currently, There Is No Diagnostic Test Available To Determine If A Case Of Lems Is A Paraneoplastic Syndrome Or Immunotherapy-Related Adverse Effect. In Our Patient, We Felt That Lems Was An Immunotherapy-Related Adverse Effect Rather Being A Paraneoplastic Syndrome. Our Determination Was Based On The Time Of Onset Of Muscular Weakness, Presence Of Other Immunotherapy-Mediated Adverse Events, And The Appearance Of Symptoms In Spite Of Sclc That Had Been Stabilized On Immunotherapy. Accordingly, Immunotherapy Was Stopped And A Brief Tapering Course Of Steroids Was Initiated. Our Patient'S Muscular Weakness From Lems Responded Well. His Clinical Improvement Persisted Even With Radiologic Progression Of Disease After Cessation Of Immunotherapy.|"[('Male With', 'no label'), ('Confirmed Diagnosis', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Progressive Disease', 'no label'), ('Cycles', 'no label'), ('Cisplatin', 'no label'), ('Etoposide Chemotherapy', 'no label'), ('Radiation', 'no label'), ('Started', 'no label'), ('Immunotherapy', 'no label'), ('Nivolumab', 'no label'), ('Weeks', 'no label'), ('Ipilimumab', 'no label'), ('Weeks', 'no label'), ('Months', 'no label'), ('Immunotherapy', 'no label'), ('Extreme Fatigue', 'no label'), ('Muscular Weakness', 'no label'), ('Poor Appetite', 'no label'), ('Diagnosed', 'no label'), ('Hypothyroidism', 'no label'), ('Primary Adrenal Insufficiency', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Lems', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Sclc', 'no label'), ('Adverse Effect', 'no label'), ('Immunotherapy', 'no label'), ('No Diagnostic Test', 'no label'), ('Case', 'no label'), ('Lems', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Patient', 'no label'), ('Lems', 'no label'), ('Immunotherapy-Related Adverse Effect', 'no label'), ('Being A', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Determination', 'no label'), ('Time', 'no label'), ('Muscular Weakness', 'no label'), ('Immunotherapy-Mediated Adverse Events', 'no label'), ('Appearance', 'no label'), ('Symptoms', 'no label'), ('Sclc', 'no label'), ('Stabilized', 'no label'), ('Immunotherapy', 'no label'), ('Immunotherapy', 'no label'), ('Stopped', 'no label'), ('Brief Tapering Course', 'no label'), ('Steroids', 'no label'), (""Patient'S"", 'no label'), ('Muscular Weakness', 'no label'), ('Lems Responded Well', 'no label'), ('Clinical Improvement', 'no label'), ('Persisted', 'no label'), ('Radiologic', 'no label'), ('Progression', 'no label'), ('Disease', 'no label'), ('Cessation', 'no label'), ('Immunotherapy', 'no label')]"|[('Cisplatin', 'no label'), ('Steroids', 'no label'), ('His', 'no label')]|[('His', 'no label')]|[('Lung Cancer', 'no label'), ('Cisplatin', 'no label'), ('Etoposide', 'no label'), ('Fatigue', 'no label'), ('Muscular Weakness', 'no label'), ('Hypothyroidism', 'no label'), ('Primary Adrenal Insufficiency', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Muscular Weakness', 'no label'), ('Steroids', 'no label'), ('Muscular Weakness', 'no label')]|[('Small-Cell Lung Cancer', 'no label'), ('Cisplatin', 'no label'), ('Etoposide', 'no label'), ('Ipilimumab', 'no label'), ('Muscular', 'no label'), ('Be Both A', 'no label'), ('A Case', 'no label'), ('Lems', 'no label'), ('Lems', 'no label'), ('Muscular Weakness', 'no label'), ('Steroids', 'no label'), ('Patient', 'no label'), ('Muscular Weakness', 'no label')]
lambert eaton syndrome|pubmed~21328260|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disorder Of Neuromuscular Transmission. Treatments Attempt To Overcome The Harmful Autoimmune Process, Or Improve Residual Neuromuscular Transmission The Objective Was To Examine The Efficacy Of Treatment In Lambert-Eaton Myasthenic Syndrome. We Searched The Cochrane Neuromuscular Disease Group Specialized Register (12 October 2010), The Cochrane Central Register Of Controlled Trials (Central) (12 October 2010, Issue 4 2010 In The Cochrane Library), Medline (January 1966 To September 2010) And Embase (January 1980 To September 2010). All Randomised Or Quasi-Randomised Trials Of Adults And Children With A Diagnosis Of Lambert-Eaton Myasthenic Syndrome, With Or Without Small-Cell Lung Cancer, Receiving Any Form Of Pharmacological Or Physical Treatment. All Authors Independently Assessed Studies For Inclusion And Extracted Data. Study Authors Were Contacted For Missing Information When Possible. Four Controlled Trials Of 3,4-Diaminopyridine Compared With Placebo In A Total Of 54 Participants With Lambert-Eaton Myasthenic Syndrome Were Eligible: Three Cross-Over Trials And One Parallel Group. Two Were Added At This Update. One Of These Trials Also Assessed Pyridostigmine In Conjunction With 3,4-Diaminopyridine. A Further Cross-Over Trial Compared Intravenous Immunoglobulin (Ivig) To Placebo In Nine Participants.Four Trials Of 3,4-Diaminopyridine Reported Significant Improvement In The Primary Outcome, Muscle Strength Score, Or Myometric Limb Measurement For Between Hours And A Week Following Treatment, And Significant Improvement In Resting Compound Muscle Action Potential (Cmap) Amplitude Following 3,4-Diaminopyridine, Compared With Placebo.A Meta-Analysis Of The Primary Endpoint Showed Quantitative Myasthenia Gravis (Qmg) Muscle Score Assessed Between Three And Eight Days Was Likely To Improve By A Mean Of 2.44 Points (95% Confidence Interval 3.6 To 1.22). Meta-Analysis Of The Secondary Endpoint Cmap Amplitude Also Showed A Mean Improvement Of 1.36 Mv (95% Confidence Interval 0.99 To 1.72) Over The Same Period. The Risk Of Bias Was Determined To Be Low, And Quality Of Evidence Moderate To High.A Single Cross-Over Trial Reported Significant Improvement In Myometric Limb Strength And Non-Significant Improvement In Mean Resting Cmap Amplitude With Ivig Compared To Placebo. Clinical Improvement Lasted For Up To Eight Weeks. Limited But Moderate To High Quality Evidence From Randomised Controlled Trials Showed That Over Days 3,4-Diaminopyridine, Or For Up To 8 Weeks Ivig, Improved Muscle Strength Scores And Cmap Amplitudes In Participants With Lambert-Eaton Myasthenic Syndrome. There Are Insufficient Data At Present To Quantify This Effect. Other Possible Treatments Have Not Been Tested In Randomised Controlled Trials.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disorder', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Treatments', 'no label'), ('Attempt', 'no label'), ('Overcome', 'no label'), ('Autoimmune Process', 'no label'), ('Improve', 'no label'), ('Residual', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Objective', 'no label'), ('Efficacy', 'no label'), ('Treatment', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Cochrane Neuromuscular Disease Group Specialized Register', 'no label'), ('Cochrane Central Register Of Controlled Trials', 'no label'), ('Central', 'no label'), ('Cochrane Library', 'no label'), ('Medline', 'no label'), ('Embase', 'no label'), ('Randomised Or Quasi-Randomised Trials', 'no label'), ('Adults', 'no label'), ('Children', 'no label'), ('Diagnosis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Small-Cell', 'no label'), ('Lung Cancer', 'no label'), ('Receiving', 'no label'), ('Pharmacological', 'no label'), ('Physical Treatment', 'no label'), ('Assessed Studies', 'no label'), ('Inclusion', 'no label'), ('Extracted Data', 'no label'), ('Study', 'no label'), ('Authors', 'no label'), ('Contacted', 'no label'), ('Missing Information', 'no label'), ('Controlled Trials', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Placebo', 'no label'), ('Participants', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Cross-Over Trials', 'no label'), ('Parallel Group', 'no label'), ('Added', 'no label'), ('Update', 'no label'), ('Trials', 'no label'), ('Assessed', 'no label'), ('Pyridostigmine', 'no label'), ('Conjunction', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Cross-Over Trial', 'no label'), ('Intravenous Immunoglobulin', 'no label'), ('Ivig', 'no label'), ('Placebo', 'no label'), ('Participants', 'no label'), ('Trials', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Significant', 'no label'), ('Improvement', 'no label'), ('Primary Outcome', 'no label'), ('Muscle Strength Score', 'no label'), ('Myometric Limb Measurement', 'no label'), ('Hours', 'no label'), ('Week', 'no label'), ('Treatment', 'no label'), ('Significant', 'no label'), ('Improvement', 'no label'), ('Resting Compound Muscle Action Potential', 'no label'), ('Cmap', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Placebo', 'no label'), ('Meta-Analysis', 'no label'), ('Primary Endpoint', 'no label'), ('Quantitative Myasthenia Gravis', 'no label'), ('Muscle Score', 'no label'), ('Assessed', 'no label'), ('Days', 'no label'), ('Confidence Interval', 'no label'), ('Meta-Analysis', 'no label'), ('Secondary Endpoint Cmap', 'no label'), ('Mean Improvement', 'no label'), ('Confidence Interval', 'no label'), ('Period', 'no label'), ('Risk', 'no label'), ('Bias', 'no label'), ('Low', 'no label'), ('Quality', 'no label'), ('Evidence', 'no label'), ('Moderate', 'no label'), ('Single Cross-Over Trial', 'no label'), ('Significant', 'no label'), ('Improvement', 'no label'), ('Myometric Limb Strength', 'no label'), ('Resting Cmap Amplitude', 'no label'), ('Placebo', 'no label'), ('Clinical Improvement', 'no label'), ('Weeks', 'no label'), ('Moderate', 'no label'), ('Quality', 'no label'), ('Evidence', 'no label'), ('Randomised Controlled Trials', 'no label'), ('Days', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Improved', 'no label'), ('Muscle Strength Scores', 'no label'), ('Cmap', 'no label'), ('Amplitudes', 'no label'), ('Participants', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Insufficient', 'no label'), ('Data', 'no label'), ('Quantify', 'no label'), ('Effect', 'no label'), ('Treatments', 'no label'), ('Tested', 'no label'), ('Randomised Controlled Trials', 'no label')]|[('Pyridostigmine', 'no label'), ('Trial', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Trial', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Neuromuscular Disease', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lung Cancer', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Pyridostigmine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Myasthenia Gravis', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Myasthenic Syndrome', 'no label')]|[('Neuromuscular', 'no label'), ('Neuromuscular', 'no label'), ('Issue 4', 'no label'), ('Children', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Immunoglobulin', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Muscle', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Muscle', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Muscle', 'no label')]
lambert eaton syndrome|pubmed~23785168|We Developed A Novel Calcium (Ca(2+)) Channel Agonist That Is Selective For N- And P/Q-Type Ca(2+) Channels, Which Are The Ca(2+) Channels That Regulate Transmitter Release At Most Synapses. We Have Shown That This New Molecule (Gv-58) Slows The Deactivation Of Channels, Resulting In A Large Increase In Presynaptic Ca(2+) Entry During Activity. Gv-58 Was Developed As A Modification Of (R)-Roscovitine, Which Was Previously Shown To Be A Ca(2+) Channel Agonist, In Addition To Its Known Cyclin-Dependent Kinase Activity. In Comparison With The Parent Molecule, (R)-Roscovitine, Gv-58 Has A ∼20-Fold Less Potent Cyclin-Dependent Kinase Antagonist Effect, A ∼3- To 4-Fold More Potent Ca(2+) Channel Agonist Effect, And ∼4-Fold Higher Efficacy As A Ca(2+) Channel Agonist. We Have Further Evaluated Gv-58 In A Passive Transfer Mouse Model Of Lambert-Eaton Myasthenic Syndrome And Have Shown That Weakened Lambert-Eaton Myasthenic Syndrome-Model Neuromuscular Synapses Are Significantly Strengthened Following Exposure To Gv-58. This New Ca(2+) Channel Agonist Has Potential As A Lead Compound In The Development Of New Therapeutic Approaches To A Variety Of Disorders That Result In Neuromuscular Weakness.|[('Novel', 'no label'), ('Calcium', 'no label'), ('Ca(2+)) Channel Agonist', 'no label'), ('Ca(2+) Channels', 'no label'), ('Regulate', 'no label'), ('Transmitter Release', 'no label'), ('Synapses', 'no label'), ('New Molecule', 'no label'), ('Gv-58', 'no label'), ('Slows', 'no label'), ('Deactivation', 'no label'), ('Channels', 'no label'), ('Increase', 'no label'), ('Presynaptic Ca(2+)', 'no label'), ('Activity', 'no label'), ('Modification', 'no label'), ('(R)-Roscovitine', 'no label'), ('Ca(2+) Channel Agonist', 'no label'), ('Cyclin-Dependent Kinase', 'no label'), ('Activity', 'no label'), ('Comparison', 'no label'), ('Parent Molecule', 'no label'), ('(R)-Roscovitine', 'no label'), ('Gv-58', 'no label'), ('Cyclin-Dependent Kinase Antagonist', 'no label'), ('Effect', 'no label'), ('Ca(2+) Channel Agonist', 'no label'), ('Effect', 'no label'), ('Efficacy', 'no label'), ('Ca(2+) Channel Agonist', 'no label'), ('Evaluated', 'no label'), ('Gv-58', 'no label'), ('Passive Transfer Mouse Model', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Weakened', 'no label'), ('Lambert-Eaton Myasthenic Syndrome-Model', 'no label'), ('Neuromuscular Synapses', 'no label'), ('Strengthened', 'no label'), ('Exposure To', 'no label'), ('Gv-58', 'no label'), ('New Ca(2+) Channel Agonist', 'no label'), ('Lead Compound', 'no label'), ('Development', 'no label'), ('Therapeutic Approaches', 'no label'), ('Result', 'no label'), ('Neuromuscular Weakness', 'no label')]|[('Calcium', 'no label'), ('Agonist', 'no label'), ('Synapses', 'no label'), ('Molecule', 'no label'), ('Modification', 'no label'), ('Agonist', 'no label'), ('Agonist', 'no label'), ('∼4-Fold', 'no label'), ('Agonist', 'no label'), ('Mouse', 'no label'), ('Synapses', 'no label'), ('Agonist', 'no label')]|[('Cyclin-Dependent Kinase', 'no label')]|[('Calcium', 'no label'), ('(R)-Roscovitine', 'no label'), ('(R)-Roscovitine', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Neuromuscular Weakness', 'no label')]|[('Calcium', 'no label'), ('P/Q-Type Ca(2+', 'no label'), ('Synapses', 'no label'), ('Presynaptic', 'no label'), ('Be A', 'no label'), ('Cyclin-Dependent Kinase', 'no label'), ('Mouse', 'no label'), ('Neuromuscular Synapses', 'no label'), ('A Lead Compound', 'no label'), ('Neuromuscular', 'no label')]
lambert eaton syndrome|pubmed~23690300|To Report A Case Of Lambert-Eaton Myasthenic Syndrome (Lems) In A Child And Review The Existing Literature Of Lems In Children. We Report A Pediatric Case Of Lems With The Classic Clinical Triad Of Proximal Weakness, Autonomic Dysfunction, And Areflexia; The Characteristic Increment In Compound Motor Action Potential On High-Frequency Repetitive Nerve Stimulation; And Positive Serum P/Q-Type Voltage-Gated Calcium Channel Antibodies. Only 11 Pediatric Cases Of Lems Have Been Reported In The Literature. The Patient'S Presentation With Lems Led To The Diagnosis Of Occult Neuroblastoma. Based On Review Of The Existing Pediatric Literature, No Consistent Clinical Or Electrodiagnostic Criteria Exist To Diagnose Lems In Children. There Exists A Need For Consistent Clinical Criteria And Electrodiagnostic Testing For Prompt Diagnosis Of Lems In Children. Prompt Identification Of Lems Will Alert The Physician To Search For Malignancy Or Another Immune-Mediated Process.|"[('Report', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Child', 'no label'), ('Literature', 'no label'), ('Lems', 'no label'), ('Children', 'no label'), ('Report', 'no label'), ('Pediatric', 'no label'), ('Classic Clinical Triad', 'no label'), ('Proximal Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Areflexia', 'no label'), ('Characteristic Increment', 'no label'), ('Compound Motor Action', 'no label'), ('High-Frequency', 'no label'), ('Repetitive Nerve', 'no label'), ('Positive Serum P/Q-Type Voltage-Gated Calcium Channel Antibodies', 'no label'), ('Pediatric', 'no label'), ('Cases', 'no label'), ('Lems', 'no label'), ('Literature', 'no label'), (""Patient'S"", 'no label'), ('Presentation', 'no label'), ('Lems', 'no label'), ('Diagnosis', 'no label'), ('Occult', 'no label'), ('Neuroblastoma', 'no label'), ('Review', 'no label'), ('Pediatric Literature', 'no label'), ('Clinical', 'no label'), ('Electrodiagnostic Criteria', 'no label'), ('Exist', 'no label'), ('Children', 'no label'), ('Exists A', 'no label'), ('Need', 'no label'), ('Clinical Criteria', 'no label'), ('Electrodiagnostic Testing', 'no label'), ('Prompt Diagnosis', 'no label'), ('Lems', 'no label'), ('Children', 'no label'), ('Prompt', 'no label'), ('Identification', 'no label'), ('Lems Will Alert', 'no label'), ('Physician', 'no label'), ('Malignancy', 'no label'), ('Immune-Mediated Process', 'no label')]"|[('Calcium', 'no label'), ('Antibodies', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Areflexia', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Occult Neuroblastoma', 'no label'), ('Malignancy', 'no label')]|[('Lems', 'no label'), ('Children', 'no label'), ('Lems', 'no label'), ('Triad', 'no label'), ('Nerve', 'no label'), ('Serum P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Lems', 'no label'), ('Patient', 'no label'), ('Lems Led', 'no label'), ('Neuroblastoma', 'no label'), ('Lems', 'no label'), ('Children', 'no label'), ('Lems', 'no label'), ('Children', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~23505075|We Analyzed 82 Single-Fiber Emg (Sfemg) Tests In The Extensor Digitorum Communis Muscle In 30 Lambert-Eaton Myasthenic Syndrome (Lems) Patients To Study The Relationship Between Electrodiagnostic Findings And Clinical Severity. The Repetitive Nerve Stimulation Test Was Performed In The Abductor Digiti Quinti And Flexor Carpi Ulnaris Muscles. Sfemg Was Performed In The Extensor Digitorum Communis Muscle Using The Conventional Method. Fiber Density Was Normal In All Patients. Jitter Was Abnormal In All Patients At The First Evaluation Regardless Of Clinical Severity. The Jitter Was Increasingly Abnormal With Worsening Disease Severity. Mean Mcd Correlated Well With Clinical And Electrophysiological Severity. In 5 Potential Pairs In 3 Patients, Mcd Analysis In Relation To Firing Rate Showed Improvement With Increasing Firing Rates, Which Is Consistent With Presynaptic Neuromuscular Transmission Disorders. In All Lems Studies, Sfemg Was Abnormal On The First Evaluation. The Mean Mcd Correlated Well With Clinical And Electrophysiological Disease Severity On The Repetitive Nerve Stimulation Test.|[('Analyzed', 'no label'), ('Single-Fiber Emg', 'no label'), ('Extensor Digitorum Communis Muscle', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Relationship', 'no label'), ('Electrodiagnostic Findings', 'no label'), ('Clinical Severity', 'no label'), ('Repetitive Nerve Stimulation Test', 'no label'), ('Abductor Digiti Quinti', 'no label'), ('Flexor Carpi Ulnaris Muscles', 'no label'), ('Sfemg', 'no label'), ('Performed', 'no label'), ('Extensor Digitorum Communis Muscle', 'no label'), ('Conventional Method', 'no label'), ('Fiber Density', 'no label'), ('Patients', 'no label'), ('Jitter', 'no label'), ('Abnormal', 'no label'), ('Patients', 'no label'), ('Evaluation', 'no label'), ('Clinical Severity', 'no label'), ('Jitter', 'no label'), ('Abnormal', 'no label'), ('Worsening', 'no label'), ('Disease Severity', 'no label'), ('Mcd', 'no label'), ('Correlated', 'no label'), ('Clinical', 'no label'), ('Electrophysiological Severity', 'no label'), ('Potential', 'no label'), ('Pairs', 'no label'), ('Patients', 'no label'), ('Mcd Analysis', 'no label'), ('Firing Rate', 'no label'), ('Improvement', 'no label'), ('Increasing', 'no label'), ('Firing', 'no label'), ('Rates', 'no label'), ('Presynaptic Neuromuscular Transmission Disorders', 'no label'), ('Lems Studies', 'no label'), ('Sfemg', 'no label'), ('Abnormal', 'no label'), ('Evaluation', 'no label'), ('Mcd', 'no label'), ('Correlated', 'no label'), ('Clinical', 'no label'), ('Severity', 'no label'), ('Repetitive Nerve Stimulation Test', 'no label')]|[('Mcd', 'no label')]|[('Emg', 'no label'), ('Mcd', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Carpi Ulnaris Muscles', 'no label'), ('Worsening Disease', 'no label'), ('Mcd', 'no label'), ('Mcd', 'no label'), ('Neuromuscular Transmission Disorders', 'no label'), ('Mcd', 'no label')]|[('Extensor Digitorum Communis Muscle', 'no label'), ('Patients', 'no label'), ('Abductor Digiti', 'no label'), ('Flexor Carpi Ulnaris', 'no label'), ('Extensor Digitorum Communis Muscle', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Mcd', 'no label'), ('Mcd', 'no label'), ('Presynaptic Neuromuscular', 'no label'), ('Mcd', 'no label')]
lambert eaton syndrome|pubmed~26998103|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disorder Of The Neuromuscular Junction That Is Characterized By Muscle Weakness. Lems Is Usually Associated With Cancer, Most Commonly Small Cell Lung Cancer (Sclc). The Potassium-Channel Blocker 3,4-Diaminopyridine (3,4-Dap), Has Been Previously Used For The Symptomatic Treatment Of Lems. 3,4-Dap Increases The Release Of Acetylcholine And Prolongs The Duration Of Nerve Action Potentials At The Presynaptic Membrane Of The Neuromuscular Junction. The Present Study Describes The Case Of A Patient With Lems And Sclc, For Which The Symptoms Did Not Improve With Anticancer Therapy, But Did So Markedly Following Treatment With 3,4-Dap. The Present Study Illustrates That 3,4-Dap Is A Useful Treatment Choice In Patients With Lems, Particularly For Patients Who Do Not Fully Improve Following Anticancer Therapy.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disorder', 'no label'), ('Neuromuscular Junction', 'no label'), ('Characterized', 'no label'), ('Muscle Weakness', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Cancer', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Potassium-Channel Blocker 3,4-Diaminopyridine', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label'), ('Increases', 'no label'), ('Release', 'no label'), ('Acetylcholine', 'no label'), ('Prolongs', 'no label'), ('Duration', 'no label'), ('Nerve Action', 'no label'), ('Presynaptic Membrane', 'no label'), ('Neuromuscular Junction', 'no label'), ('Study', 'no label'), ('Describes', 'no label'), ('Patient', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Symptoms', 'no label'), ('Did Not Improve', 'no label'), ('Anticancer Therapy', 'no label'), ('Markedly', 'no label'), ('Treatment', 'no label'), ('Study', 'no label'), ('Treatment', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Fully Improve', 'no label'), ('Anticancer Therapy', 'no label')]|[('Cell', 'no label'), ('Acetylcholine', 'no label'), ('Membrane', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Muscle Weakness', 'no label'), ('Cancer', 'no label'), ('Potassium-Channel Blocker 3,4-Diaminopyridine', 'no label'), ('Acetylcholine', 'no label')]|[('Neuromuscular', 'no label'), ('Muscle', 'no label'), ('Cancer', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Potassium-Channel', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Acetylcholine', 'no label'), ('Nerve', 'no label'), ('Presynaptic Membrane', 'no label'), ('Neuromuscular', 'no label'), ('Patient', 'no label'), ('Lems', 'no label'), ('Anticancer', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Anticancer', 'no label')]
lambert eaton syndrome|pubmed~23612377|Paraneoplastic Syndromes May Affect The Central And Peripheral Nervous System Of Adults And Children With Cancer. Neurological Symptoms May Resolve With Treatment Of The Underlying Neoplasm. We Report The Case Of A Child With Wilms Tumor Who Presented With Generalized Weakness, Fatigue, Ptosis, Hypokinesis, Dysarthria, Urinary Retention, Facial Diplegia, Ophthalmoplegia, And Autonomic Dysfunction. Routine Electrodiagnostic Testing, Including Repetitive Nerve Stimulation, Was Normal. Clinical Features And Stimulation Single-Fiber Electromyogram Were Consistent With A Neuromuscular Junction Transmission Disorder, Likely Lambert-Eaton Myasthenic Syndrome. The Child'S Neurological Status Returned To Normal With Successful Treatment Of The Tumor.|"[('Paraneoplastic Syndromes', 'no label'), ('Affect', 'no label'), ('Central', 'no label'), ('Peripheral Nervous System', 'no label'), ('Adults', 'no label'), ('Children', 'no label'), ('Cancer', 'no label'), ('Neurological Symptoms May', 'no label'), ('Treatment', 'no label'), ('Neoplasm', 'no label'), ('Wilms Tumor', 'no label'), ('Generalized Weakness', 'no label'), ('Fatigue', 'no label'), ('Ptosis', 'no label'), ('Hypokinesis', 'no label'), ('Dysarthria', 'no label'), ('Urinary Retention', 'no label'), ('Facial Diplegia', 'no label'), ('Ophthalmoplegia', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Routine', 'no label'), ('Electrodiagnostic Testing', 'no label'), ('Repetitive Nerve', 'no label'), ('Clinical Features', 'no label'), ('Stimulation', 'no label'), ('Consistent With', 'no label'), ('Neuromuscular Junction Transmission Disorder', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), (""Child'S"", 'no label'), ('Neurological Status', 'no label'), ('Returned', 'no label'), ('Treatment', 'no label'), ('Tumor', 'no label')]"|[]|[('Wilms Tumor Who', 'no label')]|[('Paraneoplastic Syndromes', 'no label'), ('Cancer', 'no label'), ('Neoplasm', 'no label'), ('Wilms Tumor', 'no label'), ('Fatigue', 'no label'), ('Ptosis, Hypokinesis, Dysarthria', 'no label'), ('Urinary Retention', 'no label'), ('Ophthalmoplegia', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Disorder', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Tumor', 'no label')]|[('Peripheral Nervous System', 'no label'), ('Children', 'no label'), ('Cancer', 'no label'), ('Neoplasm', 'no label'), ('Wilms Tumor', 'no label'), ('Urinary', 'no label'), ('Facial Diplegia', 'no label'), ('Nerve', 'no label'), ('Single-Fiber Electromyogram', 'no label'), ('Tumor', 'no label')]
lambert eaton syndrome|pubmed~32554206|We Aimed To Specify And Quantify The Characteristics Of The Decrement In Low-Frequency Repetitive Nerve Stimulation Response In Lambert-Eaton Myasthenia Syndrome (Lems) And Compare It To Those Of Myasthenia Gravis (Mg). We Retrospectively Reviewed 18 Patients With Lems And 24 Patients With Mg. Ten Consecutive Stimulations Were Applied At 3 Hz To The Abductor Pollicis Brevis. We Determined The Position Of The Smallest Wave In The Stimulation Sequence, And We Calculated The Decrement And Recovery. The Median Sequential Order Of The Minimum Wave Was 8 In The Lems Group And 5 In The Mg Group (P < 0.001). The Median Decrement In The Lems Group Was 36.7%, While That In The Mg Group Was 21.0% (P = 0.047). The Recovery Percentage Was 1.4% In The Lems Group And 3.5% In The Mg Group (P = 0.001). The Area Under The Curve For The Sequential Order Of The Minimum Wave Was 0.90, And The Reciprocal Optimum Cut-Off Point Was 6.5. We Elucidated A Pattern With A Delayed Nadir And Subsequent Poor Recovery, Featuring A Low-Frequency Decrement; Furthermore, We Determined The Most Likely Sequential Order Of The Minimum Wave In Patients With Lems, And The Indicator Was Useful For Differentiation.|[('Specify', 'no label'), ('Quantify', 'no label'), ('Characteristics', 'no label'), ('Decrement', 'no label'), ('Low-Frequency', 'no label'), ('Repetitive Nerve', 'no label'), ('Stimulation', 'no label'), ('Response', 'no label'), ('Lambert-Eaton Myasthenia Syndrome', 'no label'), ('Lems', 'no label'), ('Compare', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Retrospectively', 'no label'), ('Reviewed', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Consecutive', 'no label'), ('Stimulations', 'no label'), ('Applied', 'no label'), ('Abductor Pollicis Brevis', 'no label'), ('Smallest Wave', 'no label'), ('Stimulation Sequence', 'no label'), ('Decrement', 'no label'), ('Recovery', 'no label'), ('Median Sequential Order', 'no label'), ('Minimum Wave', 'no label'), ('Lems Group', 'no label'), ('Mg', 'no label'), ('Group', 'no label'), ('P\xa0<\xa00.001', 'no label'), ('Median Decrement', 'no label'), ('Lems Group', 'no label'), ('Mg', 'no label'), ('Group', 'no label'), ('Recovery', 'no label'), ('Percentage', 'no label'), ('Lems Group', 'no label'), ('Mg', 'no label'), ('Group', 'no label'), ('Area', 'no label'), ('Sequential', 'no label'), ('Order', 'no label'), ('Minimum Wave', 'no label'), ('Reciprocal Optimum', 'no label'), ('Cut-Off Point', 'no label'), ('Pattern', 'no label'), ('Delayed', 'no label'), ('Nadir', 'no label'), ('Poor Recovery', 'no label'), ('Featuring A', 'no label'), ('Low-Frequency Decrement', 'no label'), ('Sequential', 'no label'), ('Order', 'no label'), ('Minimum Wave', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Indicator', 'no label'), ('Differentiation', 'no label')]|[('Sequence', 'no label')]|[]|[('Lambert-Eaton Myasthenia Syndrome', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Mg', 'no label')]|[('Nerve', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Abductor Pollicis Brevis', 'no label'), ('Wave', 'no label'), ('Wave', 'no label'), ('Lems', 'no label'), ('Mg', 'no label'), ('Lems', 'no label'), ('Mg', 'no label'), ('Lems', 'no label'), ('Mg', 'no label'), ('Wave', 'no label'), ('Wave', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~23545618|Lambert-Eaton Myasthenic Syndrome (Lems) Is Frequently Associated With Malignancy, Especially Small Cell Lung Cancer (Sclc). Here, We Describe A Patient With A 5-Year History Of Cervical Myelopathy Who Presented With Recurrent Limb Weakness Of Her Limbs And Complained Of Recent Progressive Weakness. Following An Examination That Included Electromyography, A Chest Ct Scan, And A Bronchofiberscopy Examination With Brushing Biopsy, The Patient Was Diagnosed With Lems And Sclc. This Case Report Highlights The Ongoing Need For Clinicians To Be Observant For Cases Of Lems, To Consider Both Patient History And Physical Examination Data, And To Accurately Obtain A Differential Diagnosis Between Lems And Other Diseases, Which Also Cause Weakness.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Malignancy', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Patient', 'no label'), ('Cervical Myelopathy', 'no label'), ('Recurrent Limb Weakness', 'no label'), ('Limbs', 'no label'), ('Complained', 'no label'), ('Progressive Weakness', 'no label'), ('Examination', 'no label'), ('Electromyography', 'no label'), ('Chest Ct Scan', 'no label'), ('Bronchofiberscopy Examination', 'no label'), ('Brushing Biopsy', 'no label'), ('Patient', 'no label'), ('Diagnosed', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Case Report', 'no label'), ('Need', 'no label'), ('Clinicians', 'no label'), ('Observant', 'no label'), ('Cases', 'no label'), ('Lems', 'no label'), ('Patient History', 'no label'), ('Physical Examination', 'no label'), ('Obtain', 'no label'), ('Differential Diagnosis', 'no label'), ('Lems', 'no label'), ('Diseases', 'no label'), ('Cause Weakness', 'no label')]|[('Cell', 'no label')]|[('Ct', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Malignancy', 'no label'), ('Myelopathy', 'no label'), ('Weakness', 'no label')]|[('Small Cell Lung Cancer', 'no label'), ('Cervical', 'no label'), ('Limb', 'no label'), ('Biopsy', 'no label'), ('Patient', 'no label'), ('Lems', 'no label'), ('Patient', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~26622673|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Neuromuscular Junction Disorder Characterized By Fluctuating Proximal Limb Muscle Weakness, Decreased Deep Tendon Reflexes And Various Autonomic Symptoms. Lems Is Reportedly The Most Common Neurological Paraneoplastic Syndrome. This Is The Case Report Of A Patient With Small-Cell Lung Cancer (Sclc) Who Developed Lems. A 68-Year-Old Male Patient Presented With A 6-Month History Of Progressive Weakness Of The Proximal Limbs And A 2-Month History Of Xerostomia. The Patient Was Admitted To The Department Of Neurology Of The People'S Liberation Army General Hospital Of Shenyang Military Region (Shenyang, China). The Symptoms Of The Patient Were Not Relieved With Supportive Therapy. Further Laboratory Tests, Electrodiagnostic Studies, Chest Computed Tomography And Immunohistochemical Staining Confirmed The Diagnosis Of Lems In The Presence Of Sclc. Following Administration Of Two Cycles Of Rescue Chemotherapy With A Combination Of Etoposide And Cisplatin, The Symptoms Of The Patient Were Gradually Relieved And, After Six Cycles Of Therapy, The Primary Malignancy Completely Regressed. In Conclusion, A Diagnosis Of Lems May Lead To The Timely Detection Of Sclc, Significantly Improving Patient Prognosis And Survival.|"[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Neuromuscular Junction Disorder', 'no label'), ('Characterized', 'no label'), ('Fluctuating', 'no label'), ('Proximal Limb Muscle Weakness', 'no label'), ('Decreased', 'no label'), ('Deep Tendon', 'no label'), ('Reflexes', 'no label'), ('Autonomic Symptoms', 'no label'), ('Lems', 'no label'), ('Neurological Paraneoplastic Syndrome', 'no label'), ('Case Report', 'no label'), ('Patient', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Developed Lems', 'no label'), ('Male', 'no label'), ('Patient', 'no label'), ('6-Month', 'no label'), ('History', 'no label'), ('Progressive Weakness', 'no label'), ('Proximal Limbs', 'no label'), ('History', 'no label'), ('Xerostomia', 'no label'), ('Patient', 'no label'), ('Department', 'no label'), (""People'S"", 'no label'), ('Liberation Army', 'no label'), ('General Hospital', 'no label'), ('Shenyang Military Region', 'no label'), ('Shenyang', 'no label'), ('China', 'no label'), ('Symptoms', 'no label'), ('Patient', 'no label'), ('Supportive Therapy', 'no label'), ('Laboratory Tests', 'no label'), ('Electrodiagnostic Studies', 'no label'), ('Chest Computed Tomography', 'no label'), ('Immunohistochemical Staining', 'no label'), ('Confirmed', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Administration', 'no label'), ('Rescue Chemotherapy', 'no label'), ('Combination', 'no label'), ('Etoposide', 'no label'), ('Cisplatin', 'no label'), ('Symptoms', 'no label'), ('Patient', 'no label'), ('Therapy', 'no label'), ('Primary Malignancy', 'no label'), ('Completely Regressed', 'no label'), ('Diagnosis', 'no label'), ('Lems May Lead', 'no label'), ('Timely', 'no label'), ('Detection', 'no label'), ('Sclc', 'no label'), ('Improving', 'no label'), ('Patient Prognosis', 'no label'), ('Survival', 'no label')]"|[]|[]|[('Myasthenic Syndrome', 'no label'), ('Muscle Weakness', 'no label'), ('Neurological Paraneoplastic Syndrome', 'no label'), ('Lung Cancer', 'no label'), ('Weakness Of The Proximal Limbs And A 2-Month', 'no label'), ('Xerostomia', 'no label'), ('Chest', 'no label'), ('Etoposide', 'no label'), ('Cisplatin', 'no label'), ('Primary Malignancy Completely Regressed', 'no label')]|[('Patient', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Patient', 'no label'), ('A 2-Month', 'no label'), ('Patient', 'no label'), ('People', 'no label'), ('Shenyang Military', 'no label'), ('Patient', 'no label'), ('Lems', 'no label'), ('Etoposide', 'no label'), ('Cisplatin', 'no label'), ('Patient', 'no label'), ('Primary Malignancy', 'no label'), ('Lems', 'no label'), ('Patient', 'no label')]
lambert eaton syndrome|pubmed~23470889|A 62-Year-Old Man Who Had Suffered From Instability Of Gait And Double Vision For Two Months Was Admitted To Our Hospital Because Of Weakness Of The Extremities And Ataxia Of The Extremities And Trunk. Chest X-Rays And Ct Scans Showed Enlargement Of The Left Hilar Lymph Nodes And A Nodular Shadow In The Left Lung. Transbronchial Biopsy Revealed Small Cell Lung Cancer. We Diagnosed The Patient With Two Conditions: Paraneoplastic Cerebellar Degeneration (Pcd), Based On Cerebellar Ataxia, The Presence Of Hu Antineuronal Antibodies, And The Absence Of Cerebellar Atrophy And Malignancy; And Lambert-Eaton Myasthenic Syndrome (Lems), Based On Weakness Of The Extremities, The Presence Of P/Q-Type Voltage-Gated Calcium Channel Antibodies, And Waxing In The Evoked Electromyogram. Anticancer Chemoradiation Therapy That Was Started Within Three Months Of Symptom Onset Resulted In Reductions In Size Of The Hilar Lymph Nodes And The Nodule. Concurrently, Cerebellar Ataxia, Weakness Of The Extremities, And Double Vision All Disappeared. Anticancer Chemotherapy Is Effective Against Lems While Usually Less Effective Against Pcd. Early Commencement Of Anticancer Chemotherapy Is Recommended For The Treatment Of Pcd With Lems.|[('Suffered', 'no label'), ('Instability', 'no label'), ('Gait', 'no label'), ('Double Vision', 'no label'), ('Months', 'no label'), ('Hospital', 'no label'), ('Weakness', 'no label'), ('Extremities', 'no label'), ('Ataxia', 'no label'), ('Extremities', 'no label'), ('Trunk', 'no label'), ('Chest X-Rays', 'no label'), ('Enlargement', 'no label'), ('Left Hilar Lymph Nodes', 'no label'), ('Nodular', 'no label'), ('Shadow', 'no label'), ('Left Lung', 'no label'), ('Transbronchial Biopsy', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Diagnosed', 'no label'), ('Patient', 'no label'), ('Conditions', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Pcd', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Hu Antineuronal Antibodies', 'no label'), ('Absence', 'no label'), ('Cerebellar Atrophy', 'no label'), ('Malignancy', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Weakness', 'no label'), ('Extremities', 'no label'), ('P/Q-Type Voltage-Gated Calcium Channel Antibodies', 'no label'), ('Waxing', 'no label'), ('Evoked Electromyogram', 'no label'), ('Anticancer Chemoradiation Therapy', 'no label'), ('Months', 'no label'), ('Symptom Onset', 'no label'), ('Reductions', 'no label'), ('Hilar Lymph Nodes', 'no label'), ('Nodule', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Weakness', 'no label'), ('Extremities', 'no label'), ('Double Vision', 'no label'), ('Disappeared', 'no label'), ('Anticancer Chemotherapy', 'no label'), ('Effective', 'no label'), ('Lems', 'no label'), ('Effective', 'no label'), ('Against', 'no label'), ('Pcd', 'no label'), ('Early Commencement', 'no label'), ('Anticancer Chemotherapy', 'no label'), ('Treatment', 'no label'), ('Pcd With Lems', 'no label')]|[('Cell', 'no label'), ('Antibodies', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('Chemotherapy', 'no label')]|[('Ct', 'no label'), ('Hu Antineuronal Antibodies', 'no label')]|[('Weakness Of The Extremities', 'no label'), ('Ataxia', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Cerebellar Atrophy', 'no label'), ('Malignancy', 'no label'), ('Myasthenic Syndrome', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Weakness Of The Extremities', 'no label'), ('Disappeared', 'no label')]|[('Extremities', 'no label'), ('Extremities', 'no label'), ('Left Hilar Lymph Nodes', 'no label'), ('Nodular Shadow', 'no label'), ('Left Lung.', 'no label'), ('Transbronchial Biopsy Revealed Small Cell Lung Cancer', 'no label'), ('Patient', 'no label'), ('Cerebellar', 'no label'), ('Hu Antineuronal Antibodies', 'no label'), ('Cerebellar', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Anticancer', 'no label'), ('Hilar Lymph', 'no label'), ('Cerebellar', 'no label'), ('Anticancer', 'no label'), ('Anticancer', 'no label')]
lambert eaton syndrome|pubmed~26170921|Lambert-Eaton Myasthenic Syndrome (Lems) Is Typically Characterized As A Paraneoplastic Syndrome Associated With Small Cell Lung Carcinoma. The Presence Of Lems In Association With Other Neuroendocrine Lung Tumors, Including Carcinoids Or Large Cell Lung Carcinoma, Is Highly Unusual. The Present Case Study Reports The Very Rare Case Of A Patient With Mediastinal Small Cell Cancer Combined With Lems. A 53-Year-Old Man Was Admitted To The Bethune First Hospital With A 3-Month History Of Weakness In The Lower Extremities That Had Become Aggravated During The Previous 20 Days. A Positron Emission Tomography-Computed Tomography (Ct) Examination Demonstrated Multiple Enlarged, Hypermetabolic Lymph Nodes Between The Vena Cava And Trachea, Indicating The Presence Of Inflammation. No Other Abnormalities Were Identified. A Mediastinal Lymph Node Biopsy Revealed A High Prevalence Of Small Cell Neuroendocrine Carcinoma. The Immunohistochemistry Results Were As Follows: Ki-67 (+50, Meaning That 50% Of The Cells Exhibited Ki-67 Expression), Cytokeratin (Ck; +), Cluster Of Differentiation (Cd)56 (+), Synaptophysin (+), Thyroid Transcriptional Factor-1 (+), Epithelial Membrane Antigen (+), Neuron-Specific Enolase (+), P63 (Weakly +), Leukocyte Common Antigen (-), Cd99 (-), Vimentin (-) And Ck5/6 (-). Following A Diagnosis Of Lems, The Patient Underwent One Course Of Cisplatin + Etoposide Chemotherapy, Which Was Ineffective. Subsequently, The Patient Underwent A Different Chemotherapy Regimen (Cisplatin + Etoposide + Ifosfamide), Which Significantly Improved The Symptoms Of Myasthenia. Following Completion Of This Treatment Regimen, The Primary Lesion Was Not Observed On A Lung Ct Scan, And The Mediastinal Lymph Nodes Had Clearly Diminished. Subsequently, The Patient Underwent Two Courses Of Radiotherapy (40 Gy/22F/6W).|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Characterized', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Lems', 'no label'), ('Neuroendocrine Lung Tumors', 'no label'), ('Carcinoids', 'no label'), ('Lung Carcinoma', 'no label'), ('Unusual', 'no label'), ('Present Case Study', 'no label'), ('Reports', 'no label'), ('Case', 'no label'), ('Patient', 'no label'), ('Mediastinal Small Cell Cancer', 'no label'), ('Lems', 'no label'), ('Bethune First Hospital', 'no label'), ('3-Month History', 'no label'), ('Weakness', 'no label'), ('Lower Extremities', 'no label'), ('Aggravated', 'no label'), ('Days', 'no label'), ('Positron Emission Tomography-Computed Tomography', 'no label'), ('Hypermetabolic Lymph Nodes', 'no label'), ('Vena Cava', 'no label'), ('Trachea', 'no label'), ('Presence', 'no label'), ('Inflammation', 'no label'), ('Abnormalities', 'no label'), ('Identified', 'no label'), ('Mediastinal', 'no label'), ('Lymph Node Biopsy', 'no label'), ('Revealed', 'no label'), ('High Prevalence', 'no label'), ('Small Cell', 'no label'), ('Neuroendocrine Carcinoma', 'no label'), ('Immunohistochemistry', 'no label'), ('Results', 'no label'), ('Ki-67', 'no label'), ('Meaning', 'no label'), ('Cells', 'no label'), ('Ki-67 Expression', 'no label'), ('Cytokeratin', 'no label'), ('Cluster', 'no label'), ('Differentiation', 'no label'), ('Synaptophysin', 'no label'), ('Thyroid Transcriptional Factor-1', 'no label'), ('Epithelial Membrane Antigen', 'no label'), ('Neuron-Specific Enolase', 'no label'), ('P63', 'no label'), ('Leukocyte Common Antigen', 'no label'), ('Cd99', 'no label'), ('Vimentin', 'no label'), ('Ck5/6', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Patient', 'no label'), ('Course', 'no label'), ('Cisplatin', 'no label'), ('Etoposide', 'no label'), ('Chemotherapy', 'no label'), ('Ineffective', 'no label'), ('Patient', 'no label'), ('Chemotherapy', 'no label'), ('Regimen', 'no label'), ('Cisplatin', 'no label'), ('Etoposide', 'no label'), ('Ifosfamide', 'no label'), ('Symptoms', 'no label'), ('Myasthenia', 'no label'), ('Completion', 'no label'), ('Treatment Regimen', 'no label'), ('Primary Lesion', 'no label'), ('Observed', 'no label'), ('Lung Ct Scan', 'no label'), ('Mediastinal Lymph Nodes', 'no label'), ('Diminished', 'no label'), ('Patient', 'no label'), ('Courses', 'no label'), ('Radiotherapy', 'no label'), ('Gy/22F/6W', 'no label')]|[('Cell', 'no label'), ('Cell', 'no label'), ('Cell', 'no label'), ('Positron', 'no label'), ('Cell', 'no label'), ('Cells', 'no label'), ('Cytokeratin', 'no label'), ('Synaptophysin', 'no label'), ('Neuron-Specific Enolase', 'no label'), ('P63', 'no label'), ('Leukocyte', 'no label'), ('Cd99', 'no label'), ('Vimentin', 'no label'), ('Ck5/6', 'no label'), ('Cisplatin +', 'no label'), ('Cisplatin +', 'no label')]|[('Mediastinal Small Cell Cancer', 'no label'), ('Synaptophysin', 'no label'), ('Thyroid Transcriptional Factor-1', 'no label'), ('Epithelial Membrane Antigen', 'no label'), ('Neuron-Specific Enolase', 'no label'), ('P63', 'no label'), ('Vimentin', 'no label'), ('Ck5/6', 'no label'), ('Lung Ct', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Neuroendocrine Lung Tumors', 'no label'), ('Mediastinal Small Cell', 'no label'), ('Cancer', 'no label'), ('Weakness', 'no label'), ('Inflammation', 'no label'), ('Small Cell Neuroendocrine Carcinoma', 'no label'), ('Cisplatin', 'no label'), ('Etoposide', 'no label'), ('Cisplatin', 'no label'), ('Etoposide', 'no label'), ('Ifosfamide', 'no label'), ('Myasthenia', 'no label')]|[('Small Cell Lung Carcinoma', 'no label'), ('Lems', 'no label'), ('Neuroendocrine Lung Tumors', 'no label'), ('Carcinoids', 'no label'), ('Cell Lung Carcinoma', 'no label'), ('Patient', 'no label'), ('Small Cell Cancer', 'no label'), ('Lower Extremities', 'no label'), ('Lymph Nodes', 'no label'), ('Vena Cava', 'no label'), ('Lymph Node', 'no label'), ('Small Cell Neuroendocrine Carcinoma.', 'no label'), ('Ki-67', 'no label'), ('Cells', 'no label'), ('Ki-67', 'no label'), ('Cytokeratin', 'no label'), ('Synaptophysin', 'no label'), ('Thyroid Transcriptional Factor-1', 'no label'), ('Epithelial Membrane Antigen', 'no label'), ('Neuron-Specific Enolase', 'no label'), ('P63', 'no label'), ('Leukocyte', 'no label'), ('Cd99', 'no label'), ('Vimentin', 'no label'), ('Ck5/6', 'no label'), ('Patient', 'no label'), ('Cisplatin', 'no label'), ('Etoposide', 'no label'), ('Patient', 'no label'), ('Cisplatin', 'no label'), ('Etoposide', 'no label'), ('Ifosfamide', 'no label'), ('Lung', 'no label'), ('Lymph Nodes', 'no label'), ('Patient', 'no label')]
lambert eaton syndrome|pubmed~23278580|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disorder Of The Neuromuscular Synapse. About Half Of Lems Patients Have An Associated Small Cell Lung Carcinoma (Sclc), Which Is Usually Detected After Diagnosis Of Lems. This Short Review Summarizes Clinical And Serological Markers Shown To Predict The Presence Of Sclc In Lems Patients. Sox1 Antibodies Are A Specific Marker For Sclc-Lems But They Are Also Found In Sclc Patients Without Paraneoplastic Neurological Syndromes. No Relation To Any Clinical Characteristic Or Survival Effect Has Been Found For Sox1-Positive Patients. Several Clinical Markers Also Discriminate Between Sclc-Lems And Nontumor Lems. Detailed Analysis Of These Clinical And Demographic Characteristics From Two Independent Patient Cohorts Has Led To Development Of The Delta-P Score. This Prediction Model Has Provided For A Simple Clinical Tool To Indicate The Presence Of Sclc Early In The Course Of The Disease. The Delta-P Score Can Be Used To Guide Tumor Screening In Individual Patients.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disorder', 'no label'), ('Neuromuscular Synapse', 'no label'), ('Lems Patients', 'no label'), ('Associated Small Cell', 'no label'), ('Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Detected', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Short Review Summarizes Clinical', 'no label'), ('Serological', 'no label'), ('Markers', 'no label'), ('Presence', 'no label'), ('Sclc', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Sox1 Antibodies', 'no label'), ('Marker', 'no label'), ('Sclc-Lems', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Paraneoplastic Neurological Syndromes', 'no label'), ('Clinical Characteristic', 'no label'), ('Survival Effect', 'no label'), ('Sox1-Positive Patients', 'no label'), ('Clinical Markers', 'no label'), ('Discriminate', 'no label'), ('Sclc-Lems', 'no label'), ('Nontumor Lems', 'no label'), ('Analysis', 'no label'), ('Clinical', 'no label'), ('Demographic Characteristics', 'no label'), ('Independent', 'no label'), ('Patient Cohorts', 'no label'), ('Development', 'no label'), ('Delta-P Score', 'no label'), ('Prediction Model', 'no label'), ('Simple Clinical Tool', 'no label'), ('Presence', 'no label'), ('Sclc', 'no label'), ('Early', 'no label'), ('Course', 'no label'), ('Disease', 'no label'), ('Delta-P Score', 'no label'), ('Tumor Screening', 'no label'), ('Patients', 'no label')]|[('Cell', 'no label'), ('Sox1 Antibodies', 'no label'), ('Sclc-Lems', 'no label'), ('Sclc-Lems', 'no label')]|[('Sox1 Antibodies', 'no label'), ('Sclc-Lems', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Paraneoplastic Neurological Syndromes', 'no label'), ('Tumor', 'no label')]|[('Neuromuscular', 'no label'), ('Lems Patients', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Lems Patients', 'no label'), ('Sox1', 'no label'), ('Sclc-Lems', 'no label'), ('Sclc Patients', 'no label'), ('Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Nontumor', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~33324947|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare, Autoimmune Or Paraneoplastic Condition Characterized By Muscle Weakness And Fatigability. In Cancer Therapy, Immune Checkpoint Inhibitors (Ici) Sensitize The Immune System For Tumor Antigens. We Report A 62-Year-Old, Female Patient With Paraneoplastic Lems As First Manifestation Of Merkel Cell Carcinoma. Under Avelumab, The Lems Exacerbated With Worsening Of Limb Weakness And A Severely Reduced Vital Capacity (< 1 L). To Treat This Immunological Side Effect, We Added A Regimen With Intravenous Immunoglobulins. Hereby, The Lems Improved Significantly. As We Were Able To Continue The Cancer Treatment, The Merkel Cell Carcinoma Has Been In Remission So Far. This Is The First Description Of Paraneoplastic Lems, Avelumab, And Merkel Cell Carcinoma. We Conclude That Immunoglobulins Are An Option To Control An Ici-Associated Deterioration Of Paraneoplastic Symptoms.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Autoimmune', 'no label'), ('Paraneoplastic Condition', 'no label'), ('Characterized', 'no label'), ('Muscle Weakness', 'no label'), ('Fatigability', 'no label'), ('Cancer Therapy', 'no label'), ('Immune Checkpoint Inhibitors\xa0(Ici)', 'no label'), ('Sensitize', 'no label'), ('Immune System', 'no label'), ('Tumor Antigens', 'no label'), ('Female', 'no label'), ('Patient', 'no label'), ('Paraneoplastic Lems', 'no label'), ('Manifestation', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Avelumab', 'no label'), ('Lems Exacerbated', 'no label'), ('Worsening', 'no label'), ('Limb Weakness', 'no label'), ('Severely Reduced', 'no label'), ('Vital Capacity', 'no label'), ('Treat', 'no label'), ('Immunological', 'no label'), ('Side Effect', 'no label'), ('Added', 'no label'), ('Regimen', 'no label'), ('Intravenous Immunoglobulins', 'no label'), ('Lems', 'no label'), ('Cancer Treatment', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Remission', 'no label'), ('Description', 'no label'), ('Paraneoplastic Lems', 'no label'), ('Avelumab', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Conclude', 'no label'), ('Immunoglobulins', 'no label'), ('Ici-Associated', 'no label'), ('Deterioration', 'no label'), ('Paraneoplastic Symptoms', 'no label')]|[('Inhibitors', 'no label'), ('Cell', 'no label'), ('Cell', 'no label'), ('Cell', 'no label')]|[('Immunoglobulins', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Or Paraneoplastic Condition Characterized By', 'no label'), ('Muscle Weakness', 'no label'), ('Cancer', 'no label'), ('Tumor', 'no label'), ('Paraneoplastic', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Weakness', 'no label'), ('Cancer', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Paraneoplastic', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Paraneoplastic Symptoms', 'no label')]|[('Muscle', 'no label'), ('Cancer', 'no label'), ('Immune Checkpoint Inhibitors', 'no label'), ('Immune System', 'no label'), ('Tumor Antigens', 'no label'), ('Patient', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Lems', 'no label'), ('Limb', 'no label'), ('Intravenous', 'no label'), ('Lems', 'no label'), ('Cancer', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Conclude', 'no label'), ('Immunoglobulins', 'no label'), ('Paraneoplastic', 'no label')]
lambert eaton syndrome|pubmed~21678709|Lambert-Eaton Myasthenic Syndrome Is A Rare Neurological Syndrome Of Autoimmune Origin. It Is Usually Associated With Small-Cell Lung Cancer But May Be Idiopathic. The Main Clinical Feature Is Potentially Disabling Limb Muscle Weakness. Clinical Signs Of Autonomic Nervous System Involvement Are Frequent. The Muscle Weakness Often Improves With Physical Exercise, Which Distinguishes This Syndrome From Myasthenia. Tendon Reflexes Are Reduced Or Absent But Reappear Temporarily After Brief Muscle Contraction. Diagnosis Is Confirmed By Electromyographic Findings. Management Is Generally Based On Treatment Of The Underlying Malignancy. Immunosuppressants Are Used In Severe Disease And In Cases Not Associated With Cancer, But They Have Limited Efficacy. Symptomatic Treatments Are Available But Their Efficacy Is Poorly Documented.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Rare', 'no label'), ('Neurological Syndrome', 'no label'), ('Autoimmune Origin', 'no label'), ('Associated With', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Idiopathic', 'no label'), ('Clinical Feature', 'no label'), ('Disabling', 'no label'), ('Limb Muscle Weakness', 'no label'), ('Clinical Signs', 'no label'), ('Autonomic Nervous System', 'no label'), ('Involvement', 'no label'), ('Frequent', 'no label'), ('Muscle Weakness', 'no label'), ('Physical Exercise', 'no label'), ('Distinguishes', 'no label'), ('Syndrome', 'no label'), ('Myasthenia', 'no label'), ('Tendon Reflexes', 'no label'), ('Reduced', 'no label'), ('Absent', 'no label'), ('Reappear', 'no label'), ('Brief Muscle Contraction', 'no label'), ('Diagnosis', 'no label'), ('Confirmed', 'no label'), ('Electromyographic Findings', 'no label'), ('Management', 'no label'), ('Treatment', 'no label'), ('Malignancy', 'no label'), ('Immunosuppressants', 'no label'), ('Severe Disease', 'no label'), ('Cases', 'no label'), ('Associated With', 'no label'), ('Cancer', 'no label'), ('Limited Efficacy', 'no label'), ('Symptomatic', 'no label'), ('Treatments', 'no label'), ('Efficacy', 'no label'), ('Poorly Documented', 'no label')]|[]|[]|[('Myasthenic Syndrome', 'no label'), ('Neurological Syndrome', 'no label'), ('Muscle Weakness', 'no label'), ('Muscle Weakness', 'no label'), ('Myasthenia', 'no label'), ('Diagnosis', 'no label'), ('Malignancy', 'no label'), ('Immunosuppressants', 'no label'), ('Cancer', 'no label')]|[('Small-Cell Lung Cancer', 'no label'), ('Muscle', 'no label'), ('Autonomic Nervous', 'no label'), ('Muscle', 'no label'), ('Muscle', 'no label'), ('Cancer', 'no label')]
lambert eaton syndrome|pubmed~34030742|Anti-Glial Nuclear Antibody (Agna) Is An Onconeuroal Antibody Targeting The Nuclei Of Bergmann Glia In The Cerebellum And Anti-Sry-Related Hmg-Box 1 (Sox1). It Is Highly Specific For Small Cell Lung Cancer (Sclc) And Correlates To The Appearance Of Paraneoplastic Neurological Syndromes Such As Lambert-Eaton Myasthenic Syndrome (Plems) And Paraneoplastic Cerebellar Degeneration (Pcd) Amongst Others. Herein, We Present A Sclc Patient With Rapidly Progressive Pcd, Lems And Axonal Polyneuropathy Associated With Agna/Sox1-Antibodies, Successfully Treated With Plasma-Exchange (Plex).|[('Anti-Glial Nuclear Antibody', 'no label'), ('Agna', 'no label'), ('Onconeuroal', 'no label'), ('Antibody', 'no label'), ('Targeting', 'no label'), ('Nuclei', 'no label'), ('Bergmann Glia', 'no label'), ('Cerebellum', 'no label'), ('Hmg-Box\xa01', 'no label'), ('Sox1', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Appearance', 'no label'), ('Paraneoplastic Neurological Syndromes', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Plems', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Pcd', 'no label'), ('Sclc', 'no label'), ('Patient', 'no label'), ('Progressive', 'no label'), ('Axonal Polyneuropathy', 'no label'), ('Associated With', 'no label'), ('Agna/Sox1-Antibodies', 'no label'), ('Successfully', 'no label'), ('Treated With', 'no label'), ('Plasma-Exchange', 'no label'), ('Plex', 'no label')]|[('Antibody', 'no label'), ('Nuclei', 'no label'), ('Glia', 'no label'), ('Sox1', 'no label'), ('Cell', 'no label'), ('Axonal', 'no label')]|[('Anti-Glial Nuclear Antibody', 'no label'), ('Sox1', 'no label')]|[('Paraneoplastic Neurological Syndromes', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Polyneuropathy', 'no label')]|[('Anti-Glial Nuclear Antibody', 'no label'), ('Nuclei', 'no label'), ('Bergmann Glia', 'no label'), ('Cerebellum', 'no label'), ('Sox1', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Agna/Sox1-Antibodies', 'no label')]
lambert eaton syndrome|pubmed~31191084|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Uncommon Disorder Of Neuromuscular Transmission With Distinctive Pathophysiological, Clinical, Electrophysiological And Laboratory Features. There Are Two Forms Of Lems. The Paraneoplastic (P-Lems) Form Is Associated With A Malignant Tumor That Is Most Frequently A Small Cell Lung Carcinoma (Sclc), And The Autoimmune (A-Lems) Form Is Often Related To Other Dysimmune Diseases. Approximately 90% Of Lems Patients Present Antibodies Against Presynaptic Membrane P/Q-Type Voltage-Gated Calcium Channels (Vgcc). These Antibodies Are Directly Implicated In The Pathophysiology Of The Disorder, Provoke Reduced Acetylcholine (Ach) At The Nerve Terminal And Consequently Lead To Muscle Weakness. Lems Is Clinically Characterized By Proximal Muscle Weakness, Autonomic Dysfunction And Areflexia. In Clinically Suspected Cases, Diagnoses Are Confirmed By Serological And Electrodiagnostic Tests. The Detection Of P/Q-Type Vgcc Antibodies Is Supportive When There Is Clinical Suspicion But Should Be Carefully Interpreted In The Absence Of Characteristic Clinical Or Electrodiagnostic Features. Typical Electrodiagnostic Findings (Ie, Reduced Compound Motor Action Potentials (Cmaps), Significant Decrements In The Responses To Low Frequency Stimulation And Incremental Responses After Brief Exercise Or High-Frequency Stimulation) Reflect The Existence Of A Presynaptic Transmission Defect And Are Key Confirmatory Criteria. Diagnosis Requires A High Level Of Awareness And Necessitates The Initiation Of A Prompt Screening And Surveillance Process To Detect And Treat Malignant Tumors. In Clinically Affected Patients Without Cancer And After Cancer Treatment, Symptomatic Treatment With 3,4-Diaminopyridine Or Immunosuppressive Agents Can Significantly Improve Neurologic Symptoms And The Quality Of Life. We Present A Detailed Review Of Lems With Special Emphasis On The Pathophysiological Mechanisms, Clinical Manifestation And Diagnostic Procedure.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Uncommon Disorder', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Pathophysiological', 'no label'), ('Clinical', 'no label'), ('Electrophysiological', 'no label'), ('Laboratory Features', 'no label'), ('Lems', 'no label'), ('Paraneoplastic (P-Lems) Form', 'no label'), ('Associated With', 'no label'), ('Malignant Tumor', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Autoimmune (A-Lems) Form', 'no label'), ('Dysimmune Diseases', 'no label'), ('Lems Patients', 'no label'), ('Antibodies', 'no label'), ('Presynaptic Membrane', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Vgcc', 'no label'), ('Antibodies', 'no label'), ('Pathophysiology', 'no label'), ('Disorder', 'no label'), ('Provoke', 'no label'), ('Reduced', 'no label'), ('Acetylcholine', 'no label'), ('Ach', 'no label'), ('Nerve', 'no label'), ('Terminal', 'no label'), ('Lead', 'no label'), ('Muscle Weakness', 'no label'), ('Lems', 'no label'), ('Clinically Characterized', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Areflexia', 'no label'), ('Clinically Suspected', 'no label'), ('Cases', 'no label'), ('Diagnoses', 'no label'), ('Confirmed', 'no label'), ('Serological', 'no label'), ('Electrodiagnostic Tests', 'no label'), ('Detection', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Supportive', 'no label'), ('Clinical Suspicion', 'no label'), ('Absence', 'no label'), ('Characteristic Clinical Or', 'no label'), ('Electrodiagnostic Features', 'no label'), ('Electrodiagnostic Findings', 'no label'), ('Ie', 'no label'), ('Reduced', 'no label'), ('Compound Motor Action Potentials', 'no label'), ('Cmaps', 'no label'), ('Decrements', 'no label'), ('Responses', 'no label'), ('Low Frequency Stimulation', 'no label'), ('Incremental Responses', 'no label'), ('Brief Exercise', 'no label'), ('High-Frequency Stimulation', 'no label'), ('Existence', 'no label'), ('Presynaptic Transmission Defect', 'no label'), ('Key Confirmatory Criteria', 'no label'), ('Diagnosis', 'no label'), ('Requires', 'no label'), ('Level', 'no label'), ('Awareness', 'no label'), ('Necessitates', 'no label'), ('Initiation', 'no label'), ('Prompt', 'no label'), ('Screening', 'no label'), ('Surveillance Process', 'no label'), ('Detect', 'no label'), ('Treat', 'no label'), ('Malignant Tumors', 'no label'), ('Clinically Affected', 'no label'), ('Patients', 'no label'), ('Cancer', 'no label'), ('Cancer Treatment', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Immunosuppressive Agents', 'no label'), ('Neurologic Symptoms', 'no label'), ('Quality Of Life', 'no label'), ('Review', 'no label'), ('Emphasis', 'no label'), ('Pathophysiological', 'no label'), ('Mechanisms', 'no label'), ('Clinical Manifestation', 'no label')]|[('Cell', 'no label'), ('Antibodies', 'no label'), ('Membrane P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('Acetylcholine', 'no label'), ('Lead', 'no label'), ('P/Q-Type', 'no label'), ('Antibodies', 'no label')]|[('P/Q-Type Vgcc Antibodies', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Uncommon Disorder Of', 'no label'), ('Paraneoplastic', 'no label'), ('Tumor', 'no label'), ('Dysimmune Diseases', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Disorder', 'no label'), ('Acetylcholine', 'no label'), ('Ach', 'no label'), ('Muscle Weakness', 'no label'), ('Muscle Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Areflexia', 'no label'), ('Malignant Tumors', 'no label'), ('Cancer', 'no label'), ('Cancer', 'no label'), ('3,4-Diaminopyridine', 'no label')]|[('Neuromuscular', 'no label'), ('A Malignant Tumor', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Dysimmune', 'no label'), ('Lems Patients', 'no label'), ('Membrane P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Ach', 'no label'), ('Nerve Terminal And', 'no label'), ('Muscle', 'no label'), ('Muscle', 'no label'), ('P/Q-Type Vgcc Antibodies', 'no label'), ('Presynaptic', 'no label'), ('Malignant Tumors', 'no label'), ('Patients', 'no label'), ('Cancer', 'no label'), ('Cancer', 'no label'), ('3,4-Diaminopyridine Or', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~20392978|Paraneoplastic Cerebellar Degeneration May Occur In Association With Lambert-Eaton Myasthenic Syndrome (Lems), But To Our Knowledge, The Co-Occurrence Of Paraneoplastic Opsoclonus-Myoclonus Syndrome And Lems Has Not Been Previously Reported. A 67-Year-Old Woman Presented With A Complex Partial Seizure And Evolving Ocular Flutter, Opsoclonus, Myoclonus And 'Cerebellar' Signs, All Of Which Improved Spontaneously Within 6 Weeks. Approximately 8 Weeks After Symptom Onset, The Patient Became Encephalopathic, She Had A Further Complex Partial Seizure, And She Became Areflexic With Potentiation Of Deep Tendon Reflexes. Radiological, Bronchoscopic And Histological Investigations Revealed Small-Cell Lung Cancer, And Neurophysiological Investigations Confirmed A Diagnosis Of Lems. High-Titre Anti-P/Q-Type Voltage-Gated Calcium-Channel Antibodies Were Identified In The Serum, Which Increased As The Signs Of Opsoclonus And Myoclonus Resolved. The Encephalopathy And Clinical Features Of Lems Responded Dramatically To Chemotherapy And Radiotherapy. Spontaneous Improvement Of Paraneoplastic Opsoclonus-Myoclonus Syndrome May Occur, And This Syndrome May Occur In Association With Lems. Antivoltage-Gated Calcium-Channel Antibodies Are Not Implicated In The Pathogenesis Of Paraneoplastic Opsoclonus-Myoclonus Syndrome.|"[('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Occur', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Knowledge', 'no label'), ('Co-Occurrence', 'no label'), ('Paraneoplastic Opsoclonus-Myoclonus Syndrome', 'no label'), ('67-Year-Old Woman', 'no label'), ('Complex Partial Seizure', 'no label'), ('Evolving', 'no label'), ('Ocular Flutter', 'no label'), ('Opsoclonus', 'no label'), ('Myoclonus', 'no label'), (""Cerebellar'"", 'no label'), ('Signs', 'no label'), ('Spontaneously', 'no label'), ('Weeks', 'no label'), ('Weeks', 'no label'), ('Symptom Onset', 'no label'), ('Patient', 'no label'), ('Encephalopathic', 'no label'), ('Complex Partial Seizure', 'no label'), ('Areflexic', 'no label'), ('Potentiation', 'no label'), ('Deep Tendon', 'no label'), ('Radiological', 'no label'), ('Bronchoscopic', 'no label'), ('Histological Investigations', 'no label'), ('Revealed', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Neurophysiological Investigations', 'no label'), ('Confirmed A', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Voltage-Gated Calcium-Channel Antibodies', 'no label'), ('Identified', 'no label'), ('Serum', 'no label'), ('Increased', 'no label'), ('Signs', 'no label'), ('Opsoclonus', 'no label'), ('Myoclonus Resolved', 'no label'), ('Encephalopathy', 'no label'), ('Clinical Features', 'no label'), ('Lems Responded', 'no label'), ('Chemotherapy', 'no label'), ('Radiotherapy', 'no label'), ('Spontaneous Improvement', 'no label'), ('Paraneoplastic Opsoclonus-Myoclonus Syndrome', 'no label'), ('Occur', 'no label'), ('Syndrome', 'no label'), ('Occur', 'no label'), ('Lems', 'no label'), ('Antivoltage-Gated Calcium-Channel Antibodies', 'no label'), ('Pathogenesis', 'no label'), ('Paraneoplastic Opsoclonus-Myoclonus Syndrome', 'no label')]"|[('Calcium-Channel Antibodies', 'no label'), ('Calcium-Channel Antibodies', 'no label')]|[('High-Titre Anti-P/Q-Type', 'no label')]|"[('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Opsoclonus-Myoclonus Syndrome', 'no label'), ('Seizure', 'no label'), ('Ocular Flutter', 'no label'), ('Opsoclonus', 'no label'), ('Myoclonus', 'no label'), (""Cerebellar' Signs"", 'no label'), ('Encephalopathic', 'no label'), ('Seizure', 'no label'), ('Areflexic', 'no label'), ('Lung Cancer', 'no label'), ('Opsoclonus', 'no label'), ('Myoclonus', 'no label'), ('Encephalopathy', 'no label'), ('Paraneoplastic Opsoclonus-Myoclonus Syndrome', 'no label'), ('Pathogenesis', 'no label'), ('Paraneoplastic Opsoclonus-Myoclonus Syndrome', 'no label')]"|[('Lems', 'no label'), ('Ocular Flutter', 'no label'), ('Cerebellar', 'no label'), ('Patient', 'no label'), ('Histological Investigations', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Serum', 'no label'), ('Opsoclonus', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~22973658|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare Autoimmune Disorder Of Neuromuscular Transmission (Nmj) That Shares Many Clinical Features With Myasthenia Gravis (Mg). We Report A 73 Year-Old Lady Who Presented 10 Years Previously With Stiffness Of Both Calves, Dry Mouth, Fatigue, Proximal Weakness And Areflexia In Lower Limbs. Neurophysiological Studies Were Consistent With Lems. Her Work Up For An Underlying Neoplasm Was Negative. She Recently Developed Unilateral Ptosis And Diplopia Which Dramatically Improved With Pyridostigmine Suggesting Concomitant Mg.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Autoimmune Disorder', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Nmj', 'no label'), ('Shares', 'no label'), ('Clinical Features', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Years', 'no label'), ('Stiffness', 'no label'), ('Calves', 'no label'), ('Dry Mouth', 'no label'), ('Fatigue', 'no label'), ('Proximal Weakness', 'no label'), ('Areflexia', 'no label'), ('Lower Limbs', 'no label'), ('Neurophysiological Studies', 'no label'), ('Consistent With', 'no label'), ('Lems', 'no label'), ('Underlying Neoplasm', 'no label'), ('Unilateral Ptosis', 'no label'), ('Diplopia', 'no label'), ('Pyridostigmine', 'no label'), ('Suggesting', 'no label'), ('Concomitant', 'no label'), ('Mg', 'no label')]|[('Pyridostigmine', 'no label'), ('Concomitant Mg', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Dry Mouth', 'no label'), ('Fatigue', 'no label'), ('Weakness', 'no label'), ('Areflexia', 'no label'), ('Neoplasm', 'no label'), ('Diplopia', 'no label'), ('Pyridostigmine', 'no label'), ('Mg', 'no label')]|[('Neuromuscular', 'no label'), ('Lower Limbs', 'no label'), ('Neoplasm', 'no label'), ('Pyridostigmine', 'no label'), ('Mg', 'no label')]
lambert eaton syndrome|pubmed~26452332||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~23053834||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~22950670| Lambert-Eaton Myasthenic Syndrome Is A Rare Disorder And It Is Known As A Paraneoplastic Neurological Syndrome. Small Cell Lung Cancer Often Accompanies This Syndrome. Lambert-Eaton Myasthenic Syndrome Associated With Lung Adenocarcinoma Is Extremely Rare; There Are Only A Few Reported Cases Worldwide. A 75-Year-Old Japanese Man With A Past History Of Chronic Rheumatoid Arthritis And Sjögren Syndrome Was Diagnosed With Lambert-Eaton Myasthenic Syndrome By Electromyography And Serum Anti-P/Q-Type Voltage-Gated Calcium Channel Antibody Level Preceding The Diagnosis Of Lung Cancer. A Chest Computed Tomography To Screen For Malignant Lesions Revealed An Abnormal Shadow In The Lung. Although A Histopathological Examination By Bronchoscopic Study Could Not Reveal The Malignancy, Lung Cancer Was Mostly Suspected After The Results Of A Chest Computed Tomography And [18F]-Fluorodeoxyglucose Positron Emission Tomography. An Intraoperative Diagnosis Based On The Frozen Section Obtained By Tumor Biopsy Was Adenocarcinoma So The Patient Underwent A Lobectomy Of The Right Lower Lobe And Lymph Node Dissection With Video-Assisted Thoracoscopic Surgery. The Permanent Pathological Examination Was The Same As The Frozen Diagnosis (Pt2An1M0: Stage Iia: Tnm Staging 7Th Edition). Immunohistochemistry Revealed That Most Of The Cancer Cells Were Positive For P/Q-Type Voltage-Gated Calcium Channel. Our Case Is A Rare Combination Of Lambert-Eaton Myasthenic Syndrome Associated With Lung Adenocarcinoma, Rheumatoid Arthritis And Sjögren Syndrome, And To The Best Of Our Knowledge It Is The First Report That Indicates The Presence Of Voltage-Gated Calcium Channel In Lung Adenocarcinoma By Immunostaining.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Rare', 'no label'), ('Paraneoplastic Neurological Syndrome', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Accompanies', 'no label'), ('Syndrome', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Associated With', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Rare', 'no label'), ('Cases', 'no label'), ('Worldwide', 'no label'), ('75-Year-Old Japanese', 'no label'), ('Past History', 'no label'), ('Chronic Rheumatoid Arthritis', 'no label'), ('Diagnosed', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Electromyography', 'no label'), ('Serum Anti-P/Q-Type Voltage-Gated Calcium Channel', 'no label'), ('Antibody', 'no label'), ('Level', 'no label'), ('Preceding', 'no label'), ('Diagnosis', 'no label'), ('Lung Cancer', 'no label'), ('Chest Computed Tomography', 'no label'), ('Malignant Lesions', 'no label'), ('Revealed', 'no label'), ('Abnormal Shadow', 'no label'), ('Lung', 'no label'), ('Histopathological Examination', 'no label'), ('Bronchoscopic Study', 'no label'), ('Reveal', 'no label'), ('Malignancy', 'no label'), ('Lung Cancer', 'no label'), ('Suspected', 'no label'), ('Chest Computed Tomography', 'no label'), ('Positron Emission Tomography', 'no label'), ('Intraoperative Diagnosis', 'no label'), ('Frozen Section', 'no label'), ('Tumor Biopsy', 'no label'), ('Adenocarcinoma', 'no label'), ('Patient', 'no label'), ('Lobectomy', 'no label'), ('Right Lower Lobe', 'no label'), ('Video-Assisted Thoracoscopic Surgery', 'no label'), ('Permanent Pathological Examination', 'no label'), ('Frozen Diagnosis', 'no label'), ('Pt2An1M0', 'no label'), ('Stage Iia', 'no label'), ('Tnm Staging 7Th Edition', 'no label'), ('Immunohistochemistry', 'no label'), ('Revealed', 'no label'), ('Cancer Cells', 'no label'), ('Positive', 'no label'), ('P/Q-Type Voltage-Gated Calcium Channel', 'no label'), ('Case', 'no label'), ('Rare', 'no label'), ('Combination', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Associated With', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Rheumatoid Arthritis', 'no label'), ('Knowledge', 'no label'), ('First Report', 'no label'), ('Indicates', 'no label'), ('Presence', 'no label'), ('Voltage-Gated Calcium Channel', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Immunostaining', 'no label')]|[('Cell', 'no label'), ('Calcium', 'no label'), ('Antibody', 'no label'), ('Tnm', 'no label'), ('Cells', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label')]|[('Tnm', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Disorder', 'no label'), ('Neurological Syndrome', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Rheumatoid Arthritis', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Calcium', 'no label'), ('Lung Cancer', 'no label'), ('Malignancy', 'no label'), ('Lung Cancer', 'no label'), ('Chest', 'no label'), ('Tumor', 'no label'), ('Adenocarcinoma', 'no label'), ('Cancer', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Rheumatoid Arthritis', 'no label'), ('Sjögren Syndrome', 'no label'), ('Calcium', 'no label'), ('Lung Adenocarcinoma', 'no label')]|[('Small Cell Lung Cancer', 'no label'), ('Lung Adenocarcinoma Is', 'no label'), ('Serum Anti-P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Lung Cancer.', 'no label'), ('Malignant Lesions', 'no label'), ('Lung', 'no label'), ('Lung Cancer', 'no label'), ('Tumor Biopsy', 'no label'), ('Adenocarcinoma', 'no label'), ('Patient', 'no label'), ('Right Lower Lobe', 'no label'), ('Lymph Node', 'no label'), ('Frozen', 'no label'), ('Stage Iia', 'no label'), ('Tnm', 'no label'), ('Cancer Cells', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Case Is A', 'no label'), ('Lung Adenocarcinoma', 'no label'), ('Indicates', 'no label'), ('Calcium', 'no label'), ('Lung Adenocarcinoma', 'no label')]
lambert eaton syndrome|pubmed~23984583|A 55-Year-Old Male With Lambert-Eaton Myasthenic Syndrome Underwent Low Anterior Resection. Before Anesthetic Induction, His Arterial Blood Gas Analysis Showed Chronic Hypercapnia (Ph 7.404, Paco2 59 Mmhg, Be 9.1). Anesthesia Was Induced With Propofol, Remifentanil And Ketamine. Uneventful Tracheal Intubation Was Achieved After Superior Laryngeal Nerve Block Without Using Muscle Relaxants. Then Ultrasound-Guided Bilateral Rectus Sheath Block And Transversus Abdominis Plane Block Were Performed Using 60 Ml Of 0.375% Ropivacaine. Anesthesia Was Maintained With Propofol, Remifentanil Monitoring Bispectral Index. Good Surgical Condition Was Maintained Even Without Using Muscle Relaxants. Although Only A Small Amount Of Morphine Was Required During The Early Postoperative Days, His Postoperative Course Was Smooth And Uneventful. The Present Case Shows That Ultrasound-Guided Rectus Sheath Block And Transversus Abdominis Plane Block Are Safe And Useful For Abdominal Surgery In Patients With Neuromuscular Disease.|[('Male With', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Anterior', 'no label'), ('Resection', 'no label'), ('Anesthetic Induction', 'no label'), ('Arterial Blood Gas Analysis', 'no label'), ('Chronic Hypercapnia', 'no label'), ('Paco2', 'no label'), ('Mmhg', 'no label'), ('Anesthesia', 'no label'), ('Induced', 'no label'), ('Propofol', 'no label'), ('Remifentanil', 'no label'), ('Ketamine', 'no label'), ('Uneventful', 'no label'), ('Tracheal Intubation', 'no label'), ('Superior Laryngeal Nerve', 'no label'), ('Muscle Relaxants', 'no label'), ('Ultrasound-Guided Bilateral', 'no label'), ('Rectus Sheath', 'no label'), ('Block', 'no label'), ('Transversus Abdominis', 'no label'), ('Plane Block', 'no label'), ('Performed', 'no label'), ('Ropivacaine', 'no label'), ('Anesthesia', 'no label'), ('Propofol', 'no label'), ('Remifentanil', 'no label'), ('Monitoring Bispectral Index', 'no label'), ('Surgical Condition', 'no label'), ('Muscle Relaxants', 'no label'), ('Small', 'no label'), ('Amount', 'no label'), ('Morphine', 'no label'), ('Early', 'no label'), ('Postoperative', 'no label'), ('Days', 'no label'), ('His Postoperative Course', 'no label'), ('Smooth', 'no label'), ('Uneventful', 'no label'), ('Case', 'no label'), ('Ultrasound-Guided Rectus', 'no label'), ('Block', 'no label'), ('Transversus Abdominis', 'no label'), ('Plane Block', 'no label'), ('Abdominal Surgery', 'no label'), ('Patients', 'no label'), ('Neuromuscular Disease', 'no label')]|[('His Arterial', 'no label'), ('Paco2 59 Mmhg', 'no label'), ('Propofol', 'no label'), ('Remifentanil', 'no label'), ('Ropivacaine', 'no label'), ('Propofol', 'no label'), ('Remifentanil', 'no label'), ('Morphine', 'no label'), ('His', 'no label')]|[('55-Year-Old Male', 'no label'), ('His', 'no label'), ('His', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Hypercapnia', 'no label'), ('Propofol', 'no label'), ('Remifentanil', 'no label'), ('Ketamine', 'no label'), ('Ropivacaine', 'no label'), ('Propofol', 'no label'), ('Remifentanil', 'no label'), ('Morphine', 'no label'), ('Neuromuscular Disease', 'no label')]|[('Arterial Blood Gas', 'no label'), ('Be 9.1', 'no label'), ('Propofol', 'no label'), ('Remifentanil', 'no label'), ('Ketamine', 'no label'), ('Tracheal', 'no label'), ('Muscle', 'no label'), ('Transversus Abdominis', 'no label'), ('Ropivacaine', 'no label'), ('Propofol', 'no label'), ('Remifentanil', 'no label'), ('Muscle', 'no label'), ('Morphine', 'no label'), ('Smooth', 'no label'), ('Transversus Abdominis', 'no label'), ('Patients', 'no label'), ('Neuromuscular', 'no label')]
lambert eaton syndrome|pubmed~31366477||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~21245427|Approximately One Half Of Patients With Lambert-Eaton Myasthenic Syndrome (Lems) Have Small-Cell Lung Carcinomas (Sclc), Aggressive Tumors With Poor Prognosis. In View Of Its Profound Impact On Therapy And Survival, We Developed And Validated A Score To Identify The Presence Of Sclc Early In The Course Of Lems. We Derived A Prediction Score For Sclc In Lems In A Nationwide Cohort Of 107 Dutch Patients, And Validated It In A Similar Cohort Of 112 British Patients. A Dutch-English Lems Tumor Association Prediction (Delta-P) Score Was Developed Based On Multivariate Logistic Regression. Age At Onset, Smoking Behavior, Weight Loss, Karnofsky Performance Status, Bulbar Involvement, Male Sexual Impotence, And The Presence Of Sry-Like High-Mobility Group Box Protein 1 Serum Antibodies Were Independent Predictors For Sclc In Lems. A Delta-P Score Was Derived Allocating 1 Point For The Presence Of Each Of The Following Items At Or Within 3 Months From Onset: Age At Onset ≥ 50 Years, Smoking At Diagnosis, Weight Loss ≥ 5%, Bulbar Involvement, Erectile Dysfunction, And Karnofsky Performance Status Lower Than 70. The Area Under The Curve Of The Receiver Operating Curve Was 94.4% In The Derivation Cohort And 94.6% In The Validation Set. A Delta-P Score Of 0 Or 1 Corresponded To A 0% To 2.6% Chance Of Sclc, Whereas Scores Of 4, 5, And 6 Corresponded To Chances Of Sclc Of 93.5%, 96.6%, And 100%, Respectively. The Simple Clinical Delta-P Score Discriminated Patients With Lems With And Without Sclc With High Accuracy Early In The Course Of Lems.|[('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Small-Cell Lung Carcinomas', 'no label'), ('Sclc', 'no label'), ('Aggressive Tumors', 'no label'), ('Poor Prognosis', 'no label'), ('Profound Impact', 'no label'), ('Therapy', 'no label'), ('Survival', 'no label'), ('Validated A Score', 'no label'), ('Presence', 'no label'), ('Sclc', 'no label'), ('Early', 'no label'), ('Course', 'no label'), ('Lems', 'no label'), ('Prediction Score', 'no label'), ('Sclc', 'no label'), ('Nationwide', 'no label'), ('Cohort', 'no label'), ('Dutch Patients', 'no label'), ('Validated', 'no label'), ('Cohort', 'no label'), ('British', 'no label'), ('Patients', 'no label'), ('Dutch-English Lems Tumor Association Prediction', 'no label'), ('Delta-P', 'no label'), ('Multivariate Logistic Regression', 'no label'), ('Age', 'no label'), ('Onset', 'no label'), ('Smoking Behavior', 'no label'), ('Weight Loss', 'no label'), ('Karnofsky Performance Status', 'no label'), ('Bulbar Involvement', 'no label'), ('Male', 'no label'), ('Sexual Impotence', 'no label'), ('Presence', 'no label'), ('Sry-Like High-Mobility Group Box Protein 1 Serum Antibodies', 'no label'), ('Independent Predictors', 'no label'), ('Sclc', 'no label'), ('Delta-P', 'no label'), ('Presence', 'no label'), ('Items', 'no label'), ('Months', 'no label'), ('Onset', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('Smoking', 'no label'), ('Diagnosis', 'no label'), ('Weight Loss', 'no label'), ('Bulbar Involvement', 'no label'), ('Erectile Dysfunction', 'no label'), ('Karnofsky Performance Status', 'no label'), ('Area', 'no label'), ('Receiver Operating Curve', 'no label'), ('Derivation Cohort', 'no label'), ('Validation Set', 'no label'), ('Delta-P', 'no label'), ('Score', 'no label'), ('Corresponded', 'no label'), ('Chance', 'no label'), ('Sclc', 'no label'), ('Scores', 'no label'), ('Corresponded', 'no label'), ('Chances', 'no label'), ('Sclc', 'no label'), ('Simple Clinical Delta-P Score', 'no label'), ('Discriminated', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('High', 'no label'), ('Accuracy', 'no label'), ('Early', 'no label'), ('Course', 'no label')]|[('Antibodies', 'no label')]|[('Sry-Like High-Mobility Group Box Protein 1 Serum Antibodies', 'no label')]|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lung Carcinomas', 'no label'), ('Aggressive Tumors', 'no label'), ('Tumor', 'no label'), ('Weight Loss', 'no label'), ('Sexual Impotence', 'no label'), ('Weight Loss', 'no label'), ('Erectile Dysfunction', 'no label')]|[('Patients', 'no label'), ('Small-Cell Lung Carcinomas', 'no label'), ('Tumors', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Tumor', 'no label'), ('Sry-Like High-Mobility', 'no label'), ('Box Protein 1', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~34642096||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~20420183|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Neuromuscular Disorder In Which Autoantibodies Inhibit The Presynaptic Release Of Acetylcholine. Autoantibodies Against P/Q-Type Voltage-Gated Calcium Channels (Vgcc) Are Detected In 85% Of Patients With Lems. In Addition, Autoantibodies To Synaptotagmin, An M1-Type Muscarinic Acetylcholine Receptor And Sox1 Are Also Found In The Sera Of Patients With Lems. Lems Is Closely Associated With Small Cell Lung Cancer (Sclc) In 50-60% Of Patients. Patients With Sclc Who Have Anti-Vgcc Antibodies Have Been Reported To Have A Favorable Prognosis. In Contrast To Paraneoplatic Lems, Other Forms Of Lems May Have An Autoimmune Aspect Because Of The Established Association Between Human Leukocyte Antigen And A Family History Of Other Autoimmune Disorders In This Condition. The Clinical Features Of Lems Include Proximal Weakness, Areflexia, Ptosis, Cerebellar Ataxia And Autonomic Dysfunction. The Findings Of Electrophysiological Examination Show That Lems Is Characterized By Compound Muscle Action Potential Potentials With A Low Amplitude And Increment Upon Repetitive Nerve Stimulation At A High Rate. Tumor Removal Is The Primary Treatment Of Lems. The Efficacy Of 3,4-Diaminopyridine For The Treatment Of Lems Has Also Been Established. Patients With Lems Require The Immunotherapies Such As Plasma Exchange And The Administration Of High Doses Of Immunoglobulin And Prednisolone.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Neuromuscular Disorder', 'no label'), ('Autoantibodies', 'no label'), ('Inhibit', 'no label'), ('Presynaptic', 'no label'), ('Release', 'no label'), ('Acetylcholine', 'no label'), ('Autoantibodies', 'no label'), ('P/Q-Type Voltage-Gated Calcium Channels', 'no label'), ('Vgcc', 'no label'), ('Detected', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Addition', 'no label'), ('Autoantibodies', 'no label'), ('Synaptotagmin', 'no label'), ('Muscarinic Acetylcholine Receptor', 'no label'), ('Sox1', 'no label'), ('Sera', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Anti-Vgcc Antibodies', 'no label'), ('Favorable', 'no label'), ('Prognosis', 'no label'), ('Contrast', 'no label'), ('Autoimmune Aspect', 'no label'), ('Association', 'no label'), ('Human Leukocyte Antigen', 'no label'), ('Family History', 'no label'), ('Autoimmune Disorders', 'no label'), ('Condition', 'no label'), ('Clinical Features', 'no label'), ('Lems Include', 'no label'), ('Proximal Weakness', 'no label'), ('Areflexia', 'no label'), ('Ptosis', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Findings', 'no label'), ('Electrophysiological Examination', 'no label'), ('Lems', 'no label'), ('Characterized', 'no label'), ('Compound Muscle', 'no label'), ('Potentials', 'no label'), ('Low', 'no label'), ('Increment', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('High Rate', 'no label'), ('Tumor Removal', 'no label'), ('Primary Treatment', 'no label'), ('Lems', 'no label'), ('Efficacy', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label'), ('Established', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Require', 'no label'), ('Immunotherapies', 'no label'), ('Plasma', 'no label'), ('Administration', 'no label'), ('High Doses', 'no label'), ('Immunoglobulin', 'no label'), ('Prednisolone', 'no label')]|[('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Autoantibodies', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Sox1', 'no label'), ('Cell', 'no label'), ('Antibodies', 'no label'), ('Human Leukocyte', 'no label')]|[('Autoantibodies', 'no label'), ('M1-Type Muscarinic Acetylcholine Receptor', 'no label'), ('Sox1', 'no label'), ('Human Leukocyte Antigen', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Neuromuscular Disorder', 'no label'), ('Acetylcholine', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Prognosis', 'no label'), ('Autoimmune Disorders', 'no label'), ('Areflexia', 'no label'), ('Ptosis, Cerebellar Ataxia', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Tumor', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Prednisolone', 'no label')]|[('Neuromuscular', 'no label'), ('Presynaptic', 'no label'), ('Acetylcholine', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Patients', 'no label'), ('Synaptotagmin', 'no label'), ('Sox1', 'no label'), ('Sera', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Human Leukocyte Antigen', 'no label'), ('Lems', 'no label'), ('Cerebellar', 'no label'), ('Lems', 'no label'), ('Nerve', 'no label'), ('Tumor', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Plasma', 'no label'), ('Immunoglobulin', 'no label'), ('Prednisolone', 'no label')]
lambert eaton syndrome|pubmed~23036181||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~25698125||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~21243240|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Immune-Mediated Disorder Of The Presynaptic Neuromuscular Transmission, Which More Frequently Occurs As The Remote Effect Of A Neoplasm, In The Paraneoplastic Form (P-Lems), Or In A Non-Paraneoplastic Form (Np-Lems); But Few Studies Describe The Clinical Features Of Np-Lems. We Analyzed The Clinical Manifestations, Laboratory Findings, Electrophysiological Studies, And Treatment Responses In Ten Brazilian Patients Suffering From Np-Lems. The Mean Age Was 41.5 Years. More Often Neurological Findings Were Hyporeflexia Or Areflexia With A Post-Exercise Improvement. Treatment Response Occurred With Pyridostigmine, Guanidine, Prednisone, Azathioprine, And Cyclosporine; But Not Response Was Observed After Intravenous Immunoglobulin And Plasma Exchange. Age At Onset, Clinical Manifestations, And Electrophysiological Abnormalities Can Help More In The Diagnosis Than Serum Antibodies; The Symptomatic Treatment With Pyridostigmine Was Effective; And The Immunosuppressive Treatment With Prednisone, Azathioprine, Or Cyclosporine Was More Beneficial Than Plasma Exchange Or Intravenous Immunoglobulin Treatment.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Immune-Mediated Disorder', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Occurs', 'no label'), ('Remote', 'no label'), ('Effect', 'no label'), ('Neoplasm', 'no label'), ('Paraneoplastic Form', 'no label'), ('P-Lems', 'no label'), ('Non-Paraneoplastic Form', 'no label'), ('Np-Lems', 'no label'), ('Studies', 'no label'), ('Clinical Features', 'no label'), ('Np-Lems', 'no label'), ('Analyzed', 'no label'), ('Clinical Manifestations', 'no label'), ('Laboratory Findings', 'no label'), ('Electrophysiological Studies', 'no label'), ('Treatment Responses', 'no label'), ('Brazilian', 'no label'), ('Patients', 'no label'), ('Suffering', 'no label'), ('Np-Lems', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Neurological Findings', 'no label'), ('Hyporeflexia', 'no label'), ('Areflexia', 'no label'), ('Post-Exercise Improvement', 'no label'), ('Treatment Response', 'no label'), ('Pyridostigmine', 'no label'), ('Guanidine', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label'), ('Cyclosporine', 'no label'), ('Not Response', 'no label'), ('Observed', 'no label'), ('Intravenous Immunoglobulin', 'no label'), ('Age', 'no label'), ('Onset', 'no label'), ('Clinical Manifestations', 'no label'), ('Electrophysiological Abnormalities', 'no label'), ('Diagnosis', 'no label'), ('Serum Antibodies', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Pyridostigmine', 'no label'), ('Effective', 'no label'), ('Immunosuppressive Treatment', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label'), ('Cyclosporine', 'no label'), ('Beneficial', 'no label'), ('Plasma', 'no label'), ('Intravenous', 'no label'), ('Immunoglobulin Treatment', 'no label')]|[('Guanidine', 'no label'), ('Prednisone', 'no label'), ('Antibodies', 'no label'), ('Pyridostigmine', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Neoplasm', 'no label'), ('Paraneoplastic', 'no label'), ('Hyporeflexia', 'no label'), ('Areflexia', 'no label'), ('Pyridostigmine', 'no label'), ('Guanidine', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label'), ('Cyclosporine', 'no label'), ('Electrophysiological Abnormalities', 'no label'), ('Pyridostigmine', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label'), ('Cyclosporine', 'no label')]|[('Presynaptic Neuromuscular', 'no label'), ('A Neoplasm', 'no label'), ('Patients', 'no label'), ('Pyridostigmine', 'no label'), ('Guanidine', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label'), ('Cyclosporine', 'no label'), ('Immunoglobulin', 'no label'), ('Plasma', 'no label'), ('Serum', 'no label'), ('Pyridostigmine', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label'), ('Cyclosporine', 'no label'), ('Plasma', 'no label'), ('Intravenous Immunoglobulin', 'no label')]
lambert eaton syndrome|pubmed~21226298|A 78-Year-Old Man With Complaints Of Appetite Loss And Weight Loss Visited Our Hospital In November 2006. Positron-Emission Tomography And Computed Tomography (Pet/Ct) Showed Swollen Lymph Nodes In The Abdominal Para-Aorta, Mediastinum And Neck, With Intense Fdg Accumulation. The Pathological Findings Of The Cervical Lymph Nodes Revealed Small-Cell Cancer. We Diagnosed Extensive Small-Cell Lung Cancer (Sclc), Which Occurred Primarily In The Left Upper Lobe. As Subsequent Ct Revealed Spontaneous Shrinkage Of The Pulmonary Nodule And Swollen Lymph Nodes, The Clinical Course Was Monitored Without Anticancer Therapy. In February 2007, Progressive Muscle Weakness Of The Lower Extremities Developed. In July He Was Admitted With Respiratory Failure And Required Mechanical Ventilation. Although We Did Not Administer Anticancer Therapy Due To His Poor Performance Status, He Survived For 30 Months Receiving Mechanical Ventilation, And The Tumors Continued To Grow Moderately. We Diagnosed Lambert-Eaton Myasthenic Syndrome (Lems) Based On The Clinical Symptoms, The Presence Of Anti-Vgcc Antibodies And Waxing Phenomenon On Electromyography Obtained In April 2009. Chemotherapy With Amrubicin Shrank The Tumors, But His Muscle Weakness Did Not Improve. Previous Reports Showed That A Prognosis Of Sclc With Lems Was Better Than That Without Lems. In This Case, The Tumors Showed Spontaneous Regression Without Any Anticancer Therapy, And Then Increased Moderately. The Immune Response Was Considered To Have Affected Tumor Growth.|[('Complaints', 'no label'), ('Appetite Loss And Weight Loss Visited', 'no label'), ('Hospital', 'no label'), ('Positron-Emission Tomography', 'no label'), ('Computed Tomography', 'no label'), ('Swollen', 'no label'), ('Lymph Nodes', 'no label'), ('Abdominal Para-Aorta', 'no label'), ('Mediastinum', 'no label'), ('Neck', 'no label'), ('Intense Fdg', 'no label'), ('Accumulation', 'no label'), ('Pathological Findings', 'no label'), ('Cervical Lymph Nodes', 'no label'), ('Revealed', 'no label'), ('Small-Cell Cancer', 'no label'), ('Diagnosed', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Left Upper Lobe', 'no label'), ('Ct', 'no label'), ('Spontaneous', 'no label'), ('Shrinkage', 'no label'), ('Pulmonary Nodule', 'no label'), ('Swollen', 'no label'), ('Lymph Nodes', 'no label'), ('Clinical Course', 'no label'), ('Anticancer Therapy', 'no label'), ('Progressive Muscle Weakness', 'no label'), ('Lower Extremities', 'no label'), ('Admitted With', 'no label'), ('Respiratory Failure', 'no label'), ('Mechanical Ventilation', 'no label'), ('Not Administer', 'no label'), ('Anticancer Therapy', 'no label'), ('Poor Performance Status', 'no label'), ('Months', 'no label'), ('Mechanical Ventilation', 'no label'), ('Tumors', 'no label'), ('Grow Moderately', 'no label'), ('Diagnosed', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Clinical Symptoms', 'no label'), ('Anti-Vgcc Antibodies', 'no label'), ('Waxing', 'no label'), ('Phenomenon', 'no label'), ('Electromyography', 'no label'), ('Chemotherapy', 'no label'), ('Amrubicin', 'no label'), ('Tumors', 'no label'), ('His Muscle Weakness', 'no label'), ('Did Not Improve', 'no label'), ('Reports', 'no label'), ('Prognosis', 'no label'), ('Sclc', 'no label'), ('Lems', 'no label'), ('Lems', 'no label'), ('Case', 'no label'), ('Tumors', 'no label'), ('Spontaneous Regression', 'no label'), ('Anticancer Therapy', 'no label'), ('Increased', 'no label'), ('Moderately', 'no label'), ('Immune Response', 'no label'), ('Affected', 'no label'), ('Tumor Growth', 'no label')]|[('Antibodies', 'no label'), ('His', 'no label')]|[('Fdg', 'no label'), ('His', 'no label'), ('His', 'no label')]|[('Appetite Loss', 'no label'), ('Weight Loss', 'no label'), ('Cancer', 'no label'), ('Muscle Weakness', 'no label'), ('Respiratory Failure', 'no label'), ('Tumors', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Amrubicin', 'no label'), ('Tumors', 'no label'), ('Muscle Weakness', 'no label'), ('Tumors', 'no label'), ('Tumor', 'no label')]|[('Lymph Nodes', 'no label'), ('Mediastinum And', 'no label'), ('Fdg', 'no label'), ('Cervical Lymph', 'no label'), ('Small-Cell Cancer', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Left Upper Lobe', 'no label'), ('Pulmonary', 'no label'), ('Lymph Nodes', 'no label'), ('Anticancer', 'no label'), ('Muscle', 'no label'), ('Lower Extremities', 'no label'), ('Respiratory', 'no label'), ('Administer Anticancer', 'no label'), ('Tumors', 'no label'), ('Anti-Vgcc', 'no label'), ('Amrubicin', 'no label'), ('Tumors', 'no label'), ('Muscle', 'no label'), ('Lems', 'no label'), ('Case', 'no label'), ('Tumors', 'no label'), ('Anticancer', 'no label'), ('Immune', 'no label'), ('Tumor', 'no label')]
lambert eaton syndrome|pubmed~21741750||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~33685981||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~22352885|The Burden Of Disease In Lambert-Eaton Myasthenic Syndrome (Lems) Patients Is Unclear. This Study Focused On The Patient'S Perspective To Obtain Patient-Reported Information On Clinical Symptoms, Burden Of Illness, Impact Of Lems On Activities Of Daily Living (Adl), And Management Of Lems. Semi-Structured, Face-To-Face Interviews With Lems Patients From Two Specialized Centres In Germany Between September And December 2010. Twelve Patients Participated; Mean Age 66.7 ± 9.8 Years. First Symptoms Occurred At Age 52.5 ± 14.0 Years. Mean Time Between First Symptoms And Diagnosis Was 4.4 ± 6.2 Years. Patients Reported Neuromuscular, Cranial, And Autonomic Symptoms Plus General Fatigue. Two-Thirds Of Patients Reported 10 Or More Symptoms. The Most Frequent Symptoms Were Leg Weakness (91.7%) And General Fatigue (83.3%). Restrictions In Adl Were Reported Always Or Often In 75% Of Patients. Over Half Of The Patients (N = 7) Reported Poor Or Very Poor Health Status. Mean Eq-5D Utility Scores Were 0.34 ± 0.35, With Little Day-To-Day Variation. Patients Visited A Number Of Different Clinicians; Most Had Been Hospitalized At Some Point In The Course Of Their Disease. The Most Frequent Drug Treatments Were 3,4-Diaminopyridine (3,4-Dap) (83.3%) And Pyridostigmine (41.5%). The Study Has Several Limitations, Including Small Sample Size And The Potential Influence Of Recall Bias. Lems Patients Report Long Individual Disease Histories. Most Patients Suffer Multiple Symptoms Which Are Frequently Severe And Troublesome, And Almost All Are Restricted In Adl With Poor Health Status. There Is High Utilization Of Healthcare Resources From Diagnosis To Ongoing Treatment. Physicians Should Be Aware Of This Rare Disease To Ensure That Patients Receive An Early Diagnosis And Prompt And Appropriate Treatment.|"[('Burden', 'no label'), ('Disease', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Focused', 'no label'), (""Patient'S"", 'no label'), ('Obtain', 'no label'), ('Patient-Reported Information', 'no label'), ('Clinical Symptoms', 'no label'), ('Burden', 'no label'), ('Illness', 'no label'), ('Impact', 'no label'), ('Lems', 'no label'), ('Management', 'no label'), ('Lems', 'no label'), ('Face-To-Face Interviews', 'no label'), ('Lems Patients', 'no label'), ('Specialized Centres', 'no label'), ('Germany', 'no label'), ('Patients', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('First Symptoms', 'no label'), ('Occurred', 'no label'), ('Age', 'no label'), ('Years', 'no label'), ('First Symptoms', 'no label'), ('Diagnosis', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Neuromuscular', 'no label'), ('Cranial', 'no label'), ('Autonomic Symptoms Plus', 'no label'), ('General Fatigue', 'no label'), ('Two-Thirds', 'no label'), ('Patients', 'no label'), ('Symptoms', 'no label'), ('Frequent', 'no label'), ('Symptoms', 'no label'), ('Leg Weakness', 'no label'), ('General Fatigue', 'no label'), ('Reported', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Poor', 'no label'), ('Poor Health Status', 'no label'), ('Eq-5D', 'no label'), ('Utility Scores', 'no label'), ('Day-To-Day', 'no label'), ('Variation', 'no label'), ('Patients', 'no label'), ('Clinicians', 'no label'), ('Hospitalized', 'no label'), ('Point', 'no label'), ('Course', 'no label'), ('Disease', 'no label'), ('Frequent', 'no label'), ('Drug Treatments', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label'), ('Study', 'no label'), ('Limitations', 'no label'), ('Small Sample Size', 'no label'), ('Potential', 'no label'), ('Influence', 'no label'), ('Recall', 'no label'), ('Bias', 'no label'), ('Lems Patients', 'no label'), ('Long Individual Disease Histories', 'no label'), ('Patients', 'no label'), ('Multiple', 'no label'), ('Symptoms', 'no label'), ('Severe', 'no label'), ('Troublesome', 'no label'), ('Restricted', 'no label'), ('Poor Health Status', 'no label'), ('Utilization', 'no label'), ('Healthcare Resources', 'no label'), ('Diagnosis', 'no label'), ('Ongoing', 'no label'), ('Treatment', 'no label'), ('Physicians', 'no label'), ('Aware', 'no label'), ('Rare Disease', 'no label'), ('Ensure', 'no label'), ('Patients', 'no label'), ('Receive', 'no label'), ('Early Diagnosis', 'no label'), ('Prompt', 'no label'), ('Appropriate', 'no label'), ('Treatment', 'no label')]"|[('Drug', 'no label'), ('Pyridostigmine', 'no label')]|[]|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Fatigue', 'no label'), ('Leg Weakness', 'no label'), ('91.7', 'no label'), ('Fatigue', 'no label'), ('N\u2009=\u20097) Reported Poor Or Very Poor Health Status.', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label')]|[('Patients', 'no label'), ('Lems', 'no label'), ('Face-To-Face', 'no label'), ('Lems Patients', 'no label'), ('Germany', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Neuromuscular', 'no label'), ('Patients', 'no label'), ('Leg Weakness (', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Ensure', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~23278582|Lambert-Eaton Myasthenic Syndrome (Lems) Causes Neuromuscular Weakness As A Result Of An Autoimmune Attack On The Calcium Channels That Normally Regulate Chemical Transmitter Release At The Neuromuscular Junction. Currently There Are Limited Treatment Options For Patients With This And Other Forms Of Neuromuscular Weakness. A Novel, First-In-Class Calcium Channel Agonist That Is Selective For The Types Of Voltage-Gated Calcium Channels That Regulate Transmitter Release At Neuromuscular Synapses Has Recently Been Developed. This Compound (Gv-58) Slows Deactivation (Closing) Of The Channel, Resulting In A Large Increase In Total Calcium Entry During Motor Nerve Action Potential Activity. This New Calcium Channel Agonist Is Currently Being Evaluated For The Treatment Of Neuromuscular Weakness. Potential Applications Include Development As Single Therapeutics, Or For Combination Treatments.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Neuromuscular Weakness', 'no label'), ('Autoimmune Attack', 'no label'), ('Calcium Channels', 'no label'), ('Regulate', 'no label'), ('Chemical', 'no label'), ('Transmitter Release', 'no label'), ('Neuromuscular', 'no label'), ('Junction', 'no label'), ('Limited Treatment Options', 'no label'), ('Patients', 'no label'), ('Neuromuscular Weakness', 'no label'), ('First-In-Class', 'no label'), ('Calcium Channel Agonist', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Regulate', 'no label'), ('Transmitter Release', 'no label'), ('Neuromuscular Synapses', 'no label'), ('Compound', 'no label'), ('Gv-58', 'no label'), ('Slows Deactivation', 'no label'), ('Closing', 'no label'), ('Channel', 'no label'), ('Increase', 'no label'), ('Total Calcium', 'no label'), ('Motor Nerve', 'no label'), ('Activity', 'no label'), ('Calcium Channel Agonist', 'no label'), ('Being', 'no label'), ('Evaluated', 'no label'), ('Treatment', 'no label'), ('Neuromuscular Weakness', 'no label'), ('Applications', 'no label'), ('Single Therapeutics', 'no label'), ('Combination Treatments', 'no label')]|[('Calcium', 'no label'), ('Chemical', 'no label'), ('Calcium', 'no label'), ('Agonist', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Agonist', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Neuromuscular Weakness', 'no label'), ('Calcium', 'no label'), ('Neuromuscular Weakness', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Neuromuscular Weakness', 'no label')]|[('Neuromuscular', 'no label'), ('Calcium', 'no label'), ('Neuromuscular', 'no label'), ('Patients', 'no label'), ('Neuromuscular', 'no label'), ('First-In-Class Calcium', 'no label'), ('Calcium', 'no label'), ('Neuromuscular Synapses', 'no label'), ('Calcium', 'no label'), ('Calcium', 'no label'), ('Neuromuscular', 'no label')]
lambert eaton syndrome|pubmed~23278581|Besides Antitumor Therapy For Patients With The Paraneoplastic Form Of Lambert-Eaton Myasthenic Syndrome (Lems), The Mainstay Of Symptomatic Treatment In Lems Is 3,4-Diaminopyridine (3,4-Dap). Data From Four Randomized, Placebo-Controlled Trials Have Revealed That Muscle Strength Scores Increased Significantly With 3,4-Dap. A Limited Meta-Analysis Performed On Two Trials Using The Quantitative Myasthenia Gravis Score Indicated That The Clinical Benefits Seen Were Modest. Meta-Analysis Of The Mean Change In Compound Muscle Action Potential Amplitude Following 3,4-Dap Treatment Revealed A Significant Improvement Compared To Placebo. However, Most Patients With Noncancer Lems Require Long-Term Immunosuppression, Usually With Prednisolone And Azathioprine. A Single Crossover Study Has Previously Shown Significant Short-Term Benefit In Limb Strength Following Intravenous Immunoglobulin, And There Are Isolated Case Reports Of Medium Term Benefit From Rituximab. Overall, A Combination Of Symptomatic Treatment With 3,4-Dap And Immunosuppression, With Or Without Antitumor Therapy, Is Often Successful For Most Lems Patients, With Other More Aggressive Regimens Rarely Needed.|[('Antitumor Therapy', 'no label'), ('Patients', 'no label'), ('Paraneoplastic Form', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Mainstay', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Data', 'no label'), ('Randomized', 'no label'), ('Placebo-Controlled Trials', 'no label'), ('Revealed', 'no label'), ('Muscle Strength Scores', 'no label'), ('Increased', 'no label'), ('Limited', 'no label'), ('Meta-Analysis', 'no label'), ('Performed', 'no label'), ('Trials', 'no label'), ('Quantitative Myasthenia Gravis', 'no label'), ('Score', 'no label'), ('Indicated', 'no label'), ('Clinical Benefits Seen', 'no label'), ('Meta-Analysis', 'no label'), ('Mean Change', 'no label'), ('Compound Muscle', 'no label'), ('Amplitude', 'no label'), ('Treatment', 'no label'), ('Revealed', 'no label'), ('Significant', 'no label'), ('Improvement', 'no label'), ('Placebo', 'no label'), ('Patients', 'no label'), ('Noncancer Lems', 'no label'), ('Require', 'no label'), ('Long-Term', 'no label'), ('Immunosuppression', 'no label'), ('Prednisolone', 'no label'), ('Azathioprine', 'no label'), ('Single Crossover Study', 'no label'), ('Significant', 'no label'), ('Short-Term', 'no label'), ('Benefit', 'no label'), ('Limb Strength', 'no label'), ('Intravenous Immunoglobulin', 'no label'), ('Isolated Case Reports', 'no label'), ('Medium Term', 'no label'), ('Benefit', 'no label'), ('Rituximab', 'no label'), ('Combination', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Immunosuppression', 'no label'), ('Antitumor Therapy', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Aggressive Regimens', 'no label'), ('Rarely Needed', 'no label')]|[('Intravenous', 'no label')]|[]|[('Paraneoplastic', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Myasthenia Gravis', 'no label'), ('Prednisolone', 'no label'), ('Azathioprine', 'no label'), ('Rituximab', 'no label')]|[('Antitumor', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Muscle', 'no label'), ('Patients', 'no label'), ('Long-Term', 'no label'), ('Prednisolone', 'no label'), ('Azathioprine', 'no label'), ('Intravenous Immunoglobulin', 'no label'), ('Isolated Case', 'no label'), ('Rituximab', 'no label'), ('Antitumor', 'no label'), ('Lems Patients', 'no label')]
lambert eaton syndrome|pubmed~25133625||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~21427136|Fatigue Is A Prominent Feature Of Systemic Lupus Erythematosus (Sle), Usually Ascribed To Various Factors, Such As Muscle Or Joint Involvement, Anaemia Or Depression. The Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare Autoantibody-Mediated Disorder Of Neuro-Muscular Transmission. We Report On A Well-Defined Lems Associated With Thymus Hyperplasia In A Sle Patient. An African 41 Years-Old Sle Patient Presented With Persisting Fatigue, Myalgia And Dyspnea, Abolished Reflexes And A Bilateral Ptosis. Neuromuscular Electrodiagnostic Study Showed A Clear-Cut Potentiation That Was Typical Of A Pre-Synaptic Neuromuscular Junction Disease. Anti-Calcium Gated Channels Antibodies Were Disclosed In Serum And A Diagnosis Of Lems Was Made. A Total Body Ct-Scan Revealed An Antero-Superior Mediastinal Mass, Compatible With Thymoma. The Tumour Was Surgically Removed With A Final Diagnosis Of Follicular Thymic Hyperplasia. In Conclusion, Our Observation Provides A New Example Of Entangled Organ-Specific And Systemic Autoimmunity In The Context Of Thymus Pathology. Potentiation Study During Electromyography Should Be Performed Systematically To Rule Out Lems In Patients With Sle And Muscle Weakness.|[('Fatigue', 'no label'), ('Systemic Lupus Erythematosus', 'no label'), ('Sle', 'no label'), ('Ascribed', 'no label'), ('Factors', 'no label'), ('Muscle Or Joint Involvement', 'no label'), ('Anaemia', 'no label'), ('Depression', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Autoantibody-Mediated Disorder', 'no label'), ('Neuro-Muscular Transmission', 'no label'), ('Report', 'no label'), ('Well-Defined Lems', 'no label'), ('Associated With', 'no label'), ('Thymus Hyperplasia', 'no label'), ('Sle', 'no label'), ('Patient', 'no label'), ('African', 'no label'), ('Years-Old', 'no label'), ('Sle', 'no label'), ('Patient', 'no label'), ('Persisting', 'no label'), ('Fatigue', 'no label'), ('Myalgia', 'no label'), ('Dyspnea', 'no label'), ('Reflexes', 'no label'), ('Bilateral Ptosis', 'no label'), ('Neuromuscular Electrodiagnostic Study', 'no label'), ('Showed A Clear-Cut Potentiation', 'no label'), ('Pre-Synaptic', 'no label'), ('Neuromuscular Junction Disease', 'no label'), ('Anti-Calcium', 'no label'), ('Channels Antibodies', 'no label'), ('Disclosed', 'no label'), ('Serum', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Total Body Ct-Scan', 'no label'), ('Revealed', 'no label'), ('Antero-Superior Mediastinal Mass', 'no label'), ('Compatible', 'no label'), ('Thymoma', 'no label'), ('Tumour Was Surgically', 'no label'), ('Final Diagnosis', 'no label'), ('Follicular Thymic Hyperplasia', 'no label'), ('Observation Provides', 'no label'), ('Entangled', 'no label'), ('Organ-Specific', 'no label'), ('Systemic Autoimmunity', 'no label'), ('Context', 'no label'), ('Thymus Pathology', 'no label'), ('Potentiation Study', 'no label'), ('Electromyography', 'no label'), ('Performed', 'no label'), ('Patients', 'no label'), ('Sle', 'no label'), ('Muscle Weakness', 'no label')]|[('Antibodies', 'no label')]|[]|[('Fatigue', 'no label'), ('Systemic Lupus Erythematosus (Sle)', 'no label'), ('Anaemia', 'no label'), ('Depression', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Disorder', 'no label'), ('Thymus Hyperplasia', 'no label'), ('Fatigue', 'no label'), ('Myalgia', 'no label'), ('Dyspnea', 'no label'), ('Ptosis.', 'no label'), ('Neuromuscular Junction Disease', 'no label'), ('Disclosed', 'no label'), ('Thymoma', 'no label'), ('Tumour', 'no label'), ('Follicular Thymic Hyperplasia', 'no label'), ('Systemic Autoimmunity', 'no label'), ('Muscle Weakness', 'no label')]|[('Muscle', 'no label'), ('Joint', 'no label'), ('Thymus Hyperplasia In', 'no label'), ('Myalgia', 'no label'), ('Neuromuscular', 'no label'), ('Serum', 'no label'), ('Lems', 'no label'), ('Total Body', 'no label'), ('Thymoma', 'no label'), ('Tumour', 'no label'), ('Follicular Thymic Hyperplasia.', 'no label'), ('Thymus Pathology', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Muscle', 'no label')]
lambert eaton syndrome|pubmed~20392977|To Assess The Treatment Effects Of Rituximab In A Population Of Patients With Myasthenia Gravis And Lambert-Eaton Myasthenic Syndrome. Data On All Treated Patients In The Uk Were Collected From Referring Physicians, With Full Case Ascertainment And Follow-Up. Since 2004, 10 Patients With Generalised Myasthenia Gravis (Three Of Whom Were Positive For Muscle-Specific Tyrosine Kinase (Musk) Antibodies) And Two Patients With Lambert-Eaton Myasthenic Syndrome (Lems) Were Treated With Rituximab. Using The Myasthenia Gravis Foundation America Postintervention Status, Three Patients (25%) Achieved Remission, And A Further Five (42%) Improved Clinically Over An 18-Month Period. Only One Patient Developed Worsening Symptoms. The Probability Of Achieving Remission Was Unrelated To The Duration Of Neurological Symptoms Prior To Treatment. All Lems And Musk Antibody Patients Improved Following Rituximab Treatment. In A Relatively Large, Unselected Group Of Patients With Myasthenia Gravis And Lems, Rituximab Treatment Resulted In A Significant Clinical Improvement In Two-Thirds Of Cases. As A Selective, B Cell Targeted Therapy, Rituximab Should Be Considered As A Treatment Option For Patients With Either Myasthenia Gravis Or Lems For Whom Standard Immunosuppressive Treatments Have Been Unsuccessful.|[('Assess', 'no label'), ('Treatment', 'no label'), ('Rituximab', 'no label'), ('Population', 'no label'), ('Patients', 'no label'), ('Myasthenia Gravis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Data', 'no label'), ('Treated', 'no label'), ('Patients', 'no label'), ('Uk Were', 'no label'), ('Collected', 'no label'), ('Physicians', 'no label'), ('Case Ascertainment', 'no label'), ('Follow-Up', 'no label'), ('Patients', 'no label'), ('Generalised Myasthenia Gravis', 'no label'), ('Positive', 'no label'), ('Muscle-Specific Tyrosine Kinase', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Treated With', 'no label'), ('Rituximab', 'no label'), ('Myasthenia Gravis', 'no label'), ('Foundation America', 'no label'), ('Postintervention Status', 'no label'), ('Patients', 'no label'), ('Remission', 'no label'), ('Clinically', 'no label'), ('Period', 'no label'), ('Patient', 'no label'), ('Worsening', 'no label'), ('Symptoms', 'no label'), ('Probability', 'no label'), ('Remission', 'no label'), ('Duration', 'no label'), ('Neurological Symptoms', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label'), ('Musk Antibody', 'no label'), ('Patients', 'no label'), ('Rituximab', 'no label'), ('Treatment', 'no label'), ('Large', 'no label'), ('Unselected Group', 'no label'), ('Patients', 'no label'), ('Myasthenia Gravis', 'no label'), ('Lems', 'no label'), ('Rituximab', 'no label'), ('Treatment', 'no label'), ('Resulted', 'no label'), ('Significant', 'no label'), ('Clinical Improvement', 'no label'), ('Two-Thirds', 'no label'), ('Cases', 'no label'), ('B Cell Targeted Therapy', 'no label'), ('Rituximab', 'no label'), ('Treatment Option', 'no label'), ('Patients', 'no label'), ('Myasthenia Gravis', 'no label'), ('Standard', 'no label'), ('Immunosuppressive Treatments', 'no label')]|[('Rituximab', 'no label'), ('Tyrosine', 'no label'), ('Musk', 'no label'), ('Antibodies', 'no label'), ('Rituximab', 'no label'), ('Rituximab', 'no label'), ('Cell', 'no label'), ('Rituximab', 'no label')]|[('Muscle-Specific Tyrosine Kinase', 'no label')]|[('Rituximab', 'no label'), ('Myasthenia Gravis', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenia Gravis', 'no label'), ('Tyrosine', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Rituximab', 'no label'), ('Myasthenia Gravis', 'no label'), ('Rituximab', 'no label'), ('Myasthenia Gravis', 'no label'), ('Rituximab', 'no label'), ('Rituximab', 'no label'), ('Myasthenia Gravis', 'no label')]|[('Rituximab', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Muscle-Specific Tyrosine Kinase', 'no label'), ('Musk', 'no label'), ('Patients', 'no label'), ('Rituximab', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Musk Antibody', 'no label'), ('Patients', 'no label'), ('Rituximab', 'no label'), ('Patients', 'no label'), ('Rituximab', 'no label'), ('B Cell', 'no label'), ('Rituximab', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~18585938|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare Autoimmune Disorder Of The Neuromuscular Junction. Lems Can Be Associated With A Variety Of Neoplasms. Patients Present With Proximal Muscle Weakness And Fatigability, Often Combined With Areflexia. Only 5% Of Reported Cases Are Children. We Report A Case Of 11-Year Old Boy With Non-Neoplastic Lambert-Eaton Myasthenic Syndrome. Repetitive Nerve Stimulation Test Showed 83% Increment After Maximal Voluntary Contraction, Presence Of Antibodies Against Voltage-Gated Calcium Channels Confirmed The Diagnosis. The Boy Responded Well To Immunosuppressive Treatment With Prednisone And Azathioprine And Remains Cancer-Free For 4 Years.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Autoimmune Disorder', 'no label'), ('Neuromuscular Junction', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Neoplasms', 'no label'), ('Patients', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Fatigability', 'no label'), ('Areflexia', 'no label'), ('Cases', 'no label'), ('Children', 'no label'), ('Report', 'no label'), ('Non-Neoplastic Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Repetitive Nerve Stimulation Test', 'no label'), ('Increment', 'no label'), ('Maximal', 'no label'), ('Voluntary Contraction', 'no label'), ('Antibodies', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Confirmed', 'no label'), ('Diagnosis', 'no label'), ('Boy Responded', 'no label'), ('Immunosuppressive Treatment', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label'), ('Remains', 'no label'), ('Years', 'no label')]|[('Antibodies', 'no label'), ('Calcium', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Neoplasms', 'no label'), ('Muscle Weakness', 'no label'), ('Areflexia', 'no label'), ('Non-Neoplastic Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Calcium', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label')]|[('Neuromuscular', 'no label'), ('Neoplasms', 'no label'), ('Patients', 'no label'), ('Muscle', 'no label'), ('Children', 'no label'), ('Non-Neoplastic Lambert-Eaton', 'no label'), ('Nerve', 'no label'), ('Calcium', 'no label'), ('Prednisone', 'no label'), ('Azathioprine', 'no label')]
lambert eaton syndrome|pubmed~20377318|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare Pre-Synaptic Auto-Immune Disorder Of Neuromuscular Transmission That Is Characterised By Proximal Muscle Weakness, Depressed Tendon Reflexes And Autonomic Dysfunction. This Review Summarises The Clinical Symptoms, Aetiology, Diagnosis And Treatment Options For Lems. Focus Is Placed On Symptomatic Treatment With The Potassium Channel Blocker 3,4-Diaminopyridine (3,4-Dap). English-Language Publications Were Searched In Medline And Embase To Retrieve Relevant Literature On Lems. The Data Submitted To Obtain Regulatory Approval Of 3,4-Dap Phosphate By The European Medicines Agency (Ema) Were Also Used. Lems Is A Rare Disease With Few Treatment Options Which Are Generally Categorised As Anti-Tumour, Immunomodulating Or Immunosuppressing, And Symptomatic Treatments. Anti-Tumour Treatment Is Recommended For Patients With The Paraneoplastic Form Of Lems. While Several Immunomodulating Or Immunosuppressing Treatments Have Been Identified, These Treatments Should Be Initiated When Symptomatic Treatments Are Inadequate. As Expected, Due To The Rarity Of The Disease, Few Reports Of Randomised Controlled Trials (Rcts) Exist. Seven Rcts Have Been Conducted To Evaluate Treatment Of Patients With Lems. One Rct Evaluated Immunomodulating Treatment With Intravenous Immunoglobulin (Ivig), While Six Evaluated Symptomatic Treatment With The Potassium Channel Blocker 3,4-Dap. Improvements In Lems Symptoms After Ivig Treatment Were Observed, Leading To The Recommendation For Treatment In Patients When Symptomatic Treatment Does Not Provide Satisfactory Improvement. Potassium Channel Blockers Evaluated For The Treatment Of Lems Include Guanidine, 4-Aminopyridine (4-Ap) And 3,4-Dap. However, Only 3,4-Dap Has Been Evaluated In Rcts. Results Of These Rcts Demonstrated That Treatment With 3,4-Dap Is Efficacious In Treatment Of Lems And Has An Acceptable Tolerability Profile. Hence, 3,4-Dap Has Been Recommended As First-Line Symptomatic Treatment For Lems By The European Federation Of Neurological Societies. While 3,4-Dap Base Has Only Been Available Via Named-Patient Programmes, Requiring Ad Hoc Preparations In Compounding Pharmacies, Tablets Containing 3,4-Dap Phosphate Salt, Equivalent To 10 Mg Base, Have Become Available. This Formulation Has Obtained The Orphan Medicinal Product Status Both In The European Union And In The United States Of America, And Has Received Marketing Authorisation In Europe As Firdapse*. These Tablets Have Been Shown To Be Essentially Bioequivalent With The Base Preparation. The Results Of This Review Show That Anti-Tumour Treatment Is Recommended For Patients With The Paraneoplastic Form Of Lems And That One Rct Has Shown That Immunomodulating Treatments Should Be Initiated When Symptomatic Treatments Do Not Provide Satisfactory Results. A Number Of Rcts Have Shown That 3,4-Dap Is Effective In Symptomatic Treatment Of Patients With Lems And Has Been Recommended As First-Line Symptomatic Treatment Of Patients With Lems. The 3,4-Dap Phosphate Salt Formulation Was Shown To Be Safe And Effective In The Treatment Of Lems With A Positive Benefit:Risk Ratio.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Pre-Synaptic Auto-Immune Disorder', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Characterised', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Depressed Tendon Reflexes', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Review', 'no label'), ('Summarises', 'no label'), ('Clinical Symptoms', 'no label'), ('Aetiology', 'no label'), ('Diagnosis', 'no label'), ('Treatment Options', 'no label'), ('Lems', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Potassium Channel Blocker 3,4-Diaminopyridine', 'no label'), ('English-Language Publications', 'no label'), ('Searched', 'no label'), ('Medline', 'no label'), ('Relevant', 'no label'), ('Literature', 'no label'), ('Data Submitted', 'no label'), ('Regulatory Approval', 'no label'), ('Phosphate', 'no label'), ('European Medicines Agency', 'no label'), ('Lems', 'no label'), ('Treatment Options', 'no label'), ('Anti-Tumour', 'no label'), ('Immunomodulating', 'no label'), ('Immunosuppressing', 'no label'), ('Symptomatic', 'no label'), ('Treatments', 'no label'), ('Anti-Tumour Treatment', 'no label'), ('Patients', 'no label'), ('Paraneoplastic Form', 'no label'), ('Lems', 'no label'), ('Immunomodulating', 'no label'), ('Immunosuppressing', 'no label'), ('Treatments', 'no label'), ('Identified', 'no label'), ('Treatments', 'no label'), ('Initiated', 'no label'), ('Symptomatic', 'no label'), ('Treatments', 'no label'), ('Inadequate', 'no label'), ('Rarity', 'no label'), ('Disease', 'no label'), ('Reports', 'no label'), ('Randomised Controlled Trials', 'no label'), ('Rcts', 'no label'), ('Exist', 'no label'), ('Rcts', 'no label'), ('Evaluate Treatment', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Rct Evaluated', 'no label'), ('Immunomodulating Treatment', 'no label'), ('Intravenous Immunoglobulin', 'no label'), ('Ivig', 'no label'), ('Symptomatic', 'no label'), ('Potassium Channel Blocker', 'no label'), ('Improvements', 'no label'), ('Lems Symptoms', 'no label'), ('Ivig Treatment', 'no label'), ('Observed', 'no label'), ('Recommendation', 'no label'), ('Treatment', 'no label'), ('Patients', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Satisfactory', 'no label'), ('Improvement', 'no label'), ('Potassium Channel Blockers', 'no label'), ('Evaluated', 'no label'), ('Treatment', 'no label'), ('Lems Include', 'no label'), ('Guanidine', 'no label'), ('4-Aminopyridine', 'no label'), ('Evaluated', 'no label'), ('Rcts', 'no label'), ('Rcts', 'no label'), ('Demonstrated', 'no label'), ('Treatment', 'no label'), ('Efficacious', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label'), ('Acceptable', 'no label'), ('Tolerability Profile', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('European', 'no label'), ('Federation', 'no label'), ('Neurological Societies', 'no label'), ('Base', 'no label'), ('Named-Patient Programmes', 'no label'), ('Ad Hoc Preparations', 'no label'), ('Pharmacies', 'no label'), ('Tablets', 'no label'), ('Containing', 'no label'), ('Phosphate Salt', 'no label'), ('Formulation', 'no label'), ('Orphan Medicinal Product Status', 'no label'), ('European Union', 'no label'), ('United States', 'no label'), ('America', 'no label'), ('Received', 'no label'), ('Marketing Authorisation', 'no label'), ('Europe', 'no label'), ('Firdapse*.', 'no label'), ('Tablets', 'no label'), ('Bioequivalent', 'no label'), ('Base Preparation', 'no label'), ('Review', 'no label'), ('Anti-Tumour Treatment', 'no label'), ('Patients', 'no label'), ('Paraneoplastic Form', 'no label'), ('Rct', 'no label'), ('Immunomodulating Treatments', 'no label'), ('Initiated', 'no label'), ('Symptomatic', 'no label'), ('Treatments', 'no label'), ('Satisfactory Results', 'no label'), ('Rcts', 'no label'), ('Effective', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Phosphate Salt Formulation', 'no label'), ('Safe', 'no label'), ('Effective', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label'), ('Positive', 'no label'), ('Risk Ratio', 'no label')]|[('Potassium', 'no label'), ('Phosphate', 'no label'), ('Potassium', 'no label'), ('Potassium', 'no label'), ('Blockers', 'no label'), ('Guanidine', 'no label'), ('4-Aminopyridine', 'no label'), ('Phosphate Salt', 'no label'), ('Phosphate Salt', 'no label')]|[('Rct', 'no label'), ('Rct', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Auto-Immune Disorder', 'no label'), ('Muscle Weakness', 'no label'), ('Depressed', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Potassium', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Phosphate', 'no label'), ('Paraneoplastic', 'no label'), ('Potassium', 'no label'), ('Potassium', 'no label'), ('Guanidine', 'no label'), ('4-Aminopyridine', 'no label'), ('Phosphate', 'no label'), ('Mg', 'no label'), ('Bioequivalent', 'no label'), ('Paraneoplastic', 'no label'), ('Phosphate', 'no label')]|[('Neuromuscular', 'no label'), ('Muscle', 'no label'), ('Tendon Reflexes', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Patients', 'no label'), ('Rcts', 'no label'), ('Patients', 'no label'), ('Immunoglobulin', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Guanidine', 'no label'), ('4-Aminopyridine (4-Ap)', 'no label'), ('Rcts', 'no label'), ('Lems', 'no label'), ('Lems', 'no label'), ('Ad', 'no label'), ('Preparations', 'no label'), ('Tablets', 'no label'), ('Salt', 'no label'), ('Tablets', 'no label'), ('Base', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Rcts', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~20504215|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare Immune-Mediated Disorder Of Neuromuscular Junctions. The Knowledge Of The Effects Of Pregnancy On The Course Of Patients With Lems Is Limited. Here We Describe A Patient Without A History Of Previous Known Illness Who Has Complained Of Weakness During The Last Trimester Of Her Pregnancy, Delivered A Healthy Baby And Was Diagnosed With Non-Paraneoplastic Lems During The Postpartum Period. With This Case We Wanted To Emphasize The Effects Of Pregnancy On The Course Of Patients With Lems.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Immune-Mediated Disorder', 'no label'), ('Neuromuscular Junctions', 'no label'), ('Knowledge', 'no label'), ('Effects', 'no label'), ('Pregnancy', 'no label'), ('Course', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patient', 'no label'), ('History', 'no label'), ('Known Illness', 'no label'), ('Complained', 'no label'), ('Weakness', 'no label'), ('Last Trimester', 'no label'), ('Pregnancy', 'no label'), ('Delivered A Healthy Baby', 'no label'), ('Diagnosed', 'no label'), ('Non-Paraneoplastic Lems', 'no label'), ('Postpartum Period', 'no label'), ('Case', 'no label'), ('Emphasize', 'no label'), ('Effects', 'no label'), ('Pregnancy', 'no label'), ('Course', 'no label'), ('Patients', 'no label'), ('Lems', 'no label')]|[]|[]|[('Myasthenic Syndrome', 'no label'), ('Disorder Of Neuromuscular Junctions', 'no label')]|[('Neuromuscular', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Postpartum', 'no label'), ('Patients', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~22421253||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~22605710|The Authors Describe A Case Of 60-Year-Old Male Patient Presented With A 6 Month History Of Progressive Weakness Of All The Four Limbs, Ataxia, Droopy Eyelids And Bulbar Features. Further Laboratory And Electrodiagnostic Studies Confirmed The Diagnosis Of Lambert-Eaton Myasthenic Syndrome (Lems). Mri Of The Brain Showed A Cerebellar Tumour Which, Following Surgery Was Revealed To Be A Metastatic Small-Cell Lung Carcinoma. Paraneoplastic Lems Together With Solitary Cerebellar Metastasis Was Diagnosed But No Evidence Of Primary Malignancy Was Detected. An Extensive Search For Related Malignancies Failed To Get Any Clue. The Patient Underwent A Total Surgical Excision Of Tumour And The Histopathology Revealed A Metastatic Small Cell Carcinoma. This Case Highlights That Rarely Both Paraneoplastic Lems And Cerebellar Mass Can Precede The Primary Malignancy Causing Them.|[('60-Year-Old', 'no label'), ('Male', 'no label'), ('Patient', 'no label'), ('Month History', 'no label'), ('Progressive Weakness', 'no label'), ('Limbs', 'no label'), ('Ataxia', 'no label'), ('Droopy Eyelids', 'no label'), ('Bulbar Features', 'no label'), ('Laboratory', 'no label'), ('Electrodiagnostic Studies', 'no label'), ('Confirmed', 'no label'), ('Diagnosis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Mri', 'no label'), ('Brain', 'no label'), ('Cerebellar Tumour', 'no label'), ('Surgery', 'no label'), ('Metastatic Small-Cell', 'no label'), ('Lung Carcinoma', 'no label'), ('Paraneoplastic Lems', 'no label'), ('Solitary Cerebellar Metastasis', 'no label'), ('Diagnosed', 'no label'), ('Primary Malignancy', 'no label'), ('Detected', 'no label'), ('Extensive', 'no label'), ('Search', 'no label'), ('Related Malignancies', 'no label'), ('Failed', 'no label'), ('Clue', 'no label'), ('Patient', 'no label'), ('Total Surgical Excision', 'no label'), ('Tumour', 'no label'), ('Histopathology', 'no label'), ('Revealed', 'no label'), ('Metastatic Small Cell Carcinoma', 'no label'), ('Case Highlights', 'no label'), ('Paraneoplastic Lems', 'no label'), ('Cerebellar Mass', 'no label'), ('Primary Malignancy', 'no label'), ('Causing', 'no label')]|[('Cell', 'no label')]|[('Get', 'no label')]|[('Ataxia', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Cerebellar Tumour', 'no label'), ('Lung Carcinoma', 'no label'), ('Paraneoplastic', 'no label'), ('Solitary Cerebellar Metastasis', 'no label'), ('Primary Malignancy', 'no label'), ('Tumour', 'no label'), ('Carcinoma', 'no label'), ('Paraneoplastic Lems And Cerebellar Mass', 'no label')]|[('Patient', 'no label'), ('A 6', 'no label'), ('Brain', 'no label'), ('Cerebellar Tumour', 'no label'), ('Be A', 'no label'), ('Metastatic Small-Cell Lung Carcinoma', 'no label'), ('Solitary Cerebellar Metastasis', 'no label'), ('Primary Malignancy', 'no label'), ('Malignancies Failed', 'no label'), ('Patient', 'no label'), ('Tumour', 'no label'), ('Small Cell Carcinoma', 'no label'), ('Cerebellar Mass Can', 'no label'), ('Primary Malignancy', 'no label')]
lambert eaton syndrome|pubmed~22423246|We Present The First Case Of Small Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome During Hemodialysis (Hd). A 72-Year-Old Male Patient Receiving Hd Experienced Progressive Muscle Weakness. He Was Diagnosed With Small Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome Due To An Increased Serum Level Of Anti-Voltage-Gated Calcium Channel Antibody And Aspiration Cytology On Endobronchial Ultrasonography For The Swelling Of A Subcarinal Lymph Node. He Received Chemotherapy Consisting Of Carboplatin (300 Mg/M(2)) And Etoposide (50 Mg/M(2)), To Which He Had A Partial Response. However, The Second Therapy Course Could Not Be Administered Because Of The Unexpected Development Of Severe Hematological Adverse Events, Which Also Prevented Him From Undergoing Further Hd. This Case Indicates That Caution Should Be Taken When Using Chemotherapy For Such Patients Because Of Hypotension Due To Chemotherapy, With Which It Is Impossible To Undergo Hd.|[('First Case', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Hemodialysis', 'no label'), ('Hd', 'no label'), ('Male', 'no label'), ('Patient Receiving', 'no label'), ('Hd Experienced', 'no label'), ('Progressive Muscle Weakness', 'no label'), ('Diagnosed', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Increased', 'no label'), ('Serum', 'no label'), ('Level', 'no label'), ('Anti-Voltage-Gated', 'no label'), ('Calcium Channel Antibody', 'no label'), ('Aspiration Cytology', 'no label'), ('Endobronchial Ultrasonography', 'no label'), ('Swelling', 'no label'), ('Subcarinal Lymph Node', 'no label'), ('Chemotherapy', 'no label'), ('Consisting', 'no label'), ('Carboplatin', 'no label'), ('Etoposide', 'no label'), ('Mg/M(2', 'no label'), ('Partial', 'no label'), ('Response', 'no label'), ('Second Therapy Course', 'no label'), ('Administered', 'no label'), ('Development', 'no label'), ('Severe', 'no label'), ('Hematological Adverse Events', 'no label'), ('Prevented', 'no label'), ('Hd', 'no label'), ('Case Indicates', 'no label'), ('Caution', 'no label'), ('Chemotherapy', 'no label'), ('Patients', 'no label'), ('Hypotension', 'no label'), ('Chemotherapy', 'no label'), ('Hd', 'no label')]|[('Cell', 'no label'), ('Cell', 'no label'), ('Calcium', 'no label'), ('Antibody', 'no label'), ('Carboplatin', 'no label')]|[]|[('Small Cell Lung Cancer', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Muscle Weakness', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Calcium', 'no label'), ('Carboplatin', 'no label'), ('Etoposide', 'no label'), ('Hypotension', 'no label')]|[('Small Cell Lung Cancer', 'no label'), ('Muscle', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Serum', 'no label'), ('Calcium', 'no label'), ('Aspiration Cytology', 'no label'), ('Endobronchial', 'no label'), ('Carboplatin', 'no label'), ('Etoposide', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~19833394|In About 40% Of Patients Lems Is Not A Paraneoplastic Phenomenon (Nt-Lems). Several Clinical Aspects Important To These Patients Remain Open, Especially The Question When A Lems Can Definitely Be Diagnosed As Nt-Lems. Here We Describe A Series Of 25 German Nt-Lems Patients Regarding Their Clinical Characteristics, Duration Of Symptoms, Value Of Serological Markers, Paraneoplastic Antibodies And Fdg-Pet/Ct. Furthermore, We Discuss The Current Diagnostic Criteria Of Nt-Lems.|[('Patients Lems', 'no label'), ('Paraneoplastic Phenomenon', 'no label'), ('Clinical Aspects', 'no label'), ('Patients', 'no label'), ('Remain', 'no label'), ('Open', 'no label'), ('Question', 'no label'), ('Lems', 'no label'), ('Diagnosed', 'no label'), ('German', 'no label'), ('Patients', 'no label'), ('Clinical Characteristics', 'no label'), ('Duration', 'no label'), ('Symptoms', 'no label'), ('Value', 'no label'), ('Serological Markers', 'no label'), ('Paraneoplastic Antibodies', 'no label'), ('Fdg-Pet/Ct', 'no label'), ('Current', 'no label'), ('Diagnostic Criteria', 'no label')]|[('Antibodies', 'no label')]|[('Paraneoplastic Antibodies', 'no label')]|[]|[('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~20979551|The Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disease In Which Antibodies Against Voltage-Gated Calcium Channels Inhibit Cholinergic Neurotransmission. Lems Is Clinically Characterized By Muscle Weakness And Autonomic Dysfunction. 3,4-Diaminopyridine (3,4-Dap) Blocks Potassium Channels In Nerve Terminals, Resulting In An Increase In Acetylcholine Release. This Article Describes The Four Randomized Placebo-Controlled Trials Of 3,4-Dap In Patients With Lems. All Trials Demonstrated A Significant Effect On Muscle Strength And Compound Muscle Action Potential Amplitude. Furthermore, The Safety And Tolerability Of 3,4-Dap Are Reviewed. The Side Effects Of 3,4-Dap Are Generally Mild And Most Frequently Consist Of Paresthesias, But Epileptic Seizures And Arrhythmias Have Been Described In Patients Using High Doses. Given The Efficacy And Safety Of 3,4-Dap In Lems, This Drug Is The Mainstay For Symptomatic Treatment Of Lems.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disease', 'no label'), ('Antibodies', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Inhibit', 'no label'), ('Cholinergic', 'no label'), ('Neurotransmission', 'no label'), ('Lems', 'no label'), ('Clinically Characterized', 'no label'), ('Muscle Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Blocks', 'no label'), ('Potassium Channels', 'no label'), ('Nerve', 'no label'), ('Terminals', 'no label'), ('Increase', 'no label'), ('Acetylcholine', 'no label'), ('Article Describes', 'no label'), ('Randomized Placebo-Controlled Trials', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Trials', 'no label'), ('Demonstrated A', 'no label'), ('Significant', 'no label'), ('Effect', 'no label'), ('Muscle Strength', 'no label'), ('Compound Muscle', 'no label'), ('Potential', 'no label'), ('Amplitude', 'no label'), ('Safety', 'no label'), ('Tolerability', 'no label'), ('Reviewed', 'no label'), ('Side Effects', 'no label'), ('Mild', 'no label'), ('Consist', 'no label'), ('Paresthesias', 'no label'), ('Epileptic Seizures', 'no label'), ('Arrhythmias', 'no label'), ('Patients', 'no label'), ('High Doses', 'no label'), ('Efficacy', 'no label'), ('Safety', 'no label'), ('Drug', 'no label'), ('Mainstay', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label')]|[('Antibodies', 'no label'), ('Calcium', 'no label'), ('Potassium', 'no label'), ('Acetylcholine', 'no label'), ('Drug', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('Calcium', 'no label'), ('Muscle Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Potassium', 'no label'), ('Acetylcholine', 'no label'), ('Paresthesias', 'no label'), ('Epileptic Seizures', 'no label'), ('Arrhythmias', 'no label')]|[('Calcium', 'no label'), ('Cholinergic', 'no label'), ('Muscle', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Nerve Terminals', 'no label'), ('Acetylcholine', 'no label'), ('Patients', 'no label'), ('Muscle', 'no label'), ('Paresthesias', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~19934775|The Lambert Eaton Myasthenic Syndrome (Lems) Is A Paraneoplastic Disorder Associated With Raised Serum Voltage-Gated Calcium Channel (Vgcc) Antibodies In Patients With Small Cell Lung Cancer (Sclc). Vgcc Can Also Be Found In Patients With Sclc And Cerebellar Ataxia. This Was A Prospective Study To Assess The Incidence Of Clinical And Subclinical Lems Or Other Neurologic Disease In Patients With Sclc. Sixty-Three Unselected Patients With Cytologically Or Histologically Confirmed Sclc Consented To Participate. Pretreatment Assessment Included A Neurologic Symptom Questionnaire, Examination For Physical Signs Of Lems Or Ataxia, Measurement Of Serum Titers Of Antibodies To P/Q-Type Vgccs By Radioimmunoassay In All Patients And Electrophysiological Examination Where Appropriate. Neurologic Symptoms Unrelated To Lems Occurred In 26% Of Patients. Five Patients (8%) Had Raised Serum Vgcc Antibodies (Range, 69-1553 Pm/L) Diagnostic Of Lems, Two (3%) Of Whom Had Lems On Clinical And Electrophysiological Grounds. Both Also Had Mild Cerebellar Ataxia. There Was No Association Between Serum Vgcc Antibody Titer And Survival. Routine Measurement Of Vgcc Antibodies In Patients Without Clinical Lems Is Unlikely To Assist Either In Management Of Sclc Or In Assessment Of Prognosis.|[('Lambert Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Paraneoplastic Disorder', 'no label'), ('Associated With', 'no label'), ('Raised Serum Voltage-Gated Calcium Channel', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Vgcc', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Was A', 'no label'), ('Prospective Study', 'no label'), ('Incidence', 'no label'), ('Clinical And Subclinical Lems', 'no label'), ('Neurologic Disease', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Cytologically', 'no label'), ('Histologically', 'no label'), ('Sclc', 'no label'), ('Consented', 'no label'), ('Participate', 'no label'), ('Pretreatment Assessment', 'no label'), ('Neurologic Symptom Questionnaire', 'no label'), ('Examination', 'no label'), ('Physical Signs', 'no label'), ('Lems Or Ataxia', 'no label'), ('Measurement', 'no label'), ('Serum Titers', 'no label'), ('Antibodies', 'no label'), ('P/Q-Type Vgccs', 'no label'), ('Radioimmunoassay', 'no label'), ('Patients', 'no label'), ('Electrophysiological Examination', 'no label'), ('Appropriate', 'no label'), ('Neurologic Symptoms', 'no label'), ('Unrelated To Lems', 'no label'), ('Occurred', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Raised Serum Vgcc Antibodies', 'no label'), ('Range', 'no label'), ('Pm/L', 'no label'), ('Lems', 'no label'), ('Clinical', 'no label'), ('Electrophysiological Grounds', 'no label'), ('Mild', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Serum Vgcc', 'no label'), ('Antibody Titer', 'no label'), ('Survival', 'no label'), ('Routine', 'no label'), ('Measurement', 'no label'), ('Vgcc Antibodies', 'no label'), ('Patients', 'no label'), ('Clinical Lems', 'no label'), ('Assist', 'no label'), ('Management', 'no label'), ('Sclc', 'no label'), ('Assessment', 'no label'), ('Prognosis', 'no label')]|[('Calcium', 'no label'), ('Antibodies', 'no label'), ('Cell', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Antibody', 'no label'), ('Antibodies', 'no label')]|[('Serum Vgcc Antibodies', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Disorder', 'no label'), ('Calcium', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Neurologic Disease', 'no label'), ('Ataxia', 'no label'), ('P/Q-Type', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Prognosis', 'no label')]|[('Serum', 'no label'), ('Calcium', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Patients', 'no label'), ('Cerebellar', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Serum', 'no label'), ('P/Q-Type Vgccs', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Serum Vgcc Antibodies', 'no label'), ('Lems', 'no label'), ('Serum Vgcc Antibody', 'no label'), ('Vgcc Antibodies', 'no label'), ('Patients', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~20609193|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Neuromuscular Transmission Disease Caused By Autoantibodies Directed Against Voltage-Gated Calcium Channels (Vgcc). We Report On A Patient With Lems And A Cerebellar Syndrome Associated With Lymphatic Proliferation In The Thymus. As Thymectomy And Immunosuppressive Therapy Failed To Efficiently Reduce Clinical Symptoms And Vgcc Antibody Titer, We Performed Immunoadsorption Using A Tryptophan-Ligand Column For The First Time. Repeated Treatments Resulted In A Considerable Decrease In Antibody Levels And A Marked Subjective And Objective Amelioration Of Lems As Well As Of The Cerebellar Symptoms.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Neuromuscular Transmission Disease', 'no label'), ('Autoantibodies', 'no label'), ('Directed Against', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Vgcc', 'no label'), ('Report', 'no label'), ('Patient', 'no label'), ('Lems', 'no label'), ('Cerebellar Syndrome', 'no label'), ('Associated With', 'no label'), ('Lymphatic Proliferation', 'no label'), ('Thymus', 'no label'), ('Thymectomy', 'no label'), ('Immunosuppressive Therapy', 'no label'), ('Failed', 'no label'), ('Reduce', 'no label'), ('Clinical Symptoms', 'no label'), ('Vgcc', 'no label'), ('Antibody Titer', 'no label'), ('Performed', 'no label'), ('Immunoadsorption', 'no label'), ('Tryptophan-Ligand Column', 'no label'), ('First Time', 'no label'), ('Treatments', 'no label'), ('Resulted', 'no label'), ('Decrease', 'no label'), ('Antibody', 'no label'), ('Levels', 'no label'), ('Marked Subjective', 'no label'), ('Amelioration', 'no label'), ('Lems', 'no label'), ('Cerebellar Symptoms', 'no label')]|[('Calcium', 'no label'), ('Antibody', 'no label'), ('Antibody', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Neuromuscular Transmission Disease', 'no label'), ('Calcium', 'no label'), ('Cerebellar Syndrome', 'no label')]|[('Calcium', 'no label'), ('Lems And', 'no label'), ('A Cerebellar', 'no label'), ('Lymphatic', 'no label'), ('Thymus', 'no label'), ('Vgcc Antibody', 'no label'), ('Lems', 'no label'), ('Cerebellar', 'no label')]
lambert eaton syndrome|pubmed~24371773|Large Granular Lymphocytic (Lgl) Leukemia Is An Uncommon Clonal Lymphoproliferative Disorder. Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare Neuromuscular Autoimmune Disease Caused By Pathogenic Autoantibodies Targeting The Voltage-Gated Calcium Channels (Vgcc) On The Presynaptic Nerve Terminal. We Here Describe The Case Of A 77-Year Old Patient With Lgl Leukemia, Associated With A Seropositive And Symptomatic Lems And A Seronegative Rheumatoid Arthritis. Lgl Leukemia Treatment Clearly Improved Lems Symptoms, And Led To Anti-Vgcc Antibodies Value Decrease. To Our Knowledge, This Is The First Ever Described Association Between Lgl Leukemia And Lems. |[('Granular Lymphocytic', 'no label'), ('Lgl', 'no label'), ('Leukemia', 'no label'), ('Clonal Lymphoproliferative Disorder', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Neuromuscular Autoimmune Disease', 'no label'), ('Pathogenic Autoantibodies', 'no label'), ('Targeting', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Vgcc', 'no label'), ('Presynaptic Nerve', 'no label'), ('Terminal', 'no label'), ('Old Patient', 'no label'), ('Lgl Leukemia', 'no label'), ('Associated With', 'no label'), ('Seropositive', 'no label'), ('Symptomatic Lems', 'no label'), ('Seronegative Rheumatoid Arthritis', 'no label'), ('Lgl Leukemia', 'no label'), ('Treatment', 'no label'), ('Lems Symptoms', 'no label'), ('Value', 'no label'), ('Decrease', 'no label'), ('Knowledge', 'no label'), ('Described', 'no label'), ('Association', 'no label'), ('Lgl Leukemia', 'no label'), ('Lems', 'no label')]|[('Granular Lymphocytic (Lgl)', 'no label'), ('Pathogenic Autoantibodies', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label')]|[]|[('Leukemia', 'no label'), ('Uncommon Clonal Lymphoproliferative Disorder', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Neuromuscular Autoimmune Disease', 'no label'), ('Calcium', 'no label'), ('Leukemia', 'no label'), ('Rheumatoid Arthritis', 'no label'), ('Leukemia', 'no label'), ('Leukemia', 'no label')]|[('Calcium', 'no label'), ('Presynaptic Nerve', 'no label'), ('Patient', 'no label'), ('Lgl', 'no label'), ('Lems', 'no label'), ('Lems', 'no label'), ('Anti-Vgcc', 'no label'), ('Lgl', 'no label')]
lambert eaton syndrome|pubmed~20836646|Disorders In Which The Effects Of Cancer Occur At A Site Remote From The Primary Tumor Are Termed Paraneoplastic Disorders. The Most Well- Known Paraneoplastic Disorder Affecting The Neuromuscular Junction Is The Lambert-Eaton Myasthenic Syndrome (Lems). We Describe A Case Of The Lambert-Eaton Myasthenic Syndrome Diagnosed In A Patient With Small Cell Lung Cancer Presenting With Profound Weakness. The Discussion That Follows The Case Describes The Pathophysiology Of The Disorder, Clinical Characteristics And Therapies That Have Been Used. The Role Of The Palliative Care Team In The Case Is Described.|[('Effects Of', 'no label'), ('Cancer Occur', 'no label'), ('Site', 'no label'), ('Remote', 'no label'), ('Primary Tumor', 'no label'), ('Paraneoplastic Disorders', 'no label'), ('Paraneoplastic Disorder', 'no label'), ('Affecting', 'no label'), ('Neuromuscular Junction', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Diagnosed', 'no label'), ('Patient', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Presenting With', 'no label'), ('Profound Weakness', 'no label'), ('Case Describes', 'no label'), ('Pathophysiology', 'no label'), ('Disorder', 'no label'), ('Clinical Characteristics', 'no label'), ('Therapies', 'no label'), ('Palliative Care', 'no label'), ('Case', 'no label')]|[('Site', 'no label'), ('Cell', 'no label')]|[]|[('Cancer', 'no label'), ('Tumor', 'no label'), ('Paraneoplastic Disorders', 'no label'), ('Paraneoplastic Disorder', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Disorder', 'no label')]|[('Cancer', 'no label'), ('Primary Tumor', 'no label'), ('Well-', 'no label'), ('Neuromuscular', 'no label'), ('A Case', 'no label'), ('Patient', 'no label'), ('Small Cell Lung Cancer', 'no label')]
lambert eaton syndrome|pubmed~19635290|Lambert-Eaton Myasthenic Syndrome Is A Paraneoplastic Syndrome That May Reveal A Primitive Tumor. Neuroblastoma In Children And Small Cell Lung Carcinoma In Adults Are The Leading Tumors Revealed Or Expressed By Paraneoplastic Phenomena. The Clinical Neurologic Manifestations Of Lambert-Eaton Myasthenic Syndrome Are Muscular Weakness, Sleepiness, Absence Of Reflexes, And Dysautonomia. Neurologic Manifestations Are Explained By The Induction Of An Autoimmune Response Because Of The Presence Of Antigens That Are Expressed By The Tumor. Neurologic Paraneoplastic Disorders May Also Be The Result Of Toxicity Of Drugs, Coagulopathy, Infection, Or Metabolic Diseases. We Describe The Case Of A 13-Month-Old Child With Unusual Neurologic Symptoms Because Of The Presence Of An Abdominal Neuroblastoma.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Reveal', 'no label'), ('Primitive Tumor', 'no label'), ('Neuroblastoma', 'no label'), ('Children', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Adults', 'no label'), ('Leading Tumors', 'no label'), ('Revealed', 'no label'), ('Expressed', 'no label'), ('Paraneoplastic Phenomena', 'no label'), ('Clinical Neurologic Manifestations', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Muscular Weakness', 'no label'), ('Sleepiness', 'no label'), ('Absence', 'no label'), ('Reflexes', 'no label'), ('Dysautonomia', 'no label'), ('Neurologic Manifestations', 'no label'), ('Induction', 'no label'), ('Autoimmune Response', 'no label'), ('Presence', 'no label'), ('Antigens', 'no label'), ('Expressed', 'no label'), ('Tumor', 'no label'), ('Neurologic Paraneoplastic Disorders', 'no label'), ('Toxicity', 'no label'), ('Drugs', 'no label'), ('Coagulopathy', 'no label'), ('Infection', 'no label'), ('Metabolic Diseases', 'no label'), ('Unusual', 'no label'), ('Neurologic Symptoms', 'no label'), ('Presence', 'no label'), ('Abdominal Neuroblastoma', 'no label')]|[('Cell', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Tumor', 'no label'), ('Neuroblastoma', 'no label'), ('Tumors', 'no label'), ('Paraneoplastic', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Muscular Weakness', 'no label'), ('Sleepiness', 'no label'), ('Dysautonomia', 'no label'), ('Tumor', 'no label'), ('Neurologic Paraneoplastic Disorders', 'no label'), ('Toxicity', 'no label'), ('Coagulopathy', 'no label'), ('Infection', 'no label'), ('Abdominal Neuroblastoma', 'no label')]|[('Tumor', 'no label'), ('Neuroblastoma', 'no label'), ('Children', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Tumors', 'no label'), ('Muscular', 'no label'), ('Antigens', 'no label'), ('Tumor', 'no label'), ('Abdominal Neuroblastoma', 'no label')]
lambert eaton syndrome|pubmed~24125855||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~21485153|Although The Syndrome Of Inappropriate Secretion Of Antidiuretic Hormone (Siadh) And Lambert-Eaton Myasthenic Syndrome (Lems) Are Often Individually Accompanied By Small-Cell Lung Carcinoma, Simultaneous Occurrence Of The 2 Syndromes Is Rare. A 61-Year-Old Man Was Admitted To Our Hospital Because Of Fatigue And Myasthenia In The Extremities, And Small-Cell Lung Carcinoma With Pulmonary Metastasis Was Diagnosed, Together With Siadh And Lems. These Syndromes Markedly Ameliorated Following Tumor Shrinkage, With 4 Cycles Of Chemotherapy Consisting Of Carboplatin And Etoposide. On Progression Of The Tumor Thereafter, Neither Syndrome Recurred. A Literature Review Disclosed That These Syndromes Frequently Resolve With Tumor Shrinkage.|[('Syndrome', 'no label'), ('Secretion', 'no label'), ('Antidiuretic Hormone', 'no label'), ('Siadh', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Accompanied', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Simultaneous', 'no label'), ('Syndromes', 'no label'), ('Rare', 'no label'), ('Hospital', 'no label'), ('Fatigue', 'no label'), ('Myasthenia', 'no label'), ('Extremities', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Pulmonary Metastasis', 'no label'), ('Diagnosed', 'no label'), ('Siadh', 'no label'), ('Lems', 'no label'), ('Syndromes', 'no label'), ('Markedly', 'no label'), ('Ameliorated', 'no label'), ('Tumor Shrinkage', 'no label'), ('Cycles', 'no label'), ('Chemotherapy', 'no label'), ('Carboplatin', 'no label'), ('Etoposide', 'no label'), ('Progression', 'no label'), ('Tumor', 'no label'), ('Syndrome Recurred', 'no label'), ('Literature Review', 'no label'), ('Disclosed', 'no label'), ('Syndromes', 'no label'), ('Tumor Shrinkage', 'no label')]|[('Antidiuretic Hormone', 'no label'), ('Carboplatin', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Fatigue', 'no label'), ('Myasthenia', 'no label'), ('Lung Carcinoma', 'no label'), ('Pulmonary Metastasis', 'no label'), ('Tumor', 'no label'), ('Carboplatin', 'no label'), ('Etoposide', 'no label'), ('Tumor', 'no label'), ('Tumor', 'no label')]|[('Small-Cell Lung Carcinoma', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Pulmonary', 'no label'), ('Tumor', 'no label'), ('Carboplatin', 'no label'), ('Etoposide', 'no label'), ('Tumor', 'no label'), ('Tumor', 'no label')]
lambert eaton syndrome|pubmed~21747145|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disease Of The Neuromuscular Junction, And Approximately 60% Of Patients With Lems Have A Tumor, Mostly Small Cell Lung Cancer (Sclc), As A Paraneoplastic Neurological Syndrome. The Clinical Data Of Japanese Patients In The Present Study Are As Follows: The Ratio Of Men To Women Is 3: 1 (Mean Age, 62 Years; Age Range, 17-80 Years). Of The Patients With Lems, 61% Have Sclc, Whereas The Others Do Not Have Cancer. Clinical Symptoms Are Usually Characterized By Proximal Muscle Weakness And Dysautonomia. In Less Than 10% Of The Patients, There Are Signs Of Cerebellar Dysfunctions (Paraneoplastic Cerebellar Degeneration With Lems; Pcd-Lems), And These Are Usually Associated With Sclc. The Diagnosis Can Be Confirmed By Detecting A Specific Antibody In A Radioimmunoprecipitation Assay And Finding Reduced Amplitude Of Compound Muscle Action Potential That Increases By Over 100% After Maximum Voluntary Activation Or 50Hz Of Nerve Stimulation. The Pathomechanism Of Lems Is Characterized By Impaired Transmission Across The Neuromuscular Junction Because Of Autoantibodies Directed Against The Presynaptic P/Q-Type Voltage-Gated Calcium Channels (P/Q-Vgccs). Histopathologic Evaluation Of The Cerebellum In Patients With Pcd-Lems Showed A Reduced Number Of P/Q-Type Vgccs In The Molecular Layer. Therefore, It Was Hypothesized That P/Q-Vgcc Antibodies May Induce Cerebellar Dysfunction After Entering The Cns In Patients With Pcd-Lems. Specific Tumor Therapy In Patients With Lems As Well As Cancer Often Improves The Neurologic Deficit. Tumor Removal Is The Primary Treatment For Lems. If The Result Of The Primary Screening Is Negative, Screening Should Be Repeated After 3-6 Months And Thereafter Every 6 Months For Up To 2 Years. Most Patients Benefit From 3, 4-Diaminopyridine Administered With Pyridostigmine. In Those With Severe Weakness, Intravenous Gamma Globulin (Ivig) Or Plasmapheresis Confers Short-Term Benefits. Prednisone When Administered Alone Or In Combination With Immunosuppressive Drugs Can Achieve Long-Term Control Of The Disorder.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disease', 'no label'), ('Neuromuscular Junction', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Have A Tumor', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Paraneoplastic Neurological Syndrome', 'no label'), ('Clinical Data', 'no label'), ('Japanese', 'no label'), ('Patients', 'no label'), ('Study', 'no label'), ('Ratio', 'no label'), ('Men', 'no label'), ('Women', 'no label'), ('Mean Age', 'no label'), ('Years', 'no label'), ('Age Range', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Clinical Symptoms', 'no label'), ('Characterized', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Dysautonomia', 'no label'), ('Patients', 'no label'), ('Signs', 'no label'), ('Cerebellar Dysfunctions', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Lems', 'no label'), ('Pcd-Lems', 'no label'), ('Associated With', 'no label'), ('Sclc', 'no label'), ('Diagnosis', 'no label'), ('Confirmed', 'no label'), ('Detecting', 'no label'), ('Antibody', 'no label'), ('Radioimmunoprecipitation Assay', 'no label'), ('Reduced', 'no label'), ('Amplitude', 'no label'), ('Compound Muscle', 'no label'), ('Potential', 'no label'), ('Increases', 'no label'), ('Maximum', 'no label'), ('Voluntary Activation', 'no label'), ('Nerve Stimulation', 'no label'), ('Pathomechanism', 'no label'), ('Lems', 'no label'), ('Characterized', 'no label'), ('Impaired', 'no label'), ('Transmission', 'no label'), ('Neuromuscular Junction', 'no label'), ('Autoantibodies', 'no label'), ('Directed', 'no label'), ('Presynaptic P/Q-Type Voltage-Gated Calcium Channels', 'no label'), ('P/Q-Vgccs', 'no label'), ('Histopathologic Evaluation', 'no label'), ('Cerebellum', 'no label'), ('Patients', 'no label'), ('Pcd-Lems', 'no label'), ('Reduced', 'no label'), ('P/Q-Type Vgccs', 'no label'), ('Molecular Layer', 'no label'), ('Hypothesized', 'no label'), ('Antibodies', 'no label'), ('Induce', 'no label'), ('Cerebellar Dysfunction', 'no label'), ('Cns', 'no label'), ('Patients', 'no label'), ('Pcd-Lems', 'no label'), ('Tumor Therapy', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Cancer', 'no label'), ('Neurologic Deficit', 'no label'), ('Tumor Removal', 'no label'), ('Primary Treatment', 'no label'), ('Lems', 'no label'), ('Primary Screening', 'no label'), ('Negative', 'no label'), ('Screening', 'no label'), ('Repeated', 'no label'), ('Months', 'no label'), ('Months', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Benefit', 'no label'), ('4-Diaminopyridine', 'no label'), ('Administered', 'no label'), ('Pyridostigmine', 'no label'), ('Severe Weakness', 'no label'), ('Intravenous Gamma Globulin', 'no label'), ('Ivig', 'no label'), ('Plasmapheresis', 'no label'), ('Confers', 'no label'), ('Short-Term', 'no label'), ('Benefits', 'no label'), ('Prednisone', 'no label'), ('Administered', 'no label'), ('Alone', 'no label'), ('Combination', 'no label'), ('Immunosuppressive Drugs', 'no label'), ('Long-Term Control', 'no label'), ('Disorder', 'no label')]|[('Cell', 'no label'), ('Antibody', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Molecular', 'no label'), ('Antibodies', 'no label')]|[('Pcd-Lems', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('Tumor', 'no label'), ('Neurological Syndrome', 'no label'), ('Cancer', 'no label'), ('Muscle Weakness', 'no label'), ('Dysautonomia', 'no label'), ('Cerebellar Dysfunctions', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('P/Q-Type Vgccs', 'no label'), ('Cerebellar Dysfunction', 'no label'), ('Tumor', 'no label'), ('Cancer', 'no label'), ('Neurologic Deficit', 'no label'), ('Tumor', 'no label'), ('Pyridostigmine', 'no label'), ('Weakness', 'no label'), ('Prednisone', 'no label'), ('Administered', 'no label'), ('Disorder', 'no label')]|[('Neuromuscular', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Tumor', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Patients', 'no label'), ('Women', 'no label'), ('Patients', 'no label'), ('Cancer', 'no label'), ('Muscle', 'no label'), ('Patients', 'no label'), ('Signs Of', 'no label'), ('Cerebellar', 'no label'), ('Muscle', 'no label'), ('Nerve', 'no label'), ('Lems', 'no label'), ('Neuromuscular', 'no label'), ('Autoantibodies', 'no label'), ('Presynaptic P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Cerebellum', 'no label'), ('Patients', 'no label'), ('P/Q-Type Vgccs', 'no label'), ('P/Q-Vgcc Antibodies', 'no label'), ('Cerebellar', 'no label'), ('Cns', 'no label'), ('Patients', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Cancer', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label'), ('Pyridostigmine', 'no label'), ('Intravenous', 'no label'), ('Globulin', 'no label'), ('Prednisone', 'no label')]
lambert eaton syndrome|pubmed~20494066|We Describe A Rare Case Of Thymoma With Lambert-Eaton Myasthenic Syndrome. A 62-Year-Old Woman Reporting Weakness In Her Legs And Arms Was Found To Have An Anterior Mediastinal Mass On Computed Tomography. Electromyography Showed Incremental Response To Repeated Stimulations, And Thymoma With Lambert-Eaton Myasthenic Syndrome Was Diagnosed. The Patient Was Successfully Treated With Video-Assisted Thoracoscopic Extended Thymectomy.|[('Rare', 'no label'), ('Case', 'no label'), ('Thymoma', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Woman Reporting Weakness', 'no label'), ('Legs', 'no label'), ('Anterior Mediastinal Mass On Computed Tomography', 'no label'), ('Electromyography', 'no label'), ('Incremental Response', 'no label'), ('Stimulations', 'no label'), ('Thymoma', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Diagnosed', 'no label'), ('Patient', 'no label'), ('Successfully', 'no label'), ('Treated', 'no label'), ('Video-Assisted Thoracoscopic Extended', 'no label'), ('Thymectomy', 'no label')]|[]|[]|[('Thymoma', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Thymoma', 'no label'), ('Myasthenic Syndrome', 'no label')]|[('A Rare Case', 'no label'), ('Thymoma', 'no label'), ('Thymoma', 'no label'), ('Patient', 'no label')]
lambert eaton syndrome|pubmed~23323140|Lambert-Eaton Myasthenic Syndrome (Lems) Is A Presynaptic Neuromuscular Junction Disorder That Is Most Frequently Associated With Small-Cell Lung Cancer (Sclc). The Titers Of Antibodies Against Voltage-Gated Calcium Channels Are Frequently Increased In Lems, But Only Rarely Is Titer Of Anti-Acetylcholine-Receptor-Binding Antibodies (Achr-Abs) Increased. A 57-Year-Old Male Was Admitted To Our Hospital Due To Dry Mouth And Eyes And Progressive Proximal Limb Weakness Of 2 Months Duration. The Results Of A Repetitive Nerve Stimulation Test Disclosed All Criteria For The Electrophysiological Lems Pattern, And The Patient'S Achr-Abs Titer Was 0.587 Nmol/L. At A Follow-Up Performed 5 Years After Successful Treatment Of Sclc And Lems, His Achr-Abs Titer Had Decreased To 0.001 Nmol/L. We Suggest That This Was A Case Of Transient Pseudopositivity Of Achr-Abs In Sclc With Lems.|"[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular Junction Disorder', 'no label'), ('Associated With', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Titers', 'no label'), ('Antibodies', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Increased', 'no label'), ('Lems', 'no label'), ('Rarely', 'no label'), ('Titer', 'no label'), ('Anti-Acetylcholine-Receptor-Binding Antibodies', 'no label'), ('Increased', 'no label'), ('57-Year-Old', 'no label'), ('Male', 'no label'), ('Hospital', 'no label'), ('Dry Mouth', 'no label'), ('Eyes', 'no label'), ('Progressive', 'no label'), ('Proximal Limb Weakness', 'no label'), ('Months', 'no label'), ('Duration', 'no label'), ('Repetitive Nerve Stimulation Test Disclosed', 'no label'), ('Criteria', 'no label'), ('Electrophysiological Lems Pattern', 'no label'), (""Patient'S"", 'no label'), ('Titer', 'no label'), ('Performed 5 Years', 'no label'), ('Successful Treatment', 'no label'), ('Sclc', 'no label'), ('Lems', 'no label'), ('Titer', 'no label'), ('Decreased', 'no label'), ('Suggest', 'no label'), ('Was A', 'no label'), ('Transient', 'no label'), ('Pseudopositivity', 'no label'), ('Sclc', 'no label'), ('Lems', 'no label')]"|[('Antibodies', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('His Achr-Abs', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Neuromuscular Junction Disorder', 'no label'), ('Lung Cancer', 'no label'), ('Calcium', 'no label'), ('Dry Mouth', 'no label'), ('Achr-Abs', 'no label')]|[('Small-Cell Lung Cancer', 'no label'), ('Calcium', 'no label'), ('Eyes', 'no label'), ('A Case', 'no label')]
lambert eaton syndrome|pubmed~23091535|The Coexistence Of Myasthenia Gravis (Mg) And Lambert-Eaton Myasthenic Syndrome (Lems) Is Very Rare And Remains Controversial. A 48-Year-Old Woman Initially Presented With Noticeable Right Ptosis And Intermittent Diplopia. She Then Developed Fluctuating Proximal Limb Weakness And Difficulty In Swallowing. The Serum Titer Of Anti-Acetylcholine-Receptor Antibody Was Elevated And The Edrophonium (Tensilon) Test Was Positive. However, Repetitive Nerve Stimulation Revealed Abnormalities Typical Of Lems. The Patient Exhibited A Good Response To Treatment With Anticholinesterase Inhibitors And Steroids, And Long-Term Evaluation Disclosed That She Presented With The Clinical, Electrophysiological, And Immunological Characteristics Of Both Diseases. The Reported Clinical And Electrophysiological Features Suggest That This Patient Was A Very Rare Case Of Combined Mg And Lems.|[('Coexistence', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('48-Year-Old Woman', 'no label'), ('Noticeable Right Ptosis', 'no label'), ('Intermittent Diplopia', 'no label'), ('Proximal Limb Weakness', 'no label'), ('Difficulty', 'no label'), ('Swallowing', 'no label'), ('Serum Titer', 'no label'), ('Anti-Acetylcholine-Receptor Antibody', 'no label'), ('Elevated', 'no label'), ('Edrophonium', 'no label'), ('Positive', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Revealed Abnormalities', 'no label'), ('Lems', 'no label'), ('Patient', 'no label'), ('Exhibited', 'no label'), ('Good Response', 'no label'), ('Treatment', 'no label'), ('Anticholinesterase Inhibitors', 'no label'), ('Steroids', 'no label'), ('Long-Term Evaluation Disclosed', 'no label'), ('Clinical', 'no label'), ('Electrophysiological', 'no label'), ('Immunological', 'no label'), ('Characteristics', 'no label'), ('Diseases', 'no label'), ('Clinical', 'no label'), ('Electrophysiological Features', 'no label'), ('Patient', 'no label'), ('Case', 'no label'), ('Combined', 'no label')]|[('Antibody', 'no label'), ('Anticholinesterase Inhibitors', 'no label')]|[('Anti-Acetylcholine-Receptor Antibody', 'no label')]|[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Right Ptosis And Intermittent Diplopia', 'no label'), ('Weakness', 'no label'), ('Edrophonium', 'no label'), ('Steroids', 'no label'), ('Mg', 'no label')]|[('Serum', 'no label'), ('Edrophonium', 'no label'), ('Patient', 'no label'), ('Steroids', 'no label'), ('Patient', 'no label'), ('A Very Rare Case', 'no label'), ('Mg', 'no label')]
lambert eaton syndrome|pubmed~18653248|"The Lambert-Eaton Myasthenic Syndrome (Lems) Is A Disease Of Neuromuscular Transmission In Which Autoantibodies Against The P/Q-Type Voltage-Gated Calcium Channel (Vgcc) At The Presynaptic Nerve Terminal Play A Major Role In Decreasing Quantal Release Of Acetylcholine (Ach), Resulting In Skeletal Muscle Weakness And Autonomic Symptoms. It Is Associated With Cancer, Particularly Small-Cell Lung Carcinoma (Sclc), In 50-60% Of Lems Patients; The Nerve Terminal And Carcinoma Cells Apparently Share A Common Antigen (Vgcc), Suggesting An Immunological Cross-Reactivity That May Lead To The Neurological Abnormality. Non-Tumor Lems Has A Strong Association With Hla-Dr3-B8. In Approximately 15% Of Lems Patients, No Anti-P/Q-Type Vgcc Antibodies Are Found, Suggesting Recognition Of Other Targets(S). The Vgcc-Associated Protein Synaptotagmin Could Be One Candidate, Because It Acts As An Exocytotic Calcium Receptor, Is Implicated In Fast Ach Release; Its N-Terminus Is Exposed Extracellularly During Exocytosis And It Is Expressed In Sclc. Antibodies Against Synaptotagmin-1 Were Detected In Both Anti-Vgcc-Positive And -Negative Lems Patients (20%), And It Can Be Immunogenic, Allowing Induction Of An Animal Model Of Lems. Another Candidate Target Is The M1-Type Presynaptic Muscarinic Ach Receptor (M1 Machr), Also Expressed Extracellularly On Motor Nerve Terminals; It Modulates Cholinergic Transmission, Linking To P/Q-Type Vgcc. In Our Series Of 25 Lems Patients With And Without Sclc, Anti-M1 Machr Antibodies Were Prevalent In Both Anti-Vgcc-Positive And -Negative Lems Patients. Autonomic Symptoms Seemed More Frequent In The Latter; Serum From One Of Them Passively Transferred Lems-Type Electrophysiological Defects To Mice. As A Compensatory Mechanism, Researchers In Oxford Suggested A Shift In The Dependence Of Ach Release From The P/Q-Type To Other Types Of Vgcc. We Have Also Focused On G Protein-Coupled Machrs And Neurotrophins, Which May Affect Both P/Q-Type Vgcc And Clathrin-Independent ""Kiss-And-Run"" Synaptic Vesicle Recycling (Fast-Mode Of Endocytosis) Via Protein Kinase C Activation. We Hypothesize That These Signaling Cascades Help To Compensate For The Immune-Mediated Defects In Calcium Entry In Lems, Compensation That May Frequently Be Restricted By The Coincident Anti-M1 Machr Antibodies In This Disease."|"[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Disease', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Autoantibodies', 'no label'), ('P/Q-Type Voltage-Gated Calcium Channel', 'no label'), ('Vgcc', 'no label'), ('Presynaptic Nerve', 'no label'), ('Terminal', 'no label'), ('Play A', 'no label'), ('Decreasing', 'no label'), ('Quantal Release', 'no label'), ('Acetylcholine (', 'no label'), ('Ach', 'no label'), ('Resulting', 'no label'), ('Skeletal Muscle Weakness', 'no label'), ('Autonomic Symptoms', 'no label'), ('Associated With', 'no label'), ('Cancer', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Lems Patients', 'no label'), ('Nerve', 'no label'), ('Terminal', 'no label'), ('Cells', 'no label'), ('Share A', 'no label'), ('Vgcc', 'no label'), ('Suggesting', 'no label'), ('Immunological', 'no label'), ('Cross-Reactivity', 'no label'), ('Lead', 'no label'), ('Neurological Abnormality', 'no label'), ('Non-Tumor Lems', 'no label'), ('Association', 'no label'), ('Hla-Dr3-B8', 'no label'), ('Lems Patients', 'no label'), ('Vgcc Antibodies', 'no label'), ('Found', 'no label'), ('Suggesting', 'no label'), ('Recognition', 'no label'), ('Vgcc-Associated Protein Synaptotagmin', 'no label'), ('Exocytotic Calcium Receptor', 'no label'), ('Fast Ach Release', 'no label'), ('N-Terminus', 'no label'), ('Exposed', 'no label'), ('Extracellularly', 'no label'), ('Exocytosis', 'no label'), ('Expressed', 'no label'), ('Sclc', 'no label'), ('Antibodies', 'no label'), ('Synaptotagmin-1', 'no label'), ('Detected', 'no label'), ('Anti-Vgcc-Positive', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Immunogenic', 'no label'), ('Allowing Induction', 'no label'), ('Animal Model', 'no label'), ('Lems', 'no label'), ('Target', 'no label'), ('Presynaptic', 'no label'), ('Muscarinic Ach Receptor', 'no label'), ('Machr', 'no label'), ('Expressed', 'no label'), ('Extracellularly', 'no label'), ('Motor Nerve', 'no label'), ('Terminals', 'no label'), ('Modulates', 'no label'), ('Cholinergic', 'no label'), ('Transmission', 'no label'), ('P/Q-Type Vgcc', 'no label'), ('Lems Patients', 'no label'), ('Sclc', 'no label'), ('Anti-M1 Machr Antibodies', 'no label'), ('Prevalent', 'no label'), ('Anti-Vgcc-Positive', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Autonomic Symptoms', 'no label'), ('Frequent', 'no label'), ('Latter', 'no label'), ('Serum', 'no label'), ('Passively', 'no label'), ('Transferred', 'no label'), ('Electrophysiological Defects', 'no label'), ('Mice', 'no label'), ('Compensatory', 'no label'), ('Mechanism', 'no label'), ('Researchers', 'no label'), ('Oxford Suggested A Shift', 'no label'), ('Ach', 'no label'), ('Release', 'no label'), ('P/Q-Type', 'no label'), ('Vgcc', 'no label'), ('Focused', 'no label'), ('Neurotrophins', 'no label'), ('P/Q-Type Vgcc', 'no label'), ('Clathrin-Independent ""Kiss-And-Run"" Synaptic', 'no label'), ('Recycling', 'no label'), ('Fast-Mode', 'no label'), ('Endocytosis', 'no label'), ('Protein Kinase C', 'no label'), ('Activation', 'no label'), ('Hypothesize', 'no label'), ('Signaling Cascades', 'no label'), ('Immune-Mediated Defects', 'no label'), ('Calcium Entry', 'no label'), ('Compensation', 'no label'), ('Restricted', 'no label'), ('Coincident', 'no label'), ('Anti-M1', 'no label'), ('Machr Antibodies', 'no label'), ('Disease', 'no label')]"|[('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Cells', 'no label'), ('Lead', 'no label'), ('Antibodies', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('Synaptotagmin-1', 'no label'), ('Animal', 'no label'), ('Muscarinic Ach Receptor', 'no label'), ('P/Q-Type', 'no label'), ('Antibodies', 'no label'), ('Lems-Type', 'no label'), ('Mice', 'no label'), ('P/Q-Type', 'no label'), ('Neurotrophins', 'no label'), ('P/Q-Type', 'no label'), ('Synaptic Vesicle', 'no label'), ('Fast-Mode', 'no label'), ('Protein', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label')]|[('Presynaptic Nerve Terminal Play A Major Role', 'no label'), ('Nerve Terminal And Carcinoma Cells', 'no label'), ('Anti-P/Q-Type Vgcc Antibodies', 'no label'), ('Vgcc-Associated Protein Synaptotagmin', 'no label'), ('N-Terminus', 'no label'), ('Synaptotagmin-1', 'no label'), ('M1-Type Presynaptic Muscarinic Ach Receptor', 'no label'), ('M1', 'no label'), ('Anti-M1 Machr Antibodies', 'no label'), ('Ach', 'no label'), ('Neurotrophins', 'no label'), ('Protein Kinase C', 'no label'), ('Anti-M1 Machr Antibodies', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Ach', 'no label'), ('Muscle Weakness', 'no label'), ('Cancer', 'no label'), ('Lung Carcinoma', 'no label'), ('Carcinoma', 'no label'), ('Neurological Abnormality', 'no label'), ('Calcium', 'no label'), ('Ach', 'no label'), ('Ach', 'no label'), ('P/Q-Type', 'no label'), ('Ach', 'no label'), ('P/Q-Type', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label')]|[('Neuromuscular', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Presynaptic Nerve', 'no label'), ('Acetylcholine', 'no label'), ('Ach', 'no label'), ('Skeletal Muscle', 'no label'), ('Cancer', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Lems Patients', 'no label'), ('Nerve Terminal And', 'no label'), ('Carcinoma Cells', 'no label'), ('Vgcc', 'no label'), ('Non-Tumor Lems', 'no label'), ('Hla-Dr3-B8', 'no label'), ('Lems Patients', 'no label'), ('Vgcc-Associated Protein', 'no label'), ('Synaptotagmin', 'no label'), ('Acts', 'no label'), ('Calcium Receptor', 'no label'), ('Synaptotagmin-1', 'no label'), ('Lems Patients', 'no label'), ('Be Immunogenic', 'no label'), ('M1-Type Presynaptic', 'no label'), ('Cholinergic', 'no label'), ('P/Q-Type Vgcc', 'no label'), ('Lems Patients', 'no label'), ('Anti-M1 Machr Antibodies', 'no label'), ('Lems Patients', 'no label'), ('Serum', 'no label'), ('Mice', 'no label'), ('Ach', 'no label'), ('P/Q-Type', 'no label'), ('Vgcc', 'no label'), ('Neurotrophins', 'no label'), ('P/Q-Type Vgcc', 'no label'), ('Synaptic Vesicle', 'no label'), ('Fast-Mode', 'no label'), ('Protein Kinase C', 'no label'), ('Calcium', 'no label'), ('Anti-M1', 'no label')]
lambert eaton syndrome|pubmed~24141446||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~19005633|Paraneoplastic Neurological Disorders Are Rare Complications Of Breast Carcinoma. Lambert-Eaton Myasthenic Syndrome (Lems) Is Most Commonly Associated With Small Cell Lung Cancer. However, A Combination Of Lems And Subacute Cerebellar Degeneration As Paraneoplastic Syndromes Is Extremely Rare, And Has Never Been Described In Association With Breast Cancer. We Report For The First Time An Unusual Association Of Lems And Paraneoplastic Subacute Cerebellar Degeneration With Breast Carcinoma. In Patients With Atypical Lems, When There Is No Evidence Of Respiratory Malignancy, Breast Cancer Should Be Included In The Differential Diagnosis.|[('Paraneoplastic Neurological Disorders', 'no label'), ('Rare', 'no label'), ('Complications', 'no label'), ('Breast Carcinoma', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Combination', 'no label'), ('Lems', 'no label'), ('Subacute', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Rare', 'no label'), ('Breast Cancer', 'no label'), ('First Time', 'no label'), ('Unusual Association', 'no label'), ('Lems', 'no label'), ('Paraneoplastic Subacute', 'no label'), ('Cerebellar Degeneration', 'no label'), ('Breast Carcinoma', 'no label'), ('Patients', 'no label'), ('Atypical Lems', 'no label'), ('Respiratory Malignancy', 'no label'), ('Breast Cancer', 'no label'), ('Differential Diagnosis', 'no label')]|[('Cell', 'no label')]|[]|[('Paraneoplastic Neurological Disorders', 'no label'), ('Breast Carcinoma', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Cerebellar Degeneration', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Breast Cancer', 'no label'), ('Paraneoplastic Subacute Cerebellar Degeneration', 'no label'), ('Breast Carcinoma', 'no label'), ('Respiratory Malignancy', 'no label'), ('Breast Cancer', 'no label')]|[('Breast Carcinoma', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Lems', 'no label'), ('Cerebellar', 'no label'), ('Breast Cancer', 'no label'), ('Lems', 'no label'), ('Cerebellar', 'no label'), ('Breast Carcinoma', 'no label'), ('Patients', 'no label'), ('Respiratory Malignancy', 'no label'), ('Breast Cancer', 'no label')]
lambert eaton syndrome|pubmed~18374949|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Immune-Mediated Disorder Of The Neuromuscular Junction That Rarely Is Associated With Cerebellar Ataxia (Ca). We Describe Two Patients With Non-Paraneoplastic Lems Associated With Ca Who Showed High Levels Of Anti-P/Q-Type Voltage-Gated Calcium Channels Antibodies In The Serum And Cerebrospinal Fluid, And Reduced Cmap With Increment After Brief Maximum Voluntary Contraction In Electrophysiological Studies. We Suggest That Lems Should Be Considered In The Differential Diagnosis Of Patients With Ca.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Immune-Mediated Disorder', 'no label'), ('Neuromuscular Junction', 'no label'), ('Rarely', 'no label'), ('Associated With', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Ca', 'no label'), ('Patients', 'no label'), ('Non-Paraneoplastic Lems', 'no label'), ('Associated With', 'no label'), ('Ca Who', 'no label'), ('Levels', 'no label'), ('Voltage-Gated Calcium Channels Antibodies', 'no label'), ('Serum', 'no label'), ('Cerebrospinal Fluid', 'no label'), ('Reduced', 'no label'), ('Cmap', 'no label'), ('Increment', 'no label'), ('Brief Maximum', 'no label'), ('Voluntary Contraction', 'no label'), ('Electrophysiological Studies', 'no label'), ('Suggest', 'no label'), ('Lems', 'no label'), ('Differential Diagnosis', 'no label'), ('Patients', 'no label'), ('Ca', 'no label')]|[('Calcium', 'no label'), ('Antibodies', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Ca', 'no label'), ('Ca', 'no label'), ('Anti-P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Ca', 'no label')]|[('Neuromuscular', 'no label'), ('Cerebellar', 'no label'), ('Patients', 'no label'), ('Anti-P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Serum', 'no label'), ('Cerebrospinal Fluid', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Ca', 'no label')]
lambert eaton syndrome|pubmed~19667272|Sox1 Antibodies Are Common In Small-Cell Lung Carcinoma (Sclc) With And Without Paraneoplastic Syndrome (Pns) And Can Serve As Serological Tumor Marker. Addition Of Other Antibodies Might Improve Its Diagnostic Power. We Validated An Enzyme-Linked Immunosorbent Assay (Elisa) To Assess The Diagnostic Value Of Serum Antibodies In Sclc And Lambert-Eaton Myasthenic Syndrome (Lems). Clinical Outcome With Respect To Sox Antibodies Was Evaluated, As The Sox-Related Antitumor Immune Response Might Help To Control The Tumor Growth. We Used Recombinant Sox1, Sox2, Sox3, Sox21, Huc, Hud, Or Heln1 Proteins In An Elisa To Titrate Serum Samples And Validated The Assay By Western Blot. We Tested 136 Consecutive Sclc Patients, 86 Lems Patients (43 With Sclc), 14 Patients With Sclc And Pns (Paraneoplastic Cerebellar Degeneration Or Hu Syndrome), 62 Polyneuropathy Patients, And 18 Healthy Controls. Our Elisa Was Equally Reliable As Western Blot. Forty-Three Percent Of Sclc Patients And 67% Of Sclc-Lems Patients Had Antibodies To One Of The Sox Or Hu Proteins. Sox Antibodies Had A Sensitivity Of 67% And A Specificity Of 95% To Discriminate Between Lems With Sclc And Nontumor Lems. No Difference In Survival Was Observed Between Sox Positive And Sox Negative Sclc Patients. Sox Antibodies Are Specific Serological Markers For Sclc. Our Assay Is Suitable For High Throughput Screening, Detecting 43% Of Sclc. Sox Antibodies Have Diagnostic Value In Discriminating Sclc-Lems From Nontumor Lems, But Have No Relation To Survival In Patients With Sclc.|[('Sox1 Antibodies', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Pns', 'no label'), ('Serological Tumor', 'no label'), ('Antibodies', 'no label'), ('Diagnostic Power', 'no label'), ('Enzyme-Linked Immunosorbent Assay', 'no label'), ('Elisa', 'no label'), ('Assess', 'no label'), ('Diagnostic Value', 'no label'), ('Serum Antibodies', 'no label'), ('Sclc', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Clinical Outcome', 'no label'), ('Respect', 'no label'), ('Sox Antibodies', 'no label'), ('Evaluated', 'no label'), ('Sox-Related', 'no label'), ('Antitumor', 'no label'), ('Immune Response', 'no label'), ('Tumor Growth', 'no label'), ('Recombinant', 'no label'), ('Sox1', 'no label'), ('Sox2', 'no label'), ('Sox3', 'no label'), ('Sox21', 'no label'), ('Huc', 'no label'), ('Heln1 Proteins', 'no label'), ('Elisa', 'no label'), ('Titrate Serum Samples', 'no label'), ('Validated', 'no label'), ('Assay', 'no label'), ('Western Blot', 'no label'), ('Tested', 'no label'), ('Consecutive', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Lems Patients', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Polyneuropathy', 'no label'), ('Patients', 'no label'), ('Healthy Controls', 'no label'), ('Elisa', 'no label'), ('Western Blot', 'no label'), ('Forty-Three', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Patients', 'no label'), ('Antibodies', 'no label'), ('Sox Or', 'no label'), ('Hu Proteins', 'no label'), ('Sox Antibodies', 'no label'), ('Sensitivity', 'no label'), ('Specificity', 'no label'), ('Discriminate', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Nontumor Lems', 'no label'), ('No Difference', 'no label'), ('Survival', 'no label'), ('Sox', 'no label'), ('Positive', 'no label'), ('Sox Negative', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Sox Antibodies', 'no label'), ('Serological', 'no label'), ('Markers', 'no label'), ('Sclc', 'no label'), ('Assay', 'no label'), ('Throughput', 'no label'), ('Screening', 'no label'), ('Detecting', 'no label'), ('Sclc', 'no label'), ('Sox Antibodies', 'no label'), ('Diagnostic Value', 'no label'), ('Discriminating', 'no label'), ('Sclc-Lems', 'no label'), ('Nontumor Lems', 'no label'), ('Survival', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label')]|[('Sox1 Antibodies', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Sox1', 'no label'), ('Sox2', 'no label'), ('Sox3', 'no label'), ('Sox21', 'no label'), ('Heln1 Proteins', 'no label'), ('Sclc-Lems', 'no label'), ('Antibodies', 'no label'), ('Proteins', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Sclc-Lems', 'no label')]|[('Sox1 Antibodies', 'no label'), ('Serum Antibodies', 'no label'), ('Sox Antibodies', 'no label'), ('Sox-Related Antitumor Immune Response', 'no label'), ('Sox2', 'no label'), ('Pns', 'no label'), ('Sox Or Hu Proteins', 'no label'), ('Sox Antibodies', 'no label'), ('Sox', 'no label'), ('Sox', 'no label'), ('Sox Antibodies', 'no label'), ('Sox Antibodies', 'no label')]|[('Lung Carcinoma', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Tumor', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Tumor', 'no label'), ('Titrate', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Hu Syndrome', 'no label'), ('Polyneuropathy', 'no label')]|[('Sox1', 'no label'), ('Small-Cell Lung Carcinoma', 'no label'), ('Tumor', 'no label'), ('Serum Antibodies', 'no label'), ('Sox Antibodies', 'no label'), ('Sox-Related Antitumor Immune', 'no label'), ('Tumor', 'no label'), ('Sox1', 'no label'), ('Sox2', 'no label'), ('Sox3', 'no label'), ('Sox21', 'no label'), ('Titrate Serum Samples', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Pns', 'no label'), ('Sclc Patients', 'no label'), ('Sclc-Lems Patients', 'no label'), ('Sox', 'no label'), ('Sox Antibodies', 'no label'), ('Lems', 'no label'), ('Nontumor', 'no label'), ('Sox', 'no label'), ('Sox', 'no label'), ('Sox Antibodies', 'no label'), ('Sox Antibodies', 'no label'), ('Sclc-Lems', 'no label'), ('Nontumor', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~20120349|We Report A 64-Year-Old Man Diagnosed With Lambert-Eaton Myasthenic Syndrome (Lems) Associated With Pulmonary Squamous Cell Carcinoma. Circulating Anti-P/Q-Type Voltage-Gated Calcium Channel (Vgcc) Antibody Was Detected, And The Patient Was Treated With 3,4-Diaminopyridine. At Age 61, Chest Radiograph Revealed A Tumor Shadow In The Right Upper Lung Field. This Was Surgically Removed, And A Histological Diagnosis Of Moderately Differentiated Pulmonary Squamous Cell Carcinoma Was Obtained. After About 1 Year, Mediastinal Metastasis Was Detected And 5-Fu Was Administered. Eight Months Later, Metastasis Was Noted In The Left Frontal Hemisphere, And Radiosurgical Therapy Was Performed. The Brain Tumor Gradually Shrank But Generalized Fatigue, Thirst, And Gait Disturbance Developed After 4 Months. A Diagnosis Of Lems Was Made On The Basis Of Neurological Findings Including Proximal Muscle Weakness And Absent Tendon Reflexes; Autonomic Symptoms (Thirst, Constipation, And Impotence); Characteristic Electromyographic Findings; And Circulating Anti-P/Q-Type Vgcc Antibody. He Has Been Treated With 3,4-Diaminopyridine At A Dose Of 30 Mg/Day, Resulting In Marked Improvement In Symptoms But Little Change In Electromyographic Findings. The Present Case Is Very Rare And Suggests That Anti-P/Q-Type Vgcc Antibody May Be Involved In The Mechanism Of Lems Associated With Pulmonary Squamous Cell Carcinoma.|[('Report', 'no label'), ('64-Year-Old Man Diagnosed', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Pulmonary Squamous Cell Carcinoma', 'no label'), ('Circulating', 'no label'), ('Anti-P/Q-Type Voltage-Gated Calcium Channel', 'no label'), ('Vgcc', 'no label'), ('Antibody', 'no label'), ('Detected', 'no label'), ('Patient', 'no label'), ('Treated', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Age', 'no label'), ('Chest Radiograph Revealed', 'no label'), ('Tumor Shadow', 'no label'), ('Right Upper Lung Field', 'no label'), ('Surgically', 'no label'), ('Histological Diagnosis', 'no label'), ('Moderately Differentiated Pulmonary Squamous Cell Carcinoma', 'no label'), ('Year', 'no label'), ('Mediastinal Metastasis', 'no label'), ('Detected', 'no label'), ('Administered', 'no label'), ('Months', 'no label'), ('Metastasis', 'no label'), ('Noted', 'no label'), ('Left Frontal Hemisphere', 'no label'), ('Radiosurgical Therapy', 'no label'), ('Performed', 'no label'), ('Brain Tumor', 'no label'), ('Gradually Shrank', 'no label'), ('Generalized Fatigue', 'no label'), ('Thirst', 'no label'), ('Gait Disturbance', 'no label'), ('Months', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Neurological Findings', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Absent Tendon Reflexes', 'no label'), ('Autonomic Symptoms', 'no label'), ('Thirst', 'no label'), ('Constipation', 'no label'), ('Impotence', 'no label'), ('Characteristic Electromyographic Findings', 'no label'), ('Circulating', 'no label'), ('Antibody', 'no label'), ('Treated With', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Dose', 'no label'), ('Marked Improvement', 'no label'), ('Symptoms', 'no label'), ('Electromyographic Findings', 'no label'), ('Case', 'no label'), ('Suggests', 'no label'), ('Vgcc', 'no label'), ('Antibody', 'no label'), ('Mechanism', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Pulmonary Squamous Cell Carcinoma', 'no label')]|[('Squamous Cell', 'no label'), ('Calcium', 'no label'), ('Antibody', 'no label'), ('Squamous Cell', 'no label'), ('5-Fu', 'no label'), ('Antibody', 'no label'), ('Antibody', 'no label'), ('Squamous Cell', 'no label')]|[('Anti-P/Q-Type Vgcc Antibody', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Pulmonary Squamous Cell Carcinoma', 'no label'), ('Calcium', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Chest', 'no label'), ('Tumor', 'no label'), ('Pulmonary Squamous Cell Carcinoma', 'no label'), ('5-Fu', 'no label'), ('Tumor', 'no label'), ('Fatigue', 'no label'), ('Thirst', 'no label'), ('Muscle Weakness', 'no label'), ('Thirst', 'no label'), ('Constipation', 'no label'), ('Impotence', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Pulmonary Squamous Cell Carcinoma', 'no label')]|[('Pulmonary Squamous Cell Carcinoma', 'no label'), ('Calcium', 'no label'), ('Patient', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Tumor Shadow', 'no label'), ('Right Upper Lung', 'no label'), ('Pulmonary Squamous Cell Carcinoma', 'no label'), ('5-Fu', 'no label'), ('Left Frontal', 'no label'), ('Brain Tumor', 'no label'), ('Lems', 'no label'), ('Muscle', 'no label'), ('Tendon', 'no label'), ('Circulating Anti-P/Q-Type Vgcc Antibody', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Vgcc', 'no label'), ('Lems', 'no label'), ('Pulmonary Squamous Cell Carcinoma', 'no label')]
lambert eaton syndrome|pubmed~21822385|In Lambert-Eaton Myasthenic Syndrome (Lems), Antibodies Against Presynaptic Voltage-Gated Calcium Channels Reduce The Quantal Release Of Acetylcholine, Causing Muscle Weakness And Autonomic Dysfunction. More Than Half Of The Affected Patients Have Associated Small Cell Lung Cancer, And Thorough Screening For An Underlying Malignancy Is Crucial. The Mainstay Of Treatment For Lems Is Symptomatic But Immunotherapy Is Needed In More Severely Affected Patients. Symptomatic Therapies Aim At Increasing The Concentration Of Acetylcholine At The Muscle Endplate. While Acetylcholinesterase Inhibitors Were The First Drugs To Be Used For The Amelioration Of Symptoms, 3,4-Diaminopyridine (3,4-Dap, Amifampridine) Has Been Shown To Be More Effective. 3,4-Dap Blocks Presynaptic Potassium Channels, Thereby Prolonging The Action Potential And Increasing Presynaptic Calcium Concentrations. This Then Results In Increased Quantal Release Of Acetylcholine. The Efficacy Of 3,4-Dap For Increasing Muscle Strength And Resting Compound Muscle Action Potentials Has Been Demonstrated By Four Placebo-Controlled Trials. Side Effects Are Usually Mild, And The Most Frequently Reported Are Paresthesias. The Most Common Serious Adverse Events Are Epileptic Seizures. 3,4-Dap Is Currently The Treatment Of Choice In Patients With Lambert-Eaton Myasthenic Syndrome.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Antibodies', 'no label'), ('Presynaptic Voltage-Gated', 'no label'), ('Calcium Channels', 'no label'), ('Quantal Release', 'no label'), ('Acetylcholine', 'no label'), ('Causing Muscle Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Affected', 'no label'), ('Patients', 'no label'), ('Associated Small Cell', 'no label'), ('Lung Cancer', 'no label'), ('Screening', 'no label'), ('Malignancy', 'no label'), ('Mainstay', 'no label'), ('Treatment', 'no label'), ('Lems', 'no label'), ('Symptomatic', 'no label'), ('Immunotherapy', 'no label'), ('Severely', 'no label'), ('Affected', 'no label'), ('Patients', 'no label'), ('Symptomatic', 'no label'), ('Therapies', 'no label'), ('Increasing', 'no label'), ('Concentration', 'no label'), ('Acetylcholine', 'no label'), ('Muscle Endplate', 'no label'), ('Acetylcholinesterase Inhibitors', 'no label'), ('First Drugs', 'no label'), ('Amelioration', 'no label'), ('Symptoms', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Amifampridine', 'no label'), ('Effective', 'no label'), ('Blocks', 'no label'), ('Presynaptic Potassium Channels', 'no label'), ('Prolonging', 'no label'), ('Action', 'no label'), ('Potential', 'no label'), ('Increasing', 'no label'), ('Presynaptic', 'no label'), ('Calcium', 'no label'), ('Concentrations', 'no label'), ('Results', 'no label'), ('Increased', 'no label'), ('Quantal Release', 'no label'), ('Acetylcholine', 'no label'), ('Efficacy', 'no label'), ('Increasing', 'no label'), ('Muscle Strength', 'no label'), ('Compound Muscle', 'no label'), ('Action Potentials', 'no label'), ('Placebo-Controlled Trials', 'no label'), ('Side Effects', 'no label'), ('Mild', 'no label'), ('Reported', 'no label'), ('Paresthesias', 'no label'), ('Serious Adverse Events', 'no label'), ('Epileptic Seizures', 'no label'), ('Treatment', 'no label'), ('Choice', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label')]|[('Antibodies', 'no label'), ('Calcium', 'no label'), ('Cell', 'no label'), ('Acetylcholine', 'no label'), ('Acetylcholinesterase Inhibitors', 'no label'), ('Potassium', 'no label'), ('Calcium', 'no label')]|[('Acetylcholinesterase', 'no label')]|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Muscle Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Malignancy', 'no label'), ('Acetylcholine', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Amifampridine', 'no label'), ('Potassium', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Paresthesias', 'no label'), ('Epileptic Seizures', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label')]|[('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Muscle', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Acetylcholine', 'no label'), ('Muscle Endplate', 'no label'), ('Acetylcholinesterase', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Presynaptic', 'no label'), ('Calcium', 'no label'), ('Acetylcholine', 'no label'), ('Muscle', 'no label'), ('Paresthesias', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~19349709|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Neuromuscular Disorder Affecting The Presynaptic Neuromuscular Junction. Lems Is Considered To Be A Rare Disease, But Its Clinical Recognition And Diagnosis Are Important Due To Its High Association With Underlying Lung Cancer Which May Be Detected At The Very Early Stages. The Onset Is Insidious And Its Clinical Features Are Subtle Which Add To The Further Delay Of Diagnosis, Between Months To Years.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Neuromuscular Disorder', 'no label'), ('Affecting', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular Junction', 'no label'), ('Lems', 'no label'), ('Clinical Recognition', 'no label'), ('Diagnosis', 'no label'), ('Association', 'no label'), ('Lung Cancer', 'no label'), ('Detected', 'no label'), ('Early Stages', 'no label'), ('Onset', 'no label'), ('Insidious', 'no label'), ('Clinical Features', 'no label'), ('Subtle', 'no label'), ('Diagnosis', 'no label'), ('Months', 'no label'), ('Years', 'no label')]|[]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Neuromuscular Disorder', 'no label'), ('Lung Cancer', 'no label')]|[('Neuromuscular', 'no label'), ('Presynaptic Neuromuscular', 'no label'), ('Be A', 'no label'), ('Lung Cancer', 'no label')]
lambert eaton syndrome|pubmed~30571477|History A 29-Year-Old Woman Presented With A 6-Month History Of Progressive General Fatigue, Fluctuating Limb Weakness, And Difficulty Climbing Stairs. She Initially Experienced Occasional Episodes Of Transient Diplopia That Developed While Reading In The Evening. She Subsequently Started To Experience Dry Eyes And Mouth, Difficulty Chewing, And Mild Dysphagia That Worsened Throughout The Day. Her Medical History Included Hypothyroidism From Hashimoto Thyroiditis And Pneumonia With Left Pleural Effusion. She Had No Smoking History, And Her Body Mass Index Was Normal (23.8 Kg/M<Sup>2</Sup>). No Medication Use Was Reported At Admission. Physical Examination Revealed Mild Bilateral Ptosis, Reduced Muscle Tone And Strength That Worsened In Proximal Leg Muscles, And Decreased Deep Tendon Reflexes. An Edrophonium Test Revealed Improvement In Muscle Strength And Eyelid Ptosis. Repetitive Nerve Stimulation Revealed Low Amplitude Of Compound Muscle Action Potential At Rest (0.21 Mv), With A Marked Increase (700%; Normal Increase, <60%) At High-Rate Stimulation (50 Hz). Laboratory Work-Up Was Unremarkable Except For Detection Of Acetylcholine Receptor Antibodies In The Serum (21.30 Nmol/L) And P/Q-Type Voltage-Gated Calcium Channel Antibodies (220 Pmol/L). Recent Mri Of The Brain And Spine At An Outside Hospital Showed No Abnormal Findings. At Admission, The Patient Underwent Ct Of The Chest, Abdomen, And Pelvis Followed By Thoracic Mri To Further Evaluate Ct Findings.|[('History A 29-Year-Old Woman', 'no label'), ('History', 'no label'), ('Progressive', 'no label'), ('General Fatigue', 'no label'), ('Fluctuating Limb Weakness', 'no label'), ('Difficulty Climbing Stairs', 'no label'), ('Occasional Episodes', 'no label'), ('Transient Diplopia', 'no label'), ('Reading', 'no label'), ('Evening', 'no label'), ('Dry Eyes', 'no label'), ('Mouth', 'no label'), ('Difficulty Chewing', 'no label'), ('Mild Dysphagia', 'no label'), ('Worsened', 'no label'), ('Day', 'no label'), ('Medical History', 'no label'), ('Hypothyroidism', 'no label'), ('Hashimoto Thyroiditis', 'no label'), ('Pneumonia', 'no label'), ('Left Pleural Effusion', 'no label'), ('No Smoking History', 'no label'), ('Body Mass Index', 'no label'), ('Kg/M<Sup>2</Sup>)', 'no label'), ('Medication Use', 'no label'), ('Reported', 'no label'), ('Admission', 'no label'), ('Physical Examination', 'no label'), ('Mild Bilateral Ptosis', 'no label'), ('Reduced', 'no label'), ('Tone', 'no label'), ('Worsened', 'no label'), ('Proximal', 'no label'), ('Leg Muscles', 'no label'), ('Decreased', 'no label'), ('Deep Tendon', 'no label'), ('Reflexes', 'no label'), ('Edrophonium Test', 'no label'), ('Revealed', 'no label'), ('Improvement', 'no label'), ('Muscle Strength', 'no label'), ('Eyelid Ptosis', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Revealed', 'no label'), ('Amplitude', 'no label'), ('Compound Muscle', 'no label'), ('Potential', 'no label'), ('Rest', 'no label'), ('Increase', 'no label'), ('Normal Increase', 'no label'), ('High-Rate Stimulation', 'no label'), ('Laboratory Work-Up', 'no label'), ('Unremarkable', 'no label'), ('Detection', 'no label'), ('Acetylcholine Receptor Antibodies', 'no label'), ('Serum', 'no label'), ('P/Q-Type Voltage-Gated Calcium Channel Antibodies', 'no label'), ('Mri', 'no label'), ('Brain', 'no label'), ('Abnormal Findings', 'no label'), ('Admission', 'no label'), ('Patient', 'no label'), ('Ct', 'no label'), ('Chest', 'no label'), ('Abdomen', 'no label'), ('Pelvis', 'no label'), ('Thoracic Mri', 'no label'), ('Evaluate', 'no label'), ('Ct', 'no label'), ('Findings', 'no label')]|[('Acetylcholine Receptor Antibodies', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label')]|[('Acetylcholine Receptor Antibodies', 'no label'), ('Ct', 'no label')]|[('Fatigue', 'no label'), ('Diplopia', 'no label'), ('Dysphagia', 'no label'), ('Hypothyroidism', 'no label'), ('Hashimoto Thyroiditis', 'no label'), ('Pneumonia', 'no label'), ('Left Pleural Effusion', 'no label'), ('Edrophonium', 'no label'), ('Eyelid Ptosis', 'no label'), ('Acetylcholine', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Chest', 'no label')]|[('Limb', 'no label'), ('Experience', 'no label'), ('Eyes', 'no label'), ('Hashimoto Thyroiditis', 'no label'), ('Left Pleural Effusion', 'no label'), ('Sup>2</Sup', 'no label'), ('Muscle', 'no label'), ('Edrophonium', 'no label'), ('Muscle', 'no label'), ('Eyelid', 'no label'), ('Nerve', 'no label'), ('High-Rate', 'no label'), ('Acetylcholine Receptor Antibodies', 'no label'), ('Serum', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Brain', 'no label'), ('Patient', 'no label'), ('Abdomen', 'no label')]
lambert eaton syndrome|pubmed~19533655|A 67-Year-Old Man Was Admitted With A 2-Year History Of Dropped Head. Neurological Examination Revealed Ptosis, Dysarthria, Neck Weakness, Hyporeflexia Of All Limbs, And Autonomic Failure. Electrophysiologic Study Showed A 400% Increment Response To High-Rate Repetitive Nerve Stimulation. Serum Anti-P/Q-Voltage-Gated Calcium Channel Antibody Was Positive, Confirming The Diagnosis Of Lambert-Eaton Myasthenic Syndrome (Lems). His Symptoms And Electrophysiological Abnormalities Improved With Oral Prednisolone Following Plasmapheresis. This Is The First Report Of Lems As A Cause Of Dropped Head Syndrome.|[('67-Year-Old Man', 'no label'), ('Dropped Head', 'no label'), ('Neurological Examination', 'no label'), ('Ptosis', 'no label'), ('Dysarthria', 'no label'), ('Neck Weakness', 'no label'), ('Hyporeflexia', 'no label'), ('Limbs', 'no label'), ('Autonomic Failure', 'no label'), ('Electrophysiologic Study', 'no label'), ('Increment Response', 'no label'), ('High-Rate Repetitive Nerve', 'no label'), ('Stimulation', 'no label'), ('Serum', 'no label'), ('Anti-P/Q-Voltage-Gated Calcium Channel Antibody', 'no label'), ('Positive', 'no label'), ('Diagnosis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('His Symptoms', 'no label'), ('Electrophysiological Abnormalities', 'no label'), ('Oral Prednisolone', 'no label'), ('Plasmapheresis', 'no label'), ('Cause', 'no label'), ('Dropped Head Syndrome', 'no label')]|[('Electrophysiologic', 'no label'), ('Calcium', 'no label'), ('Antibody', 'no label'), ('His', 'no label')]|[('His', 'no label')]|[('Dropped', 'no label'), ('Dysarthria', 'no label'), ('Neck Weakness', 'no label'), ('Hyporeflexia', 'no label'), ('Autonomic Failure', 'no label'), ('Calcium', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Electrophysiological Abnormalities', 'no label'), ('Prednisolone', 'no label'), ('Dropped Head Syndrome', 'no label')]|[('Head.', 'no label'), ('High-Rate', 'no label'), ('Nerve', 'no label'), ('Serum', 'no label'), ('Calcium', 'no label'), ('Oral Prednisolone', 'no label'), ('Lems', 'no label'), ('Head Syndrome', 'no label')]
lambert eaton syndrome|pubmed~19110759|A 62-Year-Old Man Was Admitted To Our Hospital Because Of Rapidly Progressive Dysarthria, Truncal Ataxia, And Gait Disturbance. High Titers Of The Progrp And Anti-P/Q-Type Vgcc Antibody Were Detected In The Serum. High Accumulation Of [18F] Was Detected At The Hilus Of The Left Lung On [18F]-Fdg-Pet Scan. A High-Frequency Repetitive Stimulation Test Of The Median Nerve Yielded An Incremental Response. On The Basis Of These Findings, A Diagnosis Of Paraneoplastic Cerebellar Degeneration (Pcd) And Lambert-Eaton Myasthenic Syndrome (Lems) Associated With Small Cell Lung Carcinoma (Sclc) Was Diagnosed. After Intravenous Immunoglobulin Therapy (Ivig), Methylprednisolone (M-Psl) Pulse Therapy, And Other Multidisciplinary Concurrent Treatments, A Partial Regression Of The Sclc And A Significant Improvement In Neurological Symptoms Were Observed. However, Ataxia Relapsed And Brainstem Encephalitis Developed 6 Months Later. A Marginal Improvement In Neurological Symptoms Was Observed With Ivig, M-Psl Pulse Therapy, And Intravenous Cyclophosphamide Pulse Therapy (Ivcy). Sclc Also Recurred Later. We Hypothesized That Vgcc Of The Brainstem Was Damaged By Anti-P/Q-Type Vgcc Antibody.|[('Hospital', 'no label'), ('Progressive', 'no label'), ('Truncal Ataxia', 'no label'), ('Gait Disturbance', 'no label'), ('Titers', 'no label'), ('Progrp', 'no label'), ('Antibody', 'no label'), ('Detected', 'no label'), ('Serum', 'no label'), ('Accumulation', 'no label'), ('Detected', 'no label'), ('Hilus', 'no label'), ('Left Lung', 'no label'), ('[18F]-Fdg-Pet Scan', 'no label'), ('High-Frequency', 'no label'), ('Repetitive Stimulation Test', 'no label'), ('Median Nerve', 'no label'), ('Incremental Response', 'no label'), ('Findings', 'no label'), ('Diagnosis', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Diagnosed', 'no label'), ('Intravenous Immunoglobulin Therapy', 'no label'), ('Ivig', 'no label'), ('Methylprednisolone', 'no label'), ('M-Psl) Pulse Therapy', 'no label'), ('Multidisciplinary', 'no label'), ('Concurrent', 'no label'), ('Treatments', 'no label'), ('Partial Regression', 'no label'), ('Sclc', 'no label'), ('Significant', 'no label'), ('Improvement', 'no label'), ('Neurological Symptoms', 'no label'), ('Observed', 'no label'), ('Ataxia Relapsed', 'no label'), ('Brainstem Encephalitis', 'no label'), ('Months', 'no label'), ('Marginal Improvement', 'no label'), ('Neurological Symptoms', 'no label'), ('Observed', 'no label'), ('Ivig', 'no label'), ('M-Psl Pulse Therapy', 'no label'), ('Intravenous Cyclophosphamide', 'no label'), ('Pulse Therapy', 'no label'), ('Ivcy', 'no label'), ('Sclc', 'no label'), ('Recurred', 'no label'), ('Hypothesized', 'no label'), ('Vgcc', 'no label'), ('Brainstem', 'no label'), ('Damaged', 'no label'), ('Vgcc', 'no label'), ('Antibody', 'no label')]|[('Antibody', 'no label'), ('18F', 'no label'), ('Cell', 'no label'), ('Antibody', 'no label')]|[('Anti-P/Q-Type', 'no label'), ('Anti-P/Q-Type Vgcc Antibody', 'no label')]|[('Rapidly', 'no label'), ('Dysarthria', 'no label'), ('Truncal Ataxia', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Methylprednisolone', 'no label'), ('Ataxia Relapsed And Brainstem Encephalitis', 'no label'), ('Cyclophosphamide', 'no label')]|[('Vgcc', 'no label'), ('Serum', 'no label'), ('[18F] Was', 'no label'), ('Hilus', 'no label'), ('Left Lung On', 'no label'), ('Nerve', 'no label'), ('Cerebellar', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Methylprednisolone', 'no label'), ('Brainstem Encephalitis Developed 6', 'no label'), ('Intravenous Cyclophosphamide', 'no label'), ('Vgcc', 'no label'), ('Brainstem', 'no label')]
lambert eaton syndrome|pubmed~20672848|N-Glycosylation Of The Immunoglobulin Fc Moiety Influences Its Biological Activity By, For Example, Modulating The Interaction With Fc Receptors. Changes In Igg Glycosylation Have Been Found To Be Associated With Various Inflammatory Diseases. Here We Evaluated For The First Time Igg Fc N-Glycosylation Changes In Well-Defined Antibody-Mediated Autoimmune Diseases, That Is, The Neurological Disorders Lambert-Eaton Myasthenic Syndrome And Myasthenia Gravis, With Antibodies To Muscle Nicotinic Acetylcholine Receptors Or Muscle-Specific Kinase. Iggs Were Purified From Serum Or Plasma By Protein A Affinity Chromatography And Digested With Trypsin. Glycopeptides Were Purified And Analyzed By Maldi-Fticr-Ms. Glycoform Distributions Of Both Igg1 And Igg2 Were Determined For 229 Patients And 56 Controls. We Observed An Overall Age And Sex Dependency Of Igg Fc N-Glycosylation, Which Was In Accordance With Literature. All Three Disease Groups Showed Lower Levels Of Igg2 Galactosylation Compared To Controls. In Addition, Lems Patients Showed Lower Igg1 Galactosylation. Notably, The Galactosylation Differences Were Not Paralleled By A Difference In Igg Sialylation. Moreover, The Level Of Igg Core-Fucosylation And Bisecting N-Acetylglucosamine Were Evaluated. The Control And Disease Groups Revealed Similar Levels Of Igg Fc Core-Fucosylation. Interestingly, Lems Patients Below 50 Years Showed Elevated Levels Of Bisecting N-Acetylglucosamine On Igg1 And Igg2, Demonstrating For The First Time The Link Of Changes In The Level Of Bisecting N-Acetylglucosamine With Disease.|[('N-Glycosylation', 'no label'), ('Immunoglobulin Fc Moiety', 'no label'), ('Influences', 'no label'), ('Biological Activity', 'no label'), ('Modulating', 'no label'), ('Interaction', 'no label'), ('Fc Receptors', 'no label'), ('Changes', 'no label'), ('Igg', 'no label'), ('Glycosylation', 'no label'), ('Associated With', 'no label'), ('Inflammatory Diseases', 'no label'), ('Evaluated', 'no label'), ('First Time Igg', 'no label'), ('Fc', 'no label'), ('N-Glycosylation', 'no label'), ('Changes', 'no label'), ('Well-Defined Antibody-Mediated Autoimmune Diseases', 'no label'), ('Neurological Disorders Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Myasthenia Gravis', 'no label'), ('Antibodies', 'no label'), ('Muscle Nicotinic Acetylcholine Receptors', 'no label'), ('Muscle-Specific Kinase', 'no label'), ('Iggs', 'no label'), ('Purified', 'no label'), ('Serum', 'no label'), ('Plasma', 'no label'), ('Protein A Affinity Chromatography', 'no label'), ('Trypsin', 'no label'), ('Glycopeptides', 'no label'), ('Purified', 'no label'), ('Analyzed', 'no label'), ('Glycoform', 'no label'), ('Distributions', 'no label'), ('Igg1', 'no label'), ('Igg2', 'no label'), ('Patients', 'no label'), ('Controls', 'no label'), ('Overall Age', 'no label'), ('Sex Dependency', 'no label'), ('Igg', 'no label'), ('N-Glycosylation', 'no label'), ('Accordance', 'no label'), ('Literature', 'no label'), ('Disease Groups', 'no label'), ('Lower Levels', 'no label'), ('Igg2', 'no label'), ('Galactosylation', 'no label'), ('Controls', 'no label'), ('Addition', 'no label'), ('Lems Patients', 'no label'), ('Lower Igg1', 'no label'), ('Galactosylation', 'no label'), ('Galactosylation Differences', 'no label'), ('Difference', 'no label'), ('Igg', 'no label'), ('Sialylation', 'no label'), ('Level', 'no label'), ('Igg', 'no label'), ('Core-Fucosylation', 'no label'), ('Bisecting N-Acetylglucosamine', 'no label'), ('Evaluated', 'no label'), ('Control And Disease Groups', 'no label'), ('Revealed', 'no label'), ('Levels', 'no label'), ('Igg', 'no label'), ('Fc', 'no label'), ('Core-Fucosylation', 'no label'), ('Lems Patients', 'no label'), ('Years', 'no label'), ('Elevated', 'no label'), ('Levels', 'no label'), ('Bisecting N-Acetylglucosamine', 'no label'), ('Igg1', 'no label'), ('Igg2', 'no label'), ('First Time', 'no label'), ('Changes', 'no label'), ('Level', 'no label'), ('Bisecting N-Acetylglucosamine With Disease', 'no label')]|[('Antibodies', 'no label'), ('Nicotinic Acetylcholine', 'no label'), ('Iggs', 'no label'), ('Protein', 'no label'), ('Igg1', 'no label'), ('Igg2', 'no label'), ('Igg2', 'no label'), ('N-Acetylglucosamine', 'no label'), ('Igg1', 'no label'), ('N-Acetylglucosamine', 'no label')]|[('Immunoglobulin Fc', 'no label'), ('Fc Receptors', 'no label'), ('Sex', 'no label'), ('Igg Fc', 'no label'), ('Igg Fc', 'no label')]|[('Neurological Disorders Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Myasthenia Gravis', 'no label'), ('Acetylcholine', 'no label'), ('Trypsin', 'no label'), ('Bisecting N-Acetylglucosamine', 'no label'), ('Bisecting N-Acetylglucosamine', 'no label'), ('N-Acetylglucosamine', 'no label')]|[('Immunoglobulin Fc', 'no label'), ('Igg', 'no label'), ('Igg Fc', 'no label'), ('Muscle Nicotinic', 'no label'), ('Acetylcholine', 'no label'), ('Muscle-Specific Kinase', 'no label'), ('Serum', 'no label'), ('Plasma', 'no label'), ('Igg1', 'no label'), ('Igg2', 'no label'), ('Patients', 'no label'), ('Igg Fc', 'no label'), ('Igg2', 'no label'), ('Lems Patients', 'no label'), ('Lower Igg1', 'no label'), ('Igg', 'no label'), ('Igg', 'no label'), ('Bisecting N-Acetylglucosamine', 'no label'), ('Igg Fc', 'no label'), ('Lems Patients Below', 'no label'), ('Bisecting N-Acetylglucosamine', 'no label'), ('Igg1', 'no label'), ('Igg2', 'no label'), ('Link', 'no label'), ('Bisecting N-Acetylglucosamine', 'no label')]
lambert eaton syndrome|pubmed~19609921|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disease That Is Characterized By Impaired Transmission Across The Neuromuscular Junction Due To Autoantibodies Directed Against The Presynaptic Voltage-Gated Calcium Channels (Vgcc-Ab). Clinical Symptoms Are Usually Characterized By Proximal Muscle Weakness And Mild Dysautonomia. In Some Patients There Are Signs Of Cerebellar Dysfunction As Well, Usually Associated With Cancer. Here We Report The Long-Term Follow-Up Of A Patient With Vgcc-Ab-Positive Lems And A Severe Cerebellar Syndrome But Without Evidence Of Cancer Over 5 Years. While Conventional Immunosuppressive Therapy (Steroids, Azathioprine) Failed, He Improved With Plasma Exchange And Consecutive Treatment With Rituximab. Muscle Nerve 40: 305-308, 2009.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disease', 'no label'), ('Characterized', 'no label'), ('Impaired', 'no label'), ('Transmission', 'no label'), ('Neuromuscular Junction', 'no label'), ('Autoantibodies', 'no label'), ('Directed', 'no label'), ('Presynaptic Voltage-Gated Calcium Channels', 'no label'), ('Vgcc-Ab', 'no label'), ('Clinical Symptoms', 'no label'), ('Characterized', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Dysautonomia', 'no label'), ('Patients', 'no label'), ('Signs', 'no label'), ('Cerebellar Dysfunction', 'no label'), ('Associated With', 'no label'), ('Cancer', 'no label'), ('Long-Term Follow-Up', 'no label'), ('Patient', 'no label'), ('Vgcc-Ab-Positive Lems', 'no label'), ('Severe', 'no label'), ('Cerebellar Syndrome', 'no label'), ('Evidence', 'no label'), ('Cancer', 'no label'), ('Years', 'no label'), ('Conventional Immunosuppressive Therapy', 'no label'), ('Steroids', 'no label'), ('Azathioprine', 'no label'), ('Failed', 'no label'), ('Plasma Exchange', 'no label'), ('Consecutive', 'no label'), ('Treatment', 'no label'), ('Rituximab', 'no label'), ('Muscle Nerve', 'no label')]|[('Calcium', 'no label'), ('Azathioprine', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('Calcium', 'no label'), ('Muscle Weakness', 'no label'), ('Dysautonomia', 'no label'), ('Cerebellar Dysfunction', 'no label'), ('Cancer', 'no label'), ('Cerebellar Syndrome', 'no label'), ('Cancer', 'no label'), ('Steroids', 'no label'), ('Azathioprine', 'no label'), ('Rituximab', 'no label')]|[('Neuromuscular', 'no label'), ('Autoantibodies', 'no label'), ('Presynaptic', 'no label'), ('Calcium', 'no label'), ('Muscle', 'no label'), ('Patients', 'no label'), ('Signs Of', 'no label'), ('Cerebellar', 'no label'), ('Cancer', 'no label'), ('Patient', 'no label'), ('Cerebellar', 'no label'), ('Cancer', 'no label'), ('Steroids', 'no label'), ('Azathioprine', 'no label'), ('Plasma', 'no label'), ('Rituximab', 'no label'), ('Muscle Nerve', 'no label')]
lambert eaton syndrome|pubmed~27935068|We Analyzed Jitter Recordings Made With Concentric Needle Electrode (Cne) Single-Fiber Electromyography (Sfemg) In Lambert-Eaton Myasthenia (Lem). Fifteen Subjects Diagnosed With Lem Were Studied Using Cne-Sfemg In The Extensor Digitorum (Ed) And Tibialis Anterior (Ta) Muscles. Cne-Sfemg In The Ed And Ta Was Also Used To Evaluate 12 And 10 Healthy Controls (Hcs), Respectively. Ten Men And 5 Women Were Diagnosed With Lem Based On An Increase Of 100% In Compound Muscle Action Potential Amplitude During 50 Hz Repetitive Nerve Stimulation. All Patients Exhibited Markedly Greater Jitter In The Ed (88.8 ± 23.2 Μs) And Ta (92.2 ± 30.2 Μs) Than Hcs (28.3 ± 3.4 Μs And 30.9 ± 5.1 Μs, Respectively). Cne-Sfemg Is Sensitive For Discovering Abnormalities In Neuromuscular Transmission In Lem. Muscle Nerve 56: 253-257, 2017.|[('Analyzed', 'no label'), ('Jitter', 'no label'), ('Concentric Needle Electrode', 'no label'), ('Cne', 'no label'), ('Single-Fiber Electromyography', 'no label'), ('Sfemg', 'no label'), ('Lambert-Eaton Myasthenia', 'no label'), ('Subjects', 'no label'), ('Diagnosed', 'no label'), ('Lem Were Studied', 'no label'), ('Cne-Sfemg', 'no label'), ('Extensor Digitorum', 'no label'), ('Tibialis Anterior', 'no label'), ('Cne-Sfemg', 'no label'), ('Ed And Ta', 'no label'), ('Evaluate', 'no label'), ('Healthy Controls', 'no label'), ('Hcs', 'no label'), ('Men', 'no label'), ('Women', 'no label'), ('Diagnosed', 'no label'), ('Increase', 'no label'), ('Compound Muscle', 'no label'), ('Amplitude', 'no label'), ('Repetitive Nerve', 'no label'), ('Stimulation', 'no label'), ('Patients', 'no label'), ('Markedly', 'no label'), ('Jitter', 'no label'), ('Ta', 'no label'), ('Hcs', 'no label'), ('Cne-Sfemg', 'no label'), ('Sensitive', 'no label'), ('Discovering Abnormalities', 'no label'), ('Neuromuscular Transmission', 'no label')]|[('Cne-Sfemg', 'no label'), ('Cne-Sfemg', 'no label'), ('Cne-Sfemg', 'no label')]|[('Ed (88.8\u2009±\u200923.2\u2009Μs) And Ta (92.2\u2009±\u200930.2\u2009Μs) Than Hcs (28.3\u2009±\u20093.4\u2009Μs And 30.9\u2009±\u20095.1\u2009Μs, Respectively).', 'no label')]|[('Lambert-Eaton Myasthenia', 'no label'), ('Cne-Sfemg', 'no label'), ('Discovering Abnormalities In Neuromuscular Transmission', 'no label')]|[('Concentric Needle Electrode', 'no label'), ('Tibialis Anterior (', 'no label'), ('Women', 'no label'), ('Nerve', 'no label'), ('Patients', 'no label'), ('Ta (92.2\u2009±', 'no label'), ('Neuromuscular', 'no label'), ('Muscle Nerve', 'no label')]
lambert eaton syndrome|pubmed~18032743|We Reported That 43% Of Patients With Lambert-Eaton Myasthenic Syndrome (Lems) And Small Cell Lung Cancer (Sclc) Had An Antibody Called Anti-Glial Nuclear Antibody (Agna), Defined By The Immunoreaction With The Nuclei Of The Bergmann Glia Of The Cerebellum. This Study Was Undertaken To Identify The Antigen Recognized By Agna And To Confirm The Association With Paraneoplastic Lems In A Larger Series. We Probed A Fetal Brain Cdna Library With Agna-Positive Sera. The Presence Of Antibodies Against The Isolated Antigen Was Detected By Immunoblot Of Phage Plaques From Two Positive Clones. We Studied 105 Patients With Lems (55 With Sclc), 50 With Paraneoplastic Neurologic Syndromes, Sclc, And Hu Antibodies, And 50 With Only Sclc. Probing Of The Fetal Brain Expression Library With Agna Sera Resulted In The Isolation Of Sox1, A Highly Immunogenic Tumor Antigen In Sclc. Igg Eluted From Sox1 Clones Produced The Same Cerebellar Immunoreactivity As Of Agna Sera. Sox1 Antibodies Were Present In 64% Of Patients With Lems And Sclc But In None Of The 50 With Idiopathic Lems (P < 0.0001). Compared With Paraneoplastic Lems, The Frequency Of Sox1 Antibodies Was Significantly Lower In Patients With Hu Antibodies (32%, P = 0.002) And In Those With Only Sclc (22%). Sox1 Is The Antigen Recognized By Anti-Glial Nuclear Antibody-Positive Sera. The Detection Of Sox1 Antibodies In Patients With Lambert-Eaton Myasthenic Syndrome (Lems) Predicts The Presence Of Small Cell Lung Cancer And May Be Used To Follow More Closely Those Lems Patients With No Evidence Of Cancer At The Initial Workup.|[('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Antibody', 'no label'), ('Anti-Glial Nuclear Antibody', 'no label'), ('Agna', 'no label'), ('Immunoreaction', 'no label'), ('Nuclei', 'no label'), ('Bergmann Glia', 'no label'), ('Cerebellum', 'no label'), ('Study', 'no label'), ('Antigen', 'no label'), ('Recognized', 'no label'), ('Association', 'no label'), ('Paraneoplastic Lems', 'no label'), ('Series', 'no label'), ('Fetal', 'no label'), ('Agna-Positive', 'no label'), ('Sera', 'no label'), ('Antibodies', 'no label'), ('Isolated Antigen', 'no label'), ('Immunoblot', 'no label'), ('Phage Plaques', 'no label'), ('Positive Clones', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Paraneoplastic Neurologic Syndromes', 'no label'), ('Sclc', 'no label'), ('Hu Antibodies', 'no label'), ('Sclc', 'no label'), ('Fetal', 'no label'), ('Expression Library', 'no label'), ('Sera', 'no label'), ('Resulted', 'no label'), ('Isolation', 'no label'), ('Sox1', 'no label'), ('Highly Immunogenic Tumor Antigen', 'no label'), ('Sclc', 'no label'), ('Igg', 'no label'), ('Eluted', 'no label'), ('Sox1 Clones', 'no label'), ('Cerebellar', 'no label'), ('Immunoreactivity', 'no label'), ('Agna', 'no label'), ('Sera', 'no label'), ('Sox1 Antibodies', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Idiopathic Lems', 'no label'), ('Paraneoplastic Lems', 'no label'), ('Frequency', 'no label'), ('Sox1 Antibodies', 'no label'), ('Patients', 'no label'), ('Hu Antibodies', 'no label'), ('Sclc', 'no label'), ('Sox1', 'no label'), ('Antigen Recognized', 'no label'), ('Anti-Glial Nuclear Antibody-Positive Sera', 'no label'), ('Detection', 'no label'), ('Sox1 Antibodies', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Predicts', 'no label'), ('Presence', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Lems Patients', 'no label'), ('No Evidence', 'no label'), ('Cancer', 'no label'), ('Initial', 'no label'), ('Workup', 'no label')]|[('Cell', 'no label'), ('Antibody', 'no label'), ('Nuclei', 'no label'), ('Glia', 'no label'), ('Cdna', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Sox1', 'no label'), ('Sox1 Clones', 'no label'), ('Sox1 Antibodies', 'no label'), ('Sox1 Antibodies', 'no label'), ('Antibodies', 'no label'), ('Sox1', 'no label'), ('Sox1 Antibodies', 'no label'), ('Cell', 'no label')]|[('Anti-Glial Nuclear Antibody', 'no label'), ('Bergmann Glia', 'no label'), ('Fetal Brain Cdna Library', 'no label'), ('Hu Antibodies', 'no label'), ('Fetal Brain Expression Library', 'no label'), ('Sox1', 'no label'), ('Igg', 'no label'), ('Sox1 Clones', 'no label'), ('Sox1 Antibodies', 'no label'), ('Sox1 Antibodies', 'no label'), ('Hu Antibodies', 'no label'), ('Sox1', 'no label'), ('Sox1 Antibodies', 'no label')]|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Paraneoplastic', 'no label'), ('Paraneoplastic Neurologic Syndromes', 'no label'), ('Tumor', 'no label'), ('Idiopathic Lems (P < 0.0001)', 'no label'), ('Paraneoplastic', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Cancer', 'no label')]|[('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Anti-Glial Nuclear Antibody', 'no label'), ('Nuclei', 'no label'), ('Bergmann Glia', 'no label'), ('Fetal Brain Cdna', 'no label'), ('Sera', 'no label'), ('Phage', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Hu Antibodies', 'no label'), ('Fetal Brain', 'no label'), ('Sera', 'no label'), ('Sox1', 'no label'), ('Tumor Antigen', 'no label'), ('Sox1 Clones', 'no label'), ('Cerebellar', 'no label'), ('Sera', 'no label'), ('Sox1', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Sox1', 'no label'), ('Patients', 'no label'), ('Hu Antibodies', 'no label'), ('Sox1', 'no label'), ('Antigen', 'no label'), ('Sera', 'no label'), ('Sox1', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Lems Patients', 'no label'), ('Cancer', 'no label')]
lambert eaton syndrome|pubmed~19803409|We Report The Case Of A 50-Year-Old Man With Paraneoplastic Cerebellar Degeneration (Pcd) And Lambert-Eaton Myasthenic Syndrome (Lems) Associated With Primary Double Lung Cancer. He Developed Acute Progressive Double Vision, Slurred Speech, And Gait Disturbance. Neurological Examination Revealed Diplopia, Mild Ptosis, Bilateral Horizontal Gaze-Evoked Nystagmus, And Cerebellar Limb And Truncal Ataxia. The Diffusion Image Of Brain Magnetic Resonance Imaging (Mri) Revealed No Abnormal Findings In The Cerebellum. On The Basis Of The Diagnosis Of Acute Cerebelitis, He Was Given Methylprednisolone Pulse Therapy Followed By Oral Prednisolone, Which Gradually Improved His Neurological Signs And Symptoms. The Analysis Of The Possible Etiology Suggested That The Pcd Was Induced By Lung Cancer, Which Led To Ataxia. A Chest Computed Tomography Scan Revealed Mass Lesions Of Irregular Shape And Unclear Margins In The Upper Lobe Of The Right Lung And A Small Nodule Tumor In The Upper Lobe Of The Left Lung. We Performed Transbronchial Needle Aspiration And Detected The Bronchioloalveolar Carcinoma Of The Right Lung. An Electromyogram Showed Waxing Phenomenon In The Ulnar Nerve At High-Frequency (50Hz) Stimulation. The Serum Levels Of Anti-P/Q-Type Voltage-Gated Calcium Channel (Vgcc) Antibody Were Elavated In The Patient. These Findings Confirmed That The Pathogenesis Of The Condition Of This Patient To Be Associated With Lems. His Cerebellar Symptoms Were Considered To Be Caused By The Pcd, And The Diplopia, Ptosis, And Hyporeflexia Were Attributed To Lems. We Performed Upper Left Lobectomy With Mediastinal Lymphnode Dissection Via Video-Assisted Thoracoscopic Surgery. A Histological Study Detected Small Cell Carcinoma. A Diagnosis Of Double Primary Lung Cancer Was Made. Physicians Need To Be Aware That Patients May Develop Pcd And Lems Associated With Anti-Vgcc Antibody Caused By Small Cell Lung Cancer, And A Mass Survey Should Be Conducted And Careful Examinations Performed.|[('Report', 'no label'), ('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Primary Double Lung Cancer', 'no label'), ('Acute Progressive Double Vision', 'no label'), ('Slurred Speech', 'no label'), ('Gait Disturbance', 'no label'), ('Neurological Examination Revealed', 'no label'), ('Diplopia', 'no label'), ('Mild Ptosis', 'no label'), ('Bilateral', 'no label'), ('Horizontal', 'no label'), ('Gaze-Evoked Nystagmus', 'no label'), ('Cerebellar Limb', 'no label'), ('Truncal Ataxia', 'no label'), ('Diffusion Image', 'no label'), ('Brain Magnetic Resonance Imaging', 'no label'), ('Mri', 'no label'), ('Revealed', 'no label'), ('Abnormal Findings', 'no label'), ('Cerebellum', 'no label'), ('Diagnosis', 'no label'), ('Acute Cerebelitis', 'no label'), ('Methylprednisolone', 'no label'), ('Pulse Therapy', 'no label'), ('Oral', 'no label'), ('Prednisolone', 'no label'), ('His Neurological Signs And Symptoms', 'no label'), ('Analysis', 'no label'), ('Etiology', 'no label'), ('Suggested', 'no label'), ('Pcd Was Induced', 'no label'), ('Lung Cancer', 'no label'), ('Ataxia', 'no label'), ('Chest Computed Tomography Scan', 'no label'), ('Mass Lesions', 'no label'), ('Irregular', 'no label'), ('Shape', 'no label'), ('Upper Lobe', 'no label'), ('Right Lung And A Small Nodule Tumor', 'no label'), ('Upper Lobe', 'no label'), ('Left Lung', 'no label'), ('Performed', 'no label'), ('Transbronchial', 'no label'), ('Needle Aspiration', 'no label'), ('Detected', 'no label'), ('Bronchioloalveolar Carcinoma', 'no label'), ('Right Lung', 'no label'), ('Electromyogram', 'no label'), ('Waxing', 'no label'), ('Phenomenon', 'no label'), ('Ulnar Nerve', 'no label'), ('High-Frequency', 'no label'), ('Stimulation', 'no label'), ('Serum Levels', 'no label'), ('Voltage-Gated Calcium Channel', 'no label'), ('Vgcc', 'no label'), ('Antibody', 'no label'), ('Elavated', 'no label'), ('Patient', 'no label'), ('Findings', 'no label'), ('Confirmed', 'no label'), ('Pathogenesis', 'no label'), ('Condition', 'no label'), ('Patient', 'no label'), ('Associated With', 'no label'), ('Lems', 'no label'), ('Cerebellar', 'no label'), ('Symptoms', 'no label'), ('Pcd', 'no label'), ('Diplopia', 'no label'), ('Ptosis', 'no label'), ('Hyporeflexia', 'no label'), ('Performed', 'no label'), ('Upper', 'no label'), ('Left Lobectomy', 'no label'), ('Mediastinal Lymphnode Dissection', 'no label'), ('Video-Assisted Thoracoscopic Surgery', 'no label'), ('Histological Study Detected Small Cell Carcinoma', 'no label'), ('Diagnosis', 'no label'), ('Double Primary Lung Cancer', 'no label'), ('Physicians', 'no label'), ('Patients', 'no label'), ('Associated With', 'no label'), ('Anti-Vgcc Antibody', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Mass Survey', 'no label'), ('Examinations', 'no label'), ('Performed', 'no label')]|[('His', 'no label'), ('Calcium', 'no label'), ('Antibody', 'no label'), ('His', 'no label'), ('Cell', 'no label'), ('Antibody', 'no label'), ('Cell', 'no label')]|[('His', 'no label')]|[('Paraneoplastic Cerebellar Degeneration', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Lung Cancer', 'no label'), ('Vision', 'no label'), ('Diplopia', 'no label'), ('Ptosis', 'no label'), ('Nystagmus', 'no label'), ('Truncal Ataxia', 'no label'), ('Acute Cerebelitis', 'no label'), ('Methylprednisolone', 'no label'), ('Prednisolone', 'no label'), ('Lung Cancer', 'no label'), ('Ataxia', 'no label'), ('Tumor', 'no label'), ('Bronchioloalveolar Carcinoma', 'no label'), ('Anti-P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Pathogenesis', 'no label'), ('Diplopia', 'no label'), ('Hyporeflexia', 'no label'), ('Carcinoma', 'no label'), ('Primary Lung Cancer', 'no label')]|[('Case Of A 50-Year-Old', 'no label'), ('Cerebellar', 'no label'), ('Primary Double Lung Cancer', 'no label'), ('Cerebellar Limb And', 'no label'), ('Brain', 'no label'), ('Methylprednisolone', 'no label'), ('Oral Prednisolone', 'no label'), ('Lung Cancer', 'no label'), ('Lobe', 'no label'), ('Right Lung', 'no label'), ('Tumor', 'no label'), ('Lobe', 'no label'), ('Left Lung.', 'no label'), ('Transbronchial Needle', 'no label'), ('Bronchioloalveolar Carcinoma', 'no label'), ('Right Lung.', 'no label'), ('Electromyogram', 'no label'), ('Ulnar Nerve', 'no label'), ('Serum', 'no label'), ('Anti-P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Patient', 'no label'), ('Cerebellar', 'no label'), ('Lymphnode Dissection', 'no label'), ('Small Cell Carcinoma.', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Cancer', 'no label')]
lambert eaton syndrome|pubmed~19540037||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~18653245|The Lambert-Eaton Myasthenic Syndrome (Lems) Is Caused By Auto-Antibodies That Affect The Activity Of Presynaptic Calcium Channels At The Neuromuscular Junction. Weakness In Lems Is Particularly Affecting The Legs. Here We Used Leg Muscles From The Rolling Nagoya (Rn) Mouse With A R1262G Mutation In The Alpha-1 Subunit Of The P/Q-Type (Ca(V)2.1) Calcium Channel. We Found That In Homozygote Flexor Digitorum Brevis (Fdb) Muscles The Contractions By Single Pulses, Expressed As Relative To Contractions By Direct Stimulation, Were Smaller (43%) Than In Controls (94%) With 0.5 Mm Ca(2+) In The Medium. In Both Homozygote Rn And Control Animals The Contractions Of The Fdb By Single Pulses Were Affected More Than The Corresponding Contractions Of The Diaphragm; Rn Muscles With 0.5 Mm Ca(2+), Fdb 42% And Dia 91%, Respectively; Control Muscles With 0.25 Mm Ca(2+), Fdb 9% And Dia 39%, Respectively. At 40 Hz Stimulation This Difference Was 35% And 76% With 0.35 Mm Ca(2+). In Rn And Control Mice Both Muscles Were About Equally Sensitive To 200 And 400 Microm Tubocurarine. The Results Suggest That Leg Weakness In Lems May Result From A Relatively Small Safety Factor Of Neuromuscular Transmission And That This Could Become Particularly Prominent When The Activity Of Calcium Channels Is Diminished.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Auto-Antibodies', 'no label'), ('Activity', 'no label'), ('Presynaptic Calcium Channels', 'no label'), ('Neuromuscular Junction', 'no label'), ('Weakness', 'no label'), ('Lems', 'no label'), ('Affecting', 'no label'), ('Legs', 'no label'), ('Leg Muscles', 'no label'), ('Rolling Nagoya', 'no label'), ('Rn', 'no label'), ('Mouse With', 'no label'), ('R1262G Mutation', 'no label'), ('Alpha-1 Subunit', 'no label'), ('P/Q-Type (Ca(V)2.1) Calcium Channel', 'no label'), ('Homozygote', 'no label'), ('Flexor Digitorum Brevis', 'no label'), ('Contractions', 'no label'), ('Expressed', 'no label'), ('Contractions', 'no label'), ('Direct Stimulation', 'no label'), ('Controls', 'no label'), ('Ca(2+)', 'no label'), ('Medium', 'no label'), ('Homozygote Rn', 'no label'), ('Control Animals', 'no label'), ('Contractions', 'no label'), ('Affected', 'no label'), ('Contractions', 'no label'), ('Diaphragm', 'no label'), ('Rn Muscles', 'no label'), ('Ca(2+)', 'no label'), ('Dia', 'no label'), ('Control Muscles', 'no label'), ('Ca(2+)', 'no label'), ('Dia', 'no label'), ('Stimulation', 'no label'), ('Difference', 'no label'), ('Ca(2+)', 'no label'), ('Rn', 'no label'), ('Muscles', 'no label'), ('Sensitive', 'no label'), ('Tubocurarine', 'no label'), ('Results', 'no label'), ('Suggest', 'no label'), ('Leg Weakness', 'no label'), ('Lems', 'no label'), ('Result', 'no label'), ('Small Safety Factor', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Activity', 'no label'), ('Calcium Channels', 'no label'), ('Diminished', 'no label')]|[('Calcium', 'no label'), ('Mouse', 'no label'), ('Mutation', 'no label'), ('Alpha-1 Subunit Of The P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Animals', 'no label'), ('Mice', 'no label'), ('Tubocurarine', 'no label'), ('Calcium', 'no label')]|[('Alpha-1 Subunit', 'no label'), ('Homozygote Rn', 'no label'), ('Dia', 'no label'), ('Dia', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Calcium', 'no label'), ('P/Q-Type', 'no label'), ('Ca(V)2.1', 'no label'), ('Calcium', 'no label'), ('0.5 Mm', 'no label'), ('Tubocurarine', 'no label'), ('Leg Weakness', 'no label'), ('Calcium', 'no label')]|[('Auto-Antibodies', 'no label'), ('Presynaptic Calcium', 'no label'), ('Neuromuscular', 'no label'), ('Lems', 'no label'), ('Legs', 'no label'), ('Nagoya', 'no label'), ('A R1262G', 'no label'), ('Alpha-1', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Homozygote Flexor Digitorum Brevis', 'no label'), ('Contractions', 'no label'), ('Contractions', 'no label'), ('Mm Ca(2', 'no label'), ('Homozygote Rn', 'no label'), ('Contractions', 'no label'), ('Contractions', 'no label'), ('Mm Ca(2', 'no label'), ('Dia', 'no label'), ('Muscles', 'no label'), ('Mm Ca(2', 'no label'), ('Dia', 'no label'), ('Mm Ca(2', 'no label'), ('Mice', 'no label'), ('Muscles', 'no label'), ('Tubocurarine', 'no label'), ('Leg', 'no label'), ('Lems', 'no label'), ('Neuromuscular', 'no label'), ('Calcium', 'no label')]
lambert eaton syndrome|pubmed~17122730|Neuromuscular Junction Disorders Are Usually Categorized As Either Presynaptic Or Postsynaptic. The Most Frequently Encountered Disorder Of The Postsynaptic Neuromuscular Junction Is Acquired Myasthenia Gravis. Lambert-Eaton Myasthenic Syndrome Is A Well-Known Prototype Of The Presynaptic Autoimmune Disorders Of Neuromuscular Transmission. These Major Disorders Of Neuromuscular Transmission Are Relatively Common And Distinctly Recognized, But Co-Occurrence Of These Disorders (Overlap Myasthenic Syndrome) Is Rare And Has So Far Attracted Little Attention. This Report Describes A Patient With Acquired Myasthenia Gravis And Immunologic Coexistence Of Lambert-Eaton Myasthenic Syndrome (Overlap Myasthenic Syndrome) In Association With Abdominal/Uterine Leiomyosarcoma. The Patient Presented With Acute Respiratory Failure, Making Identification And Management Of Her Illness Challenging. A General Overview Of The Complexities Associated With Overlap Between Myasthenia Gravis And Lambert-Eaton Myasthenic Syndrome Is Provided And This Patient'S Complicated Clinical Course And Response To Therapy Are Discussed. To Our Knowledge, This Is The First Report Of Overlap Myasthenic Syndrome In Conjunction With Abdominal Leiomyosarcoma. The Immunologic Coexistence Of Acquired Myasthenia Gravis And Lambert-Eaton Myasthenic Syndrome In A Patient With A Malignant Smooth-Muscle Tumor Is Intriguing And Suggests That A Common Paraneoplastic Process Targeting 2 Different Onconeural Antigens Was The Underlying Pathogenic Mechanism In This Patient.|"[('Neuromuscular Junction Disorders', 'no label'), ('Categorized', 'no label'), ('Presynaptic', 'no label'), ('Postsynaptic', 'no label'), ('Encountered', 'no label'), ('Disorder', 'no label'), ('Postsynaptic Neuromuscular Junction', 'no label'), ('Acquired Myasthenia Gravis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Presynaptic Autoimmune Disorders', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Common', 'no label'), ('Recognized', 'no label'), ('Co-Occurrence', 'no label'), ('Disorders', 'no label'), ('Overlap Myasthenic Syndrome', 'no label'), ('Rare', 'no label'), ('Far', 'no label'), ('Attracted', 'no label'), ('Attention', 'no label'), ('Report', 'no label'), ('Describes', 'no label'), ('Patient', 'no label'), ('Acquired Myasthenia Gravis', 'no label'), ('Immunologic', 'no label'), ('Coexistence', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Overlap Myasthenic Syndrome', 'no label'), ('Association', 'no label'), ('Abdominal/Uterine', 'no label'), ('Leiomyosarcoma', 'no label'), ('Patient', 'no label'), ('Acute Respiratory Failure', 'no label'), ('Making Identification', 'no label'), ('Management', 'no label'), ('Illness', 'no label'), ('General Overview', 'no label'), ('Complexities', 'no label'), ('Associated With', 'no label'), ('Overlap', 'no label'), ('Myasthenia Gravis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), (""Patient'S"", 'no label'), ('Complicated', 'no label'), ('Clinical Course', 'no label'), ('Response', 'no label'), ('Therapy', 'no label'), ('Knowledge', 'no label'), ('Overlap Myasthenic Syndrome', 'no label'), ('Conjunction', 'no label'), ('Abdominal Leiomyosarcoma', 'no label'), ('Immunologic', 'no label'), ('Coexistence', 'no label'), ('Acquired Myasthenia Gravis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Patient', 'no label'), ('Malignant Smooth-Muscle Tumor', 'no label'), ('Suggests', 'no label'), ('Paraneoplastic Process', 'no label'), ('Targeting', 'no label'), ('Onconeural Antigens', 'no label'), ('Pathogenic', 'no label'), ('Mechanism', 'no label'), ('Patient', 'no label')]"|[('Pathogenic', 'no label')]|[('Onconeural Antigens', 'no label')]|[('Encountered Disorder', 'no label'), ('Myasthenia Gravis', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorders Of Neuromuscular Transmission', 'no label'), ('Disorders Of Neuromuscular Transmission', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Acquired Myasthenia Gravis And Immunologic Coexistence', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Leiomyosarcoma', 'no label'), ('Acute Respiratory Failure', 'no label'), ('Myasthenia Gravis', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Abdominal Leiomyosarcoma', 'no label'), ('Acquired Myasthenia Gravis', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Malignant Smooth-Muscle Tumor', 'no label')]|[('Presynaptic', 'no label'), ('Postsynaptic', 'no label'), ('Postsynaptic Neuromuscular', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular', 'no label'), ('Neuromuscular', 'no label'), ('Far', 'no label'), ('Abdominal/Uterine Leiomyosarcoma', 'no label'), ('Patient', 'no label'), ('Acute Respiratory', 'no label'), ('Patient', 'no label'), ('Abdominal Leiomyosarcoma', 'no label'), ('A Malignant Smooth-Muscle Tumor', 'no label'), ('Onconeural Antigens', 'no label')]
lambert eaton syndrome|pubmed~19357643|3,4-Diaminopyridine And Pyridostigmine Are Widely Used To Treat Lambert-Eaton Myasthenic Syndrome (Lems), Either Alone Or In Combination. 3,4-Diaminopyridine Enhances The Release Of Acetylcholine At The Neuromuscular Synapse, And Pyridostigmine Inhibits The Degradation Of This Neurotransmitter. Although This Could Lead To A Synergistic Effect On Neuromuscular Transmission, No Studies Have Compared The Effects Of These Drugs In Patients With Lems. Therefore, We Performed A Placebo-Controlled, Double-Dummy, Double-Blind, Randomized, Crossover Study In Nine Patients With Lems.|[('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label'), ('Treat', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Alone', 'no label'), ('Combination', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Enhances', 'no label'), ('Release', 'no label'), ('Acetylcholine', 'no label'), ('Neuromuscular Synapse', 'no label'), ('Pyridostigmine', 'no label'), ('Inhibits', 'no label'), ('Degradation', 'no label'), ('Neurotransmitter', 'no label'), ('Lead', 'no label'), ('Synergistic', 'no label'), ('Effect', 'no label'), ('Neuromuscular Transmission', 'no label'), ('No Studies', 'no label'), ('Effects', 'no label'), ('Drugs', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Performed A Placebo-Controlled', 'no label'), ('Double-Dummy', 'no label'), ('Double-Blind', 'no label'), ('Randomized', 'no label'), ('Crossover Study', 'no label'), ('Patients', 'no label'), ('Lems', 'no label')]|[('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label'), ('Acetylcholine', 'no label'), ('Pyridostigmine', 'no label'), ('Lead To', 'no label')]|[]|[('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label'), ('Myasthenic Syndrome', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Acetylcholine', 'no label'), ('Pyridostigmine', 'no label')]|[('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label'), ('Acetylcholine', 'no label'), ('Neuromuscular', 'no label'), ('Pyridostigmine', 'no label'), ('Neurotransmitter', 'no label'), ('Neuromuscular', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~19198242|A 77-Year-Old Man Was Admitted To Our Hospital With Muscle Weakness And Shortness Of Breath. Chest Ct Showed A Mass In The Left Upper Lobe, And Electromyography Showed Waxing Phenomenon With High-Frequency Repetitive Stimulation. We Diagnosed Lambert-Eaton Myasthenic Syndrome Accompanying Small Cell Lung Cancer. He Was Treated With Carboplatin And Etoposide, And Concurrent Thoracic Irradiation. Although, The Tumor Size Decreased, His Myasthenic Symptoms Remained. He Started Taking 3,4-Diaminopyridine And His Muscle Weakness Improved Dramatically, And He Was Eventually Able To Walk Finally. In Some Cases, Anti-Tumor Therapies Cannot Improve The Myasthenic Symptoms. In Such Cases, 3,4-Diaminopyridine Could Improve The Quality Of Life, And Should Be Approved In Japan.|[('Hospital', 'no label'), ('Muscle Weakness', 'no label'), ('Shortness', 'no label'), ('Breath', 'no label'), ('Chest Ct', 'no label'), ('Mass', 'no label'), ('Left Upper Lobe', 'no label'), ('Electromyography', 'no label'), ('Waxing', 'no label'), ('Phenomenon', 'no label'), ('High-Frequency', 'no label'), ('Repetitive Stimulation', 'no label'), ('Diagnosed', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lung Cancer', 'no label'), ('Treated', 'no label'), ('Carboplatin', 'no label'), ('Etoposide', 'no label'), ('Concurrent', 'no label'), ('Thoracic Irradiation', 'no label'), ('Tumor Size', 'no label'), ('Decreased', 'no label'), ('Myasthenic', 'no label'), ('Remained', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('His Muscle Weakness', 'no label'), ('Walk', 'no label'), ('Cases', 'no label'), ('Anti-Tumor Therapies', 'no label'), ('Myasthenic', 'no label'), ('Symptoms', 'no label'), ('Cases', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Quality Of Life', 'no label'), ('Japan', 'no label')]|[('Cell', 'no label'), ('His', 'no label'), ('His', 'no label')]|[('Ct', 'no label'), ('His', 'no label'), ('His', 'no label')]|[('Muscle Weakness', 'no label'), ('Shortness Of Breath', 'no label'), ('Chest', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Carboplatin', 'no label'), ('Etoposide', 'no label'), ('Tumor', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Muscle Weakness', 'no label'), ('3,4-Diaminopyridine', 'no label')]|[('Muscle', 'no label'), ('Shortness', 'no label'), ('Left Upper Lobe', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Carboplatin', 'no label'), ('Etoposide', 'no label'), ('Tumor', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Muscle', 'no label'), ('3,4-Diaminopyridine', 'no label')]
lambert eaton syndrome|pubmed~20661094||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~27471686|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disorder Mediated By Autoantibodies To Voltage-Gated Calcium Channels. The Disorder Is Diagnosed Clinically On The Basis Of A Triad Of Symptoms (Proximal Muscle Weakness, Hyporeflexia, And Autonomic Disturbance), Supported By Electrophysiological Findings And The Presence Of Autoantibodies. Between 40% And 62% Of Patients Diagnosed With Lems Are Found To Have Small-Cell Lung Cancer (Sclc), Almost All Of Whom Develop Neurological Symptoms Before Their Cancer Is Diagnosed. Prompt Identification Of Lems And Appropriate Screening For Sclc Is Key To Improving The Outcome Of Both Conditions. Here We Review The Pathophysiology And Clinical Management Of Lems, Focusing Particularly On The Relationship With Sclc. |[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disorder', 'no label'), ('Mediated', 'no label'), ('Autoantibodies', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Disorder', 'no label'), ('Diagnosed', 'no label'), ('Triad Of Symptoms', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Hyporeflexia', 'no label'), ('Autonomic Disturbance', 'no label'), ('Electrophysiological Findings', 'no label'), ('Presence', 'no label'), ('Autoantibodies', 'no label'), ('Patients', 'no label'), ('Diagnosed', 'no label'), ('Lems', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Neurological Symptoms', 'no label'), ('Cancer', 'no label'), ('Diagnosed', 'no label'), ('Prompt', 'no label'), ('Identification', 'no label'), ('Lems', 'no label'), ('Screening', 'no label'), ('Sclc', 'no label'), ('Improving', 'no label'), ('Outcome', 'no label'), ('Conditions', 'no label'), ('Review', 'no label'), ('Pathophysiology', 'no label'), ('Clinical Management', 'no label'), ('Lems', 'no label'), ('Relationship', 'no label'), ('Sclc', 'no label')]|[('Calcium', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Calcium', 'no label'), ('Disorder', 'no label'), ('Muscle Weakness', 'no label'), ('Hyporeflexia', 'no label'), ('Lung Cancer', 'no label'), ('Cancer', 'no label')]|[('Calcium', 'no label'), ('Triad', 'no label'), ('Muscle', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Small-Cell Lung Cancer', 'no label'), ('Cancer', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~18474401|To Determine Whether Titers Of Anti-P/Q Type And Anti-N Type Calcium Channel Antibodies Provide Distinct Information, Both Types Of Assay Were Performed During Follow-Up Of 7 Patients With Lambert-Eaton Myasthenic Syndrome (Lems). In 4 Patients With Both Antibody Responses, Titers Evolved Independently And Often In An Inverse Relationship. Two Patients With Squamous Cell Lung Carcinoma (Sqclc) Produced Anti-N Type Channel Antibodies, But No Detectable Anti-P/Q Channel Responses. These Results Suggest That Anti-N Channel Autoantibodies Constitute An Immune Response Distinct From The Anti-P/Q Type Channel Specificity And Can Also Correlate With Clinical Evolution. Consequently Combined Assays May Provide More Comprehensive Information During Follow-Up Of Lems.|[('Titers', 'no label'), ('Anti-P/Q Type And Anti-N Type Calcium Channel Antibodies', 'no label'), ('Information', 'no label'), ('Assay', 'no label'), ('Performed', 'no label'), ('Follow-Up', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Antibody', 'no label'), ('Responses', 'no label'), ('Titers', 'no label'), ('Evolved', 'no label'), ('Inverse', 'no label'), ('Relationship', 'no label'), ('Patients', 'no label'), ('Squamous Cell Lung Carcinoma', 'no label'), ('Sqclc', 'no label'), ('Anti-N Type Channel Antibodies', 'no label'), ('Detectable Anti-P/Q Channel', 'no label'), ('Responses', 'no label'), ('Results', 'no label'), ('Suggest', 'no label'), ('Anti-N Channel Autoantibodies', 'no label'), ('Constitute', 'no label'), ('Immune Response', 'no label'), ('Anti-P/Q Type', 'no label'), ('Clinical Evolution', 'no label'), ('Combined Assays', 'no label'), ('Provide', 'no label'), ('Comprehensive', 'no label'), ('Information', 'no label'), ('Follow-Up', 'no label'), ('Lems', 'no label')]|[('Calcium', 'no label'), ('Antibodies', 'no label'), ('Antibody', 'no label'), ('Squamous Cell', 'no label'), ('Antibodies', 'no label')]|[]|[('Calcium', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Squamous Cell Lung Carcinoma', 'no label'), ('Sqclc', 'no label')]|[('Anti-P/Q Type', 'no label'), ('Anti-N Type', 'no label'), ('Calcium Channel Antibodies', 'no label'), ('Follow-Up Of 7', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Squamous Cell Lung Carcinoma', 'no label'), ('Anti-N Type Channel Antibodies', 'no label'), ('Anti-N Channel Autoantibodies', 'no label'), ('Immune', 'no label'), ('Anti-P/Q Type', 'no label'), ('Follow-Up', 'no label')]
lambert eaton syndrome|pubmed~18288711|An Incremental Response After Brief Exercise Or High-Rate Stimulation On The Repetitive Nerve Stimulation (Rns) Test Is A Critical Diagnostic Criterion For Lambert-Eaton Myasthenic Syndrome (Lems). This Prospective Study Was Performed To Determine What Duration Of Exercise Shows The Highest Diagnostic Sensitivity For Lems. The Compound Muscle Action Potential Amplitude In The Abductor Digiti Quinti Muscle Was Obtained At Rest And After 5 S, 10 S, 15 S, 20 S, 25 S, And 30 S Of Exercise. Incremental Responses Were Compared For The Different Exercise Durations In 24 Studies Performed In Nine Lems Patients. The Increment Was Highest With 5-S And 10-S Exercises (244%-243%) And Lowest With 30-S Exercise (84%). A Gradual Decrease In The Increment Was Noted From 5- To 30-S Exercise. A Significant Difference In The Increment Was Noted Between 5- To 10-S And 20-S To 30-S Exercise. There Was Significantly Higher Diagnostic Sensitivity With The 10-S Exercise Compared With 30-S Exercise At 100% Increment And 60% Increment Levels. Higher Increment And Diagnostic Sensitivity Were Achieved With 10-S Exercise Than With 30-S Exercise. Thus, 10-S Exercise Should Be The Standard Protocol For The Rns Test For Lems.|[('Incremental Response', 'no label'), ('High-Rate Stimulation', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Critical Diagnostic Criterion', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Prospective Study', 'no label'), ('Duration', 'no label'), ('Exercise', 'no label'), ('Diagnostic Sensitivity', 'no label'), ('Lems', 'no label'), ('Compound Muscle', 'no label'), ('Amplitude', 'no label'), ('Abductor Digiti', 'no label'), ('Quinti Muscle', 'no label'), ('Rest', 'no label'), ('S', 'no label'), ('S', 'no label'), ('S', 'no label'), ('S', 'no label'), ('S', 'no label'), ('Exercise', 'no label'), ('Incremental Responses', 'no label'), ('Exercise', 'no label'), ('Durations', 'no label'), ('Studies', 'no label'), ('Performed', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Increment', 'no label'), ('5-S', 'no label'), ('Exercises', 'no label'), ('Exercise', 'no label'), ('Decrease', 'no label'), ('Increment', 'no label'), ('Exercise', 'no label'), ('Increment', 'no label'), ('Exercise', 'no label'), ('Diagnostic Sensitivity', 'no label'), ('Exercise', 'no label'), ('Exercise', 'no label'), ('Increment', 'no label'), ('Increment', 'no label'), ('Levels', 'no label'), ('Increment', 'no label'), ('Diagnostic Sensitivity', 'no label'), ('Exercise Than With', 'no label'), ('Exercise', 'no label'), ('Exercise', 'no label'), ('Standard Protocol', 'no label'), ('Rns Test', 'no label')]|[('30-S', 'no label'), ('20-S', 'no label'), ('30-S', 'no label'), ('30-S', 'no label')]|[('30-S', 'no label'), ('30-S', 'no label'), ('30-S', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Abductor Digiti Quinti Muscle', 'no label'), ('10-S', 'no label')]|[('High-Rate', 'no label'), ('Nerve', 'no label'), ('Abductor Digiti', 'no label'), ('Muscle', 'no label'), ('5 S, 10', 'no label'), ('20 S,', 'no label'), ('Lems Patients', 'no label'), ('5-S', 'no label'), ('30-S', 'no label'), ('30-S', 'no label'), ('20-S', 'no label'), ('30-S', 'no label'), ('30-S', 'no label'), ('30-S', 'no label'), ('Rns Test', 'no label')]
lambert eaton syndrome|pubmed~25792095||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~20336707||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~29365352||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~19347132|Lambert-Eaton Myasthenic Syndrome Is A Rare And Acquired Autoimmune Disorder. We Describe Two Female Patients With Medial Rectus Paresis As The Only Ocular Manifestation. After A Unilateral Medial Rectus Recession And Lateral Rectus Resection Procedure, Both Patients Recovered Normal Adduction. To Our Knowledge, This Is The First Report Of Surgery For Extraocular Muscle Paresis In Lambert-Eaton Myasthenic Syndrome.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Rare', 'no label'), ('Acquired Autoimmune Disorder', 'no label'), ('Female', 'no label'), ('Patients', 'no label'), ('Medial Rectus Paresis', 'no label'), ('Ocular Manifestation', 'no label'), ('Unilateral', 'no label'), ('Medial Rectus', 'no label'), ('Lateral Rectus Resection', 'no label'), ('Patients', 'no label'), ('Normal Adduction', 'no label'), ('Knowledge', 'no label'), ('Surgery', 'no label'), ('Extraocular Muscle Paresis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label')]|[]|[]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disorder', 'no label'), ('Medial Rectus Paresis', 'no label'), ('Ocular Manifestation', 'no label'), ('Extraocular Muscle Paresis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label')]|[('Patients', 'no label'), ('Medial Rectus', 'no label'), ('Medial Rectus', 'no label'), ('Lateral Rectus Resection', 'no label'), ('Patients', 'no label'), ('Extraocular Muscle', 'no label')]
lambert eaton syndrome|pubmed~20058696|A 58-Year-Old Man Complaining Of Increasing Weakness Of Muscular Leg Strength, Diplopia And Ptosis Was Admitted To Our Hospital. An Electromyogram (Emg) Showed Typical Waxing Phenomenon In Response To High-Frequency Repetitive Stimulation. A Diagnosis Of Lambert-Eaton Myasthenic Syndrome (Lems) Was Made From His Symptoms And Emg Results. A Chest Ct Showed Mediastinal Lymph Node Swelling. No Abnormal Mass Was Seen In Either Lung Field. His Serum Levels Of A P/Q-Type Anti-Voltage-Gated Calcium Channel (Vgcc) Antibody, Pro-Grp, And Nse Were High. Fdg-Pet Showed Accumulation Of Fdg To The Mediastinal And Left Inguinal Lymph Nodes. The Left Inguinal Lymphadenopathy Was Pathologically Diagnosed As Metastasis Of Small Cell Lung Carcinoma. No Tumor Could Be Detected By Bronchofiberscopy. No Other Distant Metastasis Was Detected By Brain Mri, Abdominal Ct, Or Fdg-Pet. After 6 Courses Of Chemotherapy For Sclc, A Partial Response And Reduction Of Symptoms Were Obtained. For Assessment Of Indistinguishable Neuropathic Symptoms, The Possible Diagnosis Of Paraneoplastic Syndrome, Such As Lems, And The Fact That Early Treatment For Primary Disease Was Effective, Should Be Considered.|[('58-Year-Old', 'no label'), ('Complaining', 'no label'), ('Increasing', 'no label'), ('Weakness', 'no label'), ('Muscular Leg Strength', 'no label'), ('Diplopia', 'no label'), ('Ptosis', 'no label'), ('Hospital', 'no label'), ('Electromyogram', 'no label'), ('Emg', 'no label'), ('Typical', 'no label'), ('Waxing', 'no label'), ('Phenomenon', 'no label'), ('Response', 'no label'), ('High-Frequency', 'no label'), ('Repetitive Stimulation', 'no label'), ('Diagnosis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('His Symptoms', 'no label'), ('Emg Results', 'no label'), ('Chest Ct', 'no label'), ('Mediastinal Lymph Node Swelling', 'no label'), ('Abnormal', 'no label'), ('Mass', 'no label'), ('Lung Field', 'no label'), ('Serum', 'no label'), ('Levels', 'no label'), ('P/Q-Type Anti-Voltage-Gated', 'no label'), ('Calcium Channel', 'no label'), ('Vgcc', 'no label'), ('Antibody', 'no label'), ('Pro-Grp', 'no label'), ('Nse', 'no label'), ('Fdg-Pet', 'no label'), ('Accumulation', 'no label'), ('Fdg', 'no label'), ('Mediastinal', 'no label'), ('Left Inguinal', 'no label'), ('Lymph Nodes', 'no label'), ('Left Inguinal Lymphadenopathy', 'no label'), ('Pathologically Diagnosed', 'no label'), ('Metastasis', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Tumor', 'no label'), ('Detected', 'no label'), ('Bronchofiberscopy', 'no label'), ('Distant Metastasis', 'no label'), ('Detected', 'no label'), ('Brain Mri', 'no label'), ('Abdominal Ct', 'no label'), ('Fdg-Pet', 'no label'), ('Courses', 'no label'), ('Chemotherapy', 'no label'), ('Sclc', 'no label'), ('Partial Response', 'no label'), ('Reduction', 'no label'), ('Symptoms', 'no label'), ('Assessment', 'no label'), ('Indistinguishable', 'no label'), ('Neuropathic Symptoms', 'no label'), ('Diagnosis', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Fact', 'no label'), ('Early Treatment', 'no label'), ('Primary Disease', 'no label'), ('Effective', 'no label')]|[('His', 'no label'), ('His', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Antibody', 'no label'), ('Nse', 'no label'), ('Cell', 'no label')]|[('His', 'no label'), ('Emg', 'no label'), ('Ct', 'no label'), ('His', 'no label'), ('Nse', 'no label'), ('Fdg-Pet', 'no label'), ('Fdg', 'no label')]|[('Weakness Of Muscular Leg Strength,', 'no label'), ('Diplopia', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Calcium', 'no label'), ('Left Inguinal Lymphadenopathy', 'no label'), ('Tumor', 'no label'), ('Neuropathic', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Primary Disease', 'no label')]|[('Muscular Leg Strength', 'no label'), ('Electromyogram', 'no label'), ('Lymph Node', 'no label'), ('Lung', 'no label'), ('Serum', 'no label'), ('A P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Nse', 'no label'), ('Fdg', 'no label'), ('Left Inguinal Lymph Nodes', 'no label'), ('Left Inguinal Lymphadenopathy', 'no label'), ('Small Cell Lung Carcinoma.', 'no label'), ('Tumor', 'no label'), ('Brain', 'no label'), ('Paraneoplastic', 'no label')]
lambert eaton syndrome|pubmed~18631847||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~18809213|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Disease In Which The Transmission Across The Neuromuscular Junction Is Disturbed By Autoantibodies Directed Against The Presynaptic P/Q-Type Voltage-Gated Calcium Channels (Vgcc). Lems Is Paraneoplastic (T-Lems) In About 60% Of Patients Mostly Associated With A Small Cellular Lung Carcinoma (Sclc), But Occurs Spontaneously Without A Tumor In 40% (Nt-Lems). In Most Cases Neurologic Symptoms Appear Before Tumor Diagnosis, But There Is As Yet No Clear Specific Serologic Marker To Distinguish Between Nt- And T-Lems. To See Whether Antibodies From Patients With Nt- And T-Lems Differentially Recognize Antigenic Sites Of The Alpha 1A Subunit Of P/Q-Type Vgcc, We Studied Serum Samples From 22 T-Lems And 24 Nt-Lems Patients. Sera Reactivity Was Tested By Western Blot Analysis To Recombinant Proteins Corresponding To The Extracellular S5-S6 Linker Region Of Three Out Of Four Domains Forming The Alpha 1 Subunit Of P/Q-Type Vgcc. Sera From 9/24 (37,5%) Nt-Lems Patients, But Only 1/22 (4,6%) T-Lems Patients Recognized Domain Iv (P=0,011). Seroreactivity To Domains I And Iii Was Similar For Nt-Lems And T-Lems Patients (Domain I: 8%/14%; Domain Iii: 46%/41%, Not Significant). These Data Suggest That An Antibody Response To Domain Iv Is More Common In Lems Without Tumor Than In Paraneoplastic Lems. This May Have Implications For Diagnostic Workup In Lems Patients Without Previously Established Diagnosis Of A Tumor. Additionally This Could Point Towards A Differential Autoimmune Pathogenesis Between T-Lems And Nt-Lems.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Disease', 'no label'), ('Transmission', 'no label'), ('Neuromuscular Junction', 'no label'), ('Autoantibodies', 'no label'), ('Directed', 'no label'), ('Presynaptic P/Q-Type Voltage-Gated Calcium Channels', 'no label'), ('Vgcc', 'no label'), ('Lems', 'no label'), ('T-Lems', 'no label'), ('Patients', 'no label'), ('Associated With', 'no label'), ('Small Cellular Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Spontaneously', 'no label'), ('Tumor', 'no label'), ('Cases', 'no label'), ('Neurologic Symptoms Appear', 'no label'), ('Tumor Diagnosis', 'no label'), ('Serologic Marker', 'no label'), ('Distinguish', 'no label'), ('Nt-', 'no label'), ('T-Lems', 'no label'), ('Antibodies', 'no label'), ('Patients', 'no label'), ('Nt-', 'no label'), ('Differentially', 'no label'), ('Antigenic Sites', 'no label'), ('Alpha 1A', 'no label'), ('Subunit', 'no label'), ('P/Q-Type Vgcc', 'no label'), ('Serum Samples', 'no label'), ('Patients', 'no label'), ('Sera Reactivity', 'no label'), ('Tested', 'no label'), ('Western Blot Analysis', 'no label'), ('Recombinant Proteins', 'no label'), ('Extracellular S5-S6 Linker Region', 'no label'), ('Domains Forming', 'no label'), ('Alpha 1 Subunit', 'no label'), ('P/Q-Type Vgcc', 'no label'), ('Sera', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Domain Iv', 'no label'), ('Seroreactivity', 'no label'), ('Domains I', 'no label'), ('Nt-Lems', 'no label'), ('T-Lems Patients', 'no label'), ('Domain I', 'no label'), ('Not Significant', 'no label'), ('Data Suggest', 'no label'), ('Antibody', 'no label'), ('Response', 'no label'), ('Lems', 'no label'), ('Tumor Than', 'no label'), ('Paraneoplastic Lems', 'no label'), ('May', 'no label'), ('Diagnostic Workup', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Diagnosis', 'no label'), ('Tumor', 'no label'), ('Differential', 'no label'), ('Autoimmune Pathogenesis', 'no label'), ('T-Lems', 'no label')]|[('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Cellular', 'no label'), ('Nt-', 'no label'), ('Antibodies', 'no label'), ('Sites', 'no label'), ('P/Q-Type', 'no label'), ('Proteins', 'no label'), ('Extracellular S5-S6', 'no label'), ('Region', 'no label'), ('P/Q-Type', 'no label'), ('Domain', 'no label'), ('Antibody', 'no label')]|[('Nt-', 'no label'), ('Nt-', 'no label'), ('T-Lems', 'no label'), ('Alpha 1A Subunit', 'no label'), ('Recombinant Proteins', 'no label'), ('Alpha 1 Subunit', 'no label'), ('T-Lems', 'no label'), ('T-Lems', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Autoimmune Disease', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Paraneoplastic', 'no label'), ('Cellular Lung Carcinoma', 'no label'), ('Tumor', 'no label'), ('Tumor', 'no label'), ('P/Q-Type', 'no label'), ('P/Q-Type', 'no label'), ('Tumor', 'no label'), ('Paraneoplastic', 'no label'), ('Tumor', 'no label'), ('Autoimmune Pathogenesis', 'no label')]|[('Neuromuscular', 'no label'), ('Presynaptic P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Paraneoplastic', 'no label'), ('Patients', 'no label'), ('A Small Cellular Lung Carcinoma', 'no label'), ('Tumor', 'no label'), ('Tumor', 'no label'), ('Nt-', 'no label'), ('T-Lems', 'no label'), ('Patients', 'no label'), ('Nt-', 'no label'), ('T-Lems', 'no label'), ('Alpha 1A', 'no label'), ('P/Q-Type Vgcc', 'no label'), ('Serum', 'no label'), ('Patients', 'no label'), ('Sera', 'no label'), ('Extracellular S5-S6', 'no label'), ('Alpha 1', 'no label'), ('P/Q-Type Vgcc', 'no label'), ('Sera', 'no label'), ('Patients', 'no label'), ('Domains I', 'no label'), ('T-Lems Patients', 'no label'), ('Lems', 'no label'), ('Tumor', 'no label'), ('Lems Patients', 'no label'), ('Tumor', 'no label'), ('T-Lems', 'no label')]
lambert eaton syndrome|pubmed~28695360||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~28623849|Lambert-Eaton Myasthenia (Lem) Is A Rare Autoimmune Disorder Associated With Debilitating Muscle Weakness. There Are Limited Treatment Options And 3,4-Diaminopyridine (3,4-Dap) Free Base Is An Investigational Orphan Drug Used To Treat Lem-Related Weakness. We Performed A Population Pharmacokinetic/Pharmacodynamic (Pk/Pd) Analysis Using 3,4-Dap And Metabolite Concentrations Collected From A Phase Ii Study In Patients With Lem. The Triple Timed Up & Go (3Tug) Assessment, Which Measures Lower Extremity Weakness, Was The Primary Outcome Measure. A Total Of 1,270 Pk Samples (49 Patients) And 1,091 3Tug Data Points (32 Randomized Patients) Were Included In The Pk/Pd Analysis. A Two-Compartment And One-Compartment Model For Parent And Metabolite, Respectively, Described The Pk Data Well. Body Weight And Serum Creatinine Partially Explained The Variability In Clearance For The Final Pk Model. A Fractional Inhibitory Maximum Effect (E<Sub>Max</Sub> ) Model Characterized The Exposure-Response Relationship Well. The Pk/Pd Model Was Applied To Identify A Suggested Dosing Approach For 3,4-Dap Free Base.|[('Lambert-Eaton Myasthenia', 'no label'), ('Rare', 'no label'), ('Autoimmune Disorder', 'no label'), ('Associated With', 'no label'), ('Debilitating Muscle Weakness', 'no label'), ('Limited Treatment Options', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Free Base', 'no label'), ('Investigational Orphan Drug', 'no label'), ('Treat', 'no label'), ('Lem-Related Weakness', 'no label'), ('Performed A', 'no label'), ('Metabolite', 'no label'), ('Concentrations', 'no label'), ('Collected', 'no label'), ('Phase Ii Study', 'no label'), ('Patients', 'no label'), ('Triple Timed Up & Go', 'no label'), ('Measures', 'no label'), ('Lower Extremity Weakness', 'no label'), ('Primary Outcome Measure', 'no label'), ('Pk', 'no label'), ('Samples', 'no label'), ('Patients', 'no label'), ('Data Points', 'no label'), ('Randomized Patients', 'no label'), ('Pk/Pd Analysis', 'no label'), ('Two-Compartment', 'no label'), ('Parent', 'no label'), ('Metabolite', 'no label'), ('Pk', 'no label'), ('Data', 'no label'), ('Body Weight', 'no label'), ('Serum Creatinine', 'no label'), ('Variability', 'no label'), ('Clearance', 'no label'), ('Final', 'no label'), ('Pk Model', 'no label'), ('Fractional Inhibitory Maximum Effect', 'no label'), ('Model', 'no label'), ('Characterized', 'no label'), ('Exposure-Response Relationship', 'no label'), ('Pk/Pd Model', 'no label'), ('Dosing', 'no label'), ('Approach', 'no label'), ('Free Base', 'no label')]|[('Drug', 'no label')]|[('Ii', 'no label')]|[('Lambert-Eaton Myasthenia', 'no label'), ('Autoimmune Disorder', 'no label'), ('Muscle Weakness', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Creatinine', 'no label')]|[('Muscle', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('A Phase Ii', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Pk Data', 'no label'), ('Serum Creatinine', 'no label'), ('Pk', 'no label'), ('E', 'no label')]
lambert eaton syndrome|pubmed~18841652|Lambert-Eaton Myasthenic Syndrome (Lems) Developed In A Patient With Presumed Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) And Negative Chest Ct. Since Antibodies Against Both Hu And Voltage-Gated Calcium Channel (Vgcc) Were Detected, Repeated Chest Ct Was Performed, Which Eventually Showed A Pulmonary Mass Lesion. Biopsy Revealed Small Cell Lung Cancer (Sclc) Indicating The Importance Of Repeated Chest Ct In Lems Even When An Existing Autoimmune-Like Disease And Negative Ct May Suggest An Autoimmune Origin. This Is The First Report Of Paraneoplastic Cidp And Lems Associated With Anti-Hu, Anti-Vgcc And Sclc.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Patient', 'no label'), ('Presumed Chronic Inflammatory Demyelinating Polyneuropathy', 'no label'), ('Cidp', 'no label'), ('Antibodies', 'no label'), ('Hu And Voltage-Gated Calcium Channel', 'no label'), ('Vgcc', 'no label'), ('Detected', 'no label'), ('Repeated Chest Ct', 'no label'), ('Showed', 'no label'), ('Pulmonary Mass Lesion', 'no label'), ('Biopsy', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Sclc', 'no label'), ('Repeated Chest Ct', 'no label'), ('Lems', 'no label'), ('Autoimmune-Like Disease', 'no label'), ('Autoimmune Origin', 'no label'), ('Paraneoplastic Cidp', 'no label'), ('Associated With', 'no label'), ('Anti-Hu', 'no label'), ('Anti-Vgcc', 'no label'), ('Sclc', 'no label')]|[('Antibodies', 'no label'), ('Calcium', 'no label'), ('Cell', 'no label')]|[('Hu', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Polyneuropathy', 'no label'), ('Calcium', 'no label'), ('Chest', 'no label'), ('Pulmonary Mass Lesion', 'no label'), ('Chest', 'no label'), ('Paraneoplastic Cidp', 'no label')]|[('Calcium', 'no label'), ('Pulmonary Mass', 'no label'), ('Biopsy Revealed Small Cell Lung Cancer', 'no label'), ('Lems', 'no label'), ('Anti-Hu', 'no label')]
lambert eaton syndrome|pubmed~18644631|Neuromuscular Symptoms In Patients With Lambert-Eaton Myasthenic Syndrome (Lems) And A Small Cell Lung Cancer (Sclc) Develop More Rapidly Than In Lems Patients Without A Sclc. We Studied How This Clinical Information, Which Is Readily Available At The First Consultation, Can Be Used To Predict The Presence Of Sclc. In Our Study We Included 52 Lems Patients With Sclc And 45 Non-Tumor Patients (Nt-Lems). We Interviewed Patients Using A Structured Checklist And Reviewed Their Clinical Records. We Compared Frequency And Onset Of Symptoms During The Course Of Lems. In The First Six Months, Over Half The Sclc-Lems Patients Had Developed Seven Separate Symptoms, While Nt-Lems Patients Developed Only Two Symptoms. Proximal Leg Weakness And Dry Mouth Were Early Symptoms In Both Groups. Rapid Involvement Of Proximal Arm Muscles (P=0.0001), Distal Arm Muscles (P=0.0037), Distal Leg Muscles (P=0.0002), Dysartria (P=0.0091) And The Presence Of Erectile Dysfunction (P=0.007) Were Found Significantly More Often In Sclc-Lems Patients In Both Cohorts. Cerebellar Symptoms, Although Present In 9% Of Lems Patients, Were Almost Exclusively Related To Sclc-Lems. A Rapidly Progressive Course Of Disease From Onset In Lems Patients Should Raise A High Suspicion Of Sclc. Special Attention Should Be Paid To Involvement Of Upper Extremities, Involvement Of Distal Arm And Distal Leg Muscles, To Erectile Dysfunction And Probably Ataxia In Order To Discriminate Between Sclc-Lems And Nt-Lems.|[('Neuromuscular Symptoms', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Sclc', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Clinical Information', 'no label'), ('Readily Available', 'no label'), ('First Consultation', 'no label'), ('Presence', 'no label'), ('Sclc', 'no label'), ('Study', 'no label'), ('Lems Patients', 'no label'), ('Sclc', 'no label'), ('Non-Tumor', 'no label'), ('Patients', 'no label'), ('Interviewed Patients', 'no label'), ('Structured Checklist', 'no label'), ('Reviewed', 'no label'), ('Clinical Records', 'no label'), ('Frequency', 'no label'), ('Symptoms', 'no label'), ('Course', 'no label'), ('Lems', 'no label'), ('Months', 'no label'), ('Sclc-Lems', 'no label'), ('Patients', 'no label'), ('Separate', 'no label'), ('Symptoms', 'no label'), ('Patients', 'no label'), ('Symptoms', 'no label'), ('Proximal Leg Weakness', 'no label'), ('Dry Mouth', 'no label'), ('Early Symptoms', 'no label'), ('Groups', 'no label'), ('Involvement', 'no label'), ('Proximal Arm Muscles', 'no label'), ('Distal Arm Muscles', 'no label'), ('Distal Leg Muscles', 'no label'), ('Dysartria', 'no label'), ('Presence', 'no label'), ('Erectile Dysfunction', 'no label'), ('Sclc-Lems', 'no label'), ('Patients', 'no label'), ('Cohorts', 'no label'), ('Cerebellar Symptoms', 'no label'), ('Lems Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Progressive Course', 'no label'), ('Lems Patients', 'no label'), ('Raise A', 'no label'), ('Suspicion', 'no label'), ('Sclc', 'no label'), ('Attention', 'no label'), ('Paid', 'no label'), ('Involvement', 'no label'), ('Upper Extremities', 'no label'), ('Involvement', 'no label'), ('Distal Arm And Distal', 'no label'), ('Leg Muscles', 'no label'), ('Erectile Dysfunction', 'no label'), ('Ataxia', 'no label'), ('Order', 'no label'), ('Discriminate', 'no label'), ('Sclc-Lems', 'no label')]|[('Cell', 'no label'), ('Sclc-Lems', 'no label'), ('Sclc-Lems', 'no label'), ('Sclc-Lems', 'no label')]|[('Distal Arm', 'no label')]|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Non-Tumor', 'no label'), ('Dry Mouth', 'no label'), ('Dysartria', 'no label'), ('Erectile Dysfunction', 'no label'), ('Upper Extremities', 'no label'), ('Erectile Dysfunction', 'no label'), ('Ataxia', 'no label')]|[('Neuromuscular', 'no label'), ('Patients', 'no label'), ('A Small Cell Lung Cancer', 'no label'), ('Lems Patients', 'no label'), ('Lems Patients', 'no label'), ('Non-Tumor Patients', 'no label'), ('Patients', 'no label'), ('Sclc-Lems Patients', 'no label'), ('Patients', 'no label'), ('Sclc-Lems Patients', 'no label'), ('Cerebellar', 'no label'), ('Lems Patients', 'no label'), ('Sclc-Lems', 'no label'), ('Lems Patients', 'no label'), ('Sclc-Lems', 'no label')]
lambert eaton syndrome|pubmed~21475559|The Following Is A Case Report Which Reviews The Essential Aspects Of Lambert-Eaton Myasthenic Syndrome (Lems) In A Patient With Long Standing Back Pain And Gait Dysfunction. The Patient Was Referred To Our Electrodiagnostics Laboratory For A 9-Month History Of Low Back Pain And Difficulty Walking Following A Charity Breast Cancer Walk. A Workup Including Magnetic Resonance Imaging Of The Brain, Entire Spine, And Emg/Ncs At Another Institution Were Reportedly Normal. A Detailed History Revealed Symptoms Of Proximal Weakness And Autonomic Dysfunction. Physical Findings Were Consistent With Proximal Weakness, A Bilateral Gluteus Medius Gait, And Diffusely Absent Reflexes Obtainable In The Biceps After 3 S Of Contraction. Electrical Testing Revealed An Initial Low Compound Muscle Action Potential Amplitude In The Deep Peroneal Nerve Recording From The Extensor Digitorum Brevis. Repetitive Stimulation At 2 Hz Revealed A Decremental Response Of 42% From The 1St Response To The 4Th Response. Following 3 S Of Exercise, The Amplitude Increased By 300%. After 30 S Of Exercise Followed By 1 Min Of Rest, There Was A Return Of The Decremental Response. The History, Physical Examination, And Electrical Findings Were Illustrative Of A Presynaptic Neuromuscular Junction Disorder, Specifically Lems.|[('Case Report', 'no label'), ('Reviews', 'no label'), ('Essential Aspects', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Patient', 'no label'), ('Long Standing Back Pain', 'no label'), ('Gait Dysfunction', 'no label'), ('Patient', 'no label'), ('Referred', 'no label'), ('Electrodiagnostics Laboratory', 'no label'), ('Back Pain', 'no label'), ('Difficulty Walking', 'no label'), ('Charity Breast Cancer', 'no label'), ('Walk', 'no label'), ('Workup', 'no label'), ('Magnetic Resonance Imaging', 'no label'), ('Brain', 'no label'), ('Entire Spine', 'no label'), ('Emg/Ncs', 'no label'), ('Institution', 'no label'), ('History', 'no label'), ('Revealed Symptoms', 'no label'), ('Proximal Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Physical Findings', 'no label'), ('Consistent With', 'no label'), ('Proximal Weakness', 'no label'), ('Bilateral', 'no label'), ('Gluteus Medius Gait', 'no label'), ('Diffusely', 'no label'), ('Obtainable', 'no label'), ('Biceps', 'no label'), ('Contraction', 'no label'), ('Electrical Testing', 'no label'), ('Initial', 'no label'), ('Compound Muscle', 'no label'), ('Amplitude', 'no label'), ('Deep Peroneal Nerve', 'no label'), ('Recording', 'no label'), ('Extensor Digitorum Brevis', 'no label'), ('Repetitive Stimulation', 'no label'), ('Revealed', 'no label'), ('Decremental Response', 'no label'), ('1St Response', 'no label'), ('Response', 'no label'), ('Exercise', 'no label'), ('Amplitude', 'no label'), ('Increased', 'no label'), ('Exercise', 'no label'), ('Min', 'no label'), ('Rest', 'no label'), ('Was A', 'no label'), ('Decremental Response', 'no label'), ('History', 'no label'), ('Physical Examination', 'no label'), ('Electrical Findings', 'no label'), ('Presynaptic', 'no label'), ('Neuromuscular Junction Disorder', 'no label')]|[]|[('Emg/Ncs', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Pain', 'no label'), ('Pain', 'no label'), ('Breast Cancer', 'no label'), ('Weakness And Autonomic Dysfunction', 'no label'), ('Neuromuscular Junction Disorder', 'no label')]|[('Patient', 'no label'), ('Charity Breast Cancer', 'no label'), ('Brain', 'no label'), ('Extensor Digitorum Brevis', 'no label'), ('Presynaptic Neuromuscular', 'no label')]
lambert eaton syndrome|pubmed~28680320||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~17058271|In Order To Determine Whether There Is Any Difference Between Voltage-Gated Calcium-Channel Antibody (Vgcc-Ab)-Positive And -Negative Groups In Lambert-Eaton Myasthenic Syndrome (Lems), We Compared The Clinical And Electrophysiological Features Between 13 Patients With Vgcc-Ab And 6 Vgcc-Ab-Negative Patients. No Obvious Difference Was Observed In The Various Clinical Features Or Findings On Single-Fiber Electromyography Between Seropositive And Seronegative Cases. In Seropositive Cases, The Compound Muscle Action Potential (Cmap) Amplitude Was Lower But The Increment On Post-Exercise Facilitation (Pef) And High-Rate Stimulation (Hrs) Was Significantly Higher Than In The Seronegative Group, Indicating That The Repetitive Nerve Stimulation (Rns) Test In The Seropositive Group Is More Typical Of Lems And More Severe. A 100% Increment As The Diagnostic Criterion In The Routine Rns Test Was Satisfied In All Seropositive Cases But In Only Three Seronegative Cases, Whereas A 60% Increment As The Diagnostic Criterion Was Found In All Seronegative Cases. The Classic Triad (Low Cmap Amplitude, Decrement At Low Rate Of Stimulation, And Increment At Pef Or Hrs) Of Rns Is Rare, Adding To The Difficulty In Diagnosing Lems In The Seronegative Group, And Making A 60% Increment Criterion More Critical For The Diagnosis Of This Disorder.|[('Order', 'no label'), ('Voltage-Gated Calcium-Channel Antibody', 'no label'), ('Groups', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Clinical', 'no label'), ('Electrophysiological Features', 'no label'), ('Patients', 'no label'), ('Vgcc-Ab', 'no label'), ('Vgcc-Ab-Negative', 'no label'), ('Patients', 'no label'), ('Obvious Difference', 'no label'), ('Observed', 'no label'), ('Clinical Features', 'no label'), ('Findings', 'no label'), ('Single-Fiber Electromyography', 'no label'), ('Seropositive', 'no label'), ('Seronegative', 'no label'), ('Cases', 'no label'), ('Seropositive', 'no label'), ('Cases', 'no label'), ('Compound Muscle Action Potential', 'no label'), ('Cmap', 'no label'), ('Increment', 'no label'), ('Post-Exercise Facilitation', 'no label'), ('Pef', 'no label'), ('High-Rate Stimulation', 'no label'), ('Hrs', 'no label'), ('Than', 'no label'), ('Seronegative Group', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Seropositive', 'no label'), ('Group', 'no label'), ('Lems', 'no label'), ('Severe', 'no label'), ('Increment', 'no label'), ('Diagnostic Criterion', 'no label'), ('Routine', 'no label'), ('Rns Test', 'no label'), ('Satisfied', 'no label'), ('Seropositive', 'no label'), ('Cases', 'no label'), ('Seronegative', 'no label'), ('Cases', 'no label'), ('Increment', 'no label'), ('Diagnostic Criterion', 'no label'), ('Seronegative', 'no label'), ('Cases', 'no label'), ('Classic Triad', 'no label'), ('Amplitude', 'no label'), ('Decrement', 'no label'), ('Low Rate', 'no label'), ('Stimulation', 'no label'), ('Increment', 'no label'), ('Pef', 'no label'), ('Hrs', 'no label'), ('Rns', 'no label'), ('Rare', 'no label'), ('Difficulty', 'no label'), ('Diagnosing', 'no label'), ('Seronegative Group', 'no label'), ('Increment', 'no label'), ('Diagnosis', 'no label'), ('Disorder', 'no label')]|[('Calcium-Channel Antibody', 'no label'), ('Vgcc-Ab', 'no label'), ('Hrs', 'no label'), ('Hrs', 'no label'), ('Rns', 'no label')]|[('Rns', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Pef', 'no label'), ('Difficulty', 'no label')]|[('Patients', 'no label'), ('Patients', 'no label'), ('Pef', 'no label'), ('High-Rate', 'no label'), ('Hrs', 'no label'), ('Nerve', 'no label'), ('Lems', 'no label'), ('Routine Rns Test', 'no label'), ('Pef', 'no label'), ('Hrs', 'no label'), ('Rns', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~16805718|Lambert-Eaton Myasthenic Syndrome Is A Rare, But Reasonably Well-Understood, Antibody-Mediated Autoimmune Disease That Is Caused By Serum Auto-Antibodies And Results In Muscle Weakness And Autonomic Dysfunction. One Half Of The Patients Have An Idiopathic Form, The Other Half A Tumour-Associated Form Of The Disease. Three Randomised Trials And A Large Number Of Smaller Clinical Studies Have Resulted In A Number Of Drugs Becoming Available For The Treatment Of Lambert-Eaton Myasthenic Syndrome. Several Drugs Are Available For The Symptomatic Treatment Of The Disease, Including Guanidine, Aminopyridines Or Acetylcholinesterase Inhibitors. Other Therapies Aim To Deplete The Serum Autoantibodies Or To Suppress The Immune System. For This Purpose, Immunomodulating Strategies, Such As Intravenous Immunoglobulins Or Plasmapheresis, Or Several Immunosuppressive Agents Are Available. Chemotherapy Has Successfully Ameliorated The Course Of Disease In Lambert-Eaton Myasthenic Syndrome Patients With An Underlying Tumour.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Rare', 'no label'), ('Antibody-Mediated Autoimmune Disease', 'no label'), ('Serum Auto-Antibodies', 'no label'), ('Results', 'no label'), ('Muscle Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Patients', 'no label'), ('Idiopathic Form', 'no label'), ('Tumour-Associated Form', 'no label'), ('Disease', 'no label'), ('Randomised Trials', 'no label'), ('Clinical Studies', 'no label'), ('Resulted', 'no label'), ('Drugs', 'no label'), ('Treatment', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Drugs', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Disease', 'no label'), ('Guanidine', 'no label'), ('Aminopyridines', 'no label'), ('Acetylcholinesterase Inhibitors', 'no label'), ('Therapies', 'no label'), ('Deplete', 'no label'), ('Serum Autoantibodies', 'no label'), ('Suppress', 'no label'), ('Immune System', 'no label'), ('Purpose', 'no label'), ('Immunomodulating Strategies', 'no label'), ('Intravenous', 'no label'), ('Plasmapheresis', 'no label'), ('Immunosuppressive Agents', 'no label'), ('Available', 'no label'), ('Chemotherapy', 'no label'), ('Successfully', 'no label'), ('Ameliorated', 'no label'), ('Course', 'no label'), ('Disease', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Patients', 'no label'), ('Tumour', 'no label')]|[('Tumour-Associated', 'no label'), ('Guanidine', 'no label'), ('Aminopyridines', 'no label'), ('Acetylcholinesterase Inhibitors', 'no label')]|[('Serum Autoantibodies', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Antibody-Mediated Autoimmune Disease', 'no label'), ('Muscle Weakness', 'no label'), ('Autonomic Dysfunction', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Guanidine', 'no label'), ('Aminopyridines', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Tumour', 'no label')]|[('Serum Auto-Antibodies', 'no label'), ('Muscle', 'no label'), ('Patients', 'no label'), ('A Tumour-Associated', 'no label'), ('Guanidine', 'no label'), ('Aminopyridines', 'no label'), ('Acetylcholinesterase', 'no label'), ('Serum Autoantibodies', 'no label'), ('Immune System', 'no label'), ('Intravenous', 'no label'), ('Patients', 'no label'), ('Tumour', 'no label')]
lambert eaton syndrome|pubmed~18295972|Several Reports Have Presented Patients With Subacute Cerebellar Ataxia (Ca) And Lambert-Eaton Myasthenic Syndrome (Lems). Some Clinical Features Of Those Patients Have Been Described In The Previous Reports, Manifestation Of Subacute Ca Prior To Lems Or A Co-Existence Of Both Diseases, A High Incidence Of Malignancy, And Less Efficacy Of The Treatment For Subacute Ca Compared With That For Lems. Cerebellar Ataxia In Some Patients With Lems Has Been Suggested To Be Caused By Antibodies To P/Q-Type Voltage-Gated Calcium Channels (Vgccs). We Report Herein A Patient With Subacute Ca And Lems. Cerebellar Ataxia Appeared 15 Months After The Occurrence Of Lems, And The Onset Of Ca Was Thought To Be Due To Serum Anti-P/Q-Type Vgcc Antibodies. The Clinical Course Of This Patient Was Atypical, As Follows: (1) Lems Preceded Subacute Ca, Which Developed After Intracranial Aneurysm Surgery, (2) No Malignancy Was Detected When Both Diseases Co-Existed, (3) Symptoms Of Lems Did Not Progress With The Onset Of Ca, And (4) There Was A Definite Improvement In Symptoms Of Ca And (123)I-Imp Spect Imaging Findings After Steroid Administration. In Addition, It Is Remarkable That Lems Became Aggravated In Electrophysiologic Examinations, In Contrast To Subacute Ca. We Suggest That These Atypical Features Of Subacute Ca And The Changes In Lems May Be Associated With A Balance Between The Amount Of Serum Anti-P/Q-Type Vgcc Antibodies And The Susceptibility Of The Cerebellum And Presynaptic Nerve Terminals To The Antibodies. More Cases Are Needed To Investigate The Mechanisms Involved. The Subacute Ca And Lems In This Patient Have Remained Comparatively Silent After The Withdrawal Of Steroids, And We Are Continuing To Observe Her Condition.|[('Reports', 'no label'), ('Patients', 'no label'), ('Subacute Cerebellar Ataxia', 'no label'), ('Ca', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Clinical Features', 'no label'), ('Patients', 'no label'), ('Reports', 'no label'), ('Manifestation', 'no label'), ('Subacute', 'no label'), ('Ca', 'no label'), ('Lems', 'no label'), ('Co-Existence', 'no label'), ('Diseases', 'no label'), ('Incidence', 'no label'), ('Malignancy', 'no label'), ('Efficacy', 'no label'), ('Treatment', 'no label'), ('Subacute', 'no label'), ('Ca', 'no label'), ('Lems', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Antibodies', 'no label'), ('P/Q-Type Voltage-Gated Calcium Channels', 'no label'), ('Vgccs', 'no label'), ('Report', 'no label'), ('Patient', 'no label'), ('Subacute', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Appeared', 'no label'), ('Months', 'no label'), ('Lems', 'no label'), ('Ca Was Thought', 'no label'), ('Serum', 'no label'), ('Vgcc Antibodies', 'no label'), ('Clinical Course', 'no label'), ('Patient', 'no label'), ('Atypical', 'no label'), ('Lems', 'no label'), ('Subacute', 'no label'), ('Ca', 'no label'), ('Intracranial Aneurysm Surgery', 'no label'), ('No Malignancy', 'no label'), ('Detected', 'no label'), ('Diseases', 'no label'), ('Co-Existed', 'no label'), ('Symptoms', 'no label'), ('Lems', 'no label'), ('Progress', 'no label'), ('Ca', 'no label'), ('Definite', 'no label'), ('Improvement', 'no label'), ('Symptoms', 'no label'), ('Ca', 'no label'), ('Spect Imaging', 'no label'), ('Findings', 'no label'), ('Steroid Administration', 'no label'), ('Lems', 'no label'), ('Aggravated', 'no label'), ('Electrophysiologic Examinations', 'no label'), ('Contrast', 'no label'), ('Subacute', 'no label'), ('Ca', 'no label'), ('Suggest', 'no label'), ('Atypical', 'no label'), ('Subacute', 'no label'), ('Ca', 'no label'), ('Changes', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Balance', 'no label'), ('Amount', 'no label'), ('Serum Anti-P/Q-Type Vgcc Antibodies', 'no label'), ('Susceptibility', 'no label'), ('Cerebellum', 'no label'), ('Presynaptic Nerve', 'no label'), ('Terminals', 'no label'), ('Antibodies', 'no label'), ('Cases', 'no label'), ('Investigate', 'no label'), ('Mechanisms', 'no label'), ('Involved', 'no label'), ('Subacute', 'no label'), ('Ca', 'no label'), ('Patient', 'no label'), ('Remained', 'no label'), ('Silent', 'no label'), ('Withdrawal', 'no label'), ('Steroids', 'no label'), ('Continuing', 'no label'), ('Condition', 'no label')]|[('Antibodies', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('Electrophysiologic', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label')]|[('Serum Anti-P/Q-Type Vgcc Antibodies', 'no label')]|[('Cerebellar Ataxia', 'no label'), ('Ca', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Ca', 'no label'), ('Diseases, A High Incidence Of', 'no label'), ('Malignancy', 'no label'), ('Ca', 'no label'), ('Cerebellar Ataxia', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Ca', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Ca', 'no label'), ('Ca', 'no label'), ('Intracranial Aneurysm', 'no label'), ('Malignancy', 'no label'), ('Diseases Co-Existed', 'no label'), ('Ca', 'no label'), ('Ca', 'no label'), ('Steroid', 'no label'), ('Ca', 'no label'), ('Ca', 'no label'), ('Ca', 'no label'), ('Steroids', 'no label')]|[('Patients', 'no label'), ('Subacute Cerebellar Ataxia', 'no label'), ('Patients', 'no label'), ('Subacute Ca', 'no label'), ('Lems', 'no label'), ('Subacute Ca', 'no label'), ('Cerebellar Ataxia', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('P/Q-Type', 'no label'), ('Calcium', 'no label'), ('Subacute Ca', 'no label'), ('Cerebellar Ataxia Appeared', 'no label'), ('Serum Anti-P/Q-Type Vgcc Antibodies', 'no label'), ('Patient', 'no label'), ('Subacute Ca', 'no label'), ('Intracranial Aneurysm', 'no label'), ('Lems', 'no label'), ('Ca', 'no label'), ('Steroid', 'no label'), ('Lems', 'no label'), ('Subacute Ca', 'no label'), ('Lems', 'no label'), ('Serum Anti-P/Q-Type Vgcc Antibodies', 'no label'), ('Cerebellum', 'no label'), ('Presynaptic Nerve', 'no label'), ('Subacute Ca', 'no label'), ('Lems', 'no label'), ('Patient', 'no label'), ('Steroids', 'no label')]
lambert eaton syndrome|pubmed~17206662|An 18-Year-Old-Woman Developed Symptoms Of Generalized Myasthenia Gravis (Mg). Antibodies To The Acetylcholine Receptor Were Found In Her Serum, But Electrodiagnostic Testing Showed Abnormalities Typical Of The Lambert-Eaton Myasthenic Syndrome (Lems). Following Thymectomy, The Thymus Gland Showed Thymic Hyperplasia Typical Of Mg, And The Patient Responded To Treatment With 3,4-Diaminopyridine And Pyridostigmine. There Have Been Few Reports In The Literature Of Mg And Lems Coexisting In The Same Patient. In This Case, Electrodiagnostic Tests, Antibody Studies, Thymus Pathology, And Response To Treatment Suggest That Both Disorders Contributed To The Patient'S Symptoms. Thymic Hyperplasia, So Far Only Known To Be Associated With Mg, Provides Strong Evidence That Both Diseases Were Symptomatic.|"[('Generalized Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Antibodies', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Serum', 'no label'), ('Electrodiagnostic Testing', 'no label'), ('Abnormalities', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Thymectomy', 'no label'), ('Thymus Gland', 'no label'), ('Thymic Hyperplasia', 'no label'), ('Mg', 'no label'), ('Patient', 'no label'), ('Treatment', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label'), ('Reports', 'no label'), ('Literature', 'no label'), ('Mg', 'no label'), ('Lems Coexisting', 'no label'), ('Patient', 'no label'), ('Case', 'no label'), ('Electrodiagnostic Tests', 'no label'), ('Antibody Studies', 'no label'), ('Thymus Pathology', 'no label'), ('Response', 'no label'), ('Disorders', 'no label'), ('Contributed', 'no label'), (""Patient'S"", 'no label'), ('Symptoms', 'no label'), ('Thymic Hyperplasia', 'no label'), ('Associated With', 'no label'), ('Mg', 'no label'), ('Provides', 'no label'), ('Evidence', 'no label'), ('Diseases', 'no label'), ('Symptomatic', 'no label')]"|[('Antibodies', 'no label'), ('Acetylcholine', 'no label'), ('Antibody', 'no label')]|[('Antibodies', 'no label'), ('Acetylcholine Receptor', 'no label')]|[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Acetylcholine', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Thymic Hyperplasia', 'no label'), ('Mg', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label'), ('Mg', 'no label'), ('Thymic Hyperplasia', 'no label'), ('Mg', 'no label'), ('Diseases Were Symptomatic.', 'no label')]|[('Acetylcholine Receptor', 'no label'), ('Serum', 'no label'), ('Thymus', 'no label'), ('Thymic Hyperplasia', 'no label'), ('Mg', 'no label'), ('Patient', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Pyridostigmine', 'no label'), ('Mg', 'no label'), ('Lems', 'no label'), ('Case', 'no label'), ('Thymus Pathology', 'no label'), ('Thymic Hyperplasia', 'no label'), ('Far', 'no label'), ('Mg', 'no label')]
lambert eaton syndrome|pubmed~23263888|Myasthenia Gravis (Mg), Lambert-Eaton Myasthenic Syndrome (Lems) And Neuromyotonia Are Neuromuscular Transmission Disorders Occurring With Or Without Associated Malignancy. Due To The Common Antibody-Mediated Pathophysiology, Immunosuppression Has An Important Role In The Treatment Of Each Of These Disorders. Symptomatic Treatment Is More Variable. Pyridostigmine Is First-Line Treatment In Generalized Mg. Response Seems To Be Better In Patients With Acetylcholine Receptor (Achr) Antibodies Than In Patients With Antibodies Against Muscle-Specific Tyrosine Kinase (Musk). Pyridostigmine Can Be Sufficient In Mild Mg, Although Most Patients Need Additional Immunosuppressive Therapy. If So, Prednisolone Is Efficient In The Majority Of The Patients, With A Relatively Early Onset Of Clinical Effect. High Drug Dosage And Treatment Duration Should Be Limited As Much As Possible Because Of Serious Corticosteroid-Related Side Effects. As Long-Term Treatment Is Needed In Most Patients For Sustainable Remission, Adding Non-Steroid Immunosuppressive Drugs Should Be Considered. Their Therapeutic Response Is Usually Delayed And Often Takes A Period Of Several Months. In The Meantime, Corticosteroids Are Continued And Doses Are Tapered Down Over A Period Of Several Months. There Are No Trials Comparing Different Immunosuppressive Drugs. Choice Is Mainly Based On The Clinician'S Familiarity With Certain Drugs And Their Side Effects, Combined With Patients' Characteristics. Most Commonly Used Is Azathioprine. Alternatively, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil Or Rituximab Can Be Used. The Use Of Cyclophosphamide Is Limited To Refractory Cases, Due To Serious Side Effects. Plasma Exchange And Intravenous Immunoglobulin Induce Rapid But Temporary Improvement, And Are Reserved For Severe Disease Exacerbations Because Of High Costs Of Treatment. It Is Recommended That Computed Tomography (Ct) Of The Thorax Is Performed In Every Achr-Positive Mg Patient, And That Patients Are Referred For Thymectomy In Case Of Thymoma. In Patients Without Thymoma, Thymectomy Can Be Considered As Well, Especially In Younger, Achr-Positive Patients With Severe Disease. However, Definite Proof Of Benefit Is Lacking And An International Randomized Trial To Clarify This Topic Is Currently Ongoing. When Lems Is Suspected, Always Search For Malignancy, Especially Small Cell Lung Carcinoma With Continued Screening Up To Two Years. In Paraneoplastic Lems, Cancer Treatment Usually Results In Clinical Improvement Of The Myasthenic Symptoms. 3,4-Diaminopyridine Is First-Line Symptomatic Treatment In Lems. It Is Usually Well Tolerated And Effective. When Immunosuppressive Therapy Is Needed, The Same Considerations Apply To Lems As Described For Mg. Peripheral Nerve Hyperexcitability In Neuromyotonia Can Be Treated With Anticonvulsant Drugs Such As Phenytoin, Valproic Acid Or Carbamazepine. When Response In Insufficient, Start Prednisolone In Mild Disease And Consider The Addition Of Azathioprine. Plasma Exchange Or Intravenous Immunoglobulin Is Indicated In Severe Neuromyotonia And In Patients With Neuromyotonia Combined With Central Nervous System Symptoms, A Clinical Picture Known As Morvan'S Syndrome.|"[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Neuromyotonia', 'no label'), ('Neuromuscular Transmission Disorders', 'no label'), ('Occurring', 'no label'), ('Associated', 'no label'), ('Malignancy', 'no label'), ('Antibody-Mediated Pathophysiology', 'no label'), ('Immunosuppression', 'no label'), ('Treatment', 'no label'), ('Disorders', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Variable', 'no label'), ('Pyridostigmine', 'no label'), ('First-Line Treatment', 'no label'), ('Generalized Mg', 'no label'), ('Response Seems', 'no label'), ('Patients', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Achr', 'no label'), ('Than', 'no label'), ('Patients', 'no label'), ('Antibodies', 'no label'), ('Muscle-Specific Tyrosine Kinase', 'no label'), ('Musk', 'no label'), ('Pyridostigmine', 'no label'), ('Sufficient', 'no label'), ('Mild Mg', 'no label'), ('Patients', 'no label'), ('Need', 'no label'), ('Immunosuppressive Therapy', 'no label'), ('Prednisolone', 'no label'), ('Efficient', 'no label'), ('Patients', 'no label'), ('Early', 'no label'), ('Clinical Effect', 'no label'), ('Drug Dosage', 'no label'), ('Treatment Duration', 'no label'), ('Serious', 'no label'), ('Corticosteroid-Related Side Effects', 'no label'), ('Long-Term Treatment', 'no label'), ('Patients', 'no label'), ('Sustainable Remission', 'no label'), ('Non-Steroid Immunosuppressive Drugs', 'no label'), ('Therapeutic Response', 'no label'), ('Delayed', 'no label'), ('Period', 'no label'), ('Months', 'no label'), ('Corticosteroids', 'no label'), ('Continued', 'no label'), ('Doses', 'no label'), ('Tapered Down', 'no label'), ('Period', 'no label'), ('Months', 'no label'), ('No Trials', 'no label'), ('Immunosuppressive Drugs', 'no label'), (""Clinician'S"", 'no label'), ('Familiarity', 'no label'), ('Drugs', 'no label'), ('Side Effects', 'no label'), (""Patients'"", 'no label'), ('Characteristics', 'no label'), ('Azathioprine', 'no label'), ('Tacrolimus', 'no label'), ('Cyclosporine A', 'no label'), ('Mycophenolate Mofetil', 'no label'), ('Rituximab', 'no label'), ('Cyclophosphamide', 'no label'), ('Refractory', 'no label'), ('Cases', 'no label'), ('Serious', 'no label'), ('Side Effects', 'no label'), ('Plasma Exchange', 'no label'), ('Intravenous', 'no label'), ('Induce', 'no label'), ('Rapid', 'no label'), ('Temporary Improvement', 'no label'), ('Disease Exacerbations', 'no label'), ('High Costs', 'no label'), ('Treatment', 'no label'), ('Recommended', 'no label'), ('Computed Tomography', 'no label'), ('Ct', 'no label'), ('Thorax', 'no label'), ('Performed', 'no label'), ('Achr-Positive Mg', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Referred', 'no label'), ('Thymectomy', 'no label'), ('Thymoma', 'no label'), ('Patients', 'no label'), ('Thymoma', 'no label'), ('Thymectomy', 'no label'), ('Younger', 'no label'), ('Achr-Positive Patients', 'no label'), ('Severe Disease', 'no label'), ('Benefit', 'no label'), ('Lacking', 'no label'), ('International Randomized Trial', 'no label'), ('Lems', 'no label'), ('Suspected', 'no label'), ('Search', 'no label'), ('Malignancy', 'no label'), ('Small Cell', 'no label'), ('Lung Carcinoma', 'no label'), ('Screening', 'no label'), ('Years', 'no label'), ('Paraneoplastic Lems', 'no label'), ('Cancer Treatment', 'no label'), ('Results', 'no label'), ('Clinical Improvement', 'no label'), ('Myasthenic', 'no label'), ('Symptoms', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Well Tolerated', 'no label'), ('Effective', 'no label'), ('Immunosuppressive Therapy', 'no label'), ('Considerations', 'no label'), ('Mg', 'no label'), ('Peripheral Nerve', 'no label'), ('Hyperexcitability', 'no label'), ('Neuromyotonia', 'no label'), ('Treated', 'no label'), ('Anticonvulsant Drugs', 'no label'), ('Phenytoin', 'no label'), ('Valproic Acid', 'no label'), ('Carbamazepine', 'no label'), ('Response', 'no label'), ('Insufficient', 'no label'), ('Prednisolone', 'no label'), ('Mild Disease', 'no label'), ('Addition', 'no label'), ('Azathioprine', 'no label'), ('Plasma', 'no label'), ('Intravenous', 'no label'), ('Severe', 'no label'), ('Neuromyotonia', 'no label'), ('Patients', 'no label'), ('Neuromyotonia', 'no label'), ('Central Nervous System Symptoms', 'no label'), ('Clinical Picture', 'no label'), (""Morvan'S Syndrome"", 'no label')]"|[('Pyridostigmine', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Antibodies', 'no label'), ('Antibodies', 'no label'), ('Tyrosine', 'no label'), ('Musk', 'no label'), ('Pyridostigmine', 'no label'), ('Drug', 'no label'), ('Tacrolimus', 'no label'), ('Mycophenolate Mofetil', 'no label'), ('Rituximab', 'no label'), ('Cyclophosphamide', 'no label'), ('Cell', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Valproic Acid', 'no label')]|[('Acetylcholine Receptor', 'no label'), ('Muscle-Specific Tyrosine Kinase', 'no label')]|"[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Neuromyotonia', 'no label'), ('Malignancy', 'no label'), ('Pyridostigmine', 'no label'), ('Mg', 'no label'), ('Acetylcholine', 'no label'), ('Tyrosine', 'no label'), ('Pyridostigmine', 'no label'), ('Mg', 'no label'), ('Prednisolone', 'no label'), ('Tapered Down', 'no label'), ('Azathioprine', 'no label'), ('Tacrolimus', 'no label'), ('Cyclosporine A', 'no label'), ('Mycophenolate Mofetil', 'no label'), ('Rituximab', 'no label'), ('Cyclophosphamide', 'no label'), ('Mg', 'no label'), ('Thymoma', 'no label'), ('Thymoma', 'no label'), ('Malignancy', 'no label'), ('Paraneoplastic', 'no label'), ('Cancer', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Mg', 'no label'), ('Peripheral Nerve Hyperexcitability', 'no label'), ('Neuromyotonia', 'no label'), ('Phenytoin', 'no label'), ('Valproic Acid', 'no label'), ('Carbamazepine', 'no label'), ('Prednisolone', 'no label'), ('Azathioprine', 'no label'), ('Neuromyotonia', 'no label'), ('Neuromyotonia', 'no label'), ('Central Nervous System Symptoms', 'no label'), (""Morvan'S Syndrome"", 'no label')]"|[('Mg', 'no label'), ('Neuromuscular', 'no label'), ('Pyridostigmine', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Acetylcholine Receptor', 'no label'), ('Patients', 'no label'), ('Muscle-Specific Tyrosine Kinase', 'no label'), ('Musk', 'no label'), ('Pyridostigmine', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Prednisolone', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Corticosteroids', 'no label'), ('Doses', 'no label'), ('Patients', 'no label'), ('Azathioprine', 'no label'), ('Tacrolimus', 'no label'), ('Cyclosporine A', 'no label'), ('Mycophenolate Mofetil Or', 'no label'), ('Rituximab', 'no label'), ('Cyclophosphamide', 'no label'), ('Plasma', 'no label'), ('Intravenous Immunoglobulin Induce', 'no label'), ('High Costs', 'no label'), ('Thorax', 'no label'), ('Patients', 'no label'), ('Case', 'no label'), ('Thymoma', 'no label'), ('Patients', 'no label'), ('Thymoma', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Paraneoplastic Lems', 'no label'), ('Cancer', 'no label'), ('3,4-Diaminopyridine', 'no label'), ('Lems', 'no label'), ('Mg', 'no label'), ('Peripheral Nerve', 'no label'), ('Phenytoin', 'no label'), ('Valproic Acid', 'no label'), ('Carbamazepine', 'no label'), ('Prednisolone', 'no label'), ('Azathioprine', 'no label'), ('Plasma', 'no label'), ('Intravenous Immunoglobulin', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~20651998|There Are Many Causes Of Prolonged Postoperative Muscle Weakness, Including Drugs, Residual Anesthetics, Cerebrovascular Events, Electrolyte Imbalance, Hypothermia, And Neuromuscular Disease. Neuromuscular Diseases Are Relatively Rare, With The Most Common Being Myasthenia Gravis And Lambert-Eaton Myasthenic Syndrome (Lems). We Report An Unusual Case In Which A Patient Who Was Given A Muscle Relaxant During Mediastinoscopy Developed Postoperative Muscle Weakness That Was Ultimately Diagnosed As Secondary To Lems.|[('Causes', 'no label'), ('Prolonged', 'no label'), ('Postoperative Muscle Weakness', 'no label'), ('Drugs', 'no label'), ('Residual', 'no label'), ('Anesthetics', 'no label'), ('Cerebrovascular Events', 'no label'), ('Electrolyte', 'no label'), ('Imbalance', 'no label'), ('Hypothermia', 'no label'), ('Neuromuscular Disease', 'no label'), ('Neuromuscular Diseases', 'no label'), ('Rare', 'no label'), ('Common Being', 'no label'), ('Myasthenia Gravis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Unusual', 'no label'), ('Case', 'no label'), ('Patient', 'no label'), ('Muscle Relaxant', 'no label'), ('Mediastinoscopy', 'no label'), ('Postoperative Muscle Weakness', 'no label'), ('Diagnosed', 'no label')]|[('Anesthetics', 'no label')]|[('Who', 'no label')]|[('Postoperative Muscle Weakness', 'no label'), ('Hypothermia', 'no label'), ('Neuromuscular Disease', 'no label'), ('Neuromuscular Diseases', 'no label'), ('Myasthenia Gravis', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Postoperative Muscle Weakness', 'no label')]|[('Muscle', 'no label'), ('Anesthetics', 'no label'), ('Cerebrovascular', 'no label'), ('Electrolyte', 'no label'), ('Neuromuscular', 'no label'), ('Patient', 'no label'), ('Muscle', 'no label'), ('Mediastinoscopy', 'no label'), ('Muscle', 'no label')]
lambert eaton syndrome|pubmed~34037996|We Studied A Patient With A Congenital Myasthenic Syndrome (Cms) Caused By A Dominant Mutation In The Synaptotagmin 2 Gene (Syt2) And Compared The Clinical Features Of This Patient With Those Of A Previously Described Patient With A Recessive Mutation In The Same Gene. We Performed Electrodiagnostic (Edx) Studies, Genetic Studies, Muscle Biopsy, Microelectrode Recordings And Electron Microscopy (Em). Both Patients Presented With Muscle Weakness And Bulbar Deficits, Which Were Worse In The Recessive Form. Edx Studies Showed Presynaptic Failure, Which Was More Prominent In The Recessive Form. Microelectrode Studies In The Dominant Form Showed A Marked Reduction Of The Quantal Content, Which Increased Linearly With Higher Frequencies Of Nerve Stimulation. The Mepp Frequencies Were Normal At Rest But Increased Markedly With Higher Frequencies Of Nerve Stimulation. The Em Demonstrated Overdeveloped Postsynaptic Folding, And Abundant Endosomes, Multivesicular Bodies And Degenerative Lamellar Bodies Inside Small Nerve Terminals. The Recessive Form Of Cms Caused By A Syt2 Mutation Showed Far More Severe Clinical Manifestations Than The Dominant Form. The Pathogenesis Of The Dominant Form Likely Involves A Dominant-Negative Effect Due To Disruption Of The Dual Function Of Synaptotagmin As A Ca<Sup>2+</Sup> -Sensor And Modulator Of Synaptic Vesicle Exocytosis.|[('Studied', 'no label'), ('Patient', 'no label'), ('Congenital Myasthenic Syndrome', 'no label'), ('Cms', 'no label'), ('Dominant', 'no label'), ('Mutation', 'no label'), ('Synaptotagmin 2 Gene', 'no label'), ('Syt2', 'no label'), ('Clinical Features', 'no label'), ('Patient', 'no label'), ('Patient', 'no label'), ('Recessive Mutation', 'no label'), ('Gene', 'no label'), ('Performed', 'no label'), ('Electrodiagnostic', 'no label'), ('Genetic Studies', 'no label'), ('Muscle Biopsy', 'no label'), ('Microelectrode Recordings', 'no label'), ('Electron Microscopy', 'no label'), ('Em', 'no label'), ('Patients', 'no label'), ('Muscle Weakness', 'no label'), ('Bulbar Deficits', 'no label'), ('Worse', 'no label'), ('Recessive Form', 'no label'), ('Edx Studies', 'no label'), ('Presynaptic', 'no label'), ('Failure', 'no label'), ('Recessive Form', 'no label'), ('Microelectrode Studies', 'no label'), ('Dominant Form', 'no label'), ('Reduction', 'no label'), ('Quantal Content', 'no label'), ('Increased', 'no label'), ('Higher', 'no label'), ('Frequencies', 'no label'), ('Nerve Stimulation', 'no label'), ('Mepp Frequencies', 'no label'), ('Normal', 'no label'), ('Rest', 'no label'), ('Increased', 'no label'), ('Markedly', 'no label'), ('Higher', 'no label'), ('Frequencies', 'no label'), ('Nerve Stimulation', 'no label'), ('Em', 'no label'), ('Overdeveloped Postsynaptic Folding', 'no label'), ('Abundant', 'no label'), ('Endosomes', 'no label'), ('Multivesicular Bodies', 'no label'), ('Degenerative', 'no label'), ('Lamellar Bodies', 'no label'), ('Terminals', 'no label'), ('Recessive Form', 'no label'), ('Cms', 'no label'), ('Syt2', 'no label'), ('Mutation', 'no label'), ('Severe', 'no label'), ('Clinical Manifestations', 'no label'), ('Dominant Form', 'no label'), ('Pathogenesis', 'no label'), ('Dominant Form', 'no label'), ('Dominant-Negative Effect', 'no label'), ('Disruption', 'no label'), ('Dual Function', 'no label'), ('Synaptotagmin', 'no label'), ('Ca<Sup>2+</Sup> -Sensor And', 'no label'), ('Modulator', 'no label'), ('Synaptic', 'no label'), ('Vesicle', 'no label'), ('Exocytosis', 'no label')]|[('Mutation', 'no label'), ('Synaptotagmin 2 Gene', 'no label'), ('Syt2', 'no label'), ('Mutation', 'no label'), ('Gene', 'no label'), ('Genetic', 'no label'), ('Electron', 'no label'), ('Form', 'no label'), ('Endosomes', 'no label'), ('Multivesicular', 'no label'), ('Nerve Terminals', 'no label'), ('Syt2 Mutation', 'no label'), ('Synaptotagmin As A Ca', 'no label'), ('Synaptic Vesicle', 'no label')]|[('Synaptotagmin 2 Gene', 'no label'), ('Same Gene', 'no label'), ('Edx', 'no label'), ('Em', 'no label'), ('Syt2 Mutation', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Muscle Weakness', 'no label'), ('Bulbar Deficits', 'no label'), ('Recessive', 'no label'), ('Recessive', 'no label'), ('Ca', 'no label')]|[('Cms', 'no label'), ('Synaptotagmin 2', 'no label'), ('Syt2', 'no label'), ('Patient', 'no label'), ('Patient', 'no label'), ('Muscle Biopsy', 'no label'), ('Patients', 'no label'), ('Muscle', 'no label'), ('Quantal', 'no label'), ('Nerve', 'no label'), ('Nerve', 'no label'), ('Endosomes', 'no label'), ('Multivesicular', 'no label'), ('Lamellar Bodies Inside Small Nerve Terminals.', 'no label'), ('Cms', 'no label'), ('A Syt2', 'no label'), ('Far', 'no label'), ('Synaptotagmin', 'no label'), ('Synaptic Vesicle', 'no label')]
lambert eaton syndrome|pubmed~16806929|The Decrement Pattern At Low Rates Of Repetitive Nerve Stimulation In Myasthenia Gravis (Mg) Is Characterized By A Decrease Of Compound Muscle Action Potential Size Within The First 4-5 Responses. With Subsequent Stimuli, Compound Muscle Action Potential Size Either Increases Or Does Not Change. Following An Observation That The Pattern Of Decrement Might Be Different In Patients With Lambert-Eaton Myasthenic Syndrome (Lems), We Retrospectively Studied Traces From Eight Lems Patients And 14 Patients With Seropositive Generalized Mg, Calculating Decrement Percent From First To Fourth And From First To Ninth Compound Muscle Action Potential. In The Lems Patients, Compound Muscle Action Potential Amplitude Decreased Progressively From First To Ninth Stimulus At 2, 3 Or 5Hz In All Traces But One. In Contrast, Mg Patients Demonstrated The Expected Improvement After The Initial Decrement In All Traces Except One. In The Evaluation Of Patients Suspected Of Having Myasthenia Gravis, The Finding Of Progressive Decrement Pattern At Low Rates Of Repetitive Nerve Stimulation May Alert The Electromyographer To The Possibility Of Lambert-Eaton Syndrome And Prompt The Performance Of Further Electrodiagnostic Tests.|[('Decrement Pattern', 'no label'), ('Low', 'no label'), ('Rates', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Characterized', 'no label'), ('Decrease', 'no label'), ('Compound Muscle', 'no label'), ('Size', 'no label'), ('Responses', 'no label'), ('Stimuli', 'no label'), ('Compound Muscle', 'no label'), ('Increases', 'no label'), ('Not Change', 'no label'), ('Observation', 'no label'), ('Pattern', 'no label'), ('Decrement', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Retrospectively', 'no label'), ('Studied Traces', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Seropositive', 'no label'), ('Generalized Mg', 'no label'), ('Calculating Decrement', 'no label'), ('Compound Muscle', 'no label'), ('Potential', 'no label'), ('Lems Patients', 'no label'), ('Compound Muscle', 'no label'), ('Amplitude', 'no label'), ('Decreased', 'no label'), ('Stimulus', 'no label'), ('Traces', 'no label'), ('Contrast', 'no label'), ('Mg', 'no label'), ('Patients', 'no label'), ('Expected Improvement', 'no label'), ('Initial', 'no label'), ('Decrement', 'no label'), ('Traces', 'no label'), ('Evaluation', 'no label'), ('Patients', 'no label'), ('Suspected', 'no label'), ('Myasthenia Gravis', 'no label'), ('Progressive Decrement', 'no label'), ('Low', 'no label'), ('Rates', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Possibility', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Prompt', 'no label'), ('Performance', 'no label'), ('Electrodiagnostic Tests', 'no label')]|[]|[]|[('Myasthenia Gravis', 'no label'), ('Mg', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Mg', 'no label'), ('Mg', 'no label'), ('Myasthenia Gravis', 'no label')]|[('Decrement Pattern', 'no label'), ('Nerve', 'no label'), ('Muscle', 'no label'), ('Patients', 'no label'), ('Lems Patients And', 'no label'), ('Patients', 'no label'), ('Mg', 'no label'), ('Lems Patients', 'no label'), ('Patients', 'no label'), ('Nerve', 'no label')]
lambert eaton syndrome|pubmed~19274011||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~18567862|Half The Patients With Lambert-Eaton Myasthenic Syndrome (Lems) Have A Small Cell Lung Carcinoma (Sclc). Sclc Is An Aggressive Tumor And Survival Is Poor. We Studied The Differences Between Lems Patients With And Without An Sclc. Several Items Were Identified, Among Which Are Age, Smoking Behavior, Sex, The Progression Of Clinical Symptoms, Hla, And Presence Of Sox1 Serum Antibodies. The Relationship Between These Parameters Is Not Fully Elucidated. Data Support A Role For The Lems-Related Immune Response In Suppressing The Tumor Activity. We Summarize The Literature And Present Data From Our Dutch Cohort Of 104 Lems Patients To Compare The Clinical And Laboratory Characteristics Of Tumor And Nontumor Related Lems Patients.|[('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Sclc', 'no label'), ('Aggressive Tumor', 'no label'), ('Survival', 'no label'), ('Differences', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Items', 'no label'), ('Identified', 'no label'), ('Age', 'no label'), ('Smoking Behavior', 'no label'), ('Sex', 'no label'), ('Progression', 'no label'), ('Clinical Symptoms', 'no label'), ('Hla', 'no label'), ('Sox1 Serum Antibodies', 'no label'), ('Relationship', 'no label'), ('Parameters', 'no label'), ('Data Support', 'no label'), ('Lems-Related Immune Response', 'no label'), ('Suppressing', 'no label'), ('Tumor Activity', 'no label'), ('Literature', 'no label'), ('Data', 'no label'), ('Dutch Cohort', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Compare', 'no label'), ('Clinical And Laboratory', 'no label'), ('Tumor', 'no label'), ('Nontumor', 'no label'), ('Patients', 'no label')]|[('Cell', 'no label'), ('Sox1', 'no label')]|[('Sox1 Serum Antibodies', 'no label')]|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Aggressive Tumor', 'no label'), ('Hla', 'no label'), ('Tumor', 'no label'), ('Tumor', 'no label')]|[('Patients', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Tumor', 'no label'), ('Lems Patients', 'no label'), ('Hla', 'no label'), ('Sox1 Serum', 'no label'), ('Immune', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label'), ('Tumor', 'no label'), ('Nontumor', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~18342060|Lambert-Eaton Myasthenic Syndrome (Lems) Is An Autoimmune Channelopathy In Which Patients Produce Autoantibodies Directed Against Voltage-Gated Calcium Channels. Lems Is Paraneoplastic In 50% Of Patients, Most Frequently Associated With Small Cell Lung Carcinoma. We Describe A Case Of Paraneoplastic Lems Associated With A Vocal Cord Carcinoma. A 64-Year-Old Man Developed In Five Months Muscle Weakness Affecting Gait. Clinical Examination Showed Proximal Muscular Deficiency, Areflexia And Dysphonia. Electrophysiologic Study Showed Potentiation Greater Than 500% After Post Exercise Facilitation And 76 Percent Increment Response At High-Rate Repetitive Nerve Stimulation (20Hz). Diagnosis Of Lems Was Confirmed By Electrophysiologic Study And Anti-Voltage Gated Calcium Channel Antibodies (90Pm, Positive Value Greater Or Equal To 70Pm). Left Vocal Cord Lesion Histology Showed Epidermoid Carcinoma. A Combination Of Vocal Cord Tumor Removal By Endoscopy And Treatment By Pyridostigmine, 3-4 Diaminopyridine And Intravenous Human Immunoglobulin Improved Neurological Symptoms. Paraneoplastic Syndromes In Association With Cancers Of The Larynx And Hypopharynx Are Unusual. Only Two Cases Are Reported With Lems Associated With Larynx Carcinoma. We Describe An Unusual Case Of Lems Associated With A Left Vocal Cord Carcinoma.|[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Autoimmune Channelopathy', 'no label'), ('Patients', 'no label'), ('Produce', 'no label'), ('Autoantibodies', 'no label'), ('Directed Against Voltage-Gated Calcium Channels', 'no label'), ('Lems', 'no label'), ('Paraneoplastic', 'no label'), ('Patients', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Paraneoplastic Lems', 'no label'), ('Associated With', 'no label'), ('Vocal Cord Carcinoma', 'no label'), ('64-Year-Old Man Developed', 'no label'), ('Months Muscle Weakness', 'no label'), ('Gait', 'no label'), ('Clinical Examination', 'no label'), ('Proximal Muscular Deficiency', 'no label'), ('Areflexia', 'no label'), ('Dysphonia', 'no label'), ('Electrophysiologic Study', 'no label'), ('Potentiation', 'no label'), ('Post Exercise Facilitation', 'no label'), ('High-Rate Repetitive Nerve Stimulation', 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Electrophysiologic Study', 'no label'), ('Anti-Voltage', 'no label'), ('Calcium Channel Antibodies', 'no label'), ('Positive Value Greater', 'no label'), ('Equal', 'no label'), ('Left Vocal Cord', 'no label'), ('Lesion Histology', 'no label'), ('Epidermoid Carcinoma', 'no label'), ('Combination', 'no label'), ('Vocal Cord', 'no label'), ('Tumor', 'no label'), ('Removal', 'no label'), ('Endoscopy', 'no label'), ('Treatment', 'no label'), ('Pyridostigmine', 'no label'), ('Diaminopyridine', 'no label'), ('Intravenous', 'no label'), ('Neurological Symptoms', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Association', 'no label'), ('Cancers', 'no label'), ('Larynx And Hypopharynx', 'no label'), ('Unusual', 'no label'), ('Cases', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Larynx Carcinoma', 'no label'), ('Unusual', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Left Vocal Cord Carcinoma', 'no label')]|[('Calcium', 'no label'), ('Cell', 'no label'), ('Electrophysiologic', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('Pyridostigmine', 'no label'), ('Human', 'no label')]|[]|[('Myasthenic Syndrome', 'no label'), ('Calcium', 'no label'), ('Paraneoplastic', 'no label'), ('Paraneoplastic', 'no label'), ('Vocal Cord Carcinoma', 'no label'), ('Muscle Weakness', 'no label'), ('Muscular Deficiency', 'no label'), ('Areflexia', 'no label'), ('Dysphonia', 'no label'), ('Calcium', 'no label'), ('Left Vocal Cord Lesion Histology Showed Epidermoid Carcinoma', 'no label'), ('Vocal Cord Tumor', 'no label'), ('Pyridostigmine', 'no label'), ('3-4 Diaminopyridine', 'no label'), ('Paraneoplastic Syndromes', 'no label'), ('Cancers', 'no label'), ('Larynx', 'no label'), ('Larynx Carcinoma', 'no label'), ('Left Vocal Cord Carcinoma', 'no label')]|[('Patients', 'no label'), ('Autoantibodies', 'no label'), ('Calcium', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('A Case', 'no label'), ('Muscle', 'no label'), ('Muscular', 'no label'), ('High-Rate', 'no label'), ('Nerve', 'no label'), ('Lems', 'no label'), ('Calcium Channel Antibodies (', 'no label'), ('Cord', 'no label'), ('Epidermoid Carcinoma.', 'no label'), ('Pyridostigmine', 'no label'), ('Intravenous', 'no label'), ('Human Immunoglobulin', 'no label'), ('Cancers', 'no label'), ('Larynx And Hypopharynx', 'no label'), ('Lems', 'no label'), ('Larynx Carcinoma', 'no label'), ('Lems', 'no label')]
lambert eaton syndrome|pubmed~17087349|A 72-Year-Old Man Was Admitted To Our Hospital With Complaints Of Dry Mouth, Muscle Weakness Of The Lower Limbs And Gait Disturbance. The Patient Had Dry Mouth, Dry Eyes, Positive Anti-Ss-B Antibody And Salivary Gland Inflammation. Sjögren'S Syndrome Was Diagnosed. Since Muscle Weakness Of The Lower Limbs And Gait Disturbance Were Not Compatible With Sjögren'S Syndrome, We Considered The Possibility Of Paraneoplastic Syndrome. Serum Levels Of Cea, Nse And Progrp Were Elevated. Chest Roentgenogram And Ct Showed A Nodular Lesion In The Right Upper Lobe Of The Lung And Swollen Lymph Nodes In The Hilum And Mediastinum. Small Cell Lung Cancer Was Diagnosed By Bronchoscopy. Anti-P/Q-Type Ca2+ Channel Antibody Was Positive. Electromyogram Showed A Reduction In The Amplitude Of The Evoked Muscle Action Potential Response After Slow Repetitive Stimulation And Did Not Show A Reduction After Rapid Repetitive Stimulation. Based On These Findings, We Made A Diagnosis Of Lambert-Eaton Myasthenic Syndrome (Lems). Concurrent Chemoradiotherapy Induced An Improvement Of Muscle Weakness Of The Lower Limbs. Lems Is Frequently Associated With A Malignant Tumor And An Autoimmune Disorder. We Thought That In This Patient, The Presentation Of Lems Was Apparent Because He Had Both Sjögren'S Syndrome And Small Cell Lung Cancer.|"[('72-Year-Old Man', 'no label'), ('Hospital', 'no label'), ('Complaints', 'no label'), ('Dry Mouth', 'no label'), ('Muscle Weakness', 'no label'), ('Lower Limbs', 'no label'), ('Gait Disturbance', 'no label'), ('Patient', 'no label'), ('Dry Mouth', 'no label'), ('Dry Eyes', 'no label'), ('Positive Anti-Ss-B Antibody', 'no label'), ('Salivary', 'no label'), ('Inflammation', 'no label'), (""Sjögren'S Syndrome"", 'no label'), ('Diagnosed', 'no label'), ('Muscle Weakness', 'no label'), ('Lower Limbs', 'no label'), ('Gait Disturbance', 'no label'), ('Compatible', 'no label'), (""Sjögren'S Syndrome"", 'no label'), ('Possibility', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Serum Levels', 'no label'), ('Nse', 'no label'), ('Elevated', 'no label'), ('Chest Roentgenogram', 'no label'), ('Nodular', 'no label'), ('Lesion', 'no label'), ('Right Upper Lobe', 'no label'), ('Lung', 'no label'), ('Swollen', 'no label'), ('Lymph Nodes', 'no label'), ('Hilum', 'no label'), ('Small Cell Lung Cancer', 'no label'), ('Diagnosed', 'no label'), ('Bronchoscopy', 'no label'), ('Ca2', 'no label'), ('Channel Antibody', 'no label'), ('Positive', 'no label'), ('Electromyogram', 'no label'), ('Reduction', 'no label'), ('Amplitude', 'no label'), ('Evoked Muscle Action', 'no label'), ('Response', 'no label'), ('Slow Repetitive Stimulation', 'no label'), ('Reduction', 'no label'), ('Repetitive Stimulation', 'no label'), ('Findings', 'no label'), ('Diagnosis', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Concurrent', 'no label'), ('Chemoradiotherapy', 'no label'), ('Induced', 'no label'), ('Improvement', 'no label'), ('Muscle Weakness', 'no label'), ('Lower Limbs', 'no label'), ('Lems', 'no label'), ('Associated With', 'no label'), ('Malignant Tumor', 'no label'), ('Autoimmune Disorder', 'no label'), ('Patient', 'no label'), ('Lems', 'no label'), (""Sjögren'S Syndrome"", 'no label')]"|[('Antibody', 'no label'), ('Nse', 'no label'), ('Cell', 'no label'), ('Antibody', 'no label'), ('Cell', 'no label')]|[('Nse', 'no label'), ('Ct', 'no label'), ('Lung And Swollen Lymph Nodes', 'no label')]|"[('Dry Mouth', 'no label'), ('Muscle Weakness', 'no label'), ('Dry Mouth', 'no label'), ('Inflammation', 'no label'), ('Muscle Weakness', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Muscle Weakness', 'no label'), ('Tumor', 'no label'), ('Autoimmune Disorder', 'no label'), (""Sjögren'S Syndrome And Small Cell Lung Cancer"", 'no label')]"|[('Muscle', 'no label'), ('Lower Limbs', 'no label'), ('Patient', 'no label'), ('Salivary', 'no label'), ('Muscle', 'no label'), ('Lower Limbs', 'no label'), ('Serum', 'no label'), ('Nse', 'no label'), ('Right Upper Lobe', 'no label'), ('Lung', 'no label'), ('Lymph Nodes', 'no label'), ('Hilum', 'no label'), ('Mediastinum.', 'no label'), ('Ca2+ Channel Antibody', 'no label'), ('Muscle', 'no label'), ('Lower Limbs', 'no label'), ('A Malignant Tumor', 'no label'), ('Lems', 'no label'), ('Small Cell Lung Cancer', 'no label')]
lambert eaton syndrome|pubmed~16794965|A Case Is Presented Of A 34-Year-Old Man Who Developed Weakness Of The Proximal Muscles Of The Extremities, Particularly Lower, Slight Myalgia, And Vegetative Symptoms (Dryness In The Mouth). Those Symptoms Progressed Within A Month. On Examination Weakness Of The Muscles Of The Extremities Was Found As Well As Weak Tendon Reflexes, Slight Atrophy Of Muscles Of The Arms And Thighs And Apokamnosis. Edrophonium Test Was Slightly Positive. Electrostimulation Revealed Changes Typical Of The Lambert-Eaton Syndrome: Low Amplitude Of The Compound Muscle Action Potential On Single Stimulus, Decreasing Amplitude Of The Subsequent Responses To 3 Hz Stimulation, Marked Facilitation On 30 Hz Stimulation. Neoplastic Etiology Was Excluded By Chest X-Ray And Ct, As Well As By Bronchoscopy, Abdominal And Prostatic Usg, And Thyroid Usg And Scintigraphy. Antibodies To Achr Were Not Found In The Serum. The Titre Of The Antibodies Against Voltage-Gated Calcium Channels Was Highly Positive Which Was Decisive In The Diagnosing Of The Lambert-Eaton Syndrome. The Patient Was Treated With Pyridostigmine, Corticosteroids, Cyclophosphamide And Immunoglobulins. Ten Years Of Follow-Up Have Fully Confirmed The Diagnosis Of A Non-Neoplastic Lambert-Eaton Syndrome.|[('Case', 'no label'), ('Developed Weakness', 'no label'), ('Proximal Muscles', 'no label'), ('Extremities', 'no label'), ('Slight Myalgia', 'no label'), ('Vegetative Symptoms', 'no label'), ('Dryness', 'no label'), ('Mouth', 'no label'), ('Symptoms', 'no label'), ('Progressed', 'no label'), ('Month', 'no label'), ('Examination Weakness', 'no label'), ('Muscles', 'no label'), ('Extremities', 'no label'), ('Weak', 'no label'), ('Tendon Reflexes', 'no label'), ('Slight Atrophy', 'no label'), ('Muscles', 'no label'), ('Thighs', 'no label'), ('Apokamnosis', 'no label'), ('Edrophonium Test', 'no label'), ('Positive', 'no label'), ('Electrostimulation', 'no label'), ('Changes', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Low Amplitude', 'no label'), ('Compound Muscle', 'no label'), ('Potential', 'no label'), ('Stimulus', 'no label'), ('Decreasing', 'no label'), ('Amplitude', 'no label'), ('Responses', 'no label'), ('Stimulation', 'no label'), ('Facilitation', 'no label'), ('Stimulation', 'no label'), ('Neoplastic Etiology', 'no label'), ('Ct', 'no label'), ('Bronchoscopy', 'no label'), ('Abdominal', 'no label'), ('Prostatic Usg', 'no label'), ('Thyroid Usg', 'no label'), ('Scintigraphy', 'no label'), ('Antibodies', 'no label'), ('Achr', 'no label'), ('Serum', 'no label'), ('Titre', 'no label'), ('Antibodies', 'no label'), ('Voltage-Gated Calcium Channels', 'no label'), ('Positive', 'no label'), ('Diagnosing', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Patient', 'no label'), ('Treated', 'no label'), ('Pyridostigmine', 'no label'), ('Corticosteroids', 'no label'), ('Cyclophosphamide', 'no label'), ('Immunoglobulins', 'no label'), ('Years', 'no label'), ('Follow-Up', 'no label'), ('Confirmed', 'no label'), ('Diagnosis', 'no label'), ('Non-Neoplastic Lambert-Eaton Syndrome', 'no label')]|[('Antibodies', 'no label'), ('Titre', 'no label'), ('Antibodies', 'no label'), ('Calcium', 'no label'), ('Cyclophosphamide And Immunoglobulins', 'no label')]|[]|[('Weakness Of The Proximal Muscles Of The Extremities', 'no label'), ('Myalgia', 'no label'), ('Dryness', 'no label'), ('Examination Weakness', 'no label'), ('Atrophy', 'no label'), ('Edrophonium', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Chest X-Ray And Ct, As Well As By Bronchoscopy, Abdominal And Prostatic Usg, And Thyroid Usg And Scintigraphy.', 'no label'), ('Calcium', 'no label'), ('Lambert-Eaton Syndrome', 'no label'), ('Pyridostigmine', 'no label'), ('Corticosteroids', 'no label'), ('Cyclophosphamide', 'no label'), ('Lambert-Eaton Syndrome', 'no label')]|[('A 34-Year-Old', 'no label'), ('Muscles', 'no label'), ('Dryness', 'no label'), ('Muscles', 'no label'), ('Muscles', 'no label'), ('Prostatic Usg', 'no label'), ('Thyroid', 'no label'), ('Serum', 'no label'), ('Titre', 'no label'), ('Calcium', 'no label'), ('Patient', 'no label'), ('Pyridostigmine', 'no label'), ('Corticosteroids', 'no label'), ('Cyclophosphamide', 'no label'), ('Immunoglobulins', 'no label'), ('A Non-Neoplastic Lambert-Eaton', 'no label')]
lambert eaton syndrome|pubmed~28006860|Merkel Cell Carcinoma Is A Rare Cutaneous, Aggressive Tumor. Although It Shares Many Neuroendocrine Features With Small Cell Lung Carcinoma, It Has Only Occasionally Been Reported With Paraneoplastic Neurological Syndromes. A Healthy 67-Year-Old Man Developed Acute Ataxia, Vertigo, And Nausea. Subsequently He Also Developed Dysarthria, Diplopia, Xerostomia, Fatigability And Progressive Anorexia. He Underwent A Full Diagnostic Workup And Was Found To Have A High Titer Of Voltage-Gated Calcium Channel Antibodies In Serum And Cerebrospinal Fluid, Neurophysiological Findings Compatible With Lambert-Eaton Myasthenia And Neurological Signs Compatible With Cerebellar Degeneration. A Positron Emission Tomography Study Revealed A Hypermetabolic Lesion In The Axilla, Subsequently Biopsied And Consistent With Merkel Cell Carcinoma. In Most Previous Reports, Neurological Symptoms Preceded The Merkel Cell Carcinoma Diagnosis, And The Primary Localization Was In Lymph Nodes. This Tumor Should Be Considered In Patients With Paraneoplastic Syndrome, And Particularly Lambert-Eaton Myasthenia After Exclusion Of Small Cell Lung Carcinoma. Muscle Nerve 56: 998-1000, 2017.|[('Merkel Cell Carcinoma', 'no label'), ('Rare', 'no label'), ('Cutaneous', 'no label'), ('Aggressive Tumor', 'no label'), ('Shares', 'no label'), ('Neuroendocrine Features', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Paraneoplastic Neurological Syndromes', 'no label'), ('Healthy 67-Year-Old Man Developed Acute Ataxia', 'no label'), ('Vertigo', 'no label'), ('Nausea', 'no label'), ('Developed Dysarthria', 'no label'), ('Diplopia', 'no label'), ('Xerostomia', 'no label'), ('Fatigability', 'no label'), ('Progressive Anorexia', 'no label'), ('Full Diagnostic Workup', 'no label'), ('Titer', 'no label'), ('Voltage-Gated Calcium Channel Antibodies', 'no label'), ('Serum', 'no label'), ('Cerebrospinal Fluid', 'no label'), ('Neurophysiological Findings', 'no label'), ('Compatible', 'no label'), ('Lambert-Eaton Myasthenia', 'no label'), ('Neurological Signs', 'no label'), ('Cerebellar Degeneration', 'no label'), ('Positron Emission Tomography Study', 'no label'), ('Revealed', 'no label'), ('Hypermetabolic', 'no label'), ('Lesion', 'no label'), ('Axilla', 'no label'), ('Biopsied', 'no label'), ('Consistent With', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Reports', 'no label'), ('Neurological Symptoms', 'no label'), ('Preceded', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Diagnosis', 'no label'), ('Primary Localization', 'no label'), ('Lymph Nodes', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Lambert-Eaton Myasthenia', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Muscle Nerve', 'no label')]|[('Cell', 'no label'), ('Cell', 'no label'), ('Calcium', 'no label'), ('Antibodies', 'no label'), ('Positron', 'no label'), ('Cell', 'no label'), ('Cell', 'no label'), ('Cell', 'no label')]|[]|[('Merkel Cell Carcinoma', 'no label'), ('Aggressive Tumor', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Paraneoplastic Neurological Syndromes', 'no label'), ('Ataxia', 'no label'), ('Vertigo', 'no label'), ('Nausea', 'no label'), ('Dysarthria', 'no label'), ('Diplopia', 'no label'), ('Xerostomia', 'no label'), ('Anorexia', 'no label'), ('Calcium', 'no label'), ('Lambert-Eaton Myasthenia', 'no label'), ('Cerebellar Degeneration', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Merkel Cell Carcinoma Diagnosis', 'no label'), ('Tumor', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Lambert-Eaton Myasthenia', 'no label'), ('Small Cell Lung Carcinoma', 'no label')]|[('Merkel Cell Carcinoma Is A', 'no label'), ('Tumor', 'no label'), ('Neuroendocrine Features With Small Cell Lung Carcinoma', 'no label'), ('Have A High Titer', 'no label'), ('Calcium Channel Antibodies', 'no label'), ('Serum', 'no label'), ('Cerebrospinal Fluid', 'no label'), ('Cerebellar', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Merkel Cell Carcinoma', 'no label'), ('Lymph Nodes', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label'), ('Small Cell Lung Carcinoma.', 'no label')]
lambert eaton syndrome|pubmed~23970984|"Lambert-Eaton Myasthenic Syndrome (Lems) Is A Rare Presynaptic Disorder Of The Neuromuscular Junction In Association With Cancer And Subsequently In Cases In Which No Neoplasm Has Been Detected (O'Neill Et Al., 1988). The Diagnosis Of Lems Is Based On The Combination Of Fluctuating Muscle Weakness, Diminished Or Absent Reflexes, And A More Than 60% Increment Of Compound Muscle Action Potential (Cmap) Amplitude After Brief Exercise Or 50 Hz Stimulation For 1 S In A Repetitive Nerve Stimulation (Rns) Test (Oh Et Al., 2005). On The Other Hand, Needle Electromyography (Emg) Findings Related To Lems Have Not Been Well Described. Here, We Report A Case Of Lems, Which Showed Apparent Myopathic Changes In Needle Emg Findings. Furthermore, We Retrospectively Examined The Needle Emg Findings In 8 Patients With Lems. In Six Of The 8 Patients, The Emg Findings Showed Myopathy-Like Findings. Although The Findings Of Needle Emg Indicated Myopathic Changes At A Glance, The Motor Unit Potential (Mup) Returned To Normal After A Sustained Strong Muscle Contraction. We Propose The Name ""Pseudomyopathic Changes"" For This Phenomenon. "|"[('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Rare', 'no label'), ('Presynaptic Disorder', 'no label'), ('Neuromuscular Junction', 'no label'), ('Cancer', 'no label'), ('Cases', 'no label'), ('Neoplasm', 'no label'), ('Detected', 'no label'), (""O'Neill Et Al"", 'no label'), ('Diagnosis', 'no label'), ('Lems', 'no label'), ('Combination', 'no label'), ('Fluctuating Muscle Weakness', 'no label'), ('Diminished', 'no label'), ('Absent', 'no label'), ('Increment', 'no label'), ('Compound Muscle', 'no label'), ('Cmap', 'no label'), ('Stimulation', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Oh Et Al', 'no label'), ('Needle Electromyography', 'no label'), ('Emg', 'no label'), ('Findings', 'no label'), ('Lems', 'no label'), ('Report', 'no label'), ('Lems', 'no label'), ('Apparent', 'no label'), ('Myopathic', 'no label'), ('Changes', 'no label'), ('Needle Emg', 'no label'), ('Findings', 'no label'), ('Retrospectively', 'no label'), ('Needle Emg Findings', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patients', 'no label'), ('Emg Findings', 'no label'), ('Myopathy-Like Findings', 'no label'), ('Findings', 'no label'), ('Needle Emg', 'no label'), ('Myopathic', 'no label'), ('Changes', 'no label'), ('Glance', 'no label'), ('Motor Unit', 'no label'), ('Potential', 'no label'), ('Returned', 'no label'), ('Strong', 'no label'), ('Muscle Contraction', 'no label'), ('Pseudomyopathic', 'no label'), ('Changes', 'no label'), ('Phenomenon', 'no label')]"|[]|[('Emg', 'no label'), ('Emg', 'no label'), ('Emg', 'no label'), ('Motor Unit', 'no label')]|[('Myasthenic Syndrome', 'no label'), ('Disorder', 'no label'), ('Cancer', 'no label'), ('Neoplasm', 'no label'), ('Muscle Weakness', 'no label'), ('Oh Et Al', 'no label')]|[('Presynaptic', 'no label'), ('Neuromuscular', 'no label'), ('Cancer', 'no label'), ('Neoplasm', 'no label'), ('Al', 'no label'), ('Lems', 'no label'), ('Muscle', 'no label'), ('Muscle', 'no label'), ('Nerve', 'no label'), ('Et Al', 'no label'), ('Lems', 'no label'), ('Needle Emg', 'no label'), ('Needle Emg', 'no label'), ('Patients', 'no label'), ('Muscle', 'no label')]
lambert eaton syndrome|pubmed~18779614|A Small-Cell Lung Carcinoma (Sclc) Is Found In 50% Of Patients With Lambert-Eaton Myasthenic Syndrome (Lems). We Evaluated Screening To Optimize Screening Strategy For Sclc. It Is Important To Detect These Tumors Early In Newly Diagnosed Patients With Lems To Offer Optimal Patient Treatment. A Large Nationwide Cohort Study Of Consecutive Patients In The Netherlands, Seen Between 1990 And 2007, Were Screened For The Presence Of A Tumor Using Chest X-Ray, Computed Tomography Of The Thorax (Ct-Thorax), [(18)F]Fluorodeoxyglucose Positron Emission Tomography (Fdg-Pet), Bronchoscopy, And/Or Mediastinoscopy. Sclc Was Found In 54 Patients, And In 46 Patients, No Tumor Was Found During A Median Follow-Up Of 8 Years (Range, 3 To 26 Years). All Patients With Sclc Had A Positive Smoking History And 86% Were Still Smoking At Diagnosis. Sclc Was Found In 92% Of These Patients Within 3 Months And In 96% Within A Year. At First Screening, Ct-Thorax Detected An Sclc In 45 Patients (83%), Whereas Chest X-Ray Found The Tumor In Only 23 Patients (51%). An Sclc Was Found During Secondary Screening In Another Nine Patients (Median, 3 Months; Range, 1 To 41 Months). In Six Patients, A Lung Tumor Was Found By Ct-Thorax Or Fdg-Pet, And In Three Patients, Extrapulmonary Metastases Were Found, Initially Without Identifiable Tumor Mass On Ct-Thorax. In Almost All Patients (96%), The Sclc Was Found Within 1 Year Of Diagnosis. Ct-Thorax Scans Detected Most Of The Tumors (93%) And Was Far More Sensitive Than Chest X-Ray (51%). Fdg-Pet May Have Additive Value In Selected Cases. We Propose A Screening Protocol Based On Ct-Thorax And Fdg-Pet.|[('Small-Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Evaluated Screening', 'no label'), ('Optimize', 'no label'), ('Screening Strategy', 'no label'), ('Sclc', 'no label'), ('Detect', 'no label'), ('Tumors', 'no label'), ('Early', 'no label'), ('Diagnosed', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Optimal', 'no label'), ('Patient Treatment', 'no label'), ('Cohort Study', 'no label'), ('Consecutive', 'no label'), ('Patients', 'no label'), ('Netherlands', 'no label'), ('Screened', 'no label'), ('Presence', 'no label'), ('Tumor', 'no label'), ('Chest X-Ray', 'no label'), ('Computed Tomography', 'no label'), ('Thorax', 'no label'), ('Ct-Thorax', 'no label'), ('[(18)F]Fluorodeoxyglucose Positron Emission Tomography', 'no label'), ('Fdg-Pet', 'no label'), ('Bronchoscopy', 'no label'), ('And/Or', 'no label'), ('Mediastinoscopy', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Tumor', 'no label'), ('Median Follow-Up', 'no label'), ('Years', 'no label'), ('Range', 'no label'), ('Years', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Positive Smoking History', 'no label'), ('Still Smoking', 'no label'), ('Diagnosis', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Months', 'no label'), ('Year', 'no label'), ('First Screening', 'no label'), ('Ct-Thorax', 'no label'), ('Detected', 'no label'), ('Sclc', 'no label'), ('Patients', 'no label'), ('Chest X-Ray', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Secondary Screening', 'no label'), ('Patients', 'no label'), ('Median', 'no label'), ('Months', 'no label'), ('Range', 'no label'), ('Months', 'no label'), ('Patients', 'no label'), ('Lung Tumor', 'no label'), ('Ct-Thorax', 'no label'), ('Fdg-Pet', 'no label'), ('Patients', 'no label'), ('Extrapulmonary Metastases', 'no label'), ('Tumor Mass', 'no label'), ('Ct-Thorax', 'no label'), ('Patients', 'no label'), ('Sclc', 'no label'), ('Year', 'no label'), ('Diagnosis', 'no label'), ('Ct-Thorax Scans', 'no label'), ('Detected', 'no label'), ('Tumors', 'no label'), ('Sensitive', 'no label'), ('X-Ray', 'no label'), ('Fdg-Pet', 'no label'), ('Additive Value', 'no label'), ('Cases', 'no label'), ('Propose', 'no label'), ('Screening Protocol', 'no label'), ('Ct-Thorax', 'no label'), ('Fdg-Pet', 'no label')]|[]|[('Fdg-Pet', 'no label'), ('Ct-Thorax', 'no label')]|[('Lung Carcinoma', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Tumors', 'no label'), ('Tumor', 'no label'), ('Chest X-Ray, Computed Tomography Of The Thorax (Ct-Thorax)', 'no label'), ('And/Or', 'no label'), ('Tumor', 'no label'), ('Chest X-Ray Found The', 'no label'), ('Tumor', 'no label'), ('Tumor', 'no label'), ('Tumor', 'no label'), ('Diagnosis', 'no label'), ('Tumors', 'no label'), ('Chest X-Ray', 'no label')]|[('Small-Cell Lung Carcinoma', 'no label'), ('Patients', 'no label'), ('Tumors', 'no label'), ('Patients', 'no label'), ('Lems', 'no label'), ('Patient', 'no label'), ('Patients', 'no label'), ('Tumor', 'no label'), ('Thorax', 'no label'), ('And/Or', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Tumor', 'no label'), ('Follow-Up Of 8', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Lung Tumor', 'no label'), ('Patients', 'no label'), ('Extrapulmonary Metastases', 'no label'), ('Tumor', 'no label'), ('Patients', 'no label'), ('Tumors', 'no label'), ('Far', 'no label')]
lambert eaton syndrome|pubmed~16526254|Paraneoplastic Neurological Syndromes Are Rare Non-Metastatic Complications Of Cancer That Have An Immune-Mediated Etiology. The Lambert-Eaton Myasthenic Syndrome (Lems) Is A Neuromuscular Disorder, Often Associated With Small Cell Lung Carcinoma (Sclc), Which Is Characterized By Reduced Quantal Release Of Acetylcholine From The Motor Nerve Terminals. Lambert-Eaton Myasthenic Syndrome: The Lambert-Eaton Myasthenic Syndrome (Lems) Is Characterized By Proximal Muscle Weakness Initially Affecting Gait, Autonomic Symptoms (Dry Mouth, Constipation, Erectile Failure) And Augmentation Of Strength During Initial Voluntary Activation. Symptomatic Treatment Of The Junctional Disorder Is Based On Cholinergic Drugs, Immunosuppression, Immunomodulation And Physical Therapy Useful In Case Of Unsuccessful Antineoplastic Therapy. A Rare Case Of Ovarian Cancer With Eaton-Lambert Syndrome Is Reported. A 50-Year-Old Woman Was Admitted To The Gynecologic Department, Complaining Of Weakness And Pain In Her Arms And Shoulders. Physical Therapy Resulted In Partial Improvement. Treatment Of Paraneoplastic Syndrome Markedly Improves The Quality Of Life Of Cancer Patients. Patients Presenting With This Syndrome Should Undergo A Careful Evaluation For The Presence Of An Occult Malignancy.|[('Paraneoplastic Neurological Syndromes', 'no label'), ('Rare', 'no label'), ('Non-Metastatic Complications', 'no label'), ('Cancer', 'no label'), ('Immune-Mediated Etiology', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Neuromuscular Disorder', 'no label'), ('Associated With', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Sclc', 'no label'), ('Characterized', 'no label'), ('Reduced', 'no label'), ('Quantal Release', 'no label'), ('Acetylcholine', 'no label'), ('Motor Nerve', 'no label'), ('Terminals', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Lems', 'no label'), ('Characterized', 'no label'), ('Proximal Muscle Weakness', 'no label'), ('Autonomic Symptoms', 'no label'), ('Dry Mouth', 'no label'), ('Constipation', 'no label'), ('Erectile Failure', 'no label'), ('Augmentation', 'no label'), ('Voluntary Activation', 'no label'), ('Symptomatic', 'no label'), ('Treatment', 'no label'), ('Junctional Disorder', 'no label'), ('Cholinergic Drugs', 'no label'), ('Immunosuppression', 'no label'), ('Immunomodulation', 'no label'), ('Physical Therapy', 'no label'), ('Antineoplastic Therapy', 'no label'), ('Rare', 'no label'), ('Case', 'no label'), ('Ovarian Cancer', 'no label'), ('Eaton-Lambert Syndrome', 'no label'), ('Woman', 'no label'), ('Gynecologic Department', 'no label'), ('Complaining', 'no label'), ('Weakness', 'no label'), ('Pain', 'no label'), ('Shoulders', 'no label'), ('Physical Therapy', 'no label'), ('Resulted', 'no label'), ('Partial', 'no label'), ('Improvement', 'no label'), ('Treatment', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Markedly', 'no label'), ('Improves', 'no label'), ('Quality', 'no label'), ('Patients', 'no label'), ('Patients', 'no label'), ('Syndrome', 'no label'), ('Evaluation', 'no label'), ('Presence', 'no label'), ('Occult Malignancy', 'no label')]|[('Cell', 'no label'), ('Acetylcholine', 'no label'), ('Antineoplastic', 'no label')]|[]|[('Paraneoplastic Neurological Syndromes', 'no label'), ('Cancer', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Neuromuscular Disorder', 'no label'), ('Acetylcholine', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Muscle Weakness', 'no label'), ('Dry Mouth', 'no label'), ('Constipation', 'no label'), ('Erectile Failure', 'no label'), ('Junctional Disorder', 'no label'), ('Ovarian Cancer', 'no label'), ('Eaton-Lambert Syndrome', 'no label'), ('Weakness', 'no label'), ('Pain', 'no label'), ('Paraneoplastic Syndrome', 'no label'), ('Cancer', 'no label'), ('Occult Malignancy', 'no label')]|[('Cancer', 'no label'), ('Neuromuscular', 'no label'), ('Small Cell Lung Carcinoma', 'no label'), ('Acetylcholine', 'no label'), ('Motor Nerve', 'no label'), ('Muscle', 'no label'), ('Case', 'no label'), ('Rare Case', 'no label'), ('Ovarian Cancer', 'no label'), ('Cancer Patients', 'no label'), ('Patients', 'no label')]
lambert eaton syndrome|pubmed~18535871||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~17636143||[]|[]|[]|[]|[]
lambert eaton syndrome|pubmed~29377152|We Report A Severe Defect Of Neuromuscular Transmission In A Consanguineous Patient With A Homozygous Variant In The Laminin Α5 Subunit Gene (Lama5). The Variant C.8046C > T (P.Arg2659Trp) Is Rare And Has A Predicted Deleterious Effect. The Affected Individual, Who Also Carries A Rare Homozygous Sequence Variant In Lama1, Had Normal Cognitive Function, But Magnetic Resonance Brain Imaging Showed Mild Volume Loss And Periventricular T2 Prolongation. Repetitive Nerve Stimulation At 2 Hz Showed 50% Decrement Of Compound Muscle Action Potential Amplitudes But 250% Facilitation Immediately After Exercise, Similar To That Seen In Lambert-Eaton Myasthenic Syndrome. Endplate Studies Demonstrated A Profound Reduction Of The Endplate Potential Quantal Content But Normal Amplitudes Of Miniature Endplate Potentials. Electron Microscopy Showed Endplates With Increased Postsynaptic Folding That Were Denuded Or Only Partially Occupied By Small Nerve Terminals. Expression Studies Revealed That P.Arg2659Trp Caused Decreased Binding Of Laminin Α5 To Sv2A And Impaired Laminin-521 Cell Adhesion And Cell Projection Support In Primary Neuronal Cultures. In Summary, This Report Describing Severe Neuromuscular Transmission Failure In A Patient With A Lama5 Mutation Expands The List Of Phenotypes Associated With Defects In Genes Encoding Α-Laminins.|[('Report', 'no label'), ('Severe', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Consanguineous', 'no label'), ('Patient', 'no label'), ('Homozygous Variant', 'no label'), ('Laminin Α5 Subunit Gene', 'no label'), ('Lama5', 'no label'), ('Variant', 'no label'), ('C.8046C', 'no label'), ('T', 'no label'), ('Rare', 'no label'), ('Has A', 'no label'), ('Predicted', 'no label'), ('Deleterious Effect', 'no label'), ('Affected', 'no label'), ('Individual', 'no label'), ('Carries', 'no label'), ('Rare', 'no label'), ('Homozygous Sequence Variant', 'no label'), ('Lama1', 'no label'), ('Normal Cognitive Function', 'no label'), ('Magnetic Resonance Brain Imaging', 'no label'), ('Mild Volume Loss', 'no label'), ('Periventricular T2', 'no label'), ('Prolongation', 'no label'), ('Repetitive Nerve Stimulation', 'no label'), ('Decrement', 'no label'), ('Compound Muscle', 'no label'), ('Amplitudes', 'no label'), ('Facilitation', 'no label'), ('Exercise', 'no label'), ('Lambert-Eaton Myasthenic Syndrome', 'no label'), ('Endplate Studies', 'no label'), ('Reduction', 'no label'), ('Endplate', 'no label'), ('Potential', 'no label'), ('Quantal', 'no label'), ('Content', 'no label'), ('Normal Amplitudes', 'no label'), ('Miniature Endplate Potentials', 'no label'), ('Electron Microscopy', 'no label'), ('Endplates', 'no label'), ('Increased', 'no label'), ('Postsynaptic Folding', 'no label'), ('Denuded', 'no label'), ('Partially', 'no label'), ('Occupied', 'no label'), ('Small Nerve', 'no label'), ('Terminals', 'no label'), ('Expression Studies', 'no label'), ('Revealed', 'no label'), ('P.Arg2659Trp Caused', 'no label'), ('Decreased', 'no label'), ('Binding', 'no label'), ('Laminin Α5', 'no label'), ('Sv2A', 'no label'), ('Impaired', 'no label'), ('Laminin-521 Cell Adhesion', 'no label'), ('Cell Projection Support', 'no label'), ('Neuronal Cultures', 'no label'), ('Report', 'no label'), ('Severe', 'no label'), ('Neuromuscular Transmission', 'no label'), ('Failure', 'no label'), ('Patient', 'no label'), ('Lama5', 'no label'), ('Mutation', 'no label'), ('Phenotypes', 'no label'), ('Associated With', 'no label'), ('Defects', 'no label'), ('Genes', 'no label'), ('Encoding', 'no label')]|[('Variant', 'no label'), ('Laminin Α5', 'no label'), ('Lama5', 'no label'), ('T', 'no label'), ('Sequence Variant', 'no label'), ('Lama1', 'no label'), ('Electron', 'no label'), ('Nerve Terminals', 'no label'), ('Laminin Α5', 'no label'), ('Cell', 'no label'), ('Cell', 'no label'), ('Neuronal', 'no label'), ('Lama5 Mutation', 'no label'), ('Genes', 'no label')]|[('Laminin Α5 Subunit Gene', 'no label'), ('Lama1', 'no label'), ('T2', 'no label'), ('P.Arg2659Trp', 'no label'), ('Laminin Α5', 'no label')]|[('Consanguineous', 'no label'), ('Volume Loss', 'no label'), ('Myasthenic Syndrome', 'no label'), ('Neuromuscular Transmission Failure', 'no label')]|[('Neuromuscular', 'no label'), ('Patient', 'no label'), ('Laminin', 'no label'), ('Lama5', 'no label'), ('Lama1', 'no label'), ('Brain', 'no label'), ('Periventricular T2', 'no label'), ('Nerve', 'no label'), ('Muscle', 'no label'), ('Endplate', 'no label'), ('Endplates', 'no label'), ('Postsynaptic', 'no label'), ('Small Nerve', 'no label'), ('Laminin', 'no label'), ('Laminin-521 Cell', 'no label'), ('Cell', 'no label'), ('Primary Neuronal Cultures', 'no label'), ('Neuromuscular', 'no label'), ('Patient', 'no label'), ('Lama5', 'no label')]
